PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	GHERSA, P; VANHUIJSDUIJNEN, RH; WHELAN, J; CAMBET, Y; PESCINI, R; DELAMARTER, JF				GHERSA, P; VANHUIJSDUIJNEN, RH; WHELAN, J; CAMBET, Y; PESCINI, R; DELAMARTER, JF			INHIBITION OF E-SELECTIN GENE-TRANSCRIPTION THROUGH A CAMP-DEPENDENT PROTEIN-KINASE PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION MOLECULE-1; NF-KAPPA-B; DIRECT EXPRESSION CLONING; CELL-SURFACE; BINDING PROTEINS; SIGNAL TRANSDUCTION; CYTOKINE INDUCTION; MAMMALIAN-CELLS; ACTIVATION; CREB	Cytokines induce the expression of E-selectin, VCAM-1, and ICAM-1 on human umbilical vein endothelial cells (HUVECs). We show that expression of these surface proteins is differently affected by cAMP. Increased cAMP levels decrease E-selectin and VCAM-1 but increase ICAM-1 expression. We demonstrate by mRNA half-life analysis and nuclear run-on assays that the cAMP repression of E-selectin occurs at the transcription level. This effect is abolished by protein kinase A inhibition, suggesting that repression is mediated by protein kinase A-driven phosphorylation. We found that a minimal E-selectin promoter sequence necessary to confer cytokine inducibility is also sufficient to mimic the cAMP effect in transfected HUVECs. Previously we characterized two regions (NF-kappa B and NF-ELAM1) of the minimal promoter that bind transcription factors necessary for E-selectin induction. Increased cAMP did not alter the binding of the complexes formed on either the NF-kappa B or NF-ELAM1 site. In contrast, in interleukin-1-treated HUVECs transactivity due to an NF-kappa B site is reduced by elevated cAMP. Increased cAMP in HUVECs appears to induce a protein kinase activity that reduces the cytokine signal for E-selectin and VCAM-1 expression. The reduction in signal may occur through an inhibitory phosphorylation of one or more of the factors responsible for regulating E-selectin expression.			GHERSA, P (corresponding author), GLAXO INST MOLEC BIOL SA,14 CHEMIN AULX,CH-1228 PLAN LES OUATES,SWITZERLAND.		van Huijsduijnen, Rob A.M. Hooft/B-3653-2009	van Huijsduijnen, Rob A.M. Hooft/0000-0002-2261-9424				Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAEUERLE PA, 1991, MOL ASPECTS CELL REG, V6, P409; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS T, 1991, J BIOL CHEM, V266, P2466; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CULLEN BR, 1987, METHOD ENZYMOL, V152, P692; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DUSTIN ML, 1986, J IMMUNOL, V137, P245; FLINT KJ, 1991, ONCOGENE, V6, P2019; GERRITSEN ME, 1993, FASEB J, V7, P523, DOI 10.1096/fasebj.7.6.8472891; GHERSA P, 1992, J BIOL CHEM, V267, P19226; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; IWASAKI T, 1992, FEBS LETT, V298, P240, DOI 10.1016/0014-5793(92)80067-Q; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; MACCHIA G, 1990, MOL CELL BIOL, V10, P2731, DOI 10.1128/MCB.10.6.2731; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; Muegge K, 1990, Cytokine, V2, P1, DOI 10.1016/1043-4666(90)90036-S; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PESCINI R, 1994, J BIOL CHEM, V269, P1159; POBER JS, 1993, J IMMUNOL, V150, P5114; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; RITCHIE AJ, 1991, J IMMUNOL, V146, P3056; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; VANHUIJSDUIJNEN RH, 1992, J BIOL CHEM, V267, P22385; VANHUIJSDUIJNEN RH, 1993, NUCLEIC ACIDS RES, V21, P3711, DOI 10.1093/nar/21.16.3711; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; WERTHEIMER S J, 1991, Journal of Cell Biology, V115, p453A; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	50	87	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29129	29137						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7525580				2022-12-25	WOS:A1994PU16800090
J	MILLER, KJ; HOFFMAN, BJ				MILLER, KJ; HOFFMAN, BJ			ADENOSINE A(3) RECEPTORS REGULATE SEROTONIN TRANSPORT VIA NITRIC-OXIDE AND CGMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; HIGH-AFFINITY UPTAKE; PROTEIN-KINASE-C; NEUROTRANSMITTER TRANSPORTERS; MEMBRANE-VESICLES; MOLECULAR-CLONING; CELL-CULTURES; GLUTAMATE; ACTIVATION; PHOSPHORYLATION	Many antidepressants inhibit 5-hydroxytryptamine (5HT) transport resulting in increased 5HT levels in the synapse. However, physiological regulation of neurotransmitter uptake has not been demonstrated. We have examined the effect of receptor-activated second messengers on the 5HT transporter in rat basophilic leukemia cells (RBL 2H3). Here, we show that activation of an A(3) adenosine receptor results in an increase of 5HT uptake in RBL cells, due to an increase in maximum velocity (V-max). The A(3) adenosine receptor-stimulated increase in transport is blocked by inhibitors of nitric oxide synthase and by a cGMP dependent kinase inhibitor. In fact, compounds that generate nitric oxide (NO) and the cGMP analog 8-bromo-cGMP mimicked the effect of A(3) receptor stimulation, suggesting that the elevation in transport occurs through the generation of the gaseous second messenger NO and a subsequent elevation in cGMP. Additionally, the 5HT transporter is differentially regulated by second messengers since direct activation of protein kinase C by phorbol esters decreases 5HT uptake by decreasing V-max. Our results suggest that the changes in transport are due to a direct modification of the 5HT transporter, possibly by phosphorylation, which appears to alter the rate at which transport occurs. As the 5HT transporter in RBL cells is identical to that in neurons, our results suggest that analogous mechanisms may operate in the brain.			MILLER, KJ (corresponding author), NIMH, CELL BIOL LAB, ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							ALI H, 1990, J BIOL CHEM, V265, P745; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ANDERSON GM, 1992, BIOCHIM BIOPHYS ACTA, V1137, P331, DOI 10.1016/0167-4889(92)90154-4; AXELROD J, 1963, J PHARMACOL EXP THER, V141, P161; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BROWNSTEIN MJ, 1993, RECENT PROG HORM RES, V49, P27; CASADO M, 1991, J NEUROCHEM, V57, P1185, DOI 10.1111/j.1471-4159.1991.tb08278.x; CASADO M, 1993, J BIOL CHEM, V268, P27313; COOL DR, 1990, BIOCHEMISTRY-US, V29, P1818, DOI 10.1021/bi00459a022; COREY JL, 1994, J BIOL CHEM, V269, P14759; CUHNAMELO JR, 1989, J IMMUNOL, V143, P2617; DOUGLAS JG, 1982, PHARMACOL THERAPEUT, V18, P351, DOI 10.1016/0163-7258(82)90037-7; FULLER RW, 1990, NEUROPHARMACOLOGY SE, V600, P68; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GLOWINSKI J, 1966, J PHARMACOL EXP THER, V164, P282; HANSSON E, 1989, LIFE SCI, V44, P27, DOI 10.1016/0024-3205(89)90214-2; HANSSON E, 1991, BRAIN RES, V548, P215, DOI 10.1016/0006-8993(91)91124-J; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; HOFFMAN BJ, 1992, SOC NEUR ABSTR, V17, P1179; JAYANTHI LD, 1994, J BIOL CHEM, V269, P14424; KANNER BI, 1985, BIOCHIM BIOPHYS ACTA, V816, P403, DOI 10.1016/0005-2736(85)90508-5; KAUFMAN M, 1994, IN PRESS J NEUROCHEM; KUHAR MJ, 1972, J PHARMACOL-PARIS, V181, P36; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; MEYERS CL, 1989, AM J PHYSIOL, V257, pL253; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MULSCH A, 1989, N-S ARCH PHARMACOL, V340, P119; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PERRY KW, 1992, LIFE SCI, V50, P1683, DOI 10.1016/0024-3205(92)90423-M; PRISTUPA ZB, 1994, MOL PHARMACOL, V45, P125; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; RAMAMOORTHY S, 1993, J BIOL CHEM, V268, P21626; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; ROSS SB, 1982, BIOL SEROTONERGIC TR, P159; ROWLAND NE, 1986, PROG NEUROBIOL, V27, P13, DOI 10.1016/0301-0082(86)90011-0; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; SHEARD MH, 1972, BRAIN RES, V43, P690, DOI 10.1016/0006-8993(72)90432-5; SNYDER SH, 1969, J PHARMACOL EXP THER, V165, P78; SOUTHAM E, 1991, NEUROSCI LETT, V130, P107, DOI 10.1016/0304-3940(91)90239-P; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; WOTHERSPOON G, 1994, NEUROSCI LETT, V173, P31, DOI 10.1016/0304-3940(94)90143-0; ZHOU M, 1993, SCIENCE, V260, P1946; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	47	170	171	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27351	27356						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525554				2022-12-25	WOS:A1994PV77100034
J	SIPPEL, CJ; FALLON, RJ; PERLMUTTER, DH				SIPPEL, CJ; FALLON, RJ; PERLMUTTER, DH			BILE-ACID EFFLUX MEDIATED BY THE RAT-LIVER CANALICULAR BILE-ACID TRANSPORT ECTO-ATPASE PROTEIN REQUIRES SERINE 503 PHOSPHORYLATION AND IS REGULATED BY TYROSINE-488 PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASIALOGLYCOPROTEIN RECEPTOR; DEPENDENT TRANSPORT; MOLECULAR-CLONING; INSULIN-RECEPTOR; BINDING PROTEIN; KINASE-C; MEMBRANE; EXPRESSION; GLYCOPROTEIN; DOMAIN	Transfection of cDNA for a hepatocyte canalicular phosphoprotein, the rat liver canalicular bile acid transporter/ecto-ATPase/cell CAM 105, confers bile acid efflux and ecto-ATPase activities on heterologous cells (Sippel, C. J., Suchy, F. J., Ananthanarayanan, M., and Perlmutter D. H. (1993) J. Biol. Chen. 268, 2083-2091). Our previous studies have also indicated that there is a positive correlation between the degree of phosphorylation of this transporter and its bile acid efflux activity. In this study, we introduced site-specific mutations of amino acid residues within a protein kinase C-dependent (T502A, S503A) and a tyrosine kinase-dependent (Y488F) phosphorylation consensus sequence in the cytoplasmic tail of this transporter in order to map the sites that are phosphorylated in vivo and to examine the functional significance of each. COS cells were transfected with mutant and wild type constructs using the pCDM8 expression vector. Metabolic labeling and cell surface labeling showed that the mutant proteins were synthesized and delivered to the cell surface as efficiently as the wild type. Phosphoamino acid analysis using lysates of transfected cells showed that the T502A, S503A mutant contained [P-32]phosphotyrosine, the Y488F mutant contained [P-32]phosphoserine, and the wild type contained both P-32-labeled amino acids, proving that Ser(503) and Tyr(488) are the only amino acids phosphorylated in this system under control conditions. Bile acid transport activity was completely abrogated in cells transfected with the T502A, S503A mutant cDNA and was retained but altered in kinetic characteristics in cells transfected with the Y488F mutant cDNA, even though both of these constructs conferred ecto-ATPase activity to the same extent as the wild type cDNA. Taken together, these data show that the bile acid efflux activity of this transporter requires site-specific phosphorylation of Ser(503) and is regulated by site specific phosphorylation of Tyr(488).	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	SIPPEL, CJ (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PEDIAT,1 CHILDRENS PL,ST LOUIS,MO 63110, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD000954, T32HD007409] Funding Source: NIH RePORTER; NICHD NIH HHS [K08 HD00954-01, T32 HD07409] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADACHI Y, 1991, HEPATOLOGY, V14, P655, DOI 10.1016/0270-9139(91)90053-X; ANANTHANARAYANA.M, 1991, AM J PHYSIOL, V261, pG2810; ARIAS IM, 1993, HEPATOLOGY, V17, P318, DOI 10.1002/hep.1840170225; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BECKER A, 1993, EUR J BIOCHEM, V214, P539, DOI 10.1111/j.1432-1033.1993.tb17952.x; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLITZER B, 1982, AM J PHYSIOL, V6, pG48; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; CULIC O, 1992, BIOCHEM J, V285, P47, DOI 10.1042/bj2850047; CULLEN BR, 1987, METHOD ENZYMOL, V152, P562; FALLON RJ, 1990, J BIOL CHEM, V265, P3401; GONG YZ, 1993, HEPATOLOGY, V18, pA144; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARRISON BC, 1991, J NEUROCHEM, V56, P1723, DOI 10.1111/j.1471-4159.1991.tb02073.x; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LIN SH, 1989, J BIOL CHEM, V264, P14408; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V166, P562, DOI 10.1016/0006-291X(90)90845-E; MARGOLIS RN, 1988, P NATL ACAD SCI USA, V85, P7256, DOI 10.1073/pnas.85.19.7256; MULLER M, 1991, J BIOL CHEM, V266, P18920; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ORR GA, 1993, J BIOL CHEM, V268, P25054; PERLMUTTER DH, 1988, J BIOL CHEM, V263, P16499; RUETZ S, 1987, J BIOL CHEM, V262, P11324; RUGOLO M, 1993, J BIOL CHEM, V268, P24779; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SIPPEL CJ, 1994, J BIOL CHEM, V269, P2820; SIPPEL CJ, 1990, AM J PHYSIOL, V258, pG728, DOI 10.1152/ajpgi.1990.258.5.G728; SWEETSER DA, 1986, J BIOL CHEM, V261, P5553; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; WONG MH, 1994, J BIOL CHEM, V269, P1340; YIH LH, 1991, CELL BIOL INT REP, V15, P253, DOI 10.1016/0309-1651(91)90157-E; ZIMNIAK P, 1993, HEPATOLOGY, V17, P330, DOI 10.1002/hep.1840170226	37	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19539	19545						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	7518458				2022-12-25	WOS:A1994NY33200053
J	IZUHARA, K; FELDMAN, RA; GREER, P; HARADA, N				IZUHARA, K; FELDMAN, RA; GREER, P; HARADA, N			INTERACTION OF THE C-FES PROTOONCOGENE PRODUCT WITH THE INTERLEUKIN-4 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TYROSINE KINASE; HEMATOPOIETIC-CELLS; SIGNAL TRANSDUCTION; PROTOONCOGENE PRODUCT; FPS/FES PROTOONCOGENE; ENCODED PROTEIN; MYELOID CELLS; B-CELLS; PHOSPHORYLATION	Interleukin-4 (IL-4) regulates proliferation and differentiation of a variety of hematopoietic cell lineages through binding to the IL-4 receptor (IL-4R). Recently, we have demonstrated that IL-4 induces tyrosine phosphorylation of several proteins including the IL-4R and also induces association of phosphatidylinositol-3 kinase with the IL-4R. Since IL-4 induces tyrosine phosphorylation, we speculated that some tyrosine kinase may associate with the IL-4R. In this study, we demonstrate that IL-4 induces tyrosine phosphorylation of a protein closely related to, or identical to the c-fes protooncogene-encoded protein tyrosine kinase (FES). Furthermore, tyrosine phosphorylated FES or the closely related protein is found associated with the IL-4R. We also demonstrate that FES associates with the IL-4R in COS7 cells transfected with cDNA expression plasmids encoding these two proteins and in transfected COS7 cells IL-4 augments association of FES with the IL-4R and tyrosine phosphorylation of both FES and the IL-4R. Through a deletion analysis of the IL-4R we have identified a putative FES-binding site in the cytoplasmic domain of the IL-4R.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304; UNIV MARYLAND,SCH MED,DEPT MICROBIOL & IMMUNOL,BALTIMORE,MD 21201; UNIV MARYLAND,MARYLAND BIOTECHNOL INST,CTR MED BIOTECHNOL,BALTIMORE,MD 21201; QUEENS UNIV,DEPT PATHOL,CANC RES LABS,KINGSTON K7L 3N6,ON,CANADA; QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ON,CANADA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Queens University - Canada; Queens University - Canada				Feldman, Ricardo A./0000-0001-6090-0439	NCI NIH HHS [R29 CA55293-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055293] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; COOPER JA, 1984, J BIOL CHEM, V259, P7835; FELDMAN RA, 1990, ONCOGENE RES, V5, P187; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FELDMAN RA, 1987, ONCOGENE RES, V1, P441; FELDMAN RA, 1986, MOL CELL BIOL, V6, P1065, DOI 10.1128/MCB.6.4.1065; GALIZZI JP, 1990, INT IMMUNOL, V2, P669, DOI 10.1093/intimm/2.7.669; GREER P, 1990, MOL CELL BIOL, V10, P2521, DOI 10.1128/MCB.10.6.2521; HANAZONO Y, 1993, BLOOD, V81, P3193; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HARADA N, 1992, J BIOL CHEM, V267, P22752; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; IZUHARA K, 1993, RES IMMUNOL, V144, P584, DOI 10.1016/S0923-2494(05)80007-0; IZUHARA K, 1993, J BIOL CHEM, V268, P13097; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; PAUL WE, 1991, BLOOD, V77, P1859; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; PLUZNIK DH, 1982, EXP HEMATOL, V10, P211; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; VELLENGA E, 1993, LEUKEMIA, V7, P1131; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOKOTA T, 1988, IMMUNOL REV, V102, P137, DOI 10.1111/j.1600-065X.1988.tb00744.x; YU G, 1989, J BIOL CHEM, V264, P10276	32	85	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18623	18629						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518439				2022-12-25	WOS:A1994NW79800062
J	MCVICAR, DW; LAL, BK; LLOYD, A; KAWAMURA, M; CHEN, YQ; ZHANG, XY; STAPLES, JE; ORTALDO, JR; OSHEA, JJ				MCVICAR, DW; LAL, BK; LLOYD, A; KAWAMURA, M; CHEN, YQ; ZHANG, XY; STAPLES, JE; ORTALDO, JR; OSHEA, JJ			MOLECULAR-CLONING OF LSK, A CARBOXYL-TERMINAL SRC KINASE (CSK) RELATED GENE, EXPRESSED IN LEUKOCYTES	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; NATURAL-KILLER-CELLS; SH3 DOMAINS; SIGNAL TRANSDUCTION; LYMPHOCYTES-T; NK CELLS; PHOSPHORYLATES; RECEPTORS; P50(CSK); ENCODES	Regulation of the activity of src-family kinases is thought to occur, in part, through the phosphorylation of conserved carboxyl-terminal tyrosine residues. Although the src-family includes several molecules with tissue or cell-type restricted expression, the only kinase implicated in the regulatory phosphorylation of these enzymes is p50(csk). Herein we report the molecular cloning of a tissue specific p50(csk)-related gene. Like p50(csk), the deduced protein sequence of this novel cDNA includes a tyrosine kinase catalytic domain, SH2 and SH3 domains, a short amino terminus, and no autophosphorylation or carboxyl-terminal tyrosine residues. Additionally, neither this novel kinase nor p50(csk) contain the amino-terminal myristoylation site characteristic of the src-family. However, whereas csk is ubiquitously expressed, mRNA corresponding to this novel gene is expressed in brain, natural killer (NK) cells, and activated T cells but not in a variety of other tissues and cell lines. In agreement with the mRNA expression pattern, antiserum reactive with the predicted carboxyl-terminus of the cDNA recognizes a 57 kDa polypeptide in immunoblots of NK cells and PHA-activated T cells, Because of its limited expression and high homology to p50(csk), we named this gene lsk; leukocyte carboxyl-terminal src kinase related gene. Identification of a molecule like lsk suggests the existence of tissue specific src-regulatory pathways that function in activated lymphocytes.	NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, MOLEC IMMUNOREGULAT LAB, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC DYNCORP, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	MCVICAR, DW (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, LEUKOCYTE CELL BIOL SECT, EXPTL IMMUNOL LAB, FREDERICK, MD 21702 USA.		McVicar, Daniel/G-1970-2015; Lal, Brajesh/AAA-2620-2022; Lloyd, Andrew/AAF-6071-2022; Lloyd, Andrew/AFJ-8960-2022; Lloyd, Andrew/E-7334-2017	Lloyd, Andrew/0000-0001-6277-8887; Lloyd, Andrew/0000-0001-6277-8887; McVicar, Daniel/0000-0002-1112-5111				BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; BROOKER GW, 1993, CELL, V73, P813; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; COOKE M P, 1989, New Biologist, V1, P66; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LANIER LL, 1992, IMMUNOL TODAY, V13, P392, DOI 10.1016/0167-5699(92)90087-N; LANIER LL, 1986, J IMMUNOL, V136, P4480; LI M, 1993, FOCUS, V15, P19; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACAULEY A, 1993, ONCOGENE, V8, P117; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; ORTALDO JR, 1986, J EXP MED, V164, P1193, DOI 10.1084/jem.164.4.1193; OSHEA JJ, 1992, J IMMUNOL, V148, P2497; PARTANEN J, 1991, ONCOGENE, V6, P2013; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; REIF AE, 1964, J EXP MED, V120, P413, DOI 10.1084/jem.120.3.413; RODEWALD HR, 1992, CELL, V69, P139, DOI 10.1016/0092-8674(92)90125-V; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TAKEYA T, 1983, CELL, V47, P277; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; YOUNG HA, 1987, J IMMUNOL, V139, P724	40	54	57	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					2037	2044						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	7516063				2022-12-25	WOS:A1994NR68500028
J	SPIVAKKROIZMAN, T; MOHAMMADI, M; HU, P; JAYE, M; SCHLESSINGER, J; LAX, I				SPIVAKKROIZMAN, T; MOHAMMADI, M; HU, P; JAYE, M; SCHLESSINGER, J; LAX, I			POINT MUTATION IN THE FIBROBLAST GROWTH-FACTOR RECEPTOR ELIMINATES PHOSPHATIDYLINOSITOL HYDROLYSIS WITHOUT AFFECTING NEURONAL DIFFERENTIATION OF PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; TYROSINE PHOSPHORYLATION; MESODERM INDUCTION; SIGNAL TRANSDUCTION; MOLECULAR SWITCH; PROTEIN-KINASES; MAP KINASES; RAS PROTEIN; SH2 DOMAIN; MICROINJECTION	Fibroblast growth factors (FGF) stimulate growth arrest and differentiation in rat pheochromocytoma PC12 cells. We examined the role of phosphatidylinositol (PI) hydrolysis in FGF-induced differentiation of PC12 cells by exploring the biological and biochemical activity of a mutant FGF receptor 1 (flg) defective in stimulation of PI hydrolysis. We show that point mutation at Tyr-766 (Y766F) of the FGF receptor prevents tyrosine phosphorylation of phospholipase C gamma and eliminates acidic FGF (aFGF)-induced stimulation of PI hydrolysis in PC12 cells. Treatment of PC12 cells expressing either wildtype or the Y766F mutant with aFGF led to tyrosine phosphorylation of Shc, the association of Shc with GRB2, a shift in the electrophoretic mobility of the Ras guanine nucleotide-releasing factor, Sos (son of sevenless), and enhancement in mitogen-activated protein kinase phosphorylation. Moreover, stimulation with aFGF led to a typical neurite outgrowth of PC12 cells expressing either wild-type or the Y766F FGF receptor mutant. These experiments indicate that PI hydrolysis is not essential for FGF-induced neuronal differentiation of PC12 cells. Moreover, the aFGF-induced Ras signaling pathway, which is essential for PC12 cell differentiation, is not affected by elimination of PI hydrolysis.	RHONE POULENC RORER INC,CENT RES,COLLEGEVILLE,PA 19426		SPIVAKKROIZMAN, T (corresponding author), NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016, USA.		Mohammadi, Moosa/ABA-6745-2020; kasaei, fahime/T-7197-2018	Mohammadi, Moosa/0000-0003-2434-9437; Hu, Patrick/0000-0002-5611-8062				ALTIN JG, 1990, J NEUROCHEM, V54, P1666, DOI 10.1111/j.1471-4159.1990.tb01220.x; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BUSA WB, 1989, DEV BIOL, V132, P315, DOI 10.1016/0012-1606(89)90228-5; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PESSIN MS, 1991, CELL REGUL, V2, P383, DOI 10.1091/mbc.2.5.383; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEEDORF K, 1992, MOL CELL BIOL, V12, P4347, DOI 10.1128/MCB.12.10.4347; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOGARI A, 1985, J NEUROSCI, V5, P307; TOGARI A, 1983, BIOCHEM BIOPH RES CO, V114, P1189, DOI 10.1016/0006-291X(83)90688-5; TRAYNOR AE, 1982, J NEUROCHEM, V39, P1677, DOI 10.1111/j.1471-4159.1982.tb08002.x; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	67	74	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14419	14423						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514169				2022-12-25	WOS:A1994NM06500020
J	CULCASI, M; LAFONCAZAL, M; PIETRI, S; BOCKAERT, J				CULCASI, M; LAFONCAZAL, M; PIETRI, S; BOCKAERT, J			GLUTAMATE RECEPTORS INDUCE A BURST OF SUPEROXIDE VIA ACTIVATION OF NITRIC-OXIDE SYNTHASE IN ARGININE-DEPLETED NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; BRAIN; RAT; CULTURES; HYDROXYL; NEUROTOXICITY; HEMOPROTEIN; CYCLASE; CGMP	We have previously shown in cultured cerebellar granule neurons (Lafon-Cazal, M., Pietri, S., Culcasi, M., and Bockaert, J. (1993) Nature 364, 535-537) that upon N-methyl-D-aspartate stimulation, a nitric oxide synthase (NOS)-independent, arachidonic acid-dependent generation of superoxide free radicals (O-2(radical anion)) is observed after a lag time of 10-15 min. Using the electron spin resonance spin trapping technique, we show that N-methyl-D-aspartate stimulation produced a more rapid burst of O-2(radical anion) in L-arginine (L-Arg)-depleted neurons, These O-2(radical anion) radicals are synthesized by NOS. KCl and kainate, which also stimulated NOS in these neurons, produced this rapid burst of O-2(radical anion), which was blocked as follows: (a) in the presence of L N-G-nitro-arginine (L-Narg), and (b) by L-Arg repletion. This burst of O-2(radical anion) was arachidonic acid-independent, and its time course was similar to that of nitric oxide production. It was also responsible for a weak but significant cell death that was suppressed by L-Narg and L-Arg.	CTR PHARMACOL ENDOCRINOL,CNRS,UR 9023,INSERM,F-34094 MONTPELLIER 5,FRANCE; UNIV AIX MARSEILLE 1,CNRS,URA 1412,F-13397 MARSEILLE 13,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite								BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUETTNER GR, 1992, J BIOCHEM BIOPH METH, V24, P147, DOI 10.1016/0165-022X(92)90054-E; BUETTNER GR, 1988, J BIOCHEM BIOPH METH, V16, P27, DOI 10.1016/0165-022X(88)90100-5; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHABARDES D, 1987, PFLUG ARCH EUR J PHY, V408, P366, DOI 10.1007/BF00581130; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; EIMERL S, 1991, BRAIN RES, V560, P282, DOI 10.1016/0006-8993(91)91244-U; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; HANNA PM, 1992, ARCH BIOCHEM BIOPHYS, V296, P640, DOI 10.1016/0003-9861(92)90620-C; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; JANZEN EG, 1971, ACCOUNTS CHEM RES, V4, P31, DOI 10.1021/ar50037a005; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; MACMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141; MARIN P, 1992, EUR J NEUROSCI, V4, P425, DOI 10.1111/j.1460-9568.1992.tb00892.x; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MAYER B, 1993, SEMIN NEUROSCI, V5, P197, DOI 10.1016/S1044-5765(05)80053-3; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NOVELLI A, 1987, J NEUROSCI, V7, P40; PAUWELS PJ, 1992, NEUROSCI LETT, V143, P27, DOI 10.1016/0304-3940(92)90225-V; POU S, 1992, J BIOL CHEM, V267, P24173; Rosen G.M., 1985, ADV FREE RADIC BIOL, V1, P345, DOI [10.1016/8755-9668(85)90012-2, DOI 10.1016/8755-9668(85)90012-2]; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; VANVLIET BJ, 1989, J NEUROCHEM, V52, P1229; VIGE X, 1993, SEMIN NEUROSCI, V55, P893; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001	35	126	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12589	12593						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7513691				2022-12-25	WOS:A1994NH71600036
J	ZHENG, MZ; FANG, H; HAKOMORI, SI				ZHENG, MZ; FANG, H; HAKOMORI, SI			FUNCTIONAL-ROLE OF N-GLYCOSYLATION IN ALPHA-5-BETA-1 INTEGRIN RECEPTOR - DE-N-GLYCOSYLATION INDUCES DISSOCIATION OR ALTERED ASSOCIATION OF ALPHA-5 AND BETA-1 SUBUNITS AND CONCOMITANT LOSS OF FIBRONECTIN-BINDING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE RECEPTORS; PLASMA FIBRONECTIN; ADHESION RECEPTOR; MELANOMA-CELLS; IDENTIFICATION; PROTEINS; GLYCOPROTEIN; LAMININ; COMPLEX; FAMILY	Fibronectin (FN)-mediated cell adhesion is controlled mainly by alpha 5 beta 1 (recognizing the RGD sequence) and alpha 4 beta 1 (recognizing the CS-1 peptide sequence of FN) integrin receptors. Integrin-dependent cell adhesion to FN is greatly promoted by optimal G(M3) concentration at the surface membrane (Zheng, M., Fang, H., Tsuruoka, T., Tsuji, T., Sasaki, T., and Hakomori, S. (1993) J. Biol. Chem. 268, 2217-2222), and cell adhesion mediated by alpha 4 beta 1 (to FN) or alpha 6 beta 1 (to laminin) is inhibited by modifying N-glycosylation processing of the integrin receptor (e.g. Akiyama, S. K., Yamada, S. S., and Yamada, K. M. (1989) J. Biol. Chem. 264, 18011-18018). We therefore studied the specific role of N-glycosylation in alpha 5 beta 1 function. Key findings of the present study were as follows. (i) Adhesion of K562 cells to FN-coated plates, which is mediated solely by alpha 5 beta 1, was inhibited when cells were treated with a mixture of endo-N-acetylglucosaminidase F and peptide-N-4-(N-acetylglucosaminyl) asparagine amidase F (endo F/PNGase-F). (ii) The alpha 5 beta 1 receptor at the K562 cell surface tended to dissociate into alpha 5 and beta 1 subunits when an extract of cells treated with endo-F/PNGase-F was precipitated by integrin subunit-specific antibodies, i.e. the alpha 5 subunit was preferentially precipitated by anti-alpha 5 monoclonal antibody ZH5, and the beta 1 subunit was preferentially precipitated by anti-beta 1 monoclonal antibody ZH1. When intact cells were extracted and treated with either ZH5 or ZH1, both alpha 5 and beta 1 were coprecipitated, indicating that the two subunits are normally tightly associated with each other. (iii) Adhesion of alpha 5 beta 1-containing liposomes (phosphatidylcholine:cholesterol liposomes incorporating purified alpha 5 beta 1) to FN-coated plates was abolished by treatment of liposomes with endo-F/PNGase-F. Liposomes incorporating alpha 5 beta 1 pretreated with endo-F/PNGase-F also did not bind to FN. When purified alpha 5 beta 1 receptor was treated with endo-F/PNGase-F followed by ZH5 or ZH1, the alpha 5 or beta 1 subunit was precipitated separately, respectively. In contrast, both subunits were always coprecipitated when intact purified alpha 5 beta 1 receptor was directly treated with ZH5 or ZH1. These findings indicate that N-glycosylation of both the alpha and beta subunits of the alpha 5 beta 1 integrin receptor is essential for association of these subunits and for optimal binding to FN.	UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	ZHENG, MZ (corresponding author), BIOMEMBRANE INST,SEATTLE,WA 98119, USA.				NCI NIH HHS [CA42505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; CHAMMAS R, 1991, J BIOL CHEM, V266, P3349; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; DEAN JW, 1990, J BIOL CHEM, V265, P12553; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GODING JW, 1980, J IMMUNOL METHODS, V39, P285, DOI 10.1016/0022-1759(80)90230-6; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HUMPHRIES MJ, 1988, J CLIN INVEST, V81, P782, DOI 10.1172/JCI113384; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1973, P NATL ACAD SCI USA, V70, P3170, DOI 10.1073/pnas.70.11.3170; ISEMURA M, 1984, J BIOCHEM-TOKYO, V96, P163, DOI 10.1093/oxfordjournals.jbchem.a134808; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MATSUURA H, 1988, J BIOL CHEM, V263, P3314; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MOULD AP, 1990, J BIOL CHEM, V265, P4020; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SHIH DT, 1993, J CELL BIOL, V122, P1361, DOI 10.1083/jcb.122.6.1361; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; SYMINGTON BE, 1989, J BIOL CHEM, V264, P13258; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; ZHENG MZ, 1992, BIOCHEM BIOPH RES CO, V186, P1397, DOI 10.1016/S0006-291X(05)81561-X; ZHENG MZ, 1993, J BIOL CHEM, V268, P2217	29	182	189	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12325	12331						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512965				2022-12-25	WOS:A1994NG37700098
J	HATTORI, Y; CAMPBELL, EB; GROSS, SS				HATTORI, Y; CAMPBELL, EB; GROSS, SS			ARGININOSUCCINATE SYNTHETASE MESSENGER-RNA AND ACTIVITY ARE INDUCED BY IMMUNOSTIMULANTS IN VASCULAR SMOOTH-MUSCLE - ROLE IN THE REGENERATION OF ARGININE FOR NITRIC-OXIDE SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ENDOTHELIAL-CELLS; NUCLEOTIDE-SEQUENCE; RELAXING FACTOR; SYNTHASE; MACROPHAGES; IDENTIFICATION; INTERLEUKIN-1; HYPOTENSION; METABOLISM; CITRULLINE	Nitric oxide synthase produces NO, citrulline, water, and NADP at the expense of arginine, NADPH, and dioxygen. While citrulline has been considered to be an inert by-product of the high output inducible isoform of NO synthase (iNOS), we show here that immunostimulants induce a metabolic pathway in vascular smooth muscle cells, which enables them to regenerate arginine from citrulline. Regeneration of arginine from citrulline is accomplished by two urea cycle enzymes: argininosuccinate synthetase (AS) and argininosuccinate lyase (AL). Whereas AL is constitutive to vascular smooth muscle cells, AS mRNA and enzyme activity is markedly induced in cells by treatment with bacterial lipopolysaccharide (LPS). The induction of AS mRNA and activity by LPS follows a time course which mirrors that for iNOS but lags 1-2 h behind. As shown for iNOS, interferon-gamma does not itself induce AS but is synergistic with LPS. AS induction is suppressed by glucocorticoids, actinomycin D, and, to a lesser extent, cycloheximide. On the other hand, AS induction is unaffected by an excess of citrulline or the inhibitor of iNOS, N(omega)-methyl-L-arginine. Our results show the urea cycle enzymes AS and AL confer cells with the capacity to produce NO without a need for exogenous arginine. In conjunction with NOS, citric acid cycle enzymes that covert fumarate to oxaloacetate (fumarase and malate dehydrogenase) and oxaloacetate to aspartate (aspartate transaminase), AS and AL form a novel arginine-citrulline cycle that enables high output NO production by cells.	CORNELL UNIV, MED CTR, COLL MED, DEPT PHARMACOL, 1300 YORK AVE, NEW YORK, NY 10021 USA	Cornell University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046403] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46403] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AISAKA K, 1989, BIOCHEM BIOPH RES CO, V160, P881, DOI 10.1016/0006-291X(89)92517-5; AMAYA Y, 1988, J BIOCHEM-TOKYO, V103, P177, DOI 10.1093/oxfordjournals.jbchem.a122227; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BILLIAR TR, 1992, J LEUKOCYTE BIOL   S, V52, P18; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHEUNG CW, 1989, J BIOL CHEM, V264, P4038; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HATTORI Y, 1993, BIOCHEM BIOPH RES CO, V195, P435, DOI 10.1006/bbrc.1993.2062; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; JACKSON MJ, 1986, ANNU REV GENET, V20, P431, DOI 10.1146/annurev.ge.20.120186.002243; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; LOCKRIDGE O, 1977, BIOCHEM GENET, V15, P395, DOI 10.1007/BF00484469; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MEIJER AJ, 1990, PHYSIOL REV, V70, P701, DOI 10.1152/physrev.1990.70.3.701; MITCHELL JA, 1990, EUR J PHARMACOL, V176, P253, DOI 10.1016/0014-2999(90)90541-D; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; OBRIEN WE, 1979, BIOCHEMISTRY-US, V18, P5353, DOI 10.1021/bi00591a015; RATNER S, 1985, METHOD ENZYMOL, V34, P298; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; SURH LC, 1988, NUCLEIC ACIDS RES, V16, P9352, DOI 10.1093/nar/16.19.9352; TERADA Y, 1992, J CLIN INVEST, V90, P659, DOI 10.1172/JCI115908; THIEMERMANN C, 1990, EUR J PHARMACOL, V182, P591, DOI 10.1016/0014-2999(90)90062-B; WU GY, 1992, BIOCHEM J, V281, P45, DOI 10.1042/bj2810045; XI QW, 1993, J EXP MED, V177, P1779; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	33	148	149	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9405	9408						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511585				2022-12-25	WOS:A1994NE05300003
J	VANNIER, E; DINARELLO, CA				VANNIER, E; DINARELLO, CA			HISTAMINE ENHANCES INTERLEUKIN (IL)-1-INDUCED IL-6 GENE-EXPRESSION AND PROTEIN-SYNTHESIS VIA H-2 RECEPTORS IN PERIPHERAL-BLOOD MONONUCLEAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; NECROSIS-FACTOR-ALPHA; SIGNAL TRANSDUCTION; ENDOTHELIAL-CELLS; KAPOSI-SARCOMA; MONOCYTES; IL1	The regulation of interleukin (IL)-6 synthesis by cAMP-increasing agents remains an unresolved issue. Since an increase in cAMP levels via activation of histamine H-2 receptors does not induce IL-1beta synthesis but enhances self-induction of IL-1 (Vannier, E., and Dinarello, C. A. (1993) J. Clin. Invest. 92, 281-287), we investigated whether histamine regulates IL-6 synthesis. Human peripheral blood mononuclear cells were stimulated with IL-1alpha in the absence or presence of histamine (1 nm to 100 muM). IL-6 was measured using a specific radioimmunoassay. Histamine alone did not induce protein synthesis or mRNA accumulation for IL-6. Histamine (1-100 muM) enhanced IL-1alpha1-induced synthesis of IL-6 (p < 0.001). Cimetidine and ranitidine, H-2 receptor antagonists structurally unrelated to each other, completely reversed the histamine-mediated increase in IL-1alpha-induced IL-6 synthesis. However, diphenhydramine, an H-1 receptor antagonist, did not reverse this effect. Prostaglandin E2, an activator of adenylate cyclase, also enhanced IL-1alpha-induced synthesis of IL-6. Histamine increased and sustained steady-state levels of IL-6 mRNA in IL-1alpha-stimulated cells, but reduced IL-6 mRNA half-life (3.5 h versus 1.8 h). Our results indicate that cAMP-increasing agents, such as histamine or prostaglandin E2, fail to induce IL-6 synthesis but rather enhance IL-1-induced IL-6 synthesis.	TUFTS UNIV NEW ENGLAND MED CTR,750 WASHINGTON ST,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111	Tufts Medical Center; Tufts University					NIAID NIH HHS [AI-15614] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015614, R01AI015614] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; BAUER J, 1988, BLOOD, V72, P1134; CAMERON W, 1986, J IMMUNOL, V136, P2116; CARLSSON R, 1985, CELL IMMUNOL, V96, P104, DOI 10.1016/0008-8749(85)90343-0; CASALE TB, 1985, INT J IMMUNOPHARMACO, V7, P639, DOI 10.1016/0192-0561(85)90147-X; FONG YM, 1989, J IMMUNOL, V142, P2321; GESPACH C, 1986, AGENTS ACTIONS, V18, P124, DOI 10.1007/BF01988001; GILLITZER R, 1991, J INVEST DERMATOL, V96, P598; HACK CE, 1989, BLOOD, V74, P1704; HELLSTRAND K, 1990, SCAND J IMMUNOL, V31, P631, DOI 10.1111/j.1365-3083.1990.tb02814.x; HELLSTRAND K, 1990, J IMMUNOL, V145, P4365; HIRANO T, 1988, EUR J IMMUNOL, V18, P1797, DOI 10.1002/eji.1830181122; KASAHARA T, 1990, BIOCHEM BIOPH RES CO, V167, P1242, DOI 10.1016/0006-291X(90)90657-9; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; LOPPNOW H, 1989, CELL IMMUNOL, V122, P493, DOI 10.1016/0008-8749(89)90095-6; LOPPNOW H, 1990, J CLIN INVEST, V85, P731, DOI 10.1172/JCI114498; LU C, 1993, J CELL BIOL, V120, P1281, DOI 10.1083/jcb.120.5.1281; MANIATIS T, 1987, MOL CLONING LABORATO, P187; MAY LT, 1988, J BIOL CHEM, V263, P7760; MERTENS WC, 1992, LANCET, V340, P397, DOI 10.1016/0140-6736(92)91474-M; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; PRESN EP, 1990, J INVEST DERMATOL, V95, pS121; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; ROSZKOWSKI W, 1977, SCIENCE, V195, P683, DOI 10.1126/science.190677; SCHINDLER R, 1990, BLOOD, V75, P40; SHALABY MR, 1989, CELL IMMUNOL, V121, P372, DOI 10.1016/0008-8749(89)90036-1; SMITH TJ, 1991, J NATL CANCER I, V83, P139, DOI 10.1093/jnci/83.2.139-a; VANDERMEER JWM, 1988, J LEUKOCYTE BIOL, V43, P216, DOI 10.1002/jlb.43.3.216; VANKOOTEN C, 1992, NEUROIMMUNOLOGY FEVE, P49; VANNIER E, 1991, J EXP MED, V174, P281, DOI 10.1084/jem.174.1.281; VANNIER E, 1993, J CLIN INVEST, V92, P281, DOI 10.1172/JCI116562; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802; ZHANG YH, 1988, J BIOL CHEM, V263, P6177; ZITNIK RJ, 1993, AM J PHYSIOL, V264, pL253, DOI 10.1152/ajplung.1993.264.3.L253	36	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9952	9956						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511596				2022-12-25	WOS:A1994NE05300085
J	SEUFFERLEIN, T; ROZENGURT, E				SEUFFERLEIN, T; ROZENGURT, E			LYSOPHOSPHATIDIC ACID STIMULATES TYROSINE PHOSPHORYLATION OF FOCAL ADHESION KINASE, PAXILLIN, AND P130 - SIGNALING PATHWAYS AND CROSS-TALK WITH PLATELET-DERIVED GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; BOMBESIN STIMULATION; ANGIOTENSIN-II; INTACT-CELLS; PROTEIN; VASOPRESSIN; ENDOTHELIN; IDENTIFICATION; ACTIVATION; RECEPTOR	Addition of 1-oleoyl-lysophosphatidic acid (LPA) induces tyrosine phosphorylation of multiple substrates in Swiss 3T3 cells including bands of M(r) 110,000-130,000 and M(r) 70,000-80,000. An increase in tyrosine phosphorylation of the M(r) 110,000-130,000 cluster of bands was detected as soon as 30 s after LPA stimulation reaching a maximum within 1 min. LPA stimulated tyrosine phosphorylation of all bands in a concentration-dependent fashion; a half-maximal effect occurred at 30 nM. Immunoprecipitation of lysates of LPA-treated cells with monoclonal antibodies that specifically recognize focal adhesion kinase (p125(FAK)), paxillin, and p130 revealed that these proteins are prominent substrates for LPA-stimulated tyrosine phosphorylation. Down-regulation of protein kinase C (PKC) by prolonged pretreatment with phorbol 12,13-dibutyrate, selective inhibition of PKC by GF109203X, or depletion of the intracellular Ca2+ pool by thapsigargin had no effect on LPA-stimulated tyrosine phosphorylation. Thus, protein tyrosine phosphorylation by LPA is largely independent of either the PKC or Ca2+ pathways. In contrast, pretreatment of the cells with cytochalasin D, which selectively disrupts the network of the actin filaments, completely inhibited LPA-induced tyrosine phosphorylation. Furthermore, tyrosine phosphorylation of p125(FAR) induced by LPA was completely prevented when cells were stimulated in the presence of platelet-derived growth factor at a concentration (30 ng/ml) that causes disruption of actin stress fibers. This suggests that the integrity of the actin cytoskeleton is essential for LPA-induced tyrosine phosphorylation and reveals a novel cross-talk between LPA and platelet-derived growth factor on p125(FAK) tyrosine phosphorylation.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Seufferlein, Thomas TW/P-7147-2018					BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BENTON AM, 1982, BLOOD, V60, P642; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; FORCE T, 1991, J BIOL CHEM, V266, P6650; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; JALINK K, 1990, J BIOL CHEM, V265, P12232; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MARGLIN A, 1970, ANNU REV BIOCHEM, V39, P841, DOI 10.1146/annurev.bi.39.070170.004205; MIURA Y, 1993, J BIOL CHEM, V268, P510; MOOLENAAR WH, 1985, NATURE, V32, P171; MOOLENAAR WH, 1992, REV PHYSL BIOCH PHAR, V119, P48; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; RANKIN S, 1994, J BIOL CHEM, V269, P704; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1990, PHILOS T ROY SOC B, V327, P209, DOI 10.1098/rstb.1990.0055; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SECKL M, 1993, J BIOL CHEM, V268, P9548; SINNETTSMITH J, 1988, J CELL BIOCHEM, V38, P237, DOI 10.1002/jcb.240380403; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; STADDON JM, 1991, J CELL BIOL, V115, P949, DOI 10.1083/jcb.115.4.949; TBULLEC D, 1991, J BIOL CHEM, V266, P15771; THASTRUP O, 1987, BIOCHIM BIOPHYS ACTA, V927, P65, DOI 10.1016/0167-4889(87)90066-8; TOKUMURA A, 1980, ARCH INT PHARMACOD T, V245, P74; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	55	260	263	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9345	9351						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510708				2022-12-25	WOS:A1994NB41100105
J	YIN, TG; YANG, YC				YIN, TG; YANG, YC			MITOGEN-ACTIVATED PROTEIN-KINASES AND RIBOSOMAL-S6 PROTEIN-KINASES ARE INVOLVED IN SIGNALING PATHWAYS SHARED BY INTERLEUKIN-11, INTERLEUKIN-6, LEUKEMIA INHIBITORY FACTOR, AND ONCOSTATIN-M IN MOUSE 3T3-L1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA STAR OOCYTES; MAP KINASE; TYROSINE PHOSPHORYLATION; S6 KINASE; MOLECULAR-CLONING; THREONINE; PP90RSK; RECEPTOR; INVITRO; RSK	The mechanisms of signaling pathways shared by interleukin (IL)-11, IL-6, leukemia inhibitory factor (LIF), and oncostatin M (ONC) remain elusive. We report here that treatment of 3T3-Ll cells with IL-11, IL-6, LIF, and ONC induces overlapping but distinct patterns of tyrosine phosphorylation and activates indistinguishable primary response genes. We further demonstrate for the first time that IL-11, IL-6, LIF, and ONC can trigger the activation of mitogen-activated protein kinases and the 85-92-kDa ribosomal S6 protein kinases (pp90rsk). In addition, our data also show that preincubation of cells with a tyrosine kinase inhibitor herbimycin A, but not with a serine/threonine kinase inhibitor H7, blocks activation of mitogen-activated protein kinases and pp90rsk. Interestingly, H7, but not herbimycin A, inhibits pp90rsk activity in the in vitro kinase assays. These results suggest that pp90rsk is one of the potential candidates for the H7-sensitive protein kinase(s), which is critical for the activation of primary response genes by these cytokines.	INDIANA UNIV,SCH MED,DEPT MED HEMATOL ONCOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis					NHLBI NIH HHS [R01HL48819] Funding Source: Medline; NIDDK NIH HHS [R01DK43105] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043105] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ANDERSON KC, 1992, BLOOD, V80, P2797; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; ERIKSON E, 1987, MOL CELL BIOL, V7, P3147, DOI 10.1128/MCB.7.9.3147; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HANGOC G, 1993, BLOOD, V81, P965; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KAWASHIMA I, 1991, FEBS LETT, V283, P199, DOI 10.1016/0014-5793(91)80587-S; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LIU JW, 1992, J BIOL CHEM, V267, P16763; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; MEHLER MF, 1993, NATURE, V362, P62, DOI 10.1038/362062a0; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NEBEN TY, 1993, BLOOD, V81, P901; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; QUESNIAUX VFJ, 1992, BLOOD, V80, P1218; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; Sambrook J, 1989, MOL CLONING LABORATO; SANGHERA JS, 1991, J BIOL CHEM, V266, P6700; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SEGER R, 1992, J BIOL CHEM, V267, P14373; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VIK TA, 1990, P NATL ACAD SCI USA, V87, P2685, DOI 10.1073/pnas.87.7.2685; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YIN TG, 1992, J EXP MED, V175, P211, DOI 10.1084/jem.175.1.211; YIN TG, 1992, J BIOL CHEM, V267, P8347; YIN TG, 1993, J IMMUNOL, V151, P2555; YIN TG, 1993, CELL GROWTH DIFFER, V4, P603	56	100	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3731	3738						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508917				2022-12-25	WOS:A1994MV63100088
J	JAMAL, HH; CANOGAUCI, DF; BUICK, RN; FILMUS, J				JAMAL, HH; CANOGAUCI, DF; BUICK, RN; FILMUS, J			ACTIVATED RAS AND SRC INDUCE CD44 OVEREXPRESSION IN RAT INTESTINAL EPITHELIAL-CELLS	ONCOGENE			English	Article							HUMAN-COLON CARCINOMA; PP60C-SRC PROTEIN-KINASE; RECEPTOR CD44; EXPRESSION; HYALURONATE; EXONS; MUTATIONS; ONCOGENE; MOLECULE; CONFERS	CD44 is an adhesion molecule that is involved in the progression of several tumor types, including those originating in the intestine. There are several alternatively spliced forms of CD44. Here we show that intestinal epithelial cells express the standard form of CD44 (CD44s). The same form of CD44 is found in IEC-18, a cell line derived from normal rat intestinal crypts. Upon transfection of IEC-18 cells with vas or src, two oncogenes that are frequently activated in intestinal tumors, a significant induction of CD44s is observed. A causal role for vas in this induction is shown by using IEC clones transfected with an inducible vas expression vector. The oncogene-transformed IEC clones display a high degree of hyaluronic acid-dependent cell-cell adhesion that is not observed in the parental IEC-18 cells suggesting that ras- and src-induced overexpression of CD44 c;ln alter the adhesion properties of intestinal cells.	SUNNYBROOK HLTH SCI CTR,DIV CANC RES,TORONTO M4N 3M5,ON,CANADA; ONTARIO CANC INST,TORONTO M4X 1K9,ON,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON,CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto								BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIRCH M, 1991, CANCER RES, V51, P6660; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; BUICK RN, 1987, EXP CELL RES, V170, P300, DOI 10.1016/0014-4827(87)90308-9; BURMER GC, 1989, P NATL ACAD SCI USA, V86, P2403, DOI 10.1073/pnas.86.7.2403; CANOGAUCI DF, 1993, EXP CELL RES, V208, P344, DOI 10.1006/excr.1993.1255; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; COOPER DL, 1992, BIOCHEM BIOPH RES CO, V182, P569, DOI 10.1016/0006-291X(92)91770-Q; FILMUS J, 1992, ONCOGENE, V7, P521; FILMUS J, 1993, ONCOGENE, V8, P1017; FILMUS J, 1988, MOL CELL BIOL, V8, P4243, DOI 10.1128/MCB.8.10.4243; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; HOFMANN M, 1993, CANCER RES, V53, P1516; KENNEL SJ, 1993, J CELL SCI, V104, P373; KUPPNER MC, 1992, INT J CANCER, V50, P572, DOI 10.1002/ijc.2910500414; LIOTTA LA, 1976, CANCER RES, V36, P889; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; OUDEJANS J J, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P293; PATTERSON DJ, 1987, MOL IMMUNOL, V24, P1281; QUARONI A, 1981, J NATL CANCER I, V67, P1353; QURESHI SA, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCREATON GR, 1993, J BIOL CHEM, V268, P12235; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; STJOHN T, 1990, CELL, V60, P45, DOI 10.1016/0092-8674(90)90714-P; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; TOLG C, 1993, NUCLEIC ACIDS RES, V21, P1225, DOI 10.1093/nar/21.5.1225; UNDERHILL C, 1992, J CELL SCI, V103, P293; WARREN SL, 1988, MOL CELL BIOL, V8, P632, DOI 10.1128/MCB.8.2.632; ZHAO JM, 1993, EXP CELL RES, V204, P82, DOI 10.1006/excr.1993.1011	41	57	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					417	423						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	7507229				2022-12-25	WOS:A1994MW24800008
J	WHITEHALL, SK; BARDELEBEN, C; KASSAVETIS, GA				WHITEHALL, SK; BARDELEBEN, C; KASSAVETIS, GA			HYDROLYTIC CLEAVAGE OF NASCENT RNA IN RNA POLYMERASE-III TERNARY TRANSCRIPTION COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-SII; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; INVITRO; GENE; DNA; INITIATION; PROTEIN; INHIBITION; TEMPLATES	Highly purified yeast RNA polymerase III ternary complexes were found to possess a hydrolytic chain retracting activity that cleaves nascent RNA from its 3'-OH end. Most of the shortened transcripts were capable of resuming RNA chain elongation, indicating that they remain stably associated with the enzyme-DNA complex. Analysis of the products of cleavage indicated that retraction primarily occurred in dinucleotide increments, but that mononucleotides were also excised at lower frequency. The ribonuclease activity was totally dependent on the presence of a divalent cation and was stimulated by the addition of non-cognate ribonucleotides. The inclusion of ATP in the reaction enhanced both the rate and extent of transcript cleavage. Evidence suggesting that the hydrolytic activity is intrinsic to RNA polymerase III and factor-independent is also presented. Transcript cleavage by RNA polymerase III ternary complexes appears to be more closely related to the intrinsic nucleolytic activity of vaccinia virus RNA polymerase ternary complexes than to TFIIS-dependent cleavage that has been described for RNA polymerase II ternary complexes.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018386, R37GM018386] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18386] Funding Source: Medline; PHS HHS [07317] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; BAKER RE, 1984, EMBO J, V3, P2793, DOI 10.1002/j.1460-2075.1984.tb02211.x; BARDELEBEN C, 1994, IN PRESS J MOL BIOL; BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BURNOL AF, 1993, NATURE, V362, P475, DOI 10.1038/362475a0; DEUSCHLE U, 1990, SCIENCE, V248, P40; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; ESCHENLAUER JB, 1993, MOL CELL BIOL, V13, P3015, DOI 10.1128/MCB.13.5.3015; FELTS SJ, 1990, MOL CELL BIOL, V10, P2390, DOI 10.1128/MCB.10.5.2390; GUO HL, 1993, J BIOL CHEM, V268, P18762; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HORIKOSHI M, 1984, J BIOL CHEM, V259, P608; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; LEVEILLARD T, 1993, J BIOL CHEM, V268, P3594; MATSUZAKI H, 1994, IN PRESS J MOL BIOL; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; MORSE RH, 1992, MOL CELL BIOL, V12, P4015, DOI 10.1128/MCB.12.9.4015; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; RAPPAPORT J, 1988, MOL CELL BIOL, V8, P3136, DOI 10.1128/MCB.8.8.3136; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; Sentenac A., 1992, TRANSCRIPTIONAL REGU, V1, P27; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SPENCER CA, 1990, ONCOGENE, V5, P777; STEINBERG TH, 1992, J BIOL CHEM, V267, P20204; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; YAGER TD, 1987, ESCHERICHIA COLI SAL, V2, P1241	44	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2299	2306						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507490				2022-12-25	WOS:A1994MR98800111
J	SMITH, JW; PIOTROWICZ, RS; MATHIS, D				SMITH, JW; PIOTROWICZ, RS; MATHIS, D			A MECHANISM FOR DIVALENT-CATION REGULATION OF BETA-3-INTEGRINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; PLATELET GLYCOPROTEIN-IIB; CALCIUM-BINDING SITES; VITRONECTIN RECEPTOR; BONE-RESORPTION; CELL ATTACHMENT; LIGAND-BINDING; VONWILLEBRAND-FACTOR; ADHESION RECEPTORS; BETA-3 INTEGRIN	Integrins alpha(IIb)beta3 and alpha(V)beta3 mediate numerous cell-matrix and cell-cell contacts. Both integrins contain multiple divalent cation-binding motifs that regulate ligand binding. Here, we elucidate a major difference in the regulation of alpha(IIb)beta3 and alpha(V)beta3 by divalent ions. Fibrinogen binding to alpha(IIb)beta3 in Ca2+-containing buffer is rapid, with an apparent association rate constant (k1app) of 8.2 x 10(5) M-1 s-1, but Ca2+ does not support association between fibrinogen and alpha(V)beta3. Interestingly, Mn2+ supports fibrinogen binding to both integrins, albeit with a relatively slow association rate (k1app = 10(4) M-1 s-1). This influence of divalent ions on ligand association rates accounts for the opposite divalent ion requirements for platelet aggregation and tumor cell adhesion to fibrinogen. Furthermore, the regulation of fibrinogen binding to alpha(V)beta3 is complex when both Ca2+ and Mn2+ are present. Physiological concentrations of Ca2+ completely ablated adhesion. Kinetic analysis demonstrated that Ca2+ is a mixed-type inhibitor of Mn2+-supported fibrinogen binding to alpha(V)beta3. Consequently, the data presented here suggest a mechanism in which two separate cation-binding sites regulate ligand binding to beta3-integrins.			SMITH, JW (corresponding author), SCRIPPS RES INST, COMM VASC BIOL CVB1, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NCI NIH HHS [CA 56468] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1990, CANCER RES, V50, P6756; ALTIERI DC, 1991, J IMMUNOL, V147, P1891; ANDRAS V, 1986, BIOCHEMISTRY-US, V25, P519; Brandt M, 1986, MANGANESE METABOLISM, P3; CHAMBERS TJ, 1986, BONE MINER, V1, P127; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; COTZIAS GC, 1958, PHYSIOL REV, V38, P505; Creighton T. E., 1984, PROTEINS STRUCTURES, V2nd; DANG CV, 1985, J BIOL CHEM, V260, P9713; DANG CV, 1989, J BIOL CHEM, V264, P15104; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; DOOLITTLE RF, 1967, ARCH BIOCHEM BIOPHYS, V118, P456, DOI 10.1016/0003-9861(67)90374-8; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; EDWARDS JG, 1988, J CELL SCI, V89, P507; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GARTNER TK, 1990, THROMB RES, V60, P291, DOI 10.1016/0049-3848(90)90108-O; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; GULINO D, 1992, J BIOL CHEM, V267, P1001; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; HOGSAN K, 1992, J BIOL CHEM, V267, P23076; HORTON MA, 1989, J BONE MINER RES, V4, P803; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JACOBS S, 1976, BIOCHIM BIOPHYS ACTA, V433, P482, DOI 10.1016/0005-2736(76)90275-3; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; LAKKAKORPI PT, 1991, J CELL BIOL, V115, P1179, DOI 10.1083/jcb.115.4.1179; LAM SCT, 1987, J BIOL CHEM, V262, P947; LAMPUGNANI MG, 1991, LAB INVEST, V65, P96; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MULLER B, 1993, J BIOL CHEM, V268, P6800; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PHILLIPS DR, 1988, BLOOD, V71, P831; POLLET RJ, 1977, J BIOL CHEM, V252, P5828; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; RIVAS GA, 1991, BIOCHEM J, V276, P35, DOI 10.1042/bj2760035; SCHRAMM VL, 1986, MANGANESE METABOLISM, P109; SCHROEDER HA, 1966, J CHRON DIS, V19, P545, DOI 10.1016/0021-9681(66)90094-4; SEGAL IH, 1975, ENZYME KINETICS; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SMITH JW, 1991, J BIOL CHEM, V266, P11429; SMTH JW, 1988, J BIOL CHEM, V263, P18726; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; STRYNADKA NCJ, 1990, PROTEINS, V7, P234, DOI 10.1002/prot.340070305; TAYLOR DB, 1992, J BIOL CHEM, V267, P11729; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325	62	172	176	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					960	967						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507113				2022-12-25	WOS:A1994MR22000031
J	KUROKI, Y; MCCORMACK, FX; OGASAWARA, Y; MASON, RJ; VOELKER, DR				KUROKI, Y; MCCORMACK, FX; OGASAWARA, Y; MASON, RJ; VOELKER, DR			EPITOPE MAPPING FOR MONOCLONAL-ANTIBODIES IDENTIFIES FUNCTIONAL DOMAINS OF PULMONARY SURFACTANT PROTEIN-A THAT INTERACT WITH LIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; II CELLS; SP-A; PHOSPHOLIPID SECRETION; HIGH-AFFINITY; BINDING PROTEIN; RAT; LUNG; APOPROTEIN; PHOSPHATIDYLCHOLINE	Pulmonary surfactant protein A (SP-A) contains 4 domains: a disulfide forming amino terminus, a collagen-like region, a neck region, and a carbohydrate recognition region. The protein binds the lipids dipalmitoylphosphatidylcholine and galactosylceramide and induces aggregation of phospholipid vesicles. SP-A also inhibits lipid secretion and enhances the uptake of phospholipid by alveolar type II cells. Previously described monoclonal antibody 1D6 blocks the inhibitory effect of SP-A on lipid secretion by type II cells, but antibody 6E3 has no effect. In the present study we mapped the epitopes for monoclonal antibodies 1D6 and 6E8 by enzyme-linked immunoassay of recombinant proteins expressed using the baculovirus system, and investigated the domain that is responsible for the SP-A interactions with lipid. Monoclonal antibody 1D6 bound to mutant SP-As in which the neck portion of the molecule was deleted or substituted with that of mannose-binding protein A, but 6E3 failed to bind to these mutants. In contrast, 1D6 did not bind to a chimera in which the carbohydrate recognition domain (CRD) was substituted with that of surfactant protein D (SP-D). In addition, 1D6 failed to recognize antigen in cells infected with the recombinant virus directing the synthesis of a Cys(204)-Cys(218) (small disulfide loop) deletion within the CRD. Antibody 1D6 completely blocked the binding of SP-A to dipalmitoylphosphatidylcholine and galactosylceramide and liposome aggregation. By comparison, 6E3 failed to completely attenuate the interactions of SP-A with lipids. However, both 6E3 and 1D6 blocked the up take of lipid by type II cells that is caused by SP-A From these data, we conclude that: I) the epitope for antibody 6E3 is located at the neck domain of SP-A and that for antibody 1D6 is at the small loop region in the CRD; 2) the CRD is essential for the SP-A functions of lipid binding, liposome aggregation, the inhibitory effect on lipid secretion, and the augmentation of lipid uptake by type II cells, and these activities are largely attributable to amino acid residues within the steric inhibitory footprint of 1D6 bound to the small disulfide loop region; and 3) the neck domain of SP-A may also be involved in the process of SP-A-mediated uptake of phospholipids by alveolar type II cells.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,LORD & TAYLOR LAB LUNG BIOCHEM,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV PULM SCI & CRIT CARE MED,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			McCormack, Francis X./ABE-8398-2020	McCormack, Francis X./0000-0001-7168-9464	NHLBI NIH HHS [HL45286, HL29891, HL02423] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045286, R01HL029891, R37HL029891] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; BOGGARAM V, 1988, J BIOL CHEM, V263, P293; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CHILDS RA, 1992, J BIOL CHEM, V267, P9972; DETHLOFF LA, 1986, BIOCHEM J, V233, P111, DOI 10.1042/bj2330111; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; FLOROS J, 1985, J BIOL CHEM, V260, P495; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMSKOV U, 1993, J BIOL CHEM, V268, P10120; JACOBS HC, 1985, BIOCHIM BIOPHYS ACTA, V837, P77, DOI 10.1016/0005-2760(85)90087-6; KING RJ, 1983, J BIOL CHEM, V258, P672; KORFHAGEN TR, 1992, AM J PHYSIOL, V263, pL546, DOI 10.1152/ajplung.1992.263.5.L546; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1988, J BIOL CHEM, V263, P17596; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; KUROKI Y, 1992, ARCH BIOCHEM BIOPHYS, V299, P261, DOI 10.1016/0003-9861(92)90273-Y; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALHOTRA R, 1992, EUR J IMMUNOL, V22, P1437, DOI 10.1002/eji.1830220616; MCCORMACK FX, 1994, J BIOL CHEM, V269, P5833; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; MURATA Y, 1993, BIOCHEM J, V291, P71, DOI 10.1042/bj2910071; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; QUESENBERRY M S, 1991, Glycobiology, V1, P615, DOI 10.1093/glycob/1.6.615; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; ROSS GF, 1991, BIOCHEMISTRY-US, V30, P858, DOI 10.1021/bi00217a040; ROSS GF, 1986, J BIOL CHEM, V261, P14283; RUST K, 1991, ARCH BIOCHEM BIOPHYS, V290, P116, DOI 10.1016/0003-9861(91)90597-C; RYAN RM, 1989, J HISTOCHEM CYTOCHEM, V37, P429, DOI 10.1177/37.4.2926121; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO K, 1987, BIOCHEM BIOPH RES CO, V144, P367, DOI 10.1016/S0006-291X(87)80519-3; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; SPISSINGER T, 1991, EUR J BIOCHEM, V199, P65, DOI 10.1111/j.1432-1033.1991.tb16092.x; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; TSUZUKI A, 1993, AM J PHYSIOL, V265, pL193, DOI 10.1152/ajplung.1993.265.2.L193; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WRIGHT JR, 1986, J APPL PHYSIOL, V60, P817, DOI 10.1152/jappl.1986.60.3.817; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; WRIGHT JR, 1989, P NATL ACAD SCI USA, V86, P5410, DOI 10.1073/pnas.86.14.5410	44	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29793	29800						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7525589				2022-12-25	WOS:A1994PU28400075
J	SCHWARZ, M; GROSS, A; STEINKAMP, T; FLUGGE, UI; WAGNER, R				SCHWARZ, M; GROSS, A; STEINKAMP, T; FLUGGE, UI; WAGNER, R			ION-CHANNEL PROPERTIES OF THE RECONSTITUTED CHLOROPLAST TRIOSE PHOSPHATE/PHOSPHATE TRANSLOCATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ASPARTATE GLUTAMATE; PHOSPHATE TRANSLOCATOR; UNIDIRECTIONAL TRANSPORT; SPINACH-CHLOROPLASTS; SH-REAGENTS; MEMBRANE; ENVELOPE; CARRIER; PROTEIN; PURIFICATION	The chloroplast triose phosphate/phosphate translocator (cTPT) was isolated from envelope membranes or from transformed yeast cells and reconstituted into artificial membranes. Ionic currents mediated by the cTPT across these membranes were investigated by flux measurements and by the patch clamp technique. The results of the flux measurements indicate that inorganic phosphate (P-i) at saturating concentrations on both sides of the membrane and chloride (Cl-) at all applied concentrations are transported by the cTPT at rates about 20-fold higher than those measured in intact chloroplasts. After reconstitution of the protein into giant liposomes, single channel currents mediated by the cTPT were resolved with the patch-clamp technique. The protein was shown to be a voltage-dependent anion channel with complex gating revealing sublevels with conductances of 12, 54, 96, and 138 pS for Cl- and 6 pS and 18 pS for P-i, respectively. Recordings from patches compromising multiple channels show a synchronously appearing nonlinear current voltage (I/V) relationship in symmetrical buffers, and a different gating at positive and negative membrane potentials. This suggests that the cTPT is incorporated into the membrane in a unidirectional orientation. 3-Phosphoglycerate, a high affinity substrate of the transporter protein, induced a reversible flickering of open channel, and the channel open probability was decreased 60%. It is concluded that, besides its normal counter-exchange mode, the cTPT can also work as a voltage-dependent anion selective channel.	UNIV OSNABRUCK,FACHBEREICH BIOL CHEM,D-49069 OSNABRUCK,GERMANY; UNIV WURZBURG,JULIUS VON SACHS INST BIOWISSENSCH,D-97082 WURZBURG,GERMANY	University Osnabruck; University of Wurzburg								CORONADO R, 1980, J GEN PHYSIOL, V76, P425, DOI 10.1085/jgp.76.4.425; CRIADO M, 1987, FEBS LETT, V224, P172, DOI 10.1016/0014-5793(87)80442-8; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P281, DOI 10.1016/0005-2736(90)90177-P; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P268, DOI 10.1016/0005-2736(90)90176-O; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FISCHER K, 1994, PLANT MOL BIOL, V25, P167, DOI 10.1007/BF00023235; FLIEGE R, 1978, BIOCHIM BIOPHYS ACTA, V502, P232, DOI 10.1016/0005-2728(78)90045-2; FLUGGE UI, 1991, ANNU REV PLANT PHYS, V42, P129, DOI 10.1146/annurev.pp.42.060191.001021; FLUGGE UI, 1991, NATURE, V353, P364, DOI 10.1038/353364a0; FLUGGE UI, 1992, BIOCHIM BIOPHYS ACTA, V1110, P112, DOI 10.1016/0005-2736(92)90301-2; FLUGGE UI, 1985, BIOCHIM BIOPHYS ACTA, V815, P299, DOI 10.1016/0005-2736(85)90300-1; FRANCIOLINI F, 1992, BIOCHIM BIOPHYS ACTA, V1113, P1, DOI 10.1016/0304-4157(92)90031-5; Gennis R. B., 1989, BIOMEMBRANES MOL STR, DOI [10.1007/978-1-4757-2065-5, DOI 10.1007/978-1-4757-2065-5]; GROSS A, 1990, PLANTA, V180, P262, DOI 10.1007/BF00194006; GROSS A, 1990, THESIS FACHBEREICH B; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Heldt H. W., 1980, METHOD ENZYMOL, V69, P604; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hille B, 1984, IONIC CHANNELS EXCIT; INDIVERI C, 1991, BIOCHIM BIOPHYS ACTA, V1069, P110, DOI 10.1016/0005-2736(91)90110-T; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KASAHARA M, 1977, J BIOL CHEM, V252, P7384; KELLER BU, 1988, PFLUG ARCH EUR J PHY, V411, P94, DOI 10.1007/BF00581652; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; LAUGER P, 1987, PHYSIOL REV, V67, P1296, DOI 10.1152/physrev.1987.67.4.1296; LAUGER P, 1984, ION CHANNELS MOL PHY, P309; LODDENKOTTER B, 1993, P NATL ACAD SCI USA, V90, P2155, DOI 10.1073/pnas.90.6.2155; MALONEY PC, 1990, RES MICROBIOL, V141, P374, DOI 10.1016/0923-2508(90)90015-I; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MARTEN I, 1993, EUR BIOPHYS J BIOPHY, V21, P403, DOI 10.1007/BF00185867; MENZLAFF E, 1993, BIOCHIM BIOPHYS ACTA, V1147, P13, DOI 10.1016/0005-2736(93)90310-V; MORAN O, 1992, J BIOENERG BIOMEMBR, V24, P91, DOI 10.1007/BF00769535; PATLAK BJ, 1988, J GEN PHYSIOL, V98, P413; PESKOFF A, 1988, BIOPHYS J, V53, P863, DOI 10.1016/S0006-3495(88)83167-9; RIORDAN JR, 1992, BIOCHIM BIOPHYS ACTA, V1101, P221, DOI 10.1016/0005-2728(92)90230-Y; SAIER MH, 1990, RES MICROBIOL, V141, P281, DOI 10.1016/0923-2508(90)90001-7; SCHULTZ JE, 1992, SCIENCE, V255, P600, DOI 10.1126/science.1371017; SPEER M, 1991, PLANT PHYSIOL, V97, P990, DOI 10.1104/pp.97.3.990; TABACHARINI JA, 1992, BIOPHYS J, V62, P1; TYERMAN SD, 1992, BIOPHYS J, V61, P736, DOI 10.1016/S0006-3495(92)81878-7; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WAGNER R, 1989, EUR J BIOCHEM, V182, P165, DOI 10.1111/j.1432-1033.1989.tb14813.x; WALLMEIER H, 1992, TRANSPORT AND RECEPTOR PROTEINS OF PLANT MEMBRANES, P77; WILLEY DL, 1991, PLANTA, V183, P451, DOI 10.1007/BF00197745	44	51	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29481	29489						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7525584				2022-12-25	WOS:A1994PU28400029
J	BAJT, ML; LOFTUS, JC				BAJT, ML; LOFTUS, JC			MUTATION OF A LIGAND-BINDING DOMAIN OF BETA(3) INTEGRIN - INTEGRAL ROLE OF OXYGENATED RESIDUES IN ALPHA(IIB)BETA(3) (GPIIB-IIIA) RECEPTOR FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; LEUKOCYTE ADHESION GLYCOPROTEIN; AMINO-ACID-SEQUENCE; ALPHA-SUBUNIT; RECOGNITION SITE; PLATELET ACTIVATION; CLONING; MODULATION; AFFINITY; COMPLEX	A single amino acid substitution in beta(3) (Asp(119) --> Tyr) abrogates the Ligand binding function of beta(3) integrins and alters the divalent cation conformation of the platelet integrin alpha(IIb)beta(3) (GPIIb-IIIa). This aspartic acid residue resides within a conserved cluster of oxygenated residues that may provide ligands for the coordination of divalent cations. To assign function to the other oxygenated residues in this group (Ser(121), Ser(123), Asp(126), Asp(127), and Ser(130)), each of these amino acids in beta(3) was individually substituted by alanine. None of these amino acid substitutions altered heterodimer formation or surface expression. However, the substitutions had differential effects on receptor function. Substitution at positions Asp(119) or Ser(121) produced a complete loss of receptor function. Cells expressing these mutants failed to adhere to fibrinogen, failed to bind activation-independent ligand-mimetic peptides, and did not bind the ligand-mimetic mAb PAC1 following activation of the receptor. Similarly, cells expressing beta(3) with a substitution at Ser(123) also failed to adhere to fibrinogen and did not bind RGD peptide or mAb PAC1. These cells did retain the capacity to bind an alpha(IIb)beta(3)-specific, high affinity peptidomimetic, but occupancy did not induce the conformational change from resting to activated state observed following occupancy of the wild type receptor. Substitution at positions Asp(126), Asp(127), or Ser(130) had no effect on ligand binding function. These data indicate that Asp(119), along with Ser(121) and Ser(123), plays an integral role in the ligand binding function of alpha(IIb)beta(3).	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728, R01HL042977, R29HL042977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR027214, R01AR027214] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 42977, HL 48728] Funding Source: Medline; NIAMS NIH HHS [AR 27214] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGRAVES WS, 1987, J CELL BIOL, V105, P1183; BAJT ML, 1992, J BIOL CHEM, V267, P22211; BAJT ML, 1992, J BIOL CHEM, V267, P3789; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GINSBERG MH, 1992, COLD SPRING HARB SYM, V57, P221, DOI 10.1101/SQB.1992.057.01.027; GINSBERG MH, 1993, THROMB HAEMOSTASIS, V70, P87; HAAS TA, 1993, THROMB HAEMOSTASIS, V69, P786; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KOUNS WC, 1992, J BIOL CHEM, V267, P18844; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MACKRELL AJ, 1988, P NATL ACAD SCI USA, V85, P2633, DOI 10.1073/pnas.85.8.2633; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOYLE M, 1991, J BIOL CHEM, V266, P19650; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NURDEN AT, 1974, BRIT J HAEMATOL, V28, P253, DOI 10.1111/j.1365-2141.1974.tb06660.x; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1989, BLOOD, V74, P14; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SUSUKI S, 1990, EMBO J, V9, P765; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TOMIYAMA Y, 1992, BLOOD, V79, P2303; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223; YONG K, 1990, BLOOD REV, V4, P211, DOI 10.1016/0268-960X(90)90001-9; 1968, J BIOL CHEM, V243, P3557	50	147	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20913	20919						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	7520434				2022-12-25	WOS:A1994PC40300018
J	MATSUOKA, A; STUEHR, DJ; OLSON, JS; CLARK, P; IKEDASAITO, M				MATSUOKA, A; STUEHR, DJ; OLSON, JS; CLARK, P; IKEDASAITO, M			L-ARGININE AND CALMODULIN REGULATION OF THE HEME IRON REACTIVITY IN NEURONAL NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PUTIDA CYTOCHROME-P-450; HYDROXY-L-ARGININE; LIGAND-BINDING; SPECTRAL CHARACTERIZATION; CRYSTAL-STRUCTURE; CARBON-MONOXIDE; BRAIN; SUBSTRATE; ENZYME; CHLOROPEROXIDASE	Neuronal nitric oxide synthase (NOS) is a calmodulin-dependent, flavin-containing hemoprotein that forms NO from L-arginine, NADPH, and molecular oxygen. Calmodulin binding to NOS triggers reduction of its heme groups (Abu-Soud, H., and Stuehr, D. J. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 10769-10762), leading to NADPH oxidation and NO synthesis. We have examined how L-arginine and calmodulin control the ligand binding and electron acceptor properties of the NOS heme iron. In the absence of bound calmodulin, ferric NOS exhibited a K-d of 0.6 mu M for L-arginine, as determined by the substrate-dependent shift in heme spin equilibrium toward a high spin state. L-Arginine binding reduced the affinity of the ferric NOS heme for cyanide by 8-fold. Carbon monoxide binding to substrate-free ferrous NOS occurred at a rate of 2 x 10(5) M(-1) s(-1); this rate was decreased 12-fold when L-arginine was bound. In contrast, bound calmodulin did not significantly affect cyanide or carbon monoxide binding to the NOS heme, nor did it alter NOS binding affinity for L-arginine. Anaerobic titration of a calmodulin-bound, L-arginine-free NOS with NADPH led to incomplete reduction of the heme iron; full reduction was achieved only in the presence of added L-arginine. Thus, our data suggest that L-arginine controls NOS heme iron reactivity in at least two ways: 1) it slows ligand interactions by binding in the distal pocket very near the heme and 2) it also appears to increase the reduction potential of the iron. In contrast, bound calmodulin does not alter the NOS affinity for L-arginine or heme ligands and may function solely as a switch that enables electrons to pass from the flavin domain onto the heme iron.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA; CLEVELAND CLIN FDN, DEPT IMMUNOL, CLEVELAND, OH 44195 USA; RICE UNIV, DEPT BIOCHEM & CELL BIOL, HOUSTON, TX 77251 USA; RICE UNIV, KECK CTR COMPUTAT BIOL, HOUSTON, TX 77251 USA	Case Western Reserve University; Cleveland Clinic Foundation; Rice University; Rice University			Ikeda-Saito, Masao/A-5992-2008; Ikeda-Saito, Masao/K-2703-2015	Olson, John/0000-0002-0760-5403	NCI NIH HHS [CA-53914] Funding Source: Medline; NHLBI NIH HHS [HL-47020] Funding Source: Medline; NIGMS NIH HHS [GM-35649] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; DAWSON JH, 1992, NEW J CHEM, V16, P577; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; IGNARRO LJ, 1992, BIOCHEM SOC T, V20, P465, DOI 10.1042/bst0200465; IKEDASAITO M, 1985, J BIOL CHEM, V260, P1688; KLATT P, 1993, J BIOL CHEM, V268, P14781; KWON NS, 1990, J BIOL CHEM, V265, P13442; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; MIMS MP, 1983, J BIOL CHEM, V258, P4219; MONCADA S, 1992, J LAB CLIN MED, V120, P187; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; PETERSON JA, 1972, ARCH BIOCHEM BIOPHYS, V151, P427, DOI 10.1016/0003-9861(72)90518-8; POULOS TL, 1985, J BIOL CHEM, V260, P6122; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; PUFAHL RA, 1993, BIOCHEM BIOPH RES CO, V193, P963, DOI 10.1006/bbrc.1993.1719; REISBERG PI, 1980, J BIOL CHEM, V255, P4151; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SLIGAR SG, 1976, BIOCHEMISTRY-US, V15, P5399, DOI 10.1021/bi00669a029; SLIGAR SG, 1987, CYTOCHROME P 450, P429; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; TOTANI K, 1983, ARCH BIOCHEM BIOPHYS, V222, P207, DOI 10.1016/0003-9861(83)90518-0; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; WANG JL, 1993, J BIOL CHEM, V268, P22255; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001	38	112	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20335	20339						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519607				2022-12-25	WOS:A1994PB31700022
J	MURTY, VVVS; BOSL, GJ; HOULDSWORTH, J; MEYERS, M; MUKHERJEE, AB; REUTER, V; CHAGANTI, RSK				MURTY, VVVS; BOSL, GJ; HOULDSWORTH, J; MEYERS, M; MUKHERJEE, AB; REUTER, V; CHAGANTI, RSK			ALLELIC LOSS AND SOMATIC DIFFERENTIATION IN HUMAN MALE GERM-CELL TUMORS	ONCOGENE			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; CYTOGENETIC ANALYSIS; SUPPRESSOR GENES; KIT RECEPTOR; LONG ARM; METASTASIS; EXPRESSION; CANCER; CHROMOSOME-12; MUTATIONS	The complex but poorly understood human male germ cell tumors offer unusual opportunities for the genetic analysis of malignant transformation and embryonal differentiation in a pluripotential stem cell Lineage. Histologically, these tumors are divided into two major subgroups, seminomas which are characterized by inability to express embryonal differentiation, and nonseminomas which are characterized by ability to express embryonal as well as extraembryonal patterns of differentiation. To understand the role of genetic factors in the development of these tumors and the regulation of differentiation expressed by them, we carried out a detailed allelotype analysis by the loss of heterozygosity assay. This analysis revealed frequent deletions in known tumor suppressor genes (RB1, DCC, NME), a number of previously described sites of candidate tumor suppressor genes (3p, 9p, 9q, 10q, 11p, 11q and 17p), as well as several novel sites (2p, 3q, 5p, 12q, 18p and 20p). Our results also showed that well differentiated teratomas exhibit a significantly higher level of allelic loss compared to the less differentiated embryonal carcinomas. In addition, certain loci and genes exhibited frequent non-random deletion in teratomas (D3S32, D3S42, D5S12, D10S25, D11S12, RB1, TP53, NME1, NME2, D17S4, D18S6 and D20S6) and embryonal carcinomas (IFNB, D9S27). Among these loci, the NME genes were notable for a high degree of genetic loss (> 70%) in teratomas. These results suggested that nonrandom loss or inactivation of certain genes may be associated with tumor development and loss or inactivation of other genes mag be associated with somatic differentiation.	MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,CYTOGENET SERV,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT MED,DIV SOLID TUMOR,NEW YORK,NY 10021; FORDHAM UNIV,DEPT BIOL SCI,NEW YORK,NY 10458	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Fordham University	MURTY, VVVS (corresponding author), MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [P01CA005826, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [CA-05826, CA-08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACKER JM, 1993, ONCOGENE, V8, P497; COLLINS D. H., 1964, BRIT J UROL, V36, P1; CUTICCHIA AJ, 1993, GENOME PRIORITY REPO, V1; DMITROVSKY E, 1990, ONCOGENE, V5, P543; FLEISCHMAN RA, 1993, TRENDS GENET, V9, P285, DOI 10.1016/0168-9525(93)90015-A; GODDARD AD, 1993, ADV HUM GENET, V21, P321; HEIMDAL K, 1993, GENE CHROMOSOME CANC, V6, P92, DOI 10.1002/gcc.2870060205; MANOVA K, 1993, DEV BIOL, V157, P85, DOI 10.1006/dbio.1993.1114; MATHEW S, 1992, GENOMICS, V14, P775, DOI 10.1016/S0888-7543(05)80184-3; MURTY VVVS, 1992, P NATL ACAD SCI USA, V89, P11006, DOI 10.1073/pnas.89.22.11006; MURTY VVVS, 1990, CANCER GENET CYTOGEN, V50, P67, DOI 10.1016/0165-4608(90)90239-7; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; PENG HQ, 1993, CANCER RES, V53, P3574; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; PUGH RCB, 1976, PATHOLOGY TESTIS, P245; RODRIGUEZ E, 1993, GENE CHROMOSOME CANC, V8, P230, DOI 10.1002/gcc.2870080405; RODRIGUEZ E, 1992, CANCER RES, V52, P2285; RODRIGUEZ E, 1994, IN PRESS CANCER RES; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STROHMEYER T, 1991, P NATL ACAD SCI USA, V88, P6662, DOI 10.1073/pnas.88.15.6662; STROHMEYER T, 1991, CANCER RES, V51, P1811; ULBRIGHT TM, 1987, SEMIN DIAGN PATHOL, V4, P304; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WANG N, 1981, CANCER RES, V41, P2135	27	77	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2245	2251						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7518576				2022-12-25	WOS:A1994NX62900016
J	DZAMBA, BJ; BULTMANN, H; AKIYAMA, SK; PETERS, DM				DZAMBA, BJ; BULTMANN, H; AKIYAMA, SK; PETERS, DM			SUBSTRATE-SPECIFIC BINDING OF THE AMINO-TERMINUS OF FIBRONECTIN TO AN INTEGRIN COMPLEX IN FOCAL ADHESIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST-CULTURES; MATRIX ASSEMBLY DOMAIN; CELL-ADHESION; PLASMA FIBRONECTIN; CONFORMATIONAL-CHANGES; MONOCLONAL-ANTIBODIES; BIOLOGICAL-ACTIVITY; ENDOTHELIAL-CELLS; RECEPTOR; ALPHA-5-BETA-1	The assembly of fibronectin fibrils involves the amino terminal and cell adhesion domains of fibronectin as well as alpha(5) beta(1) integrins. Efficient binding of biotinylated or radioiodinated 70-kDa amino-terminal fragments occurred only if fibroblasts were plated on fibronectin or on 180- or 85-kDa cell adhesion fragments of fibronectin. On an 11.5-kDa fragment of fibronectin that included the Arg-Gly-Asp (RGD) sequence, but not the synergy site, binding was reduced 50-fold. Conformation of the 180-kDa fragment was important for direct binding interactions with the amino terminus of fibronectin. No binding was seen if cells were plated on type I collagen, vitronectin, RGD peptides or antibodies to alpha(5) beta(1) inte grins. High affinity interactions between invasin and alpha(5) beta(1) integrin promoted low levels of binding. Monoclonal antibodies that blocked the function of either the RGD or the synergy site inhibited binding of I-125-labeled 70-kDa fragments to cells by similar to 60%. By fluorescence and interference reflection microscopy, biotinylated 70 kDa fragments were shown to co-localize with alpha(5) beta(1) integrins in focal adhesions. We propose that cell-mediated binding of the amino terminus of fibronectin involves interactions with both fibronectin and its alpha(5) beta(1) integrin receptor in an activated complex.	UNIV WISCONSIN, DEPT PATHOL & LAB MED, MADISON, WI 53706 USA; NIDR, DEV BIOL LAB, BETHESDA, MD 20892 USA	University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)					NATIONAL EYE INSTITUTE [R01EY008540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047221] Funding Source: NIH RePORTER; NCRR NIH HHS [RR570] Funding Source: Medline; NEI NIH HHS [EY08540] Funding Source: Medline; NIGMS NIH HHS [GM47221] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P3256; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; BLYSTONE SD, 1992, J BIOL CHEM, V267, P3968; CASTELLANI P, 1986, J CELL BIOL, V103, P1671, DOI 10.1083/jcb.103.5.1671; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; DEJANA E, 1988, J CELL BIOL, V107, P1215, DOI 10.1083/jcb.107.3.1215; DZAMBA BJ, 1991, J CELL SCI, V100, P605; DZAMBA BJ, 1993, J CELL BIOL, V121, P1165, DOI 10.1083/jcb.121.5.1165; EHRISMANN R, 1982, J BIOL CHEM, V257, P7381; EHRISMANN R, 1981, J BIOL CHEM, V256, P4056; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FOGERTY FJ, 1990, CELL DIFFER DEV, V32, P439, DOI 10.1016/0922-3371(90)90061-Z; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GIROUX TA, 1990, J COLLOID INTERF SCI, V139, P351, DOI 10.1016/0021-9797(90)90109-2; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; GRINNELL F, 1982, J BIOL CHEM, V257, P4888; GRINNELL F, 1981, J BIOMED MATER RES, V15, P363, DOI 10.1002/jbm.820150308; HOMANDBERG GA, 1986, BIOCHEMISTRY-US, V25, P6917, DOI 10.1021/bi00370a027; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JOHANSSON S, 1985, J BIOL CHEM, V260, P1557; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LIMPER AH, 1991, J BIOL CHEM, V266, P9697; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MCKEOWNLONGO PJ, 1987, J CELL BIOL, V104, P601, DOI 10.1083/jcb.104.3.601; MOON KY, 1994, J BIOL CHEM, V269, P7651; MORLA A, 1992, CELL BIOL, V188, P421; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; MOSHER DF, 1983, J BIOL CHEM, V258, P6595; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; NARASIMHAN C, 1989, BIOCHEMISTRY-US, V28, P5041, DOI 10.1021/bi00438a021; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; PETERS DMP, 1987, J CELL BIOL, V104, P121, DOI 10.1083/jcb.104.1.121; PETERS DMP, 1990, J CELL BIOL, V111, P249, DOI 10.1083/jcb.111.1.249; PITT WG, 1987, PROTEINS INTERFACES, P324; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; SCHWARZ MA, 1984, EXP CELL RES, V153, P550, DOI 10.1016/0014-4827(84)90624-4; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; STANISLAWSKI L, 1993, J BIOMED MATER RES, V27, P619, DOI 10.1002/jbm.820270509; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; UNDERWOOD PA, 1993, J CELL SCI, V104, P793; WOLFF C, 1989, ARCH BIOCHEM BIOPHYS, V268, P536, DOI 10.1016/0003-9861(89)90320-2; WU CY, 1993, J BIOL CHEM, V268, P21883; YANG JT, 1993, DEVELOPMENT, V119, P1093; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	52	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19646	19652						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	7518462				2022-12-25	WOS:A1994NY33200069
J	GUNDERSON, KL; KOPITO, RR				GUNDERSON, KL; KOPITO, RR			EFFECTS OF PYROPHOSPHATE AND NUCLEOTIDE ANALOGS SUGGEST A ROLE FOR ATP HYDROLYSIS IN CYSTIC-FIBROSIS TRANSMEMBRANE REGULATOR CHANNEL GATING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNELS; CONDUCTANCE REGULATOR; MULTIDRUG RESISTANCE; CL CHANNEL; CELLS; GENE; BINDING; EXPRESSION	Single channel analysis of artificial lipid planar bilayers reconstituted with wild-type human cystic fibrosis transmembrane regulator (CFTR) revealed a 10.3 pS Cl- selective channel that was activated upon phosphorylation with protein kinase A. Gating of this channel was described by a simple kinetic model consisting of a single open burst state and two closed states. The open probability of CFTR channels in bilayers increased as a function of increasing Mg-ATP concentration and exhibited negative cooperativity, suggesting the interaction of two or more ATP binding sites in channel gating. Mg-ATP increased channel open probability by decreasing the duration of the long-lived closed state but had no effect on either the mean open time or the fast closed state. ADP inhibited channel opening by precisely antagonizing the effect of ATP, suggesting that ADP inhibits the CFTR channel by competing with ATP for binding. Poorly hydrolyzable ATP analogs such as AMP-PNP and ATP gamma S, polyphosphates such as pyrophosphate (PPi) and tripolyphosphate (PPPi), and orthovanadate failed to support channel activity alone. When applied in the presence of ATP, these compounds all caused the CFTR channel to ''lock'' into a prolonged open burst state. These data support a model in which hydrolysis of ATP leads to closure of channels that have been opened by ATP.	STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA	Stanford University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008294] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43994] Funding Source: Medline; NIGMS NIH HHS [GM08294] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ASHCROFT FM, 1989, J PHYSIOL-LONDON, V416, P349, DOI 10.1113/jphysiol.1989.sp017765; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BELL CL, 1993, AM J PHYSIOL, V264, pC925, DOI 10.1152/ajpcell.1993.264.4.C925; CARSON MR, 1993, AM J PHYSIOL, V265, pL27, DOI 10.1152/ajplung.1993.265.1.L27; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; HOROWITZ B, 1993, AM J PHYSIOL, V264, pH2214, DOI 10.1152/ajpheart.1993.264.6.H2214; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LEE BS, 1991, J BIOL CHEM, V266, P11448; Miller C., 1986, ION CHANNEL RECONSTI; NAGEL G, 1992, NATURE, V360, P81, DOI 10.1038/360081a0; PENEFSKY HS, 1991, ADV ENZYMOL RELAT AR, V64, P173; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RIORDAN JR, 1989, SCIENCE, V245, P1066; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; WARD CL, 1991, P NATL ACAD SCI USA, V88, P5277, DOI 10.1073/pnas.88.12.5277; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; WONDERLIN WF, 1990, BIOPHYS J, V58, P289, DOI 10.1016/S0006-3495(90)82376-6	27	149	153	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19349	19353						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	7518455				2022-12-25	WOS:A1994NY33200025
J	SU, J; BATZER, A; SAP, J				SU, J; BATZER, A; SAP, J			RECEPTOR TYROSINE PHOSPHATASE R-PTP-ALPHA IS TYROSINE-PHOSPHORYLATED AND ASSOCIATED WITH THE ADAPTER PROTEIN GRB2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SH3 DOMAINS; PHOSPHOTYROSINE PHOSPHATASE; CLONING; KINASES; IDENTIFICATION; ACTIVATION; EXPRESSION; TRANSFORMATION; PP60(C-SRC); FAMILY	Receptor tyrosine phosphatases (R-PTPases) have generated interest because of their suspected involvement in cellular signal transduction. The adaptor pro tein Grb2 has been implicated in coupling receptor tyrosine kinases to Ras. We report that a ubiquitous R-PTPase, R-PTP-alpha, is tyrosine-phosphorylated and associated in vivo with the Grb2 protein. This association can be reproduced in stably and transiently transfected cells, as well as in vitro using recombinant Grb2 protein. Association requires the presence of an intact SH2 domain in Grb2, as well as tyrosine phosphorylation of R-PTP-alpha. This observation links a receptor tyrosine phosphatase with a key component of a central cellular signaling pathway and provides a basis for addressing R-PTP-alpha function.	NYU, CTR MED, DEPT PHARMACOL, NEW YORK, NY 10016 USA	New York University								AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DAUM G, 1994, J BIOL CHEM, V269, P10524; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DENHERTOG J, 1994, IN PRESS EMBO J; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; JIRIK FR, 1990, FEBS LETT, V273, P239, DOI 10.1016/0014-5793(90)81094-5; KAMPS MP, 1988, ONCOGENE, V2, P305; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MIKI H, 1994, J BIOL CHEM, V269, P5489; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SAP J, 1994, MOL CELL BIOL, V14, P1; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	74	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18731	18734						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7518443				2022-12-25	WOS:A1994NX32700008
J	HORUK, R; WANG, ZX; PEIPER, SC; HESSELGESSER, J				HORUK, R; WANG, ZX; PEIPER, SC; HESSELGESSER, J			IDENTIFICATION AND CHARACTERIZATION OF A PROMISCUOUS CHEMOKINE-BINDING PROTEIN IN A HUMAN ERYTHROLEUKEMIC CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; PLASMODIUM-VIVAX; CYTOKINE FAMILY; RECEPTOR; PURIFICATION; PARASITE; FORMS	The erythrocyte chemokine receptor is a cell surface protein that binds a wide array of chemokines including interleukin-8 (IL-8), melanoma growth stimulating activity (MGSA), monocyte chemotactic protein-1 (MCP-1), and RANTES (Regulated on Activation, Normal T Expressed and Secreted). This protein has also been identified as the Duffy blood group antigen, a cell surface receptor for the malarial parasite Plasmodium vivax. In the present study, we have identified a chemokine receptor-like binding protein in a human erythroleukemic cell line (HEL), which, based on its molecular properties, may be related to the erythrocyte chemokine receptor. Saturation binding studies with I-125-IL-8 revealed a single class of IL-8 binding sites in HEL cells with a K-D of 7.4 +/- 1.9 nM and a receptor density of 12,818 +/- 965 binding sites/cell. In competition studies unlabeled IL-8, MGSA, MCP-1, and RANTES were fully able to inhibit the binding of I-125-IL-8 to HEL cells. Chemical cross-linking with radiolabeled IL-8 resulted in a crosslinked species of 60 kDa in membranes from HEL cells. The labeling was specific since it was inhibited by preincubation with 1 mu m unlabeled IL-8 or MGSA. A monoclonal antibody (Fy6) to the human erythrocyte Duffy blood group antigen/chemokine receptor blocked the binding of IL-8 and other chemokines to the HEL cell chemokine receptor like binding protein. Cell membranes from HEL cells and from erythrocyte ghosts were subjected to SDS-PAGE and analyzed by Western blotting with anti-Fy6. The antibody bound to a molecule with a molecular mass of 50 kDa in HEL cell membranes and 40 kDa in erythrocyte ghosts. Northern blot analysis of mRNA revealed that the HEL chemokine-binding protein hybridized to a cDNA probe to the Duffy antigen/chemokine receptor.	UNIV LOUISVILLE,SCH MED,JAMES GRAHAM BROWN CANC CTR,HENRY VOGT CANC RES INST,LOUISVILLE,KY 40292	University of Louisville	HORUK, R (corresponding author), GENENTECH INC,DEPT PROT CHEM,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							CHAUDHURI A, 1993, P NATL ACAD SCI USA, V90, P10793, DOI 10.1073/pnas.90.22.10793; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HORUK R, 1993, BIOCHEMISTRY-US, V32, P5733, DOI 10.1021/bi00073a002; HORUK R, 1991, BIOCHEM J, V273, P79, DOI 10.1042/bj2730079; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; HORUK R, 1993, J BIOL CHEM, V268, P541; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEOTE K, 1993, J BIOL CHEM, V268, P12247; NICHOLS ME, 1987, J EXP MED, V166, P776, DOI 10.1084/jem.166.3.776; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; STECK TL, 1970, SCIENCE, V168, P255, DOI 10.1126/science.168.3928.255	18	54	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17730	17733						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	7517400				2022-12-25	WOS:A1994NU12800060
J	MIGLARESE, MR; MANNIONHENDERSON, J; WU, H; PARSONS, JT; BENDER, TP				MIGLARESE, MR; MANNIONHENDERSON, J; WU, H; PARSONS, JT; BENDER, TP			THE PROTEIN-TYROSINE KINASE SUBSTRATE CORTACTIN IS DIFFERENTIALLY EXPRESSED IN MURINE-B LYMPHOID TUMORS	ONCOGENE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; ACTIN-BINDING PROTEIN; CENTROCYTIC LYMPHOMA; SIGNAL TRANSDUCTION; RIBONUCLEIC-ACID; MULTIPLE-MYELOMA; CHROMOSOME 11Q13; HUMAN CARCINOMAS; PHOSPHOLIPASE-C; MESSENGER-RNAS	Src family protein tyrosine kinases (PTKs) actively participate in signal transduction during lymphocyte activation. However, little is known about the roles of PTKs acid their substrates in lymphocyte differentiation. To identify PTK substrates that may be differentially expressed during B lymphopoiesis, we screened a panel of murine B lymphoid tumor cell lines representing various developmental stages using monoclonal antibodies (MAbs) specific for pp60(src) substrates. A MAb specific for cortactin, a filamentous-actin binding pp60(src) substrate, immunoprecipitated proteins from murine plasmacytoma cell lines but not from pre-B cell lymphoma or B cell lymphoma cell lines. We have cloned a murine cortactin cDNA which encodes a member of a family of proteins distinguished by amino-terminal repeat domains and carboxy-terminal Src Homology 3 domains. Two members of this family (cortactin and HS1) were differentially expressed in murine B lymphoid tumor cell lines; both were detected in plasmacytoma cell lines, however HS1 was additionally detected in pre-B lymphoma and B lymphoma cell lines. Cortactin RNA was detected in most murine tissues, but was not detected in B lymphocytes or plasma cells. We hypothesize that cortactin expression is associated with transformed plasma cells and not with the terminal differentiation of normal B lymphocytes to plasma cells.	UNIV VIRGINIA, HLTH SCI CTR, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, CTR CANC, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NCI NIH HHS [CA09109, CA29243, P01CA40042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042, R01CA029243, R37CA029243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BERGSAGEL PL, 1992, ONCOGENE, V7, P2059; BERGSAGEL PL, 1992, J IMMUNOL, V148, P590; BROOKES S, 1993, GENE CHROMOSOME CANC, V6, P222, DOI 10.1002/gcc.2870060406; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER MD, 1984, FUNDAMENTAL IMMUNOLO, P43; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FIEDLER W, 1992, BRIT J HAEMATOL, V81, P58, DOI 10.1111/j.1365-2141.1992.tb08171.x; GAZDAR AF, 1986, BLOOD, V67, P1542; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KEARNEY JF, 1975, J IMMUNOL, V115, P671; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KINNON C, 1993, IMMUNOL TODAY, V14, P554, DOI 10.1016/0167-5699(93)90187-P; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LADANYI M, 1992, AM J PATHOL, V141, P949; LAMMIE GA, 1992, ONCOGENE, V7, P2381; MAA MC, 1992, ONCOGENE, V7, P2429; MAGE M, 1981, EUR J IMMUNOL, V11, P228, DOI 10.1002/eji.1830110312; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCMAHON AP, 1987, DIFFERENTIATION, V34, P68, DOI 10.1111/j.1432-0436.1987.tb00052.x; MEDEIROS LJ, 1990, BLOOD, V76, P2086; MELAMED I, 1991, J IMMUNOL, V147, P1139; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; Nusse R, 1991, Curr Top Microbiol Immunol, V171, P43; PAWSON T, 1988, ONCOGENE, V3, P491; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; PROCTOR AJ, 1991, ONCOGENE, V6, P789; RAFFELD M, 1992, LEUKEMIA LYMPHOMA, V8, P161, DOI 10.3109/10428199209054902; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TAGA T, 1992, CRIT REV IMMUNOL, V11, P265; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WILLIAMS ME, 1993, LEUKEMIA, V7, P1437; WILLIAMS ME, 1993, LEUKEMIA, V7, P241; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WONG S, 1992, ONCOGENE, V7, P2407; WORD CJ, 1981, MOL IMMUNOL, V18, P311, DOI 10.1016/0161-5890(81)90055-9; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; ZHAN X, 1993, J BIOL CHEM, V268, P24427	64	40	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					1989	1997						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	7516062				2022-12-25	WOS:A1994NR68500023
J	MURTHY, KS; MAKHLOUF, GM				MURTHY, KS; MAKHLOUF, GM			VASOACTIVE-INTESTINAL-PEPTIDE PITUITARY ADENYLATE CYCLASE-ACTIVATING PEPTIDE-DEPENDENT ACTIVATION OF MEMBRANE-BOUND NO SYNTHASE IN SMOOTH-MUSCLE MEDIATED BY PERTUSSIS-TOXIN-SENSITIVE G(I1-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NITRIC-OXIDE SYNTHASE; MOLECULAR-CLONING; ENTERIC NEURONS; CELLS; LOCALIZATION; VIP; PHOSPHORYLATION; CITRULLINE; RECEPTORS; RELEASE	Plasma membranes isolated from dispersed gastric muscle cells exhibited calmodulin dependent NOS activity that was stimulated by Ca2+ in the range 0.1-1 mM (maximum 10 mu M). Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) (in the presence of GTP), and GTP gamma S (guanosine 5'-O-(gamma-thio)triphosphate) stimulated NOS activity in a concentration-dependent fashion above that maximally stimulated by Ca2+. The increase in NOS activity induced by VIP, PACAP, and GTP gamma S was abolished by GDP beta S (guanosine 5'-O-(beta-thio) diphosphate), which had no effect on NOS activity stimulated by Ca2+. The NOS inhibitor N-G-nitro-L arginine and the calmodulin antagonist calmidazolium abolished NOS activity stimulated by all agents including Ca2+. NOS activity stimulated by GTP gamma S, VIP, and PACAP was inhibited by G(i alpha 1-2) antibody but not by G(q alpha), G(s alpha), and G(i alpha 3) antibodies. NOS activity stimulated by VIP and PACAP was inhibited by 80-83% in membranes derived from pertussis toxin-treated cells, We conclude that a Ca2+/calmodulin-dependent NOS present in plasma membranes of gastric muscle cells is activated by two homologous peptide transmitters, VIP and PACAP, via a common receptor coupled to pertussis toxin (PTx)-sensitive G(i1-2). The study provides the first evidence of receptor-mediated G protein activation of NOS in smooth muscle cells.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHYSIOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028300] Funding Source: NIH RePORTER; NIDDK NIH HHS [NIDDK DK 28300] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD S, 1988, AM J PHYSIOL, V255, pG462, DOI 10.1152/ajpgi.1988.255.4.G462; ARIMURA A, 1992, TRENDS ENDOCRIN MET, V3, P288, DOI 10.1016/1043-2760(92)90139-R; BITAR KN, 1982, SCIENCE, V216, P531, DOI 10.1126/science.6176025; BITAR KN, 1982, AM J PHYSIOL, V242, pG400, DOI 10.1152/ajpgi.1982.242.4.G400; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; BUSH PA, 1992, BIOCHEM BIOPH RES CO, V186, P308, DOI 10.1016/S0006-291X(05)80808-3; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; FURNESS JB, 1992, TRENDS NEUROSCI, V15, P66, DOI 10.1016/0166-2236(92)90029-8; GRIDER JR, 1993, NEUROSCIENCE, V54, P521, DOI 10.1016/0306-4522(93)90271-G; GRIDER JR, 1993, GASTROENTEROLOGY, V104, pA515; GRIDER JR, 1992, AM J PHYSIOL, V262, pG774, DOI 10.1152/ajpgi.1992.262.4.G774; JIN JG, 1993, AM J PHYSIOL, V264, pG470, DOI 10.1152/ajpgi.1993.264.3.G470; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LLEWELLYNSMITH IJ, 1992, BRAIN RES, V577, P337, DOI 10.1016/0006-8993(92)90294-J; MAKHLOUF GM, 1993, NEWS PHYSIOL SCI, V8, P195; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; MURTHY KS, 1991, AM J PHYSIOL, V261, pG945, DOI 10.1152/ajpgi.1991.261.6.G945; MURTHY KS, 1994, AM J PHYSIOL, V266, pG161, DOI 10.1152/ajpgi.1994.266.1.G161; MURTHY KS, 1991, AM J PHYSIOL, V261, pG937, DOI 10.1152/ajpgi.1991.261.6.G937; MURTHY KS, 1993, AM J PHYSIOL, V265, pG660, DOI 10.1152/ajpgi.1993.265.4.G660; MURTHY KS, 1994, GASTROENTEROLOGY, V106, pA545; POLLOCK JS, 1993, AM J PHYSIOL, V265, pC1379, DOI 10.1152/ajpcell.1993.265.5.C1379; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; WARD SM, 1992, AM J PHYSIOL, V263, pG277, DOI 10.1152/ajpgi.1992.263.2.G277	27	112	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					15977	15980						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	7515875				2022-12-25	WOS:A1994NQ72900006
J	SHATTIL, SJ; HAIMOVICH, B; CUNNINGHAM, M; LIPFERT, L; PARSONS, JT; GINSBERG, MH; BRUGGE, JS				SHATTIL, SJ; HAIMOVICH, B; CUNNINGHAM, M; LIPFERT, L; PARSONS, JT; GINSBERG, MH; BRUGGE, JS			TYROSINE PHOSPHORYLATION OF PP125(FAK) IN PLATELETS REQUIRES COORDINATED SIGNALING THROUGH INTEGRIN AND AGONIST RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; PROTEIN-KINASE-C; CELL-ADHESION; MONOCLONAL-ANTIBODIES; ACTIVATED PLATELETS; FIBRINOGEN BINDING; BLOOD-PLATELETS; WHOLE-BLOOD; DUAL ROLE; EPINEPHRINE	FAK is a focal adhesion kinase that is phosphorylated on tyrosine in activated platelets. Induction of FAK phosphorylation requires both fibrinogen binding to integrin alpha(IIb)beta(3) and post-occupancy events during agonist-induced platelet aggregation or platelet spreading on a fibrinogen matrix. To identify the signaling pathways necessary for tyrosine phosphorylation of FAK, we have examined the conditions that stimulate or inhibit this phosphorylation in platelets in which fibrinogen binding to alpha(IIb)beta(3) and platelet aggregation were induced directly with an anti-beta(3), Fab fragment (anti-LIBS6). Apyrase was added to prevent effects of the endogenous platelet agonist, ADP. Under these conditions, neither fibrinogen binding nor primary platelet aggregation was sufficient to induce FAK phosphorylation, suggesting that a second ''costimulatory'' event was required. Indeed, when epinephrine was added with fibrinogen and anti-LIBS6, large platelet aggregates formed and FAK phosphorylation occurred. This response was prevented by blockade of cyclooxygenase with indomethacin or thromboxane A(2) receptors with SQ 30,741. A stable thromboxane A(2) analogue (U46619) could substitute for epinephrine as the costimulus. Epinephrine costimulation of FAK phosphorylation was also prevented by chelation of intracellular Ca2+ with BAPTA or selective inhibition of protein kinase C (PKC) with bisindolylmaleimide, indicating that Ca2+ and PKC are necessary for FAK phosphorylation under these conditions. Epinephrine also promoted FAK phosphorylation and adhesive spreading of apyrase-treated platelets on a fibrinogen matrix. Cytochalasin D, an inhibitor of actin polymerization, blocked FAK phosphorylation under all these conditions. Thus, tyrosine phosphorylation of FAK in platelets requires coordinated signaling through occupied integrin and agonist receptors. These separate pathways may converge to increase free Ca2+ and activate PKC and thus promote the cytoskeletal reorganization required for activation of FAK.	UNIV PENN, SCH MED, DEPT MED, DIV HEMATOL ONCOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; UNIV MED & DENT NEW JERSEY, DEPT SURG, NEW BRUNSWICK, NJ 08903 USA; UNIV VIRGINIA, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, CTR CANC, SCH MED, CHARLOTTESVILLE, VA 22908 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA; ARIAD PHARMACEUT INC, CAMBRIDGE, MA 02138 USA	University of Pennsylvania; University of Pennsylvania; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Virginia; University of Virginia; Scripps Research Institute; Takeda Pharmaceutical Company Ltd; Takeda Oncology					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL049845, P01HL048728] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-49845, HL-40387, HL-48728] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1990, BLOOD, V75, P128; AGARWAL A, 1993, J BIOL CHEM, V268, P15900; ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; BALDASSARE JJ, 1993, BIOCHEM J, V291, P235, DOI 10.1042/bj2910235; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BLACHE D, 1986, THROMB HAEMOSTASIS, V55, P168; Burridge K., 1992, Current Biology, V2, P537, DOI 10.1016/0960-9822(92)90020-B; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; FOX JEB, 1987, THROMB DIATH HAEMO, P175; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GROVER GJ, 1988, J CARDIOVASC PHARM, V12, P701, DOI 10.1097/00005344-198812000-00012; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LANZA F, 1988, AM J PHYSIOL, V255, pH1276, DOI 10.1152/ajpheart.1988.255.6.H1276; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MOHAMMADI M, 1993, BIOCHEMISTRY-US, V32, P8742, DOI 10.1021/bi00085a004; ODA A, 1992, BLOOD, V79, P920; Otey C. A., 1993, Molecular Biology of the Cell, V4, p347A; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; SAITOH M, 1989, BLOOD, V74, P2001; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; SHATTIL SJ, 1993, THROMB HAEMOSTASIS, V70, P224; SHATTIL SJ, 1989, BLOOD, V73, P150; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHATTIL SJ, 1987, BLOOD, V70, P307; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SMITH JB, 1992, BIOCHEM J, V288, P925, DOI 10.1042/bj2880925; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SULDAN Z, 1991, BLOOD, V78, P2887; SWEATT JD, 1985, J BIOL CHEM, V260, P2910; TANGEN O, 1971, THROMB DIATH HAEMOST, V25, P268; TBULLEC D, 1991, J BIOL CHEM, V266, P15771; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; VUORI K, 1993, J BIOL CHEM, V268, P21459; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WOODS A, 1992, J CELL SCI, V101, P277; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHANG J, 1992, J BIOL CHEM, V267, P4686	66	229	231	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14738	14745						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514181				2022-12-25	WOS:A1994NM06500068
J	SLIWKOWSKI, MX; SCHAEFER, G; AKITA, RW; LOFGREN, JA; FITZPATRICK, VD; NUIJENS, A; FENDLY, BM; CERIONE, RA; VANDLEN, RL; CARRAWAY, KL				SLIWKOWSKI, MX; SCHAEFER, G; AKITA, RW; LOFGREN, JA; FITZPATRICK, VD; NUIJENS, A; FENDLY, BM; CERIONE, RA; VANDLEN, RL; CARRAWAY, KL			COEXPRESSION OF ERBB2 AND ERBB3 PROTEINS RECONSTITUTES A HIGH-AFFINITY RECEPTOR FOR HEREGULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; NEU GENE; KINASE; CELLS; HETERODIMERIZATION; EXPRESSION; PRODUCT; BINDING	The heregulin/neu differentiation factor gene products were purified and cloned based on their ability to stimulate the phosphorylation of a 185-kDa protein in human breast carcinoma cell lines known to express erbB2. However, not all cells that express erbB2 respond to heregulin, indicating that other components besides erbB2 may be required for heregulin binding. Cells that are transfected with the closely related receptor, erbB3, display a single class of lower affinity heregulin binding sites than has been previously observed on breast carcinoma cell lines. Little or no stimulation of tyrosine phosphorylation in response to heregulin occurs in cells that are transfected with erbB3 alone. Transfection of cells with erbB3 and erbB2 reconstitutes a higher affinity binding receptor, which is also capable of generating a tyrosine phosphorylation signal in response to heregulin. A monoclonal antibody to erbB2 will inhibit heregulin activation of tyrosine phosphorylation and binding in cells transfected with both receptors but not with erbB3 alone. In cells expressing erbB2 and erbB3, both proteins become tyrosine-phosphorylated upon interaction with heregulin. Direct interaction between heregulin and the two proteins was demonstrated by chemical cross-linking experiments using I-125-heregulin followed by immunoprecipitation with antibodies specific for erbB2 or erbB3.	CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV SIGNAL TRANSDUCT,BOSTON,MA 02115	Cornell University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	SLIWKOWSKI, MX (corresponding author), GENENTECH INC,390 POINT SAN BRUNO BLVD,MAIL STOP 63,S SAN FRANCISCO,CA 94080, USA.			Schaefer, Gabriele/0000-0001-9727-3555	NIGMS NIH HHS [GM40654] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FENDLY BM, 1990, CANCER RES, V50, P1550; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MORAN MF, 1988, ONCOGENE, V3, P665; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1992, ONCOGENE, V7, P1279; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	28	600	709	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14661	14665						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514177				2022-12-25	WOS:A1994NM06500057
J	ROGLER, CE; YANG, DY; ROSSETTI, L; DONOHOE, J; ALT, E; CHANG, CJ; ROSENFELD, R; NEELY, K; HINTZ, R				ROGLER, CE; YANG, DY; ROSSETTI, L; DONOHOE, J; ALT, E; CHANG, CJ; ROSENFELD, R; NEELY, K; HINTZ, R			ALTERED BODY-COMPOSITION AND INCREASED FREQUENCY OF DIVERSE MALIGNANCIES IN INSULIN-LIKE GROWTH FACTOR-II TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING-PROTEINS; LONGITUDINAL DATA-ANALYSIS; CHRONIC-RENAL-FAILURE; RAT-LIVER; IGF-II; CELL-PROLIFERATION; WILMS-TUMOR; HUMAN-SERUM; EXPRESSION; GENE	The physiological role of insulin-like growth factor (IGF) II (IGF-II) in adult humans is poorly understood. Rather high levels of IGF-II persist in adult human serum, whereas, in rodents, IGF-II levels are very low. To investigate the physiological and carcinogenic effects of persistently elevated IGF-II in adults, we have produced two lines of transgenic mice in which high levels of IGF-II (20- or 30 fold increase above normal) are persistently maintained in the blood. The transgene is driven by the major urinary protein promoter, and it is highly expressed in the liver and perputial glands in both lines. The adult transgenic mice are smaller than controls, and their body composition is altered. Their lean body mass is reduced by 5-8%, whereas fat mass is reduced between 44 and 77%. The mice expressing the highest level of IGF-II (30x) develop hypoglycemia and hypoinsulinemia and IGF-I levels are normal. Mice in the lower expression line (20-fold elevated IGF-II) develop hypoglycemia progressively over their lifetime. Mice from both lines also develop a diverse spectrum of tumors at a higher frequency than controls after 18 months of age, and the most frequent types of tumors are hepatocellular carcinomas and lymphomas. Squamous cell carcinoma, sar coma, and thyroid carcinomas also occurred in our test group. The long latent period before tumors arise and the wide spectrum of tumor types suggest that IGF-II may function primarily as a tumor progression factor in mice via autocrine and endocrine mechanisms of action.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,CTR DIABET RES & TRAINING,DEPT MED,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PATHOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10461; STANFORD UNIV,STANFORD MED CTR,DEPT PEDIAT,PALO ALTO,CA 94305	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Stanford University	ROGLER, CE (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,1300 MORRIS PK AVE,BRONX,NY 10461, USA.				NATIONAL CANCER INSTITUTE [R01CA037232, R01CA056076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK017702] Funding Source: NIH RePORTER; NCI NIH HHS [CA37232, CA56076] Funding Source: Medline; NIDDK NIH HHS [DK-17702] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AXELROD L, 1988, NEW ENGL J MED, V319, P1477, DOI 10.1056/NEJM198812013192209; BELL GI, 1984, NATURE, V310, P775, DOI 10.1038/310775a0; CAMPBELL PG, 1991, J CELL PHYSIOL, V149, P293, DOI 10.1002/jcp.1041490216; CARO JF, 1988, J CLIN INVEST, V81, P976, DOI 10.1172/JCI113451; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; CULLEN KJ, 1992, MOL ENDOCRINOL, V6, P91, DOI 10.1210/me.6.1.91; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAINIAK N, 1985, J CLIN INVEST, V76, P1237, DOI 10.1172/JCI112079; DAUGHADAY WH, 1988, NEW ENGL J MED, V319, P1434, DOI 10.1056/NEJM198812013192202; DAUGHADAY WH, 1990, ENDOCRINOLOGY, V127, P1; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DOUGLAS RG, 1991, J CLIN INVEST, V88, P614, DOI 10.1172/JCI115346; Drop S.L.S., 1991, MODERN CONCEPTS INSU, P311; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DULAK NC, 1973, J CELL PHYSIOL, V81, P153, DOI 10.1002/jcp.1040810204; FOREJT J, 1992, CELL, V70, P443, DOI 10.1016/0092-8674(92)90168-C; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; FROESCH ER, 1966, BIOCHIM BIOPHYS ACTA, V121, P360, DOI 10.1016/0304-4165(66)90125-5; FU XX, 1988, J VIROL, V62, P3422, DOI 10.1128/JVI.62.9.3422-3430.1988; HAIG D, 1991, CELL, V64, P1045; HARTMANN H, 1992, DIABETOLOGIA, V35, P216, DOI 10.1007/BF00400920; HELD WA, 1987, MOL CELL BIOL, V7, P3705, DOI 10.1128/MCB.7.10.3705; HELD WA, 1989, EMBO J, V8, P183, DOI 10.1002/j.1460-2075.1989.tb03363.x; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HUDGINS WR, 1992, J BIOL CHEM, V267, P8153; KRATZ G, 1992, EXP CELL RES, V202, P381, DOI 10.1016/0014-4827(92)90089-Q; LAMSON G, 1989, J CLIN ENDOCR METAB, V69, P852, DOI 10.1210/jcem-69-4-852; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LIU F, 1990, J CLIN ENDOCR METAB, V70, P620, DOI 10.1210/jcem-70-3-620; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; MCCUSKER RH, 1991, ENDOCRINOLOGY, V129, P939, DOI 10.1210/endo-129-2-939; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MOTTOLA C, 1984, J BIOL CHEM, V259, P2705; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; NISHIMOTO I, 1987, BIOCHEM BIOPH RES CO, V142, P275, DOI 10.1016/0006-291X(87)90481-5; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; POWELL DR, 1986, J CLIN ENDOCR METAB, V63, P1186; RECHLER MM, 1986, HORM RES, V24, P152, DOI 10.1159/000180554; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; STUMPEL F, 1992, DIABETOLOGIA, V35, P932, DOI 10.1007/BF00401421; STYLIANOPOULOU F, 1988, P NATL ACAD SCI USA, V85, P141, DOI 10.1073/pnas.85.1.141; STYLIANOPOULOU F, 1988, DEVELOPMENT, V103, P497; Werther GA, 1990, GROWTH FACTORS, V3, P171, DOI 10.3109/08977199009043902; WOLFE RR, 1984, RADIOISOTOPE STABLE, P1; YANG DY, 1991, CARCINOGENESIS, V12, P1893, DOI 10.1093/carcin/12.10.1893; YANG YWH, 1985, J BIOL CHEM, V260, P2570; ZAPF J, 1978, EUR J BIOCHEM, V87, P285, DOI 10.1111/j.1432-1033.1978.tb12377.x; ZAPF J, 1986, J CLIN INVEST, V77, P1768, DOI 10.1172/JCI112500; ZAPF J, 1984, CLIN ENDOCRINOLOGY M, P3; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	52	239	249	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13779	13784						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514593				2022-12-25	WOS:A1994NL60600013
J	DIVITA, G; RESTLE, T; GOODY, RS; CHERMANN, JC; BAILLON, JG				DIVITA, G; RESTLE, T; GOODY, RS; CHERMANN, JC; BAILLON, JG			INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE DIMERIZATION USING SYNTHETIC PEPTIDES DERIVED FROM THE CONNECTION DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HERPESVIRUS RIBONUCLEOTIDE REDUCTASE; MONOCLONAL-ANTIBODIES; ESCHERICHIA-COLI; RETROVIRUS; EXPRESSION; BINDING; AIDS	Based on presently available information on the structure of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase, peptides have been synthesized which correspond to the sequence of a particular region of the protein involved in formation of the active heterodimeric form of the enzyme. Several peptides that are 15-19 amino acids long and that are derived from the so called connection domain of the reverse transcriptase are able to inhibit dimerization of the enzyme and thus inhibit development of its enzymatic activities. In particular, a tryptophan-rich 19-mer corresponding to residues 389-407 was relatively efficient, showing an apparent dissociation constant in the micromolar range for one or both of the subunits. The sequence of this region is identical for both subunits, since one (molecular mass of 51 kDa) is the proteolytic product of the other (molecular mass of 66 kDa). Dissociation of the preformed heterodimer could not be induced by the peptides, but increasing concentrations reduced the rate of dimerization in a concentration dependent manner until it became immeasurable at high concentrations. The results suggest that inhibition of dimerization of reverse transcriptase is an attractive approach to chemotherapeutic intervention in HIV infection and that further development of peptide based inhibition strategies is worth pursuing.	MAX PLANCK INST MED RES,BIOPHYS ABT,D-69120 HEIDELBERG,GERMANY; MAX PLANCK INST MOLEK PHYSIOL,D-44139 DORTMUND,GERMANY; PARC SCI & TECHNOL LUMINY,INSERM,U322,F-13273 MARSEILLE 09,FRANCE	Max Planck Society; Max Planck Society; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			DIVITA, GILLES/AAV-9214-2021; Goody, Roger S/J-8845-2014	Goody, Roger S/0000-0002-0772-0444				BAILLON JG, 1991, NEW BIOL, V3, P1015; BALTIMORE D, 1988, NATURE, V335, P396; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDRA A, 1986, FEBS LETT, V200, P327, DOI 10.1016/0014-5793(86)81162-0; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119; DIVITA G, 1993, FEBS LETT, V324, P153, DOI 10.1016/0014-5793(93)81383-B; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; GROB PM, 1992, AIDS RES HUM RETROV, V8, P145, DOI 10.1089/aid.1992.8.145; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; MULLER B, 1989, J BIOL CHEM, V264, P13975; MULLER B, 1991, J BIOL CHEM, V266, P14709; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; RESTLE T, 1992, J BIOL CHEM, V267, P14654; RESTLE T, 1990, J BIOL CHEM, V265, P8986; REY F, 1987, J VIROL METHODS, V16, P239, DOI 10.1016/0166-0934(87)90008-5; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; ZHANG ZY, 1991, J BIOL CHEM, V266, P15591	21	84	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13080	13083						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7513698				2022-12-25	WOS:A1994NK18400007
J	PAVLOV, AR; KARAM, JD				PAVLOV, AR; KARAM, JD			BINDING-SPECIFICITY OF T4 DNA-POLYMERASE TO RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; BACTERIOPHAGE-T4; EXPRESSION; MUTATION; REPLICATION; ANTIMUTATOR; OPERATOR; PROTEIN	Bacteriophage T4 DNA polymerase, product of phage gene 43 (gp43), is a multifunctional DNA-binding protein and a key component of the phage DNA replicase. It is also an RNA-binding protein that selectively recognizes a site on its mRNA (the translational operator) and represses its own translation. We examined the ability of the protein to discriminate between DNA and RNA by using a gel mobility shift assay with defined RNA and DNA substrates. A higher affinity to RNA as compared with DNA (about 100-fold) was observed in assays that utilized synthetic DNA and in vitro transcribed RNA substrates bearing the T4 gene 43 translational operator sequence. The replacement of thymine with uracil in the synthetic DNA did not improve binding. The results suggest that the protein's selectivity for RNA is based in structure (intramolecular interactions) specific to the ribonucleotide sequence of the operator. Competition studies suggest that the protein determinants for RNA and DNA recognition are only partially overlapping.	TULANE UNIV,MED CTR,DEPT BIOCHEM,NEW ORLEANS,LA 70112	Tulane University			Pavlov, Andrey/HGB-3637-2022	Pavlov, Andrey/0000-0001-7891-269X	NIGMS NIH HHS [R01-GM18842] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018842] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRAKE M, 1988, P NATL ACAD SCI USA, V85, P7942, DOI 10.1073/pnas.85.21.7942; ANDRAKE MD, 1991, GENETICS, V128, P203; ANTAO VP, 1992, NUCLEIC ACIDS RES, V20, P819, DOI 10.1093/nar/20.4.819; BLUMBERG DD, 1987, METHOD ENZYMOL, V152, P20; DEWAARD A, 1965, P NATL ACAD SCI USA, V54, P1241; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; Fedorov V.V, 1972, THEORY OPTIMAL EXPT; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GILLIN FD, 1976, J BIOL CHEM, V251, P5225; GOULIAN M, 1968, J BIOL CHEM, V243, P627; HOCKENSMITH JW, 1993, J BIOL CHEM, V268, P15712; HSU T, 1990, J BIOL CHEM, V265, P5303; KARAM JD, 1974, J VIROL, V13, P428, DOI 10.1128/JVI.13.2.428-438.1974; LIN TC, 1987, P NATL ACAD SCI USA, V84, P7000, DOI 10.1073/pnas.84.20.7000; MCPHEETERS DS, 1988, J MOL BIOL, V201, P517, DOI 10.1016/0022-2836(88)90634-1; MILLER ES, 1994, IN PRESS MOL BIOL BA; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; PRESS WH, 1986, NUMERICAL RECIPES AR; RUSSEL M, 1973, J MOL BIOL, V79, P83, DOI 10.1016/0022-2836(73)90271-4; RUSSEL M, 1976, J BIOL CHEM, V251, P7263; SHAMOO Y, 1993, J MOL BIOL, V232, P89, DOI 10.1006/jmbi.1993.1372; SPICER EK, 1988, J BIOL CHEM, V263, P7478; TUERK C, 1990, J MOL BIOL, V213, P749, DOI 10.1016/S0022-2836(05)80261-X; UNNITHAN S, 1990, NUCLEIC ACIDS RES, V18, P7083, DOI 10.1093/nar/18.23.7083; VONHIPPEL PH, 1982, J MOL BIOL, V162, P795, DOI 10.1016/0022-2836(82)90548-4; VONHIPPEL PH, 1983, BACTERIOPHAGE T4, P202; WARNER HR, 1966, VIROLOGY, V28, P100, DOI 10.1016/0042-6822(66)90310-2	29	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12968	12972						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7513697				2022-12-25	WOS:A1994NH71600090
J	TARASEVICIENE, L; NAURECKIENE, S; UHLIN, BE				TARASEVICIENE, L; NAURECKIENE, S; UHLIN, BE			IMMUNOAFFINITY PURIFICATION OF THE ESCHERICHIA-COLI RNE GENE-PRODUCT - EVIDENCE THAT THE RNE GENE ENCODES THE PROCESSING ENDORIBONUCLEASE RNASE-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STABILITY AMS GENE; MESSENGER-RNA; RIBONUCLEASE-E; RIBOSOMAL-RNA; PROTEIN; ENZYME; DECAY; INVITRO; INVIVO; ACID	The rne gene product was highly purified from Escherichia coli cells overproducing the protein by a procedure including immunoaffinity chromatography. Expression in vivo and in vitro of the cloned 6-kilobase pair DNA fragment containing the entire rne gene resulted in the synthesis of a protein migrating as a 180-kDa polypeptide in the SDS-polyacrylamide gel. The position of the protein on the two-dimensional polyacrylamide gel indicated that the protein is highly acidic. The enzymatic activity test which used as the substrate RNA I and 9 S RNA provided evidence that the rne gene is the structural gene for the RNA processing enzyme RNAse E. The Western blot analysis performed using a rabbit antiserum raised against a truncated 110-kDa protein fragment of RNase E (containing two-thirds of the sequence from the N terminus) revealed that the 180-kDa polypeptide is the only protein recognized by the antibodies in a wild type whole cell extract of E. coli. The antibodies cross-reacted with similar molecular weight proteins from a number of different bacteria, suggesting that the rne gene product is evolutionarily conserved in the bacterial world.	UMEA UNIV, DEPT MICROBIOL, S-90187 UMEA, SWEDEN	Umea University			Uhlin, Bernt Eric/AAO-6292-2021	Uhlin, Bernt Eric/0000-0002-2991-8072				APIRION D, 1978, GENETICS, V90, P659; APIRION D, 1993, BIOESSAYS, V15, P113, DOI 10.1002/bies.950150207; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; CASAREGOLA S, 1992, J MOL BIOL, V228, P30, DOI 10.1016/0022-2836(92)90489-7; CHAUHAN AK, 1991, NUCLEIC ACIDS RES, V19, P125, DOI 10.1093/nar/19.1.125; CLAVERIEMARTIN F, 1991, J BIOL CHEM, V266, P2843; CLAVERIEMARTIN F, 1989, J BACTERIOL, V171, P5479, DOI 10.1128/jb.171.10.5479-5486.1989; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; DALLMANN G, 1987, MOL GEN LIFE SCI ADV, V6, P99; DEUTSCHER MP, 1993, J BIOL CHEM, V268, P13011; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; GAMPER M, 1993, GENE, V129, P119, DOI 10.1016/0378-1119(93)90706-9; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; HENRY MD, 1992, J BACTERIOL, V174, P743, DOI 10.1128/jb.174.3.743-748.1992; JOHNSTON KH, 1986, J EXP MED, V163, P697, DOI 10.1084/jem.163.3.697; KING TC, 1986, MICROBIOL REV, V50, P428, DOI 10.1128/MMBR.50.4.428-451.1986; KLUG G, 1992, GENE, V121, P95, DOI 10.1016/0378-1119(92)90166-M; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MCDOWALL KJ, 1993, J BACTERIOL, V175, P4245, DOI 10.1128/JB.175.13.4245-4249.1993; MELEFORS O, 1991, MOL MICROBIOL, V5, P857, DOI 10.1111/j.1365-2958.1991.tb00759.x; MISRA TK, 1979, J BIOL CHEM, V254, P1154; MUDD EA, 1988, EMBO J, V7, P3601, DOI 10.1002/j.1460-2075.1988.tb03238.x; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; MUDD EA, 1993, MOL MICROBIOL, V9, P557, DOI 10.1111/j.1365-2958.1993.tb01716.x; NILSSON P, 1991, MOL MICROBIOL, V5, P1791, DOI 10.1111/j.1365-2958.1991.tb01928.x; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; ROY MK, 1983, BIOCHIM BIOPHYS ACTA, V747, P200, DOI 10.1016/0167-4838(83)90098-5; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; SRIVASTAVA AK, 1990, ANNU REV MICROBIOL, V44, P105, DOI 10.1146/annurev.mi.44.100190.000541; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P851, DOI 10.1111/j.1365-2958.1991.tb00758.x; TARASEVICIENE L, 1993, J CELL BIOL C S, V17, P178; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; VANBOGELEN RA, 1990, P NATL ACAD SCI USA, V87, P5589, DOI 10.1073/pnas.87.15.5589	40	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12167	12172						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512961				2022-12-25	WOS:A1994NG37700075
J	ZHU, M; HIRAYAMA, K; KAPATOS, G				ZHU, M; HIRAYAMA, K; KAPATOS, G			REGULATION OF TETRAHYDROBIOPTERIN BIOSYNTHESIS IN CULTURED DOPAMINE NEURONS BY DEPOLARIZATION AND CAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-HYDROXYLASE; RAT; BIOPTERIN; COFACTOR; CYCLOHYDROLASE; CELLS; INHIBITION; INCREASES; CLONING; ENZYME	Primary cultures containing embryonic rat brain mesencephalic or hypothalamic dopamine neurons were used to examine the effects of membrane depolarization and elevations of cAMP levels on tetrahydrobiopterin cofactor content. Initial studies showed that 24-h incubations with 8-bromo-cAMP or isobutyl methylxanthine increased cofactor levels in either culture system, whereas the stimulatory effects of forskolin or depolarization of membrane potential were only observed in cultures of hypothalamus. 8-Bromo-cAMP was found to increase cofactor content in a concentration-dependent manner, with increases observed up to 5 mM, The time course of the effect of 8-bromo-cAMP was biphasic. Over the short term, an increase of 50% in cofactor content at 2 and 5 h was detected. Over the long term, by 24-48 h, cofactor levels increased by between 100% and 300%. Studies of cofactor turnover indicated that the long-term increase was due to stimulation of tetrahydrobiopterin biosynthesis with no alteration in degradation rate. Inhibitors of gene transcription and translation prevented the long- but not short-term increase in cofactor content. Levels of GTP cyclohydrolase I mRNA were increased 7-10-fold following 5 h of incubation with 8-bromo-cAMP. Tetrahydrobiopterin biosynthesis within cultured dopamine neurons of the hypothalamus and mesencephalon thus appears to be regulated by a cAMP-dependent mechanism involving enhanced gene expression of enzyme(s) involved in cofactor biosynthesis.	WAYNE STATE UNIV,SCH MED,DEPT PSYCHIAT,CELLULAR & CLIN NEUROBIOL PROGRAM,DETROIT,MI 48201	Wayne State University					NINDS NIH HHS [NS26081] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026081] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABOUDONIA MM, 1986, J NEUROCHEM, V46, P1190, DOI 10.1111/j.1471-4159.1986.tb00637.x; ABOUDONIA MM, 1981, P NATL ACAD SCI-BIOL, V78, P2703, DOI 10.1073/pnas.78.5.2703; BARUCHIN A, 1990, J NEUROCHEM, V54, P1769, DOI 10.1111/j.1471-4159.1990.tb01232.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHLSTROM A, 1964, ACTA PHYSIOL SCAND, V62, P1; DUCH DS, 1986, ENDOCRINOLOGY, V118, P1897, DOI 10.1210/endo-118-5-1897; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; GRANNEMAN JG, 1990, J NEUROCHEM, V54, P1995, DOI 10.1111/j.1471-4159.1990.tb04903.x; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; HATAKEYAMA K, 1991, J BIOL CHEM, V266, P765; HERVE D, 1993, J NEUROSCI, V13, P2237, DOI 10.1523/jneurosci.13-05-02237.1993; HIRAYAMA K, 1993, J NEUROCHEM, V61, P1006, DOI 10.1111/j.1471-4159.1993.tb03614.x; HOSSAIN MA, 1992, J NEUROCHEM, V59, P2237; INOUE Y, 1991, J BIOL CHEM, V266, P20791; KAPATOS G, 1981, SCIENCE, V213, P1129, DOI 10.1126/science.6168019; KAPATOS G, 1992, J NEUROCHEM, V59, P2048; KAPATOS G, 1990, J NEUROCHEM, V55, P1995; KAPATOS G, 1983, CHEM BIOL PTERIDINES, P171; KAPATOS G, 1989, PTERIDINES BIOGENIC, P243; KATOH S, 1982, BIOCHEM BIOPH RES CO, V105, P75, DOI 10.1016/S0006-291X(82)80012-0; KAUFMAN S, 1974, CIBA F S, V22, P85; KWON NS, 1989, J BIOL CHEM, V264, P20496; LENTZ SI, 1993, ADV EXP MED BIOL, V338, P171; SUZUKI H, 1988, BIOCHEM BIOPH RES CO, V153, P382, DOI 10.1016/S0006-291X(88)81235-X; TAYEH MA, 1989, J BIOL CHEM, V264, P19654	25	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11825	11829						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512954				2022-12-25	WOS:A1994NG37700026
J	BOWDITCH, RD; HARIHARAN, M; TOMINNA, EF; SMITH, JW; YAMADA, KM; GETZOFF, ED; GINSBERG, MH				BOWDITCH, RD; HARIHARAN, M; TOMINNA, EF; SMITH, JW; YAMADA, KM; GETZOFF, ED; GINSBERG, MH			IDENTIFICATION OF A NOVEL INTEGRIN BINDING-SITE IN FIBRONECTIN - DIFFERENTIAL UTILIZATION BY BETA-3 INTEGRINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IIB-IIIA COMPLEX; IMMUNOGLOBULIN-LIKE DOMAINS; CELL-ADHESION; DIRECTED MUTAGENESIS; VITRONECTIN RECEPTOR; SECONDARY STRUCTURE; SYNTHETIC PEPTIDES; PLASMA FIBRONECTIN; RIBBON MODELS; HUMAN CD4	Fibronectin (Fn) binding to the integrins alpha IIb beta 3 and alpha v beta 3 involves the Arg-Gly-Asp sequence. The identification of other regions of Fn that interact with alpha IIb beta 3 suggests a potential mechanism for differential ligand recognition by integrins. We report here the identification of an 11-residue peptide sequence from the 9th type III repeat of Fn (3Fn9), which inhibits ligand binding to alpha IIb beta 3 by interacting directly with this receptor. Mutational analysis demonstrated that this same region was involved in the formation of epitopes for two anti-Fn mAbs that inhibit Fn binding to alpha IIb beta 3, thus emphasizing the role of this site in the macromolecule. Molecular modeling of the 3Fn9-10 modules suggested that Fn residues Asp(1373)-Th-1383 are at least 25 Angstrom distant from the Arg-Gly-Asp site and therefore does not directly interact with it. The 3Fn9 site was differentially recognized by the beta 3 integrin family. The Asp(1373)-Thr(1383) peptide failed to inhibit ligand binding to alpha v beta 3, a recombinant Fn Ala(1235)-Ser(1436) fragment was not recognized by alpha v beta 3, and addition of the 3Fn9 module to the amino terminus of the 3Fn10 did not affect the potency of inhibiton of Fn binding to alpha v beta 3. Thus, a novel integrin recognition site in the 3Fn9 module of Fn that is differentially recognized by the beta 3 integrins has been localized within the residues Asp(1373)-Thr(1383).	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; NIDR, DEV BIOL LAB, BETHESDA, MD 20892 USA	Scripps Research Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	BOWDITCH, RD (corresponding author), SCRIPPS RES INST, DEPT VASC BIOL, COMM VASC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Yamada, Kenneth/0000-0003-1512-6805	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411, P01HL031950, R01HL028235] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28235, HL31950, HL16411] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P3256; AOTA S, 1991, J BIOL CHEM, V266, P15938; BARON M, 1992, BIOCHEMISTRY-US, V31, P2068, DOI 10.1021/bi00122a025; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BUSK M, 1992, J BIOL CHEM, V267, P5790; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; DALE GL, 1991, BLOOD, V77, P1096; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ENGVALL E, 1972, J IMMUNOL, V109, P129; FORSYTH J, 1992, METHOD ENZYMOL, V215, P311; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; GARDNER JM, 1985, CELL, V42, P439, DOI 10.1016/0092-8674(85)90101-1; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1983, J CLIN INVEST, V71, P619, DOI 10.1172/JCI110808; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; JONES FS, 1988, P NATL ACAD SCI USA, V85, P2186, DOI 10.1073/pnas.85.7.2186; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIMIZUKA F, 1991, J BIOL CHEM, V266, P3045; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM SCT, 1987, J BIOL CHEM, V262, P947; LAM SCT, 1989, J BIOL CHEM, V264, P3742; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MEINKE A, 1993, J BACTERIOL, V175, P1910, DOI 10.1128/JB.175.7.1910-1918.1993; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; ODERMATT E, 1989, FIBRONECTIN, P1; PARISE LV, 1986, J BIOL CHEM, V261, P14011; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; PLOW EF, 1981, J BIOL CHEM, V256, P9477; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; ROSS L, 1992, J BIOL CHEM, V267, P8537; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SMITH JW, 1988, J BIOL CHEM, V263, P18726; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; VAUGHAN KT, 1993, J BIOL CHEM, V268, P3670; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WATANABE T, 1990, J BIOL CHEM, V265, P15659; WOODS VL, 1986, J BIOL CHEM, V261, P5242; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	60	186	188	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10856	10863						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511609				2022-12-25	WOS:A1994NF01700098
J	CHEDID, M; RUBIN, JS; CSAKY, KG; AARONSON, SA				CHEDID, M; RUBIN, JS; CSAKY, KG; AARONSON, SA			REGULATION OF KERATINOCYTE GROWTH-FACTOR GENE-EXPRESSION BY INTERLEUKIN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; MORPHOGENESIS; KGF; DIFFERENTIATION; INDUCTION; INVITRO; FAMILY	Keratinocyte growth factor (KGF) is a stromally derived member of the fibroblast growth factor family (FGF7) with potent mitogenic activity on a variety of epithelial cells. To identify molecules that regulate the expression of this paracrine mediator of epithelial proliferation, we investigated the effects of various cytokines and growth factors on KGF production by fibroblasts. The proinflammatory cytokine interleukin 1 (IL1) strongly induced the expression of KGF RNA in fibroblasts from multiple sources. Platelet-derived growth factor BB, IL6, and transforming growth factor a caused a moderate elevation, while tumor necrosis factor a and basic FGF did not alter the level of KGF RNA expression. The induction by IL1 of KGF transcript levels was time and dose dependent and specifically blocked by anti-IL1 antibodies. Nuclear run on experiments indicated that IL1 stimulated KGF gene transcription. Western blot analysis and keratinocyte proliferation assays demonstrated a corresponding increase in mitogenically active KGF protein in conditioned medium obtained from IL1-treated fibroblasts. The stimulation of KGF expression by IL1 and other cytokines such as IL6, transforming growth factor alpha, and platelet-derived growth factor may provide a mechanism for KGF induction during inflammation that would support its proposed role as mediator of reepithelialization and wound healing.			CHEDID, M (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,BETHESDA,MD 20892, USA.							ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; CHUNG LWK, 1993, SEMIN CANCER BIOL, V4, P183; Cullen K J, 1992, Cancer Treat Res, V61, P413; CUNHA GR, 1991, DEVELOPMENT, V111, P145; Donjacour A A, 1991, Cancer Treat Res, V53, P335; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GAY CG, 1991, P NATL ACAD SCI USA, V88, P296, DOI 10.1073/pnas.88.1.296; HIRAI Y, 1992, CELL, V69, P471, DOI 10.1016/0092-8674(92)90448-L; KELLEY MJ, 1992, P NATL ACAD SCI USA, V89, P9287, DOI 10.1073/pnas.89.19.9287; KUPPER TS, 1990, J INVEST DERMATOL, V94, pS146, DOI 10.1111/1523-1747.ep12876130; LI BY, 1992, CANCER RES, V52, P2248; MARCHESE C, 1990, J CELL PHYSIOL, V144, P326, DOI 10.1002/jcp.1041440219; MERCOLA M, 1988, DEVELOPMENT, V102, P451; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; PANOS RJ, 1993, J CLIN INVEST, V92, P969, DOI 10.1172/JCI116673; Partanen A M, 1990, Curr Top Dev Biol, V24, P31, DOI 10.1016/S0070-2153(08)60083-6; PARTRIDGE M, 1991, J INVEST DERMATOL, V96, P771, DOI 10.1111/1523-1747.ep12471723; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SAKAKURA T, 1976, SCIENCE, V194, P1439, DOI 10.1126/science.827022; SARIOLA H, 1988, CELL, V54, P235, DOI 10.1016/0092-8674(88)90556-9; SAWHNEY N, 1992, CANCER, V70, P2115, DOI 10.1002/1097-0142(19921015)70:8<2115::AID-CNCR2820700818>3.0.CO;2-K; SMOLA H, 1993, J CELL BIOL, V122, P417, DOI 10.1083/jcb.122.2.417; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; TAMURA M, 1993, J BIOL CHEM, V268, P8140; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123	36	185	189	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10753	10757						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511604				2022-12-25	WOS:A1994NF01700084
J	MARI, B; IMBERT, V; BELHACENE, N; FAR, DF; PEYRON, JF; POUYSSEGUR, J; VANOBBERGHENSCHILLING, E; ROSSI, B; AUBERGER, P				MARI, B; IMBERT, V; BELHACENE, N; FAR, DF; PEYRON, JF; POUYSSEGUR, J; VANOBBERGHENSCHILLING, E; ROSSI, B; AUBERGER, P			THROMBIN AND THROMBIN RECEPTOR AGONIST PEPTIDE INDUCE EARLY EVENTS OF T-CELL ACTIVATION AND SYNERGIZE WITH TCR CROSS-LINKING FOR CD69 EXPRESSION AND INTERLEUKIN-2 PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; ANTIGEN RECEPTOR; PERTUSSIS TOXIN; PHOSPHOINOSITIDE HYDROLYSIS; PROTEOLYTIC MECHANISM; PLATELET ACTIVATION; SIGNALING PATHWAYS; STIMULATION; FIBROBLASTS; CLONING	Thrombin stimulation of the T leukemic cell line Jurkat induced a transient increase in [Ca2+](i). Proteolytic activity of the enzyme was required for this effect since diisopropyl fluorophosphate-thrombin failed to increase [Ca2+](i). Furthermore, hirudin and anti-thrombin III inhibited the thrombin-induced [Ca2+](i) rise in Jurkat T cells. A synthetic thrombin receptor agonist peptide (TRP) of 7 residues (SFLLRNP) was found to be as effective as thrombin for [Ca2+](i) mobilization, and both agonists induced Ca2+ release exclusively from internal stores. Thrombin stimulated tyrosine phosphorylation of several proteins of molecular mass 40, 42, 70, 120, and 130 kDa. There was a good correlation between thrombin-induced tyrosine phosphorylation of the latter three proteins and Ca2+ mobilization. Thrombin and TRP also caused translocation of protein kinase C from the cytosol to the plasma membrane. As a likely consequence of these events, thrombin activated the nuclear factor NF-kB. Several cell lines of hematopoietic origin including the leukemic T cell line HPB.ALL and the erythroleukemic cell line K562 were responsive to thrombin, whereas others such as THP1, a myelomonocytic cell line, and BL2, a Burkitt lymphoma were refractory to thrombin or TRP stimulation. The magnitude of the thrombin response in the different cell types paralleled the expression of the thrombin receptor mRNA. We found that activation of Jurkat T cells by a combination of phytohemagglutinin and phorbol 12-myristate 13-acetate led to a dramatic inhibition of thrombin receptor mRNA expression and to a concomitant loss of the thrombin response. Finally, we demonstrate that thrombin and TRP enhanced CD69 expression and interleukin 2 production induced by T cell receptor cross-linking in both Jurkat T cells and peripheral blood lymphocytes. These findings highlight the role of thrombin as a potential regulator of T lymphocyte activation.	FAC MED NICE, INSERM, U364, F-06107 NICE 02, FRANCE; CNRS, INSERM, CTR BIOCHIM, F-06034 NICE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur			Jean-Francois, Peyron/AAA-9496-2022; Imbert, Véronique/I-6093-2016; Mari, Bernard/Q-5832-2019; AUBERGER, Patrick/G-1491-2013; Van Obberghen-Schilling, Ellen/O-1581-2016; Mari, Bernard P/GVS-3100-2022; Peyron, Jean-Francois/M-5682-2016; Mari, Bernard P/D-7445-2015; Van Obberghen-Schilling, Ellen/Q-4372-2019; Mari, Bernard P/F-8960-2013	Jean-Francois, Peyron/0000-0001-6113-916X; Imbert, Véronique/0000-0003-2103-6718; Mari, Bernard/0000-0002-0422-9182; AUBERGER, Patrick/0000-0002-2481-8275; Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Mari, Bernard P/0000-0002-0422-9182; Peyron, Jean-Francois/0000-0001-6113-916X; Mari, Bernard P/0000-0002-0422-9182; Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Mari, Bernard P/0000-0002-0422-9182				AUBERGER P, 1989, J IMMUNOL, V142, P1253; BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; BERNDT MC, 1986, ANN NY ACAD SCI, V485, P374, DOI 10.1111/j.1749-6632.1986.tb34598.x; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHEN LB, 1976, EXP CELL RES, V101, P41, DOI 10.1016/0014-4827(76)90409-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIS L, 1985, J IMMUNOL, V135, P2946; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FERRUA B, 1987, J IMMUNOL METHODS, V97, P215, DOI 10.1016/0022-1759(87)90462-5; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARNETT M, 1992, IMMUNOL TODAY, V13, P482, DOI 10.1016/0167-5699(92)90022-Y; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P17078; HUNG DT, 1992, J BIOL CHEM, V267, P20831; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; IMBODEN JB, 1985, J IMMUNOL, V134, P663; KENNEDY ICS, 1992, J BIOL CHEM, V267, P4924; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KROLL MH, 1989, BLOOD, V74, P1181; MARI B, 1992, EMBO J, V11, P3875, DOI 10.1002/j.1460-2075.1992.tb05480.x; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MODESTO J, 1991, CELL SIGNAL, V3, P25, DOI 10.1016/0898-6568(91)90004-E; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TANTI JF, 1989, BIOCHEM J, V258, P141, DOI 10.1042/bj2580141; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TORDAI A, 1993, J IMMUNOL, V150, P4876; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; TROYER D, 1992, J BIOL CHEM, V267, P20126; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0	44	90	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8517	8523						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510689				2022-12-25	WOS:A1994NB40900103
J	TSAY, YF; SHANKWEILER, G; LAKE, J; WOOLFORD, JL				TSAY, YF; SHANKWEILER, G; LAKE, J; WOOLFORD, JL			LOCALIZATION OF SACCHAROMYCES-CEREVISIAE RIBOSOMAL-PROTEIN L16 ON THE SURFACE OF 60-S RIBOSOMAL-SUBUNITS BY IMMUNOELECTRON MICROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; RAT-LIVER RIBOSOMES; 5S RNA; CROSS-LINKING; BACILLUS-STEAROTHERMOPHILUS; ELECTROPHORETIC TRANSFER; POLYACRYLAMIDE GELS; STRUCTURAL PROTEINS; ELECTRON-MICROSCOPY; BINDING PROTEINS	Antibodies raised against a trpE-L16 fusion protein expressed in Escherichia coli were used to examine immunological relatedness between Saccharomyces cerevisiae ribosomal protein L16 and ribosomal proteins from eubacteria, halobacteria, methanogens, eocytes, and other eukaryotes. Homologues of L16 also were identified by searches of sequence data bases. Among the bacterial proteins that are immunologically related and similar in sequence to L16 are ribosomal proteins that bind 5 S rRNA. L16 protein fused near its carboxyl terminus to E. coli beta-galactosidase could assemble into functional yeast 60 S ribosomal subunits. The RPL16AlacZ gene fusion partially complemented the slow growth or lethality of mutants containing null alleles of one or both RPL16 genes, respectively. L16-beta-galactosidase fusion protein cosedimented with ribosomes and polyribosomes, and remained associated with high salt-washed ribosomes. Monoclonal antibodies against beta-galactosidase were used to map the location of L16-beta P-galactosidase on the surface of the 60 S subunit by immunoelectron microscopy. L16 was localized near the top surface of the central protuberance, where the 60 S subunit potentially contacts the 40 S subunit. This is similar to the location of the bacterial homologues of L16 in 50 S ribosomal subunits.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT BIOL, LOS ANGELES, CA 90024 USA; CARNEGIE MELLON UNIV, DEPT BIOL SCI, PITTSBURGH, PA 15213 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Carnegie Mellon University			Tsay, Yi-Fang/ABB-3662-2021	Tsay, Yi-Fang/0000-0003-4271-0687; Woolford, John/0000-0002-7553-7043	NCI NIH HHS [CA-01000] Funding Source: Medline; NIGMS NIH HHS [GM-24034, GM-28301] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024034, R01GM028301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1989, GENETICS, V121, P675; AUER J, 1989, J MOL BIOL, V209, P21, DOI 10.1016/0022-2836(89)90167-8; AURON PE, 1981, J BIOL CHEM, V256, P105; BAIM SB, 1985, MOL CELL BIOL, V5, P1839, DOI 10.1128/MCB.5.8.1839; BERNABEU C, 1982, P NATL ACAD SCI-BIOL, V79, P3111, DOI 10.1073/pnas.79.10.3111; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P1881, DOI 10.1073/pnas.68.8.1881; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; CERETTI DP, 1983, NUCLEIC ACIDS RES, V11, P2599; CHAN YL, 1992, BIOCHEM BIOPH RES CO, V185, P356, DOI 10.1016/S0006-291X(05)80993-3; CHENSCHMEISSER U, 1977, FEBS LETT, V74, P287, DOI 10.1016/0014-5793(77)80866-1; DESHMUKH M, 1993, MOL CELL BIOL, V13, P2835, DOI 10.1128/MCB.13.5.2835; DOHME F, 1976, P NATL ACAD SCI USA, V73, P2221, DOI 10.1073/pnas.73.7.2221; GRITZ L, 1985, MOL CELL BIOL, V5, P3436, DOI 10.1128/MCB.5.12.3436; GROSS B, 1983, EMBO J, V2, P255, DOI 10.1002/j.1460-2075.1983.tb01414.x; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HATAKEYAMA T, 1990, BIOCHIM BIOPHYS ACTA, V1039, P343, DOI 10.1016/0167-4838(90)90269-L; HENDERSON E, 1983, J BACTERIOL, V15, P900; HORNE JR, 1972, MOL GEN GENET, V119, P337, DOI 10.1007/BF00272091; JARVIK J, 1975, P NATL ACAD SCI USA, V72, P2738, DOI 10.1073/pnas.72.7.2738; KAHAN L, 1981, J MOL BIOL, V145, P193, DOI 10.1016/0022-2836(81)90340-5; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lake J A, 1979, Methods Enzymol, V61, P250; LAKE JA, 1984, P NATL ACAD SCI-BIOL, V81, P3786, DOI 10.1073/pnas.81.12.3786; LAKE JA, 1976, J MOL BIOL, V105, P131, DOI 10.1016/0022-2836(76)90200-X; LEE JC, 1984, J BIOL CHEM, V259, P9971; LEE JC, 1990, YEASTS, P489; LEE JC, 1986, J BIOL CHEM, V258, P854; LEER RJ, 1984, FEBS LETT, V175, P371, DOI 10.1016/0014-5793(84)80771-1; LUTSCH G, 1990, EUR J CELL BIOL, V51, P140; LUTSCH G, 1979, MOL GEN GENET, V176, P281, DOI 10.1007/BF00273223; Miller J.H., 1972, EXPT MOL GENETICS; MOORE PB, 1986, STRUCTURE FUNCTION G, P87; MORELAND RB, 1985, P NATL ACAD SCI USA, V82, P6561, DOI 10.1073/pnas.82.19.6561; MORITZ M, 1991, MOL CELL BIOL, V11, P5681, DOI 10.1128/MCB.11.11.5681; MORITZ M, 1990, J CELL BIOL, V111, P2261, DOI 10.1083/jcb.111.6.2261; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NAZAR RN, 1979, EUR J BIOCHEM, V102, P573, DOI 10.1111/j.1432-1033.1979.tb04274.x; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; OAKES MI, 1990, RIBOSOME, P180; OLSON HM, 1988, J BIOL CHEM, V263, P4801; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAUE HA, 1991, METHOD ENZYMOL, V194, P453; ROSENDAHL G, 1991, GENE, V98, P161, DOI 10.1016/0378-1119(91)90169-C; ROTENBERG MO, 1988, GENE DEV, V2, P160, DOI 10.1101/gad.2.2.160; ROTENBERG MO, 1986, MOL CELL BIOL, V6, P674, DOI 10.1128/MCB.6.2.674; SCHEINMAN A, 1992, BIOCHIMIE, V74, P307, DOI 10.1016/0300-9084(92)90108-Q; Sherman F., 1986, METHODS YEAST GENETI; SINGLETON CK, 1989, NUCLEIC ACIDS RES, V17, P9679, DOI 10.1093/nar/17.23.9679; SMITH N, 1978, EUR J BIOCHEM, V89, P501, DOI 10.1111/j.1432-1033.1978.tb12554.x; SPIERER P, 1978, BIOCHEMISTRY-US, V17, P2474, DOI 10.1021/bi00606a002; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; STEITZ JA, 1988, J CELL BIOL, V106, P545, DOI 10.1083/jcb.106.3.545; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; TEEM JL, 1984, NUCLEIC ACIDS RES, V12, P8295, DOI 10.1093/nar/12.22.8295; TERAO K, 1980, BIOCHIM BIOPHYS ACTA, V621, P72, DOI 10.1016/0005-2795(80)90063-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Traut R. R., 1980, RIBOSOMES STRUCTURE, P89; TSAY YF, 1988, GENE DEV, V2, P664, DOI 10.1101/gad.2.6.664; TSAY YF, 1990, THESIS CARNEGIEMELLO; Warner J R, 1978, Methods Cell Biol, V20, P45, DOI 10.1016/S0091-679X(08)62008-7; WOOL IG, 1990, RIBOSOME, P203; WOOLFORD JL, 1979, CELL, V18, P1247, DOI 10.1016/0092-8674(79)90236-8; WOOLFORD JL, 1991, ADV GENET, V29, P63, DOI 10.1016/S0065-2660(08)60107-8; Woolford Jr JL, 1991, MOL CELLULAR BIOL YE, P587; WORMINGTON WM, 1989, MOL CELL BIOL, V9, P5281, DOI 10.1128/MCB.9.12.5281; XIANG RH, 1989, J BIOL CHEM, V264, P10542; YEH YC, 1986, J BIOL CHEM, V261, P14148	71	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7579	7586						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7510288				2022-12-25	WOS:A1994NA03200086
J	MISSIAEN, L; DESMEDT, H; PARY, JB; OIKE, M; CASTEELS, R				MISSIAEN, L; DESMEDT, H; PARY, JB; OIKE, M; CASTEELS, R			KINETICS OF EMPTY STORE-ACTIVATED CA2+ INFLUX IN HELA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; SMOOTH-MUSCLE CELLS; CAPACITATIVE CALCIUM ENTRY; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; CA-2+ PUMP; THAPSIGARGIN; RAT; OSCILLATIONS	The intracellular Ca2+ indicator Indo-1 was used to monitor changes in cytosolic [Ca2+] ([Ca2+](i)) in single HeLa cells upon readmission of external Ca2+ after a short incubation in Ca2+-free solution. HeLa cells were responsive to histamine but not to caffeine, and their histamine-sensitive store was totally depleted by a 60-min exposure to 2 mu M thapsigargin. The resting [Ca2+](i) in thapsigargin-treated cells was higher than in control cells and low amplitude [Ca2+](i) oscillations were observed in about 20% of the cells. Readmission of external Ca2+ after a brief withdrawal of extracellular Ca2+ resulted in a transient [Ca2+](i) rise, which then decayed to the same elevated [Ca2+](i) measured before the Ca2+ withdrawal period. The [Ca2+](i) rise was associated with an increased rate of Mn2+ entry, measured as the rate of quenching of intracellular Fura-2. The same procedure did not affect the [Ca2+](i) in control cells not pretreated with thapsigargin. The amplitude of this [Ca2+](i) transient in thapsigargin pretreated cells depended on the duration of prior incubation in Ca2+-free medium, The [Ca2+](i) rise induced by elevating the extracellular [Ca2+] from 1.5 to 10 mM was more pronounced if the [Ca2+](i) during the initial incubation in 1.5 mM Ca2+ was first lowered by depolarizing the cells. We conclude that an empty store stimulates a Ca2+ entry pathway consisting of two components: a continuously elevated basal leak and a second component that is transient due to the high [Ca2+](i)-induced inhibition of the Ca2+ entry pathway. This inhibition and the subsequent recovery from it as the [Ca2+](i) is brought to resting levels could cause the oscillatory Ca2+ entry that we recorded in a fraction of the thapsigargin-treated cells.			MISSIAEN, L (corresponding author), KATHOLIEKE UNIV LEUVEN, FYSIOL LAB, CAMPUS GASTHUISBERG, HERESTR 49, B-3000 LOUVAIN, BELGIUM.			Parys, Jan/0000-0002-3591-4967				ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BECKER PL, 1989, SCIENCE, V244, P211, DOI 10.1126/science.2704996; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; CASTEELS R, 1981, J PHYSIOL-LONDON, V317, P263, DOI 10.1113/jphysiol.1981.sp013824; CHOQUETTE D, 1984, BIOCHEM BIOPH RES CO, V125, P908, DOI 10.1016/0006-291X(84)91369-X; CORCIA A, 1988, BIOCHEMISTRY-US, V27, P7499, DOI 10.1021/bi00419a048; DESMEDT H, 1991, J BIOL CHEM, V266, P7092; DESMEDT H, 1991, BIOCHEM J, V273, P219, DOI 10.1042/bj2730219; DIARRA A, 1992, PFLUG ARCH EUR J PHY, V422, P40, DOI 10.1007/BF00381511; DUDDY SK, 1989, J BIOL CHEM, V264, P20863; FOSKETT JK, 1991, J BIOL CHEM, V266, P14535; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; GILL DL, 1986, NATURE, V320, P461, DOI 10.1038/320461a0; GLENNON MC, 1992, J BIOL CHEM, V267, P8230; HALLAM TJ, 1985, FEBS LETT, V186, P175, DOI 10.1016/0014-5793(85)80703-1; HEMMERICH S, 1988, BIOCHEMISTRY-US, V27, P7488, DOI 10.1021/bi00419a047; HEMMERICH S, 1991, BIOCHEMISTRY-US, V30, P1523, DOI 10.1021/bi00220a012; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; INO M, 1989, J GEN PHYSIOL, V94, P363, DOI 10.1085/jgp.94.2.363; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KHAN AA, 1992, P NATL ACAD SCI USA, V257, P815; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LAW GJ, 1990, BIOCHEM J, V267, P359, DOI 10.1042/bj2670359; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MCDONALD TV, 1993, J BIOL CHEM, V268, P3889; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; MERTZ LM, 1992, J MEMBRANE BIOL, V126, P183; MISSIAEN L, 1993, PFLUG ARCH EUR J PHY, V423, P480, DOI 10.1007/BF00374944; MISSIAEN L, 1989, BIOCHEM J, V263, P687, DOI 10.1042/bj2630687; MISSIAEN L, 1990, J PHYSIOL-LONDON, V427, P171, DOI 10.1113/jphysiol.1990.sp018166; PANDOL SJ, 1990, J BIOL CHEM, V265, P12846; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; ROBINSON IM, 1991, J NEUROCHEM, V56, P1587, DOI 10.1111/j.1471-4159.1991.tb02055.x; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SHUTTLEWORTH TJ, 1992, CELL CALCIUM, V13, P541, DOI 10.1016/0143-4160(92)90034-P; SMALLWOOD JI, 1988, J BIOL CHEM, V263, P2195; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; SWANDULLA D, 1990, POTASSIUM CHANNELS S, P167; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TEPIKIN AV, 1992, J BIOL CHEM, V267, P14073; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TILLY BC, 1990, BIOCHEM J, V266, P235, DOI 10.1042/bj2660235; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; VROLIX M, 1988, BIOCHEM J, V255, P855, DOI 10.1042/bj2550855; ZHANG BX, 1992, J BIOL CHEM, V267, P15419	59	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5817	5823						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509791				2022-12-25	WOS:A1994MY84000054
J	DUNN, KW; PARK, J; SEMRAD, CE; GELMAN, DL; SHEVELL, T; MCGRAW, TE				DUNN, KW; PARK, J; SEMRAD, CE; GELMAN, DL; SHEVELL, T; MCGRAW, TE			REGULATION OF ENDOCYTIC TRAFFICKING AND ACIDIFICATION ARE INDEPENDENT OF THE CYSTIC-FIBROSIS TRANSMEMBRANE REGULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; WHEAT-GERM-AGGLUTININ; RECEPTOR-MEDIATED ENDOCYTOSIS; TRANSFERRIN RECEPTOR; CHLORIDE CONDUCTANCE; RAPID ENDOCYTOSIS; EPITHELIAL-CELLS; BINDING-SITES; K562 CELLS; PH	Cystic fibrosis is associated with mutations of the cystic fibrosis transmembrane regulator (CFTR), a cAMP-regulated plasma membrane Cl- channel. Mutations in the CFTR have been reported to not only impair Cl- transport at the plasma membrane but also inhibit organelle acidification and disrupt cAMP-regulated plasma membrane recycling. Comparisons of cultured pancreatic adenocarcinoma cells expressing the Delta 508 mutant CFTR (CFPAC-1 cells) with genetically matched CFPAC-1 cells transfected with the wild-type CFTR demonstrate that expression of wild-type CFTR restores cAMP-mediated plasma membrane Cl- transport, but has no effect on pH regulation of endosomes labeled with either transferrin or wheat germ agglutinin, Endosome pH was, in all cases, similar in the two cell lines and unaffected by treatment with the cAMP agonist forskolin. Forskolin treatment had no effect on transferrin internalization, but increased recycling by 30-40% in both cell Lines. The kinetics of wheat germ agglutinin recycling were negligibly affected by forskolin in either cell line. These results demonstrate that endocytic acidification and cAMP-mediated endocytic protein redistribution are similar in genetically matched CFPAC-1 cells which differ only in the expression of mutant or wildtype CFTR.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University; Columbia University								ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ALAWQATI Q, 1992, J EXP BIOL, V172, P245; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; BARASCH J, 1988, J CELL BIOL, V107, P2137, DOI 10.1083/jcb.107.6.2137; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BHAVANANDAN VP, 1979, J BIOL CHEM, V254, P4000; Boat T.J., 1989, METABOLIC BASIS INHE, P2649; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; BRADBURY NA, 1992, AM J PHYSIOL, V262, pC752, DOI 10.1152/ajpcell.1992.262.3.C752; CAIN CC, 1988, J CELL BIOL, V106, P269, DOI 10.1083/jcb.106.2.269; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FUCHS R, 1989, J BIOL CHEM, V264, P2212; JOHNSON L, 1993, IN PRESS J CELL PHYS; JOHNSON VG, 1991, INTRACELLULAR TRAFFI, P183; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; MAXFIELD FR, 1990, OPTICAL MICROSCOPY FOR BIOLOGY, P357; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MURPHY RF, 1984, J CELL BIOL, V98, P1757, DOI 10.1083/jcb.98.5.1757; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; RAUB TJ, 1990, J CELL PHYSIOL, V144, P52, DOI 10.1002/jcp.1041440108; RAUB TJ, 1990, J CELL PHYSIOL, V143, P1, DOI 10.1002/jcp.1041430102; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBBINS AR, 1984, J CELL BIOL, V99, P1296, DOI 10.1083/jcb.99.4.1296; ROBBINS AR, 1983, J CELL BIOL, V96, P1064, DOI 10.1083/jcb.96.4.1064; ROEDERER M, 1987, J CELL PHYSIOL, V131, P200, DOI 10.1002/jcp.1041310209; ROFF CF, 1986, J CELL BIOL, V103, P2283, DOI 10.1083/jcb.103.6.2283; ROSE MC, 1988, HORM METAB RES, V20, P601, DOI 10.1055/s-2007-1010896; SANDVIG K, 1990, J BIOL CHEM, V265, P6382; SIPE DM, 1987, P NATL ACAD SCI USA, V84, P7119, DOI 10.1073/pnas.84.20.7119; STEIN BS, 1986, J BIOL CHEM, V261, P319; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2723, DOI 10.1083/jcb.105.6.2723; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2713, DOI 10.1083/jcb.105.6.2713; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; ZEN K, 1992, J CELL BIOL, V119, P99, DOI 10.1083/jcb.119.1.99	44	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5336	5345						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508934				2022-12-25	WOS:A1994MX57100096
J	MAZZANTI, M; INNOCENTI, B; RIGATELLI, M				MAZZANTI, M; INNOCENTI, B; RIGATELLI, M			ATP-DEPENDENT IONIC PERMEABILITY ON NUCLEAR-ENVELOPE IN IN-SITU NUCLEI OF XENOPUS-OOCYTES	FASEB JOURNAL			English	Article						NUCLEAR ENVELOPE; PATCH-CLAMP; IONIC CHANNELS; NUCLEOCYTOPLASMIC PERMEABILITY; NUCLEAR PORES	NUCLEOCYTOPLASMIC TRANSPORT; CHANNELS; MEMBRANE; INVITRO; MYOSIN; CELLS	The nuclear envelope represents a structural and functional barrier between cytoplasm and nucleoplasm. Small molecules and solutes passively cross the nuclear envelope, whereas the transport of large proteins and RNA requires metabolic energy. Using in situ Xenopus oocyte nuclei, we characterized ATP-dependent ionic permeabilities on the external surface of the envelope. The presence, but not necessarily the hydrolysis, of ATP is crucial to maintaining the channels in an open state. Localization of the ionic channels is still unclear. From morphologic and current kinetics data, we suggest a relation between the ionic channels and the nuclear pores. We try, in this way, to explain the apparent contradiction between the presence of ion-selective channels in parallel with large aqueous pores on the nuclear envelope. Under this hypothesis, variations in the metabolic energy content of the cytoplasm would induce nucleocytoplasmic passive exchanges. The distribution and movement of charged particles across the nuclear envelope may influence many cytoplasmic functions. Regulation of the current by ATP could play an important role in hormonal stimulation, divalent ion permeation into the nucleus, and cell cycle mechanisms.			MAZZANTI, M (corresponding author), UNIV MILAN,ELETTROFISIOL LAB,DIPARTIMENTO FISIOL & BIOCHIM GEN,I-20133 MILAN,ITALY.		Mazzanti, Michele/A-8941-2011	Mazzanti, Michele/0000-0002-1819-3811				AKEY CW, 1990, BIOPHYS J, V58, P341, DOI 10.1016/S0006-3495(90)82381-X; AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; BERRIOS M, 1991, P NATL ACAD SCI USA, V88, P219, DOI 10.1073/pnas.88.1.219; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BUSTAMANTE JO, 1992, PFLUG ARCH EUR J PHY, V421, P473, DOI 10.1007/BF00370259; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; FELDHERR CM, 1990, ELECTRON MICROSC REV, V3, P73, DOI 10.1016/0892-0354(90)90014-J; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; INNOCENTI B, 1993, J MEMBRANE BIOL, V131, P137, DOI 10.1007/BF02791322; ITO S, 1965, SCIENCE, V150, P909, DOI 10.1126/science.150.3698.909; JIANG LW, 1986, J CELL BIOL, V102, P853, DOI 10.1083/jcb.102.3.853; KANNO Y, 1963, EXP CELL RES, V31, P149, DOI 10.1016/0014-4827(63)90164-2; MATZKE AJM, 1992, FEBS LETT, V302, P81, DOI 10.1016/0014-5793(92)80290-W; MATZKE AJM, 1990, FEBS LETT, V271, P161, DOI 10.1016/0014-5793(90)80397-2; MAZZANTI M, 1990, NATURE, V343, P764, DOI 10.1038/343764a0; MAZZANTI M, 1987, BIOPHYS J, V52, P95, DOI 10.1016/S0006-3495(87)83192-2; MAZZANTI M, 1991, J MEMBRANE BIOL, V121, P189, DOI 10.1007/BF01870532; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; SCHINDLER M, 1986, J CELL BIOL, V102, P859, DOI 10.1083/jcb.102.3.859; TABARES L, 1991, J MEMBRANE BIOL, V123, P49, DOI 10.1007/BF01993962	24	50	50	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1994	8	2					231	236		10.1096/fasebj.8.2.7509760	http://dx.doi.org/10.1096/fasebj.8.2.7509760			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MY299	7509760				2022-12-25	WOS:A1994MY29900030
J	CARDARELLI, PM; COBB, RR; NOWLIN, DM; SCHOLZ, W; GORCSAN, F; MOSCINSKI, M; YASUHARA, M; CHIANG, SL; LOBL, TJ				CARDARELLI, PM; COBB, RR; NOWLIN, DM; SCHOLZ, W; GORCSAN, F; MOSCINSKI, M; YASUHARA, M; CHIANG, SL; LOBL, TJ			CYCLIC RGD PEPTIDE INHIBITS ALPHA-4-BETA-1 INTERACTION WITH CONNECTING SEGMENT-1 AND VASCULAR CELL-ADHESION MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; INTEGRIN VLA-4; MONOCLONAL-ANTIBODY; LATE ANTIGEN-4; T-CELLS; ALPHA-5-BETA-1 INTEGRIN; DROSOPHILA-MELANOGASTER; ANTI-ALPHA-4 INTEGRIN; SURFACE GLYCOPROTEIN; FIBRONECTIN RECEPTOR	The integrin supergene family includes receptors for a variety of extracellular matrix as well as cell surface proteins. Integrin alpha 4 has been shown to play an important role in leukocyte adhesion and extravasation during immune and inflammatory reactions. One recognition sequence known to interact with alpha 4 is the Leu-Asp-Val (LDV) site contained in the connecting segment 1 region of fibronectin. Here we present evidence that shows that a conformationally restricted RGD-containing peptide is a potent inhibitor of cell adhesion mediated by alpha 4 beta 1, a receptor not convincingly documented to interact with RGD peptides. This peptide, 1-adamantaneacetyl-Cys- Gly-Arg-Gly-Asp-Ser-Pro-Cys (disulfide bridge between residues 1-8), blocks Jurkat cell adhesion to connecting segment 1-containing peptides as well as cell adhesion to cytokine activated endothelial cells. Adhesion of Jurkat cells to either vascular cell adhesion molecule-expressing cells or recombinant vascular cell adhesion molecule-coated plates was likewise inhibited by this peptide. Furthermore, alpha 4 beta 1 can bind directly to a cyclic RGD peptide immobilized to Sepharose. Integrins, alpha 5 beta 1, alpha v beta 3, alpha IIb/beta IIIa, alpha 2 beta 1, alpha v beta 5, alpha v beta 6, and alpha 3 beta 1, have been shown to recognize the Arg-Gly-Asp (RGD) sequence present in a variety of extracellular matrix proteins, and our data support the addition of alpha 4 beta 1 to this group. Further studies using molecular modeling of such cyclic RGD peptides could help in the design of more potent peptides or nonpeptide mimetics that could effectively block alpha 4-mediated activity and have potential application in a number of inflammatory diseases.	TANABE SEIYAKU CO LTD,TOKYO,JAPAN	Mitsubishi Tanabe Pharma Corporation	CARDARELLI, PM (corresponding author), TANABE RES LABS,4540 TOWNE CTR CT,SAN DIEGO,CA 92121, USA.							AGER A, 1990, INT IMMUNOL, V2, P921, DOI 10.1093/intimm/2.10.921; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; BELL RG, 1993, J IMMUNOL, V151, P4790; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; BUSK M, 1992, J BIOL CHEM, V267, P5790; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CARDARELLI PM, 1992, J BIOL CHEM, V267, P23159; CARDARELLI PM, 1986, P NATL ACAD SCI USA, V83, P2647, DOI 10.1073/pnas.83.8.2647; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHISHOLM PL, 1993, EUR J IMMUNOL, V23, P682, DOI 10.1002/eji.1830230317; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; ELICES MJ, 1994, J CLIN INVEST, V93, P405, DOI 10.1172/JCI116975; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FERGUSON TA, 1993, J IMMUNOL, V150, P1172; FERGUSON TA, 1991, P NATL ACAD SCI USA, V88, P8072, DOI 10.1073/pnas.88.18.8072; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HARLAN JM, 1985, BLOOD, V65, P513; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HESSION C, 1991, J BIOL CHEM, V266, P6682; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P4178; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; LAFFON A, 1991, J CLIN INVEST, V88, P546, DOI 10.1172/JCI115338; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; MORALESDUCRET J, 1992, J IMMUNOL, V149, P1424; NOWLIN DM, 1993, J BIOL CHEM, V268, P20352; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PIERSCHBACHER M, 1983, P NATL ACAD SCI-BIOL, V80, P1224, DOI 10.1073/pnas.80.5.1224; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PODOLSKY DK, 1993, J CLIN INVEST, V92, P372, DOI 10.1172/JCI116575; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SHIMIZU Y, 1990, IMMUNOL REV, V114, P109, DOI 10.1111/j.1600-065X.1990.tb00563.x; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEWART JM, 1984, SOLID PHASE PEPTIDE, P53; SZEKANECZ Z, 1992, J CELL SCI, V101, P885; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; VONKAMBER B, 1971, HELV CHIM ACTA, V94, P927; WALSH GM, 1991, J IMMUNOL, V146, P3419; WAYNER EA, 1992, J CELL BIOL, V116, P489, DOI 10.1083/jcb.116.2.489; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WEG VB, 1993, J EXP MED, V177, P561, DOI 10.1084/jem.177.2.561; WRIGHT SD, 1987, P NATL ACAD SCI USA, V84, P1965, DOI 10.1073/pnas.84.7.1965; YANG XD, 1993, P NATL ACAD SCI USA, V90, P10494, DOI 10.1073/pnas.90.22.10494; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	62	56	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18668	18673						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518441				2022-12-25	WOS:A1994NW79800069
J	CIACCIO, PJ; JAISWAL, AK; TEW, KD				CIACCIO, PJ; JAISWAL, AK; TEW, KD			REGULATION OF HUMAN DIHYDRODIOL DEHYDROGENASE BY MICHAEL ACCEPTOR XENOBIOTICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YA-SUBUNIT GENE; ANTIOXIDANT RESPONSE ELEMENT; GLUTATHIONE S-TRANSFERASES; PROSTAGLANDIN-F SYNTHASE; RAT-LIVER CYTOSOL; INDUCIBLE EXPRESSION; ETHACRYNIC-ACID; 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE; BOVINE LUNG; IDENTIFICATION	A human oxidoreductase (H-37) that is overexpressed in ethacrynic acid-resistant HT29 colon cells (Ciaccio, P. J., Stuart, J. E., and Tew, K. D. (1993) Mol. Pharmacol. 43, 845-853) has been identified as a dihydrodiol dehydro genase. Translated protein from a dihydrodiol dehydrogenase cDNA isolated from a library prepared from ethacrynic acid-resistant HT29 cell poly(A(+)) RNA was recognized by anti-H-37 IgG and was identical in molecular weight with H-37. The isolated cDNA was identical in both nucleotide and amino acid sequences with the recently cloned liver dihydrodiol dehydrogenase (Stolz, A, Hammond, L., Lou, H., Takikawa, H., Ronk, M., and Shivery, J. E. (1993) J. Biol. Chem. 268, 10448-10457). Using this cDNA as probe, we have examined its induction by Michael accepters. The steady state dihydrodiol dehydrogenase mRNA level in the ethacrynic acid-resistant line was increased 30-fold relative to that of wildtype cells. Twenty-four hour treatment of wild-type cells with ethacrynic acid or dimethyl maleate increased mRNA 10-fold and 5-fold, respectively. These changes are accompanied by both increased protein expression and increased NADP-dependent 1-acenaphthenol oxidative activity in cell cytosol. In gel shift assays, compared to wild type controls, increased binding of NAD(P)H quinone oxidoreductase human antioxidant response element (hARE) DNA to redox labile protein complexes present in treated and resistant cell nuclear extract was observed. Ethacrynic acid induced CAT activity 2-fold in Hepa1 cells stably transfected with NAD(P)H quinone oxidoreductase hARE-tk-CAT chimeric gene construct. Thus, dihydrodiol dehydrogenase protein is inducible by de novo synthesis from mRNA by structurally related monofunctional inducer Michael accepters. Altered in vitro binding of nuclear protein to the hARE is indirect evidence for the involvement of an element similar to hARE in the regulation of dihydrodiol dehydrogenase by these agents.			CIACCIO, PJ (corresponding author), FOX CHASE CANC CTR,DEPT PHARMACOL,7701 BURHOLME AVE,PHILADELPHIA,PA 19111, USA.				NCI NIH HHS [R35 CA53893] Funding Source: Medline; NCRR NIH HHS [RR05539] Funding Source: Medline; NIGMS NIH HHS [GM47466] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA053893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047466, R01GM047466] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BELINSKY M, 1993, CANCER METAST REV, V12, P103, DOI 10.1007/BF00689804; BENSON AM, 1978, CANCER RES, V38, P4486; CABRAL JRP, 1983, CANCER LETT, V19, P125, DOI 10.1016/0304-3835(83)90146-5; CIACCIO PJ, 1991, BIOCHEM PHARMACOL, V42, P1504, DOI 10.1016/0006-2952(91)90468-K; CIACCIO PJ, 1993, MOL PHARMACOL, V43, P845; CLAPPER ML, 1990, CELL PHARM, V1, P7; DAVIES LG, 1980, BASIC METHODS MOL BI, P244; DIXON KH, 1989, BIOCHEM BIOPH RES CO, V163, P815, DOI 10.1016/0006-291X(89)92295-X; FLOWERSGEARY L, 1993, CHEM RES TOXICOL, V6, P252, DOI 10.1021/tx00033a002; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; GLATT HR, 1979, NATURE, V277, P319, DOI 10.1038/277319a0; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GRAVES PE, 1990, ARCH BIOCHEM BIOPHYS, V281, P106, DOI 10.1016/0003-9861(90)90419-Y; HARA A, 1990, J BIOCHEM-TOKYO, V108, P250, DOI 10.1093/oxfordjournals.jbchem.a123189; HAYES JD, 1993, CANCER RES, V53, P3887; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; KUZMICH S, 1992, BIOCHEM J, V281, P219, DOI 10.1042/bj2810219; LI Y, 1992, J BIOL CHEM, V267, P15097; LI Y, 1992, BIOCHEM BIOPH RES CO, V188, P992, DOI 10.1016/0006-291X(92)91329-O; LOTLIKAR PD, 1984, CARCINOGENESIS, V5, P269, DOI 10.1093/carcin/5.2.269; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; PAWLOWSKI JE, 1991, J BIOL CHEM, V266, P8820; PENNING TM, 1986, STEROIDS, V47, P221; PENNING TM, 1984, BIOCHEM J, V222, P601, DOI 10.1042/bj2220601; PENNING TM, 1990, CARCINOGENESIS, V11, P1203, DOI 10.1093/carcin/11.7.1203; PENNING TM, 1992, BIOCHEM PHARMACOL, V43, P1148, DOI 10.1016/0006-2952(92)90625-S; PENNING TM, 1993, CHEM-BIOL INTERACT, V89, P1, DOI 10.1016/0009-2797(93)03203-7; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; SCHISSELBAUER JC, 1992, PHARMACOGENETICS, V2, P63, DOI 10.1097/00008571-199204000-00003; SMITHGALL TE, 1986, J BIOL CHEM, V261, P6184; SPENCER SR, 1991, BIOCHEM J, V273, P711, DOI 10.1042/bj2730711; STOLZ A, 1993, J BIOL CHEM, V268, P10448; STOLZ A, 1989, ANNU REV PHYSIOL, V51, P161, DOI 10.1146/annurev.ph.51.030189.001113; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; TELAKOWSKIHOPKINS CA, 1988, P NATL ACAD SCI USA, V85, P1000, DOI 10.1073/pnas.85.4.1000; WATANABE K, 1985, J BIOL CHEM, V260, P7035; WATANABE K, 1988, P NATL ACAD SCI USA, V85, P11, DOI 10.1073/pnas.85.1.11; WILLIAMS GM, 1986, CARCINOGENESIS, V7, P1043, DOI 10.1093/carcin/7.7.1043; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	44	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15558	15562						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	7515059				2022-12-25	WOS:A1994NP51300028
J	CAZALS, V; MOUHIEDDINE, B; MAITRE, B; LEBOUC, Y; CHADELAT, K; BRODY, JS; CLEMENT, A				CAZALS, V; MOUHIEDDINE, B; MAITRE, B; LEBOUC, Y; CHADELAT, K; BRODY, JS; CLEMENT, A			INSULIN-LIKE GROWTH-FACTORS, THEIR BINDING-PROTEINS, AND TRANSFORMING GROWTH-FACTOR-BETA-1 IN OXIDANT-ARRESTED LUNG ALVEOLAR EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATION-RELATED GENES; PULMONARY OXYGEN-TOXICITY; POSTTRANSCRIPTIONAL REGULATION; HUMAN FIBROBLASTS; DNA DAMAGE; FACTOR-II; EXPRESSION; PHOSPHORYLATION; INHIBITION; ACTIVATION	The epithelium of the pulmonary alveolus is a major target for oxidant injury, and its proper repair following injury is dependent on the proliferative response of its stem cells, the type 2 cells. We have recently shown that hyperoxia arrests proliferation of an immortalized type 2 cell line (SV40T-T2) and that expression of several growth-related genes, normally induced near the G(1)/S and boundary was altered with a block of translation of their mRNA. In the present study we examined the possible role of the insulin-like growth factor (IGF) system and of transforming growth factor-beta 1 (TGF-beta 1) in the arrest of proliferation induced by hyperoxia. We show that IGF-binding protein 2 (IGFBP-2) accumulates to higher levels in culture medium of SV40T-T2 cells whose proliferation has been arrested by hyperoxia. This proliferation arrest is associated with increased expression of IGFBP-2 mRNA and with induction of type 2 IGF receptor and IGF-II mRNAs. When O-2-arrested cells were allowed to resume proliferation in normoxia, the level of expression of these genes rapidly decreased to control levels. We also, found that TGF-beta 1 was induced by O-2 exposure, that TGF-beta 1 inhibited SV40T-T2 proliferation, and that TGF-beta 1 itself was a potent stimulator of IGFBP-2 expression. These studies suggest a regulatory link between components of the IGF system and TGF-beta 1 in hyperoxic control of cell proliferation of alveolar epithelial cells.	UNIV PARIS, HOP TROUSSEAU, ST ANTOINE MED SCH, DEPT PHYSIOL, F-75012 PARIS, FRANCE; BOSTON UNIV, SCH MED, CTR PULM, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT MED, BOSTON, MA 02118 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Boston University; Boston University				Maitre, Bernard/0000-0002-8061-1252; Brody, Jerome/0000-0002-2824-802X	NHLBI NIH HHS [P01-HL47049] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047049] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMSON IYR, 1974, LAB INVEST, V30, P35; BABAJKO S, 1993, ENDOCRINOLOGY, V132, P2586, DOI 10.1210/en.132.6.2586; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; CERUTTI PA, 1991, EUR J CLIN INVEST, V21, P1, DOI 10.1111/j.1365-2362.1991.tb01350.x; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHING G, 1988, P NATL ACAD SCI USA, V85, P151, DOI 10.1073/pnas.85.1.151; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMENT A, 1991, EXP CELL RES, V196, P198, DOI 10.1016/0014-4827(91)90251-O; CLEMENT A, 1990, P NATL ACAD SCI USA, V87, P318, DOI 10.1073/pnas.87.1.318; CLEMENT A, 1992, J CLIN INVEST, V90, P1812, DOI 10.1172/JCI116056; CLEMMONS DR, 1992, GROWTH REGULAT, V2, P80; CRAPO JD, 1986, ANNU REV PHYSIOL, V48, P721; DAVENPORT ML, 1988, EXP LUNG RES, V14, P607, DOI 10.3109/01902148809087832; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DERCOLE AJ, 1987, J DEV PHYSIOL, V9, P481; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FURUKAWA Y, 1992, J BIOL CHEM, V267, P17121; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GOLDSTEIN S, 1991, P NATL ACAD SCI USA, V88, P9680, DOI 10.1073/pnas.88.21.9680; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HAN VKM, 1988, J CLIN ENDOCR METAB, V66, P422, DOI 10.1210/jcem-66-2-422; HARRIS JB, 1991, AM J RESP CELL MOL, V4, P115, DOI 10.1165/ajrcmb/4.2.115; HILL DJ, 1989, J MOL ENDOCRINOL, V2, P31, DOI 10.1677/jme.0.0020031; HOENJE H, 1989, MUTAT RES, V219, P193; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; JACKSON RM, 1985, CHEST, V88, P900, DOI 10.1378/chest.88.6.900; JACOBS T, 1992, DEV BIOL, V153, P1, DOI 10.1016/0012-1606(92)90087-W; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; KAPANCI Y, 1969, LAB INVEST, V20, P101; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MATSUMOTO K, 1990, J CELL PHYSIOL, V145, P95, DOI 10.1002/jcp.1041450114; MILLER BE, 1990, ENVIRON HEALTH PERSP, V85, P15, DOI 10.2307/3430661; NEELY EK, 1991, ACTA PAEDIATR SCAND, P116; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARK JHY, 1992, ENDOCRINOLOGY, V131, P1359, DOI 10.1210/en.131.3.1359; PRICE WA, 1993, AM J RESP CELL MOL, V8, P425, DOI 10.1165/ajrcmb/8.4.425; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; RECHLER MM, 1992, GROWTH REGULAT, V2, P55; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; RUTANEN EM, 1990, ACTA ENDOCRINOL-COP, V123, P7, DOI 10.1530/acta.0.1230007; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; STILES AD, 1990, AM J RESP CELL MOL, V3, P93, DOI 10.1165/ajrcmb/3.2.93; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; THET LA, 1986, EXP LUNG RES, V11, P209, DOI 10.3109/01902148609064297; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; VUILLAUME M, 1987, MUTAT RES, V186, P43, DOI 10.1016/0165-1110(87)90014-5	55	55	58	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14111	14117						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514600				2022-12-25	WOS:A1994NL60600059
J	DIEGEL, ML; RANKIN, BM; BOLEN, JB; DUBOIS, PM; KIENER, PA				DIEGEL, ML; RANKIN, BM; BOLEN, JB; DUBOIS, PM; KIENER, PA			CROSS-LINKING OF FC-GAMMA RECEPTOR TO SURFACE-IMMUNOGLOBULIN ON B-CELLS PROVIDES AN INHIBITORY SIGNAL THAT CLOSES THE PLASMA-MEMBRANE CALCIUM-CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INDEPENDENT LIGAND OCCUPANCY; LYMPHOCYTES-B; TYROSINE PHOSPHORYLATION; ANTIGEN RECEPTORS; T-CELLS; PROLIFERATION SIGNALS; HUMAN-PLATELETS; DNA-SYNTHESIS; ACTIVATION	Stimulation of B lymphocytes by the cross-linking of surface Ig (sIg) with an F(ab'), antibody fragment leads to the rapid activation of several tyrosine kinases. This gives rise to the activation of phospholipase C gamma (PLCgamma) and the generation of inositol phosphates. These, in turn, lead to a prolonged elevation of intracellular Ca2+ ([Ca2+]i) consisting of a rapid release of Ca2+ from intracellular stores and a sustained influx of extracellular Ca2+. In contrast, co-cross-linking sIg to Fcgamma receptor (FcgammaRII) with intact anti-sIg induces a much more transient increase in [Ca2+]i. Stimulation of the murine B cell lymphoma, A20, with F(ab')2 anti-sIgG leads to the production of high levels of IL-2, while co-cross-linking of sIgG with FcgammaRII blocks this response. In studies reported here, we show that co-cross-linking of FcgammaRII with sIg prevents the influx of extracellular Ca2+ without significantly affecting the tyrosine phosphorylation of substrates including PLCygamma1, PLCgamma2, and Syk or the mobilization of Ca2+ from intracellular stores. In cells that had been previously activated with F(ab')2 anti-IgG, co-cross-linking of slg to FcgammaRII rapidly abrogated the influx of extracellular Ca2+ by closing the plasma membrane Ca2+ channel. Additionally, even 2-3 h after stimulation of the cells with F(ab')2 fragment, addition of intact anti-IgG to the cells, or removal of extracellular Ca2+, markedly inhibited (>90%) IL-2 production. These results indicate that co-cross-linking slg with FcgammaRII both prevented the opening of and actively closed the Ca2+ channel, and, through this mechanism, FcgammaRII was able to control production of IL-2. Overall, since influx of extracellular Ca2+ has been found to be necessary for the proliferation and differentiation of B cells, FcgammaRII may play a critical role in controlling these responses by regulating the opening of the Ca2+ channel.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543; UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195	Bristol-Myers Squibb; Bristol-Myers Squibb; University of Washington; University of Washington Seattle								BAIXERAS E, 1993, IMMUNOL REV, V132, P5, DOI 10.1111/j.1600-065X.1993.tb00836.x; BERRY N, 1990, EUR J BIOCHEM, V189, P205, DOI 10.1111/j.1432-1033.1990.tb15478.x; BIJSTERBOSCH MK, 1985, J EXP MED, V162, P1825, DOI 10.1084/jem.162.6.1825; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBELL MA, 1990, EMBO J, V9, P2125; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; CLARK EA, 1991, ANNU REV IMMUNOL, V9, P97; CLEVERS HC, 1985, J IMMUNOL, V135, P3827; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOLD MR, 1992, J IMMUNOL, V148, P2012; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAGIWARA S, 1967, J GEN PHYSIOL, V50, P583, DOI 10.1085/jgp.50.3.583; HALLAM TJ, 1985, FEBS LETT, V186, P175, DOI 10.1016/0014-5793(85)80703-1; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HAVERSTICK DM, 1993, MOL BIOL CELL, V4, P173, DOI 10.1091/mbc.4.2.173; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HUNZIKER W, 1990, NATURE, V345, P628, DOI 10.1038/345628a0; HUTCHCROFT J, 1991, J BIOL CHEM, V266, P17846; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KLAUS GGB, 1986, EUR J IMMUNOL, V16, P92, DOI 10.1002/eji.1830160118; KLAUS GGB, 1984, IMMUNOLOGY, V53, P693; KOLSCH E, 1980, IMMUNOL REV, V49, P62; LANE PJL, 1991, J IMMUNOL, V146, P715; LANE PJL, 1991, J IMMUNOL, V147, P4103; LAZARUS AH, 1990, J IMMUNOL, V144, P4147; LAZARUS AH, 1991, J IMMUNOL, V147, P1739; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; PHILLIPS NE, 1983, J IMMUNOL, V130, P602; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RANKIN BM, 1993, J IMMUNOL, V150, P605; RIGLEY KP, 1989, EUR J IMMUNOL, V19, P481, DOI 10.1002/eji.1830190311; RINK TJ, 1990, FEBS LETT, V268, P381, DOI 10.1016/0014-5793(90)81290-5; SAGE SO, 1987, J BIOL CHEM, V262, P16364; SIDMAN CL, 1976, J EXP MED, V144, P882, DOI 10.1084/jem.144.4.882; SMREKA AV, 1991, SCIENCE, V251, P804; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; UHER F, 1986, MOL IMMUNOL, V23, P1177, DOI 10.1016/0161-5890(86)90149-5; UHER F, 1986, J IMMUNOL, V137, P3124; UHER F, 1985, CELL IMMUNOL, V95, P369; WILSON HA, 1987, J IMMUNOL, V138, P1712; WILSON HA, 1987, J EXP MED, V166, P601, DOI 10.1084/jem.166.2.601	50	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11409	11416						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512564				2022-12-25	WOS:A1994NF96600065
J	WHALEY, AE; MEKA, CSR; HARBISON, LA; HUNT, JS; IMAKAWA, K				WHALEY, AE; MEKA, CSR; HARBISON, LA; HUNT, JS; IMAKAWA, K			IDENTIFICATION AND CELLULAR-LOCALIZATION OF UNIQUE INTERFERON MESSENGER-RNA FROM HUMAN PLACENTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVINE TROPHOBLAST PROTEIN-1; GENE-EXPRESSION; MESSENGER-RNA; PREGNANCY; SHEEP; EMBRYO; DNA; RECOGNITION; HORMONES; HOMOLOGY	Although constitutive expression of trophoblast or pregnancy-associated interferon (IFN) has long been recognized, their cDNA sequences have been determined for only ruminant ungulates. Here we show a human trophoblast IFN (htIFN) cDNA whose nucleotide sequence is very similar (85% identity) to that of ovine and bovine trophoblast IFNs, IFN tau s. Like ruminant IFN tau s, htIFN cDNAs contain an open reading frame of 195 codons including a signal sequence of 23 amino acids, resulting in a mature polypeptide of 172 amino acids. The deduced amino acid sequence of htIFN shares 73, 62, and 56% identities with ovine IFN tau, human IFN alpha II, and human IFN alpha I, respectively. However, the expression of htIFN is not limited to a specific period of pregnancy because transcripts of htIFN genes are detected in human lymphocytes, cells obtained by amniocentesis (amniocytes), first trimester, and term placentas. Human trophoblast IFN mRNA is localized mainly in extravillous trophoblast cells of placental villi, particularly in the migrating cytotrophoblast cells, which eventually replace maternal endothelial cells in spiral arteries of the decidua. Both sense and antisense mRNAs for human IFN alpha II are localized in the outer layer of villous structures. Coexistence of these mRNAs at the placental villi throughout pregnancy suggests that, in addition to a role in placental cell growth and differentiation, IFNs may play a role protecting the fetus in viral environments.	UNIV KANSAS,SCH MED,INST RES WOMEN & GENDER,DEPT OBSTET & GYNECOL,WICHITA,KS 67214; UNIV KANSAS,MED CTR,DEPT ANAT & CELL BIOL,KANSAS CITY,KS 66160	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center								BARLOW DP, 1984, DIFFERENTIATION, V27, P229, DOI 10.1111/j.1432-0436.1984.tb01433.x; BARTOL FF, 1985, BIOL REPROD, V32, P681, DOI 10.1095/biolreprod32.3.681; BAZER FW, 1991, AM J REPROD IMMUNOL, V26, P19, DOI 10.1111/j.1600-0897.1991.tb00696.x; BOURINBAIAR AS, 1992, FEBS LETT, V302, P206, DOI 10.1016/0014-5793(92)80441-I; BRANCA AA, 1986, J INTERFERON RES, V6, P305, DOI 10.1089/jir.1986.6.305; BULMER JN, 1990, AM J REPROD IMMUNOL, V22, P109, DOI 10.1111/j.1600-0897.1990.tb00652.x; CAPON DJ, 1985, MOL CELL BIOL, V5, P768, DOI 10.1128/MCB.5.4.768; CHARD T, 1989, J DEV PHYSIOL, V11, P271; CHARPIGNY G, 1988, FEBS LETT, V228, P12, DOI 10.1016/0014-5793(88)80574-X; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHEN HL, 1993, BIOL REPROD, V48, P707, DOI 10.1095/biolreprod48.4.707; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUCGOIRAN P, 1989, J BIOL CHEM, V264, P16507; FARIN CE, 1989, MOL ENDOCRINOL, V3, P1099, DOI 10.1210/mend-3-7-1099; FARIN CE, 1990, BIOL REPROD, V43, P210, DOI 10.1095/biolreprod43.2.210; FOWLER AK, 1980, NATURE, V286, P266, DOI 10.1038/286266a0; GODKIN JD, 1982, J REPROD FERTIL, V65, P141, DOI 10.1530/jrf.0.0650141; GREENE JJ, 1986, EXP CELL RES, V167, P400, DOI 10.1016/0014-4827(86)90180-1; HOWATSON AG, 1988, J ENDOCRINOL, V119, P531, DOI 10.1677/joe.0.1190531; IMAKAWA K, 1993, ENDOCRINOLOGY, V132, P1869, DOI 10.1210/en.132.4.1869; IMAKAWA K, 1987, NATURE, V330, P377, DOI 10.1038/330377a0; IMAKAWA K, 1989, MOL ENDOCRINOL, V3, P127, DOI 10.1210/mend-3-1-127; KELLY AC, 1991, DNA CELL BIOL, V10, P411, DOI 10.1089/dna.1991.10.411; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LAWRENCE JB, 1985, NUCLEIC ACIDS RES, V13, P1777; LEAMAN DW, 1992, J INTERFERON RES, V12, P1, DOI 10.1089/jir.1992.12.1; NEPHEW KP, 1993, BIOL REPROD, V48, P768, DOI 10.1095/biolreprod48.4.768; PONTZER CH, 1988, BIOCHEM BIOPH RES CO, V152, P801, DOI 10.1016/S0006-291X(88)80109-8; REDDY KJ, 1988, ANAL BIOCHEM, V168, P324, DOI 10.1016/0003-2697(88)90325-9; ROBERTS RM, 1989, J INTERFERON RES, V9, P175, DOI 10.1089/jir.1989.9.175; ROBERTS RM, 1992, ENDOCR REV, V13, P432, DOI 10.1210/er.13.3.432; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEWART HJ, 1987, J ENDOCRINOL, V115, pR13, DOI 10.1677/joe.0.115R013	35	53	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10864	10868						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511610				2022-12-25	WOS:A1994NF01700099
J	BERTI, L; MOSTHAF, L; KRODER, G; KELLERER, M; TIPPMER, S; MUSHACK, J; SEFFER, E; SEEDORF, K; HARING, H				BERTI, L; MOSTHAF, L; KRODER, G; KELLERER, M; TIPPMER, S; MUSHACK, J; SEFFER, E; SEEDORF, K; HARING, H			GLUCOSE-INDUCED TRANSLOCATION OF PROTEIN-KINASE-C ISOFORMS IN RAT-1 FIBROBLASTS IS PARALLELED BY INHIBITION OF THE INSULIN-RECEPTOR TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-CELLS; PHORBOL ESTERS; PHOSPHORYLATION; RESISTANCE; ADIPOCYTES; SUBUNIT; ACTIVATION; INVITRO; NIDDM; PATHOGENESIS	Rat-1 fibroblasts stably overexpressing high levels,of human insulin receptor were used as a model system to study the effects of hyperglycemia on insulin receptor tyrosine kinase (IRK) activity and protein kinase C (PKC) translocation in parallel in the intact cell. Glucose (10-25 mm) induced a significant reduction of IRK activity (tyrosine phosphorylation of IR-beta-subunit and IR-substrate-1) within 10 min. This effect was paralleled by a rapid translocation of several PKC isoforms (cPKC alpha, nPKC delta, nPKC epsilon, nPKC zeta) to the plasma membrane within 1 min. Kinetics of IRK inhibition and PKC translocation are consistent with the idea that the glucose effect on IRK is mediated by PKC activation. This hypothesis is supported by further observations. Addition of the protein kinase C inhibitor H-7 can prevent the effect of glucose on IRK. Inhibition of IRK is also observed after stimulation of the cells with the phorbol ester 12-0-tetradecanoylphorbol-13-acetate, which can substitute for a physiological activator of PKC. Glucose (25 mm) increases the P-32 incorporation in serine residues of the beta-subunit of IRK. We conclude that high levels of glucose induce inhibition of IRK in vivo. There is indirect evidence that this effect is mediated by a glucose-induced PKC translocation/activation and serine phosphorylation of the insulin receptor.	INST DIABET FORSCH MUNCHEN,KOLNER PL 1,D-80804 MUNICH,GERMANY; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Max Planck Society								BALLOTI R, 1990, COLLOQ INSE, V210, P29; BECKNIELSEN H, 1992, DIABETES CARE, V15, P418, DOI 10.2337/diacare.15.3.418; BORNER C, 1992, J BIOL CHEM, V267, P12892; CALLE R, 1992, J BIOL CHEM, V267, P18723; COOPER DR, 1990, BIOCHIM BIOPHYS ACTA, V1054, P95, DOI 10.1016/0167-4889(90)90210-5; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DRAZNIN B, 1988, BIOCHEM BIOPH RES CO, V156, P570, DOI 10.1016/S0006-291X(88)80880-5; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; ERMEL B, 1989, DIABETOLOGIA S1, V32, P485; GARVEY WT, 1992, DIABETES CARE, V15, P396, DOI 10.2337/diacare.15.3.396; HARING H, 1986, J BIOL CHEM, V261, P3869; HARING H, 1986, BIOCHEM J, V234, P59; HARING HU, 1981, AM J PHYSIOL, V240, pE556, DOI 10.1152/ajpendo.1981.240.5.E556; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; HARING HU, 1991, DIABETOLOGIA, V34, P848, DOI 10.1007/BF00400192; HARING HU, 1987, P NATL ACAD SCI USA, V84, P113, DOI 10.1073/pnas.84.1.113; HOFFMAN JM, 1991, ENDOCRINOLOGY, V128, P2937, DOI 10.1210/endo-128-6-2937; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KELLERER M, 1992, BIOCHEMISTRY-US, V31, P4588, DOI 10.1021/bi00134a008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MULLER HK, 1991, DIABETES, V40, P1440, DOI 10.2337/diabetes.40.11.1440; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OBERMAIER B, 1987, DIABETOLOGIA, V30, P93; OLEFSKY JM, 1985, AM J MED, V79, P12, DOI 10.1016/S0002-9343(85)80003-6; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; SWEET LJ, 1987, J BIOL CHEM, V262, P16730; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAVARE JM, 1991, BIOCHEM J, V274, P173, DOI 10.1042/bj2740173; VANOBBERGHEN E, 1983, P NATL ACAD SCI-BIOL, V80, P945; VUORINENMARKKOLA H, 1992, DIABETES, V41, P571, DOI 10.2337/diabetes.41.5.571; WHITE MF, 1985, J BIOL CHEM, V260, P9470; WHITE MF, 1985, NATURE, V163, P76	34	116	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3381	3386						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508912				2022-12-25	WOS:A1994MV63100040
J	WARSHAWSKY, I; BU, G; SCHWARTZ, AL				WARSHAWSKY, I; BU, G; SCHWARTZ, AL			BINDING ANALYSIS OF AMINO-TERMINAL AND CARBOXYL-TERMINAL REGIONS OF THE 39-KDA PROTEIN TO THE LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR TYPE-1; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; APOLIPOPROTEIN-E; HIGH-AFFINITY; COMPLEXES; IDENTIFICATION; LIGANDS; LIVER	A 39-kDa protein binds to the low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor (LRP/alpha2MR) and inhibits the binding of ligands to this. receptor. We recently reported that inhibition of tissue-type plasminogen activator binding to LRP/alpha2MR is mediated by both amino-terminal and carboxyl-terminal regions of the 39-kDa protein, whereas inhibition Of alpha2-macroglobulin-proteinase binding is mediated only by amino-terminal regions. In this report we show that amino-terminal and carboxyl-terminal regions of the 39-kDa protein bind specifically and with high affinity to LRP/alpha2MR on rat hepatoma MH1C1 cells. Following binding, these amino-terminal and carboxyl-terminal regions of the 39-kDa protein are each rapidly endocytosed and degraded with kinetics identical to the full-length 39-kDa protein. Competition binding experiments with these constructs demonstrate that amino-terminal and carboxyl-terminal regions of the 39-kDa protein compete with one another for binding to LRP/alpha2MR. A model is proposed in which amino-terminal and carboxyl-terminal regions of the 39-kDa protein bind to different sites on LRP/alpha2MR in order to inhibit ligand binding.	WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT MOLEC BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL017646, T32HL007275, P50HL017646] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL17646, T32HL07275] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BU GJ, 1993, J BIOL CHEM, V268, P13002; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; IODONATO SP, 1993, IN PRESS BIOCH J; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEGEL IH, 1975, ENZYME KINETICS, P125; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	24	34	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3325	3330						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508911				2022-12-25	WOS:A1994MV63100033
J	DAKSIS, JI; LU, RY; FACCHINI, LM; MARHIN, WW; PENN, LJZ				DAKSIS, JI; LU, RY; FACCHINI, LM; MARHIN, WW; PENN, LJZ			MYC INDUCES CYCLIN D1 EXPRESSION IN THE ABSENCE OF DE-NOVO PROTEIN-SYNTHESIS AND LINKS MITOGEN-STIMULATED SIGNAL-TRANSDUCTION TO THE CELL-CYCLE	ONCOGENE			English	Review							HUMAN C-MYC; DNA-BINDING; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; GROWTH-FACTOR; ORNITHINE DECARBOXYLASE; RETINOBLASTOMA PROTEIN; MESSENGER-RNA; NEGATIVE AUTOREGULATION; MAMMALIAN FIBROBLASTS	Mitogen-activated signal transduction frequently leads to the induction of the c-myc proto-oncogene, but the subsequent molecular events downstream of Myc protein expression which promote cell cycle progression remain unclear. To study Myc-specific effects, without the complexity of the broader proliferative response evoked by serum, we employed the MycER-inducible system in the non-transformed Rat-1 cell line. We demonstrate that activation of wild-type, but not mutant, MycER is sufficient to transiently induce cyclin D1 RNA as well as protein expression to physiological levels, and promote G0/G1 to S phase transition of the cell cycle. Stimulation of endogenous cyclin D1 RNA is rapid and clearly evident within 30 min of MycER-activation, reaching a peak at 3 h. Nuclear run-on analysis demonstrates that this induction occurs at the transcriptional level with a fivefold increase in the rate of transcription. Moreover, MycER induces cyclin D1 transcription with equal efficacy in the presence or absence of de novo protein synthesis. Our work shows that Myc and cyclin D1 lie consecutively in a major proliferation-control pathway, and together create a pivotal connection between signal transduction and cell cycle control.	UNIV TORONTO, TORONTO M5G 1X8, ON, CANADA; HOSP SICK CHILDREN, DEPT MICROBIOL, TORONTO M5G 1X8, ON, CANADA; HOSP SICK CHILDREN, DEPT IMMUNOL & CANC RES, TORONTO M5G 1X8, ON, CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; ASKEW DS, 1991, ONCOGENE, V6, P1915; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P71; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; COCKS BG, 1992, J BIOL CHEM, V267, P12307; CROUCH DH, 1993, ONCOGENE, V8, P1849; DAKSIS JI, 1992, VIROLOGY, V189, P196, DOI 10.1016/0042-6822(92)90695-L; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FACCHINI LM, 1994, CELL GROWTH DIFFER, V5, P637; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HERBER B, 1994, ONCOGENE, V9, P1295; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KARN J, 1989, ONCOGENE, V4, P773; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMIE GA, 1991, ONCOGENE, V6, P439; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOVEC H, 1994, ONCOGENE, V9, P323; LUKAS J, 1994, ONCOGENE, V9, P707; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NIKAIDO T, 1991, EXP CELL RES, V192, P102, DOI 10.1016/0014-4827(91)90163-O; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PALMERO I, 1993, ONCOGENE, V8, P1049; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PENA A, 1993, J BIOL CHEM, V268, P27277; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PENN LJZ, 1990, C MYC EVIDENCE MULTI, P69; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REDDY CD, 1992, ONCOGENE, V7, P2085; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG CL, 1993, ONCOGENE, V8, P519; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Sambrook J, 1989, MOL CLONING LABORATO; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WATERS CM, 1991, ONCOGENE, V6, P797; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	105	225	229	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3635	3645						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7526316				2022-12-25	WOS:A1994PT39200027
J	NADA, S; OKADA, M; AIZAWA, S; NAKAGAWA, H				NADA, S; OKADA, M; AIZAWA, S; NAKAGAWA, H			IDENTIFICATION OF MAJOR TYROSINE-PHOSPHORYLATED PROTEINS IN CSK-DEFICIENT CELLS	ONCOGENE			English	Article							SRC FAMILY; EMBRYO FIBROBLASTS; P53-DEFICIENT MICE; ANTIGEN RECEPTOR; CD4 RECEPTOR; KINASES; SUBSTRATE; GENE; ASSOCIATION; ADHESION	Csk is a non-receptor protein-tyrosine kinase that acts as a negative regulator of Src family tyrosine kinases. Csk-deficient mouse embryos exhibited developmental defects including inability to turn and impaired formation of neural tube. In these embryos, an accumulation of tyrosine phosphorylated proteins was observed as a consequence of constitutive activation of Src family kinases. In order to identify those tyrosine phosphorylated proteins, we established a Csk-deficient cell line from embryos lacking both Csk and the anti-oncogene product p53. On surveying several proteins known as Src substrates, we found that phosphorylation level of p80/85 (cortactin) was markedly elevated in the Csk-deficient cells. Enhancement of cortactin phosphorylation was also seen in Csk-deficient embryos. Furthermore, immunoprecipitated Src was able to directly phosphorylate cortactin in vitro. Thus, we suggest that cortactin is a good substrate of activated Src family kinases in vivo and may play important roles in signaling pathways mediated by Src family kinases.	KUMAMOTO UNIV, SCH MED, INST MOLEC EMBRYOL & GENET, DEPT MORPHOGENESIS, KUMAMOTO 860, JAPAN	Kumamoto University	NADA, S (corresponding author), OSAKA UNIV, INST PROT RES, DIV PROT METAB, 3-2 YAMADAOKA, SUITA, OSAKA 565, JAPAN.							BELL GM, 1992, MOL CELL BIOL, V12, P5548, DOI 10.1128/MCB.12.12.5548; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; EISEMAN E, 1992, NATURE, V355, P78; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMAGUCHI M, 1990, MOL CELL BIOL, V10, P830, DOI 10.1128/MCB.10.2.830; HARVEY M, 1993, ONCOGENE, V8, P2457; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KOZMA LM, 1990, MOL CELL BIOL, V10, P837, DOI 10.1128/MCB.10.2.837; MAA MC, 1992, ONCOGENE, V7, P2429; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; SATO N, 1992, J CELL SCI, V103, P131; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; TSUKADA T, 1993, ONCOGENE, V8, P3313; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631	38	54	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3571	3578						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7526315				2022-12-25	WOS:A1994PT39200020
J	CHRZANOWSKALIGHTOWLERS, ZMA; PREISS, T; LIGHTOWLERS, RN				CHRZANOWSKALIGHTOWLERS, ZMA; PREISS, T; LIGHTOWLERS, RN			INHIBITION OF MITOCHONDRIAL PROTEIN-SYNTHESIS PROMOTES INCREASED STABILITY OF NUCLEAR-ENCODED RESPIRATORY GENE TRANSCRIPTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; MESSENGER-RNA STABILITY; SKELETAL-MUSCLE; RAT-LIVER; THYROID-HORMONE; DIFFERENTIAL REGULATION; CONTRACTILE ACTIVITY; BINDING PROTEIN; BETA-SUBUNIT; EXPRESSION	To investigate the molecular basis of nuclear-mitochondrial communication, we have been studying the effect of mitochondrial stress (stimulated by inhibition of mitochondrial protein synthesis) on the homeostasis of transcripts encoding nuclear and mitochondrial gene products. We report that in cells treated with the inhibitor thiamphenicol, nuclear-encoded respiratory gene transcripts were dramatically stabilized. A concomitant up-regulation in the activity of the only known respiratory transcript binding protein, cytochrome c oxidase L-form transcript binding protein (COLBP), was also noted in thiamphenicol-treated cells, demonstrating a potential mechanism for the increased transcript protection. In contradistinction, stability of all mitochondrial RNAs was unaffected by the inhibitor, as were the nuclear encoded beta-actin, alpha-tubulin mRNAs and total cytosolic RNA. Steady state levels of all nuclear encoded transcripts tested remained constant after inhibition of mitochondrial protein synthesis, whereas a generalized increase in the levels of processed mitochondrial mRNA was noted. We conclude that thiamphenicol induces (i) an increase in steady state levels of mitochondrial mRNA, (ii) a selective protection of nuclear respiratory gene transcripts against degradation, and (iii) an up-regulation in activity of the respiratory transcript binding protein COLBP, consistent with this protein mediating increased transcript stability. Our results demonstrate a coordinated series of intracellular responses to thiamphenicol-induced mitochondrial stress, regulated at both the pre- and post-transcriptional levels.	UNIV NEWCASTLE UPON TYNE,SCH MED,DIV CLIN NEUROSCI,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK			Preiss, Thomas/F-7355-2010	Preiss, Thomas/0000-0001-6273-784X; Chrzanowska-Lightowlers, Zofia/0000-0002-0045-3152				ALTUS MS, 1991, J BIOL CHEM, V266, P21190; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BINDOFF LA, 1993, J BIOL CHEM, V268, P19559; Brawerman G., 1993, CONTROL MESSENGER RN, P149; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; CHRZANOWSKALIGHTOWLERS ZMA, 1993, BIOCHEM BIOPH RES CO, V196, P328, DOI 10.1006/bbrc.1993.2252; CHUNG AB, 1992, J BIOL CHEM, V267, P21154; FABRIZI GM, 1989, NUCLEIC ACIDS RES, V17, P7107, DOI 10.1093/nar/17.17.7107; GRIVELL LA, 1989, EUR J BIOCHEM, V182, P477, DOI 10.1111/j.1432-1033.1989.tb14854.x; HAMMANS SR, 1992, BRAIN, V115, P343, DOI 10.1093/brain/115.2.343; HEDDI A, 1993, J BIOL CHEM, V268, P12156; HENTZE MW, 1991, BIOCHIM BIOPHYS ACTA, V1090, P281, DOI 10.1016/0167-4781(91)90191-N; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; IZQUIERDO JM, 1990, J BIOL CHEM, V265, P9090; IZQUIERDO JM, 1993, FEBS LETT, V323, P109, DOI 10.1016/0014-5793(93)81459-D; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; JOSTE V, 1989, EUR J BIOCHEM, V184, P255, DOI 10.1111/j.1432-1033.1989.tb15015.x; KADENBACH B, 1966, REGULATION METABOLIC, P508; KHALILI K, 1984, J MOL BIOL, V180, P1007, DOI 10.1016/0022-2836(84)90268-7; KOGA Y, 1993, NUCLEIC ACIDS RES, V21, P657, DOI 10.1093/nar/21.3.657; KUZELA S, 1988, BIOCHIM BIOPHYS ACTA, V936, P372, DOI 10.1016/0005-2728(88)90013-8; LANGECARTER CA, 1991, CANCER RES, V51, P6699; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MURRAY MT, 1991, J CELL BIOL, V112, P1, DOI 10.1083/jcb.112.1.1; MUTVEI A, 1989, EUR J BIOCHEM, V180, P235, DOI 10.1111/j.1432-1033.1989.tb14638.x; OLSON W, 1972, ARCH NEUROL-CHICAGO, V26, P193, DOI 10.1001/archneur.1972.00490090019001; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; PASTORI RL, 1990, BIOCHEMISTRY-US, V29, P2599, DOI 10.1021/bi00462a024; PREISS T, 1994, BBA-MOL CELL RES, V1221, P286, DOI 10.1016/0167-4889(94)90252-6; PREISS T, 1993, J BIOL CHEM, V268, P10659; PREISS T, 1993, J BIOL CHEM, V268, P24523; RAIKHINSTEIN M, 1993, P NATL ACAD SCI USA, V90, P10509, DOI 10.1073/pnas.90.22.10509; SEMENKOVICH CF, 1993, J BIOL CHEM, V268, P6961; SUZUKI H, 1991, J BIOL CHEM, V266, P2333; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; WIESNER RJ, 1992, MOL ENDOCRINOL, V6, P1458, DOI 10.1210/me.6.9.1458; WIESNER RJ, 1992, TRENDS GENET, V8, P264, DOI 10.1016/0168-9525(92)90129-R; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10933, DOI 10.1093/nar/16.22.10933; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; WISKOCIL R, 1980, P NATL ACAD SCI-BIOL, V77, P4474, DOI 10.1073/pnas.77.8.4474	45	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27322	27328						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525553				2022-12-25	WOS:A1994PV77100030
J	MOULD, AP; ASKARI, JA; CRAIG, SE; GARRATT, AN; CLEMENTS, J; HUMPHRIES, MJ				MOULD, AP; ASKARI, JA; CRAIG, SE; GARRATT, AN; CLEMENTS, J; HUMPHRIES, MJ			INTEGRIN ALPHA(4)BETA(1)-MEDIATED MELANOMA CELL-ADHESION AND MIGRATION ON VASCULAR CELL-ADHESION MOLECULE-1 (VCAM-1) AND THE ALTERNATIVELY SPLICED IIICS REGION OF FIBRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA FIBRONECTIN; HEPARIN-BINDING; CONNECTING SEGMENT; ENDOTHELIAL-CELLS; ALPHA-4-BETA-1 INTEGRIN; EOSINOPHIL ADHERENCE; SULFATE PROTEOGLYCAN; COUNTER-RECEPTOR; LATE ANTIGEN-4; T-CELLS	The integrin receptor alpha(4) beta(1) (also known as VLA-4) binds two different ligands, the endothelial cell surface protein vascular cell adhesion molecule-1 (VCAM-1) and the extracellular matrix component fibronectin. Three distinct sites in fibronectin are recognized by alpha(4) beta(1). Two of these (represented by peptides CS1 and CS5) are present in the alternatively spliced IIICS region and lie in separate, independently spliced segments of this region. A third site resides in the adjacent constitutively expressed HepII domain. Recombinant proteins containing the HepII domain and different splice variants of the IIICS have been generated and compared for their ability to mediate cell attachment, spreading and migration. The activity of these proteins has also been compared with that of a recombinant soluble form of VCAM-1 (rsVCAM-1). All the recombinant proteins supported A375-SM human melanoma cell attachment and spreading in an alpha(4) beta(1)-dependent manner, but had varied adhesive activities with rsVCAM-1 > fibronectin variants containing the CS1 sequence >> other fibronectin variants. Low concentrations of rsVCAM-1 and CS1-containing fibronectin variants effectively supported cell migration in a trans-filter assay; however, cell motility was retarded at high concentrations of the same proteins. Fibronectin variants lacking CS1 supported little or no migration. To obtain further insight into the molecular basis of this varied adhesive activity apparent dissociation constants for each of the recombinant proteins were measured using a solid phase receptor-ligand binding assay. The results revealed a hierarchy of ligand affinities that mirrored their adhesive activity (rsVCAM-1 > fibronectin variants containing CS1 >> other fibronectin variants).	BRITISH BIOTECHNOL LTD, OXFORD OX4 5LY, ENGLAND		MOULD, AP (corresponding author), UNIV MANCHESTER, SCH BIOL SCI, MANCHESTER M13 9PT, LANCS, ENGLAND.		Garratt, Alistair/AAG-2715-2021; Garratt, Alistair N/D-9893-2013	Garratt, Alistair N/0000-0001-9631-3041; Humphries, Martin/0000-0002-4331-6967	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALBELDA SM, 1990, CANCER RES, V50, P6757; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BAO L, 1993, DIFFERENTIATION, V52, P239, DOI 10.1111/j.1432-0436.1993.tb00636.x; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; BEDNARCZYK JL, 1992, CLIN EXP METASTAS, V10, P281; BERETA J, 1993, CELL IMMUNOL, V147, P313, DOI 10.1006/cimm.1993.1072; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CARLOS TM, 1990, BLOOD, V76, P965; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CLEMENTS JM, 1994, J CELL SCI, V107, P2127; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; DIMILLA PA, 1991, BIOPHYS J, V60, P15, DOI 10.1016/S0006-3495(91)82027-6; DOBRINA A, 1991, J CLIN INVEST, V88, P20, DOI 10.1172/JCI115278; DRAKE SL, 1992, J CELL BIOL, V117, P1331, DOI 10.1083/jcb.117.6.1331; DUFOUR S, 1988, EMBO J, V7, P2661, DOI 10.1002/j.1460-2075.1988.tb03119.x; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FERGUSON TA, 1991, P NATL ACAD SCI USA, V88, P8072, DOI 10.1073/pnas.88.18.8072; FREEDMAN AS, 1990, SCIENCE, V249, P1030, DOI 10.1126/science.1697696; GARCIAPARDO A, 1989, EXP CELL RES, V181, P420, DOI 10.1016/0014-4827(89)90099-2; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HAUGEN PK, 1992, J NEUROSCI, V12, P2034; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; HERSHBERGER RP, 1990, MOL CELL BIOL, V10, P662, DOI 10.1128/MCB.10.2.662; HESSION C, 1991, J BIOL CHEM, V266, P6682; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HUMPHRIES MJ, 1988, J CELL BIOL, V106, P1289, DOI 10.1083/jcb.106.4.1289; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOZLOWSKI JM, 1984, J NATL CANCER I, V72, P913; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; KUIJPERS TW, 1993, J EXP MED, V178, P279, DOI 10.1084/jem.178.1.279; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLIER T, 1993, SCIENCE, V259, P692, DOI 10.1126/science.8430321; LAUFFENBURGER D, 1989, CHEM ENG SCI, V44, P1903, DOI 10.1016/0009-2509(89)85131-0; MAKAREM R, 1994, J BIOL CHEM, V269, P4005; MCCARTHY JB, 1988, BIOCHEMISTRY-US, V27, P1380, DOI 10.1021/bi00404a044; MCCARTHY JB, 1990, J CELL BIOL, V110, P777, DOI 10.1083/jcb.110.3.777; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; MOULD AP, 1990, J BIOL CHEM, V265, P4020; MOULD AP, 1991, J BIOL CHEM, V266, P3579; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; MULLER B, 1993, J BIOL CHEM, V268, P6800; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PERRIS R, 1989, DEV BIOL, V136, P222, DOI 10.1016/0012-1606(89)90144-9; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKIGUCHI K, 1989, BIOCHEMISTRY-US, V28, P3293, DOI 10.1021/bi00434a026; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TENCHINI ML, 1993, CELL ADHES COMMUN, V1, P55, DOI 10.3109/15419069309095681; THORNHILL MH, 1991, J IMMUNOL, V146, P592; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; WALSH GM, 1991, J IMMUNOL, V146, P3419; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WELLER PF, 1991, P NATL ACAD SCI USA, V88, P7430, DOI 10.1073/pnas.88.16.7430; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	71	115	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27224	27230						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525548				2022-12-25	WOS:A1994PV77100014
J	GULLIVER, GA; VOSS, EW				GULLIVER, GA; VOSS, EW			EFFECT OF TRANSPLANTATION OF ANTIBODY HEAVY-CHAIN COMPLEMENTARITY-DETERMINING REGIONS ON LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; MONOCLONAL-ANTIBODIES; IDIOTYPE FAMILY; FAB COMPLEX; AUTOANTIBODY	Active site structure-function analyses of anti-fluorescein single chain antibody 4-4-20 and anti-single-stranded DNA single chain antibody 04-01 were conducted studying the ligand binding properties of hybrid antibodies resulting from systematic transplantation of heavy chain complementarity regions (HCDRs) from monoclonal antibody 4-4-20 into 04-01. Two prototype monoclonal antibodies were chosen because the primary structures of their respective light chains were nearly identical but the specificities and shape of their active sites were distinctly different. Based on nearly identical light chains, the diverse active site conformations (i.e. 4-4-20 pocket and 04-01 cleft) and subsequent specificities of the two antibodies were likely dictated by heavy chain properties, As a result, specificities of each HCDR transplant were analyzed in terms of binding reactivity with either fluorescein or (dT)(8). Results of binding studies, together with idiotypic and secondary structure analyses, were used to determine the relative contribution of each HCDR to the active site conformations and ligand specificities of monoclonal antibodies 4-4-20 and 04-01. Collectively the various analyses led to the conclusion that the intradomain conformational dynamics and cooperativity necessary for the structural integrity of the low affinity cleft-shaped 04-01 anti-single-stranded DNA active site are probably less stringent than those of a high affinity pocket-shaped anti-fluorescein active site.	UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign								BALLARD DW, 1984, J BIOL CHEM, V259, P3492; BATES RM, 1985, MOL IMMUNOL, V22, P871, DOI 10.1016/0161-5890(85)90072-0; BEDZYK WD, 1989, J BIOL CHEM, V264, P1565; BEDZYK WD, 1990, J BIOL CHEM, V265, P133; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; DENZIN LK, 1991, J BIOL CHEM, V266, P14095; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GULLIVER GA, 1994, J BIOL CHEM, V269, P7934; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; KRANZ DM, 1981, MOL IMMUNOL, V18, P889, DOI 10.1016/0161-5890(81)90012-2; RUMBLEY CA, 1993, J BIOL CHEM, V268, P13667; SCANDELLA D, 1985, J CELL BIOCH B, V9, P203; SMITH R G, 1989, Journal of the Indian Institute of Science, V69, P25; SMITH RG, 1990, MOL IMMUNOL, V27, P463, DOI 10.1016/0161-5890(90)90171-U; TETIN SY, 1992, BIOCHEMISTRY-US, V31, P12029, DOI 10.1021/bi00163a010	18	6	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24040	24045						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523365				2022-12-25	WOS:A1994PQ34600032
J	ZINNEN, S; HSIEH, JC; MODRICH, P				ZINNEN, S; HSIEH, JC; MODRICH, P			MISINCORPORATION AND MISPAIRED PRIMER EXTENSION BY HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-I KLENOW; MURINE LEUKEMIA-VIRUS; KINETIC MECHANISM; DNA-REPLICATION; STEADY-STATE; FIDELITY; RNA; HIV-1; TYPE-1; THERMODYNAMICS	Pre-steady-state methods were used to study the fidelity of human immunodeficiency virus reverse transcriptase. Fidelity of DNA-directed DNA synthesis can be attributed to a 1-2 order of magnitude reduction in affinity for noncomplementary dNTPs, and a 1-4 order of magnitude reduction in the rate of the conformational change that limits the rate of nucleotide addition. Affinities of reverse transcriptase for paired or mispaired primer termini are similar. Discrimination against a mispaired primer is due to reduction in affinity for the next dNTP and reduction in rate of extension. Extension of mispaired termini proceeds 20-700-fold faster than the rate of dissociation of reverse transcriptase from the primer-template and is 2-3 orders of magnitude more frequent than nucleotide misincorporation. The rate-limiting step for extension of a mispaired terminus occurs at the conformational change or chemical step, depending on the nature of the mispair. Presence of a mismatch at the 3' penultimate position reduces pyrophosphorolysis of the primer by a factor of 10(3), indicating that mispairs 5' to the site of chemistry can also affect catalysis.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University				Modrich, Paul/0000-0001-8708-9885	NIGMS NIH HHS [GM23719] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023719, R37GM023719] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTTS J, 1991, J BIOL CHEM, V266, P3937; BAKHANASHVILI M, 1992, FEBS LETT, V306, P151, DOI 10.1016/0014-5793(92)80988-S; BAKHANASHVILI M, 1992, BIOCHEMISTRY-US, V31, P9393, DOI 10.1021/bi00154a010; BAKHANASHVILI M, 1993, FEBS LETT, V319, P201, DOI 10.1016/0014-5793(93)80067-5; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOYER JC, 1992, P NATL ACAD SCI USA, V89, P6919, DOI 10.1073/pnas.89.15.6919; DEUTSCHER MP, 1969, J BIOL CHEM, V244, P3019; EGER BT, 1992, BIOCHEMISTRY-US, V31, P9227, DOI 10.1021/bi00153a016; Fersht A., 1985, ENZYME STRUCTURE MEC; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4315; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; HUBNER A, 1992, J MOL BIOL, V223, P595, DOI 10.1016/0022-2836(92)90975-P; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; KATI WM, 1992, J BIOL CHEM, V267, P25988; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUNKEL TA, 1986, J BIOL CHEM, V261, P3610; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; REARDON JE, 1993, J BIOL CHEM, V268, P8743; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; TAKEUCHI Y, 1988, J VIROL, V62, P3900, DOI 10.1128/JVI.62.10.3900-3902.1988; VARMUS H, 1985, RNA TUMOR VIRUSES, P75; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; WEBER J, 1989, NUCLEIC ACIDS RES, V17, P1379, DOI 10.1093/nar/17.4.1379; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; YU H, 1992, J BIOL CHEM, V267, P10888	36	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24195	24202						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523369				2022-12-25	WOS:A1994PQ34600056
J	WERGE, TM				WERGE, TM			IDENTIFICATION OF AN EPITOPE IN THE SUBSTANCE-P RECEPTOR IMPORTANT FOR RECOGNITION OF THE COMMON CARBOXYL-TERMINAL TACHYKININ SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; NEUROKININ-1 RECEPTOR; MONOCLONAL-ANTIBODY; BINDING; SPECIFICITY; EXPRESSION; DOMAINS; NK1; SELECTIVITY; ANTAGONIST	The substance P receptor and the anti-substance P antibody NC1 share the ability to bind to the COOH terminus of substance P. Sequence analysis identified a direct noninterrupted homology of 5 residues in the two molecules. Replacement of Gly(166) and Tyr(167) in this epitope of the substance P receptor by the corresponding substance K receptor amino acids (Cys and Phe) increases the affinity toward substance P 2-fold and toward substance K and neurokinin B 11- and 21-fold, respectively. A significantly larger effect of the mutation is observed for the hexapeptides of substance P and sub stance K which show a mutation-induced increase in binding energy of more than 2 kcal/mol. Hence, the NH2 terminus of substance P and, to a lesser extent, of substance K masks the effect of the mutation. I conclude that the epitope is important for recognition of the common COOH terminus of the tachykinins and for preservation of selectivity. The data furthermore suggest that formation of the peptide-receptor complex occurs through a composite set of interactions which are not adequately described by the two-site/no cooperativity ''address-message'' model.	CNR,INST NEUROBIOL,I-00137 ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR)								CASCIERI MA, 1992, MOL PHARMACOL, V41, P1096; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CUELLO AC, 1979, P NATL ACAD SCI USA, V76, P3532, DOI 10.1073/pnas.76.7.3532; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; FONG TM, 1992, J BIOL CHEM, V267, P25668; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FONG TM, 1993, NATURE, V362, P350; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, J BIOL CHEM, V268, P7893; GETHER U, 1993, P NATL ACAD SCI USA, V90, P6194, DOI 10.1073/pnas.90.13.6194; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; INGI T, 1991, J PHARMACOL EXP THER, V259, P968; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKANISHI S, 1987, PHYSIOL REV, V67, P1117, DOI 10.1152/physrev.1987.67.4.1117; NAKANISHI S, 1991, ANNU REV NEUROSCI, V14, P123, DOI 10.1146/annurev.ne.14.030191.001011; PICCIOLI P, 1991, P NATL ACAD SCI USA, V88, P5611, DOI 10.1073/pnas.88.13.5611; REGOLI D, 1988, TRENDS PHARMACOL SCI, V9, P290, DOI 10.1016/0165-6147(88)90013-2; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; Schwyzer R, 1977, Ann N Y Acad Sci, V297, P3, DOI 10.1111/j.1749-6632.1977.tb41843.x; SHIGEMOTO R, 1990, J BIOL CHEM, V265, P623; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	24	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22054	22058						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7520910				2022-12-25	WOS:A1994PE09800022
J	TSUKAHARA, H; ENDE, H; MAGAZINE, HI; BAHOU, WF; GOLIGORSKY, MS				TSUKAHARA, H; ENDE, H; MAGAZINE, HI; BAHOU, WF; GOLIGORSKY, MS			MOLECULAR AND FUNCTIONAL-CHARACTERIZATION OF THE NON-ISOPEPTIDE-SELECTIVE ET(B) RECEPTOR IN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; HUMAN UMBILICAL VEIN; PROTEIN-KINASE-C; VASCULAR ENDOTHELIUM; SIGNAL TRANSDUCTION; MESANGIAL CELLS; SMOOTH-MUSCLE; CLONING; EXPRESSION; DNA	There is accumulating evidence that endothelial cells express a non-isopeptide-selective endothelin (ET) receptor, ET(B), which may be responsible for ET-1-induced transient vasorelaxation. The purpose of the present study was to seek direct evidence for ET(B) receptor expression in human umbilical vein endothelial cells (HUVEC) and to characterize its functional role in HUVEC and in Chinese hamster ovary cells stably transfected with ET(B) receptor cDNA (CHO-ET(B)). Reverse polymerase chain reaction using HUVEC total RNA and ET(B) receptor-specific oligonucleotide primers firmly demonstrated the presence of an endogenous transcript of the appropriate molecular size. Next, a biotinylated ligand specifically recognizing the ET(B) receptor, IRL-1620, was synthesized, and immunocytochemical mapping of binding sites was performed in CHO-ET(B) cells. Specific binding of biotinylated IRL-1620 was evident in CHO-ET(B) cells, confirming appropriate cell surface receptor expression. continuous nitric oxide (NO) monitoring with NO-selective electrode revealed a dose-dependent ET-1 stimulation of NO production by HUVEC. Stable transfection of CHO-ET(B) cells with endothelial nitric oxide synthase (NOS), but not mock-transfection, imparted responsiveness to ET-1 similar to that for HUVEC and was characterized by the immediate release of NO. Protein tyrosine kinase-dependent and calcium-calmodulin-dependent pathways were involved in ET-1-induced activation fo the constitutive NOS in CHO-ET(B)/NOS cells, but coupling of the receptor to the enzyme in HUVEC appeared to be predominantly protein tyrosine kinase-dependent. Although sufficient calcium/calmodulin system was not an obligatory prerequisite for the ET-1-induced activation of NOS in HUVEC. In conclusion, using two cell systems, we demonstrated that the ET(B) receptor is functionally coupled to NOS and coordinates the generation of NO via a tyrosine kinase-dependent and a calcium/calmodulin-dependent pathway.	SUNY STONY BROOK,DIV NEPHROL & HYPERTENS,STONY BROOK,NY 11794; SUNY STONY BROOK,DIV HEMATOL,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT MED,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794; CUNY QUEENS COLL,DEPT BIOL,FLUSHING,NY 11367	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; City University of New York (CUNY) System; Queens College NY (CUNY)					NHLBI NIH HHS [HL-02431] Funding Source: Medline; NIDDK NIH HHS [DK-45695, DK-41573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045695, R29DK041573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; BAHOU WF, 1992, J BIOL CHEM, V267, P13986; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DONG ZY, 1993, J IMMUNOL, V151, P2717; EMORI T, 1990, FEBS LETT, V263, P261, DOI 10.1016/0014-5793(90)81388-5; FORCE T, 1991, J BIOL CHEM, V266, P6650; FUJITANI Y, 1992, FEBS LETT, V298, P79, DOI 10.1016/0014-5793(92)80026-D; HAGIWARA H, 1993, AM J PHYSIOL, V264, pR777, DOI 10.1152/ajpregu.1993.264.4.R777; HIRATA Y, 1993, J CLIN INVEST, V91, P1367, DOI 10.1172/JCI116338; IIJIMA K, 1991, AM J PHYSIOL, V260, pF848, DOI 10.1152/ajprenal.1991.260.6.F848; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KAUFMAN RJ, 1982, J MOL BIOL, V159, P601, DOI 10.1016/0022-2836(82)90103-6; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANDER HM, 1993, J IMMUNOL, V150, P1509; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; MAGAZINE HI, 1991, BIOCHEM BIOPH RES CO, V181, P1245, DOI 10.1016/0006-291X(91)92072-R; MARCZIN N, 1993, AM J PHYSIOL, V265, pH1014, DOI 10.1152/ajpheart.1993.265.3.H1014; OGAWA Y, 1991, BIOCHEM BIOPH RES CO, V178, P248, DOI 10.1016/0006-291X(91)91806-N; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHETTY SS, 1993, BIOCHEM BIOPH RES CO, V191, P459, DOI 10.1006/bbrc.1993.1240; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; SOKOLOVSKY M, 1992, J BIOL CHEM, V267, P20551; TAKAGI Y, 1990, BIOCHEM BIOPH RES CO, V168, P537, DOI 10.1016/0006-291X(90)92354-3; TAKAYANAGI R, 1991, FEBS LETT, V282, P103, DOI 10.1016/0014-5793(91)80454-B; TSUKAHARA H, 1993, BIOCHEM BIOPH RES CO, V193, P722, DOI 10.1006/bbrc.1993.1685; TSUKAHARA H, 1994, KIDNEY INT, V45, P598, DOI 10.1038/ki.1994.78; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	33	221	223	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21778	21785						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	7520443				2022-12-25	WOS:A1994PK97300060
J	MAO, XH; MIESFELDT, S; YANG, HD; LEIDEN, JM; THOMPSON, CB				MAO, XH; MIESFELDT, S; YANG, HD; LEIDEN, JM; THOMPSON, CB			THE FLI-1 AND CHIMERIC EWS-FLI-1 ONCOPROTEINS DISPLAY SIMILAR DNA-BINDING SPECIFICITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETS GENE FAMILY; TRANSCRIPTION FACTOR; PROTEIN; DOMAIN; SEQUENCE; ACTIVATION; EXPRESSION; ONCOGENE; ENHANCER; C-ETS-1	Although recent data have demonstrated that the chimeric EWS-FLI-1 cDNA isolated from cases of Ewing's sarcoma can transform NIH 3T3 cells, little is known about the basis for this transformation. Since FLI-1 and EWS-FLI-1 contain an Ets domain, both proteins may act as sequence-specific transcription factors. Here the DNA binding properties of FLI-1 and EWS-FLI-1 have been examined. An epitope-tagging strategy was developed to determine the optimum DNA-binding sequence of FLI-1. The alignment of cloned binding sequences showed a consensus DNA-binding site of ACCGGAAG/aT/c. This consensus sequence shows greater specificity for sequence 5' of the GGAA core site than those of other Ets proteins. Using several truncated forms of FLI-1, we show that the Ets domain is necessary and sufficient for the DNA binding specificity of FLI-1. The EWS-FLI-1 protein displayed the same DNA binding specificity and affinity as FLI-1 did. Despite their DNA binding similarities, the EWS-FLI-1 translocation product is likely to have a distinct pattern of expression from that of FLI-1 since the translocation results in the replacement of the 5' regulatory region of Fli-1 with that of EWS. Consistent with this we found that Fli-1 mRNA expression in lymphocytes was high in quiescent cells and disappeared upon activation while EWS mRNA expression was low in resting cells and increased in activated T cells. In summary, our data suggest that EWS-FLI-1 might act through the same target genes normally regulated by FLI-1, and EWS-FLI-1-induced transformation may result from dysregulation of FLI-1 target genes during cell proliferation and differentiation.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV MICHIGAN,MED CTR,DEPT MICROBIOL IMMUNOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Chicago; University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan								BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FISHER RJ, 1991, ONCOGENE, V6, P2249; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEDBETTER JA, 1987, P NATL ACAD SCI USA, V84, P1384, DOI 10.1073/pnas.84.5.1384; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PRASAD DDK, 1992, CANCER RES, V52, P5833; REDDY ESP, 1991, ONCOGENE, V6, P2285; SOOD AK, 1981, P NATL ACAD SCI-BIOL, V78, P616, DOI 10.1073/pnas.78.1.616; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WEIGHT WE, 1991, MOL CELL BIOL, V11, P4104; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	41	117	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18216	18222						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	7517940				2022-12-25	WOS:A1994NV42200068
J	KOMADA, M; KITAMURA, N				KOMADA, M; KITAMURA, N			REGULATORY ROLE OF MAJOR TYROSINE AUTOPHOSPHORYLATION SITE OF KINASE DOMAIN OF C-MET RECEPTOR (SCATTER FACTOR/HEPATOCYTE GROWTH-FACTOR RECEPTOR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-I; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; HUMAN FIBROBLASTS; RAT HEPATOCYTES; DNA-SYNTHESIS; PROTOONCOGENE; IDENTIFICATION; MOTILITY; INSULIN	Ligand-induced tyrosine kinase activation of the scatter factor/hepatocyte growth factor receptor (c-Met) is thought to be essential for the biological responses of target cells. To assess the regulatory role of the major tyrosine autophosphorylation site (tyrosine 1233) of the mouse c-Met receptor in the tyrosine kinase activation of the receptor, we constructed a mutant receptor in which the tyrosine residue was replaced with phenylalanine. When the cells expressing the mutant receptor were incubated with the ligand, no biological responses were observed, and the level of tyrosine phosphorylation of the receptor was very low compared with that of the wild-type receptor. The in vitro kinase activity of the mutant receptor toward an exogenous substrate and the receptor itself was also low. Furthermore, tyrosine phosphorylation of the cellular proteins by ligand stimulation was not detected in intact cells expressing the mutant receptor. The low level of kinase activity and the lack of biological activity of the mutant receptor indicate that the major autophosphorylation site positively regulates the tyrosine kinase of the c-Met receptor and phosphorylation of cellular substrates in the scatter factor/hepatocyte growth factor signaling pathway.	KANSAI MED UNIV, INST LIVER RES, MORIGUCHI, OSAKA 570, JAPAN	Kansai Medical University								ARAKAKI N, 1992, BIOCHEM BIOPH RES CO, V185, P22, DOI 10.1016/S0006-291X(05)80949-0; BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CHAN AML, 1988, ONCOGENE, V2, P593; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1991, CELL GROWTH DIFFER, V2, P483; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRONBORG M, 1993, J BIOL CHEM, V268, P23435; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; ISHIKI Y, 1992, HEPATOLOGY, V16, P1227, DOI 10.1016/0270-9139(92)90019-6; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KOMADA M, 1993, ONCOGENE, V8, P2381; KOMADA M, 1992, EUR J BIOCHEM, V204, P857, DOI 10.1111/j.1432-1033.1992.tb16705.x; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; STERN CD, 1990, DEVELOPMENT, V110, P1271; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STRAIN AJ, 1991, J CLIN INVEST, V87, P1853, DOI 10.1172/JCI115207; SUEMORI H, 1990, CELL DIFFER DEV, V29, P181, DOI 10.1016/0922-3371(90)90120-L; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WILDEN PA, 1992, J BIOL CHEM, V267, P13719	45	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16131	16136						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	7515877				2022-12-25	WOS:A1994NQ72900029
J	VANDEPUT, FHMM; DEPONT, JJHHM; WILLEMS, PHGM				VANDEPUT, FHMM; DEPONT, JJHHM; WILLEMS, PHGM			HETEROGENEITY BETWEEN INTRACELLULAR CA2+ STORES AS THE UNDERLYING PRINCIPLE OF QUANTAL CA2+ RELEASE BY INOSITOL 1,4,5-TRISPHOSPHATE IN PERMEABILIZED PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM RELEASE; LUMINAL CA2+; CA-2+ RELEASE; MOBILIZATION; HEPATOCYTES; SENSITIVITY; SIZE; POOL	Permeabilized rabbit pancreatic acinar cells were used to study the effects of Ca2+ pump inhibition and Ca2+ store depletion on the sensitivity of internal Ca2+ stores to emptying by inositol 1,4,5-trisphosphate (Ins-1,4,5-P-3). Complete inhibition of pump activity by thapsigargin resulted in the monoexponential loss of 92% of the actively stored Ca2+ with a half time of 6.2 min. Under these conditions, Ca2+ release evoked by a submaximal concentration of Ins-1,4,5-P, did not cease after 1.5 min, as was observed in the absence of thapsigargin, but continued for at least 5 min. This observation suggests that under normal conditions of Ca2+ pumping, a substantial part of the internal Ca2+ stores is not depleted by the action of Ins-1,4,5-P-3 due to compensatory Ca2+ uptake. Evidence in support of the idea of compensatory Ca2+ primping was obtained in exchange experiments performed in the absence of thapsigargin. The slow kinetics of sustained Ca2+ release in the absence of Ca2+ pump activity suggests that Ca2+ is released from stores containing either relatively few or less sensitive Ins-1,4,5-P-3-operated Ca2+ release channels. Gradual emptying of the internal Ca2+ stores by thapsigargin did not affect the potency with which Ins-1,4,5-P-3 released Ca2+, indicating that the intravesicular Ca2+ content does not control the sensitivity of the Ins-1,4,5-P-3-operated Ca2+ channel to activation by Ins-1,4,5-P-3. This was confirmed using ruthenium red, which preferentially depleted the Ins-1,4,5 P-3-releasable store without affecting the EC(50) for Ins-1,4,5 P-3-stimulated Ca2+ release. The data presented indicate that the quantal type of Ca2+ release observed with Ins 1,4,5 P-3 requires compensatory Ca2+ pumping. Moreover, they support the idea that internal Ca2+ stores display differential sensitivities toward Ins-1,4,5-P-3 rather than responding uniformly to this internal Ca2+-mobilizing messenger.	UNIV NIJMEGEN,DEPT BIOCHEM,6500 HB NIJMEGEN,NETHERLANDS	Radboud University Nijmegen			Willems, P.H.G.M./L-4759-2015	Willems, P.H.G.M./0000-0002-0915-1599				AMSTERDA.A, 1974, J CELL BIOL, V63, P1037, DOI 10.1083/jcb.63.3.1037; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; COMBETTES L, 1993, CELL CALCIUM, V14, P279, DOI 10.1016/0143-4160(93)90049-C; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; LOOMISHUSSELBEE JW, 1993, BIOCHEM J, V289, P861, DOI 10.1042/bj2890861; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; ROUXEL FP, 1992, J BIOL CHEM, V267, P20017; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; SHUTTLEWORTH TJ, 1992, J BIOL CHEM, V267, P3573; TAYLOR CW, 1985, BIOCHEM J, V232, P435, DOI 10.1042/bj2320435; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; VANDEPUT FHMM, 1993, J MEMBRANE BIOL, V135, P153, DOI 10.1007/BF00231441; VANDEPUT FHMM, 1993, EUR J BIOCHEM, V218, P959; VANDEPUT FHMM, 1991, CELL CALCIUM, V12, P587, DOI 10.1016/0143-4160(91)90056-K; WILLEMS PHGM, 1989, J BIOL CHEM, V264, P9762; ZHANG BX, 1993, J BIOL CHEM, V268, P10997	27	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12438	12443						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7513688				2022-12-25	WOS:A1994NH71600013
J	DUCHEMIN, AM; ERNST, LK; ANDERSON, CL				DUCHEMIN, AM; ERNST, LK; ANDERSON, CL			CLUSTERING OF THE HIGH-AFFINITY FC RECEPTOR FOR IMMUNOGLOBULIN-G (FC-GAMMA-RI) RESULTS IN PHOSPHORYLATION OF ITS ASSOCIATED GAMMA-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CELL ANTIGEN RECEPTOR; T-CELL; ZETA-CHAIN; SIGNAL TRANSDUCTION; CROSS-LINKING; ACTIVATION; IGG; REQUIREMENTS; ENGAGEMENT	We are investigating the role of gamma-chain in functions mediated by the high affinity Fc receptor for IgG (Fc gamma RI). In a previous study, we found that gamma-chain, which is a member of the family of zeta-chain proteins, associates with Fc gamma RI, Here we show that clustering of Fc gamma RI leads to a rapid and transient tyrosine phosphorylation of gamma-chain in U937 cells. The response was lim- ited to Fc gamma RI activation, and no phosphorylation of gamma-chain was observed after cross-linking of monoclonal antibodies to other surface receptors on these cells. The gamma-chain phosphorylated after Fc gamma RI clustering was the gamma-chain associated with the receptor. We also identified Syk as one of the kinases associated with the receptor complex. Upon Fc gamma RI activation, Syk, but not ZAP-70, was phosphorylated, and reimmunoadsorption experiments of phosphoproteins from immune complex in vitro kinase assays indicated that Syk is part of the activated gamma-chain-Fc gamma RI complex. These results suggest that gamma-chain links Fc gamma RI to intracellular transduction pathways.	OHIO STATE UNIV,COLL MED,DEPT INTERNAL MED,DAVIS MED RES CTR 2054,COLUMBUS,OH 43210	University System of Ohio; Ohio State University					NCI NIH HHS [R01-CA44983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL A, 1993, J BIOL CHEM, V268, P15900; AKERLEY WL, 1991, BLOOD, V77, P607; ANDERSON CL, 1982, J EXP MED, V156, P1794, DOI 10.1084/jem.156.6.1794; AZZONI L, 1992, J EXP MED, V176, P1745, DOI 10.1084/jem.176.6.1745; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BOLEN JB, 1993, ONCOGENE, V8, P2025; BONNEROT C, 1992, EMBO J, V11, P2747, DOI 10.1002/j.1460-2075.1992.tb05340.x; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; DEBETS JMH, 1990, J IMMUNOL, V144, P1304; EISEMAN E, 1992, NATURE, V355, P78; ENGELHARDT W, 1991, EUR J IMMUNOL, V21, P2227, DOI 10.1002/eji.1830210934; ERNST LK, 1992, J BIOL CHEM, V267, P15692; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; GUYRE PM, 1989, J IMMUNOL, V143, P1650; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HULETT MD, 1991, J IMMUNOL, V147, P1863; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; ODIN JA, 1991, SCIENCE, V254, P1785, DOI 10.1126/science.1837175; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RANKIN BM, 1993, J IMMUNOL, V150, P605; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; SCHOLL PR, 1992, J IMMUNOL, V149, P1751; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WIRTHMUELLER U, 1992, J EXP MED, V175, P1381, DOI 10.1084/jem.175.5.1381	42	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12111	12117						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512959				2022-12-25	WOS:A1994NG37700067
J	CANTIELLO, HF; PRAT, AG; REISIN, IL; ERCOLE, LB; ABRAHAM, EH; AMARA, JF; GREGORY, RJ; AUSIELLO, DA				CANTIELLO, HF; PRAT, AG; REISIN, IL; ERCOLE, LB; ABRAHAM, EH; AMARA, JF; GREGORY, RJ; AUSIELLO, DA			EXTERNAL ATP AND ITS ANALOGS ACTIVATE THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR BY A CYCLIC AMP-INDEPENDENT MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AIRWAY EPITHELIAL-CELLS; EXTRACELLULAR ATP; CHANNELS; BINDING; PROTEINS; CL	The cystic fibrosis transmembrane conductance regulator (CFTR) is a Cl- channel activated by protein kinase A and regulated by ATP in a complex manner. We have applied patch-clamp techniques to C127i mouse mammary carcinoma cells transfected with human CFTR to assess the role of external ATP in the modulation of CFTR function. Extracellular ATP was sufficient to activate non-rectifying, Cl-selective whole-cell currents in CFTR-transfected, but not mock-transfected cells. The ATP-mediated activation of CFTR was independent of protein kinase A since channel activation by ATP was preserved in cells that were (a) depleted of intracellular ATP, (b) incubated with the cAMP antagonist R(p)-cAMPS, or (c) exposed to the protein kinase A inhibitor, 5-24 amide. In each of these conditions, 8-Br-cAMP was no longer capable of activating CFTR. The possibility that the extracellular ATP activation of Cl- currents in CFTR-expressing C127i cells was mediated by a P2-type purinergic receptor was supported by studies in which the effect of external ATP on the Cl- currents was mimicked by the ATP analogs, ATP-gammaS and beta,gamma-methylene ATP, but not the uridine nucleotide, UTP. Single-channel analysis of ATP-activated Cl- currents under both cell-attached and excised, inside-out patch-clamp configurations indicated that this channel is only present in CFTR-transfected cells and indistinguishable from CFTR. External ATP also activated ATP currents in CFTR-transfected cells, a novel function of CFTR. These findings are consistent with the presence of a purinergic receptor signal transduction mechanism in C127i cells whose activation by external ATP is linked to the activation of CFTR in a cAMP-independent manner. The. data provide additional support for the use of ATP and its analogs as alternative therapies in cystic fibrosis.	MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; GENZYME CORP,FRAMINGHAM,MA 01701	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Sanofi-Aventis; Genzyme Corporation								ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; BOUCHER RC, 1988, J PHYSIOL-LONDON, V405, P77, DOI 10.1113/jphysiol.1988.sp017322; CANTIELLO HF, 1990, J BIOL CHEM, V265, P21624; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; CANTIELLO HF, 1993, J BIOL CHEM, V268, P4596; CHENG HC, 1986, J BIOL CHEM, V261, P989; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; DUBYAK GR, 1990, BIOL ACTIONS EXTRACE, V603; EGAN M, 1992, NATURE, V358, P531; FALKE LC, 1989, J GEN PHYSIOL, V94, pA34; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; LEVITAN ES, 1990, NATURE, V348, P545, DOI 10.1038/348545a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; Reisin I. L., 1992, Journal of General Physiology, V100, p33A; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RUGGIERI MR, 1990, ANN NY ACAD SCI, V603, P458; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; VANHAASTERT PJM, 1984, J BIOL CHEM, V259, P20; YANKASKAS JR, 1985, AM REV RESPIR DIS, V132, P1281	23	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11224	11232						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512560				2022-12-25	WOS:A1994NF96600040
J	ALLANDER, SV; LARSSON, C; EHRENBORG, E; SUWANICHKUL, A; WEBER, G; MORRIS, SL; BAJALICA, S; KIEFER, MC; LUTHMAN, H; POWELL, DR				ALLANDER, SV; LARSSON, C; EHRENBORG, E; SUWANICHKUL, A; WEBER, G; MORRIS, SL; BAJALICA, S; KIEFER, MC; LUTHMAN, H; POWELL, DR			CHARACTERIZATION OF THE CHROMOSOMAL GENE AND PROMOTER FOR HUMAN INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; MAMMALIAN-CELLS; IGF-II; IDENTIFICATION; LOCALIZATION; REGION; ACID; IGFBP-5; VECTORS; SERUM	To better understand the regulation of insulin-like growth factor binding protein-5 (IGFBP-5) expression, we cloned the IGFBP-5 gene from human genomic libraries and identified a region in the 5' flanking sequence which functions as a promoter. The human IGFBP-5 gene is divided into four exons which, primarily due to a first intron of similar to 25 kilobases, span similar to 33 kilobases of DNA. Southern analysis identified a single copy of the IGFBP-5 gene in the haploid human genome, and several independent mapping strategies found this gene tightly linked with, and in opposite transcriptional orientation to, the IGFBP-2 gene at chromosomal region 2q33-34. Primer extension studies identified the IGFBP-5 mRNA cap site 772 base pairs (bp) 5' to the first nucleotide of the translation start codon. Analysis of the 5'-flanking sequence identified a potential TATA element beginning 33 bp 5' to the mRNA cap site. When a DNA fragment containing this cap site and 461 bp of upstream sequence was placed 5' to the chloramphenicol acetyltransferase reporter gene and transfected into MDA-MB-468 human breast cancer cells, it directed chloramphenicol acetyltransferase expression in an orientation specific manner, suggesting that this region contains elements essential for IGFBP-5 promoter activity.	KAROLINSKA INST, DEPT CLIN GENET, S-17176 STOCKHOLM, SWEDEN; BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA; CHIRON CORP, EMERYVILLE, CA 94608 USA	Karolinska Institutet; Baylor College of Medicine; Novartis			Weber, Günther/F-3410-2016	Ehrenborg, Ewa/0000-0003-1993-2468	NIDDK NIH HHS [R01 DK-38773] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038773] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; ANDRESS DL, 1991, BIOCHEM BIOPH RES CO, V176, P213, DOI 10.1016/0006-291X(91)90911-P; BACKELJAUW PF, 1993, ENDOCRINOLOGY, V132, P1677, DOI 10.1210/en.132.4.1677; BAJALICA S, 1992, HUM GENET, V89, P234; BAUTISTA CM, 1991, BIOCHEM BIOPH RES CO, V176, P756, DOI 10.1016/S0006-291X(05)80249-9; BERGERHEIM U, 1989, CANCER RES, V49, P1390; BERGERSL, 1987, METHDOS ENZYMOL, V152, P604; BINKERT C, 1992, MOL ENDOCRINOL, V6, P826, DOI 10.1210/me.6.5.826; BODMER WF, 1990, CYTOGENET CELL GENET, V55, P1; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CANNIZZARO LA, 1987, AM J HUM GENET, V41, P1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONOVER CA, 1993, ENDOCRINOLOGY, V132, P2525, DOI 10.1210/en.132.6.2525; CONOVER CA, 1993, J CLIN ENDOCR METAB, V76, P1153, DOI 10.1210/jc.76.5.1153; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; CUBBAGE ML, 1989, MOL ENDOCRINOL, V3, P846, DOI 10.1210/mend-3-5-846; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EHRENBORG E, 1992, GENOMICS, V12, P497, DOI 10.1016/0888-7543(92)90440-4; EHRENBORG E, 1991, BIOCHEM BIOPH RES CO, V176, P1250, DOI 10.1016/0006-291X(91)90420-C; ERICKSON GF, 1992, ENDOCRINOLOGY, V130, P1867, DOI 10.1210/en.130.4.1867; EVANS GA, 1989, GENE, V79, P9, DOI 10.1016/0378-1119(89)90088-7; FIGUEROA JA, 1993, J CELL BIOCHEM, V52, P196, DOI 10.1002/jcb.240520211; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JANSON M, 1991, P NATL ACAD SCI USA, V88, P10609, DOI 10.1073/pnas.88.23.10609; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; KUO JL, 1993, GENOMICS, V16, P173, DOI 10.1006/geno.1993.1155; LEE PDK, 1993, P SOC EXP BIOL MED, V204, P4; LEE YL, 1988, MOL ENDOCRINOL, V2, P404, DOI 10.1210/mend-2-5-404; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PENDLETON JW, 1993, P NATL ACAD SCI USA, V90, P6300, DOI 10.1073/pnas.90.13.6300; POWELL D, 1993, GROWTH REGULAT, V3, P11; POWELL DR, 1991, J BIOL CHEM, V266, P18868; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SHEIKH MS, 1992, BIOCHEM BIOPH RES CO, V183, P1003, DOI 10.1016/S0006-291X(05)80290-6; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SUWANICHKUL A, 1990, J BIOL CHEM, V265, P21185; SUWANICHKUL A, 1993, J BIOL CHEM, V268, P9730; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; UPTON Z, 1993, GROWTH REGULAT, V3, P29; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160; ZHU X, 1993, BIOCHEM BIOPH RES CO, V190, P1045, DOI 10.1006/bbrc.1993.1154; ENDOCRINOLOGY, V130, P1736	50	54	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10891	10898						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511611				2022-12-25	WOS:A1994NF01700103
J	MATSUGUCHI, T; SALGIA, R; HALLEK, M; EDER, M; DRUKER, B; ERNST, TJ; GRIFFIN, JD				MATSUGUCHI, T; SALGIA, R; HALLEK, M; EDER, M; DRUKER, B; ERNST, TJ; GRIFFIN, JD			SHC PHOSPHORYLATION IN MYELOID CELLS IS REGULATED BY GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR, INTERLEUKIN-3, AND STEEL FACTOR AND IS CONSTITUTIVELY INCREASED BY P210(BCR/ABL)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; RECEPTOR GENE FAMILY; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; PHILADELPHIA-CHROMOSOME; EXPRESSION CLONING; GM-CSF; PROTEINS; ACTIVATION	Granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor induce proliferation of hematopoietic cells through binding to specific, high affinity, cell surface receptors. However, little is known about post-receptor signal transduction pathways. Here we report that an SH2 domain containing protein previously implicated in the activation of p21(ras), Shc, is transiently tyrosine phosphorylated in myeloid cells after stimulation with granulocyte macrophage colony-stimulating factor, interleukin-3, or steel factor. Also, Shc was found to be constitutively tyrosine phosphorylated in myeloid cell Lines made factor independent by expression of p210(BCR/ABL). A Shc-associated 140-kDa protein was identified, which was phosphorylated on tyrosine residues transiently after cytokine stimulation and constitutively after expression of p210(BCR/ABL). These findings suggest that She could play an important role in a signal transduction pathway, which leads to the proliferation of myeloid cells.	DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115; DANA FARBER CANC INST,DIV MOLEC & CELLULAR BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School			Hallek, Michael/Y-3191-2019	Hallek, Michael/0000-0002-7425-4455; Druker, Brian/0000-0001-8331-8206	NCI NIH HHS [CA 34183, CA 36167] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036167, P01CA034183, R37CA036167] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BERNSTEIN A, 1991, SEMIN HEMATOL, V28, P138; BROXMEYER HE, 1988, CRC CR REV ONCOL-HEM, V8, P173, DOI 10.1016/S1040-8428(88)80016-7; CANNISTRA SA, 1990, P NATL ACAD SCI USA, V87, P93, DOI 10.1073/pnas.87.1.93; CANNISTRA SA, 1988, SEMIN HEMATOL, V25, P173; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COLLINS MKL, 1988, J CELL PHYSIOL, V137, P293, DOI 10.1002/jcp.1041370212; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DRUCKER B, 1992, BLOOD, V79, P2215; DRUKER B, 1992, BLOOD, V79, P2215; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GASSON JC, 1990, PROG CLIN BIOL RES, V352, P375; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HALLEK M, 1992, J CELL PHYSIOL, V153, P176, DOI 10.1002/jcp.1041530122; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KANAKURA Y, 1991, BLOOD, V77, P243; KANAKURA Y, 1990, BLOOD, V76, P706; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KUWAKI T, 1989, BIOCHEM BIOPH RES CO, V161, P16, DOI 10.1016/0006-291X(89)91553-2; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCOLL SR, 1991, BLOOD, V78, P1842; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; METCALF D, 1992, BLOOD, V79, P2861; METCALF D, 1986, BLOOD, V67, P257; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; PARK LS, 1990, PROG CLIN BIOL RES, V352, P189; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	46	166	168	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5016	5021						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508932				2022-12-25	WOS:A1994MX57100051
J	BUELT, MK; GLIDDEN, BJ; STORM, DR				BUELT, MK; GLIDDEN, BJ; STORM, DR			REGULATION OF P68 RNA HELICASE BY CALMODULIN AND PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID-SEQUENCE; BINDING-PROTEIN; PHOSPHORYLATION SITE; IDENTIFICATION; NEUROMODULIN; PURIFICATION; BRAIN; MEMBRANES; CLONING; CALCIUM	Human p68 RNA helicase is a nuclear RNA-dependent ATPase that belongs to a family of putative helicases known as the DEAD box proteins. These proteins have been implicated in aspects of RNA function including translation initiation, splicing, and ribosome assembly in a variety of organisms ranging from Escherichia coli to humans. While members of this family are believed to function in the manipulation of RNA secondary structure, little is known about the regulation of these enzymes. By immunological methods and sequence comparison, we have found that p68 possesses a region of sequence similarity to the conserved protein kinase C phosphorylation site and calmodulin binding domain (also known as the IQ domain) of the neural-specific proteins neuromodulin (GAP-43) and neurogranin (RC3). We report that p68 is phosphorylated by protein kinase C in vitro and binds calmodulin in a Ca2+- dependent manner. Both phosphorylation and calmodulin binding inhibited p68 ATPase activity, suggesting that the RNA unwinding activity of p68 may be regulated by dual Ca2+ signal transduction pathways through its IQ domain.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031496] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 31496, NS09174] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; Apel E D, 1992, Perspect Dev Neurobiol, V1, P3; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; BACHS O, 1987, J BIOL CHEM, V262, P10786; BAETGE EE, 1991, NEURON, V6, P21, DOI 10.1016/0896-6273(91)90118-J; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNELIUSSEN D, 1994, NATURE, V368, P760; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; HLOCH P, 1990, NUCLEIC ACIDS RES, V18, P3045, DOI 10.1093/nar/18.10.3045; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PATTERSON LF, 1992, NUCLEIC ACIDS RES, V20, P3063, DOI 10.1093/nar/20.12.3063; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKAGI T, 1990, J BIOL CHEM, V265, P19721; TALLANT EA, 1983, METHOD ENZYMOL, V102, P244; VENDRELL M, 1991, J NEUROCHEM, V57, P622, DOI 10.1111/j.1471-4159.1991.tb03793.x; WAKIM BT, 1987, BIOCHEMISTRY-US, V26, P7466, DOI 10.1021/bi00397a040; WATSON JB, 1990, J NEUROSCI RES, V26, P397, DOI 10.1002/jnr.490260402	34	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29367	29370						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7525583				2022-12-25	WOS:A1994PU28400009
J	SHANG, J; CLAYTON, DA				SHANG, J; CLAYTON, DA			HUMAN MITOCHONDRIAL TRANSCRIPTION TERMINATION EXHIBITS RNA-POLYMERASE INDEPENDENCE AND BIASED BIPOLARITY IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; TRANSFER RNALEU(UUR) GENE; STROKE-LIKE EPISODES; LACTIC-ACIDOSIS; POINT MUTATION; MELAS SUBGROUP; MYOPATHY; INVITRO; SITE; ENCEPHALOMYOPATHIES	Human mitochondrial 16 S rRNA 3'-end formation requires a tridecamer template sequence and a trans-acting protein of similar to 34 kDa. This protein binds tightly to its target sequence and further analysis of the protein-DNA complex revealed that the DNA is bent. Either T3, T7, Escherichia coli, or yeast mitochondrial RNA polymerase produced transcripts mapping at this termination site. With these heterologous RNA polymerases, RNA 3'-end formation was detected only in the transcription polarity opposite that of mitochondrial rRNA synthesis; the efficiency of termination in the homologous human RNA polymerase system is approximately a-fold greater in this same opposite polarity. These results suggested the possible importance of biased bipolar transcription termination in vivo. For wild-type mtDNA the apparent relative efficiency of termination in vivo reflected the values determined in vitro. Examination of a pathogenic human mtDNA mutation known to result in impaired termination in vitro showed no significant differences in relative transcript abundances in vivo, despite a loss of in vitro termination efficiency in both directions. Recently, six additional mitochondrial disease-associated point mutations have been reported that cluster at the human mitochondrial transcription termination site. None of these resulted in significantly impaired transcription termination in vitro.			SHANG, J (corresponding author), STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305, USA.				NIGMS NIH HHS [GM33088-24] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033088, R01GM033088] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATTEY J, 1980, J BIOL CHEM, V255, P1599; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; CHRISTIANSON TW, 1988, MOL CELL BIOL, V8, P4502, DOI 10.1128/MCB.8.10.4502; CHRISTIANSON TW, 1986, P NATL ACAD SCI USA, V83, P6277, DOI 10.1073/pnas.83.17.6277; DAGA A, 1993, J BIOL CHEM, V268, P8123; FISHER RP, 1985, J BIOL CHEM, V260, P1330; FISHER RP, 1992, J BIOL CHEM, V267, P3358; FISHER RP, 1991, J BIOL CHEM, V266, P9153; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; GOTO Y, 1992, ANN NEUROL, V31, P672, DOI 10.1002/ana.410310617; GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GRUMMT I, 1985, CELL, V43, P801, DOI 10.1016/0092-8674(85)90253-3; HAYASHI JI, 1993, BIOCHEM BIOPH RES CO, V197, P1049, DOI 10.1006/bbrc.1993.2584; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; KUHN A, 1990, NATURE, V344, P559, DOI 10.1038/344559a0; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913; MORTEN K, 1992, 2ND INT C HUM MIT PA, P39; OJALA D, 1981, NATURE, V290, P410; PAVCO PA, 1991, NUCLEIC ACIDS RES, V19, P4639, DOI 10.1093/nar/19.17.4639; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; PRENTKI P, 1987, NUCLEIC ACIDS RES, V15, P10060, DOI 10.1093/nar/15.23.10060; SACCOMANNO CF, 1992, BIOTECHNIQUES, V13, P846; SCHON EA, 1992, BIOCHIM BIOPHYS ACTA, V1101, P206, DOI 10.1016/S0005-2728(05)80021-0; SMID A, 1992, J MOL BIOL, V227, P635, DOI 10.1016/0022-2836(92)90213-4; SWEENEY MG, 1993, Q J MED, V86, P709; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D	34	42	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29112	29120						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7525579				2022-12-25	WOS:A1994PU16800088
J	WU, RL; CHEN, TT; SUN, TT				WU, RL; CHEN, TT; SUN, TT			FUNCTIONAL IMPORTANCE OF AN SP1-RELATED AND AN NFKB-RELATED NUCLEAR-PROTEIN IN A KERATINOCYTE-SPECIFIC PROMOTER OF RABBIT K3 KERATIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-SPECIFIC EXPRESSION; B TRANSCRIPTION FACTOR; BOX-BINDING-PROTEINS; KAPPA-B; CELL-TYPE; TRANSGENIC MICE; INTERMEDIATE FILAMENTS; BASEMENT-MEMBRANE; EPITHELIAL-CELLS; ACTIVATION	We have shown previously that a 300-base pair (bp) 5' upstream sequence of rabbit keratin K3 gene (RK3) can function as a keratinocyte-specific promoter in transient transfection assays. Electrophoretic mobility shift assays using various overlapping and mutated oligonucleotides established that corneal keratinocyte nuclear proteins bound in vitro to two sites (B and E). Immuno-supershift and UV cross-linking established that the keratinocyte nuclear binding protein of site B (5'-GGGGCTTTCC-3', -262 to -253 bp) was NFkB consisting of the p65 and p50 subunits. The E site contained an unusual GC-rich motif (5'-CCGCCCCCTG-3', -203 to -194 bp) whose sequence deviated from the Spl consensus in 4 out of 10 positions; this site bound an Sp1-related keratinocyte nuclear protein. Mutagenesis of the NFkB, GC motif, and both sites abolished 20, 50, and 75%, respectively, of the promoter activity in transfected keratinocytes. The NFkB-like keratinocyte nuclear protein was barely detectable in kidney epithelial cells, HeLa, and fibroblasts. The Sp1-related nuclear protein was abundant in keratinocytes and simple epithelial cells, but was much less abundant in fibroblasts. These results indicate that NFkB is present in significant quantities in keratinocyte nuclei and that the tissue restriction of the NFkB- and Sp1-related proteins, in combination with other factors, may contribute to the keratinocyte specificity of RK3 promoter.	NYU, SCH MED, RONALD O PERELMAN DEPT DERMATOL, EPITHELIAL BIOL UNIT, NEW YORK, NY 10016 USA; NYU, SCH MED, KAPLAN COMPREHENS CANC CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA	New York University; New York University			Sun, Tung-Tien/J-4425-2015	Sun, Tung-Tien/0000-0002-6841-1063	NEI NIH HHS [EY04722] Funding Source: Medline; NIAMS NIH HHS [AR7190-20] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007190] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ADAMS BS, 1991, NEW BIOL, V3, P1063; ALBERS K, 1992, INT REV CYTOL, V134, P243, DOI 10.1016/S0074-7696(08)62030-6; ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BESSEREAU JL, 1993, EMBO J, V12, P443, DOI 10.1002/j.1460-2075.1993.tb05676.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BLESSING M, 1989, EMBO J, V8, P117, DOI 10.1002/j.1460-2075.1989.tb03355.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUCHER P, 1992, MOL CELL BIOL, V13, P3176; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CHODOSH LA, 1989, CURRENT PROTOCOLS MO; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORAN TI, 1980, CELL, V22, P17, DOI 10.1016/0092-8674(80)90150-6; EICHNER R, 1984, J CELL BIOL, V98, P1388, DOI 10.1083/jcb.98.4.1388; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HUFF CA, 1993, J BIOL CHEM, V268, P377; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JAMIESON C, 1989, J EXP MED, V170, P1737, DOI 10.1084/jem.170.5.1737; JIANG CK, 1990, NUCLEIC ACIDS RES, V18, P247, DOI 10.1093/nar/18.2.247; JIANG CK, 1993, P NATL ACAD SCI USA, V90, P6786, DOI 10.1073/pnas.90.14.6786; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOLEGA J, 1989, DIFFERENTIATION, V42, P54, DOI 10.1111/j.1432-0436.1989.tb00607.x; KURPAKUS MA, 1992, DEV BIOL, V150, P243, DOI 10.1016/0012-1606(92)90239-D; LATTION AL, 1992, MOL CELL BIOL, V12, P5217, DOI 10.1128/MCB.12.11.5217; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; MACCHI M, 1989, EMBO J, V8, P4215, DOI 10.1002/j.1460-2075.1989.tb08607.x; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MCKNIGTH S, 1992, TRANSCRIPTIONAL REGU; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NEHLS MC, 1992, DNA CELL BIOL, V11, P443, DOI 10.1089/dna.1992.11.443; NEZNANOV NS, 1993, MOL CELL BIOL, V13, P1815, DOI 10.1128/MCB.13.3.1815; OGUIN WM, 1990, CELLULAR MOL BIOL IN, P301; OSHIMA R G, 1992, Current Opinion in Cell Biology, V4, P110, DOI 10.1016/0955-0674(92)90067-M; PECORINO LT, 1991, MOL CELL BIOL, V11, P3139, DOI 10.1128/MCB.11.6.3139; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; QUINLAN RA, 1985, ANN NY ACAD SCI, V455, P282, DOI 10.1111/j.1749-6632.1985.tb50418.x; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3796, DOI 10.1128/MCB.12.9.3796; ROMAN D, 1990, New Biologist, V2, P642; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCHERMER A, 1989, DIFFERENTIATION, V42, P103, DOI 10.1111/j.1432-0436.1989.tb00611.x; SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SNAPE AM, 1991, DEVELOPMENT, V113, P283; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STUN TT, 1984, TRANSFORMED PHENOTYP, P169; TSENG H, 1992, P NATL ACAD SCI USA, V89, P10311, DOI 10.1073/pnas.89.21.10311; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; WU RL, 1993, J CELL SCI, V105, P303; YU CY, 1990, MOL CELL BIOL, V10, P282, DOI 10.1128/MCB.10.1.282	75	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28450	28459						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525574				2022-12-25	WOS:A1994PV77200099
J	TAOUIS, M; LEVYTOLEDANO, R; ROACH, P; TAYLOR, SI; GORDEN, P				TAOUIS, M; LEVYTOLEDANO, R; ROACH, P; TAYLOR, SI; GORDEN, P			RESCUE AND ACTIVATION OF A BINDING DEFICIENT INSULIN-RECEPTOR - EVIDENCE FOR INTERMOLECULAR TRANSPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; STRUCTURAL BASIS; SIGNAL TRANSDUCTION; MUTATION; PHOSPHORYLATION; AUTOPHOSPHORYLATION; RESISTANCE; SUBSTRATE; PROTEIN	Binding of insulin to the a subunit of the insulin receptor (IR) leads to autophosphorylation of the beta subunit. The reaction proceeds as intramolecular transphosphorylation between alpha beta half-receptors of the heterotetrameric receptor dimer (alpha(2) beta(2)). Since IRs are mobile in the plane of the plasma membrane, it is also possible that transphosphorylation may occur between adjacent holoreceptors (alpha(2) beta(2)) by an intermolecular reaction. To address this question, we cotransfected NIH-3T3 cells with two IR cDNA constructs: a truncated but functionally normal IR lacking the C-terminal 43 amino acids (Delta 43) and a full-length Leu(323) mutant receptor that is expressed on the cell surface but that does not bind insulin. A clonal cell line was selected from cells cotransfected with a 1/5 ratio of Delta 43 cDNA/Leu(323) cDNA. The two homodimers (Leu(323) and Delta 43) were expressed without detectable formation of hybrid receptors. By using specific antibodies, we demonstrate that in cells coexpressing both homodimers, the Leu(323) mutant receptor was phosphorylated in vivo by the Delta 43 IR in an insulin-dependent manner. However, when the Leu(323) mutant receptor was expressed alone, no phosphorylation was detected. In addition, we demonstrate the association of the phosphorylated Leu(323) mutant receptor with insulin receptor substrate-1 and with phosphatidylinositol 3-kinase. These findings indicate that insulin binding is not required for phosphorylation of the Leu(323) mutant receptor, that the phosphorylation of the Leu(323) mutant receptor occurs by an intermolecular transphosphorylation mechanism, and, finally, that the Leu(323) mutant receptor, once phosphorylated, can associate with insulin receptor substrate-1 and phosphatidylinositol 3-kinase.	NIDDKD,DIABET BRANCH,BETHESDA,MD 20892; INRA,RECH AVICOLES STN,F-37380 NOUZILLY,FRANCE	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); INRAE			Taouis, Mohammed/CAA-1797-2022	Taouis, Mohammed/0000-0002-4101-691X				ACCILI D, 1991, J BIOL CHEM, V266, P434; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; CAMA A, 1988, DIABETES, V37, P982, DOI 10.2337/diabetes.37.7.982; CAMA A, 1992, J BIOL CHEM, V267, P8383; CAMA A, 1991, J CLIN ENDOCR METAB, V73, P894, DOI 10.1210/jcem-73-4-894; DEMEYTS P, 1994, IN PRESS DIABETOLOGI; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; GORDEN P, 1978, P NATL ACAD SCI USA, V75, P5025, DOI 10.1073/pnas.75.10.5025; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KATO H, 1993, J BIOL CHEM, V268, P2655; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LEE JS, 1993, J BIOL CHEM, V268, P4092; LEVYTOLEDANO R, 1994, EMBO J, V13, P835, DOI 10.1002/j.1460-2075.1994.tb06326.x; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MYERS MG, 1991, J BIOL CHEM, V266, P10616; ROACH P, 1994, DIABETES, V43, P1096, DOI 10.2337/diabetes.43.9.1096; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SHOELSON SE, 1993, J BIOL CHEM, V268, P4085; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; TAOUIS M, 1994, J BIOL CHEM, V269, P14912; TAOUIS M, 1993, MOL CELL ENDOCRINOL, V96, P113, DOI 10.1016/0303-7207(93)90101-O; TAYLOR SI, 1984, J CLIN ENDOCR METAB, V58, P182, DOI 10.1210/jcem-58-1-182; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; ZANG B, 1991, P NATL ACAD SCI USA, V88, P9858	31	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27762	27766						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525562				2022-12-25	WOS:A1994PV77100093
J	MCEWAN, IJ; ALMLOF, T; WIKSTROM, AC; DAHLMANWRIGHT, K; WRIGHT, APH; GUSTAFSSON, JA				MCEWAN, IJ; ALMLOF, T; WIKSTROM, AC; DAHLMANWRIGHT, K; WRIGHT, APH; GUSTAFSSON, JA			THE GLUCOCORTICOID RECEPTOR FUNCTIONS AT MULTIPLE STEPS DURING TRANSCRIPTION INITIATION BY RNA-POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAINS; PREINITIATION COMPLEX; MONOCLONAL-ANTIBODIES; ACTIVATION DOMAIN; IMMUNOCYTOCHEMICAL LOCALIZATION; TRANSACTIVATION DOMAIN; DEOXYRIBONUCLEIC-ACID; PROGESTERONE-RECEPTOR; BASAL TRANSCRIPTION; GENE-EXPRESSION	We have used a panel of monoclonal antibodies and a cell-free transcription assay to study the function of the tau(1) transactivation domain of the human glucocorticoid receptor. Three antibodies (monoclonal antibodies 250, 275, and 286) specifically inhibited tau(1)-dependent transcription, but had little or no effect on either basal transcription or the activity of an unrelated yeast transcription factor. This inhibition was not due to interference of DNA binding activity, as all three antibodies super shifted tau(1)-containing protein-DNA complexes. Epitopes for all three antibodies were localized to a region between amino acids 190 and 200, which lies within the recently defined 41-amino acid core region of tau(1) that is required for transactivation (Dahlman-Wright, K., Almlof, T., McEwan, I.J., Gustafsson, J-A., and Wright, A. P. H. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 1619-1623). In contrast to the effect on tau(1)-dependent transcription none of the antibodies tested antagonized the squelching ability of the tau(1) domain, suggesting that tau(1)-mediated transactivation involves interactions in addition to those identified by the squelching assay. Consistent with this, a comparison of the kinetics of tau(1) squelching and inhibition of transactivation by monoclonal antibodies suggested a role for tau(1) mediated transcriptional induction at two or more steps during transcription initiation by RNA polymerase II.	KAROLINSKA INST,NOVUM,DEPT MED NUTR,S-14157 HUDDINGE,SWEDEN; KAROLINSKA INST,NOVUM,CTR STRUCT BIOCHEM,S-14157 HUDDINGE,SWEDEN	Karolinska Institutet; Karolinska Institutet	MCEWAN, IJ (corresponding author), KAROLINSKA INST,NOVUM,CTR BIOTECHNOL,S-14157 HUDDINGE,SWEDEN.		Wright, Anthony PH/J-8187-2015					AKNER G, 1990, EUR J CELL BIOL, V53, P390; ANTAKLY T, 1984, ENDOCRINOLOGY, V115, P1984, DOI 10.1210/endo-115-5-1984; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARLSTEDTDUKE J, 1982, P NATL ACAD SCI-BIOL, V79, P4260, DOI 10.1073/pnas.79.14.4260; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DAHLMANWRIGHT K, 1994, P NATL ACAD SCI USA, V91, P1619, DOI 10.1073/pnas.91.5.1619; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; EISEN HJ, 1980, P NATL ACAD SCI-BIOL, V77, P3893, DOI 10.1073/pnas.77.7.3893; EISEN LP, 1985, J BIOL CHEM, V260, P1805; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FREEDMAN LP, 1989, SCIENCE, V245, P298, DOI 10.1126/science.2473529; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOVINDAN MV, 1984, J BIOL CHEM, V259, P2915; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; ING NH, 1992, J BIOL CHEM, V267, P17617; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LINDEMEYER RG, 1990, CANCER RES, V50, P7985; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; MCEWAN IJ, 1993, MOL CELL BIOL, V13, P399, DOI 10.1128/MCB.13.1.399; MEYER ME, 1992, J BIOL CHEM, V267, P10882; OKRET S, 1984, P NATL ACAD SCI-BIOL, V81, P1609, DOI 10.1073/pnas.81.6.1609; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; ROBERTSON NM, 1987, BIOCHEM J, V246, P55, DOI 10.1042/bj2460055; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SHEMSHEDINI L, 1992, J BIOL CHEM, V267, P1834; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI SY, 1990, J BIOL CHEM, V265, P17055; WESTPHAL HM, 1982, EMBO J, V1, P1467, DOI 10.1002/j.1460-2075.1982.tb01339.x; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; WHITE JH, 1991, P NATL ACAD SCI USA, V88, P7674, DOI 10.1073/pnas.88.17.7674; WIKSTROM AC, 1987, ENDOCRINOLOGY, V120, P1232, DOI 10.1210/endo-120-4-1232; WILSON EM, 1988, MOL ENDOCRINOL, V2, P1018, DOI 10.1210/mend-2-11-1018; WRIGHT APH, 1993, J STEROID BIOCHEM, V47, P11, DOI 10.1016/0960-0760(93)90052-X; WRIGHT APH, 1991, P NATL ACAD SCI USA, V88, P8283, DOI 10.1073/pnas.88.19.8283; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763; WRIGHT APH, 1991, MOL ENDOCRINOL, V5, P1366, DOI 10.1210/mend-5-10-1366; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5291, DOI 10.1073/pnas.89.12.5291; ZILLIACUS J, 1991, J BIOL CHEM, V266, P3101	54	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25629	25636						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523389				2022-12-25	WOS:A1994PQ49100062
J	SCHWINDINGER, WF; MIRIC, A; ZIMMERMAN, D; LEVINE, MA				SCHWINDINGER, WF; MIRIC, A; ZIMMERMAN, D; LEVINE, MA			A NOVEL G(S)ALPHA MUTANT IN A PATIENT WITH ALBRIGHT HEREDITARY OSTEODYSTROPHY UNCOUPLES CELL-SURFACE RECEPTORS FROM ADENYLYL-CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE REGULATORY PROTEIN; STIMULATORY G-PROTEIN; GTP-BINDING PROTEIN; ALPHA-SUBUNIT; DEFICIENT ACTIVITY; S49 LYMPHOMA; GENE; PSEUDOHYPOPARATHYROIDISM; IDENTIFICATION; MUTATIONS	Albright hereditary osteodystrophy (AHO) is an autosomal-dominant disorder characterized by decreased expression of G(s) alpha and widespread tissue resistance to hormones that activate adenylyl cyclase. We identified a single mutation, R385H, in the G(s) alpha gene of a subject with AHO who had evidence for a dysfunctional G(s) alpha protein. The R385H substitution is near the carboxyl terminus of the G(s) alpha protein and is located five amino acids upstream of the R389P mutation that uncouples G(s) alpha from cell surface receptors in the une clone of S49 murine lymphoma. To test the biological activity of the R385H mutant, we transiently expressed wild type, R385H, and R389P G(s) alpha cDNAs in COS-1 cells. Neither of the mutant G(s) alpha proteins stimulated adenylyl cyclase in response to l-isoproterenol (1 to 30 mu M). By contrast, both mutant G(s) alpha proteins showed activation of adenylyl cyclase in response to forskolin (10 mu M) and fluoroaluminate (10 mM). We propose that the R385H mutation produces a G(s) alpha molecule that is unable to interact with hormone receptors and results in uncoupling of adenylyl cyclase from cell surface receptors. This uncoupling mutation represents a new type of molecular defect that can result in AHO.	JOHNS HOPKINS UNIV,SCH MED,DIV ENDOCRINOL & METAB,BALTIMORE,MD 21205; MAYO CLIN & MAYO FDN,DIV PEDIAT ENDOCRINOL & METAB,ROCHESTER,MN 55905	Johns Hopkins University; Mayo Clinic				Levine, Michael/0000-0003-0036-7809	NCRR NIH HHS [RR0035] Funding Source: Medline; NIDDK NIH HHS [DK-08725, DK34281] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008725, R01DK034281] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBRIGHT F, 1952, T ASSOC AM PHYSICIAN, V65, P337; BOURNE HR, 1982, MOL PHARMACOL, V22, P204; CARTER A, 1987, P NATL ACAD SCI USA, V84, P7266, DOI 10.1073/pnas.84.20.7266; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; HIGICHI R, 1988, NATURE, V332, P543; INOUE Y, 1990, J BIOL CHEM, V265, P10645; JONES DT, 1987, J BIOL CHEM, V262, P14241; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVINE MA, 1983, J CLIN INVEST, V72, P316, DOI 10.1172/JCI110971; LEVINE MA, 1980, BIOCHEM BIOPH RES CO, V94, P1319, DOI 10.1016/0006-291X(80)90563-X; LEVINE MA, 1983, AM J MED, V74, P545, DOI 10.1016/0002-9343(83)91008-2; LEVINE MA, 1988, P NATL ACAD SCI USA, V85, P617, DOI 10.1073/pnas.85.2.617; LEVINE MA, 1989, ENDOCRINOLOGY, P1065; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MIRIC A, 1993, J CLIN ENDOCR METAB, V76, P1560, DOI 10.1210/jc.76.6.1560; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PATTEN JL, 1990, NEW ENGL J MED, V322, P1412, DOI 10.1056/NEJM199005173222002; PATTEN JL, 1990, J CLIN ENDOCR METAB, V71, P1208, DOI 10.1210/jcem-71-5-1208; RALL T, 1987, FEBS LETT, V224, P365, DOI 10.1016/0014-5793(87)80486-6; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEAMON K, 1981, J BIOL CHEM, V256, P9799; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; WEINSTEIN LS, 1990, P NATL ACAD SCI USA, V87, P8287, DOI 10.1073/pnas.87.21.8287; WEINSTEIN LS, 1992, GENOMICS, V13, P1319, DOI 10.1016/0888-7543(92)90056-X; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WEST RE, 1985, J BIOL CHEM, V260, P4428	32	78	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25387	25391						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523385				2022-12-25	WOS:A1994PQ49100027
J	OKUDA, K; ERNST, TJ; GRIFFIN, JD				OKUDA, K; ERNST, TJ; GRIFFIN, JD			INHIBITION OF P21(RAS) ACTIVATION BLOCKS PROLIFERATION BUT NOT DIFFERENTIATION OF INTERLEUKIN-3-DEPENDENT MYELOID CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; NERVE GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; RECEPTOR GENE FAMILY; SIGNAL-TRANSDUCTION; BETA-SUBUNIT; T-CELLS; RAS; PROTEIN; PHOSPHORYLATION	Interleukin-5 (IL-3) induces proliferation of immature myeloid cells and mast cells and prevents programmed cell death (apoptosis) in vitro. These activities are exerted through binding of IL-3 to specific, high affinity receptors that then initiate a series of intracellular signaling events. Among the earliest of these signaling events in an IL-3-dependent cell line such as 32Dc13 are activation of one or more receptor-associated tyrosine kinases followed by activation of p21(ras). In an effort to define the functional role of p21(ras) activation in mediating the effects of IL-3, we constructed a series of sublines of 32Dc13 in which a dominant inhibitory mutant of Ha-ras (c-Ha-ras(Asn-17)) was expressed under the control of a steroid-inducible promoter. Steroid treatment (dexamethasone, 1 mu M) specifically induced c-Ha-ras(Asn-17) protein and mRNA and blocked IL-3-induced accumulation of p21(ras)-GTP in 32Dc13/p21(ras)N17 cell lines, but not in control cells. Dexamethasone slightly inhibited IL-3-dependent proliferation of control 32Dc13 cell lines (to 80% of maximum), but it completely blocked proliferation of 32Dc13/p21(ras)N17 cell lines and induced cell cycle arrest in G(0)/G(1). This proliferative block could be overcome by cotransfection with v-ras, and was reversible if dexamethasone was washed out. Cells arrested by c-Ha-ras(Asn-17) were viable in culture for >2 weeks, despite their inability to proliferate. Notably, however, these cells remained dependent on IL-3 for viability and initiated apoptosis within 18 h of IL-3 deprivation. Finally, granulocyte colony-stimulating factor-induced differentiation of 32Dc13/p21(ras)N17 cells to neutrophils was not affected by steroid-induced expression of c-Ha-ras(Asn-17) and did not require removal of IL-3. These results suggest that IL-3-induced proliferation and maintenance of cell viability are either initiated through separate signal transduction pathways or require different degrees of p21(ras) activation. Similarly, granulocyte colony-stimulating factor-induced neutrophil differentiation is not blocked by expression of c-Ha-ras(Asn-17).	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV HEMATOL MALIGNANCIES, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA047843, R37CA036167, P01CA034183, R01CA036167] Funding Source: NIH RePORTER; NCI NIH HHS [CA47843, CA34183, CA36167] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUDEL LM, 1990, BLOOD, V75, P1439; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; Ihle J N, 1989, Year Immunol, V5, P59; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KANAKURA Y, 1990, BLOOD, V76, P706; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LOPEZ AF, 1990, J ALLERGY CLIN IMMUN, V85, P99, DOI 10.1016/0091-6749(90)90229-W; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PARK LS, 1989, J BIOL CHEM, V264, P5420; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1992, J BIOL CHEM, V267, P25423; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SORENSEN P, 1986, J BIOL CHEM, V261, P9094; STACEY DW, 1991, ONCOGENE, V6, P2297; SZEBERENYI J, 1992, ONCOGENE, V7, P2105; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TORIGOE T, 1992, BLOOD, V80, P617; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WOODROW MA, 1993, J IMMUNOL, V150, P3853	43	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24602	24607						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7523375				2022-12-25	WOS:A1994PQ49000017
J	ISHIWATA, N; TAKIO, K; KATAYAMA, M; WATANABE, K; TITANI, K; IKEDA, Y; HANDA, M				ISHIWATA, N; TAKIO, K; KATAYAMA, M; WATANABE, K; TITANI, K; IKEDA, Y; HANDA, M			ALTERNATIVELY SPLICED ISOFORM OF P-SELECTIN IS PRESENT IN-VIVO AS A SOLUBLE MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE MEMBRANE-PROTEIN; ENDOTHELIAL VONWILLEBRAND-FACTOR; SYSTEMIC LUPUS-ERYTHEMATOSUS; FACTOR-BINDING DOMAIN; WEIBEL-PALADE BODIES; AMINO-ACID SEQUENCE; MONOCLONAL-ANTIBODY; CELL-SURFACE; ACTIVATED PLATELETS; ADHESION RECEPTORS	To demonstrate the presence of a soluble isoform of P-selectin predicted from cDNA sequencing (Johnston, G. I., Bliss, G. A., Newman, P. J., and McEver, R. P. (1990) J. Biol. Chem. 265, 21381-21885), we immunoisolated and compared structurally P-selectin from fresh frozen human plasma with that from washed intact platelets. Plasma P-selectin was reactive with rabbit antiserum to a synthesized peptide (residues 762-774 of mature P-selectin) but was significantly less reactive with antibody to a peptide (residues 747-760). In contrast, platelet P-selectin reacted with both antibodies. S-Pyridylethylated plasma P-selectin was fractionated by reversed phase-high performance liquid chromatography into two major species. From platelets, two virtually identical species were separated. Sequential digestion with Achromobacter protease I and then Staphylococcus V8 protease produced peptides assigned to the tail region of the protein including the putative spliced site. From the more hydrophilic species in both plasma and platelets, a peptide completely lacking the sequence of the putative spliced site was identified. In contrast, the more hydrophobic species yielded a peptide with an intact transmembrane sequence. Hence, these results provide direct evidence that the previously predicted soluble isoform of P-selectin is actually synthesized in vivo and is present as a circulating molecule.	KEIO UNIV,CTR BLOOD,SCH MED,DEPT INTERNAL MED,SHINJUKU KU,TOKYO 160,JAPAN; KEIO UNIV,SCH MED,DEPT LAB MED,TOKYO 160,JAPAN; INST PHYS & CHEM RES,DIV BIOMOLEC CHARACTERIZAT,WAKO,SAITAMA 35101,JAPAN; TAKARA SHUZO CO LTD,BIOTECHNOL RES LABS,OTSU,SHIGA 52021,JAPAN; FUJITA HLTH UNIV,SCH MED,INST COMPREHENS MED SCI,DIV BIOMED POLYMER SCI,TOYOAKE,AICHI 47011,JAPAN	Keio University; Keio University; RIKEN; Takara Holdings Inc.; Fujita Health University			Handa, Makoto/B-1121-2014					ARVAN P, 1987, J CELL BIOL, V104, P243, DOI 10.1083/jcb.104.2.243; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BONFANTI R, 1989, BLOOD, V73, P1109; Bornstein P, 1977, Methods Enzymol, V47, P132; CARSON CW, 1993, J RHEUMATOL, V20, P809; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; DORE M, 1993, BLOOD, V82, P1308; Drapeau G R, 1977, Methods Enzymol, V47, P189; DUNLOP LC, 1992, J EXP MED, V175, P1147, DOI 10.1084/jem.175.4.1147; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; GAMBLE JR, 1990, SCIENCE, V249, P414; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; GENG JG, 1992, J BIOL CHEM, V267, P19846; GOLDBERGER A, 1992, BLOOD, V80, pA266; GUNNING P, 1991, FASEB J, V5, P3064, DOI 10.1096/fasebj.5.15.1835946; HANDA M, 1986, J BIOL CHEM, V261, P2579; HANDAGAMA PJ, 1989, J CLIN INVEST, V84, P73, DOI 10.1172/JCI114173; HANDAGAMA PJ, 1987, P NATL ACAD SCI USA, V84, P851; HARLOW E, 1988, ANTIBODIES LABORATOR; HATTORI R, 1989, J BIOL CHEM, V264, P9053; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; ISHIWATA N, 1993, THROMB HAEMOSTASIS, V69, pA2860; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; JOHNSTON GI, 1990, J BIOL CHEM, V265, P21381; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JYONOUCHI H, 1991, J ALLERGY CLIN IMMUN, V87, P965, DOI 10.1016/0091-6749(91)90418-N; KATAYAMA M, 1993, BRIT J HAEMATOL, V84, P702, DOI 10.1111/j.1365-2141.1993.tb03149.x; KATAYAMA M, 1992, J IMMUNOL METHODS, V153, P41, DOI 10.1016/0022-1759(92)90303-B; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEROITH D, 1993, ANN NY ACAD SCI, V692, P1; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P51, DOI 10.1016/0005-2744(81)90107-8; MATSUI M, 1993, FEBS LETT, V335, P51, DOI 10.1016/0014-5793(93)80437-Y; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MOORE HPH, 1985, J CELL BIOL, V101, P1773, DOI 10.1083/jcb.101.5.1773; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029; NEWMAN W, 1993, J IMMUNOL, V150, P644; NORMENT AM, 1988, EMBO J, V7, P3433, DOI 10.1002/j.1460-2075.1988.tb03217.x; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; Ruegg U T, 1977, Methods Enzymol, V47, P111; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SAWADA S, 1992, AM J MED, V92, P134, DOI 10.1016/0002-9343(92)90103-I; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; SETH R, 1991, LANCET, V338, P83, DOI 10.1016/0140-6736(91)90077-3; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SPERTINI O, 1992, J IMMUNOL METHODS, V156, P115, DOI 10.1016/0022-1759(92)90017-N; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; TAYLOR P, 1993, CHEM-BIOL INTERACT, V87, P199, DOI 10.1016/0009-2797(93)90043-X; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; WELLICOME SM, 1993, CLIN EXP IMMUNOL, V92, P412; WONG CS, 1991, P NATL ACAD SCI USA, V88, P2397, DOI 10.1073/pnas.88.6.2397; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	62	117	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23708	23715						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7522232				2022-12-25	WOS:A1994PQ34500050
J	MORRIS, CA; UNDERWOOD, PA; BEAN, PA; SHEEHAN, M; CHARLESWORTH, JA				MORRIS, CA; UNDERWOOD, PA; BEAN, PA; SHEEHAN, M; CHARLESWORTH, JA			RELATIVE TOPOGRAPHY OF BIOLOGICALLY-ACTIVE DOMAINS OF HUMAN VITRONECTIN - EVIDENCE FROM MONOCLONAL-ANTIBODY EPITOPE AND DENATURATION STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM SPREADING FACTOR; S-PROTEIN VITRONECTIN; THROMBIN-ANTITHROMBIN-III; HEPARIN-BINDING PROPERTIES; PLASMINOGEN-ACTIVATOR; HUMAN-PLASMA; STAPHYLOCOCCUS-AUREUS; COMPLEX-FORMATION; COLLAGEN-BINDING; SC5B-9 COMPLEX	A panel of monoclonal antibodies to human vitronectin was used to define some epitopes for the multifunctions of this protein. Separate antibodies were identified which strongly inhibited cell spreading activity and which prevented binding to collagen. A third group interfered with the ability of vitronectin to inhibit complement-mediated guinea pig erythrocyte reactive lysis. None of the antibodies from these three groups prevented heparin binding, providing evidence that this reaction occurs at a fourth location; a different monoclonal antibody partially inhibited the binding of heparin, The relative accessibility of each biologically active epitope was assessed by the differential binding of the monoclonals to native and denatured vitronectin. Reactivity of the antibody which inhibited heparin binding greatly increased upon denaturation of vitronectin, implying that this region is normally inaccessible in the native form of the molecule. By contrast, epitopes for cell spreading, collagen binding, and inhibition of terminal complement complex lysis were destroyed by denaturation. On the basis of denaturation data and epitope mapping by competitive exclusion of monoclonal antibodies, a Venn diagram was constructed to represent overlap of monoclonal antibody epitopes in the tertiary structure. Linear epitopes for the antibodies were identified using cyanogen bromide and plasmin-derived peptides from vitronectin, The antibody which strongly inhibited cell binding reacted with a region containing the RGD site, whereas linear epitopes for collagen binding and complement inhibition appeared to reside in a 43-kDa peptide representing the internal region of the amino acid sequence, excluding the heparin-binding site. The latter two epitopes were differentiated from each other by reactivity of the antibody which inhibited collagen binding toward a smaller 20-kDa plasmin-derived peptide.	PRINCE HENRY HOSP,DEPT NEPHROL,LITTLE BAY,NSW 2036,AUSTRALIA; CSIRO,DIV BIOMOLEC ENGN,N RYDE,NSW 2113,AUSTRALIA	Commonwealth Scientific & Industrial Research Organisation (CSIRO)								BARNES DW, 1985, J BIOL CHEM, V260, P9117; BIESECKER G, 1990, J IMMUNOL, V145, P209; CHHATWAL GS, 1987, INFECT IMMUN, V55, P1878, DOI 10.1128/IAI.55.8.1878-1883.1987; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; FUQUAY JI, 1986, INFECT IMMUN, V52, P714, DOI 10.1128/IAI.52.3.714-717.1986; GEBB C, 1986, J BIOL CHEM, V261, P6698; GECHTMAN Z, 1993, FEBS LETT, V315, P293, DOI 10.1016/0014-5793(93)81181-X; HAYASHI M, 1985, J BIOCHEM-TOKYO, V98, P1135, DOI 10.1093/oxfordjournals.jbchem.a135363; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HETLAND G, 1989, SCAND J IMMUNOL, V29, P15, DOI 10.1111/j.1365-3083.1989.tb01094.x; HEUSSER C, 1973, J IMMUNOL, V110, P820; HILDEBRAND A, 1988, J BIOL CHEM, V263, P2436; HOGASEN K, 1992, J BIOL CHEM, V267, P23076; Hunt L T, 1987, Protein Seq Data Anal, V1, P21; ILL CR, 1985, J BIOL CHEM, V260, P5610; ISHIKAWA M, 1992, BIOCHIM BIOPHYS ACTA, V1121, P173, DOI 10.1016/0167-4838(92)90351-D; IZUMI M, 1988, CELL STRUCT FUNCT, V13, P217, DOI 10.1247/csf.13.217; JENNE D, 1985, THROMB RES, V38, P401, DOI 10.1016/0049-3848(85)90138-0; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; KANZ L, 1988, BLOOD S, V72, P327; KITAGAKIOGAWA H, 1990, BIOCHIM BIOPHYS ACTA, V1033, P49, DOI 10.1016/0304-4165(90)90193-Z; KOST C, 1992, J BIOL CHEM, V267, P12098; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILIS L, 1993, CLIN EXP IMMUNOL, V92, P114; Murphy B F, 1989, Int Immunol, V1, P551, DOI 10.1093/intimm/1.5.551; PARKER CJ, 1989, BRIT J HAEMATOL, V71, P245, DOI 10.1111/j.1365-2141.1989.tb04262.x; PODACK ER, 1984, ACTA PATH MICRO IM C, V92, P89; PODACK ER, 1977, J IMMUNOL, V119, P2024; PREISSNER KT, 1990, BIOCHEM BIOPH RES CO, V168, P966, DOI 10.1016/0006-291X(90)91123-A; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PREISSNER KT, 1989, BLOOD, V74, P1989; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; PREISSNER KT, 1987, BIOCHEM J, V243, P105, DOI 10.1042/bj2430105; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; SANE DC, 1991, THROMB HAEMOSTASIS, V66, P310; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SORENSEN K, 1986, EXPERIENTIA, V42, P161, DOI 10.1007/BF01952446; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; TOMASINI BR, 1988, BLOOD, V72, P903; TOMASINI BR, 1990, PROG HEMOSTASIS THRO, V10, P269; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P4103, DOI 10.1021/bi00411a029; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P4109; UNDERWOOD PA, 1988, J IMMUNOL METHODS, V107, P119; UNDERWOOD PA, 1983, J IMMUNOL METHODS, V60, P33, DOI 10.1016/0022-1759(83)90332-0; UNDERWOOD PA, 1982, J GEN VIROL, V62, P153, DOI 10.1099/0022-1317-62-1-153; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	53	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23845	23852						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7522235				2022-12-25	WOS:A1994PQ34500069
J	DESEPULVEDA, P; PEYRIERAS, N; PANTHIER, JJ				DESEPULVEDA, P; PEYRIERAS, N; PANTHIER, JJ			INSTABILITY AT THE W/C-KIT LOCUS IN MICE - ANALYSIS OF MELANOCYTE CELL-LINES DERIVED FROM REVERSION SPOTS	ONCOGENE			English	Article							W-MUTANT MICE; C-KIT; MITOTIC RECOMBINATION; MOUSE MELANOCYTES; RECEPTOR KINASE; NEURAL CREST; HOUSE MOUSE; MUTATIONS; EXPRESSION; GENE	Mutations at the mouse W/c-kit locus have pleiotropic defects including impaired development of the melanocyte lineage. We have characterized the molecular basis of the W-ei mutation. We show here that W-ei is the result of a missense mutation in the ATP binding site domain of c-kit proto-oncogene which affects the tyrosine kinase function of the receptor. As a result, few melanoblasts survive during embryogenesis in heterozygous W-ei/+ foetuses. Therefore the adult skin is partly devoid of differentiated pigmented cells giving rise to a mottled coat colour phenotype. However, three per cent of W-ei/+mice exhibit spots of wild-type pigmentation on the coat which is otherwise of mutant phenotype. Such areas are known as phenotypic reversions. To dissect the molecular events responsible for the phenotypic instability of the W-ei mutation, we have isolated pure cultures of continuously proliferating melanocytes from two independent reversion spots. These melanocyte lines, designated W-ei-R1 and W-ei-R2, were shown to exhibit none of the characteristics associated with transformed melanocytes. We have used a polymorphic restriction site generated by the W-ei mutation to show that both melanocyte lines are still heterozygous at the W focus. Furthermore, W-ei-R1 and W-ei-R2 melanocytes express both the mutated and the wild-type c-kit RNA. These results indicate that the somatic mutation events responsible for reversion spots are not necessarily associated with loss of heterozygosity at the W/c-kit locus. Together with previous data, this points to the fact that several mechanisms account for the coat colour reversion phenotype.	ECOLE NATL VET, INRA, URA GENET MOLEC, F-94704 MAISONS ALFORT, FRANCE; CNRS MARSEILLE LUMINY, INSERM, CTR IMMUNOL, F-13288 MARSEILLE 9, FRANCE	Ecole Nationale Veterinaire d'Alfort (ENVA); INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			PANTHIER, Jean-Jacques/I-4366-2014; De sepulveda, paulo/K-6043-2015	PANTHIER, Jean-Jacques/0000-0002-7966-0663; De sepulveda, paulo/0000-0001-8295-5414; Peyrieras, Nadine/0000-0002-4905-6414				BENNETT DC, 1989, DEVELOPMENT, V105, P379; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; DUBREUIL P, 1990, ANN NY ACAD SCI, V599, P58; DUTTLINGER R, 1993, DEVELOPMENT, V118, P705; EICHE A, 1984, HEREDITAS, V101, P273; EICHE A, 1982, HEREDITAS, V97, P316; FLEISCHMAN RA, 1993, TRENDS GENET, V9, P285, DOI 10.1016/0168-9525(93)90015-A; GEISSLER EN, 1981, GENETICS, V97, P337; GOKKEL E, 1992, ONCOGENE, V7, P1423; Green MC., 1989, GENETIC VARIANTS STR, P12; GUENET JL, 1979, J HERED, V70, P9, DOI 10.1093/oxfordjournals.jhered.a109202; HALABAN R, 1984, IN VITRO CELL DEV B, V20, P447; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Herlyn M, 1990, Adv Cancer Res, V54, P213, DOI 10.1016/S0065-230X(08)60812-X; HUSZAR D, 1991, DEVELOPMENT, V112, P131; IWAMOTO T, 1992, EXP CELL RES, V200, P410, DOI 10.1016/0014-4827(92)90189-F; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; LARUE L, 1992, P NATL ACAD SCI USA, V89, P7816, DOI 10.1073/pnas.89.16.7816; LARUE L, 1993, ONCOGENE, V8, P523; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MINTZ B, 1974, ANNU REV GENET, V8, P411, DOI 10.1146/annurev.ge.08.120174.002211; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; MINTZ B, 1970, 25TH S INT SOC CELL, P15; MOTRO B, 1991, DEVELOPMENT, V113, P1207; MURPHY M, 1992, DEV BIOL, V153, P396, DOI 10.1016/0012-1606(92)90124-Y; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; PANTHIER JJ, 1990, GENETICS, V125, P175; PANTHIER JJ, 1991, BIOESSAYS, V13, P351, DOI 10.1002/bies.950130709; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; Sambrook J, 1989, MOL CLONING LABORATO; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SPANAKIS E, 1992, DEVELOPMENT, V114, P675; STEEL KP, 1992, DEVELOPMENT, V115, P1111; STERNBERG MJE, 1984, FEBS LETT, V175, P387, DOI 10.1016/0014-5793(84)80774-7; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; TSUJIMURA T, 1993, BLOOD, V81, P2530; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	46	13	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2655	2661						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	7520149				2022-12-25	WOS:A1994PC05400026
J	ACTON, SL; SCHERER, PE; LODISH, HF; KRIEGER, M				ACTON, SL; SCHERER, PE; LODISH, HF; KRIEGER, M			EXPRESSION CLONING OF SR-BI, A CD36-RELATED CLASS-B SCAVENGER RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CONFORMATIONALLY MODIFIED ALBUMINS; GLYCOPROTEIN-IV CD36; MEDIATED ENDOCYTOSIS; ENDOTHELIAL-CELLS; MEMBRANE-PROTEIN; PERITONEAL-MACROPHAGES; CHOLESTEROL DEPOSITION; MALEYL-ALBUMIN; SERUM-ALBUMIN	Scavenger receptors are integral membrane proteins that mediate the endocytosis of modified lipoproteins. The first of these to be purified and cloned were the type I and II macrophage scavenger receptors (SR-AI and SR-AII; class A scavenger receptors). Subsequently, the cell surface protein CD36 was shown to bind oxidized low density lipoprotein (oxidized LDL). From a Chinese hamster ovary (CHO) cell variant we have cloned by expression the cDNA for a new member of the CD36 family of membrane proteins, SR-BI, whose predicted protein sequence of 509 amino acids is similar to 30% identical to those of the four previously identified family members. Both SR-BI and CD36 displayed high affinity binding for acetylated LDL with an apparent dissociation constant on the order of similar to 5 mu g of protein/ml. The ligand binding specificities of CD36 and SR-BI, determined by direct binding or competition assays, were similar, but not identical; both bind modified proteins (acetylated LDL, oxidized LBL, maleylated bovine serum albumin), but not the broad array of other polyanions (e.g. fucoidin, polyguanosinic acid, carrageenan) which are ligands of the class A receptors. Thus, SR-BI and CD36 define a second class of scavenger receptors, designated class B. Native LDL, which does not bind to either class A receptors or CD36, unexpectedly bound with high affinity to SR-BI. Northern blot analysis of murine tissues showed that SR-BI was most abundantly expressed in fat and was present at moderate levels in lung and liver. Furthermore, SR-BI mRNA expression was induced upon differentiation of 3T3-L1 cells into adipocytes. Thus, the tissue distribution of expression and ligand binding properties of SR-BI raise the possibility that this cell surface receptor may play an important role in lipid metabolism.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute			Scherer, Philipp E/K-7819-2012	Scherer, Philipp E/0000-0003-0680-3392	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41484] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ACTON S, 1993, J BIOL CHEM, V268, P3530; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARAI H, 1989, BIOCHEM BIOPH RES CO, V159, P1375, DOI 10.1016/0006-291X(89)92262-6; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CALVO D, 1993, J BIOL CHEM, V268, P18929; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P3123; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOI T, 1993, J BIOL CHEM, V268, P2126; ELSAADANI M, 1989, J LIPID RES, V30, P627; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GHITESCU L, 1992, J CELL BIOL, V117, P745, DOI 10.1083/jcb.117.4.745; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GREENWALT DE, 1992, BLOOD, V80, P1105; HABERLAND ME, 1986, J CLIN INVEST, V77, P681, DOI 10.1172/JCI112362; HABERLAND ME, 1989, J IMMUNOL, V142, P855; HART K, 1993, J MOL BIOL, V234, P249, DOI 10.1006/jmbi.1993.1580; HORIUCHI S, 1985, J BIOL CHEM, V259, P53; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUNT C, 1990, GENE, V87, P199, DOI 10.1016/0378-1119(90)90302-8; KINGSLEY DM, 1986, MOL CELL BIOL, V6, P2734, DOI 10.1128/MCB.6.7.2734; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRIEGER M, 1986, METHOD ENZYMOL, V128, P608; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; KRIEGER M, 1979, J SUPRAMOL STR CELL, V10, P467, DOI 10.1002/jss.400100409; KRIEGER M, 1992, TRENDS BIOCHEM SCI, V17, P141, DOI 10.1016/0968-0004(92)90322-Z; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRIEGER M, 1983, P NATL ACAD SCI-BIOL, V80, P5607, DOI 10.1073/pnas.80.18.5607; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; NAITO M, 1991, AM J PATHOL, V139, P1411; OCKENHOUSE CF, 1989, J CLIN INVEST, V84, P468, DOI 10.1172/JCI114188; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; OTTNAD E, 1992, BIOCHEM J, V281, P745, DOI 10.1042/bj2810745; PITAS RE, 1985, J CELL BIOL, V100, P103, DOI 10.1083/jcb.100.1.103; PREDESCU D, 1988, J CELL BIOL, V107, P1729, DOI 10.1083/jcb.107.5.1729; ROHER L, 1990, NATURE, V343, P570; Sambrook J, 1989, MOL CLONING LABORATO; SAVILL J, 1991, CHEST S, V99, P7; SCHNITZER JE, 1993, J BIOL CHEM, V268, P7562; SCHNITZER JE, 1992, J BIOL CHEM, V267, P24544; SEGE RD, 1986, MOL CELL BIOL, V6, P3268, DOI 10.1128/MCB.6.9.3268; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TANDON NN, 1989, J BIOL CHEM, V264, P7576; VASILE E, 1985, GLOMERULAR DYSFUNCTI, P87; VEGA MA, 1991, J BIOL CHEM, V266, P16818; VIA D, 1992, FASEB J, V6, pA371; VILLASCHI S, 1986, MICROVASC RES, V32, P190, DOI 10.1016/0026-2862(86)90053-1	61	716	747	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21003	21009						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	7520436				2022-12-25	WOS:A1994PC40300031
J	SHWORAK, NW; SHIRAKAWA, M; MULLIGAN, RC; ROSENBERG, RD				SHWORAK, NW; SHIRAKAWA, M; MULLIGAN, RC; ROSENBERG, RD			CHARACTERIZATION OF RYUDOCAN GLYCOSAMINOGLYCAN ACCEPTOR SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; CELL-SURFACE PROTEOGLYCAN; HUMAN-ENDOTHELIAL CELLS; HUMAN-LUNG FIBROBLASTS; HUMAN GROWTH-HORMONE; CHONDROITIN SULFATE; MOLECULAR-CLONING; CORE PROTEIN; MAST-CELLS; BIOSYNTHESIS	The specificity of the glycosaminoglycan (GAG) acceptor sites of ryudocan was examined by stably expressing epitope-tagged ryudocan cDNA constructs in mouse L cells, which normally produce this proteoglycan. Immunopurified ryudocan was glycanated with both heparan sulfate (HS) and chondroitin sulfate (CS). The attachment of GAGs to ryudocan was prevented by creating Ser --> Thr mutations in all possible combinations at positions 44, 65, and 67. The resulting ryudocan of exogenous origin was immunopurified and evaluated with regard to attached GAG chains. The data reveal that ryudocan possesses three functional GAG attachment sites, that the sites are always occupied with GAG chains, and that each site is capable of bearing either HS or CS. The sodium dodecyl sulfate-polyacrylamide gel electrophoresis patterns of GAG lyase digests of intact ryudocan reveal the production of the following multiple isoforms: pure HS-ryudocan, various HS/CS-hybrids, and pure CS-ryudocan. The data suggest that the occupancy bias of each site for HS or CS is slight and that each site functions in a relatively independent fashion. The GAG lyase analysis of partially purified L cell proteoglycans shows two pure CS-homoglycans with core proteins of M(r) = 130,000 and 52,000, respectively. A similar analysis of immunopurified L cell glypican demonstrates that this species only exists as a pure HS-homoglycan. The production of pure homoglycans by this clonal cell line strongly suggests that the functional promiscuity of GAG attachment sites of ryudocan must be encoded in the core protein structure. This property of ryudocan is not peculiar to L cells, as ryudocan synthesized by early passage human endothelial cells also bears both HS and CS. The production of multiple isoforms of ryudocan may serve to expand the functional versatility of this cell surface component and allow it to participate in many different biologic processes.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02215 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT MED, BOSTON, MA 02215 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484, P01HL033014] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41484, HL-33014, HL-437771] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BOURDON MA, 1985, P NATL ACAD SCI USA, V82, P1321, DOI 10.1073/pnas.82.5.1321; BOURDON MA, 1986, J BIOL CHEM, V261, P2534; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAREW JA, 1990, BLOOD, V76, P2530; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; DIETRICH CP, 1984, BRAZ J MED BIOL RES, V17, P5; ENERBACK L, 1985, BIOCHEM J, V227, P661, DOI 10.1042/bj2270661; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FOXALL TL, 1986, J SURG RES, V41, P158, DOI 10.1016/0022-4804(86)90021-1; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HASLINGER A, 1985, P NATL ACAD SCI USA, V82, P8572, DOI 10.1073/pnas.82.24.8572; HORTIN G, 1986, BIOCHEM BIOPH RES CO, V141, P326, DOI 10.1016/S0006-291X(86)80372-2; HUTTNER WB, 1982, NATURE, V299, P273, DOI 10.1038/299273a0; ISHIHARA M, 1992, ANAL BIOCHEM, V206, P400, DOI 10.1016/0003-2697(92)90385-K; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KARIN M, 1982, NATURE, V299, P797, DOI 10.1038/299797a0; KEARNS AE, 1991, BIOCHEMISTRY-US, V30, P7477, DOI 10.1021/bi00244a016; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLINGER MM, 1985, J BIOL CHEM, V260, P4082; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KOKENYESI R, 1994, J BIOL CHEM, V269, P12304; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIND T, 1993, J BIOL CHEM, V268, P20705; LITWACK ED, 1994, J NEUROSCI, V14, P3713; LORIES V, 1989, J BIOL CHEM, V264, P7009; MANN DM, 1990, J BIOL CHEM, V265, P5317; NADER HB, 1991, J BIOL CHEM, V266, P10518; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; RAPRAEGER A, 1989, J CELL BIOL, V109, P2509, DOI 10.1083/jcb.109.5.2509; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; ROBINSON HC, 1978, J BIOL CHEM, V253, P6687; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANDERSON RD, 1992, J INVEST DERMATOL, V99, P390, DOI 10.1111/1523-1747.ep12616103; SCHMIDTCHEN A, 1990, BIOCHEM J, V265, P289, DOI 10.1042/bj2650289; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SELDIN DC, 1985, J BIOL CHEM, V260, P1131; SHWORAK NW, 1993, J BIOL CHEM, V268, P24460; SIMONS M, 1993, J BIOL CHEM, V268, P627; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; TSUKADA T, 1987, AM J PATHOL, V126, P51; VERTEL BM, 1993, J BIOL CHEM, V268, P11105; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; WASTESON A, 1971, BIOCHEM J, V122, P477, DOI 10.1042/bj1220477; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YURT RW, 1977, J BIOL CHEM, V252, P518; ZUCKER M, 1981, NUCLEIC ACIDS RES, V9, P133	68	81	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21204	21214						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	7520439				2022-12-25	WOS:A1994PC40300059
J	KAO, PN; CHEN, L; BROCK, G; NG, J; KENNY, J; SMITH, AJ; CORTHESY, B				KAO, PN; CHEN, L; BROCK, G; NG, J; KENNY, J; SMITH, AJ; CORTHESY, B			CLONING AND EXPRESSION OF CYCLOSPORINE-A-SENSITIVE AND FK506-SENSITIVE NUCLEAR FACTOR OF ACTIVATED T-CELLS - NF45 AND NF90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE-SPECIFIC FACTORS; DOUBLE-STRANDED-RNA; HUMAN IL-2 GENE; INTERLEUKIN-2 GENE; ANTIGEN RECEPTOR; VACCINIA VIRUS; BINDING; TRANSCRIPTION; PROMOTER; PROTEINS	Nuclear Factor of Activated T-cells (NF-AT) is a crucial transcription factor required for T-cell expression of interleukin 2. Purified NF-AT contains 45-kDa and 90-kDa subunits (Corthesy, B., and Kao, P. N. (1994) J. Biol. Chem. 269, 20682-20690). Partial internal amino acid sequences derived from each subunit indicate that these proteins are novel, The amino acid sequences were used to clone the cDNAs encoding each subunit. The cDNAs predict proteins of novel structures: NF45 has limited similarity to prokaryotic transcription factor sigma-54 and to human DNA topoisomerase II; NF90 has limited similarity to Drosophila Staufen in a domain predicted to bind double-stranded RNA. RNA encoding NF45 and NF90 exists in nonstimulated Jurkat T-cells and in all other cell types examined (HeLa, HepG2, K562). Immunofluorescence microscopy was used to demonstrate that both proteins are located in the nucleus of Jurkat T-cells. Clones NF45 and NF90 with a polyhistidine fusion tag were transiently expressed and processed in the native environment of Jurkat T-cells. Histidine-tagged NF45 and NF90 proteins, affinity-purified on nickel chelate columns, encode a NF-AT DNA-binding activity that is enhanced following T-cell stimulation, and this enhancement is blocked when T-cells are stimulated in the presence of cyclosporin A or FK506.	STANFORD UNIV, MED CTR, SCH MED, DEPT PATHOL, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, PROT & NUCLE ACID FACIL, STANFORD, CA 94305 USA; UNIV LAUSANNE, INST BIOL ANIM, CH-1015 LAUSANNE, SWITZERLAND	Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University; University of Lausanne	KAO, PN (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DIV PULM & CRIT CARE MED, STANFORD, CA 94305 USA.				NIAID NIH HHS [1-K04-AI01147-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI001147] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJI SS, 1991, MOL CELL BIOL, V11, P4074, DOI 10.1128/MCB.11.8.4074; BICKEL M, 1987, P NATL ACAD SCI USA, V84, P3274, DOI 10.1073/pnas.84.10.3274; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BRUNVAND MW, 1988, J BIOL CHEM, V263, P18904; BRUTLAG DL, 1993, COMPUT CHEM, V17, P203, DOI 10.1016/0097-8485(93)85011-Z; CHANG HW, 1993, VIROLOGY, V194, P537, DOI 10.1006/viro.1993.1292; CORTHESY B, 1994, J BIOL CHEM, V269, P20682; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; ELLIOTT JF, 1984, SCIENCE, V226, P1439, DOI 10.1126/science.6334364; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; GRANELLIPIPERNO A, 1990, J EXP MED, V172, P1869, DOI 10.1084/jem.172.6.1869; GRANELLIPIPERNO A, 1991, P NATL ACAD SCI USA, V88, P11431, DOI 10.1073/pnas.88.24.11431; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LI C, 1991, P NATL ACAD SCI USA, V88, P7739, DOI 10.1073/pnas.88.17.7739; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; MOUZAKI A, 1991, EMBO J, V10, P1399, DOI 10.1002/j.1460-2075.1991.tb07660.x; NABEL GJ, 1988, P NATL ACAD SCI USA, V85, P2934, DOI 10.1073/pnas.85.9.2934; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; ONEILL EA, 1993, TRANSPLANT SCI, V3, P77; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; RIEGEL JS, 1992, CHEM IMMUNOL, V51, P266; Sambrook J, 1989, MOL CLONING LABORATO; SAWADA S, 1987, J IMMUNOL, V139, P1797; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHIBUYA H, 1989, NUCLEIC ACIDS RES, V17, P9173, DOI 10.1093/nar/17.22.9173; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TOCCI MJ, 1989, J IMMUNOL, V143, P718; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; WILLIAMS TM, 1988, J IMMUNOL, V141, P662; YASEEN NR, 1993, J BIOL CHEM, V268, P14285	51	165	172	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20691	20699						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519613				2022-12-25	WOS:A1994PB31700074
J	THOMAS, PE; WHARRAM, BL; GOYAL, M; WIGGINS, JE; HOLZMAN, LB; WIGGINS, RC				THOMAS, PE; WHARRAM, BL; GOYAL, M; WIGGINS, JE; HOLZMAN, LB; WIGGINS, RC			GLEPP1, A RENAL GLOMERULAR EPITHELIAL-CELL (PODOCYTE) MEMBRANE PROTEIN-TYROSINE-PHOSPHATASE - IDENTIFICATION, MOLECULAR-CLONING, AND CHARACTERIZATION IN RABBIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; LEUKOCYTE-COMMON ANTIGEN; CENTRAL-NERVOUS-SYSTEM; AMINONUCLEOSIDE NEPHROSIS; ESCHERICHIA-COLI; MESSENGER-RNA; HPTP-BETA; RECEPTOR; CD45; PURIFICATION	Podocytes are specialized epithelial cells with delicate interdigitating foot processes which cover the exterior basement membrane surface of the glomerular capillary. They are in part responsible for the extraor dinary charge and size filtration characteristics of the glomerulus. To better understand disease processes affecting the glomerular filter, we searched for proteins with relative specificity to the podocyte using a monoclonal antibody strategy. The first such protein characterized (designated glomerular epithelial protein 1 (GLEPP1)) is a membrane protein-tyrosine phosphatase (PTPase) with a large extracellular domain containing eight fibronectin type III-like repeats, a hydrophobic transmembrane segment, and a single PTPase domain. The GLEPP1 PTPase domain shows homology with two other single domain transmembrane PTPases,(PTP beta and Drosophila central nervous system PTP10D). This homology includes 2 cysteines in the PTPase domain not present in intracellular or tandem domain membrane PTPases. GLEPP1 PTPase protein is distributed to the podocyte foot processes themselves. RNase protection assay shows that GLEPP1 mRNA is also present in brain. By analogy with the CD45 PTPase of T cells, we expect that this receptor might play a role in maintaining foot process structure and/or function by regulating tyrosine phosphorylation of podocyte proteins.	UNIV MICHIGAN,DEPT INTERNAL MED,DIV NEPHROL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan				Wiggins, Roger/0000-0002-1166-2849; Holzman, Lawrence/0000-0002-8961-234X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038149, P50DK039255] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39255, DK38149] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARIMURA Y, 1992, TUMOR BIOL, V13, P180, DOI 10.1159/000217763; Austen BM, 1981, BIOCH SOC S, V46, P235; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOWNER G, 1988, J CLIN INVEST, V82, P998, DOI 10.1172/JCI113710; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GOYAL M, 1991, J AM SOC NEPHROL, V1, P1334; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HEBERT S, 1993, DIS KIDNEY, P1; ITOH M, 1992, J BIOL CHEM, V267, P12356; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; KERJASCHKI D, 1985, AM J PATHOL, V118, P343; KORETZKY GA, 1993, FASEB J, V7, P420, DOI 10.1096/fasebj.7.5.8462784; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREUGER NX, 1990, EMBO J, V9, P3241; KURIHARA H, 1992, AM J PATHOL, V141, P805; LEVY JB, 1993, J BIOL CHEM, V268, P10573; LOGIN GR, 1987, LAB INVEST, V57, P585; MERRITT SE, 1990, LAB INVEST, V63, P762; NADASDY T, 1989, RENAL PATHOLOGY, P330; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SIBLEY RK, 1989, RENAL PATHOLOGY, P1291; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOW JL, 1989, AM J PATHOL, V135, P637; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WANG Y, 1992, J BIOL CHEM, V267, P16696; WIGGINS R, 1987, LAB INVEST, V56, P264; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; YOUNG RA, 1985, GENETIC ENG, P29; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134	47	141	156	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19953	19961						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	7519601				2022-12-25	WOS:A1994PA12600047
J	ANDERSSON, O; NORDLUNDMOLLER, L; BARNES, HJ; LUND, J				ANDERSSON, O; NORDLUNDMOLLER, L; BARNES, HJ; LUND, J			HETEROLOGOUS EXPRESSION OF HUMAN UTEROGLOBIN POLYCHLORINATED BIPHENYL-BINDING PROTEIN - DETERMINATION OF LIGAND-BINDING PARAMETERS AND MECHANISM OF PHOSPHOLIPASE A(2) INHIBITION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL 10-KDA PROTEIN; C2221 CRYSTAL FORM; POLYCHLORINATED-BIPHENYLS; PROGESTERONE-BINDING; METABOLITE 4,4'-BIS(METHYLSULFONYL)-2,2',5,5'-TETRACHLOROBIPHENYL; AMINO-ACID; BRONCHOALVEOLAR LAVAGE; OXIDIZED UTEROGLOBIN; RABBIT UTEROGLOBIN; RUTHENIUM RED	High level expression of a human polychlorinated biphenyl-binding protein (hPCB-BP; also termed uteroglobin or CC10) was achieved in Escherichia coli. The recombinant protein (rhPCB-BP) constituted similar to 1% of total bacterial lysate proteins as judged from in vitro ligand binding assays using 4,4'-bis([H-3]methylsulfonyl)-2,2',5,5'-tetrachlorobiphenyl. rhPCB-BP was purified to homogeneity in its native dimeric form. Saturation analysis experiments indicated a K-d of similar to 69 nM for the binding of 4,4'-bis([H-3]methylsulfonyl)-2,2',5,5'-tetrachlorobiphenyl to rhPCB-BP. The average number of binding sites (B-max) calculated from such experiments on purified rhPCB-BP was 49 nmol/mg of protein and is close to the theoretical value of 1 mol of ligand associating with 1 mol of dimeric protein. Purified rhPCB-BP was also found to cause a dose-dependent inhibition of the enzyme orcine pancreatic phospholipase A(2) (PLA(2)) in vitro. Increasing the concentrations of calcium abolished the inhibition of PLA(2) by rhPCB-BP, suggesting that the protein functions in vitro by sequestering Ca2+ an essential PLA(2) cofactor. This notion was further supported by direct evidence that Ca-45(2+) binds to rhPCB-BP. 1 mol of dimeric protein was also found to bind 2 mol of ruthenium red, an organic dye that detects Ca2+-binding proteins, with a K-d of 3 mu M. This binding was inhibited by Ca2+, with an IC50 of 7 mM. Finally, it was demonstrated that the addition of a high affinity ligand for the protein had no effect on its ability to inhibit PLA(2) under conditions of limiting concentrations of calcium, and the addition of Ca2+ did not affect the binding characteristics of the PCB ligand, suggesting that these two properties of the protein are independent. Our results strongly support the notion that ligand binding is a conserved feature of the homologous uteroglobin/PCB-BP/CC10 proteins in different species, whereas our results question the suggested role of these proteins as specific inhibitors of PLA(2).	KAROLINSKA INST,HUDDINGE UNIV HOSP F60,NOVUM,DEPT LUNG MED,S-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,HUDDINGE UNIV HOSP F60,NOVUM,DEPT MED NUTR,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet; Karolinska Institutet								ACHARYA KR, 1991, J MOL BIOL, V221, P571; ANDERSSON O, 1991, AM J RESP CELL MOL, V5, P6, DOI 10.1165/ajrcmb/5.1.6; BALLY R, 1989, J MOL BIOL, V206, P153, DOI 10.1016/0022-2836(89)90530-5; BARTON GJ, 1991, EUR J BIOCHEM, V198, P749, DOI 10.1111/j.1432-1033.1991.tb16076.x; BEATO M, 1975, BIOCHIM BIOPHYS ACTA, V392, P346, DOI 10.1016/0304-4165(75)90016-1; BEIER HM, 1968, BIOCHIM BIOPHYS ACTA, V160, P289, DOI 10.1016/0005-2795(68)90108-6; BEIER HM, 1978, CELL TISSUE RES, V190, P15; BOCHSKANL R, 1988, CELL TISSUE RES, V252, P625, DOI 10.1007/BF00216650; BOCHSKANL R, 1984, HISTOCHEMISTRY, V80, P581, DOI 10.1007/BF00553721; BRANDT I, 1985, DRUG METAB DISPOS, V13, P490; BROERS JLV, 1992, LAB INVEST, V66, P337; CHARUK JHM, 1990, ANAL BIOCHEM, V188, P123, DOI 10.1016/0003-2697(90)90539-L; DAVIDSON FF, 1987, J BIOL CHEM, V262, P1698; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DAVIDSON FF, 1989, BIOCHEM PHARMACOL, V38, P3645, DOI 10.1016/0006-2952(89)90567-4; FACCHIANO A, 1991, LIFE SCI, V48, P453, DOI 10.1016/0024-3205(91)90501-2; GARRIGOS M, 1991, ANAL BIOCHEM, V194, P82, DOI 10.1016/0003-2697(91)90154-L; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GILLNER M, 1988, J STEROID BIOCHEM, V31, P27, DOI 10.1016/0022-4731(88)90201-4; GLASER KB, 1993, TRENDS PHARMACOL SCI, V14, P92, DOI 10.1016/0165-6147(93)90071-Q; HAGEN G, 1990, NUCLEIC ACIDS RES, V18, P2939, DOI 10.1093/nar/18.10.2939; HALDANE JBS, 1957, NATURE, V179, P832, DOI 10.1038/179832b0; HARAGUCHI H, 1984, FOOD CHEM TOXICOL, V22, P283, DOI 10.1016/0278-6915(84)90007-3; KLASSONWEHLER E, 1983, J LABELLED COMPD RAD, V20, P1407, DOI 10.1002/jlcr.2580201212; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN SW, 1986, LIFE SCI, V38, P1813, DOI 10.1016/0024-3205(86)90135-9; LUND J, 1988, DRUG METAB DISPOS, V16, P590; LUND J, 1986, TOXICOL APPL PHARM, V83, P486, DOI 10.1016/0041-008X(86)90231-0; LUND J, 1985, MOL PHARMACOL, V27, P314; MANTILE G, 1993, J BIOL CHEM, V268, P20343; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MASUDA Y, 1985, ENVIRON HEALTH PERSP, V60, P321, DOI 10.2307/3429976; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MIELE L, 1987, ENDOCR REV, V8, P474, DOI 10.1210/edrv-8-4-474; MIELE L, 1990, J BIOL CHEM, V265, P6427; MIELE L, 1988, NATURE, V335, P726, DOI 10.1038/335726a0; MORIZE I, 1987, J MOL BIOL, V194, P725, DOI 10.1016/0022-2836(87)90250-6; MORNON JP, 1980, J MOL BIOL, V137, P415, DOI 10.1016/0022-2836(80)90166-7; MUKHERJEE AB, 1992, DNA CELL BIOL, V11, P233, DOI 10.1089/dna.1992.11.233; NORDLUNDMOLLER L, 1990, J BIOL CHEM, V265, P12690; PETER W, 1992, PROTEIN ENG, V5, P351, DOI 10.1093/protein/5.4.351; PETER W, 1991, J STEROID BIOCHEM, V38, P27, DOI 10.1016/0960-0760(91)90397-N; POLLARD TD, 1984, NATURE, V312, P403, DOI 10.1038/312403a0; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI T, 1992, J BIOL CHEM, V267, P21518; SHIGEMATSU N, 1978, ENVIRON RES, V16, P92, DOI 10.1016/0013-9351(78)90146-9; SINGH G, 1988, BIOCHIM BIOPHYS ACTA, V950, P329, DOI 10.1016/0167-4781(88)90129-7; SINGH G, 1988, J HISTOCHEM CYTOCHEM, V36, P73, DOI 10.1177/36.1.3275712; SINGH G, 1990, BIOCHIM BIOPHYS ACTA, V1039, P348, DOI 10.1016/0167-4838(90)90270-P; STRUM JM, 1990, ANAT REC, V227, P77, DOI 10.1002/ar.1092270109; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; VANBINSBERGEN J, 1989, FEBS LETT, V247, P293, DOI 10.1016/0014-5793(89)81355-9; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R	53	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19081	19087						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7518449				2022-12-25	WOS:A1994NX32700058
J	WEAVER, CD; SHOMER, NH; LOUIS, CF; ROBERTS, DM				WEAVER, CD; SHOMER, NH; LOUIS, CF; ROBERTS, DM			NODULIN-26, A NODULE-SPECIFIC SYMBIOSOME MEMBRANE-PROTEIN FROM SOYBEAN, IS AN ION-CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR INTRINSIC PROTEIN; CELL CHIP28 PROTEIN; PERIBACTEROID MEMBRANE; XENOPUS-OOCYTES; WATER CHANNELS; MIP FAMILY; PHOSPHORYLATION; RECONSTITUTION; EVOLUTION	Nodulin 26 is an integral symbiosome membrane protein of nitrogen-fixing soybean nodules. Nodulin 26 is a member of a family of structurally homologous membrane proteins with diverse transport functions. Thus, it has been proposed to be involved in symbiosome membrane transport. Despite this claim, there has not been any evidence that nodulin 26 has a transport activity. In this study, nodulin 26 was purified from soybean nodules by a non-denaturing protocol and was reconstituted into liposomes for channel studies in planar lipid bilayers. Nodulin 26 readily incorporated into bilayers, forming single channels with a maximum unitary conductance of 3.1 nanosiemens (nS) in a recording buffer of 20 mM 3-(N-morpholino)propanesulfonate-NaOH, pH 7.4, 1 M KCl. Nodulin 26 also exhibited multiple, discreet lower conductance states ranging from 0.5 to 2.5 nS. Nodulin 26 channels were voltage-sensitive. The maximal 3.1-nS state was preferentially occupied at lower applied voltages, whereas the lower conductance states were more frequently occupied at higher voltage potentials. Nodulin 26 channels transported both cations and anions, but showed a weak selectivity for anions. These results represent the first purification and functional characterization of the nodulin 26 channel and support a role for this protein in symbiosome membrane transport.	UNIV TENNESSEE,DEPT BIOCHEM,KNOXVILLE,TN 37996; UNIV TENNESSEE,CTR LEGUME RES,KNOXVILLE,TN 37996; UNIV MINNESOTA,DEPT BIOCHEM,ST PAUL,MN 55108; UNIV MINNESOTA,DEPT VET PATHOBIOL,ST PAUL,MN 55108	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities				Shomer, Nirah/0000-0003-2520-0108	NATIONAL EYE INSTITUTE [R01EY005684] Funding Source: NIH RePORTER; NEI NIH HHS [EY 05684] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		DAY DA, 1993, SYMBIOSIS, V14, P175; EHRING GR, 1990, J GEN PHYSIOL, V96, P631, DOI 10.1085/jgp.96.3.631; EHRING GR, 1991, J MEMBRANE BIOL, V126, P75; FORTIN MG, 1987, NUCLEIC ACIDS RES, V15, P813, DOI 10.1093/nar/15.2.813; FRANSSEN HJ, 1992, BIOL NITROGEN FIXATI, P598; HAMILTON SL, 1989, ANAL BIOCHEM, V183, P31, DOI 10.1016/0003-2697(89)90167-X; HELLER KB, 1980, J BACTERIOL, V144, P274, DOI 10.1128/JB.144.1.274-278.1980; JOHNSON KR, 1986, J CELL BIOL, V102, P1334, DOI 10.1083/jcb.102.4.1334; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPE PD, 1990, EUR J BIOCHEM, V194, P541, DOI 10.1111/j.1432-1033.1990.tb15650.x; LEVITAN IB, 1985, J MEMBRANE BIOL, V87, P177, DOI 10.1007/BF01871217; LIN ECC, 1986, METHOD ENZYMOL, V125, P467; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; OUYANG LJ, 1991, FEBS LETT, V293, P188, DOI 10.1016/0014-5793(91)81183-9; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRICE GD, 1987, J PLANT PHYSIOL, V130, P157, DOI 10.1016/S0176-1617(87)80219-5; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; RONSON CW, 1981, P NATL ACAD SCI-BIOL, V78, P4284, DOI 10.1073/pnas.78.7.4284; Roth L.E., 1988, MOL GENETICS PLANT M, P220; SANDAL NN, 1988, NUCLEIC ACIDS RES, V16, P9347, DOI 10.1093/nar/16.19.9347; SHIELS A, 1988, NUCLEIC ACIDS RES, V16, P9348, DOI 10.1093/nar/16.19.9348; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUSSMAN MR, 1989, PLANT CELL, V1, P953, DOI 10.1105/tpc.1.10.953; UDVARDI MK, 1988, FEBS LETT, V231, P36, DOI 10.1016/0014-5793(88)80697-5; UDVARDI MK, 1989, PLANT PHYSIOL, V90, P982, DOI 10.1104/pp.90.3.982; UDVARDI MK, 1992, ARCH MICROBIOL, V156, P362; VANDONGEN AMJ, 1992, BIOPHYS J, V61, pA256; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; VERMA DPS, 1992, TRANSPORT AND RECEPTOR PROTEINS OF PLANT MEMBRANES, P113; WEAVER CD, 1991, PLANT PHYSIOL, V95, P222, DOI 10.1104/pp.95.1.222; WEAVER CD, 1992, BIOCHEMISTRY-US, V31, P8954, DOI 10.1021/bi00152a035; YANG LJO, 1990, PLANTA, V182, P437, DOI 10.1007/BF02411397; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002	34	99	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17858	17862						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	7517934				2022-12-25	WOS:A1994NV42200019
J	GUPTA, S; WEISS, A; KUMAR, G; WANG, S; NEL, A				GUPTA, S; WEISS, A; KUMAR, G; WANG, S; NEL, A			THE T-CELL ANTIGEN RECEPTOR UTILIZES LCK, RAF-1, AND MEK-1 FOR ACTIVATING MITOGEN-ACTIVATED PROTEIN-KINASE - EVIDENCE FOR THE EXISTENCE OF A 2ND PROTEIN-KINASE C-DEPENDENT PATHWAY IN AN LCK-NEGATIVE JURKAT CELL MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VAV PROTOONCOGENE PRODUCT; TYROSINE KINASE; MAP KINASE; SIGNAL TRANSDUCTION; GENE-PRODUCT; CROSS-LINKING; LYMPHOCYTES-T; CD4 RECEPTOR; ZETA-CHAIN; PHOSPHORYLATION	T cell antigen receptor (TCR) ligation of an Lck-deficient Jurkat mutant, J.CaM1, with anti-CD3 or anti-TCR beta monoclonal antibodies failed to induce tyrosine phosphorylation and activation of p42(MAPK). The same stimuli activated mitogen-activated protein (MAP) kinase in J.CaM1 cells transfected with Lck, demonstrating that Lck plays a critical role in MAP kinase activation. Utilizing immunocomplex kinase assays, we demonstrated that TCR/CD3 ligation activated a MAP kinase kinase kinase (Raf-1) as well as a MAP kinase kinase (MEK-1) in Jurkat but not in J.CaM1 cells. It was possible, however, to activate Raf-1, MEK-1, and p42(MAPK) in J.CaM1 cells during treatment with the phorbol ester phorbol 12-myristate 13-acetate, which activates protein kinase C (PKC). This demonstrates the presence of a PKC-dependent pathway which functions independently from Lck in MAP kinase activation. Stimulation of Jurkat cells with either anti-TCR beta or anti-CD3 monoclonal antibody failed to induce substantial tyrosine phosphorylation of She proteins or their association with Grb2 which forms a complex with the guanine nucleotide exchange factor hSOS. However, the same stimuli induced tyrosine phosphorylation of another putative guanine nucleotide exchange factor, p95(Vav), in Jurkat but not J.CaM1 cells. Moreover, Lck was reversibly co-immunoprecipitated with p95(Vav), and the stoichiometry of binding increased in anti-CD3-treated Jurkat cells. Phorbol 12-myristate 13-acetate did not induce tyrosine phosphorylation of p95(Vav). These data show that the TCR activates MAP kinase by way of a signaling cascade, which depends upon Lck, and may be mediated by downstream events involving PKC or p95(Vav) which act on Raf-1 and MEK-1.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED CIA,DIV CLIN IMMUNOL & ALLERGY,LOS ANGELES,CA 90024; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco			Nel, Andre E/J-2808-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039553] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41576, GM39553] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAMEN JE, 1993, BLOOD, V82, P296; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARTH JD, 1989, J IMMUNOL, V142, P2430; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEL AE, 1991, J IMMUNOL, V147, P1933; NEL AE, 1987, J IMMUNOL, V138, P3519; NEL AE, 1990, J IMMUNOL, V145, P971; NEL AE, 1990, J IMMUNOL, V144, P2683; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OWAKI H, 1993, EMBO J, V12, P4367, DOI 10.1002/j.1460-2075.1993.tb06121.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEGER R, 1992, J BIOL CHEM, V267, P14373; SIEGEL JN, 1993, J IMMUNOL, V151, P4116; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	54	118	119	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17349	17357						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516337				2022-12-25	WOS:A1994NT84600055
J	JIN, DJ				JIN, DJ			SLIPPAGE SYNTHESIS AT THE GALP2 PROMOTER OF ESCHERICHIA-COLI AND ITS REGULATION BY UTP CONCENTRATION AND CAMP-CENTER-DOT-CAMP RECEPTOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; TRANSCRIPTION INITIATION; GALACTOSE OPERON; ACID; SEQUENCES; INVITRO; POOLS; GENE	An intriguing mechanism in regulating transcription initiation from the gal operon in Escherichia coli is described. Initiation from galP2, one of the two promoters of the E. coli galactose operon, is shown to be subject to promoter clearance control in responding to changes in UTP concentration. In vitro, RNA polymerase (RNAP) makes a large amount of nonproductive ''stuttering'' initiation products at the galP2 promoter at high concentrations of UTP and less of the stuttered products at low concentrations of UTP. Conversely, RNAP makes more productive initiation products at low UTP concentration than at high UTP concentration. The transcription factor cAMP CRP complex which normally inhibits transcription from galP2 also represses the stuttering synthesis from galP2. When galactose is used as a sole carbon source and the internal UTP pools are adjusted externally, a cya mutant (in which galP2 is mainly responsible for the expression of the gal operon and galP1 activity is minimal) has a slower growth rate and lower expression of the gal operon at high UTP pools than at low UTP pools. Such an apparent correlation between the in vitro and in vivo results allows one to speculate that changes in UTP concentration can modulate the expression of the gal operon. The implication of a gal promoter being controlled by UTP is discussed.			JIN, DJ (corresponding author), NCI,MOLEC BIOL LAB,9000 ROCKVILLE PIKE,BLDG 37,RM 2E14,BETHESDA,MD 20892, USA.							ADHYA S, 1979, NATURE, V279, P492, DOI 10.1038/279492a0; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAMBERLIN M, 1964, J MOL BIOL, V8, P708, DOI 10.1016/S0022-2836(64)80120-0; CHOY HE, 1992, P NATL ACAD SCI USA, V89, P11264, DOI 10.1073/pnas.89.23.11264; DONAHUE JP, 1990, J BIOL CHEM, V265, P19091; GOODRICH JA, 1992, J MOL BIOL, V224, P1; GUO HC, 1990, BIOCHEMISTRY-US, V29, P10702, DOI 10.1021/bi00499a019; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HARLEY CB, 1990, NUCLEIC ACIDS RES, V18, P547, DOI 10.1093/nar/18.3.547; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; JACQUES JP, 1990, GENE DEV, V4, P1801, DOI 10.1101/gad.4.10.1801; JIN DJ, 1994, J MOL BIOL, V236, P72, DOI 10.1006/jmbi.1994.1119; Johnston D. E., 1976, RNA POLYMERASE, P413; KAMMERER W, 1986, EMBO J, V5, P2995, DOI 10.1002/j.1460-2075.1986.tb04597.x; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; MAJUMDAR A, 1987, J BIOL CHEM, V262, P2326; MATHEWS CK, 1972, J BIOL CHEM, V247, P7430; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; MUNSON LM, 1981, BIOCHEMISTRY-US, V20, P2081, DOI 10.1021/bi00511a003; MUSSO RE, 1977, CELL, V12, P847, DOI 10.1016/0092-8674(77)90283-5; POULSEN P, 1987, MOL GEN GENET, V208, P152, DOI 10.1007/BF00330436; QUEEN C, 1981, CELL, V25, P241, DOI 10.1016/0092-8674(81)90249-X; ROLAND KL, 1988, P NATL ACAD SCI USA, V85, P7149, DOI 10.1073/pnas.85.19.7149; RYU S, 1993, P NATL ACAD SCI USA, V90, P75, DOI 10.1073/pnas.90.1.75; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WILSON DB, 1966, METHOD ENZYMOL, V8, P229; XIONG XF, 1993, J MOL BIOL, V231, P569, DOI 10.1006/jmbi.1993.1310	29	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17221	17227						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516334				2022-12-25	WOS:A1994NT84600038
J	MINOGUCHI, K; BENHAMOU, M; SWAIM, WD; KAWAKAMI, Y; KAWAKAMI, T; SIRAGANIAN, RP				MINOGUCHI, K; BENHAMOU, M; SWAIM, WD; KAWAKAMI, Y; KAWAKAMI, T; SIRAGANIAN, RP			ACTIVATION OF PROTEIN-TYROSINE KINASE P72(SYK) BY FC-EPSILON-RI AGGREGATION IN RAT BASOPHILIC LEUKEMIA-CELLS P72(SYK) IS A MINOR COMPONENT BUT THE MAJOR PROTEIN-TYROSINE KINASE OF PP72	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY; ANTIGEN RECEPTOR; IMMUNOGLOBULIN-E; PHOSPHOLIPASE C-GAMMA-1; SIGNAL TRANSDUCTION; MAST-CELLS; ZETA-CHAIN; MONOCLONAL-ANTIBODIES; CROSS-LINKING; RBL-2H3 CELLS	Aggregation of the high affinity IgE receptors (Fc epsilon RI) on rat basophilic leukemia RBL-2H3 cells results in protein tyrosine phosphorylations. Previously we reported that there is prominent tyrosine phosphorylation of similar to 72-kDa proteins (pp72) and that the tyrosine kinase p72(syk) is one component of pp72. Here we studied further the relationship of p72(syk) to pp72. The aggregation of Fc epsilon RI induced the activation of p72(syk) which was parallel to its tyrosine phosphorylation. By in vitro kinase assay of immune complexes purified with anti-phosphotyrosine antibodies, p72(syk) was the major pp72 tyrosine kinase. However, by immunoblotting with anti-phosphotyrosine antibodies, p72(syk) was a minor component of pp72. The heterogeneous nature of pp72 was indicated by different studies. Under optimum conditions of one-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis, pp72 consisted of a heterogeneous group of 69-, 71-, and 72-kDa tyrosine-phosphorylated proteins. There were differences in the tyrosine phosphorylation of these proteins in cells activated in the absence of extracellular calcium or when stimulation was with the calcium ionophore A23187 or with phorbol myristate acetate. One of the proteins migrating at 69 kDa was p72(syk). By two-dimensional gel electrophoresis pp72 was found to consist of multiple tyrosine-phosphorylated proteins including 71-80-kDa proteins that associate with p53/56(lyn). A 75-kDa tyrosine-phosphorylated protein, different from pp72, was identified as p75(HS1) (SPY75). These results demonstrate the heterogeneous nature of the pp72 and that p72(syk) is activated after Fc epsilon RI aggregation.	LA JOLLA INST ALLERGY & IMMUNOL, DIV IMMUNOBIOL, LA JOLLA, CA 92037 USA	La Jolla Institute for Immunology	MINOGUCHI, K (corresponding author), NIDR, IMMUNOL LAB, BLDG 10, RM 1N106, BETHESDA, MD 20892 USA.		Kawakami, Toshiaki/O-1616-2015	Benhamou, Marc/0000-0001-7763-3795				AGARWAL A, 1993, J BIOL CHEM, V268, P15900; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; DASILVA AJ, 1993, J BIOL CHEM, V268, P16537; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; EISEMAN E, 1992, NATURE, V355, P78; FUKAMACHI H, 1992, P NATL ACAD SCI USA, V89, P9524, DOI 10.1073/pnas.89.20.9524; FUKAMACHI H, 1994, J IMMUNOL, V152, P642; FUKAMACHI H, 1993, INT ARCH ALLERGY IMM, V102, P15, DOI 10.1159/000236546; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; KAMPS MP, 1988, ONCOGENE, V2, P305; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MINOGUCHI K, 1994, J BIOL CHEM, V269, P5249; MINOGUCHI K, 1994, IN PRESS MOL IMMUNOL, V31; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; SANTINI F, 1993, J BIOL CHEM, V268, P22716; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SIRAGANIAN RP, 1988, INFLAMMATION BASIC P, P513; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; STRACKE ML, 1987, MOL IMMUNOL, V24, P347, DOI 10.1016/0161-5890(87)90176-3; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; WANGE RL, 1992, J BIOL CHEM, V267, P11685; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; YU KT, 1991, J BIOL CHEM, V266, P22564	49	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16902	16908						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	7515887				2022-12-25	WOS:A1994NR29600059
J	STRASSHEIM, D; MALBON, CC				STRASSHEIM, D; MALBON, CC			PHOSPHORYLATION OF G(I-ALPHA-2) ATTENUATES INHIBITORY ADENYLYL-CYCLASE IN NEUROBLASTOMA/GLIOMA HYBRID (NG-108-15) CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; PROTEIN-MEDIATED PATHWAYS; STEADY-STATE LEVELS; CYCLIC-AMP ACCUMULATION; CROSS-REGULATION; MESSENGER-RNA; BINDING-PROTEIN; BETA-2-ADRENERGIC RECEPTORS; INTACT HEPATOCYTES; HUMAN-PLATELETS	Cross-regulation from the stimulatory phospholipase C to the adenylyl cyclase pathways was explored in neuroblastoma-glioma NG-108-15 cells in culture. Activation of protein kinase C by phorbol myristic acid resulted in a markedly attenuated activation of the inhibitory adenylyl cyclase response to delta-opiate agonists and epinephrine but not to the muscarinic agonist carbachol. The ability of okadaic acid to mimic the effects of phorbol myristic acid on the inhibitory response suggested a role for protein phosphorylation. Adenylyl cyclase activity from cells in which protein kinase C had been activated demonstrated a loss in the inhibitory adenylyl cyclase response at the level of the G-protein. Activation of protein kinase C prompted a 2-4-fold increase in phosphorylation of G(i alpha 2) in cells metabolically labeled with [P-32]orthophosphate. The phosphate content of G(i alpha 2) was determined to be similar to-0.5 mol/mol subunit in the unstimulated cells and similar to-1.5 mol/mol subunit for cells in which protein kinase C was activated. The effects of okadaic acid, 4-alpha-phorbol, and calphostin C on inhibition of adenylyl cyclase in cells treated with phorbol myristic acid correlate with the effects of these agents on phosphorylation of G(i alpha 2). The time courses for attenuation of inhibitory adenylyl cyclase and that for phosphorylation of G(i alpha 2) were similar in cells challenged with phorbol myristic acid. These data argue for cross-regulation from the stimulatory protein kinase C to inhibitory adenylyl cyclase pathways at the level of G(i alpha 2) via protein phosphorylation.			STRASSHEIM, D (corresponding author), SUNY STONY BROOK,HLTH SCI CTR,SCH MED,DEPT MOLEC PHARMACOL,DIABET & METAB DIS RES PROGR,STONY BROOK,NY 11794, USA.		STRASSHEIM, DEREK/AHB-1158-2022; malbon, craig/ABF-3604-2020		NIDDK NIH HHS [DK30111] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030111] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BUSHFIELD M, 1991, BIOCHEM J, V274, P317, DOI 10.1042/bj2740317; BUSHFIELD M, 1990, BIOCHEM J, V271, P365, DOI 10.1042/bj2710365; BUSHFIELD M, 1990, BIOCHEM J, V268, P449, DOI 10.1042/bj2680449; BUSHFIELD M, 1990, EUR J BIOCHEM, V192, P537, DOI 10.1111/j.1432-1033.1990.tb19258.x; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; COLE GM, 1991, CELL, V64, P703, DOI 10.1016/0092-8674(91)90500-X; DANIELISSAKANI S, 1989, J BIOL CHEM, V264, P20240; ENGLAND PJ, 1976, ANAL BIOCHEM, V15, P429; EVANS CJ, 1992, SCIENCE, V258, P1882; GERHARDT MA, 1991, MOL PHARMACOL, V40, P707; GRAESER D, 1993, MOL PHARMACOL, V43, P434; GUNDERSEN RE, 1990, SCIENCE, V248, P591, DOI 10.1126/science.2110382; HADCOCK JR, 1991, J BIOL CHEM, V266, P11915; HADCOCK JR, 1992, J BIOL CHEM, V267, P26017; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P8415, DOI 10.1073/pnas.85.22.8415; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; HADCOCK JR, 1989, J BIOL CHEM, V264, P13956; HADCOCK JR, 1989, AM J PHYSIOL, V256, pC457, DOI 10.1152/ajpcell.1989.256.3.C457; HADCOCK JR, 1988, BIOCHEM BIOPH RES CO, V154, P676; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JACOBS KH, 1985, EUR J BIOCHEM, V151, P425; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALBON CC, 1980, BIOCHEM J, V188, P593, DOI 10.1042/bj1880593; MALBON CC, 1993, HDB EXPT PHARM; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MORRIS GM, 1991, J BIOL CHEM, V266, P2233; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; PORT JD, 1992, J BIOL CHEM, V267, P8468; PORT JD, 1993, IN PRESS TRENDS CARD; PYNE NJ, 1992, BIOCHEM BIOPH RES CO, V186, P1081, DOI 10.1016/0006-291X(92)90857-H; PYNE NJ, 1989, FEBS LETT, V243, P77, DOI 10.1016/0014-5793(89)81221-9; PYNE NJ, 1992, BIOCHEM J, V285, P333, DOI 10.1042/bj2850333; ROS M, 1988, J BIOL CHEM, V263, P4362; SABOL SL, 1979, J BIOL CHEM, V254, P1913; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCARPACE PJ, 1985, MOL PHARMACOL, V28, P495; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SMITH DE, 1987, J CELL BIOL, V105, P771, DOI 10.1083/jcb.105.2.771; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; WANG HY, 1989, J BIOL CHEM, V264, P14424; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; ZACHARY I, 1991, NATURE, V321, P63	51	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14307	14313						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514603				2022-12-25	WOS:A1994NL60600088
J	LINCHAO, S; WONG, TT; MCDOWALL, KJ; COHEN, SN				LINCHAO, S; WONG, TT; MCDOWALL, KJ; COHEN, SN			EFFECTS OF NUCLEOTIDE-SEQUENCE ON THE SPECIFICITY OF RNE-DEPENDENT AND RNASE E-MEDIATED CLEAVAGES OF RNA I-ENCODED BY THE PBR322 PLASMID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-AMS; MESSENGER-RNA; RIBONUCLEASE-E; RIBOSOMAL-PROTEIN; STABILITY AMS; BACTERIOPHAGE-T4 GENE-32; ENDONUCLEOLYTIC CLEAVAGE; STRUCTURAL-ANALYSIS; CELL-DIVISION; INVITRO	RNase E, an endoribonuclease encoded by the Escherichia coli ams/rne/hmp1 locus, cleaves RNA I, an antisense regulator of the replication of ColE1 type plasmids, in a single-stranded region near its 5' end. The rne-3071 mutation prolongs the RNA I half-life in cells cultured at an elevated temperature and imparts temperature sensitivity on RNase E isolated from the mutant strain. Here we report the effects of specific sequence changes introduced by site-directed mutagenesis on the location of ribonucleolytic cleavage near the 5' end of pBR322 RNA I in rne-3071 and congenic rne(+) E. coli and on cleavage of RNA I by RNase E in vitro. Primer extension analyses showed that the occurrence and position of cleavages in vivo and in vitro are altered highly specifically by sequence changes but that the site of cleavage bears no simple relationship to a particular nucleotide order. Our results do not support either the notion that cleavage by RNase E is determined by a consensus sequence or the contrary view that RNase E is a virtually nonspecific single-stranded endonuclease with a preference for cutting 5' to an AU dinucleotide.	NATL YANG MING MED COLL, INST BIOCHEM, TAIPEI 11221, TAIWAN; STANFORD UNIV, SCH MED, DEPT GENET, STANFORD, CA 94305 USA	National Yang Ming Chiao Tung University; Stanford University	LINCHAO, S (corresponding author), ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN.		Lin-Chao, Sue/AAZ-8246-2021; McDowall, Kenneth/GYA-5735-2022; Lin-Chao, Sue/AGI-2030-2022; Wong, Ten-Tsao/J-7524-2017	Lin-Chao, Sue/0000-0002-8415-9304; Lin-Chao, Sue/0000-0002-8415-9304; Wong, Ten-Tsao/0000-0001-5573-9767; McDowall, Kenneth/0000-0003-2528-2190	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027241] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27241] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; CARPOUSIS AJ, 1989, MOL GEN GENET, V219, P39, DOI 10.1007/BF00261155; CASAREGOLA S, 1992, J MOL BIOL, V228, P30, DOI 10.1016/0022-2836(92)90489-7; CESARENI G, 1991, TRENDS GENET, V7, P230, DOI 10.1016/0168-9525(91)90370-6; CHAMBERLIN M, 1983, METHOD ENZYMOL, V101, P540; CLAVERIEMARTIN F, 1991, J BIOL CHEM, V266, P2843; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; FAUBLADIER M, 1990, J MOL BIOL, V212, P461, DOI 10.1016/0022-2836(90)90325-G; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; GUREVITZ M, 1983, P NATL ACAD SCI-BIOL, V80, P4450, DOI 10.1073/pnas.80.14.4450; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; KOKOSKA RJ, 1990, BIOCHIMIE, V72, P803, DOI 10.1016/0300-9084(90)90189-N; Lin-Chao S, 1992, MOL MICROBIOL, V6, P3385, DOI 10.1111/j.1365-2958.1992.tb02206.x; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LOAYZA D, 1991, MOL MICROBIOL, V5, P715, DOI 10.1111/j.1365-2958.1991.tb00742.x; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; MACKIE GA, 1992, J BIOL CHEM, V267, P1054; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; Maniatis T., 1982, MOL CLONING; MCDOWALL KJ, 1993, J BACTERIOL, V175, P4245, DOI 10.1128/JB.175.13.4245-4249.1993; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; MEACOCK PA, 1980, CELL, V20, P529, DOI 10.1016/0092-8674(80)90639-X; MELEFORS O, 1991, MOL MICROBIOL, V5, P857, DOI 10.1111/j.1365-2958.1991.tb00759.x; MELEFORS O, 1993, CONTROL MESSENGER RN, P53; MORITA M, 1979, EUR J BIOCHEM, V97, P435, DOI 10.1111/j.1432-1033.1979.tb13131.x; MUDD EA, 1988, EMBO J, V7, P3601, DOI 10.1002/j.1460-2075.1988.tb03238.x; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; NILSSON G, 1988, EMBO J, V7, P2269, DOI 10.1002/j.1460-2075.1988.tb03067.x; NILSSON P, 1991, MOL MICROBIOL, V5, P1791, DOI 10.1111/j.1365-2958.1991.tb01928.x; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PRAGAI B, 1982, J MOL BIOL, V154, P465, DOI 10.1016/S0022-2836(82)80007-7; REGNIER P, 1991, J MOL BIOL, V217, P283, DOI 10.1016/0022-2836(91)90542-E; ROTH JR, 1970, METHODS ENZYMOL    A, V17, P3; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; SRIVASTAVA RK, 1990, BIOCHIMIE, V72, P791, DOI 10.1016/0300-9084(90)90188-M; SUBBARAO MN, 1989, MOL GEN GENET, V217, P499, DOI 10.1007/BF02464923; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P851, DOI 10.1111/j.1365-2958.1991.tb00758.x; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; TUCKER WT, 1984, CELL, V38, P191, DOI 10.1016/0092-8674(84)90540-3; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756; YARCHUK O, 1992, J MOL BIOL, V226, P581, DOI 10.1016/0022-2836(92)90617-S; YOST HJ, 1990, TRENDS GENET, V6, P223, DOI 10.1016/0168-9525(90)90183-7	48	101	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10797	10803						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511607				2022-12-25	WOS:A1994NF01700091
J	SONCIN, F; SHAPIRO, R; FETT, JW				SONCIN, F; SHAPIRO, R; FETT, JW			A CELL-SURFACE PROTEOGLYCAN MEDIATES HUMAN ADENOCARCINOMA HT-29 CELL-ADHESION TO HUMAN ANGIOGENIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL RIBONUCLEASE INHIBITOR; MAMMARY EPITHELIAL-CELLS; HEPARAN-SULFATE PROTEOGLYCANS; AMINO-ACID SEQUENCE; CANCER METASTASIS; ENDOTHELIAL-CELLS; TUMOR-CELLS; BINDING; PROTEIN; PURIFICATION	Human angiogenin is an excellent substrate for the adhesion of HT-29 human colon adenocarcinoma cells. These cells adhere more quickly to human angiogenin than to fibronectin, laminin, collagen I, and collagen IV. Anti-angiogenin antibodies and the angiogenesis inhibitors platelet factor-4 and placental ribonuclease inhibitor prevent adhesion of HT-29 cells to angiogenin. Calcium and magnesium ions are not required for adhesion and Arg Gly-Asp-Ser has no effect, indicating that the interaction is integrin-independent. Instead, adhesion seems to involve a heparan/chondroitin sulfate proteoglycan. Treatment of the cells with heparinase or heparitinase decreases HT-29 cell adhesion onto angiogenin but not onto collagen I. Moreover, cell adhesion is decreased by the presence of heparin or chondroitin sulfates and by preincubation of the cells with inhibitors of proteoglycan synthesis or secretion. In addition, angiogenin binds tightly to heparin-Sepharose, requiring 0.78 M NaCl for elution. Angiogenin-affinity chromatography of a S-35-, H-3-labeled HT-29 cell fraction enriched in cell-surface proteoglycans yields a single, heparinase-sensitive component of apparent molecular mass >200 kDa, as detected by autoradiography after SDS-polyacrylamide gel electrophoresis. These results suggest that angiogenin could be an effective substrate for tumor cell adhesion during metastasis and may provide a basis for the design of inhibitors of this process.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BIOCHEM & BIOPHYS SCI & MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			SONCIN, Fabrice/A-1475-2009	SONCIN, Fabrice/0000-0001-6312-0673				BADET J, 1989, P NATL ACAD SCI USA, V86, P8427, DOI 10.1073/pnas.86.21.8427; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BICKNELL R, 1989, P NATL ACAD SCI USA, V86, P1573, DOI 10.1073/pnas.86.5.1573; BRENNAN MJ, 1983, CANCER RES, V43, P4302; CRISCUOLO GR, 1988, J NEUROSURG, V69, P254, DOI 10.3171/jns.1988.69.2.0254; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; HALLAHAN TW, 1991, P NATL ACAD SCI USA, V88, P2222, DOI 10.1073/pnas.88.6.2222; HANDIN RI, 1976, J BIOL CHEM, V251, P4273; HEATH WF, 1989, P NATL ACAD SCI USA, V86, P2718, DOI 10.1073/pnas.86.8.2718; HU GF, 1993, P NATL ACAD SCI USA, V90, P1217, DOI 10.1073/pnas.90.4.1217; HUANG SS, 1982, J BIOL CHEM, V257, P1546; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KODA JE, 1985, J BIOL CHEM, V260, P8157; KURACHI K, 1985, BIOCHEMISTRY-US, V24, P5494, DOI 10.1021/bi00341a032; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE FS, 1988, BIOCHEMISTRY-US, V27, P8545, DOI 10.1021/bi00423a007; LEE FS, 1989, BIOCHEMISTRY-US, V28, P225, DOI 10.1021/bi00427a031; Linker A., 1972, METHODS ENZYMOL, P902; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1986, CANCER RES, V46, P1; LOBB RR, 1986, ANAL BIOCHEM, V154, P1, DOI 10.1016/0003-2697(86)90487-2; LOESER RF, 1992, J BIOL CHEM, V267, P9459; MAES P, 1988, FEBS LETT, V241, P41, DOI 10.1016/0014-5793(88)81027-5; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; NICOLSON GL, 1975, NATURE, V255, P230, DOI 10.1038/255230a0; PATTHY L, 1987, J MOL BIOL, V198, P567, DOI 10.1016/0022-2836(87)90200-2; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; RAPRAEGER AC, 1983, J BIOL CHEM, V258, P3632; RYBAK SM, 1987, BIOCHEM BIOPH RES CO, V146, P1240, DOI 10.1016/0006-291X(87)90781-9; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SCHWARTZ NB, 1977, J BIOL CHEM, V252, P6316; SHAPIRO R, 1989, BIOCHEMISTRY-US, V28, P7401, DOI 10.1021/bi00444a038; SHAPIRO R, 1986, BIOCHEMISTRY-US, V25, P3527, DOI 10.1021/bi00360a008; SHAPIRO R, 1987, BIOCHEMISTRY-US, V26, P5141, DOI 10.1021/bi00390a037; SHAPIRO R, 1987, P NATL ACAD SCI USA, V84, P2238, DOI 10.1073/pnas.84.8.2238; SHAPIRO R, 1988, ANAL BIOCHEM, V175, P450, DOI 10.1016/0003-2697(88)90569-6; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SONCIN F, 1992, P NATL ACAD SCI USA, V89, P2232, DOI 10.1073/pnas.89.6.2232; STRYDOM DJ, 1985, BIOCHEMISTRY-US, V24, P5486, DOI 10.1021/bi00341a031; TAYLOR S, 1982, NATURE, V297, P307, DOI 10.1038/297307a0; TERRANOVA VP, 1982, CANCER RES, V42, P2265; TWINING SS, 1984, ANAL BIOCHEM, V143, P30, DOI 10.1016/0003-2697(84)90553-0; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YAMAGISHITA M, 1987, METHOD ENZYMOL, V138, P279	50	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8999	9005						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510698				2022-12-25	WOS:A1994NB41100058
J	RILEY, GR; CORELL, RA; STUART, K				RILEY, GR; CORELL, RA; STUART, K			MULTIPLE GUIDE RNAS FOR IDENTICAL EDITING OF TRYPANOSOMA-BRUCEI APOCYTOCHROME-B MESSENGER-RNA HAVE AN UNUSUAL MINICIRCLE LOCATION AND ARE DEVELOPMENTALLY-REGULATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETOPLASTID MITOCHONDRIA; LEISHMANIA-TARENTOLAE; AFRICAN TRYPANOSOME; NUCLEOTIDE-SEQUENCE; NADH DEHYDROGENASE; MESSENGER-RNA; DNA; TRANSCRIPTS; AMPLIFICATION; ENCODE	We identified four different guide RNAs (gRNAs) that specify identical editing of Typanosoma brucei apocytochrome b (CYb) mRNA, which indicates gRNA redundancy in T. brucei. All four gRNAs appear functional since they occur in chimeras, some of which contain an interesting gRNA 3' ''extension.'' The gRNAs are encoded in different minicircles, rather than maxicircles as in other species. However, these gRNA genes are not between 18-base pair repeats as are the other minicircle gRNA genes in T. brucei. The three minicircles cloned contain the same gRNA genes, one of which is substantially diverged, all in the same order, indicating that they are related. CYb gRNA is less abundant in procyclic than bloodstream forms. Procyclic forms contain abundant edited CYb mRNA unlike bloodstream forms thus suggesting that CYb mRNA editing may be regulated at the level of gRNA utilization.	SEATTLE BIOMED RES INST,SEATTLE,WA 98109	Center for Infectious Disease Research					NIGMS NIH HHS [1 F32 GM14126-01A1, GM42188] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014126] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BHAT GJ, 1991, NUCLEIC ACIDS RES, V19, P398, DOI 10.1093/nar/19.2.398; BIENEN EJ, 1991, MOL BIOCHEM PARASIT, V45, P185, DOI 10.1016/0166-6851(91)90085-K; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKSON AB, 1989, J BIOL CHEM, V264, P17770; CORELL RA, 1993, NUCLEIC ACIDS RES, V21, P4313, DOI 10.1093/nar/21.18.4313; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; FEAGIN JE, 1990, J BIOL CHEM, V265, P19373; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; FEAGIN JE, 1988, MOL CELL BIOL, V8, P1259, DOI 10.1128/MCB.8.3.1259; FEAGIN JE, 1987, M COLD SPRINGS HARBO, P113; Fourney R.M., 1988, FOCUS, V10, P5; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; JASMER DP, 1986, MOL BIOCHEM PARASIT, V18, P257, DOI 10.1016/0166-6851(86)90084-8; JASMER DP, 1986, MOL BIOCHEM PARASIT, V18, P321, DOI 10.1016/0166-6851(86)90089-7; KOSLOWSKY DJ, 1991, CELL, V67, P537, DOI 10.1016/0092-8674(91)90528-7; KOSLOWSKY DJ, 1992, MOL CELL BIOL, V12, P2043, DOI 10.1128/MCB.12.5.2043; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; Maniatis T., 1982, MOL CLONING; MARINI JC, 1980, J BIOL CHEM, V255, P4976; MYLER PJ, 1993, NUCLEIC ACIDS RES, V21, P687, DOI 10.1093/nar/21.3.687; POLLARD VW, 1991, MOL CELL BIOL, V11, P1668, DOI 10.1128/MCB.11.3.1668; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; READ LK, 1992, NUCLEIC ACIDS RES, V20, P2341, DOI 10.1093/nar/20.9.2341; READ LK, 1992, J BIOL CHEM, V267, P1123; ROHRER SP, 1987, CELL, V49, P625, DOI 10.1016/0092-8674(87)90538-1; SIMPSON L, 1987, J BIOL CHEM, V262, P6182; SOLLNERWEBB B, 1992, NATURE, V356, P743, DOI 10.1038/356743a0; SOUZA AE, 1992, MOL CELL BIOL, V12, P2100, DOI 10.1128/MCB.12.5.2100; SPENCER E, 1978, P NATL ACAD SCI USA, V75, P4793, DOI 10.1073/pnas.75.10.4793; STUART K, 1983, J CELL BIOCHEM, V23, P13, DOI 10.1002/jcb.240230103; STUART K, 1984, J PARASITOL, V70, P747, DOI 10.2307/3281757; STUART K, 1979, PLASMID, V2, P520, DOI 10.1016/0147-619X(79)90051-9; STUART K, 1991, ANNU REV MICROBIOL, V45, P327, DOI 10.1146/annurev.mi.45.100191.001551; STURM NR, 1992, CELL, V70, P469, DOI 10.1016/0092-8674(92)90171-8; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; VANDERSPEK H, 1991, EMBO J, V10, P1217, DOI 10.1002/j.1460-2075.1991.tb08063.x	46	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6101	6108						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509798				2022-12-25	WOS:A1994MY84000094
J	SAITO, S; LEVERY, SB; SALYAN, MEK; GOLDBERG, RI; HAKOMORI, S				SAITO, S; LEVERY, SB; SALYAN, MEK; GOLDBERG, RI; HAKOMORI, S			COMMON TETRASACCHARIDE EPITOPE NEUAC-ALPHA-2-]3GAL-BETA-1-],3(NEUAC-ALPHA-2-]6)GALNAC, PRESENTED BY DIFFERENT CARRIER GLYCOSYLCERAMIDES OR O-LINKED PEPTIDES, IS RECOGNIZED BY DIFFERENT ANTIBODIES AND LIGANDS HAVING DISTINCT SPECIFICITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY REGULATED ANTIGEN; UROPATHOGENIC ESCHERICHIA-COLI; IONIZATION MASS-SPECTROMETRY; METHYLATED ALDITOL ACETATES; HUMAN TERATOCARCINOMA CELLS; MONOCLONAL-ANTIBODY; GLOBO-SERIES; CONFORMATIONAL-ANALYSIS; STRUCTURAL-ANALYSIS; EPITHELIAL-CELLS	A novel globe-series disialoganglioside, disialosyl galactosyl globoside (Structure 1 below), defined by new monoclonal antibody (mAb) RM2, was isolated and characterized as having terminal structure identical to that of ganglio-series ganglioside GD1 alpha (Structure 2) and a common mucin-type epitope (Structure 3) widely distributed in glycoproteins such as glycophorin A. While these three structures share a common nonreducing tetrasaccharide terminus, mAb RM2 showed strong specific reactivity only with Structure 1, not with Structures 2 or 3. Another mAb, QSH2, reacted strongly with Structure 3 but did not cross-react with Structures I or 2. Conformational molecular models based on minimum energy hard sphere exoanomeric calculations suggest that Structure 1 presents a unique surface topology distinct from that of Structures 2 or 3. Our findings suggest the novel concept that reactivity of a common carbohydrate epitope with different antibodies or Ligands is highly dependent on the type of carrier glycosylceramide or carrier O-Iinked peptide. [GRAPHICS]	BIOMEMBRANE INST, SEATTLE, WA 98119 USA; UNIV WASHINGTON, DEPT PATHOBIOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle				Saito, Seiichi/0000-0001-8734-4591	NCI NIH HHS [CA42505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BJORNDAL H, 1970, CARBOHYD RES, V15, P339, DOI 10.1016/S0008-6215(00)80450-4; BJORNDAL HAKAN, 1967, CAR BOHYD RES, V5, P433, DOI 10.1016/S0008-6215(00)81115-5; BLOMBERG J, 1982, BIOCHIM BIOPHYS ACTA, V711, P466, DOI 10.1016/0005-2760(82)90061-3; BOCK K, 1985, J BIOL CHEM, V260, P8545; BREMER EG, 1984, J BIOL CHEM, V259, P4773; CHIEN JL, 1983, J BIOL CHEM, V258, P727; CLAUSEN H, 1984, BIOCHEM BIOPH RES CO, V124, P523, DOI 10.1016/0006-291X(84)91585-7; DABROWSKI J, 1980, BIOCHEMISTRY-US, V19, P5652, DOI 10.1021/bi00565a030; DABROWSKI J, 1989, J AM CHEM SOC, V111, P1510, DOI 10.1021/ja00186a063; DASGUPTA S, 1991, J LIPID RES, V32, P499; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUJII I, 1985, J CHEM SOC CHEM COMM, P405, DOI 10.1039/c39850000405; GILLECECASTRO BL, 1990, METHOD ENZYMOL, V193, P689, DOI 10.1016/0076-6879(90)93445-Q; HAKOMORI SI, 1971, J BIOL CHEM, V246, P2271; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HAKOMORI SI, 1983, SPHINGOLIPID BIOCH, P1; HANISCH FG, 1993, CANCER RES, V53, P4367; ISOBE R, 1987, TRAC-TREND ANAL CHEM, V6, P78, DOI 10.1016/0165-9936(87)87037-1; Jansson P-E., 1976, CHEM COMMUN U STOCKH, V8, P1; KANNAGI R, 1983, J BIOL CHEM, V258, P8934; KANNAGI R, 1983, EMBO J, V2, P2355, DOI 10.1002/j.1460-2075.1983.tb01746.x; KANNAGI R, 1984, J BIOL CHEM, V259, P8444; KANNAGI R, 1982, J BIOL CHEM, V257, P4865; KANNAGI R, 1983, CANCER RES, V43, P4997; KARLSSON KA, 1992, APMIS, V100, P71; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KLENK E, 1951, H-S Z PHYSIOL CHEM, V288, P220; KUNDY SJ, 1983, J BIOL CHEM, V147, P13857; LAINE RA, 1981, ANAL BIOCHEM, V116, P383, DOI 10.1016/0003-2697(81)90376-6; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; LI YT, 1974, METHODOLOGIE STRUCTU, P339; MAGNANI JL, 1980, ANAL BIOCHEM, V109, P399, DOI 10.1016/0003-2697(80)90667-3; MARCUS DM, 1981, SEMIN HEMATOL, V18, P63; MCNEIL M, 1977, CARBOHYD RES, V56, P239, DOI 10.1016/S0008-6215(00)83346-7; MURAYAMA K, 1986, CANCER RES, V46, P1395; NUDELMAN E, 1986, J BIOL CHEM, V261, P1247; NYHOLM PG, 1990, CHEM PHYS LIPIDS, V52, P1, DOI 10.1016/0009-3084(90)90002-9; PAULSEN H, 1984, LIEBIGS ANN CHEM, P951; POPPE L, 1990, J AM CHEM SOC, V112, P7762, DOI 10.1021/ja00177a042; POULTER L, 1990, METHOD ENZYMOL, V193, P661, DOI 10.1016/0076-6879(90)93444-P; SCARSDALE JN, 1988, J COMPUT CHEM, V9, P133, DOI 10.1002/jcc.540090206; SCARSDALE JN, 1986, J AM CHEM SOC, V108, P6778, DOI 10.1021/ja00281a053; SCARSDALE JN, 1990, ACS SYM SER, V430, P240; SCHWONZEN M, 1992, BRIT J CANCER, V65, P559, DOI 10.1038/bjc.1992.114; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; SIDDIQUI B, 1971, J BIOL CHEM, V246, P5766; STAPLETON A, 1992, J CLIN INVEST, V90, P965, DOI 10.1172/JCI115973; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P21, DOI 10.1515/bchm2.1973.354.1.21; STROMBERG N, 1991, P NATL ACAD SCI USA, V88, P9340, DOI 10.1073/pnas.88.20.9340; TAI T, 1975, J BIOCHEM-TOKYO, V78, P679, DOI 10.1093/oxfordjournals.jbchem.a130955; TAKI T, 1986, J BIOL CHEM, V261, P3075; THOMAS DB, 1969, J BIOL CHEM, V244, P5943; YAMAKAWA T, 1963, J BIOCHEM, V53, P28, DOI 10.1093/oxfordjournals.jbchem.a127654; YAMAKAWA T, 1965, JPN J EXP MED, V35, P201; YAMAKAWA T, 1951, J BIOCHEM-TOKYO, V38, P199, DOI 10.1093/oxfordjournals.jbchem.a126242	58	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5644	5652						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509790				2022-12-25	WOS:A1994MY84000028
J	MADSHUS, IH; WIEDLOCHA, A; SANDVIG, K				MADSHUS, IH; WIEDLOCHA, A; SANDVIG, K			INTERMEDIATES IN TRANSLOCATION OF DIPHTHERIA-TOXIN ACROSS THE PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW PH; B-FRAGMENT; VERO CELLS; ENTRY; PROTEIN; EXPRESSION; SEQUENCES; CHANNELS; RECEPTOR	Active diphtheria toxin consists of two parts, fragments A and B. Fragment A has enzymatic activity and inhibits protein synthesis. Fragment B binds to cellular receptors, and upon exposure to low pH it inserts into the membrane and facilitates translocation of the A fragment into the cytosol, concomitantly with formation of cation-selective channels. Reduction of the interfragment disulfide bridge is required for release of fragment A and intoxication. In cells treated with N-ethylmaleimide (NEM), which inhibits reduction of the disulfide bridge, fragment A was translocated to the cytosol but not released from fragment B. In the presence of NEM a peptide larger than fragment A was protected against extracellularly added Pronase. This peptide (M(r) similar to 24,000) was released to the supernatant fraction of saponin-treated cells. This indicates that fragment A, which is 21 kDa, is covalently attached via a disulfide bond to an N-terminal (M(r) similar to 3,000) piece of fragment B. The 24-kDa fragment disappeared upon reduction, and the 21-kDa fragment A appeared instead. NEM did not prevent channel activity by fragment B in the context of full-length toxin, demonstrating that channel formation occurs in spite of inhibited reduction of the disulfide bond. Thus, channel formation is not dependent on release of fragment A from the toxin-receptor complex.			MADSHUS, IH (corresponding author), NORWEGIAN RADIUM HOSP,INST CANC RES,N-0310 OSLO,NORWAY.							CABIAUX V, 1993, INFECT IMMUN, V61, P2200, DOI 10.1128/IAI.61.5.2200-2202.1993; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; FALNES PO, 1992, J BIOL CHEM, V267, P12284; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GILLILAND DG, 1981, J BIOL CHEM, V256, P2731; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; MCGILL S, 1989, EMBO J, V8, P2843, DOI 10.1002/j.1460-2075.1989.tb08431.x; MINDELL JA, 1992, BIOPHYS J, V62, P41, DOI 10.1016/S0006-3495(92)81772-1; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; MOSKAUG JO, 1987, J BIOL CHEM, V262, P10339; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; OKEEFE DO, 1992, 92, V89, P6202; OLSNES S, 1990, MICROB PATHOGENESIS, V8, P163, DOI 10.1016/0882-4010(90)90043-P; OLSNES S, 1980, J BIOL CHEM, V255, P284; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; SANDVIG K, 1988, J BIOL CHEM, V263, P12352; SANDVIG K, 1986, J BIOL CHEM, V261, P1639; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SANDVIG K, 1988, J CELL BIOCHEM, V36, P73, DOI 10.1002/jcb.240360108; SJOSTROM M, 1987, EMBO J, V6, P823, DOI 10.1002/j.1460-2075.1987.tb04825.x; STENMARK H, 1992, BIOCHEM J, V281, P619, DOI 10.1042/bj2810619; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	27	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4648	4652						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508447				2022-12-25	WOS:A1994MW98900110
J	KALAB, P; VISCONTI, P; LECLERC, P; KOPF, GS				KALAB, P; VISCONTI, P; LECLERC, P; KOPF, GS			P95, THE MAJOR PHOSPHOTYROSINE-CONTAINING PROTEIN IN MOUSE SPERMATOZOA, IS A HEXOKINASE WITH UNIQUE PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RAT-BRAIN HEXOKINASE; BINDING REGULATORY PROTEIN; INDUCED ACROSOME REACTION; OUTER MITOCHONDRIAL-MEMBRANE; SODIUM DODECYL-SULFATE; ZONA-PELLUCIDA; PERTUSSIS TOXIN; CLONED CDNA; MAMMALIAN SPERM	Mouse sperm contain a major phosphotyrosine-containing protein of M(r) 95,000 (nonreducing conditions) which has been implicated as a sperm membrane receptor for the egg zona pellucida glycoprotein, ZP3 (Leyton, L., and Saling, P. (1989) Cell 57, 1123-1130; Leyton, L., LeGuen, P., Bunch, D., and Saling, P. (1992) Proc. Natl. Acad. Sci. U. S. A. 89,11692-11695). This protein was purified and subjected to limited tryptic digestion and subsequent amino acid analysis. Three sequenced peptides revealed 100% amino acid identity to a mouse hepatoma hexokinase (Arora, K. K., Fanciulli, M., and Pederson, P. L. (1990) J. Biol. Chem. 265, 6481-6488). The purified protein, which migrated at M(r) 116,000 under reducing conditions (p95/116), reacted with an antiserum to the purified rat brain hexokinase, type 1, and comigrated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with the purified rat brain enzyme under both nonreducing and reducing conditions. Unlike p95/116, the rat brain enzyme was not a phosphotyrosine-containing protein. The p95/116 protein could be immunoprecipitated with the hexokinase antiserum or an O-phosphotyrosine antibody. Limited tryptic digestion of the purified p95/116 and the rat brain enzyme generated subsets of identical peptides which reacted with the hexokinase antiserum. However, p95/116 also contained phosphotyrosine-containing peptides that were not present in the rat brain hexokinase. When different mouse tissues were probed with the hexokinase antiserum all tissues, with the exception of liver, contained immunoreactive protein. In contrast, only sperm and testis possessed a phosphotyrosine-containing form of hexokinase. These data suggest that the germ cell component of the testis possesses a unique tyrosine-phosphorylated form of hexokinase.	UNIV PENN,SCH MED,DEPT OBSTET & GYNECOL,DIV REPROD BIOL,RM 313,JOHN MORGAN BLDG,PHILADELPHIA,PA 19104	University of Pennsylvania			Kalab, Petr/B-2478-2009	Leclerc, Pierre/0000-0003-2053-3958	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD022732] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD028514, P01HD006274] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 22732, HD 28514, HD 06274] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS V, 1991, BIOCHEM BIOPH RES CO, V177, P1101, DOI 10.1016/0006-291X(91)90652-N; ADAMS V, 1991, BIOCHEM MED METAB B, V45, P271, DOI 10.1016/0885-4505(91)90032-G; ANDREONE TL, 1989, J BIOL CHEM, V264, P363; ARORA KK, 1990, J BIOL CHEM, V265, P6481; ARORA KK, 1993, ARCH BIOCHEM BIOPHYS, V304, P515, DOI 10.1006/abbi.1993.1384; Bessman S P, 1980, Curr Top Cell Regul, V16, P55; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BLEIL JD, 1983, DEV BIOL, V95, P317, DOI 10.1016/0012-1606(83)90032-5; BUNCH DO, 1991, BIOL REPROD, V44, P672, DOI 10.1095/biolreprod44.4.672; CLARSON KE, 1989, J BIOL CHEM, V264, P5348; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORONEL CE, 1987, BIOL REPROD, V37, P1097, DOI 10.1095/biolreprod37.5.1097; EKMAN P, 1988, ARCH BIOCHEM BIOPHYS, V261, P275, DOI 10.1016/0003-9861(88)90342-6; ENDO Y, 1987, DEV BIOL, V119, P210, DOI 10.1016/0012-1606(87)90222-3; ENDO Y, 1988, DEV BIOL, V129, P12, DOI 10.1016/0012-1606(88)90157-1; FELGNER PL, 1977, ARCH BIOCHEM BIOPHYS, V182, P282, DOI 10.1016/0003-9861(77)90309-5; FELGNER PL, 1979, J BIOL CHEM, V254, P4946; FERNANDEZ R, 1988, J GEN MICROBIOL, V134, P2493; FLORMAN HM, 1989, DEV BIOL, V135, P133, DOI 10.1016/0012-1606(89)90164-4; GELB BD, 1992, P NATL ACAD SCI USA, V89, P202, DOI 10.1073/pnas.89.1.202; GRIFFIN LD, 1991, GENOMICS, V11, P1014, DOI 10.1016/0888-7543(91)90027-C; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASHIMOTO E, 1982, J BIOL CHEM, V257, P727; HERRERO P, 1989, J GEN MICROBIOL, V135, P1209; HOPPE PC, 1976, BIOL REPROD, V15, P39, DOI 10.1095/biolreprod15.1.39; HUANG CL, 1989, J BIOL CHEM, V264, P4391; IMAMURA K, 1988, J BIOL CHEM, V263, P14093; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KATZEN HM, 1965, P NATL ACAD SCI USA, V54, P1218, DOI 10.1073/pnas.54.4.1218; KLIGMAN I, 1991, DEV BIOL, V145, P344, DOI 10.1016/0012-1606(91)90133-N; KOPF GS, 1986, J BIOL CHEM, V261, P7327; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MA, 1989, GAMETE RES, V24, P303, DOI 10.1002/mrd.1120240307; LEE MA, 1985, BIOL REPROD, V33, P235, DOI 10.1095/biolreprod33.1.235; LEE MA, 1992, MOL REPROD DEV, V31, P78, DOI 10.1002/mrd.1080310114; LEYTON L, 1989, J CELL BIOL, V108, P2163, DOI 10.1083/jcb.108.6.2163; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LEYTON L, 1992, P NATL ACAD SCI USA, V89, P11692, DOI 10.1073/pnas.89.24.11692; LEYTON L, 1993, J REPROD DEV S, V39, P57; LIANG M, 1991, J BIOL CHEM, V266, P13342; LUTTRELL L, 1990, J BIOL CHEM, V265, P16873; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; MORI C, 1993, BIOL REPROD, V49, P191, DOI 10.1095/biolreprod49.2.191; NISHI S, 1988, BIOCHEM BIOPH RES CO, V157, P937, DOI 10.1016/S0006-291X(88)80964-1; NOLAND T D, 1988, Biology of Reproduction, V38, P94; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAL N, 1988, BIOCHEM BIOPH RES CO, V154, P450, DOI 10.1016/0006-291X(88)90707-3; PARRISH JJ, 1989, BIOL REPROD, V41, P683, DOI 10.1095/biolreprod41.4.683; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; POLAKIS PG, 1984, ARCH BIOCHEM BIOPHYS, V234, P341, DOI 10.1016/0003-9861(84)90279-0; POLAKIS PG, 1985, ARCH BIOCHEM BIOPHYS, V236, P328, DOI 10.1016/0003-9861(85)90633-2; SALINOVICH O, 1986, ANAL BIOCHEM, V156, P341, DOI 10.1016/0003-2697(86)90263-0; SCHWAB DA, 1989, P NATL ACAD SCI USA, V86, P2563, DOI 10.1073/pnas.86.8.2563; SCHWAB DA, 1991, ARCH BIOCHEM BIOPHYS, V285, P365, DOI 10.1016/0003-9861(91)90373-Q; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; THELEN AP, 1991, ARCH BIOCHEM BIOPHYS, V286, P645, DOI 10.1016/0003-9861(91)90094-Y; Towbin H, 1979, P NATL ACAD SCI USA, V76, P4359; WARD CR, 1992, J BIOL CHEM, V267, P14061; WARD CR, 1993, DEV BIOL, V158, P9, DOI 10.1006/dbio.1993.1165; WASSARMAN PM, 1990, DEVELOPMENT, V108, P1; WILDE MW, 1992, MOL REPROD DEV, V31, P297, DOI 10.1002/mrd.1080310411; WILSON JE, 1978, TRENDS BIOCHEM SCI, V3, P124, DOI 10.1016/S0968-0004(78)80029-2; YANG LJ, 1991, J BIOL CHEM, V266, P22451; YANG LJ, 1993, J BIOL CHEM, V268, P3739; ZOLLER MJ, 1981, J BIOL CHEM, V256, P1837; 1989, PROBLOTT IMMOBILIZAT	67	162	164	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3810	3817						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508920				2022-12-25	WOS:A1994MV63100099
J	MIROCHNITCHENKO, O; INOUYE, S; INOUYE, M				MIROCHNITCHENKO, O; INOUYE, S; INOUYE, M			PRODUCTION OF SINGLE-STRANDED-DNA IN MAMMALIAN-CELLS BY MEANS OF A BACTERIAL RETRON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							REVERSE-TRANSCRIPTASE; ESCHERICHIA-COLI; MSDNA; EXPRESSION	msDNA-Ec67, a peculiar multicopy single-stranded DNA of a specific sequence was produced in NIH3T3 mouse cells. Retron-Ec67, a retroelement from Escherichia coli, was introduced under the T7 polymerase promoter and the non-translated 5'-region of the encephalomyocarditis virus. The construct was then transfected into the NIH3T3 cells constitutively producing T7 RNA polymerase. Forty-eight hours after transfection, msDNA-Ec67 was detected in the cells by means of Southern blot hybridization and reverse transcriptase extension assay. The potential use of bacterial retrons as a vector for single-stranded DNA production in mammalian cells is discussed.	ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,675 HOES LA,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center			Inouye, Sharon/R-7216-2019					CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENG H, 1991, GENE, V109, P193, DOI 10.1016/0378-1119(91)90609-F; DERAGON JM, 1990, EMBO J, V9, P3363, DOI 10.1002/j.1460-2075.1990.tb07537.x; GHOSH M, 1991, PROG NUCLEIC ACID RE, P79; INOUYE M, 1991, ANNU REV MICROBIOL, V45, P163; INOUYE M, 1991, J BACTERIOL, V174, P2419; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAMPSON BC, 1989, SCIENCE, V243, P1033, DOI 10.1126/science.2466332; LAMPSON BC, 1990, J BIOL CHEM, V265, P8490; LEDOAN T, 1989, B CANCER, V76, P849; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MILLER PS, 1988, ANNU REP MED CHEM, V23, P295; MIYATA S, 1992, P NATL ACAD SCI USA, V89, P5735, DOI 10.1073/pnas.89.13.5735; NISHIKURA K, 1991, EMBO J, V10, P3523, DOI 10.1002/j.1460-2075.1991.tb04916.x; PARKS GD, 1986, J VIROL, V60, P376, DOI 10.1128/JVI.60.2.376-384.1986; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; SHIMAMOTO T, 1993, J BIOL CHEM, V268, P2684	17	23	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2380	2383						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7507924				2022-12-25	WOS:A1994MV43200009
J	YUEN, CT; BEZOUSKA, K; OBRIEN, J; STOLL, M; LEMOINE, R; LUBINEAU, A; KISO, M; HASEGAWA, A; BOCKOVICH, NJ; NICOLAOU, KC; FEIZI, T				YUEN, CT; BEZOUSKA, K; OBRIEN, J; STOLL, M; LEMOINE, R; LUBINEAU, A; KISO, M; HASEGAWA, A; BOCKOVICH, NJ; NICOLAOU, KC; FEIZI, T			SULFATED BLOOD-GROUP LEWIS(A) - A SUPERIOR OLIGOSACCHARIDE LIGAND FOR HUMAN E-SELECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOLECULE E-SELECTIN; STEREOCONTROLLED SYNTHESIS; LINKED OLIGOSACCHARIDES; CARBOHYDRATE; ADHESION; GLYCOLIPIDS; BINDING; GLYCOPROTEINS; ANTIGENS; RECEPTOR	In earlier studies of oligosaccharide probes (neoglycolipids) generated from an ovarian cystadenoma glycoprotein, one of the components that strongly supported binding of the endothelial adhesion molecule, E-selectin, was identified as an equimolar mixture of tetrasaccharides of blood group Le(a) and Le(x) type sulfated at position 3 of the outer galactose (C.-T. Yuen, A. M. Lawson, W. Chai, M. Larkin, M. S. Stoll, A. C. Stuart, F. X. Sullivan, T. J. Ahern, and T. Feizi (1992) Biochemistry 31, 9126-9131). In the present studies, the individual sulfated Le(a) and sulfated Le(x) oligosaccharides synthesized chemically have been investigated, first, for their ability to support E-selectin binding when converted into neoglycolipids, and second, for their ability to inhibit E-selectin binding to immobilized lipid-linked sialyl-Le(a), sialyl-Le(x), or sulfated Le(a) pentasaccharides; their activities have been compared with those of the sialyl-Le(a) and sialyl-Le(x) analogues. From these studies, the sulfated Le(a) tetra- and pentasaccharides emerge as the most potent E-selectin ligands so far. In particular, the inhibitory activity of the sulfated Le(a) pentasaccharide is substantially greater than that of the sialyl-Le(x) trisaccharide, which is currently the most widely used inhibitor of E-selectin binding: 45-,35-, or 15-fold greater depending on whether adhesion is to sialyl-Le(a), sulfated Le(a) or sialyl-Le(x) pentasaccharides, respectively. These findings have an important bearing on design of new generations of inhibitors of E-selectin binding as anti-inflammatory compounds.	MRC, CLIN RES CTR, GLYCOCONJUGATES SECT, WATFORD RD, HARROW HA1 3UJ, MIDDX, ENGLAND; UNIV PARIS 11, CHIM ORGAN MULTIFONCT LAB, F-91405 ORSAY, FRANCE; GIFU UNIV, DEPT BIOORGAN CHEM, GIFU 50111, JAPAN; Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA	Medical Research Council Clinical Trials Unit; UDICE-French Research Universities; Universite Paris Saclay; Gifu University; Scripps Research Institute								BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; CHILDS RA, 1992, J BIOL CHEM, V267, P9972; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; EDGINGTON SM, 1992, BIO-TECHNOL, V10, P383; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FEIZI T, 1994, METHOD ENZYMOL, V230, P484; Feizi Ten, 1993, Current Opinion in Structural Biology, V3, P701, DOI 10.1016/0959-440X(93)90053-N; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; HAKOMORI S, 1985, CANCER RES, V45, P2405; HARLAN JM, 1992, ADHESION ITS ROLE IN; HASEGAWA A, 1992, J CARBOHYD CHEM, V11, P645, DOI 10.1080/07328309208016154; HASEGAWA A, 1992, CARBOHYD RES, V230, pC1, DOI 10.1016/S0008-6215(00)90524-X; HASEGAWA A, 1994, IN PRESS ACS S SERIE; KABAT EA, 1982, AM J CLIN PATHOL, V78, P281, DOI 10.1093/ajcp/78.3.281; LARKIN M, 1992, J BIOL CHEM, V267, P13661; LUBINEAU A, 1993, J CHEM SOC CHEM COMM, P1419, DOI 10.1039/c39930001419; MULLIGAN MS, 1993, J EXP MED, V178, P623, DOI 10.1084/jem.178.2.623; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; NICOLAOU KC, 1993, J AM CHEM SOC, V115, P8843, DOI 10.1021/ja00072a049; SCHNAAR RL, 1989, METHOD ENZYMOL, V179, P542; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; TANG PW, 1985, BIOCHEM BIOPH RES CO, V132, P474, DOI 10.1016/0006-291X(85)91158-1; Watkins W M, 1980, Adv Hum Genet, V10, P1; Watkins W.M., 1980, ADV HUM GENET, V10, P379; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003	27	156	165	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1595	1598						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507478				2022-12-25	WOS:A1994MR98800008
J	SICILIANO, RA; MORRIS, HR; BENNETT, HPJ; DELL, A				SICILIANO, RA; MORRIS, HR; BENNETT, HPJ; DELL, A			O-GLYCOSYLATION MIMICS N-GLYCOSYLATION IN THE 16-KDA FRAGMENT OF BOVINE PROOPIOMELANOCORTIN - THE MAJOR O-GLYCAN ATTACHED TO THR-45 CARRIES SO4-4GALNAC-BETA-1-4GLCNAC-BETA-1-, WHICH IS THE ARCHETYPAL NONREDUCING EPITOPE IN THE N-GLYCANS OF PITUITARY GLYCOHORMONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; ENDORPHIN-DERIVED PEPTIDES; AMINO-TERMINAL FRAGMENT; ION MASS-SPECTROMETRY; GROUP CAD SPECIFICITY; VICIA-VILLOSA LECTIN; GAMMA-MSH; ACETYLGALACTOSAMINE-TRANSFERASE; ADRENOCORTICOTROPIN-ENDORPHIN; CARBOHYDRATE STRUCTURE	The NH2-terminal domain of pro-opiomelanocortin, designated as the 16-kDa fragment, is highly conserved throughout the vertebrate family and is likely therefore to have an important functional role. Bovine 16-kDa fragment is a 77-residue glycopeptide, which has been found to be glycosylated at threonine 45 and asparagine 65. Available evidence suggests that glycoforms lacking glycans at the O-linked site are processed in the intermediate pituitary at -Arg49-Lys50- to give the residue 1-49 amino-terminal peptide and a carboxyl-terminal glycopeptide referred to as Lys1gamma3-melanotropin. Glycoforms carrying O-glycans remain unprocessed in the intermediate pituitary. Thus O-glycosylation is likely to play an important role in controlling the fate of the NH2-terminal portion of proopiomelanocortin, thereby affecting the biological events that are influenced by peptides and glycopeptides derived from this domain. In a recent study (Siciliano, R. A., Morris, H. R., McDowell, R. A., Azadi, P., Rogers, M. E., Bennett, H. P. J., and Dell, A. (1993) Glycobiology 3, 225-239), we sequenced the N-glycans attached to Asn-65 of bovine 16-kDa fragment and demonstrated that the acidic components contain, in addition to neutral antennae, a single SO4-4GalNAcbeta1-4GlcNAcbeta1- antenna, which is characteristic of the pituitary glycohormone N-glycans (Baenziger, J. U., and Green, E. D. (1988) Biochim. Biophys. Acta 947, 287-306). We now report the structural characterization of the O-linked oligosaccharides found in bovine 16-kDa fragment. The major component, which constitutes about 80% of the O-glycan population, is a novel sulfated tetrasaccharide, which carries the same sulfated epitope as the N-glycans. This is the first time that the SO4-4GalNAcbeta1-4GlcNAcbeta1-moiety has been observed in O-glycans, and it raises the interesting possibility that the beta-N-acetylgalactosaminyltransferase responsible for the addition of N-acetylgalactosamine to the pituitary glycohormones (Smith, P. L., and Baenziger, J. U. (1988) Science, 242, 930-933) might be capable of glycosylating both N- and O-linked acceptors.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AZ,ENGLAND; ROYAL VICTORIA HOSP,MONTREAL H3A 1A1,QUEBEC,CANADA	Imperial College London; McGill University; Royal Victoria Hospital			Siciliano, Rosa Anna/G-9822-2013	SICILIANO, ROSAANNA/0000-0002-1042-3424	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; ALDUJAILI EAS, 1981, NATURE, V291, P156, DOI 10.1038/291156a0; ANDREWS PC, 1984, J BIOL CHEM, V259, P3267; ANGYAL SJ, 1970, AUST J CHEM, V23, P1209, DOI 10.1071/CH9701209; AZARYAN AV, 1993, J BIOL CHEM, V268, P11968; BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BENNETT HPJ, 1986, PEPTIDES, V7, P615, DOI 10.1016/0196-9781(86)90036-7; BENNETT HPJ, 1986, INT J PEPT PROT RES, V27, P306; BENNETT HPJ, 1986, J CHROMATOGR, V359, P383, DOI 10.1016/0021-9673(86)80092-9; BENNETT HPJ, 1984, BIOCHEM BIOPH RES CO, V125, P229, DOI 10.1016/S0006-291X(84)80358-7; BERGWERFF AA, 1992, FEBS LETT, V314, P389, DOI 10.1016/0014-5793(92)81512-K; BERGWERFF AA, 1992, INT J PEPT PROT RES, V314, P389; BIRCH NP, 1991, FEBS LETT, V290, P191, DOI 10.1016/0014-5793(91)81257-9; BLANCHARD D, 1983, J BIOL CHEM, V258, P7691; BLANCHARD D, 1985, BIOCHEM J, V232, P813, DOI 10.1042/bj2320813; BLANCHARD D, 1985, J BIOL CHEM, V260, P7813; BROWNE CA, 1981, BIOCHEM BIOPH RES CO, V100, P336, DOI 10.1016/S0006-291X(81)80101-5; CALLAHAN MF, 1984, CLIN EXP HYPERTENS A, V6, P1727, DOI 10.3109/10641968409046067; CAPON C, 1989, EUR J BIOCHEM, V182, P139, DOI 10.1111/j.1432-1033.1989.tb14810.x; CHAN A L, 1991, Glycobiology, V1, P173, DOI 10.1093/glycob/1.2.173; CODDEVILLE B, 1992, CARBOHYD RES, V236, P145, DOI 10.1016/0008-6215(92)85013-P; CONZELMANN A, 1984, J BIOL CHEM, V259, P2536; CONZELMANN A, 1984, J BIOL CHEM, V259, P2528; DELL A, 1990, METHOD ENZYMOL, V193, P647, DOI 10.1016/0076-6879(90)93443-O; DELL A, 1991, CARBOHYD RES, V209, P33, DOI 10.1016/0008-6215(91)80143-B; DELL A, 1993, CURR OPIN STRUC BIOL, V3, P687, DOI 10.1016/0959-440X(93)90051-L; DEWILDT DJ, 1993, EUR J PHARMACOL, V233, P157, DOI 10.1016/0014-2999(93)90362-L; Eipper B A, 1980, Endocr Rev, V1, P1; EIPPER BA, 1978, J SUPRAMOL STR CELL, V8, P247, DOI 10.1002/jss.400080304; EMESON RB, 1986, J NEUROSCI, V6, P837; ESTIVARIZ FE, 1989, J BIOL CHEM, V264, P17796; ESTIVARIZ FE, 1982, NATURE, V297, P419, DOI 10.1038/297419a0; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GORR SU, 1991, J BIOL CHEM, V266, P5780; GRUBER KA, 1989, AM J PHYSIOL, V257, pR681, DOI 10.1152/ajpregu.1989.257.4.R681; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; HIRANO T, 1993, EUR J BIOCHEM, V214, P763, DOI 10.1111/j.1432-1033.1993.tb17978.x; IWASAKI M, 1984, BIOCHEMISTRY-US, V23, P305, DOI 10.1021/bi00297a020; JAMES S, 1985, J CHROMATOGR, V326, P329, DOI 10.1016/S0021-9673(01)87458-6; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KAWAUCHI H, 1983, ARCH BIOCHEM BIOPHYS, V227, P343, DOI 10.1016/0003-9861(83)90462-9; KESSLER MJ, 1979, J BIOL CHEM, V254, P7909; KEUTMANN HT, 1981, BIOCHEMISTRY-US, V20, P4148, DOI 10.1021/bi00517a031; KHOO K-H, 1990, Glycobiology, V1, P83, DOI 10.1093/glycob/1.1.83; KHOO KH, 1993, CARBOHYD RES, V244, P205, DOI 10.1016/0008-6215(83)85002-2; KLEIN MC, 1985, LIFE SCI, V36, P769, DOI 10.1016/0024-3205(85)90197-3; LAI PH, 1986, J BIOL CHEM, V261, P3116; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LOWRY PJ, 1983, NATURE, V306, P70, DOI 10.1038/306070a0; LU CL, 1983, LIFE SCI, V33, P2599, DOI 10.1016/0024-3205(83)90343-0; MAINS RE, 1976, J BIOL CHEM, V251, P4115; MAWHINNEY TP, 1992, CARBOHYD RES, V223, P187, DOI 10.1016/0008-6215(92)80016-T; NASIRUDDIN, 1990, CARBOHYD RES, V205, P444, DOI 10.1016/0008-6215(90)80166-Z; NOEL G, 1991, MOL ENDOCRINOL, V5, P404, DOI 10.1210/mend-5-3-404; PARSONS TF, 1984, J BIOL CHEM, V259, P2662; PATZELT C, 1986, EMBO J, V5, P2103, DOI 10.1002/j.1460-2075.1986.tb04472.x; PEDERSEN RC, 1980, SCIENCE, V208, P1044, DOI 10.1126/science.6246578; PEDERSEN RC, 1980, P NATL ACAD SCI-BIOL, V77, P2239, DOI 10.1073/pnas.77.4.2239; PFEIFFER G, 1992, EUR J BIOCHEM, V205, P961, DOI 10.1111/j.1432-1033.1992.tb16863.x; ROSA P, 1985, J CELL BIOL, V101, P1977; SASAKI H, 1987, J BIOL CHEM, V262, P12059; SCAMMELL JG, 1993, TRENDS ENDOCRIN MET, V4, P14, DOI 10.1016/1043-2760(93)90058-M; SEGER MA, 1986, J STEROID BIOCHEM, V25, P703, DOI 10.1016/0022-4731(86)90298-0; SEIDAH NG, 1981, J BIOL CHEM, V256, P7977; SHIMAMURA M, 1983, BIOCHEMISTRY-US, V22, P959, DOI 10.1021/bi00273a039; SHIMOMURA K, 1988, MOL ENDOCRINOL, V2, P845, DOI 10.1210/mend-2-9-845; SICILIANO RA, 1993, GLYCOBIOLOGY, V3, P225, DOI 10.1093/glycob/3.3.225; SKELTON TP, 1992, J BIOL CHEM, V267, P12998; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1992, J BIOL CHEM, V267, P19140; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SUN XY, 1992, AM J PHYSIOL, V262, pR77, DOI 10.1152/ajpregu.1992.262.1.R77; TANAKA N, 1992, J BIOCHEM-TOKYO, V112, P68, DOI 10.1093/oxfordjournals.jbchem.a123867; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003; ZHOU A, 1993, J BIOL CHEM, V268, P1763	76	41	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					910	920						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507111				2022-12-25	WOS:A1994MR22000024
J	VILALTA, A; KICKHOEFER, VA; ROME, LH; JOHNSON, DL				VILALTA, A; KICKHOEFER, VA; ROME, LH; JOHNSON, DL			THE RAT VAULT RNA GENE CONTAINS A UNIQUE RNA-POLYMERASE-III PROMOTER COMPOSED OF BOTH EXTERNAL AND INTERNAL ELEMENTS THAT FUNCTION SYNERGISTICALLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA(SER)SEC GENE; TRANSCRIPTION FACTOR-TAU; HUMAN U6 GENE; RIBONUCLEOPROTEIN-PARTICLES; SACCHAROMYCES-CEREVISIAE; COMPLEX-FORMATION; CONTROL REGIONS; INVITRO; BINDING; UPSTREAM	A novel gene transcribed by RNA polymerase (pol) III has been recently identified that produces an RNA component of a large cytoplasmic ribonucleoprotein complex (Kickhoefer, V. A., Searles, R. P., Kedersha, N. L., Garber, M. E., Johnson, D. L., and Rome, L. H. (1993) J. Biol. Chem. 268, 7868-7873). Since sequence analysis revealed that this gene contains promoter elements from two different classes of RNA pol III gene promoters, we examined the function of the 5'-flanking type-3 and internal type-2 sequences on transcription activity and the production of stable transcription complexes. We find that the vRNA gene contains a novel RNA pol III promoter, where both the external and internal sequences are essential for template activity and for the productive interaction of TFIIIC with the internal elements. Thus, the vRNA gene represents the first example of a template that requires both type-2 and type-3 promoter elements that appear to function synergistically in the formation of productive transcription complexes. We have further examined the function of the unique arrangement of an internal A box and two B box elements. We find that at least one B element is required for template activity. In the absence of the 5'-flanking sequence the presence of both B elements inhibits transcription and the binding of TFIIIC. The formation of active complexes is restored when either the B2 element is inactivated or the distance separating the two B elements is increased. Therefore, the B2 element appears to negatively regulate template activity in the absence of the upstream sequences. This unique RNA pol III promoter arrangement may provide a novel mechanism for the regulation of vRNA gene activity.	UNIV SO CALIF,SCH PHARM,DEPT MOLEC PHARMACOL,LOS ANGELES,CA 90024; UNIV SO CALIF,SCH PHARM,DEPT BIOCHEM,LOS ANGELES,CA 90024; UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,MENTAL RETARDAT RES CTR,LOS ANGELES,CA 90024	University of Southern California; University of Southern California; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Rome, Leonard H/E-8786-2016	Rome, Leonard H/0000-0002-1236-2063	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038097, R01GM045299] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-45299, GM-38097] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKUSJARVI G, 1980, P NATL ACAD SCI-BIOL, V77, P2424, DOI 10.1073/pnas.77.5.2424; ARNOLD GJ, 1987, GENE, V51, P237, DOI 10.1016/0378-1119(87)90312-X; BAKER RE, 1986, J BIOL CHEM, V261, P5275; BAKER RE, 1987, P NATL ACAD SCI USA, V84, P8768, DOI 10.1073/pnas.84.24.8768; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BOULANGER PA, 1987, J BIOL CHEM, V262, P15098; BREDOW S, 1990, NUCLEIC ACIDS RES, V18, P6779, DOI 10.1093/nar/18.23.6779; CAMIER S, 1985, EMBO J, V4, P491, DOI 10.1002/j.1460-2075.1985.tb03655.x; CARBON P, 1991, EMBO J, V10, P599, DOI 10.1002/j.1460-2075.1991.tb07987.x; CHUGANI DC, 1993, J CELL SCI, V106, P23; DINGERMANN T, 1983, J BIOL CHEM, V258, P395; DINGERMANN T, 1981, NUCLEIC ACIDS RES, V9, P3907, DOI 10.1093/nar/9.16.3907; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HERNANDEZ N, 1988, EMBO J, V7, P3125, DOI 10.1002/j.1460-2075.1988.tb03179.x; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; HOWE JG, 1989, CELL, V57, P825, DOI 10.1016/0092-8674(89)90797-6; JOHNSONBURKE DJ, 1985, J BIOL CHEM, V260, P816; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KEDERSHA NL, 1991, J CELL BIOL, V112, P225, DOI 10.1083/jcb.112.2.225; KEDERSHA NL, 1990, J CELL BIOL, V110, P895, DOI 10.1083/jcb.110.4.895; KEDERSHA NL, 1986, J CELL BIOL, V103, P699, DOI 10.1083/jcb.103.3.699; KICKHOEFER VA, 1993, J BIOL CHEM, V268, P7868; KUNKEL GR, 1991, BIOCHIM BIOPHYS ACTA, V1088, P1, DOI 10.1016/0167-4781(91)90146-D; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6986, DOI 10.1073/pnas.88.16.6986; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MORRY MJ, 1986, MOL CELL BIOL, V6, P105, DOI 10.1128/MCB.6.1.105; MYSLINSKI E, 1992, NUCLEIC ACIDS RES, V20, P203, DOI 10.1093/nar/20.2.203; PARRY HD, 1990, EMBO J, V9, P1097, DOI 10.1002/j.1460-2075.1990.tb08215.x; Rome L, 1991, Trends Cell Biol, V1, P47, DOI 10.1016/0962-8924(91)90088-Q; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; WINGENDER E, 1986, J BIOL CHEM, V261, P1409; YOSHINAGA S, 1986, EMBO J, V5, P343, DOI 10.1002/j.1460-2075.1986.tb04218.x; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585	38	32	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29752	29759						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7525587				2022-12-25	WOS:A1994PU28400069
J	NGUYEN, TTM; HINTON, DA; SHUR, BD				NGUYEN, TTM; HINTON, DA; SHUR, BD			EXPRESSING MURINE BETA-1,4-GALACTOSYLTRANSFERASE IN HELA-CELLS PRODUCES A CELL-SURFACE GALACTOSYLTRANSFERASE-DEPENDENT PHENOTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI RETENTION; TRANSMEMBRANE DOMAIN; LOCALIZATION; ANTIBODIES; SIGNAL	beta 1,4-Galactosyltransferase is traditionally viewed as a biosynthetic component of the Golgi complex, but a portion of galactosyltransferase is also expressed on the cell surface, where it has been suggested to function as a receptor for extracellular oligosaccharide Ligands. Although results from a variety of studies are consistent with a cell adhesion function for galactosyltransferase, the most rigorous test of surface galactosyltransferase function is to produce a surface galactosyltransferase-dependent phenotype in cells that normally express negligible levels of surface galactosyltransferase. In agreement with previous reports, human HeLa cells were found to express low levels of galactosyltransferase on their surface and, therefore, were stably transfected with cDNAs encoding murine galactosyltransferase. Murine galactosyltransferase was expressed both within the presumed Golgi complex and on the cell surface, as assayed by enzyme activity and with antiserum raised against the bacterially expressed murine enzyme. HeLa cell transfectants adhered more strongly to their extracellular substrates than did control transfectants, as evidenced by a natter morphology in culture and a more rapid spreading upon plating. In contrast, cell spreading was low and similar among all cell types when plated on extracellular substrates that did not contain binding sites for galactosyltransferase. Antibodies and Fab fragments against recombinant murine galactosyltransferase inhibited the increased cell spreading characteristic of galactosyltransferase transfectants, as did soluble recombinant galactosyltransferase and a variety of galactosyltransferase perturbants. Thus, expression of heterologous galactosyltransferase produces a surface galactosyltransferase-dependent phenotype, confirming its function as a cell adhesion molecule.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT BIOCHEM & MOLEC BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center					NICHD NIH HHS [HD07699, HD22590] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022590, F32HD007699] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		APPEDDU PA, 1994, J CELL SCI, V107, P2535; APPEDDU PA, 1994, P NATL ACAD SCI USA, V91, P2095, DOI 10.1073/pnas.91.6.2095; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ECKSTEIN DJ, 1989, J CELL BIOL, V108, P2507, DOI 10.1083/jcb.108.6.2507; EVANS SC, 1993, J CELL BIOL, V120, P1045, DOI 10.1083/jcb.120.4.1045; GAYAGONZALEZ L, 1991, J NEUROSCI RES, V29, P474, DOI 10.1002/jnr.490290407; HAGOPIAN A, 1968, ARCH BIOCHEM BIOPHYS, V128, P387, DOI 10.1016/0003-9861(68)90045-3; HATHAWAY JH, 1991, GLYCOBIOLOGY, V1, P211; LOPEZ LC, 1991, J BIOL CHEM, V266, P15984; LOPEZ LC, 1989, MOL CELL BIOL, V9, P2370, DOI 10.1128/MCB.9.6.2370; MASIBAY AS, 1993, J BIOL CHEM, V268, P9908; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MENGLEGAW L, 1991, BIOCHEM BIOPH RES CO, V176, P1269, DOI 10.1016/0006-291X(91)90423-5; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTH S, 1971, J CELL BIOL, V51, P536, DOI 10.1083/jcb.51.2.536; RUNYAN RB, 1988, J CELL BIOL, V107, P1863, DOI 10.1083/jcb.107.5.1863; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; Shur BD, 1993, CURR OPIN CELL BIOL, V5, P854, DOI 10.1016/0955-0674(93)90035-O; SHUR BD, 1977, DEV BIOL, V58, P40, DOI 10.1016/0012-1606(77)90073-2; STROUS GJAM, 1982, J BIOL CHEM, V257, P7623; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; WATZELE G, 1991, EUR J CELL BIOL, V56, P451; WILLINGHAM MC, 1985, ATLAS IMMUNOFLUORESC; YOUAKIM A, 1993, GLYCOBIOLOGY, V3, P155, DOI 10.1093/glycob/3.2.155; YOUAKIM A, 1994, IN PRESS P NATL ACAD	31	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28000	28009						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525565				2022-12-25	WOS:A1994PV77200038
J	WALTZ, DA; CHAPMAN, HA				WALTZ, DA; CHAPMAN, HA			REVERSIBLE CELLULAR ADHESION TO VITRONECTIN LINKED TO UROKINASE RECEPTOR OCCUPANCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; BOUND UROKINASE; HUMAN-MONOCYTES; BINDING-SITE; TYPE-1; CELLS; DIFFERENTIATION; INTERNALIZATION; IDENTIFICATION; PURIFICATION	Urokinase receptors are distributed on surfaces of many cell types where they are thought to focus plasminogen-dependent proteolysis important to migration and tissue remodeling to the immediate pericellular space. in addition to its well characterized role in proteolysis, urokinase receptor binding per se promotes the adhesiveness of leukemic cell Lines exposed to differentiating cytokines in vitro. We sought to determine if a serum or matrix component is involved in urokinase-dependent adhesion. We now report that cytokine-stimulated human myelomonocytic cells express a divalent cation- and Arg-Gly-Asp-independent high affinity receptor for urea-purified vitronectin (K-d < 10 nM). Soluble native vitronectin does not effectively bind to the receptor, while cellular adhesion was noted to both urea-purified and native vitronectin when adsorbed to plastic. The activity of this receptor is tightly coupled to urokinase receptor occupancy. Urokinase receptor binding thus induces selective and reversible cellular adhesion to the matrix form of vitronectin. Because transfer of vitronectin-bound plasminogen activator inhibitor type 1 to urokinase promotes rapid turnover of receptor-bound enzyme, these results illuminate a novel binding cycle by which urokinase receptor occupancy coordinately regulates cellular adhesiveness and pericellular proteolysis.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV RESP,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044712] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-44712] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; CHAPMAN HA, 1990, J IMMUNOL, V145, P3398; CHAPMAN HA, 1982, CELL, V28, P653, DOI 10.1016/0092-8674(82)90220-3; Colton T., 1974, STAT MED, V1; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIRCHHEIMER JC, 1989, BLOOD, V74, P1396; KIRCHHEIMER JC, 1989, J IMMUNOL, V143, P2634; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; MANCHANDA N, 1990, J IMMUNOL, V145, P4174; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; NUSRAT AR, 1991, J CLIN INVEST, V87, P1091, DOI 10.1172/JCI115070; OLSON D, 1992, J BIOL CHEM, V267, P9129; PANETTI TS, 1993, J BIOL CHEM, V268, P11988; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; Scopes RK., 1987, PROTEIN PURIFICATION, V2nd ed; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	33	215	220	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14746	14750						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514182				2022-12-25	WOS:A1994NM06500069
J	MEERZAMAN, D; CHARLES, P; DASKAL, E; POLYMEROPOULOS, MH; MARTIN, BM; ROSE, MC				MEERZAMAN, D; CHARLES, P; DASKAL, E; POLYMEROPOULOS, MH; MARTIN, BM; ROSE, MC			CLONING AND ANALYSIS OF CDNA-ENCODING A MAJOR AIRWAY GLYCOPROTEIN, HUMAN TRACHEOBRONCHIAL MUCIN (MUC5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Two unique nucleotide probes for human tracheobronchial mucin glycoprotein (TBM) were generated via polymerase chain reaction with degenerate primers deduced from the TBM:TR-3A tryptic peptide sequence and were used to isolate a 3.6 kilobase cDNA, clone NP3a, from a human nasal polyp cDNA library. Clone NP3a was localized to chromosome 11 and contained a 3168 nucleotide open reading frame which encoded three TBM peptide fragments, thus confirming that clone NP3a partially encodes TBM. TBM also contains five tandem repeats of TTVGP/S and an octapeptide GQCGTCTN, which is conserved in human intestinal mucin MUC2 and rat intestinal mucin-like protein (MLP) suggesting that this sequence has a functional significance for secreted mucins. TBM has amino acid similarity to the cysteine-rich domains at the carboxyl termini of MUC2, rat MLP, bovine and porcine submaxillary mucins, and human von Willebrand factor. Strikingly, a large percentage of the cysteine residues in the overlaps are highly conserved: 90% in MUC2 and von Willebrand factor, 80% in bovine submaxillary mucin, 70% in porcine submaxillary mucin, and 64% in rat MLP, suggesting that conserved cysteines may be important for the tertiary structure of secreted glycoproteins. These studies demonstrate that clone NP3a is a candidate for MUC5, making it the only human mucin gene reported to date whose gene product has been isolated from airway secretions.	GEORGE WASHINGTON UNIV, CHILDRENS NATL MED CTR, CHILDRENS RES INST, CTR MOLEC MECHANISMS DIS, WASHINGTON, DC 20010 USA; GEORGE WASHINGTON UNIV, DEPT PEDIAT, WASHINGTON, DC 20010 USA; GEORGE WASHINGTON UNIV, DEPT BIOCHEM & MOLEC BIOL, WASHINGTON, DC 20010 USA; ST ELIZABETH HOSP, NIMH, CTR NEUROSCI, BIOCHIM GENET LAB, WASHINGTON, DC 20032 USA; NIMH, CLIN NEUROSCI BRANCH, BETHESDA, MD 20892 USA	Children's National Health System; George Washington University; George Washington University; George Washington University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)					NHLBI NIH HHS [HL 33152] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033152] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN A, 1983, TRENDS BIOCHEM SCI, V8, P169, DOI 10.1016/0968-0004(83)90166-4; AUBERT JP, 1991, AM J RESP CELL MOL, V5, P178, DOI 10.1165/ajrcmb/5.2.178; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; CARLSTEDT I, 1983, BIOCHEM J, V213, P427, DOI 10.1042/bj2130427; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONG NV, 1990, HUM GENET, V86, P167; DONALD ASR, 1973, BIOCHIM BIOPHYS ACTA, V317, P420, DOI 10.1016/0005-2795(73)90235-3; DUFOSSE J, 1993, BIOCHEM J, V293, P329, DOI 10.1042/bj2930329; DUNSTONE JR, 1965, BIOCHIM BIOPHYS ACTA, V101, P300, DOI 10.1016/0926-6534(65)90009-6; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; FELDHOFF PA, 1979, BIOCHEMISTRY-US, V18, P2430, DOI 10.1021/bi00578a044; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GERARD C, 1990, J CLIN INVEST, V86, P1921, DOI 10.1172/JCI114925; GRIFFITHS B, 1990, ANN HUM GENET, V54, P277, DOI 10.1111/j.1469-1809.1990.tb00383.x; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1992, AM J RESP CELL MOL, V7, P557, DOI 10.1165/ajrcmb/7.6.557; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUPTA R, 1989, BIOCHEMISTRY-US, V28, P6114, DOI 10.1021/bi00440a058; HILL HD, 1977, J BIOL CHEM, V252, P3791; HOLLINGSWORTH MA, 1992, AM J RESP CELL MOL, V6, P516, DOI 10.1165/ajrcmb/6.5.516; LAN MS, 1990, J BIOL CHEM, V265, P15294; LI M, 1993, FOCUS, V15, P19; Maniatis T., 1982, MOL CLONING; MANTLE M, 1984, BIOCHEM J, V224, P345, DOI 10.1042/bj2240345; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; Neutra M.R., 1987, PHYSL GASTROINTESTIN, V2, P975; POLYMEROPOULOS MH, 1991, GENOMICS, V11, P777, DOI 10.1016/0888-7543(91)90091-R; POLYMEROPOULOS MH, 1992, GENOMICS, V12, P492, DOI 10.1016/0888-7543(92)90439-Y; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; RAO KSPB, 1977, J BIOL CHEM, V252, P7788; REDDY MS, 1992, BIOCHEM J, V287, P639, DOI 10.1042/bj2870639; ROBERTS GP, 1976, ARCH BIOCHEM BIOPHYS, V173, P528, DOI 10.1016/0003-9861(76)90289-7; ROSE MC, 1984, J BIOL CHEM, V259, P3167; ROSE MC, 1989, METHOD ENZYMOL, V179, P3; ROSE MC, 1992, AM J PHYSIOL, V263, pL413, DOI 10.1152/ajplung.1992.263.4.L413; ROSE MC, 1984, BIOCHEM J, V222, P371, DOI 10.1042/bj2220371; ROSE MC, 1987, PEDIATR RES, V22, P545, DOI 10.1203/00006450-198711000-00015; ROSE MC, 1979, BIOCHEMISTRY-US, V18, P4030, DOI 10.1021/bi00585a029; ROSE MC, 1989, J BIOL CHEM, V264, P8193; RUGGERI ZM, 1993, FASEB J, V7, P308, DOI 10.1096/fasebj.7.2.8440408; SADLER JE, 1985, P NATL ACAD SCI USA, V82, P6394, DOI 10.1073/pnas.82.19.6394; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; TOSI M, 1981, NUCLEIC ACIDS RES, V9, P2313, DOI 10.1093/nar/9.10.2313; VERMA M, 1993, P NATL ACAD SCI USA, V90, P7144, DOI 10.1073/pnas.90.15.7144; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; XU G, 1992, BIOCHEM BIOPH RES CO, V183, P821, DOI 10.1016/0006-291X(92)90557-2; XU GQ, 1992, J BIOL CHEM, V267, P5401	53	209	215	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12932	12939						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7513696				2022-12-25	WOS:A1994NH71600085
J	SCHWEMMLE, M; STAEHELI, P				SCHWEMMLE, M; STAEHELI, P			THE INTERFERON-INDUCED 67-KDA GUANYLATE-BINDING PROTEIN (HGBP1) IS A GTPASE THAT CONVERTS GTP TO GMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MX1 PROTEIN; CELLULAR PROTEINS; DOMAIN; MOTIF; P21; MECHANISM; MEMBRANE; VIRUS; GDP	hGBP1 is an interferon-induced 67-kDa protein of human cells that readily binds to agarose-immobilized GTP, GDP, and GMP but not to other nucleotides. We cloned hGBP1 cDNA into a histidine-tagging vector, produced recombinant hGBP1 with 6 extra histidine residues at its N terminus in Escherichia coli, and purified this protein to near homogeneity from bacterial lysates. Purified hGBP1 hydrolyzed radiolabeled GTP but failed to hydrolyze ATP, UTP, or CTP at significant rates. Unexpectedly, the principal product of the GTP hydrolysis reaction was GMP rather than GDP. Although significant amounts of GDP were produced when the reaction was performed at 15-degrees-C, GDP could not serve as substrate or as inhibitor of hGBP1. hGBP1 lacked guanylate cyclase and guanylyltransferase activity. Degradation of GTP to GMP most likely occurred via two consecutive cleavages of single phosphate groups, because pyrophosphate was not a reaction product, and because hGBP1 failed to hydrolyze GTPgammaS. In vitro modification assays with radiolabeled mevalonic acid and farnesyl pyrophosphate showed that the CaaX motif at the C terminus of hGBP1 functions as an isoprenylation signal. Thus, hGBP1 is a GTPase with novel biochemical properties that may be membrane-associated in eukaryotic cells.	UNIV FREIBURG,INST MIKROBIOL & HYG,VIROL ABT,HERMANN HERDER STR 11,D-79008 FREIBURG,GERMANY	University of Freiburg								BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHENG YSE, 1991, MOL CELL BIOL, V11, P4717, DOI 10.1128/MCB.11.9.4717; CHENG YSE, 1983, J BIOL CHEM, V258, P7746; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HORISBERGER MA, 1992, J VIROL, V66, P4705, DOI 10.1128/JVI.66.8.4705-4709.1992; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; NAKAYAMA M, 1991, J BIOL CHEM, V266, P21404; NAKAYAMA M, 1992, VIRUS RES, V22, P227, DOI 10.1016/0168-1702(92)90054-D; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PITOSSI F, 1993, J VIROL, V67, P6726, DOI 10.1128/JVI.67.11.6726-6732.1993; PROCHAZKA M, 1985, VIROLOGY, V145, P273, DOI 10.1016/0042-6822(85)90160-6; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; STAEHELI P, 1984, VIROLOGY, V137, P135, DOI 10.1016/0042-6822(84)90016-3; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; Staeheli Peter, 1993, Trends in Cell Biology, V3, P268, DOI 10.1016/0962-8924(93)90055-6; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; ZWEIG G, 1971, PAPER CHROMATOGRAPHY, V2	30	125	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11299	11305						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512561				2022-12-25	WOS:A1994NF96600051
J	DHAR, A; SHUKLA, SD				DHAR, A; SHUKLA, SD			ELECTROTRANSJECTION OF PP60(V-SRC) MONOCLONAL-ANTIBODY INHIBITS ACTIVATION OF PHOSPHOLIPASE-C IN PLATELETS - A NEW MECHANISM FOR PLATELET-ACTIVATING-FACTOR RESPONSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; EXPRESS HIGH-LEVELS; PROTEIN-PHOSPHORYLATION; SIGNAL TRANSDUCTION; PP60C-SRC; CELLS; THROMBIN; STIMULATION; ONCOGENES; P60C-SRC	Antibodies to pp60(v-src)and phosphotyrosine were introduced into rabbit platelets using an electropermeabilization technique. The presence of these antibodies inside platelets was detected by flow cytometry. Platelet-activating factor (PAF)-stimulated phospholipase C activity (inositol phosphate production) and aggregation were dramatically inhibited in platelets transjected with either of these antibodies. Incubation of these antibodies with intact cells (i.e. nonpermeabilized) or electrotransjection of several nonspecific antibodies/agents (e.g. goat anti-mouse IgG, mouse serum, human platelet glycoprotein Tb monoclonal antibody, and fetal calf serum) into platelets had no effect on the PAF responses. trpE (another isotype matched control antibody of pp60(v-src) and pp56(lck) polyclonal antibody (another src-related kinase not present in platelets) also had no effect on PAF-induced aggregation and inositol phosphate production in permeabilized platelets. This indicates that the effect of internalized pp60(v-src) antibody is direct and specific in platelets. Stimulation of platelets by PAF increased the association and phosphorylation of both pp60(c-src) (60 kDa) and phospholipase C gamma 1 (145 kDa). This study provides the first evidence in platelets for a direct and specific involvement of pp60(c-src) in PAF-mediated phospholipase C activation and aggregation response.	UNIV MISSOURI,SCH MED,DEPT PHARMACOL,COLUMBIA,MO 65212	University of Missouri System; University of Missouri Columbia					NIDDK NIH HHS [R01 DK35170, DK07182] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035170] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAKRABARTI R, 1989, J BIOL CHEM, V264, P15494; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DHAR A, 1990, MOL PHARMACOL, V37, P519; DHAR A, 1993, BRIT J HAEMATOL, V84, P1, DOI 10.1111/j.1365-2141.1993.tb03018.x; DHAR A, 1991, J BIOL CHEM, V266, P1877; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; JAMIESON GA, 1988, PLATELET MEMBRANE RE; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; MICHELSON AD, 1991, BLOOD, V77, P770; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SHUKLA SD, 1992, FASEB J, V6, P2296, DOI 10.1096/fasebj.6.6.1312046; THURSTON AW, 1992, BIOCHEM BIOPH RES CO, V185, P1062, DOI 10.1016/0006-291X(92)91734-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUY FPD, 1983, NATURE, V305, P435; TUZYNSKI GP, 1987, PLATELET RESPONSES M, V2, P187; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WILSON AK, 1991, AM J PHYSIOL, V260, pC355, DOI 10.1152/ajpcell.1991.260.2.C355; ZHU CY, 1993, LIFE SCI, V53, P175, DOI 10.1016/0024-3205(93)90665-P	33	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9123	9127						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510703				2022-12-25	WOS:A1994NB41100076
J	ZHANG, HL; DIGATE, RJ				ZHANG, HL; DIGATE, RJ			THE CARBOXYL-TERMINAL RESIDUES OF ESCHERICHIA-COLI DNA TOPOISOMERASE-III ARE INVOLVED IN SUBSTRATE-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOTYPIC SELECTION; PROTEIN-OMEGA; CLEAVAGE; ENZYME; SEQUENCE; COMPLEX; GYRASE	The nucleic acid-binding domain of Escherichia coli DNA topoisomerase III (Topo III) has been identified using a selection procedure designed to isolate inactive Topo III polypeptides. Deletion of this binding domain, contained in the carboxyl terminus of Topo III, results in a drastic reduction in the ability of the enzyme to bind to single-stranded DNA and RNA substrates. Successive truncation of the enzyme within this region results in the gradual loss of nucleic acid binding activity and in a gradual change in the mechanism of Topo III catalyzed relaxation of negatively supercoiled DNA. The reduction of nucleic acid binding activity of the truncated polypeptides does not result in a loss of cleavage site specificity for the enzyme, suggesting that other amino acids are involved in the positioning of the nucleic acid within the nicking/closing site of the topoisomerase.	UNIV MARYLAND,SCH PHARM,DEPT BIOMED CHEM,BALTIMORE,MD 21201; UNIV MARYLAND,MARYLAND BIOTECHNOL INST,CTR MED BIOTECHNOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	ZHANG, HL (corresponding author), UNIV MARYLAND,MOLEC & CELL BIOL PROGRAM,BALTIMORE,MD 21201, USA.				NCRR NIH HHS [RR05770-14] Funding Source: Medline; NIGMS NIH HHS [GM48445] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048445, R29GM048445] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; DEAN F, 1984, THESIS U CHICAGO; DEPEW RE, 1978, J BIOL CHEM, V253, P511; DIGATE RJ, 1992, J BIOL CHEM, V267, P20532; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HIASA H, 1994, J BIOL CHEM, V269, P2093; KATO JI, 1990, CELL, V63, P3967; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MORHAM SG, 1990, GENE DEV, V4, P515, DOI 10.1101/gad.4.4.515; PASTORCIC M, 1982, THESIS U CHICAGO; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SRIVENUGOPAL KS, 1984, BIOCHEMISTRY-US, V23, P1899, DOI 10.1021/bi00304a002; STECK TR, 1984, CELL, V36, P1081, DOI 10.1016/0092-8674(84)90058-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; TSEDINH YC, 1986, J MOL BIOL, V191, P321, DOI 10.1016/0022-2836(86)90129-4; TSEDINH YC, 1991, J BIOL CHEM, V266, P14317; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; Wang JC, 1990, DNA TOPOLOGY ITS BIO	30	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9052	9059						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510701				2022-12-25	WOS:A1994NB41100066
J	GRONOWSKI, AM; ROTWEIN, P				GRONOWSKI, AM; ROTWEIN, P			RAPID CHANGES IN NUCLEAR-PROTEIN TYROSINE PHOSPHORYLATION AFTER GROWTH-HORMONE TREATMENT IN-VIVO - IDENTIFICATION OF PHOSPHORYLATED MITOGEN-ACTIVATED PROTEIN-KINASE AND STAT91	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; MAP KINASE; FACTOR-I; C-FOS; GENE; INDUCTION; RAT; STIMULATION; FAMILY; MEMBER	Growth hormone (GH) plays a central role in regulating growth and intermediary metabolism in vertebrates, although the mechanisms by which GH initiates these actions are largely unknown. The GH receptor, a member of the cytokine receptor superfamily, does not demonstrate homology with any known tyrosine kinases. However, addition of GH to cells in vitro has been shown to stimulate tyrosine phosphorylation of various intracellular proteins including mitogen-activated protein kinases (MAP kinases) and the newly described Janus kinase, JAK2. Subsequent steps in GH-mediated signal transduction have not been delineated. In the present study, we have examined early events in GH action in vivo. Hypophysectomized juvenile male rats were treated with GH for 15, 30, or 60 min. Rat liver whole cell and nuclear extracts were prepared and analyzed via SDS-polyacrylamide gel electrophoresis and Western blotting techniques. GH rapidly stimulated the tyrosine phosphorylation of at least 8 nuclear proteins of 205, 91, 83, 80, 65, 53, 44, and 42 kDa, and caused the dephosphorylation of a single similar to 149-kDa protein. Using specific antibodies, we have identified three of these nuclear phosphoproteins as 42- and 44-kDa MAP kinases, and as STAT91, a 91-kDa component of the interferon-stimulated gene factor-3 protein complex. One consequence of the activation of STAT91 in the nucleus is the appearance of GH-stimulated DNA binding activity, as assessed by gel-mobility shift assay using an oligonucleotide containing a c-sis-inducible element from the c-fos prometer. These results show that nuclear protein tyrosine phosphorylation is a prominent early event in GH action in vivo and demonstrate a link between GH stimulated signal transduction and target gene expression.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007120, R01DK037449] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07120, 5-RO1-DK37449] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BICHELL DP, 1992, MOL ENDOCRINOL, V6, P1899, DOI 10.1210/me.6.11.1899; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; FOLLI F, 1992, J BIOL CHEM, V267, P22171; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; HARPUR AG, 1992, ONCOGENE, V7, P1347; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; LAMY F, 1993, J BIOL CHEM, V268, P8398; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MONTMINY M, 1993, SCIENCE, V261, P1694, DOI 10.1126/science.8397444; PAQUEREAU L, 1992, EUR J BIOCHEM, V209, P1053, DOI 10.1111/j.1432-1033.1992.tb17381.x; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHAUI K, 1993, SCIENCE, V261, P1744; SHAUI K, 1992, SCIENCE, V258, P1808; SILVA CM, 1993, ENDOCRINOLOGY, V133, P2307, DOI 10.1210/en.133.5.2307; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLOOTWEG MC, 1991, J MOL ENDOCRINOL, V6, P179, DOI 10.1677/jme.0.0060179; STREHLOW I, 1993, J BIOL CHEM, V268, P16590; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; YOON JB, 1990, J BIOL CHEM, V265, P19947	31	136	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7874	7878						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510676				2022-12-25	WOS:A1994NB40900010
J	FILARDO, EJ; CHERESH, DA				FILARDO, EJ; CHERESH, DA			A BETA-TURN IN THE CYTOPLASMIC TAIL OF THE INTEGRIN ALPHA-V SUBUNIT INFLUENCES CONFORMATION AND LIGAND-BINDING OF ALPHA-V-BETA-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN-IIB; ASP-DIRECTED RECEPTOR; CELL-ADHESION; FIBRONECTIN RECEPTOR; VITRONECTIN RECEPTOR; GPIIB-IIIA; ELECTRON-MICROSCOPY; DOMAIN; FIBRINOGEN; SITE	Integrins undergo conformational alterations in response to extracellular or intracellular stimuli, suggesting that structural elements within their exo- and cytoplasmic domains cooperate during transmembrane signaling. In this report, we identify a beta turn in the cytoplasmic tail of the alpha v subunit that impacts the ligand binding and conformation of the alpha v beta 3 heterodimer. Cells expressing a mutant alpha v beta 3 heterodimer composed of a truncated alpha v subunit, alpha v1000, lacking 18 carboxyl-terminal amino acids exhibits wild-type receptor structure and function. However, a truncation mutant, alpha v995, lacking five additional residues (PPQEE), which define a beta turn, is deficient in vitronectin and fibrinogen adhesion. This alteration in adhesive function is associated with two detectable structural changes in the alpha v beta 3 heterodimer. First, the alpha v995 membrane-spanning light chain exhibits retarded electrophoretic mobility on SDS-polyacrylamide gels. Second, the alpha v995 beta 3 receptor shows an altered chymotryptic profile as measured by the loss of a 39-kDa proteolytic fragment from its ectodomain. These findings demonstrate that the ligand binding and structural properties of the intact alpha v beta 3 heterodimer can be influenced by a beta turn within the cytoplasmic tail of its alpha v subunit. The presence of homologous beta turns within other alpha subunit cytoplasmic tails suggests that this structural motif may play a role in regulating integrin-mediated bidirectional transmembrane signals.	SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				Filardo, Edward/0000-0002-3930-324X	NATIONAL CANCER INSTITUTE [R01CA050286, R37CA050286, R01CA045726] Funding Source: NIH RePORTER; NCI NIH HHS [CA50286, CA45726] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BOSSY B, 1991, EMBO J, V10, P2375, DOI 10.1002/j.1460-2075.1991.tb07776.x; BURGESS WH, 1980, BIOCHIM BIOPHYS ACTA, V623, P257, DOI 10.1016/0005-2795(80)90254-8; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COBURN J, 1993, P NATL ACAD SCI USA, V90, P7059, DOI 10.1073/pnas.90.15.7059; DAVIS LS, 1990, J IMMUNOL, V145, P785; DEDHAR S, 1987, J CELL BIOL, V105, P1175, DOI 10.1083/jcb.105.3.1175; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; FELDINGHABERMANN B, 1992, J BIOL CHEM, V267, P5070; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MERCURIO AM, 1988, J CELL BIOL, V107, P1873, DOI 10.1083/jcb.107.5.1873; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PEPINSKY RB, 1983, J VIROL, V45, P648, DOI 10.1128/JVI.45.2.648-658.1983; PONCZ M, 1987, J BIOL CHEM, V262, P8476; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; RELMAN D, 1990, CELL, V61, P1375, DOI 10.1016/0092-8674(90)90701-F; ROSE GD, 1978, NATURE, V272, P586, DOI 10.1038/272586a0; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STUPACK DG, 1992, EXP CELL RES, V203, P443, DOI 10.1016/0014-4827(92)90019-5; SUZUKI S, 1986, P NATL ACAD SCI USA, V83, P8614, DOI 10.1073/pnas.83.22.8614; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149; YAMADA KM, 1990, CANCER RES, V50, P4485; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	55	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4641	4647						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508446				2022-12-25	WOS:A1994MW98900109
J	WARREN, JB				WARREN, JB			NITRIC-OXIDE AND HUMAN SKIN BLOOD-FLOW RESPONSES TO ACETYLCHOLINE AND ULTRAVIOLET-LIGHT	FASEB JOURNAL			English	Article						PROSTAGLANDINS; CYCLOOXYGENASE; INFLAMMATION; CORTICOSTEROIDS	CYCLASE ACTIVATING POLYPEPTIDE; GENE-RELATED PEPTIDE; SMOOTH-MUSCLE CELLS; POTENT VASODILATOR; L-ARGININE; PROSTAGLANDIN SYNTHESIS; EDEMA POTENTIATOR; RELAXING FACTOR; RABBIT SKIN; RELEASE	Nitric oxide (NO) is a potent endogenous vasodilator of large blood vessels but its role in the physiological and pathological control of the human microcirculation is not known. This study was designed to assess whether NO contributes to the control of blood flow in the human skin microcirculation in vivo. Local changes in blood flow were measured in the forearm skin microcirculation of normal volunteers. The responses to agents injected intradermally were assessed with a laser Doppler flow probe. NO was generated in local areas of skin by the injection of the NO donor, sodium nitroprusside. Endogenous NO was generated by the injection of acetylcholine and the exposure of skin to ultraviolet light (UVB) to stimulate the constitutive and inducible forms of nitric oxide synthase (NOS), respectively. The skin microvasculature was comparatively insensitive to exogenous NO derived from the NO donor sodium nitroprusside, being 10,000-fold more sensitive to the vasodilator prostaglandin PGE(2) (P < 0.001). However, the rapid onset, dose-dependent local vasodilation caused by acetylcholine was blocked by the NOS inhibitor N-G-monomethyl-L-arginine, L-NMMA (P < 0.05), but not by the cyclooxygenase inhibitor indomethacin. The delayed local blood flow response to UVB was attenuated by either L-NMMA or indomethacin (P < 0.05 in each case). The UVB response was abolished by a combination of L-NMMA and indomethacin or by local, topical corticosteroid treatment (P < 0.01 in each case). This study indicates that NO increases blood flow in the human microcirculation in vivo. NOS inhibition attenuated both the rapid blood how response to acetylcholine and the delayed response to UVB. Both NOS and cyclooxygenase contributed to the erythema response to UVB, and dual inhibition of both enzymes would explain the mechanism of action of the corticosteroid in this model of inflammation.			WARREN, JB (corresponding author), NATL HEART & LUNG INST,DEPT APPL PHARMACOL,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND.							AXELROD L, 1983, LANCET, V2, P904; BARRY BW, 1978, J CLIN PHARMACY, V3, P43, DOI 10.1111/j.1365-2710.1978.tb00102.x; BRAIN SD, 1988, NATURE, V335, P73, DOI 10.1038/335073a0; BRAIN SD, 1986, J INVEST DERMATOL, V87, P533, DOI 10.1111/1523-1747.ep12455620; BRAIN SD, 1989, J CARDIOVASC PHARM, V13, pS147, DOI 10.1097/00005344-198900135-00037; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CHARO IF, 1984, J CLIN INVEST, V74, P914, DOI 10.1172/JCI111509; CHESTER AH, 1990, LANCET, V336, P897, DOI 10.1016/0140-6736(90)92269-N; FLOWER RJ, 1979, NATURE, V278, P456, DOI 10.1038/278456a0; FORTES ZB, 1990, EUR J PHARMACOL, V182, P143, DOI 10.1016/0014-2999(90)90503-X; GERRITSEN ME, 1983, J CLIN INVEST, V72, P1656; HUGHES GS, 1992, DERMATOLOGY, V184, P54, DOI 10.1159/000247500; Johnson J.M., 1990, LASER DOPPLER BLOOD, P121; LEFROY DC, 1992, CIRCULATION, V86, P118; Lewis T, 1927, HEART-J STUD CIRC, V14, P1; LEY K, 1989, AM J PHYSIOL, V256, pH85, DOI 10.1152/ajpheart.1989.256.1.H85; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; Messina E J, 1980, Adv Prostaglandin Thromboxane Res, V7, P719; MESSINA EJ, 1975, CIRC RES, V37, P430, DOI 10.1161/01.RES.37.4.430; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONCADA S, 1991, TRENDS PHARMACOL SCI, V12, P130, DOI 10.1016/0165-6147(91)90528-Z; MURPHY GM, 1989, PHOTODERMATOLOGY, V6, P268; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; SCHINI VB, 1991, BIOCHEM BIOPH RES CO, V176, P114, DOI 10.1016/0006-291X(91)90897-G; SCHWARZ T, 1987, J IMMUNOL, V138, P1457; VALLANCE P, 1989, CARDIOVASC RES, V23, P1053, DOI 10.1093/cvr/23.12.1053; VALLANCE P, 1989, LANCET, V2, P997; WALKER BR, 1992, CLIN SCI, V82, P597, DOI 10.1042/cs0820597; WARREN JB, 1990, P ROY SOC B-BIOL SCI, V241, P127, DOI 10.1098/rspb.1990.0076; WARREN JB, 1993, BRIT J PHARMACOL, V109, P802, DOI 10.1111/j.1476-5381.1993.tb13645.x; WARREN JB, 1992, BRIT J PHARMACOL, V106, P331, DOI 10.1111/j.1476-5381.1992.tb14336.x; WARREN JB, 1992, BRIT J PHARMACOL, V106, P953, DOI 10.1111/j.1476-5381.1992.tb14441.x; WARREN JB, 1992, J CARDIOVASC PHARM, V20, P83, DOI 10.1097/00005344-199220010-00011; WARREN JB, 1992, BR J PHARM, V107; WILLIAMS TJ, 1982, BRIT J PHARMACOL, V77, P505, DOI 10.1111/j.1476-5381.1982.tb09324.x; WILLIAMS TJ, 1979, BRIT J PHARMACOL, V65, P517, DOI 10.1111/j.1476-5381.1979.tb07860.x; WILLIAMS TJ, 1977, NATURE, V270, P530, DOI 10.1038/270530a0; WILSON AJ, 1993, BRIT J PHARMACOL, V110, P633, DOI 10.1111/j.1476-5381.1993.tb13858.x; WOOLFSON RG, 1990, CLIN SCI, V79, P273, DOI 10.1042/cs0790273	40	111	113	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1994	8	2					247	251		10.1096/fasebj.8.2.7509761	http://dx.doi.org/10.1096/fasebj.8.2.7509761			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MY299	7509761				2022-12-25	WOS:A1994MY29900032
J	BRASS, LF; PIZARRO, S; AHUJA, M; BELMONTE, E; BLANCHARD, N; STADEL, JM; HOXIE, JA				BRASS, LF; PIZARRO, S; AHUJA, M; BELMONTE, E; BLANCHARD, N; STADEL, JM; HOXIE, JA			CHANGES IN THE STRUCTURE AND FUNCTION OF THE HUMAN THROMBIN RECEPTOR DURING RECEPTOR ACTIVATION, INTERNALIZATION, AND RECYCLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PLATELET ACTIVATION; PHOSPHOINOSITIDE HYDROLYSIS; HOMOLOGOUS DESENSITIZATION; PROTEOLYTIC MECHANISM; ENDOTHELIAL-CELLS; AGONIST PEPTIDES; ALPHA-THROMBIN; MOBILIZATION; BINDS; SITE	According to current models, human thrombin receptors are activated when thrombin cleaves the receptor's N terminus, exposing the tethered ligand domain, SFLLRN. In the megakaryoblastic CHRF-288 cell line, thrombin receptor activation is followed by the rapid internalization of >90% of the receptors. In the present studies, antibodies directed at the site of cleavage by thrombin were used to examine changes in receptor structure during activation, internalization, and recovery. As would be expected, the initial rate of receptor cleavage was directly related to the thrombin concentration. However, even after prolonged incubation, receptor cleavage was incomplete until the thrombin concentration exceeded the receptor concentration. Only cleaved receptors were internalized in response to thrombin and only catalytically active thrombin and active variants of SFLLRN-containing peptides caused receptor internalization. Over a 3-h period following receptor activation by thrombin, there was a gradual recovery of approximately one-quarter of the receptors on the cell surface. These receptors were detectable with antibodies directed at retained portions of the receptor N terminus, but not with antibodies directed at the proposed site of cleavage, confirming that they are recycled, rather than new, receptors. At 4-degrees-C two-thirds of the receptors cleaved by thrombin were retained on the cell surface. Like recycled receptors these ''cold-cleaved'' receptors failed to self-activate when warmed to 37-degrees-C, but could be activated by SFLLRN. Unlike recycled receptors, however, the cold-cleaved receptors were also internalized and appeared to be activated by a second addition of thrombin. These results 1) provide strong evidence at the protein level that thrombin cleaves its receptors at the predicted site, 2) show that receptor activation is necessary for internalization, 3) suggest that each thrombin molecule may not activate large numbers of receptors, 4) demonstrate that a substantial fraction of internalized thrombin receptors can be recycled, and 5) suggest that the failure of recycled receptors to be reactivated by thrombin may involve a change in the receptor that does not occur at 4-degrees-C. Finally, the inability of cold-cleaved receptors to self activate in the absence of thrombin, suggests that in addition to cleaving the receptor, thrombin may also play an important role in guiding the tethered ligand domain to regions on the remainder of the receptor that mediate activation.	UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104; SMITHKLINE BEECHAM PHARMACEUT,DEPT CARDIOVASC PHARMACOL,KING OF PRUSSIA,PA 19406	University of Pennsylvania; GlaxoSmithKline	BRASS, LF (corresponding author), UNIV PENN,DEPT MED,DIV HEMATOL ONCOL,SILVERSTEIN 7,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.			Pizarro, Shelly/0000-0002-3193-7037	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL049987] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL49987, P01 HL40387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; BRASS LF, 1991, J BIOL CHEM, V266, P958; BRASS LF, 1992, J BIOL CHEM, V267, P6044; BRASS LF, 1992, J BIOL CHEM, V267, P13795; BRASS LF, 1985, J BIOL CHEM, V260, P5172; CHAO BH, 1992, BIOCHEMISTRY-US, V31, P6175, DOI 10.1021/bi00142a001; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; DORN GW, 1992, AM J PHYSIOL, V263, pC864, DOI 10.1152/ajpcell.1992.263.4.C864; FUGMAN DA, 1990, BLOOD, V75, P1252; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HARMON JT, 1986, J BIOL CHEM, V261, P5928; HOLLENBERG MD, 1992, MOL PHARMACOL, V42, P186; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUANG EM, 1987, BIOCHEM J, V242, P11, DOI 10.1042/bj2420011; HUANG RS, 1991, J BIOL CHEM, V266, P18435; HUI KY, 1992, BIOCHEM BIOPH RES CO, V184, P790, DOI 10.1016/0006-291X(92)90659-9; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; ISHII K, 1993, J BIOL CHEM, V268, P9780; JAFFE EA, 1987, J BIOL CHEM, V262, P8557; JONES LG, 1989, MOL PHARMACOL, V36, P142; JOSEPH S, 1993, BIOCHEM J, V290, P571, DOI 10.1042/bj2900571; LEONG L, 1992, BIOCHEMISTRY-US, V31, P2567, DOI 10.1021/bi00124a017; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; PARIS S, 1988, J BIOL CHEM, V263, P11250; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SABO T, 1992, BIOCHEM BIOPH RES CO, V188, P604, DOI 10.1016/0006-291X(92)91099-C; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; TIRUPPATHI C, 1992, AM J PHYSIOL, V263, pL595, DOI 10.1152/ajplung.1992.263.5.L595; TROYER D, 1992, J BIOL CHEM, V267, P20126; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975	37	143	147	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2943	2952						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7507931				2022-12-25	WOS:A1994MV43200085
J	LEGROS, Y; MEYER, A; ORY, K; SOUSSI, T				LEGROS, Y; MEYER, A; ORY, K; SOUSSI, T			MUTATIONS IN P53 PRODUCE A COMMON CONFORMATIONAL EFFECT THAT CAN BE DETECTED WITH A PANEL OF MONOCLONAL-ANTIBODIES DIRECTED TOWARD THE CENTRAL PART OF THE P53 PROTEIN	ONCOGENE			English	Note							LARGE T-ANTIGEN; BREAST-CANCER; SUPPRESSOR; EPITOPES; CELLS; GENE	Human p53 displays two immunodominant regions localized in the amino and carboxy termini of the protein. Using a truncated p53 (residues 66 to 361), we selected eight new monoclonal antibodies directed to the central part of the protein. We identified the epitopes recognized by seven out of eight antibodies with a set of overlapping peptides. One of these antibodies had an epitope similar to PAb240, whereas the others recognized novel and diverse antigenic determinants. Using a series of 19 p53 mutants, we show that the behavior of several of the new monoclonal antibodies is similar to that of PAb240 despite their various epitope localizations. This suggests that different mutations in the p53 protein induce an overall conformational change that can be detected by various monoclonal antibodies directed toward the central part of the protein.	INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE; ESTBA,F-75020 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)				soussi, thierry/0000-0001-8184-3293				BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINAUT P, 1994, ONCOGENE, V9, P299; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LANE DP, 1994, MOL BIOL REP, V19, P23, DOI 10.1007/BF00987319; LEBROS Y, 1994, ONCOGENE, V9, P2071; LEGROS Y, 1993, B CANCER, V80, P102; LUBIN R, 1993, CANCER RES, V53, P5872; MEDCALF EA, 1992, ONCOGENE, V7, P71; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1987, ONCOGENE, V1, P453; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380; SCHLICHTHOLZ B, 1994, BRIT J CANCER, V69, P809, DOI 10.1038/bjc.1994.159; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; SOUSSI T, 1990, ONCOGENE, V5, P945; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	22	81	86	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3689	3694						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7526318				2022-12-25	WOS:A1994PT39200033
J	CHEN, YH; POUYSSEGUR, J; COURTNEIDGE, SA; VANOBBERGHENSCHILLING, E				CHEN, YH; POUYSSEGUR, J; COURTNEIDGE, SA; VANOBBERGHENSCHILLING, E			ACTIVATION OF SRC FAMILY KINASE-ACTIVITY BY THE G-PROTEIN-COUPLED THROMBIN RECEPTOR IN GROWTH RESPONSIVE FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; TYROSINE PHOSPHORYLATION; ALPHA-THROMBIN; HUMAN PLATELETS; SIGNAL-TRANSDUCTION; NEURITE RETRACTION; PERTUSSIS TOXIN; ASSOCIATION; PP60C-SRC; PATHWAY	Thrombin stimulates G protein-coupled signaling pathways in target cells by proteolytic cleavage of its seven transmembrane domain receptor. Protein tyrosine phosphorylation is also stimulated by the protease via poorly defined mechanisms. In human platelets, thrombin has been shown to activate the nonreceptor tyrosine kinase Src. To elucidate the signal transduction pathways involved in transmission of thrombin's cellular effects, we have examined the ability of thrombin to activate Src family tyrosine kinases in a growth-responsive line of lung fibroblasts (CCL39 cells). We report here that thrombin induces a rapid (less than or equal to 30 s) and transient increase in the kinase activity of Src and Fyn as determined by autophosphorylation in immune complex kinase assays. Activation is mediated by the G protein-coupled thrombin receptor since a synthetic peptide agonist of the receptor mimics thrombin action. The involvement of one or more G proteins in this response was confirmed by the observation that thrombin's effect is partially sensitive to pertussis toxin. Furthermore, both alpha(2)-adrenegic and muscarinic m(1) receptors are able to increase Src kinase activity via pertussis toxin-sensitive and insensitive G proteins, respectively. These findings suggest that nonreceptor tyrosine kinases of the Src family may represent a novel effector system linking G protein-coupled receptors to downstream activation of Ras and the mitogen-activated protein kinase cascade.	CTR BIOCHIM,CNRS,UMR 134,F-06108 NICE 2,FRANCE; EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; European Molecular Biology Laboratory (EMBL)			Van Obberghen-Schilling, Ellen/O-1581-2016; Van Obberghen-Schilling, Ellen/Q-4372-2019	Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Van Obberghen-Schilling, Ellen/0000-0003-2961-0059				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; CARNEY DH, 1992, THROMBIN STRUCTURE F, P351; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HORAK ID, 1990, ONCOGENE, V5, P597; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KOHNO M, 1986, BIOCHEM J, V238, P451, DOI 10.1042/bj2380451; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; LIEBENHOFF U, 1993, BIOCHEM J, V295, P41, DOI 10.1042/bj2950041; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MARI B, 1994, J BIOL CHEM, V269, P8517; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; OFFERMANNS S, 1993, BIOCHEM J, V290, P27, DOI 10.1042/bj2900027; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; POUYSSEGUR J, 1990, G PROTEINS, P555; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SEUWEN K, 1990, CELL REGUL, V1, P445, DOI 10.1091/mbc.1.6.445; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEISS RH, 1993, J BIOL CHEM, V268, P5724; WEISS RH, 1992, J BIOL CHEM, V267, P5608; WINITZ S, 1993, J BIOL CHEM, V268, P19196	48	176	177	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27372	27377						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525555				2022-12-25	WOS:A1994PV77100037
J	EYTAN, GD; BORGNIA, MJ; REGEV, R; ASSARAF, YG				EYTAN, GD; BORGNIA, MJ; REGEV, R; ASSARAF, YG			TRANSPORT OF POLYPEPTIDE IONOPHORES INTO PROTEOLIPOSOMES RECONSTITUTED WITH RAT-LIVER P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANALICULAR MEMBRANE-VESICLES; MULTIDRUG-RESISTANCE PUMP; CLASS-II REGION; GENE-PRODUCT; PLASMA-MEMBRANE; DRUG TRANSPORT; CELL-LINES; MDR-GENE; EXPRESSION; PROTEIN	The aim of this study was to examine the peptide transport activity of a naturally occurring P-glycoprotein such as that present in rat liver canalicular membrane vesicles. The peptide ionophores valinomycin and gramicidin D, which are known substrates of P-glycoprotein, served to monitor the P-glycoprotein activity indirectly as the ATP-dependent uptake of Rb-86(+) mediated by these ionophores. Canalicular membrane vesicles proved inherently permeable to K+ ions, which prevented assay of transport ionophore activity. Therefore, P-glycoprotein was extracted from canalicular membrane vesicles and reconstituted into proteoliposomes that are relatively impermeable to cations. P-glycoprotein activity in the proteoliposomes was dependent on ATP hydrolysis since it was not observed with non-hydrolyzable analogs of ATP. Maximal ATP-dependent Rb-86(+) uptake occurred at 50 nM gramicidin D and at 500 nM valinomycin thus possibly reflecting higher affinity of P-glycoprotein for gramicidin D. Nigericin, which does not participate in the multidrug resistance phenomenon, did not support an ATP-depend ent uptake of Rb-86(+). ATP hydrolysis increased the amount of Rb-86(+) transported into the proteoliposomes. Furthermore, preincubation of the proteoliposomes in the presence of gramicidin D and Rb-86(+), allowing for maximal ATP-independent Rb-86(+) uptake to occur, did not interfere with subsequent ATP-dependent uptake, indicating the latter to constitute an active transport mechanism, The ATP-dependent component of Rb-86(+) uptake occurred neither with liposomes nor with proteoliposomes reconstituted with proteins extracted from sinusoidal vesicles that lack P-glycoprotein. The ATP-dependent uptake was blocked by the known inhibitors of the ATPase activity associated with P-glycoprotein, oligomycin and vanadate, as well as by its established substrates, daunorubicin, doxorubicin, vinblastine, and the tripeptide N-acetyl-leucyl-leucyl-norleucinal. Thus, the reconstituted P-glycoprotein catalyzes the ATP-dependent Rb-86(+) uptake that appears to occur by an energy-dependent translocation of the Rb-86(+)-ionophore complex. In this case, the actual substrate of P-glycoprotein is the ionophore cation complex, which is both hydrophobic and positively charged as are most of the substrates of P-glycoprotein. This is the first demonstration of transport of a naturally occurring polypeptide by proteoliposomes reconstituted with physiologically expressed P-glycoprotein.			EYTAN, GD (corresponding author), TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL.							ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ALTUVIA S, 1993, J BIOL CHEM, V268, P27127; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; ASSARAF YG, 1994, EUR J BIOCHEM, V222, P813, DOI 10.1111/j.1432-1033.1994.tb18928.x; CHABNER BA, 1990, CANCER CHEMOTHERAPY; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; CURRIER SJ, 1992, J BIOL CHEM, V267, P25153; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; ESEN A, 1978, ANAL BIOCHEM, V89, P264, DOI 10.1016/0003-2697(78)90749-2; FREI E, 1985, CANCER RES, V45, P6523; GARTY H, 1989, METHOD ENZYMOL, V172, P155; GASKO OD, 1976, ANAL BIOCHEM, V72, P57, DOI 10.1016/0003-2697(76)90506-6; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; INOUE M, 1982, HEPATOLOGY, V2, P572; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; LINCKE CR, 1990, CANCER RES, V50, P1779; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MUKHOPADHYAY T, 1988, J NATL CANCER I, V80, P269, DOI 10.1093/jnci/80.4.269; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; ROMAN LM, 1983, J CELL BIOL, V96, P1548, DOI 10.1083/jcb.96.6.1548; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SINICROPE FA, 1992, J BIOL CHEM, V267, P24995; SLOVAK ML, 1988, CANCER RES, V48, P2793; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SUGAWARA I, 1988, CANCER RES, V48, P1926; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0	40	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26058	26065						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523400				2022-12-25	WOS:A1994PQ93000022
J	HARROCH, S; REVEL, M; CHEBATH, J				HARROCH, S; REVEL, M; CHEBATH, J			INTERLEUKIN-6 SIGNALING VIA 4 TRANSCRIPTION FACTORS BINDING PALINDROMIC ENHANCERS OF DIFFERENT GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON REGULATORY FACTOR; PROTEIN-TYROSINE KINASE; GAMMA-INTERFERON; ALPHA-INTERFERON; TRANSDUCTION PATHWAYS; NUCLEAR FACTOR; IFN-GAMMA; M1 CELLS; FACTOR-I; ACTIVATION	Interferons (IFNs), as well as some interleukins, growth factors, and hormones, all induce tyrosine phosphorylation of STAT1 and additional transcription factors of similar sizes. These factors are activated to translocate to nucleus and bind to enhancers of consensus sequence TTnCnnnAA (gamma-IFN activated sequence like enhancers). In mammary cells or hybridoma B9 cells, four distinct tyrosine phosphorylated transcription complexes activated by interleukin-6 (IL-6) and IFN-beta were observed: pIRFA and complexes I, II, and III (of increasing electrophoretic mobility). The factors have unequal affinities for enhancers of different genes; they are activated with distinct kinetics and to different extents by IL-6 and IFNs. The pIRFA band isolated from IL-6-stimulated B9 hybridoma cells revealed three DNA-interacting components: two large subunits of 91 and 98 kDa, as well as a small component of 46 kDa not seen in other complexes analyzed. One of the large pIRFA subunits may be APRF/STAT3, since pIRFA reacted with anti-APRF antibodies as do complexes I and II. However, pIRFA did not react with antibodies to STAT1, indicating STAT1 is not the other large component of pIRFA. Complex II, which reacted to anti-acute phase response factor antibodies also reacted to anti-STAT1 antibodies, whereas complex III reacted only to anti-STAT1 and was the only complex resistant to N-ethylmaleimide. By its multimeric subunit structure and its cytokine and enhancer sequence specificities, the slowly migrating pIRFA band appears as a novel tyrosine-phosphorylated transcription complex acting on a subset of gamma-IFN activated sequence-like enhancers.			HARROCH, S (corresponding author), WEIZMANN INST SCI,DEPT MOLEC GENET,IL-76100 REHOVOT,ISRAEL.			Chebath, Judith/0000-0002-8151-7428				ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; AKYIAMA T, 1987, J BIOL CHEM, V262, P5592; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; GOTHELF Y, 1991, LYMPHOKINE CYTOK RES, V10, P369; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; HARROCH S, 1993, J BIOL CHEM, V268, P9092; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	36	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26191	26195						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523403				2022-12-25	WOS:A1994PQ93000040
J	WARD, CL; KOPITO, RR				WARD, CL; KOPITO, RR			INTRACELLULAR TURNOVER OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - INEFFICIENT PROCESSING AND RAPID DEGRADATION OF WILD-TYPE AND MUTANT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; ENDOPLASMIC-RETICULUM; NUCLEOTIDE-BINDING; MOLECULAR-BASIS; TRANSPORT; COMPARTMENT; DELTA-F508; MUTATIONS; CELL; GENE	Mutant (Delta F508) and wild-type cystic fibrosis transmembrane conductance regulator (CFTR) were synthesized initially as an similar to 140-kDa core-glycosylated precursor, which, in the case of wild-type CFTR, was chased to an similar to 160 kDa form bearing complex oligosaccharides. Mutant CFTR disappeared from the detergent-soluble cell extract with rapid (t(1/2) = 27 min) kinetics. Only similar to 25% of the initially synthesized wild-type 140-kDa CFTR precursor was detected as mature protein; the remaining similar to 75% decayed with kinetics (t(1/2) = 33 min) indistinguishable from those of the mutant. Rapid degradation kinetics and inefficient processing of wild-type CFTR were also observed in the colonic carcinoma lines HT29 and T84 and in stably transfected C127 cells, which express 5-50 times lower levels of CFTR. These results suggest that inefficient processing and rapid degradation of wild-type CFTR precursor are an intrinsic property of CFTR in these diverse cell types and are not an artifact of overexpression. Degradation of wild-type and mutant 140-kDa CFTR began without significant lag following synthesis. These data suggest that wild-type and Delta F508 CFTR differ in the efficiency of folding of the core glycosylated primary translation product.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NIDDK NIH HHS [DK43994] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043994] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DOOLITTLE RF, 1987, URFS ORFS PRIMER ANA; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUNDERSON MS, 1994, VIROLOGY, V269, P19349; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BS, 1991, J BIOL CHEM, V266, P11448; LODISH HF, 1971, BIOCHEMISTRY-US, V10, P2348, DOI 10.1021/bi00788a027; MARSHALL J, 1994, J BIOL CHEM, V269, P2987; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PIND S, 1994, J BIOL CHEM, V269, P12784; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; THOMAS PJ, 1992, FEBS LETT, V312, P7, DOI 10.1016/0014-5793(92)81399-7; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; WARD CL, 1991, P NATL ACAD SCI USA, V88, P5277, DOI 10.1073/pnas.88.12.5277; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139	34	401	406	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25710	25718						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523390				2022-12-25	WOS:A1994PQ49100072
J	GUO, B; YU, Y; LEIBOLD, EA				GUO, B; YU, Y; LEIBOLD, EA			IRON REGULATES CYTOPLASMIC LEVELS OF A NOVEL IRON-RESPONSIVE ELEMENT-BINDING PROTEIN WITHOUT ACONITASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; TRANSFERRIN RECEPTOR; UNTRANSLATED REGION; CYTOSOLIC ACONITASE; REPRESSOR PROTEIN; HEART ACONITASE; SULFUR CLUSTER; RAT-LIVER; TRANSLATION; PURIFICATION	Iron-responsive element-binding proteins (IRE-BPs) are cytosolic proteins that bind to a conserved RNA stem-loop, termed the iron-responsive element (IRE), that is located in the 5'- or 3'-untranslated regions of mRNAs involved in iron metabolism. Binding of the IRE-BP to 5'-IREs represses translation, whereas binding to 3'-IREs stabilizes the mRNA. The previously identified IRE-BP (BP1) contains a 4Fe-4S cluster and has sequence homology to mitochondrial aconitase. The 4Fe-4S cluster is important for iron-dependent regulation: BP1 containing iron has low affinity for the IRE and contains aconitase activity, whereas BP1 lacking iron has high affinity for the IRE, but lacks aconitase activity. A second IRE-BP (BP2) has been identified in rat tissues and cells and exhibits many of the hallmarks of an IRE BP, including binding to the IRE and functioning as a translational repressor of IRE-containing RNAs, BP1 and BP2 RNA binding activities are decreased in extracts from cells treated with iron, indicating that BP1 and BP2 are negatively regulated by iron. Although BP1 and BP2 share similar characteristics, they differ in two significant ways. Unlike BP1 levels, which do not change when RNA binding activity decreases in response to iron, BP2 decreases to undetectable levels in extracts from cells treated with iron; and unlike BP1, BP2 does not have aconitase activity. These data indicate that BP1 and BP2 are distinct proteins that have similar specificity for IRE binding and that function similarly in translation, but are regulated by iron via different mechanisms.	UNIV UTAH, DEPT MED, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, ECCLES PROGRAM HUMAN MOLEC BIOL & GENET, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045201] Funding Source: NIH RePORTER; NCI NIH HHS [CA42014] Funding Source: Medline; NIGMS NIH HHS [GM45201] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZIZ N, 1986, NUCLEIC ACIDS RES, V14, P915, DOI 10.1093/nar/14.2.915; AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BASILION JP, 1994, P NATL ACAD SCI USA, V91, P574, DOI 10.1073/pnas.91.2.574; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; GOESSLING LS, 1992, SCIENCE, V256, P670, DOI 10.1126/science.1316633; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; KENNEDY MC, 1988, J BIOL CHEM, V263, P8194; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KLAUSNER RD, 1993, MOL BIOL CELL, V4, P1; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; LEIBOLD EA, 1990, NUCLEIC ACIDS RES, V18, P1819, DOI 10.1093/nar/18.7.1819; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PATINO MM, 1992, J BIOL CHEM, V267, P19011; PHILPOTT CC, 1991, NUCLEIC ACIDS RES, V19, P6333, DOI 10.1093/nar/19.22.6333; POLSON A, 1980, IMMUNOL COMMUN, V9, P475, DOI 10.3109/08820138009066010; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; TANG CK, 1992, J BIOL CHEM, V267, P24466; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; YU Y, 1992, J BIOL CHEM, V267, P19005; ZAHRINGER J, 1976, P NATL ACAD SCI USA, V73, P857, DOI 10.1073/pnas.73.3.857; ZHENG L, 1992, J BIOL CHEM, V267, P7895; ZHENG LM, 1990, J BIOL CHEM, V265, P2814	39	234	238	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24252	24260						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523370				2022-12-25	WOS:A1994PQ34600063
J	MOORE, KL; EATON, SF; LYONS, DE; LICHENSTEIN, HS; CUMMINGS, RD; MCEVER, RP				MOORE, KL; EATON, SF; LYONS, DE; LICHENSTEIN, HS; CUMMINGS, RD; MCEVER, RP			THE P-SELECTIN GLYCOPROTEIN LIGAND FROM HUMAN NEUTROPHILS DISPLAYS SIALYLATED, FUCOSYLATED, O-LINKED POLY-N-ACETYLLACTOSAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE-1 ELAM-1; MYELOID CELLS; BACTEROIDES-FRAGILIS; CARBOHYDRATE LIGAND; ENDOTHELIAL-CELLS; GMP-140 BINDS; OLIGOSACCHARIDES; IDENTIFICATION; RECOGNITION; EXPRESSION	We previously demonstrated that P-selectin binds with high affinity to a trace, homodimeric glycoprotein ligand on human myeloid cells. The ligand carries the sialyl Lewis x (sLe(x)) epitope, a limited number of N-linked glycans, and clustered, sialylated O-linked glycans. In this study we demonstrate that the polypeptide component of this ligand is identical to that of P-selectin glycoprotein ligand-1 (PSGL-1), a molecule recently identified by expression cloning from a human myeloid cell cDNA library. We have examined the effects of glycosidases on purified, radioiodinated PSGL-1 from human neutrophils to further characterize the structure and function of the attached oligosaccharides. We found that PSGL-1 had poly-N-acetyllactosamine, only some of which could be removed with endo-beta-galactosidase. The majority of the Le(x) and sLe(x) structures were on endo-beta-galactosidase-sensitive chains. Peptide:N-glycosidase F (PNGaseF) treatment removed at least two of the three possible N-linked oligosaccharides from PSGL-1. Expression of Le(x) and sLe(x) was not detectably altered by PNGaseF digestion, indicating that these structures were primarily on O-linked poly-N-acetyllactosamine. Endo-beta-galactosidase-treated PSGL-1 retained the ability to bind to P-selectin, suggesting that some of the oligosaccharides recognized by P-selectin were either on enzyme-resistant poly-N-acetyllactosamine or on chains which lack poly-N-acetyllactosamine. PNGaseF treatment did not affect the ability of PSGL-1 to bind to P-selectin, demonstrating that the oligosaccharides required for P-selectin recognition are O-linked. PSGL-1 also bound to E-selectin, but with at least 50-fold lower affinity than to P-selectin. These data suggest that PSGL-1 from human neutrophils displays complex, sialylated, and fucosylated O-linked poly-N-acetyllactosamine that promote high affinity binding to P-selectin, but not to E-selectin.	UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,WK WARREN MED RES INST,OKLAHOMA CITY,OK 73104; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104; UNIV NEW HAMPSHIRE,DEPT BIOCHEM,DURHAM,NH 03824; AMGEN INC,THOUSAND OAKS,CA 91320	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; University System Of New Hampshire; University of New Hampshire; Amgen	MOORE, KL (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,DEPT MED,825 NE 13TH ST,OKLAHOMA CITY,OK 73104, USA.				NATIONAL CANCER INSTITUTE [R01CA037626] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045510] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37626] Funding Source: Medline; NHLBI NIH HHS [HL 45510] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BOURDREL L, 1993, PROTEIN EXPRES PURIF, V4, P130, DOI 10.1006/prep.1993.1019; CUMMINGS RD, 1994, METHOD ENZYMOL, V230, P66; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HANISCH FG, 1989, J BIOL CHEM, V264, P872; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; Laue T. M, 1981, THESIS U CONNECTICUT; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MCEVER RP, 1994, CURR OPIN IMMUNOL, V6, P75, DOI 10.1016/0952-7915(94)90037-X; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MULLIGAN MS, 1991, J CLIN INVEST, V88, P1396, DOI 10.1172/JCI115446; NELSON RM, 1993, J CLIN INVEST, V91, P1157, DOI 10.1172/JCI116275; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; OGATA S, 1975, J BIOCHEM, V78, P687, DOI 10.1093/oxfordjournals.jbchem.a130956; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SANO M, 1992, J BIOL CHEM, V267, P1522; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SCUDDER P, 1984, J BIOL CHEM, V259, P6586; SCUDDER P, 1983, BIOCHEM J, V213, P485, DOI 10.1042/bj2130485; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STEININGER CN, 1992, BIOCHEM BIOPH RES CO, V188, P760, DOI 10.1016/0006-291X(92)91121-6; TURNER AM, 1992, BLOOD, V80, P374; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; WALCHECK B, 1993, J EXP MED, V178, P853, DOI 10.1084/jem.178.3.853; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	55	258	271	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23318	23327						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7521878				2022-12-25	WOS:A1994PQ16400064
J	WOLF, A; SHAW, EW; NIKAIDO, K; AMES, GFL				WOLF, A; SHAW, EW; NIKAIDO, K; AMES, GFL			THE HISTIDINE-BINDING PROTEIN UNDERGOES CONFORMATIONAL-CHANGES IN THE ABSENCE OF LIGAND AS ANALYZED WITH CONFORMATION-SPECIFIC MONOCLONAL-ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; SALMONELLA-TYPHIMURIUM; ACTIVE-TRANSPORT; PERIPLASMIC TRANSPORT; ESCHERICHIA-COLI; RHODOBACTER-CAPSULATUS; RESOLUTION STRUCTURE; ARGININE-BINDING; LYSINE-BINDING; RECEPTOR	The periplasmic histidine-binding protein, HisJ, and the lysine-, arginine-, ornithine-binding protein (LAO) are receptors for histidine transport via the histidine permease of Salmonella typhimurium. The receptors have similar structures, being composed of two lobes held together by two peptide segments, with the ligand-binding site located in a cleft between the lobes. The two lobes are far apart in the unliganded structure (open conformation) and are drawn close together in the liganded structure (closed conformation). The tight binding of the ligand via protein side chains as well as the peptide backbone from both lobes stabilizes the closed conformation (Oh, B.-H., Pandit, J., Kang, C.-H., Nikaido, K., Gokcen, S., Ames, G. F.-L., and Kim, S.-H. (1993) J. Biol. Chem. 268, 11348-11353; Oh, B.-H., hang C.-H., De Bondt, H., Kim, S.-H., Nikaido, K., Joshi, A., and Ames, G. F.-L. (1994) J. Biol. Chem. 269, 4135-4143). In this study two conformation-specific monoclonal antibodies (mAbs) that trap the protein in the closed empty form have been characterized and used to provide evidence that HisJ can assume the closed empty form in the absence of ligand. Several pieces of evidence were provided to demonstrate that these mAbs are specific for HisJ in the closed form. Histidine improves the interaction of these mAbs with immobilized HisJ. The mAbs inhibit both the exchange and the dissociation of histidine from HisJ, indicating that they are able to trap the protein in the closed liganded form. The characterization of the epitopes of the conformation-specific mAbs shows that they include residues that are located in both lobes and that are far apart in the open form but close to each other in the closed form, so that the mAbs must be sensitive to their spatial orientation. Two mAbs that are not conformation-specific according to these criteria were also identified.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NIDDK NIH HHS [DK12121] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK012121, R01DK012121] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES BN, 1952, J AM CHEM SOC, V74, P252; AMES GF, 1989, J BIOL CHEM, V264, P3998; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; BENNETT WS, 1984, CRIT REV BIOCH, V15, P290; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; CARREY EA, 1990, PROTEIN STRUCTURE PR, P117; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; FLOCCO MM, 1994, J BIOL CHEM, V269, P8931; FRIGUET B, 1990, IMMUNOCHEMICAL ANAL, P287; GILLILAND GL, 1981, J MOL BIOL, V146, P341, DOI 10.1016/0022-2836(81)90392-2; GOLDBERG ME, 1991, TRENDS BIOCHEM SCI, V16, P358, DOI 10.1016/0968-0004(91)90148-O; HIGGINS CF, 1981, P NATL ACAD SCI-BIOL, V78, P6038, DOI 10.1073/pnas.78.10.6038; KANG CH, 1991, J BIOL CHEM, V266, P23893; KATCHALSKIKATZIR E, 1988, B CHEM SOC JPN, V61, P133, DOI 10.1246/bcsj.61.133; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; LEVER JE, 1972, J BIOL CHEM, V247, P4317; LEVER JE, 1972, ANAL BIOCHEM, V50, P73, DOI 10.1016/0003-2697(72)90487-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCK LA, 1991, BIOCHEMISTRY-US, V30, P4248, DOI 10.1021/bi00231a021; MAO B, 1982, J BIOL CHEM, V257, P1131; MILLER DM, 1983, J BIOL CHEM, V258, P3665; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; NIKAIDO K, 1992, J BIOL CHEM, V267, P20706; NOEL D, 1979, BIOCHEMISTRY-US, V18, P4159, DOI 10.1021/bi00586a017; OH BH, 1993, J BIOL CHEM, V268, P11348; OH BH, 1994, J BIOL CHEM, V269, P4135; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; PROSSNITZ E, 1988, J BIOL CHEM, V263, P17917; PROSSNITZ E, 1989, J BIOL CHEM, V265, P5006; PROSSNITZ E, 1989, THESIS U CALIFORNIA; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SACK JS, 1989, J MOL BIOL, V206, P193, DOI 10.1016/0022-2836(89)90532-9; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SHARMA S, 1991, P NATL ACAD SCI USA, V88, P4877, DOI 10.1073/pnas.88.11.4877; SPEISER DM, 1989, THESIS U CALIFORNIA; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; WALMSLEY AR, 1992, BIOCHEMISTRY-US, V31, P11175, DOI 10.1021/bi00160a031; WALMSLEY AR, 1992, J BIOL CHEM, V267, P8064; ZOU JY, 1993, J MOL BIOL, V233, P739, DOI 10.1006/jmbi.1993.1549	42	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23051	23058						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7521874				2022-12-25	WOS:A1994PQ16400026
J	GROUPP, ER; CRAWFORD, N; LOCKER, J				GROUPP, ER; CRAWFORD, N; LOCKER, J			CHARACTERIZATION OF THE DISTAL ALPHA-FETOPROTEIN ENHANCER, A STRONG, LONG-DISTANCE, LIVER-SPECIFIC ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; TISSUE-SPECIFIC EXPRESSION; DNA-BINDING SPECIFICITY; HEPATITIS-B VIRUS; TRANSCRIPTION FACTORS; ALPHA-1-FETOPROTEIN GENE; FUNCTIONAL-ANALYSIS; RESPONSE ELEMENT; ALBUMIN GENE; PROMOTER	High level expression of the alpha-fetoprotein (AFP) gene is controlled by three upstream enhancers which function even in hepatic cell lines that repress the AFP gene promoter. The most distal (''Complex 3,'' at -6 kilobases) is the strongest in HepG2 cells. We mapped the main activity of Complex 3 to a 170-base pair (BP) region from -6069 to -5900; progressive deletion of the 5'- and 3'-ends identified an 84-bp segment which accounted for 90% of enhancer activity. Expression studies, which combined the deleted Complex 3 with an AFP or tk promoter chloramphenicol acetyltransferase gene fusion, resolved five regions in the enhancer (Ia, Ib, II, III, and IV). Deletion of Regions Ia or II strongly reduced stimulation of the AFP promoter, while Regions Ia and Ib were essential for stimulation of the tk promoter. Footprinting indicated multiple binding sites in regions Ia, Ib, and II. Gel shift and oligonucleotide competition demonstrated that Regions Ia and II had high affinity HNF3- and C/EBP-binding sites, respectively, while additional unidentified factors bound throughout Regions I-III. Complex 3 is a powerful liver-specific transcriptional regulator and an important model of long distance gene activation.	UNIV PITTSBURGH, SCH MED, DEPT PATHOL, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [CA43909] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043909] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERNIER D, 1993, MOL CELL BIOL, V13, P1619, DOI 10.1128/MCB.13.3.1619; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Buzard G, 1990, DNA Seq, V1, P33, DOI 10.3109/10425179009041345; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHEVRETTE M, 1987, NUCLEIC ACIDS RES, V15, P1338, DOI 10.1093/nar/15.3.1338; CHILES TC, 1991, J IMMUNOL, V146, P1730; COSTA RH, 1988, MOL CELL BIOL, V8, P81, DOI 10.1128/MCB.8.1.81; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GODHOUT R, 1988, MOL CELL BIOL, V8, P1169; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; INGRAM RS, 1981, P NATL ACAD SCI-BIOL, V78, P4694, DOI 10.1073/pnas.78.8.4694; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; LOCKER J, 1993, TRANSCRIPTIONAL CONT, P321; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Miller JH., 1972, EXPT MOL GENETICS; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NAKABAYASHI H, 1991, MOL CELL BIOL, V11, P5885, DOI 10.1128/MCB.11.12.5885; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; Sambrook J, 1989, MOL CLONING; SHAUL Y, 1987, EMBO J, V6, P1913, DOI 10.1002/j.1460-2075.1987.tb02451.x; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; TAM SP, 1985, J BIOL CHEM, V260, P1670; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TILGHMAN SM, 1982, P NATL ACAD SCI-BIOL, V79, P5254, DOI 10.1073/pnas.79.17.5254; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TRONCHE F, 1990, MOL BIOL MED, V7, P173; TRUJILLO MA, 1991, P NATL ACAD SCI USA, V88, P3797, DOI 10.1073/pnas.88.9.3797; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; WANG WD, 1991, MOL CELL BIOL, V11, P4561, DOI 10.1128/MCB.11.9.4561; WEN P, 1993, NUCLEIC ACIDS RES, V21, P1911, DOI 10.1093/nar/21.8.1911; WEN P, 1991, DNA CELL BIOL, V10, P525, DOI 10.1089/dna.1991.10.525; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; ZHANG DE, 1990, J BIOL CHEM, V265, P3382	56	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22178	22187						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7520913				2022-12-25	WOS:A1994PE09800041
J	ADEMA, GJ; DEBOER, AJ; VOGEL, AM; LOENEN, WAM; FIGDOR, CG				ADEMA, GJ; DEBOER, AJ; VOGEL, AM; LOENEN, WAM; FIGDOR, CG			MOLECULAR CHARACTERIZATION OF THE MELANOCYTE LINEAGE-SPECIFIC ANTIGEN GP100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINASE-RELATED PROTEIN; PRE-MESSENGER-RNA; MONOCLONAL-ANTIBODY; GENE; EXPRESSION; SEQUENCE; CDNA; LYMPHOCYTES; LOCUS; PIGMENTATION	The glycoproteins recognized by monoclonal antibody (mAb) NKI-beteb are among the best diagnostic markers for human melanoma because their expression is restricted to melanocytic cells. Recently, we isolated a cDNA clone, termed gp100-c1, which confers immunoreactivity not only to mAb NKI-beteb, but also to two other mAbs used to diagnose malignant melanoma, HMB-50 and HRIB-45. In this report, we demonstrate that gp100-c1 cDNA encodes glycoproteins of 100 kDa (gp100) and 10 kDa (gp10) which are recognized by these mAbs in human melanoma cells. The translation product deduced from the open reading frame present in gp100-c1 cDNA is highly homologous to another melanocyte-specific protein, Pmel17. Nucleotide sequence analysis of genomic DNA indicates that the transcripts corresponding to gp100 and Pmel17 cDNAs originate from a single gene via alternative splicing. In all normal and malignant melanocytic cells analyzed, gp100 and Pmel17 RNAs are simultaneously expressed.	NETHERLANDS CANC INST, DIV IMMUNOL, 1066 CX AMSTERDAM, NETHERLANDS; ST LOUIS UNIV, DEPT PATHOL, ST LOUIS, MO 63104 USA	Netherlands Cancer Institute; Saint Louis University			Figdor, Carl G/A-4232-2010; Adema, G.J./H-8007-2014	Figdor, Carl G/0000-0002-2366-9212; 				ADEMA GJ, 1993, AM J PATHOL, V143, P1579; ADEMA GJ, 1991, BIOCHEM BIOPH RES CO, V178, P985, DOI 10.1016/0006-291X(91)90989-K; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANICHINI A, 1993, J EXP MED, V177, P989, DOI 10.1084/jem.177.4.989; BAKKER ABH, 1994, J EXP MED, V179, P1005, DOI 10.1084/jem.179.3.1005; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; ESCLAMADO RM, 1986, AM J SURG, V152, P376, DOI 10.1016/0002-9610(86)90308-9; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GOWN AM, 1986, AM J PATHOL, V123, P195; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; KAPUR RP, 1992, J HISTOCHEM CYTOCHEM, V40, P207, DOI 10.1177/40.2.1552165; KIM RY, 1992, EXP EYE RES, V55, P657, DOI 10.1016/0014-4835(92)90170-W; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KNUTH A, 1992, CANCER SURV, V13, P39; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KSANDER BR, 1991, INVEST OPHTH VIS SCI, V32, P3198; KWON BS, 1991, P NATL ACAD SCI USA, V88, P9228, DOI 10.1073/pnas.88.20.9228; KWON BS, 1987, MOL BIOL MED, V4, P339; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; MATTES MJ, 1983, INT J CANCER, V32, P717, DOI 10.1002/ijc.2910320610; MOCHII M, 1991, PIGM CELL RES, V4, P41, DOI 10.1111/j.1600-0749.1991.tb00312.x; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RUITER D J, 1990, Current Opinion in Oncology, V2, P377; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBAHARA S, 1986, NUCLEIC ACIDS RES, V14, P2413, DOI 10.1093/nar/14.6.2413; SMIT N, 1993, ARCH DERMATOL RES, V285, P356, DOI 10.1007/BF00371837; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; VENNEGOOR C, 1988, AM J PATHOL, V130, P179; VIJAYASARADHI S, 1990, J EXP MED, V171, P1375, DOI 10.1084/jem.171.4.1375; VOGEL AM, 1988, CANCER RES, V48, P1286; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	42	161	176	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20126	20133						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	7519602				2022-12-25	WOS:A1994PA12600070
J	KRAUZEWICZ, N; ELLIOTT, J; GRIFFIN, BE				KRAUZEWICZ, N; ELLIOTT, J; GRIFFIN, BE			CELL FRACTIONATION IN NONIONIC DETERGENT DISTINGUISHES SUBPOPULATIONS OF POLYOMA-VIRUS MIDDLE T-ANTIGEN AND REVEALS A NOVEL FORM	ONCOGENE			English	Article							TUMOR-ANTIGEN; MONOCLONAL-ANTIBODIES; KINASE-ACTIVITY; EARLY REGION; PROTEIN; PP60C-SRC; TRANSFORMATION; ASSOCIATION; COMPLEX; BINDING	The transforming function of polyoma virus, middle T antigen (MT), interacts with several cellular enzymes, essential to its oncogenic activity. We have used cell fractionation to study the various MT/cellular protein complexes. We demonstrate that MT can be separated into three sub-species, dependent upon extraction in two buffers that we designate A and B: Antigen extracted from whole cells by both buffers (called MT(1)) is associated with most of the phosphorylated phosphatidylinositol kinase 85 kD subunit, pp85, and protein phosphatase 2A. Antigen (MT(2)), associated with the greater portion of pp60c-src, is extracted by buffer B, but not buffer A. A third population (MT(3)), resistant to extraction by either buffer, is not detectably associated with protein phosphatase 2A or pp85. It is, however, associated with a low level kinase activity. The interaction between pp60c-src and MT appears to influence the formation of both MT(2) and MT(3). MT(2) fractionates with the cellular microtubule network, but does not appear to be directly associated with it. MT(3), a previously undescribed population, comprises about one third of MT in wild type antigen-containing cells. It is missing in mutants incapable of interacting with pp60c-src, but exists in the absence of an interaction with pp85. We suggest that MT(3) may be an intermediate in, or product of, one of the MT/pp60c-src signalling pathways, distinct from that involving pp85.	ROYAL POSTGRAD MED SCH,DEPT VIROL,LONDON W12 0NN,ENGLAND	Imperial College London								ANDREWS DW, 1993, MOL CELL BIOL, V13, P4703, DOI 10.1128/MCB.13.8.4703; BOLEN JB, 1985, J VIROL, V53, P114, DOI 10.1128/JVI.53.1.114-119.1985; BOLEN JB, 1987, J VIROL, V61, P3299, DOI 10.1128/JVI.61.10.3299-3305.1987; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CHENG SH, 1986, EMBO J, V5, P325, DOI 10.1002/j.1460-2075.1986.tb04216.x; CHENG SH, 1990, MOL CELL BIOL, V10, P5569, DOI 10.1128/MCB.10.10.5569; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DILWORTH SM, 1982, P NATL ACAD SCI-BIOL, V79, P1059, DOI 10.1073/pnas.79.4.1059; DILWORTH SM, 1986, EMBO J, V5, P491, DOI 10.1002/j.1460-2075.1986.tb04238.x; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; GRIFFIN BE, 1979, J VIROL, V31, P645, DOI 10.1128/JVI.31.3.645-656.1979; GRIFFIN BE, 1983, ADV CANCER RES, V39, P183, DOI 10.1016/S0065-230X(08)61036-2; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; GRUSSENMEYER T, 1987, J VIROL, V61, P3902, DOI 10.1128/JVI.61.12.3902-3909.1987; HOFER KB, 1988, ONCOGENE, V3, P365; KAPLAN DR, 1989, BIOCHIM BIOPHYS ACTA, V948, P345, DOI 10.1016/0304-419X(89)90006-1; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KRAUZEWICZ J, 1992, THESIS LONDON U; KRAUZEWICZ N, 1993, ELECTROPHORESIS, V15, P491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENSTRA JA, 1983, EUR J BIOCHEM, V135, P413, DOI 10.1111/j.1432-1033.1983.tb07668.x; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MAGNUSSON G, 1979, J VIROL, V32, P523, DOI 10.1128/JVI.32.2.523-529.1979; MARKLAND W, 1986, J VIROL, V59, P82, DOI 10.1128/JVI.59.1.82-89.1986; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; OSBORN M, 1977, EXP CELL RES, V106, P339, DOI 10.1016/0014-4827(77)90179-3; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; PONTEN J, 1971, VIROL MONOGR, P45; RAPTIS L, 1991, J VIROL, V65, P5203, DOI 10.1128/JVI.65.10.5203-5210.1991; SCHAFFHAUSEN BS, 1982, MOL CELL BIOL, V2, P1187, DOI 10.1128/MCB.2.10.1187; SEGAWA K, 1982, P NATL ACAD SCI-BIOL, V79, P6812, DOI 10.1073/pnas.79.22.6812; SMITH AE, 1979, CELL, V18, P915, DOI 10.1016/0092-8674(79)90204-6; SMITH AE, 1980, COLD SPRING HARB SYM, V1, P141; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STRAUSS M, 1986, GENE, V49, P331, DOI 10.1016/0378-1119(86)90369-0; STREULI CH, 1990, J VIROL, V64, P3570, DOI 10.1128/JVI.64.8.3570-3580.1990; TALMAGE DA, 1988, MOL CELL BIOL, V8, P2309, DOI 10.1128/MCB.8.6.2309; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; WALTER G, 1982, P NATL ACAD SCI-BIOL, V79, P4025, DOI 10.1073/pnas.79.13.4025; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WYSS A, 1990, J VIROL, V64, P5163, DOI 10.1128/JVI.64.10.5163-5166.1990; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	49	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2283	2291						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7518577				2022-12-25	WOS:A1994NX62900021
J	KIRKEN, RA; RUI, H; MALABARBA, MG; FARRAR, WL				KIRKEN, RA; RUI, H; MALABARBA, MG; FARRAR, WL			IDENTIFICATION OF INTERLEUKIN-2 RECEPTOR-ASSOCIATED TYROSINE KINASE P116 AS NOVEL LEUKOCYTE-SPECIFIC JANUS KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; IL-2 RECEPTOR; GAMMA-CHAIN; FUNCTIONAL COMPONENT; BETA-SUBUNIT; SUPERFAMILY; JAK2; PHOSPHORYLATION; DOMAIN; FAMILY	Janus tyrosine kinase (JAK) has recently been linked to signal transduction by cytokine receptors of the hematopoietin family. We have recently described a 116-kDa tyrosine kinase (p116) present in interleukin-2 (IL-2) receptor complexes in human YT cells that showed functional characteristics of a JAK kinase. These included receptor association, rapid and transient tyrosine phosphorylation kinetics in response to ligand, and in vitro autophosphorylating tyrosine kinase activity (Kirken, R. A., Rui, H., Evans, G. A., and Farrar, W. L. (1993) J. Biol. Chem. 268, 22765-22770). Here we extend these observations by demonstrating structural homologies between IL-2-modulated p116 and prolactin-modulated JAK2 in the rat T cell line Nb2. These include similar net charge as determined by nonequilibrium pH gradient electrofocusing and related primary structure based upon phosphopeptide mapping of V8 protease-digested hyperphosphorylated proteins. This putative JAK kinase underwent marked tyrosine phosphorylation in response to IL-2, IL-4, and IL-7, lymphoid growth factors that use the common IL-2 receptor gamma-chain, but not in response to prolactin. Furthermore, polyclonal antisera to JAK1, JAK2, or tyrosine kinase 2 did not recognize either rat or human p116. However, we identified the IL-2-modulated p116 as the recently cloned novel leukocyte Janus kinase, L-JAK, using an antiserum to a peptide corresponding to the COOH terminus of human L-JAK.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	KIRKEN, RA (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21702, USA.		Malabarba, Maria Grazia/L-4805-2015	Malabarba, Maria Grazia/0000-0002-9457-2047				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLOSI P, 1993, J BIOL CHEM, V268, P12617; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FERRIS DK, 1989, LYMPHOKINE RES, V8, P215; FOXWELL BMJ, 1992, CLIN EXP IMMUNOL, V90, P61; GRIMM EA, 1982, J EXP MED, V155, P1823, DOI 10.1084/jem.155.6.1823; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HENNEY CS, 1981, NATURE, V291, P335, DOI 10.1038/291335a0; JUNG LKL, 1984, J EXP MED, V160, P1597, DOI 10.1084/jem.160.5.1597; KAWAMURA M, 1994, IN PRESS P NATL ACAD; KIRKEN RA, 1993, J BIOL CHEM, V268, P22765; Kirken Robert A., 1994, Progress in Growth Factor Research, V5, P195, DOI 10.1016/0955-2235(94)90005-1; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; RAYHEL EJ, 1988, BIOCHEM J, V249, P333, DOI 10.1042/bj2490333; RUI H, 1994, J BIOL CHEM, V269, P5364; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TAKAHASHI T, 1994, FEBS LETT, V342, P124, DOI 10.1016/0014-5793(94)80485-0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	32	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19136	19141						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7518451				2022-12-25	WOS:A1994NX32700066
J	HOWELL, S; LANCTOT, C; BOILEAU, G; CRINE, P				HOWELL, S; LANCTOT, C; BOILEAU, G; CRINE, P			A CLEAVABLE N-TERMINAL SIGNAL PEPTIDE IS NOT A PREREQUISITE FOR THE BIOSYNTHESIS OF GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLYCOPHOSPHOLIPID MEMBRANE ANCHOR; ENDOPEPTIDASE 24.11 ENKEPHALINASE; KIDNEY BRUSH-BORDER; NEUTRAL ENDOPEPTIDASE; CELLS; ATTACHMENT; EXPRESSION; SECRETION; DOMAINS; DNA	During the biosynthesis of glycosylphosphatidylinositol (GPI)-anchored proteins, an N-terminal signal peptide is used to direct biosynthesis to the endoplasmic reticulum. It was previously unknown whether or not this signal must be removed during the biosynthesis of GPI-anchored proteins. Using neutral endopeptidase (EC 3.4.24.11), a well characterized type II membrane protein that is attached to the membrane via an uncleaved N-terminal signal peptide, we extended its C terminus with 33 of the 37 amino acids of the GPI anchor signal sequence of decay-accelerating factor. When expressed in COS-1 and Chinese hamster fibroblast (CHW) cells, the protein was shown to possess both transmembrane and GPI anchors, indicating that a cleavable N-terminal signal peptide is not a prerequisite for the biosynthesis of GPI-anchored proteins.	UNIV MONTREAL,FAC MED,DEPT BIOCHIM,MONTREAL H3C 3J7,PQ,CANADA	Universite de Montreal				Lanctot, Christian/0000-0003-3211-3061				AUBRY M, 1988, BIOCHIM BIOPHYS ACTA, V967, P56, DOI 10.1016/0304-4165(88)90188-2; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CARAS IW, 1991, J CELL BIOL, V113, P77, DOI 10.1083/jcb.113.1.77; CARAS IW, 1989, SCIENCE, V243, P1196, DOI 10.1126/science.2466338; CORBEIL D, 1992, J BIOL CHEM, V267, P2798; CRINE P, 1985, BIOCHEM BIOPH RES CO, V131, P255, DOI 10.1016/0006-291X(85)91796-6; DEVAULT A, 1987, EMBO J, V6, P1317, DOI 10.1002/j.1460-2075.1987.tb02370.x; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1992, BIOCHEM SOC T, V20, P243, DOI 10.1042/bst0200243; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; HOOPER NM, 1990, MOL CELL BIOL MEMBRA, P129; HOWELL S, 1993, FEBS LETT, V317, P109, DOI 10.1016/0014-5793(93)81502-Q; HOWELL S, 1994, BIOCHEM J, V299, P171, DOI 10.1042/bj2990171; KERR MA, 1974, BIOCHEM J, V137, P477, DOI 10.1042/bj1370477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; Maniatis T., 1982, MOL CLONING; MATTER K, 1991, BIOCHEMISTRY-US, V30, P1916, DOI 10.1021/bi00221a026; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; TARTAKOFF AM, 1992, TRENDS BIOCHEM SCI, V17, P470, DOI 10.1016/0968-0004(92)90491-Q; TURNER AJ, 1990, MOL CELL BIOL MEMBRA	23	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					16993	16996						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516327				2022-12-25	WOS:A1994NT84600003
J	KUHNE, MR; ZHAO, ZH; ROWLES, J; LAVAN, BE; SHEN, SH; FISCHER, EH; LIENHARD, GE				KUHNE, MR; ZHAO, ZH; ROWLES, J; LAVAN, BE; SHEN, SH; FISCHER, EH; LIENHARD, GE			DEPHOSPHORYLATION OF INSULIN-RECEPTOR SUBSTRATE-1 BY THE TYROSINE PHOSPHATASE PTP2C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; GROWTH-FACTOR RECEPTOR; INTACT-CELLS; PROTEIN; PHOSPHORYLATION; BINDING; KINASE; PURIFICATION; ACTIVATION; EXPRESSION	The phosphotyrosine (Tyr(P)) form of insulin receptor substrate 1 (IRS-1) is a key component in insulin signaling. Our previous study revealed that Tyr(P) IRS-1 binds to the widely distributed tyrosine phosphatase PTP2C through the src homology 2 (SH2) domains of the latter. In the present study, we examined the activity of this enzyme and of a truncated form lacking the SH2 domains (Delta PTP2C) toward IRS-1 and also toward the cytoplasmic domain of the insulin receptor. Tyr(P) IRS-1 was prepared by phosphorylation of recombinant IRS-1 with recombinant cytoplasmic insulin receptor kinase (CIRK). PTP2C rapidly dephosphorylated Tyr(P) IRS-1; dephosphorylation by Delta PTP2C was approximately one-third as fast, Other substrates, including Tyr(P) CIRK, were not dephosphorylated as rapidly by PTP2C; moreover, Delta PTP2C was at least 10 times more active than PTP2C toward CIRK and other substrates. These results indicate that the binding of Tyr(P) residues on IRS-1 to the SH2 domain(s) of PTP2C enhances its activity toward IRS-1 and suggest that PTP2C is the phosphatase responsible for the dephosphorylation of IRS-1 in vivo. In addition, with the expectation that a PTP2C-resistant form of IRS-1 will be useful in investigations of IRS-1 function, we determined that IRS-1 can be thiophosphorylated with adenosine 5'-O-(3-thiotriphosphate) and CIRK and that this form of IRS-1 is resistant to PTP2C.	DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; NIDDKD, CLIN DIABET & NUTR SECT, PHOENIX, AZ 85016 USA; NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, MONTREAL H4P 2R2, PQ, CANADA	Dartmouth College; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Research Council Canada					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042816, T32DK007508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 07902, DK 42816, DK 07508] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GIORGINO F, 1992, ENDOCRINOLOGY, V130, P1433, DOI 10.1210/en.130.3.1433; KELLER SR, 1991, J BIOL CHEM, V266, P12817; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LAMPHERE L, 1992, ENDOCRINOLOGY, V131, P2196, DOI 10.1210/en.131.5.2196; LAMPHERE L, 1994, AM J PHYSIOL, V266, pE486, DOI 10.1152/ajpendo.1994.266.3.E486; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAVARE JM, 1991, J BIOL CHEM, V266, P1390; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; TONKS NK, 1988, J BIOL CHEM, V263, P6722; VILLALBA M, 1989, P NATL ACAD SCI USA, V86, P7848, DOI 10.1073/pnas.86.20.7848; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	23	71	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15833	15837						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	7515062				2022-12-25	WOS:A1994NP51300068
J	RUZZENE, M; JAMES, P; BRUNATI, AM; DONELLADEANA, A; PINNA, LA				RUZZENE, M; JAMES, P; BRUNATI, AM; DONELLADEANA, A; PINNA, LA			REGULATION OF C-FGR PROTEIN-KINASE BY C-SRC KINASE (CSK) AND BY POLYCATIONIC EFFECTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; GENE-PRODUCT; RAT SPLEEN; TPK-IIB; PP60C-SRC; PHOSPHORYLATION; PEPTIDES; POLYLYSINE; ONCOGENE; AUTOPHOSPHORYLATION	The protein tyrosine kinase expressed by the protooncogene c-fgr is phosphorylated and down-regulated in vitro by the c-Src kinase (CSK). CSK catalyzed phosphorylation affects Tyr-511 of c-Fgr, homologous to Tyr-527 of c-Src and it prevents the autophosphorylation normally occurring at c-Fgr Tyr-800, homologous to c-Src Tyr-416. Polylysine, histones H1 and H2A and other polycationic proteins on the other hand stimulate c-Fgr activity while promoting enhanced autophosphorylation of both Tyr-400 and Tyr-511. Once phosphorylated at Tyr-511 and down-regulated by CSK, c-Fgr is no more susceptible to polylysine stimulation. Previous autophosphorylation (at Tyr-400) reduces c-Fgr susceptibility to down-regulation by CSK, although Tyr-511 can be still phosphorylated by it. If a more exhaustive autophosphorylation (of both Tyr-4OO and Tyr-811) is performed in the presence of polylysine, c-Fgr becomes totally insensitive to CSK down-regulation. These data support the concept that down-regulation of c-Fgr by Tyr-511 phosphorylation is prevented if Tyr-400 is also phosphorylated and they are consistent with an outcompetition of phospho Tyr-511 from the Src homology 2 domain by phospho-Tyr-400, which, in c-Fgr, is surrounded by an amino acid sequence divergent from that of the other Src-related protein tyrosine kinases.	UNIV PADUA, DIPARTIMENTO CHIM BIOL, I-35121 PADUA, ITALY; CNR, CTR STUDIO FISIOL MITOCONDRIALE, I-35121 PADUA, ITALY; ETH ZENTRUM, PROT CHEM LAB, ZURICH, SWITZERLAND	University of Padua; Consiglio Nazionale delle Ricerche (CNR); ETH Zurich			Brunati, Anna Maria/I-8136-2018	Brunati, Anna Maria/0000-0002-3481-9503; Ruzzene, Maria/0000-0001-8712-8151				ABDELGHANY M, 1990, P NATL ACAD SCI USA, V87, P7061, DOI 10.1073/pnas.87.18.7061; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BRUNATI AM, 1988, EUR J BIOCHEM, V172, P451, DOI 10.1111/j.1432-1033.1988.tb13909.x; BRUNATI AM, 1992, FEBS LETT, V313, P291, DOI 10.1016/0014-5793(92)81212-5; BRUNATI AM, 1993, EUR J BIOCHEM, V216, P323, DOI 10.1111/j.1432-1033.1993.tb18149.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHEAH MSC, 1986, NATURE, V319, P238, DOI 10.1038/319238a0; COLA C, 1989, BIOCHIM BIOPHYS ACTA, V1012, P191, DOI 10.1016/0167-4889(89)90095-5; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DONELLADEANA A, 1992, EUR J BIOCHEM, V204, P1159, DOI 10.1111/j.1432-1033.1992.tb16742.x; FUJITAYAMAGUCHI Y, 1989, P NATL ACAD SCI USA, V86, P7306, DOI 10.1073/pnas.86.19.7306; GATICA M, 1987, P NATL ACAD SCI USA, V84, P324, DOI 10.1073/pnas.84.2.324; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MACAULEY A, 1993, ONCOGENE, V8, P117; MARIN O, 1991, J BIOL CHEM, V266, P17798; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1988, J BIOCHEM-TOKYO, V104, P297, DOI 10.1093/oxfordjournals.jbchem.a122461; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SARNO S, 1993, BIOCHEM BIOPH RES CO, V194, P83, DOI 10.1006/bbrc.1993.1788; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TURCK C W, 1991, Peptide Research, V4, P36; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15885	15891						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	7515063				2022-12-25	WOS:A1994NP51300075
J	DUBOIS, MF; NGUYEN, VT; BELLIER, S; BENSAUDE, O				DUBOIS, MF; NGUYEN, VT; BELLIER, S; BENSAUDE, O			INHIBITORS OF TRANSCRIPTION SUCH AS 5,6-DICHLORO-1-BETA-D-RIBOFURANOSYLBENZIMIDAZOLE AND ISOQUINOLINE SULFONAMIDE DERIVATIVES (H-8 AND H-7-ASTERISK) PROMOTE DEPHOSPHORYLATION OF THE CARBOXYL-TERMINAL DOMAIN OF RNA-POLYMERASE-II LARGEST SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; HEAT-SHOCK; MAMMALIAN-CELLS; CALF THYMUS; PHOSPHORYLATION; INITIATION; INVITRO; REPEAT; ELONGATION; EXPRESSION	The RNA polymerases IIO and IIA differ by the extent of phosphorylation in the carboxyl-terminal domain (CTD) of the largest subunit. It has been proposed that the IIA form of RNA polymerase II interacts with the promoter to form a stable preinitiation complex whereas the IIO form would be generated upon entry into initiation of transcription. Phosphorylation of the CTD might be required to release the interaction between the polymerase and the promoter binding factors. In this paper, we show that in the presence of actinomycin D, the phosphorylated IIO form accumulates. In contrast, the dephosphorylated IIA form accumulates while the amount of phosphorylated IIo form decreases in cells treated with CTD-kinase inhibitors such as the nucleoside analog, 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole or the isoquinoline sulfonamide derivatives H-7* or H-8. These changes are fast and suggest a very rapid phosphate turnover on the CTD. Transcription is inhibited in intact cells by drug concentrations that are effective in altering CTD phosphorylation, although no causal relationship is established yet. These effects do not concern other cellular functions such as protein synthesis, Thus isoquinoline sulfonamide derivatives might be helpful to further dissect the role of CTD phosphorylation in transcription.			DUBOIS, MF (corresponding author), ECOLE NORMALE SUPER, GENET MOLEC LAB, CNRS, URA 1302, 46 RUE ULM, F-75230 PARIS 05, FRANCE.			Bensaude, Olivier/0000-0002-0259-6608; Bellier, Sylvain/0000-0002-7590-4907				ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; CORDEN JL, 1993, CURR OPIN GENET DEV, V3, P213, DOI 10.1016/0959-437X(93)90025-K; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DAHMUS ME, 1981, J BIOL CHEM, V256, P3332; DAHMUS ME, 1994, IN PRESS PROG NUCLEI; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUBOIS MF, 1994, J CELL PHYSIOL, V158, P417, DOI 10.1002/jcp.1041580305; DUBOIS MF, 1991, CR ACAD SCI III-VIE, V313, P165; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FOECKING MK, 1986, GENE, V45, P101, DOI 10.1016/0378-1119(86)90137-X; FRASER NW, 1978, NATURE, V272, P590, DOI 10.1038/272590a0; GIARDINA C, 1993, J BIOL CHEM, V268, P23806; HIDAKA H, 1991, METHOD ENZYMOL, V201, P328; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KIM WY, 1986, J BIOL CHEM, V261, P14219; KIM WY, 1988, J BIOL CHEM, V263, P18880; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KRAMER A, 1980, MOL GEN GENET, V180, P193, DOI 10.1007/BF00267369; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LEGAGNEUX V, 1990, EUR J BIOCHEM, V193, P121, DOI 10.1111/j.1432-1033.1990.tb19312.x; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MEULIA T, 1993, MOL CELL BIOL, V13, P5647, DOI 10.1128/MCB.13.9.5647; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; NGUYEN VT, 1988, ANAL BIOCHEM, V171, P404, DOI 10.1016/0003-2697(88)90505-2; NOVER L., 1991, HEAT SHOCK RESPONSE; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PAYNE JM, 1993, J BIOL CHEM, V268, P80; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; STEVENS A, 1989, BIOCHEM BIOPH RES CO, V159, P508, DOI 10.1016/0006-291X(89)90022-3; STONE N, 1992, J BIOL CHEM, V267, P6353; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; TAMM I, 1976, J CELL BIOL, V69, P229, DOI 10.1083/jcb.69.2.229; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WIBORG O, 1985, EMBO J, V4, P755, DOI 10.1002/j.1460-2075.1985.tb03693.x; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZANDOMENI R, 1984, J BIOL CHEM, V259, P4804; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; ZANDOMENI R, 1983, J MOL BIOL, V167, P561, DOI 10.1016/S0022-2836(83)80098-9; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHANG J, 1991, J BIOL CHEM, V266, P2297	58	112	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13331	13336						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7513701				2022-12-25	WOS:A1994NK18400044
J	GRIBKOFF, VK; CHAMPIGNY, G; BARBRY, P; DWORETZKY, SI; MEANWELL, NA; LAZDUNSKI, M				GRIBKOFF, VK; CHAMPIGNY, G; BARBRY, P; DWORETZKY, SI; MEANWELL, NA; LAZDUNSKI, M			THE SUBSTITUTED BENZIMIDAZOLONE NS004 IS AN OPENER OF THE CYSTIC-FIBROSIS CHLORIDE CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL-CELLS; GENE; IDENTIFICATION; EXPRESSION; CFTR; DELTA-F508; CL	Cystic fibrosis is a major inherited disorder involving abnormalities of fluid and electrolyte transport in a number of different organs. Epithelial cells of cystic fibrosis patients have a decreased capacity to secrete chloride in response to cAMP-mobilizing agents because of the mutation of a single gene. The gene product, the cystic fibrosis transmembrane conductance regulator or CFTR, is a chloride channel. The most frequent mutation is a deletion of phenylalanine in position 508 (DELTAF08-CFTR) that reduces both the expression of the CFTR protein at the cell surface, and the activity of the Cl- channel. This work presents the properties of NS004, a substituted benzimidazolone, which is the first activator of normal and mutant CFTR-associated chloride channels to be described. NS004 activated CFTR and DELTAF508-CFTR Cl- channels expressed in Xenopus oocytes, and increased I-125 efflux (via the Cl- channel) from Vero cells expressing CFTR and DELTAF508-CFTR. Application of NS004 to the external side of outside-out patches excised from these CFTR- and DELTAF508-CFTR-expressing cells induced a marked and reversible increase in channel activity.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DIV CHEM,WALLINGFORD,CT 06492; CNRS,INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE	Bristol-Myers Squibb; Centre National de la Recherche Scientifique (CNRS)	GRIBKOFF, VK (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT CNS BIOPHYS & MOLEC BIOL 405,5 RES PKWY,WALLINGFORD,CT 06492, USA.		Barbry, Pascal/O-5021-2016	Barbry, Pascal/0000-0001-9632-6483; Meanwell, Nicholas/0000-0002-8857-1515				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BECQ F, 1993, FEBS LETT, V327, P337, DOI 10.1016/0014-5793(93)81016-S; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BOUCHER RC, 1992, DRUGS, V43, P431, DOI 10.2165/00003495-199243040-00001; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIGGINS CF, 1992, BRIT MED BULL, V48, P754, DOI 10.1093/oxfordjournals.bmb.a072576; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LI CH, 1993, NAT GENET, V3, P311, DOI 10.1038/ng0493-311; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; OLESEN SP, 1992, Patent No. 477819; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R	27	97	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					10983	10986						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512555				2022-12-25	WOS:A1994NF96600005
J	KRAMER, KK; DUFFY, JY; KLEMANN, SW; BIXBY, JA; LOW, BG; POPE, WF; ROBERTS, RM				KRAMER, KK; DUFFY, JY; KLEMANN, SW; BIXBY, JA; LOW, BG; POPE, WF; ROBERTS, RM			SELECTIVE CLONING OF CDNA FOR SECRETORY PROTEINS OF EARLY EMBRYOS - IDENTIFICATION OF A TRANSIENTLY EXPRESSED KUNITZ DOMAIN PROTEIN FROM PREIMPLANTATION SHEEP TROPHOBLAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; MOLECULAR-WEIGHT PROTEIN; AMINO-ACID-SEQUENCE; ANTIGENIC DETERMINANTS; INTERFERON; RNA; TROPHECTODERM; PURIFICATION; PREGNANCY; PRECURSOR	The preimplantation ovine conceptus transiently secretes several proteins, including a type I interferon (IFN-tau), that are likely involved in establishment of pregnancy. A method has been developed to identify proteins produced simultaneously with IFN-tau. An antiserum against total ovine conceptus secretory proteins, from which IFN-tau and proteins common to maternal uterine tract secretions had first been removed, was used to immunoscreen cDNA libraries created from mRNA of days 13 and 15 ovine conceptuses. This approach has allowed several unique cDNA to be identified, including one particularly abundant transcript for a novel member of the Kunitz family of serine protease inhibitors. This cDNA encodes a 265-amino acid protein with a 20-amino acid signal sequence. A 64-amino acid Kunitz domain occupies the carboxyl terminus. It is preceded by two similar repeats of 84 residues that bear no obvious similarity to any sequences present in the protein data banks. The protein present in conceptus secretions (M(r) of similar to 14,000) represents only the carboxyl terminus of the molecule. The mRNA for this putative proteinase inhibitor was confined to trophectoderm and was highly expressed for only a few days (similar to 13-18) of development. A similar transcript was detected during the days 17-21 period in cattle embryos. Despite their high expression, no proteinase-inhibitory activity can so far be ascribed to either the ovine or bovine proteins. The P-1 residue, an asparagine, is not represented in any other known Kunitz inhibitors.	UNIV MISSOURI, DEPT ANIM SCI, COLUMBIA, MO 65211 USA; UNIV MISSOURI, DEPT BIOCHEM, COLUMBIA, MO 65211 USA; OHIO STATE UNIV, DEPT ANIM SCI, COLUMBUS, OH 43210 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; Ohio State University					NICHD NIH HHS [HD21980] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021980] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; [Anonymous], 1982, REPROD MAMMALS; BAZER FW, 1987, REPRODUCTION FARM AN, P210; BOSHIER DP, 1969, J REPROD FERTIL, V19, P51, DOI 10.1530/jrf.0.0190051; BRENNAN GL, 1983, BIOTECHNIQUES, V1, P78; BRUCK C, 1982, J IMMUNOL METHODS, V53, P313, DOI 10.1016/0022-1759(82)90178-8; CECHOVA D, 1971, COLLECT CZECH CHEM C, V36, P3342; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER H, 1988, CURRENT PROTOCOLS MO; CREIGHTON TE, 1987, J MOL BIOL, V194, P11, DOI 10.1016/0022-2836(87)90711-X; CREIGHTON TE, 1987, COLD SPRING HARB SYM, V52, P511, DOI 10.1101/SQB.1987.052.01.058; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; FARIN CE, 1989, MOL ENDOCRINOL, V3, P1099, DOI 10.1210/mend-3-7-1099; FULLER SA, 1988, CURRENT PROTOCOLS MO; GODKIN JD, 1982, J REPROD FERTIL, V65, P141, DOI 10.1530/jrf.0.0650141; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAMMARBACK JA, 1990, J BIOL CHEM, V265, P12763; HANDYSIDE AH, 1991, REPROD BIOL, P273; HANSEN TR, 1988, J BIOL CHEM, V263, P12801; HOOG C, 1991, NUCLEIC ACIDS RES, V19, P6123, DOI 10.1093/nar/19.22.6123; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HYNES TR, 1990, BIOCHEMISTRY-US, V29, P10018, DOI 10.1021/bi00495a002; IMAKAWA K, 1987, NATURE, V330, P377, DOI 10.1038/330377a0; IMAKAWA K, 1989, MOL ENDOCRINOL, V3, P127, DOI 10.1210/mend-3-1-127; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; KAZEMI M, 1990, BIOL REPROD, V43, P80, DOI 10.1095/biolreprod43.1.80; KINGSTON IB, 1986, BIOCHEM J, V233, P443, DOI 10.1042/bj2330443; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; MCDONALD NQ, 1993, TRENDS BIOCHEM SCI, V18, P208, DOI 10.1016/0968-0004(93)90190-X; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; RASP G, 1987, BIOL CHEM H-S, V368, P727, DOI 10.1515/bchm3.1987.368.1.727; REDDY KJ, 1988, ANAL BIOCHEM, V168, P324, DOI 10.1016/0003-2697(88)90325-9; ROBERTS RM, 1992, ENDOCR REV, V13, P432, DOI 10.1210/er.13.3.432; SINHA S, 1991, J BIOL CHEM, V266, P21011; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; STRYDOM DJ, 1973, NATURE-NEW BIOL, V243, P88; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VETR H, 1988, FEBS LETT, V245, P137; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WACHTER E, 1980, FEBS LETT, V119, P58, DOI 10.1016/0014-5793(80)80997-5; WILMUT I, 1981, J REPROD FERTIL, V61, P179, DOI 10.1530/jrf.0.0610179; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6	44	18	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7255	7261						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7510284				2022-12-25	WOS:A1994NA03200036
J	COMINELLI, F; BORTOLAMI, M; PIZARRO, TT; MONSACCHI, L; FERRETTI, M; BREWER, MT; EISENBERG, SP; NG, RK				COMINELLI, F; BORTOLAMI, M; PIZARRO, TT; MONSACCHI, L; FERRETTI, M; BREWER, MT; EISENBERG, SP; NG, RK			RABBIT INTERLEUKIN-1 RECEPTOR ANTAGONIST - CLONING, EXPRESSION, FUNCTIONAL-CHARACTERIZATION, AND REGULATION DURING INTESTINAL INFLAMMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-1 RECEPTOR; HUMAN-MONOCYTES; RECOMBINANT INTERLEUKIN-1; IL-1-BETA PRODUCTION; CELLS; GENE; DNA; PURIFICATION; INHIBITOR; PROTEIN	Genomic and cDNA clones for rabbit interleukin-l re antagonist (IL-1ra) were isolated based on homology with the human, mouse, and rat IL-1ra gene. A partial genomic clone, obtained by screening a rabbit genomic library, contained coding sequences for the carboxyl-terminal 108 amino acids of rabbit IL-1ra. Two classes of cDNA for rabbit IL-1ra were obtained using RNA from inflamed rabbit colon tissue. One class of cDNA coded for a secreted form of IL-1ra, whereas the other coded for a putative intracellular form of rabbit IL-1ra. The latter form is similar to that isolated from human epithelial cells. A partially synthetic rabbit IL-1ra gene was constructed and expressed in Escherichia coli. The recombinant rabbit IL-1ra was purified to ho mogeneity by ion exchange chromatography. Its affinity was similar to that of human IL-1ra for the human and mouse type I IL-1 receptor. From the cDNA clone and the purified recombinant protein, specific probes were developed for measuring levels of rabbit IL-1ra mRNA and protein in normal and inflamed rabbit tissues. Unlike IL-1 alpha and IL-1 beta, IL-1ra mRNA and protein were present at detectable levels in normal rabbit colon. During the development of an experimental formalin-immune complex colitis, rabbit IL-1 alpha showed a dramatic increase in tissue levels, consistent with previous results; IL-1ra also increased 3-4-fold. Treatment of colitis rabbits with corticosteroids significantly suppressed neutrophil infiltration, IL-1 alpha levels, but not IL-1ra levels. In contrast, corticosteroid treatment suppressed IL-1ra but not IL-1 alpha mRNA steady-state levels. Our observations demonstrate that IL-1 and IL-1ra synthesis is differentially regulated in healthy and inflamed intestinal tissue.	UNIV SO CALIF, SCH MED, DEPT MED, LOS ANGELES, CA 90033 USA; SYNERGEN INC, BOULDER, CO 80301 USA	University of Southern California					NIDDK NIH HHS [DK45740, DK42191] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042191, R37DK042191, R01DK045740, R01DK042191] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AREND WP, 1991, J IMMUNOL, V147, P1530; AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; AREND WP, 1990, J CLIN INVEST, V85, P1694, DOI 10.1172/JCI114622; AREND WP, 1985, J IMMUNOL, V134, P3868; AREND WP, 1990, ARTHRITIS RHEUM-US, V33, P305, DOI 10.1002/art.1780330302; BHATTACHERJEE P, 1987, CURR EYE RES, V6, P929, DOI 10.3109/02713688709034861; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK BD, 1991, J APPL PHYSIOL, V71, P2412, DOI 10.1152/jappl.1991.71.6.2412; CLINTON SK, 1991, AM J PATHOL, V138, P1005; COMINELLI F, 1990, J CLIN INVEST, V86, P972, DOI 10.1172/JCI114799; COMINELLI F, 1990, J CLIN INVEST, V85, P582, DOI 10.1172/JCI114476; COMINELLI F, 1992, GASTROENTEROLOGY, V103, P65, DOI 10.1016/0016-5085(92)91096-M; COMINELLI F, 1992, GASTROENTEROLOGY, V102, pA608; DINARELLO CA, 1986, J CLIN INVEST, V77, P1734, DOI 10.1172/JCI112495; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; DRIPPS DJ, 1991, J BIOL CHEM, V266, P20311; EISENBERG SP, 1991, P NATL ACAD SCI USA, V88, P5232, DOI 10.1073/pnas.88.12.5232; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENTON MJ, 1987, J IMMUNOL, V138, P3972; FISCHER E, 1992, BLOOD, V79, P2196; GILLIS S, 1979, J IMMUNOL, V123, P1624; GOTO F, 1992, IMMUNOLOGY, V77, P235; GRANOWITZ EV, 1991, LANCET, V338, P1423, DOI 10.1016/0140-6736(91)92725-H; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUSS HJ, 1992, LANCET, V340, P968; HAMMERBERG C, 1992, J CLIN INVEST, V90, P571, DOI 10.1172/JCI115896; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HASKILL S, 1991, P NATL ACAD SCI USA, V88, P3681, DOI 10.1073/pnas.88.9.3681; HAZUDA DJ, 1990, J BIOL CHEM, V265, P6318; HENDERSON B, 1988, CLIN EXP IMMUNOL, V74, P371; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; KERN JA, 1988, J CLIN INVEST, V81, P237, DOI 10.1172/JCI113301; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204; LEW W, 1988, J IMMUNOL, V140, P1895; Maniatis T, 1989, MOL CLONING; MATSUKAWA A, 1992, BIOMED RES-TOKYO, V13, P269, DOI 10.2220/biomedres.13.269; MAYBUTT HN, 1990, ENDOCRINOLOGY, V127, P476; MILLER LC, 1993, LANCET, V341, P146, DOI 10.1016/0140-6736(93)90006-3; MORIMOTO A, 1989, AM J PHYSIOL, V256, pR35, DOI 10.1152/ajpregu.1989.256.1.R35; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; OPP MR, 1991, AM J PHYSIOL, V260, pR453, DOI 10.1152/ajpregu.1991.260.2.R453; POUTSIAKA DD, 1991, BLOOD, V78, P1275; RAMBALDI A, 1991, BLOOD, V78, P3248; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS AA, 1993, ARCH SURG-CHICAGO, V128, P138; SAUKKONEN K, 1990, J EXP MED, V171, P439, DOI 10.1084/jem.171.2.439; SECKINGER P, 1987, J IMMUNOL, V139, P1546; SHUCK ME, 1991, EUR J IMMUNOL, V21, P2775, DOI 10.1002/eji.1830211119; SNYDER DS, 1982, J IMMUNOL, V129, P1803; STOCKMAN BJ, 1992, BIOCHEMISTRY-US, V31, P5237, DOI 10.1021/bi00138a001; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635	58	40	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6962	6971						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509813				2022-12-25	WOS:A1994MZ50300107
J	SERVE, H; HSU, YC; BESMER, P				SERVE, H; HSU, YC; BESMER, P			TYROSINE RESIDUE-719 OF THE C-KIT RECEPTOR IS ESSENTIAL FOR FINDING OF THE P85 SUBUNIT OF PHOSPHATIDYLINOSITOL (PI) 3-KINASE AND FOR C-KIT-ASSOCIATED PI 3-KINASE ACTIVITY IN COS-1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC SIGNALING PROTEINS; GTPASE-ACTIVATING PROTEIN; GROWTH-FACTOR RECEPTORS; KINASE INSERT DOMAIN; W-MUTANT MICE; PDGF RECEPTOR; SH2 DOMAINS; SI-LOCUS; V-KIT; LIGAND	The receptor tyrosine kinase c-kit is thought to mediate its diverse effects on different cell lineages by association and activation of distinct second messenger systems. One of the immediate events after binding of the kit ligand to the receptor is its association with the 85-kDa subunit (p85) of the phosphatidylinositol (PI) 2-kinase and the activation of the enzyme. In the present study, we examined the association and activation of PI 3-kinase with mutant forms of the c-kit receptor transiently expressed in COS-1 cells. To define the binding site of p85 we substituted the putative tyrosine phosphorylation sites in the kinase insert region of the c-Kit receptor by phenylalanine (YF702, YF719, YF728, and YF745, respectively). The results indicate that, upon stimulation of cells with kit ligand, 1) the wild-type c-kit protein was readily autophosphorylated and autophosphorylation was not diminished significantly with any of the mutant proteins; 2) p85 and PI 3-kinase activity associated with wild-type c-Kit protein as well as with the mutant proteins YF702, YF728, and YF745. Ligand-induced association of p85 and PIS-kinase activity were abolished with the YF719 c-Kit protein, and this was not due to different levels of expression of p85 or c-kit; and 3) c-kit receptor-bound p85 was not phosphorylated on tyrosine residues. These results indicate that tyrosine 719 within the (719)YMDM motif in the kinase insert plays an important role in binding of p85 and that its phosphorylation is a prerequisite for binding of p85 and the subsequent activation of PI 3-kinase.	SLOAN KETTERING INST,MOLEC BIOL PROGRAM,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University					NCI NIH HHS [R37 CA 32926] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA032926] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUANG EJ, 1993, DEV BIOL, V157, P100, DOI 10.1006/dbio.1993.1115; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; MANOVA K, 1992, J NEUROSCI, V12, P4663; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RAY P, 1991, GENE DEV, V5, P2265, DOI 10.1101/gad.5.12a.2265; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Silver W. K., 1979, COAT COLORS MICE MOD, P243; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YEE NS, 1993, J BIOL CHEM, V268, P14189; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	58	127	130	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6026	6030						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509796				2022-12-25	WOS:A1994MY84000083
J	SETH, A; ROBINSON, L; PANAYIOTAKIS, A; THOMPSON, DM; HODGE, DR; ZHANG, XK; WATSON, DK; OZATO, K; PAPAS, TS				SETH, A; ROBINSON, L; PANAYIOTAKIS, A; THOMPSON, DM; HODGE, DR; ZHANG, XK; WATSON, DK; OZATO, K; PAPAS, TS			THE ENDOA ENHANCER CONTAINS MULTIPLE ETS BINDING-SITE REPEATS AND IS REGULATED BY ETS PROTEINS	ONCOGENE			English	Article							GENE FAMILY; C-FOS; TRANSCRIPTIONAL ACTIVATION; C-ETS-1 PROTOONCOGENE; ONCOGENIC ACTIVITY; EXPRESSION; MEMBER; MOUSE; PHOSPHORYLATION; IDENTIFICATION	EndoA is a type II keratin and with EndoB (type T keratin), constitutes intermediate filaments in various simple epithelial tissues. EndoA is developmentally regulated and has an enhancer that is located at the 3' - end of the gene. This enhancer contains two single and five dual Ets binding sites. Thus far, no other promoter or enhancer has been shown to contain as many potential clustered Ets binding sites. To study the transcriptional regulation of EndoA by the ETS family proteins, we amplified the EndoA enhancer fragment from mouse genomic DNA by PCR, and cloned it into the pBLCAT2 vector upstream from the CAT reporter gene. Several pBLCAT-ENDOA clones were squenced to verify the presence of all the ETS binding sites. Clones that did not show any point mutations in the ETS binding sites were chosen to study the transcription regulation by ETS1, ETS2 and ERGB/FLI-1 gene products. EMSA results indicated that the ETS1, ETS2 and ERGB/FLI-1 proteins bind to the enhancer sequence, and DNase I protection data demonstrated that the ETS proteins protect all seven EBS core sequences. Cotransfection of the COS cells with the pBLCAT-ENDOA construct, along with increasing amounts of different ETS expression vectors, resulted in a significant induction of CAT reporter gene expression. Previously, we have shown that the overexpression of the ETS1 gene transforms NIH3T3, and these transformed cells (7AQS2.1) produce high levels of ETS1 protein (Seth and Papas, 1990). In this report, we show that the undifferentiated P19 EC cells do not express detectable levels of ETS1; however, an elevated level of ETS1 is expressed in differentiated derivatives of these cells. We therefore used these two cell lines to examine the activity of the EndoA enhancer with the ETS1 product. Transfection of the pBLCAT-ENDOA construct alone in undifferentiated P19 EC cells results in very low CAT gene expression; however, upon differentiation with retinoic acid the level of CAT gene activity increases dramatically. Similarly, an increase in CAT expression from the same construct (pBLCAT-ENDOA) was also observed in 7AQS2.1 cells. Our results therefore indicate that the EndoA enhancer is regulated by ETS proteins via interaction with multiple ETS-binding site sequences.	PROGRAM RESOURCES INC,DYNCORP,FREDERICK,MD 21702									ASCIONE R, 1992, INT J ONCOL, V1, P631; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FISHER RJ, 1991, ONCOGENE, V6, P1001; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; HASHIDO K, 1991, EXP CELL RES, V192, P203, DOI 10.1016/0014-4827(91)90177-V; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HODGE DR, 1993, IN PRESS METHODS MOL; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; MCLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OSHIMA RG, 1985, CELL PROLIFERAT, V10, P51; PANAYIOTAKIS A, 1993, J VIRAL DISEASES, V1, P53; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; SAMBROOK J, 1989, MOL CLONING LABORATO, P542; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1989, ONCOGENE RES, V5, P61; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SETH A, 1993, INT J ONCOL, V2, P739; SETH A, 1993, CANCER PRINCIPLES PR, P23; TAKEMOTO Y, 1991, NUCLEIC ACIDS RES, V19, P2761, DOI 10.1093/nar/19.10.2761; TOPOL LZ, 1992, CANCER LETT, V67, P71, DOI 10.1016/0304-3835(92)90010-S; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	39	33	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					469	477						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	7507230				2022-12-25	WOS:A1994MW24800014
J	MELEN, K; RONNI, T; LOTTA, T; JULKUNEN, I				MELEN, K; RONNI, T; LOTTA, T; JULKUNEN, I			ENZYMATIC CHARACTERIZATION OF INTERFERON-INDUCED ANTIVIRAL GTPASES MURINE MX1 AND HUMAN MXA PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA SYNTHESIS; INFLUENZA-VIRUS; CELLULAR PROTEINS; BINDING PROTEINS; LEUCINE ZIPPER; DYNAMIN; RESISTANCE; GTP; EXPRESSION; INHIBITION	Interferons induce a number of different proteins which mediate the antiproliferative, antiviral, and immunomodulatory functions of interferons. Interferon-induced Mx proteins, which confer resistance to influenza, vesicular stomatitis, and measles viruses, contain consensus GTPase sequence elements. Insect cell produced purified murine Mx1 and human MxA proteins were found to hydrolyze GTP with K(m) = 65 muM (V(max), 7.1 min-1) and 62 muM (V(max), 3.1 min-1), respectively. The GTPase activity of Mx1 and MxA proteins was strictly dependent on Mg2+ ions. Murine Mx1 protein was inactivated at 10-degrees-C lower temperatures than MxA protein. As analyzed, by filter binding assay, Mx1 protein (at 1 muM) showed a relatively high affinity for GDP (K(d) = 1.0 x 10(-7) m) and approximately 340-fold lower affinity for guanosine 5'-3-0-(thio)triphosphate (GTPgammaS) (K(d) = 3.4 x 10(-5) m). The K(d) values for MxA protein were 2.0 x 10(-7) m for GDP and 5.9 x 10(-6) m for GTPgammaS, showing approximately a 30-fold affinity difference. ATP, UTP, or CTP did not inhibit the Mx protein-dependent GTPase activity, suggesting that Mx1 and MxA proteins are highly specific for guanosine nucleotides. In conclusion recombinant nuclear murine Mx1 and cytoplasmic human MxA proteins show clear differences in their enzymatic activities and nucleotide binding characteristics. How these differences influence their cellular functions and antiviral potential is presently not known.	NATL PUBL HLTH INST,MOLEC BIOL PROGRAM,MANNERHEIMINTE 166,SF-00300 HELSINKI,FINLAND; ORION FARMOS PHARMACEUT,ORION RES CTR,SF-02100 ESPOO,FINLAND	Finland National Institute for Health & Welfare								AEBI M, 1989, MOL CELL BIOL, V9, P5062, DOI 10.1128/MCB.9.11.5062; ARNHEITER H, 1990, CELL, V62, P51, DOI 10.1016/0092-8674(90)90239-B; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HORISBERGER MA, 1991, VIROLOGY, V180, P185, DOI 10.1016/0042-6822(91)90022-4; HORISBERGER MA, 1992, J VIROL, V66, P4705, DOI 10.1128/JVI.66.8.4705-4709.1992; HORISBERGER MA, 1990, J VIROL, V64, P1171, DOI 10.1128/JVI.64.3.1171-1181.1990; JOHN J, 1988, J BIOL CHEM, V263, P12792; KRUG RM, 1985, J VIROL, V56, P201, DOI 10.1128/JVI.56.1.201-206.1985; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MELEN K, 1992, J BIOL CHEM, V267, P25898; NAKAYAMA M, 1991, J BIOL CHEM, V266, P21404; NAKAYAMA M, 1992, VIRUS RES, V22, P227, DOI 10.1016/0168-1702(92)90054-D; NEAL SE, 1988, J BIOL CHEM, V263, P19718; NOTEBORN M, 1987, J INTERFERON RES, V7, P657, DOI 10.1089/jir.1987.7.657; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PAVLOVIC J, 1990, J VIROL, V64, P3370, DOI 10.1128/JVI.64.7.3370-3375.1990; PAVLOVIC J, 1992, J VIROL, V66, P2564, DOI 10.1128/JVI.66.4.2564-2569.1992; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; RONNI T, 1993, J IMMUNOL, V150, P1715; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SCHNORR JJ, 1993, J VIROL, V67, P4760, DOI 10.1128/JVI.67.8.4760-4768.1993; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; STAEHELI P, 1991, J VIROL, V65, P4498, DOI 10.1128/JVI.65.8.4498-4501.1991; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; STRIDH S, 1983, ARCH VIROL, V77, P223, DOI 10.1007/BF01309269; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555, P11; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WEITZ G, 1989, J INTERFERON RES, V9, P679, DOI 10.1089/jir.1989.9.679	37	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2009	2015						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507489				2022-12-25	WOS:A1994MR98800071
J	NANDA, A; ROMANEK, R; CURNUTTE, JT; GRINSTEIN, S				NANDA, A; ROMANEK, R; CURNUTTE, JT; GRINSTEIN, S			ASSESSMENT OF THE CONTRIBUTION OF THE CYTOCHROME-B MOIETY OF THE NADPH OXIDASE TO THE TRANSMEMBRANE H+ CONDUCTANCE OF LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; HUMAN-NEUTROPHILS; INTRACELLULAR PH; ACTIVATION; MEMBRANE; CELLS; CURRENTS; CHANNEL	Phagocytic cells can kill microorganisms by synthesizing superoxide. Activation of the NADPH oxidase that generates superoxide is accompanied by a large intracellular burst of metabolic acid production. Despite the excess acid generation, cytosolic pH (pH(i)) remains near neutrality due to the concomitant stimulation of several homeostatic H+ extrusion mechanisms including a recently described H+-conductive pathway. Activation of the conductance by phorbol esters is defective in neutrophils of chronic granulomatous disease (CGD) patients lacking the transmembrane cytochrome b subunits of the NADPH oxidase. This finding suggests that the oxidase itself undertakes H+ translocation or that, alternatively, assembly of the oxidase is required to activate a separate H+ conducting entity. To distinguish between these possibilities, the presence of the conductive pathway was assessed in unstimulated normal and CGD cells by manipulating pH(i) and the transmembrane potential. Using fluorimetric determinations of pH(i), a conductive, Zn2+-sensitive alkalinization was observed in neutrophils from both normal and cytochrome b deficient CGD donors. The electrophysiological properties of the conductance were defined in purified blood monocytes using the whole cell configuration of the patch clamp. Depolarizing pulses induced slowly activating outward currents in cells from both normal and cytochrome b deficient individuals. The elicited currents were potentiated by cytosolic acidification and did not inactivate within the times tested. As in control leukocytes, the reversal potential of tail currents in the CGD cells closely approximated the H+ equilibrium potential and was unaffected by substitution of the major ionic components of the external bathing medium. At all voltages tested, the magnitude of the evoked currents was comparable in normal and CGD cells. The results indicate that, like macrophages and granulocytes, human monocytes display a voltage-gated highly H+-selective conductance. More importantly, our findings imply that the conductive pathway is present in cells devoid of cytochrome b. Therefore, the defective activation of the conductive pathway by protein kinase C agonists in CGD cells is not due to the physical absence of the transporter. Instead we propose that the oxidase functions in a regulatory capacity, facilitating the opening of a distinct H+ conductance during cellular stimulation.	HOSP SICK CHILDREN, RES INST, DIV CELL BIOL, TORONTO M5G 1X8, ON, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO, ON, CANADA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Scripps Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024838] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00833] Funding Source: Medline; NIAID NIH HHS [AI24838] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABIOR BM, 1992, ADV ENZYMOL RAMB, V65, P49; BORREGAARD N, 1984, J CLIN INVEST, V74, P455, DOI 10.1172/JCI111442; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; COLLETTE J, 1956, J AM CHEM SOC, V78, P3819, DOI 10.1021/ja01596a070; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; CURNUTTE J T, 1992, Immunodeficiency Reviews, V3, P149; CURNUTTE JT, 1988, J CLIN INVEST, V81, P606, DOI 10.1172/JCI113360; DECOURSEY TE, 1993, BIOPHYS J, V65, P1590, DOI 10.1016/S0006-3495(93)81198-6; DEMAUREX N, 1993, J PHYSIOL-LONDON, V466, P329; GRINSTEIN S, 1986, AM J PHYSIOL, V250, pC283, DOI 10.1152/ajpcell.1986.250.2.C283; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; HENDERSON LM, 1988, BIOCHEM J, V255, P285; HENDERSON LM, 1988, BIOCHEM J, V251, P563, DOI 10.1042/bj2510563; Henderson Lydia M., 1994, European Journal of Clinical Investigation, V24, pA32; HOPKINS PJ, 1992, AM J HUM GENET, V51, P37; KAPUS A, 1994, J BIOL CHEM, V269, P4736; KAPUS A, 1993, J GEN PHYSIOL, V102, P729, DOI 10.1085/jgp.102.4.729; KAPUS A, 1992, BIOCHEM J, V281, P697, DOI 10.1042/bj2810697; LEBANOFF SJ, 1995, INFLAMMATION BASIC P, P541; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; NANDA A, 1993, P NATL ACAD SCI USA, V90, P760, DOI 10.1073/pnas.90.2.760; NANDA A, 1994, J CLIN INVEST, V93, P1770, DOI 10.1172/JCI117162; NANDA A, 1992, J BIOL CHEM, V267, P22740; NANDA A, 1991, P NATL ACAD SCI USA, V88, P10816, DOI 10.1073/pnas.88.23.10816; QU AY, 1994, AM J PHYSIOL, V35, pC1263; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SIMCHOWITZ L, 1985, J BIOL CHEM, V260, P3248; SMITH RM, 1991, BLOOD, V77, P673; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012	31	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27280	27285						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525551				2022-12-25	WOS:A1994PV77100023
J	STAUBS, PA; REICHART, DR; SALTIEL, AR; MILARSKI, KL; MAEGAWA, H; BERHANU, P; OLEFSKY, JM; SEELY, BL				STAUBS, PA; REICHART, DR; SALTIEL, AR; MILARSKI, KL; MAEGAWA, H; BERHANU, P; OLEFSKY, JM; SEELY, BL			LOCALIZATION OF THE INSULIN-RECEPTOR BINDING-SITES FOR THE SH2 DOMAIN PROTEINS P85, SYP, AND GAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; GTPASE-ACTIVATING PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE-PHOSPHATASE; INTACT-CELLS; SIGNAL TRANSDUCTION; BETA-SUBUNIT; IRS-1; ENDOCYTOSIS; KINASE	The insulin receptor is known to interact with the SH2 domain proteins p85 (the regulatory subunit of phosphatidylinositol 3-kinase), Syp (a tyrosine phosphatase), and GAP (GTPase-activating protein). In this study, we mapped the insulin receptor binding sites for each of these proteins by examining the ability of phosphopeptides, corresponding to insulin receptor phosphorylation sites, and mutant insulin receptors to inhibit an insulin receptor-SH2 domain interaction. Precipitation of partially purified insulin receptors by glutathione S-transferase fusion proteins containing the N-terminal SH2 domains of p85 and GAP and both SH2 domains of Syp was demonstrated. The effect of the addition of each phosphopeptide on insulin receptor precipitation was tested. pY1322, the C-terminal insulin receptor peptide, inhibited insulin receptor precipitation by both p85- and Syp GST. The NPXY internalization domain peptide inhibited insulin receptor precipitation by GAP GST. These data were confirmed by mutant insulin receptor experiments. The insulin receptor C-terminal mutants, Delta CT and Y/F2, were not precipitated by p85 or Syp GST and the NPXY mutant insulin receptors, Delta Ex16 and HI Delta NPEY, were not precipitated by GAP-GST. Therefore, we conclude that p85 and Syp bind to the insulin receptor C terminus at tyrosine 1322 and GAP binds to the insulin receptor NPXY domain at tyrosine 960.	UNIV CALIF SAN DIEGO, DEPT BIOMED SCI, DIVEND, LA JOLLA, CA USA; VET ADM MED CTR, SAN DIEGO, CA 92161 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	STAUBS, PA (corresponding author), UNIV CALIF SAN DIEGO, DEPT MED 0673, DIV ENDOCRINOL & METAB, 9500 GILMAN DR, LA JOLLA, CA 92093 USA.		Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828; Maegawa, Hiroshi/0000-0002-4611-8149	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, K08DK002162, R01DK033651, R01DK032880] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 02162-02, DK 32880, DK 33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BERHANU P, 1991, MOL ENDOCRINOL, V5, P1827, DOI 10.1210/mend-5-12-1827; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MAEGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P208, DOI 10.1006/bbrc.1993.1805; MAEGAWA H, 1994, BIOCHEM BIOPH RES CO, V199, P780, DOI 10.1006/bbrc.1994.1297; MCCLAIN DA, 1990, J BIOL CHEM, V265, P21363; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, DIABETES, V43, pA1; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; PRONK GJ, 1992, J BIOL CHEM, V267, P24058; RIEDEL H, 1987, SCIENCE, V236, P197, DOI 10.1126/science.3494307; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAKATA Y, 1992, J BIOL CHEM, V267, P9065; TAMEMOTO H, 1994, J CELL BIOCHEM, P148; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; THIES RS, 1990, J BIOL CHEM, V265, P10132; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	84	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27186	27192						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525547				2022-12-25	WOS:A1994PV77100009
J	TECTOR, M; ZHANG, Q; SALTER, RD				TECTOR, M; ZHANG, Q; SALTER, RD			PHOSPHATASE INHIBITORS BLOCK IA VIVO BINDING OF PEPTIDES TO CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX-MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-GOLGI COMPARTMENT; HLA-B ANTIGENS; ENDOPLASMIC-RETICULUM; BREFELDIN-A; INTRACELLULAR-TRANSPORT; MONOCLONAL-ANTIBODY; POST-ER; RMA-S; MHC; PROTEINS	Class I major histocompatibility complex (MHC) molecules are heterotrimers of heavy chains, beta(2)-microglobulin, and 8-10 amino acid-long peptides. Assembly of class I MHC molecules into complexes which are stable and can be transported to the cell surface occurs soon after insertion of individual subunits into the endoplasmic reticulum (ER). To identify subcellular compartments required for class I MHC assembly, we studied class I biosynthesis in human cell lines treated with several inhibitors of intracellular transport. We found that HLA-B701 molecules do not assemble in CIR transfectants in which a block in protein transport from the ER is established by treatment with phosphatase inhibitors. In contrast, stable HLA-B701 complexes form in cells in which the ER becomes mixed with the Golgi after treatment with brefeldin A. Neither treatment impaired binding of HLA-B701 to the ER-resident protein calnexin, and unassembled heavy chains in phosphatase-inhibited cells showed prolonged association with calnexin. In addition, the mouse class I molecule H-2D(b), which binds beta(2)-microglobulin in human T2 cells in the absence of transporter of antigenic peptides, formed complexes in CIR cell transfectants treated with phosphatase inhibitors. Taken together, these data demonstrate that phosphatase inhibitors do not prevent assembly of class I heavy chain-beta(2)-microglobulin dimers, but instead interfere with peptide loading. These results are consistent with the possibility that class I MHC molecules are transported from their initial site of insertion into the rough ER before binding peptides, or alternatively that peptide loading mediated by transporter of antigenic peptides is blocked by phosphatase inhibitors.	UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Salter, Russell/0000-0003-4553-2986				ALEXANDER J, 1989, IMMUNOGENETICS, V29, P380, DOI 10.1007/BF00375866; ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; ANDERSON KS, 1993, J IMMUNOL, V151, P3407; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; BONATTI S, 1989, J BIOL CHEM, V264, P12590; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DAVIS JE, 1990, J IMMUNOL, V144, P990; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; HAMADA H, 1987, CANCER RES, V47, P2860; HOBMAN TC, 1992, J CELL BIOL, V118, P795, DOI 10.1083/jcb.118.4.795; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; LAPHAM CK, 1993, J EXP MED, V177, P1633, DOI 10.1084/jem.177.6.1633; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LUCOCQ J, 1991, J CELL SCI, V100, P753; MELLADO W, 1987, BIOCHEMISTRY-US, V26, P6900, DOI 10.1021/bi00396a005; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; NEEFJES JJ, 1988, EUR J IMMUNOL, V18, P801, DOI 10.1002/eji.1830180522; NEEFJES JJ, 1986, IMMUNOGENETICS, V23, P164, DOI 10.1007/BF00373817; NISHIWAKI S, 1990, CARCINOGENESIS, V11, P1837, DOI 10.1093/carcin/11.10.1837; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PARHAM P, 1981, HUM IMMUNOL, V3, P277, DOI 10.1016/0198-8859(81)90065-3; PARHAM P, 1979, J IMMUNOL, V123, P342; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SALTER RD, 1992, HUM IMMUNOL, V35, P40, DOI 10.1016/0198-8859(92)90093-3; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286	45	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25816	25822						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523393				2022-12-25	WOS:A1994PQ49100086
J	KNAUS, HG; EBERHART, A; KACZOROWSKI, GJ; GARCIA, ML				KNAUS, HG; EBERHART, A; KACZOROWSKI, GJ; GARCIA, ML			COVALENT ATTACHMENT OF CHARYBDOTOXIN TO THE BETA-SUBUNIT OF THE HIGH-CONDUCTANCE CA2+-ACTIVATED K+ CHANNEL - IDENTIFICATION OF THE SITE OF INCORPORATION AND IMPLICATIONS FOR CHANNEL TOPOLOGY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; AORTIC SMOOTH-MUSCLE; ALPHA-1 SUBUNIT; CA2+ CHANNELS; BINDING; RECEPTOR; INHIBITOR; PORE; PHOSPHORYLATION; MECHANISM	Purified high conductance Ca2+ activated K+ (maxi-K) channels hom bovine tracheal smooth muscle have been covalently labeled employing monoiodotyrosine charybdotoxin ([I-125]ChTX), and different bifunctional crosslinking reagents. [I-125]ChTX was specifically incorpo rated into the beta-subunit, which was thereafter isolated by size exclusion high performance liquid chromatography. Proteolytic fragments of the [I-125]ChTX-labeled beta-subunit were generated by digestion with various endoproteinases. Glu-C or Asp-N cleavage yielded a glycosylated [I-125]ChTX-labeled fragment of 13-14 kDa. A site-directed antiserum raised against residues 62-75 of the cloned beta-subunit of the maxi-K channel specifically recognizes the beta-subunit in immunostaining experiments and was capable of immunoprecipitating these ChTX-labeled peptides. Lys-C cleavage resulted in two fragments of 16 and 28 kDa, respectively, which were both precipitated by anti-beta((62-75)). However, only the 28-kDa fragment was recognized by anti-beta((118-132)) and shown to carry double the amount of N-linked carbohydrates. Taken together, these data restrict the site of covalent incorporation of ChTX into the beta-subunit exclusively at Lys(69), confirm the predicted topology of this subunit, and indicate that both canonical N-linked glycosylation sites are occupied with complex carbohydrates of 5-6 kDa each. We propose that an extracellularly located portion of the beta-subunit is located within 7.7 Angstrom of the ChTX receptor site and could even participate in the formation of this receptor by close apposition of its extracellular domain with structural elements provided by the alpha-subunit.	MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT MEMBRANE BIOCHEM & BIOPHYS, RAHWAY, NJ 07065 USA	Merck & Company	KNAUS, HG (corresponding author), UNIV INNSBRUCK, INST BIOCHEM PHARMACOL, PETER MAYR STR 1, A-6020 INNSBRUCK, AUSTRIA.							BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; GARCIACALVO M, 1991, BIOCHEMISTRY-US, V30, P11157, DOI 10.1021/bi00110a020; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; GIMENEZGALLEGO G, 1988, P NATL ACAD SCI USA, V85, P3329, DOI 10.1073/pnas.85.10.3329; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; KNAUS HG, 1994, BIOCHEMISTRY-US, V33, P5819, DOI 10.1021/bi00185a021; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MACKINNON R, 1989, BIOCHEMISTRY-US, V28, P8092, DOI 10.1021/bi00446a020; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1989, SCIENCE, V245, P1383; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; PARK CS, 1992, BIOCHEMISTRY-US, V31, P7749, DOI 10.1021/bi00149a002; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; SUGG EE, 1990, J BIOL CHEM, V265, P18745; TEJEDOR FJ, 1988, P NATL ACAD SCI USA, V85, P8742, DOI 10.1073/pnas.85.22.8742; VAZQUEZ J, 1989, J BIOL CHEM, V264, P20902; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494	26	59	59	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23336	23341						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7521879				2022-12-25	WOS:A1994PQ16400066
J	FONG, AM; SANTORO, SA				FONG, AM; SANTORO, SA			TRANSCRIPTIONAL REGULATION OF ALPHA(IIB) INTEGRIN GENE-EXPRESSION DURING MEGAKARYOCYTIC DIFFERENTIATION OF K562 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE RECEPTORS; BINDING; ENHANCER; PROMOTER; LINE; FIBRONECTIN; INHIBITION; ADHESION; ELEMENTS; DOMAIN	A portion of the 5'-flanking region of the glycoprotein IIb (alpha(IIb)) integrin gene extending from -598 to +32 base pairs was isolated. This DNA segment is capable of driving low level base-line transcription in undifferentiated K562 cells. It also contains elements which direct the markedly increased expression observed following megakaryocytic differentiation of K562 cells with phorbol dibutyrate. Analysis of hybrid alpha(IIb)-chloramphenicol acetyltransferase reporter gene constructs indicates that at least three regions within the -598 to +32 region control differentiation dependent alpha(IIb) transcription. Two enhancer elements as well as a silencer domain all regulate chloramphenicol acetyltransferase transcriptional activity in K562 cells. Gel mobility shift experiments revealed that nuclear binding proteins are able to interact with all three DNA regions. A small region lying between -124 and -99 bases is able to bind to nuclear proteins in undifferentiated cells but not in differentiated cells as evidenced by gel mobility shift and footprinting studies and corresponds to the silencer element identified in the functional studies. Therefore, the tissue-specific expression of (alpha(IIb) may be controlled transcriptionally by both positive and negative factors with the silencer element playing a major role in regulating differentiation-dependent expression.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110	Washington University (WUSTL)	FONG, AM (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110, USA.				NHLBI NIH HHS [F32 HL08686] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008686] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM., 2006, ENZYMATIC MANIPULATI; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; BURGER SR, 1992, EXP CELL RES, V202, P28, DOI 10.1016/0014-4827(92)90400-3; CAEN JP, 1966, AM J MED, V41, P4, DOI 10.1016/0002-9343(66)90003-9; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; HAVERSTICK DM, 1985, BLOOD, V66, P946; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; INOSTROZA JA, 1992, CELL, V70, P477; LEARY JF, 1987, LEUKEMIA RES, V11, P807, DOI 10.1016/0145-2126(87)90065-8; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; PHILLIPS DR, 1988, BLOOD, V71, P831; PRANDINI MH, 1988, BIOCHEM BIOPH RES CO, V156, P595, DOI 10.1016/S0006-291X(88)80884-2; PRANDINI MH, 1992, J BIOL CHEM, V267, P10370; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; TABILIO A, 1983, CANCER RES, V43, P4569; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; ULRICH MJ, 1990, BLOOD, V75, P990; UZAN G, 1991, J BIOL CHEM, V266, P8932; ZUTTER MM, 1994, J BIOL CHEM, V269, P463; ZUTTER MM, 1992, J BIOL CHEM, V267, P20233	31	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18441	18447						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518432				2022-12-25	WOS:A1994NW79800035
J	BRIZZI, MF; BLECHMAN, JM; CAVALLONI, G; GIVOL, D; YARDEN, Y; PEGORARO, L				BRIZZI, MF; BLECHMAN, JM; CAVALLONI, G; GIVOL, D; YARDEN, Y; PEGORARO, L			PROTEIN-KINASE C-DEPENDENT RELEASE OF A FUNCTIONAL WHOLE EXTRACELLULAR DOMAIN OF THE MAST-CELL GROWTH-FACTOR (MGF) RECEPTOR BY MGF-DEPENDENT HUMAN MYELOID CELLS	ONCOGENE			English	Article							TYROSINE KINASE; SIGNAL TRANSDUCTION; KIT PROTOONCOGENE; PHORBOL ESTERS; SI-LOCUS; LIGAND; BINDING; MOUSE; INHIBITION; FORM	The mast cell growth factor (MGF) affects migration, proliferation and differentiation of erythroid and myeloid progenitor cells by binding to a transmembrane receptor tyrosine kinase encoded by the c-Kit proto-oncogene. By using MGF-dependent human myeloid cell lines (M-07e and TF-1), here we show that a Kit-related 100 kDa protein is associated with the cell but it undergoes release into the medium upon treatment with the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA), an activator of protein kinase C. Immunological analysis with a series of antibodies to Kit indicated that the released protein (p100(Kit)) contains the whole glycosylated extracellular portion of the transmembrane Kit protein (p145(Kit)). The secreted protein retained the ability to specifically bind MGF. Moreover, p100(Kit) was able to block the mitogenic effect of MGF on cultured M-07e cells, suggesting that the soluble protein may function as a physiological antagonist of MGF.	UNIV TURIN,DIPARTIMENTO SCI BIOMED & ONCOL UMANA,SEZ CLIN,I-10149 TURIN,ITALY; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	University of Turin; Weizmann Institute of Science			YARDEN, YOSEF/K-1467-2012; Brizzi, Maria Felice/J-7882-2016	Cavalloni, Giuliana/0000-0002-9965-3436				ABKOWITZ JL, 1992, BLOOD, V79, P25, DOI 10.1182/blood.V79.1.25.bloodjournal79125; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BLECHMAN JM, 1993, J BIOL CHEM, V268, P4399; BUDEL LM, 1993, LEUKEMIA, V7, P426; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LEE LS, 1979, P NATL ACAD SCI USA, V10, P5178; LEV S, 1992, J BIOL CHEM, V267, P10866; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MCCAFFREY PG, 1984, J BIOL CHEM, V259, P2502; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P1710, DOI 10.1073/pnas.89.5.1710; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SIBLEY DR, 1988, ENDOCR REV, V9, P38, DOI 10.1210/edrv-9-1-38; THOMOPOULOS P, 1982, EUR J BIOCHEM, V129, P389, DOI 10.1111/j.1432-1033.1982.tb07062.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VU TH, 1989, MOL CELL BIOL, V9, P4563, DOI 10.1128/MCB.9.10.4563; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YEE NS, 1993, J BIOL CHEM, V268, P14189; ZINI MG, 1993, COMMUNICATION; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	37	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1583	1589						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	7514283				2022-12-25	WOS:A1994NL81500008
J	CECCONI, O; NELSON, RM; ROBERTS, WG; HANASAKI, K; MANNORI, G; SCHULTZ, C; ULICH, TR; ARUFFO, A; BEVILACQUA, MP				CECCONI, O; NELSON, RM; ROBERTS, WG; HANASAKI, K; MANNORI, G; SCHULTZ, C; ULICH, TR; ARUFFO, A; BEVILACQUA, MP			INOSITOL POLYANIONS - NONCARBOHYDRATE INHIBITORS OF L-SELECTIN AND P-SELECTIN THAT BLOCK INFLAMMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION MOLECULES; HIGH ENDOTHELIAL VENULES; FIBROBLAST GROWTH-FACTOR; CARBOHYDRATE LIGAND; SULFATED POLYSACCHARIDES; GLYCOPROTEIN LIGAND; NATURAL ANTIOXIDANT; MYELOID CELLS; LUNG INJURY; TUMOR-CELLS	Selectins are cell adhesion molecules known to support the initial attachment of leukocytes to inflamed vascular endothelium through their recognition of carbohydrate ligands such as the tetrasaccharide sialyl Lewis(x) (NeuSAc alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc-). In the present study, we describe the inhibition of L- and P-selectin function by inositol polyanions, simple 6-carbon ring structures that have multiple ester-linked phosphate or sulfate groups. In a purified component competition assay, binding of L- and P-selectin-Ig fusion proteins to immobilized bovine serum albumin-sialyl Lewis(x) neoglycoprotein was inhibited by inositol hexakisphosphate (InsP(6) IC50 = 2.1 +/- 1.4 mu M and 160 +/- 40 mu M), by inositol pentakisphosphate (InsP(5), IC50 = 1.4 +/- 0.2 and 260 +/- 40 mu M), and by inositol hexakissulfate (InsS(6),, IC50 = 210 +/- 80 mu M and 2.8 +/- 0.9 mM); E-selectin-Ig binding was unaffected. Inositol polyanions diminished the adhesion of LS180 colon carcinoma cells to plates coated with L- and P-selectin-Ig but not with E-selectin-Ig. Inositol polyanions blocked polymorphonuclear leukocyte (PMN) adhesion to COS cells expressing recombinant transmembrane P-selectin but not to those expressing E-selectin. In addition, inositol polyanions diminished PMN adhesion to activated endothelial cells under rotation-induced shear stress, a process known to require L-selectin function. In vivo, the effects of inositol polyanions were studied in two murine models of acute inflammation. Intravenously administered InsP(6), (two doses of 40 mu mol/kg) inhibited PMN accumulation in thioglycolate-induced inflammation (55 +/- 10% inhibition) and in zymosan-induced inflammation (61 L 4% inhibition), InsP(5) and Ins(6), also inhibited inflammation in these models, although higher doses were required for InsS(6). In conclusion, inositol polyanions are noncarbohydrate small molecules that inhibit L- and P-selectin function in vitro and inflammation in vivo.	UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, SEATTLE, WA 98121 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Bristol-Myers Squibb				Schultz, Carsten/0000-0002-5824-2171				ARNONE A, 1974, NATURE, V249, P34, DOI 10.1038/249034a0; ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P2292, DOI 10.1073/pnas.89.6.2292; ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; ARUFFO A, 1992, CURRENT PROTOCOLS MO; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BENESCH R, 1976, BIOCHEMISTRY-US, V15, P3396, DOI 10.1021/bi00660a035; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BEVILACQUA MP, 1994, ANNU REV MED, V45, P361, DOI 10.1146/annurev.med.45.1.361; BEVILACQUA MP, 1993, THROMB HAEMOSTASIS, V70, P152; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BURKE CJ, 1993, BIOCHEMISTRY-US, V32, P6419, DOI 10.1021/bi00076a015; Cosgrove D., 1980, INOSITOL PHOSPHATES; DABORA JM, 1991, J BIOL CHEM, V266, P23637; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GEOFFROY JS, 1989, J CELL BIOL, V109, P2463, DOI 10.1083/jcb.109.5.2463; GERSONDE K, 1981, TOXICOLOGY, V22, P279, DOI 10.1016/0300-483X(81)90022-6; GRAF E, 1987, J BIOL CHEM, V262, P11647; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; GUSE AH, 1992, J IMMUNOL, V149, P2452; GUSE AH, 1991, J BIOL CHEM, V266, P24498; HESLOP JP, 1985, J EXP BIOL, V119, P395; HOLLENBAUGH D, 1993, BIOCHEMISTRY-US, V32, P2960, DOI 10.1021/bi00063a006; IMAI Y, 1992, GLYCOBIOLOGY, V2, P373, DOI 10.1093/glycob/2.4.373; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; KOTOVUORI P, 1993, GLYCOBIOLOGY, V3, P131, DOI 10.1093/glycob/3.2.131; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; LARKIN M, 1992, J BIOL CHEM, V267, P13661; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LEY K, 1991, AM J PHYSIOL, V260, pH1667, DOI 10.1152/ajpheart.1991.260.5.H1667; LEY K, 1993, BLOOD, V81, P177; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MULLIGAN MS, 1993, J EXP MED, V178, P623, DOI 10.1084/jem.178.2.623; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; NELSON RM, 1993, BLOOD, V82, P3253; NELSON RM, 1993, J CLIN INVEST, V91, P1157, DOI 10.1172/JCI116275; NELSON RM, 1992, S QUANT BIOL, V57, P271; NICKOLOFF BJ, 1990, J INVEST DERMATOL, V94, pS151, DOI 10.1111/1523-1747.ep12876134; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PERICH JW, 1987, TETRAHEDRON LETT, V28, P101, DOI 10.1016/S0040-4039(00)95660-0; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; PITTET D, 1989, J BIOL CHEM, V264, P18489; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; RAO PS, 1991, ANN THORAC SURG, V52, P908, DOI 10.1016/0003-4975(91)91254-S; SIREN M, 1991, ACS SYM SER, V463, P103; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; SLODKI ME, 1987, IND POLYSACCHARIDES, P109; SPERTINI O, 1991, J IMMUNOL, V147, P2565; SPERTINI O, 1991, J IMMUNOL, V147, P942; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; STOOLMAN LM, 1984, J CELL BIOL, V99, P1535, DOI 10.1083/jcb.99.4.1535; SZWERGOLD BS, 1987, BIOCHEM BIOPH RES CO, V149, P874, DOI 10.1016/0006-291X(87)90489-X; TANGELDER GJ, 1991, BLOOD, V77, P1565; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; ULICH TR, 1991, AM J PATHOL, V138, P1485; VALLEJO M, 1987, NATURE, V330, P656, DOI 10.1038/330656a0; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WONG NS, 1992, BIOCHEM J, V286, P459, DOI 10.1042/bj2860459; YEDNOCK TA, 1987, J CELL BIOL, V104, P713, DOI 10.1083/jcb.104.3.713	73	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15060	15066						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7515048				2022-12-25	WOS:A1994NP73800035
J	YU, JS; YANG, SD				YU, JS; YANG, SD			OKADAIC ACID, A SERINE/THREONINE PHOSPHATASE INHIBITOR, INDUCES TYROSINE DEPHOSPHORYLATION INACTIVATION OF PROTEIN-KINASE F-A/GSK-3-ALPHA IN A431 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLYCOGEN-SYNTHASE KINASE-3; RABBIT SKELETAL-MUSCLE; BRAIN MICROTUBULES; ACTIVATING FACTOR; CROSS-LINKING; SYNAPSIN-I; PIG BRAIN; PHOSPHORYLATION; FA; IDENTIFICATION	The signal transduction mechanism of protein kinase F-A/GSK-3 alpha by tyrosine phosphorylation in A431 cells was investigated. Kinase F(A)GSK-3 alpha was found to exist in a highly tyrosine-phosphorylated/activated state in resting cells but could be tyrosine-dephosphorylated and inactivated down to less than 15% of control values in a concentration-dependent manner by 50-400 nM okadaic acid (a specific inhibitor of protein phosphatase types 1 and 2A), as demonstrated by metabolic P-32 labeling the cells, followed by immunoprecipitation and two dimensional phosphoamino acid analysis and by immunodetection in an anti-kinase F-A/GSK-3 alpha immunoprecipitate kinase assay. Taken together, the results provide initial evidence that serine/threonine phosphatase(s) may play a role involved in the modulation of kinase F-A/GSK-3 alpha activity in cells, suggesting an involvement of serine/ threonine dephosphorylation in the modulation of tyrosine phosphorylation and activation of protein kinase F-A/GSK-3 alpha, representing a new mode of signal transduction pathway for the regulation of this multisubstrate protein kinase in cells.	NATL TSING HUA UNIV, INST BIOMED SCI, HSINCHU, TAIWAN; CHANG GUNG MED COLL, INST BASIC MED, TAYUAN, TAIWAN	National Tsing Hua University; Chang Gung University				Yu, Jau-Song/0000-0002-4295-983X				BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DENT P, 1989, FEBS LETT, V248, P67, DOI 10.1016/0014-5793(89)80433-8; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; GUAN RJ, 1991, J BIOL CHEM, V266, P8262; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HARLOW E, 1988, ANTIBODIES LABORATOR; HEMMINGS BA, 1981, EUR J BIOCHEM, V119, P443, DOI 10.1111/j.1432-1033.1981.tb05628.x; HEMMINGS BA, 1982, EUR J BIOCHEM, V127, P473; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; HUGHES K, 1992, BIOCHEM J, V288, P309, DOI 10.1042/bj2880309; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKIE K, 1989, J NEUROSCI, V9, P1883; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; Reichlin M, 1980, Methods Enzymol, V70, P159; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TANIUCHI M, 1986, J BIOL CHEM, V261, P3342; VANDENHEEDE JR, 1980, J BIOL CHEM, V255, P1768; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; YANG SD, 1987, J NEUROCHEM, V48, P160, DOI 10.1111/j.1471-4159.1987.tb13141.x; YANG SD, 1986, J BIOL CHEM, V261, P5590; YANG SD, 1993, J NEUROCHEM, V61, P1742, DOI 10.1111/j.1471-4159.1993.tb09811.x; YANG SD, 1986, J BIOL CHEM, V261, P1786; YANG SD, 1992, BIOCHEM BIOPH RES CO, V184, P973, DOI 10.1016/0006-291X(92)90686-F; YANG SD, 1992, J PROTEIN CHEM, V11, P539, DOI 10.1007/BF01025031; YANG SD, 1980, J BIOL CHEM, V255, P1759; YANG SD, 1991, J PROTEIN CHEM, V10, P171, DOI 10.1007/BF01024781; YANG SD, 1993, BIOCHEM BIOPH RES CO, V193, P1202, DOI 10.1006/bbrc.1993.1753; YANG SD, 1993, J PROTEIN CHEM, V12, P393, DOI 10.1007/BF01025039; YANG SD, 1992, DIABETES, V41, P68, DOI 10.2337/diabetes.41.1.68; YANG SD, 1991, ADV PROT PHOSPHATASE, V6, P133; YU JS, 1993, J PROTEIN CHEM, V12, P667, DOI 10.1007/BF01024925; YU JS, 1989, J PROTEIN CHEM, V8, P499, DOI 10.1007/BF01026435	37	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14341	14344						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514166				2022-12-25	WOS:A1994NM06500004
J	MISRA, UK; CHU, TC; GAWDI, G; PIZZO, SV				MISRA, UK; CHU, TC; GAWDI, G; PIZZO, SV			EVIDENCE FOR A 2ND ALPHA(2)-MACROGLOBULIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; LIPOPROTEIN RECEPTOR; ALPHA-MACROGLOBULIN; BINDING DOMAIN; FAST FORMS; INOSITOL TRISPHOSPHATE; PLASMINOGEN-ACTIVATOR; CHYLOMICRON REMNANTS; MURINE MACROPHAGES; APOLIPOPROTEIN-E	alpha(2)-Macroglobulin (alpha(2)M)-methylamine binds to purified low density lipoprotein receptor-related protein (LRP), and it is assumed that LRP functions as the alpha(2)M receptor in vivo. Binding of alpha(2)M-methylamine to macrophage receptors elevates intracellular calcium ([Ca2+](i)), inositol phosphates, and cyclic AMP. We have employed human alpha(2)M-methylamine and recombinant receptor binding fragment (RBF) to study transduction mechanisms. Macrophages exposed to either ligand demonstrated a rapid rise in [Ca2+](i). Since the 39-kDa LRP/alpha(2)M receptor-associated protein (RAP) blocks alpha(2)M binding to LRP, we explored the effects of RAP upon signaling. Pretreatment of macrophages with RAP did not block the increase in [Ca2+], elicited by alpha(2)M-methylamine or RBF, suggesting a distinct binding site. RBF also elicited a transient 1.5-2.0 fold increase in inositol 1,4,B-triphosphate. In permeabilized macrophages, GTP gamma S and Gpp(NH)p potentiated and sustained this inositol 1,4,5-triphosphate increase. Preincubation of permeabilized macrophages with GDP beta S abrogated the effects of GTP gamma S. Our results suggest that the signaling alpha(2)M receptor is coupled to a pertussis toxin-insensitive G protein and possibly to a cholera toxin-sensitive G protein. We conclude that macrophages contain a second alpha(2)M receptor that is G protein-coupled.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University			Chu, Charleen/B-1601-2008	Chu, Charleen/0000-0002-5052-8271	NCI NIH HHS [CA-29589] Funding Source: Medline; NHLBI NIH HHS [HL-24066] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA029589] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024066, R37HL024066] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P709; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHOI SY, 1993, J BIOL CHEM, V268, P15804; CHU CT, 1993, J IMMUNOL, V150, P48; ENGHILD JJ, 1989, BIOCHEMISTRY-US, V28, P1400; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLIEMANN J, 1989, BIOCHIM BIOPHYS ACTA, V980, P326, DOI 10.1016/0005-2736(89)90320-9; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAACK BM, 1993, J IMMUNOL, V150, P2599; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1990, J BIOL CHEM, V265, P21355; HOFFMAN M, 1983, BIOCHIM BIOPHYS ACTA, V760, P421, DOI 10.1016/0304-4165(83)90384-7; HUETTINGER M, 1992, J BIOL CHEM, V267, P18551; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; JACKLE S, 1993, J LIPID RES, V34, P309; JENSEN PEH, 1989, BIOCHEM ARCH, V5, P171; JOHNSON WJ, 1982, SCIENCE, V218, P574, DOI 10.1126/science.6289443; JONES LG, 1988, CIRC RES, V62, P299, DOI 10.1161/01.RES.62.2.299; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LAMARRE J, 1991, LAB INVEST, V65, P3; MILLIGAN G, 1991, TRENDS PHARMACOL SCI, V12, P207, DOI 10.1016/0165-6147(91)90551-3; MISRA UK, 1993, BIOCHEM J, V290, P885, DOI 10.1042/bj2900885; MITCHELL FM, 1993, BIOCHEM J, V293, P495, DOI 10.1042/bj2930495; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; OKONOGI K, 1991, J BIOL CHEM, V266, P10305; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PIZZO SV, 1988, ISI ATLAS-BIOCHEM, V1, P242; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SALVESEN G, 1992, FEBS LETT, V313, P198, DOI 10.1016/0014-5793(92)81443-P; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SOTTRUPJENSEN L, 1986, FEBS LETT, V205, P20, DOI 10.1016/0014-5793(86)80857-2; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; UHING RJ, 1991, BIOCHIM BIOPHYS ACTA, V1093, P115, DOI 10.1016/0167-4889(91)90111-A; VANDIJK MCM, 1992, J BIOL CHEM, V267, P17732; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; VANDIJK MCM, 1992, BIOCHEM J, V287, P447, DOI 10.1042/bj2870447; VANLEUVEN F, 1986, J BIOL CHEM, V261, P1369; VANLEUVEN F, 1992, J BIOL CHEM, V267, P17732; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	56	100	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12541	12547						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7513689				2022-12-25	WOS:A1994NH71600029
J	NAKAYAMA, I; KAWAHARA, Y; TSUDA, T; OKUDA, M; YOKOYAMA, M				NAKAYAMA, I; KAWAHARA, Y; TSUDA, T; OKUDA, M; YOKOYAMA, M			ANGIOTENSIN-II INHIBITS CYTOKINE-STIMULATED INDUCIBLE NITRIC-OXIDE SYNTHASE EXPRESSION IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCTION; LIPOPOLYSACCHARIDE; PROLIFERATION; MACROPHAGES; ACTIVATION; RECEPTORS; CLONING; BINDING; INJURY	In cultured vascular smooth muscle cells (VSMC), inflammatory cytokines such as interleukin 1beta (IL-1beta) and tumor necrosis factor a stimulated nitric oxide (NO) production via the expression of an inducible type of NO synthase (iNOS). A potent vasoconstrictor, angiotensin II (Ang II), which causes a rapid phospholipase C-mediated phosphoinositide hydrolysis via the Ang II type 1 (AT1) receptor in VSMC, by itself did not stimulate the production of nitrite, a stable metabolite of NO, but dose dependently inhibited the IL-1beta-induced nitrite production. This inhibitory effect of Ang II was blocked by an AT1 receptor antagonist, CV-11974, but not by an Ang II type 2 receptor antagonist, PD 123319. The presence of Ang II during the early induction phase of iNOS was required for this inhibition. Consistently, Ang II suppressed IL-1beta-induced increases in iNOS mRNA and protein levels. Ang II also inhibited increases in nitrite production and iNOS mRNA and protein levels caused by tumor necrosis factor alpha. A protein kinase C-activating phorbol ester, phorbol 12-myristate 13-acetate, and a membrane-permeable diacylglycerol, 1,2-dioctanoyl-glycerol, similarly inhibited the IL-1beta-induced nitrite production and iNOS mRNA and protein expression, although repetitive additions were needed in the case of diacylglycerol. These results indicate that Ang II negatively modulates cytokine-induced NO production by blocking iNOS expression via the AT1 receptor in VSMC and suggest that protein kinase C could be involved in this process.	KOBE UNIV,SCH MED,DEPT INTERNAL MED,DIV 1,7-5-1 KUSUNOKI CHO,CHUO KU,KOBE 650,JAPAN	Kobe University								ASAOKA Y, 1991, P NATL ACAD SCI USA, V88, P8681, DOI 10.1073/pnas.88.19.8681; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUMPUS FM, 1991, HYPERTENSION, V17, P720, DOI 10.1161/01.HYP.17.5.720; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DINERMAN JL, 1993, CIRC RES, V73, P217, DOI 10.1161/01.RES.73.2.217; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; FLEMING I, 1990, BIOCHEM BIOPH RES CO, V171, P562, DOI 10.1016/0006-291X(90)91183-S; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HAUSCHILDT S, 1990, BIOCHEM J, V270, P351, DOI 10.1042/bj2700351; HORTELANO S, 1992, J BIOL CHEM, V267, P24937; JOLY GA, 1992, CIRC RES, V71, P331, DOI 10.1161/01.RES.71.2.331; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; KOIDE M, 1993, J BIOL CHEM, V268, P24959; KOIDE M, 1993, FEBS LETT, V318, P213, DOI 10.1016/0014-5793(93)80514-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBBY P, 1991, LAB INVEST, V64, P5; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NODA M, 1993, BIOCHEM PHARMACOL, V46, P311; OHSHIMA H, 1992, BIOCHEM BIOPH RES CO, V187, P1291, DOI 10.1016/0006-291X(92)90443-O; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	26	119	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11628	11633						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512570				2022-12-25	WOS:A1994NF96600097
J	KOLB, JP; PAULEUGENE, N; DAMAIS, C; YAMAOKA, K; DRAPIER, JC; DUGAS, B				KOLB, JP; PAULEUGENE, N; DAMAIS, C; YAMAOKA, K; DRAPIER, JC; DUGAS, B			INTERLEUKIN-4 STIMULATES CGMP PRODUCTION BY IFN-GAMMA-ACTIVATED HUMAN MONOCYTES - INVOLVEMENT OF THE NITRIC-OXIDE SYNTHASE PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONONUCLEAR PHAGOCYTES; TUMOR-NECROSIS-FACTOR; INTERFERON-GAMMA; L-ARGININE; MURINE MACROPHAGES; SUPEROXIDE PRODUCTION; SIGNAL-TRANSDUCTION; EFFECTOR MECHANISM; NITROGEN-OXIDES; IL-4	Resting human blood monocytes from some donors were found to produce a small amount of 3'-5' guanine cyclic monophosphate (CGMP) in response to interleukin 4 (IL-4). A much higher response was observed when monocytes were preincubated with interferon (IFN-gamma), which alone was ineffective. Preincubation of monocytes with IL-4 led, in contrast, to their subsequent incapacity to generate cGMP in response to IL-4. The accumulation of cGMP induced by IL-4 in IFN-gamma preincubated monocytes was dose-dependent and peaked about 15 min after its addition. It was inhibited in the presence of N(G)-mono-methyl-L-arginine (L-NMMA), an inhibitor of the nitric oxide synthase pathway. This suppressive effect Of L-NMMA was reverted by an excess Of L- but not of D-arginine. Accumulation of cGMP was significantly reduced by addition of soluble guanylyl cyclase inhibitors, such as LY83853 and methylene blue, but was not impaired in the presence of EGTA, suggesting that the pathway involved is calcium independent. In addition, IL-4 induced an increased secretion of nitrite by monocytes, that was potentiated by IFN-gamma and inhibited by L-NMMA. Taken together, these results suggest that the sequential exposure of monocytes to IFN-gamma and IL-4 elicits the release of NO from L-arginine, which in turn is capable to stimulate soluble guanylyl cyclase.	CHU PITIE SALPETRIERE, INSERM, U313, F-75634 PARIS 13, FRANCE; INSERM, F-34100 MONTPELLIER, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	KOLB, JP (corresponding author), INST CURIE, INSERM, U365, 26 RUE ULM, F-75231 PARIS 05, FRANCE.							ABRAMSON SL, 1990, J IMMUNOL, V144, P625; BECKER S, 1990, CELL IMMUNOL, V129, P351, DOI 10.1016/0008-8749(90)90211-9; BELENKY SN, 1993, J LEUKOCYTE BIOL, V53, P498, DOI 10.1002/jlb.53.5.498; BOGDAN C, 1991, EUR J IMMUNOL, V21, P327, DOI 10.1002/eji.1830210213; CAMERON ML, 1990, AM REV RESPIR DIS, V142, P1313, DOI 10.1164/ajrccm/142.6_Pt_1.1313; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; DENIS M, 1991, J LEUKOCYTE BIOL, V49, P380, DOI 10.1002/jlb.49.4.380; DRANSFIELD I, 1988, IMMUNOLOGY, V63, P491; DRAPIER JC, 1988, EUR J IMMUNOL, V18, P1587, DOI 10.1002/eji.1830181018; FIGDOR CG, 1992, IL 4 STRUCTURE FUNCT, P187; FINNEY M, 1990, EUR J IMMUNOL, V20, P151, DOI 10.1002/eji.1830200122; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GREEN SJ, 1991, J LEUKOCYTE BIOL, V50, P93, DOI 10.1002/jlb.50.1.93; HAMILTON TA, 1987, IMMUNOL TODAY, V8, P151, DOI 10.1016/0167-5699(87)90145-9; HIBBS JB, 1992, J CLIN INVEST, V89, P867, DOI 10.1172/JCI115666; HIBBS JB, 1990, INT CONGR SER, V897, P189; HUNT NCA, 1992, J HEPATOL, V14, P146, DOI 10.1016/0168-8278(92)90150-N; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IGNARRO LJ, 1990, PHARMACOL TOXICOL, V67, P1, DOI 10.1111/j.1600-0773.1990.tb00772.x; KARLSEN AE, 1993, ENDOTHELIUM S, V1, pS26; LEE CE, 1993, CELL IMMUNOL, V146, P171, DOI 10.1006/cimm.1993.1015; LEHN M, 1989, J IMMUNOL, V143, P3020; LIEW FY, 1991, EUR J IMMUNOL, V21, P2489, DOI 10.1002/eji.1830211027; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MAIER R, 1993, ENDOTHELIUM S, V1, pS48; MARTIN JHJ, 1993, J IMMUNOL, V150, P3478; MAUTINO G, 1994, IN PRESS J LEUKOCYTE; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUNOZFERNANDEZ MA, 1992, IMMUNOL LETT, V33, P35, DOI 10.1016/0165-2478(92)90090-B; MURRAY HW, 1992, J INFECT DIS, V165, P513, DOI 10.1093/infdis/165.3.513; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NUSSLER AK, 1992, J EXP MED, V176, P261, DOI 10.1084/jem.176.1.261; OCHOA JB, 1992, J NATL CANCER I, V84, P864, DOI 10.1093/jnci/84.11.864; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; PAULEUGENE N, 1992, J IMMUNOL, V149, P3066; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; SALVEMINI D, 1989, P NATL ACAD SCI USA, V86, P6328, DOI 10.1073/pnas.86.16.6328; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHNEEMANN M, 1993, J INFECT DIS, V167, P1358, DOI 10.1093/infdis/167.6.1358; SCHWARTZ D, 1963, METHODES STATISTIQUE, P151; SIEBERT PD, 1992, CLONTECHNIQUES, V7, P1; STUEHR DJ, 1987, J IMMUNOL, V139, P518; STUEHR DJ, 1992, ADV ENZYMOL, V65, P287; TEVELDE AA, 1988, J IMMUNOL, V140, P1548	45	105	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9811	9816						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511593				2022-12-25	WOS:A1994NE05300065
J	FISONE, G; CHENG, SXJ; NAIRN, AC; CZERNIK, AJ; HEMMINGS, HC; HOOG, JO; BERTORELLO, AM; KAISER, R; BERGMAN, T; JORNVALL, H; APERIA, A; GREENGARD, P				FISONE, G; CHENG, SXJ; NAIRN, AC; CZERNIK, AJ; HEMMINGS, HC; HOOG, JO; BERTORELLO, AM; KAISER, R; BERGMAN, T; JORNVALL, H; APERIA, A; GREENGARD, P			IDENTIFICATION OF THE PHOSPHORYLATION SITE FOR CAMP-DEPENDENT PROTEIN-KINASE ON NA+,K+-ATPASE AND EFFECTS OF SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+-ATPASE ACTIVITY; POLYACRYLAMIDE GELS; CYCLIC-AMP; CAUSES INHIBITION; XENOPUS OOCYTES; TUBULE CELLS; RAT-BRAIN; (NA++K+)-ATPASE; STIMULATION; BINDING	Phosphorylation of purified Na+,K+-ATPase by cAMP-dependent protein kinase (protein kinase A) decreases the activity of this enzyme. We have now shown, using several experimental approaches, that a highly conserved seryl residue on the catalytic (alpha) subunit of Na+,K+-ATPase, corresponding to Ser(943) of the rat alpha 1 isoform, is the phosphorylation site for protein kinase A. cDNAs corresponding to wild-type Na+,K+-ATPase and Na+,K+-ATPase in which Ser(943) was mutated to Ala were transfected into COS cells. Treatment of the transfected cells with forskolin plus 3-isobutyl-1-methylxanthine resulted in a decrease in the activity of the wild-type enzyme but not in that of the mutated enzyme. The results suggest that, in intact cells, the activity of the Na+,K+-ATPase is regulated in part by signal transduction pathways that use protein kinase A-dependent phosphorylation of the Na+,K+-ATPase alpha subunit.	ROCKEFELLER UNIV, MOLEC & CELLULAR NEUROSCI LAB, NEW YORK, NY 10021 USA; KAROLINSKA INST, ST GORANS CHILDRENS HOSP, DEPT PEDIAT, S-11281 STOCKHOLM, SWEDEN; CORNELL UNIV, MED CTR, COLL MED, DEPT ANESTHESIOL, NEW YORK, NY 10021 USA; KAROLINSKA INST, DEPT CHEM 1, S-17177 STOCKHOLM, SWEDEN	Rockefeller University; Karolinska Institutet; Cornell University; Karolinska Institutet				Nairn, Angus/0000-0002-7075-0195; Fisone, Gilberto/0000-0002-0719-8000	NIMH NIH HHS [MH-40899] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; APERIA A, 1987, AM J PHYSIOL, V252, pF39, DOI 10.1152/ajprenal.1987.252.1.F39; BEACH RE, 1987, AM J PHYSIOL, V252, pF215, DOI 10.1152/ajprenal.1987.252.2.F215; BERGMAN T, 1987, EUR J BIOCHEM, V169, P9, DOI 10.1111/j.1432-1033.1987.tb13573.x; BERTORELLO AM, 1990, NATURE, V347, P386, DOI 10.1038/347386a0; BERTORELLO AM, 1992, J CELL SCI, V101, P343; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIBALIN AV, 1992, J BIOL CHEM, V267, P22378; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CZERNIK AJ, 1991, METHOD ENZYMOL, V201, P264; FRYCKSTEDT J, 1992, ACTA PHYSIOL SCAND, V144, P185, DOI 10.1111/j.1748-1716.1992.tb09284.x; HERMENEGILDO C, 1992, J NEUROCHEM, V58, P1246, DOI 10.1111/j.1471-4159.1992.tb11335.x; HORIUCHI A, 1993, MOL PHARMACOL, V43, P281; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IBARRA F, 1993, P NATL ACAD SCI USA, V90, P21, DOI 10.1073/pnas.90.1.21; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGHAM RB, 1982, BIOCHIM BIOPHYS ACTA, V688, P475, DOI 10.1016/0005-2736(82)90359-5; LOWNDES JM, 1990, BIOCHIM BIOPHYS ACTA, V1052, P143, DOI 10.1016/0167-4889(90)90069-P; LYNCH CJ, 1986, J BIOL CHEM, V261, P4551; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NELLES LP, 1976, ANAL BIOCHEM, V73, P522, DOI 10.1016/0003-2697(76)90202-5; PESSIN MS, 1993, IN PRESS 1992 P WENN; SATOH T, 1992, J CLIN INVEST, V89, P1496, DOI 10.1172/JCI115740; SHAHEDI M, 1992, PFLUG ARCH EUR J PHY, V420, P269, DOI 10.1007/BF00374458; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SHYIAN AW, 1990, P NATL ACAD SCI USA, V87, P1178; SKOU JC, 1979, BIOCHIM BIOPHYS ACTA, V567, P436, DOI 10.1016/0005-2744(79)90129-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VASILETS LA, 1992, J MEMBRANE BIOL, V125, P119; YEH LA, 1983, J BIOL CHEM, V258, P6567	35	140	143	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9368	9373						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510709				2022-12-25	WOS:A1994NB41100108
J	NATHANSON, MH; FALLON, MB; PADFIELD, PJ; MARANTO, AR				NATHANSON, MH; FALLON, MB; PADFIELD, PJ; MARANTO, AR			LOCALIZATION OF THE TYPE-3 INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR IN THE CA2+ WAVE TRIGGER ZONE OF PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSMEMBRANE CONDUCTANCE REGULATOR; ADRENAL CHROMAFFIN CELLS; AGONIST-INDUCED CHANGES; CYTOSOLIC CALCIUM; SECRETION; PROTEINS; RELEASE; FURA-2; CA-2+	Agonist-induced cytosolic Ca2+ (Ca-i(2+)) signals begin as apical-to-basal Ca-i(2+) waves in pancreatic acinar cells and in other polarized epithelia. However, the basis of this polarized Ca-i(2+) signaling pattern is unknown. Here we use immunocytochemistry to demonstrate that the type 3 inositol trisphosphate receptor is localized to the extreme apex of pancreatic acinar cells, the region which corresponds to the trigger zone from which Ca-i(2+) signals originate in this cell type (Kasai, H., Li, Y.X., and Miyashita, Y. (1993) Cell 74, 669-677). We also show that inositol trisphosphate-mediated Ca2+ release induces amylase release from permeabilized pancreatic acini. Since Ca-i(2+) signals begin by inositol trisphosphate mediated Ca-i(2+) release, these findings suggest that localization of the type 3 inositol trisphosphate receptor to the trigger zone is responsible for the generation of apical-to-basal Ca-i(2+) waves, and that this organization may be important for regulating apical exocytosis in pancreatic acinar cells.	ST LOUIS UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63104; TUFTS UNIV,ST ELIZABETHS MED CTR,SCH MED,DEPT MED,BOSTON,MA 02135; TUFTS UNIV,ST ELIZABETHS MED CTR,SCH MED,DEPT BIOMED RES,BOSTON,MA 02135	Saint Louis University; St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University	NATHANSON, MH (corresponding author), YALE UNIV,SCH MED,CTR LIVER,LIVER STUDY UNIT,1080 LMP,333 CEDAR ST,NEW HAVEN,CT 06510, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989, K11DK002030, R29DK044475] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK34989, DK02030, DK44475] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRAND SH, 1991, J BIOL CHEM, V266, P1899; CHEEK TR, 1989, J CELL BIOL, V109, P1219, DOI 10.1083/jcb.109.3.1219; FITZ JG, 1993, J CLIN INVEST, V91, P319, DOI 10.1172/JCI116188; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KITAGAWA M, 1990, AM J PHYSIOL, V259, pG157, DOI 10.1152/ajpgi.1990.259.2.G157; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MARINO CR, 1991, J CLIN INVEST, V88, P712, DOI 10.1172/JCI115358; MARUYAMA Y, 1988, J PHYSIOL-LONDON, V406, P299, DOI 10.1113/jphysiol.1988.sp017381; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; NATHANSON MH, 1993, HEPATOLOGY, V18, pA134; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; PADFIELD PJ, 1991, BIOCHEM BIOPH RES CO, V174, P536, DOI 10.1016/0006-291X(91)91450-Q; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; SALUJA AK, 1992, J BIOL CHEM, V267, P11202; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SUDHOF TC, 1991, EMBO J, V10, P199; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0	27	188	188	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4693	4696						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508924				2022-12-25	WOS:A1994MX57100001
J	KNAUS, HG; GARCIACALVO, M; KACZOROWSKI, GJ; GARCIA, ML				KNAUS, HG; GARCIACALVO, M; KACZOROWSKI, GJ; GARCIA, ML			SUBUNIT COMPOSITION OF THE HIGH-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNEL FROM SMOOTH-MUSCLE, A REPRESENTATIVE OF THE MSLO AND SLOWPOKE FAMILY OF POTASSIUM CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SKELETAL-MUSCLE; PROTEIN; BINDING; BRAIN; CHARYBDOTOXIN; DROSOPHILA; SEQUENCE; RECEPTOR	High conductance Ca2+-activated K+ (maxi-K) channels from bovine tracheal and aortic smooth muscle membranes have been purified employing monoiodotyrosine charybdotoxin binding as a marker for the channel and conventional chromatographic techniques. This K+ channel is composed of two subunits, alpha and beta, of 62 and 31 kDa, respectively. After sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the electroeluted tracheal smooth muscle alpha-subunit was subjected to tryptic cleavage and a number of fragments were isolated by microbore C-18 high performance liquid chromatography. Several of these peptides were microsequenced using Edman degradation techniques. Amino acid sequence information obtained from these fragments reveals the existence of very high sequence homology with the recently cloned mSlo maxi-K channel (Butler, A., Tsunoda, S., McCobb, D. P., Wei, A., and Salkoff, L. (1993) Science 261, 221-224). A specific antipeptide antibody directed against the amino acid sequence of one of the fragments of the alpha-subunit is capable of specifically immunoprecipitating not only the denatured I-125-Bolton-Hunter-labeled alpha-subunit, but also, under nondenaturing conditions, the complex of alpha and beta subunits, demonstrating specific noncovalent association of both subunits. Thus, our results indicate that the alpha-subunit of the purified tracheal smooth muscle maxi-K channel is a member of the mSlo family of K+ channels and forms a noncovalent complex with a beta-subunit. It is concluded that the extensive biochemical information acquired to date on smooth muscle charybdotoxin receptors is pertinent to the structure of native maxi-K channels.	MERCK RES LABS, DEPT MEMBRANE BIOCHEM & BIOPHYS, RAHWAY, NJ 07065 USA; UNIV INNSBRUCK, DEPT BIOCHEM PHARMACOL, A-6020 INNSBRUCK, AUSTRIA	Merck & Company; University of Innsbruck								ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GARCIACALVO M, 1991, BIOCHEMISTRY-US, V30, P11157, DOI 10.1021/bi00110a020; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; SCOTT VES, 1990, J BIOL CHEM, V265, P20094; SEAGAR MJ, 1986, BIOCHEMISTRY-US, V25, P4051, DOI 10.1021/bi00362a010; SMITH JA, 1993, CURRENT PROTOCOLS MO; STOSCHECK CM, 1987, ANAL BIOCHEM, V160, P301, DOI 10.1016/0003-2697(87)90051-0; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; VAZQUEZ J, 1989, J BIOL CHEM, V264, P20902	19	189	192	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3921	3924						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508434				2022-12-25	WOS:A1994MW98900005
J	SHIMADA, M; HOSAKA, H; TAKAKU, H; SMITH, JS; ROTH, MJ; INOUYE, S; INOUYE, M				SHIMADA, M; HOSAKA, H; TAKAKU, H; SMITH, JS; ROTH, MJ; INOUYE, S; INOUYE, M			SPECIFICITY OF PRIMING REACTION OF HIV-1 REVERSE-TRANSCRIPTASE, 2'-OH OR 3'-OH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note								It has not been unambiguously demonstrated whether the priming reaction of human immunodeficiency virus, type 1 (HIV-1) cDNA synthesis initiates with either the 2'-OH or 3'-OH group of the 3'-terminal adenosine residue of tRNA(Lys-3). In this report, we synthesized tRNA(Lys-3) Of which the 3'-terminal adenosine residue lacks either a 2'-OH or 3'-OH. These tRNA molecules were used for the HIV-1 cDNA-priming reaction in a cell-free system consisting of a 141-base RNA template and purified HIV-1 reverse transcriptase. It was found that under the conditions used, the tRNA containing the 2'-deoxyadenosine was able to initiate the cDNA synthesis, while the tRNA with the 3'-deoxyadenosine was not. The results show that retroviral reverse transcriptase specifically primes cDNA synthesis from the 3'-OH group. This is in contrast to bacterial reverse transcriptase, which initiates cDNA synthesis from the 2'-OH group of an internal guanosine residue of a template RNA.	CHIBA INST TECHNOL,DEPT IND CHEM,NARASHINO,CHIBA 275,JAPAN	Chiba Institute of Technology	SHIMADA, M (corresponding author), ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854, USA.		Roth, Monica/AAN-8742-2020; Inouye, Sharon/R-7216-2019					ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751; BENN S, 1985, SCIENCE, V230, P949, DOI 10.1126/science.2997922; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; COBRINIK D, 1988, J VIROL, V62, P3622, DOI 10.1128/JVI.62.10.3622-3630.1988; INOUYE M, 1991, ANNU REV MICROBIOL, V45, P163; RICHTERCOOK NJ, 1992, J BIOL CHEM, V267, P15952; SAKATSUME O, 1991, TETRAHEDRON, V47, P8717, DOI 10.1016/S0040-4020(01)96193-9; WEISS R, 1985, RNA TUMOR VIRUS, P76	9	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3925	3927						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508435				2022-12-25	WOS:A1994MW98900006
J	KLATT, P; SCHMIDT, K; BRUNNER, F; MAYER, B				KLATT, P; SCHMIDT, K; BRUNNER, F; MAYER, B			INHIBITORS OF BRAIN NITRIC-OXIDE SYNTHASE - BINDING-KINETICS, METABOLISM, AND ENZYME INACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC ENDOTHELIAL-CELLS; METHYL-L-ARGININE; RELAXING FACTOR; PORCINE CEREBELLUM; NG-NITROARGININE; GUANYLYL CYCLASE; PURIFICATION; MACROPHAGE; IDENTIFICATION; BIOSYNTHESIS	Nitric oxide (NO) is synthesized from L-arginine by different NO synthase isozymes, which are inhibited by the substrate analogs N(G)-methyl- and N(G)-nitro-L-arginine. We studied binding of H-3-labeled N(G)-nitro-L-arginine to purified brain NO synthase and compared the data with results obtained in enzyme kinetic experiments. Binding data revealed a single binding site for N(G)-nitro-L-[H-3]arginine (K(I) = 0.17 muM). Binding was competitively antagonized by L-arginine (K(I) = 2.9 mum). The half-time of dissociation was remarkably slow (9.4 min) and closely correlated with the time necessary for surmounting NO synthase inhibition by dilution. Although an apparently less potent inhibitor, N(G)-methyl-L-arginine exhibited the same affinity for brain NO synthase as the nitro derivative (K(I) = 0.17 muM), and in initial rate experiments, almost equal K(I) values were obtained for N(G)-methyl-L-arginine (0.61 muM) and N(G)-nitro-L-arginine (0.53 muM). However, after prolonged incubation periods, N(G)-nitro-L-arginine induced a rapid inactivation of the enzyme, whereas the methyl derivative turned out to be a substrate of NO synthase, which was slowly converted into stoichiometric amounts of NO and L-citrulline.	GRAZ UNIV,INST PHARMACOL & TOXIKOL,UNIV PL 2,A-8010 GRAZ,AUSTRIA	University of Graz			Mayer, Bernd/B-9391-2008	Mayer, Bernd/0000-0002-2921-3494				ARCHER SL, 1992, BIOCHEM BIOPH RES CO, V188, P590, DOI 10.1016/0006-291X(92)91097-A; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNNER F, 1991, BRIT J PHARMACOL, V102, P373, DOI 10.1111/j.1476-5381.1991.tb12181.x; DWYER MA, 1991, BIOCHEM BIOPH RES CO, V176, P1136, DOI 10.1016/0006-291X(91)90403-T; FELDMAN PL, 1993, J MED CHEM, V36, P491, DOI 10.1021/jm00056a009; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; Hammes G.G., 1970, ENZYMES, V2, P67; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; KAWATA S, 1983, BIOCHEM PHARMACOL, V32, P3723; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KLATT P, 1993, J BIOL CHEM, V268, P14781; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KLATT P, 1992, J BIOL CHEM, V267, P11374; KNOWLES RG, 1990, BIOCHEM J, V269, P207, DOI 10.1042/bj2690207; KWON NS, 1990, J BIOL CHEM, V265, P13442; LEONE AM, 1991, J BIOL CHEM, V266, P23790; MAELICKE A, 1977, J BIOL CHEM, V252, P4811; MAYER B, 1991, J CARDIOVASC PHARM, V17, pS46, DOI 10.1097/00005344-199117003-00009; MAYER B, 1992, J NEUROCHEM, V59, P2024; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MAYER B, 1993, SEMIN NEUROSCI, V5, P197, DOI 10.1016/S1044-5765(05)80053-3; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURPHY ME, 1991, J BIOL CHEM, V266, P19378; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; OLKEN NM, 1991, BIOCHEM BIOPH RES CO, V177, P828, DOI 10.1016/0006-291X(91)91864-9; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; POU S, 1992, J BIOL CHEM, V267, P24173; PUFAHL RA, 1992, BIOCHEMISTRY-US, V31, P6822, DOI 10.1021/bi00144a024; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TSENG CM, 1993, J APPL PHYSIOL, V74, P549, DOI 10.1152/jappl.1993.74.2.549; WALLACE GC, 1991, J MED CHEM, V34, P1746, DOI 10.1021/jm00109a032; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WINN MJ, 1993, J PHARMACOL EXP THER, V264, P265; WOLFF DJ, 1992, BIOCHEM J, V285, P201, DOI 10.1042/bj2850201; ZHANG J, 1993, BRAIN RES, V606, P56, DOI 10.1016/0006-8993(93)91569-E	51	158	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1674	1680						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507482				2022-12-25	WOS:A1994MR98800023
J	NAGATA, K; TSUJI, T; HANAI, N; IRIMURA, T				NAGATA, K; TSUJI, T; HANAI, N; IRIMURA, T			ROLE OF O-LINKED CARBOHYDRATE CHAINS ON LEUKOCYTE CELL-MEMBRANES IN PLATELET-INDUCED LEUKOCYTE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-SELECTIN CD62; GLYCOPROTEIN LIGAND; T-CELLS; OLIGOSACCHARIDES; NEUTROPHILS; MONOCYTES; ADHESION; IDENTIFICATION; GLYCOSYLATION; BIOSYNTHESIS	We previously reported that activated platelets stimulated neutrophils and monocytes to produce superoxide anion (O-2(-)) through the interaction between P-selectin and its carbohydrate ligand, sialyl Lewis X (sLe(X)) (Nagata, K., Tsuji, T., Todoroki, N., Katagiri, Y., Tanoue, K., Yamazaki, H., Hanai N., and Irimura, T. (1993) J. Immunol. 151, 3267-3273). In the present study, we investigated the role of cell surface carbohydrate chains of leukocytes in this process. Glycoconjugate-specific hydrolytic enzymes and inhibitors of glycosylation processing were applied. Granulocyte-like differentiated HL-60 (gHL-60) cells released an increased amount of O-2(-) in response to activated platelets in a beta-selectin-dependent manner. When HL-60 cells were differentiated in the presence of benzyl-alpha-N-acetylgalactosaminide (Bzl-alpha-GalNAc), an inhibitor of chain elongation of O-linked carbohydrates, the enhanced generation of O-2(-) was abrogated in parallel with decrease in the expression of sLe(X) structure and in the adhesion capacity to activated platelets, In contrast, treatment with swainsonine or 1-deoxymannojirimycin, inhibitors of processing of N-linked carbohydrate chains, did not show such effects. O-Sialoglycoprotease treatment of gHL-60 cells decreased the activated platelet-induced O-2(-) production with concomitant reduction of cell surface sLe(X) expression. Treatment of these cells with N-glycanase did not affect the O-2(-) production. These results strongly suggested that serine/threonine-linked carbohydrate chains containing sLe(X) played an essential role in the P-selectin-mediated leukocyte activation. By Western blotting analysis of gHL-60 cell lysates, we identified two glycoproteins which carried sLe(X) structures and were sensitive to Bzl-alpha-GalNAc treatment.	UNIV TOKYO,FAC PHARMACEUT SCI,DIV CHEM TOXICOL & IMMUNOCHEM,BUNKYO KU,TOKYO 113,JAPAN; KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,MACHIDA 194,TOKYO,JAPAN	University of Tokyo; Kyowa Kirin Ltd								BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FUKUDA MN, 1979, J BIOL CHEM, V254, P5458; GALLAGHER JT, 1985, BIOCHEM J, V231, P115, DOI 10.1042/bj2310115; IMAI Y, 1988, MOL IMMUNOL, V25, P419; KOJIMA N, 1992, BIOCHEM BIOPH RES CO, V182, P1288, DOI 10.1016/0006-291X(92)91872-N; KUAN SF, 1989, J BIOL CHEM, V264, P19271; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MCEVER RP, 1991, J CELL BIOCHEM, V45, P156, DOI 10.1002/jcb.240450206; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; NAGATA K, 1993, J IMMUNOL, V151, P3267; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; PICK E, 1981, J IMMUNOL METHODS, V46, P211, DOI 10.1016/0022-1759(81)90138-1; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; RINDER HM, 1991, BLOOD, V78, P1760; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SHITARA K, 1987, CANCER RES, V47, P1267; SUTHERLAND DR, 1992, J IMMUNOL, V148, P1458; TANOUE K, 1993, PLATELETS, V4, P31, DOI 10.3109/09537109309013193; TSUNEHISA S, 1984, BIOCHIM BIOPHYS ACTA, V797, P10; YAMASHITA Y, 1989, J BIOCHEM-TOKYO, V106, P961, DOI 10.1093/oxfordjournals.jbchem.a122982	27	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23290	23295						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7521876				2022-12-25	WOS:A1994PQ16400060
J	LAFLEUR, DW; FAGIN, JA; FORRESTER, JS; RUBIN, SA; SHARIFI, BG				LAFLEUR, DW; FAGIN, JA; FORRESTER, JS; RUBIN, SA; SHARIFI, BG			CLONING AND CHARACTERIZATION OF ALTERNATIVELY SPLICED ISOFORMS OF RAT TENASCIN - PLATELET-DERIVED GROWTH FACTOR-BB MARKEDLY STIMULATES EXPRESSION OF SPLICED VARIANTS OF TENASCIN MESSENGER-RNA IN ARTERIAL SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; HEXABRACHION TENASCIN; FIBRONECTIN; MIGRATION; FRAGMENTS; PHENOTYPE; ADHESION; SEQUENCE; LAMININ; BINDING	To understand the alteration of extracellular matrix composition evoked by chemotactic factors, we have studied the expression of adhesive (fibronectin) and anti-adhesive (tenascin) proteins in response to platelet-derived growth factor-BB (PDGF-BB), a potent chemoattractant for rat aortic smooth muscle cells (ASMC). PDGF-BB markedly induced two major tenascin mRNA transcripts, whereas fibronectin mRNA levels did not change. The results of immunoprecipitation studies paralleled Northern blot data. Since alternative splicing is responsible for the generation of multiple tenascin mRNAs in other cell types, we studied the effect of chemotactic factors on the relative abundance of tenascin isoforms. The alternatively spliced region of ASMC-derived rat tenascin was amplified and the identity of the products confirmed by sequencing. Three major polymerase chain reaction products were detected: a 1727-base pair unspliced form which was maximal at 2 h and 635- and 362-base pair products which were more abundant at 8 h after treatment with PDGF-BB or angiotensin II, Functional studies showed that the unspliced isoform of human tenascin inhibited attachment of both human and rat ASMC to fibronectin. These results suggest that PDGF-BB markedly up-regulates the expression of tenascin variants, which may bad to destabilization of cell matrix interactions and promotion of cell migration.	UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DIV CARDIOL,LOS ANGELES,CA 90048	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043802] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43802] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUKHIL I, 1990, MATRIX, V10, P98, DOI 10.1016/S0934-8832(11)80176-9; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chiquet-Ehrismann R, 1991, CURR OPIN CELL BIOL, V3, P800, DOI 10.1016/0955-0674(91)90053-2; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOWES AW, 1985, CIRC RES, V56, P139, DOI 10.1161/01.RES.56.1.139; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; DURNAM DM, 1983, ANAL BIOCHEM, V131, P385, DOI 10.1016/0003-2697(83)90188-4; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GLUKHOVA MA, 1989, J CELL BIOL, V109, P357, DOI 10.1083/jcb.109.1.357; GOODMAN SL, 1989, J CELL BIOL, V109, P799, DOI 10.1083/jcb.109.2.799; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; HEDIN U, 1991, AM J PATHOL, V139, P649; HEDIN U, 1988, J CELL BIOL, V107, P307, DOI 10.1083/jcb.107.1.307; HUSMANN K, 1992, J CELL BIOL, V116, P1475, DOI 10.1083/jcb.116.6.1475; Hynes RO, 1990, FIBRONECTIN; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LIGHTNER VA, 1990, J CELL SCI, V95, P263; MERRIL CR, 1980, ANAL BIOCHEM, V105, P361; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; SAGA Y, 1991, GENE, V104, P177, DOI 10.1016/0378-1119(91)90248-A; SHARIFI BG, 1992, J BIOL CHEM, V267, P23910; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; STEIN WD, 1989, CELL SHAPE; WELLER A, 1991, J CELL BIOL, V112, P355, DOI 10.1083/jcb.112.2.355; WOODS A, 1988, COLLAGEN REL RES, V8, P155	29	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20757	20763						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519614				2022-12-25	WOS:A1994PB31700083
J	WADDELL, TK; FIALKOW, L; CHAN, CK; KISHIMOTO, TK; DOWNEY, GP				WADDELL, TK; FIALKOW, L; CHAN, CK; KISHIMOTO, TK; DOWNEY, GP			POTENTIATION OF THE OXIDATIVE BURST OF HUMAN NEUTROPHILS - A SIGNALING ROLE FOR L-SELECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-INDUCED DEGRANULATION; INTEGRIN-ASSOCIATED PROTEIN; ADHERENT HUMAN NEUTROPHILS; CYTOSOLIC FREE CA-2+; HYDROGEN-PEROXIDE; RESPIRATORY BURST; ENDOTHELIAL-CELLS; CD11B CD18; P-SELECTIN	Production of reactive oxygen intermediates (ROI) by the NADPH oxidase of neutrophils is a major mechanism of bacterial killing and, in pathologic circumstances, tissue damage. Integrins and selectins participate in neutrophil adhesion but may also play a role in intracellular signaling. The role of L-selectin in ROI production and Ca2+ signaling in suspended neutrophils was examined using the DREG series of anti-L-selectin antibodies. NADPH oxidase activation was assessed in three ways: H2O2 production using either scopoletin or dihydrorhodamine and O-2(-) production using cytochrome c. Alterations in [Ca2+](i) were measured using Fura 2-AM and fluorescence spectrophotometry, Cross-linking of L-selectin with DREG and 2 degrees antibody did not trigger production of H2O2 by itself but significantly enhanced the subsequent response to two soluble activating agents; the formyl peptide formyl-Met-Leu-Phe (fMLP) and tumor necrosis factor (TNF). Potentiation of the oxidative burst was observed using F(ab')(2) fragments but not with irrelevant antibodies and was observed whether 2 degrees antibody was added before or after fMLP. Cross linking of L-selectin also triggered a rise in [Ca2+](i), due, in part, to release from intracellular stores. The intracellular Ca2+ chelator BAPTA blocked both the rise in [Ca2+](i) and the potentiation of the oxidative burst in response to fMLP or TNF. We conclude that cross linking of L-selectin induces intracellular signals, including release of Ca2+, which may contribute to potentiation of the oxidative burst.	UNIV TORONTO,DEPT MED,TORONTO M5S 1A8,ON,CANADA; BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT IMMUNOL,RIDGEFIELD,CT 06877	University of Toronto; Boehringer Ingelheim				Downey, Gregory P/0000-0003-3253-5862				BERTON G, 1992, J CELL BIOL, V116, P1007, DOI 10.1083/jcb.116.4.1007; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; ENTMAN ML, 1990, J CLIN INVEST, V85, P1497, DOI 10.1172/JCI114596; FUORTES M, 1993, J CELL BIOL, V120, P777, DOI 10.1083/jcb.120.3.777; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; HASLETT C, 1985, AM J PATHOL, V119, P101; ISHII Y, 1992, J CELL PHYSIOL, V153, P187, DOI 10.1002/jcp.1041530123; JACONI MEE, 1991, J CELL BIOL, V112, P1249, DOI 10.1083/jcb.112.6.1249; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; LO SK, 1993, AM J PHYSIOL, V264, pL406; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; LORANT DE, 1993, J CLIN INVEST, V92, P559, DOI 10.1172/JCI116623; LUNDJOHANSEN F, 1992, J IMMUNOL, V148, P3221; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MURAKAWA Y, 1992, J IMMUNOL, V148, P1771; NAGATA K, 1993, J IMMUNOL, V151, P3267; NASMITH PE, 1987, J BIOL CHEM, V262, P13558; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NATHAN CF, 1977, J EXP MED, V146, P1648, DOI 10.1084/jem.146.6.1648; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; NGSIKORSKI J, 1991, EXP CELL RES, V195, P504, DOI 10.1016/0014-4827(91)90402-G; OBRIEN PJ, 1984, METHOD ENZYMOL, V105, P370; PATEL KD, 1991, J CELL BIOL, V112, P749, DOI 10.1083/jcb.112.4.749; RICHTER J, 1990, P NATL ACAD SCI USA, V87, P9472, DOI 10.1073/pnas.87.23.9472; RICHTER J, 1990, J BIOL CHEM, V265, P14358; ROTHE G, 1988, NATURWISSENSCHAFTEN, V75, P354, DOI 10.1007/BF00368326; ROTHLEIN R, 1994, J IMMUNOL, V152, P2488; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; SETH A, 1991, P NATL ACAD SCI USA, V88, P7877, DOI 10.1073/pnas.88.17.7877; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SNYDERMAN R, 1993, INFLAMMATION BASIC P; STRAUCH UG, 1993, INT IMMUNOL, V5, P393, DOI 10.1093/intimm/5.4.393; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538	38	159	161	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18485	18491						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518434				2022-12-25	WOS:A1994NW79800042
J	BOULTON, TG; STAHL, N; YANCOPOULOS, GD				BOULTON, TG; STAHL, N; YANCOPOULOS, GD			CILIARY NEUROTROPHIC FACTOR LEUKEMIA INHIBITORY FACTOR INTERLEUKIN-6 ONCOSTATIN-M FAMILY OF CYTOKINES INDUCES TYROSINE PHOSPHORYLATION OF A COMMON SET OF PROTEINS OVERLAPPING THOSE INDUCED BY OTHER CYTOKINES AND GROWTH-FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; SH3 DOMAINS; TRANSCRIPTION FACTOR; INTERFERON-ALPHA; FACTOR RECEPTOR; KINASE-ACTIVITY; CELLS; GP130; DIFFERENTIATION	Ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), oncostatin M (OSM), and interleukin-6 (IL6) compose a family of distantly related cytokines that initiate signaling by inducing either homodimerization of the ''beta'' signal transducing receptor component gp130 (in the case of IL6) or heterodimerization between gp130 and the gp130-related LIFRbeta (in the case of CNTF, LIF, and OSM); dimerization of beta receptor components in turn activates members of the Jak/Tyk family of receptor-associated tyrosine kinases. Here we report that CNTF, LIF, OSM, and IL6 induce most of the same protein tyrosine phosphorylations, regardless of the cell type assayed or whether they initiate signaling by inducing homo- or heterodimerization of beta components. Although several of the protein tyrosine phosphorylations induced by the CNTF/LIF/OSM/IL6 family of factors may correspond to novel tyrosine kinase targets, we have been able to demonstrate the involvement of known signaling molecules, such as phospholipase Cgamma, phosphoinositol 3-kinase, phosphotyrosine phosphatase (PTP1D), pp120, SHC, GRB2, STAT91, Paf-1, and the mitogen-activated protein kinases ERK1 and ERK2, revealing substantial convergence not only between the pathways activated by this cytokine family and other cytokines, but with pathways previously known to be activated only by factors that utilize receptor tyrosine kinases. Our data suggest the beta receptor components can form complexes with some of the signaling proteins identified and may play some role in their recruitment.	REGENERON PHARMACEUT INC, TARRYTOWN, NY 10591 USA	Regeneron								ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAEIPOUR M, 1993, J IMMUNOL, V150, P4743; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; FLYNN DC, 1992, ONCOGENE, V7, P579; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GOMEZCAMBRONERO J, 1992, P NATL ACAD SCI USA, V89, P7551, DOI 10.1073/pnas.89.16.7551; HALLEK M, 1992, J CELL PHYSIOL, V153, P176, DOI 10.1002/jcp.1041530122; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VENKITARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083, DOI 10.1073/pnas.89.24.12083; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WELHAM MJ, 1992, J IMMUNOL, V149, P2772; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	58	321	324	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11648	11655						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512571				2022-12-25	WOS:A1994NF96600100
J	DRUKER, BJ; NEUMANN, M; OKUDA, K; FRANZA, BR; GRIFFIN, JD				DRUKER, BJ; NEUMANN, M; OKUDA, K; FRANZA, BR; GRIFFIN, JD			REL IS RAPIDLY TYROSINE-PHOSPHORYLATED FOLLOWING GRANULOCYTE-COLONY-STIMULATING FACTOR TREATMENT OF HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DNA-BINDING SUBUNIT; VIRUS STRAIN-T; C-REL; SIGNAL TRANSDUCTION; FACTOR RECEPTOR; PROTO-ONCOGENE; PROTEINS; DORSAL; DROSOPHILA	Stimulation of neutrophils with granulocyte-colony stimulating factor (G-CSF) results in an enhanced respiratory burst, prolonged survival, and increased tumor cell killing. The effects of G-CSF are mediated by binding to specific, high affinity receptors. G-CSF receptors lack intrinsic tyrosine kinase activity, but activation of the receptor results in the rapid induction of tyrosine kinase activity. Antiphosphotyrosine immunoblots of whole cell lysates prepared from neutrophils show that the G-CSF rapidly induces prominent tyrosine phos phosphorylation of a protein of a relative molecular mass of 80 kDa. Using monospecific antibodies, the 80-kDa tyrosine-phosphorylated protein has been shown to be p80(c-rel), a proto-oncogene belonging to a family of transcriptional regulators which include NF-kB. The induction of tyrosine phosphorylation of p80(c-rel) was unique to G-CSF in that granulocyte-macrophage colony stimulating factor which also stimulates neutrophils and induces tyrosine phosphorylation does not result in tyro sine phosphorylation of p80(c-rel). The consequences of p80(c-rel) tyrosine phosphorylation are not yet known; however, tyrosine-phosphorylated p80(c-rel) is capable of binding to DNA, and G-CSF stimulation results in an increase in the amount of p80(c-rel) which binds to DNA, These results demonstrate that one of the first biochemical events which occurs in neutrophils following G-CSF stimulation, activation of a tyrosine kinase, leads directly to the tyrosine phosphorylation of p80(c-rel). Thus, the tyrosine kinase activated by G-CSF appears to directly transduce a signal to a protein which functions as a transcriptional regulator.	DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115; DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; COLD SPRING HARBOR LAB,FREEMAN LAB CANC CELL BIOL,COLD SPRING HARBOR,NY 11724	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Cold Spring Harbor Laboratory				Druker, Brian/0000-0001-8331-8206	NATIONAL CANCER INSTITUTE [P01CA034183, R37CA036167, R01CA036167, K08CA001422] Funding Source: NIH RePORTER; NCI NIH HHS [CA34183, CA01422, CA36167] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63; BAUERLE PA, 1988, SCIENCE, V242, P540; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMETRI GD, 1991, BLOOD, V78, P2791; DRUKER B, 1992, BLOOD, V79, P2215; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HALLEK M, 1992, J CELL PHYSIOL, V153, P176, DOI 10.1002/jcp.1041530122; IP YT, 1991, CELL, V64, P439; KANAKURA Y, 1990, BLOOD, V76, P706; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; NAGATA S, 1991, Progress in Growth Factor Research, V3, P131, DOI 10.1016/S0955-2235(05)80004-3; NEUMANN M, 1992, ONCOGENE, V7, P2095; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OKUDA K, 1992, BLOOD, V79, P2880; RICE NR, 1988, ONCOGENE HDB, P495; ROBINSON FR, 1974, AVIAN DIS, V18, P278, DOI 10.2307/1589142; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; YUO A, 1993, BIOCHIM BIOPHYS ACTA, V1156, P197, DOI 10.1016/0304-4165(93)90136-V	29	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5387	5390						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508937				2022-12-25	WOS:A1994MX57100103
J	STACEY, SN; EKLUND, C; JORDAN, D; SMITH, NK; STERN, PL; DILLNER, J; ARRAND, JR				STACEY, SN; EKLUND, C; JORDAN, D; SMITH, NK; STERN, PL; DILLNER, J; ARRAND, JR			SCANNING THE STRUCTURE AND ANTIGENICITY OF HPV-16 E6 AND E7 ONCOPROTEINS USING ANTIPEPTIDE ANTIBODIES	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; SEQUENCE-ANALYSIS PROGRAMS; ANTI-PEPTIDE ANTIBODIES; AMINO-ACID-SEQUENCE; OPEN READING FRAMES; CERVICAL-CANCER; GENE-PRODUCTS; SYNTHETIC PEPTIDES; ESCHERICHIA-COLI; ATOMIC MOBILITY	The structure and antigenicity of the HPV-16 E6 and E7 oncoproteins was studied using a set of antisera against overlapping synthetic peptides. We report that antigenic, mobile regions of the native proteins, as defined by reactivity with antipepide antisera, occur at the N-termini of both E6 and E7 proteins, corresponding to regions of known or suspected protein-protein interactions. The putative zinc finger domains were consistently non-reactive, despite computer predictions of relatively high antigenicity, suggesting that the proposed zinc finger regions are held in stable secondary structures that the peptides were not able to mimic. In E6, the linker region between the two zinc fingers was antigenic, indicating that the two zinc finger structures might be able to articulate relative to one another by a flexible linker region. The highly antigenic N-terminal region of HPV-16 E7 was also found to be antigenic in E7 of both HPV-11 and HPV-18, indicating that the E7 proteins of different HPV types have similar antigenic structures. The identification of antigenic regions of the E6 and E7 proteins should be therefore be useful in the design of site-directed antibodies against E6 and E7 for numerous HPV types.	CHRISTIE HOSP, PATERSON INST CANC RES, CANC RES CAMPAIGN, DEPT IMMUNOL, MANCHESTER M20 9BX, LANCS, ENGLAND; KAROLINSKA INST, DEPT VIROL, STOCKHOLM, SWEDEN	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Karolinska Institutet	STACEY, SN (corresponding author), CHRISTIE HOSP, PATERSON INST CANC RES, CANC RES CAMPAIGN, DEPT MOLEC BIOL, MANCHESTER M20 9BX, LANCS, ENGLAND.							ARMSTRONG DJ, 1992, J GEN VIROL, V73, P1275, DOI 10.1099/0022-1317-73-5-1275; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BERZOFSKY JA, 1985, SCIENCE, V229, P932, DOI 10.1126/science.2410982; BURNETT TS, 1983, J GEN VIROL, V64, P1509, DOI 10.1099/0022-1317-64-7-1509; CHAMBERS MA, 1994, J GEN VIROL, V75, P165, DOI 10.1099/0022-1317-75-1-165; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; COMERFORD SA, 1991, J VIROL, V65, P4681, DOI 10.1128/JVI.65.9.4681-4690.1991; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DARMANN K, 1986, VIROLOGY, V151, P124, DOI 10.1016/0042-6822(86)90110-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DILLNER J, 1990, INT J CANCER, V46, P703, DOI 10.1002/ijc.2910460426; DIMAIO D, 1991, ADV CANCER RES, V56, P133; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GAUTHIER JM, 1991, NUCLEIC ACIDS RES, V19, P7073, DOI 10.1093/nar/19.25.7073; GEYSEN HM, 1987, SCIENCE, V235, P1184, DOI 10.1126/science.3823878; GHOSH AK, 1993, INT J CANCER, V53, P591, DOI 10.1002/ijc.2910530411; GROSSMAN SR, 1989, J VIROL, V63, P366, DOI 10.1128/JVI.63.1.366-374.1989; GROSSMAN SR, 1989, ONCOGENE, V4, P1089; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HOUGHTEN RA, 1986, INT J PEPT PROT RES, V27, P673; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; JEMMERSON R, 1987, P NATL ACAD SCI USA, V84, P9180, DOI 10.1073/pnas.84.24.9180; JENISON SA, 1991, J VIROL, V65, P1208, DOI 10.1128/JVI.65.3.1208-1218.1991; JENSON AB, 1990, PAPILLOMAVIRUSES HUM; JOCHMUSKUDIELKA I, 1989, J NATL CANCER I, V81, P1698, DOI 10.1093/jnci/81.22.1698; JONES RE, 1990, J BIOL CHEM, V265, P12782; KANDA T, 1991, VIROLOGY, V182, P723, DOI 10.1016/0042-6822(91)90613-G; KOCHEL HG, 1991, INT J CANCER, V48, P682, DOI 10.1002/ijc.2910480509; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRCHNAK V, 1990, J GEN VIROL, V71, P2719, DOI 10.1099/0022-1317-71-11-2719; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; MACKETT M, 1985, DNA CLONING PRACTICA, V11, P191; MALLON RG, 1987, J VIROL, V61, P1655, DOI 10.1128/JVI.61.5.1655-1660.1987; MANN VM, 1990, CANCER RES, V50, P7815; MATLASHEWSKI G, 1989, ANTICANCER RES, V9, P1447; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; MULLER M, 1990, J GEN VIROL, V71, P2709, DOI 10.1099/0022-1317-71-11-2709; MULLER M, 1992, VIROLOGY, V187, P508; MUNGER K, 1992, CANCER SURV, V12, P197; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Munoz N, 1992, IARC SCI PUBLICATION; NIEDOBITEK G, 1991, CANCER J - FRANCE, V4, P163; PAGE MJ, 1989, NUCLEIC ACIDS RES, V17, P454, DOI 10.1093/nar/17.1.454; PATRICK DR, 1992, J BIOL CHEM, V267, P6910; RHODES D, 1988, NUCLEIC ACIDS MOL BI, V2; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SECKLER R, 1986, BIOCHEMISTRY-US, V25, P2403, DOI 10.1021/bi00357a016; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STACEY SN, 1993, J MED VIROL, V40, P14, DOI 10.1002/jmv.1890400105; STACEY SN, 1992, J GEN VIROL, V73, P2337, DOI 10.1099/0022-1317-73-9-2337; SUTCLIFFE JG, 1983, SCIENCE, V219, P660, DOI 10.1126/science.6186024; TAINER JA, 1985, ANNU REV IMMUNOL, V3, P501, DOI 10.1146/annurev.iy.03.040185.002441; TAINER JA, 1984, NATURE, V312, P127, DOI 10.1038/312127a0; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; TINDLE RW, 1990, J GEN VIROL, V71, P1347, DOI 10.1099/0022-1317-71-6-1347; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WESTHOF E, 1984, NATURE, V311, P123, DOI 10.1038/311123a0; WOLF H, 1988, COMPUT APPL BIOSCI, V4, P187	62	19	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					635	645						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	7507231				2022-12-25	WOS:A1994MW24800032
J	HSU, YT; MOLDAY, RS				HSU, YT; MOLDAY, RS			INTERACTION OF CALMODULIN WITH THE CYCLIC GMP-GATED CHANNEL OF ROD PHOTORECEPTOR CELLS - MODULATION OF ACTIVITY, AFFINITY PURIFICATION, AND LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER SEGMENTS; GUANYLATE-CYCLASE; FUNCTIONAL EXPRESSION; BINDING-PROTEINS; PLASMA-MEMBRANE; CONDUCTANCE; PHOSPHODIESTERASE; SPECTRIN	The cGMP-gated cation channel of rod photoreceptor cells plays a central role in the phototransduction process by controlling the influx of cations into the rod outer segment in response to changes in cGMP levels. Previous studies have shown that the cGMP-gated channel in native rod outer segment membrane vesicles is modulated by calmodulin in a calcium-dependent manner. In this study we report that the immunoaffinity-purified channel consisting of the 63-kDa alpha-subunit and a 240-kDa protein is also modulated by calmodulin when reconstituted into lipid vesicles. In the absence of calmodulin, the purified channel had an apparent k(m) of 33 mu M and a Hill coefficient of 33 for cGMP-dependent efflux of Ca2+ from reconstituted lipid vesicles. In the presence of calmodulin, the K-m increased to 44 mu M without affecting the Hill coefficient or maximum velocity of ion efflux. CalModulin modulation of the channel is inhibited by the calmodulin antagonist, mastoparan. In the absence of mastoparan, the half-maximum inhibition of channel activity (IC50) occurred at 1.85 +/- 0.25 nM calmodulin at a cGMP concentration of 12.5 mu M in the presence of mastoparan, the IC50 value increased to 20.3 +/- 3.8 mu M calmodulin. Based on the strong, selective interaction of calmodulin with the channel, an efficient, general method has been developed to isolate functionally active cGMP-gated channels from mammalian and amphibian photoreceptor membranes. Calmodulin extraction studies, Western blotting, and channel activity measurements indicate that endogenous rod outer segment calmodulin modulates the activity of the channel through its binding to the 240-kDa protein. From these studies we conclude that the 240-kDa protein of the cGMP-gated channel is a major calmodulin target protein of rod outer segment membranes.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia					NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER; NEI NIH HHS [EY 02422] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BIEL M, 1993, FEBS LETT, V329, P134, DOI 10.1016/0014-5793(93)80209-D; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; CHEN TY, 1994, INVEST OPHTH VIS SCI, V35, P1474; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; FLANAGAN SD, 1984, ANAL BIOCHEM, V140, P510, DOI 10.1016/0003-2697(84)90202-1; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; GORDON SE, 1994, BIOPHYS J, V66, pA355; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; JOHNSON LV, 1984, CURR EYE RES, V3, P969, DOI 10.3109/02713688409167215; KAUPP UB, 1992, ANNU REV PHYSIOL, V54, P153; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KLEE CB, 1988, MOL ASPECTS CELLULAR, V5, P35; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOHNKEN RE, 1981, J BIOL CHEM, V256, P2517; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; MOLDAY LL, 1990, J BIOL CHEM, V265, P18690; MOLDAY RS, 1991, J BIOL CHEM, V266, P21917; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; NAGAO S, 1987, BIOCHEMISTRY-US, V26, P1659, DOI 10.1021/bi00380a026; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; STRYER L, 1991, J BIOL CHEM, V266, P10711; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; WONG S, 1986, BIOCHEMISTRY-US, V25, P6294, DOI 10.1021/bi00368a069; WYLIE DC, 1988, MOL ASPECTS CELLULAR, V5, P1; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; YAU KW, 1985, NATURE, V317, P252, DOI 10.1038/317252a0	35	66	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29765	29770						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7525588				2022-12-25	WOS:A1994PU28400071
J	BRDICZKA, D; KALDIS, P; WALLIMANN, T				BRDICZKA, D; KALDIS, P; WALLIMANN, T			IN-VITRO COMPLEX-FORMATION BETWEEN THE OCTAMER OF MITOCHONDRIAL CREATINE-KINASE AND PORIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; OUTER-MEMBRANE PORE; SARCOPLASMIC-RETICULUM; CONTACT SITES; PURIFICATION; METABOLISM; TISSUES; PROTEIN; FORMS	An interaction of mitochondrial creatine kinase with purified outer mitochondrial porin (voltage-dependent anion channel) was shown by co sedimentation assays as well as by gel permeation chromatography. Porin formed high M(r) complexes with wild-type mitochondrial creatine kinase as well as with an N-terminal deletion mutant, lacking the first five N-terminal amino acids. The complexes were identified by creatine kinase activity in parallel with immunoblotting using specific antibodies against the two proteins. In addition, porin induced octamerization of the N-terminal creatine kinase mutant, which under the same conditions without porin, did not polymerize but remained more than 90% dimeric. Furthermore, binding of mitochondrial creatine kinase to porin affected the conductance of porin when reconstituted in ''black membranes.'' At 10 mV the pore in the complex adopted a low conductance (1.5-2 nanosiemens) state, compared to the high conductance state (3-4 nanosiemens) of the free incorporated pores. The former state of the pore is known to be cationically selective. Thus, besides a specific structural interaction, a defined physiological function is assumed of the mitochondrial creatine kinase porin complexes that are discussed here.	ETH HONGGERBERG, INST CELL BIOL, CH-8093 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich	BRDICZKA, D (corresponding author), UNIV KONSTANZ, FAC BIOL, D-78434 CONSTANCE, GERMANY.		Kaldis, Philipp/G-2714-2010; Wallimann, Theo/C-6047-2008	Kaldis, Philipp/0000-0002-7247-7591; Wallimann, Theo/0000-0003-4957-5836				BENZ R, 1990, BIOCHIM BIOPHYS ACTA, V1022, P311, DOI 10.1016/0005-2736(90)90279-W; BENZ R, 1992, J BIOENERG BIOMEMBR, V24, P33, DOI 10.1007/BF00769528; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; BRDICZKA D, 1991, BIOCHIM BIOPHYS ACTA, V1071, P291, DOI 10.1016/0304-4157(91)90018-R; BROOKS SPJ, 1987, ARCH BIOCHEM BIOPHYS, V257, P144, DOI 10.1016/0003-9861(87)90553-4; Bucher T, 1964, HOPPESEYLER THIERFEL, P293; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V905, P499, DOI 10.1016/0005-2736(87)90480-9; DEPINTO V, 1991, BIOCHEMISTRY-US, V30, P10191, DOI 10.1021/bi00106a017; ERICKSONVIITANEN S, 1982, J BIOL CHEM, V257, P4395; GELLERICH FN, 1994, NATO ASI SER H, V83, P337; JACOBS H, 1964, BIOCHEM BIOPH RES CO, V16, P516, DOI 10.1016/0006-291X(64)90185-8; JACOBUS WE, 1985, ANNU REV PHYSIOL, V47, P707; KALDIS P, 1994, BIOCHEMISTRY-US, V33, P952, DOI 10.1021/bi00170a014; KALDIS P, 1994, THESIS ETH ZURICH; KORGE P, 1993, EUR J BIOCHEM, V213, P973, DOI 10.1111/j.1432-1033.1993.tb17842.x; KOTTKE M, 1994, BIOCHEM MED METAB B, V51, P105, DOI 10.1006/bmmb.1994.1015; KOTTKE M, 1991, BIOCHIM BIOPHYS ACTA, V1061, P215, DOI 10.1016/0005-2736(91)90287-I; KRAUSE SM, 1992, J BIOL CHEM, V267, P2480; LINDEN M, 1983, BIOCHIM BIOPHYS ACTA, V736, P125, DOI 10.1016/0005-2736(83)90177-3; MULLER M, 1985, J BIOL CHEM, V260, P3839; ROJO M, 1991, J BIOL CHEM, V266, P20290; ROOS N, 1982, BIOCHIM BIOPHYS ACTA, V686, P204, DOI 10.1016/0005-2736(82)90114-6; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; SAKS VA, 1978, CAN J PHYSIOL PHARM, V56, P691, DOI 10.1139/y78-113; SAKS VA, 1993, BIOCHIM BIOPHYS ACTA, V1144, P134, DOI 10.1016/0005-2728(93)90166-D; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; SCHLEGEL J, 1988, J BIOL CHEM, V263, P16942; SCHNYDER T, 1988, J BIOL CHEM, V263, P16954; THINNES FP, 1989, BIOL CHEM H-S, V370, P1253; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Wallimann T, 1985, Cell Muscle Motil, V6, P239; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9	33	84	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27640	27644						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525559				2022-12-25	WOS:A1994PV77100075
J	DELUDE, RL; FENTON, MJ; SAVEDRA, R; PERERA, PY; VOGEL, SN; THIERINGER, R; GOLENBOCK, DT				DELUDE, RL; FENTON, MJ; SAVEDRA, R; PERERA, PY; VOGEL, SN; THIERINGER, R; GOLENBOCK, DT			CD14-MEDIATED TRANSLOCATION OF NUCLEAR FACTOR-KAPPA-B INDUCED BY LIPOPOLYSACCHARIDE DOES NOT REQUIRE TYROSINE KINASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LPS BINDING-PROTEIN; TRANSCRIPTION FACTOR; SOLUBLE CD14; BACTERIAL LIPOPOLYSACCHARIDE; INTERLEUKIN-6 GENE; BEARING PARTICLES; ENDOTHELIAL-CELLS; CNTF RECEPTOR; ACTIVATION; MACROPHAGES	During the course of serious bacterial infections, lipopolysaccharide (LPS) is believed to interact with macrophage receptors, resulting in the generation of inflammatory mediators and systemic symptoms including hemodynamic instability and shock. CD14, a glycosylphosphatidylinositol-linked antigen, functions as an LPS signaling receptor. A critical issue concerns the mechanism by which CD14, which has no transmembrane domain, transduces its signal following LPS binding. Recently, investigators have hypothesized that CD14-mediated signaling is effected through a receptor-associated tyrosine kinase (TK), suggesting a multicomponent receptor model of LPS signaling. Wild-type Chinese hamster ovary (CHO)-K1 cells can be activated by endotoxin to release arachidonate following transfection with human CD14 (CHO/CD14). Nuclear translocation of cytosolic NF-kappa B is correlated with a number of LPS-inducible responses. We sought to determine if this pathway were present in CHO/CD14 cells and to elucidate the relationship of NF-kappa B activation to the CD14 receptor system. LPS-stimulated translocation of NF-kappa B in CHO/CD14 cells resembled the same response in the murine macrophage-like cell line RAW 264.7. Protein synthesis inhibitors and corticosteroids, which suppress arachidonate release and the synthesis of proinflammatory cytokines, had no effect on translocation of NF-kappa B in CHO/CD14 or RAW 264.7 cells, demonstrating that NF-kappa B translocation is an early event. Although TK activity was consistently observed by immunoblotting extracts from activated RAW 264.7 cells, LPS-induced phosphotyrosine residues were not observed from similarly treated CHO/CD14 cells. Furthermore, the TK inhibitors herbimycin A and genistein failed to inhibit translocation of NF-kappa B in CHO/CD14 or RAW 264.7 cells, although both of these agents inhibited LPS-induced TK activity in RAW 264.7 cells. These results imply that TK activity is not obligatory for CD14-mediated signal transduction to occur in response to LPS.	BOSTON CITY HOSP,MAXWELL FINLAND LAB INFECT DIS,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,RES IMMUNOL SECT,BOSTON,MA 02118; UNIFORMED SERV UNIV HLTH SCI,DEPT MICROBIOL & IMMUNOL,BETHESDA,MD 20814; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT BIOCHEM,RAHWAY,NJ 07065	Boston Medical Center; Boston University; Boston University; Uniformed Services University of the Health Sciences - USA; Merck & Company					NIAID NIH HHS [AI18797, AI33087] Funding Source: Medline; NIGMS NIH HHS [GM47127] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018797, R56AI018797, R01AI018797, P01AI033087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047127] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARDITI M, 1993, INFECT IMMUN, V61, P3149, DOI 10.1128/IAI.61.8.3149-3156.1993; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GOLDBLUM SE, 1994, J CLIN INVEST, V93, P692, DOI 10.1172/JCI117022; GOLENBOCK DT, 1993, J BIOL CHEM, V268, P22055; HAILMANE, 1994, J EXP MED, V179, P269; HAN JH, 1993, J BIOL CHEM, V268, P25009; HAZIOT A, 1988, J IMMUNOL, V141, P547; HAZIOT A, 1993, J IMMUNOL, V151, P1500; HEUMANND, 1992, J IMMUNOL, V148, P35056; HUNNINGHAKE GW, 1992, MOL CELL BIOL, V12, P3439, DOI 10.1128/MCB.12.8.3439; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LYNN WA, 1993, INFECT IMMUN, V61, P4452, DOI 10.1128/IAI.61.10.4452-4461.1993; LYNN WA, 1991, J IMMUNOL, V147, P3072; MANTHEY CL, 1993, J EXP MED, V178, P695, DOI 10.1084/jem.178.2.695; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; READ MA, 1993, P NATL ACAD SCI USA, V90, P9887, DOI 10.1073/pnas.90.21.9887; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; TAMURA GS, 1984, ANAL BIOCHEM, V136, P458, DOI 10.1016/0003-2697(84)90244-6; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WEINSTEIN SL, 1993, J IMMUNOL, V151, P3829; WEINSTEINSL, 1992, J BIOL CHEM, V267, P14955; WRIGHT SD, 1992, J EXP MED, V176, P719, DOI 10.1084/jem.176.3.719; WRIGHT SD, 1989, J EXP MED, V170, P1231, DOI 10.1084/jem.170.4.1231; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	38	111	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22253	22260						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7520914				2022-12-25	WOS:A1994PE09800052
J	LEPOIVRE, M; FLAMAN, JM; BOBE, P; LEMAIRE, G; HENRY, Y				LEPOIVRE, M; FLAMAN, JM; BOBE, P; LEMAIRE, G; HENRY, Y			QUENCHING OF THE TYROSYL FREE-RADICAL OF RIBONUCLEOTIDE REDUCTASE BY NITRIC-OXIDE - RELATIONSHIP TO CYTOSTASIS INDUCED IN TUMOR-CELLS BY CYTOTOXIC MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED MACROPHAGES; MOLECULAR-CLONING; SMALL-SUBUNIT; PLASMODIUM-FALCIPARUM; ADENOCARCINOMA CELLS; MAMMALIAN-CELLS; IRON COMPLEXES; TARGET-CELLS; SYNTHASE; INHIBITION	Nitric oxide (NO) synthesized by macrophages inhibits tumor cell replication. NO also inhibits ribonucleotide reductase, an enzyme essential for DNA synthesis, probably by quenching the catalytically active tyrosyl free radical of its R2 subunit. The role of this inhibition in NO-mediated cytostasis was thus evaluated. After a 4-h coculture with macrophages, quenching of the radical was demonstrated by electron paramagnetic resonance spectroscopy in transfected L1210-R2 cells overexpressing the R2 protein. Pronounced cytostasis was simultaneously observed. A NO synthase inhibitor greatly reduced both phenomena. Target cells withdrawn from macrophages partially recovered from cytostasis and radical loss within 90 min. Deoxyribonucleosides added to by-pass ribonucleotide reductase inhibition efficiently reversed cytostasis of K-562 cells. After a 24-h coculture, the quenched tyrosyl radical still reappeared in L1210-R2 cells withdrawn from macrophages, but DNA synthesis did not resume. Moreover, deoxyribonucleosides marginally reversed overnight cytostasis of K-562 cells mediated by macrophages but were efficient against cytostasis induced by hydroxyurea, a ribonucleotide reductase inhibitor. Autocrine cytostasis observed early in TA3-H2 cells committed to produce NO was closely correlated with quenching of the tyrosyl radical but not with formation of dinitrosyl-iron complexes. We thus propose that NO-dependent cytostasis begins with a rapid and reversible inhibition of ribonucleotide reductase, progressively reinforced by other, long-lasting antiproliferative effects.	INST CURIE, INSERM, U350, F-91405 ORSAY, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	LEPOIVRE, M (corresponding author), UNIV PARIS 11, INST BIOCHIM, CNRS, URA 1116, F-91405 ORSAY, FRANCE.		Flaman, Jean-Michel/K-8415-2018; Lepoivre, Michel/J-8578-2013	Flaman, Jean-Michel/0000-0003-3544-0199; Bobe, Pierre/0000-0002-8835-6786				BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CAVANAUGH PF, 1985, CANCER RES, V45, P4754; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; ERIKSSON S, 1979, BIOCHEMISTRY-US, V18, P2948, DOI 10.1021/bi00581a005; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; FILATOV D, 1992, J BIOL CHEM, V267, P15816; GIRARD P, 1993, FEBS LETT, V320, P7, DOI 10.1016/0014-5793(93)81645-G; HENRY Y, 1993, FASEB J, V7, P1124, DOI 10.1096/fasebj.7.12.8397130; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIBBS JB, 1990, INT CONGR SER, V897, P189; HOWELL ML, 1992, J BIOL CHEM, V267, P1705; HURTA RAR, 1992, J BIOL CHEM, V267, P7066; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KELLER R, 1990, CANCER RES, V50, P1421; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LEPOIVRE M, 1992, J BIOL CHEM, V267, P22994; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MAYER J, 1993, INFECT IMMUN, V61, P491, DOI 10.1128/IAI.61.2.491-497.1993; MCCLARTY GA, 1987, BIOCHEMISTRY-US, V26, P8004, DOI 10.1021/bi00398a068; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULSCH A, 1993, BIOCHEM BIOPH RES CO, V196, P1303, DOI 10.1006/bbrc.1993.2394; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NUSSLER AK, 1993, BIOCHEM BIOPH RES CO, V194, P826, DOI 10.1006/bbrc.1993.1896; NYHOLM S, 1993, BIOCHEMISTRY-US, V32, P11569, DOI 10.1021/bi00094a013; NYHOLM S, 1993, J BIOL CHEM, V268, P26200; PADMAJA S, 1993, BIOCHEM BIOPH RES CO, V195, P539, DOI 10.1006/bbrc.1993.2079; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; ROCKETT KA, 1991, INFECT IMMUN, V59, P3280, DOI 10.1128/IAI.59.9.3280-3283.1991; RUBIN H, 1993, P NATL ACAD SCI USA, V90, P9280, DOI 10.1073/pnas.90.20.9280; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; THELANDER M, 1989, EMBO J, V8, P2475, DOI 10.1002/j.1460-2075.1989.tb08383.x; TIPPLES G, 1991, J BACTERIOL, V173, P4932, DOI 10.1128/jb.173.16.4932-4940.1991; VANIN AF, 1993, BIOCHIM BIOPHYS ACTA, V1177, P37, DOI 10.1016/0167-4889(93)90154-H; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YIM CY, 1993, CANCER RES, V53, P5507	50	168	174	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21891	21897						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	7520445				2022-12-25	WOS:A1994PK97300074
J	KORTH, HG; SUSTMANN, R; THATER, C; BUTLER, AR; INGOLD, KU				KORTH, HG; SUSTMANN, R; THATER, C; BUTLER, AR; INGOLD, KU			ON THE MECHANISM OF THE NITRIC-OXIDE SYNTHASE-CATALYZED CONVERSION OF N-OMEGA-HYDROXY-L-ARGININE TO CITRULLINE AND NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOND-DISSOCIATION ENERGIES; OLEFIN FORMATION; CYTOCHROME-P-450; RADICALS; DEFORMYLATION; INVOLVEMENT; POTENTIALS; AROMATASE; OXIDATION	The mechanism of oxidation of N-omega-hydroxy-L-arginine (NHA) by the iron-dioxygen complex in nitric oxide synthase (NOS) is still uncertain. The uncertainty has not been helped by a lack of precision in the notation used to describe the oxidation states and electrical charges on the iron and oxygen in some of the suggested mechanisms. These problems of notation are addressed, and, in addition, a cyclic voltammetric measurement of the oxidation potential of NHA, namely +0.10 +/- 0.04 V versus normal hydrogen electrode, is used to argue that the sometimes postulated oxidation of NHA by the iron-dioxygen complex to form an intermediate radical cation, NHA(.+), is very unlikely for thermodynamic reasons. Instead, it is suggested that this oxidation occurs by a thermodynamically favored abstraction of the hydrogen atom from the >C=NOH moiety of NHA to form an intermediate iminoxyl radical, 2C=NO.. A subsequent nucleophilic attack by the iron hydroperoxide species formed by this H-atom abstraction on the carbon atom of the iminoxyl radical moiety leads to the production of nitric oxide (NO) and citrulline.	UNIV ST ANDREWS,DEPT CHEM,ST ANDREWS KY16 9ST,FIFE,SCOTLAND; NATL RES COUNCIL CANADA,STEACIE INST MOLEC SCI,OTTAWA K1A 0R6,ON,CANADA	University of St Andrews; National Research Council Canada	KORTH, HG (corresponding author), UNIV ESSEN GESAMTHSCH,INST ORGAN CHEM,UNIV STR 5,D-45117 ESSEN,GERMANY.							AKHTAR M, 1993, J STEROID BIOCHEM, V44, P375, DOI 10.1016/0960-0760(93)90241-N; AKHTAR M, 1982, BIOCHEM J, V201, P569, DOI 10.1042/bj2010569; AKHTAR M, 1991, NAT PROD REP, P527; ATKINSON JK, 1993, BIOCHEMISTRY-US, V32, P9209, DOI 10.1021/bi00086a028; CLEMENT B, 1993, ENDOTHELIUM S, V1, pS18; COLE PA, 1991, J AM CHEM SOC, V113, P8130, DOI 10.1021/ja00021a044; FELDMAN PL, 1993, CHEM ENG NEWS, V71, P26; FUKUZUMI S, 1987, J AM CHEM SOC, V109, P305, DOI 10.1021/ja00236a003; FUKUZUMI S, 1983, B CHEM SOC JPN, V56, P2220, DOI 10.1246/bcsj.56.2220; GERSONDE K, 1983, BIOCH OXIDATIONS, P170; GOLDEN DM, 1990, J PHYS CHEM-US, V94, P5413, DOI 10.1021/j100376a046; GRIVA AP, 1973, INT J CHEM KINET, V5, P869; GROVES JT, 1978, BIOCHEM BIOPH RES CO, V81, P154, DOI 10.1016/0006-291X(78)91643-1; GROVES JT, 1985, J CHEM EDUC, V62, P928, DOI 10.1021/ed062p928; HAWKER PN, 1987, COMPREHENSIVE COORDI, V4, P1185; HILL HAO, 1978, COMPREHENSIVE COORDI, V2, P315; Jefcoate C.R., 1986, CYTOCHROME P 450 STR, P387; KAIM W, 1991, BIOANORGANISCHE CHEM, P87; MAHONEY LR, 1975, J AM CHEM SOC, V97, P4722, DOI 10.1021/ja00849a039; MAHONEY LR, 1973, J AM CHEM SOC, V95, P8610, DOI 10.1021/ja00807a018; MAHONEY LR, 1970, J AM CHEM SOC, V92, P4063, DOI 10.1021/ja00716a039; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MERENYI G, 1990, J PHYS CHEM-US, V94, P5412, DOI 10.1021/j100376a044; MILLER LL, 1988, J AM CHEM SOC, V110, P3982, DOI 10.1021/ja00220a042; PUFAHL RA, 1993, BIOCHEM BIOPH RES CO, V193, P963, DOI 10.1006/bbrc.1993.1719; ROBERTS ES, 1991, P NATL ACAD SCI USA, V88, P8963, DOI 10.1073/pnas.88.20.8963; VAZ ADN, 1991, J AM CHEM SOC, V113, P5886, DOI 10.1021/ja00015a066; WELBORN CH, 1981, J AM CHEM SOC, V103, P2869, DOI 10.1021/ja00400a067; WHITE RE, 1991, PHARMACOL THERAPEUT, V49, P21, DOI 10.1016/0163-7258(91)90020-M	29	115	117	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17776	17779						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	7517932				2022-12-25	WOS:A1994NV42200006
J	BURGAYA, F; GARCIAFERNANDEZ, J; RIUTORT, M; BAGUNA, J; SALO, E				BURGAYA, F; GARCIAFERNANDEZ, J; RIUTORT, M; BAGUNA, J; SALO, E			STRUCTURE AND EXPRESSION OF SPK-1, AN SRC-RELATED GENE-PRODUCT FOUND IN THE PLANARIAN DUGESIA-(G)-TIGRINA	ONCOGENE			English	Note							PROTEIN-TYROSINE KINASE; SIGNAL TRANSDUCTION; PATTERN-FORMATION; SEQUENCE-ANALYSIS; FAMILY; DOMAIN; REGENERATION; NEOBLASTS; PHYLOGENY; RNAS	A cDNA clone encoding a 497 amino acid protein 75% similar to most Src proteins has been isolated from the planarian Dugesia (Girardia) tigrina (Platyhelminthes; Turbellaria) by PCR followed by screening procedures. This gene product has been designated Spk-1 as it is the first Src-related kinase isolated in a planarian. The predicted amino acid sequence of Spk-1 suggest that it is anchored to the plasma membrane and that it interacts with other phosphotyrosine proteins. Spk-1 is expressed in both intact and regenerating organisms as an mRNA transcript of about 1.9 kb. Planarians, which conserve most features of the common ancestor to protostomian and deuterostomian phyla, are the most primitive triploblastic organisms from which a protein tyrosine kinase gene product has been isolated. The presence of this gene product in such a primitive organism, and its presumed role, are discussed.	UNIV BARCELONA,FAC BIOL,DEPT GENET,DIAGONAL 645,E-08028 BARCELONA,SPAIN	University of Barcelona			Salo, Emili/M-3928-2014; Garcia-Fernandez, Jordi/B-3839-2013; Riutort, Marta/B-6441-2009	Salo, Emili/0000-0001-5460-9223; Garcia-Fernandez, Jordi/0000-0001-5677-5970; Riutort, Marta/0000-0002-2134-7674				BAGUNA J, 1981, NATURE, V290, P14, DOI 10.1038/290014b0; BAGUNA J, 1989, DEVELOPMENT, V107, P77; BAGUNA J, 1990, EXPT EMBRYOLOGY AQUA, P129; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BERGSTROM L, 1987, MOL PHARMACOL, V32, P764; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOSCH TCG, 1989, MOL CELL BIOL, V9, P4141, DOI 10.1128/MCB.9.10.4141; BUSS JE, 1988, MOL CELL BIOL, V8, P3960, DOI 10.1128/MCB.8.9.3960; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GALLIOT B, 1993, TRENDS GENET, V9, P3, DOI 10.1016/0168-9525(93)90051-I; GARCIAFERNANDEZ J, 1993, DEVELOPMENT, V118, P241; GARCIAFERNANDEZ J, 1991, P NATL ACAD SCI USA, V88, P7338, DOI 10.1073/pnas.88.16.7338; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; Karlstedt K.A., 1990, Acta Academiae Aboensis Ser B Mathematica et Physica Matematik Naturvetenskaper Teknik, V50, P59; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; OTTILIE S, 1992, ONCOGENE, V7, P1625; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1992, NATURE, V356, P285, DOI 10.1038/356285a0; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RIDLEY AJ, 1992, NATURE, V355, P497, DOI 10.1038/355497a0; RIUTORT M, 1992, CAN J ZOOL, V70, P1425, DOI 10.1139/z92-199; SALO E, 1984, J EMBRYOL EXP MORPH, V83, P63; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; STERNBERG PW, 1991, TRENDS GENET, V7, P366, DOI 10.1016/0168-9525(91)90257-Q; Willmer P., 1990, INVERTEBRATE RELATIO	36	7	10	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1267	1272						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	7510865				2022-12-25	WOS:A1994NC04800033
J	MCDONOUGH, PM; STELLA, SL; GLEMBOTSKI, CC				MCDONOUGH, PM; STELLA, SL; GLEMBOTSKI, CC			INVOLVEMENT OF CYTOPLASMIC CALCIUM AND PROTEIN-KINASES IN THE REGULATION OF ATRIAL-NATRIURETIC-FACTOR SECRETION BY CONTRACTION RATE AND ENDOTHELIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK HEART-CELLS; VENTRICULAR MYOCYTES; CARDIAC MYOCYTES; PEPTIDE SECRETION; HUMAN FIBROBLASTS; PHOSPHOLIPASE-C; PHORBOL ESTERS; GROWTH-FACTORS; ANP SECRETION; CA-2+	To characterize the effects of the cellular events associated with contraction on atrial natriuretic factor (ANF) secretion, primary neonatal rat atrial myocytes were electrically paced to contract while being monitored for ANF release, cytoplasmic calcium, phosphoinositide hydrolysis, and protein kinase C activation. Similar measurements were also carried out in the presence of endothelin-1 (ET) for comparison of contraction-related and hormone-stimulated ANF secretion. Pacing (6-8 Hz) immediately increased ANF secretion by 3-5-fold and the time-averaged cytoplasmic calcium concentration (as monitored with indo-1 fluorescence) varied with pace frequency in a similar manner, suggesting that cytoplasmic calcium may play a key role in pace-induced ANF secretion. Furthermore, nifedipine and ryanodine, which inhibited the contractile calcium transients, inhibited pace-induced ANF release, whereas Bay K 8644 increased both the calcium transients and ANF secretion. Pace-induced ANF release was also completely inhibited by KN-62, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMK) but was not inhibited by chelerythrine, a protein kinase C-selective inhibitor. Pace-induced ANF release averaged 40% of that elicited by ET which is known to require both PKC and CaMK for maximal effects on ANF secretion. The effects of pacing and ET on ANF secretion were approximately additive. In contrast to pacing, ET strongly stimulated phosphoinositide hydrolysis, activated PKC, and did not increase cytoplasmic calcium. Thus, regulation of ANF secretion by contraction rate depends primarily on the contractile calcium transients and CaMK and is independent of PKC.	SAN DIEGO STATE UNIV,INST MOLEC BIOL,SAN DIEGO,CA 92182	California State University System; San Diego State University	MCDONOUGH, PM (corresponding author), SAN DIEGO STATE UNIV,DEPT BIOL,SAN DIEGO,CA 92182, USA.			Stella Jr., Salvatore/0000-0003-1971-2537	NHLBI NIH HHS [HL46345] Funding Source: Medline; NINDS NIH HHS [NS-25037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADOLPH EF, 1967, AM J PHYSIOL, V212, P595, DOI 10.1152/ajplegacy.1967.212.3.595; BALS S, 1990, CELL CALCIUM, V11, P385, DOI 10.1016/0143-4160(90)90050-5; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BEST L, 1986, BIOCHEM J, V238, P773, DOI 10.1042/bj2380773; BILDER GE, 1989, CIRC RES, V64, P799, DOI 10.1161/01.RES.64.4.799; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BREVET A, 1976, SCIENCE, V193, P1152, DOI 10.1126/science.959833; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CFHRISTENSEN G, 1989, AM J PHYSIOL, V256, pR1245; CHO KW, 1991, AM J PHYSIOL, V260, pR39, DOI 10.1152/ajpregu.1991.260.1.R39; CHRISTENSEN G, 1988, ACTA PHYSIOL SCAND, V134, P263, DOI 10.1111/j.1748-1716.1988.tb08487.x; DIETZ JR, 1987, AM J PHYSIOL, V252, pR498, DOI 10.1152/ajpregu.1987.252.3.R498; DOUBELL AF, 1991, HYPERTENSION, V18, P648, DOI 10.1161/01.HYP.18.5.648; DOUBELL AF, 1989, LIFE SCI, V45, P2193, DOI 10.1016/0024-3205(89)90059-3; ETSCHEID BG, 1991, CELL REGUL, V2, P229, DOI 10.1091/mbc.2.3.229; FABIATO A, 1985, FED PROC, V44, P2970; FISHER SK, 1989, MOL PHARMACOL, V35, P195; FURUKAWA T, 1992, CIRC RES, V71, P1242, DOI 10.1161/01.RES.71.5.1242; GALRON R, 1989, BIOCHEM BIOPH RES CO, V163, P936, DOI 10.1016/0006-291X(89)92312-7; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANSFORD RG, 1987, J PHYSIOL-LONDON, V390, P453, DOI 10.1113/jphysiol.1987.sp016711; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HOVEMADSEN L, 1992, BIOPHYS J, V63, P89, DOI 10.1016/S0006-3495(92)81597-7; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; IRONS CE, 1992, J BIOL CHEM, V267, P5211; JOHNSON CL, 1990, AM J PHYSIOL, V258, pC533, DOI 10.1152/ajpcell.1990.258.3.C533; JONES LG, 1988, CIRC RES, V62, P299, DOI 10.1161/01.RES.62.2.299; KIM D, 1991, CIRC RES, V69, P250, DOI 10.1161/01.RES.69.1.250; KNIGHT DE, 1989, TRENDS NEUROSCI, V12, P451, DOI 10.1016/0166-2236(89)90095-7; KOJIMA S, 1993, AM J PHYSIOL, V264, pH183, DOI 10.1152/ajpheart.1993.264.1.H183; LAUER MR, 1992, J PHYSIOL-LONDON, V448, P729, DOI 10.1113/jphysiol.1992.sp019067; LEE HC, 1989, PFLUG ARCH EUR J PHY, V413, P225, DOI 10.1007/BF00583534; MALATINO LS, 1990, AM HEART J, V119, P97, DOI 10.1016/S0002-8703(05)80088-2; MARBAN E, 1985, CIRC RES, V56, P133, DOI 10.1161/01.RES.56.1.133; MATSUBARA H, 1988, AM J PHYSIOL, V255, pH405, DOI 10.1152/ajpheart.1988.255.3.H405; MCDONOUGH PM, 1988, MOL PHARMACOL, V33, P310; PEETERS GA, 1987, AM J PHYSIOL, V253, pH1400, DOI 10.1152/ajpheart.1987.253.6.H1400; PETERSON MW, 1992, AM J PHYSIOL, V263, pC1216, DOI 10.1152/ajpcell.1992.263.6.C1216; POPOLI M, 1993, FEBS LETT, V317, P85, DOI 10.1016/0014-5793(93)81496-M; QIU ZH, 1992, EUR J PHARMACOL, V214, P293; RANKIN AJ, 1986, LIFE SCI, V38, P1951, DOI 10.1016/0024-3205(86)90224-9; RENARD D, 1990, J MOL CELL CARDIOL, V22, P13, DOI 10.1016/0022-2828(90)90968-8; RIDDERVOLD F, 1991, AM J PHYSIOL, V260, pH1953, DOI 10.1152/ajpheart.1991.260.6.H1953; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; SCHIEBINGER RJ, 1990, ENDOCRINOLOGY, V127, P119, DOI 10.1210/endo-127-1-119; SCHIEBINGER RJ, 1992, ENDOCRINOLOGY, V130, P1017, DOI 10.1210/en.130.2.1017; SCHIEBINGER RJ, 1986, AM J PHYSIOL, V251, P1095; SCHRAMM M, 1983, NATURE, V303, P535, DOI 10.1038/303535a0; SEI CA, 1990, J BIOL CHEM, V265, P7166; SHIELDS PP, 1988, J BIOL CHEM, V263, P12619; SHIELDS PP, 1989, J BIOL CHEM, V264, P9322; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SPURGEON HA, 1990, AM J PHYSIOL, V258, pH574, DOI 10.1152/ajpheart.1990.258.2.H574; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; VIGNE P, 1990, J BIOL CHEM, V265, P6782; WIER WG, 1985, FED PROC, V44, P2989	59	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9466	9472						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511588				2022-12-25	WOS:A1994NE05300014
J	WEISZ, A; OGUCHI, S; CICATIELLO, L; ESUMI, H				WEISZ, A; OGUCHI, S; CICATIELLO, L; ESUMI, H			DUAL MECHANISM FOR THE CONTROL OF INDUCIBLE-TYPE NO SYNTHASE GENE-EXPRESSION IN MACROPHAGES DURING ACTIVATION BY INTERFERON-GAMMA AND BACTERIAL LIPOPOLYSACCHARIDE - TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; MOLECULAR-CLONING; PROPIONIBACTERIUM-ACNES; DEPENDENT FORMATION; CELL-LINE; LIVER; RATS; IDENTIFICATION; PURIFICATION; CALMODULIN	Production of nitric oxide (NO) by macrophages is enhanced upon activation by bacterial endotoxins and cytokines mainly via an increase of the intracellular content of the inducible isoform of nitric oxide synthase (i-NOS). We have studied in detail the effect of several modulators of macrophage activity on steady state levels of i-NOS mRNA in the mouse macrophage-like cell line RAW 264.7. Bacterial lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma) were found to be effective inducers of i-NOS mRNA, in accordance with their known ability to stimulate both i-NOS activity and NO production in macrophages from different sources, while TNF-alpha, IL-1, or IL-6 was ineffective in this regard. Accumulation of i-NOS mRNA in response to either LPS or IFN-gamma stimulation was accompanied by increased i-NOS gene transcription, as detected both by using a nuclear ''run-on'' transcription assay and by transient transfection of the cloned gene promoter in RAW 264.7 cells. Co-stimulation of the cells with both inducers resulted in higher steady state levels of i-NOS mRNA in the absence, however, of a corresponding potentiation of the rate of gene transcription. This was due primarily to a considerable effect of LPS on i-NOS mRNA stability, with prolongation of its half-life from 1-1.5 h, in the presence of LFN-gamma alone, to 4-6 h in the presence of both LPS and IFN-gamma.	NATL CANC CTR,RES INST,DIV BIOCHEM,CHUO KU,TOKYO 104,JAPAN	National Cancer Center - Japan			Weisz, Alessandro/A-1317-2014	Weisz, Alessandro/0000-0003-0455-2083				ADACHI H, 1993, EUR J BIOCHEM, V217, P37, DOI 10.1111/j.1432-1033.1993.tb18215.x; ADAMS DO, 1992, MACROPHAGE, P75; AMBER IJ, 1988, J LEUKOCYTE BIOL, V44, P58, DOI 10.1002/jlb.44.1.58; AMBROSINO C, 1993, IN PRESS MOL ENDOCRI; Auger M. J., 1992, MACROPHAGE, P1; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BRENDT DS, 1990, P NATL ACAD SCI USA, V87, P682; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; CUNHA FQ, 1993, J IMMUNOL, V150, P1908; DING AH, 1988, J IMMUNOL, V141, P2407; EIZIRIK DL, 1993, FEBS LETT, V317, P62, DOI 10.1016/0014-5793(93)81492-I; FARBER JM, 1992, MOL CELL BIOL, V12, P1535, DOI 10.1128/MCB.12.4.1535; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GOUREAU O, 1993, P NATL ACAD SCI USA, V90, P4276, DOI 10.1073/pnas.90.9.4276; HAMILTON TA, 1987, IMMUNOL TODAY, V8, P151, DOI 10.1016/0167-5699(87)90145-9; HECK DE, 1992, J BIOL CHEM, V267, P21277; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; IIDA S, 1992, J BIOL CHEM, V267, P25385; KNOWLES RG, 1992, TRENDS BIOCHEM SCI, V17, P399, DOI 10.1016/0968-0004(92)90008-W; KNOWLES RG, 1990, BIOCHEM BIOPH RES CO, V172, P1042, DOI 10.1016/0006-291X(90)91551-3; KOIDE M, 1993, FEBS LETT, V318, P213, DOI 10.1016/0014-5793(93)80514-U; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MIWA M, 1989, BIOCHEM BIOPH RES CO, V159, P373, DOI 10.1016/0006-291X(89)90001-6; MOLLACE V, 1993, BIOCHEM BIOPH RES CO, V191, P327, DOI 10.1006/bbrc.1993.1221; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; OGUCHI S, 1992, FEBS LETT, V308, P22, DOI 10.1016/0014-5793(92)81041-J; OHSHIMA H, 1991, CARCINOGENESIS, V12, P1217, DOI 10.1093/carcin/12.7.1217; OHSHIMA H, 1992, BIOCHEM BIOPH RES CO, V187, P1291, DOI 10.1016/0006-291X(92)90443-O; RUCO LP, 1978, J IMMUNOL, V121, P2035; SEN GC, 1992, J BIOL CHEM, V267, P5017; SESSA WC, 1992, J BIOL CHEM, V267, P15274; STUEHR DJ, 1987, CANCER RES, V47, P5590; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WEISZ A, 1990, MOL ENDOCRINOL, V4, P1041, DOI 10.1210/mend-4-7-1041; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; WOOD ER, 1993, BIOCHEM BIOPH RES CO, V191, P767, DOI 10.1006/bbrc.1993.1283; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; YUI Y, 1991, J BIOL CHEM, V266, P12544	54	158	161	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8324	8333						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510685				2022-12-25	WOS:A1994NB40900075
J	CHOQUET, D; KU, G; CASSARD, S; MALISSEN, B; KORN, H; FRIDMAN, WH; BONNEROT, C				CHOQUET, D; KU, G; CASSARD, S; MALISSEN, B; KORN, H; FRIDMAN, WH; BONNEROT, C			DIFFERENT PATTERNS OF CALCIUM SIGNALING TRIGGERED THROUGH 2 COMPONENTS OF THE B-LYMPHOCYTE ANTIGEN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA-2+; PLASMA-MEMBRANE; CELLS; PHOSPHORYLATION; IMMUNOGLOBULIN; OSCILLATIONS; COMPLEX; STORES; IG; TRANSDUCTION	The engagement of the B cell antigen receptor is the first step of antigenic stimulation of B lymphocytes. This step is followed by a series of biochemical events, including the activation of protein-tyrosine kinases, phosphoinositide turnover, and multiple patterns of calcium mobilization, which lead to the regulation of gene transcription and cellular responses. The B cell antigen receptor complex is composed of membrane immunoglobulins (as antigen recognition subunits) and associated chains (Ig-alpha and Ig-beta) that couple the receptor to cytoplasmic protein kinases. To investigate independently the relative signaling capacity of Ig-alpha and Ig-beta, chimeric proteins containing their cytoplasmic domains were expressed in a B cell line. We found that Ig-alpha and Ig-beta activate two distinct intracellular signaling pathways. The engagement of Ig-alpha chimeras induces a complete release of calcium from intracellular stores, followed by transmembrane calcium influx and late cell activation signals, detected by lymphokine secretion. In contrast, Ig-beta chimeras do not induce lymphokine secretion or calcium influx, but induce short oscillatory release of calcium, dependent on the activity of the Ca-ATPase pump of the endoplasmic reticulum. These results provide a structural basis for the diversity of B cell responses.	INST CURIE, INSERM, U255, F-75005 PARIS, FRANCE; INST PASTEUR, INSERM, U261, F-75015 PARIS, FRANCE; CNRS MARSEILLE LUMINY, INSERM, CTR IMMUNOL, F-13288 MARSEILLE 9, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			Malissen, Bernard/AAK-4659-2020; Choquet, Daniel/K-7893-2018; Choquet, Daniel/GOJ-8825-2022; Choquet, Daniel/E-4203-2013	Choquet, Daniel/0000-0003-4726-9763; Choquet, Daniel/0000-0003-4726-9763; fridman, wolf herman/0000-0002-1332-0973				BONNEROT C, 1992, EMBO J, V11, P2747, DOI 10.1002/j.1460-2075.1992.tb05340.x; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; CAMBIER JC, 1992, FASEB J, V6, P3207, DOI 10.1096/fasebj.6.13.1397843; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CARAFOLI E, 1991, ANNU REV PHYSIOL, V53, P531, DOI 10.1146/annurev.physiol.53.1.531; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CUSHLEY W, 1993, BIOCHEM J, V292, P313, DOI 10.1042/bj2920313; DENNIS GJ, 1987, J IMMUNOL, V138, P4307; DONNADIEU E, 1992, J BIOL CHEM, V267, P25864; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.physiol.55.1.427; FISHER CL, 1991, J IMMUNOL, V146, P1743; FRIEDRICH RJ, 1993, J IMMUNOL, V150, P2814; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HESS SD, 1993, J IMMUNOL, V150, P2620; HIDERO Y, 1993, J EXP MED, V177, P1613; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; ISHIHARA K, 1993, J IMMUNOL, V150, P2253; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEWIS RS, 1989, CELL REGUL, V1, P199; MASON MJ, 1991, J BIOL CHEM, V266, P10872; PIKE BL, 1987, IMMUNOL REV, V99, P119, DOI 10.1111/j.1600-065X.1987.tb01175.x; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Rink TJ, 1990, CURR OPIN CELL BIOL, V2, P198, DOI 10.1016/0955-0674(90)90007-2; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; TADA M, 1988, METHOD ENZYMOL, V157, P107; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WILSON HA, 1987, J EXP MED, V166, P601, DOI 10.1084/jem.166.2.601; XU A, 1993, J BIOL CHEM, V268, P8394	43	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6491	6497						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509805				2022-12-25	WOS:A1994MZ50300037
J	SANDOVAL, IV; ARREDONDO, JJ; ALCALDE, J; NORIEGA, AG; VANDEKERCKHOVE, J; JIMENEZ, MA; RICO, M				SANDOVAL, IV; ARREDONDO, JJ; ALCALDE, J; NORIEGA, AG; VANDEKERCKHOVE, J; JIMENEZ, MA; RICO, M			THE RESIDUES LEU(ILE)(475)-ILE(LEU,VAL,ALA)(476), CONTAINED IN THE EXTENDED CARBOXYL CYTOPLASMIC TAIL, ARE CRITICAL FOR TARGETING OF THE RESIDENT LYSOSOMAL MEMBRANE-PROTEIN LIMP-II TO LYSOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; TRANS-GOLGI-APPARATUS; HAMSTER OVARY CELLS; CASEIN KINASE-II; RAT-LIVER; INTERNALIZATION SIGNAL; ACID-PHOSPHATASE; RECOGNITION MARKER; SYNTHETIC PEPTIDES; INVARIANT CHAIN	LIMP II, a type II lysosomal integral membrane protein, and the CD36/LIMP II construct are targeted to lysosomes by means of a signal expressed in the tyrosine-lacking carboxyl cytoplasmic tail of LIMP II (Vega, M. A., Rodriguez, F., Segui, B., Cales, C., Alcalde, J., and Sandoval, I. V. (1991) J. Biol. Chem. 266, 16269-16272; Vega, M. A., Segui-Real, B., Garcia, J. A., Cales, C., Rodriguez, F., Vandekerckhove, J., and Sandoval, I. V. (1991) J. Biol. Chem. 266, 16818-16824). Substitution of Leu(475) with Ile resulted in a decreased efficiency of targeting. Mutant forms produced by substituting Leu(475) by hydrophobic residues with either large (Val) or small (Ala, Gly) side chains, or by a charged residue (Asp), showed inhibited targeting. In contrast, the contiguous Ile(476) residue could be replaced by either Leu, without loss in the efficiency of targeting, or by Val or Ala, with some impediment. Substitution of Ile(476) by either Gly or Asp inhibited completely the targeting. The addition of the sequence Ser-Trp-Asp to the carboxyl end of the construct did not interfere with targeting. Data from H-1 NMR analysis of the icosapeptide corresponding to the carboxyl cytoplasmic tail of LIMP II indicated the predominance of structures with extended random coil conformations, suggesting that the targeting signal is contained in a domain with an extended configuration.	STATE UNIV GHENT,PHYSIOL CHEM LAB,B-9000 GHENT,BELGIUM; CSIC,INST ESTRUCTURA MAT,E-28006 MADRID,SPAIN; UNIV NACL AUTONOMA MEXICO,INST INVEST BIOMED,UNIDAD GENET NUTR,MEXICO CITY 04530,DF,MEXICO	Ghent University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Estructura de la Materia (IEM); Universidad Nacional Autonoma de Mexico	SANDOVAL, IV (corresponding author), UNIV AUTONOMA MADRID,CSIC,FAC CIENCIAS,CTR BIOL MOLEC SEVERO OCHOA,CANTOBLANCO,E-28049 MADRID,SPAIN.		Jimenez, M. Angeles/C-7193-2008; Arredondo, Juan/L-2404-2013	Jimenez, M. Angeles/0000-0001-6835-5850; Arredondo, Juan/0000-0002-6784-0990				ALCALDE J, 1992, J CELL BIOL, V116, P69, DOI 10.1083/jcb.116.1.69; ANE WP, 1976, J CHEM PHYS, V64, P222; ARMSTRONG J, 1991, J CELL SCI, V98, P567; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BARRIOCANAL JG, 1986, J BIOL CHEM, V261, P6755; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1986, J MAGN RESON, V70, P327, DOI 10.1016/0022-2364(86)90018-1; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRAULKE T, 1987, EUR J CELL BIOL, V43, P316; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; CAMPBELL CH, 1983, J BIOL CHEM, V258, P3347; CARLSSON SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P630, DOI 10.1016/0003-9861(92)90619-8; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; de Duve D, 1963, CIBA F S LYSOSOMES, P1; DENG YP, 1991, J CELL SCI, V99, P571; DEUTSCHER SL, 1983, P NATL ACAD SCI-BIOL, V80, P3938, DOI 10.1073/pnas.80.13.3938; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FEDDE KN, 1985, BIOCHEM BIOPH RES CO, V133, P614, DOI 10.1016/0006-291X(85)90949-0; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; GEUZE HJ, 1987, J CELL BIOL, V104, P1715, DOI 10.1083/jcb.104.6.1715; GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HOFLACK B, 1985, P NATL ACAD SCI USA, V82, P4428, DOI 10.1073/pnas.82.13.4428; HOFLACK B, 1985, J BIOL CHEM, V260, P2008; HUGHES EN, 1982, J BIOL CHEM, V257, P3970; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; JADOT M, 1992, J BIOL CHEM, V267, P11069; JIMENEZ MA, 1986, J MOL STRUCT, V143, P435, DOI 10.1016/0022-2860(86)85294-2; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KAPLAN A, 1977, P NATL ACAD SCI USA, V74, P2026, DOI 10.1073/pnas.74.5.2026; KIEFFER N, 1989, BIOCHEM J, V262, P835, DOI 10.1042/bj2620835; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LEMANSKY P, 1987, J CELL BIOL, V104, P1743, DOI 10.1083/jcb.104.6.1743; LERHMAN MA, 1985, CELL, V41, P735; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MALISSEN B, 1982, EUR J IMMUNOL, V12, P734; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARION D, 1985, FEBS LETT, V192, P99, DOI 10.1016/0014-5793(85)80051-X; MATHEWS PM, 1992, J CELL BIOL, V118, P1027, DOI 10.1083/jcb.118.5.1027; MEGGIO F, 1984, J BIOL CHEM, V259, P4576; MERESSE S, 1990, J BIOL CHEM, V265, P18833; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MINNIFIELD N, 1986, EUR J CELL BIOL, V42, P92; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Murphy R F, 1991, Trends Cell Biol, V1, P77, DOI 10.1016/0962-8924(91)90022-2; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; NIETO A, 1990, BIOCHEM J, V267, P317, DOI 10.1042/bj2670317; NOVIKOFF AB, 1963, CIBA F S LYSOSOMES, P36; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; POHLMANN R, 1982, J BIOL CHEM, V257, P5323; SAHAGIAN GG, 1983, J BIOL CHEM, V258, P7121; SCHMID S, 1989, J CELL BIOL, V108, P1291, DOI 10.1083/jcb.108.4.1291; STRAUS W, 1963, CIBA F S LYSOSOMES, P151; VEGA MA, 1991, J BIOL CHEM, V266, P16818; VEGA MA, 1991, J BIOL CHEM, V266, P16269; VLADUTIU GD, 1983, BIOCHIM BIOPHYS ACTA, V760, P363, DOI 10.1016/0304-4165(83)90374-4; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215	78	122	125	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6622	6631						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509809				2022-12-25	WOS:A1994MZ50300057
J	ELEMER, GS; EDGINGTON, TS				ELEMER, GS; EDGINGTON, TS			MICROFILAMENT REORGANIZATION IS ASSOCIATED WITH FUNCTIONAL ACTIVATION OF ALPHA(M)BETA(2) ON MONOCYTIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULES; FACTOR-X; MONOCLONAL-ANTIBODIES; DEOXYRIBONUCLEASE-I; MEMBRANE SKELETON; HUMAN-NEUTROPHILS; ACTIN-FILAMENTS; ANTIGEN FAMILY; CYTOCHALASIN-B; BETA-SUBUNIT	Selected agonists convert the leukocyte integrin alpha(M)beta(2) on monocytes from a low to a high affinity, state competent to bind factor X and fibrinogen. Conformational, changes of alpha(M)beta2 are hypothesized to account for this functional transition. Here we report that cytochalasins known to interfere with actin filaments induce the alpha(M)beta2 functional transition. Upon exposure to cytochalasin B, isolated human blood monocytes and cells of the monocytic cell line THP-1 bound I-125-factor X (X) or I-125-fibrinogen (Fg) in a Ca2+-dependent, saturable manner. Monoclonal antibodies (mAbs) to the alpha(M) subunit and the common beta2 subunit of leukocyte integrins inhibited X and Fg binding, whereas mAbs to the a chains of the other leukocyte integrins had no effect. Anti-alpha(M) mAb immunoprecipitated I-125-X that had been chemically cross-linked to its cognate receptor. Specific binding was not associated with an increased surface density of beta2 integrins consistent with conformational remodeling of the receptor. Simultaneous analysis of actin forms in viable monocytes indicated a dynamic redistribution of cellular actin. The transient increase in G actin concurrent with an agonist action such as cytochalasin or ADP was reversed by an increase in F actin coincident with X/Ca2+ binding. A potential role of actin redistribution in alpha(M)beta2 functional transition is supported by the finding that cells in which cellular actin is restricted to G rather than F form bound X and initiated a rapid coagulant response. We propose that a transient disassembly of actin filaments may relieve constraints on alpha(M)beta2 via the cytoplasmic domains, permitting the conformational dynamics required for recognition of ligands.	Scripps Res Inst, DEPT IMMUNOL,VASC CELL MOLEC BIOL PROGRAM,IMM-17, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411] Funding Source: NIH RePORTER; NHLBI NIH HHS [P0 HL-16411] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALI IU, 1977, BIOCHIM BIOPHYS ACTA, V471, P16, DOI 10.1016/0005-2736(77)90388-1; ALTIERI DC, 1988, J IMMUNOL, V141, P2656; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ALTIERI DC, 1989, J BIOL CHEM, V264, P2969; ALTIERI DC, 1988, P NATL ACAD SCI USA, V85, P7462, DOI 10.1073/pnas.85.20.7462; ARNAOUT MA, 1990, BLOOD, V75, P1037; ARNAOUT MA, 1988, J CELL PHYSIOL, V137, P305, DOI 10.1002/jcp.1041370214; BURN P, 1988, P NATL ACAD SCI USA, V85, P497, DOI 10.1073/pnas.85.2.497; CAO LG, 1992, J CELL BIOL, V117, P1023, DOI 10.1083/jcb.117.5.1023; CARTER SB, 1967, NATURE, V213, P261, DOI 10.1038/213261a0; CASELLA JF, 1981, NATURE, V293, P302, DOI 10.1038/293302a0; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; ESCANDEGERAUD ML, 1988, BIOCHIM BIOPHYS ACTA, V939, P247, DOI 10.1016/0005-2736(88)90068-5; FAIR DS, 1979, J CLIN INVEST, V64, P884, DOI 10.1172/JCI109554; FAULSTICH H, 1988, J MUSCLE RES CELL M, V9, P370, DOI 10.1007/BF01774064; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1988, BIOESSAYS, V8, P14, DOI 10.1002/bies.950080105; GOLDMAN RD, 1973, P NATL ACAD SCI USA, V70, P750, DOI 10.1073/pnas.70.3.750; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; GROVE DS, 1992, EXP CELL RES, V202, P303, DOI 10.1016/0014-4827(92)90079-N; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HITCHCOCK SE, 1980, J BIOL CHEM, V255, P5668; HO MK, 1983, J BIOL CHEM, V258, P2766; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KEIZER GD, 1985, EUR J IMMUNOL, V15, P1142, DOI 10.1002/eji.1830151114; KURKINEN M, 1978, EXP CELL RES, V111, P127, DOI 10.1016/0014-4827(78)90243-4; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; MAEKAWA S, 1989, J BIOL CHEM, V264, P7458; MANNHERZ HG, 1980, EUR J BIOCHEM, V104, P367, DOI 10.1111/j.1432-1033.1980.tb04437.x; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; Pollard TD, 1990, CURR OPIN CELL BIOL, V2, P33, DOI 10.1016/S0955-0674(05)80028-6; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SANGER JM, 1990, P NATL ACAD SCI USA, V87, P5474, DOI 10.1073/pnas.87.14.5474; SCHWARTING R, 1985, BLOOD, V65, P974; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TELLAM R, 1982, BIOCHEMISTRY-US, V21, P3207, DOI 10.1021/bi00256a027; THERRIEN S, 1989, J CELL BIOL, V109, P1125, DOI 10.1083/jcb.109.3.1125; TRACY PB, 1985, J BIOL CHEM, V260, P2119; WALLIS WJ, 1986, BLOOD, V67, P1007; WEHLAND J, 1981, EUR J CELL BIOL, V24, P176; WESSELLS NK, 1971, SCIENCE, V171, P135, DOI 10.1126/science.171.3967.135; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699	47	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3159	3166						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508910				2022-12-25	WOS:A1994MV63100010
J	MARSHALL, J; FANG, S; OSTEDGAARD, LS; ORIORDAN, CR; FERRARA, D; AMARA, JF; HOPPE, H; SCHEULE, RK; WELSH, MJ; SMITH, AE; CHENG, SH				MARSHALL, J; FANG, S; OSTEDGAARD, LS; ORIORDAN, CR; FERRARA, D; AMARA, JF; HOPPE, H; SCHEULE, RK; WELSH, MJ; SMITH, AE; CHENG, SH			STOICHIOMETRY OF RECOMBINANT CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IN EPITHELIAL-CELLS AND ITS FUNCTIONAL RECONSTITUTION INTO CELLS IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED GENE-TRANSFER; CFTR CHLORIDE CHANNEL; MOUSE CELLS; R-DOMAIN; EXPRESSION; KINASE; IDENTIFICATION; TRANSPORT; MUTATIONS; DNA	We have generated several clones of Chinese hamster ovary, mouse epitheloid C127, and pig kidney epithelial LLCPK1 cells producing high levels of functional recombinant human cystic fibrosis transmembrane conductance regulator (CFTR). Processing of CFTR to the mature and fully glycosylated form in these cells is inefficient with only approximately 40% of all newly synthesized CFTR being converted to the mature form. Furthermore, expression of the most frequent mutant allele of the cystic fibrosis (CF) gene, the DELTAF508 mutant in these epithelial cells, indicated that it is biosynthetically arrested at the endoplasmic reticulum and fails to traffic to the plasma membrane. Using a combination of CFTR mutants and monoclonal antibodies, all the detectable recombinant CFTR in these cells was determined at least under the conditions used, to be present as a monomer. To demonstrate the feasibility of protein replacement therapy, we were able to effect the physical transfer of functional recombinant CFTR produced in Chinese hamster ovary cells to the plasma membranes of Ha3b fibroblasts, a cell line devoid of cAMP-stimulated chloride channels. Transfer of CFTR was mediated by the hemagglutinin viral fusion protein of influenza virus present on the Ha3b cells. Efficiency of transfer was up to 25% of the target cells, and CFTR chloride channel activity was detectable for up to 12 h post-fusion. Therefore, with the development of an appropriate formulation of fusogenic proteoliposome or virosome containing reconstituted purified CFTR, it should be feasible to introduce functional CFTR into CF-affected cells.	GENZYME CORP,MT RD,FRAMINGHAM,MA 01701; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Sanofi-Aventis; Genzyme Corporation; Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa			Cheng, Seng H/AAC-6564-2022	Welsh, Michael/0000-0002-1646-6206; Ostedgaard, Lynda/0000-0001-7717-3442; Marshall, John/0000-0003-1361-2869				ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDREWS GK, 1987, NUCLEIC ACIDS RES, V15, P5461, DOI 10.1093/nar/15.13.5461; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; Cheng Seng H., 1993, P175; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DEYDALEMANS W, 1991, NATURE, V354, P524; DITULLIO P, 1992, BIO-TECHNOL, V10, P74, DOI 10.1038/nbt0192-74; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; ELLENS H, 1990, BIOCHEMISTRY-US, V29, P9697, DOI 10.1021/bi00493a027; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; FIDDES J C, 1981, Journal of Molecular and Applied Genetics, V1, P3; GOULDFOGERITE S, 1993, LIPOSOME TECHNOLOGY, V3, P261; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GUNZBURG JD, 1989, P NATL ACAD SCI USA, V86, P4007; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LI CH, 1993, NAT GENET, V3, P311, DOI 10.1038/ng0493-311; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; OSTEDGAARD LS, 1992, J BIOL CHEM, V267, P26142; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; REDDY VB, 1987, DNA-J MOLEC CELL BIO, V6, P461, DOI 10.1089/dna.1987.6.461; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, HUM GENE THER, V4, P461, DOI 10.1089/hum.1993.4.4-461; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RICH DP, 1993, IN PRESS RECEPTOR SC; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; SAMBROOK J, 1985, EMBO J, V4, P91, DOI 10.1002/j.1460-2075.1985.tb02322.x; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; SMITH AE, 1992, ANNU REP MED CHEM, V27, P235; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; TILLY BC, 1992, J BIOL CHEM, V267, P9470; Tsui Lap-Chee, 1992, Human Mutation, V1, P197, DOI 10.1002/humu.1380010304; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WANG HY, 1989, J BIOL CHEM, V264, P14424; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YOSHIMURA K, 1992, NUCLEIC ACIDS RES, V20, P3233, DOI 10.1093/nar/20.12.3233; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	62	104	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2987	2995						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7507932				2022-12-25	WOS:A1994MV43200090
J	GAO, AG; FRAZIER, WA				GAO, AG; FRAZIER, WA			IDENTIFICATION OF A RECEPTOR CANDIDATE FOR THE CARBOXYL-TERMINAL CELL-BINDING DOMAIN OF THROMBOSPONDINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; DIFFERENTIAL EXPRESSION; TRITON X-114; PLATELET; CD36; SPECIFICITY; REQUIREMENT; CARCINOMA; PEPTIDES; MATRIX	The carboxyl-terminal cell binding domain (CBD) of thrombospondin-1 (TS1) contains two cell attachment peptides, 4N1s (RFYVVMWK) and 7N3 (FIRVVMYGKK), which share the sequence VVM. These peptides, and more soluble derivatives have been radiolabeled with I-125 and used in conjunction with a variety of membrane impermeant cross-linking reagents to identify and characterize receptor candidates on several cell types. All of the VVM containing peptides tested with five different cross-linking reagents specifically labeled a 52-kDa protein, which was also affinity labeled by the recombinant TS1 CBD. After cross-linking peptide to K562 cells to block the 52-kDa protein, both cell adhesion to and affinity labeling by VVM peptides were inhibited in a concentration-dependent manner. Peptide labeling, like cell adhesion, was partially inhibited by heparin and stimulated by EDTA The 52-kDa protein did not appear to contain sulfated glycan chains and was trypsin sensitive. It was recovered in a membrane fraction and was readily solubilized with Triton X-100 and X-114. Upon phase separation of the Triton X-114, the 52-kDa protein partitioned into the hydrophobic detergent phase. The detergent-solubilized receptor candidate bound selectively to wheat germ agglutinin-Sepharose, and after cell surface labeling with a membrane impermeant biotinylating reagent, bound 60 streptavidin-Sepharose. Furthermore, fluorescent beads covalently derivatized with peptide specifically decorated intact K562 cells. Thus the properties of the 52-kDa protein are consistent with those of a receptor for the CBD of TS1 and other TS isoforms.	WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)					NHLBI NIH HHS [HL14147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS J, 1993, CURR BIOL, V3, P188, DOI 10.1016/0960-9822(93)90270-X; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; FRAZIER WA, 1993, THROMBOSPONDIN, P91; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GREENWALT DE, 1990, BIOCHEMISTRY-US, V29, P7054, DOI 10.1021/bi00482a015; IMAI Y, 1993, NATURE, V361, P555; INGALLS HM, 1986, P NATL ACAD SCI USA, V83, P4779, DOI 10.1073/pnas.83.13.4779; IRUELAARISPE ML, 1993, DEV DYNAM, V197, P40, DOI 10.1002/aja.1001970105; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; JANSSEN K, 1993, CURR PROT MOL BIOL, V2; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; KOSFELD MD, 1993, J BIOL CHEM, V268, P8808; KOSFELD MD, 1992, J BIOL CHEM, V267, P16230; KOSFELD MD, 1991, J BIOL CHEM, V266, P24257; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLER J, 1989, BLOOD, V74, P2022; LI WX, 1993, J BIOL CHEM, V268, P16179; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; NEWMAN PJ, 1982, THROMB RES, V27, P221, DOI 10.1016/0049-3848(82)90202-X; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RAUGI GJ, 1987, J INVEST DERMATOL, V89, P551, DOI 10.1111/1523-1747.ep12461198; REED MJ, 1993, J HISTOCHEM CYTOCHEM, V41, P1467, DOI 10.1177/41.10.8245406; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; SHEPHARD EG, 1988, ANAL BIOCHEM, V168, P306, DOI 10.1016/0003-2697(88)90323-5; SORENSEN P, 1986, J BIOL CHEM, V261, P9094; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; SUN XJ, 1989, J BIOL CHEM, V264, P11288; SUNDBLAD G, 1988, J BIOL CHEM, V263, P8890; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TUSZYNSKI GP, 1993, J CELL BIOL, V120, P513, DOI 10.1083/jcb.120.2.513; YABKOWITZ R, 1991, CANCER RES, V51, P3648	36	65	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29650	29657						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7525586				2022-12-25	WOS:A1994PU28400054
J	MA, L; RAYCROFT, L; ASA, D; ANDERSON, DC; GENG, JG				MA, L; RAYCROFT, L; ASA, D; ANDERSON, DC; GENG, JG			A SIALOGLYCOPROTEIN FROM HUMAN-LEUKOCYTES FUNCTIONS AS A LIGAND FOR P-SELECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE MEMBRANE-PROTEIN; CARBOHYDRATE LIGAND; GLYCOPROTEIN LIGAND; MYELOID CELLS; ADHESION MOLECULE-1; ENDOTHELIAL-CELLS; MEDIATES ADHESION; GMP-140 BINDS; LECTIN DOMAIN; SIALYL-LEX	P-selectin (CD62P), a Ca2+-dependent lectin expressed on activated platelets and endothelial cells, functions as a receptor for myeloid and monocytoid cells. Previous reports have described a homodimeric sialoglycoprotein from human leukocytes and HL-60 cells specifically recognized by P-selectin. We describe here a panel of monoclonal antibodies prepared against high molecular weight fractions of HL-60 cell membranes. These antibodies are of IgM isotype, bind to a similar to 240-kDa protein from human leukocyte membranes which is also reactive with P-selectin. They recognize a Ca2+-dependent, sialidase-sensitive determinant on myeloid and monocytoid cell lines. Each antibody specifically inhibits adhesion of neutrophils or HL-60 cells to: 1) purified P-selectin, 2) thrombin-stimulated platelets, and 3) phorbol 12-myristate 13-acetate-activated endothelial cells. These results suggest that the sialoglycoprotein recognized by this panel of monoclonal antibodies may function as a cell surface ligand for P-selectin.	UPJOHN CO,UPJOHN LABS,CELL BIOL & INFLAMMAT RES,KALAMAZOO,MI 49001	Pfizer								ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P2292, DOI 10.1073/pnas.89.6.2292; ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; ASA D, 1992, GLYCOBIOLOGY, V2, P395, DOI 10.1093/glycob/2.5.395; BAJORATH J, 1994, BIOCHEMISTRY-US, V33, P1332, DOI 10.1021/bi00172a007; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERG EL, 1991, J BIOL CHEM, V266, P14869; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BRANDLEY BK, 1993, GLYCOBIOLOGY, V3, P633, DOI 10.1093/glycob/3.6.633; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GENG JG, 1991, J BIOL CHEM, V266, P22313; GENG JG, 1992, J BIOL CHEM, V267, P19846; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; HAMBURGER SA, 1990, BLOOD, V75, P550; HANDA K, 1991, BIOCHEM BIOPH RES CO, V181, P1223, DOI 10.1016/0006-291X(91)92069-V; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JOHNSTON GI, 1989, J BIOL CHEM, V264, P1816; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; LARKIN M, 1992, J BIOL CHEM, V267, P13661; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; MYADAS TN, 1993, CELL, V74, P541; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; PALABRICA T, 1992, NATURE, V359, P848, DOI 10.1038/359848a0; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SAWADA R, 1994, J BIOL CHEM, V269, P1425; SKINNER MP, 1989, BIOCHEM BIOPH RES CO, V164, P1373, DOI 10.1016/0006-291X(89)91821-4; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STONE JP, 1993, J CLIN INVEST, V92, P804, DOI 10.1172/JCI116654; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; Watkins W M, 1980, Adv Hum Genet, V10, P1; WEYRICH AS, 1993, J CLIN INVEST, V91, P2620, DOI 10.1172/JCI116501; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	50	95	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27739	27746						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525560				2022-12-25	WOS:A1994PV77100090
J	CLARK, EA; TRIKHA, M; MARKLAND, FS; BRUGGE, JS				CLARK, EA; TRIKHA, M; MARKLAND, FS; BRUGGE, JS			STRUCTURALLY DISTINCT DISINTEGRINS CONTORTROSTATIN AND MULTISQUAMATIN DIFFERENTIALLY REGULATE PLATELET TYROSINE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLYCOPROTEIN-IIB-IIIA; ACTIVATOR-INDUCED THROMBOLYSIS; PLASMINOGEN-ACTIVATOR; AGGREGATION INHIBITOR; CORONARY-THROMBOSIS; INTEGRIN RECEPTORS; CONTAINING PEPTIDE; VIPER VENOMS; CANINE MODEL; GPIIB-IIIA	Tyrosine phosphorylation of multiple platelet proteins is regulated by the integrin alpha(IIb)beta(3). In order to further examine integrin-regulated tyrosine phosphorylation, we have used small Arg-Gly-Asp-containing snake venom proteins (termed disintegrins) that inhibit platelet aggregation to competitively block the agonist-induced binding of fibrinogen to alpha(IIb)beta(3). One structurally unique disintegrin, contortrostatin (which appears to be a disulfide-linked dimer of 13.5 kDa with two Arg-Gly-Asp sites), was found to trigger signaling events typically mediated by fibrinogen cross-linking of alpha(IIb)beta(3), as demonstrated by tyrosine phosphorylation of the tyrosine kinase pp72(syk) and a 140-kDa protein. Contortrostatin and another disintegrin, multisquamatin (a monomer of 5.7 kDa with a single Arg-Gly-Asp site), did not affect thrombin-induced platelet shape change, secretion, or integrin-independent tyrosine phosphorylation; however, they inhibited aggregation and aggregation-dependent tyrosine phosphorylation of numerous proteins, including the focal adhesion kinase pp125(FAK). Our results suggest that structurally distinct disintegrins have varying effects on tyrosine phosphorylation; while monomeric multisquamatin and dimeric contortrostatin both inhibit aggregation-dependent tyrosine phosphorylation, contortrostatin also possesses a unique functional activity that allows it to activate an intracellular signaling pathway leading to tyrosine phosphorylation. This activity may be involved in the function of this snake venom protein on hemostasis.	ARIAD PHARMACEUT INC,CAMBRIDGE,MA 02139; UNIV PENN,SCH MED,GRAD GRP CELL BIOL,PHILADELPHIA,PA 19104; UNIV SO CALIF,SCH MED,DEPT BIOCHEM & MOLEC BIOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,KENNETH NORRIS JR COMPREHENS CANC CTR,LOS ANGELES,CA 90033	Takeda Pharmaceutical Company Ltd; Takeda Oncology; University of Pennsylvania; University of Southern California; University of Southern California			Clark, Edward/K-3462-2012		NATIONAL CANCER INSTITUTE [R01CA047527] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA47527] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; CHAO BH, 1989, P NATL ACAD SCI USA, V86, P8050, DOI 10.1073/pnas.86.20.8050; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; CLARK EA, 1993, TRENDS CARDIOVAS MED, V3, P218, DOI 10.1016/1050-1738(93)90043-6; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COLLER BS, 1989, CIRCULATION, V80, P1766, DOI 10.1161/01.CIR.80.6.1766; COOK JJ, 1989, AM J PHYSIOL, V256, pH1038, DOI 10.1152/ajpheart.1989.256.4.H1038; DENNIS MS, 1990, P NATL ACAD SCI USA, V87, P2471, DOI 10.1073/pnas.87.7.2471; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FOX JEB, 1993, J BIOL CHEM, V268, P25973; GAN ZR, 1988, J BIOL CHEM, V263, P19827; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HOLAHAN MA, 1991, PHARMACOLOGY, V42, P340, DOI 10.1159/000138817; Huang E. M., 1986, BIOCH PLATELETS, P1; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SAUDEK V, 1991, EUR J BIOCHEM, V202, P329, DOI 10.1111/j.1432-1033.1991.tb16380.x; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14733; SHEBUSKI RJ, 1990, CIRCULATION, V82, P169, DOI 10.1161/01.CIR.82.1.169; TENG CM, 1991, THROMB HAEMOSTASIS, V65, P624; TRIKHA M, 1994, THROMB RES, V73, P39, DOI 10.1016/0049-3848(94)90052-3; TRIKHA M, 1994, IN PRESS CANCER RES; WENCELDRAKE JD, 1993, BLOOD, V81, P62; WILLIAMS JA, 1992, PATHOL BIOL, V40, P813; WONG S, 1992, ONCOGENE, V7, P2407; YASUDA T, 1991, CIRCULATION, V83, P1038, DOI 10.1161/01.CIR.83.3.1038	32	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					21940	21943						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7520909				2022-12-25	WOS:A1994PE09800005
J	KOLEV, K; LERANT, I; TENEKEJIEV, K; MACHOVICH, R				KOLEV, K; LERANT, I; TENEKEJIEV, K; MACHOVICH, R			REGULATION OF FIBRINOLYTIC-ACTIVITY OF NEUTROPHIL LEUKOCYTE ELASTASE, PLASMIN, AND MINIPLASMIN BY PLASMA PROTEASE INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-PROTEINASE INHIBITOR; ALPHA-2-MACROGLOBULIN; ALPHA-2-ANTIPLASMIN; STREPTOKINASE; ACTIVATION; KINETICS; HEPARIN	The effect of solid-phase fibrin on the inactivation of plasmin, miniplasmin, and neutrophil leukocyte elastase (PMN elastase) by plasma protease inhibitors (alpha(2)-antiplasmin, alpha(1)-protease inhibitor, alpha(2)-macroglobulin) was studied. In Hanks' balanced salt solution, fibrin reduces the second order rate constant for the inhibition of PMN elastase by alpha(1)-protease inhibitor from 8,760 x 10(4) to 4 x 10(4) M(-1).S-1 and by alpha(2)-macroglobulin from 121 x 10(4) to 1.8 x 10(4) M(-1) S-1. The rate constant for miniplasmin inactivation by alpha(2)-antiplasmin decreases from 99 x 10(4) to 1 x 10(4) M(-1).S-1, by alpha(2)-macroglobulin from 78 x 10(4) to 1.8 x 10(4) M(-1).S-1, and by alpha(1)-protease inhibitor from 0.11 x 10(4) M(-1).S-1 to 0. Plasmin bound to fibrin is completely protected against alpha(2)-macroglobulin and alpha(1)-protease inhibitor, whereas the rate constant for the inactivation by its primary plasma inhibitor alpha(2)-antiplasmin is reduced from 430 x 10(4) to 1.08 x 10(4) M(-1).S-1. The competition of substrate and inhibitor for the enzyme was also studied, using fibrin preincubated with inhibitor. Under our pseudo-first-order experimental conditions, fibrin completely eliminates those interactions, the second-order rate constant of which is 1.1 x 10(5) M(-1).S-1 or less in a system without fibrin surface.	SEMMELWEIS UNIV MED,DEPT BIOCHEM 2,H-1444 BUDAPEST,HUNGARY	Semmelweis University			Kolev, Krasimir/A-3517-2008; Tenekedjiev, Kiril/D-8141-2012; Kolev, Krasimir/J-7648-2019	Kolev, Krasimir/0000-0002-5612-004X; Tenekedjiev, Kiril/0000-0003-3549-0671; Kolev, Krasimir/0000-0002-5612-004X				ANONICK PK, 1990, THROMB RES, V59, P449, DOI 10.1016/0049-3848(90)90406-3; BACHMANN F, 1987, THROMB DIATH HAEMO, P227; BEATTY K, 1980, J BIOL CHEM, V255, P3931; CEDERHOLMWILLIAMS SA, 1979, EUR J BIOCHEM, V100, P125, DOI 10.1111/j.1432-1033.1979.tb02040.x; FROMMHERZ KJ, 1991, J BIOL CHEM, V266, P15356; GONIAS SL, 1988, BIOCHEM J, V255, P725; GUREWICH V, 1992, ANN NY ACAD SCI, V667, P224, DOI 10.1111/j.1749-6632.1992.tb51619.x; HEKMAN CM, 1987, SEMIN THROMB HEMOST, V13, P514, DOI 10.1055/s-2007-1003527; MACHOVICH R, 1989, BIOCHEMISTRY-US, V28, P4517, DOI 10.1021/bi00436a059; Machovich R, 1990, Blood Coagul Fibrinolysis, V1, P79, DOI 10.1097/00001721-199003000-00011; NIEWIAROWSKI S, 1972, ANN NY ACAD SCI, V201, P72, DOI 10.1111/j.1749-6632.1972.tb16288.x; PETERSEN LC, 1981, BIOCHEM J, V199, P121, DOI 10.1042/bj1990121; PLOW EF, 1980, BIOCHIM BIOPHYS ACTA, V630, P47, DOI 10.1016/0304-4165(80)90136-1; STEINER JP, 1987, BIOCHEMISTRY-US, V26, P8487, DOI 10.1021/bi00399a068; THORSEN S, 1992, ANN NY ACAD SCI, V667, P52, DOI 10.1111/j.1749-6632.1992.tb51597.x; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255	16	69	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17030	17034						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516329				2022-12-25	WOS:A1994NT84600010
J	WILLNOW, TE; ORTH, K; HERZ, J				WILLNOW, TE; ORTH, K; HERZ, J			MOLECULAR DISSECTION OF LIGAND-BINDING SITES ON THE LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR TYPE-1; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; LDL-RECEPTOR; APOLIPOPROTEIN-E; CHYLOMICRON REMNANTS; MEDIATED ENDOCYTOSIS; HEYMANN NEPHRITIS; CULTURED-CELLS; RAT-LIVER	The low density lipoprotein receptor-related protein (LRP) is a large multifunctional receptor that is involved in the cellular uptake of a number of functionally diverse ligands including apoE-rich remnant lipoproteins, lipoprotein lipase, alpha(2)-macroglobulin-protease complexes, plasminogen activator-inhibitor complexes, and the active protease tissue-type plasminogen activator. Ligand binding and competition experiments suggest that most LRP ligands bind to specific, independent sites on the large 515-kDa subunit of the receptor. In a previous study (Moestrup, S. K., Holtet, T. L., Etzerodt, M., Thogersen, H. C., Nykjaer, A., Andreasen, P. A., Rasmussen, H. H., Sottrup-Jensen, L., and Gliemann, J. (1993) J. Biol. Chem. 268, 13691-13696), ligand blotting was used to localize the binding sites for urokinase-type plasminogen activator-plasminogen activator inhibitor-1 (PAI-1) complexes and for alpha(1)-macroglobulin to a proteolytic fragment of LRP containing the second cluster of complement-type cysteine-rich repeats. Here, we have used a recombinant DNA approach to express functionally restricted chimeric ''LRP-minireceptors'' containing two different regions of the extracellular domain of the receptor in cultured cells. Receptor-associated protein, a negative modulator of LRP activity, is bound and internalized by cells transfected with either construct. A minireceptor containing the cluster of eight complement-type cysteine-rich repeats followed by four epidermal growth factor precursor homologous domains binds and internalizes I-125-labeled plasminogen activator-PAI-1 complexes. It also mediates the cellular uptake of the uncomplexed protease tissue-type plasminogen activator (tPA), suggesting that the tPA and PAI-1 binding sites on LRP are in close vicinity and might promote cooperative binding of tPA PAI-1 complexes. However, alpha(2)-macroglobulin is not internalized by this minireceptor suggesting that this ligand requires the presence of a single epidermal growth factor-repeat which is contained in the previously studied proteolytic fragment but is absent from the minireceptor.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	WILLNOW, TE (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.		Orth, Kim/AAV-4421-2021	Orth, Kim/0000-0002-0678-7620; Willnow, Thomas/0000-0001-9515-7921	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BASSELDUBY R, 1992, J BIOL CHEM, V267, P9668; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CAMANI C, 1994, J BIOL CHEM, V269, P5770; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HERZ J, 1993, CELL, V73, P428, DOI 10.1016/0092-8674(93)90130-I; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1990, J BIOL CHEM, V265, P21355; HUETTINGER M, 1992, J BIOL CHEM, V267, P18551; HUETTINGER M, 1988, CLIN BIOCHEM, V21, P87, DOI 10.1016/S0009-9120(88)80093-6; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; NGUYEN G, 1992, BIOCHEM J, V287, P911, DOI 10.1042/bj2870911; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; Sambrook J, 1989, MOL CLONING LABORATO; STIFANI S, 1991, J BIOL CHEM, V266, P19079; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; VANDIJK MCM, 1992, EUR J BIOCHEM, V205, P775, DOI 10.1111/j.1432-1033.1992.tb16842.x; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	42	121	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15827	15832						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	7515061				2022-12-25	WOS:A1994NP51300067
J	VALLETTE, FM; JUIN, P; PELLESCHI, M; HENRY, JP				VALLETTE, FM; JUIN, P; PELLESCHI, M; HENRY, JP			BASIC PEPTIDES CAN BE IMPORTED INTO YEAST MITOCHONDRIA BY 2 DISTINCT TARGETING PATHWAYS - INVOLVEMENT OF THE PEPTIDE-SENSITIVE CHANNEL OF THE OUTER-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; CATIONIC CHANNEL; SYNTHETIC PRESEQUENCE; INTERMEMBRANE SPACE; LARGE CONDUCTANCE; SIGNAL PEPTIDES; BILAYERS; CYTOCHROME-B2; PRECURSORS; TRANSPORT	The interaction of several basic peptides with yeast mitochondria has been analyzed. The peptides were selected for their ability to block a cationic channel of the outer membrane, the peptide-sensitive channel. These peptides possess common characteristics, such as a net positive charge superior to 2 and the capacity to form amphiphilic structures. They can be divided into two classes as follows: peptides of class I derived from mitochondrial signal peptides, such as the presequence of cytochrome c oxidase subunit IV, e.g. pCyt OX IV (1-12) Y; and peptides of class II unrelated to the mitochondria, such as dynorphin B (1-13). Class I peptides inhibited the translocation of a chimeric protein, cytochrome b(2)- DHFR, into the mitochondrial matrix, whereas peptides of class II failed to inhibit-this import. Experiments with iodinated pCyt OX TV (1-12) Y and dynorphin B (1-13) showed, however, that both types of peptides were imported into yeast mitochondria in vitro and subsequently degraded. At 30 degrees C, two import mechanisms could be distinguished; the mitochondrial presequences (class I) were translocated into the matrix in a temperature- and potential-sensitive manner, probably along the general import pathway, while class II dynorphin B (1-13) was imported into the intermembrane space by a process that was neither temperature- nor potential-sensitive. At 0 degrees C, both peptides were imported in a class II manner. The class II characteristics suggested the existence of a direct pathway into the intermembrane space, which may be associated with the peptide-sensitive channel. This hypothesis is substantiated by the competition for the import into the mitochondria between peptides of the two classes. The import of pCyt OX (1-12) Y was inhibited at 30 degrees C only by peptides of class I, IV whereas, at 0 degrees C, this import was also inhibited by peptides of class II. Import of peptides of the latter class was inhibited by peptides of the two classes both at 0 degrees C and 30 degrees C.			VALLETTE, FM (corresponding author), INST BIOL PHYSICOCHIM, SERV NEUROBIOL PHYSICOCHIM, CNRS, UNITE RECH ASSOCIEE 1112, F-75005 PARIS, FRANCE.		Vallette, Francois/N-2361-2018; JUIN, Philippe P/H-3636-2014; JUIN, Philippe/Q-1338-2019; Vallette, Francois M/K-9047-2015	JUIN, Philippe P/0000-0002-4997-3888; JUIN, Philippe/0000-0002-4997-3888; Vallette, Francois M/0000-0002-3296-8572; Vallette, Francois/0000-0003-0802-0519				ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; CHICH JF, 1991, EUR J BIOCHEM, V196, P29, DOI 10.1111/j.1432-1033.1991.tb15781.x; CYR DM, 1991, J BIOL CHEM, V266, P21700; DAUM G, 1982, J BIOL CHEM, V257, P3028; FEVRE F, 1990, FEBS LETT, V262, P201, DOI 10.1016/0014-5793(90)80189-P; FURUYA S, 1987, J BIOCHEM, V102, P821, DOI 10.1093/oxfordjournals.jbchem.a122121; FURUYA S, 1991, EMBO J, V10, P1759, DOI 10.1002/j.1460-2075.1991.tb07700.x; GILLESPIE LL, 1985, J BIOL CHEM, V260, P6045; GLASER SM, 1990, J BIOL CHEM, V265, P8817; GLASER SM, 1990, J BIOL CHEM, V265, P8808; GLICK B, 1991, ANNU REV GENET, V25, P21; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; GRAZIA I, 1993, P NATL ACAD SCI USA, V82, P8317; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HENRY JP, 1989, J MEMBRANE BIOL, V112, P139, DOI 10.1007/BF01871275; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; MADUKE M, 1993, SCIENCE, V260, P364, DOI 10.1126/science.8385804; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MICHEJDA J, 1989, ANION CARRIERS OF MITOCHONDRIAL MEMBRANES, P225; ONO H, 1988, J BIOL CHEM, V263, P3188; PAK YK, 1990, J BIOL CHEM, V265, P14298; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; PFANNER N, 1988, EUR J BIOCHEM, V175, P205, DOI 10.1111/j.1432-1033.1988.tb14185.x; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; ROISE D, 1992, P NATL ACAD SCI USA, V89, P608, DOI 10.1073/pnas.89.2.608; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; SEGUIREAL B, 1992, FEBS LETT, V313, P2, DOI 10.1016/0014-5793(92)81171-H; SEQUIREAL B, 1993, EMBO J, V12, P2211, DOI 10.1002/j.1460-2075.1993.tb05869.x; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SWANSON ST, 1992, BIOCHEMISTRY-US, V31, P5746, DOI 10.1021/bi00140a009; THIEFFRY M, 1988, EMBO J, V7, P1449, DOI 10.1002/j.1460-2075.1988.tb02962.x; THIEFFRY M, 1992, BIOPHYS J, V63, P333, DOI 10.1016/S0006-3495(92)81626-0	36	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13367	13374						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7513702				2022-12-25	WOS:A1994NK18400049
J	RANDALL, WR				RANDALL, WR			CELLULAR EXPRESSION OF A CLONED, HYDROPHILIC, MURINE ACETYLCHOLINESTERASE - EVIDENCE OF PALMITOYLATED MEMBRANE-BOUND FORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN ACETYLCHOLINESTERASE; CHICK-EMBRYO MUSCLE; MOLECULAR-FORMS; MESSENGER-RNA; TORPEDO ACETYLCHOLINESTERASE; DISULFIDE BONDS; PALMITIC ACID; SINGLE GENE; CELLS; ACYLATION	The expression and cellular targeting of murine acetylcholinesterase (AChE) was examined after transient transfection of a human 293 cell line with a cDNA encoding the hydrophilic T-subunit. Expression of the recombinant clone produced catalytically active AChE either bound to the cell membranes, in an intracellular pool, or secreted into the medium. About 22% of the cell-associated AChE was membrane-linked as dimers and tetramers, required Triton X-100 for extraction, and bound to Triton X-100 as assessed by sucrose gradients. Immunocytochemical staining of live and permeabilized cells showed reactive epitopes at the plasma membrane. Assays of cell surface AChE activity indicated about 18% of the cellular enzyme was oriented on the external surface of the plasma membrane. Isotopic labeling of cultures with precursors of fatty acylation showed incorporation of [H-3]palmitate into the membrane-bound fraction of AChE only. The label was sensitive to cleavage by mild alkaline methanol treatment, and the cleaved lipid was identified as methyl palmitate by thin layer chromatography, indicating covalent linkage of the fatty acid through an ester or thioester residue. Thus the membrane-bound AChE is palmitoylated, suggesting that fatty acylation may serve as an alternative mechanism for anchoring the hydrophilic polypeptide subunit of AChE to the external face of the plasma membrane.	UNIV MARYLAND, SCH MED, CTR MED BIOTECHNOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	RANDALL, WR (corresponding author), UNIV MARYLAND, SCH MED, DEPT PHARMACOL & EXPTL THERAPEUT, BALTIMORE, MD 21201 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS026885] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 26885] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMSON ED, 1977, J NEUROCHEM, V28, P605, DOI 10.1111/j.1471-4159.1977.tb10432.x; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAZAN NG, 1985, J BIOL CHEM, V260, P3677; BIZZOZERO OA, 1987, J BIOL CHEM, V262, P13550; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BULGER JE, 1982, DEV NEUROSCI-BASEL, V5, P474, DOI 10.1159/000112708; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Dittmer J, 1969, METHOD ENZYMOL, V14, P482, DOI [DOI 10.1016/S0076-6879(69)14055-0, 10.1016/S0076-6879(69)14055-0]; DUVAL N, 1992, J CELL BIOL, V118, P641, DOI 10.1083/jcb.118.3.641; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERRAND C, 1986, J NEUROCHEM, V46, P349, DOI 10.1111/j.1471-4159.1986.tb12975.x; FUTERMAN AH, 1985, J NEUROCHEM, V45, P1487, DOI 10.1111/j.1471-4159.1985.tb07217.x; GIBNEY G, 1990, J BIOL CHEM, V265, P12576; GNAGEY AL, 1987, J BIOL CHEM, V262, P13290; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HAAS R, 1986, BIOCHEMISTRY-US, V25, P3098, DOI 10.1021/bi00359a005; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOEG JM, 1986, J BIOL CHEM, V261, P3911; HUANG G, 1988, BIOCHEMISTRY-US, V27, P1395, DOI 10.1021/bi00405a001; INESTROSA NC, 1987, J BIOL CHEM, V262, P4441; JING SQ, 1990, J BIOL CHEM, V265, P11555; JOHNSON CD, 1975, ANAL BIOCHEM, V64, P229, DOI 10.1016/0003-2697(75)90423-6; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; KREJCI E, 1991, EMBO J, V10, P1285, DOI 10.1002/j.1460-2075.1991.tb08070.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR M, 1984, J BIOL CHEM, V259, P3703; LEE SL, 1982, J BIOL CHEM, V257, P2283; LEGAY C, 1993, J NEUROCHEM, V60, P337, DOI 10.1111/j.1471-4159.1993.tb05856.x; LI Y, 1991, J BIOL CHEM, V266, P23083; MACPHEEQUIGLEY K, 1986, J BIOL CHEM, V261, P3565; MARSH D, 1984, J NEUROCHEM, V43, P204, DOI 10.1111/j.1471-4159.1984.tb06698.x; MASSOULIE J, 1982, ANNU REV NEUROSCI, V5, P57, DOI 10.1146/annurev.ne.05.030182.000421; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MAULET Y, 1990, NEURON, V4, P289, DOI 10.1016/0896-6273(90)90103-M; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; OMARY MB, 1981, J BIOL CHEM, V256, P4715; PEARCE EJ, 1991, EMBO J, V10, P2741, DOI 10.1002/j.1460-2075.1991.tb07822.x; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; ROBERTS WL, 1991, J BIOL CHEM, V266, P7481; ROTUNDO RL, 1988, P NATL ACAD SCI USA, V85, P7805, DOI 10.1073/pnas.85.20.7805; ROTUNDO RL, 1980, CELL, V22, P595, DOI 10.1016/0092-8674(80)90369-4; ROTUNDO RL, 1980, CELL, V22, P583, DOI 10.1016/0092-8674(80)90368-2; ROTUNDO RL, 1979, J BIOL CHEM, V254, P4790; RUBIN LL, 1985, J NEUROCHEM, V45, P1932, DOI 10.1111/j.1471-4159.1985.tb10553.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SCHUMACHER M, 1986, NATURE, V319, P407, DOI 10.1038/319407a0; SCHUMACHER M, 1988, J BIOL CHEM, V263, P18979; SIKORAV JL, 1988, EMBO J, V7, P2983, DOI 10.1002/j.1460-2075.1988.tb03161.x; SLOMIANY BL, 1984, J BIOL CHEM, V259, P1997; STAUFENBIEL M, 1986, P NATL ACAD SCI USA, V83, P318, DOI 10.1073/pnas.83.2.318; STOFFEL W, 1983, H-S Z PHYSIOL CHEM, V364, P1455, DOI 10.1515/bchm2.1983.364.2.1455; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; VELAN B, 1991, J BIOL CHEM, V266, P23977; VELAN B, 1991, CELL MOL NEUROBIOL, V11, P143, DOI 10.1007/BF00712806; VIGNY M, 1978, EUR J BIOCHEM, V85, P317, DOI 10.1111/j.1432-1033.1978.tb12241.x; WATSON CJ, 1985, DNA CLONING PRACTICA, V1, P79; WILSON BW, 1973, DEV BIOL, V33, P285, DOI 10.1016/0012-1606(73)90138-3	58	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12367	12374						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512968				2022-12-25	WOS:A1994NG37700104
J	SCHIEMANN, WP; NATHANSON, NM				SCHIEMANN, WP; NATHANSON, NM			INVOLVEMENT OF PROTEIN-KINASE-C DURING ACTIVATION OF THE MITOGEN-ACTIVATED PROTEIN-KINASE CASCADE BY LEUKEMIA INHIBITORY FACTOR - EVIDENCE FOR PARTICIPATION OF MULTIPLE SIGNALING PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; RIBOSOMAL PROTEIN-S6; MAP KINASE; GP130; TRANSDUCER; CELLS; PHOSPHORYLATION; EXPRESSION; LIF; RAS	We show here that treatment of 3T3-L1 cells with leukemia inhibitory factor (LIF) stimulates the activation of mitogen-activated protein kinase kinase (MAPKK), mitogen-activated protein kinase (MAPK), and S6 protein kinase (S6K) activities both in a time- and dose-dependent manner. A single peak of MAPKK activity, four peaks of activity against the S6 synthetic peptide, RRLSSLRA (S6 peptide), and three distinct peaks toward myelin basic protein (MBP) were observed after Mono Q chromatography of LIF-stimulated cell extracts. Two of the MBP kinase activities correlated with the stimulation of extracellular signal-regulated kinases 1 and 2. Interestingly, down-regulation of protein kinase C (PKC) by chronic treatment of 3T3-L1 cells with phorbol ester was found to attenuate, but not block, the LIF-mediated stimulation of MAPKK, MAPK, and S6K activities in 3T3-L1 cells. Treatment of 3T3-L1 cells with epidermal growth factor increased MAPKK, MAPK, and S6K activities to a similar extent as LIF, but this activation was not attenuated by down-regulation of PKC. Our results suggest that the full activation of the MAPK cascade by LIF may require inputs from multiple signaling pathways, one of which is dependent upon the presence of functional PKC.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM07750] Funding Source: Medline; NINDS NIH HHS [NS26920] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026920] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHN NG, 1990, J BIOL CHEM, V265, P11487; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BLENIS J, 1986, P NATL ACAD SCI USA, V83, P1733, DOI 10.1073/pnas.83.6.1733; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1991, J CELL BIOCHEM, V46, P21, DOI 10.1002/jcb.240460105; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P73; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; KALBERG C, 1993, J NEUROCHEM, V60, P145, DOI 10.1111/j.1471-4159.1993.tb05832.x; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEVIN DE, 1993, J NIH RES, V5, P49; LIU JW, 1992, J BIOL CHEM, V267, P16763; METCALF D, 1991, INT J CELL CLONING, V9, P95, DOI 10.1002/stem.5530090201; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORI M, 1989, BIOCHEM BIOPH RES CO, V160, P1085, DOI 10.1016/S0006-291X(89)80114-7; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NORTHWOOD IC, 1990, P NATL ACAD SCI USA, V87, P6107, DOI 10.1073/pnas.87.16.6107; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; QURESHI SA, 1991, ONCOGENE, V6, P995; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WEIEL JE, 1990, BIOL MED SIGNAL TRAN; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YANG YC, 1992, BIOFACTORS, V4, P15	48	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6376	6382						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509801				2022-12-25	WOS:A1994MZ50300021
J	MARTINPADURA, I; BAZZONI, G; ZANETTI, A; BERNASCONI, S; ELICES, MJ; MANTOVANI, A; DEJANA, E				MARTINPADURA, I; BAZZONI, G; ZANETTI, A; BERNASCONI, S; ELICES, MJ; MANTOVANI, A; DEJANA, E			NOVEL MECHANISM OF COLON-CARCINOMA CELL - ADHESION TO THE ENDOTHELIUM TRIGGERED BY BETA(1) INTEGRIN CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MONOCLONAL-ANTIBODY; HUMAN-MELANOMA; BETA-1 INTEGRINS; LAMININ RECEPTOR; NUDE-MICE; T-CELLS; GLYCOPROTEIN; MEMBRANE; EXPRESSION	We have found a monoclonal antibody, called BV7, that rapidly stimulated by 6-10-folds HT-29 colon carcinoma cell adhesion to resting human umbilical vein endothelial cells. This effect was directed to tumor cells and not to endothelial cells and was cell-specific. BV7 was also active on the HCCP-2998 but did not change adhesion to endothelial cells of other tumor cells (MG63 osteosarcoma, A375 melanoma, MHCC-1410 and Love colon carcinoma) even if, by flow cytometry, this monoclonal antibody could bind to them. Additionally, BV7 effect was substratum-specific, since it did not increase but rather blocked HT-29 adhesion to matrix proteins. Immunoprecipitation analysis and binding to specific transfectants revealed that BV7 recognizes beta(1)-subunit of integrin receptors and antibody blocking experiments showed that alpha(2) beta(1) antibodies were able to counteract BV7 effect on HT-29 adhesion to endothelial cells. In contrast, antibodies directed to other integrins or endothelial adhesive receptors (E- and P-selectin, VCAM-1, ICAM-1, ICAM-2) were ineffective. Induction of HT-29 adhesion to endothelial cells by BV7 was Fc- and protein synthesis-independent but required metabolically active cells. The presence of physiological concentrations of divalent cations and of cytoskeletal integrity was not needed, Comparative studies with eight different prototypic beta(1) antibodies showed that five of them induced HT-29 adhesion to endothelial cells in a way unrelated to their ability to interfere with HT-29 adhesion to matrix proteins. Cross-blocking binding assays demonstrated that all the five antibodies recognized a topographically related epitope. Taken together these results provide evidence that beta(1) antibodies may trigger a novel pathway of HT-29 colon carcinoma adhesion to endothelial cells with different features in respect to other described mechanisms of tumor cell interaction with the endothelium.	CENG, DBMS, INSERM, U217, HEMATOL LAB, GRENOBLE, FRANCE; CYTEL CORP, SAN DIEGO, CA 92121 USA	Institut National de la Sante et de la Recherche Medicale (Inserm)	MARTINPADURA, I (corresponding author), IST RIC FARMACOL MARIO NEGRI, VASC BIOL LAB, VIA ERITREA 62, I-20157 MILAN, ITALY.		Mantovani, Alberto/HCI-7449-2022; adriana, zanetti/ABA-1189-2020	Mantovani, Alberto/0000-0001-5578-236X; adriana, zanetti/0000-0002-5825-9707; DEJANA, ELISABETTA/0000-0002-0007-0426				ALBELDA SM, 1993, LAB INVEST, V68, P4; ALTIERI DC, 1988, J IMMUNOL, V141, P2656; AMIOT M, 1986, SCAND J IMMUNOL, V23, P109, DOI 10.1111/j.1365-3083.1986.tb01948.x; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; ARROYO AG, 1993, J BIOL CHEM, V268, P9863; BALZAC F, 1993, J CELL BIOL, V121, P171, DOI 10.1083/jcb.121.1.171; BARBIERI B, 1981, P SOC EXP BIOL MED, V168, P204; BAZZONI G, 1993, J SURG ONCOL, P24; BELLONI PN, 1990, CANCER METAST REV, V8, P353, DOI 10.1007/BF00052608; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; CAIXIA S, 1991, CELL IMMUNOL, V138, P216, DOI 10.1016/0008-8749(91)90146-3; CAMPANERO MR, 1992, EUR J IMMUNOL, V22, P3111, DOI 10.1002/eji.1830221213; CAMPANERO MR, 1990, J CELL BIOL, V110, P2157, DOI 10.1083/jcb.110.6.2157; CARLOS TM, 1990, BLOOD, V76, P965; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; CONFORTI G, 1989, BLOOD, V73, P1576; CONFORTI G, 1992, BLOOD, V80, P437; de la Hera A, 1989, Int Immunol, V1, P598, DOI 10.1093/intimm/1.6.598; DEFILIPPI P, 1992, J BIOL CHEM, V267, P18303; DEFILIPPI P, 1991, J CELL BIOL, V114, P855, DOI 10.1083/jcb.114.4.855; DEJANA E, 1988, J CLIN INVEST, V82, P1466, DOI 10.1172/JCI113753; DEJANA E, 1988, J CELL BIOL, V107, P1215, DOI 10.1083/jcb.107.3.1215; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELBATTARI A, 1986, J CELL SCI, V80, P269; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Galfre G, 1981, Methods Enzymol, V73, P3; GIAVAZZI R, 1990, CANCER RES, V50, P4771; GIAVAZZI R, 1986, CANCER RES, V46, P1928; GROUX H, 1989, NATURE, V339, P152, DOI 10.1038/339152a0; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; HOOGENRAAD NJ, 1986, METHOD ENZYMOL, V121, P375; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LAMPUGNANI MG, 1991, J CELL BIOL, V112, P479, DOI 10.1083/jcb.112.3.479; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; LAURI D, 1991, JNCI-J NATL CANCER I, V83, P1321, DOI 10.1093/jnci/83.18.1321; LAURI D, 1991, LAB INVEST, V65, P525; LAURI D, 1991, VASCULAR ENDOTHELIUM, P111; MARCHISIO PC, 1991, J CELL BIOL, V112, P761, DOI 10.1083/jcb.112.4.761; MARTINPADURA I, 1991, CANCER RES, V51, P2239; METZELAAR MJ, 1991, VIRCHOWS ARCH B, V61, P269; MORTAMO P, 1991, J IMMUNOL, V16, P2530; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; NICOLSON GL, 1988, CANCER METAST REV, V7, P143, DOI 10.1007/BF00046483; PARHAM P, 1983, J IMMUNOL, V131, P2895; PARHAM P, 1985, HDB EXPT IMMUNOLOGY, V14, P1; PELLEGRINI R, 1992, TUMORI, V78, P1; PHILLIPS DR, 1988, BLOOD, V71, P831; PIGOTT R, 1991, J IMMUNOL, V147, P130; PULIDO R, 1991, J BIOL CHEM, V266, P10241; RICE GE, 1988, AM J PATHOL, V133, P204; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SANCHEZMATEOS P, 1993, J IMMUNOL, V151, P3817; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SONNENBERG A, 1987, J BIOL CHEM, V262, P10376; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; TIMPL R, 1979, J BIOL CHEM, V254, P9933; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; WELLICOME SM, 1990, J IMMUNOL, V144, P2558; ZHU DZ, 1992, J CLIN INVEST, V89, P1718, DOI 10.1172/JCI115773; ZYLSTRA S, 1986, CANCER RES, V46, P6446	80	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6124	6132						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509799				2022-12-25	WOS:A1994MY84000097
J	HORDIJK, PL; VERLAAN, I; JALINK, K; VANCORVEN, EJ; MOOLENAAR, WH				HORDIJK, PL; VERLAAN, I; JALINK, K; VANCORVEN, EJ; MOOLENAAR, WH			CAMP ABROGATES THE P21(RAS)-MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY IN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; CELL-PROLIFERATION; DNA-SYNTHESIS; RAS; ACTIVATION; P21RAS; PHOSPHORYLATION; TRANSFORMATION; INVOLVEMENT; STIMULATION	The mechanism by which cAMP inhibits growth factor-induced DNA synthesis in fibroblasts is not understood. Here we show that in Rat-1 fibroblasts, cAMP-raising agents inhibit p21ras-mediated mitogen-activated protein (MAP) kinase activation induced by either epidermal growth factor or lysophosphatidic acid. Under the same conditions, however, epidermal growth factor- or lysophosphatidic acid-induced protein tyrosine phosphorylation, Ca2+ mobilization, and activation of Na+/H+ exchange are not attenuated. In ras-transformed Rat-1 cells, 8-bromo-cAMP rapidly deactivates constitutively active MAP kinase without reducing p21ras.GTP levels; long term 8-bromo-cAMP treatment of these cells leads to growth arrest and reversion of the transformed phenotype. These results show that elevation of intracellular cAMP levels abrogates the p21ras MAP kinase pathway at a step downstream of p21ras activation. This finding provides a molecular basis for the growth-inhibitory action of cAMP in normal and transformed fibroblasts.			HORDIJK, PL (corresponding author), NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.			Hordijk, Peter/0000-0002-3348-078X; Jalink, Kees/0000-0001-7019-3440				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BLOMHOFF HK, 1987, J CELL PHYSIOL, V131, P426, DOI 10.1002/jcp.1041310315; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P76; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HELDIN NE, 1989, J CELL PHYSIOL, V138, P17, DOI 10.1002/jcp.1041380104; HOLLENBERG MD, 1973, P NATL ACAD SCI USA, V70, P2964, DOI 10.1073/pnas.70.10.2964; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HUGHES DA, 1993, NATURE, V364, P349, DOI 10.1038/364349a0; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; JALINK K, 1990, J BIOL CHEM, V265, P12232; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MAGNALDO I, 1989, FEBS LETT, V245, P65, DOI 10.1016/0014-5793(89)80193-0; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; NILSSON J, 1984, ATHEROSCLEROSIS, V53, P77, DOI 10.1016/0021-9150(84)90107-2; PASTAN I, 1978, NATURE, V274, P645, DOI 10.1038/274645a0; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; POLAKIS P, 1992, J BIOL CHEM, V267, P10780; PUCK TT, 1981, J CELL PHYSIOL, V107, P399, DOI 10.1002/jcp.1041070312; QUINONES MA, 1991, J BIOL CHEM, V266, P14055; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SIESS W, 1990, BIOCHEM BIOPH RES CO, V170, P944, DOI 10.1016/0006-291X(90)92182-Y; TAGLIAFERRI P, 1988, J BIOL CHEM, V263, P409; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TIGYI G, 1992, J BIOL CHEM, V267, P21360; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	44	162	164	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3534	3538						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508916				2022-12-25	WOS:A1994MV63100063
J	SEIFFERT, D; CIAMBRONE, G; WAGNER, NV; BINDER, BR; LOSKUTOFF, DJ				SEIFFERT, D; CIAMBRONE, G; WAGNER, NV; BINDER, BR; LOSKUTOFF, DJ			THE SOMATOMEDIN-B DOMAIN OF VITRONECTIN - STRUCTURAL REQUIREMENTS FOR THE BINDING AND STABILIZATION OF ACTIVE TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; EXTRACELLULAR-MATRIX; PROTEIN; HEPARIN; PLASMA; SITES; PAI-1; PURIFICATION; SPECIFICITY; ADHESION	We recently localized the high affinity binding site for activated type plasminogen activator inhibitor (PAI-1) to the somatomedin B domain (i.e. amino acid (aa) 1-51) of vitronectin (Vn). In this study to further define this site, N-terminal Vn fragments of various lengths were expressed in Escherichia coli and tested for PAI-1 binding activity. Vn polypeptides containing aa 1-52 and 1-40 retained PAI-1 binding activity and stabilized PAI-1 to a similar extent as intact Vn, but polypeptides containing aa 1-30 did not bind to PAI-1 nor stabilize its activity. The effects of monoclonal antibodies (mAbs) to Vn on PAI-1 binding was also determined. One mAb bound to Vn and blocked its ability to bind to PAI-1. It also dissociated pre-existing PAI-1.Vn complexes, and prevented the incorporation of PAI-1 into extracellular matrix of HT 1080 cells. This mAb bound to the recombinant peptide containing aa 1-40, but not to the peptide consisting of aa 1-30. A second randomly chosen mAb with similar affinity for Vn was inactive in these assays and bound to the region between aa 52 and 239. These results indicate that the high affinity binding site for active PAI-1 in Vn is between aa 1 and 40, and that this domain may also stabilize active PAI-1.	Scripps Res Inst, DEPT VASC BIOL CVB-3, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; UNIV VIENNA, DEPT MED PHYSIOL, CLIN EXPTL PHYSIOL LAB, A-1010 VIENNA, AUSTRIA	Scripps Research Institute; University of Vienna					NHLBI NIH HHS [HL31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNES DW, 1985, J BIOL CHEM, V260, P9117; CIAMBRONE GJ, 1990, J CELL BIOL, V111, P2183, DOI 10.1083/jcb.111.5.2183; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; FRYKLUND L, 1974, BIOCHEM BIOPH RES CO, V61, P950, DOI 10.1016/0006-291X(74)90247-2; FRYKLUND L, 1978, FEBS LETT, V87, P55, DOI 10.1016/0014-5793(78)80132-X; HARLOW E, 1988, ANTIBODIES LABORATOR; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HEKMAN CM, 1988, BIOCHEMISTRY-US, V27, P2911, DOI 10.1021/bi00408a037; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HELDIN CH, 1981, SCIENCE, V213, P1122, DOI 10.1126/science.6973821; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOOISTRA T, 1986, BIOCHEM J, V239, P497, DOI 10.1042/bj2390497; KOST C, 1992, J BIOL CHEM, V267, P12098; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN EG, 1987, J CELL BIOL, V105, P2543, DOI 10.1083/jcb.105.6.2543; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; LOSKUTOFF DJ, 1991, FIBRINOLYSIS, V5, P197, DOI 10.1016/0268-9499(91)90001-K; MIMURO J, 1987, BLOOD, V70, P721; MIMURO J, 1989, J BIOL CHEM, V264, P936; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHLEEF RR, 1985, J LAB CLIN MED, V106, P408; SEIFFERT D, 1990, J CELL BIOL, V111, P1283, DOI 10.1083/jcb.111.3.1283; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1991, BIOCHIM BIOPHYS ACTA, V1078, P23, DOI 10.1016/0167-4838(91)90087-G; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; WAJCHENBERG BL, 1980, HORM METAB RES, V12, P516, DOI 10.1055/s-2007-999189; WIMAN B, 1988, THROMB HAEMOSTASIS, V59, P392; WIRTH S, 1983, ACTA ENDOCRINOL-COP, V102, P16, DOI 10.1530/acta.0.1020016; YALOW RS, 1975, J CLIN INVEST, V55, P127, DOI 10.1172/JCI107903; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	42	124	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2659	2666						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7507927				2022-12-25	WOS:A1994MV43200048
J	FABBRI, M; BANNYKH, S; BALCH, WE				FABBRI, M; BANNYKH, S; BALCH, WE			EXPORT OF PROTEIN FROM THE ENDOPLASMIC-RETICULUM IS REGULATED BY A DIACYLGLYCEROL PHORBOL ESTER BINDING-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							VESICULAR STOMATITIS-VIRUS; SUCCESSIVE GOLGI COMPARTMENTS; PHOSPHOLIPID TRANSFER PROTEIN; INTEGRAL MEMBRANE-PROTEIN; ADP-RIBOSYLATION FACTOR; SEMI-INTACT CELLS; KINASE-C; BETA-COP; PHORBOL ESTERS; CAENORHABDITIS-ELEGANS	The export of vesicular stomatitis virus glycoprotein (VSV-G) from the endoplasmic reticulum (ER) involves sorting and concentration, and has been proposed to require the function of heterotrimeric G proteins. To begin to identify the basic elements of a potential signaling pathway involved in vesicle assembly, we have examined whether protein kinase C (PKC) is required for ER to Golgi transport. Calphostin C, a specific inhibitor of the highly conserved cysteine-rich C6H2 motif present in the regulatory domain of PKC was found to be a potent inhibitor of export of VSV-G and vesicle budding from the ER in vivo and in vitro (IC50 similar to 60 nM). In contrast, the diacylglycerol analog phorbol 12-myristate 13-acetate, which activates PKC, enhanced the migration of VSV-G from the ER to pre-Golgi intermediates. Neither reagent had detectable effects on the oligomerization of VSV-G prior to export nor perturbed transport of protein between compartments of the Golgi stack. In contrast to the striking effects of calphostin C, reagents that inhibit the function of the catalytic domain of PKC (including the general kinase inhibitor staurosporine, as well as the more specific inhibitors H-7, H-8, pseudosubstrate inhibitor, or chelerythrine) did not inhibit export from the ER. Export was also insensitive to down-regulation of various PKC isoforms. These results suggest that a novel protein containing the conserved C6H2 motif may serve as a potential link in a signaling pathway regulating vesicle budding from the ER.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NCRR NIH HHS [RR07273, RR08176] Funding Source: Medline; NIGMS NIH HHS [GM42336] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR007273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED S, 1992, BIOCHEM J, V287, P995, DOI 10.1042/bj2870995; AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1993, J BIOL CHEM, V268, P10709; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; AKITA Y, 1994, J BIOL CHEM, V269, P4653; ALEXANDER DR, 1989, BIOCHEM J, V260, P893, DOI 10.1042/bj2600893; BACKER JM, 1991, BIOCHEM PHARMACOL, V41, P1267, DOI 10.1016/0006-2952(91)90097-O; BALCH W E, 1992, Current Biology, V2, P157, DOI 10.1016/0960-9822(92)90276-G; Balch W. E., 1993, Methods (Orlando), V5, P258, DOI 10.1006/meth.1993.1032; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BARLOWE C, 1993, J BIOL CHEM, V268, P873; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENSHLOMO H, 1991, BIOCHEM J, V280, P65, DOI 10.1042/bj2800065; BERGMANN JE, 1981, P NATL ACAD SCI-BIOL, V78, P1746, DOI 10.1073/pnas.78.3.1746; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BUCCIONE R, 1994, BIOCHEM J, V298, P149, DOI 10.1042/bj2980149; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; CHOI OH, 1994, J BIOL CHEM, V269, P536; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COFFEY ET, 1993, J BIOL CHEM, V268, P21060; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEKKER LV, 1991, J NEUROCHEM, V54, P205; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; EICHHOLTZ T, 1990, FEBS LETT, V261, P147, DOI 10.1016/0014-5793(90)80657-5; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GSCHWENDT M, 1991, TRENDS BIOCHEM SCI, V16, P167, DOI 10.1016/0968-0004(91)90064-3; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HENDRICKS LC, 1993, MOL BIOL CELL, V4, P413, DOI 10.1091/mbc.4.4.413; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOCHS G, 1993, EUR J BIOCHEM, V216, P597, DOI 10.1111/j.1432-1033.1993.tb18179.x; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFAY F, 1974, J VIROL, V14, P1220, DOI 10.1128/JVI.14.5.1220-1228.1974; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LUINI A, 1993, TRENDS CELL BIOL, V3, P291; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OKA T, 1994, J CELL BIOL, V124, P425, DOI 10.1083/jcb.124.4.425; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; QUINN P, 1984, J CELL BIOL, V98, P2142, DOI 10.1083/jcb.98.6.2142; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Saraste J, 1992, Semin Cell Biol, V3, P343, DOI 10.1016/1043-4682(92)90020-V; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; TABAS I, 1979, J BIOL CHEM, V254, P1655; TAKIZAWA PA, 1993, CELL, V75, P593, DOI 10.1016/0092-8674(93)90477-8; TERBUSH DR, 1990, J BIOL CHEM, V265, P21179; TING AT, 1992, J BIOL CHEM, V267, P23957; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VITALE N, 1993, J BIOL CHEM, V268, P14715; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79	101	77	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26848	26857						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7523413				2022-12-25	WOS:A1994PQ93100043
J	SOM, S; FRIEDMAN, S				SOM, S; FRIEDMAN, S			INHIBITION OF TRANSCRIPTION IN-VITRO BY BINDING OF DNA(CYTOSINE-5)-METHYLASES TO DNA TEMPLATES CONTAINING CYTOSINE ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZACYTOSINE-CONTAINING DNA; ESCHERICHIA-COLI; ECORII METHYLTRANSFERASE; RNA-POLYMERASE; LAC REPRESSOR; 5-AZACYTIDINE; METHYLASE; MECHANISM; CLONING; GENE	DNA(cytosine-5)-methylases form tight complexes at their methylation sites when the target cytosine residue is substituted by analogs such as 5-azacytosine or 5-fluorocytosine. To test whether such complexes can block RNA transcription in vitro, template DNA-containing methylation sites were prepared, in which cytosine residues in either the (+)- or (-)-strand were substituted by the analogs. Such templates, irrespective of the strand in which substitution was made, could effectively block the elongation of RNA at specific sites when complexed with EcoRII methylase. The protein-DNA complex probably prevents the unwinding of the template strands or might directly present itself as a steric block to the advancing RNA polymerase. RNA synthesis was also inhibited at specific sites due to complex formation between azacytosine-containing DNA and two other methylases, HhaI and HpaII. The 3' ends of the interrupted transcripts were mapped and were found to lie within 13-14, 13, and 23 nucleotides of the binding sites on the (-)-strand for HhaI, HpaII, and EcoRII methylases, respectively. Exonuclease III footprinting revealed that the boundaries of the complexed methylases, HhaI, HpaII, and EcoRII, on the (-)-strand were within 2-3, 1-2, and 9-10 nucleotides, respectively, of the last nucleotide copied by the RNA polymerase.	SUNY HLTH SCI CTR,DEPT PHARMACOL,BROOKLYN,NY 11203	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center								BHAGWAT AS, 1987, J BACTERIOL, V169, P1537, DOI 10.1128/jb.169.4.1537-1546.1987; CARD CO, 1990, NUCLEIC ACIDS RES, V18, P1377, DOI 10.1093/nar/18.6.1377; CASERTA M, 1987, J BIOL CHEM, V262, P4770; DEUSCHLE U, 1990, SCIENCE, V248, P480, DOI 10.1126/science.2158670; DEUSCHLE U, 1986, P NATL ACAD SCI USA, V83, P4134, DOI 10.1073/pnas.83.12.4134; DOSKOCIL J, 1967, BIOCHIM BIOPHYS ACTA, V145, P771, DOI 10.1016/0005-2787(67)90136-0; FRIEDMAN S, 1992, NUCLEIC ACIDS RES, V20, P3241, DOI 10.1093/nar/20.12.3241; FRIEDMAN S, 1982, J BACTERIOL, V151, P262, DOI 10.1128/JB.151.1.262-268.1982; FRIEDMAN S, 1986, NUCLEIC ACIDS RES, V14, P4543, DOI 10.1093/nar/14.11.4543; FRIEDMAN S, 1981, MOL PHARMACOL, V19, P314; FRIEDMAN S, 1993, J BACTERIOL, V175, P6293, DOI 10.1128/JB.175.19.6293-6298.1993; FRIEDMAN S, 1985, J BIOL CHEM, V260, P5698; GIORDANO TJ, 1989, GENE, V84, P209, DOI 10.1016/0378-1119(89)90494-0; HUANG Y, 1991, J BIOL CHEM, V266, P17424; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; LAL D, 1988, MUTAT RES, V193, P229, DOI 10.1016/0167-8817(88)90033-8; OSTERMAN DG, 1988, BIOCHEMISTRY-US, V27, P5204, DOI 10.1021/bi00414a039; PAVCO PA, 1991, NUCLEIC ACIDS RES, V19, P4639, DOI 10.1093/nar/19.17.4639; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; Sambrook J, 1989, MOL CLONING LABORATO; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; SCHENBORN ET, 1985, NUCLEIC ACIDS RES, V13, P6223, DOI 10.1093/nar/13.17.6223; SOM S, 1987, NUCLEIC ACIDS RES, V15, P313, DOI 10.1093/nar/15.1.313; SOM S, 1990, J BIOL CHEM, V265, P4278; WU JC, 1985, BIOCH BIOL DNA METHY, P115	26	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25986	25991						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523398				2022-12-25	WOS:A1994PQ93000011
J	MELOTTI, P; CALABRETTA, B				MELOTTI, P; CALABRETTA, B			ETS-2 AND C-MYB ACT INDEPENDENTLY IN REGULATING EXPRESSION OF THE HEMATOPOIETIC STEM-CELL ANTIGEN CD34	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; MARROW-CELLS; GENE; PROMOTER; PROTEINS; BINDING; DIFFERENTIATION; INVITRO; FAMILY; DNA	CD34 is currently the only well defined human hematopoietic stem cell marker and is expressed on 1-4% of normal bone marrow cells. Putative binding sites for Ets proteins, a family of transcription factors involved in the regulation of cell differentiation and proliferation in many cell systems, are present in the 5'-flanking region of the CD34 gene. Some of these sites are in close proximity to binding sequences of the encoded product of the proto oncogene c-myb, which regulates CD34 expression by interacting with the Myb binding sites. Here we demonstrate that Ets-2 (i) transactivates the CD34 promoter in rodent fibroblasts upon interaction with Ets binding sites and (ii) induces expression of CD34 mRNA and pro protein in the CD34(-) human glioblastoma T98G cells. Ets-2 and c-Myb transactivate the CD34 promoter independently because specific transactivation is abrogated by site specific mutations of the binding sites or by competition with oligomers that include wild type but not mutated Myb or Ets binding sites. Ets-2 and c-Myb appear to have addictive effects on transactivation of the CD34 promoter and on induction of CD34 mRNA. Instead, CD34 surface protein levels might be induced synergistically, raising the possibility of a posttranslational mechanism of CD34 expression in cells constitutively expressing c-Myb and Ets-2.			MELOTTI, P (corresponding author), THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT MICROBIOL & IMMUNOL, PHILADELPHIA, PA 19107 USA.		Melotti, Paola/J-6205-2018	Melotti, Paola/0000-0002-5276-1595				AURIGEMMA RE, 1992, J VIROL, V66, P3056, DOI 10.1128/JVI.66.5.3056-3061.1992; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERENSON RJ, 1988, J CLIN INVEST, V81, P951, DOI 10.1172/JCI113409; BERENSON RJ, 1991, BLOOD, V77, P1717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN J, 1991, INT IMMUNOL, V3, P175, DOI 10.1093/intimm/3.2.175; BURN TC, 1992, BLOOD, V80, P3051; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIVIN CI, 1984, J IMMUNOL, V133, P157; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DELIA D, 1993, BLOOD, V81, P1001; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FACKLER MJ, 1990, J BIOL CHEM, V265, P11056; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HE XY, 1992, BLOOD, V79, P2296; HUTTNER KM, 1981, J CELL BIOL, V91, P153, DOI 10.1083/jcb.91.1.153; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KATZ FE, 1985, LEUKEMIA RES, V9, P191, DOI 10.1016/0145-2126(85)90082-7; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SATTERTHWAITE AB, 1990, BLOOD, V75, P2299; SIMMONS PJ, 1991, BLOOD, V78, P2848; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x	34	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25303	25309						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523384				2022-12-25	WOS:A1994PQ49100013
J	BONNER, G; LAFER, EM; SOUSA, R				BONNER, G; LAFER, EM; SOUSA, R			THE THUMB SUBDOMAIN OF T7 RNA-POLYMERASE FUNCTIONS TO STABILIZE THE TERNARY COMPLEX DURING PROCESSIVE TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ACTIVE-SITE; 3-DIMENSIONAL STRUCTURE; ANGSTROM RESOLUTION; KLENOW FRAGMENT; BACTERIOPHAGE-T7; DNA; INITIATION; TERMINATION	To examine the function of the thumb subdomain in bacteriophage T7 RNA polymerase we constructed a set of deletion mutants within this subdomain. These mutants exhibited reduced processivity during the processive, but not the abortive, stage of transcription. Reduced processivity was found to be due primarily to an increase in the processive ternary complex dissociation rate (destabilization of the processive ternary complex). The destabilization of the ternary complex does not appear to be due to a decrease in the affinity of the polymerase for the nascent RNA. These observations support the proposal that the thumb subdomain functions to stabilize the processive ternary complex during the processive (but not the abortive) stage of transcription, probably by wrapping around the template to prevent polymerase dissociation.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,PROGRAM MOLEC MED,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio				Sousa, Rui/0000-0003-4314-121X; Lafer, Eileen/0000-0002-0493-6522				ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; AUSUBEL MF, 1987, CURRENT PROTOCOLS MO, V1; BASU S, 1986, J MOL BIOL, V190, P425, DOI 10.1016/0022-2836(86)90013-6; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BONNER G, 1994, J BIOL CHEM, V269, P25120; BONNER G, 1992, EMBO J, V11, P3767, DOI 10.1002/j.1460-2075.1992.tb05462.x; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; GOLOMB M, 1974, J BIOL CHEM, V249, P2858; GROSS L, 1992, J MOL BIOL, V228, P488, DOI 10.1016/0022-2836(92)90837-A; IKEDA RA, 1987, J BIOL CHEM, V262, P3790; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LING ML, 1989, NUCLEIC ACIDS RES, V17, P1605, DOI 10.1093/nar/17.4.1605; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; McClure W R, 1980, Methods Enzymol, V64, P277; MOOKHTIAR KA, 1991, BIOCHEMISTRY-US, V30, P6305, DOI 10.1021/bi00239a032; MULLER DK, 1988, BIOCHEMISTRY-US, V27, P5763, DOI 10.1021/bi00415a055; OLLIS DL, 1985, NATURE, V313, P765; OSUMIDAVIS PA, 1992, J MOL BIOL, V226, P37, DOI 10.1016/0022-2836(92)90122-Z; PATRA D, 1992, J MOL BIOL, V224, P307, DOI 10.1016/0022-2836(92)90996-W; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SANKAR S, 1992, J BIOL CHEM, V267, P10168; SHI YB, 1988, J BIOL CHEM, V263, P527; SOUSA R, 1992, J MOL BIOL, V224, P319, DOI 10.1016/0022-2836(92)90997-X; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895	32	33	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25129	25136						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7523379				2022-12-25	WOS:A1994PQ49000090
J	BUSCONI, L; MICHEL, T				BUSCONI, L; MICHEL, T			ENDOTHELIAL NITRIC-OXIDE SYNTHASE MEMBRANE TARGETING - EVIDENCE AGAINST INVOLVEMENT OF A SPECIFIC MYRISTATE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; PLASMA-MEMBRANE; N-MYRISTOYLATION; PROTEIN; PHOSPHORYLATION; TRANSLOCATION; ASSOCIATION; BINDING; MARCKS; DOMAIN	The endothelial isoform of nitric oxide synthase (ecNOS) is targeted to the particulate subcellular fraction by means of N-terminal myristoylation. However, the association of ecNOS with the particulate subcellular fraction appears to be dynamically regulated, in that agonist treatment of endothelial cells induces translocation of the enzyme from membrane to cytosol (Michel, T., Li, G., and Busconi, L. (1993) Proc. Natl, Acad. Sci. U. S. A. 90, 6252-6255). cDNA encoding wild-type and myristoylation-deficient mutant (myr-()) ecNOS was transcribed and translated in vitro, and we found that the recombinant wild-type but not the myr(-) mutant protein undergoes myristoylation and is able to associate with biological membranes prepared from diverse cell sources. Treatment of these cell membranes with heat or with trypsin did not affect their ability subsequently to serve as acceptor membranes for the wild-type recombinant enzyme. The wild-type ecNOS, but not the myr(-) mutant, is able to form stable associations with phospholipid liposomes. We also explored the possibility that a polybasic domain within the ecNOS protein might serve as a secondary structural determinant for ecNOS membrane association and constructed truncation mutants that flank a polybasic domain present in the ecNOS. These truncation mutants, transcribed and translated in vitro or transfected into COS-7 cells, undergo myristoylation and are able to associate with biological membranes in a fashion indistinguishable from the wild type ecNOS. Taken together, these results indicate that ecNOS binding to biological membranes is dependent upon interactions of the N-terminal myristoyl moiety of ecNOS with lipid components of the membrane, and this association does not require a specific membrane protein functioning as a myristate receptor nor the presence of a polybasic domain within the ecNOS.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DIV CARDIOVASC, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School					NHLBI NIH HHS [HL46457] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046457, R29HL046457] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARBOGAST LY, 1976, P NATL ACAD SCI USA, V73, P3680, DOI 10.1073/pnas.73.10.3680; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; KOTKOW KJ, 1993, J BIOL CHEM, V268, P15633; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; SCHERERSINGLER U, 1983, J NEUROSCI METH, V9, P229, DOI 10.1016/0165-0270(83)90085-7; SESSA WC, 1993, CIRC RES, V72, P921, DOI 10.1161/01.RES.72.4.921; SILVERMAN L, 1992, J CELL BIOL, V119, P415, DOI 10.1083/jcb.119.2.415; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WALKER F, 1993, J BIOL CHEM, V268, P19552; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	26	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25016	25020						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7523377				2022-12-25	WOS:A1994PQ49000075
J	HIRAOKA, O; ANAGUCHI, H; YAMASAKI, G; FUKUNAGA, R; NAGATA, S; OTA, Y				HIRAOKA, O; ANAGUCHI, H; YAMASAKI, G; FUKUNAGA, R; NAGATA, S; OTA, Y			LIGAND-BINDING DOMAIN OF GRANULOCYTE-COLONY-STIMULATING FACTOR-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; ESCHERICHIA-COLI; EXTRACELLULAR DOMAIN; MUTATIONAL ANALYSIS; DRUG-THERAPY; PURIFICATION; SECRETION; DESIGN	The amino-terminal domain of the cytokine receptor homologous region (BN domain; roughly 100 amino acid residues) in the receptor for murine granulocyte colony-stimulating factor (G-CSF) was secreted as a maltose-binding protein fusion into the Escherichia coli periplasm. The murine BN domain (mBN) was prepared from the fusion protein by restriction protease Factor Xa digestion and purified to homogeneity. The purified BN domain specifically and stoichiometrically bound G-CSF, with an apparent dissociation constant (K-d) of 3-8 x 10-(8) M. The CD spectrum of the mBN domain was similar to that of the extracellular region of the human growth hormone (GH) receptor, which is composed of turns and beta-sheets held together by disulfide bonds, Tertiary folding and the beta-sheet of this small domain was confirmed by NMR spectroscopy. Disulfide bonds determined by peptide mapping were in the following locations: Cys(107)-Cys(118), Cys(153)-Cys(162), and Cys(143)-Cys(194). Among them, the first and the second produce small loops (roughly 10 amino acid residues) as found in the human GH receptor. These results suggested that the mBN domain of the G-CSF receptor expressed by E. coli has a GH receptorlike structure. However, the third disulfide bond varied considerably between the G-CSF and GH receptors. Disruption of these disulfide bonds in the BN domain of the G-CSP receptor suggested that all of them are critical for maintaining a stably folded protein. Our results will facilitate understanding of the biophysical and structural properties of this receptor.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN; OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN				Nagata, Shigekazu/AAG-3203-2019; Yamasaki, Kazuhiko/L-7108-2018; Fukunaga, Rikiro/CAG-2891-2022	Nagata, Shigekazu/0000-0001-9758-8426; Yamasaki, Kazuhiko/0000-0003-0320-9697; 				BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CLEARY S, 1989, BIOCHEMISTRY-US, V28, P1884, DOI 10.1021/bi00430a068; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEMETRI GD, 1991, BLOOD, V78, P2791; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FOUNTOULAKIS M, 1990, J BIOL CHEM, V265, P13268; FUH G, 1990, J BIOL CHEM, V265, P3111; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GOLDENBERG DP, 1992, TRENDS BIOCHEM SCI, V17, P257, DOI 10.1016/0968-0004(92)90405-X; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; HARRIS KW, 1992, J BIOL CHEM, V267, P15205; IZHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123; LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P99; LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P28; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; NAGATA S, 1991, Progress in Growth Factor Research, V3, P131, DOI 10.1016/S0955-2235(05)80004-3; NAGATA S, 1990, HDB EXPT PHARM, V95, P699; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; OTA Y, 1991, GENE, V106, P159, DOI 10.1016/0378-1119(91)90195-H; ROZAKISADCOCK M, 1991, J BIOL CHEM, V266, P16472; SETO Y, 1992, J IMMUNOL, V148, P259; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; Wuthrich K., 1986, NMR PROTEINS NUCL AC	28	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22412	22419						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7520915				2022-12-25	WOS:A1994PE09800073
J	MISRA, UK; CHU, CTC; GAWDI, G; PIZZO, SV				MISRA, UK; CHU, CTC; GAWDI, G; PIZZO, SV			THE RELATIONSHIP BETWEEN LOW-DENSITY LIPOPROTEIN-RELATED PROTEIN ALPHA(2)-MACROGLOBULIN (ALPHA(2)M) RECEPTORS AND THE NEWLY DESCRIBED ALPHA(2)M SIGNALING RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SMOOTH-MUSCLE CELLS; ALPHA-2-MACROGLOBULIN RECEPTOR; GROWTH-FACTOR; BINDING-PROTEIN; MULTIFUNCTIONAL RECEPTOR; INOSITOL TRISPHOSPHATE; PLASMINOGEN-ACTIVATOR; PHOSPHOLIPASE-C; PERTUSSIS TOXIN; GI-PROTEIN	alpha(2)-Macroglobulin (alpha(2)M)-methylamine binding to macrophages appears to involve two receptors. Binding of alpha(2)M-methylamine to low density lipoprotein-related protein (LRP) results in cellular uptake and degradation, while binding to a newly described alpha(2)M signaling receptor elevates intracellular calcium ([Ca2+](i)) and inositol phosphates. We now demonstrate that binding of lactoferrin, Pseudomonas exotoxin A, and lipoprotein lipase to LRP on macrophages results in increased [Ca2+](i) and inositol 1,4,5-triphosphate. Receptor-associated protein, which binds to LRP but not the alpha(2)M signaling receptor, blocks the lactoferrin signal but has no effect on alpha(2)M-methylamine signaling. The latter observation supports our hypothesis that a distinct signaling receptor binds alpha(2)M-methylamine. We further demonstrate that the signaling events induced by lactoferrin may involve a pertussis toxin-sensitive G protein, while the alpha(2)M signaling receptor appears to be coupled to a pertussis toxin-insensitive G protein.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University			Chu, Charleen/B-1601-2008	Chu, Charleen/0000-0002-5052-8271	NCI NIH HHS [NCI CA-29589] Funding Source: Medline; NHLBI NIH HHS [NHLBI HL-24066] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA029589] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL024066, R01HL024066] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P709; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BYER S, 1993, BIOCHEM BIOPH RES CO, V196, P99; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHOUDHURY GG, 1991, J BIOL CHEM, V266, P23147; DELAIN E, 1992, ELECTRON MICROSC REV, V5, P231, DOI 10.1016/0892-0354(92)90012-F; GARFINKEL AS, 1983, J LIPID RES, V24, P775; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HUANG CL, 1989, J BIOL CHEM, V264, P4391; HUETTINGER M, 1992, J BIOL CHEM, V267, P18551; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; KATAOKA R, 1993, J BIOL CHEM, V268, P19851; KONDO T, 1993, J BIOL CHEM, V268, P4458; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; MISRA UK, 1993, BIOCHEM J, V290, P885, DOI 10.1042/bj2900885; MISRA UK, 1994, J BIOL CHEM, V269, P12541; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; OKAMOTO T, 1993, FEBS LETT, V334, P143, DOI 10.1016/0014-5793(93)81700-A; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PIZZO SV, 1988, ISI ATLAS-BIOCHEM, V1, P242; PONZONI M, 1993, BIOCHEM J, V294, P893, DOI 10.1042/bj2940893; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YANG LJ, 1991, J BIOL CHEM, V266, P22451; YANG LJ, 1993, J BIOL CHEM, V268, P3739	32	74	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18303	18306						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518427				2022-12-25	WOS:A1994NW79800012
J	DONAHUE, JP; TURNBOUGH, CL				DONAHUE, JP; TURNBOUGH, CL			NUCLEOTIDE-SPECIFIC TRANSCRIPTIONAL PAUSING IN THE PYRBI LEADER REGION OF ESCHERICHIA-COLI K-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; SALMONELLA-TYPHIMURIUM; OPERON EXPRESSION; GUANOSINE TETRAPHOSPHATE; TERMINATION; ATTENUATION; INVITRO; HAIRPIN; PROTEIN; GENES	Expression of the pyrBI operon, which encodes the subunits of the pyrimidine biosynthetic enzyme aspartate transcarbamylase, is regulated primarily through a UTP-sensitive transcriptional attenuation control mechanism in Escherichia coli. In this mechanism, the extent of coupling between transcription and translation within the pyrBI leader region determines the level of rho-independent transcriptional termination at an attenuator preceding the pyrB gene. A key feature in this mechanism is transcriptional pausing that occurs before the attenuator in the pyrBI leader region when UTP concentrations are low. In this study, we characterized in detail this UTP-sensitive transcriptional pausing in vitro. Our results show that pausing occurs, to different extents, before the addition of every uridine residue in the leader transcript. This pausing occurred only at low UTP concentrations (20-200 mu M) that cause high levels of pyrBI expression in vivo. Transcriptional pausing did not occur in the pyrBI leader region at 20 mu M CTP or ATP and only occurred strongly at one site at 20 mu M GTP. We also demonstrated that NusA functions as a general enhancer of UTP-sensitive transcriptional pausing in the pyrBI leader region. Finally, we identified at the 3' end of the pyrBI attenuator a 3-base region at which termination occurs. Selection of termination sites within this region was shifted by varying the UTP concentration or including NusA in the transcription reaction mixture.	UNIV ALABAMA, DEPT MICROBIOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN JT, 1991, MOL MICROBIOL, V5, P327, DOI 10.1111/j.1365-2958.1991.tb02113.x; CHAN CL, 1989, J BIOL CHEM, V264, P20796; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; DONAHUE JP, 1990, J BIOL CHEM, V265, P19091; GREENBLATT J, 1981, NATURE, V292, P215, DOI 10.1038/292215a0; JENSEN KF, 1979, J BACTERIOL, V138, P731, DOI 10.1128/JB.138.3.731-738.1979; JENSEN KF, 1986, J BACTERIOL, V166, P857, DOI 10.1128/jb.166.3.857-865.1986; KASSAVETIS GA, 1981, J BIOL CHEM, V256, P2777; KINGSTON RE, 1981, J BIOL CHEM, V256, P2787; KNAPP G, 1989, METHOD ENZYMOL, V180, P192; LAU LF, 1983, J BIOL CHEM, V258, P9391; LEE DN, 1990, J BIOL CHEM, V265, P15145; LEVIN HL, 1989, J BIOL CHEM, V264, P14638; LIU C, 1990, THESIS U ALABAMA BIR; LIU CG, 1989, J BACTERIOL, V171, P3337, DOI 10.1128/jb.171.6.3337-3342.1989; LIU CG, 1993, J BACTERIOL, V175, P2363, DOI 10.1128/JB.175.8.2363-2369.1993; Maxam A M, 1980, Methods Enzymol, V65, P499; Neuhard J, 1987, ESCHERICHIA COLI SAL, P445; Nishimura S, 1972, Prog Nucleic Acid Res Mol Biol, V12, P49; POULSEN P, 1987, MOL GEN GENET, V208, P152, DOI 10.1007/BF00330436; ROLAND KL, 1988, P NATL ACAD SCI USA, V85, P7149, DOI 10.1073/pnas.85.19.7149; ROLAND KL, 1985, J BACTERIOL, V163, P991, DOI 10.1128/JB.163.3.991-999.1985; SIGMUND CD, 1988, BIOCHEMISTRY-US, V27, P5622, DOI 10.1021/bi00415a034; TURNBOUGH CL, 1983, J BACTERIOL, V153, P998, DOI 10.1128/JB.153.2.998-1007.1983; TURNBOUGH CL, 1983, P NATL ACAD SCI-BIOL, V80, P368, DOI 10.1073/pnas.80.2.368; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241	26	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18185	18191						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	7517939				2022-12-25	WOS:A1994NV42200064
J	BROWN, VK; OGLE, EW; BURKHARDT, AL; ROWLEY, RB; BOLEN, JB; JUSTEMENT, LB				BROWN, VK; OGLE, EW; BURKHARDT, AL; ROWLEY, RB; BOLEN, JB; JUSTEMENT, LB			MULTIPLE COMPONENTS OF THE B-CELL ANTIGEN RECEPTOR COMPLEX ASSOCIATE WITH THE PROTEIN-TYROSINE-PHOSPHATASE, CD45	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTES-B; CROSS-LINKING; MEMBRANE IMMUNOGLOBULIN; SIGNAL TRANSDUCTION; SRC FAMILY; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOTYROSINE PHOSPHATASE; PHOSPHOLIPASE C-GAMMA-2; KINASE PP56LCK; IG-ALPHA	Signal transduction via the B cell antigen receptor complex is regulated by changes in tyrosine phosphorylation of several proteins. The equilibrium between tyrosine phosphorylation and dephosphorylation is regulated by the combined action of protein tyrosine kinase and protein tyrosine phosphatase enzymes. In particular, the protein tyrosine phosphatase, CD45, has been shown to play an essential role in signal transduction via the B cell antigen receptor. Therefore, experiments were performed to examine the intermolecular associations between CD45 and phosphotyrosine containing proteins in the B cell to identify potential substrates for CD45. Based on coprecipitation experiments, CD45 was found to be physically associated with multiple components of the B cell antigen receptor complex including the MB-1/B29 heterodimer. Additionally, CD45 was selectively associated with the src family protein tyrosine kinase, lyn. Neither blk nor fyn, were observed to interact with CD45 even though they have been implicated in antigen receptor signal transduction. This finding suggests that CD45 may preferentially regulate the phosphorylation of lyn and thus, its activity. In summary, these studies provide evidence to support the hypothesis that CD45 regulates antigen receptor-mediated signal transduction by controlling the tyrosine phosphorylation of multiple components of the antigen receptor complex.	UNIV TEXAS,MED BRANCH,DEPT MICROBIOL & IMMUNOL,GALVESTON,TX 77555; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543	University of Texas System; University of Texas Medical Branch Galveston; Bristol-Myers Squibb				Justement, Louis/0000-0001-7058-867X	NIGMS NIH HHS [GM-46524] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046524, R01GM046524] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1991, J IMMUNOL, V146, P2075; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, 1991, J IMMUNOL, V147, P1575; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CARTER RH, 1991, J IMMUNOL, V147, P3663; CASILLAS A, 1991, J BIOL CHEM, V266, P19088; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1993, J IMMUNOL, V150, P377; GOLD MR, 1992, J IMMUNOL, V148, P2012; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; JULIUS MH, 1984, EUR J IMMUNOL, V14, P753, DOI 10.1002/eji.1830140816; JUSTEMENT LB, 1990, J IMMUNOL, V144, P3272; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KORETZKY GA, 1993, J BIOL CHEM, V268, P8958; LANE PJL, 1991, J IMMUNOL, V146, P715; LI ZH, 1992, BIOCHEM BIOPH RES CO, V187, P1536, DOI 10.1016/0006-291X(92)90477-3; LIN JJ, 1992, J IMMUNOL, V149, P3182; LIN JJ, 1992, J IMMUNOL, V149, P1548; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MIZUGUCHI J, 1992, J IMMUNOL, V148, P689; Morrison M, 1974, Methods Enzymol, V32, P103; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, ONCOGENE, V5, P809; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; ROIFMAN CM, 1992, BIOCHEM BIOPH RES CO, V183, P411, DOI 10.1016/0006-291X(92)90496-8; RUFFJAMISON S, 1991, J BIOL CHEM, V266, P6607; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SCHRAVEN B, 1992, EUR J IMMUNOL, V22, P1857, DOI 10.1002/eji.1830220727; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SPANA C, 1993, PROTEIN EXPRES PURIF, V4, P390, DOI 10.1006/prep.1993.1051; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; TROWBRIDGE IS, 1978, J EXP MED, V148, P313, DOI 10.1084/jem.148.1.313; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17238	17244						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516335				2022-12-25	WOS:A1994NT84600040
J	GAISANO, HY; SHEU, L; FOSKETT, JK; TRIMBLE, WS				GAISANO, HY; SHEU, L; FOSKETT, JK; TRIMBLE, WS			TETANUS TOXIN LIGHT-CHAIN CLEAVES A VESICLE-ASSOCIATED MEMBRANE-PROTEIN (VAMP) ISOFORM-2 IN RAT PANCREATIC ZYMOGEN GRANULES AND INHIBITS ENZYME-SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLES; NEUROTRANSMITTER RELEASE; REGULATED EXOCYTOSIS; SYNTHETIC PEPTIDES; CHROMAFFIN CELLS; EFFECTOR DOMAIN; FUSION; SYNAPTOBREVIN; BINDING; FAMILY	Pancreatic acinar cells, a model cell type for the study of exocytosis in non-excitable cells, were used here to test the hypothesis that molecular mechanisms regulating exocytosis from neuronal and neuroendocrine cells may also be utilized in exocrine cells. Using specific antisera raised against vesicle-associated membrane protein (VAMP) isoforms 1 and 2, we have identified VAMP-2, but not VAMP-1, immunoreactive proteins on rat pancreatic acinar cell secretory (zymogen) granules. This 18-kDa protein co-migrated with rat brain synaptic vesicle VAMP-2. Tetanus toxin (TeTx) light chain caused complete cleavage of this protein, which was prevented by the addition of EDTA. This toxin also inhibited in a dose-dependent manner Ca2+-stimulated enzyme secretion by up to similar to 30% in streptolysin O-permeabilized acini. This effect of TeTx on secretion was prevented by the zinc endopeptidase inhibitor captopril or by boiling the toxin. Incomplete inhibition of secretion by TeTx may suggest that TeTx-insensitive or VAMP-2-independent mechanisms also regulate exocytosis. In support, TeTx light chain was without effect on Rab3AL, (effector domain peptide of Rab3)-mediated potentiation of Ca2+-stimulated secretion. These results indicate that a TeTx-sensitive VAMP-2-like protein on zymogen granules participates in Ca2+-regulated pancreatic enzyme secretion and that undefined Rab3AL-activated mechanisms may act independently to regulate exocytosis.	TORONTO HOSP,TORONTO M5S 1A8,ON,CANADA; HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,TORONTO M5G 1X8,ON,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO M5S 1A8,ON,CANADA; UNIV TORONTO,CTR RES NEURODEGENERAT DIS,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	GAISANO, HY (corresponding author), UNIV TORONTO,DEPT MED,RM 7226,MED SCI BLDG,TORONTO M5S 1A8,ON,CANADA.		Foskett, Kevin/R-2549-2019	Foskett, J. Kevin/0000-0002-8854-0268				AHNERTHILGER G, 1989, FEBS LETT, V242, P245, DOI 10.1016/0014-5793(89)80478-8; AHNERTHILGER G, 1989, J NEUROCHEM, V52, P1751, DOI 10.1111/j.1471-4159.1989.tb07253.x; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BEAUDOIN AR, 1992, INT REV CYTOL, V132, P177, DOI 10.1016/S0074-7696(08)62456-0; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN JEA, 1994, J BIOL CHEM, V269, P5328; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CAMERON RS, 1986, J CELL BIOL, V103, P1299, DOI 10.1083/jcb.103.4.1299; CARLSON SS, 1978, BIOCHEMISTRY-US, V17, P1188, DOI 10.1021/bi00600a009; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DAYANITHI G, 1994, NEUROSCIENCE, V58, P423, DOI 10.1016/0306-4522(94)90048-5; EDWARDSON JM, 1993, FEBS LETT, V320, P52, DOI 10.1016/0014-5793(93)81656-K; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; GAISANO HY, 1989, J CLIN INVEST, V83, P321, DOI 10.1172/JCI113877; HORIKAWA HPM, 1993, FEBS LETT, V330, P236, DOI 10.1016/0014-5793(93)80281-X; JENA BP, 1994, J CELL BIOL, V124, P43, DOI 10.1083/jcb.124.1.43; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW GJ, 1993, FEBS LETT, V333, P56, DOI 10.1016/0014-5793(93)80374-4; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MACLEAN CM, 1993, BIOCHEM J, V294, P325, DOI 10.1042/bj2940325; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; PADFIELD PJ, 1992, P NATL ACAD SCI USA, V89, P1656, DOI 10.1073/pnas.89.5.1656; PAQUET MR, 1982, EUR J CELL BIOL, V28, P20; PENNER R, 1986, NATURE, V324, P719; SCHIAVO G, 1990, INFECT IMMUN, V58, P4136, DOI 10.1128/IAI.58.12.4136-4141.1990; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SENYSHYN J, 1992, FEBS LETT, V309, P41, DOI 10.1016/0014-5793(92)80735-Y; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STETCHER B, 1992, BIOCHEM J, V283, P899; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TRIMBLE WS, 1990, J NEUROSCI, V10, P1380; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; TRIMBLE WS, 1993, J PHYSIOLOGY-PARIS, V87, P107, DOI 10.1016/0928-4257(93)90004-D; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WELLER U, 1989, EUR J BIOCHEM, V182, P649, DOI 10.1111/j.1432-1033.1989.tb14874.x; [No title captured]	41	131	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17062	17066						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516331				2022-12-25	WOS:A1994NT84600015
J	SRINIVASAN, M; BEGUM, N				SRINIVASAN, M; BEGUM, N			STIMULATION OF PROTEIN PHOSPHATASE-1 ACTIVITY BY PHORBOL ESTERS - EVALUATION OF THE REGULATORY ROLE OF PROTEIN-KINASE-C IN INSULIN ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; GLUCOSE-TRANSPORT; SKELETAL-MUSCLE; RAT ADIPOCYTES; RIBOSOMAL PROTEIN-S6; GLYCOGEN-SYNTHESIS; BC3H-1 MYOCYTES; PHOSPHORYLATION; ACTIVATION; CELLS	In this study, we examined the role of insulin, protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) cascade in activation of protein phosphatase-1 (PP-1) by using three complementary approaches. First, differentiated L6 cells were acutely exposed to 12-O-tetradecanoylphorbol-13-acetate (TPA, 400 nM) to activate PKC. In these cells, TPA caused 32% stimulation of PP-1 activity. The PP-1 stimulation by TPA was comparable to stimulation by insulin (t(1/2) = 1 min and EC(50) = 5 nM) with a maximum effect in 5 min. The effects of insulin and TPA were not additive. Insulin and TPA also stimulated MAPK (>2-fold increase over basal, with myelin basic protein as a substrate). ML-9, a myosin light chain kinase inhibitor, blocked the effects of insulin and TPA on both MAPK and PP-1 activation. In the second approach, PKC was down-regulated by chronic treatment with TPA. In these cells subsequent effects of insulin on MAPK and PP-1 activation were blocked, without an effect on basal enzyme levels. In the third approach, two selective inhibitors of PKC, calphostin and chelerythrine chloride, were used to inhibit PKC. These inhibitors completely prevented insulin and TPA stimulation of MAPK and PP-1 and blocked insulin induced translocation of PKC to the plasma membranes. We conclude that PKC plays an important role in insulin stimulation of PP-1 via the activation of MAPK cascade.	WINTHROP UNIV HOSP, DIABET RES LAB, MINEOLA, NY 11501 USA; SUNY STONY BROOK, DEPT MED, STONY BROOK, NY 11790 USA	Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BEGUM N, 1993, J BIOL CHEM, V268, P7917; BLENIS J, 1984, P NATL ACAD SCI-BIOL, V81, P6408, DOI 10.1073/pnas.81.20.6408; CARO JF, 1992, MOL CELL BIOCHEM, V109, P115; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; CLARKE PR, 1993, FEBS LETT, V336, P37, DOI 10.1016/0014-5793(93)81604-X; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1983, METHOD ENZYMOL, V99, P243; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; FARESE RV, 1992, CELL SIGNAL, V4, P133, DOI 10.1016/0898-6568(92)90077-L; GRANOT Y, 1993, J BIOL CHEM, V268, P9564; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDENREICH KA, 1993, J BIOL CHEM, V268, P14663; HENRIKSEN EJ, 1989, J BIOL CHEM, V264, P21536; HOFFMAN JM, 1991, ENDOCRINOLOGY, V128, P2937, DOI 10.1210/endo-128-6-2937; INOUE G, 1993, J BIOL CHEM, V268, P5272; KLIP A, 1987, BIOCHEM J, V242, P131, DOI 10.1042/bj2420131; KLIP A, 1984, AM J PHYSIOL, V247, pE291, DOI 10.1152/ajpendo.1984.247.3.E291; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARNER J, 1990, ADV ENZYMOL RAMB, V63, P173; MEIER KE, 1991, J BIOL CHEM, V266, P1914; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; RAPP UR, 1991, ONCOGENE, V6, P495; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SRINIVASAN M, 1994, J BIOL CHEM, V269, P12514; STANDAERT ML, 1990, METABOLISM, V39, P1170, DOI 10.1016/0026-0495(90)90090-Y; STANDAERT ML, 1993, ENDOCRINOLOGY, V132, P689, DOI 10.1210/en.132.2.689; TANG PM, 1991, J BIOL CHEM, V266, P15782; TREVILLYAN JM, 1984, J BIOL CHEM, V259, P897; VILLAMORUZZI E, 1989, FEBS LETT, V258, P208, DOI 10.1016/0014-5793(89)81654-0; WELSH GI, 1993, FEBS LETT, V316, P241, DOI 10.1016/0014-5793(93)81300-O; YU BZ, 1992, ENDOCRINOLOGY, V130, P3345, DOI 10.1210/en.130.6.3345	36	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16662	16667						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	7515882				2022-12-25	WOS:A1994NR29600025
J	PERSECHINI, A; MCMILLAN, K; LEAKEY, P				PERSECHINI, A; MCMILLAN, K; LEAKEY, P			ACTIVATION OF MYOSIN LIGHT-CHAIN KINASE AND NITRIC-OXIDE SYNTHASE ACTIVITIES BY CALMODULIN FRAGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL HELIX; PEPTIDE COMPLEX; BASIC RESIDUES; BINDING; PROTEINS; ENZYME; IDENTIFICATION; CHROMATOGRAPHY; PURIFICATION; DELETIONS	We have investigated the abilities of calmodulin (CaM) tryptic fragments 1-75 (TRCI) or 78-148 (TRCII) to activate gizzard smooth muscle myosin light chain kinase (gMLCK), rabbit skeletal muscle myosin light chain kinase (skMLCK), and neural nitric oxide synthase (nNOS) activities. Our results indicate for all three enzymes that binding of CaM follows an ordered mechanism wherein the C-terminal lobe, represented by TRCII, binds specifically to a site we designated as A, followed by binding of the N-terminal lobe, represented by TRCI, to a site designated as B. With TRCII and TRCI bound to their respective sites, skMLCK and gMLCK activities are both activated to about 80% of their maximum levels. Occupancy of both sites in the MLCK enzymes by TRCI results in only low levels of enzyme activation; occupancy of both sites by TRCII also results in low levels of gMLCK activity, but activates skMLCK activity to 65% of the maximum level. With TRCI bound at site B and either TRCII or TRCI bound at site A, nNOS activity is 50% of the maximum level. Apparent dissociation constants for TRCII binding to site A and TRCI binding to site B are, respectively; 0.3 and 3 mu M (skMLCK); 1.2 and 0.8 mu M (gMLCK); 10 nM and 150 mu M (nNOS). Our results demonstrate that the CaM lobes can make distinct contributions to binding and/or activation of different CaM-dependent enzymes and that the tethering function of the central helix can be mimicked by sufficiently high concentrations of the CaM fragments. We have modeled tethering as if it stabilizes the CaM-enzyme complex by creating a high effective concentration of the N-terminal lobe. Calculated values for this concentration term indicate essentially identical contributions by the central helix to the observed nanomolar dissociation constants of the three CaM-enzyme complexes examined.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio	PERSECHINI, A (corresponding author), UNIV ROCHESTER,MED CTR,DEPT PHYSIOL,ROCHESTER,NY 14642, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030050, R37HL030050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044322] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30050] Funding Source: Medline; NIDDK NIH HHS [DK44322] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; CROTHERS DM, 1972, IMMUNOCHEMISTRY, V9, P341, DOI 10.1016/0019-2791(72)90097-3; FITZSIMONS DP, 1992, J BIOL CHEM, V267, P23903; GUERINI D, 1985, ANAL BIOCHEM, V150, P178, DOI 10.1016/0003-2697(85)90458-0; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HERRING BP, 1991, J BIOL CHEM, V266, P11838; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KUZNICKI J, 1981, FEBS LETT, V130, P141, DOI 10.1016/0014-5793(81)80683-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANALAN AS, 1984, ADV CYCLIC NUCL PROT, V18, P227; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1985, P NATL ACAD SCI USA, V82, P7939, DOI 10.1073/pnas.82.23.7939; NEWTON D, 1985, BIOCHIM BIOPHYS ACTA, V845, P533, DOI 10.1016/0167-4889(85)90222-8; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; NI WC, 1985, J BIOL CHEM, V260, P6974; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; PERSECHINI A, 1988, J CARDIOVASC PHARM, V12, pS1; PERSECHINI A, 1993, FASEB J, V7, pA1141; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; PUTKEY JA, 1988, J BIOL CHEM, V263, P11242; SANYAL G, 1988, BIOCHEMISTRY-US, V27, P6229, DOI 10.1021/bi00417a006; THULIN E, 1984, BIOCHEMISTRY-US, V23, P1862, DOI 10.1021/bi00303a043; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750	31	85	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16148	16154						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	7515878				2022-12-25	WOS:A1994NQ72900032
J	IGARASHI, K; GAROTTA, G; OZMEN, L; ZIEMIECKI, A; WILKS, AF; HARPUR, AG; LARNER, AC; FINBLOOM, DS				IGARASHI, K; GAROTTA, G; OZMEN, L; ZIEMIECKI, A; WILKS, AF; HARPUR, AG; LARNER, AC; FINBLOOM, DS			INTERFERON-GAMMA INDUCES TYROSINE PHOSPHORYLATION OF INTERFERON-GAMMA RECEPTOR AND REGULATED ASSOCIATION OF PROTEIN-TYROSINE KINASES, JAK1 AND JAK2, WITH ITS RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SIGNAL TRANSDUCER; DOMAIN	Interferon-gamma (IFN-gamma) induces the expression of a set of early response genes by tyrosine phosphorylation of latent transcription factors such as p91. Although the tyrosine kinases, Jak1 and Jak2, have recently been shown to be critical for signal transduction by IFN-gamma, evidence is lacking for both tyrosine phosphorylation of the IFN-gamma receptor (IFN-gamma R) and the interaction between Jak1, Jak2, and the IFN-gamma R. In this report, we show that binding of IFN-gamma to HeLa cells initiated a series of events that resulted in the extremely rapid (15 s) tyrosine phosphorylation of not only Jak1, Jak2, and p91 but also the IFN-gamma R. Coimmunoprecipitation experiments revealed that Jak1 was associated with the IFN-gamma R prior to ligand binding, whereas Jak2 became part of the IFN-gamma R Jak1 complex immediately after ligand binding. H2O2/vanadate treatment of cells for 15 min resulted in only the tyrosine phosphorylation of Jak1 and IFN-gamma R. Only after 60 min of this treatment did we observe tyrosine phosphorylation of Jak2 and p91 and assembly of the transcription factor complex FcRF gamma that binds to the promoter of the fcgr1 gene. These data suggest that JAK1 associates with the IFN-gamma R prior to ligand binding. IFN-gamma treatment of cells results in recruitment of JAK2 into the IFN-gamma R-Jak1 complex followed by assembly of the transcription factor FcRF gamma complex.	US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892; HOFFMANN LA ROCHE AG,PHARMACEUT RES NEW TECHNOL,CH-4002 BASEL,SWITZERLAND; UNIV BERN,INST CLIN & EXPTL CANC RES,CH-3004 BERN,SWITZERLAND; LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,MELBOURNE,VIC 3050,AUSTRALIA	US Food & Drug Administration (FDA); Roche Holding; University of Bern; Ludwig Institute for Cancer Research			Wilks, Andrew F/R-5542-2019	Wilks, Andrew F/0000-0002-8554-2399				AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GAROTTA G, 1990, J BIOL CHEM, V265, P6908; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; HARPUR AG, 1992, ONCOGENE, V7, P1347; HEMMI S, 1992, P NATL ACAD SCI USA, V89, P2737, DOI 10.1073/pnas.89.7.2737; HOWARD OMZ, 1992, ONCOGENE, V7, P895; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; JUNG V, 1987, P NATL ACAD SCI USA, V84, P6934; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964	22	211	216	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14333	14336						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514165				2022-12-25	WOS:A1994NM06500002
J	SASAOKA, T; ROSE, DW; JHUN, BH; SALTIEL, AR; DRAZNIN, B; OLEFSKY, JM				SASAOKA, T; ROSE, DW; JHUN, BH; SALTIEL, AR; DRAZNIN, B; OLEFSKY, JM			EVIDENCE FOR A FUNCTIONAL-ROLE OF SHE PROTEINS IN MITOGENIC SIGNALING INDUCED BY INSULIN, INSULIN-LIKE GROWTH-FACTOR-I, AND EPIDERMAL GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; RAS; TRANSDUCTION; DOMAINS; CELLS; MICROINJECTION; REQUIREMENT; ASSOCIATION; PI3-KINASE; CLONING	Shc proteins contain a single SH2 domain, lack catalytic activity, and are substrates for activated receptors for insulin, insulin-like growth factor-1 (IGF-1), and epidermal growth factor (EGF). Treatment with these growth factors induced rapid tyrosine phosphorylation of Shc. We investigated the potential role of Shc in mitogenic signaling. Affinity-purified antibodies were microinjected into living Rat1 fibroblasts overexpressing human insulin receptors. Bromodeoxyuridine incorporation into newly synthesized DNA was subsequently studied to assess the importance of Shc. Cellular microinjection of anti-Shc antibody inhibited BrdU incorporation induced by insulin, IGF-1, and EGF, but did not affect cells stimulated by fetal calf serum. Microinjection of an oncogenic p21(ras) protein (T24) into quiescent cells produced constitutively active mitogenic signaling, and comicroinjection of T24 with the anti-Shc antibody restored insulin and EGF stimulation of DNA synthesis. Immunoprecipitates of Shc from lysates of insulin-stimulated cells removed 70-80% of guanine nucleotide-releasing factor activity. These results indicate that Shc is an important component in a mitogenic signal transduction pathway that is shared by insulin, IGF-1, and EGF. The functional locus of Shc is either upstream of p21(ras) or lies on a distinct branch of the pathway leading to cell cycle progression.	VET ADM MED CTR,MED RES SERV 111G,SAN DIEGO,CA 92161; UNIV CALIF SAN DIEGO,DEPT MED,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105; VET AFFAIRS MED CTR,MED RES SERV,DENVER,CO 80220; VET AFFAIRS MED CTR,DEPT MED,DENVER,CO 80220; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80220	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; Pfizer; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, R01DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COCHET C, 1991, J BIOL CHEM, V266, P637; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SATOH T, 1992, J BIOL CHEM, V267, P24149; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; THIES RS, 1989, J BIOL CHEM, V264, P12820; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; ZHU GC, 1993, J BIOL CHEM, V268, P1775	43	258	266	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13689	13694						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7513704				2022-12-25	WOS:A1994NK18400092
J	KOEPPE, RE; GREATHOUSE, DV; JUDE, A; SABERWAL, G; PROVIDENCE, LL; ANDERSEN, OS				KOEPPE, RE; GREATHOUSE, DV; JUDE, A; SABERWAL, G; PROVIDENCE, LL; ANDERSEN, OS			HELIX SENSE OF GRAMICIDIN CHANNELS AS A NONLOCAL FUNCTION OF THE PRIMARY SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Gramicidin A (gA) channels are dimers formed by right-handed beta(6.3)-helical monomers. The stereochemical basis for the preference of a right-handed conformation remains obscure, but it has earlier been demonstrated that the handedness can be shifted by changing the chirality of each residue in the LD-sequence and therefore is determined by the peptide itself and not by channel-membrane interactions, We now examine the contributions of Trp(15), the central Val residues 6-8, and residues 1-5. None of these alone are sufficient to specify the helix sense. To examine the D-Va(6)-L-Val(7)-D-Val(8) sequence, the register of the 3 valines was shifted by one to L-Val(5)-D-Val(6)-Val(7). The resulting analogue, [Val(5),D-AlA(8)]gA, forms channels with a conductance and duration that are both somewhat less than those of gA channels. The reduced channel duration can be attributed to a steric conflict between the side chains of Val(1) in one monomer and Val(5) in the other monomer. The helix handedness is not altered by this modification, as shown by circular dichroism and two-dimensional nuclear magnetic resonance spectroscopy and by hybrid channel experiments. [Val(5),D-Ala(8)]gA forms hybrid channels with gA (which forms right-handed channels), but not with des-Val(1)-gA(-) (which forms left-handed channels). Similar hybrid channel analysis shows that des-Trp(15)-gA and [L-Ala(1),D-Ala(2),L-Ala(3),D-Ala(4)]gA also form right-handed channels. We conclude that the helix handedness most probably is a complex function of the arrangement of both the D-Val-L-Val-D-Val and the L-Trp-(D-Leu-L-Trp)(3) segments.	CORNELL UNIV, COLL MED, DEPT PHYSIOL & BIOPHYS, NEW YORK, NY 10021 USA	Cornell University	KOEPPE, RE (corresponding author), UNIV ARKANSAS, DEPT CHEM & BIOCHEM, FAYETTEVILLE, AR 72701 USA.			Koeppe, Roger/0000-0003-0676-6413	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021342, R01GM034968] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM021342, GM34968, GM21342] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN O S, 1992, Biophysical Journal, V61, pA526; ANDERSEN OS, 1992, PHYSIOL REV, V72, pS89, DOI 10.1152/physrev.1992.72.suppl_4.S89; ANDERSEN OS, 1983, BIOPHYS J, V41, P119, DOI 10.1016/S0006-3495(83)84414-2; ARSENIEV AS, 1986, BIOL MEMBRANY, V3, P1077; ARSENIEV AS, 1985, FEBS LETT, V186, P168, DOI 10.1016/0014-5793(85)80702-X; BANO MC, 1992, BIOPHYS J, V63, P70, DOI 10.1016/S0006-3495(92)81590-4; BANO MC, 1991, BIOCHEMISTRY-US, V30, P886, DOI 10.1021/bi00218a002; BARANY G, 1987, INT J PEPT PROT RES, V30, P707; BARSUKOV IL, 1987, BIOORG KHIM+, V13, P1501; BECKER MD, 1991, BIOCHEMISTRY-US, V30, P8830, DOI 10.1021/bi00100a015; BUSATH DD, 1993, ANNU REV PHYSIOL, V55, P473; BYSTROV VF, 1988, TETRAHEDRON, V44, P925, DOI 10.1016/S0040-4020(01)86126-3; CIFU AS, 1992, BIOPHYS J, V61, P189, DOI 10.1016/S0006-3495(92)81826-X; COX DR, 1966, STATISTICAL ANAL SER; DURKIN JT, 1992, BIOPHYS J, V62, P145, DOI 10.1016/S0006-3495(92)81801-5; DURKIN JT, 1993, J MOL BIOL, V231, P1102, DOI 10.1006/jmbi.1993.1355; DURKIN JT, 1990, J MOL BIOL, V211, P221, DOI 10.1016/0022-2836(90)90022-E; ETCHEBEST C, 1988, JERUS SYM Q, V21, P167; ETCHEBEST C, 1985, BIOCHIM BIOPHYS ACTA, V818, P23, DOI 10.1016/0005-2736(85)90133-6; FONSECA V, 1992, BIOCHEMISTRY-US, V31, P5340, DOI 10.1021/bi00138a014; HALL P, 1981, J PHYS CHEM-US, V85, P2941, DOI 10.1021/j150620a019; HEITZ F, 1982, BIOPHYS J, V40, P87, DOI 10.1016/S0006-3495(82)84462-7; HLADKY SB, 1972, BIOCHIM BIOPHYS ACTA, V274, P294, DOI 10.1016/0005-2736(72)90178-2; KETCHEM RR, 1993, SCIENCE, V261, P1457, DOI 10.1126/science.7690158; KILLIAN JA, 1992, BIOCHEMISTRY-US, V31, P11283, DOI 10.1021/bi00161a004; KILLIAN JA, 1988, BIOCHEMISTRY-US, V27, P4848, DOI 10.1021/bi00413a040; KILLIAN JA, 1992, BIOCHIM BIOPHYS ACTA, V1113, P391; KOEPPE R E II, 1991, Biophysical Journal, V59, p319A; KOEPPE RE, 1984, BIOPOLYMERS, V23, P23, DOI 10.1002/bip.360230104; KOEPPE RE, 1992, PROTEINS, V12, P49, DOI 10.1002/prot.340120107; KOEPPE RE, 1994, BIOPHYS J, V66, pA219; LANGS DA, 1988, SCIENCE, V241, P188, DOI 10.1126/science.2455345; MASOTTI L, 1980, CELL BIOPHYS, V2, P241, DOI 10.1007/BF02790452; MATTICE GL, 1993, BIOPHYS J, V64, pA300; MAZET JL, 1984, BIOPHYS J, V45, P263, DOI 10.1016/S0006-3495(84)84153-3; MONOI H, 1993, BIOPHYS J, V64, P36, DOI 10.1016/S0006-3495(93)81338-9; MYERS VB, 1972, BIOCHIM BIOPHYS ACTA, V274, P313, DOI 10.1016/0005-2736(72)90179-4; NICHOLSON LK, 1989, BIOCHEMISTRY-US, V28, P9379, DOI 10.1021/bi00450a019; OCONNELL AM, 1990, SCIENCE, V250, P1256, DOI 10.1126/science.1700867; RUSSELL EWB, 1986, BIOPHYS J, V49, P673, DOI 10.1016/S0006-3495(86)83694-3; SABERWAL G, 1994, BIOPHYS J, V66, pA219; SARGES R, 1965, BIOCHEMISTRY-US, V4, P2491, DOI 10.1021/bi00887a031; SAWYER DB, 1990, BIOPHYS J, V57, P515, DOI 10.1016/S0006-3495(90)82567-4; SAWYER DB, 1990, BIOPHYS J, V58, P1207, DOI 10.1016/S0006-3495(90)82461-9; SOEH SA, 1993, BIOPHYS J, V65, P1817; TURNER GL, 1983, BIOCHIM BIOPHYS ACTA, V756, P133, DOI 10.1016/0304-4165(83)90083-1; URRY DW, 1971, P NATL ACAD SCI USA, V68, P672, DOI 10.1073/pnas.68.3.672; VEATCH WR, 1974, BIOCHEMISTRY-US, V13, P5249, DOI 10.1021/bi00723a001; VEATCH WR, 1974, BIOCHEMISTRY-US, V13, P5257, DOI 10.1021/bi00723a002; VENKATACHALAM CM, 1983, J COMPUT CHEM, V4, P461, DOI 10.1002/jcc.540040403; WALLACE BA, 1981, BIOCHEMISTRY-US, V20, P5754, DOI 10.1021/bi00523a018; WALLACE BA, 1990, ANNU REV BIOPHYS BIO, V19, P127, DOI 10.1146/annurev.bb.19.060190.001015; WALLACE BA, 1988, SCIENCE, V241, P182, DOI 10.1126/science.2455344; WEISS LB, 1985, INT J PEPT PROT RES, V26, P305; WILLIAMS LP, 1992, BIOCHEMISTRY-US, V31, P7311, DOI 10.1021/bi00147a015; Wuthrich K., 1986, NMR PROTEINS NUCL AC; 1984, EUR J BIOCHEM, V188, P9	57	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12567	12576						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7513690				2022-12-25	WOS:A1994NH71600033
J	PIND, S; RIORDAN, JR; WILLIAMS, DB				PIND, S; RIORDAN, JR; WILLIAMS, DB			PARTICIPATION OF THE ENDOPLASMIC-RETICULUM CHAPERONE CALNEXIN (P88, IP90) IN THE BIOGENESIS OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR EXPRESSION; GENE; PROTEIN; IDENTIFICATION; PURIFICATION; DELTA-F508; MOLECULES; PRODUCT; PEPTIDE; CELLS	Deletion of phenylalanine at position 508 (Delta F508) in the first nucleotide binding fold of the cystic fibrosis transmembrane conductance regulator (CFTR) is the most common mutation in patients with cystic fibrosis. Although retaining functional Cl- channel activity, this mutant is recognized as abnormal by the cellular ''quality control'' machinery and is retained within the endoplasmic reticulum (ER). We have used human epithelial cells and recombinant Chinese hamster ovary cells to identify molecular interactions that may contribute to this intracellular retention. Based upon coimmunoprecipitation and cosedimentation through glycerol density gradients, newly synthesized wild-type and Delta F508 mutant CFTRs associated specifically with calnexin, the calcium-binding transmembrane chaperone of the ER. This association was restricted to the immature (or ER-associated) forms of the CFTR proteins. Although the bulk of wild-type and Delta F508 CFTRs were present initially in complexes containing calnexin, only wild-type CFTR was able to escape from this association and exit the ER. Calnexin retains misfolded or incompletely assembled proteins in the ER and thus is likely to contribute to the mislocalization of mutant CFTR.	UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ON,CANADA; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5S 1A8,ON,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ON,CANADA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BIRREN BW, 1986, NUCLEIC ACIDS RES, V14, P853, DOI 10.1093/nar/14.2.853; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; GALVIN K, 1992, P NATL ACAD SCI USA, V89, P8452, DOI 10.1073/pnas.89.18.8452; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI CH, 1993, NAT GENET, V3, P311, DOI 10.1038/ng0493-311; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SFERRA TJ, 1993, ANNU REV MED, V44, P133, DOI 10.1146/annurev.med.44.1.133; SMALL GM, 1988, ANAL BIOCHEM, V169, P405, DOI 10.1016/0003-2697(88)90304-1; SOOD R, 1992, EMBO J, V11, P2487, DOI 10.1002/j.1460-2075.1992.tb05313.x; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; WADA I, 1991, J BIOL CHEM, V266, P19559; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K	45	305	314	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12784	12788						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7513695				2022-12-25	WOS:A1994NH71600064
J	MCDOWALL, KJ; LINCHAO, S; COHEN, SN				MCDOWALL, KJ; LINCHAO, S; COHEN, SN			A+U CONTENT RATHER THAN A PARTICULAR NUCLEOTIDE ORDER DETERMINES THE SPECIFICITY OF RNASE E-CLEAVAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; RIBONUCLEASE-E; RIBOSOMAL-RNA; PLASMID DNA; ENDONUCLEOLYTIC CLEAVAGE; STRUCTURAL-ANALYSIS; GROWTH-RATE; REPLICATION; GENE	Ribonuclease E has a central role in Escherichia coli mRNA decay and is dependent on a functional product of the me (also called ams or hmp1) gene. We investigated the requirements for RNase E cleavage by introducing random mutations into the decanucleotide region at the 5' end of pACYC184 RNA I and studying the effects of these mutations on the position of rne-dependent cleavage in vivo and RNase E-mediated cutting in vitro. We find that the precise point of RNase E cleavage can be altered specifically and reproducibly by sequence changes in the region cleaved and, therefore, is not determined by a distance measured in nucleotides from any other sequence or region of secondary structure in RNA I. Although cleavage by RNase E occurs within sequences rich in A and/or U nucleotides and is affected by the extent of continuity of A and U nucleotides in the regions cleaved, there is no simple relationship between the order of nucleotides and the phosphodiester bond cleaved. Thus, our results are not consistent with either the notion that RNase E cleavages are determined by a simple consensus sequence or the contrary view that RNase E has few primary structural constraints other than a preference for cleaving 5' to an AU dinucleotide.	STANFORD UNIV, MED CTR, SCH MED, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT MED, STANFORD, CA 94305 USA; ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN	Stanford University; Stanford University; Academia Sinica - Taiwan			Lin-Chao, Sue/AAZ-8246-2021; Lin-Chao, Sue/AGI-2030-2022; McDowall, Kenneth/GYA-5735-2022	Lin-Chao, Sue/0000-0002-8415-9304; Lin-Chao, Sue/0000-0002-8415-9304; McDowall, Kenneth/0000-0003-2528-2190	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027241] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27241] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APIRION D, 1978, J BIOL CHEM, V253, P1738; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BIEK DP, 1989, J BACTERIOL, V171, P2066, DOI 10.1128/jb.171.4.2066-2074.1989; BOLIVAR F, 1977, P NATL ACAD SCI USA, V74, P5265, DOI 10.1073/pnas.74.12.5265; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; BRUN YV, 1990, J MOL BIOL, V214, P845, DOI 10.1016/0022-2836(90)90340-R; CESARENI G, 1991, TRENDS GENET, V7, P230, DOI 10.1016/0168-9525(91)90370-6; CHAMBERLIN M, 1983, METHOD ENZYMOL, V101, P540; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHAUHAN AK, 1991, MOL GEN GENET, V228, P49, DOI 10.1007/BF00282446; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; DAVISON J, 1984, GENE, V28, P1, DOI 10.1016/0378-1119(84)90082-9; DOOLEY TP, 1985, J MOL BIOL, V186, P87, DOI 10.1016/0022-2836(85)90259-1; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; EHRETSMANN CP, 1992, FASEB J, V6, P3186, DOI 10.1096/fasebj.6.13.1397840; GEGENHEIMER P, 1977, J BIOL CHEM, V252, P3064; GEORGELLIS D, 1992, J BACTERIOL, V174, P5382, DOI 10.1128/JB.174.16.5382-5390.1992; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; JAURIN B, 1982, EMBO J, V1, P875, DOI 10.1002/j.1460-2075.1982.tb01263.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUWANO M, 1977, MOL GEN GENET, V154, P279, DOI 10.1007/BF00571283; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; MACKIE GA, 1992, J BIOL CHEM, V267, P1054; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MCDOWALL KJ, 1993, J BACTERIOL, V175, P4245, DOI 10.1128/JB.175.13.4245-4249.1993; MELEFORS O, 1992, CONTROL MRNA STABILI, P53; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3642, DOI 10.1073/pnas.74.9.3642; MESSING J, 1983, METHOD ENZYMOL, V101, P20; NER SS, 1989, BIORAD MOL BIOL REP, V7, P1; NILSSON G, 1984, NATURE, V312, P75, DOI 10.1038/312075a0; NORDSTROM K, 1977, PLASMID, V1, P117, DOI 10.1016/0147-619X(77)90013-0; POLISKY B, 1988, CELL, V55, P929, DOI 10.1016/0092-8674(88)90235-8; REGNIER P, 1991, J MOL BIOL, V217, P283, DOI 10.1016/0022-2836(91)90542-E; RESNEKOV O, 1990, P NATL ACAD SCI USA, V87, P8355, DOI 10.1073/pnas.87.21.8355; ROTH JR, 1970, METHODS ENZYMOL    A, V17, P3; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT JR, 1984, MICROBIOL REV, V48, P1; SELZER G, 1983, CELL, V32, P119, DOI 10.1016/0092-8674(83)90502-0; SOM T, 1982, MOL GEN GENET, V187, P375, DOI 10.1007/BF00332615; TAMM J, 1983, NUCLEIC ACIDS RES, V11, P6381, DOI 10.1093/nar/11.18.6381; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P851, DOI 10.1111/j.1365-2958.1991.tb00758.x; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; TOMIZAWA J, 1977, P NATL ACAD SCI USA, V74, P1865, DOI 10.1073/pnas.74.5.1865; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133; ZVEREV VV, 1985, PLASMID, V14, P192, DOI 10.1016/0147-619X(85)90002-2	51	208	208	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10790	10796						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511606				2022-12-25	WOS:A1994NF01700090
J	LOEB, DM; STEPHENS, RM; COPELAND, T; KAPLAN, DR; GREENE, LA				LOEB, DM; STEPHENS, RM; COPELAND, T; KAPLAN, DR; GREENE, LA			A TRK NERVE GROWTH-FACTOR (NGF) RECEPTOR POINT MUTATION AFFECTING INTERACTION WITH PHOSPHOLIPASE C-GAMMA-1 ABOLISHES NGF-PROMOTED PERIPHERIN INDUCTION BUT NOT NEURITE OUTGROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES TYROSINE PHOSPHORYLATION; INTERMEDIATE FILAMENT PROTEIN; PC12 CELLS; PHEOCHROMOCYTOMA CELLS; PROTOONCOGENE PRODUCT; KINASE-ACTIVITY; HIGH-AFFINITY; MONOCLONAL-ANTIBODIES; SIGNALING COMPLEX; C-GAMMA	We analyzed the function of Trk nerve growth factor (NGF) receptors containing a point mutation (Tyr --> Phe) in a major autophosphorylation site (Tyr-785). Tyr-785 is required for phospholipase C-gamma 1 to interact with Trk and to become tyrosine-phosphorylated in response to NGF. The altered receptors were transfected into a mutant subline of PC12 rat pheochromocytoma cells (designated PC12nnr5) that, unlike wild-type PC12 cells, lack expression of endogenous Trk and responsiveness to NGF. PC12nnr5 cells permanently transfected with Trk Y785F exhibit NGF-dependent autophosphorylation and normal NGF binding and internalization. Moreover, Trk Y785F mediates NGF-stimulated neurite outgrowth as well as a variety of additional responses including induction of immediate-early and late genes. However, in contrast to cells expressing wild-type Trk, cells expressing Trk Y785F lack NGF-promoted elevation of peripherin intermediate filament mRNA and protein. These observations indicate that phospholipase C-gamma 1 activation or other signaling pathways dependent on Tyr-785 autophosphorylation are selectively required for regulation of peripherin expression by NGF, but not for many other functional NGF responses. This supports the presence of multiple and separable signaling pathways in the NGF mechanism of action.	COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA; NCI, FREDERICK CANC RES CTR, ADV BIOSCI LABS, BASIC RES PROGRAM, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES CTR,ADV BIOSCI LABS, BASIC RES PROGRAM,PROT STRUCT GRP, FREDERICK, MD 21702 USA	Columbia University; Columbia University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALETTA JM, 1990, FID RES FDN, V3, P203; ALETTA JM, 1988, J NEUROCHEM, V51, P1317, DOI 10.1111/j.1471-4159.1988.tb03104.x; ALETTA JM, 1988, J CELL BIOL, V106, P1573, DOI 10.1083/jcb.106.5.1573; ALTIN JG, 1990, J NEUROCHEM, V54, P1666, DOI 10.1111/j.1471-4159.1990.tb01220.x; BATISTATOU A, 1992, MOL BIOL CELL, V3, P363, DOI 10.1091/mbc.3.3.363; BERND P, 1984, J BIOL CHEM, V259, P5509; BLOOM GS, 1985, P NATL ACAD SCI USA, V82, P5404, DOI 10.1073/pnas.82.16.5404; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUCK CR, 1988, DEV BRAIN RES, V44, P259, DOI 10.1016/0165-3806(88)90224-6; BURSTEIN DE, 1982, DEV BIOL, V94, P477, DOI 10.1016/0012-1606(82)90364-5; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; EAGER KB, 1991, ONCOGENE, V6, P819; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GREEN SH, 1986, J BIOL CHEM, V261, P5316; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1981, J BIOL CHEM, V256, P6363; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GREENE LA, 1991, CULTURING NERVE CELL, P207; HARI J, 1987, J BIOL CHEM, V262, P15341; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KUJUBU DA, 1987, ONCOGENE, V1, P257; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEONARD DGB, 1988, J CELL BIOL, V106, P181, DOI 10.1083/jcb.106.1.181; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LEVI A, 1991, ANNU REV PHARMACOL, V31, P205; LILLIEN LE, 1985, NATURE, V317, P632, DOI 10.1038/317632a0; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LOEB DM, 1993, J NEUROSCI, V13, P2919; MACHIDA CM, 1991, J CELL BIOL, V114, P1037, DOI 10.1083/jcb.114.5.1037; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P215, DOI 10.1159/000112348; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; SUH PG, 1988, J BIOL CHEM, V263, P14497; Summers MD, 1987, MANUAL METHODS BACUL; THOMPSON MA, 1992, MOL CELL BIOL, V117, P1085; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROY CM, 1992, J CELL BIOL, V117, P1085, DOI 10.1083/jcb.117.5.1085; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650	71	121	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8901	8910						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510697				2022-12-25	WOS:A1994NB41100044
J	MELILLO, G; COX, GW; BIRAGYN, A; SHEFFLER, LA; VARESIO, L				MELILLO, G; COX, GW; BIRAGYN, A; SHEFFLER, LA; VARESIO, L			REGULATION OF NITRIC-OXIDE SYNTHASE MESSENGER-RNA EXPRESSION BY INTERFERON-GAMMA AND PICOLINIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MURINE PERITONEAL-MACROPHAGES; HUMAN-CELLS INVITRO; IFN-GAMMA; L-ARGININE; EFFECTOR MECHANISM; HUMAN-MONOCYTES; FACTOR-ALPHA; INDOLEAMINE 2,3-DIOXYGENASE; TRYPTOPHAN DEGRADATION	Picolinic acid, a catabolite of L-tryptophan, is a potent co-stimulatory agent for the induction of tumoricidal activity and the production of L-arginine-dependent reactive nitrogen intermediates (RNI) in murine macrophages. We studied whether picolinic acid could affect nitric-oxide synthase (NOS) expression at the gene level in the macrophage cell line ANA-1. NOS mRNA was neither constitutively expressed nor induced by treatment with picolinic acid alone. However, low levels of NOS mRNA were induced by interferon (IFN)-gamma alone. In contrast, a major increase of NOS mRNA expression was observed after treatment with IFN-gamma plus picolinic acid. The synergism was already detectable after 5-6 h and increased up to 20 h of treatment. The ability of picolinic acid to augment IFN-gamma-dependent NOS mRNA expression was associated with a parallel increase in transcription, as demonstrated by nuclear run-on experiments. Protein synthesis was required for the induction of NOS mRNA because addition of cycloheximide dramatically reduced IFN-gamma plus picolinic acid-induced NOS mRNA expression. Finally, interleukin-4 significantly decreased IFN-gamma plus picolinic acid-induced NOS mRNA expression and NOS transcription. These data provide evidence of a molecular event connecting arginine and tryptophan metabolic pathways in the generation of RNI, and they indicate that picolinic acid can induce transcriptional activation of gene expression.	NCI, FREDERICK CANC RES & DEV CTR, DIV CANC TREATMENT, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	MELILLO, G (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, DIV CANC TREATMENT, BRMP, EXPTL IMMUNOL LAB, FREDERICK, MD 21702 USA.		varesio, luigi/J-8261-2016	varesio, luigi/0000-0001-5659-2218				AUSUBAL FM, 1989, CURRENT PROTOCOLS MO; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BLASI E, 1988, J IMMUNOL, V141, P2153; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BROWN RR, 1989, CANCER RES, V49, P4941; BYRNE GI, 1986, J INTERFERON RES, V6, P389, DOI 10.1089/jir.1986.6.389; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COX GW, 1992, J IMMUNOL, V149, P3290; COX GW, 1991, J IMMUNOL, V147, P3809; DENIS M, 1991, J LEUKOCYTE BIOL, V49, P380, DOI 10.1002/jlb.49.4.380; DING A, 1990, J IMMUNOL, V145, P940; DING AH, 1988, J IMMUNOL, V141, P2407; DOKTER WHA, 1993, BLOOD, V81, P337; DONNELLY RP, 1991, J IMMUNOL, V146, P3431; DRAPIER JC, 1988, EUR J IMMUNOL, V18, P1587, DOI 10.1002/eji.1830181018; ESSNER R, 1989, J IMMUNOL, V142, P3857; EVANS GW, 1980, PEDIATR RES, V14, P867; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAUTAM S, 1992, J IMMUNOL, V148, P1725; HART PH, 1989, P NATL ACAD SCI USA, V86, P3803, DOI 10.1073/pnas.86.10.3803; HEYES MP, 1992, FASEB J, V6, P2977, DOI 10.1096/fasebj.6.11.1322853; HIBBS JB, 1992, J CLIN INVEST, V89, P867, DOI 10.1172/JCI115666; HIBBS JB, 1987, J IMMUNOL, V138, P550; HIBBS JB, 1990, INT CONGR SER, V897, P189; HIGUCHI M, 1990, J IMMUNOL, V144, P1425; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; LAHN M, 1989, J IMMUNOL, V143, P3020; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LARNER AC, 1993, J IMMUNOL, V150, P1944; LEUTHAUSER SWC, 1982, J NATL CANCER I, V68, P123; LIEW FY, 1991, EUR J IMMUNOL, V21, P2489, DOI 10.1002/eji.1830211027; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MAZA LM, 1988, CANCER RES, V48, P346; MELILLO G, 1993, J IMMUNOL, V150, P4031; MURRAY HW, 1989, INFECT IMMUN, V57, P845, DOI 10.1128/IAI.57.3.845-849.1989; NARUMI S, 1990, J BIOL CHEM, V265, P7036; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OSIPOVICH OA, 1993, J IMMUNOL, V150, P4958; OZAKI Y, 1988, P NATL ACAD SCI USA, V85, P1242, DOI 10.1073/pnas.85.4.1242; REBELLO T, 1982, AM J CLIN NUTR, V35, P1; RUFFMANN R, 1984, J IMMUNOPHARMACOL, V6, P291, DOI 10.3109/08923978409028605; RUFFMANN R, 1987, DRUG EXP CLIN RES, V13, P607; SESSA WC, 1992, J BIOL CHEM, V267, P15274; STUEHR DJ, 1987, J IMMUNOL, V139, P518; TEVELDE AA, 1990, BLOOD, V76, P1392; VARESIO L, 1990, J IMMUNOL, V145, P4265; VARESIO L, 1992, CURR TOP MICROBIOL, V181, P208; WERNER ER, 1987, BIOL CHEM H-S, V368, P1407, DOI 10.1515/bchm3.1987.368.2.1407; WERNERFELMAYER G, 1989, BIOCHIM BIOPHYS ACTA, V1012, P140, DOI 10.1016/0167-4889(89)90087-6; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YOSHIDA R, 1978, P NATL ACAD SCI USA, V75, P3998, DOI 10.1073/pnas.75.8.3998	53	116	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8128	8133						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510678				2022-12-25	WOS:A1994NB40900047
J	HASEGAWA, H; MA, TH; SKACH, W; MATTHAY, MA; VERKMAN, AS				HASEGAWA, H; MA, TH; SKACH, W; MATTHAY, MA; VERKMAN, AS			MOLECULAR-CLONING OF A MERCURIAL-INSENSITIVE WATER CHANNEL EXPRESSED IN SELECTED WATER-TRANSPORTING TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL CHIP28 PROTEIN; RECONSTITUTION; BRAIN	Two mercurial-inhibitable water-transporting proteins have been identified: CHIP28, an erythrocyte water channel also expressed in kidney tubules and selected extrarenal epithelia, and WCH-CD, a kidney collecting duct water channel. In searching for a protein responsible for the high transcellular water permeability in lung alveolus, we cloned a 32-kDa water channel (mercurial-insensitive water channel (MIWC)) from a rat lung cDNA library with several novel features. Water permeability was strongly increased,in Xenopus oocytes expressing MIWC in a-mercurial-insensitive manner, in contrast to known water channels. By in situ hybridization, MIWC showed an unique distribution in cells that do not express CHIP28, including kidney papillary vasa recta, cells lining ther subarachnoid space and ventricles in brain, the inner nuclear layer in retina, and the conjunctival epithelium. An alternatively spliced form of MIWC with a 165-base pair deletion in the coding sequence was also identified; relative expression of the spliced mRNA was tissue-specific. The MIWC water channel may participate in the urinary concentrating mechanism, the absorption of cerebrospinal fluid, and other physiological processes.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco				Ma, Tonghui/0000-0001-9338-1030	NHLBI NIH HHS [HL42368] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; BONDY C, 1993, P NATL ACAD SCI USA, V90, P4500, DOI 10.1073/pnas.90.10.4500; DEEN PMT, 1992, BIOCHEM BIOPH RES CO, V188, P1267, DOI 10.1016/0006-291X(92)91368-Z; FOLKESSON HG, 1994, IN PRESS P NATL ACAD; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HASEGAWA H, 1992, SCIENCE, V258, P1477, DOI 10.1126/science.1279809; HASEGAWA H, 1993, AM J PHYSIOL, V264, pC237, DOI 10.1152/ajpcell.1993.264.1.C237; HASEGAWA H, 1994, IN PRESS AM J PHYSL; MA TH, 1994, AM J PHYSIOL, V266, pC189, DOI 10.1152/ajpcell.1994.266.1.C189; MOON C, 1993, J BIOL CHEM, V268, P15772; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; PALLONE TL, 1991, J CLIN INVEST, V87, P12, DOI 10.1172/JCI114960; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; RAO Y, 1990, NATURE, V345, P163, DOI 10.1038/345163a0; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; Verkman AS, 1993, WATER CHANNELS; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG RB, 1993, J CELL BIOL, V120, P359, DOI 10.1083/jcb.120.2.359	21	451	487	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5497	5500						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509789				2022-12-25	WOS:A1994MY84000005
J	KUME, T; TSUNEIZUMI, K; WATANABE, T; THOMAS, ML; OISHI, M				KUME, T; TSUNEIZUMI, K; WATANABE, T; THOMAS, ML; OISHI, M			INDUCTION OF SPECIFIC PROTEIN-TYROSINE-PHOSPHATASE TRANSCRIPTS DURING DIFFERENTIATION OF MOUSE ERYTHROLEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ERYTHROID-DIFFERENTIATION; MEL CELLS; INVITRO DIFFERENTIATION; DIMETHYL SULFOXIDE; FRIEND-CELLS; KINASES; CLONING; IDENTIFICATION; INHIBITORS; EXPRESSION	We reported previously that most of the phosphotyrosine-containing cellular proteins were quickly dephosphorylated at the very early stage of erythroid differentiation of mouse erythroleukemia (MEL) cells. These and other experimental results implicated a specific protein tyrosine phosphatase(s) (PTPase(s)) involved in the commitment of the erythroid differentiation. We have investigated the pattern of transcripts of PTPases during MEL cell differentiation and found that while the transcripts of most PTPases were unchanged or undetected in the cells, transcripts for two PTPases (PTP beta 2 and RIP) exhibited distinct patterns of induction at a very early stage of differentiation. Some of the mutant cells defective in differentiation did not show the induction of these PTPase transcripts. We discuss the possible role played by the PTPases in the commitment of MEL cell differentiation.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	KUME, T (corresponding author), UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN.							FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; KAKIZUKA A, 1992, GENE DEV, V6, P578, DOI 10.1101/gad.6.4.578; KANEKO T, 1984, CANCER RES, V44, P1756; KONDO K, 1989, J CELL BIOL, V109, P285, DOI 10.1083/jcb.109.1.285; LEDER A, 1975, CELL, V5, P319, DOI 10.1016/0092-8674(75)90107-5; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; NUDEL U, 1977, CELL, V12, P463, DOI 10.1016/0092-8674(77)90122-2; OISHI M, 1990, MECHANISM DIFFERENTI, V2, P129; REUBEN RC, 1976, P NATL ACAD SCI USA, V73, P862, DOI 10.1073/pnas.73.3.862; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI H, 1987, JPN J CANCER RES, V78, P776; SODHU K, 1990, P NATL ACAD SCI USA, V87, P5139; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; SWARUP G, 1991, FEBS LETT, V280, P65, DOI 10.1016/0014-5793(91)80205-H; TAKAHASHI E, 1975, GANN, V66, P577; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; THOMAS ML, 1993, PROG IMMUNOL, V8, P213; WATANABE T, 1991, CANCER RES, V51, P764; WATANABE T, 1992, EXP CELL RES, V199, P269, DOI 10.1016/0014-4827(92)90434-A; WATANABE T, 1992, J BIOL CHEM, V267, P17116; WATANABE T, 1989, EXP CELL RES, V183, P335, DOI 10.1016/0014-4827(89)90394-7; WATANABE T, 1987, P NATL ACAD SCI USA, V84, P6481, DOI 10.1073/pnas.84.18.6481; WATANABE T, 1992, CELL GROWTH DIFFER, V3, P865; YOSHIDA M, 1987, CANCER RES, V47, P3688	28	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4709	4712						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508927				2022-12-25	WOS:A1994MX57100005
J	XIE, QW; KASHIWABARA, Y; NATHAN, C				XIE, QW; KASHIWABARA, Y; NATHAN, C			ROLE OF TRANSCRIPTION FACTOR NF-KAPPA-B/REL IN INDUCTION OF NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOUSE MACROPHAGES; INHIBITORS; CELLS	The promoter of the murine gene encoding inducible nitric oxide synthase (iNOS) contains an NF-kappa B site beginning 55 base pairs upstream of the TATA box, designated NF-kappa Bd. Reporter constructs containing truncated promoter regions, when transfected into macrophages, revealed that NF-kappa Bd is necessary to confer inducibility by bacterial lipopolysaccharide (LPS). Oligonucleotide probes containing NF-kappa Bd plus the downstream 9 or 47 base pairs bound proteins that rapidly appeared in the nuclei of LPS-treated macrophages. The nuclear proteins bound to both probes in an NF-kappa Bd-dependent manner, but binding was resistant to cycloheximide only for the shorter probe. The proteins binding both probes reacted with antibodies against p50 and c-rel but not RelB; those binding the shorter probe also reacted with anti-RelA (p65). Pyrrolidine dithiocarbamate, which acts as a specific inhibitor of NF-kappa B, blocked both the activation of the NF-kappa Bd-binding proteins and the production of NO in LPS-treated macrophages. Thus, activation of NF-kappa Bd/Rel is critical in the induction of iNOS by LPS. However, additional, newly synthesized proteins contribute to the NF-kappa Bd-dependent transcription factor complex on the iNOS promoter in LPS treated mouse macrophages.			XIE, QW (corresponding author), CORNELL UNIV,COLL MED,DEPT MED,BEATRICE & SAMUEL A SEAVER LAB,BOX 57,1300 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034543, R21AI034543] Funding Source: NIH RePORTER; NIAID NIH HHS [AI/CA 34543] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COLLART MA, 1990, MOL CELL BIOL, V10, P2598; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; DING AH, 1988, J IMMUNOL, V141, P2407; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GRILLI M, 1993, INT REV CYTOL, V143, P1; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; KARUPIAH G, 1993, SCIENCE, V261, P445; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KLEEMANN R, 1993, FEBS LETT, V328, P9, DOI 10.1016/0014-5793(93)80954-S; LANDER HM, 1993, J IMMUNOL, V150, P1509; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; MCCARTNEYFRANCIS N, 1993, J EXP MED, V178, P749, DOI 10.1084/jem.178.2.749; MULSCH A, 1993, FEBS LETT, V321, P215, DOI 10.1016/0014-5793(93)80111-7; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SHERMAN MP, 1993, BIOCHEM BIOPH RES CO, V191, P1301, DOI 10.1006/bbrc.1993.1359; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; THAMOS D, 1992, CELL, V71, P777; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; XIE QW, 1993, T ASSOC AM PHYSICIAN, V106, P1; ZHENG S, 1993, J BIOL CHEM, V268, P17233	27	2039	2092	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4705	4708						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508926				2022-12-25	WOS:A1994MX57100004
J	CLARK, BR; DESHPANDE, SV; SHARMA, SD; NAG, B				CLARK, BR; DESHPANDE, SV; SHARMA, SD; NAG, B			ANTIGEN-SPECIFIC DELETION OF CLONED T-CELLS USING PEPTIDE-TOXIN CONJUGATE COMPLEXED WITH PURIFIED CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; MYELIN BASIC-PROTEIN; MYCOPHENOLIC-ACID; AUTOIMMUNE ENCEPHALOMYELITIS; ACETYLCHOLINE-RECEPTOR; IMMUNE INTERVENTION; RECOGNITION; MOLECULES; LYMPHOCYTES; ADRIAMYCIN	In a previous report, we showed that cloned T cells incubated with soluble, cognate major histocompatibility complex (MHC) II-peptide complex internalized the peptide moiety of the complex. Here, we report antigen-specific deletion of cloned T cells by treatment with soluble, cognate MHC II-(peptide-toxin) complexes. Toxin (doxorubicin or mycophenolic acid) was attached to synthetic AcMBP(1-14)Ala4 peptide, an analog of the natural acetylated NH2-terminal segment, AcMBP(1-14), of rat myelin basic protein (MBP). IA(k)-restricted, AcMBP(1-14)-specific AJ1.2 and 4R3.9 cloned murine T cells were killed by IA(k)-(AcMBP(1-14)Ala4-toxin). No killing resulted from incubating A.J1.2 and 4R3.9 cells with irrelevant MHC II-(peptide-toxin) or treating IE(k)-restricted, pigeon cytochrome c-specific A.E7 cloned murine T cells with IA(k)-(AcMBP(1-14)Ala4-toxin). T cell receptor-mediated T cell uptake of the peptide-toxin moiety of relevant complex was blocked by anti-T cell receptor-alpha/beta antibody and by excess toxin-free complex. LD50 determinations revealed that cognate MHC II-(peptide-toxin) killed T cells much more effectively than did peptide-toxin conjugate alone. Finally, T cell uptake of peptide-toxin and intracellular release of toxin occurred after incubation with relevant MHC II-(peptide-toxin) containing radiolabeled toxin. These findings, which provide the first evidence that cloned T cells can be deleted with soluble, cognate MHC II-(peptide-toxin) complexes, may have significant clinical relevance for antigen-specific therapy of autoimmune or other T cell-mediated diseases.	ANERGEN INC,301 PENOBSCOT DR,REDWOOD CITY,CA 94063									ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; ALLEN PM, 1987, IMMUNOL REV, V98, P171, DOI 10.1111/j.1600-065X.1987.tb00524.x; ALLISON AC, 1991, TRANSPL P, V23, P10; Arcamone F, 1972, INT S ADRIAMYCIN SPR, P9, DOI [10.1007/978-3-642-95227-2_2, DOI 10.1007/978-3-642-95227-2_2]; BLATTLER WA, 1985, BIOCHEMISTRY-US, V24, P1517, DOI 10.1021/bi00327a034; BLUM RH, 1974, ANN INTERN MED, V80, P249, DOI 10.7326/0003-4819-80-2-249; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; BUUS S, 1987, IMMUNOL REV, V98, P115, DOI 10.1111/j.1600-065X.1987.tb00522.x; CALENDI E, 1965, BIOCHIM BIOPHYS ACTA, V103, P25, DOI 10.1016/0005-2787(65)90539-3; DAVIS CB, 1989, J IMMUNOL, V143, P2083; DIMARCO A, 1975, CANCER CHEMOTH REP 3, V6, P91; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EUGUI EM, 1991, SCAND J IMMUNOL, V33, P175, DOI 10.1111/j.1365-3083.1991.tb03747.x; HAUGHTON G, 1986, IMMUNOL REV, V93, P35, DOI 10.1111/j.1600-065X.1986.tb01501.x; HECHT TT, 1983, J IMMUNOL, V131, P1049; KILLEN JA, 1984, J IMMUNOL, V133, P2549; KIM KJ, 1979, J IMMUNOL, V122, P549; MORRIS RE, 1990, TRANSPLANT P, V22, P1659; NAG B, 1993, J BIOL CHEM, V268, P14360; NAG B, 1991, J IMMUNOL METHODS, V142, P105, DOI 10.1016/0022-1759(91)90297-S; NAG B, 1992, J IMMUNOL, V148, P369; OKSENBERG JR, 1990, CURR OPIN IMMUNOL, V2, P619, DOI 10.1016/0952-7915(90)90021-8; OLSBERG CA, 1985, J IMMUNOL, V135, P3062; PURI J, 1980, EUR J IMMUNOL, V10, P273, DOI 10.1002/eji.1830100410; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SHEN WC, 1981, BIOCHEM BIOPH RES CO, V102, P1048, DOI 10.1016/0006-291X(81)91644-2; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; TRITTON TR, 1982, SCIENCE, V217, P248, DOI 10.1126/science.7089561; URBATSCH IL, 1993, EUR J IMMUNOL, V23, P776, DOI 10.1002/eji.1830230332; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; WRAITH DC, 1989, CELL, V57, P709, DOI 10.1016/0092-8674(89)90786-1; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0	34	9	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					94	99						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506264				2022-12-25	WOS:A1994MR21900022
J	BURGER, RM; DRLICA, K; BIRDSALL, B				BURGER, RM; DRLICA, K; BIRDSALL, B			THE DNA CLEAVAGE PATHWAY OF IRON BLEOMYCIN - STRAND SCISSION PRECEDES DEOXYRIBOSE 3-PHOSPHATE BOND-CLEAVAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE PROPENAL FORMATION; ACTIVATED BLEOMYCIN; MECHANISM; DEGRADATION; SITE; ABSTRACTION; RESOLUTION; RELEASE; OXYGEN; ORIGIN	DNA strand scission initiated by bleomycin is a multistep process. Three C-C or C-O bonds are broken, releasing base propenal, a nucleic base derivative with deoxyribose carbons 1-3. Either C-3'-(phosphate-O) cleavage or C-3'-C-4' plus C-1'-(ring-O) bond cleavages could cause strand cleavage. To determine the sequence of bond breakage, d(CAAGCTTG) duplex was examined for rates of 1) strand scission, monitored by the hyperchromicity of cleavage-induced denaturation; 2) base propenal formation, monitored by H-1 NMR spectroscopy; 3) 5'-terminal phosphomonoester formation, monitored by P-31 NMR spectroscopy. Strand scission occurred with t(1/2) = 4.1 +/- 0.5 min at 4 degrees C, faster than base propenal formation (t(1/2) = 6.7 +/- 0.3 min). Thus newly cleaved DNA includes a base propenal precursor (t(1/2) = 2-3 min). The 5'-phosphate terminus forms (t(1/2) = 7.4 +/- 0.8 min) concurrently with base propenal. Since strand scission precedes phosphomonoester formation, strand scission cannot arise from C-3'-(phosphate-O) cleavage. Instead, the base propenal precursor must be linked to the future 5'-phosphate terminus, with strand scission arising from a combination of C-3'-C-4' and C-1'-(ring-O) bond cleavages. These results provide experimental support for a recently proposed mechanism that accommodates an early oxygen attack at C-4' and 2'-deprotonation without requiring simultaneous strand scission and 5'-phosphate terminus formation.	NATL INST MED RES,MOLEC STRUCT LAB,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	BURGER, RM (corresponding author), PUBL HLTH RES INST CITY NEW YORK INC,455 1ST AVE,NEW YORK,NY 10016, USA.				NIAID NIH HHS [AI 35257, AI 23337] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023337, R01AI035257] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AJMERA S, 1986, BIOCHEMISTRY-US, V25, P6586, DOI 10.1021/bi00369a037; BERTINI I, 1993, CHEM REV, V93, P2833, DOI 10.1021/cr00024a009; Borer P. N., 1975, CRC HDB BIOCH MOL BI, V1, P589; BURGER RM, 1981, J BIOL CHEM, V256, P1636; BURGER RM, 1982, J BIOL CHEM, V257, P3372; BURGER RM, 1979, J BIOL CHEM, V254, P906; BURGER RM, 1985, J BIOL CHEM, V260, P5406; BURGER RM, 1980, J BIOL CHEM, V255, P1832; BURGER RM, 1982, J BIOL CHEM, V257, P8612; BURGER RM, 1985, BIOCHEMISTRY-US, V24, P3623, DOI 10.1021/bi00335a034; BURGER RM, 1986, J BIOL CHEM, V261, P5955; CRAIG ME, 1971, J MOL BIOL, V62, P383, DOI 10.1016/0022-2836(71)90434-7; GILONI L, 1981, J BIOL CHEM, V256, P8608; Gorenstein DG, 1984, PHOSPHORUS 31 NMR PR; GROLLMAN AP, 1985, CANCER RES, V45, P1127; Hecht S. M., 1979, BLEOMYCIN CHEM BIOCH; HECHT SM, 1986, FASEB J, V45, P2784; ILES RA, 1982, PROG NUCL MAG RES SP, V15, P49, DOI 10.1016/0079-6565(82)80008-3; KOZARICH JW, 1989, SCIENCE, V245, P1396, DOI 10.1126/science.2476851; KURAMOCHI H, 1981, J ANTIBIOT TOKYO, V34, P578; LEVITT MH, 1983, ADV MAGN RESON, V11, P47; MCGALL GH, 1992, J AM CHEM SOC, V114, P4958, DOI 10.1021/ja00039a002; PORCHKE D, 1971, J MOL BIOL, V62, P361; SAITO I, 1987, J ORG CHEM, V52, P1008, DOI 10.1021/jo00382a007; SHIPLEY JB, 1988, CHEM RES TOXICOL, V1, P25, DOI 10.1021/tx00001a004; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; SUGIYAMA H, 1985, J AM CHEM SOC, V107, P7765, DOI 10.1021/ja00311a092; SUZUKI H, 1969, J ANTIBIOT, V22, P446, DOI 10.7164/antibiotics.22.446; SUZUKI H, 1968, J ANTIBIOT, V21, P379, DOI 10.7164/antibiotics.21.379; TAKESHITA M, 1979, BLEOMYCIN CHEM BIOCH, P207; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; UMEZAWA H, 1966, J ANTIBIOT, V19, P200; UMEZAWA H, 1966, J ANTIBIOT, V19, P210; WU JC, 1983, J BIOL CHEM, V258, P4694; WU JC, 1985, BIOCHEMISTRY-US, V24, P7562, DOI 10.1021/bi00347a009	35	39	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25978	25985						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523397				2022-12-25	WOS:A1994PQ93000010
J	TAKAHARA, K; KESSLER, E; BINIAMINOV, L; BRUSEL, M; EDDY, RL; JANISAIT, S; SHOWS, TB; GREENSPAN, DS				TAKAHARA, K; KESSLER, E; BINIAMINOV, L; BRUSEL, M; EDDY, RL; JANISAIT, S; SHOWS, TB; GREENSPAN, DS			TYPE-I PROCOLLAGEN COOH-TERMINAL PROTEINASE ENHANCER PROTEIN - IDENTIFICATION, PRIMARY STRUCTURE, AND CHROMOSOMAL LOCALIZATION OF THE COGNATE HUMAN GENE (PCOLCE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; C-PROTEINASE; MOUSE FIBROBLASTS; HUMAN GENOME; PURIFICATION; COLLAGEN; DNA; GLYCOPROTEIN; QUANTITIES; EXPRESSION	Type I procollagen COOH-terminal proteinase (C-proteinase) enhancer, a glycoprotein that binds to the COOH-terminal propeptide of type I procollagen and enhances procollagen C-proteinase activity, was purified from mouse fibroblast culture media. Partial amino acid sequences obtained from proteolytic fragments were found to have identity with the deduced amino acid sequence of a cDNA clone of unknown function, previously isolated from a mouse astrocyte library. Sequences of mouse enhancer cDNA, obtained in the present study, predict a similar to 50-kDa, 468-amino acid protein that differs from the 43-kDa, 402-amino acid protein predicted by the previously reported astrocyte-derived clone. Human cDNAs encode an enhancer of 449 amino acids. Previous biochemical studies have found the mouse enhancer as a 55-kDa form, which is readily processed to 36- and 34-kDa forms, retaining full C-proteinase enhancing activity and the ability to bind the COOH-terminal propeptide. Data presented here show the 36-kDa form to correspond to the amino-terminal portion of the 55-kDa protein. This is the most conserved region between mouse and human enhancers, comprising two domains with homology to domains found in a number of proteases and proteins with developmental functions. Such domains are thought to mediate interactions between proteins. Mouse enhancer RNA is shown to be at highest levels in collagen-rich tissues, especially tendon. The human enhancer gene, PCOLCE, is localized to 7q21.3-->q22, the same chromosomal region containing the type I collagen alpha 2 chain gene, COL1A2.	UNIV WISCONSIN,DEPT PATHOL & LAB MED,MADISON,WI 53706; UNIV WISCONSIN,CELL & MOLEC BIOL PROGRAM,MADISON,WI 53706; TEL AVIV UNIV,FAC MED,SHEBA MED CTR,MAURICE & GABRIELA GOLDSCHLEGER EYE RES INST,IL-52621 TEL HASHOMER,ISRAEL; NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT HUMAN GENET,BUFFALO,NY 14263	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Chaim Sheba Medical Center; Tel Aviv University; Roswell Park Cancer Institute				Greenspan, Daniel/0000-0001-8096-7446	NIGMS NIH HHS [GM46846] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAR R, 1986, COLLAGEN REL RES, V6, P267; ARLAUD GJ, 1987, IMMUNOL TODAY, V8, P106, DOI 10.1016/0167-5699(87)90860-7; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P9383; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREENSPAN DS, 1991, GENE EXPRESSION, V1, P29; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; KESSLER E, 1990, BIOCHEM BIOPH RES CO, V173, P81, DOI 10.1016/S0006-291X(05)81024-1; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; KIVIRIKKO KI, 1984, EXTRACELLULAR MATRIX, P83; KUHN K, 1987, STRUCTURE FUNCTION C, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECAIN E, 1991, J NEUROCHEM, V56, P2133, DOI 10.1111/j.1471-4159.1991.tb03476.x; LEE ST, 1988, J BIOL CHEM, V263, P13414; LEPAGE T, 1992, DEVELOPMENT, V114, P147; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PERETZ M, 1989, BIOCHEMISTRY-US, V28, P6549, DOI 10.1021/bi00442a004; PESCIOTTA DM, 1982, IMMUNOCHEMISTRY EXTR, V1, P91; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; REYNOLDS SD, 1992, DEVELOPMENT, V114, P769; RHYNER TA, 1990, J NEUROSCI RES, V27, P144, DOI 10.1002/jnr.490270204; SATO SM, 1990, DEV BIOL, V137, P135, DOI 10.1016/0012-1606(90)90014-A; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SHOWS T, 1984, SOMAT CELL MOLEC GEN, V10, P315, DOI 10.1007/BF01535253; SHOWS TB, 1983, ISOZYMES-CURR T BIOL, V10, P323; SHOWS TB, 1982, ADV HUM GENET, V12, P341; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TRASK B, 1991, METHOD CELL BIOL, V35, P1; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	35	87	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26280	26285						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523404				2022-12-25	WOS:A1994PQ93000054
J	KUO, SR; LIU, JS; BROKER, TR; CHOW, LT				KUO, SR; LIU, JS; BROKER, TR; CHOW, LT			CELL-FREE REPLICATION OF THE HUMAN PAPILLOMAVIRUS DNA WITH HOMOLOGOUS VIRAL E1 AND E2 PROTEINS AND HUMAN CELL-EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; BOVINE PAPILLOMAVIRUS; TRANSCRIPTIONAL ACTIVATION; BINDING-SITE; TRANSIENT REPLICATION; REGULATORY PROTEINS; TYPE-11 ORIGIN; MESSENGER-RNAS; INVITRO; INITIATION	We have established the first homologous cell-free DNA replication system for a papillomavirus. The replication of the human papillomavirus type 11 (HPV-11) origin was achieved by using human 293 cell extracts supplemented with the HPV-11 E1 and E2 proteins purified from insect cells infected with recombinant baculoviruses. Efficient replication depends on the HPV-11 origin, the HPV-11 E1 and E2 proteins, as well as human DNA polymerase alpha, delta, replication protein A, topoisomerase I, and topoisomerase II. High concentrations of E1 protein also promoted a low level of origin-independent replication which was suppressed by the addition of the E2 protein, whereas E2 protein stimulated origin-dependent replication. We also show that an intact E2 protein binding site was absolutely necessary for origin activity, as a strong HPV-11 origin was rendered inactive when one half-site of each of the three E2 binding sites was mutated. In contrast, there was only a relatively small reduction in this mutant origin activity when the cell extracts were supplemented with the bovine papillomavirus type 1 (BPV-1) proteins. These results suggest that the HPV-11 E2 protein plays a primary role in HPV origin recognition. Furthermore, unlike transient replication in which HPV-11 and BPV-1 viral proteins promote efficient replication of homologous and heterologous origins, efficient cell-free replication took place only with the homologous combinations.	UNIV ALABAMA, SCH MED & DENT, DEPT BIOCHEM & MOLEC GENET, BIRMINGHAM, AL 35294 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA	University of Alabama System; University of Alabama Birmingham; University of Rochester					NATIONAL CANCER INSTITUTE [R01CA036200] Funding Source: NIH RePORTER; NCI NIH HHS [CA36200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEDROSIAN CL, 1990, VIROLOGY, V174, P557, DOI 10.1016/0042-6822(90)90109-5; BLITZ IL, 1991, J VIROL, V65, P649, DOI 10.1128/JVI.65.2.649-656.1991; BREAM GL, 1993, J VIROL, V67, P2655, DOI 10.1128/JVI.67.5.2655-2663.1993; BROKER TR, 1989, CANCER CEL, V7, P197; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CHENG LZ, 1992, P NATL ACAD SCI USA, V89, P589, DOI 10.1073/pnas.89.2.589; CHIANG CM, 1992, P NATL ACAD SCI USA, V89, P5799, DOI 10.1073/pnas.89.13.5799; CHIANG CM, 1992, J VIROL, V66, P5224, DOI 10.1128/JVI.66.9.5224-5231.1992; CHIANG CM, 1991, J VIROL, V65, P3317, DOI 10.1128/JVI.65.6.3317-3329.1991; DELVECCHIO AM, 1992, J VIROL, V66, P5949, DOI 10.1128/JVI.66.10.5949-5958.1992; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, P99; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOLLARD SC, 1992, GENE DEV, V6, P1131, DOI 10.1101/gad.6.7.1131; DONG G, 1994, J VIROL, V68, P1115, DOI 10.1128/JVI.68.2.1115-1127.1994; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; Harlow E., 1988, ANTIBODIES LABORATOR, P511; HOLT SE, 1994, J VIROL, V68, P1094, DOI 10.1128/JVI.68.2.1094-1102.1994; HUGHES FJ, 1993, NUCLEIC ACIDS RES, V21, P5817, DOI 10.1093/nar/21.25.5817; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI R, 1994, P NATL ACAD SCI USA, V91, P7051, DOI 10.1073/pnas.91.15.7051; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIU LF, 1990, DNA TOPOLOGY ITS BIO, P371; LU JZJ, 1993, J VIROL, V67, P7131, DOI 10.1128/JVI.67.12.7131-7139.1993; LUSKY M, 1991, P NATL ACAD SCI USA, V88, P6363, DOI 10.1073/pnas.88.14.6363; LUSKY M, 1993, J BIOL CHEM, V268, P15795; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; MEYERS C, 1992, SCIENCE, V257, P971, DOI 10.1126/science.1323879; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MUNGAL S, 1992, J VIROL, V66, P3220, DOI 10.1128/JVI.66.5.3220-3224.1992; REMM M, 1992, NUCLEIC ACIDS RES, V20, P6015, DOI 10.1093/nar/20.22.6015; ROTENBERG MO, 1989, VIROLOGY, V172, P468, DOI 10.1016/0042-6822(89)90189-X; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SCHIRMBECK R, 1991, J VIROL, V65, P2578, DOI 10.1128/JVI.65.5.2578-2588.1991; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; SPALHOLZ BA, 1993, VIROLOGY, V193, P201, DOI 10.1006/viro.1993.1116; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; STOLER MH, 1989, VIROLOGY, V172, P331, DOI 10.1016/0042-6822(89)90135-9; STOLER MH, 1990, J VIROL, V64, P3310, DOI 10.1128/JVI.64.7.3310-3318.1990; SVERDRUP F, 1994, J VIROL, V68, P505, DOI 10.1128/JVI.68.1.505-509.1994; THORNER LK, 1993, J VIROL, V67, P6000, DOI 10.1128/JVI.67.10.6000-6014.1993; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; USTAV E, 1993, P NATL ACAD SCI USA, V90, P898, DOI 10.1073/pnas.90.3.898; USTAV M, 1991, EMBO J, V10, P4321, DOI 10.1002/j.1460-2075.1991.tb05010.x; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WEBB N R, 1990, Technique (Philadelphia), V2, P173; WILSON VG, 1991, J VIROL, V65, P5314, DOI 10.1128/JVI.65.10.5314-5322.1991; WINOKUR PL, 1992, EMBO J, V11, P4111, DOI 10.1002/j.1460-2075.1992.tb05504.x; YANG L, 1991, COLD SPRING HARB SYM, V56, P335; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	60	102	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24058	24065						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523366				2022-12-25	WOS:A1994PQ34600035
J	COCCIA, EM; KRUST, B; HOVANESSIAN, AG				COCCIA, EM; KRUST, B; HOVANESSIAN, AG			SPECIFIC-INHIBITION OF VIRAL PROTEIN-SYNTHESIS IN HIV-INFECTED CELLS IN RESPONSE TO INTERFERON TREATMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; GENE-EXPRESSION; ENVELOPE GLYCOPROTEINS; 2-5A SYNTHETASE; MESSENGER-RNA; REPLICATION; TYPE-1; ALPHA; TRANSLATION; KINASE	The mechanism of action of different types of interferons (IFN-alpha, -beta, and -gamma) against human immunodeficiency virus (HIV)-1 infection was investigated in chronically infected monocytoid U937 cells and during an acute infection of the T lymphoblastoid CEM cells. Two chronically infected U937 cell populations, obtained independently (referred to as type A and B cells), were analyzed for their response to IFNs. In type A cells, IFNs mainly inhibited virus particle release, whereas in type B cells, the anti-HIV effect of IFNs cells was found to be largely due to a specific inhibition of viral protein synthesis without any apparent effect on total cellular protein synthesis. Interestingly, such a differential inhibition of HIV protein synthesis could also be demonstrated in acutely infected CEM cells in response to treatment with IFN-a. Both in chronically infected U937 type B and acutely infected CEM cells, equivalent amounts of nuclear and cytoplasmic HIV-1 mRNA were detected in control and IFN-treated cells in spite of at least 80% inhibition of HIV protein synthesis. Analysis of the distribution of cellular and viral mRNAs on polysomes in HIV-1-infected cells demonstrated that IFN treatment induces a specific block on viral mRNA translation. These results indicate that the antiviral mechanism of IFN on later stages of HIV replication cycle may be partly due to the inhibition of HIV mRNA translation, besides an effect on virus budding or release.	INST PASTEUR,CNRS,UNITE VIROL & IMMUNOL CELLULAIRE 1157,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Coccia, Eliana M/B-4752-2013	Coccia, Eliana M/0000-0002-1606-2949				AGY MB, 1990, VIROLOGY, V177, P251, DOI 10.1016/0042-6822(90)90478-A; ARRIGO SJ, 1991, GENE DEV, V5, P808, DOI 10.1101/gad.5.5.808; BISWAS P, 1992, J EXP MED, V176, P739, DOI 10.1084/jem.176.3.739; BOULERICE F, 1990, J VIROL, V64, P1745, DOI 10.1128/JVI.64.4.1745-1755.1990; CULLEN BR, 1991, ANNU REV MICROBIOL, V45, P19; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; FRANCIS ML, 1992, AIDS RES HUM RETROV, V8, P199, DOI 10.1089/aid.1992.8.199; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; GENDELMAN HE, 1990, J IMMUNOL, V145, P2669; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HAMMER SM, 1986, P NATL ACAD SCI USA, V83, P8734, DOI 10.1073/pnas.83.22.8734; HANSEN BD, 1992, J VIROL, V66, P7543, DOI 10.1128/JVI.66.12.7543-7548.1992; HO DD, 1985, LANCET, V1, P602; HOVANESSIAN AG, 1987, EMBO J, V6, P1273, DOI 10.1002/j.1460-2075.1987.tb02364.x; HOVANESSIAN AG, 1993, SEMIN VIROL, V4, P237, DOI 10.1006/smvy.1993.1020; HOVANESSIAN AG, 1991, J INTERFERON RES, V11, P199, DOI 10.1089/jir.1991.11.199; Hovanessian Ara G., 1993, P41; KATZE MG, 1990, ENZYME, V44, P332, DOI 10.1159/000468769; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KORNBLUTH RS, 1990, CLIN IMMUNOL IMMUNOP, V54, P200, DOI 10.1016/0090-1229(90)90082-2; KRUST B, 1993, AIDS RES HUM RETROV, V9, P1081; LAURENT AG, 1989, J VIROL, V63, P4074, DOI 10.1128/JVI.63.9.4074-4078.1989; LAURENTCRAWFORD AG, 1993, J GEN VIROL, V74, P2619, DOI 10.1099/0022-1317-74-12-2619; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LAURENTCRAWFORD AG, 1993, AIDS RES HUM RETROV, V9, P761, DOI 10.1089/aid.1993.9.761; LODISH HF, 1977, J BIOL CHEM, V252, P8804; LODISH HF, 1976, ANNU REV BIOCHEM, V45, P39, DOI 10.1146/annurev.bi.45.070176.000351; Maniatis T., 1982, MOL CLONING; MARIE I, 1989, BIOCHEM BIOPH RES CO, V160, P580, DOI 10.1016/0006-291X(89)92472-8; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; MASSARI FE, 1990, J IMMUNOL, V144, P4628; MCELRATH MJ, 1989, P NATL ACAD SCI USA, V86, P675, DOI 10.1073/pnas.86.2.675; MELTZER MS, 1990, IMMUNOL TODAY, V11, P217, DOI 10.1016/0167-5699(90)90086-O; MICHAELIS B, 1989, AIDS, V3, P27, DOI 10.1097/00002030-198903010-00006; PEDEN K, 1991, VIROLOGY, V185, P661, DOI 10.1016/0042-6822(91)90537-L; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PITHA PM, 1979, J GEN VIROL, V42, P467, DOI 10.1099/0022-1317-42-3-467; PITHA PM, 1991, J INTERFERON RES, V11, P313, DOI 10.1089/jir.1991.11.313; POLI G, 1989, SCIENCE, V244, P575, DOI 10.1126/science.2470148; REY MA, 1989, VIROLOGY, V173, P258, DOI 10.1016/0042-6822(89)90242-0; REY MA, 1989, J VIROL, V63, P647, DOI 10.1128/JVI.63.2.647-658.1989; ROSENBERG ZF, 1991, FASEB J, V5, P2382, DOI 10.1096/fasebj.5.10.1676689; SHIRAZI Y, 1992, J VIROL, V66, P1321, DOI 10.1128/JVI.66.3.1321-1328.1992; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; WAINHOBSON S, 1991, SCIENCE, V252, P961, DOI 10.1126/science.2035026	45	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23087	23094						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7521875				2022-12-25	WOS:A1994PQ16400031
J	CHITTENDEN, K; BLACK, SD; ZWIEB, C				CHITTENDEN, K; BLACK, SD; ZWIEB, C			SYSTEMATIC SITE-DIRECTED MUTAGENESIS OF PROTEIN SRP19 - IDENTIFICATION OF THE RESIDUES ESSENTIAL FOR BINDING TO SIGNAL RECOGNITION PARTICLE RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SYNTHESIZING SECRETORY PROTEIN; RICIN-A-CHAIN; MICROSOMAL-MEMBRANES; TETRANUCLEOTIDE LOOP; RIBOSOMAL-RNA; TRANSLOCATION; SEQUENCE; CATALYSIS; DOMAIN	Protein SRP19 is an important structural and functional constituent of the signal recognition particle (SRP) and belongs to a group of RNA binding proteins that specifically recognize certain tetranucleotide loops. Systematic site-directed mutagenesis was used to identify the amino acid residues in human SRP19 essential for interaction with SRP RNA. In our studies, three different groups of mutants were constructed, and each group covered essentially the entire sequence of the SRP19 protein in a consecutive nonoverlapping fashion. Results from 10 deletion mutants followed by the analysis of 24 mutants in which adjacent five residues were changed to pentaglycine suggested that a large portion of the protein may be required for RNA binding. Further examination of 53 mutant polypeptides in which adjacent dipeptide segments were altered showed, however, that 84 of the 144 SRP19 amino acids (58%) were not important for binding to the SRP RNA. The essential amino acids cluster in five regions which encompass most of the SRP19 sequence, with the exception of residues located at the N and C termini and a predicted internal loop. The results from the systematic site-directed mutagenesis study, when combined with protein secondary structure calculations, demonstrate that SRP19 is a precisely tooled protein which associates intimately with the SRP RNA.	UNIV TEXAS, HLTH SCI CTR, DEPT MOLEC BIOL, TYLER, TX 75710 USA; UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, TYLER, TX 75710 USA	University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT); University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)								AERNE BL, 1993, NUCLEIC ACIDS RES, V21, P3575, DOI 10.1093/nar/21.15.3575; BENNER SA, 1992, CURR OPIN STRUC BIOL, V2, P402; BLACK SD, 1986, BIOTECHNIQUES, V4, P448; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GLUCK A, 1992, J MOL BIOL, V226, P411, DOI 10.1016/0022-2836(92)90956-K; HAMMES SR, 1993, VIROLOGY, V193, P41, DOI 10.1006/viro.1993.1101; Held W.A., 1974, RIBOSOMES, P193; HSIAO KC, 1991, NUCLEIC ACIDS RES, V19, P2787, DOI 10.1093/nar/19.10.2787; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN N, 1993, NUCLEIC ACIDS RES, V21, P3019, DOI 10.1093/nar/21.13.3019; LARSEN N, 1991, NUCLEIC ACIDS RES, V19, P209, DOI 10.1093/nar/19.2.209; LINGELBACH K, 1988, NUCLEIC ACIDS RES, V16, P9431, DOI 10.1093/nar/16.20.9431; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MORRIS KN, 1992, P NATL ACAD SCI USA, V89, P4869, DOI 10.1073/pnas.89.11.4869; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; PREHN S, 1987, EMBO J, V6, P2093, DOI 10.1002/j.1460-2075.1987.tb02475.x; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RENNELL D, 1991, J MOL BIOL, V222, P67, DOI 10.1016/0022-2836(91)90738-R; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1993, TRENDS BIOCHEM SCI, V18, P120, DOI 10.1016/0968-0004(93)90017-H; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; STIRLING CJ, 1992, NATURE, V356, P534, DOI 10.1038/356534a0; STRUB K, 1991, MOL CELL BIOL, V11, P3949, DOI 10.1128/MCB.11.8.3949; TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723; TREICH I, 1992, NUCLEIC ACIDS RES, V20, P4721, DOI 10.1093/nar/20.18.4721; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1983, CELL, V34, P525, DOI 10.1016/0092-8674(83)90385-9; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; ZWIEB C, 1992, NUCLEIC ACIDS RES, V20, P4397, DOI 10.1093/nar/20.17.4397; ZWIEB C, 1989, PROG NUCLEIC ACID RE, V37, P207; ZWIEB C, 1991, NUCLEIC ACIDS RES, V19, P2955, DOI 10.1093/nar/19.11.2955; ZWIEB C, 1992, J BIOL CHEM, V267, P15650; ZWIEB C, 1991, BIOCHEM CELL BIOL, V69, P649, DOI 10.1139/o91-096; ZWIEB C, 1994, IN PRESS EUR J BIOCH	43	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20497	20502						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519610				2022-12-25	WOS:A1994PB31700046
J	RAO, BNN; ANDERSON, MB; MUSSER, JH; GILBERT, JH; SCHAEFER, ME; FOXALL, C; BRANDLEY, BK				RAO, BNN; ANDERSON, MB; MUSSER, JH; GILBERT, JH; SCHAEFER, ME; FOXALL, C; BRANDLEY, BK			SIALYL-LEWIS-X MIMICS DERIVED FROM A PHARMACOPHORE SEARCH ARE SELECTIN INHIBITORS WITH ANTIINFLAMMATORY ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LEUKOCYTE ADHESION MOLECULE-1; ACUTE LUNG INJURY; H-1-NMR SPECTRA; OLIGOSACCHARIDES; SPECTROSCOPY; LIGANDS; BINDING; ELAM-1; NMR	The selectins, a family of adhesion receptors involved in leukocyte extravasation, recognize sialyl Lewis X (sLe(x); NeuAc alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc) and related oligosaccharides. We used conformational energy computations, high field NMR, and structure-function studies to define distance parameters of critical functional groups of sLe(x). This sLe(x) pharmacophore was used to search a three dimensional data base of chemical structures. Compounds that had a similar spatial relationship of functional groups were tested as inhibitors of selectin binding. Glycyrrhizin, a triterpene glycoside, was identified and found to block selectin binding to sLe(x) in vitro. We substituted different sugars for the glucuronic acids of glycyrrhizin and found the L-fucose derivative to be the most active in vitro and in vivo. A C-fucoside derivative, synthesized on a linker designed for stability and to more closely approximate the original sLe(x) pharmacophore, resulted in an easily synthesized, effective selectin blocker with anti-inflammatory activity,			RAO, BNN (corresponding author), GLYCOMED INC,860 ATLANTIC AVE,ALAMEDA,CA 94501, USA.							BALL GE, 1992, J AM CHEM SOC, V114, P5449, DOI 10.1021/ja00039a080; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; BRANDLEY BK, 1993, GLYCOBIOLOGY, V3, P633, DOI 10.1093/glycob/3.6.633; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DAVIS EA, 1991, MOL CELL ENDOCRINOL, V1, P5; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; GUNDEL RH, 1991, J CLIN INVEST, V88, P1407, DOI 10.1172/JCI115447; HARRIS R R, 1990, Skin Pharmacology, V3, P29; HEAVNER GA, 1993, INT J PEPT PROT RES, V42, P484; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LIN YC, 1992, J AM CHEM SOC, V114, P5452, DOI 10.1021/ja00039a082; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MILLER KE, 1992, BIOCHEMISTRY-US, V31, P6703, DOI 10.1021/bi00144a009; MULLIGAN MS, 1991, J CLIN INVEST, V88, P1396, DOI 10.1172/JCI115446; MULLIGAN MS, 1993, J EXP MED, V178, P623, DOI 10.1084/jem.178.2.623; MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029; MUSSER JH, 1993, TRENDS DRUG RES, V20, P33; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RAO BNN, 1991, MED CHEM RES, V1, P1; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; YUEN CT, 1994, J BIOL CHEM, V269, P1595; YUENCT, 1992, BIOCHEMISTRY-US, V31, P9126	28	108	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19663	19666						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	7519598				2022-12-25	WOS:A1994PA12600002
J	CHANG, XB; HOU, YX; JENSEN, TJ; RIORDAN, JR				CHANG, XB; HOU, YX; JENSEN, TJ; RIORDAN, JR			MAPPING OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEMBRANE TOPOLOGY BY GLYCOSYLATION SITE INSERTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; PROTEIN EXPORT SIGNALS; BETA-LACTAMASE; PROTEOLIPID PROTEIN; GENETIC-ANALYSIS; PLASMA-MEMBRANE; MYELIN; ORGANIZATION; ARRANGEMENT; ANTIBODIES	Technical difficulties in obtaining three-dimensional structures of intrinsic membrane proteins continues to limit understanding of their function. However, considerable insight can be gained from their two-dimensional topological arrangement in the lipid bilayer. Efficient molecular genetic approaches are available to discern the topology of prokaryotic but not of eukaryotic membrane proteins. The absolute asymmetry of the sidedness of their N-glycosylation was employed here to develop such a method using the cystic fibrosis transmembrane conductance regulator (CFTR). Insertion by in vitro mutagenesis of N-glycosylation consensus sequences (NXS/T) in predicted cytoplasmic and extracytoplasmic loops between hydrophobic sequences capable of traversing the membrane established the membrane topology of CFTR. This provides the first experimental evaluation of the original topological model of CFTR based solely on hydropathy algorithms and a method which may be generally applicable for the in vivo evaluation of the topology of other mammalian membrane proteins.	HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ON,CANADA; UNIV TORONTO,TORONTO M5G 1X8,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BROOMESMITH JK, 1986, GENE, V49, P341, DOI 10.1016/0378-1119(86)90370-7; BROOMESMITH JK, 1990, MOL MICROBIOL, V4, P1637, DOI 10.1111/j.1365-2958.1990.tb00540.x; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; EDELMAN A, 1987, MOL MICROBIOL, V1, P101, DOI 10.1111/j.1365-2958.1987.tb00533.x; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HUDSON LD, 1989, J CELL BIOL, V109, P717, DOI 10.1083/jcb.109.2.717; HUGHES EN, 1981, J BIOL CHEM, V256, P664; KAHANE I, 1978, SCIENCE, V201, P351, DOI 10.1126/science.663661; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEELING P, 1983, J MEMBRANE BIOL, V74, P217, DOI 10.1007/BF02332125; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDOLTMARTICOR.C, 1994, IN PRESS BIOCH J; LAURSEN RA, 1984, P NATL ACAD SCI-BIOL, V81, P2912, DOI 10.1073/pnas.81.9.2912; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; PHILLIPS DR, 1980, THROMB HAEMOSTASIS, V42, P1638; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; SKATCH WR, 1993, J BIOL CHEM, V268, P6903; STOFFEL W, 1984, P NATL ACAD SCI-BIOL, V81, P5012, DOI 10.1073/pnas.81.16.5012; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; Tsui Lap-Chee, 1992, Human Mutation, V1, P197, DOI 10.1002/humu.1380010304; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; ZHANG JT, 1993, J BIOL CHEM, V268, P15101	31	108	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18572	18575						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518437				2022-12-25	WOS:A1994NW79800054
J	LICHENSTEIN, HS; LYONS, DE; WURFEL, MM; JOHNSON, DA; MCGINLEY, MD; LEIDLI, JC; TROLLINGER, DB; MAYER, JP; WRIGHT, SD; ZUKOWSKI, MM				LICHENSTEIN, HS; LYONS, DE; WURFEL, MM; JOHNSON, DA; MCGINLEY, MD; LEIDLI, JC; TROLLINGER, DB; MAYER, JP; WRIGHT, SD; ZUKOWSKI, MM			AFAMIN IS A NEW MEMBER OF THE ALBUMIN, ALPHA-FETOPROTEIN, AND VITAMIN-D-BINDING PROTEIN GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-SPECIFIC COMPONENT; HUMAN-SERUM-ALBUMIN; FULMINANT HEPATIC-NECROSIS; C5A DES ARG; FATTY-ACIDS; GC-GLOBULIN; ANTENATAL DIAGNOSIS; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; SPINA-BIFIDA	A novel human serum protein with a molecular mass of 87,000 daltons was purified to homogeneity and subjected to amino acid sequence analyses. These sequences were used to design oligonucleotide primers and to isolate a full-length cDNA. The amino acid sequence encoded by the cDNA shares strong similarity to albumin family members and shares the characteristic pattern of Cys residues observed in this family. In addition, the gene maps to chromosome 4 as do other members of the albumin gene family. Based upon these observations, we conclude that the 87,000-dalton protein, which we designate afamin (AFM), is the fourth member of the albumin family of proteins. Afamin cDNA was stably transfected into Chinese hamster ovary cells and recombinant protein (rAFM) was purified from conditioned medium. Both rAFM and AFM purified from human serum react with a polyclonal antibody that was raised against a synthetic peptide derived from the deduced amino acid sequence of AFM.	ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021	Rockefeller University	LICHENSTEIN, HS (corresponding author), AMGEN INC,THOUSAND OAKS,CA 91320, USA.							ALLAN LD, 1973, LANCET, V2, P522; ALPERT E, 1978, IMMUNOL COMMUN, V7, P163, DOI 10.3109/08820137809033882; Atherton E., 1990, SOLID PHASE PEPTIDE; AUER IO, 1977, CELL IMMUNOL, V30, P173, DOI 10.1016/0008-8749(77)90058-2; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BELANGER L, 1973, PATHOL BIOL, V21, P449; BELANGER L, 1973, PATHOL BIOL, V21, P457; BERDE CB, 1979, J BIOL CHEM, V254, P2609; BOURDREL L, 1993, PROTEIN EXPRES PURIF, V4, P130, DOI 10.1006/prep.1993.1019; BROCK DJH, 1972, LANCET, V2, P197; BROWN JR, 1976, FED PROC, V35, P2141; CHAKRABORTY M, 1993, IMMUNOL INVEST, V22, P329, DOI 10.3109/08820139309063412; COOKE NE, 1985, J CLIN INVEST, V76, P2420, DOI 10.1172/JCI112256; DAIGER SP, 1975, P NATL ACAD SCI USA, V72, P2076, DOI 10.1073/pnas.72.6.2076; DUGAICZYK A, 1982, P NATL ACAD SCI-BIOL, V79, P71, DOI 10.1073/pnas.79.1.71; GIBBS PEM, 1987, BIOCHEMISTRY-US, V26, P1332, DOI 10.1021/bi00379a020; GOLDSCHMIDTCLERMONT PJ, 1988, GASTROENTEROLOGY, V94, P1454, DOI 10.1016/0016-5085(88)90686-5; GUTTERIDGE JMC, 1986, BIOCHIM BIOPHYS ACTA, V869, P119, DOI 10.1016/0167-4838(86)90286-4; HADDAD JG, 1992, BIOCHEMISTRY-US, V31, P7174, DOI 10.1021/bi00146a021; HARPER ME, 1983, AM J HUM GENET, V35, P565; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOLT ME, 1984, BRIT J EXP PATHOL, V65, P231; KEW RR, 1988, J CLIN INVEST, V82, P364, DOI 10.1172/JCI113596; KOJ A, 1985, ACUTE PHASE RESPONSE, P45; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LAWN RM, 1981, NUCLEIC ACIDS RES, V9, P6103, DOI 10.1093/nar/9.22.6103; LEE WM, 1989, CIRC SHOCK, V28, P249; MIKKELSEN M, 1977, HUM HERED, V27, P105, DOI 10.1159/000152857; MINGHETTI PP, 1986, J BIOL CHEM, V261, P6747; MORINAGA T, 1983, P NATL ACAD SCI-BIOL, V80, P4604, DOI 10.1073/pnas.80.15.4604; NATHAN C, 1993, J CELL BIOL, V122, P243, DOI 10.1083/jcb.122.1.243; PARMELEE DC, 1978, J BIOL CHEM, V253, P2114; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEREZ HD, 1988, J CLIN INVEST, V82, P360, DOI 10.1172/JCI113595; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; RUOSLAHTI E, 1974, TRANSPLANT REV-DENMA, V20, P38; SAKAI M, 1985, J BIOL CHEM, V260, P5055; SARKAR B, 1983, LIFE CHEM REPORTS, V1, P165; SHAW CF, 1979, INORG PERSPECT BIOL, V2, P287; TAMAOKI T, 1984, RECOMBINANT DNA CELL, P145; TURNER AM, 1992, BLOOD, V80, P374; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VANBAELEN H, 1980, J BIOL CHEM, V255, P2270; WALDMANN TA, 1972, LANCET, V2, P1112; WILLIAMS MH, 1988, BIOCHEM BIOPH RES CO, V153, P1019, DOI 10.1016/S0006-291X(88)81330-5; WITKE WF, 1993, GENOMICS, V16, P751, DOI 10.1006/geno.1993.1258; YACHNIN S, 1976, P NATL ACAD SCI USA, V73, P2857, DOI 10.1073/pnas.73.8.2857; YAMAMOTO N, 1991, P NATL ACAD SCI USA, V88, P8539, DOI 10.1073/pnas.88.19.8539; YANG F, 1985, P NATL ACAD SCI USA, V82, P7994, DOI 10.1073/pnas.82.23.7994; YOUNG WO, 1987, J LAB CLIN MED, V110, P83	51	116	143	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18149	18154						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	7517938				2022-12-25	WOS:A1994NV42200060
J	BAUMANN, H; GEARING, D; ZIEGLER, SF				BAUMANN, H; GEARING, D; ZIEGLER, SF			SIGNALING BY THE CYTOPLASMIC DOMAIN OF HEMATOPOIETIN RECEPTORS INVOLVES 2 DISTINGUISHABLE MECHANISMS IN HEPATIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GROWTH-HORMONE RECEPTOR; PLASMA-PROTEIN GENES; RAT ALPHA-1-ACID GLYCOPROTEIN; ACUTE-PHASE RESPONSE; ERYTHROPOIETIN RECEPTOR; CYTOKINE RECEPTORS; INTERLEUKIN-4 RECEPTOR; MOLECULAR-CLONING; TYROSINE KINASE	The receptor for granulocyte colony stimulating factor (G-CSFR) and chimeric receptors consisting of the extracellular domain of G-CSFR and the transmembrane and cytoplasmic domain of the leukemia inhibitory factor receptor, gp130, or c-mpl function as homodimeric complexes. These receptors mediate a similar stimulation of gene transcription via separate regulatory elements of acute phase plasma protein genes. To identify the receptor regions within the cytoplasmic domains necessary for transcriptional regulation, the receptors were transiently expressed in rat hepatoma cells. Each receptor form reconstituted G-CSF-induced expression of a chloramphenicol acetyltransferase gene construct containing the cytokine response element of the rat cu,acid glycoprotein gene. This regulation required the presence of two conserved sequence motifs (referred to as box 1 and box 2) in the cytoplasmic domains of each receptor. With the exception of G-CSFR-MPL chimera, the receptors also mediated a similarly high stimulation via the IL-6 response element of the rat beta-fibrinogen and hemopexin genes. Regulation of the IL-6 response element required, however, in addition to boxes 1 and 2, a third sequence motif (box 3). This motif is absent in the cytoplasmic domain of c-mpl, possibly explaining its inability to activate the IL-6 response element. When cells which express receptor forms with prominent box 3 function were treated with suramin, a ligand-independent gene stimulation via the IL-6 response element was observed. The suramin effect probably involves a receptor dimerization mediated by the extracellular G-CSFR domain and by the intracellular regions that include box 3.	IMMUNEX CORP,SEATTLE,WA 98101	Immunex Corporation	BAUMANN, H (corresponding author), ROSWELL PK CANC INST,DEPT MOLEC & CELLULAR BIOL,BUFFALO,NY 14263, USA.				NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER; NCI NIH HHS [CA26122] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAUMANN H, 1993, J IMMUNOL, V151, P1456; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BAUMANN H, 1988, J BIOL CHEM, V263, P17390; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CAMPOS SP, 1993, J IMMUNOL, V151, P7128; CHENG J, 1990, NUCLEIC ACIDS RES, V18, P4261, DOI 10.1093/nar/18.14.4261; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLOSI P, 1993, J BIOL CHEM, V268, P12617; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; GEARING DP, 1994, IN PRESS P NATL ACAD; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; HARADA N, 1992, J BIOL CHEM, V267, P22752; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAGAE Y, 1992, BIOCHEM BIOPH RES CO, V185, P420, DOI 10.1016/S0006-291X(05)81002-2; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SADOWSKI HB, 1993, SCIENCE, V262, P1019; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STRASSMANN G, 1993, J CLIN INVEST, V92, P2152, DOI 10.1172/JCI116816; VIGON I, 1993, ONCOGENE, V8, P2607; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965; WON KA, 1991, MOL CELL BIOL, V11, P3001, DOI 10.1128/MCB.11.6.3001; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	48	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16297	16304						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	7515879				2022-12-25	WOS:A1994NQ72900054
J	KLATT, P; SCHMID, M; LEOPOLD, E; SCHMIDT, K; WERNER, ER; MAYER, B				KLATT, P; SCHMID, M; LEOPOLD, E; SCHMIDT, K; WERNER, ER; MAYER, B			THE PTERIDINE BINDING-SITE OF BRAIN NITRIC-OXIDE SYNTHASE - TETRAHYDROBIOPTERIN BINDING-KINETICS, SPECIFICITY, AND ALLOSTERIC INTERACTION WITH THE SUBSTRATE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC ENDOTHELIAL-CELLS; PORCINE CEREBELLUM; L-ARGININE; PURIFICATION; COFACTOR; REDUCTASE; FLAVIN; ENZYME; IDENTIFICATION; FLAVOPROTEIN	Nitric oxide (NO) synthases contain FAD, FMN, heme, and (6R)-5,6,7,8-tetrahydro-L-biopterin as prosthetic groups. We have characterized the pteridine-binding site of purified brain NO synthase, using H-3-labeled (6R)-5,6,7,8-tetrahydro-L-biopterin as radioligand. Asso ciation of [H-3]tetrahydrobiopterin followed second order kinetics (k(on) = 1.3 x 10(6) M(-1) min(-1)), the dissociation reaction was reversible and first-order (k(off) = 3.2 x 10(-1) min(-1)), yielding a kinetic K-D of 0.25 mu M. Binding of the radioligand was competitively antagonized by several pteridine derivatives with the following order of potency (K-I): 7,8-dihydro-L-biopterin (2.2 mu M), (6S)-5,6,7,8-tetrahydro- L-biopterin (19 mu M), (6R,S)-6-methyl-5,6,7,8-tetrahydropterin (240 mu M), and 6,7-dimethyl-5,6,7,8-tetrahydropterin (> 1 mM). The affinity of NO synthase for tetrahydrobiopterin was increased 6-fold in the pres ence of 0.1 mM L-argnine (K-D = 37 nM), and, conversely, tetrahydrobiopterin enhanced the affinity of the enzyme for H-3-labeled N-G-nitro-L-arginine about 2-fold. 7-Nitroindazole, which presumably binds to the heme group of NO synthase, competitively inhibited binding of [H-3]tetrahydrobiopterin and [H-3]N-G-nitro-L-arginine with similar K-I values (0.1 mu M). Functional as well as binding studies revealed that 7-nitroindazole was competitive with both L-arginine and tetrahydrobiopterin. Our data indicate that brain NO synthase exhibits a highly specific binding site for (6R)-5,6,7,8-tetrahydro-L-biopterin, which allosterically interacts with the substrate domain and may be located proximal to the prosthetic heme group of NO synthase.	GRAZ UNIV, INST PHARMAKOL & TOXICOL, A-8010 GRAZ, AUSTRIA; UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, A-6020 INNSBRUCK, AUSTRIA	University of Graz; University of Innsbruck			Mayer, Bernd/B-9391-2008	Mayer, Bernd/0000-0002-2921-3494; Werner, Ernst R./0000-0003-1948-3391				ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BABBEDGE RC, 1993, BRIT J PHARMACOL, V110, P225, DOI 10.1111/j.1476-5381.1993.tb13796.x; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BAILEY SW, 1978, J BIOL CHEM, V253, P1598; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNNER F, 1991, BRIT J PHARMACOL, V102, P373, DOI 10.1111/j.1476-5381.1991.tb12181.x; EVANS T, 1992, P NATL ACAD SCI USA, V89, P5361, DOI 10.1073/pnas.89.12.5361; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; KATOH S, 1971, ARCH BIOCHEM BIOPHYS, V146, P202, DOI 10.1016/S0003-9861(71)80057-7; KATZENMEIER G, 1990, FEMS MICROBIOL LETT, V66, P231; KLATT P, 1994, J BIOL CHEM, V269, P1674; KLATT P, 1993, J BIOL CHEM, V268, P14781; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KLATT P, 1992, J BIOL CHEM, V267, P11374; KWON NS, 1989, J BIOL CHEM, V264, P20496; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MAYER B, 1991, J CARDIOVASC PHARM, V17, pS46, DOI 10.1097/00005344-199117003-00009; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MAYER B, 1993, SEMIN NEUROSCI, V5, P197, DOI 10.1016/S1044-5765(05)80053-3; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; MICHEL AD, 1993, BRIT J PHARMACOL, V109, P287, DOI 10.1111/j.1476-5381.1993.tb13566.x; MOORE PK, 1993, BRIT J PHARMACOL, V108, P296, DOI 10.1111/j.1476-5381.1993.tb12798.x; MOORE PK, 1993, BRIT J PHARMACOL, V110, P219, DOI 10.1111/j.1476-5381.1993.tb13795.x; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; PARK YS, 1990, BIOCHIM BIOPHYS ACTA, V1038, P186, DOI 10.1016/0167-4838(90)90203-R; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; POU S, 1992, J BIOL CHEM, V267, P24173; PUFAHL RA, 1993, BIOCHEM BIOPH RES CO, V193, P963, DOI 10.1006/bbrc.1993.1719; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; WATANABE Y, 1993, CHEM BIOL PTERIDINES, P301; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425	43	218	219	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13861	13866						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514595				2022-12-25	WOS:A1994NL60600024
J	MUDGAPALLI, A; ROY, SK; HOLMES, EH; VIJAY, IK				MUDGAPALLI, A; ROY, SK; HOLMES, EH; VIJAY, IK			PHOTOIDENTIFICATION OF MANNOSYLTRANSFERASES OF DOLICHOL CYCLE IN THE MAMMARY-GLAND - PURIFICATION AND CHARACTERIZATION OF GDP-MAN MAN-BETA-1-]4GLCNAC-BETA-1-]4GLCNAC-P-P-DOLICHOL MANNOSYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; ASPARAGINE-LINKED OLIGOSACCHARIDE; 35-KDA MEMBRANE-PROTEIN; UDP-N-ACETYLGLUCOSAMINE; CULTURED SOYBEAN CELLS; MOLECULAR-CLONING; MURINE BETA-1,4-GALACTOSYLTRANSFERASE; TRANSCRIPTIONAL REGULATION; GLYCOSYLATION PATHWAY; TRANSMEMBRANE DOMAIN	Glc3Man9GlcNAc2-P-P-Dol serves as the major precursor for the biosynthesis of asparagine-linked glycoproteins in eukaryotes. The first 5 of the 9 mannosyl residues during the assembly of the oligosaccharide moiety within the dolichol cycle in the endoplasmic reticulum are incorporated directly by the action of GDP-Man-requiring mannosyltransferases while the remaining last 4 mannosyl residues are transferred by Man-P-Dol-requiring enzymes. In an earlier study (Shailubhai, K., Illeperuma, C., Tayal, M., and Vijay, I. K. (1990) J. Biol. Chem. 265,14105-14108), we identified the enzyme UDPGlc:Dol-P glucosyltransferase by photolabeling rat mammary microsomes with 5-N3-[beta-P-32]UDP-Glc. Applying a similar strategy, GDP-hexanolamine-I-125-azidosalicylic acid, an analog of GDP-Man, was found to photolabel two polypeptides of 37 and 69 kDa among the microsomal proteins of the rat mammary gland. A differential ammonium sulfate saturation (60-80%) of the detergent-solubilized microsomal proteins enriched the 69-kDa polypeptide. Photolabeling of this polypeptide was specifically inhibited by guanine-containing nucleotides and nucleotide-sugars and was associated with a GDP-Man-requiring mannosyltransferase. The mannosyltransferase was purified nearly 16,000-fold and shown to contain the 69-kDa polypeptide. The purified enzyme catalyzes the transfer of [C-14]Man from GDP-[C-14]Man to Manbeta1 --> 4GlcNAcbeta1 --> 4GlcNAc-P-P-Dol in alpha1,3-linkage to give [C-14]Manalpha1 --> 3Manbeta1 --> 4GlcNAcbeta1 --> 4GlcNAc-P-P-Dol as the product. Antibodies raised against the 69-kDa polypeptide removed the enzymatic activity from the detergent extract of the rat mammary microsomes and reacted specifically with a polypeptide band of the same size on immunoblots. The purified enzyme showed a pH optima of 7.4-7.8, K(m) approximately 4 muM for GDP-Man, approximately 2-fold activation by phosphatidylcholine, and a strong inhibition by sulfhydryl-selective reagents, N-ethylmaleimide and p-chloromercuribenzoate. The availability of the highly purified enzyme and a monospecific antibody should allow its molecular cloning for investigating the regulation of the machinery for protein N-glycosylation upon hormonally modulated growth and differentiation of the mammary gland during its ontogeny.	UNIV MARYLAND, DEPT ANIM SCI, COLL PK, MD 20742 USA; PACIFIC NW RES FDN, SEATTLE, WA 98122 USA	University System of Maryland; University of Maryland College Park					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019682] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19682] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBRIGHT CF, 1990, J BIOL CHEM, V265, P7042; ALBRIGHT CF, 1989, P NATL ACAD SCI USA, V86, P7366, DOI 10.1073/pnas.86.19.7366; AMES BN, 1960, J BIOL CHEM, V235, P769; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; CHATTERJEE S, 1992, J BIOL CHEM, V267, P7148; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; CZICHI U, 1977, J BIOL CHEM, V252, P7901; D'SOUZA-SCHOREY C, 1993, J BIOL CHEM, V268, P4720; DRAKE R, 1990, BIOSCIENCE REP, V10, P61, DOI 10.1007/BF01116852; DRAKE RR, 1991, PLANT PHYSIOL, V97, P396, DOI 10.1104/pp.97.1.396; ESTON BW, 1991, J BIOL CHEM, V267, P4152; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; GOLD P, 1983, J BIOL CHEM, V258, P2967; HASELBECK A, 1989, EUR J BIOCHEM, V181, P663, DOI 10.1111/j.1432-1033.1989.tb14774.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; HOLLIS GF, 1989, BIOCHEM BIOPH RES CO, V162, P1069, DOI 10.1016/0006-291X(89)90782-1; HOLMES EH, 1990, J BIOL CHEM, V265, P13150; HORI H, 1985, PLANT PHYSIOL, V77, P840, DOI 10.1104/pp.77.4.840; JENSEN JW, 1981, J BIOL CHEM, V256, P2899; JENSEN JW, 1985, EUR J BIOCHEM, V153, P41, DOI 10.1111/j.1432-1033.1985.tb09264.x; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; JOZIASSE DH, 1991, J BIOL CHEM, V266, P6991; KAUSHAL GP, 1986, PLANT PHYSIOL, V82, P748, DOI 10.1104/pp.82.3.748; KAUSHAL GP, 1985, J BIOL CHEM, V260, P6303; KAUSHAL GP, 1986, PLANT PHYSIOL, V81, P1086, DOI 10.1104/pp.81.4.1086; KAUSHAL GP, 1986, ARCH BIOCHEM BIOPHYS, V250, P38, DOI 10.1016/0003-9861(86)90699-5; KAUSHAL GP, 1987, BIOCHEMISTRY-US, V26, P7953, DOI 10.1021/bi00398a061; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; KUMAR R, 1991, J BIOL CHEM, V266, P21777; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; Lowe J B, 1991, Semin Cell Biol, V2, P289; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MATERN H, 1990, EUR J BIOCHEM, V190, P99, DOI 10.1111/j.1432-1033.1990.tb15551.x; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PALAMARCZYK G, 1990, P NATL ACAD SCI USA, V87, P2666, DOI 10.1073/pnas.87.7.2666; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PRAKASH C, 1984, EUR J BIOCHEM, V139, P87, DOI 10.1111/j.1432-1033.1984.tb07980.x; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROBBINS PW, 1991, BIOCHEM SOC T, V19, P642, DOI 10.1042/bst0190642; ROYCHOUDHURY S, 1989, J BIOL CHEM, V264, P9380; RUNGE KW, 1984, J BIOL CHEM, V259, P412; RUNGE KW, 1986, J BIOL CHEM, V261, P5582; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SARNESTO A, 1992, J BIOL CHEM, V267, P2737; SARNESTO A, 1992, J BIOL CHEM, V267, P2745; SCHUTZBACH JS, 1980, J BIOL CHEM, V255, P4170; SHAILUBHAI K, 1990, J BIOL CHEM, V265, P14105; SHAILUBHAI K, 1988, J BIOL CHEM, V263, P15964; SHAPER NL, 1990, P NATL ACAD SCI USA, V87, P791, DOI 10.1073/pnas.87.2.791; SHARMA CB, 1990, BIOCHEMISTRY-US, V29, P8901, DOI 10.1021/bi00490a004; SHARMA CB, 1982, EUR J BIOCHEM, V126, P319; SHIELDS D, 1978, J BIOL CHEM, V253, P3753; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; SILBERSTEIN S, 1992, J BIOL CHEM, V267, P23658; SVENSSON EC, 1992, J BIOL CHEM, V267, P3466; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; TAI T, 1977, BIOCHEM BIOPH RES CO, V78, P434, DOI 10.1016/0006-291X(77)91273-6; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TRIMBLE RB, 1979, J BIOL CHEM, V254, P9708; VIJAY IK, 1980, J BIOL CHEM, V255, P1221; VIJAY IK, 1980, J BIOL CHEM, V255, P1210; VIJAY IK, 1977, J SUPRAMOL STR CELL, V7, P251, DOI 10.1002/jss.400070209; VIJAY IK, 1984, ADV CHITIN CHITOSAN, P347; WANG XC, 1990, J BIOL CHEM, V265, P17849; WEN DX, 1992, J BIOL CHEM, V267, P21011; WEN DX, 1992, J BIOL CHEM, V267, P2512; WESTPHAL H, 1989, FASEB J, V3, P117, DOI 10.1096/fasebj.3.2.2492478; YADAV SP, 1991, J BIOL CHEM, V266, P698	76	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11327	11336						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512562				2022-12-25	WOS:A1994NF96600055
J	DING, YG; BRUNDEN, KR				DING, YG; BRUNDEN, KR			THE CYTOPLASMIC DOMAIN OF MYELIN GLYCOPROTEIN P-0 INTERACTS WITH NEGATIVELY CHARGED PHOSPHOLIPID-BILAYERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL-NERVE MYELIN; PERFORMANCE LIQUID-CHROMATOGRAPHY; PROTEIN-INDUCED AGGREGATION; SHIVERER MUTANT MICE; BASIC-PROTEIN; UNMYELINATED NERVES; SCHWANN-CELLS; PO-PROTEIN; PHOSPHORYLATION; GENE	The intracellular COOH-terminal domain of the glycoprotein, P-0, has been proposed to be involved in the formation of the major dense line of peripheral myelin. We have addressed this hypothesis by generating and subsequently isolating a peptide fragment that contains 65 of the 69 residues of the cytoplasmic region of rat P-0. This peptide, termed P-0(intra), bound to artificial phospholipid vesicles and caused their rapid aggregation. The peptide-induced aggregation of membrane bilayers appeared to result from ionic interactions, since P-0(intra)-vesicle association was decreased by 1) reducing the phosphatidylserine content of the membranes, 2) increasing the NaCl concentration of the surrounding buffer, or 3) elevating the divalent cation concentration within the buffers. Cationic disc gel electrophoresis of P-0(intra), revealed at least four charge isoforms of the peptide. Treatment of sciatic nerve slices with phorbol ester prior to isolation of P-0(intra), increased the amount of the more negatively charged species, suggesting that at least some of the charge heterogeneity of the peptide can be attributed to differing phosphorylation states. The ability of P-0(intra), to bind to phospholipid bilayers implies that the cytoplasmic domain of P-0 may be responsible for the formation and maintenance of the myelin major dense line.	GLIATECH INC, DISCOVERY RES GRP, CLEVELAND, OH 44122 USA; UNIV MISSISSIPPI, MED CTR, DEPT BIOCHEM, JACKSON, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center			Brunden, Kurt/D-1994-2009		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS027587] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-27587] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGRAWAL HC, 1990, NEUROCHEM RES, V15, P993, DOI 10.1007/BF00965745; AGUAYO AJ, 1976, J NEUROCYTOL, V5, P565, DOI 10.1007/BF01175570; AGUAYO AJ, 1976, BRAIN RES, V104, P1, DOI 10.1016/0006-8993(76)90643-0; ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BIZZOZERO OA, 1989, ANAL BIOCHEM, V180, P59, DOI 10.1016/0003-2697(89)90087-0; BRAY GM, 1981, ANNU REV NEUROSCI, V4, P127, DOI 10.1146/annurev.ne.04.030181.001015; BRUNDEN KR, 1987, ANAL BIOCHEM, V164, P474, DOI 10.1016/0003-2697(87)90521-5; BRUNDEN KR, 1987, J NEUROCHEM, V49, P1863, DOI 10.1111/j.1471-4159.1987.tb02448.x; CHEIFETZ S, 1985, BIOCHEMISTRY-US, V24, P5170, DOI 10.1021/bi00340a032; CHEIFETZ S, 1985, BIOCHEMISTRY-US, V24, P1909, DOI 10.1021/bi00329a016; DAVIDSON VL, 1984, J BIOL CHEM, V259, P594; DEAN WL, 1984, MEMBRANE BIOCHEM, V5, P181, DOI 10.3109/09687688409150277; DURSO D, 1990, NEURON, V4, P449, DOI 10.1016/0896-6273(90)90057-M; DYCK PJ, 1970, MAYO CLIN PROC, V45, P286; FILBIN MT, 1990, NATURE, V344, P871, DOI 10.1038/344871a0; GREENFIELD S, 1973, J NEUROCHEM, V20, P1207, DOI 10.1111/j.1471-4159.1973.tb00089.x; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; HAYASAKA K, 1993, NAT GENET, V5, P31, DOI 10.1038/ng0993-31; HAYASAKA K, 1993, BIOCHEM BIOPH RES CO, V194, P1317, DOI 10.1006/bbrc.1993.1968; KITAMURA K, 1976, BIOCHIM BIOPHYS ACTA, V455, P806, DOI 10.1016/0005-2736(76)90050-X; KULKENS T, 1993, NAT GENET, V5, P35, DOI 10.1038/ng0993-35; LEBLANC AC, 1990, J NEUROSCI RES, V26, P317, DOI 10.1002/jnr.490260308; LEBLANC AC, 1987, MOL BRAIN RES, V2, P57, DOI 10.1016/0169-328X(87)90021-0; LEMKE G, 1985, CELL, V40, P501, DOI 10.1016/0092-8674(85)90198-9; MAHONEY WC, 1981, BIOCHEMISTRY-US, V20, P443, DOI 10.1021/bi00505a033; MATTHIEU JM, 1975, BIOCHIM BIOPHYS ACTA, V392, P167, DOI 10.1016/0304-4165(75)90177-4; MEZEI C, 1981, J NEUROCHEM, V37, P550; PAULSON JR, 1992, ANAL BIOCHEM, V203, P227, DOI 10.1016/0003-2697(92)90307-S; POPKO B, 1988, NEURON, V1, P221, DOI 10.1016/0896-6273(88)90142-0; ROACH A, 1985, CELL, V42, P149, DOI 10.1016/S0092-8674(85)80110-0; ROACH A, 1983, CELL, V34, P799, DOI 10.1016/0092-8674(83)90536-6; ROOMI MW, 1978, BIOCHIM BIOPHYS ACTA, V536, P112, DOI 10.1016/0005-2795(78)90057-0; SALZER JL, 1989, DEV NEUROSCI-BASEL, V11, P377, DOI 10.1159/000111914; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SINGH H, 1976, BIOCHIM BIOPHYS ACTA, V448, P325, DOI 10.1016/0005-2736(76)90246-7; SUZUKI M, 1990, J NEUROCHEM, V55, P1966, DOI 10.1111/j.1471-4159.1990.tb05783.x; TRAPP BD, 1988, J NEUROSCI, V8, P3515; WEINBERG HJ, 1976, BRAIN RES, V113, P363, DOI 10.1016/0006-8993(76)90947-1; WEINBERG HJ, 1975, J NEUROCYTOL, V4, P395, DOI 10.1007/BF01261372; WIGGINS RC, 1980, J NEUROCHEM, V34, P627, DOI 10.1111/j.1471-4159.1980.tb11190.x; WOOD DD, 1989, J BIOL CHEM, V264, P5121; YOUNG PR, 1982, J AM CHEM SOC, V104, P7287, DOI 10.1021/ja00389a062	42	71	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10764	10770						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511605				2022-12-25	WOS:A1994NF01700086
J	CONOVER, CA; DELEON, DD				CONOVER, CA; DELEON, DD			ACID-ACTIVATED INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-3 PROTEOLYSIS IN NORMAL AND TRANSFORMED-CELLS - ROLE OF CATHEPSIN-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; PROTEASE; PREGNANCY; SECRETION; INDUCTION; COMPLEX; SURGERY	Insulin like growth factor-binding protein-3 (IGFBP-3) is an important member of a family of proteins which binds IGF peptides and modulates their biological actions. In this study, we describe an acid-activated IGFBP-3 protease in media derived from a variety of human cell lines. Radiolabeled IGFBP-3 remained intact during incubation (pH 5.5-8) in media conditioned by normal and transformed human fibroblasts, MG-63 osteoblastic cells, and breast cancer cell lines MCF-7 and Hs578T. However, acidification of the conditioned medium samples (pH < 5.5) resulted in I-125-IGFBP-3 hydrolysis and the appearance of specific radiolabeled fragments. No proteolysis of I-125-IGFBP-3 occurred during incubation in unconditioned medium at neutral or acid pH. Estrogen treatment of estrogen receptor-positive MCF-7 cells enhanced acid-activatable IGFBP-3 proteolysis in the cell conditioned medium but had no effect on proteolytic activity in estrogen receptor negative Hs578T cells. The cell-derived IGFBP-3 protease was identified as the aspartic proteinase cathepsin D, based on acidic pH optimum, inhibition by pepstatin, distinctive proteolytic fragment pattern, and immunoreactivity with cathepsin D antisera. Furthermore, immunodepletion of cathepsin D effectively attenuated acid-activated IGFBP-3 proteolysis. These data suggest a role for cathepsin D in the regulation of cellular IGF action by virtue of its potential to alter the structure/function of IGFBP-3.	MAYO CLIN & MAYO FDN,ENDOCRINE RES UNIT,ROCHESTER,MN 55905; NCI,BETHESDA,MD 20892	Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				De Leon, Daisy D./0000-0002-2693-0957	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043258, R01DK043258] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43258] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALE LK, 1992, ENDOCRINOLOGY, V131, P608, DOI 10.1210/en.131.2.608; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; CAMPBELL PG, 1992, ENDOCRINOLOGY, V130, P1401, DOI 10.1210/en.130.3.1401; Carrel A, 1926, J EXP MED, V44, P503, DOI 10.1084/jem.44.4.503; CLEMMONS DR, 1990, TRENDS ENDOCRIN MET, V1, P412, DOI 10.1016/1043-2760(90)90102-9; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; CONOVER CA, 1993, J CLIN INVEST, V91, P1129, DOI 10.1172/JCI116272; DAVENPORT ML, 1992, J CLIN ENDOCR METAB, V75, P590, DOI 10.1210/jc.75.2.590; DAVIES SC, 1991, J ENDOCRINOL, V130, P469, DOI 10.1677/joe.0.1300469; DAVIES SC, 1991, CLIN ENDOCRINOL, V34, P501, DOI 10.1111/j.1365-2265.1991.tb00331.x; DELEON DD, 1989, MOL ENDOCRINOL, V3, P567, DOI 10.1210/mend-3-3-567; FIGUEROA JA, 1992, BREAST CANCER RES TR, V22, P81, DOI 10.1007/BF01833336; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; GIUDICE LC, 1990, J CLIN ENDOCR METAB, V71, P806, DOI 10.1210/jcem-71-4-806; HASSAGER C, 1992, J CLIN ENDOCR METAB, V75, P228, DOI 10.1210/jc.75.1.228; HOSSENLOPP P, 1990, J CLIN ENDOCR METAB, V71, P797, DOI 10.1210/jcem-71-4-797; HUANG JS, 1979, J BIOL CHEM, V254, P1405; HUGHES SCC, 1992, J ENDOCRINOL, V135, P135, DOI 10.1677/joe.0.1350135; LAMSON G, 1991, J CLIN ENDOCR METAB, V72, P1391, DOI 10.1210/jcem-72-6-1391; LU L, 1993, 75TH ANN M END SOC L, P421; MATHIEU M, 1991, MOL ENDOCRINOL, V5, P815, DOI 10.1210/mend-5-6-815; MONTCOURRIER P, 1990, CANCER RES, V50, P6045; NISSLEYP, 1992, INSULIN LIKE GROWTH, P111; ROCHEFORT H, 1990, CANCER METAST REV, V9, P321, DOI 10.1007/BF00049522; ROSENFEELD RG, 1990, RECENT PROG HORM RES, V4, P99; SAHAGIAN GG, 1981, THESIS U MICHIGAN; SHIMASAKI S, 1989, BIOCHEM BIOPH RES CO, V165, P907, DOI 10.1016/S0006-291X(89)80052-X; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; VANBEEK WP, 1973, CANCER RES, V33, P2913; WOOD WI, 1988, MOL ENDOCRINOL, V2, P1175	31	99	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7076	7080						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7510281				2022-12-25	WOS:A1994NA03200008
J	RUI, H; KIRKEN, RA; FARRAR, WL				RUI, H; KIRKEN, RA; FARRAR, WL			ACTIVATION OF RECEPTOR-ASSOCIATED TYROSINE KINASE JAK2 BY PROLACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH SIGNAL TRANSDUCTION; PROTEIN-KINASE; CYTOKINE RECEPTORS; CYTOPLASMIC REGION; BETA-SUBUNIT; FAMILY; HORMONE; DOMAIN; FORM; PHOSPHORYLATION	JAK family tyrosine kinases have recently been implicated in intracellular signal transduction by transmembrane cytokine receptors of the interferon (IFN) and hematopoietin receptor families. Using the prolactin (PRL) dependent rat pre-T cell line Nb2, a PRL receptor-associated, candidate tyrosine kinase of 120-130 kDa was recently characterized (1). In the present work this protein is identified as JAK2, based upon reciprocal anti-JAK2 and anti-phosphotyrosine immunoprecipitation and immunoblotting. JAK2 underwent rapid and transient tyrosine phosphorylation in response to receptor activation, reaching peak levels within 5 min of exposure to 100 nm PRL at 37 degrees C. In vitro tyrosine kinase assays using either [gamma-P-32]ATP and autoradiography or unlabeled ATP combined with anti-phosphotyrosine immunoblotting, demonstrated that the activity of JAK2 was stimulated by PRL. Phosphoamino acid analysis of JAK2 after in vitro tyrosine kinase assay revealed that the majority of phosphate was incorporated into tyrosine residues. Furthermore, JAK2 was associated with PRL receptors to a comparable extent before and after PRL binding, as demonstrated by anti-receptor immunoprecipitation and subsequent anti-JAK2 immunoblotting. We propose that binding of ligand to the PRL receptor activates preassociated JAK2, and that this enzyme generates the initial signal in the intracellular communication cascade.			RUI, H (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, DIV CANC TREATMENT, FREDERICK, MD 21702 USA.				FOGARTY INTERNATIONAL CENTER [F05TW004300] Funding Source: NIH RePORTER; FIC NIH HHS [5FO5 TWO4300-02] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ALI S, 1991, J BIOL CHEM, V266, P20110; ALI S, 1992, MOL ENDOCRINOL, V6, P1242, DOI 10.1210/me.6.8.1242; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BERNARDS A, 1991, ONCOGENE, V6, P1185; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; COLOSI P, 1993, J BIOL CHEM, V268, P12617; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; HARADA N, 1992, J BIOL CHEM, V267, P22752; HARPUR AG, 1992, ONCOGENE, V7, P1347; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HOWARD OMZ, 1992, ONCOGENE, V7, P895; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LESUEUR L, 1991, P NATL ACAD SCI USA, V88, P824, DOI 10.1073/pnas.88.3.824; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NICOLL CS, 1980, FED PROC, V39, P2563; OKAMURA H, 1989, ENDOCRINOLOGY, V124, P2499, DOI 10.1210/endo-124-5-2499; PRITCHARD MA, 1992, MAMM GENOME, V3, P36, DOI 10.1007/BF00355839; RILLEMA JA, 1992, ENDOCRINOLOGY, V131, P973, DOI 10.1210/en.131.2.973; RUI H, 1992, J BIOL CHEM, V267, P24076; RUSSELL DH, 1989, TRENDS PHARMACOL SCI, V10, P40, DOI 10.1016/0165-6147(89)90106-5; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	47	317	320	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5364	5368						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508935				2022-12-25	WOS:A1994MX57100099
J	MAKAREM, R; NEWHAM, P; ASKARI, JA; GREEN, LJ; CLEMENTS, J; EDWARDS, M; HUMPHRIES, MJ; MOULD, AP				MAKAREM, R; NEWHAM, P; ASKARI, JA; GREEN, LJ; CLEMENTS, J; EDWARDS, M; HUMPHRIES, MJ; MOULD, AP			COMPETITIVE-BINDING OF VASCULAR CELL-ADHESION MOLECULE-1 AND THE HEPII/IIICS DOMAIN OF FIBRONECTIN TO THE INTEGRIN ALPHA-4-BETA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III CONNECTING SEGMENT; HUMAN-PLASMA FIBRONECTIN; LYMPHOCYTE ADHESION; ENDOTHELIAL-CELLS; MELANOMA ADHESION; GERMINAL-CENTERS; COUNTER-RECEPTOR; SPLICED DOMAIN; LATE ANTIGEN-4; T-CELLS	The integrin receptor alpha 4 beta 1 binds to two different ligands, the extracellular matrix glycoprotein fibronectin and the endothelial cell surface protein vascular cell adhesion molecule-1 (VCAM-1). Using probes derived from each ligand and a variety of cell adhesion and ligand-receptor binding assays, we have investigated the relationship between the mechanisms of fibronectin and VCAM-1 interaction with alpha 4 beta 1. CS1 peptide, which represents the dominant active site from the HepII/IIICS recognition domain in fibronectin, was found to inhibit VCAM-1-dependent adhesion in three different assays: MOLT-4 T lymphoblastic leukaemia cell attachment to immobilized recombinant soluble VCAM-1 (rsVCAM-1), MOLT-4 cell attachment to monolayers of VCAM-1-transfected COS-1 cells, and A375-SM melanoma cell spreading on immobilized rsVCAM-1. Half-maximal inhibition required CS1 concentrations of 1.7-3.0 mg/ml, some 3-7-fold higher than that needed to autoinhibit adhesion to CS1-IgG conjugate. Using a more sensitive solid phase receptor-ligand binding assay, CS1 was found to be a potent inhibitor of the binding of rsVCAM-1 to alpha 4 beta 1 (half maximal inhibition at 13 mu g/ml). In agreement with cell-based assays, severalfold lower concentrations of CS1 were required to inhibit binding of recombinant HepII/IIICS region of fibronectin (half-maximal inhibition at 3 mu g/ml). VCAM-1-alpha 4 beta 1 binding was blocked not only by CS1 peptide but also by the recombinant HepII/IIICS region of fibronectin. Kinetic analysis of CS1 inhibition of VCAM-1 binding revealed that it was directly competitive in nature, indicating that VCAM-1 and fibronectin recognize either identical or spatially overlapping binding sites on alpha 4 beta 1. The implications of these results for the future design of VCAM-1 antagonists are discussed.	UNIV MANCHESTER,SCH BIOL SCI,DEPT BIOCHEM & MOLEC BIOL,MANCHESTER M13 9PT,ENGLAND; BRITISH BIOTECHNOL LTD,OXFORD OX4 5LY,ENGLAND	University of Manchester				Humphries, Martin/0000-0002-4331-6967	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGER A, 1990, INT IMMUNOL, V2, P921, DOI 10.1093/intimm/2.10.921; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; CARLOS TM, 1990, BLOOD, V76, P965; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CLARK EA, 1992, J IMMUNOL, V148, P3327; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; CYBULSKY MI, 1991, AM J PATHOL, V138, P815; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DUFOUR S, 1988, EMBO J, V7, P2661, DOI 10.1002/j.1460-2075.1988.tb03119.x; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FERGUSON TA, 1991, P NATL ACAD SCI USA, V88, P8072, DOI 10.1073/pnas.88.18.8072; FREEDMAN AS, 1992, BLOOD, V79, P206; FREEDMAN AS, 1990, SCIENCE, V249, P1030, DOI 10.1126/science.1697696; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; HESSION C, 1991, J BIOL CHEM, V266, P6682; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HUMPHRIES MJ, 1988, J CELL BIOL, V106, P1289, DOI 10.1083/jcb.106.4.1289; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KOZLOWSKI JM, 1984, J NATL CANCER I, V72, P913; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFON A, 1991, J CLIN INVEST, V88, P546, DOI 10.1172/JCI115338; LAM SCT, 1987, J BIOL CHEM, V262, P947; MAHLER HR, 1966, BIOL CHEM, P250; MASINOVSKY B, 1990, J IMMUNOL, V145, P2886; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; MOULD AP, 1990, J BIOL CHEM, V265, P4020; MOULD AP, 1991, J BIOL CHEM, V266, P3579; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PLOW EF, 1985, BLOOD, V66, P724; POLTE T, 1990, NUCLEIC ACIDS RES, V18, P5901, DOI 10.1093/nar/18.19.5901; POLTE T, 1991, DNA CELL BIOL, V10, P349, DOI 10.1089/dna.1991.10.349; PULIDO R, 1991, J BIOL CHEM, V266, P10241; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; SAMBROOK T, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SIMMONS PJ, 1992, BLOOD, V80, P388; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; TEIXIDO J, 1992, J CLIN INVEST, V90, P358, DOI 10.1172/JCI115870; THORNHILL MH, 1991, J IMMUNOL, V146, P592; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; WALMSLEY AR, 1985, COMPUT METH PROG BIO, V21, P113, DOI 10.1016/0169-2607(85)90070-7; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; ZARDI L, 1985, EUR J BIOCHEM, V146, P571, DOI 10.1111/j.1432-1033.1985.tb08690.x	55	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4005	4011						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508437				2022-12-25	WOS:A1994MW98900019
J	PALMER, FBS; THEOLIS, R; COOK, HW; BYERS, DM				PALMER, FBS; THEOLIS, R; COOK, HW; BYERS, DM			PURIFICATION OF 2 IMMUNOLOGICALLY RELATED PHOSPHATIDYLINOSITOL-(4,5)-BISPHOSPHATE PHOSPHATASES FROM BOVINE BRAIN CYTOSOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAT-BRAIN; INOSITOL POLYPHOSPHATE-5-PHOSPHATASE; HUMAN-ERYTHROCYTES; 4,5-BISPHOSPHATE; MEMBRANE; POLYPHOSPHOINOSITIDES; 5-PHOSPHATASE; 4-PHOSPHATE; PHOSPHOMONOESTERASE	Two phosphatidylinositol-(4,5)-bisphosphate (PtdIns(4,5)P2) phosphatase activities were isolated from a 45% saturated (NH4)2SO4 fraction of the soluble cytosol (100,000 x g supernatant) of bovine cerebral 'hemispheres by ion-exchange chromatography on Q-Sepharose (Q-1 and Q-2). Each was further purified on heparin-Sepharose, butyl-agarose, and/or Cibacron blue F3GA to yield products of similar specific activity (70-100 mumol/min/mg protein, 1000-2000-fold purification). Salt was required to stabilize activity and dithiothreitol was required to preserve maximum activity and to prevent or reverse aggregation that resisted disruption by mercaptoethanol and/or SDS. Monoclonal antibodies were prepared that recognized several components in the partially purified preparations. Immunoabsorption of activity by monoclonal antibodies that had been chemically cross-linked to protein A-Sepharose followed by SDS-polyacrylamide gel electrophoresis of absorbed proteins was used to identify the active components as a 155-kDa protein in Q-1 and a 115-kDa protein in Q-2. Two antibodies recognized different epitopes in the 155-kDa phosphatase. A third antibody recognized a common epitope in both phosphatases indicating that the two enzymes are related. Both phosphatases were Me2+-dependent, exhibited similar kinetic properties, and hydrolyzed PtdIns(4,5)P2 but not PtdIns(4)P, phosphatidic acid, or several other phosphate monoesters. They hydrolyzed inositol (1,4,5)-trisphosphate at 30% of the rate with PtdIns(4,5)P2 and this activity co-purified with PtdIns(4,5)P2 phosphatase activity. High molecular weight PtdIns(4,5)P2 phosphatases may be precursors of lower molecular weight soluble Type II inositol polyphosphate-5-phosphatases shown to account for the PtdIns(4,5)P2 phosphatase activity in platelets (Matzaris, M., Jackson, S. P., Laxminarayan, M., Speed, C. J., and Mitchell, C. A. (1994) J. Biol. Chem. 269,3397-3402). The three antibodies did not inhibit activity but recognized both native and denatured (Western blots) phosphatases and should be useful tools to study the distribution, structure, and regulation of the two forms of PtdIns(4,5)P2 phosphatase.	DALHOUSIE UNIV, DEPT BIOCHEM, HALIFAX B3H 4H7, NS, CANADA; DALHOUSIE UNIV, DEPT PEDIAT, HALIFAX B3H 4H7, NS, CANADA	Dalhousie University; Dalhousie University	PALMER, FBS (corresponding author), DALHOUSIE UNIV, ATLANTIC RES CTR, CLIN RES CTR, RM C-202, 5894 UNIV AVE, HALIFAX B3H 4H7, NS, CANADA.							BECK KA, 1991, J BIOL CHEM, V266, P4442; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BORDIN L, 1992, BIOCHEM BIOPH RES CO, V187, P853, DOI 10.1016/0006-291X(92)91275-U; BROCKMAN JL, 1991, J BIOL CHEM, V266, P2508; BUTLER JE, 1992, J IMMUNOL METHODS, V150, P77, DOI 10.1016/0022-1759(92)90066-3; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHAUHAN A, 1991, ARCH BIOCHEM BIOPHYS, V287, P283, DOI 10.1016/0003-9861(91)90480-7; DIVECHA N, 1992, BIOCHEM J, V288, P637, DOI 10.1042/bj2880637; DOBOS GJ, 1992, J IMMUNOL, V149, P609; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; ERNEUX C, 1989, EUR J BIOCHEM, V181, P317, DOI 10.1111/j.1432-1033.1989.tb14726.x; FOWLER CJ, 1990, BIOCHEM J, V271, P735, DOI 10.1042/bj2710735; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GARFIN DE, 1990, METHOD ENZYMOL, V182, P459; GLANVILLE NT, 1989, BIOCHIM BIOPHYS ACTA, V1004, P169, DOI 10.1016/0005-2760(89)90265-8; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HARLOW E, 1988, ANTIBODIES LABORATOR; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HUANG FL, 1991, J BIOL CHEM, V266, P8727; IMES SS, 1987, ANAL BIOCHEM, V161, P316, DOI 10.1016/0003-2697(87)90457-X; INOKUCHI S, 1990, J BIOL CHEM, V265, P5983; KING CE, 1989, BIOCHEM J, V259, P893, DOI 10.1042/bj2590893; KINOUCHI H, 1990, MOL CHEM NEUROPATHOL, V12, P215, DOI 10.1007/BF03159946; KNOWLES AF, 1985, BIOCHEM BIOPH RES CO, V129, P220, DOI 10.1016/0006-291X(85)91425-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSING I, 1990, FEBS LETT, V262, P231, DOI 10.1016/0014-5793(90)80197-Q; LEE MH, 1991, BIOCHEMISTRY-US, V30, P1041, DOI 10.1021/bi00218a023; MACK SE, 1988, BIOCHEM CELL BIOL, V66, P199, DOI 10.1139/o88-027; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; MEMON AR, 1989, BIOCHEM BIOPH RES CO, V162, P1295, DOI 10.1016/0006-291X(89)90814-0; MISSIAEN L, 1989, BIOCHEM J, V261, P1055, DOI 10.1042/bj2611055; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NIJJAR MS, 1977, BIOCHIM BIOPHYS ACTA, V480, P390, DOI 10.1016/0005-2744(77)90032-8; ORDOVAS JM, 1987, J LIPID RES, V28, P371; PALMER FBS, 1990, BIOCHEM CELL BIOL, V68, P800; PALMER FBS, 1985, ANAL BIOCHEM, V150, P345, DOI 10.1016/0003-2697(85)90521-4; PALMER FBS, 1987, BIOCHEM CELL BIOL, V65, P890, DOI 10.1139/o87-115; PALMER FBSC, 1977, PREP BIOCHEM, V7, P457, DOI 10.1080/00327487708065513; PALMER FBSC, 1981, CAN J BIOCHEM CELL B, V59, P469, DOI 10.1139/o81-065; PIKE LJ, 1992, ENDOCR REV, V13, P692, DOI 10.1210/er.13.4.692; ROACH PD, 1981, BIOCHIM BIOPHYS ACTA, V661, P323, DOI 10.1016/0005-2744(81)90021-8; ROSS TS, 1991, J BIOL CHEM, V266, P20283; SAHYOUN NE, 1989, J BIOL CHEM, V264, P1062; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SEYFRED MA, 1984, J BIOL CHEM, V259, P3204; SMITH CD, 1984, ARCH BIOCHEM BIOPHYS, V235, P529, DOI 10.1016/0003-9861(84)90226-1; SMITH CD, 1988, BIOCHEM J, V256, P125, DOI 10.1042/bj2560125; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SORENSEN K, 1986, J IMMUNOL METHODS, V95, P291, DOI 10.1016/0022-1759(86)90419-9; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TAKIMOTO K, 1989, J BIOCHEM-TOKYO, V106, P684, DOI 10.1093/oxfordjournals.jbchem.a122917; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERJANS B, 1992, EUR J BIOCHEM, V204, P1083, DOI 10.1111/j.1432-1033.1992.tb16732.x	55	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3403	3410						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508913				2022-12-25	WOS:A1994MV63100043
J	KEW, Y; SONG, QB; PRASAD, VR				KEW, Y; SONG, QB; PRASAD, VR			SUBUNIT-SELECTIVE MUTAGENESIS OF GLU-89 RESIDUE IN HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE - CONTRIBUTION OF P66 AND P51 SUBUNITS TO NUCLEOSIDE ANALOG SENSITIVITY, DIVALENT-CATION PREFERENCE, AND STEADY-STATE KINETIC-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; ZIDOVUDINE AZT; HIV-1; RESISTANCE	The E89G alteration in the human immunodeficiency virus type 1 reverse transcriptase has been shown to confer resistance to nucleoside analogs and a loss of magnesium cation preference (Prasad, V. R., Lowy, I., De Los Santos, T., Chiang, L., and Goff, S. P. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 11363-11367. The wild type reverse transcriptase heterodimer, chimeric reverse transcriptases that contain the E89G alteration in one of the subunits (p66(wt)/p51(m) and p66(m)/p51(wt)), and the mutant enzyme (p66(m)/p51(m)) were prepared. Analysis of steady state kinetic parameters showed that the mutant enzyme (p66(m)/p5l(m)) displayed a higher V-max a higher K-m for 2'-deoxythymidine triphosphate, and a higher K-i for 2',3'-dideoxythymidine triphosphate than the wild type enzyme. The increased K-m and K-i values were observed only when a heterodimer contained the alteration in the p66 subunit. Tests for divalent cation requirement showed that only the dimers containing the wild type p66 (p66(wt)/p51(wt) and p66(wt)/p51(m)) displayed a preference for magnesium. Our results indicate that p66 plays a dominant role in deoxynucleotide triphosphate substrate recognition (K-m), nucleoside analog sensitivity (K-i), and magnesium preference. However, the increased V-max displayed by the mutant enzyme (p66(m)/p51(m)) appeared to be determined by both of the subunits.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine			Prasad, Vinayaka R./A-1029-2011	Prasad, Vinayaka/0000-0002-9461-0189	NIAID NIH HHS [AI-30861] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI030861, R37AI030861, R01AI030861] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9908; Cleland W W, 1979, Methods Enzymol, V63, P103; HOSTOMSKY Z, 1992, J VIROL, V66, P3197; HOWARD KJ, 1991, J BIOL CHEM, V266, P23003; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; PRASAD VR, 1991, P NATL ACAD SCI USA, V88, P11363, DOI 10.1073/pnas.88.24.11363; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SONG QG, 1992, J VIROL, V66, P7568, DOI 10.1128/JVI.66.12.7568-7571.1992; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TANESE N, 1988, DNA-J MOLEC CELL BIO, V7, P407, DOI 10.1089/dna.1.1988.7.407; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	20	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15331	15336						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7515055				2022-12-25	WOS:A1994NP73800071
J	MALHERBE, P; KOHLER, C; DAPRADA, M; LANG, G; KIEFER, V; SCHWARCZ, R; LAHM, HW; CESURA, AM				MALHERBE, P; KOHLER, C; DAPRADA, M; LANG, G; KIEFER, V; SCHWARCZ, R; LAHM, HW; CESURA, AM			MOLECULAR-CLONING AND FUNCTIONAL EXPRESSION OF HUMAN 3-HYDROXYANTHRANILIC-ACID DIOXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOLINIC ACID; RAT-BRAIN; KYNURENIC ACID; INDOLEAMINE 2,3-DIOXYGENASE; TRYPTOPHAN DEGRADATION; OXYGENASE ACTIVITY; DISEASE; LOCALIZATION; PROTEINS; INVITRO	Increased cerebral levels of the endogenous excitotoxin quinolinic acid (QUIN) have been speculatively linked to neuronal damage following neurological and inflammatory disorders. 3-Hydroxyanthranilic-acid dioxygenase (3-HAO; 3-hydroxyanthranilate 3,4-dioxygenase, EC 1.13.11.6) is the enzyme that catalyzes the synthesis of QUIN from 3-hydroxyanthranilic acid, and evidence suggests that it could play a role in disorders associated with altered tissue levels of QUIN. In this report, we describe the isolation of a full-length cDNA clone encoding human 3-HAO (h3-HAO). Degenerate oligonucleotides were designed from the amino acid se quences of tryptic peptides of rat liver 3-HAO, and they were used as primers for reverse transcription-polymerase chain reaction of rat liver RNA. The resulting rat cDNA product was used to screen a human hepatoma cell line (HepG(2)) cDNA library and to isolate a human 3-HAO cDNA clone. This clone was found to have an insert of 1276 nucleotides. The deduced primary structure of h3-HAO is composed of 286 amino acid residues with a predicted molecular mass of similar to 32.6 kDa. The human sequence exhibits high similarity (94%) to the rat partial amino acid sequence deduced from the rat reverse transcription-polymerase chain reaction fragment. Insertion of the h3-HAO coding sequence into a eukaryotic expression vector yielded relatively high amounts of the active enzyme in human embryonic kidney HEK-293 cells. The K-m value of 3-HANA for recombinant h3-HAO (similar to 2 mu M) was in good agreement with that reported for the native enzyme. Immunoblot analysis of recombinant h3-HAO revealed a polypeptide with an apparent molecular mass of 32 kDa, as predicted from the deduced amino acid sequence. RNA blot analysis of human liver and HepG(2) cells revealed one major species of h3-HAO mRNA of similar to 1.3 kilobases.	F HOFFMANN LA ROCHE & CO LTD,DIV PHARMA,PRECLIN RES,NERVOUS SYST,CH-4002 BASEL,SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD,NEW TECHNOL,CH-4002 BASEL,SWITZERLAND; UNIV MARYLAND,SCH MED,MARYLAND PSYCHIAT RES CTR,CATONSVILLE,MD 21228	Roche Holding; Roche Holding								BAUW G, 1989, P NATL ACAD SCI USA, V86, P7701, DOI 10.1073/pnas.86.20.7701; BEAL MF, 1990, J NEUROCHEM, V55, P1327, DOI 10.1111/j.1471-4159.1990.tb03143.x; BERTOCCI B, 1991, P NATL ACAD SCI USA, V88, P1416, DOI 10.1073/pnas.88.4.1416; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DU F, 1993, NEUROSCIENCE, V55, P975, DOI 10.1016/0306-4522(93)90312-4; FOSTER AC, 1986, J NEUROCHEM, V47, P23; HALPERIN JJ, 1992, NEUROLOGY, V42, P43, DOI 10.1212/WNL.42.1.43; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; HEYES MP, 1992, FASEB J, V6, P2977, DOI 10.1096/fasebj.6.11.1322853; HEYES MP, 1993, BIOCHEM SOC T, V21, P83, DOI 10.1042/bst0210083; HUYNH TV, 1984, PRACTICAL APPROACHES, P49; KOHLER C, 1988, NEUROSCIENCE, V27, P49, DOI 10.1016/0306-4522(88)90219-9; KOONTZ WA, 1976, J BIOL CHEM, V251, P368; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEFFLER JP, 1990, J NEUROCHEM, V54, P1812, DOI 10.1111/j.1471-4159.1990.tb01240.x; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MORONI F, 1984, BRAIN RES, V295, P352, DOI 10.1016/0006-8993(84)90984-3; MORONI F, 1991, J NEUROCHEM, V57, P1630, DOI 10.1111/j.1471-4159.1991.tb06361.x; NAKANO K, 1991, AGR BIOL CHEM TOKYO, V55, P1195, DOI 10.1080/00021369.1991.10870719; OKUNO E, 1987, J NEUROCHEM, V49, P771, DOI 10.1111/j.1471-4159.1987.tb00960.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERKINS MN, 1983, J PHARMACOL EXP THER, V226, P551; SAITO K, 1993, BIOCHEM J, V291, P11, DOI 10.1042/bj2910011; SAITO K, 1993, J NEUROCHEM, V60, P180, DOI 10.1111/j.1471-4159.1993.tb05836.x; SAITO K, 1993, J BIOL CHEM, V268, P15496; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHWARCZ R, 1992, ANN NY ACAD SCI, V648, P140; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; SCHWARCZ R, 1988, P NATL ACAD SCI USA, V85, P4079, DOI 10.1073/pnas.85.11.4079; SCHWARCZ R, 1993, BIOCHEM SOC T, V21, P77, DOI 10.1042/bst0210077; SCHWARCZ R, 1992, DRUG RES RELATED NEU, P287; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; TAKIKAWA O, 1986, J BIOL CHEM, V261, P3648; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VESCIA A, 1962, J BIOL CHEM, V237, P2318; WALSH JL, 1991, BIOCHEM PHARMACOL, V42, P985, DOI 10.1016/0006-2952(91)90279-E	38	60	62	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13792	13797						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514594				2022-12-25	WOS:A1994NL60600015
J	FALLON, RJ; DANAHER, M; SAYLORS, RL; SAXENA, A				FALLON, RJ; DANAHER, M; SAYLORS, RL; SAXENA, A			DEFECTIVE ASIALOGLYCOPROTEIN RECEPTOR ENDOCYTOSIS MEDIATED BY TYROSINE KINASE INHIBITORS - REQUIREMENT FOR A TYROSINE IN THE RECEPTOR INTERNALIZATION SIGNAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; EPIDERMAL GROWTH-FACTOR; COATED PIT FORMATION; HEPATOMA-CELL LINE; PROTEIN-KINASE; PHORBOL ESTERS; EGF RECEPTOR; STAUROSPORINE; PHOSPHORYLATION; AUTOPHOSPHORYLATION	Regulated endocytosis by growth factor receptors requires intact receptor-associated tyrosine kinase activity. To determine whether a similar requirement exists for the asialoglycoprotein (ASGP) receptor which lacks intrinsic tyrosine kinase activity and participates in constitutive endocytosis, we examined the effect of three tyrosine kinase inhibitors, tyrphostin, genistein, and staurosporine, on receptor-mediated endocytosis in the human hepatoma line HepG2. These compounds inhibited early receptor internalization from the plasma membrane to internal protease-resistant sites in a concentration-dependent manner. This effect correlated with their inhibition of tyrosine phosphorylation of the ASGP receptor in vitro. Receptor trafficking subsequent to receptor internalization was unaffected. Endocytosis of another constitutively internalized protein, the transferrin receptor, was also inhibited by these compounds. In contrast, pinocytosis of the fluid-phase marker Lucifer yellow was not inhibited. The tyrosine kinase inhibitors also decreased the endocytic rate of transfected ASGP receptor H1 subunit in SK-Hep-1 cells. Therefore an intact ASGP receptor heterooligomeric complex is not required for this effect. Mutation of the single cytoplasmic tyrosine at position 5 of the HI subunit to phenylalanine produced an ASGP receptor which was endocytosed regardless of treatment with the tyrosine kinase inhibitors. We conclude that tyrosine kinase activity modulates the rate of receptor endocytosis at a point early in the internalization process.	WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL)	FALLON, RJ (corresponding author), WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,1 CHILDRENS PL,BOX 8116,ST LOUIS,MO 63110, USA.				NIDDK NIH HHS [DK42081] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042081] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BERG T, 1980, BIOCHEM PHARMACOL, V29, P917, DOI 10.1016/0006-2952(80)90222-1; BISCHOFF J, 1988, J CELL BIOL, V106, P1067, DOI 10.1083/jcb.106.4.1067; BRAITERMAN LT, 1989, J BIOL CHEM, V264, P1682; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTIER JL, 1993, J CELL BIOL, V122, P1243, DOI 10.1083/jcb.122.6.1243; CLARKE BL, 1985, J BIOL CHEM, V260, P128; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; FALLON RJ, 1987, MOL PHARMACOL, V32, P348; FALLON RJ, 1992, EXP CELL RES, V203, P420, DOI 10.1016/0014-4827(92)90016-2; FALLON RJ, 1990, J BIOL CHEM, V265, P3401; FALLON RJ, 1988, J BIOL CHEM, V263, P13159; FALLON RJ, 1990, BIOCHEM BIOPH RES CO, V170, P1191, DOI 10.1016/0006-291X(90)90519-S; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; GEFFEN I, 1991, P NATL ACAD SCI USA, V88, P8425, DOI 10.1073/pnas.88.19.8425; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GEFFEN I, 1989, EMBO J, V8, P2855, DOI 10.1002/j.1460-2075.1989.tb08433.x; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HARI J, 1987, J BIOL CHEM, V262, P15341; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; NAKANO H, 1987, J ANTIBIOT, V40, P706, DOI 10.7164/antibiotics.40.706; OKA JA, 1989, J BIOL CHEM, V264, P12016; OSHEROV N, 1993, J BIOL CHEM, V268, P11134; OZAKI K, 1993, J BIOCHEM-TOKYO, V113, P271, DOI 10.1093/oxfordjournals.jbchem.a124038; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PURE E, 1992, P NATL ACAD SCI USA, V89, P114, DOI 10.1073/pnas.89.1.114; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SCHWARTZ AL, 1982, J BIOL CHEM, V257, P4230; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; SIMMONS CF, 1984, MOL PHARMACOL, V26, P509; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; SPIESS M, 1985, J BIOL CHEM, V260, P1979; SWANSON JA, 1985, J CELL BIOL, V100, P851, DOI 10.1083/jcb.100.3.851; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; WESSELS HP, 1989, J BIOL CHEM, V264, P17; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILEY HS, 1991, J BIOL CHEM, V263, P13159; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	48	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11011	11017						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512556				2022-12-25	WOS:A1994NF96600010
J	SAENKO, EL; SHIMA, M; RAJALAKSHMI, KJ; SCANDELLA, D				SAENKO, EL; SHIMA, M; RAJALAKSHMI, KJ; SCANDELLA, D			A ROLE FOR THE C2 DOMAIN OF FACTOR-VIII IN BINDING TO VON-WILLEBRAND-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND FACTOR; COAGULATION FACTOR-VIII; ACTIVATED PROTEIN-C; LIGHT CHAIN; MONOCLONAL-ANTIBODIES; INHIBITOR ANTIBODIES; LOCALIZATION; PEPTIDES; SITE	We examined the possibility that the C2 domain, amino acid residues 2173-2332, of factor VIII (fVIII) contains a binding site for von Willebrand factor (vWf) to clarify previous data showing that some monoclonal and human inhibitor antibodies with epitopes in C2 prevent fVIII-vWf binding. We constructed a fusion protein, glutathione S-transferase-C2, which binds to immobilized vWf in a dose-dependent saturable fashion, suggesting that the fVIII C2 domain contains a binding site for vWf. This site was further localized by testing the effect of a synthetic peptide on fVIII-vWf binding. Peptide 23032332, consisting of a previously identified phosphatidylserine binding site, prevented fVIII binding to vWf, suggesting that the sites for fVIII binding to vWf or phosphatidylserine have some overlap. The effect of anti-C2 domain antibodies further supported these observations. The inhibition of fVIII binding to vWf by monoclonal antibody NMC-VIII/5 IgG or F(ab)'2 (epitope within residues 2170-2327) and by inhibitor antibody MU IgG or Fab' (epitope within residues 2248-2312) was demonstrated by a fluid-phase binding assay and enzyme-linked immunosorbent assay. Two monoclonal antibodies with epitopes within amino acid residues 2170-2218 or 2248-2285, which do not overlap the phosphatidylserine binding site, did not have any inhibitory effect. Our data suggest that the previously described antagonistic binding of vWf and phospholipid to fVIII is due to the involvement of some C2 domain amino acids in both processes.			SAENKO, EL (corresponding author), AMER RED CROSS,HOLLAND LAB,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855, USA.				NHLBI NIH HHS [P50-HL44336, R01-HL36094] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL044336] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BLOOM JW, 1987, THROMB RES, V48, P439, DOI 10.1016/0049-3848(87)90401-4; CHOPEK MW, 1986, BIOCHEMISTRY-US, V25, P3146, DOI 10.1021/bi00359a012; DENT JA, 1991, J CLIN INVEST, V88, P774, DOI 10.1172/JCI115376; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FOSTER PA, 1990, BLOOD, V75, P1999; FOSTER PA, 1988, J BIOL CHEM, V263, P5230; GRIFFIN BD, 1986, THROMB HAEMOSTASIS, V55, P40; HAMER RJ, 1987, EUR J BIOCHEM, V166, P37, DOI 10.1111/j.1432-1033.1987.tb13480.x; HAY JM, 1992, BIOTECHNIQUES, V13, P856; HOYER LW, 1982, METHOD ENZYMOL, V84, P51; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; LAJMANOVICH A, 1981, BIOCHIM BIOPHYS ACTA, V678, P132, DOI 10.1016/0304-4165(81)90056-8; LAZARCHICK J, 1978, J CLIN INVEST, V62, P1048, DOI 10.1172/JCI109209; LEYTE A, 1989, BIOCHEM J, V257, P679, DOI 10.1042/bj2570679; LEYTE A, 1991, J BIOL CHEM, V266, P740; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; NESHEIM M, 1991, J BIOL CHEM, V266, P17815; SCANDELLA D, 1989, BLOOD, V74, P1618; SCANDELLA D, 1992, THROMB HAEMOSTASIS, V67, P665; SCANDELLA D, 1988, P NATL ACAD SCI USA, V85, P6152, DOI 10.1073/pnas.85.16.6152; SHIMA M, 1991, INT J HEMATOL, V54, P515; SHIMA M, 1993, THROMB HAEMOSTASIS, V69, P240; TULEY EA, 1991, P NATL ACAD SCI USA, V88, P6377, DOI 10.1073/pnas.88.14.6377; UEHLINGER J, 1991, TRANSFUSION, V31, P265, DOI 10.1046/j.1537-2995.1991.31391165179.x; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WALKER FJ, 1990, J BIOL CHEM, V265, P1484	28	157	165	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11601	11605						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512568				2022-12-25	WOS:A1994NF96600093
J	BELANGER, L; ROY, S; ALLARD, D				BELANGER, L; ROY, S; ALLARD, D			NEW ALBUMIN GENE 3' ADJACENT TO THE ALPHA(1)-FETOPROTEIN LOCUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT ALPHA-FETOPROTEIN; ALPHA-1-FETOPROTEIN GENE; BINDING-PROTEIN; SERUM-ALBUMIN; 5'-FLANKING REGION; PROMOTER; ENHANCER; REPRESSION; EXPRESSION; SEQUENCES	The albumin multigene family encodes proteins synthesized in the liver and secreted in the serum to fulfill ligand-carrier functions. The albumin (ALB), alpha(1)-fetoprotein (AFP), and vitamin D-binding protein genes are syntenic, the ALB and AFP genes are organized in tandem, and the AFP gene is selectively expressed in the fetal liver. We how report the existence of a fourth member of the albumin gene family, located 10 kilobases downstream from the AFP locus. The new gene, named alpha-albumin (alpha ALB), is selectively expressed in the liver at late stages of development. The alpha ALB mRNA sequence encodes a predicted secreted protein with the typical triple domain disulfide cross-linked structure. Comparisons of coding and promoter sequences suggest that alpha ALB could be a phylogenetic intermediate between the ALB and AFP genes. The developmental switch between alpha ALB gene activation and AFP gene repression suggests new regulatory interplays at the albumin locus and adult stage-specific ligand binding functions carried out by the alpha ALB gene product.			BELANGER, L (corresponding author), UNIV LAVAL,HOTEL DIEU QUEBEC,CTR RECH CANCEROL,QUEBEC CITY G1R 2J6,PQ,CANADA.							ATTARDI B, 1976, NATURE, V263, P685, DOI 10.1038/263685a0; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BAYARD B, 1983, EUR J BIOCHEM, V137, P319, DOI 10.1111/j.1432-1033.1983.tb07831.x; BELANGER L, 1975, NATURE, V256, P657, DOI 10.1038/256657a0; BELANGER L, 1983, ADV ENZYME REGUL, V23, P73; BERNIER D, 1993, MOL CELL BIOL, V13, P1619, DOI 10.1128/MCB.13.3.1619; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BOMAN H, 1976, CLIN GENET, V9, P513; BROWN JR, 1976, FED PROC, V35, P2141; CHEVRETTE M, 1987, NUCLEIC ACIDS RES, V15, P1338, DOI 10.1093/nar/15.3.1338; GITLIN D, 1971, NEW ENGL J MED, V285, P1436; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; HAEFLIGER DN, 1989, J MOL EVOL, V29, P344, DOI 10.1007/BF02103621; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; JAGODZINSKI LL, 1981, P NATL ACAD SCI-BIOL, V78, P3521, DOI 10.1073/pnas.78.6.3521; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAGASE S, 1979, SCIENCE, V205, P590, DOI 10.1126/science.451621; NAHON JL, 1987, P NATL ACAD SCI USA, V84, P2135, DOI 10.1073/pnas.84.8.2135; NUNEZ E, 1971, CR ACAD SCI D NAT, V273, P831; PARMELEE DC, 1978, J BIOL CHEM, V253, P2114; PETERSON KR, 1993, MOL CELL BIOL, V13, P4836, DOI 10.1128/MCB.13.8.4836; RAY K, 1991, J BIOL CHEM, V266, P6221; SARGENT TD, 1981, MOL CELL BIOL, V1, P871, DOI 10.1128/MCB.1.10.871; TAMAOKI T, 1984, RECOMBINANT DNA CELL, P145; THOMASSIN H, 1992, NUCLEIC ACIDS RES, V20, P3091, DOI 10.1093/nar/20.12.3091; Tilghman S M, 1985, Oxf Surv Eukaryot Genes, V2, P160; TRONCHE F, 1990, MOL BIOL MED, V7, P173; TURCOTTE B, 1985, NUCLEIC ACIDS RES, V13, P2387, DOI 10.1093/nar/13.7.2387; TURCOTTE B, 1986, NUCLEIC ACIDS RES, V14, P9827, DOI 10.1093/nar/14.24.9827; WITKE WF, 1993, GENOMICS, V16, P751, DOI 10.1006/geno.1993.1258	31	60	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5481	5484						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509788				2022-12-25	WOS:A1994MY84000001
J	MOHRAZ, M; ARYSTARKHOVA, E; SWEADNER, KJ				MOHRAZ, M; ARYSTARKHOVA, E; SWEADNER, KJ			IMMUNOELECTRON MICROSCOPY OF EPITOPES ON NA,K-ATPASE CATALYTIC SUBUNIT - IMPLICATIONS FOR THE TRANSMEMBRANE ORGANIZATION OF THE C-TERMINAL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; SARCOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODY; OUABAIN BINDING; OUTER MEDULLA; ION-TRANSPORT; NA+,K+-ATPASE; IDENTIFICATION; TOPOLOGY; VESICLES	The transmembrane folding of the alpha subunit of Na,K-ATPase was studied by using immunoelectron microscopy to determine whether monoclonal antibodies with defined epitopes bind to the extracellular or cytoplasmic surface. In double labeling experiments, an antibody and a reference marker were bound to purified membrane-associated Na,K-ATPase and were visualized by employing colloidal gold particles of two different sizes. Wheat germ agglutinin and a previously characterized monoclonal antibody were used as control markers for the exoplasmic and cytoplasmic surfaces, respectively. Three antibodies, VG4, VG2, and IIC9, unambiguously bound to the extracellular surface. Previously IIC9 had been assigned to the cytoplasmic surface because, in immunofluorescence studies, it stained intact cells only when they were detergent-permeabilized. To investigate the basis for this contradiction, a third assay for sidedness was used: competition binding in solution to right-side-out renal medullary vesicles. IIC9 was found to bind to the extracellular surface of sealed vesicles, but only in certain experimental conditions. It was concluded that IIC9 has an epitope that is not always accessible and that in this instance, studies of binding to intact and detergent-treated cells had given misleading results. An extracellular disposition for all three antibodies is not compatible with existing folding models, and new models are presented.	MASSACHUSETTS GEN HOSP,WELLMAN 4,FRUIT ST,BOSTON,MA 02114; NYU,DEPT CELL BIOL,NEW YORK,NY 10016; MM SHEMYAKIN INST BIOORGAN CHEM,117871 MOSCOW,RUSSIA; HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; New York University; Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035399] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36271] Funding Source: Medline; NIGMS NIH HHS [GM35399] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BALL WJ, 1986, BIOCHEMISTRY-US, V25, P7155, DOI 10.1021/bi00370a058; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; DELEMOSCHIARANDINI C, 1987, J CELL BIOL, V104, P209, DOI 10.1083/jcb.104.2.209; DEWEER P, 1988, ANNU REV PHYSIOL, V50, P225, DOI 10.1146/annurev.physiol.50.1.225; DZHANDZHUGAZYAN KN, 1985, BIOCHIM BIOPHYS ACTA, V817, P165, DOI 10.1016/0005-2736(85)90079-3; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; FORBUSH B, 1982, J BIOL CHEM, V257, P2678; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; JORGENSEN PL, 1992, MOL ASPECTS TRANSPOR, P1; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KNAUF PA, 1974, J GEN PHYSIOL, V63, P305, DOI 10.1085/jgp.63.3.305; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; MODYANOV N, 1992, ACTA PHYSIOL SCAND, V146, P49; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; OMORI K, 1983, J BIOCHEM-TOKYO, V94, P1857, DOI 10.1093/oxfordjournals.jbchem.a134539; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; SWEADNER KJ, 1975, J BIOL CHEM, V250, P4022; SWEADNER KJ, 1992, ANN NY ACAD SCI, V671, P217, DOI 10.1111/j.1749-6632.1992.tb43798.x; SWEADNER KJ, 1985, J BIOL CHEM, V260, P1508; XU KY, 1989, BIOCHEMISTRY-US, V28, P5764, DOI 10.1021/bi00440a010	24	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2929	2936						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7507930				2022-12-25	WOS:A1994MV43200083
J	VILLALBA, M; MARTINEZSERRANO, A; GOMEZPUERTAS, P; BLANCO, P; BORNER, C; VILLA, A; CASADO, M; GIMENEZ, C; PEREIRA, R; BOGONEZ, E; POZZAN, T; SATRUSTEGUI, J				VILLALBA, M; MARTINEZSERRANO, A; GOMEZPUERTAS, P; BLANCO, P; BORNER, C; VILLA, A; CASADO, M; GIMENEZ, C; PEREIRA, R; BOGONEZ, E; POZZAN, T; SATRUSTEGUI, J			THE ROLE OF PYRUVATE IN NEURONAL CALCIUM HOMEOSTASIS - EFFECTS ON INTRACELLULAR CALCIUM POOLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM NEURONS; ENDOPLASMIC-RETICULUM; SYMPATHETIC NEURONS; CYTOSOLIC CALCIUM; GROWTH-FACTOR; CELLS; CA-2+; CA2+; MEMBRANE; SYNAPTOSOMES	It has long been known that pyruvate is essential for survival of prenatal neurons in culture. To understand the role of exogenous pyruvate in neuronal calcium homeostasis, we have investigated the effects of pyruvate (plus malate) addition to dissociated adult rat hippocampal and cerebral cortex cells and cultured CNS neurons having an unrestricted glucose supply. We found that pyruvate (plus malate) increased the respiration rate while ATP levels were unchanged. At the same time, cytosolic free calcium concentrations, [Ca2+]i, decreased while total CA-45(2+) and CA-40(2+) accumulation increased. The extra Ca2+ accumulated by the cells is attributable to an increase in the size of the intracellular calcium pools. Two such pools were identified on the basis of their sensitivity to specific drugs. The first pool was mobilized by thapsigargin plus tert-butyl hydroquinone and caffeine while the second pool was discharged by the mitochondrial uncoupler carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) (plus oligomycin). The two pools represented about 15-20% and 15-30%, respectively, of the rapidly exchangeable Ca-45(2+) pools in cerebral cortex cells. In cultured hippocampal neurons, the collapse of the mitochondrial membrane potential (as induced by uncouplers (FCCP) or respiratory chain inhibitors (antimycin) caused a large increase in [Ca2+]i which varied in size and shape among cells and was reduced by external Ca2+ chelation. The latter condition also resulted in a partial discharge of FCCP-releasable Ca-45(2+). The effects of FCCP did not result simply from ATP depletion since incubation in glucose-free medium and sequential additions of 2 mM deoxyglucose and 10 muM oligomycin, conditions that led to a dramatic reduction in cellular ATP levels, did not abolish the FCCP-induced [Ca2+]i rise. Taken together, the results indicate that mitochondria harbor a significant proportion of cellular Ca2+. The sensitivity of the mitochondrial pool size to pyruvate (plus malate) questions previous hypotheses concerning a kinetic limitation for Ca2+ accumulation in mitochondria in resting neurons.	CSIC,CTR BIOL MOLEC SEVERO OCHOA,DEPT BIOL MOLEC,E-28049 MADRID,SPAIN; UNIV AUTONOMA MADRID,E-28049 MADRID,SPAIN; UNIV PADUA,CNR,CTR BIOMEMBRANES,INST GEN PATHOL,I-35100 PADUA,ITALY	Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Consiglio Nazionale delle Ricerche (CNR); University of Padua			Satrustegui, Jorgina/R-6732-2019; Gimenez, Cecilio/K-8027-2014; Gomez-Puertas, Paulino/G-8821-2014; Martínez-Serrano, Alberto/J-8146-2014; villalba, martin/N-7123-2017	Gimenez, Cecilio/0000-0001-6726-8405; Gomez-Puertas, Paulino/0000-0003-3131-729X; Villa Diaz, Ana/0000-0001-5419-3387; Blanco Morales, Pablo/0000-0003-1933-6818; Martinez Serrano, Alberto/0000-0003-3927-6699; Casado, Mariano/0000-0001-8049-8096; villalba, martin/0000-0002-4385-4888				AKERMAN KEO, 1981, BIOCHIM BIOPHYS ACTA, V645, P41, DOI 10.1016/0005-2736(81)90509-5; BRECHT M, 1992, BIOCHEM J, V283, P399, DOI 10.1042/bj2830399; BREWER GJ, 1989, BRAIN RES, V494, P65, DOI 10.1016/0006-8993(89)90144-3; CHACON E, 1992, BIOCHEM J, V281, P871, DOI 10.1042/bj2810871; CHEESEMAN AJ, 1988, J NEUROCHEM, V50, P1559, DOI 10.1111/j.1471-4159.1988.tb03044.x; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cellbio.4.1.155; CHOI DW, 1987, J NEUROSCI, V7, P369; COLLINS F, 1991, J NEUROSCI, V11, P2582; CORKEY BE, 1988, J BIOL CHEM, V263, P4247; DUCHEN MR, 1992, BIOCHEM J, V283, P41, DOI 10.1042/bj2830041; DUCHEN MR, 1992, J PHYSIOL-LONDON, V450, P33, DOI 10.1113/jphysiol.1992.sp019115; FACCI L, 1985, J NEUROCHEM, V45, P926, DOI 10.1111/j.1471-4159.1985.tb04082.x; FACCI L, 1986, BIOCHEM J, V234, P605, DOI 10.1042/bj2340605; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; GLENNON MC, 1992, J BIOL CHEM, V267, P25568; GOMEZA J, 1991, BIOCHEM J, V275, P435, DOI 10.1042/bj2750435; GOMEZPUERTAS P, 1991, J NEUROCHEM, V56, P2039, DOI 10.1111/j.1471-4159.1991.tb03464.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HERTZ L, 1989, BRAIN RES REV, V14, P335, DOI 10.1016/0165-0173(89)90017-9; HERZENBERG LA, 1960, EXP CELL RES, V21, P430, DOI 10.1016/0014-4827(60)90275-5; HOLLIDAY J, 1991, NEURON, V7, P787, DOI 10.1016/0896-6273(91)90281-4; JENSEN JR, 1991, BRAIN RES, V551, P311, DOI 10.1016/0006-8993(91)90947-T; KAUFMAN EE, 1992, J NEUROCHEM, V58, P258, DOI 10.1111/j.1471-4159.1992.tb09304.x; KAUPPINEN RA, 1986, EUR J BIOCHEM, V158, P159, DOI 10.1111/j.1432-1033.1986.tb09733.x; KOIKE T, 1991, P NATL ACAD SCI USA, V88, P3892, DOI 10.1073/pnas.88.9.3892; LAW GJ, 1990, BIOCHEM J, V267, P359, DOI 10.1042/bj2670359; Lemasters J.J., 1978, BIOLUMINESCENCE CHEM, P36, DOI [10.1016/0076-6879(78)57006-7, DOI 10.1016/0076-6879(78)57006-7]; MARRION NV, 1992, J PHYSIOL-LONDON, V445, P515, DOI 10.1113/jphysiol.1992.sp018937; MARTINEZSERRANO A, 1992, J BIOL CHEM, V267, P4672; MARTINEZSERRANO A, 1992, MOL BIOL CELL, V3, P235, DOI 10.1091/mbc.3.2.235; MATTSON MP, 1989, J NEUROSCI, V9, P3728; MELDOLESI J, 1990, BIOCHIM BIOPHYS ACTA, V1055, P130, DOI 10.1016/0167-4889(90)90113-R; MILLER RJ, 1992, TRENDS NEUROSCI, V15, P317, DOI 10.1016/0166-2236(92)90045-A; MILLS LR, 1990, NEURON, V2, P149; MINTA A, 1989, J BIOL CHEM, V264, P8171; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; NOBES CD, 1990, J BIOL CHEM, V265, P12910; NOBES CD, 1990, J BIOL CHEM, V265, P12903; PIKE SE, 1991, P NATL ACAD SCI USA, V88, P11081, DOI 10.1073/pnas.88.24.11081; PRENTKI M, 1984, J BIOL CHEM, V259, P118; REBER BFX, 1991, J PHYSIOL-LONDON, V435, P145, DOI 10.1113/jphysiol.1991.sp018502; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; SCHARFMAN HE, 1989, SCIENCE, V246, P257, DOI 10.1126/science.2508225; SELAK I, 1985, J NEUROSCI, V5, P23; SHANK RP, 1984, J NEUROCHEM, V42, P1153, DOI 10.1111/j.1471-4159.1984.tb12724.x; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VILLALBA M, 1992, BRAIN RES, V570, P347, DOI 10.1016/0006-8993(92)90600-E; VITORICA J, 1986, BRAIN RES, V378, P36, DOI 10.1016/0006-8993(86)90284-2; VITORICA J, 1984, J NEUROCHEM, V42, P531; WILLOUGHBY J, 1986, BIOCHEM J, V235, P2105; WINGROVE DE, 1984, J BIOL CHEM, V259, P9390	53	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2468	2476						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7507925				2022-12-25	WOS:A1994MV43200022
J	ATTANASIO, R; STUNZ, GW; KENNEDY, RC				ATTANASIO, R; STUNZ, GW; KENNEDY, RC			FOLDING PATTERNS OF IMMUNOGLOBULIN MOLECULES IDENTIFIED BY UREA GRADIENT ELECTROPHORESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LIGHT CHAIN; CONSTANT FRAGMENT; 3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODIES; TRYPTOPHAN SYNTHASE; FAB FRAGMENT; FV FRAGMENT; PROTEINS; EXPRESSION	The reversible denaturant-induced unfolding of immunoglobulin molecules has been analyzed by transverse urea gradient gel electrophoresis and the effects that urea-induced unfolding exerts on the functional properties associated with their variable region, i.e. antigen binding and idiotypic expression, have been determined by Western blot analysis. Results obtained from these experiments indicate that urea-induced unfolding of the immunoglobulin molecule is a highly cooperative reversible process that occurs through a two-state transition with no accumulation of intermediates. The unfolding transition has its midpoint at about 6.5 m urea and appears to be slow on the time scale of electrophoresis. Folding intermediates in rapid equilibrium with the unfolded state as well as molecular forms with different electrophoretic mobility can be detected during refolding reactions. Results from Western blot analysis confirm the highly cooperative reversible urea-induced unfolding of immunoglobulin molecules and demonstrate that the unfolding transition leads to disappearance of both antigen binding and idiotypic expression, whereas the ability to interact with antibodies directed to continuous epitopes of the variable region is preserved. After progressive removal of the denaturing agent, the variable region refolds into structures that regain the functional properties of the native conformation.	SW FDN BIOMED RES,CTR AIDS RES,SAN ANTONIO,TX 78228	Texas Biomedical Research Institute	ATTANASIO, R (corresponding author), SW FDN BIOMED RES,DEPT VIROL & IMMUNOL,SAN ANTONIO,TX 78228, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI026462] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 26462] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; ATTANASIO R, 1993, MOL IMMUNOL, V30, P9, DOI 10.1016/0161-5890(93)90421-7; ATTANASIO R, 1991, J BIOL CHEM, V266, P14611; ATTANASIO R, 1990, MOL IMMUNOL, V27, P513, DOI 10.1016/0161-5890(90)90070-G; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BLOND S, 1987, P NATL ACAD SCI USA, V84, P1147, DOI 10.1073/pnas.84.5.1147; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOSS MA, 1984, NUCLEIC ACIDS RES, V12, P3791, DOI 10.1093/nar/12.9.3791; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P6922, DOI 10.1021/bi00242a016; CABILLY S, 1984, P NATL ACAD SCI-BIOL, V81, P3273, DOI 10.1073/pnas.81.11.3273; Creighton T E, 1986, Methods Enzymol, V131, P156; CREIGHTON TE, 1980, J MOL BIOL, V137, P61, DOI 10.1016/0022-2836(80)90157-6; DAVIES DR, 1983, ANNU REV IMMUNOL, V1, P87, DOI 10.1146/annurev.iy.01.040183.000511; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; GOLDENBERG DP, 1984, ANAL BIOCHEM, V138, P1, DOI 10.1016/0003-2697(84)90761-9; GOTO Y, 1988, BIOCHEMISTRY-US, V27, P1670, DOI 10.1021/bi00405a043; GOTO Y, 1987, BIOCHEMISTRY-US, V26, P1879, DOI 10.1021/bi00381a014; GOTO Y, 1982, J MOL BIOL, V156, P891, DOI 10.1016/0022-2836(82)90146-2; HORWITZ AH, 1988, P NATL ACAD SCI USA, V85, P8678, DOI 10.1073/pnas.85.22.8678; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; KAWATA Y, 1991, BIOCHEMISTRY-US, V30, P4367, DOI 10.1021/bi00232a001; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KUROKAWA T, 1983, NUCLEIC ACIDS RES, V11, P3077, DOI 10.1093/nar/11.10.3077; MAKHATADZE GI, 1992, J MOL BIOL, V226, P491, DOI 10.1016/0022-2836(92)90963-K; MARQUART M, 1982, IMMUNOL TODAY, V3, P160, DOI 10.1016/0167-5699(82)90107-4; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MURPHY KP, 1992, J MOL BIOL, V227, P293, DOI 10.1016/0022-2836(92)90699-K; MURRYBRELIER A, 1988, BIOCHEMISTRY-US, V27, P7633, DOI 10.1021/bi00420a010; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; PARHAM P, 1982, J IMMUNOL METHODS, V53, P133, DOI 10.1016/0022-1759(82)90137-5; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; RIECHMANN L, 1988, J MOL BIOL, V203, P825, DOI 10.1016/0022-2836(88)90214-8; ROWE ES, 1976, BIOCHEMISTRY-US, V15, P905, DOI 10.1021/bi00649a028; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; TSUNENAGA M, 1987, BIOCHEMISTRY-US, V26, P6044, DOI 10.1021/bi00393a015	36	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1834	1838						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507486				2022-12-25	WOS:A1994MR98800045
J	BURG, DL; FURLONG, MT; HARRISON, ML; GEAHLEN, RL				BURG, DL; FURLONG, MT; HARRISON, ML; GEAHLEN, RL			INTERACTIONS OF LYN WITH THE ANTIGEN RECEPTOR DURING B-CELL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL TRANSDUCTION; LYMPHOCYTES-B; ZETA-CHAIN; PHOSPHATIDYLINOSITOL 3-KINASE; IG-BETA; PHOSPHORYLATION; COMPLEX; ASSOCIATION; COMPONENTS	Signaling through the B cell antigen receptor requires a complex set of interactions involving transmembrane components of the IgM receptor complex and cytosolic protein-tyrosine kinases. We have focused on the nature of these protein-protein interactions, the requirements for their occurrence, as well as the temporal sequence of events during the activation process. me found that cross-linking B cell antigen receptors at 0 degrees C resulted in the rapid association of the Src-family protein-tyrosine kinase, Lyn, with the antigen receptor complex as judged by the presence of Lyn in anti-IgM and anti-phosphotyrosine immune complexes and the presence of MB-1 in anti-Lyn immune complexes. Receptor engagement also resulted in the rapid association of Lyn with the phosphotyrosine phosphatase, CD45. This association of Lyn with receptor components was stable in the detergent Brij 96, but was readily disrupted by Nonidet P-40, suggesting the involvement of hydrophobic interactions in stabilizing formation of the Lyn-receptor complex. The protein-tyrosine kinase, Syk, was also found associated with activated receptor complexes. This association of Syk with components of the antigen receptor complex was stable to Nonidet P-40. Antibodies directed against the carboxyl teminus of Syk, but not against the amino-terminal SH2 domain, co-immunoprecipitated MB-1 from activated cells, consistent with the binding of Syk through an SH2 domain-phosphotyrosine interaction.	PURDUE UNIV, DEPT MED CHEM & PHARMACOGNOSY, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Geahlen, Robert/0000-0001-8400-2924	NATIONAL CANCER INSTITUTE [R01CA037372] Funding Source: NIH RePORTER; NCI NIH HHS [CA37372] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BRAUN J, 1982, J IMMUNOL, V128, P1198; BROWN VK, 1994, J BIOL CHEM, V269, P17238; BURG DL, 1993, J BIOL CHEM, V268, P2304; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LANE PJL, 1991, J IMMUNOL, V146, P715; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; LAW DA, 1992, MOL IMMUNOL, V29, P917, DOI 10.1016/0161-5890(92)90130-P; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; LIN JJ, 1992, J IMMUNOL, V149, P1548; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; ROIFMAN CM, 1993, BIOCHEM BIOPH RES CO, V194, P222, DOI 10.1006/bbrc.1993.1807; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	43	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28136	28142						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525568				2022-12-25	WOS:A1994PV77200056
J	CZUBAYKO, F; SMITH, RV; CHUNG, HC; WELLSTEIN, A				CZUBAYKO, F; SMITH, RV; CHUNG, HC; WELLSTEIN, A			TUMOR-GROWTH AND ANGIOGENESIS INDUCED BY A SECRETED BINDING-PROTEIN FOR FIBROBLAST GROWTH-FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBENDOTHELIAL EXTRACELLULAR-MATRIX; HEPARIN AFFINITY; BREAST-CANCER; BOVINE BRAIN; CELLS; PROLIFERATION; PURIFICATION; ANTIBODIES; EXPRESSION; CLONING	Basic fibroblast growth factor (bFGF) is a strong inducer of angiogenesis and thus may play an important role in the growth of solid tumors. However, bFGF is usually found immobilized on the extracellular matrix, and it is only partly understood how it is solubilized to reach and activate its extracellular receptors. We studied the potential contribution to this process by a secreted binding protein (BP) with high affinity for FGFs. An expression vector for BP was transfected into a human cell line (SW-13) that contains constitutively high levels of bFGF. The BP-expressing cells began to grow colonies in soft agar due to their autocrine stimulation by bFGF and released biologically active bFGF into their media. Furthermore, they grew into well vascularized tumors in athymic nude mice. In addition, we found the BP mRNA expressed at high levels in squamous cell carcinoma (SCC) tissues from patients and in SCC cell lines of different origin as well as in immortalized keratinocytes. However, we failed to detect EP mRNA in normal adult tissues or in a number of non-SCC tumor cell lines. Expression of the secreted EP appears to be a mechanism through which immobilized FGF can be activated to support tumor growth and angiogenesis.	GEORGETOWN UNIV,VT LOMBARDI CANC CTR,DEPT PHARMACOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,DEPT OTOLARYNGOL HEAD & NECK SURG,WASHINGTON,DC 20007	Georgetown University; Georgetown University				Wellstein, Anton/0000-0002-0570-4950	NATIONAL CANCER INSTITUTE [U01CA051908, P50CA058185] Funding Source: NIH RePORTER; NCI NIH HHS [CA51908, CA58185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAIRD A, 1990, HDB EXPT PHARM, V95, P369; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; HORAK ER, 1992, LANCET, V340, P1120, DOI 10.1016/0140-6736(92)93150-L; HUANG YQ, 1993, J CLIN INVEST, V91, P1191, DOI 10.1172/JCI116279; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; LOBB RR, 1984, BIOCHEMISTRY-US, V23, P6295, DOI 10.1021/bi00321a001; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MATSUZAKI K, 1989, P NATL ACAD SCI USA, V86, P9911, DOI 10.1073/pnas.86.24.9911; MERLO GR, 1990, CELL GROWTH DIFFER, V1, P463; MOSCATELLI D, 1986, J CELL PHYSIOL, V129, P273, DOI 10.1002/jcp.1041290220; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; PARUMS DV, 1990, J CLIN PATHOL, V43, P752, DOI 10.1136/jcp.43.9.752; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; RISAU W, 1986, P NATL ACAD SCI USA, V83, P3855, DOI 10.1073/pnas.83.11.3855; RISAU W, 1988, EMBO J, V7, P959, DOI 10.1002/j.1460-2075.1988.tb02901.x; ROBERTSON PL, 1985, DEV BRAIN RES, V23, P219, DOI 10.1016/0165-3806(85)90044-6; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTZHECTOR S, 1993, CANCER RES, V53, P1444; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VLODAVSKY I, 1991, ANN NY ACAD SCI, V638, P207; Vlodavsky I, 1988, Adv Exp Med Biol, V233, P201; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; WELLSTEIN A, 1991, JNCI-J NATL CANCER I, V83, P716, DOI 10.1093/jnci/83.10.716; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; WU DQ, 1991, J BIOL CHEM, V266, P16778	32	113	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28243	28248						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525570				2022-12-25	WOS:A1994PV77200071
J	QUON, MJ; BUTTE, AJ; ZARNOWSKI, MJ; SESTI, G; CUSHMAN, SW; TAYLOR, SI				QUON, MJ; BUTTE, AJ; ZARNOWSKI, MJ; SESTI, G; CUSHMAN, SW; TAYLOR, SI			INSULIN-RECEPTOR SUBSTRATE-1 MEDIATES THE STIMULATORY EFFECT OF INSULIN ON GLUT4 TRANSLOCATION IN TRANSFECTED RAT ADIPOSE-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT ACTIVITY; SIGNAL TRANSDUCTION; PLASMA-MEMBRANE; SH2 DOMAINS; IRS-1; SYSTEMS; GENE; SITE	Insulin signaling is initiated at least in part by activation of the insulin receptor tyrosine kinase and subsequent phosphorylation of cellular substrates such as insulin receptor substrate 1 (IRS-l). Previous studies have focused on the role of IRS-1 in the mitogenic actions of insulin. We have now investigated the possible role of IRS 1 in mediating the effect of insulin to stimulate glucose transport in a physiologically relevant insulin target tissue. In this study, we transfected rat adipose cells in primary culture with an antisense ribozyme directed against rat IRS-l. Expression of the ribozyme in these cells caused a 4.4-fold increase in the concentration of insulin required to achieve half-maximal stimulation of the translocation of cotransfected epitope-tagged GLUT4 without changing the maximal insulin response. Overexpression of human IRS-1 increased the basal cell surface GLUT4 to nearly the maximal level in the absence of insulin. When the ribozyme (specific to rat IRS-1) was cotransfected along with human IRS-1, the insulin dose-response curve was shifted to the left when compared with cells transfected with the ribozyme alone. These data provide strong support for the hypothesis that IRS-1 plays a role in insulin-stimulated glucose transport in insulin-responsive cells.	NIDDK, DIABET BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Sesti, Giorgio/B-1509-2012; Quon, Michael/B-1970-2008	QUON, MICHAEL/0000-0002-5289-3707; Quon, Michael/0000-0002-9601-9915; Sesti, Giorgio/0000-0002-1618-7688				ALMIND K, 1993, LANCET, V342, P828, DOI 10.1016/0140-6736(93)92694-O; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; CUSHMAN SW, 1978, J LIPID RES, V19, P269; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; IMAI Y, 1994, IN PRESS J CLIN ENDO; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; OKADA T, 1994, J BIOL CHEM, V269, P3568; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; QUON MJ, 1993, BIOCHEM BIOPH RES CO, V194, P338, DOI 10.1006/bbrc.1993.1825; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P5587, DOI 10.1073/pnas.91.12.5587; QUON MJ, 1994, AM J PHYSIOL, V266, pE144, DOI 10.1152/ajpendo.1994.266.1.E144; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SATOH S, 1993, J BIOL CHEM, V268, P17820; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAMEMOTO H, 1994, DIABETES, V43, pA144; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; ZAIA JA, 1992, ANN NY ACAD SCI, V660, P95, DOI 10.1111/j.1749-6632.1992.tb21062.x	28	123	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27920	27924						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525563				2022-12-25	WOS:A1994PV77200026
J	SILVA, CM; LU, HW; WEBER, MJ; THORNER, MO				SILVA, CM; LU, HW; WEBER, MJ; THORNER, MO			DIFFERENTIAL TYROSINE PHOSPHORYLATION OF JAK1, JAK2, AND STAT1 BY GROWTH-HORMONE AND INTERFERON-GAMMA IN IM-9 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; DNA-BINDING PROTEINS; ERYTHROPOIETIN RECEPTOR; EXTRACELLULAR DOMAIN; CYTOKINE RECEPTORS; ACTIVATION; KINASE; TRANSCRIPTION; ALPHA; GENE	Both the growth hormone (GH) and interferon gamma (IFN gamma) receptors are members of the cytokine receptor family that activate tyrosine phosphorylation despite the lack of a tyrosine kinase domain. Recently, the Janus kinase (JAK) family of tyrosine kinases have been shown to play an integral role in intracellular signaling by the cytokine receptors. We demonstrate that, in the human IM-9 lymphocyte, both JAK1 and JAK2 are tyrosine-phosphorylated in response to IFN gamma, whereas only JAK2 is tyrosine-phosphorylated in response to GH. Furthermore, dimerization of the GH receptor appears to be necessary for GH stimulated tyrosine phosphorylation of JAK2. We provide two lines of evidence that the JAK2 kinases can be regulated independently by GH and IFN gamma in IM-9 cells: 1) desensitization of JAK2 to GH stimulation does not affect the IFN gamma stimulated tyrosine phosphorylation of JAK2; and 2) JAK2 tyrosine phosphorylation by GH and IFN gamma is additive to that seen with either hormone alone. Furthermore, we demonstrate that although IFN gamma activates the tyrosine phosphorylation of the p91 signal transducer and activator of transcription (STAT1) in IM-9 cells, GH does not. GH does activate the tyrosine phosphorylation of a 93-kDa protein that appears to be distinct from STAT1.	UNIV VIRGINIA, HLTH SCI CTR, DEPT MED, DIV ENDOCRINOL & METAB, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NCI NIH HHS [CA39076] Funding Source: Medline; NIDDK NIH HHS [DK-32632, DK-08942] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA039076, R01CA039076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032632, F33DK008942] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; FELDMAN GM, 1994, J BIOL CHEM, V269, P10747; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; KITAMURA T, 1994, TRENDS ENDOCRIN MET, V5, P8, DOI 10.1016/1043-2760(94)90115-5; KOZMA LM, 1991, METHOD ENZYMOL, V201, P28; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUI H, 1994, J BIOL CHEM, V269, P5364; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVA CM, 1993, ENDOCRINOLOGY, V133, P2307, DOI 10.1210/en.133.5.2307; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	50	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27532	27539						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525556				2022-12-25	WOS:A1994PV77100059
J	LANIADOSCHWARTZMAN, M; LAVROVSKY, Y; STOLTZ, RA; CONNERS, MS; FALCK, JR; CHAUHAN, K; ABRAHAM, NG				LANIADOSCHWARTZMAN, M; LAVROVSKY, Y; STOLTZ, RA; CONNERS, MS; FALCK, JR; CHAUHAN, K; ABRAHAM, NG			ACTIVATION OF NUCLEAR FACTOR KAPPA-B AND ONCOGENE EXPRESSION BY 12(R)-HYDROXYEICOSATRIENOIC ACID, AN ANGIOGENIC FACTOR IN MICROVESSEL ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTACT-LENS WEAR; ARACHIDONIC-ACID; 12-HYDROXYEICOSATRIENOIC ACID; CORNEAL EPITHELIUM; PROTEIN SUBUNITS; GENE-EXPRESSION; METABOLISM; TISSUES; INITIATION; INDUCTION	12(R)-Hydroxy-5,8,14(Z,Z,Z)-eicosatrienoic acid (12(R)-HETrE) is an arachidonic acid metabolite formed by the corneal epithelium of several species, porcine leukocytes, and human and rat epidermal cells. It is a potent, stereospecific proinflammatory and angiogenic factor and its synthesis is increased manyfold in inflamed tissues, e.g. cornea and skin. It is possible that the angiogenic activity of 12(R)-HETrE is due to a direct mitogenic effect on microvessel endothelial cells via yet to be elucidated cellular and molecular mechanisms. In the present study, we demonstrated the ability of 12(R)-HETrE to stimulate the growth of quiescent endothelial cells in a time- and concentration-dependent manner with a maximal effect at 0.1 nM. This effect was highly stereospecific since its enantiomer, 12(S)-HETrE, had no effect within the same concentration range. Northern blot analysis and transient transfection experiments with chloramphenicol acetyltransferase constructs of oncogene promoter regions demonstrated significant increases over control (0.5% fetal calf serum) in c-myc, c-jun, and c-fos mRNA levels and expression in cells treated with 0.1 nM 12(R)-HETrE. Electrophoretic mobility shift assay of nuclear protein extracts from cells treated with 12(R)-HETrE with specific radiolabeled oligonucleotides corresponding to known transcriptional binding sites, including AP-1, AP-2, SP1, TRE, NF kappa B, TFIID, OKT1, CREB, CTF/NF1, and GRE demonstrated a markedly rapid and specific increase in the binding activity of NF kappa B and to a lesser extent, AP-1. No significant increase was observed in the binding of other transcription factors assayed as compared to control (untreated) cells. Since the protooncogenes (c-fos, c-jun, and c-myc) are immediate early response genes that are implicated in the process of cell proliferation and differentiation, and activation of certain transcription factors, in particular NF kappa B, is associated with the immediate response of the cell to an injury, we propose that 12(R)HETrE's mitogenic and angiogenic activities are mediated, in part, via the activation of NF kappa B and expression of these protooncogenes,	ROCKEFELLER UNIV HOSP, DEPT PHARMACOL, NEW YORK, NY 10021 USA; UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	Rockefeller University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	LANIADOSCHWARTZMAN, M (corresponding author), NEW YORK MED COLL, DEPT PHARMACOL, VALHALLA, NY 10595 USA.			Falck, John/0000-0002-9219-7845	NEI NIH HHS [EY05613] Funding Source: Medline; NIGMS NIH HHS [GM31278] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1991, MOL ASPECTS CELL REG, V6, P409; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINS T, 1993, LAB INVEST, V68, P499; CONNERS MS, 1993, INVEST OPHTH VIS SCI, V34, P1406; CONNERS MS, 1992, INVEST OPHTH VIS SCI, V33, P780; CONNERS MS, 1994, IN PRESS J INVEST DE; Cotran RS, 1989, ROBBINS PATHOLOGIC B; DAVIS KL, 1992, INVEST OPHTH VIS SCI, V33, P291; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Folkman J., 1992, INFLAMMATION BASIC P, P821; GERRITSEN ME, 1993, FASEB J, V7, P523, DOI 10.1096/fasebj.7.6.8472891; GERRITSEN ME, 1988, ADV CELL CULT, V6, P35; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAEBER JE, 1990, PROSTAGLANDINS, V39, P665, DOI 10.1016/0090-6980(90)90026-R; GRIFFIN M O, 1990, Investigative Ophthalmology and Visual Science, V31, P505; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HOLTZMAN MJ, 1989, J CLIN INVEST, V84, P1446, DOI 10.1172/JCI114319; HURST JS, 1991, J BIOL CHEM, V266, P6726; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; LAVROVSKY Y, 1994, GENE, V142, P285, DOI 10.1016/0378-1119(94)90276-3; LAVROVSKY YV, 1993, FEBS LETT, V316, P161, DOI 10.1016/0014-5793(93)81207-G; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIN MT, 1993, BIOCHEM BIOPH RES CO, V190, P1122, DOI 10.1006/bbrc.1993.1166; MASFERRER JL, 1991, EXP EYE RES, V52, P417, DOI 10.1016/0014-4835(91)90037-F; MASFERRER JL, 1989, INVEST OPHTH VIS SCI, V30, P454; MURPHY RC, 1988, J BIOL CHEM, V263, P17197; NISHIMURA M, 1991, ARCH BIOCHEM BIOPHYS, V290, P326, DOI 10.1016/0003-9861(91)90548-W; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; SCHWARTZMAN ML, 1987, P NATL ACAD SCI USA, V84, P8125, DOI 10.1073/pnas.84.22.8125; SCHWARTZMAN ML, 1990, METHOD ENZYMOL, V187, P372; SCHWARTZMAN ML, 1987, CURR EYE RES, V6, P623, DOI 10.3109/02713688709025223; SCHWARTZMAN ML, 1993, INVEST OPHTH VIS SCI, V34, P1405; SETTY BNY, 1987, J BIOL CHEM, V262, P17613; SHIN DS, 1989, TETRAHEDRON LETT, V30, P3923, DOI 10.1016/S0040-4039(00)99285-2; SINKOVICS JG, 1988, CRC CR REV IMMUNOL, V8, P217; TRAVALI S, 1990, FASEB J, V4, P3209, DOI 10.1096/fasebj.4.14.2227212; VANWAUWE J, 1991, EICOSANOIDS, V4, P155; WAINWRIGHT S, 1990, BIOCHEMISTRY-US, V29, P10126, DOI 10.1021/bi00495a017; WILLIAMS RN, 1985, EXP EYE RES, V41, P733, DOI 10.1016/0014-4835(85)90181-2; YAMAMOTO S, 1993, BIOCHIM BIOPHYS ACTA, V1210, P217	44	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24321	24327						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523372				2022-12-25	WOS:A1994PQ34600073
J	GRUBE, BJ; COCHRANE, CG				GRUBE, BJ; COCHRANE, CG			IDENTIFICATION OF A REGULATORY DOMAIN OF THE INTERLEUKIN-6 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; STIMULATORY FACTOR-II; HUMAN GROWTH-HORMONE; HUMAN IL-6 RECEPTOR; B-CELL HYBRIDOMA; HEPATOMA-CELLS; EXTRACELLULAR DOMAIN; SIGNAL TRANSDUCTION; CRYSTAL-STRUCTURE; HUMAN CD4	IL-6 signal transduction occurs when the liganded interleukin-6 receptor (IL-6R) interacts with glycoprotein (gp) 130. We hypothesized that synthetic peptides modeled from the extramembranous domain of the IL-6R may interfere with the IL-6-induced reaction between IL-6R and gp130 and may serve to elucidate the initial steps in IL-6 signal transduction. The capacity of such peptides to modulate two different IL-6 functions was evaluated: 1) IL-6-dependent B9 cell mitogenesis, and 2) IL-6-induced acute phase protein synthesis in HepG2 cells. A synthetic peptide, (249)Y16T(264), corresponding to residues 249-264, inhibited IL-6-dependent B9 proliferation and IL-6-induced acute phase protein up-regulation in HepG2 cells. Other peptides modeled from different regions of the IL-6R were not inhibitory. (249)Y16T(264) did not inhibit IL-6-independent HepG2 cell proliferation or total cellular protein synthesis. The inhibitory effect was reversible, indicating that the peptide was not cytotoxic. (249)Y16T(264) did not inhibit I-125-IL-6 binding in U266 cells. Delineation of this domain identified (249)Y10R(258) as the minimum effective sequence capable of inhibiting fibrinogen synthesis. Amino acid substitutions in (249)Y10R(258) obliterated the inhibitory effect on fibrinogen synthesis. In conclusion, a region of the extramembranous domain of the IL-6R has been identified that is involved in the regulation of IL-6 signal transmission. A synthetic peptide representing this region inhibits IL-6-dependent B9 cell mitogenesis and IL-6-stimulated acute phase response in HepG2 cells without affecting ligand binding.			GRUBE, BJ (corresponding author), SCRIPSS RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NIGMS NIH HHS [GM-37696] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BAUMANN H, 1988, J BIOL CHEM, V263, P17390; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; COULIE PG, 1987, EUR J IMMUNOL, V17, P1435, DOI 10.1002/eji.1830171008; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DALESSANDRO F, 1993, J BIOL CHEM, V268, P2149; DARLINGTON GJ, 1987, IN VITRO CELL DEV B, V23, P349; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUKOVICH M, 1987, NATURE, V327, P518, DOI 10.1038/327518a0; FIORILLO MT, 1992, EUR J IMMUNOL, V22, P799, DOI 10.1002/eji.1830220325; GRUBE BJ, 1994, J BIOL CHEM, V269, P8477; GRUBE BJ, 1993, J IMMUNOL, V150, pA217; GRUBE BJ, 1993, CIRC SHOCK S2, V39, P47; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANSDORP PM, 1986, CURR TOP MICROBIOL, V132, P105; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MACKIEWICZ A, 1992, FEBS LETT, V306, P257, DOI 10.1016/0014-5793(92)81012-B; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MYRSET AH, 1993, EUR J CELL BIOL, V60, P108; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NAKAJIMA T, 1992, JPN J CANCER RES, V83, P373, DOI 10.1111/j.1349-7006.1992.tb00117.x; PIETZKO D, 1993, J BIOL CHEM, V268, P4250; ROSEJOHN S, 1991, J BIOL CHEM, V266, P3841; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SABOURIN LA, 1990, J CELL PHYSIOL, V145, P564, DOI 10.1002/jcp.1041450325; SAVINO R, 1994, EMBO J, V13, P1357, DOI 10.1002/j.1460-2075.1994.tb06389.x; SAVINO R, 1993, P NATL ACAD SCI USA, V90, P4067, DOI 10.1073/pnas.90.9.4067; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; SCHREIBER G, 1982, J BIOL CHEM, V257, P271; STANLEY ER, 1981, J IMMUNOL METHODS, V42, P253, DOI 10.1016/0022-1759(81)90156-3; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1987, J EXP MED, V166, P967, DOI 10.1084/jem.166.4.967; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; VANDAM M, 1993, J BIOL CHEM, V268, P15285; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YASUKAWA K, 1990, J BIOCHEM-TOKYO, V108, P673, DOI 10.1093/oxfordjournals.jbchem.a123261; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x; ZOHLNHOFER D, 1992, FEBS LETT, V306, P219, DOI 10.1016/0014-5793(92)81004-6	49	12	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20791	20797						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519615				2022-12-25	WOS:A1994PB31700088
J	ZHAN, X; PLOURDE, C; KU, XG; FRIESEL, R; MACIAG, T				ZHAN, X; PLOURDE, C; KU, XG; FRIESEL, R; MACIAG, T			ASSOCIATION OF FIBROBLAST GROWTH-FACTOR RECEPTOR-1 WITH C-SRC CORRELATES WITH ASSOCIATION BETWEEN C-SRC AND CORTACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ROUS-SARCOMA VIRUS; TRANSFORMED CELLS; FACTOR-I; TYROSINE PHOSPHORYLATION; NUCLEAR TRANSLOCATION; PP60(SRC) SUBSTRATE; PP60SRC SUBSTRATE; HUMAN CARCINOMAS; FOCAL ADHESIONS; 3T3 CELLS	The initiation of maximal DNA synthesis by fibroblast growth factor (FGF)-1 requires the presence of the growth factor during the entire G(0) to G(1) transition period of the cell cycle (Zhan, X., Hu, X., Friesel, R., and Maciag, T. (1993) J. Biol. Chem. 268, 9611-9620). During this time, the phosphorylation of several novel proteins on tyrosine residues occurs, and one of these phosphotyrosyl-containing proteins has been characterized as the murine homolog of the chicken cortactin gene (Zhan, X., Hu, X., Hampton, B., Burgess, W. H., Friesel, R., and Maciag, T. (1993) J. Biol. Chem. 268, 24427-24431), a putative substrate for v-Src. We have examined the possibility that FGF-1 employs c-Src or Src-like kinases as signaling intermediates during the mid and late G(1) phase of the NIH 3T3 cell cycle using immunoprecipitation and immunoblot analysis. We have demonstrated that c-Src can associate with cortactin in a FGF-1-dependent manner. We have also demonstrated that a monoclonal antibody prepared against FGF receptor (R)-1 is able to co-precipitate Src-related proteins in lysates from FGF-1-treated NIH 3T3 cells. Furthermore, a kinase-active form of FGFR-1 expressed in a bacterial system was also able to associate with Src kinases in a manner dependent on the phosphorylation status of the FGFR-1 protein. Lastly, the Src homology (SH)-2 domain of v-Src was able to recognize a recombinant form of FGFR-1. Because (i) the association between FGFR-1 and Src-like kinases exhibits kinetics similar to those observed between the Src kinases and cortactin and (ii) the Src-SH2 domain is likely to be involved in the association with FGFR-1, we propose that the association of c-Src with activated FGF receptors may be responsible for the tyrosine phosphorylation of cortactin during the mid to late G(1) phase of the cell cycle.	AMER RED CROSS,HOLLAND LAB,DEPT MOLEC BIOL,ROCKVILLE,MD 20855; ST FRANCIS HOSP & MED CTR,HOFFMAN HEART INST,RES DEPT,HARTFORD,CT 06105; UNIV CONNECTICUT,SCH MED,DEPT MED,FARMINGTON,CT 06030	American Red Cross; Saint Francis Hospital & Medical Center; University of Connecticut					NHLBI NIH HHS [HL44336, HL32348] Funding Source: Medline; NICHD NIH HHS [HD29561] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029561] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL044336, R01HL032348] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; BROWN SAN, 1993, BIOCHEM BIOPH RES CO, V193, P1116, DOI 10.1006/bbrc.1993.1741; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DECLUE JE, 1987, MOL CELL BIOL, V7, P371, DOI 10.1128/MCB.7.1.371; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIEBL EC, 1992, ONCOGENE, V7, P2417; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1992, ONCOGENE, V7, P355; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHAN X, 1993, J BIOL CHEM, V268, P9611; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	30	159	159	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20221	20224						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519605				2022-12-25	WOS:A1994PB31700004
J	SEIFFERT, D; CRAIN, K; WAGNER, NV; LOSKUTOFF, DJ				SEIFFERT, D; CRAIN, K; WAGNER, NV; LOSKUTOFF, DJ			VITRONECTIN GENE-EXPRESSION IN-VIVO - EVIDENCE FOR EXTRAHEPATIC SYNTHESIS AND ACUTE-PHASE REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; POLYMERASE CHAIN-REACTION; S-PROTEIN VITRONECTIN; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-BETA; MESSENGER-RNA; ANTITHROMBIN-III; BINDING-PROTEIN; TYPE-1; SPECIFICITY	A competitive polymerase chain reaction (PCR) assay was developed to quantitate vitronectin (Vn) mRNA in murine tissues using a synthetic RNA as an external standard. Although the liver contained the highest concentration of Vn mRNA, significant levels were also detected in the brain (25-fold less) and in adipose tissue, heart, and skeletal muscle (100-fold less than liver). Lower concentrations also were detected in the lung, uterus, testis, and thymus, and little or no Vn mRNA could be detected in kidney, spleen, and blood. These results indicate that significant amounts of Vn mRNA are produced in extrahepatic organs. The regulation of Vn gene expression in vivo was studied in a murine model system in which acute systemic inflammation was induced by endotoxin administration. Plasma Vn levels increased 2- to 3-fold within 16 h after endotoxin administration and remained elevated for up to 72 h. This increase appeared to result from increased synthesis in the liver since the steady-state level of hepatic Vn mRNA increased 4-fold after endotoxin administration. Moreover, Vn mRNA levels in heart, lung, and brain were not significantly increased by endotoxin. These results suggest that Vn gene expression in vivo is regulated in a tissue-specific manner and identify Vn as a novel acute phase reactant.			SEIFFERT, D (corresponding author), SCRIPPS RES INST, DEPT VASC BIOL VB3, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NHLBI NIH HHS [HL48728, HL31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728, P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER S, 1993, INT CONGR SER, V1042, P83; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; Gauldie J, 1991, CYTOKINES INFLAMMATI, P275; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; HARLOW E, 1988, ANTIBODIES LABORATOR; ILL CR, 1985, J BIOL CHEM, V260, P5610; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; KOLI K, 1991, EUR J BIOCHEM, V199, P337, DOI 10.1111/j.1432-1033.1991.tb16129.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; MIMURO J, 1989, J BIOL CHEM, V264, P936; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; NASKI MC, 1993, J BIOL CHEM, V268, P12367; PODOR TJ, 1993, THROMB HAEMOSTASIS, V69, P1026; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SAWA H, 1993, CIRC RES, V73, P671, DOI 10.1161/01.RES.73.4.671; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SAWDEY MS, 1991, J CLIN INVEST, V88, P1346, DOI 10.1172/JCI115440; SEIFFERT D, 1990, J CELL BIOL, V111, P1283, DOI 10.1083/jcb.111.3.1283; SEIFFERT D, 1991, P NATL ACAD SCI USA, V88, P9402, DOI 10.1073/pnas.88.21.9402; SEIFFERT D, 1993, GENE, V134, P303, DOI 10.1016/0378-1119(93)90113-H; SEIFFERT D, 1993, INT CONGR SER, V1042, P75; SOLEM M, 1991, MOL CELL BIOCHEM, V100, P141; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; TOMASINI BR, 1990, PROGR HEMOSTASIS THR, P269; VANDENHEUVEL JP, 1993, BIOTECHNIQUES, V14, P395; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WIMAN B, 1988, THROMB HAEMOSTASIS, V59, P392	36	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19836	19842						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	7519600				2022-12-25	WOS:A1994PA12600030
J	PETRONILLI, V; COSTANTINI, P; SCORRANO, L; COLONNA, R; PASSAMONTI, S; BERNARDI, P				PETRONILLI, V; COSTANTINI, P; SCORRANO, L; COLONNA, R; PASSAMONTI, S; BERNARDI, P			THE VOLTAGE SENSOR OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE IS TUNED BY THE OXIDATION-REDUCTION STATE OF VICINAL THIOLS - INCREASE OF THE GATING POTENTIAL BY OXIDANTS AND ITS REVERSAL BY REDUCING AGENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CA-2+-INDUCED MEMBRANE TRANSITION; PARA-BENZOQUINONE IMINE; CYCLOSPORINE-A; HEART-MITOCHONDRIA; DIVALENT-CATIONS; CA-2+-DEPENDENT PORE; PROTECTS HEPATOCYTES; RECEPTOR-CHANNEL; INNER MEMBRANE	Reaction of isolated mitochondria with a variety of agents that lead to oxidation or cross-linking of sulfhydryl groups leads to an increased ''open'' probability of the permeability transition pore, a cyclosporin A-sensitive channel. We have investigated the mechanism by which the pore is induced by menadione, diamide, arsenite, and tert-butylhydroperoxide. We find that these inducers increase the probability of pore opening by shifting its gating potential to higher values. Furthermore, the induced shift was prevented by treatment with N-ethylmaleimide or dithiothreitol. At moderate levels of depolarization an apparent I-50 for N-ethylmaleimide of about 5 mu M can be defined, while the N-ethylmaleimide or dithiothreitol effects are overcome by maximal depolarization. We conclude that the oxidation-reduction state of vicinal thiols in cysteinyl residues plays a critical role in tuning the voltage sensor of the transition pore, with an increase of gating potential (i.e. an increase in the probability of pore opening despite a high transmembrane potential difference) as the couple is poised to a more oxidized state. These findings may have implications for the mechanism of cell damage under oxidative stress.	UNIV PADUA,SCH MED,CNR,STUDY PHYSIOL MITOCHONDRIA UNIT,I-35121 PADUA,ITALY; UNIV PADUA,SCH MED,DEPT BIOMED SCI,BIOPHYS & MEMBRANE BIOL LAB,I-35121 PADUA,ITALY; UNIV TRIESTE,DEPT BIOCHEM BIOPHYS & CHEM MACROMOLECULES,I-34127 TRIESTE,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; University of Trieste			Petronilli, Valeria/C-3558-2015; Scorrano, Luca/A-6652-2008; Sabina Passamonti, Medical degree/G-4299-2012; Bernardi, Paolo/C-3656-2008	Petronilli, Valeria/0000-0003-4026-6404; Scorrano, Luca/0000-0002-8515-8928; Sabina Passamonti, Medical degree/0000-0001-7876-4666; Bernardi, Paolo/0000-0001-9187-3736				AIZENMAN E, 1989, NEURON, V2, P1257, DOI 10.1016/0896-6273(89)90310-3; ALNASSER I, 1986, BIOCHEM J, V239, P19, DOI 10.1042/bj2390019; ASMUS KD, 1990, METHOD ENZYMOL, V186, P168; BEATRICE MC, 1984, J BIOL CHEM, V259, P1279; BELLOMO G, 1984, EUR J BIOCHEM, V140, P1, DOI 10.1111/j.1432-1033.1984.tb08058.x; BELLOMO G, 1982, J BIOL CHEM, V257, P1558; BELLOMO G, 1980, METHOD ENZYMOL, V186, P627; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BERNARDI P, 1984, EUR J BIOCHEM, V134, P377; BROEKEMEIER KM, 1992, FEBS LETT, V304, P192, DOI 10.1016/0014-5793(92)80616-O; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; CROMPTON M, 1987, BIOCHEM J, V245, P915, DOI 10.1042/bj2450915; CROMPTON M, 1988, BIOCHEM J, V255, P357; CROMPTON M, 1988, EUR J BIOCHEM, V178, P488; DALTON LA, 1993, BIOCHEM J, V269, P563; DIMONTE D, 1984, ARCH BIOCHEM BIOPHYS, V235, P343, DOI 10.1016/0003-9861(84)90207-8; FLIER EAM, 1984, BIOCHEMISTRY-US, V23, P5142; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; GRIFFITHS EJ, 1993, J MOL CELL CARDIOL, V25, P1461, DOI 10.1006/jmcc.1993.1162; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; IGBAVBOA U, 1988, J BIOL CHEM, V263, P1405; IGBAVBOA U, 1991, J BIOL CHEM, V266, P4283; IMBERTI R, 1993, J PHARMACOL EXP THER, V265, P392; JEWELL SA, 1982, SCIENCE, V217, P1257, DOI 10.1126/science.7112127; JIMENEZ JS, 1982, BIOCHEMISTRY-US, V21, P1623, DOI 10.1021/bi00536a024; KASS GEN, 1992, BIOCHEM PHARMACOL, V44, P1995, DOI 10.1016/0006-2952(92)90102-O; KINNALLY KW, 1989, J BIOENERG BIOMEMBR, V21, P497, DOI 10.1007/BF00762521; KOSOWER NS, 1969, BIOCHEM BIOPH RES CO, V37, P593, DOI 10.1016/0006-291X(69)90850-X; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LOTSCHER HR, 1979, P NATL ACAD SCI USA, V76, P4340, DOI 10.1073/pnas.76.9.4340; MOORE M, 1985, J BIOL CHEM, V260, P3035; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAZARETH W, 1991, J MOL CELL CARDIOL, V23, P1351, DOI 10.1016/0022-2828(91)90181-K; NICOLLI A, 1993, BIOCHEMISTRY-US, V32, P4461, DOI 10.1021/bi00067a039; NOVGORODOV SA, 1987, J BIOENERG BIOMEMBR, V19, P191, DOI 10.1007/BF00762412; PASSAMONTI S, 1989, BIOCHIM BIOPHYS ACTA, V979, P294, DOI 10.1016/0005-2736(89)90247-2; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PETRONILLI V, 1993, J BIOL CHEM, V268, P1011; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; ROBILLARD GT, 1982, EUR J BIOCHEM, V127, P597; SILIPRANDI D, 1978, Journal of Bioenergetics and Biomembranes, V10, P1, DOI 10.1007/BF00743223; SZABO I, 1992, J BIOL CHEM, V267, P2940; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; TANG LH, 1993, MOL PHARMACOL, V44, P473; THOR H, 1982, J BIOL CHEM, V257, P2419; WEIS M, 1992, J BIOL CHEM, V267, P804; ZAHLER WL, 1968, J BIOL CHEM, V243, P716; ZORATTI M, 1986, BIOCHEMISTRY-US, V25, P760, DOI 10.1021/bi00352a004	59	486	491	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16638	16642						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	7515881				2022-12-25	WOS:A1994NR29600021
J	HUSI, H; LUYTEN, MA; ZURINI, MGM				HUSI, H; LUYTEN, MA; ZURINI, MGM			MAPPING OF THE IMMUNOPHILIN-IMMUNOSUPPRESSANT SITE OF INTERACTION ON CALCINEURIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL-PROLYL ISOMERASE; CYCLOSPORINE-A; MOLECULAR-CLONING; HUMAN CYCLOPHILIN; PROTEIN; ACTIVATION; RAPAMYCIN; RECEPTOR; COMPLEX; IDENTIFICATION	The interaction of the immunosuppressive complexes cyclosporin A-cyclophilin A and FK506 binding protein-FK506 with the Ca2+- and calmodulin-dependent protein phosphatase calcineurin has been investigated by means of photoaffinity labeling and chemical cross-linking. Photolabeling of purified bovine brain calcineurin with the affinity label [O-[4-[4-(1-diazo-2,2,2-trifluoroethyl)benzoyl] aminobutanoyl]-D-serine(8)]cyclosporin in the presence of cyclophilin A results, in addition to the labeling of cyclophilin itself, in the transfer of some of the chemical probe to both the catalytic subunit A and the regulatory subunit B of calcineurin. Chemical cross-linking studies with disuccinimidyl suberate in the presence of either cyclophilin A, B, or C in complex with cyclosporin A or FK506 binding protein-FK506 result on the other hand in the apparently exclusive and strictly immunosuppressant-dependent formation of covalent immunophilin-calcineurin B subunit products. Cross-linking of immunophilins to calcineurin B subunit requires the presence of subunit A. In the present study, using a set of recombinant maltose-binding protein fusion products representing different stretches of the catalytic subunit A, we were able to map the minimal calcineurin A sequence necessary for immunophilin-ligand-calcineurin B interaction to occur.	SANDOZ PHARMA LTD,PRECLIN RES,MOLEC BIOL LAB,DRUG DESIGN GRP,CH-4002 BASEL,SWITZERLAND	Novartis; Sandoz	HUSI, H (corresponding author), SANDOZ PHARMA LTD,PRECLIN RES,BIOCHEM LAB,DRUG DESIGN GRP,CH-4002 BASEL,SWITZERLAND.							ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN DJ, 1984, ANN INTERN MED, V101, P667, DOI 10.7326/0003-4819-101-5-667; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FOXWELL BMJ, 1992, BIOCHIM BIOPHYS ACTA, V1138, P1115; FRANSSON C, 1992, FEBS LETT, V296, P90, DOI 10.1016/0014-5793(92)80410-I; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GUERINI D, 1992, J BIOL CHEM, V267, P22542; HADDY A, 1992, FEBS LETT, V314, P37, DOI 10.1016/0014-5793(92)81456-V; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; KAHAN BD, 1991, TRANSPLANTATION, V52, P185, DOI 10.1097/00007890-199108000-00001; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KIEFFER LJ, 1992, J BIOL CHEM, V267, P5503; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CY, 1982, ANAL BIOCHEM, V111, P385; LI W, 1993, J BIOL CHEM, V268, P14040; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PALLEN CJ, 1988, CALCIUM BINDING PROT, V1, P51; PFLUGL G, 1993, NATURE, V361, P91, DOI 10.1038/361091a0; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; SCHONBRUNNER ER, 1991, J BIOL CHEM, V266, P3630; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; THOMSON AW, 1989, IMMUNOL TODAY, V10, P6, DOI 10.1016/0167-5699(89)90057-1; UEKI K, 1993, J BIOL CHEM, V268, P6554; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; YANG D, 1993, J AM CHEM SOC, V115, P819, DOI 10.1021/ja00055a081	41	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14199	14204						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514602				2022-12-25	WOS:A1994NL60600072
J	KOVALA, T; LORIMER, IAJ; BRICKENDEN, AM; BALL, EH; SANWAL, BD				KOVALA, T; LORIMER, IAJ; BRICKENDEN, AM; BALL, EH; SANWAL, BD			PROTEIN-KINASE-A REGULATION OF CAMP-PHOSPHODIESTERASE EXPRESSION IN RAT SKELETAL MYOBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; DROSOPHILA DUNCE+ GENE; MOLECULAR-CLONING; ADENYLYL CYCLASE; HORMONAL-REGULATION; CELL; DIFFERENTIATION; MYOGENESIS; SUBUNIT; BETA	We have been studying cAMP signaling in L6 myoblasts because of its potential role in regulating the differentiation of these cells into multinucleate myotubes. Previous studies have shown that treatment of L6 myoblasts with cAMP analogs causes an increase in cAMP phosphodiesterase activity. To assess the role of protein kinase A in this cAMP-mediated increase in cAMP phosphodiesterase activity, L6 myoblasts were transfected with a plasmid containing the cDNA for a mutant regulatory subunit of protein kinase A, which functions as a dominant negative inhibitor of this enzyme. The cDNA was under control of the metallothionein promoter in the construct. Induction of the mutant regulatory subunit with Zn2+ decreased cAMP-dependent protein kinase activity by 90%. Zn2+ treatment was also able to completely block the cAMP-mediated increase in phosphodiesterase activity, showing that this effect is mediated by protein kinase A. The activity of the cAMP-induced phosphodiesterase was inhibited by low concentrations of RO 20-1724, showing that it was a member of the type IV low K-m cAMP phosphodiesterase family of enzymes. We used the polymerase chain reaction and consensus primers designed to amplify phosphodiesterase sequences to show that L6 myoblasts also contain mRNA for a type IV low K-m cAMP phosphodiesterase designated PDES3.1. The levels of this mRNA were increased greatly by treatment with dibutyryl cAMP or forskolin in L6 myoblasts and also in differentiated L6 myotubes. Run off transcription assays showed that this increase in PDE mRNA was regulated, at least in part, by an increase in the rate of transcription of the PDES gene. The induction of PDES message by cAMP was blocked when the L6 transfectants were treated with Zn2+ to induce protein kinase A inhibition. Therefore, some of the cAMP-mediated increase in phosphodiesterase activity seen in L6 myoblasts is due to a protein kinase A-mediated increase in PDE3 mRNA. This pathway may serve as a feedback mechanism to modulate the inhibitory effects of cAMP on myogenesis.			KOVALA, T (corresponding author), UNIV WESTERN ONTARIO, DEPT BIOCHEM, LONDON N6A 5C1, ON, CANADA.			Ball, Eric/0000-0003-2542-9156				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BALL EH, 1980, J BIOL CHEM, V255, P2962; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BENTLEY JK, 1992, J BIOL CHEM, V267, P18676; BOURNE HR, 1973, SCIENCE, V181, P952, DOI 10.1126/science.181.4103.952; CASPERSON GF, 1987, ANNU REV PHARMACOL, V27, P371; CATES GA, 1984, J BIOL CHEM, V259, P2646; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLLINS S, 1992, TRENDS BIOCHEM SCI, V17, P37, DOI 10.1016/0968-0004(92)90425-9; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; DAVIS RL, 1991, TRENDS GENET, V7, P224, DOI 10.1016/0168-9525(91)90369-2; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSS RE, 1990, J BIOL CHEM, V265, P8152; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HU JS, 1988, J BIOL CHEM, V263, P19670; JIN SLC, 1992, J BIOL CHEM, V267, P18929; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; LORIMER IAJ, 1987, J BIOL CHEM, V262, P17200; LORIMER IAJ, 1989, BIOCHEM J, V264, P305, DOI 10.1042/bj2640305; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; MEDFORD RM, 1983, J BIOL CHEM, V258, P1063; NARINDRASORASAK S, 1982, J BIOL CHEM, V257, P4618; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; REPASKE DR, 1992, J BIOL CHEM, V267, P18683; ROGERS JE, 1985, J BIOL CHEM, V260, P8002; Rosen K., 1990, FOCUS, V12, P23; SALMINEN A, 1991, J CELL BIOL, V115, P905, DOI 10.1083/jcb.115.4.905; SMITH CJ, 1991, J BIOL CHEM, V266, P13385; SWINNEN JV, 1991, J BIOL CHEM, V266, P18370; SWINNEN JV, 1991, J BIOL CHEM, V266, P14383; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; WAHRMANN JP, 1973, NATURE-NEW BIOL, V245, P112, DOI 10.1038/newbio245112a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WINTER B, 1993, J BIOL CHEM, V268, P9869; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; [No title captured]	48	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8680	8685						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510696				2022-12-25	WOS:A1994NB41100012
J	LACRAZ, S; DAYER, JM; NICOD, L; WELGUS, HG				LACRAZ, S; DAYER, JM; NICOD, L; WELGUS, HG			1,25-DIHYDROXYVITAMIN D-3 DISSOCIATES PRODUCTION OF INTERSTITIAL COLLAGENASE AND 92-KDA GELATINASE IN HUMAN MONONUCLEAR PHAGOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALVEOLAR MACROPHAGES; HUMAN SYNOVIAL-CELLS; HUMAN-MONOCYTES; IV COLLAGENASE; VITAMIN-D; METALLOPROTEINASE PRODUCTION; MYCOBACTERIUM-TUBERCULOSIS; STIMULATES COLLAGENASE; INTERFERON-GAMMA; GENE-EXPRESSION	To study the effect of mononuclear cell differentiation on metalloproteinase production, the human monocytic cell lines U937 and THP-1 were exposed to two well known differentiating agents, the phorbol esters (phorbol myristate acetate (PMA)) and 1,25-dihydroxyvitamin D-3 (1,25-(OH)(2)D-3). With U937 cells, PMA-induced differentiation increased the production of both interstitial collagenase and 92-kDa gelatinase, whereas exposure to 1,25-(OH)(2)D-3 induced full interstitial collagenase expression in the absence of any detectable 92-kDa gelatinase production, In fact, when U937 cells were differentiated with PMA and then exposed to vitamin D-3, the hormone actually suppressed phorbol-induced 92-kDa gelatinase biosynthesis. With THP-1 cells, PMA also induced the production of 92-kDa gelatinase fully, but unlike U937 cells, the combination of PMA and 1,25-(OH)(2)D-3 was required for substantial interstitial collagenase biosynthesis. As with U937 cells, the addition of 1,25-(OH)(2)D-3 to PMA differentiated THP-1 cells caused a dose-dependent inhibition of 92-kDa gelatinase production. Northern hybridizations demonstrated that both phorbol esters and vitamin D-3 act on monocytic cell lines at a pretranslational level. To determine whether metalloproteinase biosynthesis in normal differentiated mononuclear phagocytes was also modified by 1,25-(OH)(2)D-3, human blood monocytes and alveolar macrophages were exposed to this hormone. In both cell types, basal and Staphylococcal-stimulated 92-kDa gelatinase production was markedly inhibited by 1,25-(OH)(2)D-3. In contrast, interstitial collagenase production was completely unaffected by the hormone. In summary, the two major metalloproteinases produced by monocytic cells are regulated via distinct molecular pathways by the action of PMA and 1,25-(OH)(2)D-3. Furthermore, vitamin D-3 completely dissociates the production of 92-kDa gelatinase and interstitial collagenase in human mononuclear phagocytes.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,DIV DERMATOL,ST LOUIS,MO 63110; UNIV HOSP GENEVA,DEPT MED,DIV IMMUNOL & ALLERGY,GENEVA,SWITZERLAND; UNIV HOSP GENEVA,DEPT MED,DIV PULM,GENEVA,SWITZERLAND	Barnes-Jewish Hospital; Washington University (WUSTL); University of Geneva; University of Geneva			Nicod, Laurent/ABD-3360-2020	Nicod, Laurent P/0000-0002-0905-916X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087, R01AR035805] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29594] Funding Source: Medline; NIAMS NIH HHS [AR32087, AR35805] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE E, 1984, P NATL ACAD SCI-BIOL, V81, P7112, DOI 10.1073/pnas.81.22.7112; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BERGMANN U, 1989, J CLIN CHEM CLIN BIO, V27, P351; BHALLA AK, 1986, CELL IMMUNOL, V98, P311, DOI 10.1016/0008-8749(86)90291-1; BHALLA AK, 1991, IMMUNOLOGY, V72, P61; BLIFELD C, 1991, TRANSPLANTATION, V51, P498, DOI 10.1097/00007890-199102000-00043; CAMPBELL EJ, 1991, J IMMUNOL, V146, P1286; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN MS, 1986, J IMMUNOL, V136, P1049; CONCA W, 1991, J BIOL CHEM, V266, P1625; COOPER TW, 1983, COLLAGEN REL RES, V3, P205; CORCORAN ML, 1992, J BIOL CHEM, V267, P515; CURY JD, 1988, J IMMUNOL, V141, P4306; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; DENIS M, 1991, CLIN EXP IMMUNOL, V84, P200, DOI 10.1111/j.1365-2249.1991.tb08149.x; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GALVEDEROCHEMONTEIX B, 1990, AM J RESP CELL MOL, V3, P355, DOI 10.1165/ajrcmb/3.4.355; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; KELSEY SM, 1992, LEUKEMIA RES, V16, P427, DOI 10.1016/0145-2126(92)90167-6; LACRAZ S, 1992, J CLIN INVEST, V90, P382, DOI 10.1172/JCI115872; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MUNKER R, 1986, J CLIN INVEST, V78, P424, DOI 10.1172/JCI112593; PROVENDINI DM, 1984, SCIENCE, V221, P1181; RASTOGI N, 1990, ZBL BAKT-INT J MED M, V273, P344; ROUXLOMBARD P, 1986, CELL IMMUNOL, V97, P286, DOI 10.1016/0008-8749(86)90399-0; SATO H, 1993, ONCOGENE, V8, P395; SENIOR RM, 1982, J CLIN INVEST, V69, P384, DOI 10.1172/JCI110462; SHAPIRO SD, 1990, J CLIN INVEST, V86, P1204, DOI 10.1172/JCI114826; SHAPIRO SD, 1991, J IMMUNOL, V146, P2724; SHAPIRO SD, 1993, J BIOL CHEM, V268, P8170; SUDA T, 1992, J CELL BIOCHEM, V49, P53, DOI 10.1002/jcb.240490110; UCLA C, 1990, J CLIN INVEST, V85, P1181; VEY E, 1992, J IMMUNOL, V149, P2040; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WELGUS HG, 1986, J CLIN INVEST, V77, P1675, DOI 10.1172/JCI112485; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	42	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6485	6490						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509804				2022-12-25	WOS:A1994MZ50300036
J	TANG, CL; WILKENS, S; CAPALDI, RA				TANG, CL; WILKENS, S; CAPALDI, RA			STRUCTURE OF THE GAMMA-SUBUNIT OF ESCHERICHIA-COLI F1 ATPASE PROBED IN TRYPSIN DIGESTION AND BIOTIN-AVIDIN BINDING-STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; ADENOSINE-TRIPHOSPHATASE; EPSILON-SUBUNIT; F1 ATPASE; H+-ATPASE; SECONDARY-STRUCTURE; CROSS-LINKING; F1-ATPASE; SYNTHASE; PROTEINS	The arrangement and functional role of the gamma subunit of the Escherichia coli F(1)ATPase (ECF(1)) has been probed by protease digestion and avidin-biotin labeling experiments using wild-type enzyme and four mutants, gamma S8C, gamma T106C, gamma S179C, and gamma V286C, respectively. Trypsin was found to cleave the gamma subunit at four sites, Arg(70), Lys(199), Lys(201), and Lys(212). Cleavage at these four sites did not greatly reduce the high ATPase activity of the enzyme that is obtained when the epsilon subunit is removed by the protease treatment. However, prolonged trypsin cleavage led to loss of inhibition by epsilon subunit added back to the trypsin-treated enzyme. Endoproteinase-Lys-C cleaves the gamma subunit of ECF(1) at three of the four sites, i.e. Lys(199), Lys(201), and Lys(212), but not at Arg(70). The enzyme was activated by treatment with this protease because of degradation and release of the epsilon subunit, but added pure epsilon subunit still caused inhibition of ATPase activity. Therefore, cleavage at Arg(70) by trypsin is responsible for the loss of response to the epsilon subunit inhibition. Biotin was reacted with Cys residues at positions 8, 106, 179, and 286 in different gamma subunit mutants and the accessibility of the biotin to avidin monitored in the intact ECF(1) from the different mutants. Avidin was able to react with biotin when incorporated at position 106, not at 8, 179, or 286. The four trypsin cleavage sites, Arg(70), Lys(199), Lys(201), and Lys(212), as well as Thr(106) are in regions of the gamma subunit predicted to be mainly beta-sheet and beta-turn structures.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA	University of Oregon					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 24526] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1993, EMBO J, V12, P1775, DOI 10.1002/j.1460-2075.1993.tb05825.x; AGGELER R, 1993, J BIOL CHEM, V268, P14576; AGGELER R, 1990, BIOCHEMISTRY-US, V29, P10387, DOI 10.1021/bi00497a013; AGGELER R, 1993, J BIOL CHEM, V268, P20831; AGGELER R, 1992, J BIOL CHEM, V267, P21355; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; BRAGG PD, 1980, EUR J BIOCHEM, V106, P495, DOI 10.1111/j.1432-1033.1980.tb04596.x; BRAGG PD, 1987, BIOCHIM BIOPHYS ACTA, V894, P127, DOI 10.1016/0005-2728(87)90182-4; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; DUNN SD, 1982, J BIOL CHEM, V257, P7354; DUNN SD, 1986, ANAL BIOCHEM, V159, P35, DOI 10.1016/0003-2697(86)90304-0; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1977, BIOCHEM BIOPH RES CO, V79, P1231, DOI 10.1016/0006-291X(77)91138-X; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GAVILANESRUIZ M, 1988, BIOCHEMISTRY-US, V27, P603, DOI 10.1021/bi00402a016; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; GROMETELHANAN Z, 1992, BIOCHIM BIOPHYS ACTA, V1102, P379, DOI 10.1016/0167-4838(92)90525-I; HARATA M, 1990, BIOCHIM BIOPHYS ACTA, V1056, P279; ISHII N, 1993, J BIOCHEM-TOKYO, V113, P245, DOI 10.1093/oxfordjournals.jbchem.a124034; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; KAIBARA C, 1993, FEBS LETT, V321, P46, DOI 10.1016/0014-5793(93)80618-5; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MIWA K, 1989, P NATL ACAD SCI USA, V86, P6484, DOI 10.1073/pnas.86.17.6484; NAKAMOTO RK, 1993, J BIOL CHEM, V268, P867; NELSON N, 1972, J BIOL CHEM, V247, P7657; NOUMI T, 1987, FEBS LETT, V213, P381, DOI 10.1016/0014-5793(87)81526-0; OHTA S, 1990, BIOCHEM BIOPH RES CO, V171, P1258, DOI 10.1016/0006-291X(90)90821-4; PATEL AM, 1990, MOL MICROBIOL, V4, P1941, DOI 10.1111/j.1365-2958.1990.tb02043.x; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RICHTER ML, 1984, J BIOL CHEM, V259, P7371; SCHUMANN J, 1985, J BIOL CHEM, V260, P1817; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SHIN K, 1992, J BIOL CHEM, V267, P20835; SMITH JB, 1977, BIOCHEMISTRY-US, V16, P306, DOI 10.1021/bi00621a023; SOTEROPOULOS P, 1992, J BIOL CHEM, V267, P10348; TUTTASDORSCHUG R, 1989, BIOCHEMISTRY-US, V28, P5107, DOI 10.1021/bi00438a030; WILKENS S, 1992, ARCH BIOCHEM BIOPHYS, V299, P105, DOI 10.1016/0003-9861(92)90250-Z; WISE JG, 1981, J BIOL CHEM, V256, P383; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480	43	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4467	4472						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508444				2022-12-25	WOS:A1994MW98900087
J	WANG, MH; YOSHIMURA, T; SKEEL, A; LEONARD, EJ				WANG, MH; YOSHIMURA, T; SKEEL, A; LEONARD, EJ			PROTEOLYTIC CONVERSION OF SINGLE-CHAIN PRECURSOR MACROPHAGE-STIMULATING PROTEIN TO A BIOLOGICALLY-ACTIVE HETERODIMER BY CONTACT ENZYMES OF THE COAGULATION CASCADE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; AMINO-ACID-SEQUENCE; SCATTER FACTOR; HUMAN-PLASMA; ACTIVATION; PLASMINOGEN; PROTHROMBIN; UROKINASE; CLEAVAGE; HOMOLOGY	Human serum macrophage stimulating protein (MSP) is a disulfide-linked heterodimer that induces motile and phagocytic activity of mouse resident peritoneal macrophages. It is a member of the family of kringle proteins, which typically exist in extracellular fluid as single chain precursors that are activated by proteolytic cleavage. In this work, we expressed [S-35]cysteine-labeled recombinant pro-MSP in MSP cDNA-transfected Chinese hamster ovary cells and studied proteolytic processing of pro-MSP and the requirement of cleavage for biological activity. In media containing heat-inactivated fetal bovine serum, the protein was secreted as single chain pro-MSP, which was cleaved over a period of hours to the mature heterodimer. Cleavage was prevented by serine protease inhibitors such as leupeptin or aprotinin; it did not occur if cells were cultured in serum-free medium. Nanomolar concentrations of coagulation proteases kallikrein, factor XIIa or factor XIa cleaved pro-MSP to MSP within 30 min. Pro-MSP had no biological activity. After cleavage by kallikrein, biological activity was quantitatively comparable to that of natural MSP isolated from human plasma. These results support our hypothesis that MSP circulates as the biologically inactive precursor and can be activated by enzymes of the intrinsic coagulation cascade.			WANG, MH (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,IMMUNOPATHOL SECT,BLDG 506,RM 12-71,FREDERICK,MD 21702, USA.							COLVIN RB, 1973, J EXP MED, V138, P686, DOI 10.1084/jem.138.3.686; FRANCIS CW, 1990, HEMATOLOGY, P1313; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GREGORY SA, 1985, J CLIN INVEST, V76, P2440, DOI 10.1172/JCI112260; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; KAPLAN AP, 1987, BLOOD, V70, P1; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LEONARD EJ, 1978, EXP CELL RES, V114, P117, DOI 10.1016/0014-4827(78)90043-5; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIZUNO K, 1992, BIOCHEM BIOPH RES CO, V189, P1631, DOI 10.1016/0006-291X(92)90264-L; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; PARK CH, 1986, BIOCHEMISTRY-US, V25, P3977, DOI 10.1021/bi00362a001; SCOTT CF, 1986, J CLIN INVEST, V77, P631, DOI 10.1172/JCI112346; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SOTTRUPJENSEN L, 1975, P NATL ACAD SCI USA, V72, P2577, DOI 10.1073/pnas.72.7.2577; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; WANG MH, 1993, J LEUKOCYTE BIOL, V54, P289, DOI 10.1002/jlb.54.4.289; WUN TC, 1982, J BIOL CHEM, V257, P7262; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	22	83	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3436	3440						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508914				2022-12-25	WOS:A1994MV63100048
J	LI, WQ; MISCHAK, H; YU, JC; WANG, LM; MUSHINSKI, JF; HEIDARAN, MA; PIERCE, JH				LI, WQ; MISCHAK, H; YU, JC; WANG, LM; MUSHINSKI, JF; HEIDARAN, MA; PIERCE, JH			TYROSINE PHOSPHORYLATION OF PROTEIN-KINASE C-DELTA IN RESPONSE TO ITS ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSFORM FIBROBLASTS; SIGNAL TRANSDUCTION; MAP KINASES; RECEPTOR; CELLS; STIMULATION; PATHWAYS; ALPHA; CDNA; IL-3	Retroviral vectors containing five different protein kinase C (PKC) isoenzymes (alpha, delta, epsilon, eta, xeta) were expressed in 32D hematopoietic cells and NIH-3T3 fibroblasts. In an effort to investigate signaling events regulated by PKC activation, we analyzed whether tyrosine phosphorylation of cellular proteins would occur after 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment of the various transfectants. While no detectable tyrosine-specific phosphorylation was observed after treatment of the majority of the transfectants, pronounced TPA-dependent tyrosine phosphorylation of an 82-kDa protein was detected in the 32D/PKC-delta and NIH-3T3/PKC-delta lines. Interestingly, the 82-kDa substrate proved to be PKC-delta itself. Tyrosine phosphorylation of purified PKC-delta by src family or receptor tyrosine kinases in vitro enhanced PKC-delta activity, suggesting that tyrosine phosphorylation of PKC-delta may positively affect its function.	NCI,MOLEC GENET SECT,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; NCI,MOLEC GENET SECT,GENET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Mischak, Harald/E-8685-2011	Mischak, Harald/0000-0003-0323-0306				ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BEELER JF, 1994, IN PRESS MOL CELL BI; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; EINSPAHR KJ, 1990, J IMMUNOL, V145, P1490; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG K-P, 1990, Biofactors, V2, P171; JENSEN RA, 1992, BIOCHEMISTRY-US, V31, P10887, DOI 10.1021/bi00159a032; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; NEL AE, 1990, J IMMUNOL, V145, P971; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PIERCE JH, 1990, P NATL ACAD SCI USA, V87, P5613, DOI 10.1073/pnas.87.15.5613; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032	26	178	180	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2349	2352						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7507923				2022-12-25	WOS:A1994MV43200001
J	CHATTERJEE, S				CHATTERJEE, S			NEUTRAL SPHINGOMYELINASE ACTION STIMULATES SIGNAL-TRANSDUCTION OF TUMOR-NECROSIS-FACTOR-ALPHA IN THE SYNTHESIS OF CHOLESTERYL ESTERS IN HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED FIBROBLASTS; GENTAMICIN	We have investigated biochemical mechanisms of tumor necrosis factor (TNF)-alpha signaling in cultured human skin fibroblasts. We found that TNF-alpha signaling may involve activation of a cell membrane neutral sphingomyelinase (N-SMase) in that within 2.5-5 min of treatment of cells with TNF-alpha there was a 2-fold increase in the activity of N-SMase compared to control. This reaction led to the hydrolysis of sphingomyelin as evidenced by a decrease in sphingomyelin mass and in the radioactivity associated with [C-14]choline-labeled sphingomyelin. This was accompanied by a 4-fold increase in the formation of cholesteryl [C-14]oleate within 2.5 min of incubation with TNF-alpha. This reaction also stimulated the mobilization of cell surface-associated [H-3]cholesterol and its utilization in the synthesis of [H-3]cholesteryl esters via acyl coenzyme-A cholesterol acyltransferase (ACAT). Gas chromatographic analysis revealed that the cellular level of cholesteryl esters increased about 2.5-3-fold following treatment with TNF-alpha compared to control. Cholesteryl ester synthesis was compromised upon incubation of cells with antibody against N-SMase and remained unaltered with TNF-beta and fibroblast growth factor. Furthermore, TNF-alpha-mediated stimulation of cholesteryl ester synthesis was compromised by incubation of cells with an inhibitor of ACAT. These findings suggest a possible biological role of N-SMase in the signal transduction of TNF-alpha in the synthesis of cholesteryl esters in human fibroblasts.			CHATTERJEE, S (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21287, USA.				NIDDK NIH HHS [R01-DK-31722] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031722] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; CHATTERJEE S, 1993, J BIOL CHEM, V268, P3401; CHATTERJEE S, 1993, ADV LIPID RES, V26, P25; CHATTERJEE S, 1989, J BIOL CHEM, V264, P12554; CHATTERJEE S, 1988, J BIOCHEM TOXICOL, V3, P47, DOI 10.1002/jbt.2570030106; CHATTERJEE S, 1991, FASEB J, V5, P6364; CHATTERJEE S, 1987, BIOCH TOXICOL, V19, P181; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; GHOSH P, 1987, J BIOL CHEM, V262, P12550; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; IKEKAWA N, 1971, JPN J EXP MED, V41, P163; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACGEE J, 1973, J LAB CLIN MED, V82, P656; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; SHUTZE S, 1992, CELL, V71, P765; SLOTTE JP, 1990, BIOCHIM BIOPHYS ACTA, V1025, P152; SLOTTE JP, 1987, BIOCHIM BIOPHYS ACTA, V917, P231, DOI 10.1016/0005-2760(87)90127-5; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SPENCE MW, 1989, METABOLIC BASIS INHE, P1655; YOUNGKIM M, 1991, J BIOL CHEM, V266, P484	20	84	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					879	882						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507110				2022-12-25	WOS:A1994MR22000020
J	MUCA, C; VALLAR, L				MUCA, C; VALLAR, L			EXPRESSION OF MUTATIONALLY ACTIVATED G-ALPHA(S) STIMULATES GROWTH AND DIFFERENTIATION OF THYROID FRTL5 CELLS	ONCOGENE			English	Article							ADENYLATE-CYCLASE ACTIVITY; HUMAN PITUITARY-TUMORS; G-PROTEIN; THYROTROPIN RECEPTOR; IODIDE EFFLUX; GSP ONCOGENE; TSH RECEPTOR; CAMP; INHIBITION; ALPHA	The alpha subunit of the GTP-binding protein G(s) mediates hormonal stimulation of adenylyl cyclase. Human pituitary and thyroid tumours harbour mutations of G alpha(s) that constitutively activate the protein by inhibiting its intrinsic GTPase activity. We have investigated the mitogenic action of mutationally activated alpha(s) in thyroid FRTL5 cells, a cell line dependent upon thyroid-stimulating hormone (TSH) for both growth and differentiation. Introduction of alpha(s) carrying the substitution of glutamine-227 with leucine (Q227L alpha(s)) by retroviral infection of FRTL5 cells resulted in the expected stimulation of membrane adenylyl cyclase activity and in increased intracellular accumulation of cAMP. Measurements of cytosolic Ca2+ levels did not detect any concomitant effect on the polyphosphoinositide-Ca2+ signalling pathway. Expression of Q227L alpha(s) conferred to FRTL5 cells the ability to synthesize DNA in the absence of TSH, as revealed by [H-3]thymidine incorporation experiments, and to proliferate independently of the mitogenic hormone, although with a rate of growth slower than that observed with TSH stimulation. The effect of Q227L alpha(s) on cell proliferation was associated with the constitutive activation of iodide the constitutive uptake. The results indicate that expression of mutationally activated G alpha(s) is sufficient to bypass the requirement for TSH and promotes autonomous growth and activation of thyroid-specific differentiated functions in FRTL5 cells.	UNIV MILAN,DIBIT,SCI INST SAN RAFFAELE,I-20132 MILAN,ITALY; UNIV MILAN,CNR,CTR CYTOPHARMACOL,DEPT PHARMACOL,I-20132 MILAN,ITALY	University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); University of Milan								AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; BENDER JL, 1983, J BIOL CHEM, V258, P2432; BONE EA, 1986, ENDOCRINOLOGY, V119, P2193, DOI 10.1210/endo-119-5-2193; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; CLEMENTI E, 1990, ONCOGENE, V5, P1059; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CORDA D, 1985, J BIOL CHEM, V260, P9230; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; FAURE M, 1994, J BIOL CHEM, V269, P7851; FRODIN M, 1994, J BIOL CHEM, V269, P6207; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HEN R, 1989, P NATL ACAD SCI USA, V86, P4785, DOI 10.1073/pnas.86.12.4785; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MA YH, 1994, ENDOCRINOLOGY, V134, P42, DOI 10.1210/en.134.1.42; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MEINKOTH JL, 1992, J BIOL CHEM, V267, P13239; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; OKAJIMA F, 1988, ENDOCRINOLOGY, V123, P1035, DOI 10.1210/endo-123-2-1035; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; SPADA A, 1990, J CLIN ENDOCR METAB, V71, P1421, DOI 10.1210/jcem-71-6-1421; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; SUAREZ HG, 1991, ONCOGENE, V6, P677; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; VALENTE WA, 1983, ENDOCRINOLOGY, V112, P71, DOI 10.1210/endo-112-1-71; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0; VALLAR L, 1990, J BIOL CHEM, V265, P10320; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1099, DOI 10.1210/endo-114-4-1099; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390; YATANI A, 1988, J BIOL CHEM, V263, P9887; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K	43	44	44	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3647	3653						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7526317				2022-12-25	WOS:A1994PT39200028
J	STAPPENBECK, TS; LAMB, JA; CORCORAN, CM; GREEN, KJ				STAPPENBECK, TS; LAMB, JA; CORCORAN, CM; GREEN, KJ			PHOSPHORYLATION OF THE DESMOPLAKIN COOH TERMINUS NEGATIVELY REGULATES ITS INTERACTION WITH KERATIN INTERMEDIATE FILAMENT NETWORKS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CULTURED-CELLS; DESMOSOME; DOMAINS; PROTEIN; PLAQUE; FORM	Desmoplakins (DPs) are the most abundant proteins in the innermost portion of the desmosomal plaque and have been proposed to play a role in the attachment of intermediate filaments (IF) to cell-cell contact sites. Our previous results suggest that the globular end domains of DP perform dual functions: first, to target DP to the desmosome via the NH2 terminus and second, to attach IF to the desmosomal plaque via the COOH terminus. When ectopically expressed in most cultured cells, the COOH terminus plus the rod domain (DP.Delta N.SerC23) exhibits striking coalignment with keratin IF networks. However, in certain cell types (e.g. PtK2) or in cells treated with forskolin to activate protein kinase A, DP.Delta N.SerC23 exhibits a diffuse cytoplasmic distribution. A Variant molecule (DP.Delta N.GlyC23) in which a serine located 23 amino acids from the COOH terminus is altered to a glycine, thereby disrupting a protein kinase A consensus phosphorylation site, co-localizes with keratin IF networks regardless of cell type or forskolin treatment. Analysis of the phosphopeptide maps of these DP variants and endogenous DP is consistent with the phosphorylation of the serine 23 residues from the COOH terminus. These results suggest that phosphorylation of a specific residue in the DP COOH terminus may negatively regulate its interaction with keratin IF networks.	NORTHWESTERN UNIV, SCH MED, DEPT PATHOL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, DEPT DERMATOL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, ROBERT H LURIE CANC CTR, CHICAGO, IL 60611 USA	Northwestern University; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center								ALLEN TD, 1975, J ULTRA MOL STRUCT R, V51, P94, DOI 10.1016/S0022-5320(75)80011-6; BARIBAULT H, 1991, J CELL BIOL, V115, P1675, DOI 10.1083/jcb.115.6.1675; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Buxton R S, 1992, Semin Cell Biol, V3, P157; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; FRANKE WW, 1982, CELL, V30, P103, DOI 10.1016/0092-8674(82)90016-2; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; Green Kathleen J., 1994, P157; GREEN KJ, 1990, J BIOL CHEM, V265, P2603; GREEN KJ, 1990, CELLULAR MOL BIOL IN, P147; JONES JCR, 1985, J CELL BIOL, V101, P506, DOI 10.1083/jcb.101.2.506; Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955-0674(93)90030-T; LOWEY S, 1969, J MOL BIOL, V42, P1, DOI 10.1016/0022-2836(69)90483-5; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; OKEEFE EJ, 1989, J BIOL CHEM, V264, P8310; OUYANG P, 1992, J CELL BIOL, V118, P1477, DOI 10.1083/jcb.118.6.1477; PASDAR M, 1988, J CELL BIOL, V106, P677, DOI 10.1083/jcb.106.3.677; SKALLI O, 1994, J CELL BIOL, V125, P159, DOI 10.1083/jcb.125.1.159; SKERROW CJ, 1974, J CELL BIOL, V63, P515, DOI 10.1083/jcb.63.2.515; STANLEY JR, 1993, ADV IMMUNOL, V53, P291, DOI 10.1016/S0065-2776(08)60503-9; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; STAPPENBECK TS, 1993, J CELL BIOL, V123, P691, DOI 10.1083/jcb.123.3.691; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TROYANOVSKY SM, 1993, CELL, V72, P561, DOI 10.1016/0092-8674(93)90075-2; WICHE G, 1993, J CELL BIOL, V121, P607, DOI 10.1083/jcb.121.3.607	26	106	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29351	29354						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7525582				2022-12-25	WOS:A1994PU28400005
J	NISHIMURA, SL; SHEPPARD, D; PYTELA, R				NISHIMURA, SL; SHEPPARD, D; PYTELA, R			INTEGRIN ALPHA-V-BETA-8 - INTERACTION WITH VITRONECTIN AND FUNCTIONAL, DIVERGENCE OF THE BETA-8 CYTOPLASMIC DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MELANOMA CELLS; ALPHA-V; BIOLOGICAL PROPERTIES; FIBRONECTIN RECEPTOR; GLYCOPROTEIN-IIIA; SURFACE-ANTIGENS; ADHESION; SUBUNIT; BINDING; PROTEIN	The integrin beta 8 subunit was identified by cloning and sequencing of the cDNA and has been shown to associate with the alpha v subunit (Moyle, M., Napier, M. A., and McLean, J. W. (1991) J. Biol. Chem. 266, 19650-19658). We now present initial data on its functional properties. We produced a recombinant secreted form of alpha v beta 8 and used it to raise monoclonal antibodies that recognize the alpha v beta 8 complex or the beta 8 subunit alone on the surface of melanoma cells and on beta 8-transfected human embryonic kidney (293) cells. Affinity chromatography experiments showed that secreted alpha v beta 8 bound to vitronectin but not to fibronectin, collagen, or fibrinogen. Supporting evidence that intact full-length alpha v beta 8 could also bind to vitronectin-Sepharose was provided by performing affinity chromatography with the melanoma cell line MeWo, which normally expresses the intact beta 8 subunit. By studying the adhesive properties of melanoma cells and beta 8-transfected 293 cells, we found that alpha v beta 8 by itself does not promote cell adhesion on a vitronectin-coated substrate. To test the respective functional activities of the beta 8 extracellular and cytoplasmic domains, we analyzed chimeric beta 8/beta 3 subunit constructs. The beta 3 subunit was chosen because full-length beta 3, when transfected into 293 cells, strongly supports cell adhesion. We found that a chimeric integrin containing the beta 3 extracellular domain combined with the beta 8 transmembrane and cytoplasmic domains did not promote 293 cell adhesion. Conversely, a chimeric integrin construct combining the beta 8 extracellular domain with the beta 3 transmembrane and cytoplasmic domains did promote adhesion of transfected 293 cells. This suggests that the ps cytoplasmic domain does not interact with the cytoskeleton and with cytoplasmic signaling pathways in an adhesion-promoting fashion. We conclude that the beta 8 cytoplasmic domain, which is structurally unrelated to the conserved cytoplasmic domains of other beta subunits, is functionally distinct.	UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	NISHIMURA, SL (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MED, CTR LUNG BIOL, BOX 0854, SAN FRANCISCO, CA 94143 USA.				NCI NIH HHS [CA53259] Funding Source: Medline; NHLBI NIH HHS [HLA133259, HL191551] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JC, 1993, J CELL SCI, V104, P1061; ALBELDA SM, 1990, CANCER RES, V50, P6757; BODARY SC, 1989, J BIOL CHEM, V264, P18859; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BUSK M, 1992, J BIOL CHEM, V267, P5790; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; CHENG YF, 1991, EXP CELL RES, V194, P69, DOI 10.1016/0014-4827(91)90131-D; CHERESH DA, 1991, CANCER METAST REV, V10, P3, DOI 10.1007/BF00046839; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHUNTHARAPAI A, 1993, EXP CELL RES, V205, P345, DOI 10.1006/excr.1993.1096; CREASEY AA, 1979, IN VITRO CELL DEV B, V15, P342; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DEJANA E, 1989, J CELL BIOL, V109, P367, DOI 10.1083/jcb.109.1.367; DEJANA E, 1990, BLOOD, V75, P1509; DITTEL BN, 1993, BLOOD, V81, P2272; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FREED E, 1989, EMBO J, V8, P2955, DOI 10.1002/j.1460-2075.1989.tb08445.x; HARLOW E, 1988, ANTIBODIES LABORATOR, P311; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAWAGUCHI S, 1993, J BIOL CHEM, V268, P16279; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; KORHONEN M, 1992, KIDNEY INT, V41, P641, DOI 10.1038/ki.1992.98; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; MOYLE M, 1991, J BIOL CHEM, V266, P19650; NEWMAN PJ, 1985, BLOOD, V65, P227; NIP J, 1992, J CLIN INVEST, V90, P1406, DOI 10.1172/JCI116007; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PASQUALINI R, 1994, J CELL BIOL, V125, P447, DOI 10.1083/jcb.125.2.447; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SOLOWSKA J, 1991, J CELL BIOL, V114, P1079, DOI 10.1083/jcb.114.5.1079; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; SRIRAMARAO P, 1993, J CELL SCI, V105, P1001; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	48	117	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28708	28715						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7525578				2022-12-25	WOS:A1994PU16800032
J	BENZ, R; MAIER, E; LADANT, D; ULLMANN, A; SEBO, P				BENZ, R; MAIER, E; LADANT, D; ULLMANN, A; SEBO, P			ADENYLATE-CYCLASE TOXIN (CYAA) OF BORDETELLA-PERTUSSIS - EVIDENCE FOR THE FORMATION OF SMALL ION-PERMEABLE CHANNELS AND COMPARISON WITH HLYA OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; TARGET-CELL MEMBRANES; MATRIX PROTEIN PORIN; NUCLEOTIDE-SEQUENCE; HEMOLYSIN HLYA; ACTINOBACILLUS-PLEUROPNEUMONIAE; ERYTHROCYTE-MEMBRANES; CHROMOSOMAL HEMOLYSIN; ELECTRICAL-PROPERTIES; LIPID-MEMBRANES	The interaction between the adenylate cyclase toxin (CyaA) of Bordetella pertussis and lipid was studied using the lipid bilayer assay. The addition of CyaA to the aqueous phase bathing lipid bilayer membranes composed of different lipids resulted in the increase of the membrane conductance. This increase was rather small for membranes formed of pure lipids as compared with lipid mixtures such as asolectin. The toxin formed in asolectin membranes small transient ion-permeable channels with a single-channel conductance of 27 pS in 1 M KCl, which is considerably smaller than that of the alpha-hemeolysin (HlyA) of Escherichia coli (1500 pS). Experiments with different salts suggested that the CyaA-induced channels were exclusively cation-selective because of negative charges localized at the channel mouth. The single-channel conductance of channels initiated by CyaA was independent of whether the toxin was purified from B. pertussis or from recombinant E. coli. However, the channel-forming activity of the CyaA expressed in B. pertussis was substantially higher than that of the recombinant toxin. Experiments with mutant forms of CyaA suggested that both the activation of CyaA. by CyaC and the hemeolytic part of the toxin, but not the repeats and the cyclase activity are required for channel formation in lipid bilayer membranes.	INST PASTEUR, UNITE BIOCHIM REGULAT CELLULAIRES, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	BENZ, R (corresponding author), UNIV WURZBURG, BIOZENTRUM, THEODOR BOVERI INST, LEHRSTUHL BIOTECHNOL, HUBLAND, D-97074 WURZBURG, GERMANY.		SEBO, Peter/N-2043-2019; SEBO, Peter/F-7423-2011	SEBO, Peter/0000-0002-9755-7715; SEBO, Peter/0000-0002-9755-7715; LADANT, Daniel/0000-0003-1955-548X; Benz, Roland/0000-0002-9510-9265				BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BELLALOU J, 1990, INFECT IMMUN, V58, P1195, DOI 10.1128/IAI.58.5.1195-1200.1990; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1988, ANNU REV MICROBIOL, V42, P359, DOI 10.1146/annurev.mi.42.100188.002043; BENZ R, 1989, INFECT IMMUN, V57, P887, DOI 10.1128/IAI.57.3.887-895.1989; BENZ R, 1994, EUR J BIOCHEM, V220, P339, DOI 10.1111/j.1432-1033.1994.tb18630.x; Benz R., 1994, BACTERIAL CELL WALL, P397; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; BHAKDI S, 1989, J EXP MED, V169, P737, DOI 10.1084/jem.169.3.737; BHAKDI S, 1986, INFECT IMMUN, V52, P63, DOI 10.1128/IAI.52.1.63-69.1986; BOEHM DF, 1990, INFECT IMMUN, V58, P1959, DOI 10.1128/IAI.58.6.1959-1964.1990; BOEHM DF, 1990, INFECT IMMUN, V58, P1951, DOI 10.1128/IAI.58.6.1951-1958.1990; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; COOTE JG, 1992, FEMS MICROBIOL LETT, V88, P137, DOI 10.1016/0378-1097(92)90688-K; DEVENISH J, 1989, INFECT IMMUN, V57, P3210, DOI 10.1128/IAI.57.10.3210-3213.1989; EHRMANN IE, 1991, FEBS LETT, V278, P79, DOI 10.1016/0014-5793(91)80088-K; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; FREY J, 1991, INFECT IMMUN, V59, P3026, DOI 10.1128/IAI.59.9.3026-3032.1991; GENTILE F, 1990, J BIOL CHEM, V265, P10686; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GORDON VM, 1989, J BIOL CHEM, V264, P14792; HANSKI E, 1989, TRENDS BIOCHEM SCI, V14, P459, DOI 10.1016/0968-0004(89)90106-0; HANSKI E, 1985, J BIOL CHEM, V260, P5526; Hanski E, 1991, SOURCEBOOK BACTERIAL, P349; HESS J, 1986, FEMS MICROBIOL LETT, V34, P1, DOI 10.1016/0378-1097(86)90261-2; HEWLETT EL, 1991, J BIOL CHEM, V266, P17503; HEWLETT EL, 1989, J BIOL CHEM, V264, P19379; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; LADANT D, 1992, J BIOL CHEM, V267, P2244; LADANT D, 1989, J BIOL CHEM, V264, P4015; LALONDE G, 1989, J BIOL CHEM, V264, P13559; LO RYC, 1987, INFECT IMMUN, V55, P1987, DOI 10.1128/IAI.55.9.1987-1996.1987; LUDWIG A, 1988, MOL GEN GENET, V214, P553, DOI 10.1007/BF00330494; LUDWIG A, 1993, MOL GEN GENET, V241, P89, DOI 10.1007/BF00280205; LUDWIG A, 1987, MOL GEN GENET, V206, P238, DOI 10.1007/BF00333579; LUDWIG A, 1991, MOL GEN GENET, V226, P198, DOI 10.1007/BF00273604; LUDWIG A, 1992, BACTERIAL PROTEIN TO, P450; MASURE HR, 1989, BIOCHEMISTRY-US, V28, P438, DOI 10.1021/bi00428a005; MENESTRINA G, 1987, BIOCHIM BIOPHYS ACTA, V905, P109, DOI 10.1016/0005-2736(87)90014-9; NELSON AP, 1975, J THEOR BIOL, V55, P13, DOI 10.1016/S0022-5193(75)80106-8; OROPEZAWEKERLE RL, 1992, MOL MICROBIOL, V6, P115, DOI 10.1111/j.1365-2958.1992.tb00843.x; PEARSON RD, 1987, J IMMUNOL, V139, P2749; ROGEL A, 1989, EMBO J, V8, P2755, DOI 10.1002/j.1460-2075.1989.tb08417.x; ROGEL A, 1992, J BIOL CHEM, V267, P22599; ROPELE M, 1989, BIOCHIM BIOPHYS ACTA, V985, P9, DOI 10.1016/0005-2736(89)90096-5; SAKAMOTO H, 1992, J BIOL CHEM, V267, P13598; Sambrook J, 1989, MOL CLONING LABORATO; SEBO P, 1993, MOL MICROBIOL, V9, P999, DOI 10.1111/j.1365-2958.1993.tb01229.x; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; WOLFF J, 1980, P NATL ACAD SCI-BIOL, V77, P3841, DOI 10.1073/pnas.77.7.3841	54	130	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27231	27239						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525549				2022-12-25	WOS:A1994PV77100015
J	SHARIF, KA; FUJITA, N; JIN, RH; IGARASHI, K; ISHIHAMA, A; KRAKOW, JS				SHARIF, KA; FUJITA, N; JIN, RH; IGARASHI, K; ISHIHAMA, A; KRAKOW, JS			EPITOPE MAPPING AND FUNCTIONAL-CHARACTERIZATION OF MONOCLONAL-ANTIBODIES SPECIFIC FOR THE ALPHA-SUBUNIT OF ESCHERICHIA-COLI RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTATIONS; TRANSCRIPTION ACTIVATION; RPOA MUTATION; GENE; EXPRESSION; BIOSYNTHESIS; PROTEINS; IMPAIRS; ENVZ; OMPR	The epitopes have been localized for a set of monoclonal antibodies specific for the alpha subunit of the Escherichia coli RNA polymerase. The antibodies are classified into three groups based on their epitopic assignments. Group 1, mAb 123C2, maps in the N terminus of cu between amino acids 1 and 23; Group 2 antibodies (mAb 129C4, mAb 124D1 and mAb 121C5) map in the central region between amino acids 190 and 210; Group 3 antibodies (mAb 130B1 and mAb 125C6) map in the C terminus between amino acids 310 and 320, mAb 130C2 is anomalous since it maps to the N terminus between amino acids 1 and 23 as well as to the C terminus between amino acids 320 and 329. The antibodies were used to investigate the role of cu in transcription activation with cAMP receptor protein dependent promoters. Three antibodies (130C2, 121C5, and 125C6) inhibited cAMP receptor protein-dependent initiation with lac P+ but not with lac UV5 or gal P+. Inhibition was observed with free RNA polymerase and the closed promoter complex; the preformed open promoter complex was insensitive. Only lac P+ was sensitive to these anti-alpha antibodies supporting the concept that the mode of interaction of RNA polymerase with cAMP receptor protein differs between lac P+ and gal PC.	CUNY HUNTER COLL, DEPT BIOL SCI, NEW YORK, NY 10021 USA; NATL INST GENET, DEPT MOLEC GENET, MISHIMA, SHIZUOKA 411, JAPAN	City University of New York (CUNY) System; Hunter College (CUNY); Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan				Igarashi, Kazuhiko/0000-0002-2470-2475	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022619] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22619] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Battey, 1986, BASIC METHODS MOL BI; BENJAMIN DC, 1992, BIOCHEMISTRY-US, V31, P9539, DOI 10.1021/bi00155a005; DALE EC, 1986, J MOL BIOL, V192, P793, DOI 10.1016/0022-2836(86)90029-X; DALLAVENEZIA N, 1990, J BIOL CHEM, V265, P8122; FUJITA N, 1987, J BIOL CHEM, V262, P1855; GARRETT S, 1987, J BACTERIOL, V169, P1379, DOI 10.1128/jb.169.4.1379-1385.1987; GIFFARD PM, 1988, MOL GEN GENET, V214, P148, DOI 10.1007/BF00340193; HAYWARD RS, 1991, J MOL BIOL, V221, P23, DOI 10.1016/0022-2836(91)80197-3; IGARASHI K, 1990, NUCLEIC ACIDS RES, V18, P5945, DOI 10.1093/nar/18.20.5945; IGARASHI K, 1991, P NATL ACAD SCI USA, V88, P8958, DOI 10.1073/pnas.88.20.8958; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; ISHIHAMA A, 1987, PROTEINS, V2, P42, DOI 10.1002/prot.340020106; ISHIHAMA A, 1980, J MOL BIOL, V137, P137, DOI 10.1016/0022-2836(80)90321-6; IWAKURA Y, 1974, MOL GEN GENET, V133, P1, DOI 10.1007/BF00268673; KAWAKAMI K, 1980, BIOCHEMISTRY-US, V19, P3491, DOI 10.1021/bi00556a013; KUMAR A, 1994, J MOL BIOL, V235, P405, DOI 10.1006/jmbi.1994.1001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; LOMBARDO MJ, 1991, J BACTERIOL, V173, P7511, DOI 10.1128/jb.173.23.7511-7518.1991; LUO JY, 1992, J BIOL CHEM, V267, P18175; MATSUYAMA S, 1987, J MOL BIOL, V195, P847, DOI 10.1016/0022-2836(87)90489-X; NIELSEN DA, 1986, NUCLEIC ACIDS RES, V14, P5936, DOI 10.1093/nar/14.14.5936; RIFTINA F, 1989, BIOCHEMISTRY-US, V28, P3299, DOI 10.1021/bi00434a027; ROCKWELL P, 1985, BIOCHEMISTRY-US, V24, P3240, DOI 10.1021/bi00334a025; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SLAUCH JM, 1991, J BACTERIOL, V173, P7501, DOI 10.1128/jb.173.23.7501-7510.1991; SUNSHINE MG, 1975, P NATL ACAD SCI USA, V72, P2770, DOI 10.1073/pnas.72.7.2770; THOMAS MS, 1991, MOL MICROBIOL, V5, P2719, DOI 10.1111/j.1365-2958.1991.tb01980.x; YAN C, 1994, SCIENCE, V265, P90; ZOU C, 1992, MOL MICROBIOL, V6, P2599, DOI 10.1111/j.1365-2958.1992.tb01437.x	32	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23655	23660						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7522231				2022-12-25	WOS:A1994PQ34500042
J	CHEN, RH; DERYNCK, R				CHEN, RH; DERYNCK, R			HOMOMERIC INTERACTIONS BETWEEN TYPE-II TRANSFORMING GROWTH-FACTOR-BETA RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; TGF-BETA; SIGNAL TRANSDUCTION; ACTIVIN RECEPTOR; XENOPUS EMBRYOS; EXPRESSION CLONING; EGF RECEPTOR; BINDING; LIGAND; CELLS	Transforming growth factor-beta (TGF-beta) binds with high affinity to three cell-surface receptors. Both type I and II receptors are transmembrane serine/threonine kinases and thought to mediate TGF-beta responses by forming a heteromeric complex in the presence of TGF-beta. We investigated whether the type II receptors form a homomeric complex in the presence or absence of ligand. Double immunoprecipitation analyses were performed using lysates from metabolically labeled cells cotransfected with differentially epitope-tagged type II receptors. We demonstrate that the type II receptors can form a homomeric complex even in the absence of their ligand, TGF-beta. This pre-existing type II receptor complex has the ability to bind TGF-beta. Moreover, in addition to the extracellular and transmembrane domains, the cytoplasmic portions of the receptors are also able to interact with each other, indicating that multiple contact points are involved in the formation of the homemeric type II receptor complex. Our results suggest a novel mechanism of complex formation and receptor activation of the serine/threonine kinase receptor family	UNIV CALIF SAN FRANCISCO, DEPT GROWTH & DEV, CELL BIOL PROGRAMME, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, CELL BIOL PROGRAMME, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, PROGRAM DEV BIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Chen, Ruey-Hwa/G-6121-2019	Chen, Ruey-Hwa/0000-0001-8124-5832				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BRAND T, 1993, J BIOL CHEM, V268, P11500; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GARBERS DL, 1994, MOL BIOL CELL, V5, P1; GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HERREN B, 1993, J BIOL CHEM, V268, P15088; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LAX I, 1991, J BIOL CHEM, V266, P13828; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZ AR, 1992, MOL CELL BIOL, V12, P1674, DOI 10.1128/MCB.12.4.1674; LUCAS C, 1991, METHOD ENZYMOL, V198, P303; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MATHEWS LS, 1993, J BIOL CHEM, V268, P19013; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE MF, 1994, J BIOL CHEM, V269, P1; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	41	124	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22868	22874						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7521335				2022-12-25	WOS:A1994PQ16300062
J	CASATORRES, J; NAVARRO, JM; BLESSING, M; JORCANO, JL				CASATORRES, J; NAVARRO, JM; BLESSING, M; JORCANO, JL			ANALYSIS OF THE CONTROL OF EXPRESSION AND TISSUE-SPECIFICITY OF THE KERATIN-5 GENE, CHARACTERISTIC OF BASAL KERATINOCYTES - FUNDAMENTAL ROLE OF AN AP-1 ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS TYPE-18; EPIDERMOLYSIS-BULLOSA SIMPLEX; TRANSCRIPTION FACTOR AP-1; MOUSE EPIDERMAL-CELLS; C-JUN; RETINOIC ACID; INTERMEDIATE FILAMENTS; NEGATIVE REGULATOR; CYTOKERATIN GENES; ENHANCER ELEMENTS	The keratin 5 gene presents a complex regulation, since it is expressed at different rates in the basal cells of most, if not all, stratified epithelia. We have analyzed the 5'-upstream region of the bovine keratin 5 (BK5) gene and found that the 5.2 kilobases preceding the gene mimic in vitro the cell type-specific expression of BK5. Most of the transcriptional activity maps to an enhancer located between positions -762 and -1009. The only regulatory element found in this enhancer by electrophoretic mobility shift, competition, and footprinting experiments is a consensus AP-1 site. Mutation of this site abolishes the activity of tire enhancer and reduces to 25% the activity of the 5.2-kilobase upstream promoter region. Surprisingly, although the AP-1 presents indistinguishable footprints in all cell types tested, the enhancer is active only in some of them. Even an oligonucleotide containing the AP-1 region protected from DNase I is active in epithelial cell lines but not in NIH 3T3 fibroblasts, suggesting that this region could constitute an epithelium-specific AP-1 element. We also show that BK5 does not respond to phorbol ester induction, which suggests that the regulation of this gene by AP-1 must be complex and probably different from several other suprabasal, AP-1-regulated cellular and viral genes.	CIEMAT, DEPT CELL & MOLEC BIOL, E-28040 MADRID, SPAIN; VANDERBILT UNIV, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Vanderbilt University				Navarro, Manuel/0000-0003-1118-8531				ALBERS K, 1992, INT REV CYTOL, V134, P243, DOI 10.1016/S0074-7696(08)62030-6; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; Bernerd Francoise, 1993, Gene Expression, V3, P187; BLESSING M, 1989, EMBO J, V8, P117, DOI 10.1002/j.1460-2075.1989.tb03355.x; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHAN YM, 1993, P NATL ACAD SCI USA, V90, P7414, DOI 10.1073/pnas.90.15.7414; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG T, 1991, J VIROL, V65, P5933, DOI 10.1128/JVI.65.11.5933-5943.1991; CHUVPILO SA, 1985, FEBS LETT, V179, P34, DOI 10.1016/0014-5793(85)80185-X; COOPER D, 1985, LAB INVEST, V52, P243; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; CRIPE T P, 1990, New Biologist, V2, P450; FISHER C, 1991, DEVELOPMENT, V111, P253; FUCHS E, 1988, TRENDS GENET, V4, P277, DOI 10.1016/0168-9525(88)90169-2; FUCHS EV, 1981, CELL, V27, P75, DOI 10.1016/0092-8674(81)90362-7; GARCIACARRANCA A, 1988, J VIROL, V62, P4321, DOI 10.1128/JVI.62.11.4321-4330.1988; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HATZFELD M, 1991, J CELL SCI, V99, P351; HEID HW, 1986, DIFFERENTIATION, V32, P101, DOI 10.1111/j.1432-0436.1986.tb00562.x; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUFF CA, 1993, J BIOL CHEM, V268, P377; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JORCANO JL, 1984, DIFFERENTIATION, V28, P155, DOI 10.1111/j.1432-0436.1984.tb00278.x; KLEINSZANTO AJP, 1984, MECHANISMS TUMOR PRO, V2, P41; KULESZMARTIN M, 1983, CARCINOGENESIS, V4, P1367, DOI 10.1093/carcin/4.11.1367; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEE WY, 1993, MOL CARCINOGEN, V7, P26, DOI 10.1002/mc.2940070106; LERSCH R, 1989, MOL CELL BIOL, V9, P3685, DOI 10.1128/MCB.9.9.3685; LICHTI U, 1988, CANCER RES, V48, P74; LIEW FM, 1992, EXP CELL RES, V202, P310, DOI 10.1016/0014-4827(92)90080-R; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LYNCH MH, 1986, J CELL BIOL, V103, P2593, DOI 10.1083/jcb.103.6.2593; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MIKSICEK R, 1986, CELL, V46, P283, DOI 10.1016/0092-8674(86)90745-2; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLLOY CJ, 1987, CANCER RES, V47, P4674; NELSON WG, 1983, J CELL BIOL, V97, P244, DOI 10.1083/jcb.97.1.244; OFFORD EA, 1990, J VIROL, V64, P4792, DOI 10.1128/JVI.64.10.4792-4798.1990; OHTSUKI M, 1992, J INVEST DERMATOL, V99, P206, DOI 10.1111/1523-1747.ep12650436; Ohtsuki Mamitaro, 1993, Gene Expression, V3, P201; QUINLAN RA, 1984, J MOL BIOL, V178, P365, DOI 10.1016/0022-2836(84)90149-9; QUINTANILLA M, 1991, CARCINOGENESIS, V12, P1875, DOI 10.1093/carcin/12.10.1875; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; RYSECK RP, 1991, ONCOGENE, V6, P533; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID E, 1983, J CELL BIOL, V96, P37, DOI 10.1083/jcb.96.1.37; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SCHWEIZER J, 1987, J INVEST DERMATOL, V89, P125, DOI 10.1111/1523-1747.ep12470544; Schweizer Juergen, 1993, P33; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SLAGA T J, 1989, P1; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Sun TT, 1984, CANCER CELLS, V1, P169; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; TOFTGARD R, 1985, CANCER RES, V45, P5845; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	79	87	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20489	20496						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519609				2022-12-25	WOS:A1994PB31700045
J	FEARON, K; MCCLENDON, V; BONETTI, B; BEDWELL, DM				FEARON, K; MCCLENDON, V; BONETTI, B; BEDWELL, DM			PREMATURE TRANSLATION TERMINATION MUTATIONS ARE EFFICIENTLY SUPPRESSED IN A HIGHLY CONSERVED REGION OF YEAST STE6P, A MEMBER OF THE ATP-BINDING CASSETTE (ABC) TRANSPORTER FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; CYSTIC-FIBROSIS GENE; GLUTAMINE TRANSFER-RNA; PROTEIN-SYNTHESIS; MESSENGER-RNA; IMPORT SIGNAL; READ-THROUGH; STOP CODON; IDENTIFICATION; SEQUENCE	The requirements for efficient translation termination are incompletely understood. Since the local context surrounding stop codons can influence the efficiency of translation termination, premature termination codons introduced by random mutation may not always terminate at the optimal efficiencies expected of naturally occurring stop codons. To investigate whether this could result in physiologically significant levels of read through, we examined the suppression of premature translation termination mutations within a sequence motif of the yeast Ste6 protein (Ste6p) that is highly conserved among members of the ATP-binding cassette (ABC) transporter family. The human cystic fibrosis transmembrane conductance regulator (CFTR), which is defective in individuals with the disease cystic fibrosis, is also a member of this protein family. The mutations examined in Ste6p were chosen because a premature termination codon at the corresponding residue of CFTR has previously been reported to cause less severe pulmonary involvement than some missense mutations, suggesting that low level suppression of this stop codon could be occurring. Our results indicate that these premature stop codons in Ste6p can be suppressed at frequencies as high as 10%. Characterization of this phenomenon using a beta-galactosidase read through assay system showed that a limited sequence context surrounding this site contained information that was sufficient to cause suppression of translation termination. Amino acid sequence analysis of the full length translation products produced by read through of an amber codon demonstrated that termination suppression was mediated by near-cognate tRNA mispairing that resulted in the insertion of tyrosine, lysine, or tryptophan.	UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham				Bedwell, David/0000-0002-6605-818X; BONETTI, Bruno/0000-0002-3944-4165	NIAID NIH HHS [P30 AI27767] Funding Source: Medline; NIDDK NIH HHS [DK38518] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038518] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; BEDWELL DM, 1989, MOL CELL BIOL, V9, P1014, DOI 10.1128/MCB.9.3.1014; BEIER H, 1984, EMBO J, V3, P351, DOI 10.1002/j.1460-2075.1984.tb01810.x; BELCOURT MF, 1990, CELL, V62, P339, DOI 10.1016/0092-8674(90)90371-K; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; BROWN CM, 1990, NUCLEIC ACIDS RES, V18, P6339, DOI 10.1093/nar/18.21.6339; CHAMORRO M, 1992, P NATL ACAD SCI USA, V89, P713, DOI 10.1073/pnas.89.2.713; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; CUTTING GR, 1990, NEW ENGL J MED, V323, P1685, DOI 10.1056/NEJM199012133232407; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; FARABAUGH PJ, 1993, CELL, V74, P93, DOI 10.1016/0092-8674(93)90297-4; FENG YX, 1989, J VIROL, V63, P2870, DOI 10.1128/JVI.63.6.2870-2873.1989; FENG YX, 1992, J VIROL, V66, P5127, DOI 10.1128/JVI.66.8.5127-5132.1992; FENG YX, 1990, P NATL ACAD SCI USA, V87, P8860, DOI 10.1073/pnas.87.22.8860; GESTELAND RF, 1992, SCIENCE, V257, P1640, DOI 10.1126/science.1529352; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KUCHINO Y, 1987, P NATL ACAD SCI USA, V84, P2668, DOI 10.1073/pnas.84.9.2668; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN JP, 1986, GENE, V49, P383, DOI 10.1016/0378-1119(86)90375-6; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SKUZESKI JM, 1991, J MOL BIOL, V218, P365, DOI 10.1016/0022-2836(91)90718-L; SMITH D, 1989, P NATL ACAD SCI USA, V86, P4397, DOI 10.1073/pnas.86.12.4397; TATE WP, 1992, BIOCHEMISTRY-US, V31, P2443, DOI 10.1021/bi00124a001; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; VALLE RPC, 1987, EMBO J, V6, P3049, DOI 10.1002/j.1460-2075.1987.tb02611.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEISS R, 1988, J MOL BIOL, V203, P403, DOI 10.1016/0022-2836(88)90008-3; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078; WEISS WA, 1986, J MOL BIOL, V192, P725, DOI 10.1016/0022-2836(86)90024-0; WILLS NM, 1991, P NATL ACAD SCI USA, V88, P6991, DOI 10.1073/pnas.88.16.6991; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOSHINAKA Y, 1985, P NATL ACAD SCI USA, V82, P1618, DOI 10.1073/pnas.82.6.1618	38	72	73	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17802	17808						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	7517933				2022-12-25	WOS:A1994NV42200010
J	REX, G; SURIN, B; BESSE, G; SCHNEPPE, B; MCCARTHY, JEG				REX, G; SURIN, B; BESSE, G; SCHNEPPE, B; MCCARTHY, JEG			THE MECHANISM OF TRANSLATIONAL COUPLING IN ESCHERICHIA-COLI - HIGHER-ORDER STRUCTURE IN THE ATPHA MESSENGER-RNA ACTS AS A CONFORMATIONAL SWITCH REGULATING THE ACCESS OF DE-NOVO INITIATING RIBOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; RNA SECONDARY STRUCTURE; REPRESSOR MESSENGER-RNA; SP STRAIN PCC-7120; NUCLEOTIDE-SEQUENCE; BINDING SITE; BETA-SUBUNIT; LYSIS GENE; UNC OPERON; H+-ATPASE	Bacterial genes are commonly transcribed to form polycistronic mRNAs bearing reading frames whose respective translational efficiencies are not independently determined. As in many bacterial operons, expression of the atp genes of Escherichia coli is strongly influenced by translational coupling. The gene pair atpHA is tightly coupled, whereby atpA is translated at least three times more efficiently than atpH. However, there is no fixed stoichiometry of coupling: mutations in atpH lead to increases in the translation ratio (atpA/ atpH) of up to approximately 40-fold. We have demonstrated that secondary structure sequestering the atpA translational initiation region (TIR) is important to the coupling mechanism in that it inhibits de novo translational initiation at the atpA start codon. Genetic and structural analyses indicate that this inhibitory structure can be induced to refold into a less inhibitory con formation either by introducing two single-base substitutions or as a result of ribosomes translating atpH. We propose a model in which the secondary structure of the atpA TIR acts analogously to a ''gating device'' in that it restricts de novo ribosomal initiation until it is ''switched'' into a more open conformation. This contrasts with the function of a stem-loop structure located immediately downstream of atpA and upstream of the Shine-Dalgarno region of atpG, which was found to inhibit translation, but not to mediate tight coupling. Results obtained using the ''specialized'' ribosome system of Hui and de Boer ((1987) Proc. Natl. Acad. Sci. U. S. A. 84, 4762-4766) indicate that primarily ribosomes reinitiating after termination on atpH are responsible for inducing refolding of the atpA TIR. The principle of alternative mRNA conformations with different functional properties embodied in the model presented here can only be fulfilled by certain types of structure. It is likely to operate in several steps of prokaryotic gene expression, underlying a range of regulatory events including transcriptional attenuation and translational activation.	GESELL BIOTECHNOL FORSCH MBH, DEPT GENE EXPRESS SCI, D-38124 BRAUNSCHWEIG, GERMANY	Gesellschaft fur Biotechnologische Forschung mbH				Surin, Prayoon/0000-0002-9529-6427				ADHIN MR, 1989, MOL GEN GENET, V218, P137, DOI 10.1007/BF00330576; ALTUVIA S, 1987, P NATL ACAD SCI USA, V84, P6511, DOI 10.1073/pnas.84.18.6511; ARIS JP, 1985, J BIOL CHEM, V260, P1207; BAUGHMAN G, 1983, CELL, V34, P979, DOI 10.1016/0092-8674(83)90555-X; BERKHOUT B, 1987, J MOL BIOL, V195, P517, DOI 10.1016/0022-2836(87)90180-X; BRUSILOW WSA, 1989, J BIOL CHEM, V264, P1528; BRUSILOW WSA, 1987, J BACTERIOL, V169, P4984, DOI 10.1128/jb.169.11.4984-4990.1987; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; COZENS AL, 1987, J MOL BIOL, V194, P359, DOI 10.1016/0022-2836(87)90667-X; CURTIS SE, 1987, J BACTERIOL, V169, P80, DOI 10.1128/jb.169.1.80-86.1987; DEBOER H, 1985, SEQUENCE SPECIFICITY, P419; DESMIT MH, 1990, PROG NUCLEIC ACID RE, V38, P1; DUBNAU D, 1984, CRC CR REV BIOCH MOL, V16, P103, DOI 10.3109/10409238409102300; DUNN SD, 1990, J BACTERIOL, V172, P2782, DOI 10.1128/jb.172.5.2782-2784.1990; DUNN SD, 1980, J BIOL CHEM, V255, P113; ENGELBRECHT S, 1990, BIOCHIM BIOPHYS ACTA, V1015, P379, DOI 10.1016/0005-2728(90)90072-C; FALK G, 1985, BIOCHEM J, V228, P391, DOI 10.1042/bj2280391; FILLINGAME RH, 1986, J BACTERIOL, V165, P244, DOI 10.1128/jb.165.1.244-251.1986; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GATENBY AA, 1989, P NATL ACAD SCI USA, V86, P4066, DOI 10.1073/pnas.86.11.4066; GERSTEL B, 1989, MOL MICROBIOL, V3, P851, DOI 10.1111/j.1365-2958.1989.tb00234.x; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GUALERZI CO, 1988, GENETICS TRANSLATION, P317; HATFIELD GW, 1987, TRANSLATIONAL REGULA, P447; HELLMUTH K, 1991, MOL MICROBIOL, V5, P813, DOI 10.1111/j.1365-2958.1991.tb00754.x; HUI A, 1987, P NATL ACAD SCI USA, V84, P4762, DOI 10.1073/pnas.84.14.4762; IVEYHOYLE M, 1989, J MOL BIOL, V208, P233, DOI 10.1016/0022-2836(89)90385-9; KASTELEIN RA, 1983, NATURE, V305, P741, DOI 10.1038/305741a0; KLIONSKY DJ, 1986, J BIOL CHEM, V261, P8096; KNAPP G, 1989, METHOD ENZYMOL, V180, P192; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRUMHOLZ LR, 1989, NUCLEIC ACIDS RES, V17, P7993, DOI 10.1093/nar/17.19.7993; LANG V, 1989, J MOL BIOL, V210, P659, DOI 10.1016/0022-2836(89)90140-X; LASO MRV, 1993, J BIOL CHEM, V268, P6453; LINDAHL L, 1986, ANNU REV GENET, V20, P297; Lindahl L, 1992, CURR OPIN GENET DEV, V2, P720, DOI 10.1016/S0959-437X(05)80132-7; LITTLE S, 1989, J BACTERIOL, V171, P3518, DOI 10.1128/jb.171.6.3518-3522.1989; MARSH S, 1990, POST TRANSCRIPTIONAL, P249; MATTESON RJ, 1991, NUCLEIC ACIDS RES, V19, P3499, DOI 10.1093/nar/19.13.3499; MCCARN DF, 1988, J BACTERIOL, V170, P3448, DOI 10.1128/jb.170.8.3448-3458.1988; MCCARTHY JEG, 1988, MOL MICROBIOL, V2, P455, DOI 10.1111/j.1365-2958.1988.tb00051.x; MCCARTHY JEG, 1990, TRENDS GENET, V6, P78, DOI 10.1016/0168-9525(90)90098-Q; MCCARTHY JEG, 1990, MOL MICROBIOL, V4, P1233, DOI 10.1111/j.1365-2958.1990.tb00702.x; MCCARTHY JEG, 1985, EMBO J, V4, P519, DOI 10.1002/j.1460-2075.1985.tb03659.x; MCCARTHY JEG, 1990, POSTTRANSCRIPTIONAL, P157; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; PATI S, 1992, MOL MICROBIOL, V6, P3559, DOI 10.1111/j.1365-2958.1992.tb01791.x; PETERSEN C, 1989, J MOL BIOL, V206, P323, DOI 10.1016/0022-2836(89)90482-8; PHILIPPE C, 1993, P NATL ACAD SCI USA, V90, P4394, DOI 10.1073/pnas.90.10.4394; PRASZKIER J, 1992, J BACTERIOL, V174, P2376, DOI 10.1128/JB.174.7.2376-2383.1992; RINGQUIST S, 1992, MOL MICROBIOL, V6, P1219, DOI 10.1111/j.1365-2958.1992.tb01561.x; SCHUMPERLI D, 1982, CELL, V30, P865, DOI 10.1016/0092-8674(82)90291-4; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SPANJAARD RA, 1989, NUCLEIC ACIDS RES, V17, P5501, DOI 10.1093/nar/17.14.5501; STEEGE DA, 1977, P NATL ACAD SCI USA, V74, P4163, DOI 10.1073/pnas.74.10.4163; TYBULEWICZ VLJ, 1984, J MOL BIOL, V179, P185, DOI 10.1016/0022-2836(84)90465-0; VONMEYENBURG K, 1985, EMBO J, V4, P2357, DOI 10.1002/j.1460-2075.1985.tb03939.x; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WALKER JE, 1982, FEBS LETT, V146, P393, DOI 10.1016/0014-5793(82)80960-5; WU RP, 1992, J BACTERIOL, V174, P7620, DOI 10.1128/JB.174.23.7620-7628.1992; YATES JL, 1981, NATURE, V294, P190, DOI 10.1038/294190a0; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	64	47	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18118	18127						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	7517937				2022-12-25	WOS:A1994NV42200056
J	SUGAWARA, E; NIKAIDO, H				SUGAWARA, E; NIKAIDO, H			OMPA PROTEIN OF ESCHERICHIA-COLI OUTER-MEMBRANE OCCURS IN OPEN AND CLOSED CHANNEL FORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ENVELOPE MEMBRANE; TRANSPORT SPECIFICITY FRACTIONATION; PSEUDOMONAS-AERUGINOSA; MAJOR PROTEINS; LIPID BILAYER; PORIN; RECONSTITUTION; PERMEABILITY; PURIFICATION; K-12	OmpA protein of Escherichia coli outer membrane can produce diffusion channels when reconstituted into proteoliposomes (Sugawara, E., and Nikaido, H. (1992) J. Biol. Chem. 267, 2507-2511). The pore size is similar to that of the classical E. coli porins OmpF and OmpC, but the penetration rates of small solutes through the OmpA channel are about 50 times slower than that through the OmpF channel. Here we examined the possibility that only a small fraction of the OmpA molecules produces open channels. Unilamellar proteoliposomes were made so that each vesicle contained only a small number of OmpA molecules. These vesicles, containing 0.3 M urea within, were fractionated on a linear iso-osmolar density gradient made of urea and sucrose. This resulted in the clear separation of vesicles not containing any open channel, staying on top of the gradient, from those containing at least one open channel, sedimenting close to the bottom. Calculation using Poisson distribution indicated that only between 2 and 3% of the OmpA molecules contained open channel. The open form is estimated to allow the diffusion of L-arabinose at a rate comparable with that through the OmpF porin channel. The open and closed states were relatively stable properties of the protein. Denaturation of open form OmpA and its subsequent renaturation converted it into a nonfunctional or closed form, suggesting that the open and closed forms represent two alternative conformers of this protein.			SUGAWARA, E (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,229 STANLEY HALL,BERKELEY,CA 94720, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009644, R37AI009644] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-09644] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMBUDKAR SV, 1986, METHOD ENZYMOL, V125, P558; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANGUS BL, 1982, ANTIMICROB AGENTS CH, V21, P299, DOI 10.1128/AAC.21.2.299; BAVOIL P, 1977, MOL GEN GENET, V158, P23, DOI 10.1007/BF00455116; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1981, BIOCHIM BIOPHYS ACTA, V646, P298, DOI 10.1016/0005-2736(81)90336-9; BREMER E, 1982, EUR J BIOCHEM, V122, P223, DOI 10.1111/j.1432-1033.1982.tb05870.x; CHAI T, 1978, J BACTERIOL, V135, P164, DOI 10.1128/JB.135.1.164-170.1978; CHEN CC, 1984, J BIOL CHEM, V259, P150; CHEN R, 1980, P NATL ACAD SCI-BIOL, V77, P4592, DOI 10.1073/pnas.77.8.4592; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DATTA DB, 1977, J BACTERIOL, V131, P821, DOI 10.1128/JB.131.3.821-829.1977; DORNMAIR K, 1990, J BIOL CHEM, V265, P18907; FINNEN RL, 1992, J BACTERIOL, V174, P4977, DOI 10.1128/JB.174.15.4977-4985.1992; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; GOLDIN SM, 1980, P NATL ACAD SCI-BIOL, V77, P6884, DOI 10.1073/pnas.77.11.6884; GOLDIN SM, 1978, J BIOL CHEM, V253, P2575; HARRIS AL, 1989, J MEMBRANE BIOL, V109, P243, DOI 10.1007/BF01870281; HESS GP, 1977, P NATL ACAD SCI USA, V74, P482, DOI 10.1073/pnas.74.2.482; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; MORONA R, 1984, J BACTERIOL, V159, P570, DOI 10.1128/JB.159.2.570-578.1984; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NIKAIDO H, 1983, J BACTERIOL, V153, P241, DOI 10.1128/JB.153.1.241-252.1983; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; Nikaido H., 1986, BACTERIA, V10, P145; PAPAZIAN D, 1979, P NATL ACAD SCI USA, V76, P3708, DOI 10.1073/pnas.76.8.3708; ROBINSON RA, 1955, ELECTROLYTE SOLUTION, P247; SCHIRMER T, 1993, PROTEIN SCI, V2, P1361, DOI 10.1002/pro.5560020820; SCHWEIZER M, 1977, J BACTERIOL, V129, P1651, DOI 10.1128/JB.129.3.1651-1652.1977; SCHWEIZER M, 1978, EUR J BIOCHEM, V82, P211, DOI 10.1111/j.1432-1033.1978.tb12013.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONNTAG I, 1978, J BACTERIOL, V136, P280, DOI 10.1128/JB.136.1.280-285.1978; SUGAWARA E, 1992, J BIOL CHEM, V267, P2507; SURREY T, 1992, P NATL ACAD SCI USA, V89, P7457, DOI 10.1073/pnas.89.16.7457; VANALPHEN L, 1977, FEBS LETT, V75, P285, DOI 10.1016/0014-5793(77)80104-X; VOGEL H, 1986, J MOL BIOL, V190, P191, DOI 10.1016/0022-2836(86)90292-5; WOODRUFF WA, 1989, J BACTERIOL, V171, P3304, DOI 10.1128/jb.171.6.3304-3309.1989; WOODRUFF WA, 1986, J BACTERIOL, V167, P473, DOI 10.1128/jb.167.2.473-479.1986; YOSHIMURA F, 1982, J BACTERIOL, V152, P636; YOSHIMURA F, 1983, J BIOL CHEM, V258, P2308	42	103	104	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17981	17987						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	7517935				2022-12-25	WOS:A1994NV42200037
J	WILDE, CG; SEILHAMER, JJ; MCGROGAN, M; ASHTON, N; SNABLE, JL; LANE, JC; LEONG, SR; THORNTON, MB; MILLER, KL; SCOTT, RW; MARRA, MN				WILDE, CG; SEILHAMER, JJ; MCGROGAN, M; ASHTON, N; SNABLE, JL; LANE, JC; LEONG, SR; THORNTON, MB; MILLER, KL; SCOTT, RW; MARRA, MN			BACTERICIDAL PERMEABILITY-INCREASING PROTEIN AND LIPOPOLYSACCHARIDE (LPS)-BINDING PROTEIN - LPS BINDING-PROPERTIES AND EFFECTS ON LPS-MEDIATED CELL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTOXIN; CD14; CLONING; CDNA	We have previously shown that human bactericidal/ permeability-increasing protein (BPI) is able to inhibit serum-dependent lipopolysaccharide (LPS)-mediated activation of human monocytes and neutrophils in vitro, and to counteract the lethal effects of LPS challenge in vivo. Lipopolysaccharide-binding protein (LBP) is a serum protein which participates in LPS-mediated activation of cells (Tobias, P. S., Mathison, J., Mintz, D., Lee, J. D., Kravchenko, V., Kato, K., Pugin, J., and Ulevitch, R. J. (1992) Am. J. Respir: Cell. Mel. Biol. 7, 239-245). We have proposed that BPI functions in a negative feedback loop which opposes this activation (Marra, M. N., Wilde, C. G., Collins, M. S., Snable, J. L., Thornton, M. E., and Scott, R. W. (1992) J. Immunol. 148, 532-537). We have now cloned and expressed recombinant forms of human BPI and LBP. Here we demonstrate that purified recombinant human LBP can replace the serum requirement for both LPS binding to human monocytes and LPS-mediated secretion of tumor necrosis factor alpha from these cells. These activities of LBP are inhibited by a neutralizing anti-CD14 monoclonal antibody. We further demonstrate that purified recombinant human BPI can inhibit LBP-mediated LPS binding to cells and their subsequent activation. Comparison of the LPS binding properties of BPI and LBP in enzyme-linked immunosorbent type assays and in the Limulus amebocyte lysate assay suggest that BPI has a stronger affinity for LPS than does LBP. Direct competition between BPI and LBP for LPS may ex plain the inhibition by EPI of the proinflammatory effects of LBP in the presence of LPS.	INCYTE PHARMACEUT,PALO ALTO,CA 94304; GENENTECH INC,S SAN FRANCISCO,CA 94080	Incyte; Roche Holding; Genentech								BAZIL V, 1986, EUR J IMMUNOL, V16, P1583, DOI 10.1002/eji.1830161218; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; Elsbach P, 1992, INFLAMMATION BASIC P, P603; GRAY PW, 1989, J BIOL CHEM, V264, P9505; HEUMANN D, 1993, J INFECT DIS, V167, P1351, DOI 10.1093/infdis/167.6.1351; LYNN WA, 1992, IMMUNOL TODAY, V13, P271, DOI 10.1016/0167-5699(92)90009-V; MARRA MN, 1990, J IMMUNOL, V144, P662; MARRA MN, 1992, J IMMUNOL, V148, P532; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; MORRISON DC, 1978, AM J PATHOL, V93, P527; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; TOBIAS PS, 1992, AM J RESP CELL MOL, V7, P239, DOI 10.1165/ajrcmb/7.3.239; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; WRIGHT SD, 1992, J EXP MED, V176, P719, DOI 10.1084/jem.176.3.719; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	19	69	73	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17411	17416						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	7517398				2022-12-25	WOS:A1994NU12800013
J	LUO, YQ; LU, SJ; CHEN, P; WANG, D; HALPERN, M				LUO, YQ; LU, SJ; CHEN, P; WANG, D; HALPERN, M			IDENTIFICATION OF CHEMOATTRACTANT RECEPTORS AND G-PROTEINS IN THE VOMERONASAL SYSTEM OF GARTER SNAKES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEINS; SENSITIVE ADENYLATE-CYCLASE; OLFACTORY RECEPTOR; ADP-RIBOSYLATION; PHOSPHOINOSITIDE TURNOVER; INOSITOL TRISPHOSPHATE; ADRENERGIC-RECEPTORS; SIGNAL TRANSDUCTION; VAGINAL DISCHARGE; HUMAN FIBROBLASTS	Garter snakes respond to purified chemoattractants derived from prey. The specific binding sites for one of these chemoattractants, ES20, in the vomeronasal organ was saturable and reversible. Binding sites for ES20 were abolished by heating or greatly reduced by Pronase digestion. ES20 chemoattractant activity and receptor binding required Ca2+. Binding of ES20 to sensory epithelium derived from animals with bipolar neurons depleted by denervation was reduced 22-43% as compared to control animals. However, there was an up-regulation of the ES20 receptor population in the nonsensory cells following nerve cuts. Three G-proteins (G(s), G(i), and G(o)) were tentatively identified using immunoreactivity and ADP-ribosylation techniques. G(i) and G(o) proteins were shown to be coupled with ES20-receptor and effecters as evidenced by: 1) the affinity of ES20-receptor was decreased by GTP gamma S; 2) ES20-receptor binding caused a reduction in ADP-ribosylation of pertussis toxin-susceptible G-proteins, and the inhibitory effect of ES20-receptor on ADP-ribosylation was attenuated by GDP beta S; 3) the effect of ES20-receptor on ADP-ribosylation of the pertussis toxin-susceptible G-proteins could be mimicked by G-protein activators, such as GTP gamma S or AIF(3); 4) ES20-receptor binding resulted in a decrease of the basal level of cAMP; 5) the binding of ES20 to its receptors caused an increase in the level of D-myo-inositol 1,4,5-trisphosphate.	SUNY HLTH SCI CTR, DEPT BIOCHEM, BROOKLYN, NY 11203 USA; SUNY HLTH SCI CTR, DEPT ANAT & CELL BIOL, BROOKLYN, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center					NIDCD NIH HHS [DC 00104] Funding Source: Medline	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BASU SK, 1978, J BIOL CHEM, V253, P3852; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BORISY FF, 1992, J NEUROSCI, V12, P915; BOSCH F, 1986, BIOCHEM J, V239, P523, DOI 10.1042/bj2390523; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOYD ND, 1991, BIOCHEMISTRY-US, V30, P336, DOI 10.1021/bi00216a005; BRAND JG, 1987, BRAIN RES, V416, P119, DOI 10.1016/0006-8993(87)91503-4; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BRUCH RC, 1988, COMP BIOCHEM PHYS B, V91, P535, DOI 10.1016/0305-0491(88)90018-1; CALDWELL PC, 1970, CALCIUM CELLULAR FUN, P11; Caprio J, 1982, CHEMORECEPTION FISHE, P109; CUATRECASAS P, 1971, J BIOL CHEM, V246, P7265; DEMOLIOUMASON CD, 1986, J NEUROCHEM, V46, P1118, DOI 10.1111/j.1471-4159.1986.tb00626.x; FRANCES B, 1985, EUR J PHARMACOL, V117, P223, DOI 10.1016/0014-2999(85)90607-7; GILL DM, 1991, METHOD ENZYMOL, V195, P267; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOEDERT M, 1989, METHOD ENZYMOL, V168, P462; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GRAF R, 1992, EUR J BIOCHEM, V210, P609, DOI 10.1111/j.1432-1033.1992.tb17461.x; HOMBURGER V, 1987, MOL PHARMACOL, V31, P313; HUQUE T, 1986, BIOCHEM BIOPH RES CO, V137, P36, DOI 10.1016/0006-291X(86)91172-1; INOUCHI J, 1993, BRAIN BEHAV EVOLUT, V41, P171, DOI 10.1159/000113835; JIANG XC, 1990, J BIOL CHEM, V265, P8736; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KRUEGER JM, 1976, J BIOL CHEM, V251, P88; LEFF SE, 1985, MOL PHARMACOL, V27, P184; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; LEFKOWITZ RJ, 1983, ANNU REV BIOCHEM, V52, P159, DOI 10.1146/annurev.bi.52.070183.001111; LI CS, 1993, SOC NEUROSCI, V23, P122; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MAEHAMA T, 1991, J BIOL CHEM, V266, P10062; Means G E, 1977, Methods Enzymol, V47, P469; MILLIGAN G, 1987, BIOCHIM BIOPHYS ACTA, V929, P197, DOI 10.1016/0167-4889(87)90176-5; MILLIGAN G, 1988, BIOCHEM J, V255, P1; MOODY TW, 1989, METHOD ENZYMOL, V168, P481; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OCONNELL RJ, 1978, BEHAV BIOL, V24, P244, DOI 10.1016/S0091-6773(78)93110-3; OLSON KS, 1992, BRAIN RES, V583, P262, DOI 10.1016/S0006-8993(10)80032-0; OPPENHEIMER NJ, 1978, J BIOL CHEM, V253, P4907; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; RENSDOMIANO S, 1992, J NEUROCHEM, V58, P1987, DOI 10.1111/j.1471-4159.1992.tb10938.x; RONNETT GV, 1993, J NEUROSCI, V13, P1751; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SCHMIDT A, 1991, J BIOL CHEM, V266, P18025; SHEPHERD GM, 1991, CELL, V67, P845, DOI 10.1016/0092-8674(91)90358-6; SHINOHARA H, 1992, J NEUROSCI, V12, P1275; SINGER AG, 1984, PHYSIOL BEHAV, V33, P639, DOI 10.1016/0031-9384(84)90384-6; SINGER AG, 1986, J BIOL CHEM, V261, P3323; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; VANDOP C, 1984, J BIOL CHEM, V259, P23; WANG D, 1993, BRAIN BEHAV EVOLUT, V41, P246, DOI 10.1159/000113846; WANG D, 1988, ARCH BIOCHEM BIOPHYS, V267, P459, DOI 10.1016/0003-9861(88)90051-3; WANG D, 1992, CHEM SIGNALS VERTEBR, V6, P107; WANG RT, 1980, AM J ANAT, V157, P399, DOI 10.1002/aja.1001570408; WANG RT, 1980, J MORPHOL, V164, P47, DOI 10.1002/jmor.1051640105; WEISS ER, 1990, J MOL ENDOCRINOL, V4, P71, DOI 10.1677/jme.0.0040071	68	69	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16867	16877						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	7515886				2022-12-25	WOS:A1994NR29600055
J	AKABAS, MH; KAUFMANN, C; COOK, TA; ARCHDEACON, P				AKABAS, MH; KAUFMANN, C; COOK, TA; ARCHDEACON, P			AMINO-ACID-RESIDUES LINING THE CHLORIDE CHANNEL OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SITE-DIRECTED MUTAGENESIS; XENOPUS OOCYTES; CYSTEINE-SUBSTITUTION; MILD-DISEASE; CL CHANNELS; CFTR GENE; R-DOMAIN; RECEPTOR; SELECTIVITY; MUTATIONS	The cystic fibrosis transmembrane conductance regulator forms a chloride channel that is regulated by phosphorylation and intracellular ATP levels. The structure of the channel-forming domains is undetermined. To identify the residues lining this channel we substituted cysteine, one at a time, for 9 consecutive residues (91-99) in the M1 membrane spanning segment. The cysteine substitution mutants were expressed in Xenopus oocytes. We determined the accessibility of the engineered cysteine to charged, sulfhydryl-specific methanethiosulfonate reagents added extracellularly. We assume that, among residues in membrane-spanning segments, only those lining the channel will be accessible to react with these hydrophilic reagents and that such a reaction would irreversibly alter conduction through the channel. Only the cysteines substituted for Gly-91, Lys-95, and Gln-98 were accessible to the reagents. We conclude that these residues are in the channel lining. The periodicity of these residues is consistent with an alpha-helical secondary structure.	COLUMBIA UNIV, DEPT PHYSIOL & CELLULAR BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT MED, NEW YORK, NY 10032 USA	Columbia University; Columbia University	AKABAS, MH (corresponding author), COLUMBIA UNIV, CTR MOLEC RECOGNIT, 630 W 168TH ST, NEW YORK, NY 10032 USA.			Akabas, Myles/0000-0001-8781-7846	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK041146] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41146] Funding Source: Medline; NIGMS NIH HHS [GM08224] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BEAR CE, 1991, J BIOL CHEM, V266, P19142; CHALKLEY G, 1991, J MED GENET, V28, P875, DOI 10.1136/jmg.28.12.875; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CUNNINGHAM SA, 1992, AM J PHYSIOL, V262, pC783, DOI 10.1152/ajpcell.1992.262.3.C783; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; FINKELSTEIN A, 1981, J MEMBRANE BIOL, V59, P155, DOI 10.1007/BF01875422; FLOTTE TR, 1993, J BIOL CHEM, V268, P3781; GUILLERMIT H, 1993, HUM GENET, V91, P233; HASEGAWA H, 1992, SCIENCE, V258, P1477, DOI 10.1126/science.1279809; JAKES KS, 1990, J BIOL CHEM, V265, P6984; Kenyon G L, 1977, Methods Enzymol, V47, P407; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; TODD AP, 1989, PROTEINS, V6, P294, DOI 10.1002/prot.340060312; Tsui L C, 1991, Adv Hum Genet, V20, P153; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; XU M, 1993, J BIOL CHEM, V268, P21505; ZIELENSKI J, 1991, GENOMICS, V10, P229, DOI 10.1016/0888-7543(91)90504-8	30	138	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14865	14868						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7515047				2022-12-25	WOS:A1994NP73800005
J	BARNEA, G; GRUMET, M; MILEV, P; SILVENNOINEN, O; LEVY, JB; SAP, J; SCHLESSINGER, J				BARNEA, G; GRUMET, M; MILEV, P; SILVENNOINEN, O; LEVY, JB; SAP, J; SCHLESSINGER, J			RECEPTOR TYROSINE PHOSPHATASE-BETA IS EXPRESSED IN THE FORM OF PROTEOGLYCAN AND BINDS TO THE EXTRACELLULAR-MATRIX PROTEIN TENASCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHONDROITIN SULFATE PROTEOGLYCANS; CELL-ADHESION MOLECULE; NEURITE OUTGROWTH; NERVOUS-SYSTEM; CYTOTACTIN; BRAIN; J1/TENASCIN; INHIBITION; BOUNDARIES; TISSUES	The extracellular domain of receptor type protein tyrosine phosphatase beta (RPTP beta) exhibits striking sequence similarity with a soluble, rat brain chondroitin sulfate proteoglycan (3F8 PG). Immunoprecipitation experiments of cells transfected with RPTP beta expression vector and metabolically labeled with [S-35]sulfate and [S-35]methionine indicate that the transmembrane form of RPTP beta is indeed a chondroitin sulfate proteoglycan. The 3F8 PG is therefore a variant form composed of the entire extracellular domain of RPTP beta probably generated by alternative RNA splicing. Previous immunohistochemical studies indicated that both RPTP beta and the extracellular matrix protein tenascin are localized in similar regions of the central nervous system. We have performed co-aggregation assays with red and green Covaspheres coated with tenascin and 3F8 PG, respectively, showing that the extracellular domain of RPTP beta (3F8 PG) binds specifically to tenascin. The interaction between a receptor tyrosine phosphatase and an extracellular matrix protein may have a role in development of the mammalian central nervous system.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University			grumet, martin/ABC-6462-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021629, R01NS013876] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-00129] Funding Source: Medline; NINDS NIH HHS [NS-21629, NS-13876] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; BARNEA G, 1994, CELL, V76, P205, DOI 10.1016/0092-8674(94)90328-X; BRACKENBURY R, 1977, J BIOL CHEM, V252, P6835; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; CANOLL PD, 1993, DEV BRAIN RES, V75, P293, DOI 10.1016/0165-3806(93)90035-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIQUET M, 1991, SEMIN NEUROSCI, V3, P341; CROSSIN KL, 1991, P NATL ACAD SCI USA, V88, P11403, DOI 10.1073/pnas.88.24.11403; CROSSIN KL, 1989, DEV BIOL, V136, P381, DOI 10.1016/0012-1606(89)90264-9; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FALTZ LL, 1979, J BIOL CHEM, V254, P1375; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GRUMET M, 1985, P NATL ACAD SCI USA, V82, P8075, DOI 10.1073/pnas.82.23.8075; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; GRUMET M, 1984, J CELL BIOL, V98, P1746, DOI 10.1083/jcb.98.5.1746; GRUMET M, 1988, J CELL BIOL, V106, P487, DOI 10.1083/jcb.106.2.487; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; LEVY JB, 1993, J BIOL CHEM, V268, P10573; LOCHTER A, 1991, J CELL BIOL, V113, P1159, DOI 10.1083/jcb.113.5.1159; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MILEV P, 1993, J NEUROCHEM, V61, pS110; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; PERRIS R, 1990, DEV BIOL, V137, P1, DOI 10.1016/0012-1606(90)90002-Z; PRIETO AL, 1990, J CELL BIOL, V111, P685, DOI 10.1083/jcb.111.2.685; RAUCH U, 1991, J BIOL CHEM, V266, P14785; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; SAITO H, 1991, CELL GROWTH DIFFER, V2, P59; SAP J, 1994, MOL CELL BIOL, V14, P1; SNOW DM, 1990, DEV BIOL, V138, P359, DOI 10.1016/0012-1606(90)90203-U; STEINDLER DA, 1989, DEV BIOL, V131, P243, DOI 10.1016/S0012-1606(89)80056-9	36	176	178	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14349	14352						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514167				2022-12-25	WOS:A1994NM06500006
J	LEE, KH; BAEK, MY; MOON, KY; SONG, WK; CHUNG, CH; HA, DB; KANG, MS				LEE, KH; BAEK, MY; MOON, KY; SONG, WK; CHUNG, CH; HA, DB; KANG, MS			NITRIC-OXIDE AS A MESSENGER MOLECULE FOR MYOBLAST FUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYCLIC-GMP; L-ARGININE; PROTEIN-KINASE; SYNTHASE; ENZYME; PHOSPHORYLATION; CALMODULIN; RADIOIMMUNOASSAY; RELAXATION; INHIBITION	Nitric oxide (NO) is a messenger molecule of vascular endothelial cells, macrophages, and neurons. Here, we demonstrate that the activity of NO synthase increases transiently but dramatically in chick embryonic myoblasts that are competent for fusion. This activity requires Ca2+, calmodulin, and NADPH. In addition, the increase in NO synthase activity coincides with an increase in cellular cGMP level. Furthermore, NO generated by treatment with sodium nitroprusside induces precocious myoblast fusion, while treatment with N-G-monomethyl-L-arginine, a competitive inhibitor of NO synthase, or methylene blue, an inhibitor of guanylate cyclase, delays fusion. These results provide the first evidence for a strong association of NO with myoblast fusion.	SEOUL NATL UNIV,COLL NAT SCI,DEPT MOLEC BIOL,SEOUL 151742,SOUTH KOREA; SEOUL NATL UNIV,COLL NAT SCI,SRC CELL DIFFERENTIAT,SEOUL 151742,SOUTH KOREA	Seoul National University (SNU); Seoul National University (SNU)								BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNE B, 1991, BIOCHEM BIOPH RES CO, V181, P921, DOI 10.1016/0006-291X(91)91279-L; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; CHOI SW, 1992, EXP CELL RES, V199, P129, DOI 10.1016/0014-4827(92)90470-S; DAVID JD, 1981, DEV BIOL, V82, P297, DOI 10.1016/0012-1606(81)90453-X; ENTWISTLE A, 1988, J CELL BIOL, V106, P1693, DOI 10.1083/jcb.106.5.1693; EPPENBERGER HM, 1967, J BIOL CHEM, V242, P204; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HERMANN H, 1970, CURRENT TOPICS DEVEL, V5, P181; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IZUMI Y, 1992, SCIENCE, V257, P1273, DOI 10.1126/science.1519065; KIM HS, 1992, DEV BIOL, V150, P223, DOI 10.1016/0012-1606(92)90237-B; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; KWON NS, 1990, J BIOL CHEM, V265, P13442; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LEE LJ, 1969, TOXICOLOGY, V3, P281; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MONCADA S, 1991, P NATL ACAD SCI USA, V88, P2166, DOI 10.1073/pnas.88.6.2166; MONCADA S, 1991, PHARMACOL REV, V43, P109; Murad F, 1978, Adv Cyclic Nucleotide Res, V9, P145; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; PALMER RMJ, 1989, BIOCHEM BIOPH RES CO, V158, P348, DOI 10.1016/S0006-291X(89)80219-0; PALMER RMJ, 1988, BIOCHEM BIOPH RES CO, V153, P1251, DOI 10.1016/S0006-291X(88)81362-7; PRZYBYLSKI RJ, 1989, IN VITRO CELL DEV B, V25, P830; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; STEINER AL, 1972, J BIOL CHEM, V247, P1106; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAKELAM MJO, 1985, BIOCHEM J, V228, P1	35	135	143	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14371	14374						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514168				2022-12-25	WOS:A1994NM06500012
J	KING, SL; LICHTLER, AC; ROWE, DW; XIE, RL; LONG, GL; ABSHER, MP; CUTRONEO, KR				KING, SL; LICHTLER, AC; ROWE, DW; XIE, RL; LONG, GL; ABSHER, MP; CUTRONEO, KR			BLEOMYCIN STIMULATES PRO-ALPHA-1(I) COLLAGEN PROMOTER THROUGH TRANSFORMING GROWTH-FACTOR-BETA RESPONSE ELEMENT BY INTRACELLULAR AND EXTRACELLULAR SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PULMONARY FIBROSIS; MESSENGER-RNA LEVELS; HUMAN DERMAL FIBROBLASTS; HUMAN-LUNG FIBROBLASTS; STEADY-STATE LEVELS; SHORT-PATCH REPAIR; I PROCOLLAGEN; CHLORAMPHENICOL ACETYLTRANSFERASE; GENE-EXPRESSION; MAMMALIAN-CELLS	The role of transforming growth factor beta as a mediator of the fibrogenic effect of bleomycin in lung has been investigated at the transcriptional level. Several constructs containing the rat pro-alpha 1(I) collagen promoter fused to the chloramphenicol acetyltransferase gene were transfected into rat lung fibroblasts. Both bleomycin and transforming growth factor beta 1 increased promoter activity in fibroblasts transfected with constructs containing the transforming growth factor beta response element. Fibroblasts transfected with a deletion construct that lacks this response element did not respond to either bleomycin or transforming growth factor beta 1. Anti-transforming growth factor beta 1-neutralizing antibodies did not block the increase in promoter activity induced by bleomycin, suggesting intracellular signaling. Mutation of the transforming growth factor beta response element greatly reduced the bleomycin effect, which also infers intracellular signaling. In addition, plasmin added to the media greatly enhanced bleomycin stimulation of promoter activity demonstrating that transforming growth factor beta mediates the bleomycin effect through extracellular signaling.	UNIV VERMONT,COLL MED,DEPT BIOCHEM,BURLINGTON,VT 05405; UNIV VERMONT,COLL MED,DEPT MED,BURLINGTON,VT 05405; UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,FARMINGTON,CT 06032; UNIV CONNECTICUT,CTR HLTH,DEPT MED,FARMINGTON,CT 06032	University of Vermont; University of Vermont; University of Connecticut; University of Connecticut					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045138] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45138] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABSHER M, 1984, AM REV RESPIR DIS, V129, P125; ADAMSON IYR, 1976, ENVIRON HEALTH PERSP, V16, P119, DOI 10.2307/3428592; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAGHOW R, 1989, J CLIN INVEST, V84, P1836; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BECKMANN RP, 1987, BIOCHEMISTRY-US, V26, P5409, DOI 10.1021/bi00391a029; BENNETT JM, 1979, ANN INTERN MED, V90, P945, DOI 10.7326/0003-4819-90-6-945; BLUM RH, 1973, CANCER, V31, P903, DOI 10.1002/1097-0142(197304)31:4<903::AID-CNCR2820310422>3.0.CO;2-N; BREEN E, 1992, AM J RESP CELL MOL, V6, P146, DOI 10.1165/ajrcmb/6.2.146; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CLARK JG, 1980, BIOCHIM BIOPHYS ACTA, V631, P359, DOI 10.1016/0304-4165(80)90309-8; DANDREA AD, 1978, P NATL ACAD SCI USA, V75, P3608, DOI 10.1073/pnas.75.8.3608; DIGIUSEPPE JA, 1989, BIOCHEMISTRY-US, V28, P9515, DOI 10.1021/bi00450a040; FINE A, 1990, CONNECT TISSUE RES, V24, P237, DOI 10.3109/03008209009152152; GIRI SN, 1980, EXP MOL PATHOL, V33, P1, DOI 10.1016/0014-4800(80)90002-7; GOLDSTEIN RH, 1990, J BIOL CHEM, V265, P13623; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARRISON JH, 1989, MOL PHARMACOL, V36, P231; HOYT DG, 1988, J PHARMACOL EXP THER, V246, P765; HUSSAR DA, 1974, AM J PHARM, V146, P37; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; KALTER VG, 1991, AM J RESP CELL MOL, V4, P397, DOI 10.1165/ajrcmb/4.5.397; KELLEY J, 1991, AM J PHYSIOL, V260, pL123, DOI 10.1152/ajplung.1991.260.2.L123; KELLEY J, 1985, BIOCHEM BIOPH RES CO, V131, P836, DOI 10.1016/0006-291X(85)91315-4; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; KROSS J, 1982, BIOCHEMISTRY-US, V21, P4310, DOI 10.1021/bi00261a021; LAURENT GJ, 1983, AM REV RESPIR DIS, V128, P82, DOI 10.1164/arrd.1983.128.1.82; LAZO JS, 1983, P NATL ACAD SCI-BIOL, V80, P3064, DOI 10.1073/pnas.80.10.3064; LICHTLER A, 1989, J BIOL CHEM, V264, P3072; LOPEZLARRAZA DM, 1993, ENVIRON MOL MUTAGEN, V21, P258, DOI 10.1002/em.2850210309; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MCANULTY RJ, 1991, BIOCHIM BIOPHYS ACTA, V1091, P231, DOI 10.1016/0167-4889(91)90066-7; MURRAY V, 1985, J BIOL CHEM, V260, P389; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NIGHTINGALE KP, 1993, NUCLEIC ACIDS RES, V21, P2549, DOI 10.1093/nar/21.11.2549; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PHAN SH, 1985, J CLIN INVEST, V76, P241, DOI 10.1172/JCI111953; PHAN SH, 1992, EXP LUNG RES, V18, P29, DOI 10.3109/01902149209020649; QUINONES F, 1986, AM REV RESPIR DIS, V134, P1163; RAGHOW R, 1985, J CLIN INVEST, V76, P1733, DOI 10.1172/JCI112163; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; RAGHU G, 1989, AM REV RESPIR DIS, V140, P95, DOI 10.1164/ajrccm/140.1.95; RITZENTHALER JD, 1993, J BIOL CHEM, V268, P13625; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SIDIK K, 1990, BIOCHEMISTRY-US, V29, P7501, DOI 10.1021/bi00484a020; SNIDER GL, 1978, AM REV RESPIR DIS, V117, P1099; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; STERLING KM, 1982, CANCER RES, V42, P3502; STERLING KM, 1983, J BIOL CHEM, V258, P4438; TOM WM, 1980, TOXICOL APPL PHARM, V53, P64, DOI 10.1016/0041-008X(80)90382-8; UMEZAWA H, 1984, TETRAHEDRON, V40, P501, DOI 10.1016/0040-4020(84)85055-3; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; VARGA J, 1986, BIOCHEM BIOPH RES CO, V138, P974, DOI 10.1016/S0006-291X(86)80591-5	62	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13156	13161						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7513699				2022-12-25	WOS:A1994NK18400019
J	STUTTS, MJ; GABRIEL, SE; PRICE, EM; SARKADI, B; OLSEN, JC; BOUCHER, RC				STUTTS, MJ; GABRIEL, SE; PRICE, EM; SARKADI, B; OLSEN, JC; BOUCHER, RC			PYRIDINE-NUCLEOTIDE REDOX POTENTIAL MODULATES CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CL- CONDUCTANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RESISTANCE P-GLYCOPROTEIN; CFTR CHLORIDE CHANNEL; MULTIDRUG-RESISTANCE; ANION SELECTIVITY; APICAL MEMBRANE; CELL-LINE; CAMP; TRANSPORT; GENE	Cl- conductance of the apical membrane of airway epithelial cells has properties of a passive diffusion mechanism but is decreased by inhibition of oxidative metabolism. Recent reports that cAMP-dependent Cl- conductance also requires ATP at the intracellular domains of the cystic fibrosis transmembrane conductance regulator (CFTR) suggest that ATP concentration could mediate metabolic regulation of Cl- conductance. However, metabolic inhibitors affect processes other than ATP free energy levels, including notably the metabolic pathways that set the redox potential of pyridine nucleotides within the cell. We have investigated the possibility that CFTR-mediated Cl- conductance is affected by the ratio of oxidized to reduced intracellular pyridine nucleotides. CFTR was expressed in airway and heterologous cells and studied under whole cell. voltage clamp conditions, which permitted the intracellular NAD(P)(+)/ NAD(P)H ratio to be varied independently of ATP concentration. In three cell types expressing CFTR, whole cell dialysis with reduced pyridine nucleotides inhibited activation of Cl- currents by forskolin and 8-(4-chlorophenylthio)-cAMP (CPT-cAMP), whereas dialysis with oxidized pyridines increased both basal and stimulated CFTR-mediated Cl- conductance. In cell-attached membrane patches, the open probability of 5-6-picosiemens Cl- channels that had been activated by forskolin and CPT-cAMP was further and reversibly increased by permeant oxidants. Neither swelling-induced whole cell K+ currents in CFTR-expressing cells nor swelling-induced whole cell Cl- currents in multidrug resistance protein-expressing cells were affected by NADPH. Pyridine nucleotide redox potential had little effect on phosphorylation of histone by protein kinase A. We conclude that CFTR Cl- conductance function can be modulated by pyridine nucleotide redox potential. This effect points to the existence of a mechanism or mechanisms by which cytosolic nucleotides other than ATP can affect plasma membrane Cl- conductance and may help explain how a passive ion conductance is linked to cellular energy metabolism.	UNIV N CAROLINA, DEPT PHARMACOL, LINEBERGER CANC CTR, CYST FIBROSIS RES CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	STUTTS, MJ (corresponding author), UNIV N CAROLINA, DEPT MED, LINEBERGER CANC CTR, CYST FIBROSIS RES CTR, CB 7020, CHAPEL HILL, NC 27599 USA.		Sarkadi, Balazs/I-5024-2013					ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BELL CL, 1992, AM J PHYSIOL, V262, pC555, DOI 10.1152/ajpcell.1992.262.3.C555; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COHN JA, 1992, P NATL ACAD SCI USA, V89, P2340, DOI 10.1073/pnas.89.6.2340; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DEJONGE HR, 1989, BIOCHEM SOC T, V17, P816, DOI 10.1042/bst0170816; DIAMOND G, 1991, J BIOL CHEM, V266, P22761; FLOCKHART DA, 1984, EUR J BIOCHEM, V140, P289, DOI 10.1111/j.1432-1033.1984.tb08100.x; FORSYTH GW, 1989, J MEMBRANE BIOL, V107, P137, DOI 10.1007/BF01871719; FUHRMANN GF, 1985, BIOCHIM BIOPHYS ACTA, V820, P223, DOI 10.1016/0005-2736(85)90116-6; GABRIEL SE, 1992, AM J PHYSIOL, V263, pC708, DOI 10.1152/ajpcell.1992.263.3.C708; GAETANI GF, 1989, BLOOD, V73, P334; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GLOCK GE, 1955, BIOCHEM J, V61, P388, DOI 10.1042/bj0610388; GRAY MA, 1990, AM J PHYSIOL, V259, pC752, DOI 10.1152/ajpcell.1990.259.5.C752; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAWS C, 1992, AM J PHYSIOL, V263, pL692, DOI 10.1152/ajplung.1992.263.6.L692; HEDESKOV CJ, 1987, BIOCHEM J, V241, P161, DOI 10.1042/bj2410161; HIGGINS CF, 1985, EMBO J, V4, P1033, DOI 10.1002/j.1460-2075.1985.tb03735.x; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KREBS HA, 1967, ADV ENZYME REGUL, V5, P405; LARSEN EH, 1992, PEDIATR PULM S, V8, P267; MARSHALL J, 1991, J BIOL CHEM, V266, P22749; OLSEN JC, 1992, HUM GENE THER, V3, P253, DOI 10.1089/hum.1992.3.3-253; PARKER JC, 1969, J CLIN INVEST, V48, P117, DOI 10.1172/JCI105960; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RAN S, 1992, J BIOL CHEM, V267, P3618; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SCHINDLER H, 1984, P NATL ACAD SCI-BIOL, V81, P6222, DOI 10.1073/pnas.81.19.6222; SHOTT S, 1990, STATISTICS HLTH PROF, P342; STUTTS MJ, 1988, J APPL PHYSIOL, V64, P253, DOI 10.1152/jappl.1988.64.1.253; STUTTS MJ, 1993, J BIOL CHEM, V268, P20653; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TABCHARANI JA, 1992, BIOPHYS J, V62, P1, DOI 10.1016/S0006-3495(92)81759-9; TATA F, 1991, GENOMICS, V10, P301, DOI 10.1016/0888-7543(91)90312-3; TIETZE F, 1970, ARCH BIOCHEM BIOPHYS, V138, P177, DOI 10.1016/0003-9861(70)90297-3; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; YANKASKAS JR, 1993, AM J PHYSIOL, V264, pC1219, DOI 10.1152/ajpcell.1993.264.5.C1219	45	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8667	8674						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510695				2022-12-25	WOS:A1994NB41100010
J	BAHK, YY; LEE, YH; LEE, TG; SEO, JK; RYU, SH; SUH, PG				BAHK, YY; LEE, YH; LEE, TG; SEO, JK; RYU, SH; SUH, PG			2 FORMS OF PHOSPHOLIPASE C-BETA-1 GENERATED BY ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; BOVINE BRAIN; TYROSINE PHOSPHORYLATION; COMPLETE CDNA; C ISOZYMES; ACTIVATION; PURIFICATION; KINASE; LYMPHOCYTES; C-GAMMA-1	Phospholipase C-beta 1 (PLC-beta 1) exists as two immunologically indistinguishable polypeptides of 150 and 140 kDa and is encoded in rat brain by two distinct transcripts of 5.4 and 7.2 kilobases (kb). cDNA corresponding to the entire 5.4-kb transcript as reported previously reveals an open reading frame that is capable of coding a 1216-amino acid polypeptide (Suh, P. G., Ryu, S. H., Moon, K. H., Suh, H. W., and Rhee, S. G. (1988) Cell 54, 161-169). We have now isolated cDNAs corresponding to the entire 7.2-kb transcript from a rat brain cDNA library. The 7.2-kb transcript differs from the previously reported 5.4-kb transcript by possessing both an additional 118 nucleotides located near the end of the coding sequence and a 1738-nucleotide extension of the 3'-flanking region. The presence of the 118-nucleotide insert in the cumulative 7.2-kb sequence gives rise to an open reading frame that is capable of coding a 1173-amino acid polypeptide (PLC-beta 1b), the carboxyl terminal sequence of which differs from that of the 1216-amino acid polypeptide (PLC-beta 1a) derived from the 5.4-kb transcript. Antibodies were raised against synthetic peptides corresponding to the carboxyl-terminal portions of PLC- beta 1a and PLC-beta 1b. Immunoblot analysis with these isozyme specific antibodies revealed that both PLC-beta 1a and PLC-beta 1b are expressed in rat brain and C(6)Bu-1 glioma cells and that PLC-beta 1a and PLC-beta 1b correspond to the previously identified 150- and 140-kDa PLC-beta 1 enzymes, respectively. Analysis of PLC-beta 1 genomic DNA indicates that PLC-beta 1a and PLC-beta 1b are derived from a single gene by alternative RNA splicing.	POHANG UNIV SCI & TECHNOL, DEPT LIFE SCI, POHANG 790600, SOUTH KOREA	Pohang University of Science & Technology (POSTECH)			Seo, Jeong Kon/H-4770-2016; Suh, Pann-Ghill/F-3610-2010	Ryu, Sung Ho/0000-0003-0913-3048				BANNO Y, 1990, BIOCHEM BIOPH RES CO, V167, P396, DOI 10.1016/0006-291X(90)92035-X; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BRADFORD PG, 1986, BIOCHEM J, V239, P97, DOI 10.1042/bj2390097; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERREIRA PA, 1993, P NATL ACAD SCI USA, V90, P6042, DOI 10.1073/pnas.90.13.6042; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; HARLOW E, 1988, ANTIBODIES LABORATOR; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; JHON DY, 1993, J BIOL CHEM, V268, P6654; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KATAN M, 1987, EUR J BIOCHEM, V168, P413, DOI 10.1111/j.1432-1033.1987.tb13435.x; KIM MJ, 1993, BIOCHEM BIOPH RES CO, V194, P706, DOI 10.1006/bbrc.1993.1879; KRIZ R, 1990, CIBA F SYMP, V150, P112; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MIN DS, 1993, J BIOL CHEM, V268, P12207; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHTA S, 1988, FEBS LETT, V242, P31, DOI 10.1016/0014-5793(88)80979-7; PARK D, 1992, J BIOL CHEM, V267, P16048; PARK DG, 1993, J BIOL CHEM, V268, P3710; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1987, J BIOL CHEM, V262, P12511; RYU SH, 1986, BIOCHEM BIOPH RES CO, V141, P137, DOI 10.1016/S0006-291X(86)80345-X; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, J BIOL CHEM, V263, P14497; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WU DQ, 1993, J BIOL CHEM, V268, P3704; WU DQ, 1992, J BIOL CHEM, V267, P25798	47	93	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8240	8245						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510682				2022-12-25	WOS:A1994NB40900063
J	HAN, JH; MATHISON, JC; ULEVITCH, RJ; TOBIAS, PS				HAN, JH; MATHISON, JC; ULEVITCH, RJ; TOBIAS, PS			LIPOPOLYSACCHARIDE (LPS) BINDING-PROTEIN, TRUNCATED AT ILE-197, BINDS LPS BUT DOES NOT TRANSFER LPS TO CD14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ACUTE PHASE REACTANT; PARTICIPATION	Lipopolysaccharide (LPS) binding protein (LBP), a 58-60 kDa glycoprotein, binds to the lipid A region of LPS. The resulting LPS.LBP complex is recognized by both the membrane-bound (mCD14) and soluble forms of CD14 (sCD14), thereby enhancing the ability of LPS to activate myeloid, endothelial, and epithelial cells. To begin to characterize the structure-function relationships within LBP, we have created and expressed a truncated form of human LBP (herein called NH-LBP) comprising amino acid residues 1-197 of the parent molecule. Experiments were done to characterize the ability of NH-LBP to bind LPS and to promote LPS binding to CD14. We found that NH-LBP efficiently binds LPS but does not transfer the LPS to either mCD14 or sCD14. Additionally, NH-LBP inhibited LPS binding to LBP, inhibited the LBP-promoted binding of LPS to CD14, and inhibited the LBP-dependent activation of rabbit peritoneal exudate macrophages. The apparent dissociation constant for LPS NH-LBP complexes is less than 1 x 10(-8) M which compares well with the dissociation constant for LPS.LBP complexes of approximately 1 x 10(-9) M. We conclude from these studies that the LPS binding site of LBP resides in the amino terminal half of LBP and that the CD14 interaction site resides in the carboxyl-terminal half of LBP. These data suggest that appropriately modified fragments of LBP might provide novel reagents with high LPS binding affinity that could be useful in inhibiting LPS-dependent cellular activation in vivo.			HAN, JH (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.		Han, J/G-4671-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015136, R01AI032021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15136, AI32021] Funding Source: Medline; NIGMS NIH HHS [GM37696] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; HEUMANN D, 1992, J IMMUNOL, V148, P3505; KIRKLAND TN, 1993, J BIOL CHEM, V268, P24818; MATHISON JC, 1988, J CLIN INVEST, V81, P1925, DOI 10.1172/JCI113540; OOI CE, 1991, J EXP MED, V174, P649, DOI 10.1084/jem.174.3.649; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; Sambrook J., 1989, MOL CLONING; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SKELLY RR, 1979, INFECT IMMUN, V23, P287, DOI 10.1128/IAI.23.2.287-293.1979; SUMMERS MD, 1988, MANUAL METHODS BACUL; SWENSON TL, 1988, J BIOL CHEM, V263, P5150; TOBIAS PS, 1993, J IMMUNOL, V150, P3011; TOBIAS PS, 1992, AM J RESP CELL MOL, V7, P239, DOI 10.1165/ajrcmb/7.3.239; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; ULEVITCH RJ, 1993, IN PRESS CURR OPIN I; WOLLENWEBER HW, 1985, J BIOL CHEM, V260, P5068; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	20	59	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8172	8175						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510680				2022-12-25	WOS:A1994NB40900054
J	LI, H; KUO, A; KOCHAN, J; STRICKLAND, D; KARIKO, K; BARNATHAN, ES; CINES, DB				LI, H; KUO, A; KOCHAN, J; STRICKLAND, D; KARIKO, K; BARNATHAN, ES; CINES, DB			ENDOCYTOSIS OF UROKINASE-PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 COMPLEXES BOUND TO A CHIMERIC TRANSMEMBRANE UROKINASE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; GLYCOSYL-PHOSPHATIDYLINOSITOL; CELLULAR RECEPTOR; IL-2 RECEPTOR; DEGRADATION; CELLS; CHAIN; INTERNALIZATION; LOCALIZATION; EXPRESSION	The urokinase receptor (uPAR) is linked to plasma membranes through a glycosylphosphatidylinositol (GPI) anchor. It has been posited that the GPI anchor facilitates clearance of uPAR-bound complexes between two chain urokinase (tcuPA) and plasminogen activator inhibitor type 1 (PAI-1) by the alpha(2)-macroglobulin receptor (alpha(2)MR) which permits re-expression of unoccupied uPA receptors on the cell surface. To test this hypothesis we compared internalization and degradation of I-125-labeled tcuPA.PAI-1 by COS cells expressing either transfected wild-type, GPI-linked uPAR (uPAR/GPI), or a chimeric receptor composed of the extracellular domains of uPAR linked to the transmembrane and cytosolic domains of the alpha chain (p55 subunit) of the interleukin-2 receptor (uPAR/IL-2R(alpha)). The kinetics of binding, internalization and degradation of tcuPA.PAI-1 by COS cells expressing each form of uPAR were virtually identical. However, internalization of complexes by uPAR/IL-2R(alpha) was more susceptible to inhibition by recombinant soluble 39-kDa alpha(2)MR-associated protein (RAP) which competes for binding of tcuPA.PAI-1 complexes to alpha(2)MR (p < 0.001), and the internalization was accompanied by a greater reduction in the number of surface uPAR/IL-2R(alpha), than uPAR/GPI (p < 0.05). These studies indicate that the rate of internalization of tcuPA. PAI-1 is governed primarily by the extracellular domains of uPAR, whereas the GPI anchor may facilitate internalization of complexes and re-expression of uPAR when binding sites on (alpha(2)MR are limiting.	HOSP UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104; HOSP UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104; HOFFMANN LA ROCHE INC,DEPT BRONCHOPULM RES,NUTLEY,NJ 07110; AMER RED CROSS,DEPT BIOCHEM,ROCKVILLE,MD 20855	University of Pennsylvania; University of Pennsylvania; Roche Holding; American Red Cross					NHLBI NIH HHS [HL47839, HL 40387, F32HL08621] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047839, F32HL008621, P01HL040387] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNATHAN ES, 1990, BLOOD, V76, P1795; BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELAHUNTY MD, 1993, J BIOL CHEM, V268, P12017; DUPREZ V, 1992, J BIOL CHEM, V267, P18639; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FUNG MR, 1988, J EXP MED, V168, P1928; GROBMYER SR, 1993, J BIOL CHEM, V268, P13291; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; HUETTINGER M, 1992, J BIOL CHEM, V267, P18551; MOLLER LB, 1992, EUR J BIOCHEM, V208, P493, DOI 10.1111/j.1432-1033.1992.tb17213.x; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OLSON D, 1992, J BIOL CHEM, V267, P9129; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PLESNER T, 1992, BLOOD S, V80, pA98; PLOUG M, 1991, J BIOL CHEM, V266, P1926; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; POLLANEN J, 1990, P NATL ACAD SCI USA, V87, P2230, DOI 10.1073/pnas.87.6.2230; SHULDINER AR, 1991, ANAL BIOCHEM, V194, P9, DOI 10.1016/0003-2697(91)90144-I; SINGH N, 1991, MOL CELL BIOL, V11, P2362, DOI 10.1128/MCB.11.5.2362; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TODD RF, 1988, J IMMUNOL, V140, P1095; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035	30	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8153	8158						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510679				2022-12-25	WOS:A1994NB40900051
J	AMARAVADI, L; KING, MW				AMARAVADI, L; KING, MW			CHARACTERIZATION AND EXPRESSION OF THE XENOPUS C-MYB HOMOLOG	ONCOGENE			English	Note							PROTO-ONCOGENE; HEMATOPOIETIC-CELLS; NUCLEOTIDE-SEQUENCE; DNA; GENE; PROLIFERATION; TRANSCRIPTION; ORGANIZATION; ACTIVATION; PROTEINS	The c-Myb protein is a sequence specific DNA-binding transcriptional regulator that is critically involved in the regulation of hematopoietic differentiation. Its role in these processes suggests that the function of c-Myb may be important early in the establishment of the hematopoietic lineage. We have isolated cDNA and partial genomic clones representing the Xenopus c-Myb homolog (Xc-Myb) in order to examine the role this gene plays in early mesodermal patterning in the frog embryo. The establishment of these clones as c-Myb homologs, as opposed to Myb-related sequences, is based upon both predicted amino acid sequences and the location of the exon-intron boundaries within the Xc-Myb gene. Maternally derived Xc-Myb RNA is degraded following fertilization then, beginning at midblastula, re-accumulates throughout early development. Xc-Myb RNA is localized to the animal cap region of the early blastula. Following the onset of gastrulation expression predominates in the ventral half of the embryo. During neurulation expression of Xc-Myb is observed in both the anterior dorsal and ventral vegetal regions of the embryo. Expression of Xc-Myb occurs in several adult tissues, the highest levels of which are in the intestine, heart, liver, lung and ovary. Xc-Myb encodes a protein of 624 amino acids and exhibits a mobility in SDS-PAGE of approximately 75 kDa, identical with that of the murine c-Myb protein. Xc-Myb protein exhibits 70% identity with avian and 67% identity with mammalian c-Myb proteins.	INDIANA UNIV,SCH MED,TERRE HAUTE CTR MED SCI,DEPT BIOCHEM & MOLEC BIOL,TERRE HAUTE,IN 47809; INDIANA STATE UNIV,DEPT LIFE SCI,TERRE HAUTE,IN 47809	Indiana University System; Indiana State University								ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; BANKER DE, 1991, MOL CELL BIOL, V11, P5079, DOI 10.1128/MCB.11.10.5079; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; DESBIENS X, 1991, DEVELOPMENT, V111, P699; DUPASQUIER L, 1989, ANNU REV IMMUNOL, V7, P251, DOI 10.1146/annurev.immunol.7.1.251; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GREEN N, 1979, Cellular Immunology, V48, P59, DOI 10.1016/0008-8749(79)90099-6; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; KATAGIRI C, 1986, CURR TOP DEV BIOL, V98, P315; KING MW, 1993, CELL GROWTH DIFFER, V4, P85; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NIEUWKOOP PD, 1967, NORMAL TABLE XENOPUS, P162; REILLY CF, 1989, J BIOL CHEM, V264, P6990; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SLACK JMW, 1993, MECH DEVELOP, V41, P91, DOI 10.1016/0925-4773(93)90040-5; THEILE CJ, 1988, MOL CELL BIOL, V8, P1677; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043	30	18	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					971	974						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	7509053				2022-12-25	WOS:A1994MW55100036
J	MEYER, DJ; CAMPBELL, GS; COCHRAN, BH; ARGETSINGER, LS; LARNER, AC; FINBLOOM, DS; CARTERSU, C; SCHWARTZ, J				MEYER, DJ; CAMPBELL, GS; COCHRAN, BH; ARGETSINGER, LS; LARNER, AC; FINBLOOM, DS; CARTERSU, C; SCHWARTZ, J			GROWTH-HORMONE INDUCES A DNA-BINDING FACTOR-RELATED TO THE INTERFERON-STIMULATED 91-KDA TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-TYROSINE KINASES; SERUM RESPONSE ELEMENT; C-FOS; ALPHA; GENE; PHOSPHORYLATION; REGION; ACTIVATION; INDUCTION; SECRETION	Signaling mechanisms leading to regulation of gene transcription by growth hormone (GH) and other molecules that signal via the cytokine receptor family have been elusive. Based upon recent findings that GH and interferons activate JAK family tyrosine kinases, we have identified a novel signaling pathway leading from the GH receptor to the nucleus. We report that in 3T3-F442A fibroblasts, GH stimulates tyrosyl phosphorylation of a protein recognized by antibody to p91, a component of DNA-binding complexes that are activated by tyrosyl phosphorylation in response to interferons alpha and gamma. In addition, a GH-inducible DNA binding factor (GHIF) is identified that binds to the c-sis-inducible element of the c-fos promoter. GHIF contains a protein antigenically related to p91 and is tyrosyl-phosphorylated. These findings indicate that in signaling between their receptors and the nucleus, GH and interferons utilize related or identical components, including JAK family tyrosine kinases and proteins in the p91 family. When combined with recent findings that many members of the cytokine receptor family activate JAK kinases, including some cytokines that activate p91-related proteins, these findings suggest that signaling pathways involving JAB kinases and p91 family members may be broadly distributed.	UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111; CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892	University of Michigan System; University of Michigan; Tufts University; US Food & Drug Administration (FDA)					NCI NIH HHS [P01-CA42063] Funding Source: Medline; NIDDK NIH HHS [DK34171, R01 DK034171] Funding Source: Medline; NIGMS NIH HHS [GM07315, T32 GM007315] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034171, R37DK034171] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; DAVID M, 1993, J BIOL CHEM, V268, P6593; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; EDEN S, 1979, ENDOCRINOLOGY, V105, P555, DOI 10.1210/endo-105-2-555; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GUAN K, 1990, SCIENCE, V257, P813; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; HANNIGAN GE, 1992, J INTERFERON RES, V12, P355, DOI 10.1089/jir.1992.12.355; HARPUR AG, 1992, ONCOGENE, V7, P1347; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; MEYER DJ, 1993, P NATL ACAD SCI USA, V90, P6721, DOI 10.1073/pnas.90.14.6721; MORIKAWA M, 1982, CELL, V29, P783, DOI 10.1016/0092-8674(82)90440-8; NIXON T, 1984, ENDOCRINOLOGY, V114, P527, DOI 10.1210/endo-114-2-527; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHINDLER C, 1992, ENDOCRINOLOGY, V89, P7836; SHNAI K, 1993, SCIENCE, V268, P7427; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1994, IN PRESS SCIENCE; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	41	172	174	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4701	4704						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508925				2022-12-25	WOS:A1994MX57100003
J	LI, SH; BURNS, DK; RUMBERGER, JM; PRESKY, DH; WILKINSON, VL; ANOSTARIO, M; WOLITZKY, BA; NORTON, CR; FAMILLETTI, PC; KIM, KJ; GOLDSTEIN, AL; COX, DC; HUANG, KS				LI, SH; BURNS, DK; RUMBERGER, JM; PRESKY, DH; WILKINSON, VL; ANOSTARIO, M; WOLITZKY, BA; NORTON, CR; FAMILLETTI, PC; KIM, KJ; GOLDSTEIN, AL; COX, DC; HUANG, KS			CONSENSUS REPEAT DOMAINS OF E-SELECTIN ENHANCE LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION MOLECULE-1; CARBOHYDRATE-RECOGNITION DOMAINS; NODE HOMING RECEPTOR; NEUTROPHIL ADHERENCE; CELL-ADHESION; VASCULAR ENDOTHELIUM; SIALYL-LEX; PROTEINS; EXPRESSION; GMP-140	To study the structural characteristics of E-selectin necessary for mediating cell adhesion, we examined the role of the consensus repeat (CR) domains in E-selectin function. Soluble constructs containing different numbers of CR domains were stably expressed in Chinese hamster ovary cells, purified to homogeneity, and characterized. The minimum functional unit of soluble E-selectin consisted of the lectin (Lee) and epidermal growth factor (EGF) domains alone (Lec-EGF) as indicated by its ability to mediate in vitro HL-60 cell adhesion. However, E-selectin containing all six CR domains (Lec-EGF-CR6) at its COOH terminus was the most potent in blocking neutrophil or HL-60 cell adhesion to either immobilized E-selectin or cytokine-stimulated human umbilical vein endothelial cells. This increased potency of Lec-EGF-CR6 in blocking cell adhesion was not due to CR-mediated oligomerization of the protein. Lec-EGF-CR6 was most likely monomeric in solution, as judged by gel filtration fast protein liquid chromatography, membrane ultrafiltration, and chemical cross-linking analysis. Therefore, although the lectin and EGF do mains are necessary and sufficient for mediating cell adhesion, the additional six CR domains, present in native E-selectin, contribute to the enhanced binding of E-selectin to its ligand.	HOFFMANN LA ROCHE INC,DEPT INFLAMMAT AUTOIMMUNE DIS,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,DEPT MOLEC SCI,NUTLEY,NJ 07110	Roche Holding; Roche Holding								ARNAOUT MA, 1988, J CELL PHYSIOL, V137, P305, DOI 10.1002/jcp.1041370214; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CAMERINI D, 1989, NATURE, V342, P78, DOI 10.1038/342078a0; COCKETT MI, 1990, BIO-TECHNOL, V8, P662, DOI 10.1038/nbt0790-662; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; GIMBRONE M A JR, 1978, TCA (Tissue Culture Association) Manual, V4, P813, DOI 10.1007/BF00918403; HARLAN JM, 1985, BLOOD, V66, P167; HENSLEY P, 1993, BIOPHYS J, V64, pA375; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUTILA MA, 1992, J EXP MED, V175, P1565, DOI 10.1084/jem.175.6.1565; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LUSCINSKAS FW, 1989, J IMMUNOL, V142, P2257; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NEWMAN W, 1993, J IMMUNOL, V150, P644; NORTON C R, 1990, Journal of Cell Biology, V111, p158A; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; PIGOTT R, 1991, J IMMUNOL, V147, P130; POBER JS, 1986, J IMMUNOL, V136, P1680; POHLMAN TH, 1986, J IMMUNOL, V136, P4548; SCALLON BJ, 1992, BIO-TECHNOL, V10, P550, DOI 10.1038/nbt0592-550; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON SR, 1991, J CELL BIOL, V115, P235, DOI 10.1083/jcb.115.1.235; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	40	57	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4431	4437						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508442				2022-12-25	WOS:A1994MW98900083
J	PETERSON, JE; JELINEK, T; KALEKO, M; SIDDLE, K; WEBER, MJ				PETERSON, JE; JELINEK, T; KALEKO, M; SIDDLE, K; WEBER, MJ			C-PHOSPHORYLATION AND ACTIVATION OF THE IGF-I RECEPTOR IN SRC-TRANSFORMED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; ROUS-SARCOMA VIRUS; CHICKEN-EMBRYO FIBROBLASTS; PHOSPHOTYROSINE-CONTAINING PROTEINS; TYROSINE KINASE-ACTIVITY; HUMAN INSULIN-RECEPTOR; HUMAN-SKIN FIBROBLASTS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; BETA-SUBUNIT	Using a panel of src mutants partially defective for malignant transformation, our laboratory has previously identified the insulin-like growth factor (IGF-I) receptor as a protein whose tyrosine phosphorylation correlates with transformation by src in embryonic chick cells (Kozma ct al., 1990; Kozma and Weber, 1990). It has not been clear, however, whether are-induced phosphorylation altered the enzymatic or signaling properties of the IGF-I receptor and thus whether the IGF-I receptor could be a functionally significant target for pp(60v.src). To examine the effect of src expression on the activity of the IGF-I receptor, the human IGF-I receptor was expressed in Rat-1 fibroblasts co-expressing the temperature-sensitive v-src mutant, tsLA29, The IGF-I receptor exhibited an elevated level of tyrosine phosphorylation in are transformed cells even in the absence of IGF-I treatment. Increased receptor phosphorylation occurred rapidly when cells expressing a temperature-conditional are mutant were shifted from the restrictive to the permissive temperature. Src-induced phosphorylation of the receptor was correlated with an increase in the in vitro tyrosine kinase activity of the receptor, both toward itself and exogenous substrates. The are-induced increase in receptor activity was shown to be dependent on tyrosine phosphorylation, as treatment with a tyrosine-specific phosphatase lowered receptor activity. A kinase-defective mutant of the IGF-I receptor also became constitutively phosphorylated in are-transformed cells, ruling out a possible autocrine mechanism for this phosphorylation. Collectively these data indicate that pp(60v.src) induces ligand-independent phosphorylation and activation of the IGF-I receptor by an intracellular mechanism, consistent with the possibility that receptor phosphorylation could contribute to the genesis of the transformed phenotype.	UNIV VIRGINIA,HLTH SCI CTR,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; GENET THERAPY INC,GAITHERSBURG,MD 20878; UNIV CAMBRIDGE,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND	University of Virginia; Novartis; University of Cambridge					NATIONAL CANCER INSTITUTE [R37CA039076, R01CA039076, P01CA040042] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39076, CA 40042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMO M, 1992, BIOFACTORS, V3, P151; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BARON V, 1992, J BIOL CHEM, V267, P23290; BEGUM N, 1993, J BIOL CHEM, V268, P7917; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; CHAIKEN RL, 1986, J CLIN ENDOCR METAB, V63, P1181, DOI 10.1210/jcem-63-5-1181; Chen E, 1986, Biochem Soc Symp, V52, P65; COOPER J, 1983, J VIROL, V46, P15, DOI 10.1128/JVI.46.1.15-28.1983; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; CZECH MP, 1982, CELL, V31, P8, DOI 10.1016/0092-8674(82)90399-3; FALCO JP, 1988, ONCOGENE, V2, P573; FLIER JS, 1986, P NATL ACAD SCI USA, V83, P664, DOI 10.1073/pnas.83.3.664; FORMISANO P, 1993, J BIOL CHEM, V268, P5241; FRATTALI AL, 1993, J BIOL CHEM, V268, P7393; GAMMELTOFT S, 1989, PEPTIDE HORMONES PRO, P176; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; JACOBS S, 1990, HDB EXPT PHARM, V92, P267; JANICOT M, 1991, J BIOL CHEM, V266, P9382; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KATO H, 1993, J BIOL CHEM, V268, P2655; KOZMA LM, 1990, MOL CELL BIOL, V10, P837, DOI 10.1128/MCB.10.2.837; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LAMPHERE L, 1994, AM J PHYSIOL, V266, P486; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LINDER ME, 1988, P NATL ACAD SCI USA, V85, P2608, DOI 10.1073/pnas.85.8.2608; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LIU DL, 1992, J VIROL, V66, P374, DOI 10.1128/JVI.66.1.374-385.1992; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MARTINEZ R, 1982, MOL CELL BIOL, V2, P653, DOI 10.1128/MCB.2.6.653; MCCLAIN DA, 1990, J BIOL CHEM, V265, P1678; MOONEY RA, 1992, J BIOL CHEM, V267, P23443; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; PARSONS JT, 1989, CURR TOP MICROBIOL I, V147, P80; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PENHOAT A, 1988, ENDOCRINOLOGY, V122, P2518, DOI 10.1210/endo-122-6-2518; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SASOAKA T, 1988, DIABETES, V37, P1515; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SOOS MA, 1989, BIOCHEM J, V263, P553, DOI 10.1042/bj2630553; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WEBER MJ, 1979, CELL, V16, P25, DOI 10.1016/0092-8674(79)90184-3; WEBER MJ, 1984, ADV VIRAL ONCOL, V4, P249; WHITE MF, 1984, J CELL BIOCHEM, V26, P169, DOI 10.1002/jcb.240260305; WHITE MF, 1988, J BIOL CHEM, V263, P2969; YAMAMOTO K, 1992, J BIOL CHEM, V267, P11337; YAMASAKI H, 1992, J BIOL CHEM, V267, P20953; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; YU KT, 1985, J BIOL CHEM, V260, P5838; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	59	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27315	27321						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525552				2022-12-25	WOS:A1994PV77100029
J	CHIAVAROLI, C; BIRD, GS; PUTNEY, JW				CHIAVAROLI, C; BIRD, GS; PUTNEY, JW			DELAYED ALL-OR-NONE ACTIVATION OF INOSITOL 1,4,5-TRISPHOSPHATE-DEPENDENT CALCIUM SIGNALING IN SINGLE-RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACRIMAL ACINAR-CELLS; PERMEABILIZED HEPATOCYTES; STIMULATED HEPATOCYTES; CA2+ MOBILIZATION; OSCILLATIONS; VASOPRESSIN; RELEASE; FURA-2; SEQUESTRATION; SECRETION	When single rat hepatocytes were stimulated with the phospholipase C-activating hormone, vasopressin (from 300 pM to 1 mu M), the [Ca2+](i) signals were always ''all-or-none'' responses. At low concentrations of vasopressin, Ca2+ release was maximal because liberation of additional inositol 1,4,5-trisphosphate (IP3) by photolysis of its caged precursor at the top of the [Ca2+](i) spike failed to increase [Ca2+](i) further. However, if IP3 was generated by photolysis of caged IP3 in previously unstimulated cells, [Ca2+](i) increased immediately, and the magnitude of the response was a graded function of the quantity of IP3 released. We also analyzed the kinetics of activation of intracellular IP3 receptor/Ca2+ channels by monitoring the quench of sequestered dye by the entry of cytoplasmic Mn2+ into fura-2-loaded intracellular IP3-sensitive organelles. This Mn2+-induced quench was precipitous and always preceded by a delay inversely related to the vasopressin concentration. In hepatocytes stimulated with 10 nM vasopressin, IP3 increased slowly, and the half-time of the IP3 rise was comparable with the latency for the release of intracellular calcium. The slow rise in IP3 would be predicted to produce accelerating Ca2+ release. This is consistent with the results of the Mn2+ quench experiments, which revealed accelerating activation of intracellular IP3-regulated calcium channels. We conclude that this accelerating release of Ca2+, which does not occur with instantaneous increases in IP3 due to flash photolysis, is likely to be important for generating the all-or-none Ca2+ mobilization that initiates the processes of intracellular [Ca2+](i) oscillations.			CHIAVAROLI, C (corresponding author), NIEHS,CELLULAR & MOLEC PHARMACOL LAB,RES TRIANGLE PK,NC 27709, USA.		Bird, Gary/AAI-8186-2021; Putney, James/F-7247-2019	Bird, Gary/0000-0003-1389-8748; Putney, James/0000-0002-3379-4789				Berridge Michael J., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P211; BIRD GS, 1992, J BIOL CHEM, V267, P18382; BIRD GS, 1992, J BIOL CHEM, V267, P17722; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; BLATTER LA, 1990, BIOPHYS J, V58, P1491, DOI 10.1016/S0006-3495(90)82494-2; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; CANNY BJ, 1992, J BIOL CHEM, V267, P8325; DIVIRGILIO F, 1990, CELL CALCIUM, V11, P57, DOI 10.1016/0143-4160(90)90059-4; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GLENNON MC, 1992, J BIOL CHEM, V267, P8230; GRAY PTA, 1988, J PHYSIOL-LONDON, V406, P35, DOI 10.1113/jphysiol.1988.sp017367; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; KWAN CY, 1990, J BIOL CHEM, V265, P678; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MONCK JR, 1988, J BIOL CHEM, V263, P4569; PETERSEN CCH, 1991, EMBO J, V10, P527, DOI 10.1002/j.1460-2075.1991.tb07979.x; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	25	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25570	25575						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523388				2022-12-25	WOS:A1994PQ49100053
J	WEIL, R; VEILLETTE, A				WEIL, R; VEILLETTE, A			INTRAMOLECULAR AND EXTRAMOLECULAR MECHANISMS REPRESS THE CATALYTIC FUNCTION OF P56(LCK) IN RESTING T-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PROTEIN-KINASE; CELL ANTIGEN RECEPTOR; SH3 DOMAINS; ZETA-CHAIN; PHENYLARSINE OXIDE; PHOSPHATASE CD45; PHOSPHORYLATION; P56LCK; LCK; EXPRESSION	Accumulating data show that the catalytic function of the Src-related tyrosine protein kinase p56(lck) is repressed by phosphorylation of a conserved carboxyl-terminal tyrosine residue (tyrosine 505). However, previous findings (Abraham, N., Miceli, M. C., Parnes, J. R., and Veillette, A. (1991) Nature 350, 62-66) suggest that mechanisms unrelated to tyrosine 505 phosphorylation repress the catalytic function of p56(lck) in resting T-cells. In keeping with this view, we report herein that the Src homology 3 (SH3) and SH2 domains negatively regulate the catalytic activity of p56(lck), by a process independent of carboxyl-terminal tyrosine phosphorylation. While the exact mechanism of this inhibition are not established, its structural requirements in the SH2 domain are distinct hom those allowing recruitment of Lck in T-cell receptor signaling. In addition, we obtained evidence that the elevated tyrosine protein phosphatase activity present in T-cells also contributes to inhibit the enzymatic function of p56(lck). Such an effect is seemingly mediated by dephosphorylation of tyrosine 394, the site of positive regulation of p56(lck). Collectively these results indicate that the catalytic function of p56(lck) in resting T-cells is repressed by a complex set of processes, which involves both intramolecular and extramolecular mechanisms.	MCGILL UNIV,MCGILL CTR,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL H3G 1Y6,PQ,CANADA; MONTREAL GEN HOSP,DEPT MED,MONTREAL H3G 1A4,PQ,CANADA; MONTREAL GEN HOSP,DEPT ONCOL,MONTREAL H3G 1A4,PQ,CANADA	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University				Weil, Robert/0000-0001-5235-0932				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BUDAY L, 1994, J BIOL CHEM, V269, P9019; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CASNELLIE JE, 1987, J BIOL CHEM, V262, P9858; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FLETCHER MC, 1993, J BIOL CHEM, V268, P23697; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; LUO K, 1990, ONCOGENE, V5, P803; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; PERI KG, 1993, ONCOGENE, V8, P2765; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RESKEKUNZ AB, 1985, EUR J IMMUNOL, V15, P1048, DOI 10.1002/eji.1830151017; REYNOLDS PJ, 1992, ONCOGENE, V7, P1949; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SOULA M, 1993, J BIOL CHEM, V268, P27420; STANNERS CP, 1971, NATURE-NEW BIOL, V230, P52, DOI 10.1038/newbio230052a0; Veillette A, 1991, Semin Immunol, V3, P143; VEILLETTE A, 1992, ONCOGENE, V7, P971; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	51	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22830	22838						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7521333				2022-12-25	WOS:A1994PQ16300057
J	STANCATO, LF; CHOW, YH; OWENSGRILLO, JK; YEM, AW; DEIBEL, MR; JOVE, R; PRATT, WB				STANCATO, LF; CHOW, YH; OWENSGRILLO, JK; YEM, AW; DEIBEL, MR; JOVE, R; PRATT, WB			THE NATIVE V-RAF-CENTER-DOT-HSP90-CENTER-DOT-P50 HETEROCOMPLEX CONTAINS A NOVEL IMMUNOPHILIN OF THE FK506 BINDING CLASS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COMPLEXES; ROUS-SARCOMA VIRUS; HEAT-SHOCK PROTEINS; PEPTIDYL-PROLYL ISOMERASE; CELL-FREE SYSTEM; GLUCOCORTICOID RECEPTOR; PROGESTERONE-RECEPTOR; FK506-BINDING PROTEIN; IMMUNOSUPPRESSANT FK506; TRANSFORMING PROTEIN	We have recently reported that v-Raf forms a native heterocomplex with rat heat shock protein (hsp) 90 and a 50-kDa phosphoprotein (p50) in stably transfected 3Y1 fibroblasts (Stancato, L. F., Chow, Y-H., Hutchison, K. A., Perdew, G. H., Jove, R., and Pratt, W. B. (1993) J. Biol. Chem. 268, 21711-21716). Several members of the nuclear receptor family exist in heterocomplexes containing hsp90 and various members of the immunophilin protein family, including hsp56, an immunophilin of the FK506 binding class (Pratt, W E. (1993) J. Biol. Chem. 268, 21455-21458). In this work, we have asked if Raf is also associated with an immunophilin. We have immunoadsorbed v-Raf from stably transfected rat 3Y1 fibroblasts and show that the immunoadsorbed v-Raf.hsp90.p50 p50 heterocomplex binds the immunosuppressant drug [H-3]FK506. The binding is of high affinity (K-D 82 nM) and specific in the sense that it is competed by nonradioactive FK506 and rapamycin but not by cyclosporin A. The [H-3]FK506 binding activity is eliminated when the heterocomplex proteins are dissociated from v Raf. Using the 22W mutant of c-Raf in which the NH2-terminal half has been deleted, we show that the catalytic domain of the kinase is sufficient for the immunophilin association. We have shown that hsp90 and p50 do not bind FK506, and the v-Raf heterocomplex does not contain any of the established FK506-binding proteins. Thus, we propose that Raf is associated with a novel immunophilin.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109; UPJOHN CO,DEPT BIOCHEM,KALAMAZOO,MI 49001	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Pfizer					NATIONAL CANCER INSTITUTE [R01CA028010, R01CA055652] Funding Source: NIH RePORTER; NCI NIH HHS [CA28010, CA55652] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; HUTCHISON KA, 1993, BIOCHEMISTRY-US, V32, P3953, DOI 10.1021/bi00066a015; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JIN YJ, 1992, J BIOL CHEM, V267, P10942; KIEFFER LJ, 1992, J BIOL CHEM, V267, P5503; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; PARK ST, 1992, J BIOL CHEM, V267, P3316; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PRATT WB, 1993, J STEROID BIOCHEM, V46, P269, DOI 10.1016/0960-0760(93)90216-J; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; RATAJCZAK T, 1990, J STEROID BIOCHEM, V35, P543, DOI 10.1016/0022-4731(90)90197-Z; RUFF VA, 1992, J BIOL CHEM, V267, P21285; RUFF VA, 1992, IMMUNOL INVEST, V21, P259, DOI 10.3109/08820139209072263; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1993, J BIOL CHEM, V268, P24270; SMITH DF, 1993, J BIOL CHEM, V268, P18365; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; TAI PKK, 1993, BIOCHEMISTRY-US, V32, P8842, DOI 10.1021/bi00085a015; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; YEM AW, 1992, J BIOL CHEM, V267, P2868	39	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22157	22161						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7520912				2022-12-25	WOS:A1994PE09800037
J	OKAMURA, H; RESH, MD				OKAMURA, H; RESH, MD			DIFFERENTIAL BINDING OF PP60(C-SRC) AND PP60(V-SRC) TO CYTOSKELETON IS MEDIATED BY SH2 AND CATALYTIC DOMAINS	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; PHOSPHOTYROSINE-CONTAINING PROTEINS; GTPASE-ACTIVATING PROTEIN; INSOLUBLE CELLULAR MATRIX; GROWTH-FACTOR RECEPTORS; TYROSINE KINASE; SIGNAL TRANSDUCTION; SRC GENE; MORPHOLOGICAL TRANSFORMATION; PP60C-SRC	The transforming protein of Rous sarcoma virus, pp60(v-src), and its normal cellular homolog, pp60(c-src), differ not only in oncogenic potential but also in their subcellular localization and cytoskeletal binding ability. pp60(v-src) has been shown to stably associate with a detergent-insoluble cytoskeletal matrix, whereas pp60(c-src) does not. We have generated a series of precise deletion and truncations of the Src homology domains within pp60(v-src) and pp60(c-src), based on the crystal and solution structures of these regions, to determine not only the region responsible for cytoskeletal association but also the mechanism accounting for the differential binding observed. Here we show that the SH2 domain, but not the SH3 domain, mediates cytoskeletal association of pp60(v-src) through a phosphotyrosine-dependent interaction. The ability to interact with the cytoskeletal matrix is regulated by the catalytic (SH1) domain. Truncation of the pp60(v-src) catalytic domain results in lower binding while removal of the catalytic domain of pp60(c-src) results in the acquisition of cytoskeletal binding similar to that of the analogous v-src construct. These results indicate that the SH2 and catalytic domains function coordinately to regulate the cytoskeletal association of pp60(v-src) and pp60(c-src).	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Memorial Sloan Kettering Cancer Center; Princeton University				Resh, Marilyn/0000-0001-6118-9466	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [NCI-P30-CA-08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HAMAGUCHI M, 1989, ONCOGENE RES, V4, P29; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KLAPPER A, 1992, BIOTECHNIQUES, V12, P651; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU XQ, 1993, ONCOGENE, V8, P1119; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; RESH MD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P307, DOI 10.1016/0304-419X(93)90012-2; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SILVERMAN L, 1992, J CELL BIOL, V119, P415, DOI 10.1083/jcb.119.2.415; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	50	46	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2293	2303						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7518578				2022-12-25	WOS:A1994NX62900022
J	SHIMADA, M; INOUYE, S; INOUYE, M				SHIMADA, M; INOUYE, S; INOUYE, M			REQUIREMENTS OF THE SECONDARY STRUCTURES IN THE PRIMARY TRANSCRIPT FOR MULTICOPY SINGLE-STRANDED-DNA SYNTHESIS BY REVERSE-TRANSCRIPTASE FROM BACTERIAL RETRON-EC107	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-LINKED MSDNA; ESCHERICHIA-COLI; MYXOCOCCUS-XANTHUS; EXTRACTION	Multicopy single-stranded DNA (msDNA) is produced by bacterial retroelements called retrons. It consists of single-stranded DNA that is linked to an internal G residue of an RNA molecule by a 2',5'-phosphodiester linkage. It has been demonstrated that specific primary sequences, as well as the secondary structures immediately downstream of the G residue, are essential for the cDNA priming reaction (Shimamoto, T, Hsu, M.-Y., Inouye, S., and Inouye, M. (1993) J. Biol. Chem. 268, 2684-2692). We have now examined the requirement of the structures in the region corresponding to DNA for msDNA synthesis. The upper stem region consisting of 71 bases of msDNA-Ec107 was found not to be essential, and this region could be deleted to efficiently produce a truncated msDNA containing only a 36-base single-stranded DNA. Various mutations including base replacements, deletions, and insertions were constructed in the lower stem region. It was found that any mutations resulting in more stable secondary structures caused reduction in msDNA synthesis. The results indicated that reverse transcriptase requires a loose secondary structure in the template RNA near the cDNA priming site for cDNA elongation.			SHIMADA, M (corresponding author), ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854, USA.		Inouye, Sharon/R-7216-2019		NIGMS NIH HHS [GM44012] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044012] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR A, 1994, J VIROL, V68, P611, DOI 10.1128/JVI.68.2.611-618.1994; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; BERKHOUT B, 1993, NUCLEIC ACIDS RES, V21, P1171, DOI 10.1093/nar/21.5.1171; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; HERZER PJ, 1992, MOL MICROBIOL, V6, P345, DOI 10.1111/j.1365-2958.1992.tb01477.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HSU MY, 1989, J BIOL CHEM, V264, P6214; HSU MY, 1992, J BIOL CHEM, V267, P13823; INOUYE M, 1991, ANNU REV MICROBIOL, V45, P163; INOUYE M, 1992, J BACTERIOL, V174, P2412; INOUYE S, 1991, DIRECTED MUTAGENESIS, P71; LAMPSON BC, 1989, SCIENCE, V243, P1033, DOI 10.1126/science.2466332; LERNER CG, 1990, NUCLEIC ACIDS RES, V18, P4631, DOI 10.1093/nar/18.15.4631; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MIROCHNITCHENKO O, 1994, J BIOL CHEM, V269, P2380; MIYATA S, 1992, P NATL ACAD SCI USA, V89, P5735, DOI 10.1073/pnas.89.13.5735; MOUGEL M, 1993, NUCLEIC ACIDS RES, V21, P4677, DOI 10.1093/nar/21.20.4677; RICE SA, 1993, J BACTERIOL, V175, P4250, DOI 10.1128/JB.175.13.4250-4254.1993; SALSER W, 1977, COLD SPRING HARB SYM, V42, P985; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PA, 1973, BIOCHEMISTRY-US, V12, P3055, DOI 10.1021/bi00740a018; SHIMAMOTO T, 1993, J BIOL CHEM, V268, P2684; SUN J, 1991, J BACTERIOL, V173, P4171, DOI 10.1128/jb.173.13.4171-4181.1991; WAKEFIELD JK, 1994, J VIROL, V68, P1605, DOI 10.1128/JVI.68.3.1605-1614.1994; YEE T, 1984, CELL, V38, P203, DOI 10.1016/0092-8674(84)90541-5	27	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14553	14558						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514172				2022-12-25	WOS:A1994NM06500040
J	SUGIMOTO, S; WANDLESS, TJ; SHOELSON, SE; NEEL, BG; WALSH, CT				SUGIMOTO, S; WANDLESS, TJ; SHOELSON, SE; NEEL, BG; WALSH, CT			ACTIVATION OF THE SH2-CONTAINING PROTEIN-TYROSINE-PHOSPHATASE, SH-PTP2, BY PHOSPHOTYROSINE-CONTAINING PEPTIDES DERIVED FROM INSULIN-RECEPTOR SUBSTRATE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-2 DOMAINS; SIGNAL TRANSDUCTION; SH2 DOMAIN; PHOSPHATIDYLINOSITOL 3'-KINASE; IRS-1; LOCALIZATION; INTERMEDIATE; ASSOCIATION; EXPRESSION; CORKSCREW	The cytoplasmic insulin receptor substrate-1 (IRS-1), which is multiply phosphorylated in vivo on tyrosine residues, is a known binding protein for the tandem src homology 2 (SH2) domain containing protein tyrosine phosphatase, SH-PTP2. Eleven phosphotyrosyl (pY) pep- tides from IRS-1 were screened for allosteric activation of SH-PTP2 phosphatase activity toward phosphorylated, reduced, carboxyamidomethylated, and maleylated-lysozyme. Peptides IRS-1pY895, IRS-1pY1172, and IRS-1pY1222 showed up to 50-fold acceleration of dephosphorylation. Analyses of Arg to Lys mutants in either or both SH2 domains indicate that both the N-terminal (N-SH2) and C-terminal (C-SH2) domains function in allosteric activation. Direct determination by surface plasmon resonance of the dissociation constants between pY peptides and glutathione S-transferase fusions to N-SH2 and C-SH2 domains reveals a 240-fold preference of the N-SH2 domain (compared with the C-SH2 domain) for IRS-1pY1172. The N-SH2 domain prefers IRS-1pY1172>IRS-1pY895> IRS 1pY1222, whereas C-SH2 domain prefers IRS-1pY1222>IRS-1pY895>IRS-1pY1172. These data suggest that each SH2 domain can bind to a distinct pY sequence of multiply phosphorylated protein substrates such as IRS-1, while activating hydrolysis at a third pY sequence bound in the SH-PTP2 active site. In addition, proteolysis and truncation studies reveal an autoregulatory function for the C-terminal region of SH-PTP2. Limited tryptic cleavage within the C terminus results in 27-fold activation of protein tyrosine phosphatase activity. The activated tryptic fragment cannot be further activated by pY peptide binding to the SH2 do mains indicating that autoregulatory functions of the SH2 domains are dependent on the C-terminal region. These data suggest that multiple levels for control of SH-PTP2 enzymatic activity may exist in vitro and in vivo.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, JOSLIN DIABET CTR, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, MOLEC MED UNIT, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020011, R37GM020011] Funding Source: NIH RePORTER; NIDCR NIH HHS [DERC 36836] Funding Source: Medline; NIGMS NIH HHS [GM20011] Funding Source: Medline; PHS HHS [49152] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CASE RD, 1994, J BIOL CHEM, V269, P10467; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GRANZOW R, 1992, BIO-TECHNOL, V10, P390, DOI 10.1038/nbt0492-390; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KITAS EA, 1991, HELV CHIM ACTA, V74, P1314, DOI 10.1002/hlca.19910740621; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; PLUTZKY J, 1992, GENOMICS, V13, P869, DOI 10.1016/0888-7543(92)90172-O; POT DA, 1992, J BIOL CHEM, V267, P140; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TOBE K, 1993, J BIOL CHEM, V268, P11167; TONKS NK, 1988, J BIOL CHEM, V263, P6731; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VILLAMORUZZI E, 1993, J BIOL CHEM, V268, P18176; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	55	190	192	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13614	13622						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7513703				2022-12-25	WOS:A1994NK18400081
J	KANE, SA; NATRAJAN, A; HECHT, SM				KANE, SA; NATRAJAN, A; HECHT, SM			ON THE ROLE OF THE BITHIAZOLE MOIETY IN SEQUENCE-SELECTIVE DNA CLEAVAGE BY FE-CENTER-DOT-BLEOMYCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID; NUCLEOTIDE-SEQUENCE; BINDING; DEGRADATION; RECOGNITION; FLUORESCENCE; INHIBITION; CHEMISTRY; MOLECULES; CONTACTS	A recent study of Fe(II) bleomycin-mediated DNA strand scission suggested that the metal binding domain of the drug is also the primary determinant of the observed sequence selectivity of strand scission (Carter, B. J., Murty, V. S., Reddy, K. S., Wang, S.-N., and Hecht, S. M. (1990) J. Biol. Chem. 265, 4193-4196). Although it is well established that the bithiazole moiety + C-terminal substituent of bleomycin are required for DNA binding, the role of the bithiazole in sequence-selective DNA recognition remains unclear. To determine whether the bithiazole moiety exhibits an intrinsic DNA binding selectivity, three synthetic EDTA-conjugated bithiazole derivatives were used to mediate DNA cleavage in the presence of Fe2+ and dithiothreitol. Incubation of these Fe(II) EDTA-bithiazoles in the presence of a 5'-P-32 end-labeled DNA duplex resulted in strand scission at every position to essentially the same extent. The relative cleavage efficiencies among the bithiazoles were a strong function of their ionic state. These findings imply that the bithiazoles can bind to many sites on the DNA; they support a model of bleomycin-DNA interaction in which the bithiazole moiety + C-terminal substituent are required only for DNA binding, whereas the metal binding domain is responsible for metal ion coordination and oxygen activation as well as being the primary determinant of sequence selective DNA cleavage.	UNIV VIRGINIA, DEPT CHEM, CHARLOTTESVILLE, VA 22901 USA; UNIV VIRGINIA, DEPT BIOL, CHARLOTTESVILLE, VA 22901 USA	University of Virginia; University of Virginia					NATIONAL CANCER INSTITUTE [R35CA053913] Funding Source: NIH RePORTER; NCI NIH HHS [CA53913] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGELICI RJ, 1968, J AM CHEM SOC, V90, P2499, DOI 10.1021/ja01012a010; ANGELICI RJ, 1967, J AM CHEM SOC, V89, P4605, DOI 10.1021/ja00994a007; BERRY DE, 1985, BIOCHEMISTRY-US, V24, P3207, DOI 10.1021/bi00334a020; BEYER VL, 1965, Z ANORG CHEM, V339, P8; CARTER BJ, 1990, J BIOL CHEM, V265, P4193; CARTER BJ, 1990, P NATL ACAD SCI USA, V87, P9373, DOI 10.1073/pnas.87.23.9373; CARTER BJ, 1991, TETRAHEDRON, V47, P2463, DOI 10.1016/S0040-4020(01)81781-6; CASTRO B, 1975, TETRAHEDRON LETT, P1219; CHIEN M, 1977, BIOCHEMISTRY-US, V16, P3641, DOI 10.1021/bi00635a021; DABROWIAK JC, 1980, J INORG BIOCHEM, V13, P317, DOI 10.1016/S0162-0134(00)80252-4; DANDREA AD, 1978, P NATL ACAD SCI USA, V75, P3608, DOI 10.1073/pnas.75.8.3608; DERVAN PB, 1986, SCIENCE, V232, P464, DOI 10.1126/science.2421408; FISHER LM, 1985, BIOCHEMISTRY-US, V24, P3199, DOI 10.1021/bi00334a019; GRIFFIN JH, 1987, J AM CHEM SOC, V109, P6840, DOI 10.1021/ja00256a043; HAY RW, 1974, J CHEM SOC DALTON, P2542, DOI 10.1039/dt9740002542; HECHT SM, 1986, ACCOUNTS CHEM RES, V19, P383, DOI 10.1021/ar00132a002; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HERTZBERG RP, 1988, BIOCHEMISTRY-US, V27, P3164, DOI 10.1021/bi00409a007; HOLMES CE, 1993, BIOCHEMISTRY-US, V32, P4293, DOI 10.1021/bi00067a019; HUANG CH, 1980, BIOCHEMISTRY-US, V19, P1761, DOI 10.1021/bi00550a006; KANE SA, 1993, THESIS U VIRGINIA; KILKUSKIE RE, 1985, J AM CHEM SOC, V107, P260, DOI 10.1021/ja00287a052; KROSS J, 1982, BIOCHEMISTRY-US, V21, P3711, DOI 10.1021/bi00258a029; KUWAHARA J, 1988, P NATL ACAD SCI USA, V85, P2459, DOI 10.1073/pnas.85.8.2459; LEACH BE, 1968, J AM CHEM SOC, V90, P2504, DOI 10.1021/ja01012a011; LEVIN MD, 1980, J AM CHEM SOC, V102, P1452, DOI 10.1021/ja00524a055; LEVY MJ, 1988, BIOCHEMISTRY-US, V27, P2647, DOI 10.1021/bi00408a002; MCGOWAN DA, 1977, J AM CHEM SOC, V99, P8078, DOI 10.1021/ja00466a066; POVIRK LF, 1979, BIOCHEMISTRY-US, V18, P96, DOI 10.1021/bi00568a015; SAKAI TT, 1983, BIOCHIM BIOPHYS ACTA, V758, P176, DOI 10.1016/0304-4165(83)90299-4; Sambrook J, 1989, MOL CLONING LABORATO; SCHULTZ PG, 1983, J AM CHEM SOC, V105, P7748, DOI 10.1021/ja00364a049; SHIPLEY JB, 1988, CHEM RES TOXICOL, V1, P25, DOI 10.1021/tx00001a004; SHIPLEY JB, 1986, THESIS U VIRGINIA; Slick B. I., 1985, BLEOMYCIN CHEMOTHERA; SLUKA JP, 1987, SCIENCE, V238, P1129, DOI 10.1126/science.3120311; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; SUGIURA Y, 1982, J BIOL CHEM, V257, P544; SUGIYAMA H, 1985, J AM CHEM SOC, V107, P7765, DOI 10.1021/ja00311a092; SUGIYAMA H, 1986, J AM CHEM SOC, V108, P352; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; TAKESHITA M, 1978, P NATL ACAD SCI USA, V75, P5983, DOI 10.1073/pnas.75.12.5983; Tanaka W., 1977, J ANTIBIOT, V30, pS; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; TULLIUS TD, 1985, SCIENCE, V230, P679, DOI 10.1126/science.2996145; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; WU JC, 1983, J BIOL CHEM, V258, P4694; YOUNGQUIST RS, 1985, P NATL ACAD SCI USA, V82, P2565, DOI 10.1073/pnas.82.9.2565; ZEE-CHENG K Y, 1970, Journal of Heterocyclic Chemistry, V7, P1439	49	65	66	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10899	10904						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511612				2022-12-25	WOS:A1994NF01700104
J	ANEL, A; RICHIERI, GV; KLEINFELD, AM				ANEL, A; RICHIERI, GV; KLEINFELD, AM			A TYROSINE PHOSPHORYLATION REQUIREMENT FOR CYTOTOXIC T-LYMPHOCYTE DEGRANULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CELL ANTIGEN RECEPTOR; FREE FATTY-ACIDS; MEDIATED LYSIS; ACTIVATION; EXOCYTOSIS; DIACYLGLYCEROL; STIMULATION; PHOSPHATASE; GRANULES	Phorbol myristate acetate (PMA) plus ionomycin induces the tyrosine phosphorylation of several cytotoxic T lymphocyte (CTL) substrates, including one with an apparent molecular weight of 100,000 (pp100) in cloned murine CTL. cis-Unsaturated fatty acids and low concentrations of phenylarsine oxide specifically inhibit the tyrosine phosphorylation of pp100. Genistein also inhibits tyrosine phosphorylation of pp100, but not with the same specificity as cis-fatty acids or low concentrations of phenylarsine oxide. Degranulation triggered by PMA plus ionomycin is inhibited by cis-fatty acids, low concentrations of phenylarsine oxide, and genistein, under the same conditions that these agents inhibit tyrosine phosphorylation of pp100. Depleting CTL of protein kinase C (PKC) activity by prolonged exposure to PMA eliminates the increase in tyrosine phosphorylation when challenged by PMA plus ionomycin, but not when these PKC-depleted CTL are activated by cognate target cells, immobilized anti-T cell receptor (TCR) antibodies, or concanavalin A. Tyrosine phosphorylation of pp100 triggered by TCR engagement in PKC-depleted cells is inhibited by cis-fatty acids and phenylarsine oxide, indicating that the inhibitory mechanism of the tyrosine phosphorylation of pp100 is independent of PKC. Furthermore, because all three tyrosine phosphorylation inhibitors are unlikely to inhibit PKC, these results suggest that, in addition to PKC activation and a rise in intracellular Ca2+, CTL degranulation requires the tyrosine phosphorylation of a CTL substrate(s), in addition to phospholipase C, and the present results are consistent with pp100 as that substrate. Taken together with previous studies, these results suggest that tyrosine phosphorylation of pp100 may play a central role in CTL function.	MED BIOL INST,DIV MEMBRANE BIOL,11077 N TORREY PINES RD,LA JOLLA,CA 92037				Anel, Alberto/Z-3068-2019					ANEL A, 1993, BIOCHEMISTRY-US, V32, P530, DOI 10.1021/bi00053a018; ANEL A, 1993, J BIOL CHEM, V268, P17578; ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; BOYER C, 1991, EUR J IMMUNOL, V21, P1623, DOI 10.1002/eji.1830210707; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CASNELLIE JE, 1986, J BIOL CHEM, V261, P4921; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; FLETCHER MC, 1993, J BIOL CHEM, V268, P23697; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAVERSTICK DM, 1991, J IMMUNOL, V146, P3306; HENGEL H, 1991, J IMMUNOL, V147, P1115; HENKART PA, 1984, J EXP MED, V160, P75, DOI 10.1084/jem.160.1.75; HSI ED, 1989, J BIOL CHEM, V264, P10836; JUNE CH, 1990, J IMMUNOL, V144, P1591; KALDJIAN E, 1988, FASEB J, V2, P2801, DOI 10.1096/fasebj.2.12.3261700; KANAKURA Y, 1991, J BIOL CHEM, V266, P490; KHAN WA, 1992, J BIOL CHEM, V267, P3605; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KLEINFELD AM, 1993, CYTOTOXIC CELLS GENE, P321; KOLBER MA, 1989, J IMMUNOL, V143, P1461; KRAHENBUHL O, 1991, IMMUNOL TODAY, V12, P399, DOI 10.1016/0167-5699(91)90139-K; LANCKI DW, 1989, J IMMUNOL, V142, P416; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARTH JD, 1989, J IMMUNOL, V142, P2430; MESCHER MF, 1992, J IMMUNOL, V149, P2402; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OROURKE AM, 1992, NATURE, V358, P253, DOI 10.1038/358253a0; OSTERGAARD HL, 1989, J IMMUNOL, V143, P2120; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; PODACK ER, 1985, P NATL ACAD SCI USA, V82, P8629, DOI 10.1073/pnas.82.24.8629; RATNER A, 1991, J IMMUNOL, V147, P55; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; RICHIERI GV, 1993, BIOCHEMISTRY-US, V32, P7574, DOI 10.1021/bi00080a032; RICHIERI GV, 1990, J IMMUNOL, V145, P1074; RICHIERI GV, 1989, J IMMUNOL, V143, P2302; RICHIERI GV, 1990, J IMMUNOL, V144, P671; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; SPECTOR AA, 1975, J LIPID RES, V16, P165; STAERZ UD, 1985, J IMMUNOL, V134, P3994; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; TAKAYAMA H, 1987, J EXP MED, V166, P725, DOI 10.1084/jem.166.3.725; YOSHIDA K, 1992, P NATL ACAD SCI USA, V89, P6443, DOI 10.1073/pnas.89.14.6443	48	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9506	9513						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511589				2022-12-25	WOS:A1994NE05300020
J	LANDESMAN, Y; BRINGOLD, F; KIMCHI, A				LANDESMAN, Y; BRINGOLD, F; KIMCHI, A			P53 UNDERGOES EPITOPIC CHANGES IN-VITRO BY SODIUM-VANADATE	ONCOGENE			English	Note							TUMOR-SUPPRESSOR PROTEIN; KERATINOCYTE CELL-LINE; VIRUS-40 T-ANTIGEN; BINDING-SITE; WILD-TYPE; MUTANT; KINASE; GENE; PHOSPHORYLATION; SEQUENCE	p53 has at least two conformations that differ in their immunoreactivity. They consist of the functional tumor suppressor form, characteristic of the wild type p53 and the mutant form, generated by changes in the primary amino acid sequence of the protein. It has been previously shown that the wild type p53 protein also acquires the mutant conformation upon certain changes in growth conditions. Here we report that similar epitopic changes can be induced in crude cell lysate by addition of vanadate anions at 1 mm final concentration. A panel of anti p53 antibodies was used to discriminate between the different immunoreactive forms of wild type p53 in SV80 fibroblasts. It was found that addition of sodium vanadate to the lysis buffer converted part of p53 molecules into a mutant conformation that is recognized by the PAb 240 monoclonal antibodies. The effect of vanadate on p53 conformation was prominent even if it was added to the cell lysates after 15 min of preincubation at 37-degrees-C. This further excluded its possible role as phosphatase inhibitor in the system and suggested a direct interaction with the p53 protein itself. Based on these data we recommend to avoid using sodium vanadate as a phosphatase inhibitor in experiments where in vivo conformational changes of wild type p53 are studied.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL; GERMAN CANC RES CTR,DIV DIFFERENTIAT & CARCINOGENESIS IN VITRO 0240,D-69120 HEIDELBERG,GERMANY	Weizmann Institute of Science; Helmholtz Association; German Cancer Research Center (DKFZ)								BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOUKAMP P, 1993, P53 GROWTH CONTROL N; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HIRATSUKA T, 1990, J BIOL CHEM, V265, P18791; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JENKINS JR, 1988, ONCOGENE HDB, P403; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANDESMAN Y, 1992, ONCOGENE, V7, P1661; LANE PD, 1991, CURR OPIN CELL BIOL, V2, P581; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER W E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P251; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1990, ONCOGENE, V5, P1683; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; MONTENARH M, 1992, Critical Reviews in Oncogenesis, V3, P233; NECHAY BR, 1986, FASEB J, V45, P123; OREN M, 1991, BIOCH MOL ASPECTS SE, P373; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SOUSSI T, 1990, ONCOGENE, V5, P945; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; TAKAHASHI K, 1992, JPN J CANCER RES, V83, P358, DOI 10.1111/j.1349-7006.1992.tb00115.x; TOMINAGA O, 1992, Critical Reviews in Oncogenesis, V3, P257; TRACEY AS, 1986, P NATL ACAD SCI USA, V83, P609, DOI 10.1073/pnas.83.3.609; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	40	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1241	1245						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	7510864				2022-12-25	WOS:A1994NC04800029
J	GRUBE, BJ; COCHRANE, CG; YE, RD; GREEN, CE; MCPHAIL, ME; ULEVITCH, RJ; TOBIAS, PS				GRUBE, BJ; COCHRANE, CG; YE, RD; GREEN, CE; MCPHAIL, ME; ULEVITCH, RJ; TOBIAS, PS			LIPOPOLYSACCHARIDE-BINDING PROTEIN EXPRESSION IN PRIMARY HUMAN HEPATOCYTES AND HEPG2 HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE PROTEINS; STIMULATING FACTORS; GENE-EXPRESSION; PLASMA-PROTEINS; TUMOR NECROSIS; LPS; INTERLEUKIN-1; PATHOGENESIS; INFLAMMATION; RECOGNITION	Lipopolysaccharide (LPS)-binding protein (LBP) is a normal plasma protein and an acute phase reactant important for host responses to Gram-negative bacteria and LPS. LBP forms high affinity complexes with LPS which bind to CD14, a monocyte surface protein, to initiate the release of inflammatory mediators. We found that human primary hepatocytes synthesize LBP and that the synthesis is up-regulated by interleukin (IL)-6. To examine this phenomenon in more detail, we evaluated the capacity of IL-6, IL-1, and tumor necrosis factor to induce LBP synthesis in HepG2 cells in the presence or absence of dexamethasone. IL-6 induced LBP synthesis. Dexamethasone, IL-1, and tumor necrosis factor had a synergistic effect when combined with IL-6, but demonstrated minimal effect independently. LBP biosynthesis was evaluated by immunoprecipitation of S-35-labeled LBP from HepG2 supernatants, measurement of steady-state LBP mRNA levels, and analysis of LBP-dependent LPS binding to CD14 positive cells. An S-35-labeled, 60-kDa protein was immunoprecipitated with anti-LBP antibody from IL-6-stimulated HepG2 cell supernatants. Northern blot analysis of cellular RNA revealed an increase in LBP mRNA in IL-6-stimulated cells. CD14 expressing cells bound fluoresceinated LPS in the presence of supernatants from HepG2 cells treated with IL-6. These data provide the first information about specific cytokine and dexamethasone regulation of LBP expression in HepG2 cells. LBP behaves like a Type 1 acute phase protein.	SRI INT, MENLO PK, CA 94025 USA	SRI International	GRUBE, BJ (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Ye, Richard/O-5223-2016; Ye, Richard/ABF-2413-2020	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL023584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-23584] Funding Source: Medline; NIAID NIH HHS [AI-15136] Funding Source: Medline; NIGMS NIH HHS [GM-37696] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen Katherine L., 1993, P262; BAUMANN H, 1987, J IMMUNOL, V139, P4122; BAUMANN H, 1989, J IMMUNOL, V143, P1163; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BAUMANN H, 1987, J BIOL CHEM, V262, P9756; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; DARLINGTON GJ, 1987, IN VITRO CELL DEV B, V23, P349; DINARELLO CA, 1984, NEW ENGL J MED, V311, P1413; DUNN JCY, 1989, FASEB J, V3, P174, DOI 10.1096/fasebj.3.2.2914628; EY PL, 1986, METHOD ENZYMOL, V121, P497; GALANOS C, 1985, EUR J BIOCHEM, V148, P1, DOI 10.1111/j.1432-1033.1985.tb08798.x; GELLER DA, 1993, ARCH SURG-CHICAGO, V128, P22; GREEN CE, 1983, ANAL BIOCHEM, V129, P269, DOI 10.1016/0003-2697(83)90550-X; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; LETURCQ D, 1992, J CELL BIOCHEM, V16, P161; MACKIEWICZ A, 1991, J IMMUNOL, V146, P3032; MACKIEWICZ A, 1990, P NATL ACAD SCI USA, V87, P1491, DOI 10.1073/pnas.87.4.1491; MAGIELSKAZERO D, 1988, BIOCHEM INT, V17, P17; MAHER JJ, 1988, HEPATOLOGY, V8, P1162, DOI 10.1002/hep.1840080534; MATHISON JC, 1992, J IMMUNOL, V149, P200; MORRISON DC, 1978, AM J PATHOL, V93, P526; MUNRO H. N., 1966, METHOD BIOCHEM ANAL, V14, P113; PERLMUTTER DH, 1986, J CLIN INVEST, V78, P1349, DOI 10.1172/JCI112721; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; RAMADORI G, 1990, PATHOBIOLOGY, V58, P89, DOI 10.1159/000163569; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; SCHNEIDER WC, 1957, METHOD ENZYMOL, V3, P680, DOI 10.1016/S0076-6879(57)03442-4; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SEHGAL PB, 1990, MOL BIOL MED, V7, P117; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; Tobias PS, 1992, J CELL BIOCHEM, V16C, P151; Ulevitch R J, 1989, Prog Clin Biol Res, V299, P193; WRIGHT SD, 1989, J EXP MED, V170, P1231, DOI 10.1084/jem.170.4.1231; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	38	96	100	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8477	8482						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510687				2022-12-25	WOS:A1994NB40900096
J	BUTTON, D; ROTHMAN, A; BONGIORNO, C; KUPPERMAN, E; WOLNER, B; TAYLOR, P				BUTTON, D; ROTHMAN, A; BONGIORNO, C; KUPPERMAN, E; WOLNER, B; TAYLOR, P			AGONIST-SELECTIVE REGULATION OF POLYPHOSPHOINOSITIDE METABOLISM IN PULMONARY-ARTERY SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; EPIDERMAL GROWTH-FACTOR; MIDDLE T-ANTIGEN; SIGNAL TRANSDUCTION; TYROSINE KINASE; HUMAN PLATELETS; ANGIOTENSIN-II; ACINAR-CELLS; C-FOS; RECEPTOR	Using a rat pulmonary artery smooth muscle cell line (PAC1), detailed analysis of polyphosphoinositide (PPI) metabolism reveals receptor type-selective patterns in the formation of inositol phosphates and and 3-hydroxy-phosphorylated PPIs. Responses to several agonists that stimulate hypertrophy or proliferation were examined, and distinct categories of response profile were observed. Thrombin and angiotensin II stimulated the hydrolysis of phosphatidylinositol (PI) 4,5-bisphosphate and the formation of several cytosolic species of inositol phosphates without the activation of PI 3-hydroxykinase. The response to thrombin was distinctive because a very large production of inositol 1,4-bisphosphate was accompanied by hydrolysis of PI 4 phosphate. The response to platelet-derived growth factor (PDGF) was distinguished by the production of the PI 3-hydroxykinase product, PI 3,4,5-trisphosphate, and the appearance of PI 3-hydroxykinase activity in immunoprecipitates. PDGF treatment of PAC1 cultures did not produce accumulation of detectable amounts of inositol 1,4,5-trisphosphate, although a small sustained elevation in the level of inositol monophosphate and a gradual accumulation of inositol 1,3,4 trisphosphate were observed. Characterization of these distinctive responses permitted us to correlate agonist-regulated PPI metabolism with induction of immediate-early genes and stimulation of hypertrophy or proliferation of PAC1 cultures (Rothman, A., Wolner, B., Button, D., and Taylor, P. (1994) J. Biol. Chem. 269, 6399-6404). Thrombin-stimulated PPI turnover and the production of a high level of inositol bisphosphate may be early signals linked to the induction of fosB and PAC1 cell hypertrophy, whereas the activation of PI 5-hydroxykinase and the accumulation of PI 3,4,5-trisphosphate in response to PDGF appear to be associated with mitogenesis.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PEDIAT, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			Wolner, Branden/A-9615-2015	Wolner, Branden/0000-0003-0021-2073	NHLBI NIH HHS [HL 35018] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL035018] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BALLA T, 1988, J BIOL CHEM, V263, P4083; BATTY IH, 1989, BIOCHEM J, V260, P237, DOI 10.1042/bj2600237; BERK BC, 1989, J CLIN INVEST, V83, P822, DOI 10.1172/JCI113964; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BROWN DM, 1966, BIOCHIM BIOPHYS ACTA, V125, P413, DOI 10.1016/0005-2760(66)90029-4; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER AN, 1992, J BIOL CHEM, V267, P14563; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GEISTERFER AAT, 1989, HYPERTENSION, V14, P413, DOI 10.1161/01.HYP.14.4.413; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HUGHES AR, 1989, J BIOL CHEM, V264, P9400; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; MILLER ES, 1990, BIOCHEM BIOPH RES CO, V173, P289, DOI 10.1016/S0006-291X(05)81055-1; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; POYNER DR, 1993, BIOCHEM J, V290, P901, DOI 10.1042/bj2900901; POYNER DR, 1990, BIOCHEM J, V271, P605, DOI 10.1042/bj2710605; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; ROTHMAN A, 1994, J BIOL CHEM, V269, P6399; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SANCHEZBUENO A, 1993, BIOCHEM J, V291, P163, DOI 10.1042/bj2910163; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8	38	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6390	6398						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509802				2022-12-25	WOS:A1994MZ50300023
J	KOO, PH; QIU, WS				KOO, PH; QIU, WS			MONOAMINE-ACTIVATED ALPHA(2)-MACROGLOBULIN BINDS TRK RECEPTOR AND INHIBITS NERVE GROWTH FACTOR-STIMULATED TRK PHOSPHORYLATION AND SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; PC12 PHEOCHROMOCYTOMA CELLS; PHOSPHOLIPASE-C-GAMMA; HUMAN NGF RECEPTOR; PROTEIN-KINASE; ALPHA-2-MACROGLOBULIN RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; ALPHA-MACROGLOBULIN; PROTOONCOGENE PRODUCT; MOLECULAR-CLONING	Monoamine-activated alpha(2)-macroglobulin (alpha(2)M) has been shown to inhibit beta-nerve growth factor (NGF)-promoted neurite outgrowth and the survival of embryonic sensory and forebrain neurons, whereas normal alpha(2)M has little or no such activity. The objective of this study is to elucidate the mechanism of inhibition by monoamine-activated alpha(2)M. Methylamine-activated alpha(2)M (MA-alpha(2)M) and serotonin-activated alpha(2)M (5HT-alpha(2)M) dose dependently inhibit NGF-promoted neurite outgrowth of the pheochromocytoma PC12 cell and its subline PC12(6- 24) which overexpresses human trk protooncogene product, but have no effect on their viability, and this inhibition can be blocked by high concentrations of NGF. The binding of MA-alpha(2)M to trk, which is a part of high-affinity NGF receptor, was studied with PC12(6-24) cells and NIH-3T3 fibroblasts expressing trk (trk-3T3). In each case MA-alpha(2)M readily forms stable complexes with trk in vivo, whereas normal alpha(2)M does not. Both 5HT-alpha(2)M and MA-alpha(2)M also dose dependently block NGF-promoted autophosphorylation of trk in vivo, whereas normal alpha(2)M and plasmin-reacted alpha(2)M are inactive or much less active. MA-alpha(2)M also blocks NGF-promoted incorporation of P-32 from [P-32]ATP into trk receptors in vitro, Neither MA-alpha(2)M, 5HT-alpha(2)M, nor normal alpha(2)M, however, blocks either platelet-derived growth factor-stimulated or epidermal growth factor-stimulated tyrosine phosphorylation of the respective receptors. Tyrosine phosphorylation of two of the intracellular substrates, phospholipase C-gamma 1 and extracellular signal-regulated kinase-2, in the NGF-promoted pathways is also dose dependently blocked by MA-alpha(2)M. However, by comparison MA-alpha(2)M is more effective in inhibiting the activation of phospholipase C-gamma 1 than trk. We conclude that monoamine-activated alpha(2)M may block neurite outgrowth and neuronal survival by its specific binding to NGF receptors, thus inhibiting the NGF-promoted activation of intracellular second messenger pathways.			KOO, PH (corresponding author), NE OHIO UNIV,COLL MED,DEPT MICROBIOL & IMMUNOL,POB 95,ROOTSTOWN,OH 44272, USA.				NINDS NIH HHS [NS30698] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIN JG, 1993, NEUROTROPHIC FACTORS, P129; Altin JG, 1991, GROWTH FACTORS, V4, P145, DOI 10.3109/08977199109000265; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BLENIS J, 1986, EMBO J, V5, P3441, DOI 10.1002/j.1460-2075.1986.tb04667.x; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CARTER AN, 1992, J BIOL CHEM, V267, P14563; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; GARTON MJ, 1991, J NEUROL SCI, V104, P74, DOI 10.1016/0022-510X(91)90218-V; GLIEMANN J, 1986, BIOCHIM BIOPHYS ACTA, V885, P49, DOI 10.1016/0167-4889(86)90037-6; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1980, ANNU REV NEUROSCI, V3, P353, DOI 10.1146/annurev.ne.03.030180.002033; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1990, J NEUROSCI, V10, P1479; HELDIN CH, 1983, J BIOL CHEM, V258, P54; HELGOUA S, 1991, CURR TOP MICROBIOL I, V165, P119; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HUDSON NW, 1982, BIOCHIM BIOPHYS ACTA, V704, P290, DOI 10.1016/0167-4838(82)90159-5; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAPLAN J, 1979, J BIOL CHEM, V254, P7323; KEMP BE, 1988, METHOD ENZYMOL, V159, P173; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNUSEL B, 1992, NEUROREPORT, V3, P885; KOIZUMI S, 1988, J NEUROSCI, V8, P715; KOO PH, 1992, J NEUROSCI RES, V31, P678, DOI 10.1002/jnr.490310412; KOO PH, 1989, J NEUROSCI RES, V22, P247, DOI 10.1002/jnr.490220304; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEVI-MONTALCINI RITA, 1966, HARVEY LECT, V60, P217; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; LIEBL DJ, 1993, J NEUROSCI RES, V35, P170, DOI 10.1002/jnr.490350207; LIM RW, 1987, ONCOGENE, V1, P263; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LONGO FM, 1990, CELL REGUL, V1, P189, DOI 10.1091/mbc.1.2.189; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MUROYA K, 1992, BIOCHIM BIOPHYS ACTA, V1135, P353, DOI 10.1016/0167-4889(92)90243-5; MUTOH T, 1988, J BIOL CHEM, V263, P15853; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P2579, DOI 10.1073/pnas.74.6.2579; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SOTTRUPJENSEN L, 1981, FEBS LETT, V128, P127, DOI 10.1016/0014-5793(81)81097-6; SOTTRUPJENSEN L, 1981, FEBS LETT, V128, P123, DOI 10.1016/0014-5793(81)81096-4; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; STRAIGHT DL, 1988, BIOCHEMISTRY-US, V27, P2885, DOI 10.1021/bi00408a033; STRAUSS S, 1992, LAB INVEST, V66, P223; SWENSON RP, 1979, P NATL ACAD SCI USA, V76, P4313, DOI 10.1073/pnas.76.9.4313; TSAO H, 1990, J BIOL CHEM, V265, P15471; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANLEUVEN F, 1979, J BIOL CHEM, V254, P5155; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; VOLONTE C, 1989, J CELL BIOL, V109, P2395, DOI 10.1083/jcb.109.5.2395; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WRANN MM, 1979, J BIOL CHEM, V254, P8083	70	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5369	5376						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508936				2022-12-25	WOS:A1994MX57100100
J	HASSE, A; SCHULZ, WA				HASSE, A; SCHULZ, WA			ENHANCEMENT OF REPORTER GENE DE-NOVO METHYLATION BY DNA FRAGMENTS FROM THE ALPHA-FETOPROTEIN CONTROL REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERATOCARCINOMA CELLS; CPG ISLANDS; METHYLTRANSFERASE; PATTERNS; PROMOTERS; INVITRO; CLONING	The 5'-upstream region of the rat a-fetoprotein (AFP) gene strongly increased de novo methylation of an adjacent chloramphenicol acetyltransferase (CAT) gene upon transfection into F9 mouse embryonal carcinoma cells. The same effect was exerted by a distal 775-base pair (bp) fragment and by 300- and 1-kb fragments preceding the transcriptional start site, but not by other parts of the control region. Further division of the larger, strongly active fragments resulted in a gradual decrease of methylation and clonal variation in the methylation patterns. The effect of the 775-bp fragment did not depend on its orientation. It was ablated by insertion of the mouse metallothionein I promoter between the AFP gene fragment and the CAT gene, but not by its insertion upstream of the AFP gene fragment. Two fragments from the AFP control region increasing methylation contained B1 and B2 small interspersed repetitive elements, respectively. B1 and B2 sequences of different origin also acted strongly to increase methylation. These findings support the idea that mammalian genes contain specific sequences involved in regulating their methylation. The effects of these sequences appear to be exerted in cis, to be dependent on proximity, but not on orientation, and to require an optimal size of 500-700 bp. Small retrotransposon sequences within such elements may be particularly effective in attracting de novo methylation.	HEINRICH HEINE UNIV, INST PHYS CHEM 1, POSTFACH 101007, D-40001 DUSSELDORF, GERMANY	Heinrich Heine University Dusseldorf			Schulz, Wolfgang A./A-6523-2008	Schulz, Wolfgang/0000-0002-2196-463X				ALTON NK, 1979, NATURE, V282, P864, DOI 10.1038/282864a0; BESTOR T, 1987, NUCLEIC ACIDS RES, V15, P3835, DOI 10.1093/nar/15.9.3835; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, GENET ANAL-BIOMOL E, V9, P48, DOI 10.1016/1050-3862(92)90030-9; BOLDEN AH, 1986, PROG NUCLEIC ACID RE, V33, P231, DOI 10.1016/S0079-6603(08)60025-2; CAROTTI D, 1986, BIOCHIM BIOPHYS ACTA, V866, P135, DOI 10.1016/0167-4781(86)90110-7; DOERFLER W, 1991, BIOL CHEM H-S, V372, P557; FRANK D, 1991, NATURE, V351, P239, DOI 10.1038/351239a0; FREBOURG T, 1988, GENE, V65, P315, DOI 10.1016/0378-1119(88)90468-4; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; HASSE A, 1992, BIOCHIM BIOPHYS ACTA, V1131, P16, DOI 10.1016/0167-4781(92)90092-E; Hasties ND, 1989, GENETIC VARIANTS STR, P559; JAHNER D, 1985, DNA METHYLATION BIOC, P189; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MEUNIERROTIVAL M, 1982, P NATL ACAD SCI-BIOL, V79, P355, DOI 10.1073/pnas.79.2.355; MONK M, 1987, DEVELOPMENT, V99, P371; MUGLIA L, 1986, P NATL ACAD SCI USA, V83, P7653, DOI 10.1073/pnas.83.20.7653; MUMMANENI P, 1993, J BIOL CHEM, V268, P552; NIWA O, 1985, MOL CELL BIOL, V5, P2325, DOI 10.1128/MCB.5.9.2325; OREND G, 1991, J VIROL, V65, P4301, DOI 10.1128/JVI.65.8.4301-4308.1991; Razin A., 1993, Experientia Supplementum (Basel), V64, P343; RAZIN A, 1984, P NATL ACAD SCI-BIOL, V81, P2275, DOI 10.1073/pnas.81.8.2275; SCHULZ WA, 1989, BIOCHIM BIOPHYS ACTA, V1013, P125, DOI 10.1016/0167-4889(89)90040-2; SHEMER R, 1991, P NATL ACAD SCI USA, V88, P11300, DOI 10.1073/pnas.88.24.11300; SHEMER R, 1991, J BIOL CHEM, V266, P23676; SMITH SS, 1991, J MOL BIOL, V217, P39, DOI 10.1016/0022-2836(91)90609-A; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; SZYF M, 1990, MOL CELL BIOL, V10, P4396, DOI 10.1128/MCB.10.8.4396; SZYF M, 1991, BIOCHEM CELL BIOL, V69, P764, DOI 10.1139/o91-117; TURKER MS, 1991, SOMAT CELL MOLEC GEN, V17, P151, DOI 10.1007/BF01232972; WEN P, 1991, DNA CELL BIOL, V10, P525, DOI 10.1089/dna.1991.10.525	31	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1821	1826						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507485				2022-12-25	WOS:A1994MR98800043
J	FREY, C; NARAYANAN, K; MCMILLAN, K; SPACK, L; GROSS, SS; MASTERS, BS; GRIFFITH, OW				FREY, C; NARAYANAN, K; MCMILLAN, K; SPACK, L; GROSS, SS; MASTERS, BS; GRIFFITH, OW			L-THIOCITRULLINE - A STEREOSPECIFIC, HEME-BINDING INHIBITOR OF NITRIC-OXIDE SYNTHASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; METHYL-L-ARGININE; ENDOTHELIAL-CELLS; NG-METHYLARGININE; SELECTIVE-INHIBITION; CARBON-MONOXIDE; BLOOD-PRESSURE; L-CITRULLINE; MACROPHAGE; ENZYME	Nitric-oxide synthase (NOS) catalyzes the oxidation of L-arginine to citrulline and nitric oxide (NO). The enzyme is inhibited by a variety of N-omega-monosubstituted L-arginine analogs, and some of these compounds are useful in reversing pathologies associated with the overproduction of NO (e.g. the hypotension of septic shock). We report here that L-thiocitrulline (gamma-thioureido-L-norvaline) is a potent, stereospecific inhibitor of the constitutive brain and endothelial isoforms of NOS as well as the isoform induced in vascular smooth muscle cells by lipopolysaccharide and interferon-gamma. Steady state kinetic studies show L-thiocitrulline inhibition is competitive with L-arginine (K-i similar to 4-20% of K-m(Arg)), indicating that initial binding is as a substrate/product analog. In contrast to L-arginine and N-omega-methyl-L-arginine, the prototypic NOS inhibitor, L-thiocitrulline binding elicits a ''Type II'' difference spectrum, indicating a high spin to low spin transition of the iron in the heme cofactor. This finding suggests that L-thiocitrulline is contributing the sixth ligand to heme iron, probably through the thioureido sulfur. Such interaction with heme iron neither stimulates nor inhibits the direct flavin-mediated cytochrome c reduction activity of the enzyme, but it does inhibit heme-dependent superoxide formation. In vivo, L-thiocitrulline is a potent presser agent in both normal and endotoxemic rats, the latter finding suggesting utility in treating the hypotension of septic shock.	MED COLL WISCONSIN, DEPT BIOCHEM, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DEPT PEDIAT, MILWAUKEE, WI 53226 USA; UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, SAN ANTONIO, TX 78284 USA; CORNELL UNIV, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10021 USA	Medical College of Wisconsin; Medical College of Wisconsin; University of Texas System; University of Texas Health San Antonio; Cornell University								ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; AISAKA K, 1989, BIOCHEM BIOPH RES CO, V163, P710, DOI 10.1016/0006-291X(89)92281-X; AISAKA K, 1989, BIOCHEM BIOPH RES CO, V160, P881, DOI 10.1016/0006-291X(89)92517-5; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; BUZZARD CJ, 1993, CIRC RES, V72, P1023, DOI 10.1161/01.RES.72.5.1023; CORBIN JL, 1974, ANAL BIOCHEM, V57, P310, DOI 10.1016/0003-2697(74)90080-3; DESAI KM, 1991, NATURE, V351, P477, DOI 10.1038/351477a0; DESAI VS, 1993, CHEST, V104, P1254, DOI 10.1378/chest.104.4.1254; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; FELDMAN PL, 1993, J MED CHEM, V36, P491, DOI 10.1021/jm00056a009; FELDMAN PL, 1993, CHEM ENG NEWS, V71, P26; FELDMAN PL, 1991, TETRAHEDRON LETT, V32, P875, DOI 10.1016/S0040-4039(00)92109-9; FORSTERMANN U, 1989, N-S ARCH PHARMACOL, V340, P771; FUKUTO JM, 1990, BIOCHEM BIOPH RES CO, V168, P458, DOI 10.1016/0006-291X(90)92343-X; FURFINE ES, 1993, BIOCHEMISTRY-US, V32, P8512, DOI 10.1021/bi00084a017; GRIFFITH OW, 1992, FASEB J, V6, pA1255; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; GROSS SS, 1992, J BIOL CHEM, V267, P25722; GUENGERICH FP, 1990, FASEB J, V4, P2453, DOI 10.1096/fasebj.4.8.2185971; HATTORI Y, 1994, J BIOL CHEM, V269, P9405; HECKER M, 1990, BIOCHEM BIOPH RES CO, V167, P1037, DOI 10.1016/0006-291X(90)90627-Y; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; JONES BN, 1983, J CHROMATOGR, V266, P471, DOI 10.1016/S0021-9673(01)90918-5; KILBOURN RG, 1992, J NATL CANCER I, V84, P827, DOI 10.1093/jnci/84.11.827; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; KLATT P, 1994, J BIOL CHEM, V269, P1674; KLATT P, 1993, J BIOL CHEM, V268, P14781; KLATT P, 1992, J BIOL CHEM, V267, P11374; KWON NS, 1990, J BIOL CHEM, V265, P13442; LIEW FY, 1993, ANN TROP MED PARASIT, V87, P637, DOI 10.1080/00034983.1993.11812822; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; MCCALL TB, 1991, BRIT J PHARMACOL, V102, P234, DOI 10.1111/j.1476-5381.1991.tb12159.x; MCCARTNEYFRANCIS N, 1993, J EXP MED, V178, P749, DOI 10.1084/jem.178.2.749; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; MITCHELL JA, 1991, BIOCHEM BIOPH RES CO, V176, P1417, DOI 10.1016/0006-291X(91)90444-C; NARAYANAN K, 1994, J MED CHEM, V37, P885, DOI 10.1021/jm00033a004; NARAYANAN K, 1994, IN PRESS 3RD INT M B; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NISHIKAWA T, 1993, STROKE, V24, P1717, DOI 10.1161/01.STR.24.11.1717; OLKEN NM, 1993, BIOCHEMISTRY-US, V32, P9677, DOI 10.1021/bi00088a020; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; ROGERS NE, 1992, BIOCHEM BIOPH RES CO, V189, P242, DOI 10.1016/0006-291X(92)91550-A; ROTH M, 1971, ANAL CHEM, V43, P880, DOI 10.1021/ac60302a020; SCHENKMAN JB, 1967, MOL PHARMACOL, V3, P113; SCHMIDT K, 1993, MOL PHARMACOL, V44, P615; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SHETA EA, 1994, J BIOL CHEM, V269, P15147; SONNTAG M, 1992, PFLUG ARCH EUR J PHY, V420, P194, DOI 10.1007/BF00374990; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; WEINBERG JB, 1994, J EXP MED, V179, P651, DOI 10.1084/jem.179.2.651; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	60	99	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26083	26091						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523401				2022-12-25	WOS:A1994PQ93000025
J	CARTER, BZ; HABIB, GM; SEPULVEDA, AR; BARRIOS, R; WAN, DF; LEBOVITZ, RM; LIEBERMAN, MW				CARTER, BZ; HABIB, GM; SEPULVEDA, AR; BARRIOS, R; WAN, DF; LEBOVITZ, RM; LIEBERMAN, MW			TYPE-VI RNA IS THE MAJOR GAMMA-GLUTAMYL-TRANSPEPTIDASE RNA IN THE MOUSE SMALL-INTESTINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBRAL ENDOTHELIAL-CELLS; TRANSFERASE TRANSPEPTIDASE; MESSENGER-RNAS; RAT-KIDNEY; HEPATOCARCINOGENESIS; GLUTATHIONE; EXPRESSION; SEQUENCE; FETAL; LIVER	Mouse gamma-glutamyl transpeptidase (gamma GT) is encoded by a single copy gene with at least five and probably six different promoters directing the transcription of six types of gamma GT RNAs. In mouse small intestine, only Type I, V, and VI gamma GT RNAs are detected, and ribonuclease protection assays reveal that Type VI represents more than 90% of gamma GT RNA. To investigate the structure of intestinal gamma GT RNA in greater detail, we cloned and sequenced mouse intestinal gamma GT cDNAs. Seven of eight informative clones were Type VI and consisted of Type VI unique exons, VIa and VIb (as described previously by us) (Rajagopalan, S., Wan, D.-F., Habib, G. M., Sepulveda, A. R., McLeod, M. R., Lebovitz, R. M., and Lieberman, M. W. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6179-6183) as well as common 3' sequences. Exon VIb contains two alternative splice accepters, one previously identified by us and the other 17 bases 5' of this site. Another clone contained a previously unidentified gamma GT mRNA designated as Type VII. Type VII consists of a unique 5' exon which is 315 base pairs upstream of the exon VIa splice donor site and is spliced to exon VIb. Regulation of gamma GT expression in the small intestine is complex and involves at least three previously described promoters, alternative splicing, and a previously undescribed exonic sequence (Type VII RNA) 5' of promoter VI.	BAYLOR COLL MED, DEPT PATHOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine					NATIONAL CANCER INSTITUTE [R37CA039392, R01CA039392] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39392] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUER HC, 1990, BIOCHEM BIOPH RES CO, V168, P358, DOI 10.1016/0006-291X(90)91716-6; BEACHY PA, 1985, NATURE, V313, P545, DOI 10.1038/313545a0; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; CHEVEZBARRIOS P, 1993, AM J PATHOL, V143, P20; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURTHOYS NP, 1983, MINER ELECTROL METAB, V9, P236; DARBOUY M, 1991, AM J PHYSIOL, V261, pC1130, DOI 10.1152/ajpcell.1991.261.6.C1130; GE H, 1990, P NATL ACAD SCI USA, V87, P3338, DOI 10.1073/pnas.87.9.3338; HABIB GM, 1992, MOL CARCINOGEN, V5, P75; HANIGAN MH, 1985, CARCINOGENESIS, V6, P165, DOI 10.1093/carcin/6.2.165; IANNACCONE PM, 1983, J HISTOCHEM CYTOCHEM, V31, P1312, DOI 10.1177/31.11.6194205; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; JACQUEMIN E, 1990, J PEDIATR GASTR NUTR, V11, P89, DOI 10.1097/00005176-199007000-00018; LAPERCHE Y, 1986, P NATL ACAD SCI USA, V83, P937, DOI 10.1073/pnas.83.4.937; MARATHE GV, 1979, FEBS LETT, V107, P436, DOI 10.1016/0014-5793(79)80425-1; MAXWELL K, 1987, BRAIN RES, V410, P309, DOI 10.1016/0006-8993(87)90329-5; ORMSTAD K, 1983, GLUTATHIONE STORAGE, P107; RAJAGOPALAN S, 1993, P NATL ACAD SCI USA, V90, P6179, DOI 10.1073/pnas.90.13.6179; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; ROSALKI SB, 1972, CLIN CHIM ACTA, V39, P41, DOI 10.1016/0009-8981(72)90297-5; SAWABU N, 1983, CANCER, V51, P327, DOI 10.1002/1097-0142(19830115)51:2<327::AID-CNCR2820510227>3.0.CO;2-C; SEPULVEDA AR, 1994, J BIOL CHEM, V269, P10699; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; TATE SS, 1985, METHOD ENZYMOL, V113, P400; WINOKUR TS, 1990, CARCINOGENESIS, V11, P365, DOI 10.1093/carcin/11.3.365	26	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24581	24585						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7523374				2022-12-25	WOS:A1994PQ49000014
J	ENSLEN, H; SODERLING, TR				ENSLEN, H; SODERLING, TR			ROLES OF CALMODULIN-DEPENDENT PROTEIN-KINASES AND PHOSPHATASE IN CALCIUM-DEPENDENT TRANSCRIPTION OF IMMEDIATE-EARLY GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; AMP-RESPONSIVE ELEMENT; C-FOS GENE; MEMBRANE DEPOLARIZATION; CYCLOSPORINE-A; T-CELLS; PROTOONCOGENE EXPRESSION; SOMATOSTATIN GENE; BINDING PROTEINS; FACTORS ENCODES	Recent studies indicate multiple mechanisms are involved in Ca2+ stimulation of gene expression. We have used cell-permeable, specific inhibitors of calmodulin-dependent protein kinases (CaM kinases) and phosphatase (calcineurin) to investigate the involvement of these enzymes in transcriptional regulation of three immediate early genes in PC12 cells stimulated with A(23187) or KCl. Preincubation of PC12 cells with the CaM kinase inhibitor KN-62 blocked autophosphorylation of CaM kinase II in response to stimulation by the Ca2+ ionophore A(23187). KN-62 treatment also resulted in a 60-70% inhibition of Ca2+-dependent transcription of c-fos, NGFI-A (zif 268), and NGFI-B (nur77) as assessed by either Northern or nuclear run-on analyses. Preincubation with the calcineurin inhibitors FK-506 or cyclosporin A strongly enhanced expression of NGFI-A and blocked transcription of NGFI-B, but it had no significant effect on Ca2+-stimulated transcription of c-fos. Both FK-506 and KN-62 were specific for Ca2+-stimulated transcription as neither effected transcription in response to forskolin or phorbol ester (12-O-tetradecanoylphorbol-13-acetate) treatment. This is the first report of CaM kinase and calcineurin involvement in transcriptional regulation of NGFI-A and NGFI-B. Activation of CaM kinases and calcineurin, in response to elevated intracellular Ca2+, would exert antagonistic effects on transcription of NGFI-A. Since inhibition of either the kinase or phosphatase decreased transcription of NGFI-B by 60-90%, this suggests that each enzyme is necessary but not sufficient for Ca2+ stimulation. These results indicate that CaM kinases and calcineurin can mediate broad and complex regulation of Ca2+-stimulated gene expression.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University			Enslen, Hervé/M-3400-2017	Enslen, Hervé/0000-0001-9741-5293	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044239] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44239] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; CORBIN JD, 1973, J BIOL CHEM, V248, P1813; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FARBER LH, 1987, J NEUROCHEM, V49, P404, DOI 10.1111/j.1471-4159.1987.tb02880.x; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GARGLIO P, 1981, NUCLEIC ACIDS RES, V9, P2589; Ginty D D, 1992, Curr Opin Neurobiol, V2, P312, DOI 10.1016/0959-4388(92)90121-Z; GINTY DD, 1991, J BIOL CHEM, V266, P17454; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; GRANELLIPIPERNO A, 1986, J EXP MED, V163, P922, DOI 10.1084/jem.163.4.922; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MACNICOL M, 1990, J BIOL CHEM, V265, P16055; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MIYANO O, 1992, J BIOL CHEM, V267, P1198; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MOSHIZUKI H, 1993, J BIOL CHEM, V268, P9143; NATAZUKA T, 1993, INT J CANCER, V54, P348, DOI 10.1002/ijc.2910540230; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PUJOL MJ, 1993, J NEUROCHEM, V60, P1422, DOI 10.1111/j.1471-4159.1993.tb03304.x; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SCHWANINGER M, 1993, J BIOL CHEM, V268, P23111; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SODERLING TR, 1972, J BIOL CHEM, V248, P1822; TANSEY MG, 1992, J BIOL CHEM, V267, P12511; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WERLEN G, 1993, J BIOL CHEM, V268, P16596; YOON JK, 1993, J BIOL CHEM, V268, P9148	57	151	154	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20872	20877						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	7520433				2022-12-25	WOS:A1994PC40300013
J	SHETA, EA; MCMILLAN, K; MASTERS, BSS				SHETA, EA; MCMILLAN, K; MASTERS, BSS			EVIDENCE FOR A BIDOMAIN STRUCTURE OF CONSTITUTIVE CEREBELLAR NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; HYDROXY-L-ARGININE; CYTOCHROME-C REDUCTASE; SMOOTH-MUSCLE CELLS; NITROGEN-OXIDES; LIMITED PROTEOLYSIS; ENDOTHELIAL-CELLS; RELAXING FACTOR; BRAIN; OXIDATION	Nitric oxide synthase (NOS) catalyzes the NADPH-dependent, Ca2+/calmodulin dependent formation of NO and citrulline from L-arginine and molecular oxygen. The localization of the heme-binding consensus sequence in the NH2-terminal half of NOS and of the bind sequences for nucleotides (FMN and FAD) in the COOH-terminal half suggests a bidomain structure. In addition, the presence of a putative calmodulin-binding sequence between the heme- and flavin-binding domains of the enzyme suggests a role for calmodulin in modulating a spatial orientation of these domains that is required for catalytic activity. First, to determine the effects of calmodulin and the functionality of the separated domains, Ca2+/calmodulin binding-induced conformational changes in NOS were measured by fluorescence quenching from which a binding constant of similar to 1 nM for calmodulin was calculated. Second, electron transport to various artificial accepters was measured. The addition of Ca2+/calmodulin increased cytochrome c reduction from 10-15-fold while stimulating the rate of 2,6-dichlorophenolindophenol and ferricyanide reduction only slightly, if at all. Calmodulin stimulation of NOS results in NADPH-mediated cytochrome c reduction, which is sensitive to superoxide dismutase, and the reduction of acetylated cytochrome c, which is only weakly reducible by unstimulated NOS. Thus, this stimulated activity is presumably superoxide anion-mediated. Third, limited proteolysis of NOS in the absence of calmodulin resulted in a time dependent increase in cytochrome c reductase activity, which was not inhibitable by superoxide dismutase, and a decrease in catalysis of NO formation, SDS-polyacrylamide gel electrophoresis analysis of the tryptic digest demonstrated the formation of similar to 89- and similar to 79-kDa fragments. Sequence analysis of the peptides confirmed that trypsin cleaves the enzyme in the putative calmodulin-binding region beginning with Ala(728). This region was protected from proteolysis by the addition of Ca2+/calmodulin, The separated NH2-terminal domain exhibited the characteristic spectrum of bound heme, while the COOH-terminal domain showed the characteristic spectrum of bound flavins. Other cleavage patterns were obtained in the presence of calmodulin. The data demonstrate that the heme- and flavin-binding domains of NOS can be isolated in functionally intact forms.	UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio					NHLBI NIH HHS [HL30050] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL130050, R37HL030050, R01HL030050] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRONIKLION V, 1992, BIOCHEM BIOPH RES CO, V185, P452, DOI 10.1016/S0006-291X(05)81006-X; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BLUMENTHAL DK, 1987, METHOD ENZYMOL, V139, P115; BOUCHER JL, 1992, BIOCHEM BIOPH RES CO, V187, P880, DOI 10.1016/0006-291X(92)91279-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; DINERMAN JL, 1993, CIRC RES, V73, P217, DOI 10.1161/01.RES.73.2.217; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KELM M, 1988, BIOCHEM BIOPH RES CO, V154, P236, DOI 10.1016/0006-291X(88)90675-4; KILBOURN RG, 1990, J NATL CANCER I, V82, P772, DOI 10.1093/jnci/82.9.772; KLATT P, 1992, J BIOL CHEM, V267, P11374; KWON NS, 1989, J BIOL CHEM, V264, P20496; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; Masters B, 1967, METHOD ENZYMOL, V10, P565; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; MONCADA S, 1991, PHARMACOL REV, V43, P109; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; POU S, 1992, J BIOL CHEM, V267, P24173; PROUGH RA, 1973, ANN NY ACAD SCI, V212, P89, DOI 10.1111/j.1749-6632.1973.tb47588.x; PUFAHL RA, 1993, BIOCHEM BIOPH RES CO, V193, P963, DOI 10.1006/bbrc.1993.1719; RENAUD JP, 1993, BIOCHEM BIOPH RES CO, V192, P53, DOI 10.1006/bbrc.1993.1380; SCHINI VB, 1991, BIOCHEM BIOPH RES CO, V176, P114, DOI 10.1016/0006-291X(91)90897-G; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WALSH C, 1979, ENZYMATIC REACTION M, P388; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WILSON JE, 1991, METHOD BIOCHEM ANAL, V35, P207; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425	43	201	203	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15147	15153						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7515050				2022-12-25	WOS:A1994NP73800046
J	BORCHELT, DR; KOLIATSOS, VE; GUARNIERI, M; PARDO, CA; SISODIA, SS; PRICE, DL				BORCHELT, DR; KOLIATSOS, VE; GUARNIERI, M; PARDO, CA; SISODIA, SS; PRICE, DL			RAPID ANTEROGRADE AXONAL-TRANSPORT OF THE CELLULAR PRION GLYCOPROTEIN IN THE PERIPHERAL AND CENTRAL NERVOUS SYSTEMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB DISEASE; ASPARAGINE-LINKED GLYCOSYLATION; GERSTMANN-STRAUSSLER SYNDROME; SCRAPIE-ASSOCIATED FORM; MOUSE SCRAPIE; CULTURED-CELLS; ALZHEIMERS-DISEASE; AMYLOID PROTEIN; NEURAL SPREAD; PRP 27-30	In prion diseases, the cellular prion protein (PrPC), abundant in neurons, is converted posttranslationally into an amyloid-forming scrapie prion protein (PrPSc), which accumulates in white matter tracts and nerve terminals. The trafficking of PrPC in neurons was investigated in vivo by injecting [S-35]methionine into the L4 and L5 dorsal root ganglia and the entorhinal cortices of adult rats and by tracing the movement of radiolabeled PrPC. In both paradigms, labeled 33-55-kDa PrPC was transported, within 4 h, to distal axons and nerve terminals cofractionating with proteins in the fast component. Future studies using these methods may allow us to determine whether PrPC is converted into Prp(Sc) during axonal transport and whether PrPSc is transported in animals with prion diseases.	JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	BORCHELT, DR (corresponding author), JOHNS HOPKINS UNIV,SCH MED,NEUROPATHOL LAB,558 ROSS RES BLDG,720 RUTLAND AVE,BALTIMORE,MD 21205, USA.		Pardo, Carlos A./A-5192-2008	Pardo, Carlos A./0000-0002-4128-5335	NIA NIH HHS [AG 05146] Funding Source: Medline; NINDS NIH HHS [NS 20471, NS 10580] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS020471, P01NS020471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005146] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BENDHEIM PE, 1984, NATURE, V310, P418, DOI 10.1038/310418a0; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; BOLTON DC, 1985, J VIROL, V53, P596, DOI 10.1128/JVI.53.2.596-606.1985; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BORCHELT DR, 1993, GLYCOBIOLOGY, V3, P319, DOI 10.1093/glycob/3.4.319; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; BUYUKMIHCI N, 1983, EXP NEUROL, V81, P396, DOI 10.1016/0014-4886(83)90271-6; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; DEARMOND SJ, 1985, CELL, V41, P221, DOI 10.1016/0092-8674(85)90076-5; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; FRASER H, 1985, BRAIN RES, V346, P32, DOI 10.1016/0006-8993(85)91091-1; FRASER H, 1982, NATURE, V295, P149, DOI 10.1038/295149a0; GAJDUSEK DC, 1966, NATURE, V209, P794, DOI 10.1038/209794a0; GAJDUSEK DC, 1977, SCIENCE, V197, P943, DOI 10.1126/science.142303; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GIBBS CJ, 1968, SCIENCE, V161, P388, DOI 10.1126/science.161.3839.388; GOLDFARB LG, 1993, P NATL ACAD SCI USA, V90, P4451, DOI 10.1073/pnas.90.10.4451; GRAFSTEIN B, 1967, SCIENCE, V157, P196, DOI 10.1126/science.157.3785.196; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; JENDROSKA K, 1991, NEUROLOGY, V41, P1482, DOI 10.1212/WNL.41.9.1482; KIMBERLIN RH, 1982, J ROY SOC MED, V75, P618; KIMBERLIN RH, 1980, J GEN VIROL, V51, P183, DOI 10.1099/0022-1317-51-1-183; KIMBERLIN RH, 1983, J NEUROL SCI, V61, P315, DOI 10.1016/0022-510X(83)90165-X; KIMBERLIN RH, 1983, J GEN VIROL, V64, P713, DOI 10.1099/0022-1317-64-3-713; KITAMOTO T, 1986, ANN NEUROL, V20, P204, DOI 10.1002/ana.410200205; KITAMOTO T, 1992, AM J PATHOL, V140, P1285; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; KRETZSCHMAR HA, 1986, AM J PATHOL, V122, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASEK RAYMOND, 1968, BRAIN RES, V7, P360, DOI 10.1016/0006-8993(68)90003-6; LUBINSKA L, 1964, J NEUROCHEM, V11, P493, DOI 10.1111/j.1471-4159.1964.tb07498.x; MASTERS CL, 1981, BRAIN, V104, P535, DOI 10.1093/brain/104.3.535; MASTERS CL, 1981, BRAIN, V104, P559, DOI 10.1093/brain/104.3.559; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; OCHS S, 1967, J NEUROCHEM, V14, P317, DOI 10.1111/j.1471-4159.1967.tb09529.x; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1992, ADV VIRUS RES, V41, P241, DOI 10.1016/S0065-3527(08)60038-X; ROBERTS GW, 1988, NEUROLOGY, V38, P1534, DOI 10.1212/WNL.38.10.1534; SARBAN D, 1990, NEUROLOGY, V40, P110; SISODIA SS, 1993, J NEUROSCI, V13, P3136; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STAHL N, 1990, MOL CELL BIOL MEMBRA, P189; STEWARD O, 1976, J COMP NEUROL, V167, P285, DOI 10.1002/cne.901670303; STEWARD O, 1976, J COMP NEUROL, V169, P347, DOI 10.1002/cne.901690306; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; TARABOULOS A, 1991, Journal of Cell Biology, V115, p473A; VALLEE RB, 1991, ANNU REV NEUROSCI, V14, P59, DOI 10.1146/annurev.ne.14.030191.000423; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	62	101	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14711	14714						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514179				2022-12-25	WOS:A1994NM06500064
J	NUTTLE, LC; DUBYAK, GR				NUTTLE, LC; DUBYAK, GR			DIFFERENTIAL ACTIVATION OF CATION CHANNELS AND NONSELECTIVE PORES BY MACROPHAGE P-2Z PURINERGIC RECEPTORS EXPRESSED IN XENOPUS-OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; EXTRACELLULAR ATP; MOUSE MACROPHAGES; PLASMA-MEMBRANE; AMILORIDE ANALOGS; HUMAN-LYMPHOCYTES; ION CHANNEL; MAST-CELLS; CA-2+; PERMEABILITY	In macrophages and certain other cell types, extracellular ATP(4-) can increase plasma membrane permeability through activation of the P-2z purinergic receptor. This permeability change involves the induction of non-selective pores which are permeable to molecules with M(r) less than or equal to 900. Electrophysiological studies indicate that agonist occupation of P-2z purinergic receptors can additionally activate cation channels which may be distinct from the non selective pores. We have observed that mammalian P-2z purinergic receptors can be expressed in Xenopus oocytes injected with mRNA from the BAC1.2F5 murine macrophage cell line. Under voltage-clamp analysis, these oocytes exhibit a multiphasic inward current in response to ATP or 3'-O-(4-benzoyl)benzoyl-ATP (BzATP), a selective agonist for the P-2z purinergic receptor. This ATP/BzATP-induced current is characterized by a rapidly activated phase which is followed by a delayed, but steady, increase in conductance. We have used two-electrode voltage-clamp analysis and ion substitution to further characterize these P-2z purinergic receptor-induced currents as expressed in mRNA-injected oocytes. N,N-Hexamethylene amiloride (HMA), a potent inhibitor of various exchangers and channels, selectively and reversibly inhibited the delayed component of the BzATP-induced inward current. This delayed HMA-sensitive current can be carried by large organic cations, such as N-methyl-D-glucamine (NMG(+)) and Tris(+), in addition to small inorganic cations including Na+, Li+, and K+. In contrast, the rapidly activated HMA-insensitive current is readily carried by Na+, Li+, and K+, but is poorly carried by NMG(+) and Tris(+). Additional studies characterized P-2z receptor regulation of Ca2+ influx, depolarization, ethidium uptake, and fura-2 loss in native BAC1.2F5 macrophages. Reduced temperature permitted discrimination of two distinct permeability pathways which could be activated by BzATP. At 20 degrees C, BzATP did not significantly increase membrane permeability to NMG(+) (M(r) 195), ethidium(+) (M(r) 314), or fura-2 (M(r) 831) but did stimulate an ion conducting pathway which could be competitively permeated by Na+ or Ca2+. At 37 degrees C, BzATP treatment increased membrane permeability to NMG(+), ethidium(+), and fura-2, in addition to Na+ and Ca2+. These data indicate that macrophage P-2z purinergic receptors can be differentially coupled to: 1) a rapidly gated cation channel, and 2) a time- and temperature-dependent formation of non selective pores. These two permeability pathways can be distinguished by their rates of activation, ion selectivities, sensitivities to amiloride analogs, and temperature dependence.			NUTTLE, LC (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106, USA.			Dubyak, George/0000-0001-9720-4226; Nuttle, Louise/0000-0003-0073-0743	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036387] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07653] Funding Source: Medline; NIGMS NIH HHS [GM-36387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBUQUERQUE C, 1993, AM J PHYSIOL, V265, pC1663, DOI 10.1152/ajpcell.1993.265.6.C1663; ALONSOTORRE SR, 1993, J BIOL CHEM, V268, P18640; BEAN BP, 1992, TRENDS PHARMACOL SCI, V13, P87, DOI 10.1016/0165-6147(92)90032-2; BLANCHARD DK, 1991, J IMMUNOL, V147, P2579; BUISMAN HP, 1988, P NATL ACAD SCI USA, V85, P7988, DOI 10.1073/pnas.85.21.7988; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCKCROFT S, 1979, NATURE, V279, P541, DOI 10.1038/279541a0; DAHLQUIST R, 1974, ACTA PHARMACOL TOX, V35, P11; DIVIRGILIO F, 1988, BIOCHEM J, V256, P959, DOI 10.1042/bj2560959; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; DUBYAK GR, 1986, ARCH BIOCHEM BIOPHYS, V245, P84, DOI 10.1016/0003-9861(86)90192-X; ELMOATASSIM C, 1993, J BIOL CHEM, V268, P15571; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; ELMOATASSIM C, 1989, FEBS LETT, V242, P391, DOI 10.1016/0014-5793(89)80508-3; ELMOATASSIM C, 1990, EUR J PHARMACOL, V18, P111; GARRITSEN A, 1990, BIOCHEM PHARMACOL, V40, P827, DOI 10.1016/0006-2952(90)90323-D; GARRITSEN A, 1991, J RECEPTOR RES, V11, P891, DOI 10.3109/10799899109064686; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARA N, 1990, COMP BIOCHEM PHYS A, V97, P417, DOI 10.1016/0300-9629(90)90633-4; HOWARD MJ, 1987, MOL PHARMACOL, V32, P53; HOWARD MJ, 1987, AM J PHYSIOL, V253, pF21, DOI 10.1152/ajprenal.1987.253.1.F21; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; NAUMOV AP, 1992, FEBS LETT, V313, P285, DOI 10.1016/0014-5793(92)81210-D; NUTTLE LC, 1993, MOL PHARMACOL, V44, P93; PIZZO P, 1991, BIOCHEM J, V274, P139, DOI 10.1042/bj2740139; ROZENGURT E, 1975, BIOCHEM BIOPH RES CO, V67, P1581, DOI 10.1016/0006-291X(75)90207-7; ROZENGURT E, 1977, J BIOL CHEM, V252, P4584; SOLTOFF SP, 1992, AM J PHYSIOL, V262, pC934, DOI 10.1152/ajpcell.1992.262.4.C934; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; STEINBERG TH, 1991, CURR OPIN IMMUNOL, V3, P711; SUNG SSJ, 1985, J BIOL CHEM, V260, P3442; TATHAM PER, 1990, J GEN PHYSIOL, V95, P459, DOI 10.1085/jgp.95.3.459; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; WHETTON AD, 1988, BIOCHEM BIOPH RES CO, V152, P1173, DOI 10.1016/S0006-291X(88)80408-X; WILEY JS, 1990, ARCH BIOCHEM BIOPHYS, V280, P263, DOI 10.1016/0003-9861(90)90328-V; WILEY JS, 1992, ARCH BIOCHEM BIOPHYS, V292, P411, DOI 10.1016/0003-9861(92)90010-T; WILEY JS, 1993, ARCH BIOCHEM BIOPHYS, V305, P54, DOI 10.1006/abbi.1993.1392	41	159	160	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13988	13996						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514597				2022-12-25	WOS:A1994NL60600042
J	SHANKAR, R; DELAMOTTE, CA; POPTIC, EJ; DICORLETO, PE				SHANKAR, R; DELAMOTTE, CA; POPTIC, EJ; DICORLETO, PE			THROMBIN RECEPTOR-ACTIVATING PEPTIDES DIFFERENTIALLY STIMULATE PLATELET-DERIVED GROWTH-FACTOR PRODUCTION, MONOCYTIC CELL-ADHESION, AND E-SELECTIN EXPRESSION IN HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; PROSTACYCLIN PRODUCTION; TRANSCRIPTIONAL REGULATION; RELEASE; MECHANISM; PATHWAYS; PROTEIN; PDGF; REQUIREMENTS; FIBROBLASTS	Recent studies have shown that the synthetic peptides SFL LRN and SFL LRN PND KYEPF (thrombin receptor-activating peptides (TRAP)) derived from the deduced sequence of the new amino terminus of the cleaved thrombin receptor can mimic thrombin receptor activation, act as full agonists for platelet activation, and induce prostaglandin I-2 production as well as cytosolic Ca2+ increase in human umbilical vein endothelial cells (HUVEC). Here, we have compared the ability of these synthetic peptide ligands and thrombin to stimulate platelet-derived growth factor (PDGF) production by, and monocyte adhesion to, HUVEC. Thrombin (50 units/ ml) and TRAP (25 mu M) maximally stimulated monocyte adhesion. Furthermore, the stimulation of E-selectin cell surface expression and the steady-state E-selectin mRNA levels by thrombin and TRAP were comparable. Thrombin (50 units/ml) stimulated PDGF production 400% above the basal level in 24 h, whereas the 6-mer and 14-mer TRAP, even at 200 mu M, did not significantly stimulate PDGF production. Northern analysis, however, revealed that TRAP at 100 mu M stimulated PDGF-A and -B chain mRNA expression to a level similar to that induced by thrombin. These results suggest that activation of cell signaling by TRAP can mimic thrombin and is sufficient for the stimulation of monocyte adhesion to HUVEC; however, thrombin-stimulated PDGF production by HUVEC may require mechanisms in addition to the signaling events initiated by TRAP or may require the participation of a novel thrombin receptor.	LOYOLA UNIV, MED CTR, DEPT SURG, MAYWOOD, IL 60153 USA; CLEVELAND CLIN RES INST, DEPT CELL BIOL, CLEVELAND, OH 44196 USA	Loyola University Chicago; Cleveland Clinic Foundation	SHANKAR, R (corresponding author), LOYOLA UNIV, MED CTR, INST SHOCK TRAUMA, 2160 S 1ST AVE, MAYWOOD, IL 60153 USA.				NHLBI NIH HHS [HL 29582, HL 34727] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029582, R01HL034727] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARSHAVIT R, 1983, LAB INVEST, V49, P702; BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; BARSHAVIT R, 1986, J CELL BIOCHEM, V32, P261, DOI 10.1002/jcb.240320403; BARTHA K, 1993, J BIOL CHEM, V268, P421; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; CARNEY DH, 1992, J CLIN INVEST, V89, P1469, DOI 10.1172/JCI115737; CARNEY DH, 1978, J CELL PHYSIOL, V95, P13, DOI 10.1002/jcp.1040950103; CHEN LB, 1976, EXP CELL RES, V101, P41, DOI 10.1016/0014-4827(76)90409-2; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANIEL TO, 1987, J BIOL CHEM, V262, P11893; DANIEL TO, 1988, J BIOL CHEM, V263, P19815; DICORLETO PE, 1989, BIOCHEM J, V264, P71, DOI 10.1042/bj2640071; DICORLETO PE, 1983, P NATL ACAD SCI-BIOL, V80, P1919, DOI 10.1073/pnas.80.7.1919; DICORLETO PE, 1989, J IMMUNOL, V143, P3666; DICORLETO PE, 1985, J CLIN INVEST, V75, P1153, DOI 10.1172/JCI111810; EDIT JF, 1989, J CLIN INVEST, V84, P18; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; FITZGERALD DJ, 1989, P NATL ACAD SCI USA, V86, P7585, DOI 10.1073/pnas.86.19.7585; FUKUSHIMA M, 1989, INVEST OPHTH VIS SCI, V30, P1576; GELEHRTER TD, 1986, J CLIN INVEST, V77, P165, DOI 10.1172/JCI112271; HALLAM TJ, 1988, BIOCHEM J, V251, P243, DOI 10.1042/bj2510243; HARLAN JM, 1986, J CELL BIOL, V103, P1129, DOI 10.1083/jcb.103.3.1129; HELDIN CH, 1979, P NATL ACAD SCI USA, V76, P3722, DOI 10.1073/pnas.76.8.3722; JAFFE EA, 1987, HUM PATHOL, V18, P234, DOI 10.1016/S0046-8177(87)80005-9; KAVANAUGH WM, 1988, J BIOL CHEM, V263, P8470; LEVIN EG, 1984, J CLIN INVEST, V74, P1988, DOI 10.1172/JCI111620; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; NGAIZA JR, 1991, BIOCHEM BIOPH RES CO, V179, P1656, DOI 10.1016/0006-291X(91)91765-5; PEREZRODRIGUEZ R, 1981, CELL BIOL INT REP, V5, P347, DOI 10.1016/0309-1651(81)90004-7; POHJANPELTO P, 1977, J CELL PHYSIOL, V91, P387, DOI 10.1002/jcp.1040910308; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SCHINI VB, 1989, EUR J PHARMACOL, V165, P333, DOI 10.1016/0014-2999(89)90733-4; SHANKAR R, 1992, AM J PHYSIOL, V262, pC199, DOI 10.1152/ajpcell.1992.262.1.C199; SHANKAR R, 1992, J BIOL CHEM, V267, P9376; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X; SUGAMA Y, 1992, J CELL BIOL, V119, P935, DOI 10.1083/jcb.119.4.935; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WEKSLER BB, 1978, J CLIN INVEST, V62, P923, DOI 10.1172/JCI109220	49	100	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13936	13941						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514596				2022-12-25	WOS:A1994NL60600036
J	SCHWARTZ, MA; DENNINGHOFF, K				SCHWARTZ, MA; DENNINGHOFF, K			ALPHA(V)-INTEGRINS MEDIATE THE RISE IN INTRACELLULAR CALCIUM IN ENDOTHELIAL-CELLS ON FIBRONECTIN EVEN THOUGH THEY PLAY A MINOR ROLE IN ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; VONWILLEBRAND-FACTOR; RECEPTOR; INTEGRIN; VITRONECTIN; ATTACHMENT; IDENTIFICATION; SURFACE; SUBUNIT; INTEGRIN-ALPHA-V-BETA-5	We have investigated which integrins mediate the elevation of intracellular calcium ([Ca2+]i) triggered by spreading of endothelial cells on fibronectin (FN). Specific anti-integrin monoclonal antibodies immobilized on glass surfaces were used as agonists to trigger cell spreading. These experiments demonstrated that an antibody to alpha(v), could induce the rise in [Ca2+]i, whereas two antibodies to alpha5beta1 were inactive, despite their ability to induce cell spreading and elevation of intracellular pH. Antibodies in solution were then used as agonists to block association of specific integrins with FN. These experiments also showed that alpha(v) integrin(s) but not alpha5beta1 mediated the rise in [Ca2+]i in cells spreading on FN. Adhesion assays in the presence of function-blocking anti-integrin antibodies and affinity chromatography on FN columns of surface-labeled cell extracts were carried out to characterize the integrins that bind to FN. Both methods showed that alpha(v) integrin(s) and alpha5beta1 participate in FN binding, however, the contribution from alpha(v) integrin(s) was much less than that of alpha5beta1. These results demonstrate that two receptors for FN on the same cells can trigger distinct intracellular signaling pathways and, furthermore, that an integrin whose contribution to adhesion is barely detectable can have a major effect on cellular responses. The results also suggest that the specificity for activation of the calcium signaling pathway resides primarily in the integrin alpha subunit.			SCHWARTZ, MA (corresponding author), SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA.			schwartz, martin/0000-0002-2071-1243	NHLBI NIH HHS [P01 HL48728] Funding Source: Medline; NIGMS NIH HHS [R01 GM47214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBELDA SM, 1989, J CLIN INVEST, V83, P1992, DOI 10.1172/JCI114109; BUSK M, 1992, J BIOL CHEM, V267, P5790; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHERESH DA, 1987, J BIOL CHEM, V262, P1434; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; PASQUALINI R, 1993, J CELL SCI, V105, P101; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SMITH JW, 1990, J BIOL CHEM, V265, P11008; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877	29	109	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11133	11137						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512559				2022-12-25	WOS:A1994NF96600027
J	BUDAY, L; EGAN, SE; VICIANA, PR; CANTRELL, DA; DOWNWARD, J				BUDAY, L; EGAN, SE; VICIANA, PR; CANTRELL, DA; DOWNWARD, J			A COMPLEX OF GRB2 ADAPTER PROTEIN, SOS EXCHANGE FACTOR, AND A 36-KDA MEMBRANE-BOUND TYROSINE PHOSPHOPROTEIN IS IMPLICATED IN RAS ACTIVATION IN T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE C-GAMMA-1; PHOSPHORYLATION; P21RAS; VAV; STIMULATION; SHC	T lymphocytes contain both Grb2, an SH2 and SH3 domain containing adaptor protein, and Sos, a guanine nucleotide exchange factor for Ras. Immunoprecipitates of Sos from the lysates of T cells contain a 36-kDa protein which is phosphorylated on tyrosine residues in response to T cell receptor/CD3 cross-linking. In vitro studies using different bacterially synthesized GST-Sos fusion proteins confirm the formation of complexes con taining p36 and the proline-rich COOH-terminal domain of Sos. The use of mutant GST-Grb2 proteins in which both SH3 domains have been mutationally inactivated shows that Grb2 binds to tyrosine phosphorylated p36 via its SH2 domain. In Jurkat cells phosphorylated p36 is localized exclusively in the particulate fraction. In addition, another SH2 domain-containing protein, p52(She) is tyrosine phosphorylated upon TCR.CD3 crosslinking and associates with a 150-kDa phosphotyrosine containing protein. Taken together these data suggest that activation of Ras in T cells via the TCR.CD3 complex might be controlled, at least in part, by mechanisms similar to those found in fibroblasts, involving in this case formation of a complex of Grb2, Sos, and a membrane-bound tyrosine phosphoprotein of molecular mass 36-kDa.	IMPERIAL CANC RES FUND,SIGNAL TRANSDUCT LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,LYMPHOCYTE ACTIVAT LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; Cancer Research UK				Downward, Julian/0000-0002-2331-4729				ADAMS JM, 1992, ONCOGENE, V7, P611; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; GRAVES JD, 1992, J IMMUNOL, V148, P2417; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HSI ED, 1989, J BIOL CHEM, V264, P10836; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MALISSEN B, 1993, CURR OPIN IMMUNOL, V5, P324, DOI 10.1016/0952-7915(93)90049-X; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PERI KG, 1993, ONCOGENE, V8, P2765; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SEFTON BM, 1973, J VIROL, V11, P730, DOI 10.1128/JVI.11.5.730-735.1973; SEFTON BM, 1991, ANNU REV CELL BIOL, V7, P257, DOI 10.1146/annurev.cellbio.7.1.257; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484	30	224	227	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9019	9023						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510700				2022-12-25	WOS:A1994NB41100061
J	CONDORELLI, G; BUENO, R; SMITH, RJ				CONDORELLI, G; BUENO, R; SMITH, RJ			2 ALTERNATIVELY SPLICED FORMS OF THE HUMAN INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR HAVE DISTINCT BIOLOGICAL-ACTIVITIES AND INTERNALIZATION KINETICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUXTAMEMBRANE REGION; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; PROTEIN; EXPRESSION; MUSCLE; IRS-1	Two alternatively spliced human insulin-like growth factor I (IGF I) receptor mRNA transcripts have been described that differ by three nucleotides (CAG) starting at position 2829. This results in an amino acid coding sequence change from Thr-Gly to Arg in the extracellular portion of the receptor beta subunit. To investigate the functional significance of this sequence difference, we obtained full-length cDNAs for the CAG+ and CAG- receptor forms, transfected CHO cells, and isolated multiple clones expressing approximately equal numbers of receptors (0.57-0.73 x 10(6) receptors/cell). The two receptors bound IGF I with similar affinity (K-d similar to 1.7 nM), but the CAG- form exhibited an approximately 2-fold increase in IGF I stimulation of receptor autophosphorylation, insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation, thymidine incorporation, and IRS-1-associated phosphatidylinositol 3-kinase activity. In contrast to its higher signaling activity, the rate of receptor mediated internalization of IGF I by the CAG-receptor was decreased by 50% in comparison with the CAG+ receptor. We conclude that proteins corresponding to the two alternatively spliced human IGF I receptor transcripts are biologically active, but have distinct signaling properties. These experiments further indicate a previously unrecognized role for the extramembranous portion of the beta subunit in receptor signaling and internalization.	JOSLIN DIABET CTR,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Condorelli, Gerolama/AAC-3472-2022	Condorelli, Gerolama/0000-0003-0177-8829	NIDDK NIH HHS [DK43038] Funding Source: Medline; NIGMS NIH HHS [GM07560] Funding Source: Medline; PHS HHS [36836] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043038] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOTT AM, 1992, J BIOL CHEM, V267, P10759; ALEXANDRIDES TK, 1989, J BIOL CHEM, V264, P12922; ALEXANDRIDES TK, 1993, REGUL PEPTIDES, V48, P279, DOI 10.1016/0167-0115(93)90357-E; BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GIORGINO F, 1992, ENDOCRINOLOGY, V130, P1433, DOI 10.1210/en.130.3.1433; GONCALVES E, 1993, P NATL ACAD SCI USA, V90, P5762, DOI 10.1073/pnas.90.12.5762; JUI HY, 1993, EXP CLIN ENDOCRIN S2, V101, P55; KATO H, 1993, J BIOL CHEM, V268, P2655; KELLERER M, 1990, J BIOL CHEM, V265, P9340; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUND KA, 1990, J BIOL CHEM, V265, P15713; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; MOSTHAF L, 1993, P NATL ACAD SCI USA, V90, P2633, DOI 10.1073/pnas.90.7.2633; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YEE D, 1989, J BIOL CHEM, V264, P21439	30	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8510	8516						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510688				2022-12-25	WOS:A1994NB40900102
J	SIGEL, E; BAUR, R; MALHERBE, P				SIGEL, E; BAUR, R; MALHERBE, P			PROTEIN-KINASE-C TRANSIENTLY ACTIVATES HETEROMERIC N-METHYL-D-ASPARTATE RECEPTOR CHANNELS INDEPENDENT OF THE PHOSPHORYLATABLE C-TERMINAL SPLICE DOMAIN AND OF CONSENSUS PHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA-A-RECEPTOR; NMDA-RECEPTOR; RAT-BRAIN; MOLECULAR DIVERSITY; XENOPUS OOCYTES; ALPHA-SUBUNIT; MODULATION; EXPRESSION; CLONING; POTENTIATION	We have expressed dual subunit combinations of isoforms of the N-methyl-D-aspartate receptor, NR1A-NR2A and NR1C-NR2A, in Xenopus oocytes. We show that both forms of the receptor are stereospecifically activated by low concentrations (10 nM) of the phorbol ester 4-beta-phorbol 12-myristate 13-acetate, known to activate protein kinase C (PKC). The activation is transient, and, after reaching a maximum in about 10 min, it decreases rapidly in spite of the continuous presence of phorbol ester. The addition of 2 mu M oleoylacetylglycerol had similar consequences. NR1C differs from NR1A by a deletion of 37 amino acids that include four consensus phosphorylation sites for PKC in the C-terminal region. The corresponding peptide has been shown to become phosphorylated upon activation of PKC in neurons (Tingley, W. G., Roche, K. W, Thompson, A. K., and Huganir, R. L. (1993) Nature 364, 70-73). However, the activity of NR1C-NR2A receptors was stimulated 7-fold, twice the potentiation observed for NR1A-NR2A. By site-specific mutagenesis of NR1C and NR2A, we removed additional consensus PKC phosphorylation sites located between TM3 and TM4. Coexpression of these mutant subunits showed a similar response to phorbol esters as wild type receptors. Our results indicate that neither the predicted consensus phosphorylation sites between transmembrane sequences TM3 and TM4 nor the phosphorylatable C-terminal splice domain is essential for the modulation of N-methyl-D aspartate receptors by PKC.	F HOFFMANN LA ROCHE & CO LTD, PRECLIN RES, CH-4002 BASEL, SWITZERLAND	Roche Holding	SIGEL, E (corresponding author), UNIV BERN, INST PHARMAKOL, FRIEDBUHLSTR 49, CH-3010 BERN, SWITZERLAND.		Sigel, Erwin/F-7736-2015					BENARI Y, 1992, TRENDS NEUROSCI, V15, P333, DOI 10.1016/0166-2236(92)90049-E; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; KELLENBERGER S, 1992, J BIOL CHEM, V267, P25660; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; MALHERBE P, 1990, FEBS LETT, V260, P261, DOI 10.1016/0014-5793(90)80118-3; MALHERBE P, 1990, J NEUROSCI, V10, P2330; MALHERBE P, 1990, MOL BRAIN RES, V8, P199, DOI 10.1016/0169-328X(90)90017-8; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SIGEL E, 1987, J PHYSIOL-LONDON, V386, P73, DOI 10.1113/jphysiol.1987.sp016523; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; URUSHIHARA H, 1992, J BIOL CHEM, V267, P11697; VASILETS LA, 1990, J MEMBRANE BIOL, V118, P131, DOI 10.1007/BF01868470; YAMAZAKI M, 1992, FEBS LETT, V300, P39, DOI 10.1016/0014-5793(92)80160-I	27	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8204	8208						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510681				2022-12-25	WOS:A1994NB40900058
J	GAERTNER, HF; OFFORD, RE; COTTON, R; TIMMS, D; CAMBLE, R; ROSE, K				GAERTNER, HF; OFFORD, RE; COTTON, R; TIMMS, D; CAMBLE, R; ROSE, K			CHEMOENZYMATIC BACKBONE ENGINEERING OF PROTEINS - SITE-SPECIFIC INCORPORATION OF SYNTHETIC PEPTIDES THAT MIMIC THE 64-74-DISULFIDE LOOP OF GRANULOCYTE-COLONY-STIMULATING FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; FRAGMENTS; SEMISYNTHESIS; CONDENSATION; ANALOGS	We present the concept of chemo-enzymic backbone engineering of proteins. Recombinant DNA techniques are used to produce appropriate proteins that are enzymically fragmented to give the starting materials. These fragments are modified specifically at their chain termini either enzymically (coupling of a hydrazide to the C terminus) or chemically (periodate oxidation of N-terminal serine to a glyoxylyl function). The modified fragments, which need no side protection whatever, are mixed together and religate themselves spontaneously under mild conditions. The hydrazone bond thus formed can be reduced if desired, which stabilizes the linkage and enhances the flexibility of the local conformation. In this way biologically or chemically derived structures can be incorporated into the protein, and the choice of the chemical ones is free of all of the constraints of the genetic code. We believe that this combined approach gives access to constructions that could not be derived by either recombinant or chemical methods alone. We illustrate the particularity of this concept by the engineered modifications of the 64-74 disulfide loop region of human granulocyte colony stimulating factor. Analogs constructed include one which, in spite of having nonpeptide link in its backbone, has full biological activity.	ZENECA PHARMACEUT, MACCLESFIELD SK10 4TG, CHESHIRE, ENGLAND		GAERTNER, HF (corresponding author), CTR MED UNIV GENEVA, DEPT BIOCHIM MED, 1 RUE MICHEL SERVET, CH-1211 GENEVA 4, SWITZERLAND.							Balaram P., 1992, CURR OPIN STRUC BIOL, V2, P845, DOI [10.1016/0959-440X(92)90110-S, DOI 10.1016/0959-440X(92)90110-S]; BRINKLEY M, 1992, BIOCONJUGATE CHEM, V3, P2, DOI 10.1021/bc00013a001; CAMBLE R, 1991, Patent No. 459630; CARA JF, 1990, J BIOL CHEM, V265, P17820; CORRADIN G, 1974, BIOCHEM BIOPH RES CO, V61, P1400, DOI 10.1016/S0006-291X(74)80439-0; DEFILIPPIS V, 1990, INT J PEPT PROT RES, V35, P219; FISCH I, 1992, BIOCONJUGATE CHEM, V3, P147, DOI 10.1021/bc00014a009; GAERTNER HF, 1992, BIOCONJUGATE CHEM, V3, P262, DOI 10.1021/bc00015a010; GAERTNER HF, 1992, PEPTIDES 1992, P239; GEOGHEGAN KF, 1992, BIOCONJUGATE CHEM, V3, P138, DOI 10.1021/bc00014a008; HILL CP, 1993, P NATL ACAD SCI USA, V90, P5167, DOI 10.1073/pnas.90.11.5167; Means GE, 1990, BIOCONJUGATE CHEM, V1, P2, DOI 10.1021/bc00001a001; OFFORD RE, 1990, N HORIZ TH, P253; PROUDFOOT AEI, 1989, J BIOL CHEM, V264, P8764; RIZO J, 1992, ANNU REV BIOCHEM, V61, P387, DOI 10.1146/annurev.bi.61.070192.002131; ROSE K, 1988, BIOCHEM J, V249, P83, DOI 10.1042/bj2490083; SCHNOLZER M, 1992, SCIENCE, V256, P221, DOI 10.1126/science.1566069; VITA C, 1992, EUR J BIOCHEM, V204, P631, DOI 10.1111/j.1432-1033.1992.tb16676.x; WALLACE CJA, 1991, J BIOL CHEM, V266, P21355; WINGFIELD P, 1988, BIOCHEM J, V256, P213, DOI 10.1042/bj2560213	20	39	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7224	7230						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7510283				2022-12-25	WOS:A1994NA03200031
J	BOURGET, I; DIBERARDINO, W; BREITTMAYER, JP; GRENIERBROSSETTE, N; PLANAPRADES, M; BONNEFOY, JY; COUSIN, JL				BOURGET, I; DIBERARDINO, W; BREITTMAYER, JP; GRENIERBROSSETTE, N; PLANAPRADES, M; BONNEFOY, JY; COUSIN, JL			CD20 MONOCLONAL-ANTIBODIES STIMULATE EXTRACELLULAR CLEAVAGE OF THE LOW-AFFINITY RECEPTOR FOR IGE (FC-EPSILON-RII/CD23) IN EPSTEIN-BARR-TRANSFORMED B-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON RECEPTOR; HUMAN LYMPHOCYTES-B; BINDING FACTORS; SOLUBLE CD23; CD40 LIGAND; T-CELL; ACTIVATION; EXPRESSION; SURFACE; ANTIGEN	This study demonstrates that monoclonal antibodies to the B cell-specific CD20 molecule down-regulate both constitutive and interleukin-4-induced CD23 expression on Epstein-Barr-transformed B cells. This effect of CD20 antibody B1 does not take place at the transcriptional level as shown by the lack of effect on the CD23 mRNA level. Incorporation of S-35-labeled amino acids into CD23 polypeptide chain is not affected either. In cycloheximide-treated cells, B1 increases the decline of CD23 from the cell surface. The disappearance of CD23 molecule correlates with an increase of soluble CD23 fragments detected in the culture medium. Taken collectively, these results indicate that CD20 mAb B1 stimulates the cleavage of the CD23 molecule at the sur face of B cells.	FAC MED PASTEUR, INSERM, U364, IMMUNOL CELLULAIRE & MOLEC LAB, F-06107 NICE, FRANCE; FAC MED PASTEUR, INSERM, U343, UNITE RECH INTERACT CELLULAIRES IMMUNOL & IMMUNOP, F-06107 NICE, FRANCE; GLAXO INST MOLEC BIOL, CH-1228 PLAN LES OUATES, SWITZERLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; GlaxoSmithKline				BOURGET, Isabelle/0000-0001-6369-8176				ARMITAGE RJ, 1992, EUR J IMMUNOL, V22, P2071, DOI 10.1002/eji.1830220817; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; BONNEFOY JY, 1987, J IMMUNOL, V138, P2970; BONNEFOY JY, 1993, EUR J IMMUNOL, V23, P969; BOURGET I, 1993, EUR J IMMUNOL, V23, P768, DOI 10.1002/eji.1830230330; CAIRNS J, 1988, EUR J IMMUNOL, V18, P349, DOI 10.1002/eji.1830180305; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK EA, 1987, J IMMUNOL, V138, P720; CLARK EA, 1985, P NATL ACAD SCI USA, V82, P1766, DOI 10.1073/pnas.82.6.1766; CONRAD DH, 1987, J IMMUNOL, V139, P2290; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; DELESPESSE G, 1991, ADV IMMUNOL, V49, P149; DELESPESSE G, 1992, IMMUNOL REV, V125, P77, DOI 10.1111/j.1600-065X.1992.tb00626.x; EINFELD DA, 1988, EMBO J, V7, P711, DOI 10.1002/j.1460-2075.1988.tb02867.x; GOLAY JT, 1985, J IMMUNOL, V135, P3795; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; GRENIERBROSSETTE N, 1992, EUR J IMMUNOL, V22, P1573, DOI 10.1002/eji.1830220634; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; HUDAK SA, 1987, P NATL ACAD SCI USA, V84, P4606, DOI 10.1073/pnas.84.13.4606; KIKUTANI H, 1986, J EXP MED, V164, P1455, DOI 10.1084/jem.164.5.1455; KINTNER C, 1981, NATURE, V294, P458, DOI 10.1038/294458a0; LETELLIER M, 1988, J IMMUNOL, V141, P2374; LETELLIER M, 1990, J EXP MED, V172, P693, DOI 10.1084/jem.172.3.693; MELCHERS F, 1985, NATURE, V317, P264, DOI 10.1038/317264a0; NAKAJIMA T, 1987, J IMMUNOL, V139, P848; SARFATI M, 1986, IMMUNOLOGY, V59, P569; SARFATI M, 1992, IMMUNOLOGY, V76, P662; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; STAMENKOVIC I, 1988, J EXP MED, V167, P1975, DOI 10.1084/jem.167.6.1975; SUEMURA M, 1986, J IMMUNOL, V137, P1214; TEDDER TF, 1988, P NATL ACAD SCI USA, V85, P208, DOI 10.1073/pnas.85.1.208; TEDDER TF, 1986, EUR J IMMUNOL, V16, P881, DOI 10.1002/eji.1830160802; TEDDER TF, 1985, J IMMUNOL, V135, P973; TEDDER TF, 1989, LEUKOCYTE TYPING, V4, P48; THORLEYLAWSON DA, 1985, J EXP MED, V162, P45, DOI 10.1084/jem.162.1.45; THORLEYLAWSON DA, 1986, J IMMUNOL, V136, P1745; WILSON BS, 1985, BLOOD, V66, P824	38	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6927	6930						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509812				2022-12-25	WOS:A1994MZ50300102
J	SMITH, M; HICKS, S; BAKER, K; MCCAULEY, R				SMITH, M; HICKS, S; BAKER, K; MCCAULEY, R			RUPTURE OF THE MITOCHONDRIAL OUTER-MEMBRANE IMPAIRS PORIN ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; YEAST MITOCHONDRIA; INNER MEMBRANE; PRECURSOR PROTEINS; TRANSLOCATION; INSERTION; INVITRO; INTEGRATION; SITES	Outer membranes isolated from yeast mitochondria were capable mediating the in vitro insertion of porin. As with the outer membrane of intact mitochondria, the insertion was ATP-dependent, and the inserted porin was resistant to trypsin treatment after detergent solubilization. However, the extent of porin insertion into isolated outer membranes was much less per mg of outer membrane protein than with intact mitochondria. The greater efficiency of intact mitochondria was not due to contact site-mediated translocation as isolated contact sites were less able to insert porin than isolated outer membranes, and blockade of the contact site channel in intact mitochondria did not affect porin insertion. However, mitochondria that had been subjected to osmotic shock sufficient to rupture the outer membrane and deplete the contents of the intermembrane space (i.e. mitoplasts) lost most of their ability to insert porin. Since outer membranes are isolated from mitoplasts, the low insertion activity of mitoplasts explains the low efficiency of insertion into isolated outer membranes. These results also indicate that, unlike proteins that are imported to the inner membrane and matrix of the mitochondria, porin's assembly is severely reduced by breaching the outer membrane and depletion of the intermembrane space contents.	WAYNE STATE UNIV,DEPT PHARMACOL,DETROIT,MI 48201; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080	Wayne State University; Roche Holding; Genentech					FIC NIH HHS [1 FO6 TWO1363-01] Funding Source: Medline; NIMH NIH HHS [2 R24 MH47181-04] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F06TW001363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R24MH047181] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BOLLINGER L, EMBO J, V13, P2006; DAUM G, 1982, J BIOL CHEM, V257, P3028; DECKER GL, 1977, J ULTRA MOL STRUCT R, V59, P44, DOI 10.1016/S0022-5320(77)80027-0; FUJIKI M, 1991, J BIOL CHEM, V266, P6841; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; GASSER SM, 1983, J BIOL CHEM, V258, P3427; HURT EC, 1985, EMBO J, V4, P3509, DOI 10.1002/j.1460-2075.1985.tb04110.x; HWANG ST, 1989, P NATL ACAD SCI USA, V86, P8432, DOI 10.1073/pnas.86.21.8432; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; LI JM, 1992, BIOCHIM BIOPHYS ACTA, V1106, P233, DOI 10.1016/0005-2736(92)90001-3; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MIHARA K, 1982, P NATL ACAD SCI-BIOL, V79, P7102, DOI 10.1073/pnas.79.23.7102; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; OHBA M, 1987, EMBO J, V6, P2117, DOI 10.1002/j.1460-2075.1987.tb02478.x; ONO H, 1987, EUR J BIOCHEM, V168, P509, DOI 10.1111/j.1432-1033.1987.tb13447.x; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PON L, 1989, J CELL BIOL, V109, P2603, DOI 10.1083/jcb.109.6.2603; RIEZMAN H, 1983, EMBO J, V2, P1105, DOI 10.1002/j.1460-2075.1983.tb01553.x; ROWELY N, 1994, CELL, V77, P249; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; TIKHONOV VN, 1965, ZH ANAL KHIM, V20, P390; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; ZHUANG Z, 1989, J BIOL CHEM, V264, P14594; ZHUANG ZP, 1992, J BIOL CHEM, V267, P591	29	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28460	28464						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525575				2022-12-25	WOS:A1994PV77200100
J	JARAMILLO, ML; AFAR, DEH; ALMAZAN, G; BELL, JC				JARAMILLO, ML; AFAR, DEH; ALMAZAN, G; BELL, JC			IDENTIFICATION OF TYROSINE-620 AS THE MAJOR PHOSPHORYLATION SITE OF MYELIN-ASSOCIATED GLYCOPROTEIN AND ITS IMPLICATION IN INTERACTING WITH SIGNALING MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; PROTEIN-KINASE; DOMAINS; SH2; PHOSPHOTYROSINE; SUPERFAMILY; ISOFORMS; HOMOLOGY; RECEPTOR; BRAIN	Myelin-associated glycoprotein (MAG) is a myelin-specific cell adhesion molecule of the immunoglobulin supergene family and is tyrosine-phosphorylated in the developing brain. To define the role of MAG in signal transduction, the tyrosine phosphorylation sites were analyzed. The major tyrosine phosphorylation residue was identified as Tyr-620, which was found to interact specifically with the SH2 domains of phospholipase C (PLC gamma). This domain may represent a novel protein binding motif that can be regulated by tyrosine phosphorylation. MAG also specifically bound the Fyn tyrosine kinase, suggesting that MAG serves as a docking protein that allows the interaction between different signaling molecules.	UNIV OTTAWA, DEPT BIOCHEM, OTTAWA K1H 8M5, ON, CANADA; UNIV OTTAWA, DEPT MED, OTTAWA K1H 8M5, ON, CANADA; MCGILL UNIV, DEPT PHARMACOL & THERAPEUT, MONTREAL H3G 1Y6, PQ, CANADA	University of Ottawa; University of Ottawa; McGill University								AFAR DEH, 1990, J NEUROCHEM, V55, P1418, DOI 10.1111/j.1471-4159.1990.tb03155.x; AFAR DEH, 1991, J NEUROSCI RES, V29, P429, DOI 10.1002/jnr.490290403; ALMAZAN G, 1993, J NEUROSCI RES, V36, P163, DOI 10.1002/jnr.490360206; ARQUINT M, 1987, P NATL ACAD SCI USA, V84, P600, DOI 10.1073/pnas.84.2.600; BANIK NL, 1977, BIOCHEM J, V162, P247, DOI 10.1042/bj1620247; BROWN E, 1978, VIROLOGY, V89, P7, DOI 10.1016/0042-6822(78)90035-1; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEUSTACHIO P, 1988, J NEUROCHEM, V50, P589, DOI 10.1111/j.1471-4159.1988.tb02951.x; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; DULAC C, 1992, NEURON, V8, P323, DOI 10.1016/0896-6273(92)90298-R; EDWARDS AM, 1988, MOL CELL BIOL, V8, P2655, DOI 10.1128/MCB.8.6.2655; HIGGINS GA, 1989, P NATL ACAD SCI USA, V86, P2074, DOI 10.1073/pnas.86.6.2074; JOHNSON PW, 1989, NEURON, V3, P377, DOI 10.1016/0896-6273(89)90262-6; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; LUO K, 1990, ONCOGENE, V5, P921; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; PEDRAZA L, 1991, J NEUROSCI RES, V29, P141, DOI 10.1002/jnr.490290202; PERI KG, 1993, ONCOGENE, V8, P2765; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SALZER JL, 1987, J CELL BIOL, V104, P957, DOI 10.1083/jcb.104.4.957; TROPAK MB, 1988, MOL BRAIN RES, V4, P143, DOI 10.1016/0169-328X(88)90006-X; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	31	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27240	27245						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525550				2022-12-25	WOS:A1994PV77100016
J	TATE, CG; BLAKELY, RD				TATE, CG; BLAKELY, RD			THE EFFECT OF N-LINKED GLYCOSYLATION ON ACTIVITY OF THE NA+-DEPENDENT AND CL--DEPENDENT SEROTONIN TRANSPORTER EXPRESSED USING RECOMBINANT BACULOVIRUS IN INSECT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC-ACID TRANSPORTER; PLATELET PLASMA-MEMBRANE; HUMAN-BLOOD-PLATELETS; PARTIAL-PURIFICATION; 5-HYDROXYTRYPTAMINE TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; AFFINITY-CHROMATOGRAPHY; FUNCTIONAL EXPRESSION; PROJECTION STRUCTURE; GLUCOSE-TRANSPORTER	The rat Na+- and Cl--dependent serotonin transporter was expressed in Sf9 insect cells using the baculovirus system. Expression of the serotonin transporter caused the Sf9 cells to accumulate [H-3]serotonin (K-m 78 nM) and to bind the specific transport inhibitor [I-125]RTI55 (2 beta-carbomethoxy-3 beta-(4- [I-125]iodophenyl)tropane) (K-d 0.22 nM). Ligand binding assays on isolated membranes showed 500,000 copies of the serotonin transporter/cell (9 pmol/mg of membrane protein). Immunoreactive bands of apparent M(r) 54,000 (unglycosylated) and 60,000 (glycosylated) were observed in Western blots of membrane proteins from infected cells. The 54-kDa band was significantly smaller than the expected M(r) of 72,500 predicted from the cDNA sequence. The 54-kDa band was shown to represent the intact serotonin transporter by expressing a recombinant serotonin transporter that contained c-Myc and FLAG epitope tags engineered at the N and C termini, respectively. Both tags were present on a membrane protein that migrated slightly slower than the previously observed 54-kDa band, consistent with the extra mass added by the tags. The tags did not affect the K-d for [I-125]RTI55 binding. The effect of N-linked glycosylation on ligand binding and the level of expression were studied. The expression of the serotonin transporter in tunicamycin-treated Sf9 cells resulted in low levels of ligand binding activity (0.2 pmol/mg) but unchanged K-d. Similarly, mutated serotonin transporters that contained reduced numbers of N-linked glycosylation sites had unchanged K-d for [I-125]RTI55 binding whether there were 2, 1, or 0 N-linked glycosylation sites present on the serotonin transporter. In contrast, B-max was dramatically reduced; levels of expression of the unglycosylated serotonin transporter (0.4 pmol/mg) were 20-fold lower compared with levels of the fully glycosylated serotonin transporter. The K-m for [H-3]serotonin uptake was also unchanged. These data indicate that glycosylation is required for optimal stability of the serotonin transporter in the membrane but not for serotonin transport or ligand binding per se.	EMORY UNIV, SCH MED, DEPT ANAT & CELL BIOL, ATLANTA, GA 30322 USA	Emory University	TATE, CG (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.			Tate, Christopher/0000-0002-2008-9183	NIDA NIH HHS [DA 07390] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007390] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BALKOVETZ DF, 1989, J BIOL CHEM, V264, P2195; BENDAHAN A, 1993, FEBS LETT, V318, P41, DOI 10.1016/0014-5793(93)81323-R; BIESSEN EAL, 1990, BIOCHEMISTRY-US, V29, P3349, DOI 10.1021/bi00465a029; BLAKELY RD, 1993, SOC GEN PHY, V48, P283; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; CLARK JA, 1993, BIOESSAYS, V15, P323, DOI 10.1002/bies.950150506; CONSLER TG, 1993, P NATL ACAD SCI USA, V90, P6934, DOI 10.1073/pnas.90.15.6934; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRASER MJ, 1992, CURR TOP MICROBIOL, V158, P131; GRAHAM D, 1992, BIOCHEM J, V286, P801, DOI 10.1042/bj2860801; GU H, 1994, J BIOL CHEM, V269, P7124; HAVELKA WA, 1993, J MOL BIOL, V234, P837, DOI 10.1006/jmbi.1993.1629; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; JAP BK, 1992, ULTRAMICROSCOPY, V46, P45, DOI 10.1016/0304-3991(92)90007-7; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1989, BIOCHEMISTRY-US, V28, P3722, DOI 10.1021/bi00435a015; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KLAIBER K, 1990, NEURON, V5, P221, DOI 10.1016/0896-6273(90)90311-3; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUHLBRANDT W, 1992, Q REV BIOPHYS, V25, P1; LAUNAY JM, 1992, J BIOL CHEM, V267, P11344; LODDENKOTTER B, 1993, P NATL ACAD SCI USA, V90, P2155, DOI 10.1073/pnas.90.6.2155; MARCUSSON JO, 1990, PSYCHOPHARMACOLOGY, V102, P145, DOI 10.1007/BF02245915; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MELIKIAN HE, 1994, J BIOL CHEM, V269, P12290; MELIKIAN HE, 1993, SOC NEUR ABSTR, V19; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OMURA F, 1992, EUR J BIOCHEM, V210, P591, DOI 10.1111/j.1432-1033.1992.tb17459.x; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; RAMAMOORTHY S, 1993, J BIOL CHEM, V268, P21626; RAMAMOORTHY S, 1992, BIOCHEM J, V286, P89, DOI 10.1042/bj2860089; RAMAMOORTHY S, 1993, PLACENTA, V14, P449, DOI 10.1016/S0143-4004(05)80465-5; RANDS E, 1990, J BIOL CHEM, V265, P10759; REHAVI M, 1982, FEBS LETT, V150, P514, DOI 10.1016/0014-5793(82)80802-8; RUDNICK G, 1977, J BIOL CHEM, V252, P2170; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Schertler G. F. X., 1992, CURR OPIN STRUC BIOL, V2, P534, DOI DOI 10.1016/0959-440X(92)90083-J; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Summers MD, 1987, MANUAL METHODS BACUL; TALVENHEIMO J, 1980, J BIOL CHEM, V255, P8606; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; WAEBER U, 1993, FEBS LETT, V324, P109, DOI 10.1016/0014-5793(93)81542-8; WALL SC, 1993, MOL PHARMACOL, V43, P264; WOLF WA, 1992, J BIOL CHEM, V267, P20820; YI CK, 1992, BIOCHEM J, V283, P643, DOI 10.1042/bj2830643	57	156	159	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26303	26310						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523405				2022-12-25	WOS:A1994PQ93000057
J	HENSLEY, P; MCDEVITT, PJ; BROOKS, I; TRILL, JJ; FEILD, JA; MCNULTY, DE; CONNOR, JR; GRISWOLD, DE; KUMAR, NV; KOPPLE, KD; CARR, SA; DALTON, BJ; JOHANSON, K				HENSLEY, P; MCDEVITT, PJ; BROOKS, I; TRILL, JJ; FEILD, JA; MCNULTY, DE; CONNOR, JR; GRISWOLD, DE; KUMAR, NV; KOPPLE, KD; CARR, SA; DALTON, BJ; JOHANSON, K			THE SOLUBLE FORM OF E-SELECTIN IS AN ASYMMETRIC MONOMER - EXPRESSION, PURIFICATION, AND CHARACTERIZATION OF THE RECOMBINANT PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION MOLECULE-1; SIALYL LEWIS-X; ENDOTHELIAL-CELLS; POLYACRYLAMIDE GELS; T-CELLS; CUTANEOUS INFLAMMATION; ELAM-1; BINDING; NEUTROPHILS; LIGANDS	The gene coding for a soluble form of human E-selectin (sE-selectin) has been expressed in Chinese hamster ovary (CHO) cells. Cells seeded into a hollow fiber reactor secreted protein at a level of 160 mg/liter. The protein was purified to >95% pure and low endotoxin (<2 ng/mg), using physiological pH and buffers. The amino acid composition and N-terminal sequence were as predicted from the cDNA sequence. HL-60 cells bound to sE-selectin-coated plates in a dose dependent manner, and this binding could be blocked up to 100% by pretreatment of HL60 cells with sE-selectin. The concentration of sE-selectin required for 50% inhibition was 1 mu M. This value puts an upper limit for the affinity of E-selectin for its natural receptor. sE-selectin also inhibited inflammatory migration of neutrophils in a selective fashion. Purified sE-selectin exhibited a broad band of M(r) similar to 75,000 on nonreducing SDS-PAGE. sE-selectin eluted with M(r) similar to 310,000 from size exclusion chromatography at physiological pH and buffers, suggesting an oligomeric state. Matrix-assisted laser-desorption MS gave a molecular weight of 80,000, while the minimum monomer molecular weight from the gene sequence should be 58,571, demonstrating that the monomeric molecule thus expressed had 27% carbohydrate. Equilibrium analytical ultracentrifugation gave an average solution molecular weight of 81,600 (+/- 4,500). Velocity ultracentrifugation gave a sedimentation coefficient of 4.3 S and, from this, an apparent axial ratio of 10.5:1, assuming a prolate ellipsoid of revolution. An analysis of the NMR NOESY spectra of sE-selectin, sialyl-lewis X, and sE-selectin with sialyl-Lewis X demonstrates that the recombinant protein binds sialyl-Lewis X productively. Hence, in solution, sE-selectin is a functional elongated monomer.	SMITHKLINE BEECHAM PHARMACEUT,DEPT PROT BIOCHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT GENE EXPRESS SCI,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT CELLULAR BIOCHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT INFLAMMAT & RESP PHARMACOL,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PHYS & STRUCT CHEM,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	HENSLEY, P (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT MACROMOLEC SCI UE0447B,709 SWEDELAND RD,KING OF PRUSSIA,PA 19406, USA.		Brooks, Ian/AAI-2571-2021; Carr, Steven A./AAH-8366-2019; Brooks, Ian/E-7052-2010	Brooks, Ian/0000-0002-3793-3635				ANDREWS P, 1964, BIOCHEM J, V91, P222, DOI 10.1042/bj0910222; ATHERTON A, 1972, J PHYSIOL-LONDON, V222, P447, DOI 10.1113/jphysiol.1972.sp009808; BALL GE, 1992, J AM CHEM SOC, V114, P5449, DOI 10.1021/ja00039a080; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; BROOKS I, 1994, IN PRESS METHODS ENZ, V240; BROOKS L, 1994, MODERN ANAL ULTRACEN, P15; CALTABIANO MM, 1989, GENE, V85, P479, DOI 10.1016/0378-1119(89)90442-3; CAMPBELL AP, 1991, J MAGN RESON, V93, P77, DOI 10.1016/0022-2364(91)90033-P; CAMPBELL AP, 1993, ANNU REV BIOPH BIOM, V22, P99, DOI 10.1146/annurev.bb.22.060193.000531; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P557; CARLOS T, 1991, BLOOD, V77, P2266; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; CRUMMEY A, 1987, AGENTS ACTIONS, V20, P69, DOI 10.1007/BF01965627; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GRABER N, 1990, J IMMUNOL, V145, P819; GRISWOLD DE, 1991, BIOCHEM PHARMACOL, V42, P825, DOI 10.1016/0006-2952(91)90042-4; GRISWOLD DE, 1993, INFLAMMATION, V17, P333, DOI 10.1007/BF00918994; HENSLEY P, 1986, J BIOL CHEM, V261, P1038; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P1; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Kuntz I D Jr, 1974, Adv Protein Chem, V28, P239, DOI 10.1016/S0065-3233(08)60232-6; KYANAUNG U, 1991, J IMMUNOL, V146, P521; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LIN YC, 1992, J AM CHEM SOC, V114, P5452, DOI 10.1021/ja00039a082; LOBB RR, 1991, J IMMUNOL, V147, P124; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MILLER KE, 1992, BIOCHEMISTRY-US, V31, P6703, DOI 10.1021/bi00144a009; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUKHOPADHYAY C, 1994, BIOPOLYMERS, V34, P21, DOI 10.1002/bip.360340104; MURAMATSU N, 1988, ANAL BIOCHEM, V168, P345, DOI 10.1016/0003-2697(88)90328-4; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PLAMBLAD JEW, 1992, CLIN EXP IMMUNOL, V90, P300; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; STECK G, 1980, ANAL BIOCHEM, V107, P21, DOI 10.1016/0003-2697(80)90486-8; Teller D C, 1979, Methods Enzymol, V61, P103; TINOCO I, 1978, PHYSICAL CHEM, P212; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRILL JJ, 1990, FIBRINOLYSIS, V4, P131, DOI 10.1016/S0268-9499(05)80044-X; URLAUB G, 1983, CELL, V33, P405, DOI 10.1016/0092-8674(83)90422-1; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WELLICOME SM, 1990, J IMMUNOL, V144, P2558; WHITAKER JR, 1963, ANAL CHEM, V35, P1950, DOI 10.1021/ac60205a048; WORMALD MR, 1991, BIOCHEM BIOPH RES CO, V180, P1214, DOI 10.1016/S0006-291X(05)81325-7; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	59	60	60	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23949	23958						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523364				2022-12-25	WOS:A1994PQ34600018
J	MARTINERIE, C; HUFF, V; JOUBERT, I; BADZIOCH, M; SAUNDERS, G; STRONG, L; PERBAL, B				MARTINERIE, C; HUFF, V; JOUBERT, I; BADZIOCH, M; SAUNDERS, G; STRONG, L; PERBAL, B			STRUCTURAL-ANALYSIS OF THE HUMAN NOV PROTOONCOGENE AND EXPRESSION IN WILMS-TUMORS	ONCOGENE			English	Note							FACTOR-II GENE; PLASMODIUM-FALCIPARUM; WT1	We have cloned and sequenced the nov gene (novH) which is the homolog of the chicken nov proto-oncogene overexpressed in avian nephroblastomas. The novH gene is highly conserved and encodes a putative IGF-binding protein similar to that of chicken. We report that relative to autologous normal kidney expression of novH is elevated in Wilms tumors containing predominantly stromal elements and is inversely correlated in these tumors to the expression of WT1. Our results suggest that the regulation of IGFII expression by WT1 and increase of novH in Wilms tumors might be interrelated and represent a key element in tumor development in human.	INST CURIE,ONCOL VIRALE & MOLEC LAB,F-91405 ORSAY,FRANCE; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPTL PEDIAT,HOUSTON,TX; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030; UNIV PARIS 07,UFR BIOCHIM,DENIS DIDEROT,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; UDICE-French Research Universities; Universite Paris Cite								ALEY SB, 1986, J EXP MED, V164, P1915, DOI 10.1084/jem.164.6.1915; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BECKWITH JB, 1986, J UROLOGY, V136, P320, DOI 10.1016/S0022-5347(17)44854-3; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GANSLER T, 1989, AM J PATHOL, V135, P961; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GONZALEZCRUSSI F, 1984, WILMS TUMOR NEPHROBL, P207; HEINE U, 1962, JNCI-J NATL CANCER I, V29, P41; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HUFF V, 1990, HUM GENET, V84, P253; ISHIGURO H, 1962, J NATL CANCER I, V29, P1; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; MARTINERIE C, 1992, ONCOGENE, V7, P2529; MATSUNAGA E, 1981, HUM GENET, V57, P231; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; PRITCHARDJONES K, 1991, ONCOGENE, V6, P2211; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; SORET J, 1989, J VIROL, V63, P1803, DOI 10.1128/JVI.63.4.1803-1807.1989; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828	28	65	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2729	2732						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	7520150				2022-12-25	WOS:A1994PC05400035
J	RANDOLPH, CA; CHAMPOUX, JJ				RANDOLPH, CA; CHAMPOUX, JJ			THE USE OF DNA AND RNA OLIGONUCLEOTIDES IN HYBRID STRUCTURES WITH LONGER POLYNUCLEOTIDE CHAINS TO PROBE THE STRUCTURAL REQUIREMENTS FOR MOLONEY MURINE LEUKEMIA-VIRUS PLUS STRAND PRIMING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 REVERSE-TRANSCRIPTASE; SEQUENCE FEATURES IMPORTANT; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; RIBONUCLEASE H; INTEGRATION; INITIATION; TEMPLATE; PRIMER	Plus strand priming during retroviral reverse transcription requires specific cleavage within the polypurine tract of the viral genome by the reverse transcriptase-associated RNase H. Previously it has been shown that a 190-base RNA-DNA hybrid containing the Moloney murine leukemia virus polypurine tract can serve as a substrate for the priming reaction. To investigate the structural requirements for the reaction, a series of DNA oligonucleotides was hybridized to the 190-base single stranded RNA and tested as substrates for RNase H. At low enzyme concentrations, the sites of cleavage are located 17-23 nucleotides from the 3'-end of the DNA oligonucleotide, consistent with the observations of others that binding of the DNA polymerase at a primer terminus fixes the position of cleavage by RNase H. At higher enzyme concentrations, additional cleavages are observed in the RNA 3' of these sites, but there is no preference for cleavage at the plus strand origin. In contrast to the results with DNA oligonucleotides, hybridization of RNA oligonucleotides containing the polypurine tract to the 190-base single stranded DNA generates substrates that are cleaved at the origin and efficiently extended into DNA. An RNA oligonucleotide hybridized downstream of the polypurine tract is cleaved but not extended. These results support the view that RNase H cleavage to generate the plus strand primer is uncoupled from minus strand DNA synthesis.	UNIV WASHINGTON,SCH MED,DEPT MICROBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NCI NIH HHS [CA51605] Funding Source: Medline; NIGMS NIH HHS [T32 GM07270] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA051605, R01CA051605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEEN MD, 1983, METHOD ENZYMOL, V101, P90; BENARTZI H, 1993, J BIOL CHEM, V268, P16465; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; COLICELLI J, 1985, CELL, V42, P573, DOI 10.1016/0092-8674(85)90114-X; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; FINSTON WI, 1984, J VIROL, V51, P26, DOI 10.1128/JVI.51.1.26-33.1984; FU TB, 1992, J VIROL, V66, P4271, DOI 10.1128/JVI.66.7.4271-4278.1992; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GRANDGENETT DP, 1990, CELL, V60, P3, DOI 10.1016/0092-8674(90)90707-L; HUBER HE, 1990, J BIOL CHEM, V265, P10565; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEHMAN IR, 1981, ENZYMES, V14, P51; LUO GX, 1990, J VIROL, V64, P592, DOI 10.1128/JVI.64.2.592-597.1990; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; OYAMA F, 1989, J BIOL CHEM, V264, P18808; PANGANIBAN AT, 1983, NATURE, V306, P155, DOI 10.1038/306155a0; PULLEN KA, 1993, J BIOL CHEM, V268, P6221; PULLEN KA, 1990, J VIROL, V64, P6274, DOI 10.1128/JVI.64.12.6274-6277.1990; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; RATTRAY AJ, 1987, J VIROL, V61, P2843, DOI 10.1128/JVI.61.9.2843-2851.1987; REARDON JE, 1991, J BIOL CHEM, V266, P14128; RESNICK R, 1984, J VIROL, V51, P813, DOI 10.1128/JVI.51.3.813-821.1984; RICCHETTI M, 1993, EMBO J, V12, P387, DOI 10.1002/j.1460-2075.1993.tb05670.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SKALKA A, 1993, REVERSE TRANSCRIPTAS; SMITH JK, 1984, J VIROL, V52, P314, DOI 10.1128/JVI.52.2.314-319.1984; TANESE N, 1991, J VIROL, V65, P4387, DOI 10.1128/JVI.65.8.4387-4397.1991; TELESNITSKY A, 1993, EMBO J, V12, P4433, DOI 10.1002/j.1460-2075.1993.tb06128.x; TELESNITSKY A, 1993, P NATL ACAD SCI USA, V90, P1276, DOI 10.1073/pnas.90.4.1276; VARMUS H, 1989, MOBILE DNA, P53; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P18682; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001	40	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19207	19215						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	7518453				2022-12-25	WOS:A1994NY33200005
J	BU, GJ; MAKSYMOVITCH, EA; NERBONNE, JM; SCHWARTZ, AL				BU, GJ; MAKSYMOVITCH, EA; NERBONNE, JM; SCHWARTZ, AL			EXPRESSION AND FUNCTION OF THE LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN (LRP) IN MAMMALIAN CENTRAL NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR TYPE-1; LONG-TERM POTENTIATION; PLASMINOGEN-ACTIVATOR; ALPHA-2-MACROGLOBULIN RECEPTOR; INSITU HYBRIDIZATION; APOLIPOPROTEIN-E; MEDIATED ENDOCYTOSIS; ALZHEIMERS-DISEASE; 39-KDA PROTEIN; NERVOUS-SYSTEM	The low density lipoprotein receptor-related protein (LRP) is a multifunctional cell surface receptor, expressed in liver, that binds with high affinity and endocytoses several structurally and functionally distinct ligands, including apolipoprotein E-activated beta-migrating very low density lipoprotein, tissue-type plasminogen activator, and alpha(2)-macroglobulin. Here using in situ hybridization and quantitative RNase protection assays, we show that LRP is also expressed throughout the brain. LRP message is particularly high in the cerebellum, cortex, hippocampus, and brain stem. In addition, we demonstrate that a 39-kDa protein which copurifies with LRP and regulates the binding of other ligands to LRP is also expressed throughout the brain. Interestingly, expression of the 39 kDa message is similar to 100-fold of that found in liver, suggesting that the activity of LRP is more tightly regulated in brain tissue than in liver. Using primary cultures of isolated postnatal cortical neurons, [S-35]methionine biosynthetic labeling and immunoprecipitation, we also demonstrate the de novo biosynthesis of LRP, the 39-kDa protein, as well as tissue-type plasminogen activator. Finally, using radioligand binding as well as fluorescent ligand binding and uptake studies, we show that LRP is functional in cortical neurons. These results taken together thus demonstrate expression of functional LRP in neuronal cells and suggest a potential role for LRP in brain protein and lipoprotein metabolism, development, and regeneration.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)	BU, GJ (corresponding author), WASHINGTON UNIV,SCH MED,CHILDRENS HOSP,EDWARD MALLINCKRODT DEPT PEDIAT,400 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63110, USA.				NHLBI NIH HHS [T32HL07275, HL52040] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052040, T32HL007275] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUER J, 1991, FEBS LETT, V285, P111, DOI 10.1016/0014-5793(91)80737-N; BENARI Y, 1990, TRENDS NEUROSCI, V13, P312, DOI 10.1016/0166-2236(90)90135-W; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BU GJ, 1993, J BIOL CHEM, V268, P13002; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DZIEGIELEWSKA KM, 1986, DEV BIOL, V115, P93, DOI 10.1016/0012-1606(86)90231-9; GIFFIN K, 1991, NEURON, V6, P321, DOI 10.1016/0896-6273(91)90242-R; GROBMYER SR, 1993, J BIOL CHEM, V268, P13291; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; IGNATIUS MJ, 1987, SCIENCE, V236, P959, DOI 10.1126/science.3576212; KODELJA V, 1986, EMBO J, V5, P3151, DOI 10.1002/j.1460-2075.1986.tb04622.x; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; MORTON PA, 1989, J BIOL CHEM, V264, P7228; NIELSEN FC, 1991, J NEUROCHEM, V56, P12, DOI 10.1111/j.1471-4159.1991.tb02556.x; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, P NATL ACAD SCI USA, V8972, P92; OWENSBY DA, 1989, J BIOL CHEM, V264, P18180; PIETROMONACO S, 1990, P NATL ACAD SCI USA, V87, P1811, DOI 10.1073/pnas.87.5.1811; PITAS RE, 1987, J BIOL CHEM, V262, P14352; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SINCLAIR GI, 1988, BRAIN RES, V450, P60, DOI 10.1016/0006-8993(88)91544-2; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; SWANSON LW, 1988, P NATL ACAD SCI USA, V85, P9821, DOI 10.1073/pnas.85.24.9821; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WOLF BB, 1992, AM J PATHOL, V141, P37	45	201	204	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18521	18528						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518435				2022-12-25	WOS:A1994NW79800047
J	LAWRENCE, DA; BERKENPAS, MB; PALANIAPPAN, S; GINSBURG, D				LAWRENCE, DA; BERKENPAS, MB; PALANIAPPAN, S; GINSBURG, D			LOCALIZATION OF VITRONECTIN BINDING DOMAIN IN PLASMINOGEN-ACTIVATOR INHIBITOR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE DEFICIENT MICE; EXTRACELLULAR-MATRIX; PROTEIN STABILITY; ENDOTHELIAL-CELLS; ESCHERICHIA-COLI; REACTIVE CENTER; TYPE-1; MUTANTS; HEPARIN; MUTAGENESIS	Plasminogen activator inhibitor type 1 (PAI-1) is the rapid physiologic inhibitor of tissue-type plasminogen activator and urokinase-type plasminogen activator (uPA). In plasma and the extracellular matrix, PAI-1 is associated with the adhesive glycoprotein vitronectin. In order to characterize the PAI-1 structural domain responsible for binding to vitronectin, the segment of the PAI-1 cDNA encoding amino acids 13-147 (nucleotides 248-650) was randomly mutagenized and subcloned into a bacterial expression vector containing the mature PAI-1 coding sequence. Recombinant PAI-1 mutants were expressed in Escherichia coli and bacterial lysates assayed in duplicate for uPA inhibitory activity and vitronectin binding. Of 190 clones screened, six consistently demonstrated decreased vitronectin binding relative to uPA inhibitory activity. DNA sequence analysis of four of these clones identified 10 unique missense mutations, all located between base pairs 298 and 641, with each clone containing between one and four substitutions. Each substitution was expressed independently by site-directed mutagenesis and again analyzed for uPA inhibitory activity and vitronectin binding. Five point mutations that selectively disrupt vitronectin binding were identified. All 5 residues are located on the exterior of the PAI-1 structure. These findings appear to define a complex binding surface that bridges alpha-helices C and E to beta-strand 1A and includes amino acids 55, 109, 110, 116, and 123. These results suggest that vitronectin binding may stabilize the active conformation of PAI-1 by restricting the movement of beta-sheet A and thereby preventing insertion of the reactive center loop.	UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	LAWRENCE, DA (corresponding author), UNIV MICHIGAN, HOWARD HUGHES MED INST, RM 4520 MSRB I, ANN ARBOR, MI 48109 USA.			Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039137, F32HL008572] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 39137, HL 08572] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; EDELBERG JM, 1991, J BIOL CHEM, V266, P7488; EHRLICH HJ, 1992, J BIOL CHEM, V267, P11606; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; EVNIN LB, 1990, P NATL ACAD SCI USA, V87, P6659, DOI 10.1073/pnas.87.17.6659; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUMPHREYS GO, 1976, MOL GEN GENET, V145, P101, DOI 10.1007/BF00331564; KEIJER J, 1991, BLOOD, V78, P1254; KOST C, 1992, J BIOL CHEM, V267, P12098; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; MATTHEWS BW, 1987, BIOCHEMISTRY-US, V26, P6885, DOI 10.1021/bi00396a001; MIMURO J, 1987, BLOOD, V70, P721; MIMURO J, 1989, J BIOL CHEM, V264, P5058; MIMURO J, 1993, BIOCHEMISTRY-US, V32, P2314, DOI 10.1021/bi00060a024; MISRA R, 1991, J BIOL CHEM, V266, P13592; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MUNIR KM, 1993, P NATL ACAD SCI USA, V90, P4012, DOI 10.1073/pnas.90.9.4012; NASKI MC, 1993, J BIOL CHEM, V268, P12367; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SANDKVIST M, 1993, MOL MICROBIOL, V10, P635, DOI 10.1111/j.1365-2958.1993.tb00935.x; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1991, BIOCHIM BIOPHYS ACTA, V1078, P23, DOI 10.1016/0167-4838(91)90087-G; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SIGURDARDOTTIR O, 1990, BIOCHIM BIOPHYS ACTA, V1035, P56, DOI 10.1016/0304-4165(90)90173-T; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405	41	119	128	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15223	15228						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7515053				2022-12-25	WOS:A1994NP73800056
J	WANG, QM; FIOL, CJ; DEPAOLIROACH, AA; ROACH, PJ				WANG, QM; FIOL, CJ; DEPAOLIROACH, AA; ROACH, PJ			GLYCOGEN-SYNTHASE KINASE-3-BETA IS A DUAL-SPECIFICITY KINASE DIFFERENTIALLY REGULATED BY TYROSINE AND SERINE/THREONINE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN PHOSPHATASE; SERINE THREONINE KINASES; RABBIT SKELETAL-MUSCLE; GENE-PRODUCT; CONSERVED FEATURES; ACTIVATION; SEQUENCE; PURIFICATION; RECOGNITION; MULTISITE	The enzyme glycogen synthase kinase-3 (GSK-3) has been implicated in the control of several metabolic enzymes and transcription factors in response to extracellular signals. In the past, the enzyme has been considered to be a protein Ser/Thr kinase although it was recently reported to contain Tyr(P) (Hughes, K., Nikolakaki, E., Plyte, S. E., Totty, N. F., and Woodgett, J. R. (1993) EMBO J. 12, 803-808). A cDNA encoding rabbit skeletal muscle GSK-3 beta was cloned and expressed in Escherichia coli as an active protein kinase, with apparent M(r) 46,000, capable of phosphorylating several known GSK-3 substrates. Recombinant GSK-3 beta autophosphorylated on Ser, Thr, and Tyr residues although the enzyme already contained Tyr(P) as judged by its recognition by anti-Tyr(P) antibodies. The net result of the autophosphorylation was a 3-5-fold reduction in enzyme activity. GSK-3 alpha, purified from rabbit muscle, also underwent autophosphorylation but only on Ser and Thr residues. In this case, the autophosphorylation stabilized the enzyme activity compared with the control lacking ATP/Mg2+. Of several phosphatases tested, the lambda-phage phosphatase was the most effective in dephosphorylating at Ser and Thr residues but did not dephosphorylate at Tyr residues. The action of the lambda-phosphatase caused a reactivation of GSK-3 beta to similar to 80% of the starting activity. The protein tyrosine phosphatase PTP1B was able to dephosphorylate at Tyr residues leading to a reduction in enzyme activity. A truncated form of GSK-3 beta, apparent M(r) 40,000, had a significantly higher specific activity, was defective in autophosphorylation, and was not inactivated in the autophosphorylation reaction. We conclude that GSK-3 beta is a dual specificity protein kinase in the same sense as the mitogen-activated protein kinase/ERK family of enzymes. Phosphorylation at different residues differentially controls enzyme activity, Ser/Thr phosphorylation causing inactivation and Tyr phosphorylation resulting in increased activity.			WANG, QM (corresponding author), INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA.				NIDDK NIH HHS [DK36569, DK27221] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027221, R01DK027221, R01DK036569] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Cohen P., 1986, ENZYMES, VXVII, P461; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DEGROOT RP, 1992, ONCOGENE, V7, P841; DENT P, 1989, FEBS LETT, V248, P67, DOI 10.1016/0014-5793(89)80433-8; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOODE N, 1992, J BIOL CHEM, V267, P16878; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; HEMMINGS BA, 1981, EUR J BIOCHEM, V119, P443, DOI 10.1111/j.1432-1033.1981.tb05628.x; HEMMINGS BA, 1982, EUR J BIOCHEM, V127, P473; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; HUGHES K, 1992, EUR J BIOCHEM, V203, P305, DOI 10.1111/j.1432-1033.1992.tb19860.x; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; HUGHES K, 1992, BIOCHEM J, V288, P309, DOI 10.1042/bj2880309; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; ISHIGURO K, 1993, FEBS LETT, V325, P167, DOI 10.1016/0014-5793(93)81066-9; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; NEIGEBORN L, 1991, GENE DEV, V5, P533, DOI 10.1101/gad.5.4.533; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; POSADA J, 1992, MOL BIOL CELL, V3, P583, DOI 10.1091/mbc.3.6.583; PUZISS JW, 1994, MOL CELL BIOL, V14, P831, DOI 10.1128/MCB.14.1.831; RAMAKRISHNA S, 1988, J BIOL CHEM, V263, P12677; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; RUEL L, 1993, EMBO J, V12, P1657, DOI 10.1002/j.1460-2075.1993.tb05811.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SHERO JH, 1991, GENE DEV, V5, P549, DOI 10.1101/gad.5.4.549; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TUNG HYL, 1989, J BIOL CHEM, V264, P2985; VILLAMORUZZI E, 1989, FEBS LETT, V258, P208, DOI 10.1016/0014-5793(89)81654-0; WANG QM, 1994, BIOCHEMISTRY-US, V33, P143, DOI 10.1021/bi00167a018; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YANG SD, 1988, BIOCHEM BIOPH RES CO, V151, P61, DOI 10.1016/0006-291X(88)90559-1; ZHANG WM, 1989, FASEB J, V3, P2532, DOI 10.1096/fasebj.3.13.2509275; ZHANG WM, 1993, ARCH BIOCHEM BIOPHYS, V304, P219, DOI 10.1006/abbi.1993.1342; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZHUO S, 1993, J BIOL CHEM, V268, P17754; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	78	259	263	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14566	14574						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514173				2022-12-25	WOS:A1994NM06500042
J	WANG, MH; COX, GW; YOSHIMURA, T; SHEFFLER, LA; SKEEL, A; LEONARD, EJ				WANG, MH; COX, GW; YOSHIMURA, T; SHEFFLER, LA; SKEEL, A; LEONARD, EJ			MACROPHAGE-STIMULATING PROTEIN INHIBITS INDUCTION OF NITRIC-OXIDE PRODUCTION BY ENDOTOXIN-STIMULATED OR CYTOKINE-STIMULATED MOUSE MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERITONEAL-MACROPHAGES; RELAXING FACTOR; L-ARGININE; IFN-GAMMA; MOLECULAR-CLONING; PLATELET-ADHESION; SUPEROXIDE ANION; ENDOTHELIUM; EXPRESSION; SYNTHASE	Human serum macrophage-stimulating protein (MSP) is a disulfide-linked heterodimer that induces motile and phagocytic activity of mouse resident peritoneal macrophages. In this work, we found that MSP blocked the increase in macrophage nitric oxide synthase mRNA, as well as the associated increase in nitric oxide production, that occurred in response to several stimuli. These included bacterial products and mammalian cytokines: endotoxin, and interferon-gamma plus endotoxin, interleukin-2, or tumor necrosis factor-alpha. The inhibition by MSP of induction of nitric oxide synthase mRNA and; nitric oxide secretion was concentration-dependent. The concentration of MSP that caused maximal inhibition of nitric oxide production was comparable with the optimum for stimulation of macrophage motile and phagocytic activity. Time course studies showed that nitrate was first detected in culture fluid about 8 h after endotoxin stimulation, and it accumulated at a linear rate during the ensuing 16 h. Inhibition by MSP occurred during the 8-h lipopolysaccharide (LPS) induction period; inhibition was maximal when MSP and LPS were added together and decreased progressively to no inhibition as the interval between LPS and MSP addition increased to 11 h.	NCI,FREDERICK CANC RES & DEV CTR,EXPTL IMMUNOL LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	WANG, MH (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,BLDG 560,RM 12-71,FREDERICK,MD 21702, USA.							ARNDT H, 1993, HYPERTENSION, V21, P667, DOI 10.1161/01.HYP.21.5.667; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX GW, 1992, J IMMUNOL, V149, P3290; CURRAN RD, 1991, FASEB J, V5, P2085, DOI 10.1096/fasebj.5.7.1707021; DEGRAAF JC, 1992, CIRCULATION, V85, P2284, DOI 10.1161/01.CIR.85.6.2284; DING A, 1990, J IMMUNOL, V145, P940; DING AH, 1988, J IMMUNOL, V141, P2407; GAUTAM S, 1992, J IMMUNOL, V148, P1725; GREEN SJ, 1990, J IMMUNOL, V144, P278; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HARBRECHT BG, 1992, J LEUKOCYTE BIOL, V52, P390, DOI 10.1002/jlb.52.4.390; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JOHNSTON RB, 1978, J EXP MED, V148, P115; KRONCKE KD, 1992, IMMUNOL TODAY, V13, P157; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; LEIJH PCJ, 1984, INFECT IMMUN, V46, P448, DOI 10.1128/IAI.46.2.448-452.1984; LEIJH PCJ, 1984, INFECT IMMUN, V46, P754, DOI 10.1128/IAI.46.3.754-758.1984; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LEONARD EJ, 1978, EXP CELL RES, V114, P117, DOI 10.1016/0014-4827(78)90043-5; LEONARD EJ, 1980, J RETICULOENDOTH SOC, V28, P437; LIEW FY, 1990, J IMMUNOL, V144, P4794; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LUSCHER TF, 1987, LANCET, V2, P1057; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MURRAY HW, 1984, MACROPHAGE ACTIVATIO, P97; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RADOMSKI MW, 1987, BIOCHEM BIOPH RES CO, V148, P1482, DOI 10.1016/S0006-291X(87)80299-1; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822, DOI 10.1152/ajpheart.1986.250.5.H822; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SASADA M, 1980, J EXP MED, V152, P85, DOI 10.1084/jem.152.1.85; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SKEEL A, 1994, IN PRESS J IMMUNOL; STADLER J, 1991, ARCH SURG-CHICAGO, V126, P186; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WANG MH, 1993, J LEUKOCYTE BIOL, V54, P289, DOI 10.1002/jlb.54.4.289; WANG MH, 1994, J BIOL CHEM, V269, P3436; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461; YOSHIMURA T, 1991, BIOCHEM BIOPH RES CO, V174, P504, DOI 10.1016/0006-291X(91)91445-I; ZHU L, 1992, ARCH BIOCHEM BIOPHYS, V298, P452, DOI 10.1016/0003-9861(92)90434-X	46	92	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14027	14031						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514598				2022-12-25	WOS:A1994NL60600048
J	YU, JC; MAHADEVAN, D; LAROCHELLE, WJ; PIERCE, JH; HEIDARAN, MA				YU, JC; MAHADEVAN, D; LAROCHELLE, WJ; PIERCE, JH; HEIDARAN, MA			STRUCTURAL COINCIDENCE OF ALPHA-PDGFR EPITOPES BINDING TO PLATELET-DERIVED GROWTH FACTOR-AA AND A POTENT NEUTRALIZING MONOCLONAL-ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTORS; SIGNAL TRANSDUCTION; CELLS; DIMERIZATION; LOCALIZATION; EXPRESSION; ACTIVATION; PATHWAYS; CLONING; PROTEIN	We have generated two groups of deletion mutants of the alpha PDGFR and one group of chimeras between alpha PDGFR and beta PDGFR to further investigate the structural requirements of the alpha PDGFR for binding to platelet-derived growth factor (PDGF)-AA and to a monoclonal antibody against alpha PDGFR (designated as mAb-alpha R1). The mAb-alpha R1 has recently been reported to block high affinity binding of PDGF-AA to alpha PDGFR The first group of mutants were carboxyl-terminal deletion mutants encoding the first two immunoglobulin (Ig)-like domains (alpha R1-216), the first four Ig-Like domains (alpha R1-415), or all five Ig-like domains (alpha R1-530) of the alpha PDGFR Since these mutants lacked transmembrane domains, their expression in NIH/3T3 cells resulted in secretion of the truncated alpha PDGFRs. Using conditioned medium from NIH/3T3 transfectants, we showed that mAb-alpha R1 was able to immunoprecipitate each of these secreted form of alpha PDGFRs, suggesting that the epitope recognized by mAb-alpha R1 is located within Ig-like domains 1 and 2 of the alpha PDGFR. Furthermore, PDGF-AA exhibited detectable binding to alpha R1-415 or alpha 1-530 but failed to interact with alpha R1-216, suggesting that the first two Ig-like domains of the alpha PDGFR are not sufficient for PDGF-AA binding. The second group of alpha PDGFR mutants were internal deletion mutants lacking Ig-like loop 1 (alpha R(Delta 49-100)), Ig-like loop 2 (alpha R(Delta 150-189)), Ig-like loop 3 (alpha R(Delta 235-290)), or part of Ig-like loops 4 and 5 (alpha R(Delta 375-450)). The internal deletion mutants were transfected into 32D cells which lack both alpha PDGFR and beta PDGFR PDGF-AA bound with high affinity to 32D cells expressing alpha R(Delta 375-450) but not to 32D cells expressing the other three internal deletion mutants, suggesting that the region required for PDGF-AA binding should be within the first three Ig-like domains of the alpha PDGFR. In addition, mAb-alpha R1 bound to 32D cells expressing alpha R(Delta 235-290) but failed to bind 32D cells transfected with alpha R(Delta 49-100) or alpha R(Delta 150-189). Since this antibody could immunoprecipitate alpha R(Delta 49-100), but not alpha R(Delta 150-189) in cell lysates of the 32D transfectants, these results suggest that Ig-like loop 1 is dispensible for mAb-alpha R1 recognition and deletion of Ig-like loop 1 of alpha PDGFR significantly inhibits cell surface expression. The two alpha/beta PDGFR chimeras generated were an alpha PDGFR containing the first Ig-like domain of beta PDGFR (beta(126)alpha(127)R) and a beta PDGFR possessing the first Ig-Like domain of alpha PDGFR (alpha(119)beta(119)R). PDGF-AA-bound to 32D cells expressing beta(126)alpha(127)R, but not to those expressing alpha(119)beta(119)R, suggesting that Ig-like domain 1 is not required for conferring PDGF-AA binding specificity. Taken together, we conclude that major high affinity sites for PDGF-AA binding are located within Ig-like domains 2 and 3 and that the epitope recognized by mAb-alpha R1 is located within Ig-like domain 2 of the alpha PDGFR.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DROZDOFF V, 1991, J BIOL CHEM, V266; FLEMING TP, 1992, ONCOGENE, V7, P1355; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HEIDARAN MA, 1992, J BIOL CHEM, V257, P2884; HELDIN CH, 1985, MOL CELL ENDOCRINOL, V39, P169, DOI 10.1016/0303-7207(85)90061-9; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; LAROCHELLE WJ, 1993, CELL GROWTH DIFFER, V4, P547; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MAYSIROFF M, 1993, BIOCHEMISTRY-US, V32, P11734; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; MUNSON PJ, 1984, COMPUTERS ENDOCRINOL, P117; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	32	23	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10668	10674						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511602				2022-12-25	WOS:A1994NF01700072
J	CAIRNS, J; QIN, SX; PHILP, R; TAN, YH; GUY, GR				CAIRNS, J; QIN, SX; PHILP, R; TAN, YH; GUY, GR			DEPHOSPHORYLATION OF THE SMALL HEAT-SHOCK PROTEIN HSP27 IN-VIVO BY PROTEIN PHOSPHATASE 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CHINESE-HAMSTER-CELLS; ENDOTHELIAL-CELLS; STRESS PROTEINS; ALPHA-CRYSTALLIN; MAPKAP KINASE-2; PHOSPHORYLATION; IDENTIFICATION; EXPRESSION; INTERLEUKIN-1	The phosphorylation of the Hsp27 complex is rapidly altered in MRC-5 cells when they are exposed to mitogens, cytokines, stress, or serine/threonine protein phosphatase inhibitors. Here we performed experiments to identify which cellular protein phosphatase (PP1, PP2A, or PP2B) is responsible for the in vivo phosphorylation/dephosphorylation of Hsp27. In their purified forms, PP2A dephosphorylates Hsp27 more effectively than PP2B, whereas PP1 is weakly active. Measurements of enzyme activity of lysates derived from inhibitor-treated cells indicated that Hsp27 phosphatase activity is equally sensitive to okadaic acid (PPI/PP2A inhibitor) and cyclosporin (PP2B inhibitor) and that both okadaic acid and cyclosporin treatment inhibited Hsp27 phosphatase activity additively. Together the in vitro data suggest that both PP2A and PP2B can dephosphorylate Hsp27. However, the phosphorylation of Hsp27 in vivo is only affected when cells are treated with PP1 and PP2A inhibitors (okadaic acid, calyculin A) or cantharidin (PP2A inhibitor), but not the PP2B inhibitor, cyclosporin A, suggesting PP2A to be the main enzyme dephosphorylating Hsp27 in the cells. Purification and immuoblotting of Hsp27 phosphatase from MRC-5 cells also suggest it to be PP2A and not PP1 or PP2B. The ability of PP2A to dephosphorylate Hsp27 is shown to be regulated by the phosphorylation state of PP2A itself.	NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, SIGNAL TRANSDUCT LAB, SINGAPORE 0511, SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore								ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BITAR KN, 1991, BIOCHEM BIOPH RES CO, V181, P1192, DOI 10.1016/0006-291X(91)92065-R; CAO XM, 1992, J BIOL CHEM, V267, P12991; CHAMBARD JC, 1983, BIOCHEM BIOPH RES CO, V111, P1034, DOI 10.1016/0006-291X(83)91404-3; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CIOCCA DR, 1983, CANCER RES, V43, P1204; CRETE P, 1990, RADIAT RES, V121, P320, DOI 10.2307/3577783; DARBON JM, 1986, J BIOL CHEM, V261, P8002; DEJONG WW, 1988, J BIOL CHEM, V263, P5141; DEMOLLE D, 1988, J BIOL CHEM, V263, P18459; DENAGEL DC, 1991, IMMUNOL RES, V10, P66, DOI 10.1007/BF02918168; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; FUQUA SAW, 1989, CANCER RES, V49, P4126; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; GAESTEL M, 1992, J BIOL CHEM, V267, P21607; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUESDON F, 1991, J IMMUNOL, V147, P3402; GUO H, 1993, J BIOL CHEM, V268, P11193; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; GUY GR, 1991, J BIOL CHEM, V266, P14343; GUY GR, 1992, J BIOL CHEM, V267, P1846; GUY GR, 1993, J BIOL CHEM, V268, P2141; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; HUOT J, 1991, CANCER RES, V51, P5245; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; KAUR P, 1989, FEBS LETT, V258, P269, DOI 10.1016/0014-5793(89)81671-0; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LI YM, 1992, P NATL ACAD SCI USA, V89, P11867, DOI 10.1073/pnas.89.24.11867; LINQUIST S, 1988, ANNU REV GENET, V22, P631; MENON SD, 1993, J BIOL CHEM, V268, P26805; MICHISHITA M, 1991, BIOCHEM BIOPH RES CO, V176, P979, DOI 10.1016/0006-291X(91)90378-K; MING Z, 1993, J BIOL CHEM, V268, P35; REGAZZI R, 1988, BIOCHEM BIOPH RES CO, V152, P62, DOI 10.1016/S0006-291X(88)80680-6; ROBAYE B, 1989, BIOCHEM BIOPH RES CO, V163, P301, DOI 10.1016/0006-291X(89)92135-9; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHIBANUMA M, 1991, CELL GROWTH DIFFER, V2, P583; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STRAHLER JR, 1991, BIOCHEM BIOPH RES CO, V175, P134, DOI 10.1016/S0006-291X(05)81211-2; TAN YH, 1993, SCIENCE, V262, P376, DOI 10.1126/science.7692598; TETU B, 1992, CANCER RES, V52, P2325; THOR A, 1991, J NATL CANCER I, V83, P170, DOI 10.1093/jnci/83.3.170; VITEK MP, 1984, J MOL BIOL, V178, P173, DOI 10.1016/0022-2836(84)90138-4; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; WELSH MJ, 1992, BIOCHEM BIOPH RES CO, V184, P217, DOI 10.1016/0006-291X(92)91181-O	50	87	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9176	9183						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510704				2022-12-25	WOS:A1994NB41100082
J	CASCIERI, MA; MACLEOD, AM; UNDERWOOD, D; SHIAO, LL; BER, E; SADOWSKI, S; YU, H; MERCHANT, KJ; SWAIN, CJ; STRADER, CD; FONG, TM				CASCIERI, MA; MACLEOD, AM; UNDERWOOD, D; SHIAO, LL; BER, E; SADOWSKI, S; YU, H; MERCHANT, KJ; SWAIN, CJ; STRADER, CD; FONG, TM			CHARACTERIZATION OF THE INTERACTION OF N-ACYL-L-TRYPTOPHAN BENZYL ESTER NEUROKININ ANTAGONISTS WITH THE HUMAN NEUROKININ-1 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-P; BINDING; POTENT; PROTEINS; MODEL	We have recently shown that a series of N-acyl-L-tryptophan benzyl esters are potent substance P antagonists (Macleod, A. M., Merchant, K. J., Cascieri, M. A., Sadowski, S., Ber, E., Swain, C, J., and Baker, R. (1993) J. Med Chem, 14, 2044-2045). We now report the detailed characterization of the interaction of N-acetyl-L-tryptophan-3,5-bistrifluoromethyl benzyl ester (L-732,138) with the human neurokinin-1 (NK-1) receptor. L-732,138 inhibits the binding of I-125-substance P to the cloned human NK1 receptor expressed in Chinese hamster ovary cells with an IC50 of 2.3 +/- 0.7 nM. In contrast, it has 200-fold lower affinity for the cloned rat NK-1 receptor and has > 1000-fold lower affinity for the human NK-2 and NK-3 receptors. L-732,138 acts as a competitive antagonist of substance P, as shown by functional Schild analysis of the inhibition of substance P-induced inositol phosphate synthesis, by kinetic analysis of the dissociation rate, and by thermodynamic analysis of the equilibrium binding of I-125-substance P to the NK-1 receptor. L-732,138 also competitively inhibits the binding of the quinuclidine amine antagonist, [I-125]L-703,606, to the receptor. The compound has 230- and 10-fold reduced affinity for mutant NK-1 receptors in which histidine 265 or histidine 197, respectively, are replaced with alanine. We have previously shown that these residues play key roles in the binding of quinuclidine antagonists to the NK-1 receptor. These results suggest that the tryptophan and quinuclidine series of NK-1 antagonists bind to similar binding sites on the human NK-1 receptor.	MERCK & CO INC, RES LABS, DEPT MOLEC SYST, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, RES LABS, NEUROSCI RES CTR, HARLOW CM20 2PT, ESSEX, ENGLAND	Merck & Company; Merck & Company	CASCIERI, MA (corresponding author), MERCK & CO INC, RES LABS, DEPT MOLEC PHARMACOL & BIOCHEM, BLDG 80M-213, POB 2000, RAHWAY, NJ 07065 USA.							BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CASCIERI MA, 1992, MOL PHARMACOL, V42, P458; DE KONINCK Y, 1991, P NATL ACAD SCI USA, V88, P11344, DOI 10.1073/pnas.88.24.11344; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; EGLEZOS A, 1991, EUR J PHARMACOL, V209, P277, DOI 10.1016/0014-2999(91)90183-Q; FONG TM, 1992, MOL PHARMACOL, V41, P24; FONG TM, 1993, NATURE, V362, P350; FONG TM, 1994, IN PRESS J BIOL CHEM; GARRET C, 1991, P NATL ACAD SCI USA, V88, P10208, DOI 10.1073/pnas.88.22.10208; MACLEOD AM, 1993, J MED CHEM, V36, P2044, DOI 10.1021/jm00066a015; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAGAHISA A, 1992, EUR J PHARMACOL, V217, P191, DOI 10.1016/0014-2999(92)90847-W; PERUTZ MF, 1986, J AM CHEM SOC, V108, P1064, DOI 10.1021/ja00265a036; SEWARD EM, 1993, BIOORG MED CHEM LETT, V3, P1361, DOI 10.1016/S0960-894X(00)80349-2; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; SWAIN CJ, 1993, BIOORG MED CHEM LETT, V3, P1703, DOI 10.1016/S0960-894X(00)80046-3; XU XJ, 1992, EUR J PHARMACOL, V216, P337, DOI 10.1016/0014-2999(92)90428-7	20	90	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6587	6591						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509807				2022-12-25	WOS:A1994MZ50300051
J	LI, ZW; DEUTSCHER, MP				LI, ZW; DEUTSCHER, MP			ROLE OF INDIVIDUAL EXORIBONUCLEASES IN PROCESSING AT THE 3' END OF ESCHERICHIA-COLI TRANSFER-RNA PRECURSORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; POLYNUCLEOTIDE PHOSPHORYLASE; RIBONUCLEASE; PURIFICATION; TURNOVER; INVITRO; PH; OVEREXPRESSION; VIABILITY; GENE	We have used an in vitro Escherichia coli tRNA processing system to investigate the specific role of individual exoribonucleases in the 3' maturation of tRNA precursors. The processing of pre-tRNA(Tyr)su(3)(+) and pre-tRNA(2)(Arg) was studied using extracts from cells lacking one or multiple exoribonucleases or using purified RNases. Earlier genetic studies had suggested that multiple exoribonucleases contributed to the maturation of tRNA precursors, and this was proven directly in the studies described here. Complete 3' processing required the combined action of multiple exoribonucleases, and each BNase showed distinct specificities for maturation of the different parts of the 3' precursor segment. RNase II and polynucleotide phosphorylase were most effective in shortening long 3' trailer sequences to intermediates with 2-4 extra 3' residues. Final trimming of the last few 3' nucleotides of these precursors was carried out most efficiently by RNases T and PH, but the two enzymes differed in their specificity for individual nucleotide positions. Depending on the tRNA precursor, the relative importance of the various RNases to the overall maturation process differed. We also showed that purified exoribonucleases can completely complement mutant extracts and that tRNA maturation can be totally reconstructed in vitro using purified enzymes. These studies provide the first detailed information about the specific role of individual exoribonucleases in tRNA processing, and bring us closer to defining a complete E. coli tRNA maturation pathway.	UNIV CONNECTICUT, CTR HLTH, DEPT BIOCHEM, FARMINGTON, CT 06030 USA	University of Connecticut					NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN S, 1987, MOL BIOL RNA NEW PER, P3; BIKOFF EK, 1975, J BIOL CHEM, V250, P6248; BIKOFF EK, 1975, J BIOL CHEM, V250, P6240; BOSL M, 1991, NUCLEIC ACIDS RES, V19, P5863, DOI 10.1093/nar/19.21.5863; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER S, 1965, J MOL BIOL, V13, P629, DOI 10.1016/S0022-2836(65)80131-0; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CUDNY H, 1988, J BIOL CHEM, V263, P1518; CUDNY H, 1986, J BIOL CHEM, V261, P6450; CUDNY H, 1980, P NATL ACAD SCI USA, V77, P834; DEUTSCHER MP, 1985, P NATL ACAD SCI USA, V82, P6427, DOI 10.1073/pnas.82.19.6427; DEUTSCHER MP, 1993, J BACTERIOL, V175, P4577, DOI 10.1128/JB.175.15.4577-4583.1993; DEUTSCHER MP, 1984, P NATL ACAD SCI-BIOL, V81, P4290, DOI 10.1073/pnas.81.14.4290; DEUTSCHER MP, 1985, J BIOL CHEM, V260, P7067; DEUTSCHER MP, 1988, P NATL ACAD SCI USA, V85, P4710, DOI 10.1073/pnas.85.13.4710; DEUTSCHER MP, 1994, TRANSFER RNA; DEUTSCHER MP, 1991, P NATL ACAD SCI USA, V88, P2277; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; KELLY KO, 1992, J BIOL CHEM, V267, P17153; KELLY KO, 1992, J BACTERIOL, V174, P6682, DOI 10.1128/JB.174.20.6682-6684.1992; KELLY KO, 1992, J BIOL CHEM, V267, P16015; MCCLAIN WH, 1977, ACCOUNTS CHEM RES, V10, P418, DOI 10.1021/ar50119a006; NOMURA T, 1988, EMBO J, V7, P3539, DOI 10.1002/j.1460-2075.1988.tb03230.x; REILLY RM, 1986, J BIOL CHEM, V261, P2928; REUVEN NB, 1993, FASEB J, V7, P143, DOI 10.1096/fasebj.7.1.8422961; REUVEN NB, 1993, P NATL ACAD SCI USA, V90, P4350, DOI 10.1073/pnas.90.10.4350; ROBERTSON HD, 1972, J BIOL CHEM, V247, P5243; SAKANO H, 1978, J MOL BIOL, V123, P287, DOI 10.1016/0022-2836(78)90082-7; SAKANO H, 1975, P NATL ACAD SCI USA, V72, P3369, DOI 10.1073/pnas.72.9.3369; SCHEDL P, 1976, CELL, V8, P581, DOI 10.1016/0092-8674(76)90226-9; SEKIYA T, 1979, J BIOL CHEM, V254, P5802; SHIMURA Y, 1978, EUR J BIOCHEM, V86, P267, DOI 10.1111/j.1432-1033.1978.tb12308.x; TUOHY TMF, 1993, IN PRESS J MOL BIOL; ZHANG J, 1988, J BIOL CHEM, V263, P17909; ZHU LQ, 1990, J BACTERIOL, V172, P3146, DOI 10.1128/jb.172.6.3146-3151.1990	36	75	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6064	6071						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509797				2022-12-25	WOS:A1994MY84000089
J	TRUITT, KE; MILLS, GB; TURCK, CW; IMBODEN, JB				TRUITT, KE; MILLS, GB; TURCK, CW; IMBODEN, JB			SH2-DEPENDENT ASSOCIATION OF PHOSPHATIDYLINOSITOL 3'-KINASE 85-KDA REGULATORY SUBUNIT WITH THE INTERLEUKIN-2 RECEPTOR-BETA CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; TYROSINE PHOSPHORYLATION; IL-2 RECEPTOR; SIGNAL TRANSDUCTION; PROTEIN-KINASE; LYMPHOCYTES-T; SH2 DOMAINS; GAMMA-CHAIN; EXPRESSION; ACTIVATION	Interleukin-2 (IL-2) signaling results in tyrosine phosphorylation of the 75-kDa IL-2 receptor (IL-2R) beta chain and the activation of phosphatidylinositol 3'-kinase (PI3-K). Herein, we demonstrate that the 85-kDa (p85) regulatory subunit of PI3-K physically associates with the tyrosine-phosphorylated IL-2R beta chain. A fusion protein containing both the amino- and the carboxyl-terminal src homology 2 domains of p85 precipitates an 80-kDa tyrosine-phosphorylated protein (pp80) from the lysates of IL-2-stimulated, but not unstimulated, human T lymphoblasts. Preclearing studies and immunoblot ting with an antiserum to the IL-2R beta chain demonstrates that pp80 represents a portion of the IL-2R beta chain pool. A tyrosine-phosphorylated oligopeptide corresponding to tyrosine 392 of the IL-2R beta chain partially inhibits binding of the IL-2R beta chain by p85 fusion protein, raising the possibility that this residue plays a role in the interaction of PI3-K with the receptor.	VET AFFAIRS MED CTR, ARTHRIT IMMUNOL SECT, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94121 USA; TORONTO GEN HOSP, TORONTO M5G 2C4, ON, CANADA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIAID NIH HHS [K11-AI01114, AI26644] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026644, K11AI001114] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ARIMA N, 1992, J EXP MED, V176, P1265, DOI 10.1084/jem.176.5.1265; ASAO H, 1992, FEBS LETT, V304, P141, DOI 10.1016/0014-5793(92)80605-G; ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BENEDICT SH, 1987, J IMMUNOL, V139, P1694; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Kanof M., 1991, CURRENT PROTOCOLS IM; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONO T, 1990, P NATL ACAD SCI USA, V87, P1806, DOI 10.1073/pnas.87.5.1806; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MERIDA I, 1993, J BIOL CHEM, V268, P6765; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RIGGS P, 1992, CURRENT PROTOCOLS S, V19; ROBB RJ, 1981, J EXP MED, V154, P1455, DOI 10.1084/jem.154.5.1455; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TSUDO M, 1989, P NATL ACAD SCI USA, V86, P1982, DOI 10.1073/pnas.86.6.1982; TSUDO M, 1989, J IMMUNOL, V143, P4039; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5937	5943						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509794				2022-12-25	WOS:A1994MY84000071
J	LIU, CY; ZHU, G; CONVERSE, R; KAO, CWC; NAKAMURA, H; TSENG, SCG; MUI, MM; SEYER, J; JUSTICE, MJ; STECH, ME; HANSEN, GM; KAO, WWY				LIU, CY; ZHU, G; CONVERSE, R; KAO, CWC; NAKAMURA, H; TSENG, SCG; MUI, MM; SEYER, J; JUSTICE, MJ; STECH, ME; HANSEN, GM; KAO, WWY			CHARACTERIZATION AND CHROMOSOMAL LOCALIZATION OF THE CORNEA-SPECIFIC MURINE KERATIN GENE KRT1.12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN PROLYL 4-HYDROXYLASE; EPITHELIAL DIFFERENTIATION; INTERMEDIATE FILAMENTS; CONJUNCTIVAL EPITHELIUM; MONOCLONAL-ANTIBODY; ENHANCER ELEMENTS; BETA-SUBUNIT; LINKAGE MAP; I KERATIN; EXPRESSION	Keratins are a group of water-insoluble proteins constituting paired acidic and basic keratin molecules that form 10-nm intermediate filaments in epithelial cells. Expression of the K3/K12 keratin pair characterizes the cornea-type differentiation. However, the mechanism that regulates this cornea-specific K12 expression remains unknown. To provide a better understanding of the cornea-specific expression, we have cloned the K12 cDNA (Liu, C.-Y., Zhu, G., Westerhausen-Larson, A., Converse, R., Kao, C. W.-C., Sun, T.-T., and Kao, W. W.-Y. (1993) Curr. Eye Res. 12, 963-974). In present studies, the murine K12 keratin gene (Krt1.12) was isolated and characterized. The murine Krt1.12 gene spans 6,567 base pairs of genomic DNA, and the mRNA encoding K12 keratin is distributed into eight exons. Chromosome mapping reveals that murine Krt1.12 is located within the Krt1 complex of mouse chromosome 11. In addition to the production of authentic K12 mRNA, the Krt1.12 gene gives rise to several alternate poly(A)(+) RNAs by the use of alternative splicing in intron 2, an alternative pro meter in intron 1, and/or both. Sequence analysis indicates that the transcripts derived from alternative splicing and/or the alternative promoter do not have a long open reading frame for keratin or keratin-like molecules. It is not known whether these alternate K12 poly(A)(+) RNAs have any biological functions, e.g. regulation of K12 gene expression.	UNIV CINCINNATI,DEPT OPHTHALMOL,CINCINNATI,OH 45267; UNIV MIAMI,DEPT OPHTHALMOL,MIAMI,FL 33101; UNIV TENNESSEE,DEPT BIOCHEM,MEMPHIS,TN 38104; KANSAS STATE UNIV AGR & APPL SCI,DIV BIOL,MANHATTAN,KS 66506	University System of Ohio; University of Cincinnati; University of Miami; University of Tennessee System; University of Tennessee Health Science Center; Kansas State University				Liu, Chia-yang/0000-0002-8398-5516	NATIONAL EYE INSTITUTE [R01EY006819] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER; NEI NIH HHS [EY 06819, EY 05629] Funding Source: Medline; NHLBI NIH HHS [HL 41496] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BADER BL, 1986, EMBO J, V5, P1865, DOI 10.1002/j.1460-2075.1986.tb04438.x; BARLETTA C, 1990, CYTOGENET CELL GENET, V54, P158; BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; BENNETT VD, 1990, J BIOL CHEM, V265, P2223; BLESSING M, 1989, EMBO J, V8, P117, DOI 10.1002/j.1460-2075.1989.tb03355.x; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BUCHBERG AM, 1993, MAMM GENOME, V4, P5164; CHALOINDUFAU C, 1990, CELL DIFFER DEV, V32, P97, DOI 10.1016/0922-3371(90)90103-4; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOPER D, 1985, LAB INVEST, V52, P243; COOPER D, 1986, J BIOL CHEM, V261, P4646; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH W, 1993, SSLP GENETIC MAP MOU; EICHNER R, 1986, J CELL BIOL, V102, P1767, DOI 10.1083/jcb.102.5.1767; Galvin S, 1989, Adv Dermatol, V4, P277; GREEN MC, 1989, CATALOGUE MUTANT GEN, P12; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; ISHIZAKI M, 1993, INVEST OPHTH VIS SCI, V34, P2680; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JUSTICE MJ, 1990, GENOMICS, V6, P341, DOI 10.1016/0888-7543(90)90575-F; KAO WWY, 1988, CONNECT TISSUE RES, V18, P157, DOI 10.3109/03008208809016805; KINOSHIT S, 1992, INVEST OPHTH VIS SCI, V33, P1176; KIRITOSHI A, 1992, INVEST OPHTH VIS SCI, V33, P1241; KREIG TM, 1988, J BIOL CHEM, V260, P5867; KULESH D, 1988, MOL CELL BIOL, V4, P1540; KURPAKUS MA, 1990, INVEST OPHTH VIS SCI, V31, P448; LEUBE RE, 1988, J CELL BIOL, V106, P1249, DOI 10.1083/jcb.106.4.1249; LIU CY, 1993, CURR EYE RES, V12, P963, DOI 10.3109/02713689309029222; LIU CY, 1993, DEV DYNAM, V198, P150, DOI 10.1002/aja.1001980208; Lyon ME, 1986, MOUSE NEWS LETT, V74, P96; MARCHUK D, 1985, P NATL ACAD SCI USA, V82, P1609, DOI 10.1073/pnas.82.6.1609; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGUIRE J, 1984, BRIT J DERMATOL, V111, P27, DOI 10.1111/j.1365-2133.1984.tb15579.x; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUI MM, 1993, INVEST OPHTH VIS SCI, V34, P1470; NADEAU JH, 1989, GENOMICS, V5, P454, DOI 10.1016/0888-7543(89)90009-8; NAKAZAWA M, 1988, GENE, V71, P451, DOI 10.1016/0378-1119(88)90062-5; QUINLAN RA, 1985, ANN NY ACAD SCI, V455, P282, DOI 10.1111/j.1749-6632.1985.tb50418.x; RAYCHAUDHURY A, 1986, MOL CELL BIOL, V6, P539, DOI 10.1128/MCB.6.2.539; RIEGER M, 1988, J MOL BIOL, V204, P841, DOI 10.1016/0022-2836(88)90045-9; SCHERMER A, 1989, DIFFERENTIATION, V42, P103, DOI 10.1111/j.1432-0436.1989.tb00611.x; SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49; SCHWEIZER J, 1984, CELL, V37, P159, DOI 10.1016/0092-8674(84)90311-8; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; TSENG SCG, 1982, CELL, V30, P361, DOI 10.1016/0092-8674(82)90234-3; YEN MT, 1992, INVEST OPHTH VIS SCI, V33, P3235; ZHU G, 1992, CURR EYE RES, V11, P875, DOI 10.3109/02713689209033485	52	97	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24627	24636						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7523376				2022-12-25	WOS:A1994PQ49000021
J	LIN, Q; LUO, X; SAWADOGO, M				LIN, Q; LUO, X; SAWADOGO, M			ARCHAIC STRUCTURE OF THE GENE ENCODING TRANSCRIPTION FACTOR USF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; MAJOR LATE PROMOTER; RNA POLYMERASE-II; UPSTREAM STIMULATORY FACTOR; DNA-BINDING; ENHANCER-BINDING; PROTEIN; MYC; SEQUENCE; ELEMENT	The upstream stimulatory factor (USF) is a helix-loop-helix transcription factor that interacts with specific sites on the DNA that are also recognized by the MYC oncoproteins. We isolated genomic clones to the murine 44-kDa form of USF (USF2 gene). This unique gene spans 13 kilobases of DNA and is composed of 10 exons. The gene seems to have maintained its archaic structure, since many of the exons encode discrete functional domains of the transcription factor originally identified by protein sequence comparisons. A particularly striking HpaII tiny fragment island, extending over nearly 2,000 base pairs, surrounds the USF2 translation initiation site. This region, which includes the USF2 promoter and the first four exons, is characterized by an overall GC content greater than 74%. Analysis by S1 mapping and transient transfection assays revealed that the USF2 transcripts originate from an initiator element located within a highly GC-rich region that is surrounded by two long polyadenylate stretches and functions as a bidirectional promoter. Different forms of USF2 messages result from the presence or absence of the fourth exon in the processed USF2 mRNA. Alternative splicing correlates with the lack of a consensus lariat branch point in the third intron. Transient cotransfection assays revealed that the presence or absence of the amino acid sequences encoded by exon 4 affects considerably the transcription activation properties of the USF2 protein.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC GENET, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center					NIGMS NIH HHS [GM38212] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038212] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIRD WC, 1994, J BIOL CHEM, V269, P883; ANDERS DG, 1992, J VIROL, V66, P3373, DOI 10.1128/JVI.66.6.3373-3384.1992; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; DURET L, 1993, NUCLEIC ACIDS RES, V21, P2315, DOI 10.1093/nar/21.10.2315; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GREENE JJ, 1988, CURRENT PROTOCOLS MO; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUO LH, 1983, METHOD ENZYMOL, V100, P60; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HOLLAND SK, 1987, BIOSYSTEMS, V20, P181, DOI 10.1016/0303-2647(87)90044-X; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KAULEN H, 1991, MOL CELL BIOL, V11, P412, DOI 10.1128/MCB.11.1.412; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZLOWSKI MT, 1991, DEV BIOL, V148, P625, DOI 10.1016/0012-1606(91)90280-G; KUHL DPA, 1993, CURR OPIN GENET DEV, V3, P404, DOI 10.1016/0959-437X(93)90112-3; LAVIA P, 1987, EMBO J, V6, P2773, DOI 10.1002/j.1460-2075.1987.tb02572.x; LEBEDENKO EN, 1991, NUCLEIC ACIDS RES, V19, P6757, DOI 10.1093/nar/19.24.6757; LEGRAVEREND C, 1993, NUCLEIC ACIDS RES, V21, P1735, DOI 10.1093/nar/21.8.1735; LEMAIGRE FP, 1989, EUR J BIOCHEM, V181, P555, DOI 10.1111/j.1432-1033.1989.tb14760.x; LENNARD AC, 1991, MOL CELL BIOL, V11, P1281, DOI 10.1128/MCB.11.3.1281; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; Maxam A M, 1980, Methods Enzymol, V65, P499; MICHAEL NL, 1994, J VIROL, V68, P979, DOI 10.1128/JVI.68.2.979-987.1994; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; REACH M, 1991, EMBO J, V10, P3439, DOI 10.1002/j.1460-2075.1991.tb04908.x; READ ML, 1993, BIOCHEM J, V295, P233, DOI 10.1042/bj2950233; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; RUNKEL L, 1991, MOL CELL BIOL, V11, P1270, DOI 10.1128/MCB.11.3.1270; RYON JJ, 1993, J VIROL, V67, P4006, DOI 10.1128/JVI.67.7.4006-4016.1993; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO M, 1989, J BIOL CHEM, V264, P10251; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SERFLING E, 1989, TRENDS GENET, V5, P131, DOI 10.1016/0168-9525(89)90049-8; SHRADER TE, 1990, J MOL BIOL, V216, P69, DOI 10.1016/S0022-2836(05)80061-0; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; THORN JT, 1991, ONCOGENE, V6, P1843; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WANG JC, 1993, BIOCHIM BIOPHYS ACTA, V1216, P73, DOI 10.1016/0167-4781(93)90039-G; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	72	40	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23894	23903						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523363				2022-12-25	WOS:A1994PQ34600011
J	WELHAM, MJ; DECHERT, U; LESLIE, KB; JIRIK, F; SCHRADER, JW				WELHAM, MJ; DECHERT, U; LESLIE, KB; JIRIK, F; SCHRADER, JW			INTERLEUKIN (IL)-3 AND GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR, BUT NOT IL-4, INDUCE TYROSINE PHOSPHORYLATION, ACTIVATION, AND ASSOCIATION OF SHPTP2 WITH GRB2 AND PHOSPHATIDYLINOSITOL 3'-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SIGNAL-TRANSDUCTION PATHWAYS; FACTOR RECEPTOR-BETA; SH2 DOMAIN; MOTH-EATEN; CELL LINES; PROTEIN; KINASE; EXPRESSION; MUTATIONS	Binding of interleukin (IL)-3 and granulocyte/macrophage colony stimulating factor (GM-CSF) to their high affinity cell surface receptors induces tyrosine phosphorylation of a similar set of protein substrates. We have identified one of these common substrates (p70) as the protein-tyrosine phosphatase SHPTP2. The Src homology 2 (SH2) domain of the adaptor protein Grb2 bound with high affinity to tyrosinephosphorylated SHPTP2 following treatment of cells with IL-3 or GM-CSF, but not IL-4. This interaction was inhibited by two phosphotyrosine peptides, based on sequences within SHPTP2, which conform to the postulated consensus sequence for Grb2 SH2 recognition. Following treatment with IL-3 or GM-CSF, but not IL-4, SHPTP2 co-immunoprecipitated with antibodies directed against the p85 subunit of PI 3'-kinase. This was partially blocked by the same phosphopeptides that blocked Grb2-SH2 binding to SRPTP2. Importantly treatment with IL-3 resulted in a 2-3-fold increase in SHPTP2 phosphatase activity. These results suggest that SHPTP2 may play an important role in integrating signals from the IL-3 and GM-CSF receptors to both Ras and PI 3'-kinase.	UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia	WELHAM, MJ (corresponding author), UNIV BRITISH COLUMBIA,BIOMED RES CTR,2222 HLTH SCI MALL,VANCOUVER V6T 1Z3,BC,CANADA.							BOULTON TG, 1994, J BIOL CHEM, V269, P11649; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DAUM G, 1993, ANAL BIOCHEM, V211, P50, DOI 10.1006/abio.1993.1231; DECHERT U, 1994, J BIOL CHEM, V269, P5602; DURONIO V, 1992, J BIOL CHEM, V267, P21856; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GOLD MR, 1994, J BIOL CHEM, V269, P5403; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; OKUDA K, 1992, BLOOD, V79, P2880; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; Sambrook J, 1989, MOL CLONING LABORATO; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TORIGOE T, 1992, BLOOD, V80, P617; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WELHAM MJ, 1992, J IMMUNOL, V149, P2772; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577	44	132	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23764	23768						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7522233				2022-12-25	WOS:A1994PQ34500058
J	CHEN, SRW; MACLENNAN, DH				CHEN, SRW; MACLENNAN, DH			IDENTIFICATION OF CALMODULIN, CA2+, AND RUTHENIUM RED-BINDING DOMAINS IN THE CA2+ RELEASE CHANNEL (RYANODINE RECEPTOR) OF RABBIT SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE; FUNCTIONAL EXPRESSION; ADENINE-NUCLEOTIDE; MOLECULAR-CLONING; PROTEINS; CA-2+; CDNA; PURIFICATION; SITE; ANTIBODIES	cDNAs encoding trpE fusion proteins containing fragments of the skeletal muscle Ca2+ release channel (ryanodine receptor) were expressed in bacteria. The fusion proteins, which covered about 90% of the linear sequence of the ryanodine receptor, were used to identify calmodulin- (CaM), Ca2+, and ruthenium red-binding regions in the ryanodine receptor through the use of I-125-CaM, Ca-45(2+), and ruthenium red overlay procedures. Six Ca2+-dependent CaM-binding domains were detected in the skeletal muscle ryanodine receptor. Strong CaM-binding domains were localized in regions 6, 11, 12, and 13, in subregions 6b, 11b, and 13b, and in short sequences 6b3, 11b1, and 13b2, lying between amino acid residues 2063 and 2091, 3611 and 3642, and 4303 and 4328. Weaker CaM-binding domains were localized in regions 4, 9, and 10 and in subregions 4b, 9b, and 10a, lying between residues 921 and 1173, 2804 and 2930, and 2961 and 3084. Most of these CaM-binding domains encompassed all or part of previously predicted CaM-binding sites. Strong Ca-45(2+)- and ruthenium red-binding domains were localized in the NH2- and COOH-terminal regions of the ryanodine receptor and in regions 6, 12, and 13. The Ca-45(2+)- and ruthenium red-binding sites in regions 6 and 12 were localized in subregions 6b and 12b, lying between residues 1861-2094 and 3657-3776. These data together with earlier studies (Chen, S.R W., Zhang, L., and MacLennan, D. H. (1992) J. Biol. Chem. 267, 23318-23326), show that strong CaM-, Ca2+-, and ruthenium red-binding domains are colocalized in the skeletal muscle ryanodine receptor.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ON,CANADA	University of Toronto								BRANDT NR, 1992, J MEMBRANE BIOL, V127, P35; CAMPBELL KP, 1981, J BIOL CHEM, V256, P4626; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CARLIN RK, 1981, J CELL BIOL, V89, P449, DOI 10.1083/jcb.89.3.449; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHARUK JHM, 1990, ANAL BIOCHEM, V188, P123, DOI 10.1016/0003-2697(90)90539-L; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CHEN SRW, 1993, J BIOL CHEM, V268, P13414; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; CHEN SRW, 1993, J BIOL CHEM, V268, P22642; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FLANAGAN SD, 1984, ANAL BIOCHEM, V140, P510, DOI 10.1016/0003-2697(84)90202-1; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; HOFMANN F, 1993, J BIOL CHEM, V268, P10252; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; INUI M, 1987, J BIOL CHEM, V262, P1740; KELLY GM, 1991, J BIOL CHEM, V266, P12469; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1987, BIOCHEM BIOPH RES CO, V143, P704, DOI 10.1016/0006-291X(87)91411-2; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MARKS AR, 1990, J BIOL CHEM, V265, P13143; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P244, DOI 10.1021/bi00349a034; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OTSU K, 1990, J BIOL CHEM, V265, P13472; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; Sambrook J, 1989, MOL CLONING LABORATO; SEILER S, 1984, J BIOL CHEM, V259, P8550; SMITH JS, 1989, CIRC RES, V64, P352, DOI 10.1161/01.RES.64.2.352; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREVES S, 1993, BIOCHEM J, V291, P757, DOI 10.1042/bj2910757; TUANA BS, 1988, FEBS LETT, V235, P219, DOI 10.1016/0014-5793(88)81266-3; VALE MGP, 1988, J BIOL CHEM, V263, P12872; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; YANG HC, 1994, BIOCHEMISTRY-US, V33, P518, DOI 10.1021/bi00168a017; ZARKA A, 1993, EUR J BIOCHEM, V213, P147, DOI 10.1111/j.1432-1033.1993.tb17744.x; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	43	123	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22698	22704						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7521330				2022-12-25	WOS:A1994PQ16300039
J	REISIN, IL; PRAT, AG; ABRAHAM, EH; AMARA, JF; GREGORY, RJ; AUSIELLO, DA; CANTIELLO, HF				REISIN, IL; PRAT, AG; ABRAHAM, EH; AMARA, JF; GREGORY, RJ; AUSIELLO, DA; CANTIELLO, HF			THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IS A DUAL ATP AND CHLORIDE CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; CL CHANNEL; CFTR; CELLS; GENE; EXPRESSION; BINDING; IDENTIFICATION; NUCLEOTIDES; ACTIVATION	The cystic fibrosis transmembrane conductance regulator (CFTR) belongs to a superfamily of proteins implicated in the transport of ions, proteins, and hydrophobic substances. Recent studies have demonstrated that CFTR is a protein kinase A-sensitive anion channel regulated by ATP. In the present study, patch-clamp techniques were used to assess the role of CFTR in the transport of Cl- and ATP. The stable transfection of mouse mammary carcinoma cells, C127i, with the cDNA for human CFTR resulted in the appearance of a diphenylamine-2-carboxylate-inhibitable Cl- channel, which was activated by cAMP under whole-cell and cell-attached conditions and by protein kinase A plus ATP under excised, inside-out conditions. CFTR expression was also associated with the electrodiffusional movement of ATP as indicated by the cAMP activation of ATP currents measured under whole-cell conditions. In excised, inside-out patches, it was demonstrated that ATP currents were mediated by ATP-conductive channels, which were also activated by protein kinase A and blocked by the Cl- channel blocker diphenylamine-2-carboxylate under excised, inside-out conditions. Single-channel currents observed in the presence of asymmetrical Cl-/ATP concentrations indicated that the same conductive pathway was responsible for both ATP and Cl- movement. Thus, CFTR is a multifunctional protein with more than one anion transport capability and may modify signal transduction pathways for Cl- or other secretory processes by the selective delivery of nucleotides to the extracellular domain.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA; GENZYME CORP, FRAMINGHAM, MA 01701 USA; MASSACHUSETTS GEN HOSP, RENAL UNIT, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP, DEPT RADIAT ONCOL, BOSTON, MA 02129 USA	Harvard University; Harvard Medical School; Sanofi-Aventis; Genzyme Corporation; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital								ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ARISPE N, 1992, P NATL ACAD SCI USA, V89, P1539, DOI 10.1073/pnas.89.5.1539; BANDERALI U, 1992, AM J PHYSIOL, V263, pC1200, DOI 10.1152/ajpcell.1992.263.6.C1200; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BOUCHER RC, 1988, J PHYSIOL-LONDON, V405, P77, DOI 10.1113/jphysiol.1988.sp017322; BOUCHER RC, 1984, CYSTIC FIBROSIS HORI, P167; BULL HB, 1964, INTRO PHYSICAL BIOCH; CANTIELLO HF, 1994, J BIOL CHEM, V269, P11224; CANTIELLO HF, 1990, J BIOL CHEM, V265, P21624; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DISTEFANO A, 1985, PFLUG ARCH EUR J PHY, V405, pS95, DOI 10.1007/BF00581787; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; DUBYAK GR, 1990, BIOL ACTIONS EXTRACE; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HSIUNG N, 1984, Journal of Molecular and Applied Genetics, V2, P497; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; LIN PY, 1987, J BIOL CHEM, V262, P15345; MEYERS KM, 1982, AM J PHYSIOL, V243, pR454, DOI 10.1152/ajpregu.1982.243.3.R454; Pullman B., 1963, QUANTUM BIOCH; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; Ryan J W, 1971, Trans Assoc Am Physicians, V84, P297; SIGWORTH FJ, 1984, SINGLE CHANNEL RECOR, P3; SLAKEY LL, 1990, ANN NY ACAD SCI, V603, P366; Szent-Gyorgyi A., 1960, INTRO SUBMOLECULAR B; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TRAMS EG, 1980, J THEOR BIOL, V87, P609, DOI 10.1016/0022-5193(80)90239-8; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WELSH MJ, 1989, ANN NY ACAD SCI, V574, P44	39	300	304	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20584	20591						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519611				2022-12-25	WOS:A1994PB31700059
J	BOUCHARD, P; ZHAO, ZZ; BANVILLE, D; DUMAS, F; FISCHER, EH; SHEN, SH				BOUCHARD, P; ZHAO, ZZ; BANVILLE, D; DUMAS, F; FISCHER, EH; SHEN, SH			PHOSPHORYLATION AND IDENTIFICATION OF A MAJOR TYROSINE PHOSPHORYLATION SITE IN PROTEIN-TYROSINE-PHOSPHATASE 1C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; FACTOR-RECEPTOR; SIGNAL TRANSDUCTION; SH3 DOMAINS; EXPRESSION; CORKSCREW; ASSOCIATION; ACTIVATION; SEQUENCES; KINASES	Protein tyrosine phosphatase 1C (PTP1C) was the first member of the protein tyrosine phosphatase family demonstrated to contain the src homology 2 (SH2) domain. This enzyme is believed to play a role in regulating downstream signaling in hematopoietic cells since it was predominantly expressed in these cells. However, recent studies have revealed that the protein is expressed in other tissues as well. This report describes both the phosphorylation of PTP1C in non-hematopoietic cells treated with growth factors (in vivo) and incubation of purified PTP1C with a variety of protein kinases (in vitro). PTP1C was transiently phosphorylated in A431 and 293 cells and also when the purified enzyme was incubated with receptor protein tyrosine kinases. In vitro, the tyrosine-phosphorylated PTP1C underwent rapid auto-dephosphorylation, an effect which could be blocked by the addition of sodium vanadate. On the other hand, cells containing a PTP1C in which the catalytic site had been inactivated through mutagenesis, stably phosphorylated the phosphatase. These results suggested that PTP1C was responsible for its own auto-dephosphorylation. The sites of tyrosine phosphorylation were characterized from purified enzyme following treatment with insulin receptor kinase and from PTP1C expressed in 293 cells which had been stimulated with platelet-derived growth factor. Through the techniques of peptide mapping and microsequencing, Tyr(538) was determined to be the major phosphorylation site. This result was confirmed in vivo through site-specific mutagenesis of PTP1C expressed in 293 cells; changing Tyr(538) to Phe(538) completely abolished tyrosine phosphorylation of the molecule. In addition, Tyr(538) lies within the sequence ESEYGNI which can be correlated with the consensus sequence pYXNX associated with GRB2 binding. These results suggest that PTP1C plays a prominent role in growth factor receptor-mediated signal transduction within both hematopoietic cells and tissues of non-lymphoid origin.	NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, MOLEC PHARMACEUT SECTOR, MONTREAL H4P 2R2, PQ, CANADA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	National Research Council Canada; University of Washington; University of Washington Seattle					NIDDK NIH HHS [DK07902] Funding Source: Medline; NIGMS NIH HHS [GM42508] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK007902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Gros E., 1967, METHOD ENZYMOL, V11, P238; HSU CYJ, 1990, CELL GROWTH DIFFER, V1, P191; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; SHEN SH, 1991, J BIOL CHEM, V266, P1058; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; TURCK C W, 1991, Peptide Research, V4, P36; UCHIDA T, 1993, J BIOL CHEM, V268, P11845; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VILLAMORUZZI E, 1993, J BIOL CHEM, V268, P18176; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHAO ZZ, 1991, BIOCHEM BIOPH RES CO, V176, P1454, DOI 10.1016/0006-291X(91)90450-L; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	31	69	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19585	19589						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	7518460				2022-12-25	WOS:A1994NY33200060
J	ABRAMS, C; DENG, YJ; STEINER, B; OTOOLE, T; SHATTIL, SJ				ABRAMS, C; DENG, YJ; STEINER, B; OTOOLE, T; SHATTIL, SJ			DETERMINANTS OF SPECIFICITY OF A BACULOVIRUS-EXPRESSED ANTIBODY FAB FRAGMENT THAT BINDS SELECTIVELY TO THE ACTIVATED FORM OF INTEGRIN ALPHA(IIB)BETA(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; ARG-GLY-ASP; SITE-DIRECTED MUTAGENESIS; GPIIB-IIIA; PLATELET RECEPTOR; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODY; LIGAND-BINDING; CELL-ADHESION; ALPHA-CHAIN	PAC1 is an IgM kappa murine monoclonal antibody that, like the Arg-Gly-Asp-containing ligand fibrinogen, binds to integrin alpha(IIb)beta(3) only on activated platelets. The unique binding properties of PAC1 may be determined by its large size, its multivalency, and by variable region sequences, including an Arg-Tyr-Asp at residues 100A-C in H-CDR3. To study the molecular determinants of PAC1 function, baculoviruses containing cloned cDNA for the Fd heavy and kappa light chains of PAC1 were used to coinfect Sf9 insect cells. Infected cells secreted a soluble, monovalent, 50-kDa Fab fragment that bound saturably to agonist-stimulated platelets but not to resting cells. Fab binding was inhibited >85% by 10 mM EDTA, 1 mM RGDS, 1 mM fibrinogen gamma(397-411), or 12 mu M fibrinogen, but not by 1 mM RGES. Compared to PAC1 IgM, a 60-fold higher molar concentration of PAC1 Fab was required for half-maximal binding to platelets or for half-maximal inhibition of fibrinogen binding. PAC1 Fab bound to an activated form of alpha(IIb)beta(3) expressed in Chinese hamster ovary cells, but not to the resting form of the receptor in these cells or to alpha(V) beta(3) in human endothelial cells. Conversion of Asp(100C) to Glu by site-directed mutagenesis rendered the antibody inactive, indicating that the Arg-Tyr-Asp sequence in H-CDR3 is essential for PAC1 recognition of alpha(IIb)beta(3). Binding of fibrinogen or PAC1 IgM to platelets induced tyrosine phosphorylation of a 140-kDa platelet protein, but binding of PAC1 Fab did not. These studies demonstrate that the specificity of PAC1 for activated alpha(IIb)beta(3) is determined by an integrin recognition sequence within H-CDR3. However, the strength of this binding interaction and the ability of PAC1 to trigger signaling in platelets also depend on antibody valency.	UNIV PENN, SCH MED, DEPT MED, DIV HEMATOL ONCOL, PHILADELPHIA, PA 19104 USA; F HOFFMANN LA ROCHE & CO LTD, CH-4002 BASEL, SWITZERLAND; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	University of Pennsylvania; Roche Holding; Scripps Research Institute					NHLBI NIH HHS [HL-40387, HL-49845] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL049845] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1992, J BIOL CHEM, V267, P2775; ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; ALIG L, 1992, J MED CHEM, V35, P4393, DOI 10.1021/jm00101a017; AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P10003, DOI 10.1073/pnas.90.21.10003; BEACHAM DA, 1992, J BIOL CHEM, V267, P3409; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERNY RC, 1993, J BIOL CHEM, V268, P9725; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLER BS, 1986, J CELL BIOL, V103, P451, DOI 10.1083/jcb.103.2.451; COLLER BS, 1991, BLOOD, V77, P75; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; COLLER BS, 1992, ANNU REV MED, V43, P171; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DU XP, 1993, J BIOL CHEM, V268, P23087; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FAUCHERE JL, 1993, INT J PEPT PROT RES, V42, P440; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; GRABER SG, 1992, J BIOL CHEM, V267, P13123; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HASEMANN CA, 1990, P NATL ACAD SCI USA, V87, P3942, DOI 10.1073/pnas.87.10.3942; HAWIGER J, 1989, BIOCHEMISTRY-US, V28, P2909, DOI 10.1021/bi00433a024; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JORDAN R, 1991, THROMB HAEMOSTASIS, V65, P828; Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955-0674(93)90030-T; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KOUNS WC, 1992, J BIOL CHEM, V267, P18844; KOUNS WC, 1992, BLOOD, V80, P2539; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4558, DOI 10.1093/nar/19.16.4558; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1993, PROTEIN ENG, V6, P745, DOI 10.1093/protein/6.7.745; MCLANE M, 1993, THROMB HAEMOSTASIS, V69, P925; MULLER CE, 1983, J IMMUNOL, V131, P877; NESBIT M, 1992, J IMMUNOL METHODS, V151, P201, DOI 10.1016/0022-1759(92)90118-D; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PLOW EF, 1992, SEMIN THROMB HEMOST, V18, P324, DOI 10.1055/s-2007-1002571; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PUTLITZ JZ, 1990, BIO-TECHNOL, V8, P651, DOI 10.1038/nbt0790-651; RANDEN I, 1993, EUR J IMMUNOL, V23, P2682, DOI 10.1002/eji.1830231044; RAO SN, 1992, PEPTIDE RES, V5, P148; REMOLDODONNELL E, 1992, BLOOD, V79, P1754; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SHATTIL SJ, 1993, THROMB HAEMOSTASIS, V70, P224; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHATTIL SJ, 1987, BLOOD, V70, P307; SHATTIL SJ, 1986, BLOOD, V68, P1224; SHATTIL SJ, 1992, IMMUNOMETHODS, V1, P53; SISK WP, 1992, BIOTECHNIQUES, V13, P186; SMITH JW, 1990, J BIOL CHEM, V265, P12267; TAUB R, 1989, J BIOL CHEM, V264, P259; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085; UDAKA K, 1990, MOL IMMUNOL, V27, P25, DOI 10.1016/0161-5890(90)90057-7; WEBB N R, 1990, Technique (Philadelphia), V2, P173; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WEISS HJ, 1991, THROMB HAEMOSTASIS, V65, P202; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C	69	49	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18781	18788						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7518445				2022-12-25	WOS:A1994NX32700017
J	VONZASTROW, M; KOBILKA, BK				VONZASTROW, M; KOBILKA, BK			ANTAGONIST-DEPENDENT AND ANTAGONIST-INDEPENDENT STEPS IN THE MECHANISM OF ADRENERGIC-RECEPTOR INTERNALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESENSITIZATION; ENDOCYTOSIS; MEMBRANE; SIGNAL; CELLS	Epitope tagging and immunocytochemical techniques were used to examine the agonist regulated internalization of human beta(2)-adrenergic receptors in 293 cells. In the absence of agonist, receptors tagged with monoclonal antibody remain in the plasma membrane for >1 h. In the presence of agonist, tagged receptors are endocytosed within 10 min. Endocytosed receptors are located in endosomes and can be recycled to the plasma membrane. In the prolonged presence of agonist, receptor endocytosis continues even after maximum sequestration of surface receptors (measured by radioligand binding to intact cells) has occurred. The process of receptor endocytosis requires cellular ATP and is temperature-dependent. At 4 degrees C, no agonist-induced redistribution of receptors located in the plasma membrane is observed. At 16 degrees C, agonist causes receptors to cluster in and around coated invaginations of the plasma membrane, but receptor endocytosis does not occur. Agonist treatment of cells at 16 degrees C, but not 4 degrees C, predisposes receptors to agonist independent endocytosis upon warming to 37 degrees C. These studies suggest that: 1) beta(2)-adrenerse receptors reside stably in the plasma membrane of untreated cells, while they continuously cycle between the plasma membrane and endosomes in the presence of agonist; 2) agonist regulates an early step in the endocytosis mechanism, which is associated with the redistribution of adrenergic receptors between distinct microdomains of the plasma membrane; and 3) later steps in the endocytosis mechanism do not require agonist and may utilize the same endocytic machinery that mediates the endocytosis of constitutively recycling receptors.	STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT CARDIOVASC MED, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University				Kobilka, Brian/0000-0001-5958-3990				BARAK LS, 1994, J BIOL CHEM, V269, P2790; CARON MG, 1993, RECENT PROG HORM RES, V48, P277; CLARK RB, 1986, ADV CYCLIC NUCL PROT, V20, P151; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HAUSDORFF WP, 1990, SYM SOC EXP BIOL, V44, P225; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HERTEL C, 1990, J BIOL CHEM, V265, P17988; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KURZ JB, 1992, MOL PHARMACOL, V41, P375; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PERKINS JP, 1991, BETA ADRENERGIC RECE, P73; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; ROHRER J, 1993, MOL BIOL CELL, V4, P511, DOI 10.1091/mbc.4.5.511; SCHMID SL, 1990, J CELL BIOL, V111, P2307, DOI 10.1083/jcb.111.6.2307; STAEHELIN M, 1982, EMBO J, V1, P187, DOI 10.1002/j.1460-2075.1982.tb01145.x; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; YU SS, 1993, J BIOL CHEM, V268, P337	21	161	163	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18448	18452						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518433				2022-12-25	WOS:A1994NW79800036
J	CLEGHON, V; MORRISON, DK				CLEGHON, V; MORRISON, DK			RAF-1 INTERACTS WITH FYN AND SRC IN A NON-PHOSPHOTYROSINE-DEPENDENT MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; PROTEIN-TYROSINE KINASES; GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; SH2 DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; REGULATORY DOMAIN; PHOSPHORYLATION; BINDING; ASSOCIATION	To identify novel proteins capable of associating with the Raf-1 serine/threonine kinase, we investigated whether Raf-1 could interact with the Src homology 2 (SH2) domains of various signal-transducing molecules. In this report, we demonstrate that Raf-1 associated with the SH2 domain of Fyn (a member of the Src tyrosine kinase family) but not with the SH2 domains of phospholipase C-gamma 1, the p85 alpha subunit of phosphatidylinositol 3-kinase, and SH2 containing protein tyrosine phosphatase 2. Unlike most SH2 domain interactions that require tyrosine-phosphorylated residues, the Raf-1/Fyn SH2 domain association was dependent on the serine phosphorylation of Raf-1. Our results also demonstrate that Raf-1 interacted with the SH2 domain of Src and that this interaction was destabilized by mutation of Arg(175) found within the conserved SH2 domain FLVRES sequence. In addition, we show that inclusion of additional Src sequences containing the SH3 domain increased the association of Raf-1 with the Src SH2 domain. Finally, using the baculovirus/Sf9 cell system, we show that coexpression of Raf-1 with full-length Fyn/Src resulted in the coimmunoprecipitation of Raf-1 with Fyn/Src, the tyrosine phosphorylation of Raf-1, and the stimulation of Raf-1 kinase activity. These results suggest that Raf-1 may form a functional complex with Fyn/Src mediated in part by SH2 domains and the serine phosphorylation of Raf-1.			CLEGHON, V (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MOLEC MECHANISMS CAREINOGENESIS LAB,FREDERICK,MD 21702, USA.				OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARROLL MP, 1990, J BIOL CHEM, V265, P812; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HAN M, 1993, NATURE, V363, P137; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	51	89	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17749	17755						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	7517401				2022-12-25	WOS:A1994NU12800063
J	LIU, L; CUTLER, RL; MUI, ALF; KRYSTAL, G				LIU, L; CUTLER, RL; MUI, ALF; KRYSTAL, G			STEEL FACTOR STIMULATES THE SERINE/THREONINE PHOSPHORYLATION OF THE INTERLEUKIN-3 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL GROWTH-FACTOR; PROTEIN-KINASE-C; HEMATOPOIETIC PROGENITOR CELLS; TYROSINE PHOSPHORYLATION; COLONY FORMATION; KIT-LIGAND; SIGNAL-TRANSDUCTION; PHORBOL ESTER; GENE-PRODUCT; MAST-CELLS	The murine interleukin-3 (IL-3) dependent cell line, B6SUtA(1), which expresses high IL-3 receptor (IL-3R) numbers, was found to proliferate in a greater than additive fashion when grown in the presence of IL-3 and steel factor (SF). However, pretreatment of these cells with SF had no effect on the number of IL-3Rs expressed at the cell surface nor their affinity for IL-3. Interestingly, although, SF did induce the rapid and transient serine- and threonine-specific phosphorylation of the beta(IL-3) subunit of the IL-3R. This serine/threonine phosphorylation was also observed with the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate, and both the 12-O-tetradecanoylphorbol-13-acetate- and SF-induced phosphorylation of the IL-3R could be inhibited with the highly specific protein kinase C inhibitor, bisindolyl-maleimide (Compound 3), suggesting that SF might be stimulating this phosphorylation via protein kinase C. This SF-induced phosphorylation also occurred within 10 min of incubation at 4 degrees C, indicating that this might be a relatively early event in the c-kit signaling pathway. Last, this SF-induced phosphorylation of the IL-3R occurred in the presence of the tyrosine kinase inhibitor, genistein, at levels which blocked the autophosphorylation of c-kit. This suggests that c-kit might be capable of mediating this cross-talk phenomenon in the absence of its endogenous tyrosine kinase activity.	BRITISH COLUMBIA CANC AGCY,TERRY FOX LAB,VANCOUVER V5Z 1L3,BC,CANADA; UNIV BRITISH COLUMBIA,VANCOUVER V5Z 1L3,BC,CANADA	British Columbia Cancer Agency; University of British Columbia				Krystal, Gerald/0000-0002-1961-6281				ALAI M, 1992, J BIOL CHEM, V267, P18021; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BAXTER GT, 1992, BIOCHEMISTRY-US, V31, P10950, DOI 10.1021/bi00160a002; BERNSTEIN ID, 1991, BLOOD, V77, P2316; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; BOSWELL HS, 1990, EXP HEMATOL, V18, P794; BRANDT J, 1992, BLOOD, V79, P634; BROOKS G, 1989, CARCINOGENESIS, V10, P283, DOI 10.1093/carcin/10.2.283; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; BROXMEYER HE, 1991, EXP HEMATOL, V19, P143; BROXMEYER HE, 1991, BLOOD, V77, P2142; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CATLETT JP, 1991, BLOOD, V78, P3186; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN J, 1992, BLOOD, V80, P1923; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DEVRIES P, 1991, J EXP MED, V173, P1205, DOI 10.1084/jem.173.5.1205; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; DURONIO V, 1992, J BIOL CHEM, V267, P21856; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GRUNBERGER G, 1982, AM J PHYSIOL, V243, pE319, DOI 10.1152/ajpendo.1982.243.4.E319; GUILBERT LJ, 1983, J CELL PHYSIOL, V115, P276, DOI 10.1002/jcp.1041150310; HENDRIE PC, 1991, EXP HEMATOL, V19, P1031; HERMINE O, 1993, BLOOD, V82, pA231; HEYWORTH CM, 1993, BLOOD, V81, P894; HIRAYAMA F, 1992, P NATL ACAD SCI USA, V89, P5907, DOI 10.1073/pnas.89.13.5907; HIRAYAMA F, 1993, J CELL BIOCH B, V17, P225; HORIE M, 1993, J BIOL CHEM, V268, P968; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; JACOBSEN SEW, 1992, BLOOD, V80, P678; KANAKURA Y, 1991, J BIOL CHEM, V266, P490; LEE LS, 1978, SCIENCE, V202, P313, DOI 10.1126/science.308698; Lehtola L, 1989, GROWTH FACTORS, V1, DOI 10.3109/08977198909000256; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; METCALF D, 1991, P NATL ACAD SCI USA, V88, P6239, DOI 10.1073/pnas.88.14.6239; MIGLIACCIO G, 1991, P NATL ACAD SCI USA, V88, P7420, DOI 10.1073/pnas.88.16.7420; MIYAZAWA K, 1994, BLOOD, V83, P137; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MUI ALF, 1992, P NATL ACAD SCI USA, V89, P10812, DOI 10.1073/pnas.89.22.10812; MUI ALF, 1992, EXP HEMATOL, V20, P753; MURTHY SC, 1990, EXP HEMATOL, V18, P11; MURTHY SC, 1989, BLOOD, V73, P1180; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; OEZ S, 1993, EXP HEMATOL, V21, P1144; OKUDA K, 1991, BLOOD, V78, P1928; OKUDA K, 1992, BLOOD, V79, P2880; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; TESTA U, 1993, BLOOD, V81, P1442; THOMOPOULOS P, 1982, EUR J BIOCHEM, V129, P389, DOI 10.1111/j.1432-1033.1982.tb07062.x; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TSUJI K, 1991, J CELL PHYSIOL, V148, P362, DOI 10.1002/jcp.1041480306; TSUJI K, 1991, BLOOD, V78, P1223; TSUJI K, 1992, BLOOD, V79, P2855; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALKER F, 1985, CELL, V43, P269, DOI 10.1016/0092-8674(85)90032-7; WELHAM MJ, 1991, MOL CELL BIOL, V11, P2901, DOI 10.1128/MCB.11.5.2901; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YEE NS, 1993, J BIOL CHEM, V268, P14189; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	69	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16774	16779						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	7515884				2022-12-25	WOS:A1994NR29600042
J	GROBLEWSKI, GE; WAGNER, ACC; WILLIAMS, JA				GROBLEWSKI, GE; WAGNER, ACC; WILLIAMS, JA			CYCLOSPORINE-A INHIBITS CA2+/CALMODULIN-DEPENDENT PROTEIN PHOSPHATASE AND SECRETION IN PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOCRINE PANCREAS; SIGNAL TRANSDUCTION; MEDIATOR RELEASE; HUMAN BASOPHILS; OKADAIC ACID; CALCINEURIN; CYCLOPHILIN; FK-506; FK506; EXOCYTOSIS	The immunosuppressant cyclosporin A (CsA) was utilized as a highly specific inhibitor of the Ca2+/calmodulin-dependent protein phosphatase, PP2B in rat pancreatic acinar cells. Treatment of cells with CsA for 20 min resulted in a concentration-dependent inhibition of PP2B that was maximal (>90%) at 1 mu M and exhibited an IC50 of 65 nM. CsA also inhibited cholecystokinin-, 100 pM, or carbamylcholine-, 10 mu M, induced amylase release in a concentration-dependent manner. A maximal inhibition to 55% of stimulated control cells occurred at 1 mu M CsA with half-maximal inhibition occurring at approximately 200 nM. Secretion in response to 1 mu M 12-O-tetradecanoylphorbol-13-acetate (TPA) was uneffected by CsA treatment. Conversely, amylase release stimulated by the Ca2+ mobilizing agent, thapsigargin, when added alone at 2 mu M or in combination with TPA, was inhibited by CsA to 66 and 61% of control cells, respectively. These data indicate that CsA-mediated inhibition occurs only when stimulation involves an increase in intracellular Ca2+. In addition, analogues of CsA, 6-methyl-alanine-CsA, and 11-methyl-leucine-CsA had no effect on PP2B activity or amylase secretion. The chemically distinct immunosuppressant, FK506, produced only partial inhibition of PP2B activity and did not significantly inhibit amylase secretion at concentrations up to 1 mu M. Two-dimensional gel electrophoresis of proteins from P-32-labeled acinar cells revealed that CsA specifically blocked the cholecystokinin stimulated dephosphorylation of a 24-kDa protein in a concentration range similar to that seen for inhibition of secretion. Using P-32-labeled cytosol and purified calcineurin, a Ca2+- and calmodulin-dependent dephosphorylation of the 24-kDa protein was also demonstrated in vitro. Collectively, these data indicate that the Ca2+/calmodulin-dependent protein phosphatase, PP2B, plays a significant role in stimulus-secretion coupling in pancreatic acinar cells.	UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	GROBLEWSKI, GE (corresponding author), UNIV MICHIGAN,DEPT PHYSIOL,7737 MED SCI 2,ANN ARBOR,MI 48109, USA.			Williams, John/0000-0002-6063-7615	NIDDK NIH HHS [NRSA DK08819, NIDDK DK-41122] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008819, R01DK041122] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONI FA, 1993, BIOCHEM BIOPH RES CO, V194, P226, DOI 10.1006/bbrc.1993.1808; ASWAD DW, 1981, J BIOL CHEM, V256, P3487; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BURNHAM DB, 1985, BIOCHEM J, V231, P335, DOI 10.1042/bj2310335; BURNHAM DB, 1982, J BIOL CHEM, V257, P523; BURNHAM DB, 1986, BIOCHEM J, V235, P125, DOI 10.1042/bj2350125; CHANTLER PD, 1985, J CELL BIOL, V101, P207, DOI 10.1083/jcb.101.1.207; CIRILLO R, 1990, J IMMUNOL, V144, P3891; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; DEPAULIS A, 1991, J IMMUNOL, V146, P2374; DOI R, 1993, GASTROENTEROLOGY, V104, P1153, DOI 10.1016/0016-5085(93)90287-M; DOI R, 1993, PANCREAS, V7, P197; DOI RH, 1993, J PHARMACOL EXP THER, V264, P873; DURETTE PL, 1988, TRANSPLANT P, V20, P51; FORREST MJ, 1991, BIOCHEM PHARMACOL, V42, P1221, DOI 10.1016/0006-2952(91)90257-6; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; HEMMINGS HC, 1992, J NEUROCHEM, V59, P1053, DOI 10.1111/j.1471-4159.1992.tb08347.x; HULTSCH T, 1990, J IMMUNOL, V144, P2659; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; JUNG DH, 1980, CLIN CHIM ACTA, V100, P7, DOI 10.1016/0009-8981(80)90179-5; KAYE RE, 1992, P NATL ACAD SCI USA, V89, P8542, DOI 10.1073/pnas.89.18.8542; Kincaid Randall, 1993, V27, P1; KINCAID RL, 1987, P NATL ACAD SCI USA, V84, P1118, DOI 10.1073/pnas.84.4.1118; KING MM, 1984, J BIOL CHEM, V259, P8080; LANCKI DW, 1989, J IMMUNOL, V142, P416; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; METZ DC, 1992, J BIOL CHEM, V267, P20620; MOMAYEZI M, 1987, J CELL BIOL, V105, P181, DOI 10.1083/jcb.105.1.181; RYFFEL B, 1991, IMMUNOLOGY, V72, P399; WAGNER ACC, 1992, BIOCHEM BIOPH RES CO, V189, P1606, DOI 10.1016/0006-291X(92)90260-R; WAGNER ACC, 1992, AM J PHYSIOL, V263, pC1172, DOI 10.1152/ajpcell.1992.263.6.C1172; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WASCHULEWSKI IH, 1993, BRIT J PHARMACOL, V108, P892, DOI 10.1111/j.1476-5381.1993.tb13483.x; Williams John A., 1993, P167; WISHART MJ, 1993, GASTROENTEROLOGY, V104, pA343; YULE DI, 1993, AM J PHYSIOL, V264, pG786, DOI 10.1152/ajpgi.1993.264.4.G786	40	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15111	15117						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7515049				2022-12-25	WOS:A1994NP73800041
J	GUMUCIO, DL; SHELTON, DA; BLANCHARDMCQUATE, K; GRAY, T; TARLE, S; HEILSTEDTWILLIAMSON, H; SLIGHTOM, JL; COLLINS, F; GOODMAN, M				GUMUCIO, DL; SHELTON, DA; BLANCHARDMCQUATE, K; GRAY, T; TARLE, S; HEILSTEDTWILLIAMSON, H; SLIGHTOM, JL; COLLINS, F; GOODMAN, M			DIFFERENTIAL PHYLOGENETIC FOOTPRINTING AS A MEANS TO IDENTIFY BASE CHANGES RESPONSIBLE FOR RECRUITMENT OF THE ANTHROPOID GAMMA-GENE TO A FETAL EXPRESSION PATTERN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSILON-GLOBIN GENE; STAGE SELECTOR ELEMENT; AMINO-ACID SEQUENCES; LOCUS-CONTROL REGION; HEREDITARY PERSISTENCE; 5'-FLANKING REGION; NUCLEAR-PROTEIN; FACTOR-BINDING; PROMOTER; HPFH	Expression of the anthropoid (simian) gamma gene in fetal life contrasts with the exclusively embryonic expression pattern of the gamma-like genes of other eutherian mammals. To elucidate the factors responsible for this change in expression pattern, we utilized a strategy called differential phylogenetic footprinting (DPF). This strategy entails the following: (a) identification, within regulatory regions, of the gamma promoter, of individual nucleotides that differ between human (fetal expression), and galago (embryonic expression) gamma genes, (b) analysis of the effect of these nucleotide differences on the binding of nuclear proteins to human and galago sequences, and (c) assessment of the functional consequences of these binding changes in expression assays. The DPF analysis revealed several proteins that bind upstream from the CCAAT motif in the galago gamma promoter but do not bind to the corresponding region of the human gamma promoter. In transfection assays, binding of these proteins is associated with erythroid-specific repression of promoter strength. Binding sites for these proteins also occur near the CCAAT box of other embryonically expressed genes, including rabbit, mouse, and dwarf lemur gamma genes and the human epsilon globin gene. These data are consistent with the hypothesis that sequence changes near the proximal CCAAT box in the ancestral simian gamma gene may have facilitated a novel expression pattern by reducing the binding of repressors that act in the fetal stage.	UNIV MICHIGAN, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; WAYNE STATE UNIV, SCH MED, DEPT ANAT & CELL BIOL, DETROIT, MI 48201 USA; UPJOHN CO, MOLEC BIOL UNIT 7242, KALAMAZOO, MI 49007 USA; NIH, NATL CTR HUMAN GENOME RES, BETHESDA, MD 20892 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Wayne State University; Pfizer; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	GUMUCIO, DL (corresponding author), UNIV MICHIGAN, SCH MED, DEPT ANAT & CELL BIOL, 5793A MED SCI 2, ANN ARBOR, MI 48109 USA.				NCRR NIH HHS [MO1-RR00042] Funding Source: Medline; NHLBI NIH HHS [HL-33940] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033940] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bailey WJ, 1992, MOL PHYLOGENET EVOL, V1, P97, DOI 10.1016/1055-7903(92)90024-B; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FITCH DHA, 1991, P NATL ACAD SCI USA, V88, P7396, DOI 10.1073/pnas.88.16.7396; FITCH DHA, 1990, J BIOL CHEM, V265, P781; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; GOODMAN M, 1979, SYST ZOOL, V28, P132, DOI 10.2307/2412519; GOODMAN M, 1984, J MOL BIOL, V180, P803, DOI 10.1016/0022-2836(84)90258-4; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GUMUCIO DL, 1991, BLOOD, V78, P1853; GUMUCIO DL, 1992, MOL CELL BIOL, V12, P4919, DOI 10.1128/MCB.12.11.4919; GUMUCIO DL, 1988, MOL CELL BIOL, V8, P5310, DOI 10.1128/MCB.8.12.5310; GUMUCIO DL, 1993, P NATL ACAD SCI USA, V90, P6018, DOI 10.1073/pnas.90.13.6018; GUMUCIO DL, 1991, 7TH P C HEM SWITCH, P277; HARDIES SC, 1984, J BIOL CHEM, V259, P3748; HARDISON R, 1993, NUCLEIC ACIDS RES, V21, P1265, DOI 10.1093/nar/21.5.1265; HARDISON RC, 1984, MOL BIOL EVOL, V1, P390; HAYASAKA K, 1992, J MOL BIOL, V224, P875, DOI 10.1016/0022-2836(92)90568-5; HILL A, 1984, J BIOL CHEM, V259, P3739; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; JANE SM, 1993, MOL CELL BIOL, V13, P3272, DOI 10.1128/MCB.13.6.3272; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KOOP BF, 1989, MOL BIOL EVOL, V6, P580; LLOYD JA, 1989, NUCLEIC ACIDS RES, V17, P4339, DOI 10.1093/nar/17.11.4339; MANTOVANI R, 1988, NUCLEIC ACIDS RES, V16, P7783, DOI 10.1093/nar/16.16.7783; MANTOVANI R, 1989, NUCLEIC ACIDS RES, V17, P6681, DOI 10.1093/nar/17.16.6681; MANTOVANI R, 1987, NUCLEIC ACIDS RES, V15, P9349, DOI 10.1093/nar/15.22.9349; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MOORE GW, 1973, J THEOR BIOL, V38, P459, DOI 10.1016/0022-5193(73)90252-X; MORGAN DA, 1991, BLOOD, V78, P2860; OTTOLENGHI S, 1988, BLOOD, V71, P815; PEREZSTABLE C, 1990, MOL CELL BIOL, V10, P1116, DOI 10.1128/MCB.10.3.1116; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; STOMING TA, 1989, BLOOD, V73, P329; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; SURREY S, 1988, BLOOD, V71, P807; TAGLE DA, 1988, J MOL BIOL, V203, P439, DOI 10.1016/0022-2836(88)90011-3; [No title captured]; [No title captured]	42	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15371	15380						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7515056				2022-12-25	WOS:A1994NP73800077
J	SMITH, PL; LOWE, JB				SMITH, PL; LOWE, JB			MOLECULAR-CLONING OF A MURINE N-ACETYLGALACTOSAMINE TRANSFERASE CDNA THAT DETERMINES EXPRESSION OF THE T-LYMPHOCYTE-SPECIFIC CT OLIGOSACCHARIDE DIFFERENTIATION ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSE BETA-1,4-N-ACETYLGALACTOSAMINYLTRANSFERASE; ASPARAGINE-LINKED OLIGOSACCHARIDES; TAMM-HORSFALL GLYCOPROTEIN; LEUKOCYTE-COMMON ANTIGEN; VICIA-VILLOSA LECTIN; MONOCLONAL-ANTIBODIES; SDA ANTIGEN; GUINEA-PIG; INTRAEPITHELIAL LYMPHOCYTES; SIALYLATED OLIGOSACCHARIDES	Two monoclonal antibodies termed CT1 and CT2 define a cell surface oligosaccharide molecule expressed on restricted populations of murine lymphocytes. This oligosaccharide structure is largely associated with the extracellular domain of the CD45 family of tyrosine phosphatases, molecules required for lymphocytes to proliferate in response to antigen stimulation. Previous work has shown that the oligosaccharide structure recognized by the CT antibodies is identical, at least in part, to that of the human Sd(a) blood group, a structure formed through enzymatic addition of N-acetylgalactosamine in beta 1,4-linkage to a sub-terminal galactose substituted with an alpha 2,3-linked N-acetylneuraminic acid residue. We have used a mammalian transient expression cloning approach to isolate a murine cDNA that determines expression of an oligosaccharide structure recognized by the CT antibodies as well as human anti-Sd(a) serum. The nucleotide sequence predicts a 510-amino acid type II transmembrane protein characteristic of other mammalian glycosyltransferases. Enzymatic characterization of the protein expressed by this cDNA demonstrates that it encodes a beta 1,4-N-acetylgalactosamine transferase activity that can add to the low molecular weight acceptor 3'-sialyl-N-acetyllactosamine, to form the nonreducing terminal tetrasaccharide Sd(a) blood group structure. This cDNA shares 51% nucleotide sequence identity with a cDNA encoding the human G(M2)/G(D2) synthase, particularly throughout the regions encoding their putative catalytic domains. Southern blot analysis demonstrates that these two cDNA's represent distinct loci in the murine genome. The CT-GalNAc transferase cDNA isolated here represents a tool with which to define the role(s) of lymphocyte cell surface CT determinants, and may facilitate the isolation of the human Sd(a) blood group locus through cross-hybridization approaches.	UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	SMITH, PL (corresponding author), UNIV MICHIGAN,HOWARD HUGHES MED INST,RM 3500 MSRB I,1150 W MED CTR DR,ANN ARBOR,MI 48109, USA.							ANDREW ME, 1984, J IMMUNOL, V132, P839; ARUFFO A, 1987, NATURE, V329, P840; BAENZIGER JU, 1981, ANAL BIOCHEM, V112, P357, DOI 10.1016/0003-2697(81)90305-5; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BRACIALE TJ, 1981, J EXP MED, V153, P910, DOI 10.1084/jem.153.4.910; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONZELMANN A, 1987, BIOCHEM J, V242, P817, DOI 10.1042/bj2420817; CONZELMANN A, 1988, J EXP MED, V167, P119, DOI 10.1084/jem.167.1.119; CONZELMANN A, 1984, J BIOL CHEM, V259, P2536; CONZELMANN A, 1984, J BIOL CHEM, V259, P2528; DALLOLIO F, 1987, BIOSCIENCE REP, V7, P925, DOI 10.1007/BF01122125; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DILWORTH SM, 1982, P NATL ACAD SCI-BIOL, V79, P1059, DOI 10.1073/pnas.79.4.1059; DONALD ASR, 1983, BIOCHEM BIOPH RES CO, V115, P625, DOI 10.1016/S0006-291X(83)80190-9; DONALD ASR, 1987, BIOCHEM SOC T, V15, P606, DOI 10.1042/bst0150606; ERNST LK, 1989, J BIOL CHEM, V264, P3436; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GILLARD BK, 1988, BIOCHEMISTRY-US, V27, P4601, DOI 10.1021/bi00413a003; Goldstein I., 1986, LECTINS, DOI DOI 10.1016/B978-0-12-449945-4.50007-5; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; GOODMAN TG, 1990, J IMMUNOL, V145, P2959; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P18253; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; HIRAIWA N, 1990, CANCER RES, V50, P5497; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; ITOH T, 1981, J BIOL CHEM, V256, P165; KIMURA A, 1979, J EXP MED, V149, P473, DOI 10.1084/jem.149.2.473; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LEFRANCOIS L, 1985, J IMMUNOL, V135, P374; LEFRANCOIS L, 1986, J IMMUNOL, V136, P1171; LEFRANCOIS L, 1985, NATURE, V314, P449, DOI 10.1038/314449a0; LEFRANCOIS L, 1985, J EXP MED, V162, P1275, DOI 10.1084/jem.162.4.1275; LEFRANCOIS L, 1987, J IMMUNOL, V138, P3375; Lowe J B, 1991, Semin Cell Biol, V2, P289; MACKVIE SI, 1967, VOX SANG, V13, P485; MALAGOLINI N, 1989, CANCER RES, V49, P6466; Maniatis T., 1982, MOL CLONING; MORTON JA, 1988, IMMUNOL INVEST, V17, P217, DOI 10.3109/08820138809052961; MUELLER BM, 1990, P NATL ACAD SCI USA, V87, P5702, DOI 10.1073/pnas.87.15.5702; MULLER WJ, 1984, MOL CELL BIOL, V4, P2406, DOI 10.1128/MCB.4.11.2406; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; ORR GA, 1981, J BIOL CHEM, V256, P761; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PILLER F, 1986, CARBOHYD RES, V149, P171, DOI 10.1016/S0008-6215(00)90376-8; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RENTON PH, 1967, VOX SANG, V13, P493, DOI 10.1111/j.1423-0410.1967.tb03796.x; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SERAFINICESSI F, 1988, ARCH BIOCHEM BIOPHYS, V266, P573, DOI 10.1016/0003-9861(88)90290-1; SERAFINICESSI F, 1986, CARBOHYD RES, V151, P65, DOI 10.1016/S0008-6215(00)90330-6; SERAFINICESSI F, 1983, BIOCHEM J, V215, P483, DOI 10.1042/bj2150483; SMITH PL, 1990, J BIOL CHEM, V265, P874; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SVENNERHOLM L, 1973, J BIOL CHEM, V248, P740; TAKEYA A, 1987, J BIOCHEM-TOKYO, V101, P251, DOI 10.1093/oxfordjournals.jbchem.a121898; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8	70	100	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15162	15171						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7515051				2022-12-25	WOS:A1994NP73800048
J	ALLEN, LAH; HOPE, L; RAETZ, CRH; THIERINGER, R				ALLEN, LAH; HOPE, L; RAETZ, CRH; THIERINGER, R			GENETIC-EVIDENCE SUPPORTING THE ROLE OF PEROXISOME ASSEMBLY FACTOR (PAF)-1 IN PEROXISOME BIOGENESIS - POLYMERASE CHAIN-REACTION DETECTION OF A MISSENSE MUTATION IN PAF-1 OF CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; ZELLWEGER SYNDROME; 3-KETOACYL-COA THIOLASE; HANSENULA-POLYMORPHA; DEFICIENT MUTANTS; SOMATIC-CELLS; ANIMAL-CELLS; PROTEIN; BIOSYNTHESIS; PLASMALOGENS	The peroxisome/plasmalogen-deficient Chinese hamster ovary (CHO) mutant cell line ZR-78.1 contains a mis-sense mutation in its cDNA-encoding peroxisome assembly factor-1 (PAF-1). Using a rapid polymerase chain reaction assay, we now demonstrate that the genome of ZR-78.1 contains only the mutant allele. When mutant ZR-78.1 is fused with wild-type karyoplasts, occasional ''negative nuclear hybrids'' are observed that lack peroxisomes (Allen, L.-A. H., Morand, O. H., and Raetz, C. R. H. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 7012-7016). Despite the fact that negative nuclear hybrids are tetraploid, they do not contain the wild-type PAF-1 gene, suggesting that a chromosome fragment bearing the wild-type copy of PAF-1 was lost. Negative nuclear hybrids reconstituted with wild-type cytoplasts do contain a wild-type PAF-1 gene, indicating that the cytoplasts somehow reintroduced the wild-type PAF-1 allele without increasing ploidy. These findings support the role of PAF-1 and exclude the hypothesis of an additional cytoplasmic requirement for reinitiation of peroxisome biogenesis in peroxisome-deficient CHO cells. The plasmalogen deficiency and some other biochemical properties of ZR-78.1 are partially corrected in 5-azacytidine-treated subclones. However, such pseudorevertants do not contain peroxisomes, consistent with the fact that there is no wild-type PAF-1 gene to reactivate by demethylation.	MERCK RES LABS,DEPT BIOCHEM,RAHWAY,NJ 07065; UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706	Merck & Company; University of Wisconsin System; University of Wisconsin Madison				Allen, Lee-Ann/0000-0001-8929-6968				ALLEN LAH, 1992, J BIOL CHEM, V267, P13191; ALLEN LAH, 1989, P NATL ACAD SCI USA, V86, P7012, DOI 10.1073/pnas.86.18.7012; BALFE A, 1990, PEDIATR RES, V27, P304, DOI 10.1203/00006450-199003000-00023; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORST P, 1989, BIOCHIM BIOPHYS ACTA, V1008, P1, DOI 10.1016/0167-4781(89)90163-2; BORST P, 1986, BIOCHIM BIOPHYS ACTA, V866, P179, DOI 10.1016/0167-4781(86)90044-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CREGG JM, 1990, YEAST, V6, P87, DOI 10.1002/yea.320060202; DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; DEMARS R, 1974, MUTAT RES, V24, P335, DOI 10.1016/0165-1218(74)90189-X; DIDION T, 1990, CURR GENET, V17, P113, DOI 10.1007/BF00312854; ELGERSMA Y, 1993, GENETICS, V135, P731; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; Fournier R. E. K., 1982, TECHNIQUES SOMATIC C, P309; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; GOLDFISCHER S, 1973, SCIENCE, V182, P62, DOI 10.1126/science.182.4107.62; GOULD SJ, 1992, YEAST, V8, P613, DOI 10.1002/yea.320080805; HAJRA AK, 1982, ANN NY ACAD SCI, V386, P170, DOI 10.1111/j.1749-6632.1982.tb21415.x; HALIASSOS A, 1989, NUCLEIC ACIDS RES, V17, P8093, DOI 10.1093/nar/17.20.8093; HARRIS M, 1984, SOMAT CELL MOLEC GEN, V10, P615, DOI 10.1007/BF01535227; HARRIS M, 1982, CELL, V29, P483, DOI 10.1016/0092-8674(82)90165-9; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; IMANAKA T, 1987, J CELL BIOL, V105, P2915, DOI 10.1083/jcb.105.6.2915; Jones PA, 1984, DNA METHYLATION BIOC, P165; KUNAU WH, 1993, BIOCHIMIE, V75, P209, DOI 10.1016/0300-9084(93)90079-8; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LITTLEFIELD JW, 1964, SCIENCE, V145, P709, DOI 10.1126/science.145.3633.709; LUNGU O, 1993, BIOTECHNIQUES, V14, P62; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; MORAND OH, 1988, J BIOL CHEM, V263, P11597; PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117; RAETZ CRH, 1982, P NATL ACAD SCI-BIOL, V79, P3223, DOI 10.1073/pnas.79.10.3223; RAPP S, 1993, EXP CELL RES, V205, P59, DOI 10.1006/excr.1993.1058; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; SCHLOSSMAN DM, 1976, J BIOL CHEM, V251, P5738; SHIMOZAWA N, 1992, J CLIN INVEST, V90, P1864, DOI 10.1172/JCI116063; SHIMOZAWA N, 1993, AM J HUM GENET, V52, P843; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; SIMINOVITCH L, 1976, CELL, V7, P1, DOI 10.1016/0092-8674(76)90249-X; SINGH I, 1983, J LIPID RES, V24, P662; SMALL GM, 1988, EMBO J, V7, P1167, DOI 10.1002/j.1460-2075.1988.tb02927.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPONG AP, 1993, J CELL BIOL, V123, P535, DOI 10.1083/jcb.123.3.535; STEGLICH C, 1985, SOMAT CELL MOLEC GEN, V11, P11, DOI 10.1007/BF01534730; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; THIERINGER R, 1993, J BIOL CHEM, V268, P12631; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANDERLEIJ I, 1992, J CELL BIOL, V119, P153, DOI 10.1083/jcb.119.1.153; VANHEUSDEN GPH, 1992, BIOCHIM BIOPHYS ACTA, V1126, P81, DOI 10.1016/0005-2760(92)90220-P; VOORNBROUWER T, 1993, BIOCHIM BIOPHYS ACTA, V1216, P325, DOI 10.1016/0167-4781(93)90166-B; WANDERS RJA, 1986, CLIN CHIM ACTA, V159, P1, DOI 10.1016/0009-8981(86)90160-9; WATERHAM HR, 1993, EMBO J, V12, P4785, DOI 10.1002/j.1460-2075.1993.tb06167.x; WENDLAND M, 1993, J CELL BIOL, V120, P675, DOI 10.1083/jcb.120.3.675; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; ZHANG JW, 1993, J CELL BIOL, V123, P1133, DOI 10.1083/jcb.123.5.1133; ZOELLER RA, 1986, P NATL ACAD SCI USA, V83, P5170, DOI 10.1073/pnas.83.14.5170; ZOELLER RA, 1989, J BIOL CHEM, V264, P21872; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590	66	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11734	11742						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512952				2022-12-25	WOS:A1994NG37700013
J	BAGRODIA, S; LAUDANO, AP; SHALLOWAY, D				BAGRODIA, S; LAUDANO, AP; SHALLOWAY, D			ACCESSIBILITY OF THE C-SRC SH2-DOMAIN FOR BINDING IS INCREASED DURING MITOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; HOMOLOGY REGION-2; SH3 DOMAINS; PP60C-SRC; ACTIVATION; TRANSFORMATION; PROTEINS; P60C-SRC; SITES	The Src homology 2 (SH2) region is a noncatalytic domain of Src-family tyrosine kinases and other proteins which participates in inter- and intramolecular interactions of tyrosine-phosphorylated proteins. A synthetic peptide modeled on the c-Src carboxyl terminus, which contains phosphotyrosine at position 527, binds recombinant SH2 and the SH2 domain of c-Src which lacks phosphotyrosine 527. Unphosphorylated peptide does not bind detectably. Thus, the phosphorylated peptide is a specific probe for investigating SH2 accessibility. Since Src and other tyrosine kinases may participate in regulating events in mitosis, we used the SH2-binding probe to test the prediction that decreased tyrosine 527 phosphorylation would lead to increased accessibility of the c-Src SH2-domain during mitosis. Probe binding to overexpressed chicken c-Src was enhanced at least 6-fold during mitosis, indicating that the c-Src SH2-domain is more accessible in this part of the cell cycle. This suggests that there may be mitosis-specific interactions of the c-Src SH2-domain with cellular proteins in vivo.	CORNELL UNIV, DEPT PATHOL, CANC BIOL LAB, ITHACA, NY 14853 USA; UNIV NEW HAMPSHIRE, DEPT BIOCHEM, DURHAM, NH 03825 USA	Cornell University; University System Of New Hampshire; University of New Hampshire	BAGRODIA, S (corresponding author), CORNELL UNIV, DEPT PATHOL, MOLEC & CELL BIOL LABS, BIOCHEM SECT, ITHACA, NY 14853 USA.				NCI NIH HHS [CA323178, CA56908-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R15CA056908] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHACKALAPARAMPI.I, 1994, IN PRESS ONCOGENE; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LIU XQ, 1993, ONCOGENE, V8, P1119; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SOUTHERN PJ, 1982, J MOL APPL GENET, V1, P326; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5	27	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10247	10251						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511598				2022-12-25	WOS:A1994NF01700015
J	KOBAYASHI, S; NISHIMURA, J; KANAIDE, H				KOBAYASHI, S; NISHIMURA, J; KANAIDE, H			CYTOSOLIC CA2+ TRANSIENTS ARE NOT REQUIRED FOR PLATELET-DERIVED GROWTH-FACTOR TO INDUCE CELL-CYCLE PROGRESSION OF VASCULAR SMOOTH-MUSCLE CELLS IN PRIMARY CULTURE - ACTIONS OF TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; PDGF RECEPTOR; INTRACELLULAR CALCIUM; PHOSPHORYLATION; ACTIVATION; MITOGENESIS; EXPRESSION; PROTEIN; TRANSFORMATION; STIMULATION	We investigated interrelations among changes in cytosolic Ca2+ concentrations ([Ca2+](i)), tyrosine phosphorylation, and the cell cycles of rat aorta smooth muscle cells in primary culture, as stimulated with platelet derived growth factor (PDGF). Changes in [Ca2+](i) were monitored using the microfluorometry of Fura-2. The phase of the cell cycle and the extent of tyrosine phosphorylation were examined by immunocytochemical analysis of monoclonal antibodies against cell cycle-specific nuclear antigens and against phosphotyrosine, respectively. Prior to the application of PDGF, the cell cycle was synchronized in the G(0) phase by serum deprivation for 24 h. In the presence of extracellular Ca2+, PDGF induced an initial transient (first component) and a subsequent lower steady-state (second component) elevation of [Ca2+](i). NiCl2 and the removal of extracellular Ca2+ inhibited the second, but not the first, component. The first component was inhibited by pretreatment with ryanodine. These results are compatible with the notion that the first and second components may be mediated mainly through the release of intracellular Ca2+ and the influx of extracelluIar Ca2+, respectively. After pretreatment with ryanodine and in the presence of NiCl2, PDGF also stimulated the entry of G(0) cells into G(1) phase, but there were no [Ca2+]i transients. Genistein, a tyrosine kinase blocker, inhibited tyrosine phosphorylation induced by PDGF and blocked the first, but not the second, component of [Ca2+](i) elevation induced by PDGF. However, genistein did not inhibit the release of intracellular Ca2+ induced by angiotensin II or by caffeine. Genistein prevented G(0) cells from entering the G(1) phase, as induced by PDGF, but this was not the case when serum was reapplied to the growth medium. Similar results were obtained with another tyrosine kinase blocker, tyrphostin. These data suggest that in vascular smooth muscle cells: 1) an increase in [Ca2+](i) is not required for competent (G(0) to G(1)) cell proliferation induced by PDGF; and 2) tyrosine kinase plays an important role the release of intracellular Ca2+ and in cell proliferation, as induced by PDGF.	KYUSHU UNIV,FAC MED,ANGIOCARDIOL RES INST,DIV MOLEC CARDIOL,FUKUOKA 812,JAPAN	Kyushu University								AKAIKE N, 1989, J PHYSIOL-LONDON, V416, P141, DOI 10.1113/jphysiol.1989.sp017754; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BLOCK LH, 1989, P NATL ACAD SCI USA, V86, P2388, DOI 10.1073/pnas.86.7.2388; DILIBERTO PA, 1990, J CELL BIOCHEM, V44, P39, DOI 10.1002/jcb.240440104; EK B, 1982, NATURE, V295, P419, DOI 10.1038/295419a0; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HOSHI M, 1988, J BIOL CHEM, V263, P5396; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KANAIDE H, 1988, CIRC RES, V63, P16, DOI 10.1161/01.RES.63.1.16; KANAIDE H, 1990, ASIA PAC J PHARMACOL, V5, P177; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KOBAYASHI S, 1985, SCIENCE, V229, P553, DOI 10.1126/science.3927484; KOBAYASHI S, 1986, J BIOL CHEM, V261, P5709; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LANDBERG G, 1990, EXP CELL RES, V187, P111, DOI 10.1016/0014-4827(90)90124-S; LEWIS RS, 1988, SCIENCE, V239, P771, DOI 10.1126/science.2448877; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MEISENHELDER J, 1989, CELL, V57, P1108; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NISHIMURA J, 1992, BIOCHEM BIOPH RES CO, V188, P1198, DOI 10.1016/0006-291X(92)91358-W; OLAH Z, 1990, P AM ASSOC CANC RES, V31, pA76; QU Z, 1990, NEURON, V2, P367; QUINONES MA, 1991, J BIOL CHEM, V266, P14055; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; TUCKER RW, 1989, J CELL BIOCHEM, V39, P139, DOI 10.1002/jcb.240390206; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YAMAMOTO H, 1983, BRIT J EXP PATHOL, V64, P156; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; YUKI H, 1971, GANN, V62, P199	34	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9011	9018						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510699				2022-12-25	WOS:A1994NB41100060
J	BRADBURY, NA; COHN, JA; VENGLARIK, CJ; BRIDGES, RJ				BRADBURY, NA; COHN, JA; VENGLARIK, CJ; BRIDGES, RJ			BIOCHEMICAL AND BIOPHYSICAL IDENTIFICATION OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CHLORIDE CHANNELS AS COMPONENTS OF ENDOCYTIC CLATHRIN-COATED VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; EPITHELIAL-CELL LINE; PLASMA-MEMBRANE; ELECTROLYTE TRANSPORT; CFTR; RECEPTOR; BINDING; PHOSPHORYLATION; GENE; INTERNALIZATION	Cystic fibrosis results from mutations in the gene encoding the CFTR Cl- channel. Although CFTR occurs as an integral component of the plasma membrane, recent studies implicate CFTR in endocytic recycling and suggest that the protein may also exist in intracellular vesicular compartments. To test this, we analyzed CFTR in clathrin-coated vesicles (CCV) purified from cells constitutively expressing CFTR at high levels. CFTR immunoreactivity was detected in CCV by immunoblot and was identified as CFTR based on labeling of immunoprecipitates with protein kinase A and by tryptic phosphopeptide mapping. Fusion of uncoated CCV with planar lipid bilayers resulted in the incorporation of kinase- and ATP-activated Cl- channel activity (7.8 pS at 20 degrees C; 11.9 pS at 37 degrees C), with a linear current-voltage relation under symmetrical conditions. Thus, functional CFTR occurs in CCV. Moreover, CFTR interacts with the plasma membrane specific adaptor complex during endocytosis through clathrin-coated pits. Therefore, the abundance of CFTR in the plasma membrane may be regulated by exocytic insertion and endocytic recycling, and these processes may provide an augmentation to protein kinase A activation as a mechanism for regulating CFTR Cl channels in the plasma membrane.	UNIV ALABAMA, GREGORY FLEMING CYSTIC FIBROSIS RES CTR, BIRMINGHAM, AL 35294 USA; DUKE UNIV, DEPT MED, DURHAM, NC 27710 USA; VET ADM MED CTR, DURHAM, NC 27710 USA	University of Alabama System; University of Alabama Birmingham; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	BRADBURY, NA (corresponding author), UNIV ALABAMA, DEPT PHYSIOL & BIOPHYS, UAB STN, BIRMINGHAM, AL 35294 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040701, P50DK042017, R01DK045970, R01DK040701] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45970, DK42017, DK40701] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLE S, 1989, J BIOL CHEM, V264, P20089; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1992, AM J PHYSIOL, V262, pC251, DOI 10.1152/ajpcell.1992.262.1.C251; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; BRADBURY NA, 1992, BIOCHEM BIOPH RES CO, V184, P1173, DOI 10.1016/S0006-291X(05)80006-3; BRADBURY NA, 1992, AM J PHYSIOL, V262, pC752, DOI 10.1152/ajpcell.1992.262.3.C752; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIDGES RJ, 1989, AM J PHYSIOL, V256, pC902, DOI 10.1152/ajpcell.1989.256.4.C902; BUANES T, 1988, GASTROENTEROLOGY, V95, P417, DOI 10.1016/0016-5085(88)90499-4; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHANG D, 1988, COMPUT BIOL MED, V18, P351, DOI 10.1016/0010-4825(88)90022-4; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COHN JA, 1992, P NATL ACAD SCI USA, V89, P2340, DOI 10.1073/pnas.89.6.2340; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COURTOY PJ, 1991, ENDOCYTOSIS, P163; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; FIEDLER MA, 1992, AM J PHYSIOL, V262, pL779, DOI 10.1152/ajplung.1992.262.6.L779; FORGAC M, 1983, P NATL ACAD SCI-BIOL, V80, P1300, DOI 10.1073/pnas.80.5.1300; FULLER CM, 1994, IN PRESS AM J PHYSL; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; HAWS C, 1992, AM J PHYSIOL, V263, pL692, DOI 10.1152/ajplung.1992.263.6.L692; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEEN JH, 1989, BIOCHEM BIOPH RES CO, V158, P17, DOI 10.1016/S0006-291X(89)80170-6; KEMPSON SA, 1990, AM J PHYSIOL, V258, pF1336, DOI 10.1152/ajprenal.1990.258.5.F1336; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; MARINO CR, 1993, CLIN RES, V41, pA219; MULBERG AE, 1991, J BIOL CHEM, V266, P20590; PEARSE BMF, 1985, EMBO J, V4, P2457, DOI 10.1002/j.1460-2075.1985.tb03956.x; PEARSE BMF, 1982, P NATL ACAD SCI-BIOL, V79, P451, DOI 10.1073/pnas.79.2.451; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; PUCHELLE E, 1992, AM J RESP CELL MOL, V7, P485, DOI 10.1165/ajrcmb/7.5.485; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROMMENS JM, 1988, SCIENCE, V245, P1066; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SINGH AK, 1991, AM J PHYSIOL, V260, pC51; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; STETSON DL, 1983, AM J PHYSIOL, V245, pC113, DOI 10.1152/ajpcell.1983.245.1.C113; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	54	105	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8296	8302						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510684				2022-12-25	WOS:A1994NB40900070
J	DILDA, P; LELIEVRE, LG				DILDA, P; LELIEVRE, LG			FUNCTIONAL-CHARACTERIZATION OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) IN APICAL MEMBRANES PURIFIED FROM BOVINE TRACHEAL EPITHELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CHLORIDE CHANNEL; RAT-HEART; R-DOMAIN; VESICLES; TRANSPORT; GENE; CAMP; RECONSTITUTION; INHIBITION	Inside-out apical membrane vesicles were isolated from bovine tracheal epithelium. They were enriched 13- and 18-fold in two apical membrane markers, alkaline phosphatase and gamma-glutamyltransferase, respectively, and presented a low level of contamination by basolateral and intracellular membranes. These apical membrane vesicles of homogeneous inside-out orientation were used to measure Cl-36- influx. The Cl-36- influx was found to be (i) voltage insensitive (ii) diphenylcarboxylic acid-insensitive, and (iii) from 55 to 100% activated by cAMP-dependent protein kinase according to initial rates and accumulation capacities. This rapid and ATP-dependent activation was associated with phosphorylation of a 170-180-kDa protein but was not observed with a nonhydrolyzable nucleotide like adenosine 5'-O-(3-thiotriphosphate). Immunodetection experiments showed that the mature form of bovine cystic fibrosis transmembrane conductance regulator (CFTR) was only present in the apical membranes. As compared with the previously described characteristics of CFTR, the Cl-36- uptakes detected here are the in vitro manifestation of the functional form of bovine CFTR located at the apical level in these tracheal epithelial cells. Inside-out apical membrane vesicles, with freely accessible cytoplasmic sides and functional CFTR, offer a new model system to study CFTR.	UNIV PARIS 07,PHARMACOL TRANSPORTS ION MEMBRANAIRES LAB,F-75251 PARIS 05,FRANCE	UDICE-French Research Universities; Universite Paris Cite								ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DECHECCHI MC, 1993, J BIOL CHEM, V268, P11321; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DIAMOND G, 1991, J BIOL CHEM, V266, P22761; DISTEFANO A, 1985, PFLUG ARCH EUR J PHY, V405, pS95, DOI 10.1007/BF00581787; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DUBINSKY WP, 1986, AM J PHYSIOL, V251, pC713, DOI 10.1152/ajpcell.1986.251.5.C713; EMMER E, 1989, J MEMBRANE BIOL, V108, P207, DOI 10.1007/BF01871735; FONG P, 1988, J MEMBRANE BIOL, V104, P233, DOI 10.1007/BF01872325; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; GARTY H, 1983, J BIOL CHEM, V258, P3094; GOLSTEIN P, 1992, AM J PHYSIOL, V263, pC590, DOI 10.1152/ajpcell.1992.263.3.C590; HANRAHAN JW, 1990, J MEMBRANE BIOL, V116, P65, DOI 10.1007/BF01871673; HWANG TC, 1993, 7TH ANN N AM CYST FI; JONES LR, 1977, J BIOL CHEM, V252, P3315; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEENOY MY, 1990, DIABETES RES CLIN EX, V14, P139; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY DW, 1987, J GEN PHYSIOL, V90, P779, DOI 10.1085/jgp.90.6.779; LANGRIDGESMITH JE, 1983, BIOCHIM BIOPHYS ACTA, V731, P318, DOI 10.1016/0005-2736(83)90024-X; LANGRIDGESMITH JE, 1984, BIOCHIM BIOPHYS ACTA, V777, P84, DOI 10.1016/0005-2736(84)90499-1; LELIEVRE LG, 1986, AM J PHYSIOL, V250, pH923, DOI 10.1152/ajpheart.1986.250.6.H923; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANSIER P, 1983, J BIOL CHEM, V258, P6628; ORLOWSKI M, 1963, BIOCHIM BIOPHYS ACTA, V73, P679; PLACCHI P, 1991, J MEMBRANE BIOL, V119, P25, DOI 10.1007/BF01868537; PUCHELLE E, 1992, AM J RESP CELL MOL, V7, P485, DOI 10.1165/ajrcmb/7.5.485; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; REEVES WB, 1989, J MEMBRANE BIOL, V109, P65, DOI 10.1007/BF01870791; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1066; SHEN BQ, 1991, AM J PHYSIOL, V261, pL102, DOI 10.1152/ajplung.1991.261.2.L102; THOMAS R, 1979, EUR J PHARMACOL, V53, P227, DOI 10.1016/0014-2999(79)90128-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WIDDICOMBE JH, 1985, P NATL ACAD SCI USA, V82, P6167, DOI 10.1073/pnas.82.18.6167	48	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7801	7806						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7510290				2022-12-25	WOS:A1994NA03200117
J	JOHNSON, GD; HERSH, LB				JOHNSON, GD; HERSH, LB			EXPRESSION OF MEPRIN SUBUNIT PRECURSORS - MEMBRANE ANCHORING THROUGH THE BETA-SUBUNIT AND MECHANISM OF ZYMOGEN ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY MICROVILLAR MEMBRANE; MOUSE KIDNEY; IMMUNOHISTOCHEMICAL LOCALIZATION; RAT-KIDNEY; PROTEINS; ENDOPEPTIDASE-2; CLONING; METALLOENDOPEPTIDASES; PURIFICATION; ASTACIN	The biosynthesis of the membrane-bound metalloendopeptidase meprin was studied after the introduction of cDNAs encoding the rat meprin alpha and beta subunits into human 293 cells. When expressed individually the meprin a subunit was found to be primarily secreted into the culture medium, while the beta subunit was determined to be an integral membrane protein, Coexpression of the alpha and beta subunits results in the localization of both subunits to the plasma membrane. In this case the alpha subunit is specifically released from the cell surface by dithiothreitol, indicating the a subunit is associated with the membrane via disulfide bond(s) to the beta subunit. Meprin expressed in 293 cells is similar to the rat kidney enzyme in that it forms disulfide-linked dimers and has a similar pattern of glycosylation. However, the expressed protein displayed no detectable peptidase activity against four meprin substrates. Processing of the a subunit was followed after the introduction of sequences coding for the human c-myc peptide epitope EQKLISEEDL into its cDNA in the region of its prosequence and at the COOH terminus. Detection of the resulting proteins using a monoclonal an tibody specific for the c-myc epitope indicates the a subunit is processed at its COOH terminus but retains the prosequence which is absent from the enzyme purified from rat kidney. Limited trypsin digestion of meprin precursors expressed in 293 cells results in both the activation of the enzyme and the removal of the prosequence. This result supports the hypothesis of Bode et al. (Bode W, Gomis-Ruth, F.X., Huber, R., Zwilling, R., and Stocker, W (1992) Nature 358, 164-167) that meprin and other astacin family proteases require removal of NH2-terminal prosequences at the junction of the astacin protease domain for zymogen activation. Trypsin-activated meprin was assayed with the protein substrate azocasein and three synthetic peptide substrates. The membrane-bound beta subunit was found to be more active than the secreted a subunit against azocasein but much less active toward the synthetic peptide substrates.	UNIV KENTUCKY,CHANDLER MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536	University of Kentucky					NIDA NIH HHS [DA02243] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002243] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARNES K, 1989, BIOCHEM J, V264, P335, DOI 10.1042/bj2640335; BEYNON RJ, 1981, BIOCHEM J, V199, P591, DOI 10.1042/bj1990591; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BUTLER PE, 1988, J BIOL CHEM, V263, P13419; BUTLER PE, 1987, BIOCHEM J, V241, P229, DOI 10.1042/bj2410229; CORBEIL D, 1992, FEBS LETT, V309, P203, DOI 10.1016/0014-5793(92)81095-4; CORBEIL D, 1993, FEBS LETT, V335, P361, DOI 10.1016/0014-5793(93)80420-Y; CRAIG SS, 1991, J HISTOCHEM CYTOCHEM, V39, P123, DOI 10.1177/39.1.1701182; DUMERMUTH E, 1993, FEBS LETT, V335, P367, DOI 10.1016/0014-5793(93)80421-P; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GORBEA CM, 1993, J BIOL CHEM, V268, P21035; GORBEA CM, 1991, ARCH BIOCHEM BIOPHYS, V290, P549, DOI 10.1016/0003-9861(91)90580-C; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUNBERG J, 1993, FEBS LETT, V335, P376, DOI 10.1016/0014-5793(93)80422-Q; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JOHNSON GD, 1992, J BIOL CHEM, V267, P13505; KENNY AJ, 1987, BIOCHEM J, V245, P515, DOI 10.1042/bj2450515; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17350; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPAGE T, 1992, DEVELOPMENT, V114, P147; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; SANGER F, 1977, P NATL ACAD SCI USA, V76, P4350; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STERCHI EE, 1988, ARCH BIOCHEM BIOPHYS, V265, P105, DOI 10.1016/0003-9861(88)90376-1; STOCKER W, 1993, EUR J BIOCHEM, V214, P215, DOI 10.1111/j.1432-1033.1993.tb17915.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	31	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7682	7688						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7510289				2022-12-25	WOS:A1994NA03200101
J	YONEZAWA, K; ANDO, A; KABURAGI, Y; YAMAMOTOHONDA, R; KITAMURA, T; HARA, K; NAKAFUKU, M; OKABAYASHI, Y; KADOWAKI, T; KAZIRO, Y; KASUGA, M				YONEZAWA, K; ANDO, A; KABURAGI, Y; YAMAMOTOHONDA, R; KITAMURA, T; HARA, K; NAKAFUKU, M; OKABAYASHI, Y; KADOWAKI, T; KAZIRO, Y; KASUGA, M			SIGNAL-TRANSDUCTION PATHWAYS FROM INSULIN-RECEPTORS TO RAS - ANALYSIS BY MUTANT INSULIN-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; STIMULATES TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; INTACT-CELLS; SH3 DOMAINS; FACTOR-I; PROTEIN; ACTIVATION; SUBSTRATE	We have examined the involvement of insulin receptor (IR) substrate-1 (IRS-1) and/or Shc in the upstream of Res activation in insulin signaling using Chinese hamster ovary (CHO) cell lines overexpressing wild-type (CHO-IR cells) or mutant insulin receptors. In CHO-IR cells, insulin rapidly phosphorylated IRS-1 and Shc at tyrosine residues and stimulated the formation of the active GTP-bound Ras (Ras GTP). In contrast, a CHO cell line overexpressing the kinase-negative mutant insulin receptor substituting Arg(1018) for Lys(1018) was unable to tyrosine phosphorylate IRS-1 and Shc and failed to activate Ras in response to insulin. A CHO cell line overexpressing the mutant insulin receptor, substituting Ala(960) for Tyr(960) and which was known to exhibit impaired tyrosine phosphorylation of IRS-1 and biological effects evoked by insulin, showed severely impaired insulin-dependent tyrosine phosphorylation of She and moderately impaired activation of Ras. Another cell line overexpressing the mutant insulin receptor, lacking 82 amino acids of the C terminus of beta-subunit and which was recently reported to retain normal insulin depend ent tyrosine phosphorylation of IRS-1, showed slightly impaired Ras activation at 10(-7) M insulin with severely reduced tyrosine phosphorylation of Shc protein. Furthermore, insulin did not induce the association of tyrosine-phosphorylated IRS 1 and Shc in CHO-IR cells. These results suggest that Shc and IRS-1 lie in the separate signaling pathways and that the tyrosine phos phorylation of IRS-1 with or without some low level of Shc phosphorylation may be enough to stimulate the submaximal accumulation of Ras-GTP complex and may need synergistically the higher level of tyrosine phosphorylation of Shc to induce the full activation of Ras in insulin signaling.	KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE,HYOGO 650,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO,TOKYO 113,JAPAN; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304	Kobe University; University of Tokyo; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Kitamura, Toshio/AAA-2071-2021; Nakafuku, Masato/J-3068-2013	Nakafuku, Masato/0000-0001-7783-9005				ANDO A, 1992, J BIOL CHEM, V267, P12788; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECKER AB, 1990, ANNU REV MED, V41, P99; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EAGAN SE, 1993, NATURE, V363, P45; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; IZUMI T, 1987, J BIOL CHEM, V262, P1282; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOSHIO O, 1989, FEBS LETT, V254, P22, DOI 10.1016/0014-5793(89)81001-4; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEWIS RE, 1990, J BIOL CHEM, V265, P947; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P481; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCCLADE J, 1992, P NATL ACAD SCI USA, V89, P8869; MYERS MG, 1991, J BIOL CHEM, V266, P10616; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1992, J BIOL CHEM, V267, P24149; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TASHIROHASHIMOTO Y, 1989, J BIOL CHEM, V264, P6879; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOBE K, 1993, J BIOL CHEM, V268, P11167; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAMOTOHONDA R, 1993, J BIOL CHEM, V268, P16859; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	61	122	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4634	4640						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508445				2022-12-25	WOS:A1994MW98900108
J	KAMATA, T; TAKADA, Y				KAMATA, T; TAKADA, Y			DIRECT BINDING OF COLLAGEN TO THE I-DOMAIN OF INTEGRIN ALPHA-2-BETA-1 (VLA-2, CD49B/CD29) IN A DIVALENT CATION-INDEPENDENT MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION GLYCOPROTEIN; COMPLEMENT RECEPTOR TYPE-3; AMINO-ACID SEQUENCE; VONWILLEBRAND-FACTOR; ALPHA-SUBUNIT; MONOCLONAL-ANTIBODY; CELL-ADHESION; VI COLLAGEN; FACTOR-B; FIBRONECTIN	Integrin alpha 2 beta 1 is a major divalent cation dependent receptor for collagen. Here, we show that the recombinant inserted/interactive domain (I domain) of alpha 2 specifically interacts with collagen, indicating the I domain contains all the components necessary for collagen binding. Evidence was obtained that divalent cations are not required for collagen binding to the I domain fragment, indicating that divalent cations are not involved in the actual binding to collagen but probably in the regulation of the binding. We identified Thr-221 within the previously identified putative ligand binding region as a residue critical for collagen binding to both alpha beta 1 and the I domain fragment. Thr-221 may be involved in the actual collagen binding and recognition.	Scripps Res Inst, DEPT VASC BIOL, VB-4, LA JOLLA, CA 92037 USA	Scripps Research Institute				takada, yoshikazu/0000-0001-5481-9589	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047157] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47157] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGRAVES WS, 1987, P NATL ACAD SCI USA, V84, P464, DOI 10.1073/pnas.84.2.464; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; BENTLEY DR, 1986, BIOCHEM J, V239, P339, DOI 10.1042/bj2390339; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BERGELSON JM, 1993, J CLIN INVEST, V92, P232, DOI 10.1172/JCI116555; BOCKENSTEDT P, 1986, J CLIN INVEST, V78, P551, DOI 10.1172/JCI112608; BONALDO P, 1989, J BIOL CHEM, V264, P5575; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHEN FA, 1991, J EXP MED, V173, P1111, DOI 10.1084/jem.173.5.1111; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; COLLER BS, 1989, BLOOD, V74, P182; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; GINSBERG MH, 1983, J CLIN INVEST, V71, P619, DOI 10.1172/JCI110808; GOLDMAN R, 1992, EUR J IMMUNOL, V22, P1109, DOI 10.1002/eji.1830220502; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOLE JE, 1984, J BIOL CHEM, V259, P3407; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; OCONNELL PJ, 1991, IMMUNOL CELL BIOL, V69, P103, DOI 10.1038/icb.1991.16; PISCHEL KD, 1987, J IMMUNOL, V138, P226; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANTORO SA, 1988, BIOCHEM BIOPH RES CO, V153, P217, DOI 10.1016/S0006-291X(88)81211-7; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; TAKADA Y, 1988, J CELL BIOCHEM, V37, P385, DOI 10.1002/jcb.240370406; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TENCHINI ML, 1993, CELL ADHES COMMUN, V1, P55, DOI 10.3109/15419069309095681; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; YAMADA KM, 1990, CANCER RES, V50, P4485; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YAMADA KM, 1988, FIBRONECTIN, P47	48	151	157	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26006	26010						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523399				2022-12-25	WOS:A1994PQ93000014
J	CHEN, PF; TSAI, AL; WU, KK				CHEN, PF; TSAI, AL; WU, KK			CYSTEINE-184 OF ENDOTHELIAL NITRIC-OXIDE SYNTHASE IS INVOLVED IN HEME COORDINATION AND CATALYTIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; EXPRESSION; CELLS; ENZYME; BRAIN; IDENTIFICATION; PURIFICATION; HEMOPROTEIN; CALMODULIN	Nitric oxide synthase catalyzes the formation of an important messenger molecule, nitric oxide (NO). It is a P450-type hemoprotein, containing a cysteine thiolate as its proximal heme ligand, but the exact cysteine residue involved in heme coordination has not been identified. To locate this specific cysteine, we altered three potential cysteine residues (Cys-99, Cys-184, and Cys-441) to alanine residues in human endothelial nitric oxide synthase (eNOS) by oligonucleotide directed mutagenesis and expressed the wild-type and mutant eNOSs in COS-1 and the baculovirus expression system. Mutation of Cys-235 to alanine was included to serve as a control. Mutation of Cys-184 resulted in a complete loss of NOS catalytic activity and abrogation of the formation of carbon monoxide (CO)-heme ferrous complex, which was detected on CO difference spectra as a distinct peak centered on 444-446 nm, without reduction in the quantity of eNOS protein. Mutation of Cys-99 also resulted in a loss of catalytic activity but did not eliminate the 444-446 nn peak, C441A and C235A mutants displayed considerable NOS activity and retained the CO-heme peak on CO-ferrous difference spectra. These results indicate that the cysteine 184 of human eNOS is most likely the proximal heme ligand.	UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV HEMATOL,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,VASC BIOL RES CTR,HOUSTON,TX 77030	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston			Wu, Kenneth Kun-Yu/B-1070-2010		NHLBI NIH HHS [HL-50675, HL-35387] Funding Source: Medline; NINDS NIH HHS [NS-23327] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035387, R01HL050675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ASSEFFA A, 1989, ARCH BIOCHEM BIOPHYS, V274, P481, DOI 10.1016/0003-9861(89)90461-X; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CULLEN BR, 1987, METHOD ENZYMOL, V152, P8125; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Griffin B. W., 1979, PORPHYRINS, V7, P333; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; PENG C, 1991, J VIROL, V65, P2751, DOI 10.1128/JVI.65.5.2751-2756.1991; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; WANG JL, 1993, J BIOL CHEM, V268, P22255; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WU KK, 1988, J BIOL CHEM, V263, P19043; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	32	111	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25062	25066						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7523378				2022-12-25	WOS:A1994PQ49000081
J	TAUCHI, T; FENG, GS; MARSHALL, MS; SHEN, R; MANTEL, C; PAWSON, T; BROXMEYER, HE				TAUCHI, T; FENG, GS; MARSHALL, MS; SHEN, R; MANTEL, C; PAWSON, T; BROXMEYER, HE			THE UBIQUITOUSLY EXPRESSED SYP PHOSPHATASE INTERACTS WITH C-KIT AND GRB2 IN HEMATOPOIETIC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SIGNAL TRANSDUCTION; SH3 DOMAINS; NUCLEOTIDE EXCHANGE; KINASE-ACTIVITY; RAS; RECEPTOR; PHOSPHORYLATION; ASSOCIATION	The c-kit proto oncogene encodes a transmembrane tyrosine kinase receptor, which is important for the normal development of hematopoietic cells, melanoblasts, and germ cells. Autophosphorylation of c-kit receptor on tyrosine creates binding sites for cellular src homology 2 (SH2)-containing signaling molecules. The discovery of phosphotyrosine phosphatases that contain SH2 domains suggests roles for these molecules in growth factor signaling pathways. We found that Syp, a phosphotyrosine phosphatase widely expressed in all the tissues in mammals, associates with c-kit receptor after activation with its ligand, steel factor, in the factor-dependent cell line, M07e. Both NH2-terminal and COOH-terminal SH2 domains of Syp, made as glutathione S-transferase fusion proteins, were able to bind to the activated c-kit receptor in vitro. Furthermore, Syp became marginally phosphorylated on tyrosine upon c-Kit receptor activation, and tyrosine-phosphorylated Syp was found to be complexed with Grb2 in steel factor-stimulated M07e cells. Direct binding between Syp and Grb2 was also observed in vitro. Last, Ras and Raf interacts in vitro as a result of steel factor-stimulated Ras activation. These results suggest that Syp may be an important signaling component downstream of the c-kit receptor and involved in activation of the Ras signaling pathway in hematopoietic cells.	INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MED HEMATOL ONCOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, INDIANAPOLIS, IN 46202 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ON, CANADA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Pawson, Tony J/E-4578-2013		NCI NIH HHS [R37 CA36464] Funding Source: Medline; NHLBI NIH HHS [R01 HL49202, R01 HL46549] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA036464] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049202, R01HL046549] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CULTER RL, 1993, J BIOL CHEM, V268, P21463; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HENDRIE PC, 1991, EXP HEMATOL, V19, P1031; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LENER NB, 1991, BLOOD, V77, P1876; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PAWSON T, 1992, NATURE, V356, P285, DOI 10.1038/356285a0; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	144	146	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25206	25211						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7523381				2022-12-25	WOS:A1994PQ49000101
J	NAM, KB; HUDSON, RHE; CHAPMAN, KB; GANESHAN, K; DAMHA, MJ; BOEKE, JD				NAM, KB; HUDSON, RHE; CHAPMAN, KB; GANESHAN, K; DAMHA, MJ; BOEKE, JD			YEAST LARIAT DEBRANCHING ENZYME - SUBSTRATE AND SEQUENCE SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER RNA; SINGLE-STRANDED-DNA; GROUP-II INTRON; BRANCHED RNA; STIGMATELLA-AURANTIACA; MYXOCOCCUS-XANTHUS; ESCHERICHIA-COLI; 5' END; PURIFICATION; MSDNA	Yeast RNA lariat debranching enzyme has been purified to near homogeneity using a bacterial overproducer of the enzyme. The enzyme is capable of digesting a variety of branched nucleic acid substrates, including group II intron lariats, multicopy single-stranded DNAs (msDNAs), and a variety of synthetic branched RNAs. A trinucleotide release assay using radiolabeled msDNA substrates was developed and used to determine the basic biochemical parameters for the enzyme. The debranching enzyme shows a strong preference for purines at the 2'-position in both msDNA and synthetic branched RNA substrates, in accord with the structure of its native substrate, which always has a 2'-G residue. The use of small synthetic branched RNA substrates will allow systematic mechanistic and structural studies of this unique enzyme.	MCGILL UNIV,DEPT CHEM,MONTREAL H3A 2B2,PQ,CANADA; JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205; UNIV TORONTO,DEPT CHEM,TORONTO M5S 1A4,ON,CANADA	McGill University; Johns Hopkins University; University of Toronto			Hudson, Robert/L-6325-2015; Damha, Masad J/B-5522-2013		NCI NIH HHS [ET32 CA 09139] Funding Source: Medline; NIGMS NIH HHS [GM36481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENAS J, 1987, J BIOL CHEM, V262, P4274; BOEKE JD, 1991, MOL CELLULAR BIOL YE, P193; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; DAMHA MJ, 1992, NUCLEIC ACIDS RES, V20, P6565, DOI 10.1093/nar/20.24.6565; DAMHA MJ, 1988, J ORG CHEM, V53, P3710, DOI 10.1021/jo00251a010; DHUNDALE A, 1987, CELL, V51, P1105, DOI 10.1016/0092-8674(87)90596-4; DOMDEY H, 1984, CELL, V39, P611, DOI 10.1016/0092-8674(84)90468-9; FURUICHI T, 1987, CELL, V48, P55, DOI 10.1016/0092-8674(87)90355-2; FURUICHI T, 1987, CELL, V48, P47, DOI 10.1016/0092-8674(87)90354-0; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HARTMUTH K, 1988, MOL CELL BIOL, V8, P2011, DOI 10.1128/MCB.8.5.2011; HSU MY, 1992, J BIOL CHEM, V267, P13823; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JACQUIER A, 1986, P NATL ACAD SCI USA, V83, P5835, DOI 10.1073/pnas.83.16.5835; KRAMER A, 1985, EMBO J, V4, P3571, DOI 10.1002/j.1460-2075.1985.tb04119.x; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamond AI, 1991, CURR OPIN CELL BIOL, V3, P493, DOI 10.1016/0955-0674(91)90078-D; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PARKER R, 1985, CELL, V41, P107, DOI 10.1016/0092-8674(85)90065-0; PEEBLES CL, 1993, J BIOL CHEM, V268, P11929; RUSKIN B, 1990, METHOD ENZYMOL, V181, P180; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUTTON RE, 1988, EMBO J, V7, P1431, DOI 10.1002/j.1460-2075.1988.tb02960.x; WALLACE JC, 1983, P NATL ACAD SCI-BIOL, V80, P950, DOI 10.1073/pnas.80.4.950; YEE T, 1984, CELL, V38, P203, DOI 10.1016/0092-8674(84)90541-5	33	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20613	20621						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519612				2022-12-25	WOS:A1994PB31700063
J	LUKASHEV, ME; SHEPPARD, D; PYTELA, R				LUKASHEV, ME; SHEPPARD, D; PYTELA, R			DISRUPTION OF INTEGRIN FUNCTION AND INDUCTION OF TYROSINE PHOSPHORYLATION BY THE AUTONOMOUSLY EXPRESSED BETA(1) INTEGRIN CYTOPLASMIC DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FIBRONECTIN RECEPTOR; CELL-ADHESION; EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; PROTEIN; KINASE; SUBUNIT; DIFFERENTIATION; INVITRO; GENE	The cytoplasmic domains of integrin beta subunits are essential for the function of integrins in cell adhesion and signaling. A chimera combining the transmembrane and cytoplasmic domains of the beta(1) integrin subunit with an irrelevant extracellular domain derived from L3T4 (murine CD4) was tested for its ability to interfere with integrin function. Expression of this construct in cultured human embryonic kidney cells under the control of the inducible metallothionein promoter resulted in cell rounding and detachment, and blocked cell adhesion mediated by the beta(1) and alpha(v) beta(5) integrins. Expression of the beta(1) chimera at basal levels interfered with the tyrosine phosphorylation of a 125-kDa protein induced by antibody-induced clustering of integrins. Induced expression of the chimera resulted in sustained tyrosine phosphorylation of this protein, which could be enhanced by clustering of the chimera but was insensitive to clustering of integrins. These results demonstrate that the autonomously expressed beta(1) integrin cytoplasmic domain can act as a trans-dominant inhibitor of integrin function, presumably via competitive interactions with cytoplasmic components that are required for integrin-mediated cell adhesion and tyrosine phosphorylation.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	LUKASHEV, ME (corresponding author), UNIV CALIF SAN FRANCISCO,CTR LUNG BIOL,DEPT MED,BOX 0854,SAN FRANCISCO,CA 94143, USA.				NCI NIH HHS [CA53259] Funding Source: Medline; NHLBI NIH HHS [HL191551, HL/A133259] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; DITTEL BN, 1993, BLOOD, V81, P919; GEIGER B, 1992, J CELL SCI, V103, P943; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; HUBBARD BD, 1979, J CELL BIOL, V80, P166, DOI 10.1083/jcb.80.1.166; HYNES RO, 1992, VRLL, V69, P11; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG L, 1992, TRENDS PHARMACOL SCI, V13, P93, DOI 10.1016/0165-6147(92)90034-4; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; Otey C. A., 1993, Molecular Biology of the Cell, V4, p347A; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; STEPHENS LE, 1993, J CELL BIOL, V123, P1607, DOI 10.1083/jcb.123.6.1607; TOMASELLI KJ, 1988, J CELL BIOL, V107, P1241, DOI 10.1083/jcb.107.3.1241; WEINACKER A, 1994, J BIOL CHEM, V269, P6940	26	147	150	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18311	18314						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518428				2022-12-25	WOS:A1994NW79800014
J	RIVEROLEZCANO, OM; SAMESHIMA, JH; MARCILLA, A; ROBBINS, KC				RIVEROLEZCANO, OM; SAMESHIMA, JH; MARCILLA, A; ROBBINS, KC			PHYSICAL ASSOCIATION BETWEEN SRC HOMOLOGY-3 ELEMENTS AND THE PROTEIN PRODUCT OF THE C-CBL PROTOONCOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							V-CBL; CYTOPLASMIC PROTEIN; TYROSINE KINASES; SH3 DOMAIN; CELLS; BINDING; GROWTH; RAS; NCK; SIMILARITY	To investigate the nature of proteins recognized by Src homology 3 (SH3) domains, a cDNA expression library was prepared from macrophages and screened with a probe representing the three SH3 domains of p47(nck). Two clones were isolated, and one, designated SAKAP I (for Src A box Nck-associated protein I), contained the carboxyl-terminal half of the cbl proto-oncogene product. Studies in vitro demonstrated reactivity between SAKAP I and SH3 domains derived from a variety of molecules. Wide variations in this assay suggested a high degree of specificity inherent in SAKAP I binding. Moreover, it was possible to demonstrate an in vivo association between p47(nck) and p120(c-cbl) in HL60 cells. These findings suggest that proteins containing SH3 elements regulate Cbl function.	NIDR, CELLULAR DEV & ONCOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			marcilla, antonio/F-9996-2010; Rivero-Lezcano, Octavio Miguel/J-9089-2015	marcilla, antonio/0000-0003-0004-0531; Rivero-Lezcano, Octavio Miguel/0000-0002-8793-0731				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; RIVEROLEZCANO OM, 1994, FEBS LETT, V338, P183, DOI 10.1016/0014-5793(94)80361-7; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WENG ZG, 1993, J BIOL CHEM, V268, P14956; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	27	167	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17363	17366						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	7517397				2022-12-25	WOS:A1994NU12800002
J	THOMAS, SR; MOHR, D; STOCKER, R				THOMAS, SR; MOHR, D; STOCKER, R			NITRIC-OXIDE INHIBITS INDOLEAMINE 2,3-DIOXYGENASE ACTIVITY IN INTERFERON-GAMMA PRIMED MONONUCLEAR PHAGOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI LIPOPOLYSACCHARIDE; TRYPTOPHAN DEGRADATION; L-ARGININE; ANTIMICROBIAL ACTIVITY; GLYCERYL TRINITRATE; TOXOPLASMA-GONDII; RESPIRATORY BURST; HUMAN MACROPHAGES; SUPEROXIDE ANION; QUINOLINIC ACID	Indoleamine 2,3-dioxygenase (IDO) and nitric oxide synthase are part of the anti-tumor and antimicrobial activities of mononuclear phagocytes induced by interferon-gamma (IFN gamma). As IDO is a heme containing enzyme and NO, the product of nitric oxide synthase initiated arginine degradation, is a regulator of heme enzymes, we investigated whether NO is capable of modulating IDO activity in IFN gamma-primed mononuclear phagocytes. Authentic NO gas or the NO generating compound, diethylamine dinitric oxide adduct, dose dependently inhibited IDO activity in cell lysates prepared from IFN gamma-primed human peripheral blood mononuclear cells, as assessed by the ascorbate/methylene blue assay for IDO. In contrast, neither nitrite nor nitrate affected IDO activity. Exposure of intact IFN gamma-primed human peripheral blood mononuclear cells or monocyte-derived macrophages to any of the NO-generating compounds, sodium nitroprusside, glyceryl trinitrate, S-nitroso-N-acetylpenicillamine, or diethylamine dinitric oxide adduct, resulted in inhibition of both the consumption of tryptophan from and formation of its metabolite, kynurenine, in the culture medium. The observed inhibition of IDO activity was not due to toxicity of the NO generators and was abrogated by the co-addition of oxyhemoglobin, an antagonist of NO function. Comparable concentrations of nitrite or nitrate did not inhibit IDO activity in intact cells. In contrast to human cells, addition of IFN gamma to murine macrophages, cultured in complete RPMI 1640 medium, readily induced nitric oxide synthase. Others have reported that such treatment does not induce HDO activity in these cells. However, induction of IDO activity was observed in murine macrophages when the synthesis of reactive nitrogen species was inhibited, by using arginine-free medium and/or the nitric oxide synthesis inhibitor, N-G-monomethyl-L-arginine. Together, these results demonstrate that both exogenous and endogenous NO inhibit IDO activity and that oxidative arginine and tryptophan metabolism in IFN gamma-primed mononuclear phagocytes are functionally related. Our study thereby provides an insight into how these cells may regulate some of their antimicrobial and anti-tumor activities.	HEART RES INST,BIOCHEM GRP,SYDNEY,NSW 2050,AUSTRALIA	University of Sydney; Heart Research Institute			Stocker, Roland/AAV-4489-2021					ADAMS LB, 1990, J IMMUNOL, V144, P2725; AUNE TM, 1989, J CLIN INVEST, V84, P863, DOI 10.1172/JCI114247; BYRNE GI, 1989, INFECT IMMUN, V57, P1318, DOI 10.1128/IAI.57.4.1318-1320.1989; CARLIN JM, 1989, J LEUKOCYTE BIOL, V45, P29, DOI 10.1002/jlb.45.1.29; CARLIN JM, 1989, EXPERIENTIA, V45, P535, DOI 10.1007/BF01990503; CHRISTEN S, 1990, P NATL ACAD SCI USA, V87, P2506, DOI 10.1073/pnas.87.7.2506; CHRISTEN S, 1994, IN PRESS J CLIN INVE; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; CRAVEN PA, 1983, BIOCHIM BIOPHYS ACTA, V745, P310, DOI 10.1016/0167-4838(83)90063-8; DING AH, 1988, J IMMUNOL, V141, P2407; DRAGO RS, 1960, J AM CHEM SOC, V82, P96, DOI 10.1021/ja01486a021; DRAGO RS, 1961, J AM CHEM SOC, V83, P1819, DOI 10.1021/ja01469a012; DRAPIER JC, 1988, EUR J IMMUNOL, V18, P1587, DOI 10.1002/eji.1830181018; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; FOGELMAN AM, 1979, J LIPID RES, V20, P379; HABARAOHKUBO A, 1993, INFECT IMMUN, V61, P1810, DOI 10.1128/IAI.61.5.1810-1813.1993; HAYAISHI O, 1977, J BIOL CHEM, V252, P3548; HAYAISHI O, 1985, BIKEN J, V28, P39; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; HEYES MP, 1992, BIOCHEM J, V283, P633, DOI 10.1042/bj2830633; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; JESSUP W, 1991, BIOCHEM J, V278, P163, DOI 10.1042/bj2780163; LEPOIVRE M, 1989, CANCER RES, V49, P1970; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MELILLO G, 1993, J IMMUNOL, V150, P4031; MURRAY HW, 1989, INFECT IMMUN, V57, P845, DOI 10.1128/IAI.57.3.845-849.1989; MURRAY HW, 1988, SEMIN HEMATOL, V25, P101; NATHAN C, 1988, INFLAMMATION BASIC P, P229; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; OHNISHI T, 1977, J BIOL CHEM, V252, P4643; PADGETT EL, 1992, BIOCHEM BIOPH RES CO, V186, P775, DOI 10.1016/0006-291X(92)90813-Z; PFEFFERKORN ER, 1984, P NATL ACAD SCI-BIOL, V81, P908, DOI 10.1073/pnas.81.3.908; RENGASAMY A, 1993, MOL PHARMACOL, V44, P124; SALVEMINI D, 1992, BIOCHEM PHARMACOL, V44, P17, DOI 10.1016/0006-2952(92)90032-E; SALVEMINI D, 1989, P NATL ACAD SCI USA, V86, P6328, DOI 10.1073/pnas.86.16.6328; SALVEMINI D, 1992, P NATL ACAD SCI USA, V89, P982, DOI 10.1073/pnas.89.3.982; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; SONO M, 1989, J BIOL CHEM, V264, P1616; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; THOMAS SM, 1993, J IMMUNOL, V150, P5529; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; WERNERFELMAYER G, 1989, BIOCHIM BIOPHYS ACTA, V1012, P140, DOI 10.1016/0167-4889(89)90087-6; YOSHIDA R, 1979, P NATL ACAD SCI USA, V76, P4084, DOI 10.1073/pnas.76.8.4084; ZHU L, 1992, ARCH BIOCHEM BIOPHYS, V298, P452, DOI 10.1016/0003-9861(92)90434-X	50	178	191	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14457	14464						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7514170				2022-12-25	WOS:A1994NM06500026
J	DOUGHERTY, GJ; COOPER, DL; MEMORY, JF; CHIU, RK				DOUGHERTY, GJ; COOPER, DL; MEMORY, JF; CHIU, RK			LIGAND-BINDING SPECIFICITY OF ALTERNATIVELY SPLICED CD44 ISOFORMS - RECOGNITION AND BINDING OF HYALURONAN BY CD44R1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE HOMING RECEPTOR; PROTEOGLYCAN CORE; LINK PROTEINS; CELLS; MOLECULE; VARIANT; EXONS; CDNA; DISTINCT; ANTIGEN	CD44 species of widely differing molecular mass have been identified on various normal and/or transformed cells. Recent studies have demonstrated that much of this heterogeneity is produced as a result of the alternative splicing of a series of 10 exons present within the CD44 gene generating a large number of CD44 isoforms containing additional peptide sequences of varying length inserted into a single site within the extracellular domain of the molecule. At present, the effect of such insertions on the ligand binding specificity of CD44 re mains unclear. CD44H, the major CD44 isoform expressed by most resting cell types, has been shown to function as a receptor for the glycosaminoglycan hyaluronan. In contrast, CD44E, the major isoform expressed by the colon carcinoma cell line HT29, which contains a 132-amino acid insert, is unable to recognize and bind this ligand. In the present study we demonstrate that CD44R1, an isoform isolated from the myelomonocytic cell line KG1a, that differs from CD44E by just 3 amino acid substitutions, is fully capable of mediating the attachment of transfected COS7 cells to hyaluronancoated plastic. In order to confirm that such binding was directly mediated by the introduced CD44 species, chimeric proteins containing the entire extracellular domain of CD44H or CD44R1 fused in-frame to human bone/liver/kidney alkaline phosphatase were prepared and tested for their ability to bind hyaluronan-coated plastic. Both fusion proteins bound equally well to hyaluronan and in each case their attachment could be readily inhibited by monoclonal antibodies directed against the hyaluronan-binding domain of CD44. These data indicate that the 132-amino acid insert present within the extracellular domain of CD44R1 does not interfere with the hyaluronan binding function of the molecule. Since CD44E contains an identically sized insert but is unable to bind hyaluronan, it is likely that mutation of one or more of the 3 amino acid residues that differ between CD44E and CD44R1 is responsible for the altered functional activity of this particular molecule.	BRITISH COLUMBIA CANC AGCY,TERRY FOX LAB HEMATOL ONCOL,VANCOUVER V5Z 1L3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT PATHOL,VANCOUVER,BC,CANADA; UNIV PITTSBURGH,DEPT PATHOL,PITTSBURGH,PA 15281	British Columbia Cancer Agency; University of British Columbia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BIRCH M, 1991, CANCER RES, V51, P6660; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CANNISTRA SA, 1993, CANCER RES, V53, P3830; COOPER DL, 1992, BIOCHEM BIOPH RES CO, V182, P569, DOI 10.1016/0006-291X(92)91770-Q; CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331; DOUGHERTY GJ, 1991, J EXP MED, V174, P1, DOI 10.1084/jem.174.1.1; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HAKOMORI S, 1986, HDB EXPT IMMUNOLOGY, V4; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; HE Q, 1992, J CELL BIOL, V119, P1711, DOI 10.1083/jcb.119.6.1711; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; HERRLICH P, 1993, IMMUNOL TODAY, V14, P395, DOI 10.1016/0167-5699(93)90141-7; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JALKANEN S, 1988, J IMMUNOL, V141, P1615; KOEFFLER HP, 1980, BLOOD, V56, P265; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; LEE TH, 1993, J BIOL CHEM, V268, P6154; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; NOTTENBURG C, 1989, P NATL ACAD SCI USA, V86, P8521, DOI 10.1073/pnas.86.21.8521; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; RUDY W, 1993, CANCER RES, V53, P1262; SALMI M, 1993, J CELL BIOL, V122, P431, DOI 10.1083/jcb.122.2.431; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SEITER S, 1993, J EXP MED, V177, P443, DOI 10.1084/jem.177.2.443; SHTIVELMAN E, 1991, MOL CELL BIOL, V11, P5446, DOI 10.1128/MCB.11.11.5446; St John T, 1989, Reg Immunol, V2, P300; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; TOLG C, 1993, NUCLEIC ACIDS RES, V21, P1225, DOI 10.1093/nar/21.5.1225; WEISS MJ, 1986, P NATL ACAD SCI USA, V83, P7182, DOI 10.1073/pnas.83.19.7182; WIRTH K, 1993, EUR J CANCER, V29A, P1172, DOI 10.1016/S0959-8049(05)80310-7; WOLFFE EJ, 1990, J BIOL CHEM, V265, P341	39	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9074	9078						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510702				2022-12-25	WOS:A1994NB41100069
J	MILNE, DM; CAMPBELL, DG; CAUDWELL, FB; MEEK, DW				MILNE, DM; CAMPBELL, DG; CAUDWELL, FB; MEEK, DW			PHOSPHORYLATION OF THE TUMOR-SUPPRESSOR PROTEIN P53 BY MITOGEN-ACTIVATED PROTEIN-KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; WILD-TYPE P53; MAP KINASE; TYROSINE PHOSPHORYLATION; NUCLEAR-LOCALIZATION; TRANSCRIPTION FACTOR; GENE-PRODUCT; CELL-CYCLE; MOUSE P53; 3T3 CELLS	The p53 tumor suppressor protein is tightly regulated in the cell and is phosphorylated at multiple sites by several different protein kinases. We have investigated the phosphorylation of p53 by mitogen activated protein (MAP) kinase, a protein kinase that plays a central role in mediating many mitogenic and differentiation signals. Recombinant wild-type mouse p53 was phosphorylated in vitro by activated recombinant p42-MAP kinase but not by inactive MAP kinase or by the activating protein, MAP kinase kinase. Phosphorylation of p53 by MAP kinase occurred at two N-terminal sites, threonine residues 73 and 83. Tryptic phosphopeptides of recombinant p53 phosphorylated in vitro by MAP kinase comigrated on two-dimensional maps with p53 from SV3T3 cells labeled in vivo with [P-32]orthophosphate, suggesting that MAP kinase targets a site in p53 that is phosphorylated in the cell. Following serum stimulation of quiescent C57MG cells, two p53 kinases, which were resolved by chromatography on Mono Q, were stimulated 15-20-fold within 5 min. Each of these kinase activities co-eluted with myelin basic protein kinase activity and could be inactivated following treatment with protein phosphatase 2A, a serine/threonine phosphatase, or leukocyte antigen receptor, a protein tyrosine phosphatase, suggesting that these activities were members of the MAP kinase family. The two kinase activities from the lysates targeted the same phosphorylation sites on p53 as the purified recombinant MAP kinase. These protein kinase activities were also stimulated following exposure of the cells to ultraviolet radiation, but with slightly delayed kinetics. Phorbol ester treatment of SV3T3 cells led to increased phosphorylation of the peptide containing the residues targeted by MAP kinase. The data suggest that p53 may be phosphorylated by MAP kinase physiologically and that this interaction may be involved in the cell's response to UV exposure, growth factor stimulation, or transformation by oncogenes.	UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND	University of Dundee			Campbell, David G/K-1874-2015	Campbell, David G/0000-0003-2278-2149				ADDISON C, 1990, ONCOGENE, V5, P423; AHN NG, 1991, J BIOL CHEM, V266, P4220; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN P, 1992, BIOCHEM SOC T, V20, P671, DOI 10.1042/bst0200671; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEMAGGIO AJ, 1992, P NATL ACAD SCI USA, V89, P7008, DOI 10.1073/pnas.89.15.7008; DENTP, 1992, SCIENCE, V257, P1404; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FISCELLA M, 1993, ONCOGENE, V8, P1519; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HAL PA, 1993, ONCOGENE, V8, P203; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEIER KE, 1991, J BIOL CHEM, V266, P1914; MEITZ JA, 1992, EMBO J, V11, P5013; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1990, ONCOGENE, V5, P1683; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAGIMOV N, 1993, ONCOGENE, V8, P1183; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SETH A, 1992, J BIOL CHEM, V267, P24796; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SOUSSI T, 1990, ONCOGENE, V5, P945; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VAIDYA AB, 1978, VIROLOGY, V90, P12, DOI 10.1016/0042-6822(78)90328-8; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	74	178	182	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9253	9260						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510706				2022-12-25	WOS:A1994NB41100092
J	GOLD, MR; DURONIO, V; SAXENA, SP; SCHRADER, JW; AEBERSOLD, R				GOLD, MR; DURONIO, V; SAXENA, SP; SCHRADER, JW; AEBERSOLD, R			MULTIPLE CYTOKINES ACTIVATE PHOSPHATIDYLINOSITOL 3-KINASE IN HEMATOPOIETIC-CELLS - ASSOCIATION OF THE ENZYME WITH VARIOUS TYROSINE-PHOSPHORYLATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; KINASE-ACTIVITY; INSULIN STIMULATION; INTACT-CELLS; BOVINE BRAIN; C-KIT; RECEPTOR; INTERLEUKIN-3	Activation of phosphatidylinositol (PI) 3-kinase is a common sequel to tyrosine kinase activation and appears to be essential for tyrosine kinases to induce proliferation. Since multiple hemopoietic growth factors activate tyrosine kinases, we investigated whether these growth factors activate PI 3-kinase. We show that interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-5 (IL-5), granulocyte-macrophage colony stimulating factor (GM-CSF), and steel factor (SLF) all activate PI 3-kinase. These cytokines increased the amount of PI 3-kinase activity that could be immunoprecipitated with anti-phosphotyrosine antibodies from the MC-9 mast cell line or from the hemopoietic progenitor cell line FDC-P1, Increases in this assay frequently correlate with PI 3-kinase activation in vivo, To determine directly whether these factors activate PI 3-kinase in vivo, we measured the levels of 3-phosphorylated inositol phospholipids in intact P-32-labeled MC-9 cells. IL-3, IL-4, IL-5, GM-CSF, and SLF all caused increased synthesis of the PI 3-kinase products phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate with a relative potency of SLF >> IL-3> IL-5, GM-CSF > IL-4. In contrast, IL-4 caused the largest increase in the in vitro anti-phosphotyrosine immune complex PI 3-kinase assay. Thus, the in vitro assay does not accurately reflect in vivo activation of PI 3-kinase. Cytokine treatment did not stimulate tyrosine phosphorylation of either the 85-kDa regulatory subunit or the 110-kDa catalytic subunit of PI 3-kinase and is therefore not required for activation of PI 3-kinase by these factors. Cytokine treatment did induce PI 3-kinase to associate with other tyrosine-phosphorylated proteins in a cytokine-specific manner. PI 3-kinase associated with c-kit after SLF stimulation, a 170-kDa protein after IL-4 stimulation, and a 70-kDa protein after treatment with IL 3 or GM-CSF. Thus, multiple hemopoietic growth factors that act through different types of receptors activate PI 3-kinase in vivo and induce factor-specific interactions of PI 3-kinase with other tyrosine-phosphorylated proteins.	UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT BIOCHEM & MOLEC BIOL, VANCOUVER V6T 1Z3, BC, CANADA	University of British Columbia; University of British Columbia; University of British Columbia				Gold, Michael/0000-0003-1222-3191				AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLARKLEWIS I, 1986, SCIENCE, V231, P134, DOI 10.1126/science.3079915; COREY SJ, 1992, BLOOD, V80, P150; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DURONIO V, 1992, J BIOL CHEM, V267, P21856; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GOLD MR, 1992, J IMMUNOL, V148, P2012; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; IZUMI T, 1987, J BIOL CHEM, V262, P1282; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KELLER SR, 1991, J BIOL CHEM, V266, P12817; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LIPS DL, 1989, J BIOL CHEM, V264, P8759; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; NABEL G, 1981, NATURE, V291, P332, DOI 10.1038/291332a0; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OKUDA K, 1992, BLOOD, V79, P2889; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAUL WE, 1991, BLOOD, V77, P1859; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHIEVEN GL, 1992, J IMMUNOL, V149, P1676; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; SKOLNIK RY, 1991, CELL, V65, P88; SUSA M, 1992, J BIOL CHEM, V267, P22951; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VELHAM MJ, 1992, J IMMUNOL, V149, P2772; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0	49	156	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5403	5412						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508938				2022-12-25	WOS:A1994MX57100105
J	OGAWA, W; HOSOMI, Y; SHII, K; ROTH, RA				OGAWA, W; HOSOMI, Y; SHII, K; ROTH, RA			EVIDENCE FOR 2 DISTINCT 60-KILODALTON SUBSTRATES OF THE SRC TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; GROWTH FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; CELL-TRANSFORMATION; MOLECULAR-CLONING; SH2 DOMAINS; INSULIN; RECEPTOR; RAS	A monoclonal antibody to a 60-kDa substrate of the insulin receptor tyrosine kinase is utilized in the present studies to examine this molecule in 3T3 cells expressing either the transforming chicken c-Src (mutant Phe-527), the wild type molecule, or the parental cells. The tyrosine phosphorylation of this 60-kDa protein was greatly increased in cells expressing transforming Src and partially increased in cells expressing wild type enzyme. This tyrosine phosphorylation correlated with an increased association with the GTPase-activating protein of p21(ras) (GAP). However, this 60-kDa protein did not react with antibodies to another 62-kDa tyrosine-phosphorylated protein previously isolated from Src-transformed cells (Wong, G., Muller, O., Clark, R., Conroy, L., Moran, M. F., Polakis, P., and McCormick, F. (1992) Cell 69, 551-558), although this latter antibody did react with a 62-kDa protein in anti-phosphotyrosine precipitates from cells expressing transforming c-Src but not the parental cells. These two proteins could also be distinguished by their subcellular location, the ability of the latter but not the former protein to bind RNA, and their migration in SDS gels. Moreover, the 62-kDa RNA-binding phosphoprotein could be almost completely depleted from cell lysates with poly(U)-Sepharose without affecting the amount of either the GAP-associated 60-kDa tyrosine-phosphorylated protein or the protein precipitated with the monoclonal antibody. when the two proteins were phosphorylated in vitro with purified c-Src, they were both found to bind directly to the aminoterminal SH2 domain of GAP, although the RNA-binding protein was found to have a weaker affinity. These results indicate that two distinct 60-kDa proteins are substrates for the Src tyrosine kinase, one which binds RNA and the other which constitutes the major GAP-associated 60-kDa phosphoprotein.	STANFORD UNIV,MED CTR,SCH MED,DEPT MOLEC PHARMACOL,STANFORD,CA 94305; HYOGO INST CLIN RES,AKASHI 673,HYOGO,JAPAN	Stanford University			OGAWA, Wataru/AAQ-9586-2020		NIDDK NIH HHS [DK 41765, DK 34926] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041765, R01DK034926, R37DK034926] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOLLOY CJ, 1992, MOL CELL BIOL, V12, P3903, DOI 10.1128/MCB.12.9.3903; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PORRAS A, 1992, J BIOL CHEM, V267, P21124; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHALLER MD, 1993, PROG NUCLEIC ACID RE, V44, P205, DOI 10.1016/S0079-6603(08)60221-4; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SUNG CK, 1994, J BIOL CHEM, V269, P12503; SUNG CK, 1992, BIOCHEM BIOPH RES CO, V189, P1024, DOI 10.1016/0006-291X(92)92306-I; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YAMAMOTO K, 1992, J BIOL CHEM, V267, P11337; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHANG B, 1992, J BIOL CHEM, V267, P18320	39	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29602	29608						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7525585				2022-12-25	WOS:A1994PU28400047
J	FURFINE, ES; HARMON, MF; PAITH, JE; KNOWLES, RG; SALTER, M; KIFF, RJ; DUFFY, C; HAZELWOOD, R; OPLINGER, JA; GARVEY, EP				FURFINE, ES; HARMON, MF; PAITH, JE; KNOWLES, RG; SALTER, M; KIFF, RJ; DUFFY, C; HAZELWOOD, R; OPLINGER, JA; GARVEY, EP			POTENT AND SELECTIVE-INHIBITION OF HUMAN NITRIC-OXIDE SYNTHASES - SELECTIVE-INHIBITION OF NEURONAL NITRIC-OXIDE SYNTHASE BY S-METHYL-L-THIOCITRULLINE AND S-ETHYL-L-THIOCITRULLINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN; PURIFICATION; BINDING	Potent and selective inhibition of neuronal nitric oxide synthase (nNOS) compared to endothelial NOS (eNOS) and inducible NOS (iNOS) may be useful to treat cerebral ischemia (stroke) and other neurodegenerative diseases. S-Methyl-L-thiocitrulline (Me-TC) and S-ethyll-thiocitrulline (Et-TC) inhibited the oxidation of L-arginine and the L-arginine-independent oxidation of NADPH by nNOS from human brain. Me-TC and Et-TC were slow, tight binding inhibitors of nNOS with second-order association rate constants (k(on)) of 2.6 x 10(5) M(-1) s(-1) and 1.3 x 10(5) M(-1) s(-1), respectively. The respective dissociation rate constants (k(off)) were 3 x 10(-4) s(-1) and 0.7 x 10(-4) s(-1). Thus, the K-d values calculated from k(off)/k(on) were 1.2 and 0.5 nM, respectively. L-Arginine was a competitive inhibitor of Me-TC and Et-TC binding with competition constant (K-s) values of 2.2 and 2.7 mu M respectively. The K-m of nNOS for L-arginine was 1.6 mu M. The active site concentration of nNOS was estimated by titration with Et-TC. Based on this active site concentration, a k(cat) of 0.4 s(-1) for the oxidation of L-arginine, was calculated. Me-TC and Et-TC were less potent inhibitors of human iNOS (K-i values of 34 and 17 nM, respectively) and human eNOS (K-i values of 11 and 24 nM). Thus, Me-TC and Et-TC were 10- and 50-fold, respectively, more potent inhibitors of nNOS than eNOS. Furthermore, Me-TC was also 17-fold selective for rat nNOS in neuronal tissue compared to rat eNOS in vascular endothelium, suggesting that Me-TC may be selective for nNOS in vivo and therefore, may be therapeutically useful to treat neurodegenerative diseases.	BURROUGHS WELLCOME CO,WELLCOME RES LABS,DIV ORGAN CHEM,RES TRIANGLE PK,NC 27709; WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND	Burroughs Wellcome Fund; Wellcome Research Laboratories; GlaxoSmithKline; Wellcome Research Laboratories	FURFINE, ES (corresponding author), BURROUGHS WELLCOME CO,WELLCOME RES LABS,DIV EXPTL THERAPY,RES TRIANGLE PK,NC 27709, USA.							Bevington P. R., 1969, DATA REDUCTION ERROR, P56; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOI DW, 1993, P NATL ACAD SCI USA, V90, P9741, DOI 10.1073/pnas.90.21.9741; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; FELDMAN PL, 1991, TETRAHEDRON LETT, V32, P875, DOI 10.1016/S0040-4039(00)92109-9; FERSHT A, 1985, ENZYME STRUCTURE MEC, P150; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; FURFINE ES, 1993, BIOCHEMISTRY-US, V32, P8512, DOI 10.1021/bi00084a017; GARVEY EP, 1994, ARCH BIOCHEM BIOPHYS, V311, P235, DOI 10.1006/abbi.1994.1232; GARVEY EP, 1994, J BIOL CHEM, V269, P26669; KRISHNASWAMY K, 1994, J MED CHEM, V37, P885; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OLKEN NM, 1993, BIOCHEMISTRY-US, V32, P9677, DOI 10.1021/bi00088a020; POU S, 1992, J BIOL CHEM, V267, P24173; REES DD, 1989, BRIT J PHARMACOL, V96, P418, DOI 10.1111/j.1476-5381.1989.tb11833.x; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SHERMAN PA, 1993, BIOCHEMISTRY-US, V32, P11600, DOI 10.1021/bi00094a017; STEUHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287	24	203	206	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26677	26683						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7523410				2022-12-25	WOS:A1994PQ93100018
J	DU, EZ; KURTH, J; WANG, SL; HUMISTON, P; DAVIS, RA				DU, EZ; KURTH, J; WANG, SL; HUMISTON, P; DAVIS, RA			PROTEOLYSIS COUPLED SECRETION OF THE N-TERMINUS OF APOLIPOPROTEIN-B - CHARACTERIZATION OF A TRANSIENT, TRANSLOCATION ARRESTED INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; ENDOPLASMIC-RETICULUM MEMBRANE; HEP G2 CELLS; MESSENGER-RNA; INTRACELLULAR-DISTRIBUTION; TRANSFER SEQUENCE; RAT HEPATOCYTES; PAUSE TRANSFER; APO-B; DEGRADATION	We have shown that non-hepatic Chinese hamster ovary cells (CHO) have a specific inability to translocate and secrete apolipoprotein B (apoB), leading to its complete degradation in the endoplasmic reticulum (Thrift, It. N., Drisko, J., Dueland, S., Trawick, J. D., and Davis, R. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 9161-9165). To gain an understanding why a protein having no predictable trans-membrane sequences can be stably integrated into the endoplasmic reticulum, we determined the topography and metabolic fate of apoB in both CHO cells and human hepatoma cells (HepG2). Using epitope-specific antibodies, we show that in microsomes from both cell types, apoB assumes a trans-membrane orientation having 69 kDa of its N terminus in the lumen and the remaining portion of the C terminus residing on the cytoplasmic surface. In both cell types, proteolytic cleavage of the translocation arrested apoB by a process that can be blocked by acetyl-leucine, leucine, norleucal, produces an 85-kDa N-terminal fragment that resumes translocation and is secreted. This same N-terminal 85-kDa fragment is also found in human plasma. These results show that sequences residing outside of the membrane spanning domain can block translocation. Moreover, our data provide compelling evidence showing that apoB undergoes an unusual transient, translocation arrest, that serves as an entrance into the intracellular degradative pathway regulating its secretion.	SAN DIEGO STATE UNIV,DEPT BIOL,MAMMALIAN CELL & MOLEC BIOL LAB,SAN DIEGO,CA 92182	California State University System; San Diego State University					NHLBI NIH HHS [HL51643] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELI K, 1994, J BIOL CHEM, V269, P9166; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOOGAERTS JR, 1984, AM J PHYSIOL, V246, pE77, DOI 10.1152/ajpendo.1984.246.1.E77; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; BOREN J, 1990, J BIOL CHEM, V265, P10556; CARTWRIGHT IJ, 1993, J BIOL CHEM, V268, P20937; CHEN GC, 1989, BIOCHEMISTRY-US, V28, P2477, DOI 10.1021/bi00432a019; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CHUCK SL, 1993, J BIOL CHEM, V268, P22794; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; COLEMAN RA, 1988, J LIPID RES, V29, P33; CURTISS LK, 1982, J BIOL CHEM, V257, P5213; DAVIDSON NO, 1988, J LIPID RES, V29, P1511; Davis R A, 1986, Methods Enzymol, V129, P272; Davis R.A., 1991, BIOCH LIPIDS LIPOPRO, P403; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; Davis Roger A., 1993, V21, P169; DIXON JL, 1992, J CELL BIOL, V117, P1161, DOI 10.1083/jcb.117.6.1161; DIXON JL, 1993, J LIPID RES, V34, P167; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; HARDMAN DA, 1986, BIOCHEM BIOPH RES CO, V137, P821, DOI 10.1016/0006-291X(86)91153-8; HOSPATTANKAR AV, 1987, BIOCHEM BIOPH RES CO, V148, P279, DOI 10.1016/0006-291X(87)91107-7; INNERARITY TL, 1987, J CLIN INVEST, V80, P1794, DOI 10.1172/JCI113273; INOUE S, 1991, J BIOL CHEM, V266, P13311; KANE JP, 1983, ANNU REV PHYSIOL, V45, P637, DOI 10.1146/annurev.ph.45.030183.003225; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KRISHNAIAH KV, 1980, P NATL ACAD SCI-BIOL, V77, P3806, DOI 10.1073/pnas.77.7.3806; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; MIZE NK, 1986, CELL, V47, P711, DOI 10.1016/0092-8674(86)90514-3; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; PULLINGER CR, 1989, J LIPID RES, V30, P1065; ROITELMAN J, 1991, J BIOL CHEM, V266, P16085; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; SATO R, 1990, J BIOL CHEM, V265, P11880; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SIVARAM P, 1994, J BIOL CHEM, V269, P9409; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; STEINBERG D, 1989, CIRCULATION, V80, P719, DOI 10.1161/01.CIR.80.3.719; SWINKELS DW, 1989, ARTERIOSCLEROSIS, V9, P604, DOI 10.1161/01.ATV.9.5.604; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; THEOLIS R, 1984, ARTERIOSCLEROSIS, V4, P498, DOI 10.1161/01.ATV.4.5.498; THRIFT RN, 1986, J LIPID RES, V27, P236; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; WETTERAU JR, 1992, SCIENCE, V258, P999; WILKINSON J, 1992, BIOCHEM J, V288, P413, DOI 10.1042/bj2880413; WILKINSON J, 1992, FEBS LETT, V304, P24, DOI 10.1016/0014-5793(92)80581-Z; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	57	87	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24169	24176						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523367				2022-12-25	WOS:A1994PQ34600052
J	VASSILIOU, G; STANLEY, KK				VASSILIOU, G; STANLEY, KK			EXOGENOUS RECEPTOR-ASSOCIATED PROTEIN BINDS TO 2 DISTINCT SITES ON HUMAN FIBROBLASTS BUT DOES NOT BIND TO THE GLYCOSAMINOGLYCAN RESIDUES OF HEPARAN-SULFATE PROTEOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN-RECEPTOR; ACTIVATOR INHIBITOR TYPE-1; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; LDL-RECEPTOR; APOLIPOPROTEIN-E; PROTEOHEPARAN SULFATE; HEYMANN NEPHRITIS; ENDOTHELIAL-CELLS; HIGH-AFFINITY	We have investigated the proposal that the receptor-associated protein (RAP) of the low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor binds to heparan sulfate proteoglycans (HSP). I-125-RAP binds to two sites on the surface of fibroblasts as follows: a high affinity site with a K-d of 1.4 nM and a low affinity site (K-d = 188 nM) with a capacity of more than 1000-fold the maximum amount of lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor on the cell surface. I-125-RAP binding to the low affinity site was abolished by heparin or Suramin. However, maximal digestion of the glycosaminoglycan chains of HSP with heparinase or culturing the cells in chlorate, an inhibitor of proteoglycan sulfation, did not affect the binding of I-125-RAP or of I-125-labeled, methylamine-activated alpha(2)-macroglobulin. Comparison of I-125-RAp degradation at two different concentrations suggests that the low affinity, high capacity site on the surface of human fibroblasts participates in the endocytosis of I-125-RAp. The nature of the low affinity site remains to be elucidated, but we can exclude the glycosaminoglycan chains of HSP.			VASSILIOU, G (corresponding author), HEART RES INST,145 MISSENDEN RD,SYDNEY,NSW 2050,AUSTRALIA.							ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHENG CF, 1981, J BIOL CHEM, V256, P2893; DICKSON RB, 1981, J BIOL CHEM, V256, P3454; FRANSSON LA, 1984, P NATL ACAD SCI-BIOL, V81, P5657, DOI 10.1073/pnas.81.18.5657; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; GREVE H, 1988, J BIOL CHEM, V263, P12886; HASSELL JR, 1992, INVEST OPHTH VIS SCI, V33, P547; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; JI ZS, 1993, J BIOL CHEM, V268, P10160; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; MULDER M, 1993, J BIOL CHEM, V268, P9369; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SCHON P, 1992, EUR J CELL BIOL, V59, P329; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANLEUVEN F, 1979, J BIOL CHEM, V254, P5155; WANG D, 1981, ARCH BIOCHEM BIOPHYS, V211, P500, DOI 10.1016/0003-9861(81)90483-5; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	48	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15172	15178						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7515052				2022-12-25	WOS:A1994NP73800049
J	MANOLSON, MF; WU, BG; PROTEAU, D; TAILLON, BE; ROBERTS, BT; HOYT, MA; JONES, EW				MANOLSON, MF; WU, BG; PROTEAU, D; TAILLON, BE; ROBERTS, BT; HOYT, MA; JONES, EW			STV1 GENE ENCODES FUNCTIONAL HOMOLOG OF 95-KDA YEAST VACUOLAR H+-ATPASE SUBUNIT VPH1P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASE; SHUTTLE VECTORS; EXPRESSED GENES; MEMBRANE; ACIDIFICATION; POLYPEPTIDE; PRODUCT; MUTANTS	The Saccharomyces cerevisiae gene, VPH1 (Vacuolar pH 1), encodes a 95-kDa integral membrane subunit of the vacuolar-type H+-ATPase (V-ATPase) that is required for enzyme assembly; disruption of the VPH1 gene impairs vacuolar acidification (Manolson, M. F., Proteau, D., Preston, R. A, Stenbit, A, Roberts, B. T., Hoyt, M. A., Preuss, D., Mulholland, J., Botstein, D., and Jones, E. W. (1992) J. Biol. Chem. 267, 14294-14303). Here we show that STV1 (Similar To VPH1) encodes an integral membrane polypeptide of 102 kDa with 54% identity with the peptide sequence of Vph1p. High copy expression of STV1 partially restores vacuolar acidification in a Delta vph1 mutant strain; solubilization and fractionation of membrane proteins from these vacuoles show that Stv1p co-purifies with bafilomycin A(1)-sensitive ATPase activity and with the 60- and 69-kDa V-ATPase subunits. Immunofluorescence microscopy of strains bearing a single copy of epitope tagged STV1 reveals punctate staining of the cytoplasm; overexpression of epitopetagged Stv1p reveals both punctate cytoplasmic staining and vacuolar membrane staining. Northern analysis shows that disruption of STV1 does not affect the level of transcription of VPH1 and that disruption of VPH1 does not affect the level of transcription of STV1. Strains bearing disruption of genes encoding other V-ATPase subunits (VMA1, VMA2, VMA3, and VMA4) fail to grow on media supplemented with 100 mM CaCl2 or 4 mM ZnCl2, media buffered to pH 7.5, or media with a glycerol carbon source. On the same types of media only a Delta vph1 Delta stv1 double disruption mutant has growth phenotypes equivalent to strains bearing a single disruption of the VMA1, VMA2, VMA3, and VMA4 genes; a Delta vph1 strain has only moderate growth inhibition while a Delta stv1 strain has wild type growth on the conditions listed above. We conclude that Stv1p is a functional homologue of Vph1p and suggest that Stv1p and Vph1p may be equivalent subunits for V-ATPases located on different organelles. The function of these 100-kDa homologues may be to target or regulate other common V-ATPase subunits for two distinct cellular locations.	CARNEGIE MELLON UNIV, DEPT BIOL SCI, PITTSBURGH, PA 15213 USA; CARNEGIE MELLON UNIV, CTR SCI & TECHNOL, PITTSBURGH, PA 15213 USA; JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Carnegie Mellon University; Carnegie Mellon University; Johns Hopkins University	MANOLSON, MF (corresponding author), HOSP SICK CHILDREN, DIV CELL BIOL, 555 UNIV AVE, TORONTO M5G 1X8, ON, CANADA.			Manolson, Morris/0000-0001-8755-5460	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018090, R37DK018090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049363, R01GM029713] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18090] Funding Source: Medline; NIGMS NIH HHS [GM49363, GM29713] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P960; ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANRAKU Y, 1989, J BIOENERG BIOMEMBR, V21, P589, DOI 10.1007/BF00808115; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BACHHAWAT AK, 1993, YEAST, V9, P175, DOI 10.1002/yea.320090208; BARNES DA, 1986, MOL CELL BIOL, V6, P2828, DOI 10.1128/MCB.6.8.2828; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; EIDA DJ, 1993, MOL GEN GENET, V241, P447; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FORGAC M, 1990, PHYSL REV, V265; FOURY F, 1990, J BIOL CHEM, V265, P18554; GILLESPIE J, 1991, FEBS LETT, V282, P9; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HIRATA R, 1993, J BIOL CHEM, V268, P961; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOL CHEM, V267, P447; LEE CK, 1990, MOL IMMUNOL, V27, P1137; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MANOLSON MF, 1992, J EXP BIOL, V172, P105; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OHYA Y, 1986, J GEN MICROBIOL, V132, P979; PAULOVICH AG, 1993, GENETICS, V135, P719; PERIN MS, 1991, J BIOL CHEM, V266, P3877; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; PRESTON RA, 1989, P NATL ACAD SCI USA, V86, P7027, DOI 10.1073/pnas.86.18.7027; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SHARP PM, 1986, NUCLEIC ACIDS RES, V14, P5125, DOI 10.1093/nar/14.13.5125; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; SIKORSKI RS, 1989, GENETICS, V122, P19; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WELCH J, 1989, EMBO J, V8, P255, DOI 10.1002/j.1460-2075.1989.tb03371.x; WOOLFORD CA, 1990, GENETICS, V125, P739; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	57	269	273	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14064	14074						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514599				2022-12-25	WOS:A1994NL60600053
J	FIELD, MC; MORAN, P; LI, WL; KELLER, GA; CARAS, IW				FIELD, MC; MORAN, P; LI, WL; KELLER, GA; CARAS, IW			RETENTION AND DEGRADATION OF PROTEINS CONTAINING AN UNCLEAVED GLYCOSYLPHOSPHATIDYLINOSITOL SIGNAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORED MEMBRANE-PROTEINS; ROUGH ENDOPLASMIC-RETICULUM; EXOCRINE PANCREATIC-CELLS; DECAY-ACCELERATING FACTOR; CLEAVAGE ATTACHMENT SITE; AUTOPHAGIC VACUOLE; SECRETORY PROTEINS; MOUSE FIBROBLASTS; PRE-GOLGI; BIOSYNTHESIS	Glycosylphosphatidylinositol (GPI) membrane anchor attachment is directed by a COOH-terminal signal that is proteolytically removed and replaced with a preformed GPI anchor in a coupled reaction. Failure to complete proteolytic cleavage and anchor addition results in the retention of an uncleaved precursor in a post-endoplasmic reticulum (ER) compartment. In this report, we address three issues: (i) the exact position of the transport block, (ii) the subsequent fate of the retained molecules, i.e. where are they degraded, and (iii) the mechanism whereby these proteins are selected for retention. Using decay accelerating factor (DAF), we provide evidence that failure to cleave the GPI signal totally prevents O-glycosylation, suggesting that the uncleaved polypeptides are not transported into the cis-Golgi complex. This implies that transport is blocked at the boundary between the ER-Golgi intermediate compartment and the Golgi stacks. The degradation of an intracellularly retained human growth hormone (hGH)-DAF fusion protein containing a nonfunctional GPI signal shows some features of ER degradation, i.e. the degradation is insensitive to leupeptin, chloroquine, and ammonium chloride, and is inhibited at 16 degrees C or after ATP depletion. However, morphological evidence points to a pathway resembling autophagy. To reconcile these observations, we suggest either that hGHDAF is degraded by two distinct pathways (ER degradation and autophagy) or that ER degradation takes place in an ER-associated vesicular compartment in a process resembling autophagy. Using as probes a soluble hGH receptor and an antibody recognizing only native hGH, we show that a significant fraction of the retained protein is correctly folded, ruling out general misfolding as the basis for retention. We also show that hGHDAF fusion proteins are present in high molecular weight, disulfide-linked aggregates in COS cells. We suggest a model for retention in which the uncleaved GPI signal drives the formation of large micelle-like aggregates that cannot be secreted.	GENENTECH INC,DEPT NEUROBIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PHARMACOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech			Field, Mark/AAD-6455-2021	Field, Mark/0000-0002-4866-2885; Caras, Ingrid/0000-0002-8902-808X				AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; ASCOLI M, 1979, BIOCHIM BIOPHYS ACTA, V586, P608, DOI 10.1016/0304-4165(79)90051-5; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CARAS IW, 1991, J CELL BIOL, V113, P77, DOI 10.1083/jcb.113.1.77; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEKKER J, 1990, J BIOL CHEM, V265, P18116; DELAHUNTY MD, 1993, J BIOL CHEM, V268, P12017; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; FATEMI SH, 1988, J BIOL CHEM, V263, P1288; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIELD MC, 1993, J BIOL CHEM, V268, P9570; FIELD MC, 1991, EMBO J, V10, P2731, DOI 10.1002/j.1460-2075.1991.tb07821.x; FIELD MC, 1993, CRC HDB LIPID MODIFI, P83; GERBER LD, 1992, J BIOL CHEM, V267, P12168; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; KARNOVSKY MJ, 1971, J CELL BIOL, V51, pA146; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; LOW MG, 1989, FASEB J, V3, P1601; MACHAMER CE, 1985, MOL CELL BIOL, V5, P3074, DOI 10.1128/MCB.5.11.3074; MASTERSON WJ, 1991, EMBO J, V10, P2041, DOI 10.1002/j.1460-2075.1991.tb07734.x; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; MORAN P, 1992, J CELL BIOL, V119, P763, DOI 10.1083/jcb.119.4.763; MORAN P, 1991, J BIOL CHEM, V266, P1250; NODA T, 1992, J CELL BIOL, V119, P85, DOI 10.1083/jcb.119.1.85; RABOUILLE C, 1993, J CELL BIOL, V120, P897, DOI 10.1083/jcb.120.4.897; REDDY P, 1989, J BIOL CHEM, V264, P17329; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SCHREIER H, 1994, J BIOL CHEM, V269, P9090; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; SELDEN RF, 1987, CURRENT PROTOCOLS MO; SELVARAJ P, 1987, J EXP MED, V166, P1011, DOI 10.1084/jem.166.4.1011; SINGH N, 1991, MOL CELL BIOL, V11, P2362, DOI 10.1128/MCB.11.5.2362; TOOZE J, 1989, J CELL BIOL, V109, P35, DOI 10.1083/jcb.109.1.35; TOOZE J, 1990, J CELL BIOL, V111, P329, DOI 10.1083/jcb.111.2.329	50	93	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10830	10837						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511608				2022-12-25	WOS:A1994NF01700095
J	HESS, MA; DUNCAN, RF				HESS, MA; DUNCAN, RF			RNA/PROTEIN INTERACTIONS IN THE 5'-UNTRANSLATED LEADER OF HSP70 MESSENGER-RNA IN DROSOPHILA LYSATES - LACK OF EVIDENCE FOR SPECIFIC PROTEIN-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA CAP; HEAT-SHOCK RESPONSE; PREFERENTIAL TRANSLATION; SELECTIVE TRANSLATION; UNTRANSLATED LEADER; INITIATION-FACTORS; C-MYC; CELLS; SEQUENCE; COMPLEX	We have investigated the hypothesis that preferential translation of the heat stress mRNAs requires the binding of a trans-acting protein factor. P-32-Labeled RNA probes covering the 5'-untranslated region (5'-UTR) of HSP70 mRNA were synthesized, and gel retardation and UV cross-linking assays performed to identify trans-acting sequence-specific RNA-binding factors. The results indicate that no HSP70 5'-UTR RNA-specific binding proteins exist. Reducing the ''stringency'' in the gel retardation binding analyses revealed several non-sequence-specific RNA-binding complexes. The proteins bind RNA more strongly than DNA, show minor preferences for specific sequences, but none binds more strongly to the HSP70 5'-UTR than to other non-heat stress RNAs. Ultraviolet cross-linking analysis identifies two principal HSP70 5'-UTR binding proteins, of approximately 50 and 70 kDa. The p50 binding activity is increased severalfold for all mRNAs in heat-stressed lysates, and its binding produces the primary gel-retarded complex. Further detailed analyses were performed to probe for any possible heat-influenced changes. RNA/protein interactions are not affected by capping. Neither the kinetics nor the salt sensitivity of protein binding is affected by heat. Binding analyses using partial or complete HSP70 5'-UTR give qualitatively similar conclusions. Binding analyses were also carried out with several ''normal'' 5'-UTRs to investigate whether a heat-induced repressor might be activated by heating. No normal mRNA specific heat-induced binding changes are detected. We conclude that heat-induced alterations in RNA-binding proteins do not mediate preferential translation of heat stress mRNAs or repression of nor mal mRNAs.	UNIV SO CALIF,SCH PHARM,DEPT MOLEC PHARMACOL & TOXICOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033	University of Southern California; University of Southern California					NIGMS NIH HHS [GM42644] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONNER JJ, 1984, CELL, V37, P979; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; GEHRKE L, 1983, BIOCHEMISTRY-US, V22, P5157, DOI 10.1021/bi00291a015; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; INGOLIA TD, 1980, CELL, V21, P669, DOI 10.1016/0092-8674(80)90430-4; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JOBLING SA, 1987, NATURE, V325, P622, DOI 10.1038/325622a0; JOSHIBARVE S, 1992, J BIOL CHEM, V267, P21038; KLEMENZ R, 1985, EMBO J, V4, P2053, DOI 10.1002/j.1460-2075.1985.tb03891.x; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAWSON TG, 1986, J BIOL CHEM, V261, P13979; LINDQUIST S, 1981, NATURE, V293, P311, DOI 10.1038/293311a0; LINDQUIST S, 1990, ENZYME, V44, P147, DOI 10.1159/000468754; LINDQUIST S, 1987, TRANSLATIONAL REGULA, P187; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MAROTO FG, 1988, J BIOL CHEM, V263, P15720; MCGARRY TJ, 1985, CELL, V42, P903, DOI 10.1016/0092-8674(85)90286-7; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; PANNIERS R, 1985, J BIOL CHEM, V260, P9648; PARKIN NT, 1989, ONCOGENE, V4, P815; PETERSEN NS, 1981, P NATL ACAD SCI-BIOL, V78, P1708, DOI 10.1073/pnas.78.3.1708; RYCHLIK W, 1986, J BIOL CHEM, V261, P71; SANDERS MM, 1986, J BIOL CHEM, V261, P2189; SHERMAN DR, 1989, TRENDS GENET, V5, P137; SONENBERG N, 1987, ADV VIRUS RES, V33, P175, DOI 10.1016/S0065-3527(08)60318-8; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; ZAPATA JM, 1991, J BIOL CHEM, V266, P16007; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	38	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10913	10922						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511613				2022-12-25	WOS:A1994NF01700106
J	POWERS, MF; SMITH, LL; BEAVIS, AD				POWERS, MF; SMITH, LL; BEAVIS, AD			ON THE RELATIONSHIP BETWEEN THE MITOCHONDRIAL INNER MEMBRANE ANION CHANNEL AND THE ADENINE-NUCLEOTIDE TRANSLOCASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; K+ FLUX; DIBUTYLCHLOROMETHYLTIN CHLORIDE; STRUCTURAL RELATIONSHIP; CATIONIC AMPHIPHILES; HEART MITOCHONDRIA; LIGHT-SCATTERING; CARRIER PROTEIN; INHIBITION; SEQUENCE	The mitochondrial inner membrane anion channel (IMAC) is a transport pathway which is believed to be involved in mitochondrial volume homeostasis. The protein, however, has not been identified. In this paper, we examine the relationship between IMAC and the adenine nucleotide translocator. Many inhibitors of the adenine nucleotide translocase are shown to block IMAC, including Cibacron blue 3GA, bromcresol green, alizarin red S, agaric acid, palmitoyl-CoA, and the fluorescein derivatives erythrosin B, erythrosin isothiocyanate, rose bengal, and eosin Y. The following evidence suggests that Cibacron blue, agaric acid, and palmitoyl-CoA inhibit by binding to a common site. 1) They all only partially block the transport of small anions such as Cl-, NO3-, and HCO3-, but completely block the transport of larger anions such as malonate. 2) They decrease the IC50 values of each other in a manner consistent with competitive binding. 3) N-Ethylmaleimide decreases their IC50 values by a similar extent. 4) Inhibition by all shows no dependence on matrix pH and only a small dependence on medium pH. It is suggested that these agents may selectively bind to an open state of IMAC and inhibit by decreasing its conductance. The physiological nucleotides CoA, NAD(+) NADH, NADP(+), NADH, and ATP do not inhibit; in fact, IMAC is shown to transport ATP. Despite these similarities between IMAC and the adenine nucleotide translocase, IMAC appears to be a separate entity, since some of the IC50 values differ by up to 8-fold, and carboxyatractyloside, the most selective inhibitor of the adenine nucleotide translocase, has no effect on IMAC. In addition, IMAC is also able to transport AMP, while the adenine nucleotide translocase does not.	MED COLL OHIO,DEPT PHARMACOL,TOLEDO,OH 43699						NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [S15HL047735] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47735] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONENKO Y N, 1991, Biophysical Journal, V59, p216A; AQUILA H, 1982, H-S Z PHYSIOL CHEM, V363, P345; AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; AUSTIN J, 1984, J BIOL CHEM, V259, P154; AZZI A, 1966, BIOCHIM BIOPHYS ACTA, V120, P466, DOI 10.1016/0926-6585(66)90316-5; AZZI A, 1967, BIOCHIM BIOPHYS ACTA, V131, P468, DOI 10.1016/0005-2728(67)90006-0; BABEL W, 1991, BIOCHIM BIOPHYS ACTA, V670, P176; BEAVIS AD, 1987, J BIOL CHEM, V262, P15085; BEAVIS AD, 1989, EUR J BIOCHEM, V185, P511, DOI 10.1111/j.1432-1033.1989.tb15143.x; BEAVIS AD, 1989, J BIOL CHEM, V264, P17148; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BEAVIS AD, 1992, J BIOL CHEM, V267, P3079; BEAVIS AD, 1993, J BIOL CHEM, V268, P997; BEAVIS AD, 1992, J BIOENERG BIOMEMBR, V24, P77, DOI 10.1007/BF00769534; BEAVIS AD, 1989, J BIOL CHEM, V264, P1508; BEAVIS AD, 1991, BIOCHIM BIOPHYS ACTA, V1063, P111, DOI 10.1016/0005-2736(91)90360-K; BEAVIS AD, 1988, J BIOL CHEM, V263, P7544; BEAVIS AD, 1994, MOL BIOL MITOCHONDRI, P137; BOOS KS, 1981, FEBS LETT, V127, P40, DOI 10.1016/0014-5793(81)80336-5; BRIERLEY GP, 1969, BIOCHEM BIOPH RES CO, V35, P396, DOI 10.1016/0006-291X(69)90512-9; BRIERLEY GP, 1970, BIOCHEMISTRY-US, V9, P697, DOI 10.1021/bi00806a001; BRIERLEY GP, 1970, BIOCHEMISTRY-US, V9, P677; CHAVEZ E, 1978, BIOCHEM BIOPH RES CO, V67, P272; DIWAN JJ, 1986, J BIOENERG BIOMEMBR, V18, P123, DOI 10.1007/BF00743481; DIWAN JJ, 1980, J BIOENERG BIOMEMBR, V12, P205, DOI 10.1007/BF00744684; DIWAN JJ, 1982, J BIOENERG BIOMEMBR, V14, P15, DOI 10.1007/BF00744076; DIWAN JJ, 1983, J BIOENERG BIOMEMBR, V15, P277, DOI 10.1007/BF00744525; GARLID KD, 1985, J BIOL CHEM, V260, P3434; GARLID KD, 1986, BIOCHIM BIOPHYS ACTA, V853, P187, DOI 10.1016/0304-4173(87)90001-2; GAUTHIER LM, 1979, BIOCHEM BIOPH RES CO, V87, P1072, DOI 10.1016/S0006-291X(79)80017-0; HALLESMITH SC, 1988, FEBS LETT, V236, P155, DOI 10.1016/0014-5793(88)80305-3; HARRIS EJ, 1973, FEBS LETT, V29, P339, DOI 10.1016/0014-5793(73)80054-7; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; MOREL F, 1974, FEBS LETT, V39, P133, DOI 10.1016/0014-5793(74)80035-9; MURRAY AG, 1988, EBEC REP, V5, P206; NESLUND GG, 1984, CURR TOP CELL REGUL, V24, P447; PETRESCU I, 1982, FEBS LETT, V141, P148, DOI 10.1016/0014-5793(82)80034-3; POWERS MF, 1990, BIOPHYS J, V57, pA179; POWERS MF, 1991, J BIOL CHEM, V266, P17250; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; Selwyn MJ, 1979, BIOCHEM SOC T, V7, P216, DOI 10.1042/bst0070216; SONE N, 1964, J BIOCHEM-TOKYO, V56, P151, DOI 10.1093/oxfordjournals.jbchem.a127972	43	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10614	10620						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511601				2022-12-25	WOS:A1994NF01700065
J	OKAMOTO, SI; MUKAIDA, N; YASUMOTO, K; RICE, N; ISHIKAWA, Y; HORIGUCHI, H; MURAKAMI, S; MATSUSHIMA, K				OKAMOTO, SI; MUKAIDA, N; YASUMOTO, K; RICE, N; ISHIKAWA, Y; HORIGUCHI, H; MURAKAMI, S; MATSUSHIMA, K			THE INTERLEUKIN-8 AP-1 AND KAPPA-B-LIKE SITES ARE GENETIC END TARGETS OF FK5O6-SENSITIVE PATHWAY ACCOMPANIED BY CALCIUM MOBILIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; PROTEIN-KINASE-C; CYCLOSPORINE-A; LYMPHOCYTES-T; HUMAN MONOCYTES; FACTOR BINDING; EXPRESSION; ENHANCER; REL; INTERFERON	FK506, an immunosuppressant, inhibits the production of several cytokines in T lymphocytes. We observed that FK506 suppressed the transcription of a chemotactic cytokine, interleukin-8 (IL-8) in a human T cell line, Jurkat cells, activated by phorbol 12-myristate 13-acetate (PMA) and calcium (Ca2+) ionophore (ionomycin). By deleted and mutated analysis of the IL-8 promoters, the AP-1 and kappa B-like sites were identified as the responsive elements for PMA and ionomycin. FK506 suppressed the transcriptions through the AP-1 or kappa B-like sites induced by PMA plus Ca2+-mobilizing agents, but not those induced by Ca2+-independent stimuli. In gel retardation analysis, FK506 had little effect on the binding to the AP-1 site of PMA/ionomyein-induced nuclear factors, which were recognized with anti-JunD or c-Fos antibody. In contrast, FK506 or EGTA (Ca2+ chelator) similarly affected the formation of kappa B-like site binding complexes, which were not recognized by any antibodies against the human Rel family proteins (c-Rel, p65, p50, and p49). Furthermore, we confirmed the previous report that FK506 suppressed the PMA/ionomycin-induced activation through authentic kappa B site of immunoglobulin (Ig) gene, to which NF-kappa B binding was also decreased by FK506, indicating that both IL-8 kappa B-like site and Ig kappa B Site are FK506-sensitive in spite of the difference of binding factors. Our results indicate that not only the reported IL-2 NF-AT and NFIL-2A sites and Ig kappa B site, but also the IL-8 AP-1 and kappa B-like sites are terminals of FK506-sensitive pathway involving Ca2+ mobilization.	KANAZAWA UNIV, CANC RES INST, DEPT PHARMACOL, KANAZAWA, ISHIKAWA 920, JAPAN; KANAZAWA UNIV, CANC RES INST, DEPT SURG, KANAZAWA, ISHIKAWA 920, JAPAN; KANAZAWA UNIV, CANC RES INST, DEPT BIOPHYS, KANAZAWA, ISHIKAWA 920, JAPAN; NCI, FREDERICK CANC RES & DEV CTR, ADV BIOSCI LABS, BASIC RES PROGRAM, FREDERICK, MD 21702 USA	Kanazawa University; Kanazawa University; Kanazawa University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851				ABATE C, 1991, ONCOGENE, V6, P2179; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BANERJI SS, 1991, MOL CELL BIOL, V11, P4074, DOI 10.1128/MCB.11.8.4074; BICKEL M, 1987, P NATL ACAD SCI USA, V84, P3274, DOI 10.1073/pnas.84.10.3274; BISHOP DK, 1992, J IMMUNOL, V148, P1049; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; BRABLETZ T, 1993, MOL CELL BIOL, V13, P1155, DOI 10.1128/MCB.13.2.1155; BROWNELL E, 1989, ONCOGENE, V4, P935; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLIOTT JF, 1984, SCIENCE, V226, P1439, DOI 10.1126/science.6334364; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GAWKRODGER DJ, 1986, CLIN EXP IMMUNOL, V66, P590; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANELLIPIPERNO A, 1990, J EXP MED, V172, P1869, DOI 10.1084/jem.172.6.1869; HAYRY P, 1988, ANN NY ACAD SCI, V532, P86; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; JAGELS MA, 1992, J IMMUNOL, V148, P1119; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KO YC, 1992, J IMMUNOL METHODS, V149, P227, DOI 10.1016/0022-1759(92)90254-Q; LARSEN CG, 1991, BIOCHEM BIOPH RES CO, V176, P1020, DOI 10.1016/0006-291X(91)90384-J; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; MAHE Y, 1991, J BIOL CHEM, V266, P13759; MALEFYT RD, 1991, J EXP MED, V174, P1209; MATSUSHIMA K, 1992, CHEM IMMUNOL, V51, P236; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; MUKAIDA N, 1992, MICROBIOL IMMUNOL, V36, P773, DOI 10.1111/j.1348-0421.1992.tb02080.x; OLIVEIRA IC, 1992, P NATL ACAD SCI USA, V89, P9049, DOI 10.1073/pnas.89.19.9049; PALIOGIANNI F, 1993, J CLIN INVEST, V91, P1481, DOI 10.1172/JCI116353; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; REEM GH, 1983, SCIENCE, V221, P63, DOI 10.1126/science.6407112; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; SCHMIDT A, 1990, J VIROL, V64, P4037, DOI 10.1128/JVI.64.8.4037-4041.1990; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740; STANDIFORD TJ, 1990, J IMMUNOL, V145, P1435; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; TOCCI MJ, 1989, J IMMUNOL, V143, P718; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; ZIPFEL PF, 1991, BIOCHEM BIOPH RES CO, V181, P179, DOI 10.1016/S0006-291X(05)81398-1	49	129	131	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8582	8589						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510691				2022-12-25	WOS:A1994NB40900112
J	GAGNON, Y; BRETON, R; PUTZER, H; PELCHAT, M; GRUNBERGMANAGO, M; LAPOINTE, J				GAGNON, Y; BRETON, R; PUTZER, H; PELCHAT, M; GRUNBERGMANAGO, M; LAPOINTE, J			CLUSTERING AND CO-TRANSCRIPTION OF THE BACILLUS-SUBTILIS GENES ENCODING THE AMINOACYL-TRANSFER-RNA SYNTHETASES SPECIFIC FOR GLUTAMATE AND FOR CYSTEINE AND THE FIRST ENZYME FOR CYSTEINE BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; SERINE ACETYLTRANSFERASE; REGULATORY SEQUENCE; OPERON; EXPRESSION; CLONING; CYSE; STEAROTHERMOPHILUS	The Bacillus subtilis cysE and cysS genes encoding, respectively, the serine acetyltransferase and the cysteinyl-tRNA synthetase were found downstream from the gltX gene encoding the glutamyl-tRNA synthetase. This gene organization is also conserved in Bacillus stearothermophilus where the cysE and cysS genes show high amino acid identity with those of B. subtilis. In both organisms the coding sequences of cysE and cysS overlap, suggesting a translational coupling. B. subtilis cysE and cysS were expressed in Escherichia coli using the inducible trc promoter; they functionally complement mutants of E. coli affected in those genes. Overproduction of B. subtilis CysRS in E. coli has a toxic effect on cell growth. Disruption of gltX and cysS by Campbell-type insertion is lethal for the cell, indicating that these genes code for an essential and unique function in B. subtilis. S1 mapping analysis shows that the transcription of gltX is under the control of a sigma A promoter located 43 base pairs upstream of the initiation codon. A T-box sequence and a rho-independent terminator known to regulate expression of other aminoacyl-tRNA synthetase genes and of some amino acid biosynthetic operons in Bacillus sp., were found between gltX and cysE. No sigma A promoter was detected upstream of cysE, which is consistent with the lethality of a Campbell-type insertion using a plasmid that interrupts transcription coming from the gltX promoter, and suggests that gltX, cysE, and cysS constitute an operon. This is the first case where genes implicated in the biosynthesis of an amino acid and its cognate aminoacyl-tRNA synthetase are shown to be co-transcribed.	UNIV LAVAL,FAC SCI & GENIE,DEPT BIOCHIM,QUEBEC CITY G1K 7P4,PQ,CANADA; INST BIOL PHYSICOCHIM,SERV BIOCHIM,F-75005 PARIS,FRANCE	Laval University			Putzer, Harald/GRY-6203-2022					AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; ANTONIEWSKI C, 1990, J BACTERIOL, V172, P86, DOI 10.1128/JB.172.1.86-93.1990; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BOHMAN K, 1979, MOL GEN GENET, V176, P53, DOI 10.1007/BF00334295; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETON R, 1990, J BIOL CHEM, V265, P18248; BRETON R, 1990, THESIS U LAVAL; Brun Y V, 1991, DNA Seq, V1, P285, DOI 10.3109/10425179109020784; BURKHOLDER PR, 1947, AM J BOT, V34, P345, DOI 10.2307/2437147; CAMPBELL LL, 1955, ARCH BIOCHEM BIOPHYS, V54, P154, DOI 10.1016/0003-9861(55)90018-7; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P8275; DEBARBOUILLE M, 1990, J BACTERIOL, V172, P3966, DOI 10.1128/jb.172.7.3966-3973.1990; DENK D, 1987, J GEN MICROBIOL, V133, P515; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOWNIE JA, 1989, MOL MICROBIOL, V3, P1649, DOI 10.1111/j.1365-2958.1989.tb00150.x; ERANI G, 1990, NATURE, V347, P203; EVANS DJ, 1991, J BACTERIOL, V173, P5457, DOI 10.1128/jb.173.17.5457-5469.1991; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Glaser P, 1990, J DNA MAPPING SEQUEN, V1, P251; GRANDONI JA, 1992, J BACTERIOL, V174, P3212, DOI 10.1128/jb.174.10.3212-3219.1992; GRUNBERGMANAGO M, 1989, ESCHERICHIA COLI SAL, P1386; GRUNDY FJ, 1993, CELL, V74, P475, DOI 10.1016/0092-8674(93)80049-K; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARDY KG, 1985, DNA CLONING PRACTICA, V2, P1; HENKIN TM, 1992, J BACTERIOL, V174, P1299, DOI 10.1128/jb.174.4.1299-1306.1992; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; JOHNESMORTIMER MC, 1968, BIOCHEM J, V110, P589; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI CY, 1992, GENE, V119, P113, DOI 10.1016/0378-1119(92)90074-Y; LAPOINTE J, 1986, J BACTERIOL, V165, P88, DOI 10.1128/jb.165.1.88-93.1986; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEVEQUE F, 1990, NUCLEIC ACIDS RES, V18, P305, DOI 10.1093/nar/18.2.305; MCCARTHY JEG, 1990, MOL MICROBIOL, V4, P1233, DOI 10.1111/j.1365-2958.1990.tb00702.x; MECHULAM Y, 1991, NUCLEIC ACIDS RES, V19, P3673, DOI 10.1093/nar/19.13.3673; Miller J.H., 1972, EXPT MOL GENETICS; MORAN CP, 1982, MOL GEN GENET, V186, P339, DOI 10.1007/BF00729452; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; PUTZER H, 1992, EMBO J, V11, P3117, DOI 10.1002/j.1460-2075.1992.tb05384.x; PUTZER H, 1990, J BACTERIOL, V172, P4593, DOI 10.1128/jb.172.8.4593-4602.1990; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNETZ K, 1988, EMBO J, V7, P3271, DOI 10.1002/j.1460-2075.1988.tb03194.x; SWANSON R, 1988, SCIENCE, V242, P1548, DOI 10.1126/science.3144042; VANDERHORN PB, 1992, J BACTERIOL, V174, P3928, DOI 10.1128/jb.174.12.3928-3935.1992; VARY PS, 1988, GENETICS BIOTECHNOLO, V2, P403; VELLANOWETH RL, 1992, MOL MICROBIOL, V6, P1105, DOI 10.1111/j.1365-2958.1992.tb01548.x; Vellanoweth Robert Luis, 1993, P699; WILCOX M, 1968, P NATL ACAD SCI USA, V61, P229, DOI 10.1073/pnas.61.1.229; WILLIAMS JG, 1985, NUCLEIC ACID HYBRIDI, P139; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YANOFSKY C, 1984, MOL BIOL EVOL, V1, P143	52	59	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7473	7482						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7510287				2022-12-25	WOS:A1994NA03200070
J	RIDGWELL, K; EYERS, SAC; MAWBY, WJ; ANSTEE, DJ; TANNER, MJA				RIDGWELL, K; EYERS, SAC; MAWBY, WJ; ANSTEE, DJ; TANNER, MJA			STUDIES ON THE GLYCOPROTEIN ASSOCIATED WITH RH (RHESUS) BLOOD-GROUP ANTIGEN EXPRESSION IN THE HUMAN RED-BLOOD-CELL MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; ENDO-BETA-GALACTOSIDASE; SOLID-PHASE SYNTHESIS; MONOCLONAL-ANTIBODIES; RH(D) POLYPEPTIDE; MOLECULAR-CLONING; PEPTIDE-SYNTHESIS; ANION TRANSPORT; MESSENGER-RNAS; PROTEIN	The blood group Rh antigens are associated with non-glycosylated 30-kDa erythrocyte membrane proteins (the Rh-30 polypeptides) and the Rh glycoprotein. We used antipeptide antibodies to study the Rh glycoprotein in human erythrocyte membranes. The Rh glycoprotein was present in Rh-null U+ve cells. However, the N-glycan chain of the Rh glycoprotein in Rh-null U+ve cells was smaller than in normal cells. In contrast, the N-glycan chain of the Rh glycoprotein was larger than normal in glycophorin B-deficient red cells. We suggest that this observation reflects a lower rate of movement of newly synthesized Rh glycoprotein through intracellular membranes to the cell surface in the absence of glycophorin B, and that in normal red cells glycophorin B facilitates the movement of the Rh protein complex to the cell surface. Our results provide evidence for the intracellular interaction of a least three proteins, the Rh glycoprotein, Rh-30 polypeptides, and glycophorin B during the biosynthesis and cell surface expression of the Rh complex. These observations are likely to be important for the successful design of expression systems for the blood group Rh antigens.	UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,ENGLAND; INT BLOOD GRP,REFERENCE LAB,BRISTOL BS10 5ND,ENGLAND	University of Bristol			Anstee, David/AAE-9231-2020					AGRE P, 1991, BLOOD, V78, P551, DOI 10.1182/blood.V78.3.551.bloodjournal783551; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; ANSTEE DJ, 1993, BAILLIERE CLIN HAEM, V6, P401, DOI 10.1016/S0950-3536(05)80152-0; ATHERTON E, 1981, J CHEM SOC PERK T 1, P538, DOI 10.1039/p19810000538; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; AVENT N, 1988, BIOCHEM J, V251, P499, DOI 10.1042/bj2510499; AVENT ND, 1990, BIOCHEM J, V271, P821, DOI 10.1042/bj2710821; AVENT ND, 1992, J BIOL CHEM, V267, P15134; AVENT ND, 1988, BIOCHEM J, V256, P1043, DOI 10.1042/bj2561043; BLOY C, 1988, BLOOD, V72, P661; BRUNS GAP, 1989, CYTOGENET CELL GENET, V51, P67, DOI 10.1159/000132781; CHERIFZAHAR B, 1991, HUM GENET, V86, P398, DOI 10.1007/BF00201843; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; DAHR W, 1987, BLUT, V55, P19, DOI 10.1007/BF00319637; DAHR W, 1987, BIOL CHEM H-S, V368, P659, DOI 10.1515/bchm3.1987.368.1.659; DAHR W, 1978, H-S Z PHYSIOL CHEM, V359, P1217, DOI 10.1515/bchm2.1978.359.2.1217; DAHR W, 1987, BLUT, V54, P13, DOI 10.1007/BF00326022; DRYLAND A, 1986, J CHEM SOC PERK T 1, P125, DOI 10.1039/p19860000125; EYERS SAC, 1994, J BIOL CHEM, V269, P6417; FUKUDA MN, 1979, J BIOL CHEM, V254, P5458; GAHMBERG CG, 1976, J BIOL CHEM, V251, P6108; GAHMBERG CG, 1983, EMBO J, V2, P223, DOI 10.1002/j.1460-2075.1983.tb01409.x; GROVES JD, 1992, J BIOL CHEM, V267, P22163; JARNEFELT J, 1978, J BIOL CHEM, V253, P8006; KAJII E, 1992, P JPN ACAD B-PHYS, V68, P51, DOI 10.2183/pjab.68.51; KITAMIKADO M, 1981, J BIOL CHEM, V256, P3906; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU JTY, 1983, J BIOL CHEM, V258, P5255; LEVANKIM C, 1992, P NATL ACAD SCI USA, V89, P10925, DOI 10.1073/pnas.89.22.10925; LEVANKIM C, 1992, BLOOD, V80, P1074; MACGEOCH C, 1992, CYTOGENET CELL GENET, V59, P261, DOI 10.1159/000133264; MALLINSON G, 1986, BIOCHEM J, V234, P649, DOI 10.1042/bj2340649; MALLINSON G, 1990, TRANSFUSION, V30, P222, DOI 10.1046/j.1537-2995.1990.30390194341.x; MOLLISON PL, 1987, BLOOD TRANSFUSION CL; MOORE S, 1982, NATURE, V295, P529, DOI 10.1038/295529a0; MOORE S, 1987, BIOCHEM J, V244, P735, DOI 10.1042/bj2440735; Race R. R, 1968, BLOOD GROUPS MAN; RIDGWELL K, 1992, BIOCHEM J, V287, P223, DOI 10.1042/bj2870223; RIDGWELL K, 1983, BIOCHEM J, V213, P267, DOI 10.1042/bj2130267; SABOORI AM, 1989, J CLIN INVEST, V83, P187, DOI 10.1172/JCI113857; SABOORI AM, 1988, P NATL ACAD SCI USA, V85, P4042, DOI 10.1073/pnas.85.11.4042; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT PJ, 1967, VOX SANG, V13, P18, DOI 10.1111/j.1423-0410.1967.tb03383.x; SUYAMA K, 1992, BLOOD, V79, P808; SUYAMA K, 1991, BLOOD, V77, P411; TANNER MJA, 1976, BIOCHEM J, V155, P701, DOI 10.1042/bj1550701; TARENTINO AL, 1987, METHOD ENZYMOL, V138, P770; VONDEMBORNE AEGK, 1990, BRIT J HAEMATOL, V75, P254; WAINWRIGHT SD, 1989, BIOCHEM J, V258, P211, DOI 10.1042/bj2580211	52	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6410	6416						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509803				2022-12-25	WOS:A1994MZ50300026
J	BURGESS, JW; STANLEY, KK				BURGESS, JW; STANLEY, KK			17-ALPHA-ETHINYLESTRADIOL INCREASES TRANSCYTOSIS OF ASIALOGLYCOPROTEINS IN RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-MEDIATED ENDOCYTOSIS; IMMUNOELECTRON MICROSCOPIC VISUALIZATION; CARBOHYDRATE RECOGNITION SYSTEMS; LIPID-ACCUMULATION; CELLS; BINDING; PROTEIN; HEPATOCYTES; ESTROGEN	We have measured the hepatobiliary transcytosis of asialofetuin (ASF) and low density lipoprotein (LDL) in rats following treatment with 5 mg of 17alpha-ethinylestradiol/kg of body weight for 3 days. The rate of appearance of both ligands in bile was increased 5-fold in estradiol-treated rats compared with controls. In contrast, no increase was observed in the transcytosis of dimeric IgA. The majority of the ASF recovered from the bile of estradiol-treated rats was undegraded, indicating transcytic delivery rather than lysosomal discharge. No increase in the rate of endocytosis of ASF was observed. When transcytosis of I-125-LDL was measured in the presence of excess ASF the rate decreased by approximately 70%. Moreover, sialidase treatment of LDL in vitro increased the biliary appearance of LDL 2-fold in estradiol-treated rats, suggesting that the effect of estradiol on both ligands was mediated via the asialoglycoprotein receptor. We conclude that 17alpha-ethinylestradiol increases the transcytosis of ASF and LDL through mechanisms that alter the intracellular trafficking of the asialoglycoprotein receptor.	HEART RES INST, 145 MISSENDEN RD, CAMPERDOWN, NSW 2050, AUSTRALIA	University of Sydney; Heart Research Institute								BELCHER JD, 1987, P NATL ACAD SCI USA, V84, P6785, DOI 10.1073/pnas.84.19.6785; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BERTHOIS Y, 1989, BIOCHEM BIOPH RES CO, V159, P126, DOI 10.1016/0006-291X(89)92413-3; BOMSEL M, 1991, J CELL BIOL, V115, P195; BREITFELD PP, 1985, EUR J BIOCHEM, V150, P409, DOI 10.1111/j.1432-1033.1985.tb09035.x; BROWN MS, 1978, J SUPRAMOL STR CELL, V8, P223, DOI 10.1002/jss.400080302; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHAO Y, 1979, J BIOL CHEM, V254, P1360; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHUNG BH, 1980, J LIPID RES, V21, P284; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COOPER AD, 1987, J LIPID RES, V28, P59; DAVIS RA, 1978, ATHEROSCLEROSIS, V30, P293, DOI 10.1016/0021-9150(78)90122-3; DICKSON RB, 1986, CANCER RES, V46, P1707; DICZFALUSY E, 1969, FOETUS PLACENTA, P191; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; DUFOUR JF, 1992, HEPATOLOGY, V16, P997, DOI 10.1002/hep.1840160424; FALLON RJ, 1988, J BIOL CHEM, V263, P13159; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GEFFEN I, 1991, P NATL ACAD SCI USA, V88, P8425, DOI 10.1073/pnas.88.19.8425; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HARKES L, 1984, BIOCHEM J, V224, P21, DOI 10.1042/bj2240021; HAY RV, 1971, BIOCHEM BIOPH RES CO, V44, P1471, DOI 10.1016/S0006-291X(71)80251-6; HUBBARD AL, 1979, J CELL BIOL, V83, P65, DOI 10.1083/jcb.83.1.65; HUBBARD AL, 1979, J CELL BIOL, V83, P47, DOI 10.1083/jcb.83.1.47; HUFF KK, 1988, MOL ENDOCRINOL, V2, P200, DOI 10.1210/mend-2-3-200; KAETZEL CS, 1991, P NATL ACAD SCI USA, V88, P8796, DOI 10.1073/pnas.88.19.8796; KAWASAKI T, 1976, J BIOL CHEM, V251, P1296; KLEINHERENBRINKSTINS MF, 1990, LAB INVEST, V63, P73; KOLSET SO, 1979, EXP CELL RES, V122, P159, DOI 10.1016/0014-4827(79)90570-6; KOVANEN PT, 1979, J BIOL CHEM, V254, P1367; MUELLER SC, 1986, J CELL BIOL, V102, P932, DOI 10.1083/jcb.102.3.932; OREKHOV AN, 1989, BIOCHEM BIOPH RES CO, V162, P206, DOI 10.1016/0006-291X(89)91982-7; OREKHOV AN, 1991, ATHEROSCLEROSIS, V86, P153, DOI 10.1016/0021-9150(91)90211-K; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; Pittman R C, 1986, Methods Enzymol, V129, P612; RUDLING M, 1992, P NATL ACAD SCI USA, V89, P6983, DOI 10.1073/pnas.89.15.6983; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SNELTINGHAVINGA I, 1989, EUR J CELL BIOL, V48, P27; SOBENIN IA, 1991, ATHEROSCLEROSIS, V89, P151, DOI 10.1016/0021-9150(91)90055-8; SOLARI R, 1984, CELL, V36, P61, DOI 10.1016/0092-8674(84)90074-6; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; STEER CJ, 1980, J BIOL CHEM, V255, P3008; STOORVOGEL W, 1991, J BIOL CHEM, V266, P5438; TAKAHASHI T, 1985, BIOCHEM BIOPH RES CO, V126, P1054, DOI 10.1016/0006-291X(85)90292-X; TERTOV VV, 1989, BIOCHEM BIOPH RES CO, V163, P489, DOI 10.1016/0006-291X(89)92163-3; THIRION J, 1991, BIOL CELL, V71, P267, DOI 10.1016/0248-4900(91)90269-S; WADE DP, 1988, EUR J BIOCHEM, V174, P213, DOI 10.1111/j.1432-1033.1988.tb14084.x; WAN JS, 1992, J BIOL CHEM, V267, P13446; WESTWOOD SA, 1979, BIOCHIM BIOPHYS ACTA, V583, P454, DOI 10.1016/0304-4165(79)90062-X; WINDLER E, 1991, BIOCHEM J, V276, P79, DOI 10.1042/bj2760079	53	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3482	3488						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508915				2022-12-25	WOS:A1994MV63100055
J	LIN, JH; WU, XR; KREIBICH, G; SUN, TT				LIN, JH; WU, XR; KREIBICH, G; SUN, TT			PRECURSOR SEQUENCE, PROCESSING, AND UROTHELIUM-SPECIFIC EXPRESSION OF A MAJOR 15-KDA PROTEIN SUBUNIT OF ASYMMETRIC UNIT MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT URINARY-BLADDER; TRANSITIONAL EPITHELIAL-CELLS; AMINO-ACID-SEQUENCE; LUMINAL MEMBRANE; 3-DIMENSIONAL STRUCTURE; SECONDARY-STRUCTURE; PLASMA-MEMBRANE; GOLGI-APPARATUS; UROPLAKIN-I; SURFACE	The asymmetric unit membrane (AUM) is a highly specialized biomembrane elaborated by terminally differentiated urothelial cells. It contains quasi-crystalline arrays of 12-nm protein particles each of which is composed of six dumbbell-shaped subdomains. In this paper we describe the precursor sequence, processing and in vitro membrane insertion properties of bovine uroplakin II (UPII), a 15-kDa major protein component of AUM. The cDNA-deduced amino acid sequence revealed that UPII is synthesized as a precursor protein containing a cleavable signal peptide of approximately 26 amino acids, a long pro-sequence of approximately 59 residues harboring three potential N-glycosylation sites, and the mature polypeptide of 100 residues. In vitro translation of UPII mRNA demonstrated that UPII is indeed first synthesized as a 19-kDa precursor, which loses its signal peptide upon insertion into added microsomes; this process is accompanied by the acquisition of high mannose-type oligosaccarides giving rise to a 28-kDa precursor which is completely protected from the digestion by exogenous proteases. These results, together with the presence of a stretch of 25 hydrophobic amino acids at the C terminus, suggest that UPII protein is anchored to the lipid bilayer via its C-terminal membrane-spanning domain with its major N-terminal domain exposed luminally. The formation of the 15-kDa mature UPII requires the removal of the pro-sequence by a furin-like endoprotease. Since only mature UPII devoid of this pro-sequence can interact with 27-kDa uroplakin I, the proteolytic processing of UPII precursor may play an important role in regulating the assembly of AUM. Finally, we showed that genomic sequences cross-hybridizing with bovine UPII cDNA are present in many mammals suggesting that UPII performs a highly conserved function in the terminally differentiated cells of mammalian urinary bladder epithelium.	NYU, SCH MED,RONALD O PERELMAN DEPT DERMATOL, EPITHELIAL BIOL UNIT,566 1ST AVE, NEW YORK, NY 10016 USA; NYU, SCH MED, DEPT PHARMACOL, NEW YORK, NY 10016 USA; NYU, SCH MED, KAPLAN COMPREHENS CANC CTR, DEPT CELL BIOL, NEW YORK, NY 10016 USA	New York University; New York University; New York University			Sun, Tung-Tien/J-4425-2015	Sun, Tung-Tien/0000-0002-6841-1063; Wu, Xue-Ru/0000-0001-6058-6291	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039753] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39749] Funding Source: Medline; NIDDK NIH HHS [DK39753] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALROY J, 1982, ANAT RECORD, V203, P429, DOI 10.1002/ar.1092030402; ALROY J, 1980, ANAT RECORD, V197, P75, DOI 10.1002/ar.1091970107; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BRISSON A, 1983, J MOL BIOL, V166, P21, DOI 10.1016/S0022-2836(83)80048-5; CARUTHERS JMS, 1980, J ULTRA MOL STRUCT R, V71, P288, DOI 10.1016/S0022-5320(80)90080-5; CARUTHERS JS, 1977, J CELL BIOL, V73, P382, DOI 10.1083/jcb.73.2.382; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLAUDIO T, 1989, J CELL BIOL, V108, P2277, DOI 10.1083/jcb.108.6.2277; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Gennis R., 1989, BIOMEMBRANE MOL STRU; HICKS RM, 1970, J CELL BIOL, V45, P542, DOI 10.1083/jcb.45.3.542; HICKS RM, 1969, NATURE, V224, P1304, DOI 10.1038/2241304a0; HICKS RM, 1966, J CELL BIOL, V30, P623, DOI 10.1083/jcb.30.3.623; HICKS RM, 1965, J CELL BIOL, V26, P25, DOI 10.1083/jcb.26.1.25; HICKS RM, 1975, BIOL REV, V50, P215, DOI 10.1111/j.1469-185X.1975.tb01057.x; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; KETTERER B, 1973, BIOCHIM BIOPHYS ACTA, V311, P180, DOI 10.1016/0005-2736(73)90265-4; KNUTTON S, 1976, J CELL SCI, V22, P355; KOSS LG, 1969, LAB INVEST, V21, P154; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEWIS SA, 1984, J MEMBRANE BIOL, V82, P123, DOI 10.1007/BF01868937; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; LONSDALEECCLES JD, 1981, BIOCHEM J, V197, P591, DOI 10.1042/bj1970591; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MINSKY BD, 1978, J CELL BIOL, V77, P685, DOI 10.1083/jcb.77.3.685; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; PAULI BU, 1983, PATHOLOGY BLADDER CA, P42; PORTER KR, 1967, PROTOPLASMA, V63, P262, DOI 10.1007/BF01248042; PORTER KR, 1963, INTRO FINE STRUCTURE; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; ROBERTSON JD, 1980, J CELL BIOL, V86, P514, DOI 10.1083/jcb.86.2.514; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; RYAN AM, 1993, IN PRESS MAMM GENOME; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIKAS SN, 1986, CELL TISSUE RES, V246, P109; SEVERS NJ, 1979, J ULTRA MOL STRUCT R, V69, P279, DOI 10.1016/S0022-5320(79)90117-5; STAEHELIN LA, 1972, J CELL BIOL, V53, P73, DOI 10.1083/jcb.53.1.73; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; STUBBS CD, 1979, BIOCHIM BIOPHYS ACTA, V558, P58, DOI 10.1016/0005-2736(79)90315-8; SURYA B, 1990, J CELL SCI, V97, P419; TAYLOR KA, 1984, J ULTRA MOL STRUCT R, V87, P23, DOI 10.1016/S0022-5320(84)90113-8; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; VERGARA J, 1974, J CELL BIOL, V61, P83, DOI 10.1083/jcb.61.1.83; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WARREN RC, 1970, NATURE, V227, P280, DOI 10.1038/227280b0; WU XR, 1993, J CELL SCI, V106, P31; WU XR, 1990, J BIOL CHEM, V265, P19170; YU J, 1990, J CELL BIOL, V111, P1207, DOI 10.1083/jcb.111.3.1207; YU YH, 1989, P NATL ACAD SCI USA, V86, P9931, DOI 10.1073/pnas.86.24.9931	65	74	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1775	1784						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507484				2022-12-25	WOS:A1994MR98800038
J	BOGOYEVITCH, MA; GLENNON, PE; ANDERSSON, MB; CLERK, A; LAZOU, A; MARSHALL, CJ; PARKER, PJ; SUGDEN, PH				BOGOYEVITCH, MA; GLENNON, PE; ANDERSSON, MB; CLERK, A; LAZOU, A; MARSHALL, CJ; PARKER, PJ; SUGDEN, PH			ENDOTHELIN-1 AND FIBROBLAST GROWTH-FACTORS STIMULATE THE MITOGEN-ACTIVATED PROTEIN-KINASE SIGNALING CASCADE IN CARDIAC MYOCYTES - THE POTENTIAL ROLE OF THE CASCADE IN THE INTEGRATION OF 2 SIGNALING PATHWAYS LEADING TO MYOCYTE HYPERTROPHY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MYOCARDIAL-CELLS; MAP KINASE; GENE-EXPRESSION; TYROSINE PHOSPHORYLATION; DIFFERENTIAL REGULATION; VENTRICULAR MYOCYTES; INDEPENDENT PATHWAYS; BIPHASIC ACTIVATION; SKELETAL-MUSCLE; MESANGIAL CELLS	Maximally effective concentrations of endothelin-1 (ET-1), acidic FGF (aFGF), or 12-O-tetradecanoylphorbol-13-acetate (TPA) activated mitogen-activated protein kinase (MAPK) by 3-4-fold in crude extracts of myocytes cultured from neonatal rat heart ventricles. Maximal activation was achieved after 5 min. Thereafter, MAPK activity stimulated by ET-1 or aFGF declined to control values within 1-2 h, whereas activation by TPA was more sustained. Two peaks of MAPK activity (a 42- and a 44-kDa MAPK) were resolved in cells exposed to ET-1 or aFGF by fast protein liquid chromatography on a Mono Q column. One major and one minor peak of MAPK kinase (MAPKK) was stimulated by ET-1 or aFGF. Cardiac myocytes expressed protein kinase C (PKC)-alpha, -delta, -epsilon, and -zeta as shown by immunoblotting. Exposure to 1 muM TPA for 24 h down-regulated PKC-alpha, -delta, and -epsilon, but not PKC-zeta. This maneuver wholly abolished the activation of MAPK on re-exposure to TPA but did not affect the response to aFGF. The effect of ET-1 was partially down-regulated. ET-1 stimulated phospho[H-3]inositide hydrolysis 18-fold, whereas aFGF stimulated by only 30%. Agonists which initially utilize dissimilar signaling pathways may therefore converge at the level of MAPKK/MAPK and this may be relevant to the hypertrophic response of the heart.	UNIV LONDON, NATL HEART & LUNG INST, DEPT CARDIAC MED, DOVEHOUSE ST, LONDON SW3 6LY, ENGLAND; UNIV LONDON, CHESTER BEATTY LABS, LONDON SW3 6JB, ENGLAND; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Imperial College London; University of London; University of London; Institute of Cancer Research - UK; Cancer Research UK			Lazou, Antigone/L-3878-2014; Lazou, A./I-4511-2019; Parker, Peter j/D-5192-2013	Lazou, A./0000-0002-7889-9648; Clerk, Angela/0000-0002-5658-0708; parker, peter/0000-0002-6218-2933; Bogoyevitch, Marie/0000-0001-9745-3716	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CLEMENS MJ, 1992, J CELL SCI, V103, P881; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CRABOS M, 1992, BIOCHEM J, V288, P891, DOI 10.1042/bj2880891; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; FEDIDA D, 1993, PHYSIOL REV, V73, P469, DOI 10.1152/physrev.1993.73.2.469; FORCE T, 1991, J BIOL CHEM, V266, P6650; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GRANOT Y, 1993, J BIOL CHEM, V268, P9564; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; ISHIDA Y, 1992, FEBS LETT, V310, P41, DOI 10.1016/0014-5793(92)81142-9; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KRAMER BK, 1992, CIRCULATION, V85, P350, DOI 10.1161/01.CIR.85.1.350; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEIDELL RS, 1986, AM J PHYSIOL, V251, P1076; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; OTSU M, 1993, FEBS LETT, V320, P246, DOI 10.1016/0014-5793(93)80596-M; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEARS CJ, 1991, J CELL SCI, V100, P683; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; SETH A, 1992, J BIOL CHEM, V267, P24796; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SIMPSON PC, 1989, ANNU REV PHYSIOL, V51, P189, DOI 10.1146/annurev.ph.51.030189.001201; SOKOLOVSKY M, 1991, TRENDS BIOCHEM SCI, V16, P261, DOI 10.1016/0968-0004(91)90100-A; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUGDEN PH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P327, DOI 10.1016/0167-4889(93)90225-E; SUZUKI T, 1990, FEBS LETT, V268, P149, DOI 10.1016/0014-5793(90)80995-U; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; TERZIC A, 1993, PHARMACOL REV, V45, P147; THORBURN A, 1993, J BIOL CHEM, V268, P2244; TOBE K, 1991, J BIOL CHEM, V266, P24793; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WAYS DK, 1992, J BIOL CHEM, V267, P4799; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	91	356	362	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1110	1119						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507104				2022-12-25	WOS:A1994MR22000054
J	HARRISON, ML; ISAACSON, CC; BURG, DL; GEAHLEN, RL; LOW, PS				HARRISON, ML; ISAACSON, CC; BURG, DL; GEAHLEN, RL; LOW, PS			PHOSPHORYLATION OF HUMAN ERYTHROCYTE BAND-3 BY ENDOGENOUS P72(SYK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; RED-CELL MEMBRANE; INSULIN-RECEPTOR KINASE; ANTIGEN RECEPTOR; PARTIAL-PURIFICATION; PHOSPHATASE-ACTIVITY; ACID-PHOSPHATASE; RAT ADIPOCYTES; BOVINE THYMUS; VANADATE	The anion transporter, band 3, is the major tyrosine kinase substrate in both red cell membranes and intact human erythrocytes. Using antibodies to various protein-tyrosine kinases, we found that p72syk and p56/53lyn are present in human red cells, while p56lck, pp60src, p59fyn, and p55blk are absent. Treatment of intact red cells with a combination of vanadate and hydrogen peroxide dramatically increased the tyrosine phosphorylation of band 3. This treatment increased the tyrosine kinase activity of p72syk and decreased the activity of p56/53lyn in immune complex kinase assays. Band 3 was found to be associated in immune complexes with p72syk but not with p56/53lyn. These findings suggest that p72syk is responsible, at least in part, for the tyrosine phosphorylation of band 3 in human erythrocytes.	PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus	HARRISON, ML (corresponding author), PURDUE UNIV,DEPT MED CHEM & PHARMACOGNOSY,W LAFAYETTE,IN 47907, USA.			Geahlen, Robert/0000-0001-8400-2924; Low, Philip/0000-0001-9042-5528	NCI NIH HHS [CA37372] Funding Source: Medline; NIGMS NIH HHS [GM40983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BOIVIN P, 1985, FEBS LETT, V186, P89, DOI 10.1016/0014-5793(85)81345-4; BOIVIN P, 1986, BIOCHIM BIOPHYS ACTA, V860, P243, DOI 10.1016/0005-2736(86)90520-1; BOIVIN P, 1986, BIOCHEM BIOPH RES CO, V134, P557, DOI 10.1016/S0006-291X(86)80456-9; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BURG DL, 1993, J BIOL CHEM, V268, P2304; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CLARI G, 1989, EUR J BIOCHEM, V179, P581, DOI 10.1111/j.1432-1033.1989.tb14586.x; CLARI G, 1987, BIOCHEM BIOPH RES CO, V142, P587, DOI 10.1016/0006-291X(87)90314-7; CLARI G, 1988, EUR J BIOCHEM, V175, P673, DOI 10.1111/j.1432-1033.1988.tb14243.x; CLARI G, 1986, BIOCHEM BIOPH RES CO, V137, P556; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; DEKOWSKI SA, 1983, J BIOL CHEM, V258, P2750; DONS RF, 1981, J BIOL CHEM, V256, P2982; ENGELMANN B, 1992, AM J HEMATOL, V39, P239, DOI 10.1002/ajh.2830390402; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FOULKES JG, 1985, CANCER CELL, V3, P329; GAMBHIR KK, 1978, DIABETES, V27, P701, DOI 10.2337/diabetes.27.7.701; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GRIGORESCU F, 1983, J BIOL CHEM, V258, P3708; HARRISON ML, 1991, J BIOL CHEM, V266, P4106; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HERZBERG V, 1980, NATURE, V286, P279, DOI 10.1038/286279a0; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IM JH, 1983, J BIOL CHEM, V258, P5021; KADOTA S, 1987, J BIOL CHEM, V262, P8252; KADOTA S, 1987, BIOCHEM BIOPH RES CO, V147, P259, DOI 10.1016/S0006-291X(87)80115-8; KLIMAN HJ, 1980, J BIOL CHEM, V255, P6314; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOW PS, 1987, J BIOL CHEM, V262, P4592; LOW PS, 1993, J BIOL CHEM, V268, P14627; MACARA IG, 1980, BIOCHIM BIOPHYS ACTA, V629, P95, DOI 10.1016/0304-4165(80)90268-8; MOHAMED AH, 1986, J BIOL CHEM, V261, P2804; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; PETERSON SW, 1983, J BIOL CHEM, V258, P9605; ROBINSON TJ, 1979, SCIENCE, V205, P200, DOI 10.1126/science.451590; SHIBAT, 1986, BIOCHEM BIOPH RES CO, V35, P720; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TUY FPD, 1983, NATURE, V305, P435; TUY FPD, 1985, BIOCHEM BIOPH RES CO, V126, P304; VARSHNEY GC, 1986, FEBS LETT, V205, P97, DOI 10.1016/0014-5793(86)80873-0; WANG QM, 1991, BIOCHEM J, V279, P567, DOI 10.1042/bj2790567; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893; WO YYP, 1992, J BIOL CHEM, V267, P10856; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YANNOUKAKOS D, 1991, BIOCHIM BIOPHYS ACTA, V1066, P70, DOI 10.1016/0005-2736(91)90252-4; YANNOUKAKOS D, 1991, BIOCHIM BIOPHYS ACTA, V1061, P253, DOI 10.1016/0005-2736(91)90291-F; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	54	131	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					955	959						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507112				2022-12-25	WOS:A1994MR22000030
J	YADAV, PNS; YADAV, JS; ARNOLD, E; MODAK, MJ				YADAV, PNS; YADAV, JS; ARNOLD, E; MODAK, MJ			A COMPUTER-ASSISTED ANALYSIS OF CONSERVED RESIDUES IN THE 3-DIMENSIONAL STRUCTURES OF THE POLYMERASE DOMAINS OF ESCHERICHIA-COLI DNA-POLYMERASE-I AND HIV-1 REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; KLENOW FRAGMENT; MUTATIONAL ANALYSIS; CRYSTAL-STRUCTURE; BINDING DOMAIN; IDENTIFICATION; SITE; HETERODIMER; MUTAGENESIS; INHIBITOR	Using a computer-assisted molecular modeling protocol, we have completed the three-dimensional structures of HIV-1 reverse transcriptase and the Klenow fragment of DNA polymerase I based on the Calpha crystal coordinates of the individual enzymes. The two model-built structures were then used to compare the electrostatic potential contours and analyze the spatial positions of residues conserved in the catalytic domains of the two enzymes. In spite of rather weak sequence similarity and different folding patterns between the DNA-dependent DNA polymerase (pol I) and the RNA-dependent DNA polymerases (RT), we have noted the occurrence of identical or similar residues at common spatial positions in pol I and RT in a three-dimensional context. The homologous residues present at equivalent spatial positions in the Klenow fragment and the p66 subunit of HIV-1 RT may therefore imply their functional similarity. Furthermore, these conserved residues may represent a similar structure-function feature in all polymerases.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT BIOCHEM & MOLEC BIOL,NEWARK,NJ 07103; UNIV MED & DENT NEW JERSEY,ACAD COMP CTR,NEWARK,NJ 07103; RUTGERS UNIV,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; RUTGERS UNIV,DEPT CHEM,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University New Brunswick					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI027690, R01AI027690, R01AI026652] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-27690, AI-26652] Funding Source: Medline; NIGMS NIH HHS [GM-36307] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASU A, 1987, BIOCHEMISTRY-US, V26, P1704, DOI 10.1021/bi00380a032; BASU S, 1988, BIOCHEMISTRY-US, V27, P6710, DOI 10.1021/bi00418a011; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BOYER PL, 1992, J VIROL, V66, P7533, DOI 10.1128/JVI.66.12.7533-7537.1992; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KALLAM P, 1992, P NATL ACAD SCI USA, V89, P1934; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LOWE DM, 1991, FEBS LETT, V282, P231, DOI 10.1016/0014-5793(91)80484-K; MODAK MJ, 1976, BIOCHEMISTRY-US, V15, P3620, DOI 10.1021/bi00661a033; MOHAN PM, 1988, BIOCHEMISTRY-US, V27, P226, DOI 10.1021/bi00401a034; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; PANDEY VN, 1987, BIOCHEMISTRY-US, V26, P7744, DOI 10.1021/bi00398a031; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; RUSH J, 1990, J BIOL CHEM, V265, P4821; WINTERSBERGER U, 1988, TRENDS GENET, V3, P198; YADAV PNS, 1992, BIOCHEMISTRY-US, V31, P2879, DOI 10.1021/bi00126a006	28	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					716	720						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506263				2022-12-25	WOS:A1994MR21900112
J	KOSHIMIZU, U; TSUJIMURA, T; ISOZAKI, K; NOMURA, S; FURITSU, T; KANAKURA, Y; KITAMURA, Y; NISHIMUNE, Y				KOSHIMIZU, U; TSUJIMURA, T; ISOZAKI, K; NOMURA, S; FURITSU, T; KANAKURA, Y; KITAMURA, Y; NISHIMUNE, Y			W-N MUTATION OF C-KIT RECEPTOR AFFECTS ITS POSTTRANSLATIONAL PROCESSING AND EXTRACELLULAR EXPRESSION	ONCOGENE			English	Article							CULTURED MAST-CELLS; INTRACELLULAR-TRANSPORT; PROTO-ONCOGENE; INSULIN-RECEPTOR; TYROSINE KINASE; V-KIT; MOUSE; LOCUS; MICE; DOMAIN	The W locus of mice encodes the c-kit receptor tyrosine kinase. Recently, we characterized a novel mutant allele, W-n, and demonstrated that the c-kit protein synthesized in W-n/W-n cultured mast cells (CMC) was reduced in size and not expressed on their surface (Tsujimura et al., 1993). In this study, we further examined biochemical nature of the mutant form of c-kit protein, by using W-n/W-n CMC and 293T cells transfected with W-n-type c-kit cDNA (c-kit(Wn)). The c-kit product synthesized in W-n/W-n CMC was truncated almost all cytoplasmic domain and was less glycosylated. In c-kif(Wn)-tranfected cells, both glycosylation and extracellular expression of c-kit protein was also impaired, however, no truncation was detected. These results indicate that W-n-mutant form of c-kit product is insufficient in maturation, which is associated with impairments in the transport to the plasma membrane, and retention of the mutant protein in endoplasmic reticulum is suggested. This is the first demonstration of the c-kit mutation affecting posttranslational processing its product.	OSAKA UNIV,RES INST MICROBIAL DIS,OSAKA,JAPAN; OSAKA UNIV,SCH MED,DEPT PATHOL,OSAKA,JAPAN; OSAKA UNIV,SCH MED,DEPT INTERNAL MED,OSAKA,JAPAN	Osaka University; Osaka University; Osaka University								ACCILI D, 1989, EMBO J, V8, P2509, DOI 10.1002/j.1460-2075.1989.tb08388.x; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; DOYLE C, 1985, J CELL BIOL, V100, P704, DOI 10.1083/jcb.100.3.704; DOYLE C, 1986, J CELL BIOL, V103, P1193, DOI 10.1083/jcb.103.4.1193; ESSER V, 1988, J BIOL CHEM, V263, P13276; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GEISSLER EN, 1981, GENETICS, V97, P337; GO S, 1980, J HERED, V71, P41, DOI 10.1093/oxfordjournals.jhered.a109308; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREEN MC, 1990, GENETIC VARIANTS STR, P383; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; HURTLEY SM, 1993, TRENDS BIOCHEM SCI, V18, P3, DOI 10.1016/0968-0004(93)90078-2; ISHIHARA K, 1992, P NATL ACAD SCI USA, V89, P633, DOI 10.1073/pnas.89.2.633; KADOWAKI T, 1991, J BIOL CHEM, V266, P21224; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1979, BLOOD, V53, P492; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEV S, 1993, MOL CELL BIOL, V13, P2224, DOI 10.1128/MCB.13.4.2224; LOBELL RB, 1993, J BIOL CHEM, V268, P1207; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MCCULLOCH EA, 1964, SCIENCE, V144, P844, DOI 10.1126/science.144.3620.844; MIURA O, 1989, J BIOL CHEM, V264, P18213; NAKAHATA T, 1982, BLOOD, V60, P352; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; PREFFER SR, 1987, ANN REV BIOCH, V56, P829; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, GENOME ANAL, V3, P105; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; RUSSELL ES, 1968, ARCH BIOCHEM BIOPHYS, V125, P594, DOI 10.1016/0003-9861(68)90617-6; SAKAMAKI K, 1989, BIOL REPROD, V41, P1097, DOI 10.1095/biolreprod41.6.1097; SEVERINSSON L, 1989, EUR J BIOCHEM, V182, P679, DOI 10.1111/j.1432-1033.1989.tb14879.x; Silvers W.K., 1979, COAT COLORS MICE, P206; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TONO T, 1992, BLOOD, V80, P1448; TSUJIMURA T, 1993, BLOOD, V81, P2530; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILLIAMS DB, 1988, J BIOL CHEM, V263, P4549; WILLIAMS DE, 1992, DEV BIOL, V151, P368, DOI 10.1016/0012-1606(92)90176-H; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YEE NS, 1993, J BIOL CHEM, V268, P14189	56	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					157	162						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	7508100				2022-12-25	WOS:A1994MW24700019
J	SLUNGAARD, A; KEY, NS				SLUNGAARD, A; KEY, NS			PLATELET FACTOR-4 STIMULATES THROMBOMODULIN PROTEIN-C ACTIVATING COFACTOR ACTIVITY - A STRUCTURE-FUNCTION ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN THROMBOMODULIN; GAMMA-CARBOXYGLUTAMIC ACID; FACTOR-IV; GRANULE PROTEINS; ANTICOAGULANT ACTIVITIES; PROTEOLYTIC FORMATION; BASIC-PROTEIN; BINDING; HEPARIN; INHIBITION	Thrombomodulin (TM) is an anionic (pI approximate to 4) protein cofactor that promotes thrombin (THR) cleavage of protein C to generate activated protein C (APC), a potent anticoagulant. We find that the cationic platelet alpha-granule protein platelet factor 4 (PF4) stimulates 4-25-fold the cofactor activity of rabbit TM and two differentially glycanated versions of an extracellular domain human TM polypeptide in which the glycosaminoglycan (GAG) is either present (GAG+ TM) or absent (GAG- TM) with an ED(50) of 3.3-10 mu g/ml. No such stimulation occurs in response to beta-thromboglobulin or thrombospondin, or when protein C lacking its gamma-carboxyglutamic acid (Gla) domain is the substrate. Heparin and chondroitin sulfates A and E reverse PF4 stimulation. PF4 minimally affects the K-d for THR but decreases 30-fold (from 8.3 to 0.3 mu M) the K-m for protein C of APC generation by GAG+ TM. PF4 also strikingly transforms the [Ca2+] dependence profile of rabbit and GAG+ TM to resemble that of GAG- TM. A potential explanation for this is that PF4, like Ca2+, induces heparin-reversible alterations in native (but not Gla-domainless) protein C conformation as assessed by autofluorescence emission analysis. We conclude that PF4 stimulates TM APC generation by interacting electrostatically with both the TM GAG and the protein C Gla domain to enhance markedly the affinity of the THR.TM complex for protein C. By this mechanism, PF4 may play a previously unsuspected role in the physiologic regulation of clotting.			SLUNGAARD, A (corresponding author), UNIV MINNESOTA, DEPT MED, BOX 480 UMHC, MINNEAPOLIS, MN 55455 USA.				NHLBI NIH HHS [R01 HL48915] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048915] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN DH, 1993, THROMB HAEMOSTASIS, V69, P753; BOURIN MC, 1988, J BIOL CHEM, V263, P8044; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; CAPITANIO AM, 1985, BIOCHIM BIOPHYS ACTA, V839, P161, DOI 10.1016/0304-4165(85)90033-9; CLARKE JH, 1993, J BIOL CHEM, V268, P6309; COOK JJ, 1992, CIRCULATION, V85, P1102, DOI 10.1161/01.CIR.85.3.1102; DEUEL TF, 1977, P NATL ACAD SCI USA, V74, P2256, DOI 10.1073/pnas.74.6.2256; DEUEL TF, 1981, P NATL ACAD SCI-BIOL, V78, P4584, DOI 10.1073/pnas.78.7.4584; DITTMAN WA, 1990, BLOOD, V75, P329; DUMENCO LL, 1988, J LAB CLIN MED, V112, P394; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; GLASER CB, 1992, J CLIN INVEST, V90, P2565, DOI 10.1172/JCI116151; GOLDBERG ID, 1980, SCIENCE, V209, P611, DOI 10.1126/science.6994228; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; HANDIN RI, 1976, J BIOL CHEM, V251, P4273; HAYASHI T, 1990, J BIOL CHEM, V265, P20156; HOLT JC, 1989, METHOD ENZYMOL, V169, P224; HOLT JC, 1985, SEMIN HEMATOL, V22, P151; ISHII H, 1985, J CLIN INVEST, V76, P2178, DOI 10.1172/JCI112225; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; KATZ IR, 1991, PROGR LEUKOCYTE BIOL, P11117; KUROSAWA S, 1985, THROMB RES, V37, P353, DOI 10.1016/0049-3848(85)90064-7; KUROSAWA S, 1987, J BIOL CHEM, V262, P2206; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LAWLER JW, 1981, THROMB RES, V22, P267, DOI 10.1016/0049-3848(81)90119-5; LAWLER JW, 1978, J BIOL CHEM, V253, P8609; LEATHERBARROW RJ, 1990, TRENDS BIOCHEM SCI, V15, P455, DOI 10.1016/0968-0004(90)90295-M; LONKY SA, 1981, J CLIN INVEST, V67, P817, DOI 10.1172/JCI110099; LONKY SA, 1978, BIOCHEM BIOPH RES CO, V85, P1113, DOI 10.1016/0006-291X(78)90657-5; MAIONE TE, 1991, CANCER RES, V51, P2077; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; PARKINSON JF, 1992, BIOCHEM J, V283, P151, DOI 10.1042/bj2830151; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PREISSNER KT, 1987, BIOCHEMISTRY-US, V26, P2521, DOI 10.1021/bi00383a018; PREISSNER KT, 1990, J BIOL CHEM, V265, P4915; SCULLY MF, 1980, THROMB RES, V20, P461, DOI 10.1016/0049-3848(80)90284-4; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; SLUNGAARD A, 1993, J CLIN INVEST, V91, P1721, DOI 10.1172/JCI116382; TAI PC, 1987, LANCET, V1, P643; TAKANO S, 1990, BLOOD, V76, P2024; WASSOM DL, 1981, J CLIN INVEST, V67, P651, DOI 10.1172/JCI110080; YE J, 1991, J BIOL CHEM, V266, P23016; ZUCKER MB, 1991, P SOC EXP BIOL MED, V198, P693; ZUSHI M, 1991, J BIOL CHEM, V266, P19886	49	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25549	25556						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523387				2022-12-25	WOS:A1994PQ49100050
J	KUDO, S; FUKUDA, M				KUDO, S; FUKUDA, M			CONTRIBUTION OF GENE CONVERSION TO THE RETENTION OF THE SEQUENCE FOR M-BLOOD-GROUP TYPE DETERMINANT IN GLYCOPHORIN-E GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; SOMATIC-CELL MUTATIONS; MONOCLONAL-ANTIBODIES; HOMINOID PRIMATES; CDNA CLONES; DNA; RECOMBINATION; EVOLUTION; FAMILY; IDENTIFICATION	M and N blood group antigens are presented by glycophorins A (GPA) and B (GPB) of the erythrocyte membrane. GPA expresses M or N blood group antigen depending on the allelic gene (GPA(M) gene or GPA(N) gene), while GPB expresses only the N antigen. M or N blood group antigen is specified by the first and fifth NH,terminal amino acid residues in the mature proteins, encoded by the second exon of these genes. Glycophorin E (GPE) gene, another member of this gene family, has a genomic structure very similar to that of GPB. However, a predicted product of GPE gene carries M blood group antigen. To delineate evolutionary events leading to the formation of the sequences for M or N blood group type determinant in the members of human glycophorin gene family, the nucleotide sequences of a 1.45-kilobase pair region including the 3' part of intron 1, exon 2, and the entire intron 2 were compared for GPA(M), GPA(N), GPB, and GPE genes. Encompassing exon 2, there were identical sequence stretches of 139 and 138 base pairs between GPA(M) and GPE genes and between GPA(N) and GPB genes, respectively. The data of the entire sequences in this region revealed that the divergence of the sequence between GPE and GPA genes (2.14-2.49%) is less than that of the sequence between GPE and GPB genes (3.10%). The higher rate of divergence in this region was observed between GPA and GPB genes (3.79-3.86%). These results strongly suggest that GPE gene acquired the sequence for M blood group type determinant from GPA(M) gene through gene conversion after duplication of a progenitor gene common to GPB and GPE genes.			KUDO, S (corresponding author), LA JOLLA CANC RES FDN,CANC RES CTR,10901 N TORREY PINES RD,LA JOLLA,CA 92037, USA.				NATIONAL CANCER INSTITUTE [R01CA033000, R37CA033000] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA33000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIGBEE WL, 1989, AM J HUM GENET, V44, P402; BIGBEE WL, 1990, MUTAT RES, V240, P165, DOI 10.1016/0165-1218(90)90056-8; BLUMENFELD OO, 1978, P NATL ACAD SCI USA, V75, P2727, DOI 10.1073/pnas.75.6.2727; DENDUNNEN JT, 1986, J MOL BIOL, V189, P37, DOI 10.1016/0022-2836(86)90379-7; FUKUDA M, 1993, SEMIN HEMATOL, V30, P188; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; Huang C H, 1991, Baillieres Clin Haematol, V4, P821, DOI 10.1016/S0950-3536(06)80032-6; HUANG CH, 1991, BLOOD, V77, P381; HUANG CH, 1993, J BIOL CHEM, V268, P4945; KOMATSU N, 1991, CANCER RES, V51, P341; KUDO S, 1990, J BIOL CHEM, V265, P13825; KUDO S, 1990, J BIOL CHEM, V265, P1102; KUDO S, 1989, P NATL ACAD SCI USA, V86, P4619, DOI 10.1073/pnas.86.12.4619; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LANGLOIS RG, 1985, J IMMUNOL, V134, P4009; LANGLOIS RG, 1989, P NATL ACAD SCI USA, V86, P670, DOI 10.1073/pnas.86.2.670; LANGLOIS RG, 1987, SCIENCE, V236, P445, DOI 10.1126/science.3563520; MAIZELS N, 1989, TRENDS GENET, V5, P4, DOI 10.1016/0168-9525(89)90004-8; Maniatis T., 1982, MOL CLONING; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MCINTYRE KR, 1984, NATURE, V308, P551, DOI 10.1038/308551a0; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; MOORE LA, 1992, J MOL BIOL, V223, P383, DOI 10.1016/0022-2836(92)90741-2; Nei M., 1987, MOL EVOLUTIONARY GEN; ONDA M, 1993, P NATL ACAD SCI USA, V90, P7220, DOI 10.1073/pnas.90.15.7220; ONDA M, 1994, J BIOL CHEM, V269, P13013; RADDING CM, 1982, ANNU REV GENET, V16, P405, DOI 10.1146/annurev.ge.16.120182.002201; RAHUEL C, 1988, EUR J BIOCHEM, V172, P147, DOI 10.1111/j.1432-1033.1988.tb13866.x; RAYNAUD CA, 1987, CELL, V48, P379; REARDEN A, 1990, BIOCHEM GENET, V28, P209, DOI 10.1007/BF00561338; REARDEN A, 1993, J BIOL CHEM, V268, P2260; REARDEN A, 1986, J IMMUNOL, V136, P2504; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLIGHTOM JL, 1980, CELL, V21, P627, DOI 10.1016/0092-8674(80)90426-2; SOCHA WW, 1983, BLOOD GROUPS PRIMATE, V3; TATE CG, 1988, BIOCHEM J, V254, P743, DOI 10.1042/bj2540743; VIGAL A, 1990, EUR J BIOCHEM, V191, P619	38	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					22969	22974						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7521873				2022-12-25	WOS:A1994PQ16400013
J	ZHENG, XM; PALLEN, CJ				ZHENG, XM; PALLEN, CJ			EXPRESSION OF RECEPTOR-LIKE PROTEIN-TYROSINE-PHOSPHATASE-ALPHA IN RAT EMBRYO FIBROBLASTS ACTIVATES MITOGEN-ACTIVATED PROTEIN-KINASE AND C-JUN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASES; TRANSCRIPTION FACTOR; MAP KINASE; NEURONAL DIFFERENTIATION; NUCLEAR TRANSLOCATION; SIGNAL TRANSDUCTION; TRANSFORMING GENE; MAMMALIAN-CELLS; TRANS-ACTIVATOR; DNA-BINDING	Anti-c-Src and anti-phosphotyrosine immunoprecipitates from receptor-like protein tyrosine phosphatase a (PTP alpha)-transfected and control rat embryo fibroblasts contain a 39-kDa phosphoprotein (p39) whose phosphorylation is enhanced by PTP alpha expression. The p39 that co-immunoprecipitates with c-Src has been identified as c-Jun by immunological and functional criteria; it is recognized by several different anti-c-Jun antibodies and binds to a c-Jun recognition element-containing oligonucleotide. Whereas the association of c-Src and c-Jun is unexpected, it may be of significance in PTP alpha signaling since we have previously demonstrated that c-Src is activated by PTP alpha (Zheng, X. M., Wang, Y., and Fallen, C. J. (1992) Nature 359, 336-339. Examination of c-Jun activity in these fibroblasts demonstrates that c-Jun DNA binding activity and c-Jun-mediated transcription of a chloramphenicol acetyltransferase reporter gene are elevated in PTP alpha-expressing cells. In addition to c-Jun activation, mitogen activated protein kinase is activated in PTP alpha-expressing cells and translocated to the nuclei of these cells. The nuclear localization of activated mitogen activated protein kinase and c-Jun suggests that their activation represents downstream events in the receptor-like PTP alpha-initiated signaling pathway(s).	NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, CELL REGULAT LAB, SINGAPORE 0511, SINGAPORE	Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore				Pallen, Catherine/0000-0002-3576-5295				ADLER V, 1992, J BIOL CHEM, V267, P17001; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWNSHIMER S, 1992, CANCER RES, V52, P478; CATLING AD, 1993, ONCOGENE, V8, P1875; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAUM G, 1991, J BIOL CHEM, V266, P12211; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KNUTSON JC, 1987, ANAL BIOCHEM, V164, P44, DOI 10.1016/0003-2697(87)90365-4; LEE H, 1993, J BIOL CHEM, V268, P8181; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZANDER NF, 1993, ONCOGENE, V8, P1175; ZHAO YH, 1992, P NATL ACAD SCI USA, V89, P8298, DOI 10.1073/pnas.89.17.8298; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	58	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23302	23309						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7521877				2022-12-25	WOS:A1994PQ16400062
J	OSTERMEIER, M; GEORGIOU, G				OSTERMEIER, M; GEORGIOU, G			THE FOLDING OF BOVINE PANCREATIC TRYPSIN-INHIBITOR IN THE ESCHERICHIA-COLI PERIPLASM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE-ISOMERASE; BOND FORMATION INVIVO; ENDOPLASMIC-RETICULUM; IN-VITRO; EFFICIENT CATALYSIS; DSBA; PATHWAY; VIVO; BPTI; INTERMEDIATE	PreOmpA-bovine pancreatic trypsin inhibitor (BPTI) (Goldenberg, D. P. (1988) Biochemistry 27, 2481-2489) was expressed in Escherichia coli, and the folding pathway of the mature protein in the periplasmic space was analyzed by pulse-chase experiments. Folding intermediates were trapped with iodoacetamide, immunoprecipitated with antisera specific for either the reduced or the native protein, and resolved by electrophoresis. In vivo, native BPTI formed with a half-life of 7 min which is 3-fold faster than the optimal in vitro folding rate in growth media supplemented with low molecular weight disulfides. The measured in vivo half-life includes the time required for translocation and processing by leader peptidase and therefore represents the lower limit for the actual folding rate in the cell. In addition to the native species, two-disulfide intermediates accumulated in the cell at appreciable levels and did not chase to the native species for at least 20 min. We found that the folding of BPTI in E. coli was absolutely dependent on DsbA, a protein which accelerates the formation of disulfide bonds in the periplasm. In a dsbA mutant strain, trace amounts of oxidized BPTI could be detected only in cultures grown under strongly oxidizing conditions. In wild-type cells, the addition of different concentrations of GSH/GSSG or oxidized dithiothreitol did not affect the kinetics of BPTI oxidation by DsbA. Finally, even though the folding of BPTI in vitro decreases by almost 10-fold/unit pH decrease, folding in cells grown at pH 6.0 was only marginally slower than folding in cells grown at neutral pH, despite the fact that the pH of the periplasmic space varies in response to the extracellular fluid.	UNIV TEXAS, DEPT CHEM ENGN, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin			Ostermeier, Marc/A-2697-2010	Ostermeier, Marc/0000-0003-0900-3665	NIGMS NIH HHS [1R01 GM 47520-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047520] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANEYX F, 1992, STABILITY PROTEIN PH, P69; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CHUN SY, 1993, J BIOL CHEM, V268, P20855; CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1978, J MOL BIOL, V123, P129, DOI 10.1016/0022-2836(78)90317-0; CREIGHTON TE, 1993, J MOL BIOL, V232, P1176, DOI 10.1006/jmbi.1993.1470; CREIGHTON TE, 1980, J MOL BIOL, V144, P521, DOI 10.1016/0022-2836(80)90335-6; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GEORGIOU G, 1988, BIOTECHNOL LETT, V10, P377, DOI 10.1007/BF01087432; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLDENBERG DP, 1992, TRENDS BIOCHEM SCI, V17, P257, DOI 10.1016/0968-0004(92)90405-X; GOLDENBERG DP, 1988, BIOCHEMISTRY-US, V27, P2481, DOI 10.1021/bi00407a034; HUTH JR, 1993, J BIOL CHEM, V268, P16472; MARKS CB, 1986, J BIOL CHEM, V261, P7115; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; NILSSON B, 1991, J BIOL CHEM, V266, P2970; NOIVA R, 1991, J BIOL CHEM, V266, P19645; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; REISFELD RA, 1962, NATURE, V195, P281, DOI 10.1038/195281a0; STOCK JB, 1977, J BIOL CHEM, V252, P7850; VANMIERLO CPM, 1993, J MOL BIOL, V229, P1125, DOI 10.1006/jmbi.1993.1108; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, 1993, J BIOL CHEM, V268, P24547; WUNDERLICH M, 1993, BIOCHEMISTRY-US, V32, P12251, DOI 10.1021/bi00096a039; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	36	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21072	21077						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	7520437				2022-12-25	WOS:A1994PC40300041
J	ARAI, T; PARKER, A; BUSBY, W; CLEMMONS, DR				ARAI, T; PARKER, A; BUSBY, W; CLEMMONS, DR			HEPARIN, HEPARAN-SULFATE, AND DERMATAN SULFATE REGULATE FORMATION OF THE INSULIN-LIKE GROWTH-FACTOR-I AND INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR IGF BINDING; SOMATOMEDIN-C; HUMAN FIBROBLASTS; 2 FORMS; CELLS; GLYCOSAMINOGLYCANS; IDENTIFICATION; PROTEOGLYCANS; MECHANISMS; SEQUENCE	The mechanisms by which insulin-like growth factor-I (IGF-I) is released from insulin-like growth factor binding proteins (IGFBPs) and then binds to its receptor have not been defined. This study was designed to determine the role of glycosaminoglycans in altering the formation of the IGF-I.IGFBP complexes. Heparin inhibited formation of the IGF-I.IGFBP-5 complex and also separated preformed IGF-I.IGFBP-5 complexes. Heparin also inhibited formation of the IGF-I.IGFBP-3 complex; however, it did not inhibit formation of complexes between IGF-I and IGFBP-1, -2, or -4. Heparin exposure was associated with a 17-fold decrease in the affinity of IGFBP-5 for IGF-I. A synthetic peptide that contains residues from Arg(221) to Arg(238) of IGFBP-5, and a heparin binding domain prevented the inhibitory effects of heparin on formation of the IGF-I.IGFBP-5 complex. It did not directly compete with IGF-I for binding to IGFBP-5, suggesting that heparin binding to this region of IGFBP-5 resulted in a conformational change in IGFBP-5 which lowered its affinity for IGF-I. Other glycosaminoglycans that contained O-linked sulfates in the 2 or 3 carbon positions of iduronic acid, e.g. heparan sulfate and dermatan sulfate, also inhibited the IGF-I.IGFBP-5 complex formation, whereas those that did not, such as keratan sulfate or hyaluronic acid, had minimal effects. Anionic polysaccharides that contained O-sulfate groups in the 2 or 3 positions, such as dextran sulfate, pentosan polysulfate, and fucoidan, also had inhibitory activity. The findings suggest a role for these compounds in inhibiting IGF-I.IGFBP interactions, thus making IGF-I available to bind to its receptor.	UNIV N CAROLINA,SCH MED,DEPT MED,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL026309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG002331, R37AG002331] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-26309] Funding Source: Medline; NIA NIH HHS [AG02331] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; BAXTER RC, 1990, BIOCHEM J, V271, P773, DOI 10.1042/bj2710773; BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6898, DOI 10.1073/pnas.86.18.6898; BOURNER MJ, 1992, J CELL BIOCHEM, V48, P215; BUSBY WH, 1988, J BIOL CHEM, V263, P14203; BUSBY WH, 1988, J CLIN ENDOCR METAB, V67, P1225, DOI 10.1210/jcem-67-6-1225; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CLEMMONS DR, 1983, J CLIN ENDOCR METAB, V56, P384, DOI 10.1210/jcem-56-2-384; CLEMMONS DR, 1986, J CLIN INVEST, V77, P1548, DOI 10.1172/JCI112470; COHICK WS, 1993, J CELL PHYSIOL, V157, P52, DOI 10.1002/jcp.1041570107; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; DAMON DH, 1989, J CELL PHYSIOL, V138, P221, DOI 10.1002/jcp.1041380202; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MCCUSKER RH, 1990, J CELL PHYSIOL, V144, P244, DOI 10.1002/jcp.1041440210; MERRIFIELD RB, 1964, J AM CHEM SOC, V86, P304, DOI 10.1021/ja01056a056; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; OLSON JT, 1989, J BIOL CHEM, V264, P3111; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; WILKINS JR, 1985, J CLIN INVEST, V75, P1350, DOI 10.1172/JCI111836; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	30	145	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20388	20393						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519608				2022-12-25	WOS:A1994PB31700030
J	RANE, SG; REDDY, EP				RANE, SG; REDDY, EP			JAK3 - A NOVEL JAK KINASE ASSOCIATED WITH TERMINAL DIFFERENTIATION OF HEMATOPOIETIC-CELLS	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; GAMMA SIGNAL-TRANSDUCTION; COLONY-STIMULATING FACTOR; GRANULOCYTIC DIFFERENTIATION; INTERLEUKIN-3; RECEPTOR; LINE; EXPRESSION; LEUKEMIA; PATHWAY	The Janus Kinases (JAK) JAK1, JAK2, and TYK2 are protein tyrosine kinases which play a pivotal role in the signal transduction process mediated by cytokines. These kinases appear to transduce signals via their substrates which modulate programs of gene expression specific to the respective signals. It is becoming increasingly evident that certain cytokines such as Granulocyte Colony Stimulating Factor (GCSF) can transmit signals for both cellular proliferation and differentiation. It is at present unclear whether both of these signals are transmitted by the same JAK kinase or whether an entire family of such kinases are involved in this process. To determine if additional members of JAK kinase family exist, we designed a polymerase chain reaction based strategy which resulted in the identification of a new member of the JAK kinase family. This new kinase, which we have named JAK3 is encoded by a 4.3 kb mRNA transcript. Nucleotide sequence analysis of a full length cDNA derived from this mRNA revealed that it encodes an open reading frame of 3897 bp. The protein encoded by this mRNA contains the double catalytic domain characteristic of the JAK family kinases. The most striking difference between JAK3 and the other JAK kinases is the presence of two stretches of additional amino acid sequence of 147 and 28 residues which span between amino acid positions 322 to 469 and 632 to 660 respectively. Expression studies indicate that JAK3 is expressed at very low levels in immature hematopoietic cells, but its expression is dramatically up-regulated during terminal differentiation of these cells, These results suggest that JAK3 plays an important role in the differentiation of hematopoietic cells.	TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [P30CA012227, P01CA052009] Funding Source: NIH RePORTER; NCI NIH HHS [CA 12227, CA 52009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Ausubel FM., 2006, ENZYMATIC MANIPULATI; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; ROVERA G, 1987, ONCOGENE, V1, P29; RUI H, 1994, J BIOL CHEM, V269, P5364; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	26	126	137	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2415	2423						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7518579				2022-12-25	WOS:A1994NX62900037
J	MURO, Y; TSAI, WM; HOUGHTEN, R; TAN, EM				MURO, Y; TSAI, WM; HOUGHTEN, R; TAN, EM			SYNTHETIC COMPOUND PEPTIDE SIMULATING ANTIGENICITY OF CONFORMATION-DEPENDENT AUTOEPITOPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; DNA-POLYMERASE-DELTA; MONOCLONAL-ANTIBODIES; PCNA CYCLIN; AUXILIARY PROTEIN; AMINO-ACIDS; REPLICATION; EPITOPES; AUTOANTIBODY; REPAIR	Proliferating cell nuclear antigen (PCNA), also known as auxiliary protein of DNA polymerase delta, is involved in DNA replication and repair. Certain patients with systemic lupus erythematosus (lupus) produce autoantibodies to PCNA and the autoantibody-defined epitopes of PCNA have been inferred to be conformation-dependent. Based on antigenic properties of continuous primary structure peptides, compound peptides composed of covalently linked discontinuous sequences were synthesized and used as immunogens in rabbits. One compound peptide induced an antibody response to a nuclear antigen which demonstrated a cell cycle-related pattern of nuclear immunofluorescence with maximum expression in the DNA synthesis phase of the cell cycle associated with other features which simulated the conformation -dependent properties of lupus defined autoepitopes. Other rabbit antibodies raised against different compound peptides did not show such properties and recognized epitopes which were continuous primary sequence regions. These results show that from analysis of antigenic sites on a protein, it might be possible to construct synthetic compound peptides which can mimic conformation-dependent epitopes recognized by spontaneously occurring autoantibodies.	SCRIPPS RES INST, WM KECK AUTOIMMUNE DIS CTR, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; TORREY PINES INST MOLEC STUDIES, SAN DIEGO, CA 92121 USA	Scripps Research Institute; Torrey Pines Institute for Molecular Studies, California			MURO, Yoshinao/M-8883-2014	Muro, Yoshinao/0000-0003-2329-8375	NIAID NIH HHS [AI32834] Funding Source: Medline; NIAMS NIH HHS [AR32063] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI032834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032063, R37AR032063] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTMAN JD, 1991, PROTEIN ENG, V4, P593, DOI 10.1093/protein/4.5.593; APPEL JR, 1990, J IMMUNOL, V144, P976; BIDART JM, 1990, SCIENCE, V248, P736, DOI 10.1126/science.1692160; BRAVO R, 1986, EXP CELL RES, V163, P287, DOI 10.1016/0014-4827(86)90059-5; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; GARCIA RL, 1989, AM J PATHOL, V134, P733; HOPP TP, 1986, J IMMUNOL METHODS, V88, P1, DOI 10.1016/0022-1759(86)90045-1; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HUFF JP, 1990, J EXP MED, V172, P419, DOI 10.1084/jem.172.2.419; HUMBERT C, 1992, J CELL SCI, V103, P97; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; KAMEL OW, 1991, AM J PATHOL, V138, P1471; KILL IR, 1991, J CELL SCI, V100, P869; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P233, DOI 10.1093/oxfordjournals.jbchem.a131053; LANDBERG G, 1991, CANCER RES, V51, P4570; LANDBERG G, 1991, ACTA ONCOL, V30, P917, DOI 10.3109/02841869109088244; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LEE SH, 1988, P NATL ACAD SCI USA, V85, P9469, DOI 10.1073/pnas.85.24.9469; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; MIYACHI K, 1978, J IMMUNOL, V121, P2228; OGATA K, 1987, J IMMUNOL, V139, P2942; OGATA K, 1987, EXP CELL RES, V168, P475, DOI 10.1016/0014-4827(87)90020-6; PARRY NR, 1989, J GEN VIROL, V70, P1493, DOI 10.1099/0022-1317-70-6-1493; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; REIMER G, 1988, ARTHRITIS RHEUM, V31, P525, DOI 10.1002/art.1780310409; ROOS G, 1993, LAB INVEST, V68, P204; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; TAKASAKI Y, 1984, J EXP MED, V159, P981, DOI 10.1084/jem.159.4.981; TAKASAKI Y, 1990, J IMMUNOL METHODS, V132, P227, DOI 10.1016/0022-1759(90)90034-S; TAN CK, 1987, NUCLEIC ACIDS RES, V15, P9299, DOI 10.1093/nar/15.22.9299; TAN CK, 1986, J BIOL CHEM, V261, P2310; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI WM, 1992, J IMMUNOL, V149, P2227; VANDIERENDONCK JH, 1991, AM J PATHOL, V138, P1165; WASEEM NH, 1990, J CELL SCI, V96, P121; ZUBER M, 1989, MOL CELL BIOL, V9, P57, DOI 10.1128/MCB.9.1.57	41	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18529	18534						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7518436				2022-12-25	WOS:A1994NW79800048
J	JENKINS, AL; BOOTMAN, MD; BERRIDGE, MJ; STONE, SR				JENKINS, AL; BOOTMAN, MD; BERRIDGE, MJ; STONE, SR			DIFFERENCES IN INTRACELLULAR CALCIUM SIGNALING AFTER ACTIVATION OF THE THROMBIN RECEPTOR BY THROMBIN AND AGONIST PEPTIDE IN OSTEOBLAST-LIKE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE INHIBITORS; PHOSPHOLIPASE-C; HUMAN-PLATELETS; ALPHA-THROMBIN; PHORBOL ESTERS; OKADAIC ACID; PROTEOLYTIC MECHANISM; INOSITOL PHOSPHATES; MOLECULAR-CLONING; CA2+ MOBILIZATION	Thrombin and the thrombin receptor agonist peptide (TRAP) caused a rise in intracellular calcium concentration ([Ca2+](i)) in the human osteoblast like cell line Saos-2. Striking differences in the [Ca2+](i) signals elicited by these agonists were revealed. In cell populations, thrombin induced a transient increase in [Ca2+](i) while TRAP caused a biphasic [Ca2+](i) response consisting of an initial peak and a sustained plateau phase. In individual cells, thrombin mainly caused a single [Ca2+](i) transient while TRAP induced repetitive [Ca2+](i) spikes. Neither tyrosine phosphorylation, cAMP-dependent phospho rylation, nor pertussis toxin-sensitive G proteins appeared to be involved in thrombin receptor [Ca2+](i) signaling in this cell line. However, the sustained [Ca2+](i) response caused by TRAP was converted into a transient, thrombin-like response by pretreatment with serine/threonine phosphatase inhibitors. Pretreatment with the phorbol ester phorbol 12-myristate 13-acetate (PMA) abrogated thrombin receptor [Ca2+](i) signaling, and TRAP-induced Ca2+ entry was inhibited by the acute treatment with PMA In contrast, Ca2+ entry stimulated by thapsigargin was not sensitive to agents affecting serine/threonine phosphorylation. The observation that thrombin and TRAP, despite being agonists for a common receptor, induce dissimilar [Ca2+](i) responses indicates that binding of TRAP alone is insufficient to fully regulate the thrombin receptor in Saos-2 cells.	UNIV CAMBRIDGE,CTR MRC,DEPT HEMATOL,CAMBRIDGE CB2 2QH,ENGLAND; UNIV CAMBRIDGE,DEPT ZOOL,BABRAHAM INST,MOLEC SIGNALLING LAB,CAMBRIDGE CB2 3EJ,ENGLAND	University of Cambridge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge			Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; BRASS LF, 1992, J BIOL CHEM, V267, P6044; BRASS LF, 1994, J BIOL CHEM, V269, P2943; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; FUKAYAMA S, 1993, AM J PHYSIOL, V264, pC464, DOI 10.1152/ajpcell.1993.264.2.C464; GARCIA JGN, 1993, J CELL PHYSL, V150, P4876; GRYNKIEWICZ G, 1985, J BIOL CHEM, V264, P17665; Hescheler J, 1993, Curr Opin Neurobiol, V3, P360, DOI 10.1016/0959-4388(93)90129-M; HOWELLS GL, 1993, BRIT J HAEMATOL, V84, P156, DOI 10.1111/j.1365-2141.1993.tb03039.x; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUANG RS, 1991, J BIOL CHEM, V266, P18435; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; ISHII K, 1994, J BIOL CHEM, V269, P1125; ISHII K, 1993, J BIOL CHEM, V268, P9780; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; Jenkins Alison L., 1993, Journal of Biological Chemistry, V268, P21432; KELLEHER DJ, 1986, J BIOL CHEM, V261, P4749; LEE KM, 1993, J BIOL CHEM, V268, P9945; OFORIDARKO E, 1992, AM J PHYSIOL, pC1266; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; PARK DJ, 1992, J BIOL CHEM, V267, P1496; Penner R, 1993, Curr Opin Neurobiol, V3, P368, DOI 10.1016/0959-4388(93)90130-Q; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; RAYMOND JR, 1991, J BIOL CHEM, V266, P14747; SARGEANT P, 1993, FEBS LETT, V315, P242, DOI 10.1016/0014-5793(93)81172-V; SARGEANT P, 1993, J BIOL CHEM, V268, P18151; SMITH CD, 1987, J BIOL CHEM, V262, P6121; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; TATAKIS DN, 1989, BIOCHEM BIOPH RES CO, V164, P119, DOI 10.1016/0006-291X(89)91691-4; TBRDAI A, 1993, J IMMUNOL, V150, P4876; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VALONE FH, 1987, BIOCHEM J, V247, P669, DOI 10.1042/bj2470669; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; YAMAGUCHI DT, 1989, J BIOL CHEM, V264, P197; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975	45	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17104	17110						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516333				2022-12-25	WOS:A1994NT84600021
J	MOKUNO, H; BRADY, S; KOTITE, L; HERZ, J; HAVEL, RJ				MOKUNO, H; BRADY, S; KOTITE, L; HERZ, J; HAVEL, RJ			EFFECT OF THE 39-KDA RECEPTOR-ASSOCIATED PROTEIN ON THE HEPATIC-UPTAKE AND ENDOCYTOSIS OF CHYLOMICRON REMNANTS AND LOW-DENSITY LIPOPROTEINS IN THE RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARENCHYMAL LIVER-CELLS; TRIGLYCERIDE-RICH LIPOPROTEINS; ACTIVATOR INHIBITOR TYPE-1; 3 ENDOSOMAL FRACTIONS; ALPHA-2-MACROGLOBULIN RECEPTOR; LDL-RECEPTOR; PLASMINOGEN-ACTIVATOR; APOLIPOPROTEIN-E; ARGININE-RICH; BINDING	The low density lipoprotein (LDL) receptor-related protein, which serves as the cell surface receptor for several proteins including alpha(2)-macroglobulin-protease complexes, has been proposed to be a candidate hepatocytic receptor for chylomicron remnants through its recognition of apolipoprotein E. We have studied the effect of two ligands for this receptor, activated alpha(2)-macroglobulin and the recently described 39-kDa protein that copurifies with the LDL receptor-related protein (receptor-associated protein), on the uptake and endocytosis of chylomicrons in intact rats and in isolated, perfused rat livers. Both of these ligands were rapidly taken up and endocytosed into the liver of rats. Chylomicrons from normal rats were injected in vivo and chylomicrons from estradiol-treated rats that were enriched in apolipoprotein E were added to liver perfusates. Prior administration of amounts of activated alpha(2)-macroglobulin that saturated hepatic uptake mechanisms did not inhibit hepatic uptake or endocytosis of endogenously labeled cholesteryl esters of chylomicron particles in vivo or in perfused livers over a period of 15 min. By contrast, prior administration of saturating amounts of the receptor-associated protein (expressed in bacteria as a fusion protein with glutathione S-transferase) reduced hepatic uptake by about 30% and virtually abolished endocytosis. The receptor-associated protein inhibited hepatic uptake of human LDL in vivo by 70% and endocytosis by 81%. Our results show that receptor-associated protein-sensitive processes predominate in the overall pathways by which chylomicron remnants are endocytosed by rat liver. Furthermore, they show that the receptor-associated protein binds to and inhibits the function of the LDL receptor as well as the LDL receptor-related protein.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV TEXAS,SW MED SCH,DEPT MOLEC GENET,DALLAS,TX 75235	University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NHLBI NIH HHS [HL-14237, HL-20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014237, P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BEISIEGEL U, 1982, J BIOL CHEM, V257, P3150; BELCHER JD, 1987, P NATL ACAD SCI USA, V84, P6785, DOI 10.1073/pnas.84.19.6785; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHAO Y, 1979, J BIOL CHEM, V254, P1360; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; CHOI SY, 1993, J BIOL CHEM, V268, P15804; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; FAINARU M, 1977, BIOCHIM BIOPHYS ACTA, V490, P144, DOI 10.1016/0005-2795(77)90114-3; FELKER TE, 1977, J LIPID RES, V18, P465; FIELDING CJ, 1979, BIOCHIM BIOPHYS ACTA, V573, P255, DOI 10.1016/0005-2760(79)90059-6; FOLCH J, 1957, J BIOL CHEM, V226, P497; HARKES L, 1984, BIOCHIM BIOPHYS ACTA, V794, P340, DOI 10.1016/0005-2760(84)90165-6; HARKES L, 1984, BIOCHEM J, V224, P21, DOI 10.1042/bj2240021; HAVEL RJ, 1988, HEPATOLOGY, V8, P1689, DOI 10.1002/hep.1840080637; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1990, J BIOL CHEM, V265, P21355; HOUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; HUSSAINI IM, 1990, J BIOL CHEM, V265, P19441; IMAIZUMI K, 1978, J LIPID RES, V19, P712; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JACKLE S, 1991, J LIPID RES, V32, P485; JACKLE S, 1993, J LIPID RES, V34, P309; JAECKLE S, 1989, P NATL ACAD SCI USA, V86, P1880, DOI 10.1073/pnas.86.6.1880; JONES AL, 1984, J LIPID RES, V25, P1151; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; NAGATA Y, 1988, J BIOL CHEM, V263, P15151; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; RUBINSZTEIN DC, 1990, J CLIN INVEST, V86, P1306, DOI 10.1172/JCI114839; RUNQUIST EA, 1991, J BIOL CHEM, V266, P22557; SHAFI S, 1994, J LIPID RES, V35, P709; SIGURDSSON G, 1978, J LIPID RES, V19, P628; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WINDLER E, 1980, J BIOL CHEM, V255, P8303; WINDLER E, 1980, J BIOL CHEM, V255, P5475; WINDLER EET, 1988, BIOCHEM J, V252, P553, DOI 10.1042/bj2520553	51	77	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13238	13243						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7513700				2022-12-25	WOS:A1994NK18400031
J	SHI, LB; SKACH, WR; VERKMAN, AS				SHI, LB; SKACH, WR; VERKMAN, AS			FUNCTIONAL INDEPENDENCE OF MONOMERIC CHIP28 WATER CHANNELS REVEALED BY EXPRESSION OF WILD-TYPE-MUTANT HETERODIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS OOCYTES; PROTEIN; RECONSTITUTION; MEMBRANE; CDNA; RNA	CHIP28 is a major water transporting protein in erythrocytes and kidney which forms tetramers in membranes (Verbavatz, J. M., Brown, D., Sabolic, I., Valenti, G., Ausiello, D. A., Van Hoek, A. N., Ma, T., and Verkman, A. S. (1993) J. Cell Biol. 123, 605-618). To determine whether CHIP28 monomers function independently, chimeric cDNA dimers were constructed which contained wild-type CHIP28 in series with either wild-type CHIP28, a non-water transporting CHIP28 mutant (C189W), or a functional but mercurial-insensitive CHIP28 mutant (C189S). Transcribed cRNAs were injected in Xenopus oocytes and plasma membrane expression was assayed by quantitative immunofluorescence. Water channel function was measured by osmotically induced swelling. CHIP28 homo- and heterodimers were targeted to the oocyte plasma membrane and functioned as water channels. Relative osmotic water permeability (P-f) values (normalized for plasma membrane expression of monomeric subunits) were: 1.0 (CHIP28 monomer), 0.0 (C189W), 1.07 (C189S), 1.10 (CHIP28-CHIP28 dimer) and 0.52 (CHIP28 C189W). The increase in oocyte P-f was linearly related to plasma membrane expression of wild-type CHIP28 and C189S subunits. HgCl2 (0.3 mM) inhibited channel-mediated P-f in oocytes expressing wild-type CHIP28 monomers and dimers by 85-90%, but did not inhibit P-f in oocytes expressing C189S. HgCl2 inhibited P-f in oocytes expressing CHIP28-C189S dimers by 44 +/- 7%, consistent with one mercurial-sensitive and one insensitive subunit in the heterodimer. These results indicate that despite their assembly in tetramers, monomeric CHIP28 subunits function independently as water channels.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CANC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [K11CA001614] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124] Funding Source: NIH RePORTER; NCI NIH HHS [CA01614] Funding Source: Medline; NHLBI NIH HHS [HL42368] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONDY C, 1993, P NATL ACAD SCI USA, V90, P4500, DOI 10.1073/pnas.90.10.4500; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; HASEGAWA H, 1993, AM J PHYSIOL, V264, pC237, DOI 10.1152/ajpcell.1993.264.1.C237; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; MA TH, 1993, J BIOL CHEM, V268, P22756; MA TH, 1994, AM J PHYSIOL, V266, pC189, DOI 10.1152/ajpcell.1994.266.1.C189; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; Skach W. R., 1993, Journal of the American Society of Nephrology, V4, P859; SMITH BL, 1991, J BIOL CHEM, V266, P6407; TYTGAT J, 1992, NATURE, V359, P420, DOI 10.1038/359420a0; VANHOEK AN, 1991, J BIOL CHEM, V266, P16633; VANHOEK AN, 1993, BIOCHEMISTRY-US, V32, P11847, DOI 10.1021/bi00095a013; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; VERBAVATZ JM, 1993, J CELL BIOL, V123, P605, DOI 10.1083/jcb.123.3.605; VERKMAN AS, 1984, P NATL ACAD SCI-BIOL, V81, P150, DOI 10.1073/pnas.81.1.150; VERKMAN AS, 1993, WATER CHANNELS, P74; WISTOW GJ, 1991, TRENDS BIOCHEM SCI, V16, P170, DOI 10.1016/0968-0004(91)90065-4; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZEN K, 1992, J CELL BIOL, V119, P99, DOI 10.1083/jcb.119.1.99; ZHANG R, 1990, J BIOL CHEM, V265, P15375; ZHANG RB, 1993, BIOCHEMISTRY-US, V32, P2938, DOI 10.1021/bi00063a002; ZHANG RB, 1993, J CELL BIOL, V120, P359, DOI 10.1083/jcb.120.2.359	30	103	106	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10417	10422						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511600				2022-12-25	WOS:A1994NF01700037
J	OTSU, K; NISHIDA, K; KIMURA, Y; KUZUYA, T; HORI, M; KAMADA, T; TADA, M				OTSU, K; NISHIDA, K; KIMURA, Y; KUZUYA, T; HORI, M; KAMADA, T; TADA, M			THE POINT MUTATION ARG(615)-]CYS IN THE CA2+ RELEASE CHANNEL OF SKELETAL SARCOPLASMIC-RETICULUM IS RESPONSIBLE FOR HYPERSENSITIVITY TO CAFFEINE AND HALOTHANE IN MALIGNANT HYPERTHERMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MUSCLE RYANODINE RECEPTOR; SUSCEPTIBLE PIGS; CA-2+ RELEASE; CALCIUM; MECHANISM	Malignant hyperthermia (MH) is an autosomal dominant myopathy. Molecular genetic studies have shown that the alteration of Arg615 to Cys in the Ca2+ release channel of skeletal muscle sarcoplasmic reticulum (ryanodine receptor) is cosegregated with porcine MH (Fujii, J., Otsu, K., Zorzato, F., de Leon, S., Khanna, V. K., Weiler, J. E., O'Brien, P. J., and MacLennan, D. H. (1991) Science 253, 448-451; Otsu, K., Khanna, V. K., Archibald, A., and MacLennan, D. H. (1991) Genomics 11, 744-750). Here, using the fluorescence calcium indicator indo-1, we determined the concentration of ionized cytosolic calcium in myoblastic cells transfected with either the wild-type or mutated ryanodine receptor cDNA. The cells expressing the mutant ryanodine receptor showed higher sensitivity to caffeine, which induces Ca2+ release from the sarcoplasmic reticulum through the ryanodine receptor. Exposure to clinical doses of halothane resulted in a rapid increase of [Ca2+]i in cells expressing the mutated ryanodine receptor, whereas no [Ca2+] changes were observed in cells expressing the wild-type ryanodine receptor. These results provide definite evidence that a single amino acid mutation, Arg615 --> Cys, in the ryanodine receptor is causative of MH.	OSAKA UNIV,SCH MED,DEPT MED 1,SUITA,OSAKA 565,JAPAN	Osaka University	OTSU, K (corresponding author), OSAKA UNIV,SCH MED,DEPT PATHOPHYSIOL,2-2 YAMADAOKA,SUITA,OSAKA 565,JAPAN.							BANRANY M, 1985, BIOCHEMISTRY-US, V24, P7911; BRITT BA, 1987, MALIGNANT HYPERTHERM, P11; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ENDO M, 1983, BIOMED RES-TOKYO, V4, P83, DOI 10.2220/biomedres.4.83; FILL M, 1990, BIOPHYS J, V57, P471, DOI 10.1016/S0006-3495(90)82563-7; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; GILLARD EF, 1991, GENOMICS, V11, P751, DOI 10.1016/0888-7543(91)90084-R; IAIZZO PA, 1988, PFLUG ARCH EUR J PHY, V411, P648, DOI 10.1007/BF00580861; LOPEZ JR, 1986, MUSCLE NERVE, V9, P85; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; OBRIEN PJ, 1986, CAN J VET RES, V50, P318; OHNISHI ST, 1983, FEBS LETT, V161, P103; OTSU K, 1991, GENOMICS, V11, P744, DOI 10.1016/0888-7543(91)90083-Q; OTSU K, 1990, J BIOL CHEM, V265, P13472; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0	15	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9413	9415						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511586				2022-12-25	WOS:A1994NE05300005
J	ROY, R; SCHAEFFER, L; HUMBERT, S; VERMEULEN, W; WEEDA, G; EGLY, JM				ROY, R; SCHAEFFER, L; HUMBERT, S; VERMEULEN, W; WEEDA, G; EGLY, JM			THE DNA-DEPENDENT ATPASE ACTIVITY ASSOCIATED WITH THE CLASS-II BASIC TRANSCRIPTION FACTOR BTF2/TFIIH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; MAJOR LATE PROMOTER; C-TERMINAL DOMAIN; INITIATION-FACTOR; HELICASE; COMPLEXES; INVITRO; PROTEIN; KINASE; PHOSPHORYLATION	BTF2/TFIIH from human, delta from rat, and factor b from yeast are multisubunit basal transcription factors that have been shown to be closely associated with a protein kinase capable of phosphorylating the carboxyl-terminal domain of the large subunit of RNA polymerase II (Lu, H., Zawel, L., Fischer, L., Egly, J. M., and Reinberg, D. (1992) Nature 358,641-645; Serizawa, H., Conaway, R. C., and Conaway, J. W. (1992) Proc. Natl. Acad. Sci. U.S.A. 89,7476-7480; Feaver, W. J., Gileadi, O., and Kornberg, R. D. (1991) Cell 67,1223-1230). We report here that a DNA-dependent ATPase and the previously characterized helicase (Schaeffer, L., Roy, R., Humbert, S., Moncollin, V., Vermeulen, W., Hoeijmakers, J., Chambon, P., and Egly, J. M. (1993) Science 260, 58-63) are both associated with BTF2 and reside with the p89 polypeptide subunit. The DNA requirement, the effect of Sarkosyl and staurosporine inhibitors, as well as nucleotide competition experiments, clearly distinguished ATPase/helicase from the carboxyl-terminal domain kinase. Using recombinant wild type or mutated p89/ERCC3 polypeptides and different forms of DNA template, we show the connection between ATPase and the helicase.	FAC MED STRASBOURG,INSERM,U184,CNRS,UPR 6520,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE; ERASMUS UNIV ROTTERDAM,CTR MED GENET,DEPT CELL BIOL & GENET,3000 DR ROTTERDAM,NETHERLANDS	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Erasmus University Rotterdam			Humbert, Sandrine/S-2981-2016; Vermeulen, Wim/W-8708-2019	Vermeulen, Wim/0000-0003-3616-734X; Humbert, Sandrine/0000-0002-9501-2658; schaeffer, laurent/0000-0001-6600-503X				ARIAS JA, 1989, J BIOL CHEM, V264, P3223; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CAI H, 1987, J BIOL CHEM, V262, P298; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CONAWAY JW, 1991, J BIOL CHEM, V266, P17721; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DAHMUS ME, 1992, TRANSCRIPTIONAL REGU, P109; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLORES O, 1992, J BIOL CHEM, V267, P2786; GERARD M, 1991, J BIOL CHEM, V266, P20940; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1986, J BIOL CHEM, V261, P169; MIYAMOTO NG, 1984, NUCLEIC ACIDS RES, V12, P8779, DOI 10.1093/nar/12.23.8779; NAEGELI H, 1992, J BIOL CHEM, V267, P392; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	34	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9826	9832						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511595				2022-12-25	WOS:A1994NE05300068
J	COLE, H; REYNOLDS, TR; LOCKYER, JM; BUCK, GA; DENSON, T; SPENCE, JE; HYMES, J; WOLF, B				COLE, H; REYNOLDS, TR; LOCKYER, JM; BUCK, GA; DENSON, T; SPENCE, JE; HYMES, J; WOLF, B			HUMAN SERUM BIOTINIDASE - CDNA CLONING, SEQUENCE, AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIENCY; PURIFICATION; PEPTIDES	Biotinidase (EC 3.5.1.12) catalyzes the hydrolysis of biocytin, the product of biotin-dependent carboxylase degradation, to biotin and lysine. Biotinidase deficiency is an inherited metabolic disorder of biotin recycling that is characterized by neurological and cutaneous abnormalities, and can be successfully treated with biotin supplementation. Sequences of tryptic peptides of the purified human serum enzyme were used to design oligonucleotide primers for polymerase chain reaction amplification from human hepatic total RNA to generate putative biotinidase cDNA fragments. Sequence analysis of a cDNA isolated from a human liver library by plaque hybridization with the largest cDNA probe revealed an open reading frame of 1629 bases encoding a protein of 543 amino acid residues, including 41 amino acids of a potential signal peptide. Comparison of the open reading frame with the known biotinidase tryptic peptides and recognition of the expressed protein encoded by this cDNA by monoclonal antibodies prepared against purified biotinidase demonstrated the identity of this cDNA. Southern analyses suggested that biotinidase is a single copy gene and revealed that human cDNA probes hybridized to genomic DNA from mammals, but not from chicken or yeast. Northern analysis indicated the presence of biotinidase mRNA in human heart, brain, placenta, liver lung, skeletal muscle, kidney, and pancreas.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT HUMAN GENET,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL IMMUNOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PEDIAT,RICHMOND,VA 23298; TULANE UNIV,SCH MED,DEPT MED,NEW ORLEANS,LA 70112	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Tulane University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033022] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33022] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAUHAN J, 1986, J BIOL CHEM, V261, P4268; CRAFT DV, 1985, BIOCHEMISTRY-US, V24, P2471, DOI 10.1021/bi00331a012; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GRIER RE, 1989, CLIN CHIM ACTA, V186, P397; HART PS, 1991, CLIN CHIM ACTA, V197, P257, DOI 10.1016/0009-8981(91)90146-4; HART PS, 1992, AM J HUM GENET, V50, P126; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LEE KB, 1990, APPL BIOCHEM BIOTECH, V23, P53, DOI 10.1007/BF02942052; OIZUMI J, 1989, BIOCHIMIE, V71, P1163, DOI 10.1016/0300-9084(89)90019-9; OIZUMI J, 1990, ARCH BIOCHEM BIOPHYS, V278, P381, DOI 10.1016/0003-9861(90)90274-3; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PISPA J, 1965, ANN MED EXP BIOL F S, V43, P1; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; SUCHY SF, 1985, NEUROLOGY, V35, P1510, DOI 10.1212/WNL.35.10.1510; WEINER DL, 1983, AM J HUM GENET, V34, pA56; WOLF B, 1986, J INHERIT METAB DIS, V9, P303, DOI 10.1007/BF01799736; WOLF B, 1983, J PEDIATR-US, V103, P233, DOI 10.1016/S0022-3476(83)80351-5; WOLF B, 1983, CLIN CHIM ACTA, V131, P273, DOI 10.1016/0009-8981(83)90096-7; WOLF B, 1987, CLIN CHIM ACTA, V164, P27, DOI 10.1016/0009-8981(87)90104-5; Wolf B., 1992, METABOLIC BASIS INHE, P2083; 1991, MOL GENETICS CUSTOME	25	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6566	6570						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509806				2022-12-25	WOS:A1994MZ50300048
J	TANG, YL; TAYLOR, KT; SOBIESKI, DA; MEDVED, ES; LIPSKY, RH				TANG, YL; TAYLOR, KT; SOBIESKI, DA; MEDVED, ES; LIPSKY, RH			IDENTIFICATION OF A HUMAN CD36 ISOFORM PRODUCED BY EXON SKIPPING - CONSERVATION OF EXON ORGANIZATION AND PRE-MESSENGER-RNA SPLICING PATTERNS WITH A CD36 GENE FAMILY MEMBER, CLA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IV CD36; MEMBRANE GLYCOPROTEIN; RECEPTOR; PROTEIN; ERYTHROCYTES; PLATELETS; ADHESION; ACID; RNA	During an examination of different cell types for CD36 mRNA splice variants, a partial cDNA from HEL cells was isolated and characterized. This CD36 cDNA had a 309-base pair deletion following the region encoding the first putative transmembrane domain of CD36. The open reading frame of the deleted CD36 cDNA was retained and was predicted to yield a protein lacking 103 amino acid residues. The presence of this variant was confirmed in RNA pools from placental tissue by a reverse transcriptase-coupled polymerase chain reaction assay. Comparison of the HEL CD36 cDNA with the genomic sequence revealed that the mRNA represented by this variant CD36 cDNA was produced by a pre-mRNA splicing reaction that excluded exons 4 and 5. Transient expression of the variant CD36 cDNA in COS-1 cells showed that CD36 immunoreactive protein was expressed on the cell surface but lacked an antigenic epitope defined by amino acid residues 41-143. This cell surface glycoprotein (M(r) approximate to 57,000) was of identical molecular weight as a CD36 isoform observed on the surface of HEL cells. The exclusion of exons during CD36 pre-mRNA processing appears to be conserved within one other CD36 gene family member, CLA-1.	AMER RED CROSS,DEPT CELL BIOL,JH HOLLAND LAB,ROCKVILLE,MD 20855	American Red Cross				Lipsky, Robert/0000-0001-7753-1473	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046447] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46447] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; CALVO D, 1993, J BIOL CHEM, V268, P18929; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FUJITA H, 1992, BIOCHEM BIOPH RES CO, V184, P604, DOI 10.1016/0006-291X(92)90632-U; GREENWALT DE, 1992, BLOOD, V80, P1105; HARLOW E, 1988, ANTIBODIES LABORATOR; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; INGALLS HM, 1986, P NATL ACAD SCI USA, V83, P4779, DOI 10.1073/pnas.83.13.4779; LEUNG LLK, 1992, J BIOL CHEM, V267, P18244; LIPSKY RH, 1987, CANCER RES, V47, P4900; LIPSKY RH, 1991, THROMB HAEMOSTASIS, V65, P456; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; NOGUCHI K, 1993, BIOCHEM BIOPH RES CO, V192, P88, DOI 10.1006/bbrc.1993.1385; OCKENHOUSE CF, 1991, P NATL ACAD SCI USA, V88, P3175, DOI 10.1073/pnas.88.8.3175; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TAYLOR KT, 1993, GENE, V133, P205, DOI 10.1016/0378-1119(93)90639-K; VEGA MA, 1991, J BIOL CHEM, V266, P16818; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432	25	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6011	6015						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509795				2022-12-25	WOS:A1994MY84000081
J	BUSSOLINO, F; SILVAGNO, F; GARBARINO, G; COSTAMAGNA, C; SANAVIO, F; ARESE, M; SOLDI, R; AGLIETTA, M; PESCARMONA, G; CAMUSSI, G; BOSIA, A				BUSSOLINO, F; SILVAGNO, F; GARBARINO, G; COSTAMAGNA, C; SANAVIO, F; ARESE, M; SOLDI, R; AGLIETTA, M; PESCARMONA, G; CAMUSSI, G; BOSIA, A			HUMAN ENDOTHELIAL-CELLS ARE TARGETS FOR PLATELET-ACTIVATING-FACTOR (PAF) .3. ACTIVATION OF ALPHA-PROTEIN AND BETA-PROTEIN KINASE-C ISOZYMES IN ENDOTHELIAL-CELLS STIMULATED BY PAF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTOR; RAT-BRAIN; DIFFERENTIAL REGULATION; SELECTIVE INHIBITOR; SIGNAL TRANSDUCTION; POTENT INHIBITORS; HUMAN-NEUTROPHILS; LEUKEMIA-CELLS; F-ACTIN; EXPRESSION	We evaluated the role of the protein kinase C (PKC) and its isozymes in the activation of human endothelial cells (EC) stimulated by platelet-activating factor (PAF). Exposure of confluent EC to PAF resulted in a rapid and concentration-dependent redistribution of PKC from cytosol to plasma-membrane, rearrangement of cytoskeleton (i.e. decrease in F-actin content and redistribution of vinculin), and finally increase in the transendothelial flux of I-125-albumin. Stimulation of EC with oleylacetylglycerol or phorbol 12-myristate 13-acetate induced the modification of the cytoskeletal structures and the increase of I-125-albumin clearance. Inhibitors of PKC prevented the effects induced by PAF on the cytoskeleton and on the barrier function of the EC monolayer. Confluent EC expressed only alpha, beta, and epsilon PKC isoforms. Biochemical and immunochemical analysis showed that the time course of the PKC isozymes translocation from cytosol to the membrane fraction of EC stimulated by PAF was different: beta isoform was redistributed more quickly than alpha isoform. PAF did not induce translocation of PKC epsilon. These results suggest that activation of PKC alpha and beta is an important signal transduction pathway by which PAF activates endothelial monolayer and modify its function of barrier to macromolecules.	UNIV TURIN,INST INTERNAL MED,I-10126 TURIN,ITALY; UNIV TURIN,DEPT BIOL SCI & ONCOL,I-10126 TURIN,ITALY; UNIV NAPLES,DEPT BIOCHEM & BIOPHYS,I-80138 NAPLES,ITALY	University of Turin; University of Turin; University of Naples Federico II	BUSSOLINO, F (corresponding author), UNIV TURIN,DEPT GENET BIOL & MED CHEM,VIA SANTENA 5BIS,I-10126 TURIN,ITALY.		arese, marco/J-6119-2013; Camussi, Giovanni/J-7624-2016; Bussolino, Federico/AES-3951-2022; Bussolino, Federico/K-2500-2016	arese, marco/0000-0002-7384-9406; Camussi, Giovanni/0000-0003-2795-232X; AGLIETTA, Massimo/0000-0002-2255-7972; Bussolino, Federico/0000-0002-5348-1341; PESCARMONA, GIAN PIERO/0000-0003-2143-8901	Telethon [295] Funding Source: Medline	Telethon(Fondazione Telethon)		ANTONOV AS, 1986, P NATL ACAD SCI USA, V83, P9704, DOI 10.1073/pnas.83.24.9704; APGAR JR, 1991, J CELL BIOL, V112, P1157, DOI 10.1083/jcb.112.6.1157; ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BELL RM, 1991, J BIOL CHEM, V266, P4661; BRATTON DL, 1992, J IMMUNOL, V148, P514; BROCK TA, 1986, AM J PHYSIOL, V250, P1086, DOI 10.1152/ajpheart.1986.250.6.H1086; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11856; BUSSOLINO F, 1987, J IMMUNOL, V139, P2439; BUSSOLINO F, 1985, J IMMUNOL, V135, P2748; CAMUSSI G, 1983, J IMMUNOL, V131, P2397; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DHUMIERES S, 1986, EUR J PHARMACOL, V131, P13, DOI 10.1016/0014-2999(86)90510-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREIREMOAR J, 1991, J IMMUNOL, V147, P405; GANONG BR, 1986, P NATL ACAD SCI USA, V83, P1184, DOI 10.1073/pnas.83.5.1184; GODSON C, 1990, J BIOL CHEM, V265, P8369; GORDON J, 1991, VASCULAR ENDOTHELIUM; GRIGORIAN GY, 1987, CIRC RES, V61, P389, DOI 10.1161/01.RES.61.3.389; HANDLEY DA, 1984, IMMUNOPHARMACOLOGY, V8, P137, DOI 10.1016/0162-3109(84)90017-1; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HELLER R, 1992, J IMMUNOL, V149, P3682; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HUANG FL, 1989, J BIOL CHEM, V264, P4238; Huang K P, 1989, Adv Exp Med Biol, V255, P21; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; INAGAKI M, 1988, J BIOL CHEM, V263, P5970; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V118, P736, DOI 10.1016/0006-291X(84)91456-6; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P48; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KUIJPERS TW, 1992, J CELL BIOL, V117, P565, DOI 10.1083/jcb.117.3.565; LACASSE C, 1990, J LEUKOCYTE BIOL, V49, P245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LERNER R, 1988, BIOCHEM BIOPH RES CO, V153, P805, DOI 10.1016/S0006-291X(88)81167-7; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; LYNCH JJ, 1990, J CLIN INVEST, V85, P1991, DOI 10.1172/JCI114663; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; Maniatis T., 1982, MOL CLONING; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MATILLA P, 1991, FEBS LETT, V289, P86; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; MELLONI E, 1989, J BIOL CHEM, V264, P18414; MISCHAK H, 1991, J IMMUNOL, V147, P3981; MIYATA Y, 1989, J BIOL CHEM, V264, P15565; NIELSEN TB, 1989, TISSUE CELL, V21, P813, DOI 10.1016/0040-8166(89)90032-3; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OLIVER JA, 1990, J CELL PHYSIOL, V145, P536, DOI 10.1002/jcp.1041450321; ONO Y, 1986, FEBS LETT, V203, P111, DOI 10.1016/0014-5793(86)80724-4; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PARKI R, 1992, J CELL BIOL, V116, P1211; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; PHATAK PD, 1988, J IMMUNOL, V141, P2929; PONTREMOLI S, 1990, J BIOL CHEM, V265, P706; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; PRESCOTT SM, 1984, P NATL ACAD SCI USA, V81, P3934; RENKONEN R, 1990, SCAND J IMMUNOL, V31, P523, DOI 10.1111/j.1365-3083.1990.tb02800.x; ROTROSEN D, 1986, J CELL BIOL, V103, P2379, DOI 10.1083/jcb.103.6.2379; RYAN US, 1988, NEW TRENDS LIPID MED, P144; SALARI H, 1992, BIOCHIM BIOPHYS ACTA, V1134, P81, DOI 10.1016/0167-4889(92)90030-F; SHUKLA SD, 1992, FASEB J, V6, P2296, DOI 10.1096/fasebj.6.6.1312046; Stein W., 1989, CELL SHAPE DETERMINA; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUSUMI A, 1993, J IMMUNOL, V150, P1746; UHING RJ, 1989, J BIOL CHEM, V264, P9224; WERTH DK, 1984, J BIOL CHEM, V259, P5264; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529	88	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2877	2886						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7507929				2022-12-25	WOS:A1994MV43200077
J	NUSSLER, AK; BILLIAR, TR; LIU, ZZ; MORRIS, SM				NUSSLER, AK; BILLIAR, TR; LIU, ZZ; MORRIS, SM			COINDUCTION OF NITRIC-OXIDE SYNTHASE AND ARGININOSUCCINATE SYNTHETASE IN A MURINE MACROPHAGE CELL-LINE - IMPLICATIONS FOR REGULATION OF NITRIC-OXIDE PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; NECROSIS FACTOR CACHECTIN; L-ARGININE; AMINO-ACID; METABOLISM; ENZYMES; NITRATE; UREA; CITRULLINE; TRANSPORT	In macrophages and other cell types, bacterial lipopolysaccharide and certain cytokines stimulate nitric oxide (NO) production via expression of the inducible isoform of nitric oxide synthase (NOS). Citrulline, which is the coproduct of NOS-catalyzed metabolism of arginine, can be recycled to arginine by the action of argininosuccinate synthetase and argininosuccinate lyase, which are present at high levels in hepatocytes and renal tubular cells but normally at very low levels in other cell types such as macrophages. The present study demonstrates that lipopolysaccharide and interferon-gamma, which induce NOS in the murine macrophage cell line RAW 264.7, also coinduce activity and mRNA for argininosuccinate synthetase, which is limiting for arginine synthesis. Argininosuccinate lyase activity and mRNA abundance are unaffected. Induction of argininosuccinate synthetase is not blocked by N(G)- monomethyl-L-arginine, a potent inhibitor of NOS, indicating that argininosuccinate synthetase induction is not the consequence of depleting cellular arginine levels by NOS. Because plasma levels of arginine are limiting for NO synthesis, enhanced cellular capacity to regenerate arginine from citrulline could play a significant role in regulating NO production, especially under conditions where the inducible isoform of NOS is expressed.	UNIV PITTSBURGH,SCH MED,DEPT SURG,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Nussler, Andreas/H-3557-2019; Morris, Sidney M/I-3440-2015	Nussler, Andreas/0000-0002-6666-6791; 	NIDDK NIH HHS [DK33144] Funding Source: Medline; NIGMS NIH HHS [GM37753, GM44100] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044100, R01GM037753, R29GM044100, R37GM044100] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBINA JE, 1988, AM J PHYSIOL, V254, pE459, DOI 10.1152/ajpendo.1988.254.4.E459; BEAUDET AL, 1986, ADV HUM GENET, V15, P161; BILLIAR TR, 1990, BIOCHEM BIOPH RES CO, V168, P1034, DOI 10.1016/0006-291X(90)91133-D; BILLIAR TR, 1989, J EXP MED, V169, P1467, DOI 10.1084/jem.169.4.1467; BOGLE RG, 1992, BIOCHEM J, V284, P15, DOI 10.1042/bj2840015; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BURCHETT SK, 1988, J IMMUNOL, V140, P3473; CAREY GP, 1987, J NUTR, V117, P1734, DOI 10.1093/jn/117.10.1734; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOWES GHA, 1980, JPEN-PARENTER ENTER, V4, P195, DOI 10.1177/0148607180004002195; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; CORBIN JL, 1974, ANAL BIOCHEM, V57, P310, DOI 10.1016/0003-2697(74)90080-3; CURRIE GA, 1979, BRIT J CANCER, V39, P613, DOI 10.1038/bjc.1979.112; DING AH, 1988, J IMMUNOL, V141, P2407; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GRANGER DL, 1988, J CLIN INVEST, V81, P1129, DOI 10.1172/JCI113427; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; HOFMANN F, 1978, Biochemical Society Transactions, V6, P990; IRR JD, 1978, SOMAT CELL GENET, V4, P111, DOI 10.1007/BF01546496; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; JACKSON MJ, 1988, J BIOL CHEM, V263, P16388; KATZ RA, 1983, J GEN VIROL, V64, P429, DOI 10.1099/0022-1317-64-2-429; LAMBERT MA, 1986, MOL CELL BIOL, V6, P1722, DOI 10.1128/MCB.6.5.1722; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MITCHELL JA, 1990, EUR J PHARMACOL, V182, P573, DOI 10.1016/0014-2999(90)90058-E; MORRIS SM, 1989, ARCH BIOCHEM BIOPHYS, V273, P230, DOI 10.1016/0003-9861(89)90183-5; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V256, P343, DOI 10.1016/0003-9861(87)90455-3; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; OBRIEN WE, 1981, BIOCHEMISTRY-US, V20, P2056, DOI 10.1021/bi00510a049; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; RATNER S, 1973, ADV ENZYMOL RAMB, V39, P1; SATO H, 1992, J LEUKOCYTE BIOL, V52, P161, DOI 10.1002/jlb.52.2.161; SAX HC, 1988, J SURG RES, V45, P50, DOI 10.1016/0022-4804(88)90020-0; SCHIMKE RT, 1964, J BIOL CHEM, V239, P136; STUEHR DJ, 1987, CANCER RES, V47, P5590; SU TS, 1981, BIOCHEMISTRY-US, V20, P2956, DOI 10.1021/bi00513a037; WERNER ER, 1991, BIOCHEM J, V280, P709, DOI 10.1042/bj2800709; WU GY, 1992, BIOCHEM J, V281, P45, DOI 10.1042/bj2810045; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	46	203	205	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1257	1261						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507106				2022-12-25	WOS:A1994MR22000077
J	CHINSKY, JM; BOHLEN, LM; COSTEAS, PA				CHINSKY, JM; BOHLEN, LM; COSTEAS, PA			NONCOORDINATED RESPONSES OF BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE SUBUNIT GENES TO DIETARY-PROTEIN	FASEB JOURNAL			English	Note						RNA; NUTRITIONAL REGULATION; GENE EXPRESSION; BRANCHED-CHAIN 2-OXOACID DEHYDROGENASE	SYRUP-URINE-DISEASE; ACTIVITY STATE; MESSENGER-RNA; RAT-LIVER; GLUTAMINE-SYNTHETASE; ACTIVATOR PROTEIN; 3T3-L1 ADIPOCYTES; COMPLEX; EXPRESSION; TISSUES	The response of the murine genes encoding the subunits of branched-chain alpha-ketoacid dehydrogenase complex (BCKAD) to changes in dietary protein was determined. Steady-state RNA levels for two of the subunits, E1beta and E2, decreased by two- to four-fold in the livers of mice fed 0% protein isocaloric diets compared to the levels observed in mice fed standard (23%) or high (50%) protein isocaloric diets. In contrast, the levels of RNA encoding the E1alpha subunit did not change significantly in response to these dietary protein changes. The hepatic decreases in E1beta and E2 RNA associated with 0% protein isocaloric diets were reversible, with prompt return to baseline levels following 48 hours of 50% protein isocaloric diets ad libitum. In kidney, no significant changes in the RNAs encoding any of the three BCKAD subunits were observed in response to changes in dietary protein. Studies of RNA variations associated with growth and development in several murine tissues, including liver and kidney, demonstrated coordinated changes between all subunits. Similar coordinated changes were observed during 3T3-L1 adipocyte differentiation. These studies suggest that the responses of the BCKAD subunit genes to alterations in dietary protein are noncoordinated and tissue-specific, in contrast to the coordinated changes observed during growth and/or differentiation. The differences in BCKAD subunit RNA levels observed under varying nutritional and developmental conditions suggest that multiple regulatory mechanisms modulate BCKAD subunit expression.			CHINSKY, JM (corresponding author), UNIV MARYLAND, SCH MED, DIV HUMAN GENET, 655 W BALTIMORE ST, 11-037, BALTIMORE, MD 21201 USA.			Costeas, Paul/0000-0002-7257-4746				BLOCK KP, 1988, METHOD ENZYMOL, V166, P201; CHINSKY JM, 1989, J BIOL CHEM, V264, P14561; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUANG DT, 1983, BIOCHEM J, V214, P177, DOI 10.1042/bj2140177; DANCIS J, 1972, J PEDIATR-US, V81, P312, DOI 10.1016/S0022-3476(72)80301-9; Danner DJ, 1989, METABOLIC BASIS INHE, P671; FRERMAN FE, 1983, J BIOL CHEM, V258, P7087; HARPER AE, 1984, ANNU REV NUTR, V4, P409, DOI 10.1146/annurev.nu.04.070184.002205; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HARRIS RA, 1990, ADV ENZYME REGUL, V30, P245; HARRIS RA, 1985, ARCH BIOCHEM BIOPHYS, V243, P542, DOI 10.1016/0003-9861(85)90531-4; HU CWC, 1988, J BIOL CHEM, V263, P9007; JONES SMA, 1986, BIOCHEM J, V236, P209, DOI 10.1042/bj2360209; LAD RP, 1990, BRAIN RES, V9, P239; LAMBERT MA, 1986, MOL CELL BIOL, V6, P1722, DOI 10.1128/MCB.6.5.1722; LYON MF, 1989, GENETIC VARIANTS STR, P265; MEAROW KM, 1989, MOL BRAIN RES, V6, P223, DOI 10.1016/0169-328X(89)90068-5; MIESFELD R, 1982, NUCLEIC ACIDS RES, V10, P3933, DOI 10.1093/nar/10.13.3933; MILLER RE, 1983, J BIOL CHEM, V258, P5405; MILLER RH, 1988, J BIOL CHEM, V263, P3454; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V256, P343, DOI 10.1016/0003-9861(87)90455-3; PATSTON PA, 1986, BIOCHEM J, V235, P429, DOI 10.1042/bj2350429; PATSTON PA, 1988, METHOD ENZYMOL, V166, P175; PATSTON PA, 1984, BIOCHEM J, V222, P711, DOI 10.1042/bj2220711; PAUL HS, 1983, J BIOL CHEM, V258, P1471; RANDLE PJ, 1987, ENZYMES, V18, P97; REED LJ, 1990, J BIOL CHEM, V265, P8971; SOEMITRO S, 1989, J NUTR, V119, P1203, DOI 10.1093/jn/119.8.1203; SOLOMON M, 1987, BIOCHIM BIOPHYS ACTA, V931, P335, DOI 10.1016/0167-4889(87)90224-2; SUZUKI K, 1991, J BIOL CHEM, V266, P20007; WAGENMAKERS AJM, 1984, BIOCHEM J, V220, P273, DOI 10.1042/bj2200273; ZHAO Y, 1993, BIOCHEM J, V290, P395, DOI 10.1042/bj2900395	32	16	16	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1994	8	1					114	120		10.1096/fasebj.8.1.7507870	http://dx.doi.org/10.1096/fasebj.8.1.7507870			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	7507870				2022-12-25	WOS:A1994MV28200017
J	SOUZA, SC; FRICK, GP; YIP, R; LOBO, RB; TAI, LR; GOODMAN, HM				SOUZA, SC; FRICK, GP; YIP, R; LOBO, RB; TAI, LR; GOODMAN, HM			GROWTH-HORMONE STIMULATES TYROSINE PHOSPHORYLATION OF INSULIN-RECEPTOR SUBSTRATE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE ACTIVITY; RAT ADIPOCYTES; ADIPOSE-TISSUE; HEMATOPOIETIC-CELLS; BINDING; RESPONSES; INDUCTION; IRS-1	Growth hormone (GH) produces insulin-like effects in rat adipocytes that have been deprived of GH for at least 3 h. The effect of a saturating concentration of GH is qualitatively and quantitatively similar to that produced by 2-4 ng/ml insulin but differs from that of insulin in the respect that adipocytes become refractory to prolonged or repeated stimulation with GH. Since activation of tyrosine kinase is an early event in the action of both hormones, we investigated the possibility that GH stimulation of tyrosine phosphorylation of some protein in the insulin transduction cascade might result in the similar effect of the two hormones. Adipocytes were preincubated for 3 h in the absence of hormones and then reincubated without or with 500 ng/ml GH or 4-400 ng/ml insulin for 10 min. The cells were lysed with an equal volume of buffer containing 1% SDS and preheated to 100 degrees C. Proteins were separated by electrophoresis on 7.5% polyacrylamide gels and transferred to nitrocellulose membranes, and tyrosine-phosphorylated proteins were detected using anti-phosphotyrosine antiserum coupled to horseradish peroxidase and reagents to produce chemiluminescence. The faint band seen at 185 kDa in control lanes was increased by GH treatment in five independent experiments. Insulin produced a similar effect at a concentration of 4 ng/ml, and phosphorylation increased in a dose-related manner in cells treated with higher concentrations of insulin. A prominent similar to 95-kDa band that is probably not the beta subunit of the insulin receptor was also seen in GH-treated cells. The beta subunit of the insulin receptor has similar electrophoretic mobility to the 95-kDa protein, but was not phosphorylated to an extent that allowed detection when insulin was added at concentrations below 400 ng/ml. Phosphorylation of the 185- and 95-kDa bands was evident within 1 min after addition of GH, persisted for at least 30 min, and was equally prominent in sensitive and refractory cells. Antiserum to IRS-1 immunoprecipitated the tyrosine-phosphorylated 185-kDa protein. The data suggest that IRS-1 is a substrate for a GH-activated tyrosine kinase, possibly JAK-2, which may account for the insulin-like effects of GH. The data further suggest that refractoriness to insulin-like stimulation by GH may result from an additional GH-dependent action that is distinct from phosphorylation of IRS-1.	UNIV MASSACHUSETTS,SCH MED,DEPT PHYSIOL,WORCESTER,MA 01655; UNIV SAO PAULO,FAC MED RIBEIRAO PRETO,BR-14049 RIBEIRAO PRET,SP,BRAZIL	University of Massachusetts System; University of Massachusetts Worcester; Universidade de Sao Paulo					NIDDK NIH HHS [DK 14392] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BIRNBAUM RS, 1976, ENDOCRINOLOGY, V99, P1336, DOI 10.1210/endo-99-5-1336; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; COIRO V, 1981, ENDOCRINOLOGY, V109, P2213, DOI 10.1210/endo-109-6-2213; EDEN S, 1982, ENDOCRINOLOGY, V111, P1505, DOI 10.1210/endo-111-5-1505; GOODMAN HM, 1987, ENDOCRINOL JAPON, V34, P59; GOODMAN HM, 1990, ENDOCRINOLOGY, V126, P441, DOI 10.1210/endo-126-1-441; GOODMAN HM, 1978, ENDOCRINOLOGY, V102, P210, DOI 10.1210/endo-102-1-210; GOODMAN HM, 1981, ENDOCRINOLOGY, V108, P113, DOI 10.1210/endo-108-1-113; GOODMAN HM, 1981, ENDOCRINOLOGY, V109, P120, DOI 10.1210/endo-109-1-120; GOODMAN HM, 1968, ANN NY ACAD SCI, V148, P419, DOI 10.1111/j.1749-6632.1968.tb20367.x; GOODMAN HM, 1981, HORM METAB RES, V13, P351, DOI 10.1055/s-2007-1019264; GOODMAN HM, 1988, HUMAN GROWTH HORMONE, P75; GRICHTING G, 1983, ENDOCRINOLOGY, V113, P1111, DOI 10.1210/endo-113-3-1111; HONEYMAN TW, 1980, AM J PHYSIOL, V238, P389; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MOODY AJ, 1974, HORM METAB RES, V6, P12, DOI 10.1055/s-0028-1093895; PETRUZZELLI L, 1984, P NATL ACAD SCI-BIOL, V81, P3327, DOI 10.1073/pnas.81.11.3327; RODBELL M, 1964, J BIOL CHEM, V239, P375; SCHWARTZ Y, 1991, P NATL ACAD SCI USA, V88, P6790, DOI 10.1073/pnas.88.15.6790; SCHWARTZ Y, 1990, ENDOCRINOLOGY, V126, P170; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; SMAL J, 1987, J BIOL CHEM, V262, P11071; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; VANDERKUUR JA, 1994, 76TH M END SOC AN, P456; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WANG XZ, 1994, P NATL ACAD SCI USA, V91, P1391, DOI 10.1073/pnas.91.4.1391; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1994, J BIOL CHEM, V269, P28	37	112	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30085	30088						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7527025				2022-12-25	WOS:A1994PU52500006
J	NOGUCHI, M; MIYAMOTO, S; SILVERMAN, TA; SAFER, B				NOGUCHI, M; MIYAMOTO, S; SILVERMAN, TA; SAFER, B			CHARACTERIZATION OF AN ANTISENSE INR ELEMENT IN THE EIF-2-ALPHA GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; RNA POLYMERASE-II; EUKARYOTIC INITIATION FACTOR-2-ALPHA; HUMAN SQUAMOUS CARCINOMA; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; PROTEIN-SYNTHESIS; S-POMBE; EXPRESSION; BINDING	We recently discovered an opposing initiator prometer (Inr) downstream of the sense promoter region of the eIF-2 alpha gene (Silverman, T., Noguchi, M., and Safer, B. (1992) J. Biol. Chem. 267, 9738-9742). By reverse transcriptase/polymerase chain reaction analysis of G(0) and activated (G(1)) T-lymphocyte RNAs, overlapping sense and antisense transcripts are now identified. Sense transcription of the eIF-2 alpha gene proceeds from left to right to generate alpha-mRNA; antisense transcription proceeds from right to left to generate RNA, having a sequence complementary to eIF-2 alpha mRNA. Upstream indicates a position 5' relative to the transcription start site. Using DNase I footprint analysis and EMSA, we have found a potential cis-regulatory sequence immediately upstream of the Inr which binds a 43-kDa protein. In addition to conferring protection against DNase I (+457 to +474), the factor also generates hypersensitive sites directly over the Inr (+447 to +457). Insertion of the Inr footprint region into a luciferase reporter gene construct increases expression 150-fold. While mutation of the Inr conserved sequence decreases luciferase activity by 50%, mutation of the 43-kDa factor binding site inhibits luciferase activity by 20%. Sense orientation of the Inr footprint region decreases activity by 80%. The 43-kDa Inr-associated binding protein may be involved in allowing access of RNA polymerase II transcription complexes to the initiation site of this TATA-less gene A model for the regulation of eIF-2 alpha expression involving the rapid degradation of dsRNA generated by the relative activities of the two overlapping and opposing promoters is proposed.	NHLBI,MOLEC HEMATOL BRANCH,PROT & RNA BIOSYNTH SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BEAUPAIN D, 1990, NUCLEIC ACIDS RES, V18, P6509, DOI 10.1093/nar/18.22.6509; BOAL TR, 1993, BIOCHIM BIOPHYS ACTA, V1176, P257, DOI 10.1016/0167-4889(93)90053-R; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; CHIORINI JA, 1993, J BIOL CHEM, V268, P13748; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; CROWLEY TE, 1985, CELL, V43, P633, DOI 10.1016/0092-8674(85)90235-1; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUIN M, 1989, MOL CELL BIOL, V9, P1794; FREID M, 1981, NUCLEIC ACIDS RES, V9, P6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARFINKEL S, 1990, J BIOL CHEM, V265, P10309; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HOVANESSIAN AG, 1993, TRANSLATIONAL REGULA, V2, P163; HUMBELIN M, 1989, GENE, V81, P315, DOI 10.1016/0378-1119(89)90192-3; IINO Y, 1991, EMBO J, V10, P221, DOI 10.1002/j.1460-2075.1991.tb07939.x; JACOB WF, 1989, J BIOL CHEM, V264, P20372; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRINKE L, 1987, GENE DEV, V1, P1005, DOI 10.1101/gad.1.9.1005; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LIU JM, 1991, VIROLOGY, V185, P39, DOI 10.1016/0042-6822(91)90751-V; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MEEGAN JM, 1989, SCIENCE, V244, P1089, DOI 10.1126/science.2471268; MELTON DA, 1985, P NATL ACAD SCI USA, V82, P144, DOI 10.1073/pnas.82.1.144; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; OKAMOTO K, 1986, P NATL ACAD SCI USA, V83, P5000, DOI 10.1073/pnas.83.14.5000; PAIN VM, 1986, BIOCHEM J, V235, P625, DOI 10.1042/bj2350625; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; SAFER B, 1991, J BIOL CHEM, V266, P10989; SAFER B, 1988, MOL CELL BIOL, V8, P105, DOI 10.1128/MCB.8.1.105; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SILVERMAN TA, 1992, J BIOL CHEM, V267, P9738; SKEIKY YAW, 1990, J MOL BIOL, V213, P53, DOI 10.1016/S0022-2836(05)80121-4; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SPENCER CA, 1986, NATURE, V322, P279, DOI 10.1038/322279a0; VOLK R, 1989, EMBO J, V8, P2983, DOI 10.1002/j.1460-2075.1989.tb08448.x; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; XU HP, 1990, NUCLEIC ACIDS RES, V18, P5304, DOI 10.1093/nar/18.17.5304; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	52	33	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29161	29167						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7525581				2022-12-25	WOS:A1994PU16800094
J	CHANG, CP; HUSLER, T; ZHAO, J; WIEDMER, T; SIMS, PJ				CHANG, CP; HUSLER, T; ZHAO, J; WIEDMER, T; SIMS, PJ			IDENTITY OF A PEPTIDE DOMAIN OF HUMAN C9 THAT IS BOUND BY THE CELL-SURFACE COMPLEMENT INHIBITOR, CD59	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-PLATELETS; PROTEINS C5B-9; 9TH COMPONENT; MEMBRANE; C8; INSERTION; LYSIS; CHAIN	The CD59 antigen is a plasma membrane glycoprotein that serves as an inhibitor of the C5b-9 complex of complement. This inhibitory activity appears related to the capacity of CD59 to bind with high affinity to sites that are nascently exposed in the cy-chain subunit of human C8, as well as within the C9b domain (amino acid residues 245-538) of human C9, during assembly of the C5b-9 complex on the target membrane (Ninomiya, H., and Sims, P. J. (1992) J. Biol. Chem. 267, 13675-13680). The CD59 binding site in C9 was first investigated by N-terminal sequencing of CD59-binding peptides generated by limited digest of the isolated C9b domain. These experiments revealed a 17-kDa fragment (starting at C9 residue Thr-320) that retained affinity for CD59, suggesting the possibility for localizing the CD59 binding site by mapping with small C9-derived peptides. Peptides spanning the entire C9b sequence were expressed in Escherichia coli and then probed with CD59. CD59 bound specifically to all peptides starting N-terminal to C9 residue 359 with C termini extending beyond residue 411. Little to no CD59 binding was observed for various CS derived peptides that started C-terminal to residue 359 or that were truncated N-terminal to residue 411. Affinity-purified antibody against C9 residues 320-411 inhibited CD59 binding to C9 by >50% and completely inhibited its binding to the isolated C9b domain. Little to no specific binding of CD59 was detected for peptides restricted to the putative hinge domain within C9b (residues 245-271). These results indicate that a CD59 binding site is located between residues 320 and 411 of the C9 polypeptide and suggest that the affinity of this site is principally determined by residues 359-411.	BLOOD CTR SE WISCONSIN INC,BLOOD RES INST,MILWAUKEE,WI 53233	Versiti Blood Center of Wisconsin					NHLBI NIH HHS [HL36061] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036061, R01HL036061] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIESECKER G, 1982, J BIOL CHEM, V257, P2584; BIESECKER G, 1993, MOL IMMUNOL, V30, P1369, DOI 10.1016/0161-5890(93)90098-V; DANKERT JR, 1985, P NATL ACAD SCI USA, V82, P2128, DOI 10.1073/pnas.82.7.2128; DAVIES A, 1993, IMMUNOL RES, V12, P258, DOI 10.1007/BF02918257; DISCIPIO RG, 1993, MOL IMMUNOL, V30, P1097, DOI 10.1016/0161-5890(93)90156-6; DUPUIS M, 1993, MOL IMMUNOL, V30, P95, DOI 10.1016/0161-5890(93)90430-J; HNATOWICH DJ, 1987, J NUCL MED, V28, P1294; LEHTO T, 1993, J IMMUNOL, V151, P4941; MERI S, 1990, IMMUNOLOGY, V71, P1; NINOMIYA H, 1992, J BIOL CHEM, V267, P13675; Okada N, 1989, Int Immunol, V1, P205, DOI 10.1093/intimm/1.2.205; PEITSCH M C, 1991, Current Opinion in Cell Biology, V3, P710, DOI 10.1016/0955-0674(91)90045-Z; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; ROLLINS SA, 1991, J IMMUNOL, V146, P2345; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIVER JW, 1986, J BIOL CHEM, V261, P9629; SIMS PJ, 1989, J BIOL CHEM, V264, P19228; STANLEY KK, 1987, EMBO J, V6, P1951, DOI 10.1002/j.1460-2075.1987.tb02457.x; TAKIZAWA H, 1992, EUR J IMMUNOL, V22, P1943, DOI 10.1002/eji.1830220741; TOMLINSON S, 1994, J IMMUNOL, P1927; WHITE RV, 1994, J IMMUNOL, V152, P2501; WIEDMER T, 1985, J MEMBRANE BIOL, V84, P249, DOI 10.1007/BF01871388; WIEDMER T, 1985, J BIOL CHEM, V260, P8014; ZHAO J, 1991, J BIOL CHEM, V266, P13418	24	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26424	26430						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523406				2022-12-25	WOS:A1994PQ93000074
J	NINOMIYA, N; HAZEKI, K; FUKUI, Y; SEYA, T; OKADA, T; HAZEKI, O; UI, M				NINOMIYA, N; HAZEKI, K; FUKUI, Y; SEYA, T; OKADA, T; HAZEKI, O; UI, M			INVOLVEMENT OF PHOSPHATIDYLINOSITOL 3-KINASE IN FC-GAMMA RECEPTOR SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; MYELOID DERIVED CELLS; NATURAL-KILLER-CELLS; CROSS-LINKING; PHOSPHOINOSITIDE 3-KINASE; HEMATOPOIETIC-CELLS; HUMAN PLATELETS; RBL-2H3 CELLS; HIGH-AFFINITY; PHOSPHORYLATION	Wortmannin, a potent and selective inhibitor of phosphatidylinositol (PI) 3-kinase (Okada, T., Sakuma, L., Fukui, Y., Hazeki, 0., and Ui, M. (1994) J. Biol. Chem. 269, 3563-3567), prevented Fc receptor for IgG (Fc gamma R)-dependent phagocytosis of the human monocytic cell line U937 or guinea pig neutrophils. Cross-linking of Fc gamma R on the surface of U937 cells increased PI 3-kinase activity that was immunoprecipitated with antibody against phosphotyrosine or antibody against the 85-kDa regulatory subunit of PI 3-kinase. Specific cross-linking of Fc gamma R subclass Fc gamma RI or Fc gamma RII, using monoclonal antibodies against each receptor subclass and the F(ab')(2) fragment of goat antibody against mouse IgG, increased anti-phosphotyrosine-precipitable PI 3-kinase activity. Treatment of cells with anti-Fc gamma RIII antibody plus the same F(ab')(2) did not affect the activity, reflecting the lack of Fc gamma RIII in U937 cells. Fc gamma R stimulation triggered prominent tyrosine phosphorylation of several proteins, among which the 115-kDa peptide showed strong association with PI 3-kinase. Thus, Fc gamma R appears to be coupled functionally, via a tyrosine kinase, to PI 3-kinase, which may regulate the phagocytotic activity of the cells.	INST PHYS & CHEM RES,UI LAB,WAKO,SAITAMA 35101,JAPAN; UNIV TOKYO,FAC AGR,DEPT AGR CHEM,TOKYO 113,JAPAN; CTR ADULT DIS,DEPT IMMUNOL,HIGASHINARI KU,OSAKA 537,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,BUNKYO KU,TOKYO 113,JAPAN	RIKEN; University of Tokyo; University of Tokyo			Fukui, Yasuhisa/E-8806-2010; Seya, Tsukasa/A-4336-2012					AGARWAL A, 1993, J BIOL CHEM, V268, P15900; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CONE JC, 1993, EUR J IMMUNOL, V23, P2488; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; GHAZIZADEH S, 1994, J IMMUNOL, V152, P30; GOLD MR, 1994, J IMMUNOL, V152, P42; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HUANG MM, 1992, J BIOL CHEM, V267, P5467; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KOJIMA A, 1991, SCAND J IMMUNOL, V33, P707, DOI 10.1111/j.1365-3083.1991.tb02544.x; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; LIAO F, 1993, J IMMUNOL, V150, P2668; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKADA T, 1994, J BIOL CHEM, V269, P3568; OKAJIMA F, 1984, J BIOL CHEM, V259, P3863; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P350, DOI 10.1073/pnas.88.2.350; RANKIN BM, 1993, J IMMUNOL, V150, P605; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHOLL PR, 1992, J IMMUNOL, V149, P1751; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANAKA S, 1993, JPN J CANCER RES, V84, P279, DOI 10.1111/j.1349-7006.1993.tb02868.x; TING AT, 1992, J EXP MED, V176, P1751, DOI 10.1084/jem.176.6.1751; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; UNKELESS JC, 1988, ANNU REV IMMUNOL, V6, P251, DOI 10.1146/annurev.iy.06.040188.001343; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VENKITARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083, DOI 10.1073/pnas.89.24.12083; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WARD SG, 1992, EUR J IMMUNOL, V22, P45, DOI 10.1002/eji.1830220108; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHANG J, 1992, J BIOL CHEM, V267, P4686	51	179	180	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22732	22737						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7521331				2022-12-25	WOS:A1994PQ16300044
J	BLUMEJENSEN, P; RONNSTRAND, L; GOUT, I; WATERFIELD, MD; HELDIN, CH				BLUMEJENSEN, P; RONNSTRAND, L; GOUT, I; WATERFIELD, MD; HELDIN, CH			MODULATION OF KIT STEM-CELL FACTOR RECEPTOR-INDUCED SIGNALING BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA-RECEPTOR; COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; KIT RECEPTOR; MITOGENIC SIGNAL; SH2 DOMAIN; PHOSPHOINOSITIDE 3-KINASE; AUTOPHOSPHORYLATION SITES	The Kit/stem cell factor receptor (Kit/SCF-R) is a transmembrane tyrosine kinase receptor of importance for the normal development of hemopoietic cells, melanoblasts, and germ cells. We recently reported that protein kinase C (PRC) is involved in a negative feedback loop regulating the Kit/SCF-R by direct phosphorylation on serine residues in the receptor. Inhibition of Pf(C led to increased SCF-induced tyrosine kinase activity and mitogenicity, but PKC was necessary for SCF-induced motility. In this report we have further examined the modulatory role of PKC on SCF-induced signaling. The ligand-activated Kit/SCF-R associated weakly with GRB2 and induced only little tyrosine phosphorylation of phospholipase C-gamma in porcine aortic endothelial cells transfected with Kit/SCF-R. In contrast, the SCF-stimulated Kit/SCF-R associated efficiently with, and induced tyrosine phosphorylation of, the p85 alpha regulatory subunit of phosphatidyl inositide-3'-kinase (PI-3'-kinase). Both receptor association and tyrosine phosphorylation of p85 alpha were increased after inhibition of PKC, while its serine phosphorylation was decreased. Concomitantly, the specific activity of receptor-associated PI-3'-kinase activity was increased, Inhibition of PI-3'-kinase with wortmannin inhibited SCF-induced mitogenicity. SCF-induced phosphorylation of Raf-1 and activation of ERK2 still occurred after PKC inhibition but was not increased. In conclusion, SCF-induced PI-3'-kinase activation paralleled the increased SCF-induced mitogenicity after inhibition of PKC.	LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	Ludwig Institute for Cancer Research	BLUMEJENSEN, P (corresponding author), LUDWIG INST CANC RES,CTR BIOMED,UPPSALA BRANCH,BOX 595,S-75124 UPPSALA,SWEDEN.		Ronnstrand, Lars/A-2429-2011	Ronnstrand, Lars/0000-0003-1275-5809				ALAI M, 1992, J BIOL CHEM, V267, P18021; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; FLEISCHMAN RA, 1993, TRENDS GENET, V9, P285, DOI 10.1016/0168-9525(93)90015-A; HERBST R, 1991, J BIOL CHEM, V266, P19908; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOIKE T, 1993, J IMMUNOL, V151, P359; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; RONNSTRAND L, 1987, J BIOL CHEM, V262, P2929; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSALES OR, 1992, BIOCHEM BIOPH RES CO, V189, P40, DOI 10.1016/0006-291X(92)91522-R; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SHEARMAN MS, 1993, EMBO J, V12, P3817, DOI 10.1002/j.1460-2075.1993.tb06060.x; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOZERI O, 1992, ONCOGENE, V7, P2259; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; WENNSTROM S, 1994, ONCOGENE, V9, P651; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; XU XX, 1993, MOL CELL BIOL, V13, P1522, DOI 10.1128/MCB.13.3.1522; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	66	81	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21793	21802						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	7520444				2022-12-25	WOS:A1994PK97300062
J	WESTON, SA; HULMES, DJS; MOULD, AP; WATSON, RB; HUMPHRIES, MJ				WESTON, SA; HULMES, DJS; MOULD, AP; WATSON, RB; HUMPHRIES, MJ			IDENTIFICATION OF INTEGRIN ALPHA-2-BETA-1 AS CELL-SURFACE RECEPTOR FOR THE CARBOXYL-TERMINAL PROPEPTIDE OF TYPE PROCOLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRONECTIN RECEPTOR; LAMININ RECEPTOR; I PROCOLLAGEN; C-PROPEPTIDE; COLLAGEN; ADHESION; CHONDROCALCIN; PURIFICATION; BINDING; PROTEIN	The carboxyl-terminal propeptide of procollagen type I (CPP-I) plays a key role in the regulation of collagen fibrillogenesis. In addition, it has been reported that, after cleavage from procollagen, CPP-I exerts feedback control of collagen biosynthesis. To further elucidate the mechanisms involved in each of these processes, we have investigated the nature of cell surface receptors for CPP-I. CPP-I affinity chromatography, using detergent extracts of iodinated HT1080 cells and EDTA elution, resulted in the isolation of two polypeptides of molecular mass 160 and 110 kDa. Since the migratory behavior of these polypeptides under nonreducing and reducing conditions was characteristic of a subset of integrin receptors, their reactivity with anti-integrin monoclonal antibodies was tested. Antibodies directed against the alpha 2 and beta 1 subunits specifically immunoprecipitated both CPP-I-binding polypeptides, indicating that the CPP-I receptor is the integrin alpha 2 beta 1. CPP-I was found to support the attachment and spreading of HT1080 cells, demonstrating that it can function as an adhesion protein. Two other approaches supported the identification of alpha 2 beta 1 as the CPP-I receptor. First, antifunctional anti-integrin monoclonal antibodies directed against the alpha 2 and beta 1 subunits completely abrogated the adhesive activity of CPP-I and, second, highly purified CPP-I bound specifically to alpha 2 beta 1-containing integrin preparations in a solid-phase receptor-ligand binding assay. These findings have important implications for the function of fibrillar collagen carboxyl-terminal propeptides and for the role played by integrins in the regulation of cellular phenotype.	UNIV EDINBURGH,DEPT BIOCHEM,EDINBURGH EH8 9XD,SCOTLAND	University of Edinburgh	WESTON, SA (corresponding author), UNIV MANCHESTER,SCH BIOL SCI,2205 STOPFORD BLDG,MANCHESTER M13 9PT,ENGLAND.			Hulmes, David/0000-0002-0651-1317; Humphries, Martin/0000-0002-4331-6967	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AYCOCK RS, 1986, J BIOL CHEM, V261, P14355; BARD JBL, 1993, J CELL SCI, V105, P1045; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHEN FA, 1991, J EXP MED, V173, P1111, DOI 10.1084/jem.173.5.1111; CHOGLAY AA, 1993, J BIOL CHEM, V268, P6107; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; FESSLER LI, 1981, J BIOL CHEM, V256, P9640; FLEISCHMAJER R, 1983, P NATL ACAD SCI-BIOL, V80, P3354, DOI 10.1073/pnas.80.11.3354; FLEISCHMAJER R, 1981, P NATL ACAD SCI-BIOL, V78, P7360, DOI 10.1073/pnas.78.12.7360; GERGE BR, 1992, J BONE MINER RES, V7, P807; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HORLEIN D, 1981, P NATL ACAD SCI-BIOL, V78, P6163, DOI 10.1073/pnas.78.10.6163; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KATAYAMA K, 1991, BIOCHEMISTRY-US, V30, P7097, DOI 10.1021/bi00243a009; Kielty Cay M., 1993, P103; KIRSCH T, 1992, FEBS LETT, V310, P143, DOI 10.1016/0014-5793(92)81316-E; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEBIEN TW, 1982, J IMMUNOL, V129, P2287; LEUNG MKK, 1979, J BIOL CHEM, V254, P224; MAKAREM R, 1994, J BIOL CHEM, V269, P4005; MORRIS NP, 1979, J BIOL CHEM, V254, P1024; MOULD AP, 1990, J MOL BIOL, V211, P581, DOI 10.1016/0022-2836(90)90267-P; OLSEN BR, 1977, BIOCHEMISTRY-US, V16, P3030, DOI 10.1021/bi00632a034; Olsen BR, 1991, CELL BIOL EXTRACELLU, P177; PAGLIA L, 1979, BIOCHEMISTRY-US, V18, P5030, DOI 10.1021/bi00589a034; POOLE AR, 1984, J CELL BIOL, V98, P54, DOI 10.1083/jcb.98.1.54; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SANTORO SA, 1988, BIOCHEM BIOPH RES CO, V153, P217, DOI 10.1016/S0006-291X(88)81211-7; TAKADA Y, 1988, J CELL BIOCHEM, V37, P385, DOI 10.1002/jcb.240370406; TENCHINI ML, 1993, CELL ADHES COMMUN, V1, P55, DOI 10.3109/15419069309095681; TUDERMAN L, 1978, BIOCHEMISTRY-US, V17, P2948, DOI 10.1021/bi00608a002; UITTO J, 1977, ARCH BIOCHEM BIOPHYS, V179, P654, DOI 10.1016/0003-9861(77)90154-0; VANDERREST M, 1986, BIOCHEM J, V237, P923, DOI 10.1042/bj2370923; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WIESTNER M, 1979, J BIOL CHEM, V254, P7016; WU CH, 1986, J BIOL CHEM, V261, P482; WU CH, 1991, J BIOL CHEM, V266, P2983	42	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20982	20986						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	7520435				2022-12-25	WOS:A1994PC40300028
J	ENGHILD, JJ; VALNICKOVA, Z; THOGERSEN, IB; PIZZO, SV				ENGHILD, JJ; VALNICKOVA, Z; THOGERSEN, IB; PIZZO, SV			COMPLEXES BETWEEN SERPINS AND INACTIVE PROTEINASES ARE NOT THERMODYNAMICALLY STABLE BUT ARE RECOGNIZED BY SERPIN RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEASE INHIBITOR; REACTIVE-BOND LOOP; ALPHA-1-PROTEINASE INHIBITOR; ANTITHROMBIN-III; PLASMA ELIMINATION; BETA-SHEET; SITE LOOP; ALPHA-1-ANTITRYPSIN; ALPHA-2-ANTIPLASMIN; SUBSTRATE	The serpin mechanism of action may resemble the ''standard mechanism'' described for small protein inhibitors of serine proteinases. Since these inhibitors are able to bind active site-modified target proteinases, we have investigated the interactions between two serpins and their 3,4 -dichloroisocoumarin (DCI)-inactivated target proteinases. alpha(2)-Antiplasmin and alpha(1)-proteinase inhibitor bound stoichiometrically to DCI-inactivated chymotrypsin (EC 3.4.21.1) and DCI-inactivated human neutrophil elastase, respectively. Similar to active proteinases, the DCI-inactivated proteinases failed to bind complexes between serpins and synthetic reactive site loop peptides. Thus, the abilities of active and inactive proteinases to bind the serpins probably depend on the same structural characteristics. The thermodynamic stability of the alpha(2)-antiplasmin-DCI/chymotrypsin and alpha(1)-proteinase inhibitor-DCI/human neutrophil elastase complexes was similar to that of virgin serpins. However, in mouse plasma elimination studies the two complexes were removed rapidly from the circulation, suggesting that they have adopted the receptor recognized conformation. Consequently, cleavage of the reactive center peptide bond and formation of an inhibitor-acyl enzyme complex is neither obligatory to serpin-proteinase complex formation nor essential for the conformational change responsible for receptor mediated endocytosis.			ENGHILD, JJ (corresponding author), DUKE UNIV,MED CTR,DEPT PATHOL,POB 3712,DURHAM,NC 27710, USA.			Enghild, Jan Johannes/0000-0001-9292-9172	NHLBI NIH HHS [HL24066, HL31932, HL49542] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024066, R37HL024066, R01HL031932, R01HL049542] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agostini A.D., 1988, J CLIN INVEST, V82, P700; AKO H, 1974, BIOCHEMISTRY-US, V13, P132, DOI 10.1021/bi00698a021; BJORK I, 1992, J BIOL CHEM, V267, P1976; BJORK I, 1993, BIOCHEMISTRY-US, V32, P6501; BOCK SC, 1990, PROTEIN ENG, V4, P107, DOI 10.1093/protein/4.2.107; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; Bode W, 1991, CURR OPIN STRUC BIOL, V1, P45, DOI 10.1016/0959-440X(91)90010-Q; BURY A, 1981, J CHROMATOGR, V213, P490; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; COHEN AB, 1978, BIOCHEMISTRY-US, V17, P392, DOI 10.1021/bi00596a002; DRECHSEL D, 1984, ANAL BIOCHEM, V143, P141, DOI 10.1016/0003-2697(84)90568-2; ENGHILD JJ, 1993, BIOCHEM J, V291, P933, DOI 10.1042/bj2910933; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; GONIAS SL, 1982, THROMB HAEMOSTASIS, V48, P208; HARIS PI, 1990, BIOCHEMISTRY-US, V29, P1377, DOI 10.1021/bi00458a005; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P1831, DOI 10.1021/bi00329a005; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUBER R, 1975, BIOPHYS STRUCT MECH, V3, P189; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; LASKOWSKI M, 1987, COLD SPRING HARB SYM, V52, P545, DOI 10.1101/SQB.1987.052.01.062; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LOBERMANN H, 1984, J MOL BIOL, V177, P531; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOROI M, 1977, BIOCHIM BIOPHYS ACTA, V482, P412, DOI 10.1016/0005-2744(77)90255-8; PANNELL R, 1974, BIOCHEMISTRY-US, V13, P5439, DOI 10.1021/bi00723a031; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PIZZO SV, 1988, BIOCHIM BIOPHYS ACTA, V967, P158, DOI 10.1016/0304-4165(88)90005-0; READ RJ, 1986, PROTEINASE INHIBITOR, P301; RICHARZ R, 1980, BIOCHEMISTRY-US, V19, P5711, DOI 10.1021/bi00566a007; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SCHREUDER HA, 1994, STRUCT BIOL, V1, P48; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SCHULZE AJ, 1992, BIOCHEMISTRY-US, V31, P7560, DOI 10.1021/bi00148a017; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN PE, 1989, BIOCHEM J, V262, P102; TOMONO T, 1986, ACTA HAEMATOL JAPON, V49, P969; VINCENT JP, 1974, BIOCHEMISTRY-US, V13, P4205, DOI 10.1021/bi00717a023; WIMAN B, 1980, BIOCHEM J, V191, P229, DOI 10.1042/bj1910229	46	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					20159	20166						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	7519603				2022-12-25	WOS:A1994PA12600074
J	PARSONS, JN; WIEDERRECHT, GJ; SALOWE, S; BURBAUM, JJ; ROKOSZ, LL; KINCAID, RL; OKEEFE, SJ				PARSONS, JN; WIEDERRECHT, GJ; SALOWE, S; BURBAUM, JJ; ROKOSZ, LL; KINCAID, RL; OKEEFE, SJ			REGULATION OF CALCINEURIN PHOSPHATASE-ACTIVITY AND INTERACTION WITH THE FK-506-CENTER-DOT-FK-506 BINDING-PROTEIN COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSPORINE-A; CALMODULIN-BINDING; ACTIVATION; SUBUNIT; INHIBITION; ISOFORMS; FK-506; DOMAIN; IDENTIFICATION; EXPRESSION	The immunosuppressant FK-506 (tacrolimus) forms a complex with a ubiquitous intracellular receptor, FK-506 binding protein (FKBP12), and this complex inhibits the heterodimeric Ca2+/calmodulin dependent phosphatase, calcineurin, an essential component of the T-cell receptor signal transduction pathway. Using a series of truncated calcineurin catalytic subunits, we show here that a region within the catalytic subunit that regulates phosphatase activity, the autoinhibitory domain, also regulates the Ca2+-dependent interaction of calcineurin with the FK-506 FKBP12 complex. Deletion of this domain produces constitutive activation of the phosphatase as demonstrated by transient transfection experiments in which expression of the truncated protein permitted Ca2+-independent induction of interleukin-2 transcription. Thus, deletion of the autoinhibitory domain is necessary and sufficient to constitutively activate calcineurin (CaN). Furthermore, CaN A467-492, an inhibitory peptide based on the autoinhibitory domain from calcineurin (ITSFEEAKGLDRINERMPPRRDAMP), inhibited dephosphorylation of the RII peptide substrate competitively with a K-i = 4 mu M, consistent with binding of the autoinhibitory domain at the active site of the enzyme. To assess the role of the autoinhibitory domain in regulating the interaction of CaN with the FK-506 FKBP12 complex, we reconstituted wild type and mutant phosphatase heterodimers using in vitro transcribed and translated subunits. Association of the reconstituted calcineurin heterodimers with FKBP12 was dependent on FK-506. In the case of the wild type heterodimer, association with the FK-506 FKBP12 complex was also dependent upon Ca2+; however, mutant catalytic subunits, in which the autoinhibitory domains were deleted, associated with the drug-binding protein complex in the presence of 10 mM EGTA. These results indicate that the conserved autoinhibitory domain regulates both Ca2+-dependent phosphatase activity and association with the FK-506 FKBP12 complex.	MERCK SHARP & DOHME LTD,RES LABS,DEPT MOLEC IMMUNOL,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,RES LABS,DEPT CELLULAR IMMUNOL,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,RES LABS,DEPT BIOPHYS CHEM,RAHWAY,NJ 07065; HUMAN GENOME SCI,DEPT CELL BIOL,ROCKVILLE,MD 20850	Merck & Company; Merck & Company; Merck & Company; GlaxoSmithKline; Human Genome Sciences Inc								APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DENICOLA L, 1993, J CLIN INVEST, V92, P1859, DOI 10.1172/JCI116777; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; FOOR F, 1992, NATURE, V360, P682; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HADDY A, 1992, FEBS LETT, V314, P37, DOI 10.1016/0014-5793(92)81456-V; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HOLLON T, 1989, ANAL BIOCHEM, V182, P411, DOI 10.1016/0003-2697(89)90616-7; HUBBARD MJ, 1987, J BIOL CHEM, V262, P15062; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KINCAID R, 1993, ADV SEC MESS PHOSPH, V27, P1; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; LI W, 1993, J BIOL CHEM, V268, P14040; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LYSON T, 1993, CIRC RES, V73, P596, DOI 10.1161/01.RES.73.3.596; MERAT DL, 1985, J BIOL CHEM, V260, P1053; MUKAI H, 1993, J BIOCHEM, V113, P292, DOI 10.1093/oxfordjournals.jbchem.a124041; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PERRINO BA, 1992, J BIOL CHEM, V267, P15965; RYFFEL B, 1993, BIOCHEM BIOPH RES CO, V194, P1074, DOI 10.1006/bbrc.1993.1931; SHAPIRO R, 1990, TRANSPLANT P, V22, P35; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; TALLANT EA, 1984, BIOCHEMISTRY-US, V23, P973, DOI 10.1021/bi00300a027; UEKI K, 1992, BIOCHEM BIOPH RES CO, V187, P537, DOI 10.1016/S0006-291X(05)81527-X; UEKI K, 1993, J BIOL CHEM, V268, P6554; WEIDERRECHT G, 1992, J BIOL CHEM, V267, P21753; YOKOYAMA N, 1994, FEBS LETT, V337, P128, DOI 10.1016/0014-5793(94)80258-0	32	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19610	19616						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	7518461				2022-12-25	WOS:A1994NY33200064
J	KAYANOKI, Y; FUJII, J; SUZUKI, K; KAWATA, S; MATSUZAWA, Y; TANIGUCHI, N				KAYANOKI, Y; FUJII, J; SUZUKI, K; KAWATA, S; MATSUZAWA, Y; TANIGUCHI, N			SUPPRESSION OF ANTIOXIDATIVE ENZYME EXPRESSION BY TRANSFORMING GROWTH-FACTOR-BETA-1 IN RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; TUMOR NECROSIS FACTOR; BETA MESSENGER-RNA; SERUM-FREE MEDIUM; REACTIVE OXYGEN; DNA-SYNTHESIS; FACTOR-ALPHA; CELL-LINES; LIVER; INDUCTION	We have investigated the effect of transforming growth factor-beta 1 (TGF-beta 1) and three cytokines on expression of antioxidative enzymes, manganese-superoxide dismutase, copper, zinc-superoxide dismutase, and catalase in cultured hepatocytes of rat, While interleukin-1 beta and interleukin-6 induced manganese-superoxide dismutase gene expression, they slightly suppressed catalase gene expression in rat hepatocytes. TGF-beta 1 suppressed expression of all these antioxidative enzymes in time- and cell density-dependent manners. Furthermore, we examined the effect of TGF-beta 1 on expression of glutathione peroxidase and glutathione-S-transferase, which exhibit glutathione-dependent peroxidase activity in rat hepatocytes. Expression of two major classes of the rat glutathione-S-transferase subunits 1 and 2 was also reduced by TGF-beta 1, although expression of glutathione peroxidase was not affected. Flow cytometric analysis indicated that production of peroxides was increased in hepatocytes treated with TGF-beta 1. These data suggest that augmented production of hydrogen peroxide and its intermediate through suppression of antioxidative enzyme expression may participate in cellular injury or growth inhibition promoted by TGF-beta 1.	OSAKA UNIV, SCH MED, DEPT BIOCHEM, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT INTERNAL MED 2, SUITA, OSAKA 565, JAPAN	Osaka University; Osaka University			Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; 				BASS DA, 1983, J IMMUNOL, V130, P1910; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; BRAUN L, 1990, CELL GROWTH DIFFER, V1, P103; CARR BI, 1986, CANCER RES, V46, P2330; CASTILLA A, 1991, NEW ENGL J MED, V324, P933, DOI 10.1056/NEJM199104043241401; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTENSEN MJ, 1992, J NUTR, V122, P1620, DOI 10.1093/jn/122.8.1620; DELABAR JM, 1987, EUR J BIOCHEM, V166, P181, DOI 10.1111/j.1432-1033.1987.tb13500.x; DOUGALL WC, 1991, ENDOCRINOLOGY, V129, P2376, DOI 10.1210/endo-129-5-2376; EMERIT I, 1981, NATURE, V293, P144, DOI 10.1038/293144a0; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; FURUTA S, 1986, P NATL ACAD SCI USA, V83, P313, DOI 10.1073/pnas.83.2.313; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; HO YS, 1987, NUCLEIC ACIDS RES, V15, P10070, DOI 10.1093/nar/15.23.10070; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; ISHIKAWA M, 1990, CANCER RES, V50, P2538; ITO N, 1991, CANCER RES, V51, P4080; KAWAGUCHI T, 1990, BIOCHEM BIOPH RES CO, V171, P1378, DOI 10.1016/0006-291X(90)90838-E; KAWAMURA N, 1992, FREE RADICAL BIO MED, V12, P281, DOI 10.1016/0891-5849(92)90115-W; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KILBERG MS, 1989, METHOD ENZYMOL, V173, P564; KINSELLA AR, 1978, P NATL ACAD SCI USA, V75, P6149, DOI 10.1073/pnas.75.12.6149; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; MALIK S, 1991, BRIT J CANCER, V64, P612; Maniatis T., 1982, MOL CLONING; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEYER DJ, 1985, FEBS LETT, V184, P139, DOI 10.1016/0014-5793(85)80670-0; NAKAMURA Y, 1985, CARCINOGENESIS, V6, P229, DOI 10.1093/carcin/6.2.229; NAKATA T, 1992, CARCINOGENESIS, V13, P1941, DOI 10.1093/carcin/13.10.1941; NAKATSUKASA H, 1990, J CLIN INVEST, V85, P1833, DOI 10.1172/JCI114643; NISHIURA T, 1992, CANCER LETT, V62, P211, DOI 10.1016/0304-3835(92)90098-G; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OBERLEY LW, 1978, J NATL CANCER I, V61, P375; OOKAWARA T, 1992, J BIOL CHEM, V267, P18505; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SATO K, 1992, MOL CELL BIOL, V12, P2525, DOI 10.1128/MCB.12.6.2525; SHIBANUMA M, 1991, CELL GROWTH DIFFER, V2, P583; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SIMON RH, 1981, J BIOL CHEM, V256, P7181; STCLAIR DK, 1991, CANCER RES, V51, P939; TANIGUCHI N, 1992, ADV CLIN CHEM, V29, P1, DOI 10.1016/S0065-2423(08)60221-8; TU CPD, 1984, J BIOL CHEM, V259, P9434; VISNER GA, 1990, J BIOL CHEM, V265, P2856; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703	50	164	164	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15488	15492						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	7515058				2022-12-25	WOS:A1994NP51300017
J	DONG, BH; XU, LL; ZHOU, AM; HASSEL, BA; LEE, X; TORRENCE, PF; SILVERMAN, RH				DONG, BH; XU, LL; ZHOU, AM; HASSEL, BA; LEE, X; TORRENCE, PF; SILVERMAN, RH			INTRINSIC MOLECULAR ACTIVITIES OF THE INTERFERON-INDUCED 2-5A-DEPENDENT RNASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; FREE PROTEIN-SYNTHESIS; TREATED CELLS; PPP(A2'P)NA-DEPENDENT RNASE; JLS-V9R CELLS; 2-5A; ACTIVATION; BINDING; 2',5'-OLIGOADENYLATES; ENDORIBONUCLEASE	2-5A-dependent RNase (RNase L), a unique endoribonuclease that requires 5'-phosphorylated 2',5'-linked oligoadenylates (2-5A), functions in the molecular mechanism of interferon action. Because this enzyme is present at very low levels in nature, characterization and analysis have been limited. The molecular cloning of human, 2-5A-dependent RNase cDNA has facilitated its expression to high levels in insect cells by infecting with recombinant baculovirus. To determine the properties of the enzyme in the absence of other proteins, the recombinant 2-5A-dependent RNase was purified to homogeneity. The purified enzyme migrated as a monomer upon gel filtration in the absence of activator and showed highly specific, 2-5A-dependent RNase activity. The precise activator requirements were determined by stimulating the purified enzyme with a variety of 2',5'-linked oligonucleotides. The activated enzyme was capable of cleaving poly(rU) and, to a lesser extent, poly(rA), to sets of discrete products ranging from between 4 and 22 nucleotides in length. Reduced rates of 2-5A-dependent RNA cleavage were observed even after removal of ATP and chelation of divalent cations. However, optimal RNA cleavage rates required the presence of either manganese or magnesium and ATP.	CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195; NIDDK,MED CHEM LAB,BIOMED CHEM SECT,BETHESDA,MD 20892	Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)					NATIONAL CANCER INSTITUTE [R01CA044059] Funding Source: NIH RePORTER; NCI NIH HHS [5R01 CA44059] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ball L A, 1980, Ann N Y Acad Sci, V350, P486, DOI 10.1111/j.1749-6632.1980.tb20651.x; Belasco J.G., 2012, CONTROL MESSENGER RN; BISBAL C, 1989, EUR J BIOCHEM, V179, P595, DOI 10.1111/j.1432-1033.1989.tb14588.x; BROWN GE, 1976, BIOCHEM BIOPH RES CO, V69, P114, DOI 10.1016/S0006-291X(76)80280-X; CAYLEY PJ, 1982, EUR J BIOCHEM, V122, P601; CAYLEY PJ, 1982, BIOCHEM BIOPH RES CO, V108, P1243, DOI 10.1016/0006-291X(82)92133-7; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; DEUTSCHER MP, 1993, J BIOL CHEM, V268, P13011; FERBUS D, 1981, BIOCHEM BIOPH RES CO, V100, P847, DOI 10.1016/S0006-291X(81)80251-3; FLOYDSMITH G, 1981, SCIENCE, V212, P1020; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HOVANESSIAN AG, 1977, NATURE, V268, P537, DOI 10.1038/268537a0; IMAI J, 1984, BIOCHEMISTRY-US, V23, P766, DOI 10.1021/bi00299a028; IMAI J, 1985, J ORG CHEM, V50, P1418, DOI 10.1021/jo00209a014; IMAI J, 1985, J BIOL CHEM, V260, P1390; Imai J, 1981, Methods Enzymol, V79, P233; JACOBSEN H, 1983, P NATL ACAD SCI-BIOL, V80, P4954, DOI 10.1073/pnas.80.16.4954; JACOBSEN H, 1983, VIROLOGY, V125, P496, DOI 10.1016/0042-6822(83)90222-2; KERR IM, 1976, EUR J BIOCHEM, V69, P551, DOI 10.1111/j.1432-1033.1976.tb10940.x; KERR IM, 1974, NATURE, V250, P57, DOI 10.1038/250057a0; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; KITADE Y, 1991, BIOORG CHEM, V19, P283, DOI 10.1016/0045-2068(91)90054-S; KNIGHT M, 1980, NATURE, V288, P189, DOI 10.1038/288189a0; KOVACS T, 1993, BIOORG CHEM, V21, P192, DOI 10.1006/bioo.1993.1017; KRAUSE D, 1986, J BIOL CHEM, V261, P6836; KRAUSE D, 1985, EUR J BIOCHEM, V146, P611, DOI 10.1111/j.1432-1033.1985.tb08695.x; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LESIAK K, 1993, BIOCONJUGATE CHEM, V4, P467, DOI 10.1021/bc00024a008; LESIAK K, 1987, J BIOL CHEM, V262, P1961; LESIAK K, 1983, J BIOL CHEM, V258, P3082; NILSEN TW, 1979, P NATL ACAD SCI USA, V76, P2600, DOI 10.1073/pnas.76.6.2600; NOLANSORDEN NL, 1990, ANAL BIOCHEM, V184, P298, DOI 10.1016/0003-2697(90)90684-2; SALEHZADA T, 1993, J BIOL CHEM, V268, P7733; SILVERMAN RH, 1985, ANAL BIOCHEM, V144, P450, DOI 10.1016/0003-2697(85)90141-1; SILVERMAN RH, 1988, J BIOL CHEM, V263, P7336; SILVERMAN RH, 1987, LYMPHOKINES INTERFER, P149; SLATTERY E, 1979, P NATL ACAD SCI USA, V76, P4778, DOI 10.1073/pnas.76.10.4778; SQUIRE J, 1994, GENOMICS, V19, P174, DOI 10.1006/geno.1994.1033; TORRENCE PF, 1984, J MED CHEM, V27, P726, DOI 10.1021/jm00372a004; TORRENCE PF, 1993, P NATL ACAD SCI USA, V90, P1300, DOI 10.1073/pnas.90.4.1300; TORRENCE PF, 1992, ANTIVIR RES, V18, P275, DOI 10.1016/0166-3542(92)90061-9; TORRENCE PF, 1988, J BIOL CHEM, V263, P1131; WRESCHNER DH, 1982, EUR J BIOCHEM, V124, P261; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	45	130	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14153	14158						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7514601				2022-12-25	WOS:A1994NL60600065
J	FUJIHARA, M; ITO, N; PACE, JL; WATANABE, Y; RUSSELL, SW; SUZUKI, T				FUJIHARA, M; ITO, N; PACE, JL; WATANABE, Y; RUSSELL, SW; SUZUKI, T			ROLE OF ENDOGENOUS INTERFERON-BETA IN LIPOPOLYSACCHARIDE-TRIGGERED ACTIVATION OF THE INDUCIBLE NITRIC-OXIDE SYNTHASE GENE IN A MOUSE MACROPHAGE CELL-LINE, J774	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The role of endogenous tumor necrosis factor alpha (TNF-alpha) and interferon-beta (IFN-beta) in lipopolysaccharide (LPS)-induced activation of the inducible nitric-oxide synthase (i-NOS) gene was investigated. By Northern analysis or reverse-transcription polymerase chain reaction, the mouse macrophage cell line (J774) was found to respond to LPS treatment by increased expression of mRNAs specific for TNF-alpha, IFN-beta, and i-NOS with the kinetics unique for each gene. Bioassay of the culture supernatants showed that TNF-alpha and IFN-beta secreted by J774 cells increased from an undetectable level to about 300 and 340 units/ml, respectively, 3-6 h after LPS stimulation. Nitrite concentration was found to increase from 0 to 7.8 and 28.5 mu M by 12 and 24 h, respectively, in the culture supernatant of LPS-treated J774 cells. The presence of a neutralizing dose of antibodies against IFN-beta, but not against TNF-alpha, during treatment with either 10 ng or 1 mu g of LPS/ml significantly, but not completely, decreased the level of i-NOS specific mRNA expression and NO production. The incubation of J774 cells with mouse natural IFN-beta itself (up to the level of 1,200 units/ ml) did not induce i-NOS-specific mRNA and therefore did not stimulate J774 cells to produce NO, However, natural IFN-beta synergistically augmented the expression of i-NOS mRNA and the production of NO by J774 cells triggered by suboptimal concentrations of LPS (1 to 5 ng/ml). These data thus suggest that endogenous IFN-beta, but not TNF-alpha, produced by LPS-stimulated J774 cells specifically contributes, probably in an auto/paracrine fashion, to the activation of the i-NOS gene expression by LPS.	UNIV KANSAS, MED CTR, DEPT MICROBIOL MOLEC GENET & IMMUNOL, KANSAS CITY, KS 66160 USA; UNIV KANSAS, MED CTR, DEPT PATHOL & LAB MED, KANSAS CITY, KS 66160 USA; UNIV KANSAS, MED CTR, CTR CANC, KANSAS CITY, KS 66160 USA; KYOTO UNIV, FAC PHARMACEUT SCI, DEPT MOLEC MICROBIOL, SAKYO KU, KYOTO 606, JAPAN	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; Kyoto University					NATIONAL CANCER INSTITUTE [P01CA054474, R01CA035977] Funding Source: NIH RePORTER; NCI NIH HHS [1 PO1 CA54474, 5 RO1 CA 35977] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS DO, 1989, IMMUNOL TODAY, V10, P33, DOI 10.1016/0167-5699(89)90298-3; ASSREUY J, 1993, BRIT J PHARMACOL, V108, P833, DOI 10.1111/j.1476-5381.1993.tb12886.x; BLALOCK JE, 1975, J GEN VIROL, V29, P315, DOI 10.1099/0022-1317-29-3-315; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DING A, 1990, J IMMUNOL, V145, P940; DING AH, 1988, J IMMUNOL, V141, P2407; DIRKS W, 1989, J INTERFERON RES, V9, P125, DOI 10.1089/jir.1989.9.125; EIZIRIK DL, 1993, FEBS LETT, V317, P62, DOI 10.1016/0014-5793(93)81492-I; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIHARA M, 1994, J IMMUNOL, V152, P1898; FUJIHARA M, 1993, J BIOL CHEM, V268, P14898; GESSANI S, 1989, J VIROL, V63, P2785, DOI 10.1128/JVI.63.6.2785-2789.1989; GREEN SJ, 1992, J IMMUNOL, V149, P2069; HENRICSON BE, 1993, INFECT IMMUN, V61, P2325, DOI 10.1128/IAI.61.6.2325-2333.1993; INABA K, 1986, J EXP MED, V163, P1030, DOI 10.1084/jem.163.4.1030; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; JAATTELA M, 1991, LAB INVEST, V64, P724; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KHALILI K, 1984, J BIOL CHEM, V258, P6701; KILBOURN RG, 1990, J NATL CANCER I, V82, P772, DOI 10.1093/jnci/82.9.772; LEONE AM, 1991, J BIOL CHEM, V266, P23790; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MAROTTA P, 1992, BRIT J PHARMACOL, V107, P640, DOI 10.1111/j.1476-5381.1992.tb14499.x; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; MUNOZFERNANDEZ MA, 1992, EUR J IMMUNOL, V22, P301, DOI 10.1002/eji.1830220203; MUROI M, 1993, CELL SIGNAL, V5, P289, DOI 10.1016/0898-6568(93)90019-I; MUROI M, 1993, J BIOL CHEM, V268, P19534; MYERS MJ, 1989, J IMMUNOL, V142, P153; NOVOTNEY M, 1991, BIOCHEMISTRY-US, V30, P5597, DOI 10.1021/bi00236a037; NUSSLER A, 1991, EUR J IMMUNOL, V21, P227, DOI 10.1002/eji.1830210134; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; RALPH P, 1975, J IMMUNOL, V114, P898; RICHES DWH, 1991, J BIOL CHEM, V266, P24785; SEVERN A, 1992, BIOCHEM BIOPH RES CO, V188, P997, DOI 10.1016/0006-291X(92)91330-S; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; STUEHR DJ, 1987, CANCER RES, V47, P5590; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	42	102	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12773	12778						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7513694				2022-12-25	WOS:A1994NH71600062
J	KIM, SJ; KAHN, CR				KIM, SJ; KAHN, CR			INSULIN STIMULATES PHOSPHORYLATION OF C-JUN, C-FOS, AND FOS-RELATED PROTEINS IN CULTURED ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; KINASE-C; NUCLEAR PROTEINS; GENE-EXPRESSION; TRANSCRIPTION; ACTIVATION; CELLS; COMPLEXES; GROWTH; SITES	In differentiated 3T3-F442A adipocytes, insulin stimulated rapid and transient phosphorylation of c-Jun. Insulin also stimulated phosphorylation of c-Fos and several Fos-related proteins (pp72, pp45, and pp39) as indicated by precipitation with anti-c-Fos antibody following exposure to denaturating conditions. Phosphorylation of c Fos was stimulated by 7-fold by 60 min, while phosphorylation of Fos-related proteins reached maxima of 3.5-5.5-fold at 15 to 60 min. The increase in phosphorylated c-Fos was due to an increase in both c-Fos protein and the stoichiometry of c-Fos phosphorylation, and was not observed in c-fos (-/-) cells. Additionally, insulin stimulated phosphorylation of a protein with molecular mass of similar to 82 kDa on tyrosine residues by 2.5-fold within 30 min; this protein appeared to be immunologically related to c-Fos. These increases in the phosphorylation of AP-1 transcription factors correlated with a >5-fold stimulation of expression of a 12-O-tetradecanoylphorbol-13-acetate-responsive element-chloramphenicol acetyltransferase reporter gene transiently transfected into 3T3-F442A cells. These results indicate that insulin stimulates the phosphorylation of AP-1 transcription factors and several Fos-related proteins on serine and tyrosine residues. This is associated with changes in AP-1-mediated gene expression in vivo, suggesting that AP-1 phosphorylation by insulin plays a role in insulin regulated gene expression.	BRIGHAM & WOMENS HOSP,JOSLIN DIABET CTR,DEPT MED,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033201, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33201, DK 36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1991, ONCOGENE, V6, P2179; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CSERMELY P, 1993, J BIOL CHEM, V268, P9747; CSERMELY P, 1992, BIOCHEMISTRY-US, V31, P9940, DOI 10.1021/bi00156a012; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; FEUERSTEIN N, 1991, EXP CELL RES, V194, P289, DOI 10.1016/0014-4827(91)90367-4; FIELD SJ, 1992, P NATL ACAD SCI USA, V89, P9306, DOI 10.1073/pnas.89.19.9306; FRANZA BR, 1987, ONCOGENE, V1, P213; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HONEYMAN MC, 1993, DIABETES, V42, P626, DOI 10.2337/diabetes.42.4.626; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KASUGA M, 1982, J BIOL CHEM, V257, P392; KIM SJ, 1993, J CELL PHYSIOL, V157, P217, DOI 10.1002/jcp.1041570203; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OEMAR BS, 1991, J BIOL CHEM, V266, P24241; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1988, J BIOL CHEM, V263, P12721; REUSCH JEB, 1993, CLIN RES, V41, pA210; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; TAYLOR LK, 1993, P NATL ACAD SCI USA, V90, P368, DOI 10.1073/pnas.90.2.368; ZAFARULLAH M, 1992, FEBS LETT, V306, P169, DOI 10.1016/0014-5793(92)80992-P	37	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11887	11892						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512956				2022-12-25	WOS:A1994NG37700035
J	BANKA, CL; BLACK, AS; CURTISS, LK				BANKA, CL; BLACK, AS; CURTISS, LK			LOCALIZATION OF AN APOLIPOPROTEIN-A-I EPITOPE CRITICAL FOR LIPOPROTEIN-MEDIATED CHOLESTEROL EFFLUX FROM MONOCYTIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; MONOCLONAL-ANTIBODIES; CELLULAR CHOLESTEROL; ACYLTRANSFERASE; LECITHIN; MACROPHAGES; BINDING; MEMBRANE; AII; METABOLISM	The inverse correlation between plasma high density lipoprotein (HDL) levels and the risk for cardiovascular disease has been attributed in part to the role of HDL in facilitating the transport of cholesterol to the liver for catabolism. One component of this reverse cholesterol transport is removal of excess cholesterol from peripheral cells. An immunochemical approach was employed to evaluate the role of human apolipoprotein (apo) A-I in cellular cholesterol efflux and to test the hypothesis that discrete structural domains of the molecule mediate this function. Two apoA-I-specific monoclonal antibodies (AI-11 and AI-14) inhibited in vitro cellular cholesterol efflux from THP-1 monocytic cells to HDL or apoA-I proteoliposomes by approximately 50%. Six other antibodies had no effect although three of these bound significant proportions of the apoA-I proteoliposomes. Antibody AI-11 binds apoA-I amino acid residues 96-111 (Banka, C. L., Bonnet, D. J., Black, A. S., Smith, R. S., and Curtiss, L. K, (1991) J. Biol. Chem. 266, 23886-23892). The AI-14 epitope was localized to residues 74-105. Therefore, the two antibodies that inhibited HDL promotion of cellular cholesterol efflux bound overlapping but distinct regions of the apoA-I molecule.			BANKA, CL (corresponding author), SCRIPPS RES INST, RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043815, R29HL050060] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-50060, HL-43815] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANANTHARAMAIAH GM, 1990, ARTERIOSCLEROSIS, V10, P95, DOI 10.1161/01.ATV.10.1.95; BADIMON JJ, 1992, CIRCULATION, V86, P86; BANKA CL, 1991, J LIPID RES, V32, P35; BANKA CL, 1991, J BIOL CHEM, V266, P23886; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; BURING JE, 1992, CIRCULATION, V85, P22, DOI 10.1161/01.CIR.85.1.22; CHEN CH, 1982, J LIPID RES, V23, P680; CURTISS LK, 1982, J BIOL CHEM, V257, P5213; CURTISS LK, 1983, J CLIN INVEST, V72, P1427, DOI 10.1172/JCI111099; CURTISS LK, 1988, J BIOL CHEM, V263, P13779; CURTISS LK, 1987, J CLIN INVEST, V80, P367, DOI 10.1172/JCI113081; CURTISS LK, 1990, ATHEROSCLER REV, P217; CURTISS LK, 1987, NIH872646 PUBL, P363; CURTISS LK, 1985, J BIOL CHEM, V260, P282; GAMBLE W, 1978, J LIPID RES, V19, P1068; GLOMSET JA, 1968, J LIPID RES, V9, P155; HARA H, 1991, J BIOL CHEM, V266, P3080; JJONAS A, 1990, J BIOL CHEM, V265, P22123; JJONAS A, 1993, J BIOL CHEM, V268, P1596; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KAWANO M, 1993, BIOCHEMISTRY-US, V32, P5025, DOI 10.1021/bi00070a008; KINOSHITA M, 1983, J BIOCHEM-TOKYO, V94, P615, DOI 10.1093/oxfordjournals.jbchem.a134395; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; MAHLBERG FH, 1991, J BIOL CHEM, V266, P19930; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; MENDEZ AJ, 1992, CIRCULATION, V86, P7; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MINNICH A, 1992, J BIOL CHEM, V267, P16553; OHTA T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P119, DOI 10.1016/0005-2760(92)90083-8; ORAM JF, 1991, ARTERIOSCLER THROMB, V11, P403, DOI 10.1161/01.ATV.11.2.403; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; ROUSSEAUX J, 1980, MOL IMMUNOL, V17, P469, DOI 10.1016/0161-5890(80)90087-5; SCHMITZ G, 1985, EMBO J, V4, P613, DOI 10.1002/j.1460-2075.1985.tb03674.x; SEGREST JP, 1992, J LIPID RES, V33, P141; VONECKARDSTEIN A, 1990, J BIOL CHEM, V265, P8610; YOUNG SG, 1986, CLIN CHEM, V32, P1484	41	55	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10288	10297						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511599				2022-12-25	WOS:A1994NF01700020
J	SU, ZZ; SHEN, RQ; OBRIAN, CA; FISHER, PB				SU, ZZ; SHEN, RQ; OBRIAN, CA; FISHER, PB			INDUCTION OF TRANSFORMATION PROGRESSION IN TYPE-5 ADENOVIRUS-TRANSFORMED RAT EMBRYO CELLS BY A CLONED PROTEIN-KINASE-C BETA(1)-GENE AND REVERSAL OF PROGRESSION BY 5-AZACYTIDINE	ONCOGENE			English	Article							PHORBOL ESTER RECEPTOR; ANCHORAGE-INDEPENDENT GROWTH; GENE-EXPRESSION; FIBROBLAST CELLS; CHEMICAL CARCINOGENS; TUMOR PROMOTERS; LEUCINE ZIPPER; DNA-BINDING; WILD-TYPE; PHENOTYPE	Protein kinase C (PKC) is a key component in signal transduction in eucaryotic cells and when specific PKC isoforms are over-expressed in immortal mammalian cells they can induce transformation-associated properties. In the present study we demonstrate that a cloned PKC beta1 gene can induce an enhanced expression of the transformed phenotype in type 5 adenovirus (Ad5)-transformed rat embryo (RE) cells (clone E11), a process termed transformation progression. Ell cells expressing the PKC beta1 gene, clone B1/PKC, produce PKC beta1 mRNA and display enhanced PKC enzymatic activity and binding of [H-3]-phorbol-12,13-dibutyrate (PDBu) to cell surface phorbol ester receptors. B1/PKC cells grow with increased efficiency in agar in comparison with parental Ell cells and anchorage-independence is further enhanced in both cell types by addition of the tumor promoting agent 12-0-tetradecanoyl-phorbol-13-acetate (TPA). A single-exposure of B1/PKC cells to 5-azacytidine (AZA), followed by growth in the absence of this demethylating agent, results in B1/PKC-AZA clones which display a stable reversion of the progression phenotype to that of the unprogressed parental Ell clone. Loss of the progression phenotype corresponds with a reduction in PKC beta1-induced biochemical and cellular changes. In contrast, progression-suppression does not involve an alteration in expression of the Ad5 transforming genes, E1A and E1B, or the endogenous PKC epsilon gene. TPA cannot induce the progression phenotype in B1/PKC-AZA cells, but it can reversibly induce an increase in the transcriptional rate and steady-state mRNA levels of PKC beta1 and c-jun and it increases AP-1 DNA-binding. These results indicate that the PKC beta1 gene can serve as a transformation progression-inducing gene in rat embryo cells previously transformed by Ad5 and progression may be mediated by the inactivation by methylation of an AZA-sensitive 'progression suppressor gene(s)'. The suppression process in B1/PKC cells is independent of expression of the Ad5-transforming genes but correlates directly with the reduced expression of the transfected PKC beta1 gene in AZA-treated B1/PKC cells.	COLUMBIA UNIV COLL PHYS & SURG, CTR COMPREHENS CANC, DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, CTR COMPREHENS CANC, DEPT UROL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, INST CANC RES, NEW YORK, NY 10032 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Columbia University; Columbia University; Columbia University; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA035675, R01CA043208, R29CA052460] Funding Source: NIH RePORTER; NCI NIH HHS [CA35675, CA52460, CA43208] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BABISS LE, 1983, J VIROL, V46, P454, DOI 10.1128/JVI.46.2.454-465.1983; BABISS LE, 1985, SCIENCE, V228, P1099, DOI 10.1126/science.2581317; BABISS LE, 1984, J VIROL, V49, P731, DOI 10.1128/JVI.49.3.731-740.1984; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1992, J BIOL CHEM, V267, P12892; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; BORNER C, 1988, P NATL ACAD SCI USA, V85, P2110, DOI 10.1073/pnas.85.7.2110; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DORSCHHASLER K, 1980, J VIROL, V34, P305; DUIGOU GJ, 1991, ONCOGENE, V6, P1813; DUIGOU GJ, 1990, MOL CELL BIOL, V10, P2027, DOI 10.1128/MCB.10.5.2027; DUIGOU GJ, 1989, ANN NY ACAD SCI, V567, P302, DOI 10.1111/j.1749-6632.1989.tb16487.x; ELDAR H, 1990, J BIOL CHEM, V265, P13290; FISHER PB, 1979, CELL, V18, P695, DOI 10.1016/0092-8674(79)90124-7; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FISHER PB, 1978, P NATL ACAD SCI USA, V75, P2311, DOI 10.1073/pnas.75.5.2311; FISHER PB, 1979, NATURE, V281, P591, DOI 10.1038/281591a0; FISHER PB, 1979, CANCER RES, V39, P3051; FISHER PB, 1984, MECHANISMS TUMOR PRO, V3, P57; FRIEDMAN JM, 1986, MOL CELL BIOL, V6, P3791, DOI 10.1128/MCB.6.11.3791; HALAZONETIS TD, 1992, ANTICANCER RES, V12, P285; HARRINGTON MA, 1988, MOL CELL BIOL, V8, P4322, DOI 10.1128/MCB.8.10.4322; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P197; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRAUSS RS, 1989, ONCOGENE, V4, P991; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NICOLSON GL, 1987, CANCER RES, V47, P1473; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NOWELL PC, 1986, CANCER RES, V46, P2203; OBRIAN CA, 1989, FEBS LETT, V246, P78, DOI 10.1016/0014-5793(89)80257-1; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1986, FEBS LETT, V203, P111, DOI 10.1016/0014-5793(86)80724-4; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1990, J BIOL CHEM, V265, P22434; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PERKINS AS, 1983, MOL CELL BIOL, V3, P1123, DOI 10.1128/MCB.3.6.1123; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; REDDY PG, 1993, METHODS MOL GENETICS, V1, P68; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCOTT RE, 1989, P NATL ACAD SCI USA, V86, P1652, DOI 10.1073/pnas.86.5.1652; SU ZZ, 1993, ONCOGENE, V8, P1211; SU ZZ, 1991, MOL CARCINOGEN, V4, P328, DOI 10.1002/mc.2940040412; SU ZZ, 1990, MOL CARCINOGEN, V3, P309, DOI 10.1002/mc.2940030512; SU ZZ, 1992, CELL MOL BIOL, V38, P27; SU ZZ, 1992, POLY ADP RIBOSYLATIO, P203; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; WARD NE, 1992, BIOCHEMISTRY-US, V31, P5905, DOI 10.1021/bi00140a029; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINSTEIN IB, 1988, CANCER RES, V48, P4135	68	8	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1123	1132						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	7510863				2022-12-25	WOS:A1994NC04800015
J	HSU, HY; NICHOLSON, AC; HAJJAR, DP				HSU, HY; NICHOLSON, AC; HAJJAR, DP			BASIC FIBROBLAST GROWTH FACTOR-INDUCED LOW-DENSITY-LIPOPROTEIN RECEPTOR TRANSCRIPTION AND SURFACE EXPRESSION - SIGNAL-TRANSDUCTION PATHWAYS MEDIATED BY THE BFGF RECEPTOR TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; DEPENDENT PROTEIN-KINASE; CHOLESTEROL ESTER HYDROLASE; STEROL REGULATORY ELEMENT; CULTURED FIBROBLASTS; HAMSTER FIBROBLASTS; LIPID-ACCUMULATION; ENDOTHELIAL-CELLS; ADENYLATE-CYCLASE; MAMMALIAN-CELLS	Basic fibroblast growth factor (bFGF) has been implicated in the regulation of cell proliferation and cholesterol metabolism. In studies reported herein, we show bFGF increases low density lipoprotein (LDL) binding, uptake, and degradation in arterial smooth muscle cells in a dose-dependent manner. This increase was paralleled by an increase in LDL receptor mRNA steady state levels. To determine if bFGF activated transcription of the LDL receptor gene, we transiently transfected smooth muscle cells with a gene construct consisting of the 5'-upstream promoter region of the DNA from the human LDL receptor gene ligated to a plasmid containing the luciferase gene. We found that bFGF and a protein kinase C (PKC) activator, phorbol 12-myristate 13-acetate, significantly induced luciferase activity driven by the LDL receptor promoter, whereas 25-hydroxycholesterol reduced the luciferase activity in bFGF-stimulated cells. These findings show that bFGF and PKC are inducing LDL receptor gene transcription. We also evaluated potential signal transduction pathways induced by bFGF to establish the mechanism(s) leading to the activation of the LDL receptor gene. Activation of the activity of FGF receptor tyrosine kinase in smooth muscle cells by ligand binding resulted in tyrosine phosphorylation of one of the FGF receptors and a 90-kDa-protein as well as increased tyrosine phosphorylation of phospholipase C-gamma. Parallel observations were made in that increased PKC and protein kinase A activities occurred with bFGF as compared with control cells. Inhibitors of receptor tyrosine kinase and other protein kinases significantly reduced transcription and surface expression of LDL receptor. Finally, several key enzymes that are central to the regulation of LDL-cholesteryl ester metabolism were also studied in bFGF-stimulated cells. An increase in acyl-CoA:cholesterol acyltransferase activity and cholesterol esterification was observed with bFGF stimulation, but there was no effect on the lysosomal or cytoplasmic cholesteryl ester hydrolase activities. Our findings suggest potential signal transduction pathways activated by bFGF which play a role in regulating transcription and surface expression of the LDL receptor.	CORNELL UNIV,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT PATHOL,NEW YORK,NY 10021	Cornell University; Cornell University					NCRR NIH HHS [RR-00085] Funding Source: Medline; NHLBI NIH HHS [HL-46403, HL-07423] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000085] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046403, T32HL007423] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUWERX JH, 1989, MOL CELL BIOL, V9, P2298, DOI 10.1128/MCB.9.6.2298; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; BAIRD A, 1990, NATURE, V348, P344, DOI 10.1038/348344a0; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHAIT A, 1988, BIOCHIM BIOPHYS ACTA, V960, P183, DOI 10.1016/0005-2760(88)90063-X; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JK, 1988, IN VITRO CELL DEV B, V24, P199; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5894; COLBRAN RJ, 1986, FEBS LETT, V201, P257, DOI 10.1016/0014-5793(86)80619-6; CORTON JM, 1992, EUR J BIOCHEM, V204, P203, DOI 10.1111/j.1432-1033.1992.tb16625.x; DAVIES PF, 1982, BIOCHIM BIOPHYS ACTA, V712, P26, DOI 10.1016/0005-2760(82)90080-7; DAVIS LG, 1986, BASIC METODS MOL BIO; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GHOSH S, 1989, LIPIDS, V24, P733, DOI 10.1007/BF02535213; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GROVE RI, 1991, J LIPID RES, V32, P1889; HAJJAR DP, 1980, AM J PATHOL, V100, P683; HAJJAR DP, 1982, J CLIN INVEST, V70, P479, DOI 10.1172/JCI110639; HAJJAR DP, 1991, AM J PATHOL, V139, P1195; HAJJAR DP, 1983, J LIPID RES, V24, P1176; HAJJAR DP, 1985, J BIOL CHEM, V260, P6124; HALEY NJ, 1980, J LIPID RES, V21, P961; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MAGNALDO I, 1989, CELL SIGNAL, V1, P507, DOI 10.1016/0898-6568(89)90035-1; MAGNALDO I, 1986, J BIOL CHEM, V261, P6916; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARSHALL PJ, 1985, ANAL BIOCHEM, V145, P192, DOI 10.1016/0003-2697(85)90347-1; MAZZONE T, 1990, J BIOL CHEM, V265, P5145; MAZZONE T, 1989, J BIOL CHEM, V264, P1787; MIDDLETON B, 1992, BIOCHEM J, V282, P853, DOI 10.1042/bj2820853; MOORBY CD, 1992, ATHEROSCLEROSIS, V97, P21, DOI 10.1016/0021-9150(92)90047-K; NANBERG E, 1990, J CELL PHYSIOL, V143, P232, DOI 10.1002/jcp.1041430206; NICHOLSON AC, 1992, J BIOL CHEM, V267, P25982; OSTLUND RE, 1991, JAMA-J AM MED ASSOC, V266, P1937, DOI 10.1001/jama.266.14.1937; OWEN CH, 1991, ARTERIOSCLER THROMB, V11, P1447; PARIS S, 1991, ANN NY ACAD SCI, V638, P139, DOI 10.1111/j.1749-6632.1991.tb49024.x; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PRESTA M, 1991, CELL REGUL, V2, P719, DOI 10.1091/mbc.2.9.719; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SMITH JR, 1988, J BIOL CHEM, V263, P18480; STOPECK AT, 1993, J BIOL CHEM, V268, P17489; STOUT RW, 1983, ATHEROSCLEROSIS, V46, P13, DOI 10.1016/0021-9150(83)90159-4; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; SUGDEN PH, 1976, BIOCHEM J, V159, P423, DOI 10.1042/bj1590423; TAM SP, 1991, J BIOL CHEM, V266, P16764; THERET N, 1990, BIOCHEM BIOPH RES CO, V173, P1361, DOI 10.1016/S0006-291X(05)80938-6; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WANG XD, 1993, J BIOL CHEM, V268, P14497; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; ZWILLER J, 1991, ONCOGENE, V6, P219	65	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9213	9220						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510705				2022-12-25	WOS:A1994NB41100087
J	HOTTIGER, M; PODUST, VN; THIMMIG, RL; MCHENRY, C; HUBSCHER, U				HOTTIGER, M; PODUST, VN; THIMMIG, RL; MCHENRY, C; HUBSCHER, U			STRAND DISPLACEMENT ACTIVITY OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE HETERODIMER AND ITS INDIVIDUAL SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-DELTA; CALF THYMUS; VIRAL-DNA; ENZYME; EXPRESSION; INFECTION; PROTEIN; BINDING; PRODUCT; EPSILON	By using a DNA substrate with defined gap size, we found that human immunodeficiency virus type 1 reverse transcriptase (HIV-RT) was able to perform strand displacement DNA synthesis. This activity was not affected first by calf thymus proliferating cell nuclear antigen and replication factor C and second by Escherichia coli single-stranded DNA-binding protein, which together allow DNA polymerase 8 to perform strand displacement DNA synthesis (Podust, V., and Hubscher, U. (1993) Nucleic Acids Res. 21, 841-846). 3'-Azido-2',3'-dideoxythymidine triphosphate inhibited displacement completely, indicating that DNA synthesis is required for this reaction. The HIV-RT p66 polypeptide alone could perform limited strand displacement DNA synthesis, whereas the HIV-RT p51 polypeptide was completely inactive, likely due to its inability to replicate extensively on a M13 DNA template. On the other hand the HIV-RT p51 polypeptide enhanced the strand displacement activity of the HIV-RT p66 subunit at a molar ratio of 4:1, mainly by chasing short products into longer ones. Furthermore, kinetic experiments after complementation of HIV-RT p66 with HIV-RT p5l indicated that HIV-RT p51 can restore rate and extent of strand displacement activity by HIV-RT p66 compared with the HIV-RT heterodimer p66/p5l, suggesting a function of the 51-kDa polypeptide.	UNIV ZURICH IRCHEL,DEPT VET BIOCHEM,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262	University of Zurich; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Hottiger, Michael O./J-7747-2013	Hottiger, Michael O./0000-0002-7323-2270	NIAID NIH HHS [R01 AI126600] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; BATHURST IC, 1990, BIOCHEM BIOPH RES CO, V171, P589, DOI 10.1016/0006-291X(90)91187-W; BOONE LR, 1981, J VIROL, V37, P117, DOI 10.1128/JVI.37.1.117-126.1981; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARNEAU P, 1991, J VIROL, V65, P2415, DOI 10.1128/JVI.65.5.2415-2421.1991; CULLMANN G, 1993, IN PRESS GENE AMST; DISTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; ELDIRANIDIAB R, 1992, FEBS LETT, V301, P23; HAFKEMEYER P, 1991, P NATL ACAD SCI USA, V88, P5262, DOI 10.1073/pnas.88.12.5262; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MCHENRY CS, 1989, MOL BIOL CHROMOSOME, P97; PFEIFFER P, 1983, CELL, V33, P781, DOI 10.1016/0092-8674(83)90020-X; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; PODUST VN, 1992, CHROMOSOMA, V102, P133; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROBINSON HL, 1990, J VIROL, V64, P4836, DOI 10.1128/JVI.64.10.4836-4841.1990; Sambrook J, 1989, MOL CLONING LABORATO; SHANK PR, 1978, J VIROL, V25, P104, DOI 10.1128/JVI.25.1.104-104.1978; SOENGAS MS, 1992, EMBO J, V11, P4227, DOI 10.1002/j.1460-2075.1992.tb05517.x; STARNES MC, 1988, J BIOL CHEM, V263, P5132; THIMMIG RL, 1993, J BIOL CHEM, V268, P16528; THOMMES P, 1992, J BIOL CHEM, V267, P6063; VARMUS H, 1985, RNA TUMOR VIRUSES MO, P369; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WEISER T, 1991, J BIOL CHEM, V266, P10420	30	52	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					986	991						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507115				2022-12-25	WOS:A1994MR22000035
J	YOON, KL; GUIDOTTI, G				YOON, KL; GUIDOTTI, G			STUDIES ON THE MEMBRANE TOPOLOGY OF THE (NA,K)-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE BETA-SUBUNIT; AMINO-ACID-SEQUENCE; TISSUE-SPECIFIC EXPRESSION; SITE-DIRECTED MUTAGENESIS; ALPHA-SUBUNIT; MOLECULAR-CLONING; H+-ATPASE; EXTRACELLULAR DOMAIN; CATALYTIC SUBUNIT; RAT-BRAIN	The topology of the alpha 1 and beta 1 subunits of the rat (Na,K)-ATPase has been studied by insertion of epitope(s): at the NH2 terminus and COOH terminus and between Glu-117 and Glu-118, Lys-828 and Arg-829, Gln-900 and Trp-901, and Val-939 and Phe-940 of the a subunit; and at the NH2 terminus and COOH terminus and between Glu-228 and Tyr-229 of the beta subunit. The epitope-tagged alpha 1 constructs were expressed in HeLa cells to select for stable cell lines expressing a functional (Na,K)-ATPase. The epitope-tagged beta constructs were transiently expressed in Cos-7 cells. The membrane arrangement of the epitopes was revealed by indirect immunofluorescence with cells expressing the (Na,K)-ATPase chains. The results indicate that the alpha subunit has 4 transmembrane segments in the COOH-terminal membrane-bound domain between residues 760 and 938, and that both the NH2 terminus and the COOH terminus are in the cytosol; it was not determined whether there are more transmembrane segments between residue 938 and the COOH terminus. The beta subunit has only one transmembrane spanning region with the NH2 terminus in the cytosol and the COOH terminus on the extracytoplasmic surface of the plasma membrane.			YOON, KL (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.				NHLBI NIH HHS [HL08893] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADDISON R, 1986, J BIOL CHEM, V261, P4896; ANTOLOVIC R, 1991, EUR J BIOCHEM, V199, P195, DOI 10.1111/j.1432-1033.1991.tb16109.x; BALL WJ, 1987, BIOCHIM BIOPHYS ACTA, V916, P100, DOI 10.1016/0167-4838(87)90216-0; BAYER R, 1990, BIOCHEMISTRY-US, V29, P2251, DOI 10.1021/bi00461a007; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BROWN TA, 1987, BIOCHIM BIOPHYS ACTA, V912, P244, DOI 10.1016/0167-4838(87)90095-1; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CHERTOVA EN, 1989, FEBS LETT, V254, P13, DOI 10.1016/0014-5793(89)80999-8; CHIN G, 1983, BIOCHEMISTRY-US, V22, P3405, DOI 10.1021/bi00283a016; CHIN GJ, 1985, BIOCHEMISTRY-US, V24, P5943, DOI 10.1021/bi00342a038; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; EMERICK MC, 1993, J BIOL CHEM, V268, P23455; FARLEY RA, 1986, BIOCHIM BIOPHYS ACTA, V873, P136, DOI 10.1016/0167-4838(86)90199-8; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; FISCHBARG J, 1993, P NATL ACAD SCI USA, V90, P11658, DOI 10.1073/pnas.90.24.11658; FISONE G, 1994, J BIOL CHEM, V269, P9368; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; HARA Y, 1987, J BIOCHEM-TOKYO, V102, P43, DOI 10.1093/oxfordjournals.jbchem.a122039; JORGENSEN PL, 1983, BIOCHIM BIOPHYS ACTA, V735, P291, DOI 10.1016/0005-2736(83)90304-8; JORGENSEN PL, 1982, J BIOL CHEM, V257, P7435; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KAPLAN JG, 1978, ANNU REV PHYSIOL, V40, P19, DOI 10.1146/annurev.ph.40.030178.000315; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KAWAKAMI K, 1986, NUCLEIC ACIDS RES, V14, P2833, DOI 10.1093/nar/14.7.2833; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LEMAS MV, 1992, J BIOL CHEM, V267, P20987; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MANDALA SM, 1989, J BIOL CHEM, V264, P16276; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MERCER RW, 1986, MOL CELL BIOL, V6, P3884, DOI 10.1128/MCB.6.11.3884; MODYANOV N, 1992, ACTA PHYSIOL SCAND, V146, P49; MOHRAZ M, 1994, J BIOL CHEM, V269, P2929; MONK BC, 1991, J BIOL CHEM, V266, P18097; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NOGUCHI S, 1986, FEBS LETT, V196, P315, DOI 10.1016/0014-5793(86)80270-8; OHTA T, 1986, FEBS LETT, V204, P297, DOI 10.1016/0014-5793(86)80832-8; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P269, DOI 10.1016/0014-5793(87)80676-2; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; PELMAN HRB, 1986, CELL, V46, P959; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PRICE EM, 1990, J BIOL CHEM, V265, P6638; RAO US, 1991, J BIOL CHEM, V266, P14740; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SHULL GE, 1986, NATURE, V321, P429, DOI 10.1038/321429a0; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHULL MM, 1989, J BIOL CHEM, V264, P17532; SMILEY JK, 1990, J VIROL, V64, P4558, DOI 10.1128/JVI.64.9.4558-4564.1990; SMITH DL, 1993, J BIOL CHEM, V268, P22469; TAKEYASU K, 1987, J BIOL CHEM, V262, P10733; THIBAULT D, 1993, BIOCHEMISTRY-US, V32, P2813, DOI 10.1021/bi00062a012; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VERMA AK, 1988, J BIOL CHEM, V263, P14152; YOUNG RM, 1987, J BIOL CHEM, V262, P4905	64	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28249	28258						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525571				2022-12-25	WOS:A1994PV77200072
J	JACKSON, SP; SCHOENWAELDER, SM; YUAN, YP; RABINOWITZ, I; SALEM, HH; MITCHELL, CA				JACKSON, SP; SCHOENWAELDER, SM; YUAN, YP; RABINOWITZ, I; SALEM, HH; MITCHELL, CA			ADHESION RECEPTOR ACTIVATION OF PHOSPHATIDYLINOSITOL 3-KINASE - VON-WILLEBRAND-FACTOR STIMULATES THE CYTOSKELETAL ASSOCIATION AND ACTIVATION OF PHOSPHATIDYLINOSITOL 3-KINASE AND PP60(C-SRC) IN HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IIB-IIIA; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MEMBRANE SKELETON; PHOSPHOINOSITIDE 3-KINASE; VONWILLEBRAND DISEASE; ACTIN POLYMERIZATION; GLYCOPROTEIN-IB; CELL-ADHESION; THROMBIN	The cytoskeleton participates in the coordinated regulation of intracellular signaling molecules, following agonist stimulation of cells. We have demonstrated that von Willebrand factor (vWF) induced the cytoskeletal association and activation of phosphatidylinositol 3-kinase (PtdIns 3-kinase) in human platelets. The activation of PtdIns 3-kinase coincided with the tyrosine phosphorylation of multiple platelet proteins, as assessed by anti-phosphotyrosine immunoblotting. One of these tyrosine-phosphorylated proteins, pp60(c-src), became specifically enriched in the cytoskeletal fraction of vWF-stimulated platelets. The vWF-stimulated cytoskeletal association of PtdIns 3-kinase and pp60(c-src) required platelet stirring and aggregation, was specifically blocked by an anti-GPIb monoclonal antibody, and was not observed in platelets lacking the glycoprotein Ib/IX complex (Bernard-Soulier syndrome). Pretreatment of normal platelets with 5 mM EDTA (37 degrees C for 90 min) or RODS (2 mM), which disrupts the binding of various adhesive proteins to platelet integrins and inhibits fibrinogen-mediated platelet aggregation, did not alter the vWF-stimulated activation and cytoskeletal association of PtdIns 3-kinase and pp60(c-src). Pretreatment of platelets with acetylsalicylic acid (1 mM) completely abolished vWF-stimulated production of thromboxane A(2), dense granule release, and the activation of protein kinase C, without altering the activation and cytoskeletal translocation of PtdIns 3-kinase and pp60(c-src). Our results suggest that vWF binding to the platelet adhesion receptor glycoprotein Ib/IX can mediate activation and translocation of both tyrosine and lipid kinase(s) independent of other agonists.			JACKSON, SP (corresponding author), MONASH UNIV,BOX HILL HOSP,SCH MED,DEPT MED,NELSON RD,BOX HILL,VIC 3128,AUSTRALIA.		Schoenwaelder, Simone/E-9506-2011; Jackson, Shaun P/E-9633-2011	Jackson, Shaun/0000-0002-4750-1991; Mitchell, Christina A/0000-0001-9372-3192; Schoenwaelder, Simone/0000-0003-0465-5840				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AUGER KR, 1992, J BIOL CHEM, V267, P5408; Baenziger N L, 1974, Methods Enzymol, V31, P149; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; EBERLE M, 1990, J BIOL CHEM, V265, P16725; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1993, J BIOL CHEM, V268, P25973; GEORGE JN, 1991, NEW ENGL J MED, V324, P27, DOI 10.1056/NEJM199101033240106; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JAKOBSEN E, 1973, Thrombosis Research, V3, P145, DOI 10.1016/0049-3848(73)90065-0; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MONTGOMERY RR, 1978, J CLIN INVEST, V61, P1498, DOI 10.1172/JCI109070; ODA A, 1992, J BIOL CHEM, V267, P20075; PUMIGLIA KM, 1993, BIOCHEM J, V294, P253, DOI 10.1042/bj2940253; ROTH GJ, 1991, BLOOD, V77, P5; RUGGERI ZM, 1987, BLOOD, V70, P895; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SMYTH SS, 1993, BLOOD, V81, P2827; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; SULTAN C, 1991, J BIOL CHEM, V266, P23554; SUSA M, 1992, J BIOL CHEM, V267, P22951; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; ZHANG J, 1992, J BIOL CHEM, V267, P4686	43	114	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27093	27099						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7523416				2022-12-25	WOS:A1994PQ93100076
J	KIM, JP; ZHANG, K; CHEN, JD; KRAMER, RH; WOODLEY, DT				KIM, JP; ZHANG, K; CHEN, JD; KRAMER, RH; WOODLEY, DT			VITRONECTIN-DRIVEN HUMAN KERATINOCYTE LOCOMOTION IS MEDIATED BY THE ALPHA-V-BETA-5 INTEGRIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM SPREADING FACTOR; MICROVASCULAR ENDOTHELIAL-CELLS; FIBRONECTIN RECEPTOR; ALPHA-V; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; BETA-SUBUNIT; HUMAN-PLASMA; ADHESION; MIGRATION	Vitronectin is a soluble serum factor that is known to promote epiboly of keratinocytes in explant cultures and enhance cell spreading and attachment to matrix. Recently, vitronectin was demonstrated to promote human keratinocyte locomotion. The mechanism(s) by which vitronectin enhances keratinocyte migration is unknown. In this study, we quantitated the vitronectin-driven migration of human keratinocytes in the presence of antibodies to vitronectin receptors. We found that vitronectin's effect of promoting human keratinocyte migration was inhibited by antibody-directed against the alpha v beta 5 receptor. In addition, we surface-labeled human keratinocytes, chromatographed extracts of the cell membranes on a vitronectin column, and then immunoprecipitated the bound and eluted proteins with antibodies to specific vitronectin receptors. We identified the vitronectin receptors on human keratinocytes as bands of 150,000 and 100,000 daltons without reduction and as 125,000 and 110,000 daltons under reducing conditions. Immunoprecipitation with specific antibodies identified the major receptor to be the alpha v beta 5 integrin. In addition, we quantitated vitronectin-driven migration of human keratinocytes in the presence of Arg-Gly-Asp (RGD) and control peptides. We found that the presence of RGD, but not control peptide, inhibited vitronectin-driven migration of human keratinocytes. These studies demonstrate that human keratinocytes express vitronectin receptors and use the alpha v beta 5 receptor for cellular locomotion.	STANFORD UNIV,SCH MED,DEPT DERMATOL,STANFORD,CA 94305; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH DENT,DEPT STOMATOL,SAN FRANCISCO,CA 94143	Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041045, T32AR007422, R01AR033625] Funding Source: NIH RePORTER; NIAMS NIH HHS [T32-AR07422, AR41045, AR33625] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; BARNES DW, 1983, J BIOL CHEM, V258, P2548; BASARA ML, 1985, CANCER RES, V45, P2487; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; Boyce S.T., 1983, J INVEST DERMATOL S, V81, P33; BROWN C, 1991, J INVEST DERMATOL, V96, P724, DOI 10.1111/1523-1747.ep12470960; BUSK M, 1992, J BIOL CHEM, V267, P5790; CHEN JD, 1994, DERMATOLOGY, V188, P6, DOI 10.1159/000247076; CHEN WT, 1986, J CELL BIOL, V103, P1649, DOI 10.1083/jcb.103.5.1649; CHENG YF, 1991, EXP CELL RES, V194, P69, DOI 10.1016/0014-4827(91)90131-D; CHENG YF, 1989, J CELL PHYSIOL, V139, P275, DOI 10.1002/jcp.1041390209; CHERESH DA, 1987, J BIOL CHEM, V262, P1434; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CLARK RAF, 1985, J AM ACAD DERMATOL, V13, P701, DOI 10.1016/S0190-9622(85)70213-7; COUCHMAN JR, 1979, J CELL SCI, V39, P149; DUBAND JL, 1988, J CELL BIOL, V107, P1385, DOI 10.1083/jcb.107.4.1385; DUBAND JL, 1986, J CELL BIOL, V102, P160, DOI 10.1083/jcb.102.1.160; FREED E, 1989, EMBO J, V8, P2955, DOI 10.1002/j.1460-2075.1989.tb08445.x; GARTNER TK, 1993, THROMB RES, V71, P47; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; HAYMAN EG, 1985, EXP CELL RES, V160, P245, DOI 10.1016/0014-4827(85)90173-9; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HERTLE MD, 1991, DEVELOPMENT, V112, P193; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JULIANO RL, 1987, BIOCHIM BIOPHYS ACTA, V907, P261, DOI 10.1016/0304-419X(87)90009-6; KIM JP, 1992, J INVEST DERMATOL, V98, P764, DOI 10.1111/1523-1747.ep12499947; KIM JP, 1992, J CELL PHYSIOL, V151, P443, DOI 10.1002/jcp.1041510303; KRAMER RH, 1989, CANCER RES, V49, P393; KRISSANSEN GW, 1990, J BIOL CHEM, V265, P823; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; MARKS R, 1978, BRIT J DERMATOL, V98, P631; OKEEFE EJ, 1985, J INVEST DERMATOL, V85, P125, DOI 10.1111/1523-1747.ep12276531; OKEEFE EJ, 1988, J INVEST DERMATOL, V90, P2, DOI 10.1111/1523-1747.ep12462409; PETERSEN MJ, 1987, J BIOL CHEM, V262, P835; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SARRET Y, 1992, J INVEST DERMATOL, V98, P12, DOI 10.1111/1523-1747.ep12493517; SHEPPARD D, 1992, J BIOL CHEM, V267, P17409; SMITH JW, 1990, J BIOL CHEM, V265, P12267; Stenn K.S., 1988, MOL CELLULAR BIOL WO, P321; STENN KS, 1979, NATURE, V277, P229, DOI 10.1038/277229a0; STENN KS, 1981, P NATL ACAD SCI-BIOL, V78, P6907, DOI 10.1073/pnas.78.11.6907; Stuiver I., 1993, Molecular Biology of the Cell, V4, p285A; VANDIJK S, 1993, J BONE MINER RES, V8, P1499; VANSTRIJP JAG, 1993, J IMMUNOL, V151, P3324; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WHATELEY JG, 1980, BIOCHEM J, V185, P349, DOI 10.1042/bj1850349; WOODLEY D, 1980, J INVEST DERMATOL, V75, P148, DOI 10.1111/1523-1747.ep12522536; WOODLEY DT, 1988, J CELL PHYSIOL, V136, P140, DOI 10.1002/jcp.1041360118; WOODLEY DT, 1967, J CLIN INVEST, V179, P1826; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	55	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26926	26932						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7523414				2022-12-25	WOS:A1994PQ93100054
J	RABEN, N; NICHOLS, R; DOHLMAN, J; MCPHIE, P; SRIDHAR, V; HYDE, C; LEFF, R; PLOTZ, P				RABEN, N; NICHOLS, R; DOHLMAN, J; MCPHIE, P; SRIDHAR, V; HYDE, C; LEFF, R; PLOTZ, P			A MOTIF IN HUMAN HISTIDYL-TRANSFER-RNA SYNTHETASE WHICH IS SHARED AMONG SEVERAL AMINOACYL-TRANSFER-RNA SYNTHETASES IS A COILED-COIL THAT IS ESSENTIAL FOR ENZYMATIC-ACTIVITY AND CONTAINS THE MAJOR AUTOANTIGENIC EPITOPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; CHAIN-RELEASE FACTOR; ESCHERICHIA-COLI; DIADENOSINE 5',5'''-P1,P4-TETRAPHOSPHATE; SACCHAROMYCES-CEREVISIAE; SECONDARY-STRUCTURE; CIRCULAR-DICHROISM; ANTI-JO-1 ANTIBODY; TERMINAL EXTENSION; MYOSITIS	In myositis, disease-specific autoantibodies may be directed against an aminoacyl-tRNA synthetase, usually histidyl-tRNA synthetase. To explore the basis for this phenomenon, we have made recombinant histidyl-tRNA synthetase in the baculovirus system. It was enzymatically active and recognized by human autoantibodies. A truncated protein lacking the first 60 amino acids was inactive as an antigen and as an enzyme. This region is within the first two exons, is predicted to have a coiled-coil configuration, and is found in some other synthetases but not in Escherichia coli or yeast histidyl-tRNA synthetase. Circular dichroism showed that the peptides from this region (amino acids 1-60 and 1-47) have the predicted high alpha-helical content, but smaller fragments (1-30, 14-45, and 31-60) do not. The peptides with a high alpha-helical content could inhibit autoantibodies almost completely, whereas the smaller peptides were unable to do so. The amino acid sequence of this coiled-coil domain in human histidyl-tRNA synthetase resembles the sequence of the extended this coiled-coil arm near the NH2 terminus of bacterial seryl-tRNA synthetase as well as similar regions in some eukaryotic aminoaayl-tRNA synthetases, raising the possibility that this domain serves a similar tRNA-stabilizing role and has been preserved from a common ancestor.	NIDDK,BETHESDA,MD 20892; NIAMSD,STRUCT BIOL RES LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	RABEN, N (corresponding author), NIAMSD,CTR CLIN 9N244,ARTHRIT & RHEUMATISM BRANCH,CONNECT TISSUE DIS SECT,BETHESDA,MD 20892, USA.							BERNSTEIN RM, 1985, EXCERPTA MED INT C S, V675, P273; BIERZYNSKI A, 1982, P NATL ACAD SCI-BIOL, V79, P2470, DOI 10.1073/pnas.79.8.2470; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BISWAS T, 1987, J IMMUNOL METHODS, V98, P235, DOI 10.1016/0022-1759(87)90010-X; BISWAS T, 1987, J IMMUNOL METHODS, V98, P243, DOI 10.1016/0022-1759(87)90011-1; BUNN CC, 1986, J EXP MED, V163, P1281, DOI 10.1084/jem.163.5.1281; CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DOHLMAN JG, 1993, BIOCHEM BIOPH RES CO, V195, P686, DOI 10.1006/bbrc.1993.2100; ESCALANTE C, 1993, J BIOL CHEM, V268, P6014; FAHOUM SK, 1987, BIOCHEMISTRY-US, V26, P5871, DOI 10.1021/bi00392a044; FERBER S, 1987, NATURE, V326, P808, DOI 10.1038/326808a0; FETT R, 1991, J BIOL CHEM, V266, P1448; FROLOVA LY, 1991, GENE, V109, P291, DOI 10.1016/0378-1119(91)90624-K; FROLOVA LY, 1993, EUR J BIOCHEM, V212, P457, DOI 10.1111/j.1432-1033.1993.tb17682.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GARRET M, 1991, BIOCHEMISTRY-US, V30, P7809, DOI 10.1021/bi00245a021; GUO QB, 1992, GENE DEV, V6, P1357, DOI 10.1101/gad.6.8.1357; ISOM LL, 1984, MACROMOLECULES, V17, P2445, DOI 10.1021/ma00141a042; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; JAHN MJ, 1991, NUCLEIC ACIDS RES, V19, P2786, DOI 10.1093/nar/19.10.2786; KANE SM, 1978, BIOCHEMISTRY-US, V17, P1509, DOI 10.1021/bi00601a024; KAUMAYA PTP, 1990, BIOCHEMISTRY-US, V29, P13, DOI 10.1021/bi00453a002; KERJAN P, 1992, BIOCHIMIE, V74, P195, DOI 10.1016/0300-9084(92)90046-H; LORBER B, 1988, EUR J BIOCHEM, V174, P155, DOI 10.1111/j.1432-1033.1988.tb14076.x; LOVE LA, 1991, MEDICINE, V70, P360, DOI 10.1097/00005792-199111000-00002; LUDMERER SW, 1987, J BIOL CHEM, V262, P10807; LUPUS A, 1991, SCIENCE, V252, P1162; MATHEWS MB, 1984, J EXP MED, V160, P420, DOI 10.1084/jem.160.2.420; MATHEWS MB, 1983, NATURE, V304, P177, DOI 10.1038/304177a0; MCPHIE P, 1992, ARCH BIOCHEM BIOPHYS, V293, P46, DOI 10.1016/0003-9861(92)90363-2; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; MILLER FW, 1990, J CLIN INVEST, V85, P468, DOI 10.1172/JCI114461; MILLER FW, 1990, P NATL ACAD SCI USA, V87, P9933, DOI 10.1073/pnas.87.24.9933; MIRANDE M, 1988, J BIOL CHEM, V263, P18443; MISETA A, 1991, J BIOL CHEM, V266, P19158; MOHR G, 1991, NATURE, V354, P164, DOI 10.1038/354164a0; MULLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MYSZKA DG, 1994, BIOCHEMISTRY-US, V33, P2363, DOI 10.1021/bi00175a003; NADA S, 1993, J BIOL CHEM, V268, P7660; RABEN N, 1992, NUCLEIC ACIDS RES, V20, P1075, DOI 10.1093/nar/20.5.1075; RAMSDEN DA, 1989, J IMMUNOL, V143, P2267; SMITH MW, 1992, TRENDS BIOCHEM SCI, V17, P489, DOI 10.1016/0968-0004(92)90335-7; Summers MD, 1987, MANUAL METHODS BACUL; TAKAHASHI R, 1987, ARCH GERONTOL GERIAT, V6, P73, DOI 10.1016/0167-4943(87)90040-9; TARGOFF IN, 1993, J CLIN INVEST, V91, P2556, DOI 10.1172/JCI116493; TARGOFF IN, 1987, J IMMUNOL, V138, P2874; TARGOFF IN, 1990, J IMMUNOL, V144, P1737; TING SM, 1992, J BIOL CHEM, V267, P17701; TSUI FWL, 1987, NUCLEIC ACIDS RES, V15, P3349, DOI 10.1093/nar/15.8.3349; VARSHAVSKY A, 1983, CELL, V34, P711, DOI 10.1016/0092-8674(83)90526-3; WALKER EJ, 1987, J IMMUNOL METHODS, V96, P149, DOI 10.1016/0022-1759(87)90308-5; WALTER P, 1989, J BIOL CHEM, V264, P17126; WEBB AC, 1991, BIOTECHNIQUES, V11, P512; WEBB N R, 1990, Technique (Philadelphia), V2, P173; ZAMECNIK P, 1983, ANAL BIOCHEM, V134, P1, DOI 10.1016/0003-2697(83)90255-5; ZAWADZKI V, 1991, NUCLEIC ACIDS RES, V19, P1948, DOI 10.1093/nar/19.8.1948; ZHOU NE, 1992, J BIOL CHEM, V267, P2664	62	71	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24277	24283						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523371				2022-12-25	WOS:A1994PQ34600066
J	RAZ, R; DURBIN, JE; LEVY, DE				RAZ, R; DURBIN, JE; LEVY, DE			ACUTE-PHASE RESPONSE FACTOR AND ADDITIONAL MEMBERS OF THE INTERFERON-STIMULATED GENE FACTOR-3 FAMILY INTEGRATE DIVERSE SIGNALS FROM CYTOKINES, INTERFERONS, AND GROWTH-FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; DNA-BINDING PROTEINS; MUTANT-CELL LINE; TRANSCRIPTION FACTOR; ERYTHROPOIETIN RECEPTOR; TRANSDUCTION PATHWAY; GAMMA; PHOSPHORYLATION; ALPHA; JAK2	Cytokines and growth factors elicit responses in target cells through induction of gene expression. Signaling mechanisms leading to gene transcription from cell surface receptors often require tyrosine phosphorylation. A family of transcription factors comprising the interferon (IFN)-stimulated gene factor 3 (ISGF3) multimeric complex are phosphorylated and activated in response to interferon. We describe a protein 50% identical to the 91-kDa subunit ofISGF3 that constitutes the acute phase response factor (APRF). This protein was rapidly activated by interleukin-6 to bind an enhancer element common to genes activated in liver cells during the acute phase response to inflammation. Remarkably, APRF was also activated by IFN alpha, IFN gamma, epidermal growth factor, platelet-derived growth factor, colony stimulating factor-1, and the cytokines leukemia inhibitory factor and oncostatin M. The growth factors also activated a third, distinct but related, DNA-binding protein in addition to APRF and p91. This novel factor or a closely related one, but neither APRF nor p91, was also activated in lymphoid cells by interleukin-2, erythropoietin, and interleukin-3. Activation of APRF, p91, and additional members of the ISGF3 family is thus a general feature of a wide variety of signaling pathways, integrating diverse signals through common transcriptional regulators.	NYU,SCH MED,DEPT PATHOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN COMPREHENS CANC CTR,NEW YORK,NY 10016	New York University; New York University			Levy, David/GPS-4945-2022; Levy, David/AAG-6202-2019	Levy, David/0000-0002-7320-7788	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028900] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI28900] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EILERS A, 1994, MOL CELL BIOL, V14, P1364, DOI 10.1128/MCB.14.2.1364; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; LAMB P, 1994, BLOOD, V83, P2063; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEVY D, 1990, New Biologist, V2, P923; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	42	143	146	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24391	24395						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523373				2022-12-25	WOS:A1994PQ34600084
J	ZHONG, GM; SMITH, GP; BERRY, J; BRUNHAM, RC				ZHONG, GM; SMITH, GP; BERRY, J; BRUNHAM, RC			CONFORMATIONAL MIMICRY OF A CHLAMYDIAL NEUTRALIZATION EPITOPE ON FILAMENTOUS PHAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; INFLUENZA-VIRUS HEMAGGLUTININ; TRACHOMATIS; PEPTIDES; IMMUNOGENICITY; LIBRARY; GENES; BACTERIOPHAGE; DETERMINANTS; MIMICKING	Conformational constraints were imposed on a peptide epitope from Chlamydia trachomatis to improve its ability to elicit antibodies that cross-react with native antigen. Appropriate constraints were discovered by a strategy that required no prior knowledge of the epitope's native conformation. First, we constructed a library of 3.2 x 10(5) peptides in which the epitope's contact residues were subject to random conformational constraints, each constrained peptide being fused genetically to the surface of a filamentous phage vector. Next, we selected phage displaying the most native-like peptides in the library by affinity purification with antibodies that bind the epitope only in its native conformation. Finally, we immunized mice with the selected phage and titered the resulting antisera against both whole cells and unconstrained peptide. The ratio of anti-cell titer to anti-peptide titer, which reflects the channeling of the antibody response to the native epitope, was up to five times higher for affinity-selected phage than for unselected peptide phage. In this case, therefore, ''antigenic fitness,'' the ability of a peptide to bind antibodies specific for native epitope, correlated with ''immunogenic fitness,'' its ability to elicit antibodies that are effective against the native antigen on an invading pathogen. If the correlation is general, surveying thousands or millions of peptides for antigenic fitness with phage display technology may be a simple but effective pre-screen for immunogenic fitness, which is costly to assess directly.	UNIV MISSOURI,DIV BIOL SCI,COLUMBIA,MO 65211; UNIV MANITOBA,DEPT MED MICROBIOL,WINNIPEG R3E 0W3,MB,CANADA	University of Missouri System; University of Missouri Columbia; University of Manitoba					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041478] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEHR W, 1988, P NATL ACAD SCI USA, V85, P4000, DOI 10.1073/pnas.85.11.4000; BIDART JM, 1990, SCIENCE, V248, P736, DOI 10.1126/science.1692160; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GRAYSTON JT, 1975, J INFECT DIS, V132, P87, DOI 10.1093/infdis/132.1.87; GREENWOOD J, 1991, J MOL BIOL, V220, P821, DOI 10.1016/0022-2836(91)90354-9; HAAS SJ, 1993, BIOTECHNIQUES, V15, P422; KAUMAYA PTP, 1992, J BIOL CHEM, V267, P6338; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; MCLAFFERTY MA, 1993, GENE, V128, P29, DOI 10.1016/0378-1119(93)90149-W; MULLER S, 1990, VACCINE, V8, P308, DOI 10.1016/0264-410X(90)90086-2; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; Sambrook J, 1989, MOL CLONING LABORATO; SCHULZEGAHMEN U, 1986, EUR J BIOCHEM, V159, P283, DOI 10.1111/j.1432-1033.1986.tb09865.x; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1988, VIROLOGY, V167, P156, DOI 10.1016/0042-6822(88)90065-7; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; STEPHENS RS, 1987, J BACTERIOL, V169, P3879, DOI 10.1128/jb.169.9.3879-3885.1987; SU H, 1992, J EXP MED, V175, P227, DOI 10.1084/jem.175.1.227; WILLIAMS WV, 1991, J BIOL CHEM, V266, P5182; ZHONG GM, 1992, INFECT IMMUN, V60, P3143, DOI 10.1128/IAI.60.8.3143-3149.1992; ZHONG GM, 1991, INFECT IMMUN, V59, P1141, DOI 10.1128/IAI.59.3.1141-1147.1991; ZHONG GM, 1990, INFECT IMMUN, V58, P3438, DOI 10.1128/IAI.58.10.3438-3441.1990; ZHONG GM, 1994, INFECT IMMUN, V62, P1576, DOI 10.1128/IAI.62.5.1576-1583.1994; ZHONG GM, 1993, J IMMUNOL, V151, P3728	26	84	95	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24183	24188						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7523368				2022-12-25	WOS:A1994PQ34600054
J	DO, KY; FREGIEN, N; PIERCE, M; CUMMINGS, RD				DO, KY; FREGIEN, N; PIERCE, M; CUMMINGS, RD			MODIFICATION OF GLYCOPROTEINS BY N-ACETYLGLUCOSAMINYLTRANSFERASE-V IS GREATLY INFLUENCED BY ACCESSIBILITY OF THE ENZYME TO OLIGOSACCHARIDE ACCEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; HAMSTER-KIDNEY CELLS; HUMAN-SERUM TRANSFERRIN; AMINO-ACID-SEQUENCE; SUGAR CHAINS; OVARY CELLS; ACETYLGALACTOSAMINE-TRANSFERASE; ACETYLLACTOSAMINE CHAINS; ONCOGENIC TRANSFORMATION	The formation of tri- and tetraantennary complex-type N-linked oligosaccharides in animal glycoproteins is partly regulated by UDP-N-acetylglucosamine:beta-6-D-mannoside beta-1,6-N-acetylglucosaminyltransferase (EC 2.4.1.155) (GlcNAc-T V), which generates 2,6-branched mannose. In Chinese hamster ovary (CHO) cells we found that 2,6-branched mannosyl structures are preferentially contained on lysosome-associated membrane proteins (LAMPs) and are generally low or absent in other cellular glycoproteins (Do, K.-P. and Cummings, R.D. (1993) J. Biol. Chem. 268, 22028-22035). To determine the mechanism by which GlcNAc-T V appears to preferentially recognize glycoproteins, we examined the activity of purified GlcNAc-T V toward a variety of glycoprotein accepters. Because GlcNAc-T V requires as accepters oligosaccharides lacking outer galactosyl and sialyl residues, we utilized two classes of acceptor preparations. The first class of acceptor was enzymatically desialylated (DS) and degalactosylated (DG) preparations of bovine fetuin, human transferrin, and human fibrinogen. The second class was glycoproteins in extracts of the mutant CHO cell line, Lec8 CHO, which cannot add galactose or sialic acid to N-linked oligosaccharides. GlcNAc-T V was highly active toward DSDG-fetuin, -transferrin, and -fibrinogen (K-m values ranged between 30 and 74 mu M), and the catalytic efficiencies (V-max/K-m) of the enzyme toward different accepters were comparable. In the case of fetuin, each of its three sites for attachment of N-linked oligosaccharides were shown to be utilized equally well by GlcNAc-T V. Notably, the enzyme exhibited a 2-3-fold higher rate of transfer toward DSDG-transferrin when it was further denatured by reduction and S-carboxymethylation. When extracts of Lec8 CHO cells were used as accepters, GlcNAc-T V preferentially transferred to LAMPs, and only low level transfer was observed to other cell-derived glycoproteins, thus demonstrating specificity of GlcNAc-T V to ward native glycoprotein accepters. When the cell-derived glycoproteins were denatured by reduction and S-carboxymethylation prior to use as accepters for GlcNAc-T V, significant transfer occurred to other glycoproteins. These results demonstrate that the mechanism of glycoprotein-specific branching by GlcNAc-T V is determined primarily by its accessibility to available bi/triantennary oligosaccharides on glycoproteins and not by its recognition of peptide determinants or conformation-specific determinants.	UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, OKLAHOMA CITY, OK 73190 USA; UNIV MIAMI, SCH MED, DEPT CELL BIOL & ANAT, MIAMI, FL 33101 USA; UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30605 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Miami; University System of Georgia; University of Georgia					NCI NIH HHS [CA-37626] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037626] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMOS B, 1990, J BIOL CHEM, V265, P19192; BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; BRILES EB, 1977, J BIOL CHEM, V252, P1107; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CARLSSON Sr, 1990, J BIOL CHEM, V265, P20488; CUMMINGS RD, 1982, J BIOL CHEM, V257, P13421; CUMMINGS RD, 1984, J BIOL CHEM, V259, P6253; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; CUMMINGS RD, 1992, GLYCOCONJUGATES COMP, P333; DENNIS JW, 1989, ONCOGENE, V4, P853; Dennis JW, 1992, CELL SURFACE CARBOHY, P161; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; DO KY, 1993, J BIOL CHEM, V268, P22028; DO KY, 1990, BIOCHEM BIOPH RES CO, V173, P1123, DOI 10.1016/S0006-291X(05)80902-7; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; DZIEGIELEWSKA KM, 1990, J BIOL CHEM, V265, P4354; Fukuda M., 1992, CELL SURFACE CARBOHY, P127; GREEN ED, 1988, J BIOL CHEM, V263, P18253; HEFFERNAN M, 1989, CANCER RES, V49, P6077; HUBBARD SC, 1987, J BIOL CHEM, V262, P16403; KNIBBS RN, 1989, BIOCHEMISTRY-US, V28, P6379, DOI 10.1021/bi00441a034; KOBATA A, 1992, CELL SURFACE CARBOHY, P1; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; LAFERTE S, 1989, BIOCHEM J, V259, P569, DOI 10.1042/bj2590569; LEE N, 1990, J BIOL CHEM, V265, P20476; LEMAIRE S, 1994, J BIOL CHEM, V269, P8069; MACGILLIVRAY RTA, 1982, P NATL ACAD SCI-BIOL, V79, P2504, DOI 10.1073/pnas.79.8.2504; MACGILLIVRAY RTA, 1983, J BIOL CHEM, V258, P3543; MERKLE RK, 1988, J BIOL CHEM, V263, P16143; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; ORBERGER G, 1992, EUR J BIOCHEM, V205, P257, DOI 10.1111/j.1432-1033.1992.tb16776.x; PALCIC MM, 1990, J BIOL CHEM, V265, P6759; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; PIERCE M, 1986, J BIOL CHEM, V261, P772; QUN Z, 1993, ARCH BIOCHEM BIOPHYS, V300, P6, DOI 10.1006/abbi.1993.1002; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; SANTER UV, 1979, BIOCHEMISTRY-US, V18, P2533, DOI 10.1021/bi00579a016; SANTER UV, 1989, EUR J BIOCHEM, V181, P249, DOI 10.1111/j.1432-1033.1989.tb14719.x; Schachter H, 1991, CURR OPIN STRUC BIOL, V1, P755, DOI 10.1016/0959-440X(91)90175-S; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; SPIRO RG, 1973, ADV PROTEIN CHEM, V27, P379; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; SUTTON BJ, 1983, BIOCHEM SOC T, V11, P130, DOI 10.1042/bst0110130; TAKEUCHI M, 1988, J BIOL CHEM, V263, P3657; TOWNSEND RR, 1982, J BIOL CHEM, V257, P9704; VANDENEIJNDEN DH, 1993, CURR OPIN STRUC BIOL, V3, P711, DOI 10.1016/0959-440X(93)90054-O; VONFIGURA K, 1986, ANNU REV BIOCHEM, V256, P11977; YAMASHITA K, 1989, J BIOL CHEM, V264, P2415; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; YAMASHITA K, 1982, J BIOL CHEM, V257, P2809; YET MG, 1988, J BIOL CHEM, V263, P111; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772; ZHOU Q, 1992, CELL SURFACE CARBOHY, P99	64	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23456	23464						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7522229				2022-12-25	WOS:A1994PQ34500015
J	SILVERMAN, JA; MINDELL, JA; FINKELSTEIN, A; SHEN, WH; COLLIER, RJ				SILVERMAN, JA; MINDELL, JA; FINKELSTEIN, A; SHEN, WH; COLLIER, RJ			MUTATIONAL ANALYSIS OF THE HELICAL HAIRPIN REGION OF DIPHTHERIA-TOXIN TRANSMEMBRANE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR LIPID BILAYERS; HIGH-LEVEL EXPRESSION; MEMBRANE TRANSLOCATION; ESCHERICHIA-COLI; LOW PH; MODEL MEMBRANES; FULL-LENGTH; FRAGMENT-B; CHANNELS; INSERTION	Entry of the catalytic domain of diphtheria toxin into the cytoplasm of eukaryotic cells depends on insertion of the T (transmembrane) domain into the endosomal membrane, a process triggered by low pH. To probe the mechanism of insertion, we mutated ionizable residues within the helical hairpin region of the T domain. Only three mutations caused significant effects on cytotoxicity, D295K, E349K, and D352K. Each of these represents a substitution of a basic for an acidic residue at the tip of a helical hairpin. Substitution of Lys for Glu(349) or Asp(352), in the TH8/9 hairpin, reduced toxicity for Vero cells >100-fold, whereas a Lys substitution for Asp(295), one of 3 acidic residues in the TH5/6/7 hairpin, caused a less marked reduction. Ah three mutations also altered the pH-dependent formation, and/or ion conductance, of channels formed by the toxin in artificial bilayers or the plasma membrane. E349K or D352K did not alter the pH dependence of conformational changes in the toxin occurring near pH 5. Our findings support the hypothesis that the TH8/9 hairpin inserts into the endosomal membrane after low pH-mediated partial unfolding of the T domain. A positive residue at the tip of this hairpin apparently inhibits insertion and blocks toxin action. The ion-conducting properties of channels formed by selected mutants, described elsewhere, are consistent with this model. The status of the TH5/6/7 hairpin in the integral membrane form of the T domain remains uncertain.	HARVARD UNIV, SCH MED, SHIPLEY INST MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PHYSIOL & BIOPHYS, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT NEUROSCI, BRONX, NY 10461 USA	Harvard University; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine			; Mindell, Joseph/P-4461-2017	Collier, R John/0000-0002-2427-4239; Mindell, Joseph/0000-0002-6952-8247	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022848, R01AI022021, R37AI022021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22848, AI22021] Funding Source: Medline; NIGMS NIH HHS [T32 GM07288] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARBIERI JT, 1987, INFECT IMMUN, V55, P1647, DOI 10.1128/IAI.55.7.1647-1651.1987; BISHAI WR, 1987, J BACTERIOL, V169, P5140, DOI 10.1128/jb.169.11.5140-5151.1987; BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; BOQUET P, 1976, P NATL ACAD SCI USA, V73, P4449, DOI 10.1073/pnas.73.12.4449; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CABIAUX V, 1989, J BIOL CHEM, V264, P4928; CABIAUX V, 1993, INFECT IMMUN, V61, P2200, DOI 10.1128/IAI.61.5.2200-2202.1993; CABIAUX V, 1990, J PHYSIOL-PARIS, V84, P273; CARROLL SF, 1988, METHOD ENZYMOL, V165, P218; CARROLL SF, 1988, METHOD ENZYMOL, V165, P68; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; CHUNG LA, 1988, BIOCHEMISTRY-US, V27, P1245, DOI 10.1021/bi00404a026; COLLIER RJ, 1990, ADP RIBOSYLATING TOX, P3, DOI DOI 10.1126/SCIENCE.250.4982.841-A; DELEERS M, 1983, FEBS LETT, V160, P82, DOI 10.1016/0014-5793(83)80941-7; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; DUMONT ME, 1988, J BIOL CHEM, V263, P2087; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FALNES PO, 1992, J BIOL CHEM, V267, P12284; FARAHBAKHSH ZT, 1992, PHOTOCHEM PHOTOBIOL, V56, P1019, DOI 10.1111/j.1751-1097.1992.tb09725.x; HOCH DH, 1985, P NATL ACAD SCI USA, V82, P1692, DOI 10.1073/pnas.82.6.1692; HOVDE CJ, 1988, P NATL ACAD SCI USA, V85, P2568, DOI 10.1073/pnas.85.8.2568; HU VW, 1984, J BIOL CHEM, V259, P2226; JIANG JX, 1991, BIOCHEMISTRY-US, V30, P3857, DOI 10.1021/bi00230a008; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; KIM K, 1965, J BACTERIOL, V90, P1552, DOI 10.1128/JB.90.6.1552-1556.1965; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE DM, 1985, BIOCHEMISTRY-US, V24, P5106, DOI 10.1021/bi00340a022; MERION M, 1983, P NATL ACAD SCI-BIOL, V80, P5315, DOI 10.1073/pnas.80.17.5315; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; MINDELL JA, 1994, J MEMBRANE BIOL, V137, P45; MINDELL JA, 1994, J MEMBRANE BIOL, V137, P29; MINDELL JA, 1992, BIOPHYS J, V62, P41, DOI 10.1016/S0006-3495(92)81772-1; Montal M, 1974, Methods Enzymol, V32, P545; OKEEFE DO, 1989, P NATL ACAD SCI USA, V86, P343, DOI 10.1073/pnas.86.1.343; OKEEFE DO, 1992, P NATL ACAD SCI USA, V89, P6202, DOI 10.1073/pnas.89.13.6202; OKEEFE DO, 1992, ARCH BIOCHEM BIOPHYS, V296, P678, DOI 10.1016/0003-9861(92)90626-8; Olsnes S, 1988, Cancer Treat Res, V37, P39; PAPINI E, 1988, EMBO J, V7, P3353, DOI 10.1002/j.1460-2075.1988.tb03207.x; PAPINI E, 1993, J BIOL CHEM, V268, P1567; SANDVIG K, 1988, J BIOL CHEM, V263, P12352; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; SILVERMAN JA, 1994, J MEMBRANE BIOL, V137, P17; STENMARK H, 1991, J CELL BIOL, V113, P1025, DOI 10.1083/jcb.113.5.1025; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THELESTAM M, 1988, METHOD ENZYMOL, V165, P278; TWETEN RK, 1983, J BACTERIOL, V156, P680, DOI 10.1128/JB.156.2.680-685.1983; UCHIDA T, 1971, NATURE-NEW BIOL, V233, P8, DOI 10.1038/newbio233008a0; WILSON BA, 1992, CURR TOP MICROBIOL, V175, P27; WONDERLIN WF, 1990, BIOPHYS J, V58, P289, DOI 10.1016/S0006-3495(90)82376-6; ZALMAN LS, 1984, P NATL ACAD SCI-BIOL, V81, P3341, DOI 10.1073/pnas.81.11.3341	53	73	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22524	22532						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7521329				2022-12-25	WOS:A1994PQ16300015
J	ARMESILLA, AL; VEGA, MA				ARMESILLA, AL; VEGA, MA			STRUCTURAL ORGANIZATION OF THE GENE FOR HUMAN CD36 GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET MEMBRANE GLYCOPROTEIN; IV CD36; THROMBOSPONDIN RECEPTOR; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; INFECTED ERYTHROCYTES; TRANSCRIPTION FACTORS; PROMOTER SEQUENCES; ENDOTHELIAL-CELLS; HUMAN MONOCYTES	The cell-surface glycoprotein CD36 interacts with a large variety of ligands, including collagen types I and IV, thrombospondin, erythrocytes parasitized with Plasmodium falciparum, platelet-agglutinating protein p37, oxidized low density lipoprotein, and long-chain fatty acids. Its expression is restricted to platelets, monocytes, adipocytes, and some endothelial and epithelial cells and is regulated during cell activation, differentiation, and development. CD36 belongs to a novel gene family of structurally related glycoproteins that includes CLA-1 and the lysosomal membrane glycoprotein LIMPII. To advance our knowledge on the genomic organization and the regulation of the cellular expression of the genes of this family, we have investigated the structural organization of the human CD36 gene and of its 5'-proximal flanking region. The CD36 gene is encoded by 15 exons that extend more than 32 kilobases on the human genome. Interestingly, the CD36 mRNA 5'-untranslated region is encoded by three exons. The 3'-untranslated region is contained in two exons, whose expression pattern can originate two mRNA forms. The cytoplasmic and transmembrane regions predicted at both terminal ends of the polypeptide chain are encoded by single exons, while the extracellular domain is encoded by 11 exons. The transcription initiation site of the CD36 gene is located 289 nucleotides upstream from the translational start codon. Sequence analysis of the proximal 5'-flanking region of the gene reveals the existence of a TATA box appropriately located with respect to the transcription initiation site and several potential cis-regulatory elements that might contribute to the transcriptional regulation of the CD36 gene. Delineation of the structural organization of the CD36 gene may help in defining the boundaries of relevant structural and/or functional domains in CD36 and, by extension, in the other members of the family.	HOSP PRINCESA,E-28006 MADRID,SPAIN; CSIC,E-28006 MADRID,SPAIN	Hospital de La Princesa; Consejo Superior de Investigaciones Cientificas (CSIC)			Vega, Miguel A/M-1367-2016	Vega, Miguel A/0000-0001-6151-4193; Armesilla, Angel/0000-0003-3546-5580				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; AIKEN ML, 1990, BLOOD, V76, P2501; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V88, P4123; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; CALVO D, 1993, J BIOL CHEM, V268, P18929; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CLEZARDIN P, 1985, BRIT J HAEMATOL, V60, P331, DOI 10.1111/j.1365-2141.1985.tb07419.x; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; EDELMAN P, 1986, BLOOD, V67, P56; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FERNANDEZRUIZ E, 1993, GENOMICS, V17, P759, DOI 10.1006/geno.1993.1401; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; GHOSH D, 1991, TRENDS BIOCHEM SCI, V16, P445, DOI 10.1016/0968-0004(91)90173-S; GREENWALT DE, 1990, BIOCHEMISTRY-US, V29, P7054, DOI 10.1021/bi00482a015; GREENWALT DE, 1992, BLOOD, V80, P1105; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; JUHLIN L, 1989, ACTA DERM-VENEREOL, V69, P403; KIEFFER N, 1989, BIOCHEM J, V262, P835, DOI 10.1042/bj2620835; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KNOWLES DM, 1984, J IMMUNOL, V132, P2170; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG LLK, 1992, J BIOL CHEM, V267, P18244; LIAN ECY, 1991, THROMB HAEMOSTASIS, V65, P102; LIPSKY RH, 1991, THROMB HAEMOSTASIS, V65, P456; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NOGUCHI K, 1993, BIOCHEM BIOPH RES CO, V192, P88, DOI 10.1006/bbrc.1993.1385; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; OCKENHOUSE CF, 1989, J CLIN INVEST, V84, P468, DOI 10.1172/JCI114188; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PARTHASARATHY S, 1992, ANNU REV MED, V43, P219, DOI 10.1146/annurev.me.43.020192.001251; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; RENKAWITZ R, 1984, CELL, V37, P503, DOI 10.1016/0092-8674(84)90380-5; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J, 1989, MOL CLONING LABORATO; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SCHUEPP BJ, 1991, BIOCHEM BIOPH RES CO, V175, P263, DOI 10.1016/S0006-291X(05)81229-X; SCOTT LM, 1992, BLOOD, V80, P1725; SHANNON MF, 1988, P NATL ACAD SCI USA, V85, P674, DOI 10.1073/pnas.85.3.674; SIDDIQUI FA, 1992, BIOCHEM INT, V27, P485; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; SILVERSTEIN RL, 1992, J BIOL CHEM, V267, P16607; SMITH MW, 1988, J MOL EVOL, V27, P45, DOI 10.1007/BF02099729; SWERLICK RA, 1992, J IMMUNOL, V148, P78; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANDON NN, 1991, BLOOD, V78, P2809; TREZZINI C, 1990, IMMUNOLOGY, V71, P29; VANSCHRAVENDIJK MR, 1992, BLOOD, V80, P2105; VASSEURCOGNET M, 1993, CURR OPIN GENET DEV, V3, P238, DOI 10.1016/0959-437X(93)90029-O; VEGA MA, 1991, J BIOL CHEM, V266, P16818; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; YANG Z, 1990, P NATL ACAD SCI USA, V87, P9226, DOI 10.1073/pnas.87.23.9226	61	105	112	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18985	18991						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7518447				2022-12-25	WOS:A1994NX32700044
J	AKIYAMA, SK; YAMADA, SS; YAMADA, KM; LAFLAMME, SE				AKIYAMA, SK; YAMADA, SS; YAMADA, KM; LAFLAMME, SE			TRANSMEMBRANE SIGNAL-TRANSDUCTION BY INTEGRIN CYTOPLASMIC DOMAINS EXPRESSED IN SINGLE-SUBUNIT CHIMERAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-TYROSINE KINASE; HUMAN INTERLEUKIN-2 RECEPTOR; CELL-SURFACE RECEPTORS; EXTRACELLULAR-MATRIX; FIBRONECTIN RECEPTOR; BETA-SUBUNIT; MONOCLONAL-ANTIBODIES; BOMBESIN STIMULATION; MOLECULAR-CLONING; FOCAL ADHESIONS	Integrins are heterodimeric, transmembrane cell adhesion receptors that have recently been shown to function in transmembrane signal transduction. To examine the specific role of integrin intracellular domains in signal transduction, chimeric receptors containing various integrin intracellular domains coupled to a reporter consisting of the transmembrane and extracellular domains of the small, non-signaling subunit of the interleukin-2 receptor were expressed in cultured human fibroblasts and assayed for their ability to trigger tyrosine phosphorylation of the 125-kDa cytoplasmic tyrosine kinase, pp125(FAK). Tyrosine phosphorylation of pp125(FAK) was induced in cultured fibroblasts that transiently expressed chimeric receptors containing either the beta(1), beta(3), beta(5) integrin intracellular domain and were selected by magnetic bead sorting. However, expression of chimeric receptors containing either the alpha(5) or an alternatively spliced form of the beta(3) intracellular domain (beta(3B)), as well as those lacking an intracellular domain, failed to induce tyrosine phosphorylation of pp125(FAK). These results indicate that information contained in the beta(1), beta(3), or beta(5) integrin intracellular domain is sufficient to stimulate integrin-mediated tyrosine phosphorylation of specific intracellular proteins and that integrin extracellular and transmembrane domains are not required for inducing tyrosine phosphorylation. Our results also indicate that alternative splicing can regulate the ability of beta integrin intracellular domains to participate in signal transduction, and they further suggest that the carboxyl-terminal region of specific beta integrins may play a role in the signal transduction pathway involving extracellular matrix molecules.			AKIYAMA, SK (corresponding author), NIDR, DEV BIOL LAB, BLDG 30, BETHESDA, MD 20892 USA.			Yamada, Kenneth/0000-0003-1512-6805				AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; AKIYAMA SK, 1985, J BIOL CHEM, V260, P3256; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; GEIGER B, 1992, J CELL SCI, V103, P943; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GIORDANO T, 1991, EXP CELL RES, V192, P193, DOI 10.1016/0014-4827(91)90175-T; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HOGERVORST F, 1993, J BIOL CHEM, V268, P18427; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KASSNER PD, 1993, J EXP MED, V178, P649, DOI 10.1084/jem.178.2.649; KAWAGUCHI S, 1993, J BIOL CHEM, V268, P16279; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LEEBLUNDBERG LMF, 1993, J BIOL CHEM, V268, P8151; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MCLEAN JW, 1990, J BIOL CHEM, V265, P17126; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PADMANABHAN R, 1988, ANAL BIOCHEM, V170, P341, DOI 10.1016/0003-2697(88)90640-9; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Sambrook J, 1989, MOL CLONING LABORATO; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; SUZUKI S, 1990, P NATL ACAD SCI USA, V87, P5354, DOI 10.1073/pnas.87.14.5354; TURNER CE, 1993, J CELL SCI, V105, P637; VANKUPPEVELT THMSM, 1989, P NATL ACAD SCI USA, V86, P5415; YAMADA KM, 1992, COLD SPRING HARB SYM, V57, P203, DOI 10.1101/SQB.1992.057.01.025; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	57	155	157	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					15961	15964						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	7515874				2022-12-25	WOS:A1994NQ72900002
J	MARK, MR; SCADDEN, DT; WANG, ZG; GU, QM; GODDARD, A; GODOWSKI, PJ				MARK, MR; SCADDEN, DT; WANG, ZG; GU, QM; GODDARD, A; GODOWSKI, PJ			RSE, A NOVEL RECEPTOR-TYPE TYROSINE KINASE WITH HOMOLOGY TO AXL/UFO, IS EXPRESSED AT HIGH-LEVELS IN THE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; GENE; FAMILY; ENCODES; DOMAINS; PROTOONCOGENE; ONCOGENES; FEATURES	We have isolated cDNA clones that encode the human and murine forms of a novel receptor-type tyrosine kinase termed Rse. Sequence analysis indicates that human Rse contains 890 amino acids, with an extracellular region composed of two immunoglobulin-like domains followed by two fibronectin type III domains. Murine Rse contains 880 amino acids and shares 90% amino acid identity with its human counterpart. Rse is structurally similar to the receptor-type tyrosine kinase Axl/Ufo, and the two proteins have 35 and 63% sequence identity in their extracellular and intracellular domains, respectively. To study the synthesis and activation of this putative receptor-type tyrosine kinase, we constructed a version of Rse (termed gD-Rse, where go represents glycoprotein D) that contains an NH2-terminal epitope tag NM3T3 cells were engineered to express gD-Rse, which could be detected at the cell surface by fluorescence-activated cell sorting. Moreover, gD-Rse was rapidly phosphorylated on tyrosine residues upon incubation of the cells with an antibody directed against the epitope tag, suggesting that rse encodes an active tyrosine kinase. in the human tissues we examined, the highest level of expression of rse mRNA was observed in the brain; rse mRNA was also detected in the premegakaryocytopoietic cell lines CMK11-5 and Dami. The gene for rse was localized to human chromsome 15.	GENENTECH INC, DEPT CELL GENET, San Francisco, CA 94080 USA; GENENTECH INC, DEPT MOLEC BIOL, San Francisco, CA 94080 USA; HARVARD UNIV, NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA	Roche Holding; Genentech; Roche Holding; Genentech; Harvard University; Harvard Medical School								AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LASKY LA, 1984, DNA-J MOLEC CELL BIO, V3, P23, DOI 10.1089/dna.1.1984.3.23; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MCCLAIN DA, 1990, J BIOL CHEM, V265, P21363; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PABORSKY LR, 1990, PROTEIN ENG, V3, P547, DOI 10.1093/protein/3.6.547; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; SARUP JC, 1991, GROWTH REGULAT, V1, P72; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	33	125	151	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10720	10728						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511603				2022-12-25	WOS:A1994NF01700079
J	KROLL, TG; PETERS, BP; HUSTAD, CM; JONES, PA; KILLEN, PD; RUDDON, RW				KROLL, TG; PETERS, BP; HUSTAD, CM; JONES, PA; KILLEN, PD; RUDDON, RW			EXPRESSION OF LAMININ CHAINS DURING MYOGENIC DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE PROTEINS; CELL-BINDING SITE; A-CHAIN; EXTRACELLULAR-MATRIX; PARIETAL ENDODERM; MESSENGER-RNA; BASAL LAMINA; NEUROMUSCULAR-JUNCTION; MULTIDOMAIN PROTEIN; DEVELOPING KIDNEY	Expression of two Ae-related chains of the extracellular matrix glycoprotein laminin was induced as multi potent C3H10T1/2 mouse embryo fibroblasts differentiated into myoblasts and myofibers. C3H10T1/2 fibroblasts expressed the B1e (M(r) = 215,000) and B2e (M(r) = 205,000) laminin chains based on metabolic radiolabeling, immunoprecipitation, peptide mapping, and mRNA analysis. In contrast, myoblasts derived from C3H10T1/2 fibroblasts treated with DNA demethylating agents or transfected with the cDNA encoding MyoD expressed the Ae (M(r) = 400,000) and a novel Ae-related laminin chain (designated Ac3h, M(r) = 350,000) in addition to the B1e and B2e chains. Expression of the Ae and Ac3h chains paralleled the capacity for myofiber formation in six additional C3H10T1/2 myoblast clones with varied potentials for terminal differentiation and coincided with a switch in laminin isoforms from those of M(r) = 850,000 synthesized by C3H10T1/2 fibroblasts to those of M(r) = 900,000-950,000 synthesized by C3H10T1/2 myoblasts and myofibers. Cultures of mouse C2C12, mouse BC3H1, rat L6, and primary mouse myoblasts also synthesized the Ae, Ac3h, B1e, and B2e laminin chains. The results demonstrate that expression of the Ae and Ac3h laminin chains is associated with expression of MyoD and the mammalian myogenic differentiation program.	UNIV MICHIGAN,SCH MED,PROGRAM CELLULAR & MOLEC BIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198; N CAROLINA STATE UNIV,COLL VET MED,DEPT ANAT PHYSIOL SCI & RADIOL,RALEIGH,NC 27606; UNIV SO CALIFORNIA,KENNETH NORRIS JR COMPREHENS CANC CTR,LOS ANGELES,CA 90033	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Nebraska System; University of Nebraska Medical Center; University of North Carolina; North Carolina State University; University of Southern California					NCI NIH HHS [CA-49758, CA-41359, CA-36727] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727, R01CA041359, R35CA049758] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAYNE EK, 1984, J CELL BIOL, V99, P1486, DOI 10.1083/jcb.99.4.1486; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BEDNARCZUK TA, 1991, BIOTECHNIQUES, V10, P478; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; CHIU AY, 1984, DEV BIOL, V103, P456, DOI 10.1016/0012-1606(84)90333-6; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COOPER AR, 1983, DEV BIOL, V96, P467, DOI 10.1016/0012-1606(83)90183-5; COOPER AR, 1981, EUR J BIOCHEM, V119, P189, DOI 10.1111/j.1432-1033.1981.tb05593.x; DAVIS L, 1987, BASIC METHODS MOL BI, P130; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; EKBLOM M, 1990, CELL, V60, P337, DOI 10.1016/0092-8674(90)90748-4; ENGEL J, 1991, BIOCHEM SOC T, V19, P839, DOI 10.1042/bst0190839; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; ENGVALL E, 1992, EXP CELL RES, V198, P115, DOI 10.1016/0014-4827(92)90156-3; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORSBERG E, 1990, J BIOL CHEM, V265, P6376; FRENETTE GP, 1989, J BIOL CHEM, V264, P3078; FRENETTE GP, 1988, CANCER RES, V48, P5193; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; GEORGEWEINSTEIN M, 1993, DEV BIOL, V156, P209, DOI 10.1006/dbio.1993.1071; GODFREY EW, 1988, DEV BIOL, V130, P471, DOI 10.1016/0012-1606(88)90343-0; GREEN TL, 1992, J BIOL CHEM, V267, P2014; HAAPARANTA T, 1991, MATRIX, V11, P151, DOI 10.1016/S0934-8832(11)80153-8; HANTAI D, 1985, CELL BIOL INT REP, V9, P647, DOI 10.1016/0309-1651(85)90057-8; HARRINGTON MA, 1988, MOL CELL BIOL, V8, P4322, DOI 10.1128/MCB.8.10.4322; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HUSTAD CM, 1991, MOL CARCINOGEN, V4, P153, DOI 10.1002/mc.2940040211; JAFFREDO T, 1988, DEVELOPMENT, V103, P431; KLEIN G, 1988, CELL, V55, P331, DOI 10.1016/0092-8674(88)90056-6; KLEIN G, 1990, DEVELOPMENT, V110, P823; KLEINMAN HK, 1987, DEV BIOL, V122, P373, DOI 10.1016/0012-1606(87)90302-2; Konigsberg I R, 1979, Methods Enzymol, V58, P511; KUCHEREREHRET A, 1990, DEVELOPMENT, V110, P1285; KUHL U, 1982, DEV BIOL, V93, P344, DOI 10.1016/0012-1606(82)90122-1; KULLUNKI P, 1992, J CELL BIOL, V119, P679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE GW, 1989, J CELL BIOL, V109, P1351, DOI 10.1083/jcb.109.3.1351; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; LIESI P, 1989, EXP NEUROL, V105, P86, DOI 10.1016/0014-4886(89)90175-1; LOREAL O, 1991, FEBS LETT, V290, P9, DOI 10.1016/0014-5793(91)81213-R; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; MORITA A, 1985, BIOCHEM J, V229, P259, DOI 10.1042/bj2290259; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; NURCOMBE V, 1989, EUR J BIOCHEM, V180, P9, DOI 10.1111/j.1432-1033.1989.tb14608.x; OLWIN BB, 1985, DEV BIOL, V112, P359, DOI 10.1016/0012-1606(85)90407-5; OREAR JJ, 1992, J BIOL CHEM, V267, P20555; PAULSSON M, 1991, J BIOL CHEM, V266, P17545; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; PAULSSON M, 1989, J BIOL CHEM, V264; PETERS BP, 1985, J BIOL CHEM, V260, P4732; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SASSOON DA, 1993, DEV BIOL, V156, P11, DOI 10.1006/dbio.1993.1055; SCHUBERT D, 1974, J CELL BIOL, V61, P398, DOI 10.1083/jcb.61.2.398; SEEBACHER T, 1991, EXP CELL RES, V196, P66, DOI 10.1016/0014-4827(91)90456-5; SHULL JD, 1991, GENE, V104, P203, DOI 10.1016/0378-1119(91)90251-6; SIMO P, 1991, DEVELOPMENT, V112, P477; SKUBITZ APN, 1988, J BIOL CHEM, V263, P4861; SOLURSH M, 1988, DEVELOPMENT, V104, P41; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SOROKIN L, 1990, J CELL BIOL, V111, P1265, DOI 10.1083/jcb.111.3.1265; STREULI CH, 1990, J CELL BIOL, V110, P1405; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; TIMPL R, 1979, J BIOL CHEM, V254, P9933; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TOKIDA Y, 1990, J BIOL CHEM, V265, P18123; VONDERMARK H, 1991, J BIOL CHEM, V266, P23593; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WEWER UM, 1992, LAB INVEST, V66, P378; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	81	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9270	9277						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510707				2022-12-25	WOS:A1994NB41100094
J	BEDNARCZYK, JL; SZABO, MC; WYGANT, JN; LAZAROVITS, AI; MCINTYRE, BW				BEDNARCZYK, JL; SZABO, MC; WYGANT, JN; LAZAROVITS, AI; MCINTYRE, BW			IDENTIFICATION OF A COMBINATORIAL EPITOPE EXPRESSED BY THE INTEGRIN ALPHA-4-BETA-1 HETERODIMER INVOLVED IN THE REGULATION OF CELL-ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; T-CELLS; RHEUMATOID-ARTHRITIS; LYMPHOCYTE ADHESION; MELANOMA ADHESION; ALPHA-SUBUNIT; BETA-SUBUNIT; VLA-4; FIBRONECTIN; RECEPTOR	The alpha 4 integrin subunit can associate with either the beta 1- or beta 7-integrin subunit to form two unique adhesion receptors alpha 4 beta 1 and alpha 4 beta 7. We developed a monoclonal antibody (mAb 19H8) that immunoprecipitated alpha 4 beta 1, induced homotypic leukocyte aggregation, and blocked the binding of cells to a synthetic peptide corresponding to the CS-1 peptide region of fibronectin. Aggregation cross-blocking analysis suggested that mAb 19H8 belonged to the group of mAbs that react with the B2 epitope of the alpha 4 subunit (alpha 4.B2 epitope); however, unlike the alpha 4.B2-specific mAb L25, mAb 19H8 did not immunoprecipitate alpha 4 beta 7. In addition, mAb 19H8 did not bind to beta 1-positive cells unless transfected with alpha 4 cDNA. These results indicated that mAb 19H8 was not specific for an individual alpha 4, beta 1, or beta 7 subunit but reacted with an epitope formed from the association of alpha 4 with beta 1. Separating the alpha 4 from the beta 1 subunit, by removing divalent cations or by treatment with high pH, disrupted mAb 19H8 binding. In contrast, the alpha 4-specific mAb L25 and the beta 1-specific mAb 18D3 could react with their respective subunits without subunit association. Therefore, mAb 19H8 defined a novel regulatory epitope expressed by the integrin alpha 4 beta 1.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT IMMUNOL, HOUSTON, TX 77030 USA; UNIV WESTERN ONTARIO, DEPT MED, LONDON N6A 5A5, ON, CANADA	University of Texas System; UTMD Anderson Cancer Center; Western University (University of Western Ontario)					NATIONAL CANCER INSTITUTE [R01CA062596] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 62596] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; ARROYO AG, 1993, J BIOL CHEM, V268, P9863; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; BEDNARCZYK JL, 1990, J IMMUNOL, V144, P777; BEDNARCZYK JL, 1992, J BIOL CHEM, V267, P25274; BEDNARCZYK JL, 1992, CLIN EXP METASTAS, V10, P281; BEDNARCZYK JL, 1993, J CELL BIOCHEM, V51, P465, DOI 10.1002/jcb.2400510412; BEDNARCZYK JL, 1992, J LEUKOCYTE BIOL, V52, P456, DOI 10.1002/jlb.52.4.456; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BURKLY LC, 1991, EUR J IMMUNOL, V21, P2871, DOI 10.1002/eji.1830211132; CAIXIA S, 1991, CELL IMMUNOL, V138, P216, DOI 10.1016/0008-8749(91)90146-3; CAMPANERO MR, 1992, EUR J IMMUNOL, V22, P3111, DOI 10.1002/eji.1830221213; CAMPANERO MR, 1990, J CELL BIOL, V110, P2157, DOI 10.1083/jcb.110.6.2157; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DAVIS LS, 1990, J IMMUNOL, V145, P785; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; KAPPLER J, 1983, CELL, V35, P295, DOI 10.1016/0092-8674(83)90232-5; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFON A, 1991, J CLIN INVEST, V88, P546, DOI 10.1172/JCI115338; LAZAROVITS AI, 1984, J IMMUNOL, V133, P1857; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; MCINTYRE BW, 1989, J BIOL CHEM, V264, P13745; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MOULD AP, 1990, J BIOL CHEM, V265, P4020; NEUHAUS H, 1991, J CELL BIOL, V115, P1149, DOI 10.1083/jcb.115.4.1149; PARKER CM, 1993, J BIOL CHEM, V268, P7028; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; PODOLSKY DK, 1993, J CLIN INVEST, V92, P372, DOI 10.1172/JCI116575; POSTIGO AA, 1993, J IMMUNOL, V151, P2471; PULIDO R, 1991, J BIOL CHEM, V266, P10241; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANCHEZMADRID F, 1983, J EXP MED, V158, P586, DOI 10.1084/jem.158.2.586; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SCHWEIGHOFFER T, 1993, J IMMUNOL, V151, P717; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; TAKAHASHI H, 1992, EUR J IMMUNOL, V22, P2879, DOI 10.1002/eji.1830221119; UDAGAWA T, 1992, LYMPHOKINE CYTOK RES, V11, P193; VANDINTHERJANSSEN ACHM, 1991, J IMMUNOL, V147, P4207; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; WAYNER EA, 1992, J CELL BIOL, V116, P489, DOI 10.1083/jcb.116.2.489; WIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461; YABKOWITZ R, 1993, J IMMUNOL, V151, P149; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	58	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8348	8354						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510686				2022-12-25	WOS:A1994NB40900078
J	REDDY, VY; DESROCHERS, PE; PIZZO, SV; GONIAS, SL; SAHAKIAN, JA; LEVINE, RL; WEISS, SJ				REDDY, VY; DESROCHERS, PE; PIZZO, SV; GONIAS, SL; SAHAKIAN, JA; LEVINE, RL; WEISS, SJ			OXIDATIVE DISSOCIATION OF HUMAN ALPHA(2)-MACROGLOBULIN TETRAMERS INTO DYSFUNCTIONAL DIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-2-MACROGLOBULIN; METHIONINE RESIDUES; HALF-MOLECULES; ALPHA-1-PROTEINASE INHIBITOR; NUCLEOPHILIC MODIFICATION; CONFORMATIONAL CHANGE; ALPHA-MACROGLOBULINS; GLUTAMINE-SYNTHETASE; NEUTROPHIL ELASTASE; PROTEINASE-BINDING	Human alpha(2)-macroglobulin is a broad-spectrum, homotetrameric antiproteinase that can maximally bind up to two proteinase molecules in a ternary complex. Proteinases cleave the inhibitor within a peptide stretch termed the bait region and induce the emergence of internal thiol esters whose nucleophilic scission precede a major conformational change which entraps enzymes within molecular cages. In a previous study, leukocyte generated hypohalous acids and N-haloamines were identified as the first examples of physiologically relevant inactivators of the antiproteolytic activity of alpha(2)-macroglobulin (Reddy, V.Y., Pizzo, S. V., and Weiss, S. J. (1989) J. Biol. Chem. 264, 13801-13809), but the mechanisms whereby the oxidants damaged the inhibitor remained undefined. We now demonstrate that N-chloramines (RNCl) destroy the antiproteolytic activity of alpha(2)-macroglobulin in an unusual biphasic process that results in the formation of inactive alpha(2)-macroglobulin half-molecules. In the first phase, 8 eq of RNCl reacted with each alpha(2)-macroglobulin subunit to generate a partially oxidized antiproteinase containing 8 methionyl sulfoxide residues/monomer. Structure-function analyses demonstrated that the oxidized inhibitor retained its homotetrameric structure as well as its ability to entrap proteinases. In marked contrast, the oxidation of an additional 6 methionyl residues and a single tryptophanyl residue fractured the alpha(2)M homotetramer across its non-covalent axis into two pairs of disulfide-linked dimers. Despite the fact that the oxidized dimers displayed normal bait regions whose cleavage by proteinases initiated thiol ester scission, all antiproteolytic activity was lost. Furthermore, the oxidized dimers were unable to undergo the critical conformational changes normally associated with bait region cleavage or thiol ester scission. Together, these results demonstrate that chlorinated oxidants destroy the antiproteolytic activity of alpha(2)-macroglobulin by attacking a subset of methionyl and tryptophanyl residues whose oxidation mediates the dissociation of the native homotetramer into conformationally locked dimers.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908; UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; NHLBI,BIOCHEM LAB,BETHESDA,MD 20892	Duke University; Duke University; University of Virginia; University of Virginia; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Levine, Rodney L/D-9885-2011	Reddy, Vivek/0000-0002-5638-4993	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028024] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-28024] Funding Source: Medline; NIAID NIH HHS [AI-23870] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBINK JJ, 1991, ARTHRITIS RHEUM, V34, P1139, DOI 10.1002/art.1780340910; ALEXANDER NM, 1973, J BIOL CHEM, V249, P1946; BAKER MS, 1990, BIOCHEM BIOPH RES CO, V166, P993, DOI 10.1016/0006-291X(90)90909-7; BJORK I, 1985, BIOCHEM J, V231, P451; BROWER MS, 1982, J BIOL CHEM, V257, P9849; CALDWELL P, 1978, P NATL ACAD SCI USA, V75, P5349, DOI 10.1073/pnas.75.11.5349; CHAPMAN ML, 1989, J RHEUMATOL, V16, P15; CHRISTENSEN U, 1989, BIOCHEMISTRY-US, V28, P9324, DOI 10.1021/bi00450a012; CLARK RA, 1986, BIOCHEM BIOPH RES CO, V135, P451, DOI 10.1016/0006-291X(86)90015-X; CLIMENT I, 1989, ANAL BIOCHEM, V182, P226, DOI 10.1016/0003-2697(89)90584-8; CUNNINGHAM LW, 1990, BIOCHEMISTRY-US, V29, P1638, DOI 10.1021/bi00458a040; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DELAIN E, 1988, J BIOL CHEM, V263, P2981; DELALLOSA P, 1980, CAN J BIOCHEM CELL B, V58, P745, DOI 10.1139/o80-105; DESROCHERS PE, 1991, J CLIN INVEST, V87, P2258, DOI 10.1172/JCI115262; DESROCHERS PE, 1992, J BIOL CHEM, V267, P5005; DROZDZ R, 1988, ACTA BIOCHIM POL, V35, P277; DROZDZ R, 1988, BIOCHIM BIOPHYS ACTA, V957, P47, DOI 10.1016/0167-4838(88)90155-0; ENGHILD JJ, 1989, J BIOL CHEM, V264, P11428; GONIAS SL, 1989, J BIOL CHEM, V264, P9565; GONIAS SL, 1983, BIOCHEMISTRY-US, V22, P536, DOI 10.1021/bi00272a003; GONIAS SL, 1993, J BIOL CHEM, V302, P42; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; JASIN HE, 1988, J CLIN INVEST, V81, P6, DOI 10.1172/JCI113310; KAN CC, 1985, P NATL ACAD SCI USA, V82, P2282, DOI 10.1073/pnas.82.8.2282; KNAUPER V, 1990, FEBS LETT, V263, P355, DOI 10.1016/0014-5793(90)81412-H; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON LJ, 1988, BIOCHEMISTRY-US, V27, P983, DOI 10.1021/bi00403a022; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEVINE RL, 1982, J CHROMATOGR, V236, P499; LEVINE RL, 1982, BIOCHEMISTRY-US, V21, P2600, DOI 10.1021/bi00540a004; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; LIU D, 1987, Biochemistry, V26, P5221, DOI 10.1021/bi00391a001; MAIER KL, 1992, EUR RESPIR J, V5, P651; MICHAELIS J, 1990, BIOCHEM J, V270, P809, DOI 10.1042/bj2700809; MONCINO MD, 1991, BIOCHEMISTRY-US, V30, P1545, DOI 10.1021/bi00220a015; OSSANNA PJ, 1986, J CLIN INVEST, V77, P1939, DOI 10.1172/JCI112523; POCHON F, 1987, BIOCHEM BIOPH RES CO, V149, P488, DOI 10.1016/0006-291X(87)90394-9; POCHON F, 1989, BIOCHIM BIOPHYS ACTA, V996, P132, DOI 10.1016/0167-4838(89)90105-2; POTEMPA J, 1991, J BIOL CHEM, V266, P21482; QUIGLEY JP, 1991, J BIOL CHEM, V266, P1942; REDDY VY, 1989, J BIOL CHEM, V264, P13801; ROCHE PA, 1988, BIOCHEMISTRY-US, V27, P7876, DOI 10.1021/bi00420a044; ROCHE PA, 1989, BIOCHEMISTRY-US, V28, P7629, DOI 10.1021/bi00445a019; ROCHE PA, 1987, BIOCHEMISTRY-US, V26, P486, DOI 10.1021/bi00376a021; ROSEMAN JE, 1987, J BIOL CHEM, V262, P2101; SHECHTER Y, 1975, BIOCHEMISTRY-US, V14, P4497, DOI 10.1021/bi00691a025; SHECHTER Y, 1976, BIOCHEMISTRY-US, V23, P5071; SILVERBERG M, 1977, BIOCHIM BIOPHYS ACTA, V494, P441, DOI 10.1016/0005-2795(77)90178-7; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; SPYCHER SE, 1987, J BIOL CHEM, V262, P14606; STELMASZYNSKA T, 1978, EUR J BIOCHEM, V92, P301, DOI 10.1111/j.1432-1033.1978.tb12748.x; STONE PJ, 1982, METHOD ENZYMOL, V82, P588; STRANDBERG L, 1991, J BIOL CHEM, V266, P13852; STRICKLAND DK, 1984, BIOCHEMISTRY-US, V23, P6679, DOI 10.1021/bi00321a061; STRICKLAND DK, 1984, BIOCHEMISTRY-US, V23, P3115, DOI 10.1021/bi00309a002; THOMAS D, 1988, BIOL CELL, V64, P39, DOI 10.1016/0248-4900(88)90091-3; Thomas E L, 1986, Methods Enzymol, V132, P569; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TYAGI SC, 1990, J BIOL CHEM, V266, P5279; VANLEUVEN F, 1982, BIOCHEM J, V203, P405, DOI 10.1042/bj2030405; VIRCA GD, 1984, J BIOL CHEM, V259, P8870; VIRCA GD, 1983, H-S Z PHYSIOL CHEM, V364, P1297, DOI 10.1515/bchm2.1983.364.2.1297; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; ZGLICZYNSKI JM, 1985, INT J BIOCHEM, V17, P393, DOI 10.1016/0020-711X(85)90216-2	68	95	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4683	4691						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508448				2022-12-25	WOS:A1994MW98900115
J	BALLIGAND, JL; UNGUREANULONGROIS, D; SIMMONS, WW; PIMENTAL, D; MALINSKI, TA; KAPTURCZAK, M; TAHA, Z; LOWENSTEIN, CJ; DAVIDOFF, AJ; KELLY, RA; SMITH, TW; MICHEL, T				BALLIGAND, JL; UNGUREANULONGROIS, D; SIMMONS, WW; PIMENTAL, D; MALINSKI, TA; KAPTURCZAK, M; TAHA, Z; LOWENSTEIN, CJ; DAVIDOFF, AJ; KELLY, RA; SMITH, TW; MICHEL, T			CYTOKINE-INDUCIBLE NITRIC-OXIDE SYNTHASE (INOS) EXPRESSION IN CARDIAC MYOCYTES - CHARACTERIZATION AND REGULATION OF INOS EXPRESSION AND DETECTION OF INOS ACTIVITY IN SINGLE CARDIAC MYOCYTES IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; VASCULAR SMOOTH-MUSCLE; GROWTH-FACTOR-BETA; MOUSE MACROPHAGES; INTERFERON-GAMMA; ENDOTHELIAL-CELLS; CLONING; BIOSYNTHESIS; HEPATOCYTES; PATHWAY	Cellular constituents of heart muscle contain both constitutive and inducible nitric oxide (NO) signaling pathways that modulate the contractile properties of cardiac myocytes. The identities of the inducible NO synthase (iNOS) isoform(s) expressed in cardiac muscle, and of the specific cell types expressing iNOS activity, remain poorly characterized. We amplified a 217-base pair cDNA by reverse transcriptase-polymerase chain reaction from primary cultures of inflammatory cytokine pretreated adult rat ventricular myocytes (ARVM) that was nearly identical to other NOS cDNA sequences. Using this 217-base pair cDNA as a probe in Northern blots, we found no evidence of iNOS mRNA in control myocytes, but both interleukin-1 beta and interferon-gamma individually increased MOS mRNA abundance in primary cultures of ARVM, with maximal expression at 12 h. The half life of iNOS mRNA in actinomycin C1-treated cells was 4 h. Both dexamethasone and transforming growth factor-beta attenuated the induction of iNOS mRNA abundance and enzyme activity by IL-1 beta and INF gamma. Pretreatment with dexamethasone also abolished the induction of iNOS mRNA, but not the increase in GTP cyclohydrolase mRNA in purified cardiac myocytes from lipopolysaccharide-injected rats, In order to further characterize the specific cell type producing NO, we used a NO-specific porphyrinic/Nafion-coated microsensor to record NO release from a single, isolated ARVM pretreated with IL-1 beta and IFN gamma in L-arginine-depleted medium. NO release could be detected following microinjection of L-arginine in the vicinity of the cell juxtaposed to the NO microsensor, but not following microinjection of D-arginine, and not from ARVM pretreated with L-N-monomethylarginine. Cytokine-pretreated ARVM that had been maintained in L-arginine-depleted medium also exhibited a depressed contractile response to isoproterenol after addition of L-arginine, but not D-arginine. These results indicate that altered contractile function of cardiac myocytes following exposure to specific inflammatory cytokines is due to induction of myocyte iNOS.	BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; JOHNS HOPKINS UNIV,DEPT MED,BALTIMORE,MD 21205; OAKLAND UNIV,DEPT CHEM,ROCHESTER,MI 48309; OAKLAND UNIV,INST BIOTECHNOL,ROCHESTER,MI 48309; WAYNE STATE UNIV,SCH MED,DETROIT,MI 48201	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Johns Hopkins University; Oakland University; Oakland University; Wayne State University			Balligand, Jean-Luc J/D-7543-2012	BALLIGAND, Jean-Luc/0000-0002-0522-4156; Lowenstein, Charles/0000-0003-0485-7514	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046457, R01HL046457, R01HL036141, R37HL036141] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46457, HL36141] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BALLIGAND JL, 1993, J CLIN INVEST, V91, P2314, DOI 10.1172/JCI116461; BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BALLIGAND JL, 1994, IN PRESS AM J PHYSL; BERGER HJ, 1994, AM J PHYSIOL, V266, pH341, DOI 10.1152/ajpheart.1994.266.1.H341; BOGDAN C, 1993, J IMMUNOL, V151, P301; BRADY AJB, 1992, AM J PHYSIOL, V263, pH193; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNHA FQ, 1994, IMMUNOLOGY, V81, P211; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; ELLINGSEN O, 1993, AM J PHYSIOL, V265, pH747, DOI 10.1152/ajpheart.1993.265.2.H747; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GENG Y, 1992, CIRC RES, V71, P1268, DOI 10.1161/01.RES.71.5.1268; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HAN X, 1994, IN PRESS J PHYSL; HATAKEYAMA K, 1991, J BIOL CHEM, V266, P765; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KELLY RA, 1990, J CLIN INVEST, V86, P1164, DOI 10.1172/JCI114822; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN C, 1991, P NATL ACAD SCI USA, V89, P6711; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V193, P1076, DOI 10.1006/bbrc.1993.1735; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NATHAN C, 1994, J CLIN INVEST, V93, P1875, DOI 10.1172/JCI117176; NISHIDA M, 1993, J CLIN INVEST, V91, P1934, DOI 10.1172/JCI116412; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; ROBERTS AB, 1992, J CLIN INVEST, V90, P2056, DOI 10.1172/JCI116087; SCHOEDON G, 1993, EUR J BIOCHEM, V213, P833, DOI 10.1111/j.1432-1033.1993.tb17826.x; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SCOTTBURDEN T, 1993, BIOCHEM BIOPH RES CO, V196, P1261, DOI 10.1006/bbrc.1993.2388; SHERMAN PA, 1993, BIOCHEMISTRY-US, V32, P11600, DOI 10.1021/bi00094a017; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; VOLZ A, 1991, J MOL CELL CARDIOL, V23, P1206; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; WERNERFELMAYER G, 1993, J BIOL CHEM, V268, P1842; WERNERFELMAYER G, 1993, FEBS LETT, V322, P232; WOOD ER, 1993, BIOCHEM BIOPH RES CO, V191, P767, DOI 10.1006/bbrc.1993.1283; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	47	399	405	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27580	27588						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525557				2022-12-25	WOS:A1994PV77100066
J	SEUFFERLEIN, T; ROZENGURT, E				SEUFFERLEIN, T; ROZENGURT, E			SPHINGOSINE INDUCES P125(FAK) AND PAXILLIN TYROSINE PHOSPHORYLATION, ACTIN STRESS FIBER FORMATION, AND FOCAL CONTACT ASSEMBLY IN SWISS 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDIC-ACID LEVELS; ADHESION KINASE; BOMBESIN STIMULATION; CELLULAR PROLIFERATION; EXTRACELLULAR-MATRIX; GROWTH-FACTORS; EARLY SIGNALS; DNA-SYNTHESIS; VASOPRESSIN	Treatment of Swiss 3T3 cells with sphingosine, a potential breakdown product of all sphingolipids, induced tyrosine phosphorylation of multiple substrates including bands of M(r) 110,000-130,000 and M(r) 70,000-80,000. Tyrosine phosphorylation in response to sphingosine occurred in a concentration dependent manner (EC(50) = 10 mu M) and developed gradually reaching half maximum and maximum effects at 20 and 60 min, respectively. The dihydroenantiomere of sphingosine, DL-threo-dihydrosphingosine, neither induced tyrosine phosphorylation nor interfered with sphingosine-stimulated tyrosine phosphorylation. Focal adhesion kinase (p125(FAK)) and paxillin were identified as prominent substrates for sphingosine stimulated tyrosine phosphorylation. Cell permeable ceramides also stimulated tyrosine phosphorylation of the M(r) 110,000-130,000 band as well as p125(FAK), but the effect was less pronounced than that of sphingosine. Tyrosine phosphorylation by sphingosine could be dissociated from both protein kinase C activation and Ca2+ mobilization from intracellular stores. Sphingosine stimulated striking actin stress fiber formation and focal adhesion assembly in Swiss 3T3 cells. The kinetics of actin stress fiber formation and tyrosine phosphorylation in response to sphingosine closely paralleled. Cytochalasin D, which disrupts the network of actin microfilaments, completely inhibited sphingosine induced tyrosine phosphorylation. In addition, tyrosine phosphorylation of p125(FAK) and paxillin in response to sphingosine was completely prevented when cells were stimulated in the presence of platelet-derived growth factor at a concentration (30 ng/ml) that caused disruption of the actin cytoskeleton. Our results demonstrate, for the first time, that sphingosine induces p125(FAK) and paxillin tyrosine phosphorylation, actin stress fiber formation and focal adhesion assembly in Swiss 3T3 cells.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Seufferlein, Thomas TW/P-7147-2018					BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; DESAI NN, 1992, J BIOL CHEM, V267, P23122; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; EXTON JH, 1994, CURR OPIN CELL BIOL, V6, P226, DOI 10.1016/0955-0674(94)90140-6; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HAUSER JML, 1994, J BIOL CHEM, V269, P6803; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; RANKIN S, 1994, J BIOL CHEM, V269, P704; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1983, P NATL ACAD SCI USA, V80, P7224; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SECKL M, 1993, J BIOL CHEM, V268, P9548; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; THASTRUP O, 1987, BIOCHIM BIOPHYS ACTA, V927, P65, DOI 10.1016/0167-4889(87)90066-8; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TURNER CE, 1991, EXP CELL RES, V192, P651, DOI 10.1016/0014-4827(91)90090-H; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; VUORI K, 1993, J BIOL CHEM, V268, P21459; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZHANG H, 1990, J BIOL CHEM, V265, P21309	46	113	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27610	27617						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7525558				2022-12-25	WOS:A1994PV77100070
J	PEI, DQ; MAJMUDAR, G; WEISS, SJ				PEI, DQ; MAJMUDAR, G; WEISS, SJ			HYDROLYTIC INACTIVATION OF A BREAST-CARCINOMA CELL-DERIVED SERPIN BY HUMAN STROMELYSIN-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-PROTEINASE INHIBITOR; MATRIX METALLOPROTEINASES; PROTEOLYTIC INACTIVATION; FIBROBLASTIC CELLS; TERMINAL DOMAIN; GENE; COLLAGENASE; ALPHA-1-ANTICHYMOTRYPSIN; SPECIFICITY; PROTEINS	To elucidate structure-function relationships of stromelysin-3, a putative matrix metalloproteinase originally identified at the tumor-stromal cell interface in breast carcinomas, the human cDNA was expressed in mammalian cells, and its products were isolated and characterized. In stably transfected cells, stromelysin-3 was recovered as a complex mixture of species ranging in size from similar to 20 to 65 kDa. Among these products, a major 45-kDa species with an N terminus of Phe(98) and an intact C-terminal domain was identified as a true endopeptidase on the basis of its ability to cleave the bait region of alpha(2)-macroglobulin between Phe(684) and Tyr(685), a site identical to that recognized by stromelysin-1. However, unlike stromelysin-1 or other members of the matrix metalloproteinase family, the mature form of stromelysin 3 was unable to hydrolyze a range of extracellular matrix molecules associated with either the basement membrane or interstitium. To probe for alternate substrates among tumor cell-derived products, purified stromelysin-3 was incubated with [S-35]methionine-labeled medium conditioned by the breast cancer cell line, MCF-7. Under these conditions, a single, tumor cell-derived protein was hydrolyzed as assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography. Following anion-exchange chromatography and preparative gel electrophoresis, the stromelysin-3 substrate was identified by N-terminal sequencing as the serine proteinase inhibitor, alpha(1)-proteinase inhibitor. Further studies demonstrated that stromelysin-3 rapidly destroyed the antiproteolytic function of alpha(1)-proteinase inhibitor by cleaving the antiproteinase at a distinct site between Ala(350) and Met(351) within the reactive-site loop. Together, these data not only demonstrate that human stromelysin-3 acts as a powerful endopeptidase with a restricted substrate specificity distinct from all other matrix metalloproteinases, but also serve to identify serine proteinase inhibitors as potential physiologic targets at sites of extracellular matrix remodeling.	UNIV MICHIGAN,CTR COMPREHENS CANC,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,CTR COMPREHENS CANC,DEPT DERMATOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NIAID NIH HHS [AI-23876] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023876] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASSET P, 1993, BREAST CANCER RES TR, V24, P185, DOI 10.1007/BF01833259; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; DAVIES B, 1993, CANCER RES, V53, P2087; DESROCHERS PE, 1991, J CLIN INVEST, V87, P2258, DOI 10.1172/JCI115262; DESROCHERS PE, 1992, J BIOL CHEM, V267, P5005; FINLAY TH, 1993, ENDOCRINOLOGY, V133, P996, DOI 10.1210/en.133.3.996; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAZIADEI I, 1994, BLOOD, V83, P260; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARLOW E, 1988, ANTIBODIES LABORATOR; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; MAST AE, 1991, J BIOL CHEM, V266, P15810; MURPHY G, 1993, J BIOL CHEM, V268, P15435; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY GJP, 1991, FEBS LETT, V289, P4, DOI 10.1016/0014-5793(91)80895-A; NAKAMURA T, 1984, EXP CELL RES, V154, P81; PEI DO, 1993, FASEB J, V7, pA1209; PERLMUTTER DH, 1989, J BIOL CHEM, V264, P9485; POTEMPA J, 1988, SCIENCE, V241, P699, DOI 10.1126/science.2456616; REDDY VY, 1994, J BIOL CHEM, V269, P4683; RHINEHART AR, 1993, AM J RESPIR CELL MOL, V9, P666; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; SCOTT GK, 1989, BIOCHIM BIOPHYS ACTA, V1010, P160, DOI 10.1016/0167-4889(89)90156-0; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; TORRESROSADO A, 1993, P NATL ACAD SCI USA, V90, P7191; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WINYARD PG, 1991, FEBS LETT, V279, P91, DOI 10.1016/0014-5793(91)80258-5; WOLF C, 1992, J INVEST DERMATOL, V99, P870, DOI 10.1111/1523-1747.ep12614846; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843; YAMASHITA JI, 1994, BRIT J CANCER, V69, P72, DOI 10.1038/bjc.1994.11; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	32	194	199	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25849	25855						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523394				2022-12-25	WOS:A1994PQ49100090
J	NICHOLS, RA; SUPLICK, GR; BROWN, JM				NICHOLS, RA; SUPLICK, GR; BROWN, JM			CALCINEURIN-MEDIATED PROTEIN DEPHOSPHORYLATION IN BRAIN NERVE-TERMINALS REGULATES THE RELEASE OF GLUTAMATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CORTICAL SYNAPTOSOMES; OKADAIC ACID; NEUROTRANSMITTER RELEASE; DROSOPHILA-MELANOGASTER; DYNAMIN GTPASE; CYCLIC-AMP; KINASE-C; PHOSPHORYLATION; CALCIUM; DEPOLARIZATION	In response to Ca2+ entry, several prominent brain nerve terminal phosphoproteins undergo dephosphorylation, but the relation between dephosphorylation and neurotransmitter release is unknown. Using the immunosuppressants cyclosporin A (CsA) and L-683,590 (FK-520) to inhibit specifically the Ca2+/calmodulin-dependent protein phosphatase calcineurin, we demonstrate here that Ca2+-dependent dephosphorylation in isolated rat brain nerve terminals (synaptosomes) is mediated by calcineurin. Pretreatment with micromolar CsA resulted in a 76-95% inhibition of stimulation-induced decreases in P-32-labeled dynamin (previously referred to as dephosphin), a phosphoprotein of M(r) = 145,000 (145-kDa protein), and a phosphoprotein of M(r) = 170,000 (170-kDa protein). Pretreatment with FH-520 also inhibited Ca2+ dependent dephosphorylation. Using hypotonic lysates of P-32-labeled synaptosomes, the addition of Ca2+ plus calmodulin, but not either agent alone, induced dynamin dephosphorylation. CsA and FK-520 had little to no effect on the release of glutamate induced by either K+-depolarization or the Ca2+ ionophore ionomycin. In contrast, calcineurin inhibition led to a substantial enhancement of glutamate release evoked by the K+-channel blocker 4-aminopyridine, an agent whose action most closely mimics physiological stimulation. Calcineurin inhibition had no effect on stimulation-induced changes in synaptosomal Ca2+ levels. Based on our findings, we hypothesize that Ca2+-dependent protein dephosphorylation resulting from calcineurin activation during physiological stimulation limits neu rotransmitter release from brain nerve terminal, perhaps being dependent upon cyclic repolarization of the membrane during stimulation.			NICHOLS, RA (corresponding author), MED COLL PENN,DEPT PHARMACOL,3200 HENRY AVE,PHILADELPHIA,PA 19129, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS030577] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30577] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANTHONY FA, 1988, J NEUROSCI, V8, P1245; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COOPER NGF, 1985, J CELL BIOL, V101, P1212, DOI 10.1083/jcb.101.4.1212; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; DUNKLEY PR, 1986, J NEUROCHEM, V46, P1692; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; GOMEZPUERTAS P, 1991, J NEUROCHEM, V56, P2039, DOI 10.1111/j.1471-4159.1991.tb03464.x; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALPAIN S, 1990, NATURE, V343, P369, DOI 10.1038/343369a0; HALPAIN S, 1990, NEURON, V5, P237, DOI 10.1016/0896-6273(90)90161-8; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HULTSCH T, 1990, J IMMUNOL, V144, P1000; HUTTNER WB, 1981, J BIOL CHEM, V256, P1482; HUTTNER WB, 1979, P NATL ACAD SCI USA, V76, P5402, DOI 10.1073/pnas.76.10.5402; IKEDA K, 1976, NATURE, V259, P489, DOI 10.1038/259489a0; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOENIG JH, 1983, J CELL BIOL, V96, P1517, DOI 10.1083/jcb.96.6.1517; KOENIG JH, 1989, J NEUROSCI, V9, P1937; KOMULAINEN H, 1987, NEUROCHEM INT, V10, P55, DOI 10.1016/0197-0186(87)90172-0; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KREUGER BK, 1977, J BIOL CHEM, V252, P2764; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU CM, 1978, J BIOL CHEM, V253, P5892; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCMAHON HT, 1991, J NEUROCHEM, V56, P86, DOI 10.1111/j.1471-4159.1991.tb02566.x; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NICHOLS RA, 1989, J NEUROCHEM, V52, P521, DOI 10.1111/j.1471-4159.1989.tb09151.x; NISHIWAKI S, 1990, CARCINOGENESIS, V11, P1837, DOI 10.1093/carcin/11.10.1837; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OHARA K, 1990, TRANSPLANT P, V22, P83; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; POODRY CA, 1979, J CELL BIOL, V81, P520, DOI 10.1083/jcb.81.3.520; ROBINSON PJ, 1985, J NEUROCHEM, V44, P338, DOI 10.1111/j.1471-4159.1985.tb05422.x; ROBINSON PJ, 1987, J NEUROCHEM, V48, P187, DOI 10.1111/j.1471-4159.1987.tb13146.x; ROBINSON PJ, 1983, J NEUROCHEM, V41, P909, DOI 10.1111/j.1471-4159.1983.tb09034.x; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; ROBINSON PJ, 1991, MOL NEUROBIOL, V5, P87, DOI 10.1007/BF02935541; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SIHRA TS, 1993, NEUROCHEM RES, V18, P47, DOI 10.1007/BF00966922; SIHRA TS, 1992, J BIOL CHEM, V267, P1983; SIHRA TS, 1993, J NEUROCHEM, V61, P1220, DOI 10.1111/j.1471-4159.1993.tb13612.x; SIM ATR, 1991, NEUROSCI LETT, V126, P203, DOI 10.1016/0304-3940(91)90554-7; STAMNES M A, 1992, Trends in Cell Biology, V2, P272, DOI 10.1016/0962-8924(92)90200-7; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; TIBBS GR, 1989, J NEUROCHEM, V53, P1693, DOI 10.1111/j.1471-4159.1989.tb09232.x; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WALKER RW, 1988, NEUROL CLIN, V6, P261, DOI 10.1016/S0733-8619(18)30869-7; WANG JKT, 1988, J NEUROSCI, V8, P281; ZUCKER RS, 1988, NATURE, V335, P360, DOI 10.1038/335360a0	59	115	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23817	23823						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7522234				2022-12-25	WOS:A1994PQ34500065
J	TAKUMA, T; ICHIDA, T				TAKUMA, T; ICHIDA, T			CATALYTIC SUBUNIT OF PROTEIN-KINASE-A INDUCES AMYLASE RELEASE FROM STREPTOLYSIN O-PERMEABILIZED PAROTID ACINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE PHOSPHOPROTEINS; RAT PANCREATIC ACINI; GTP-GAMMA-S; CYCLIC-AMP; MEDIATED EXOCYTOSIS; MICROSOMAL PROTEIN; EXOCRINE PANCREAS; MICROMOLAR RANGE; CELLULAR ATP; CELLS	Amylase release from parotid acinar cells is a typical model of cAMP-mediated exocytosis. To obtain unequivocal data concerning the role of cAMP-dependent protein kinase (PKA) in amylase exocytosis, we undertook the direct introduction of the PKA catalytic subunit into the parotid acini by permeabilization with streptolysin O (SLO). In the presence of 100 hemolytic units/ml SLO, cAMP increased amylase release in a time- and dose-dependent manner. PKI-(5-24)-peptide, a specific PKA inhibitor, markedly inhibited amylase release, but the extent of inhibition was approximately 50%. On the other hand, the PKA catalytic subunit highly purified from bovine hearts significantly induced amylase release. The release was strictly dependent on the presence of SLO and the catalytic activity of PKA added. The catalytic subunit dose dependently induced amylase release, but the heat-inactivated subunit had no stimulatory effect. PKI-(5-24)-peptide completely blocked amylase release evoked by the subunit. These results clearly demonstrate that the catalytic subunit of PKA regulates cAMP-mediated amylase release through phosphorylation of unidentified protein(s) directly or indirectly involved in the process of exocytosis.			TAKUMA, T (corresponding author), HLTH SCI UNIV HOKKAIDO, SCH DENT, DEPT ORAL BIOCHEM, TOBETSU, HOKKAIDO 06102, JAPAN.							AHNERTHILGER G, 1985, J BIOL CHEM, V260, P2730; BALDYSWALIGORSKA A, 1987, BIOCHIM BIOPHYS ACTA, V929, P190, DOI 10.1016/0167-4889(87)90175-3; BAUM BJ, 1981, J BIOL CHEM, V256, P9731; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; BHAKDI S, 1985, INFECT IMMUN, V47, P52; BUCKINGHAM L, 1983, BIOCHIM BIOPHYS ACTA, V729, P115, DOI 10.1016/0005-2736(83)90462-5; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; BURNHAM DB, 1982, J BIOL CHEM, V257, P523; BURNHAM DB, 1986, BIOCHEM J, V235, P125, DOI 10.1042/bj2350125; Butcher F R, 1980, Adv Cyclic Nucleotide Res, V13, P215; DOWD FJ, 1981, BIOCHEM BIOPH RES CO, V101, P281, DOI 10.1016/S0006-291X(81)80042-3; EDWARDSON JM, 1990, BIOCHIM BIOPHYS ACTA, V1053, P32, DOI 10.1016/0167-4889(90)90022-6; FREEDMAN SD, 1982, J CELL BIOL, V95, P909, DOI 10.1083/jcb.95.3.909; FREEDMAN SD, 1982, J CELL BIOL, V95, P903, DOI 10.1083/jcb.95.3.903; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; HARPER JF, 1988, ADV SEC MESS PHOSPH, V22, P193; HINCKE MT, 1988, BIOCHIM BIOPHYS ACTA, V967, P204, DOI 10.1016/0304-4165(88)90010-4; HINCKE MT, 1992, ARCH ORAL BIOL, V37, P85, DOI 10.1016/0003-9969(92)90002-P; HOOTMAN SR, 1987, PHYSL GASTROINTESTIN, P1129; HOWELL TW, 1987, BIOCHIM BIOPHYS ACTA, V927, P177, DOI 10.1016/0167-4889(87)90132-7; JAHN R, 1980, EUR J BIOCHEM, V112, P345, DOI 10.1111/j.1432-1033.1980.tb07211.x; JAHN R, 1983, FEBS LETT, V153, P71, DOI 10.1016/0014-5793(83)80121-5; KANAMORI T, 1980, BIOCHEM INT, V1, P395; KITAGAWA M, 1990, AM J PHYSIOL, V259, pG157, DOI 10.1152/ajpgi.1990.259.2.G157; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; OSULLIVAN AJ, 1992, BIOCHEM J, V287, P403, DOI 10.1042/bj2870403; QUISSELL DO, 1992, ARCH ORAL BIOL, V37, P289, DOI 10.1016/0003-9969(92)90051-9; QUISSELL DO, 1985, P NATL ACAD SCI USA, V82, P3237, DOI 10.1073/pnas.82.10.3237; RAFFANIELLO RD, 1993, J BIOL CHEM, V268, P8491; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SPEARMAN TN, 1984, J CELL BIOL, V99, P1354, DOI 10.1083/jcb.99.4.1354; STECHER B, 1992, BIOCHEM J, V283, P899, DOI 10.1042/bj2830899; TAKUMA T, 1988, J BIOCHEM-TOKYO, V103, P95, DOI 10.1093/oxfordjournals.jbchem.a122247; TAKUMA T, 1991, J BIOCHEM-TOKYO, V110, P292, DOI 10.1093/oxfordjournals.jbchem.a123573; TAKUMA T, 1991, FEBS LETT, V285, P124, DOI 10.1016/0014-5793(91)80740-T; TAKUMA T, 1988, BIOCHEM J, V256, P867, DOI 10.1042/bj2560867; TAKUMA T, 1994, FEBS LETT, V340, P29, DOI 10.1016/0014-5793(94)80167-3; TAKUMA T, 1993, FEBS LETT, V323, P145, DOI 10.1016/0014-5793(93)81467-E; TAKUMA T, 1990, J BIOCHEM, V108, P99, DOI 10.1093/oxfordjournals.jbchem.a123171; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; THIEL G, 1988, EUR J BIOCHEM, V174, P601, DOI 10.1111/j.1432-1033.1988.tb14141.x; THIEL G, 1988, EUR J BIOCHEM, V170, P643, DOI 10.1111/j.1432-1033.1988.tb13746.x; TOJYO Y, 1990, BIOCHEM PHARMACOL, V39, P1775	44	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22124	22128						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7520911				2022-12-25	WOS:A1994PE09800032
J	BEERS, MF; KIM, CY; DODIA, C; FISHER, AB				BEERS, MF; KIM, CY; DODIA, C; FISHER, AB			LOCALIZATION, SYNTHESIS, AND PROCESSING OF SURFACTANT PROTEIN SP-C IN RAT LUNG ANALYZED BY EPITOPE-SPECIFIC ANTIPEPTIDE ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; PULMONARY SURFACTANT; II CELLS; HYDROPHOBIC PROTEINS; INSITU HYBRIDIZATION; LAMELLAR BODIES; BREFELDIN-A; SP-B; PRECURSOR; BOVINE	Surfactant protein C (SP-C), a 3.7-kDa hydrophobic lung-specific protein, is synthesized and secreted by pulmonary type II cells through proteolytic processing of a 21-kDa propeptide (SP-C-21) by currently undefined pathways. Previously, we reported the production of a polyclonal antibody against rat SP-C-21 (anti-CPROSP-C) using a synthetic peptide as the immunizing antigen (Beers, M. F., Wali, A., Eckenhoff, M. E. F., Feinstein, S., Fisher, J. H., and Fisher, A. B. (1992) Am. J. Respir. Cell. Mol. Biol. 7, 368-378). In this study, two additional epitope-specific proSP-C antibodies produced using synthetic peptide sequences were utilized to examine synthetic processing of SP-C. Anti-NPROSP-C (Met(10)-Gln(23)) and anti-CTERMSP-C (Ser(149)-Ser(166)) recognized native proSP-C-21 produced from in vitro translation of SP-C cDNA. Immunocytochemistry using anti-NPROSP-C confirmed the localization of proSP-C peptides exclusively in type II cells. Western analysis of subcellular fractions identified a single 21-kDa band in microsomes and a 16-kDa form in lamellar bodies each recognized by all three antisera, while anti-NPROSP-C also uniquely identified a prominent 5-6-kDa form in lamellar bodies. In a perfused rat lung model labeled with [S-35]cysteine/methionine, immunoprecipitation of lung homogenate and lamellar body fractions identified early appearances of S-35-labeled 21-, 18-, and 16-kDa SP-C forms in homogenate and a 16-kDa intermediate form in lamellar bodies. Anti-NPROSP-C also exclusively detected time-dependent appearances of 5-10-kDa proSP-C forms in lamellar bodies and homogenates. Processing of proSP-C-21 was completely blocked by inclusion of brefeldin A (15 mu g/ml) in the perfusate. These results demonstrate that synthetic peptides can be used to produce epitope specific antisera which recognize more hydrophilic domains of proSP-C and show that proSP-C processing occurs intracellularly in subcellular compartments of type II cells which are distal to the trans-Golgi network.	HOSP UNIV PENN,DEPT MED,DIV PULM & CRIT CARE,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine	BEERS, MF (corresponding author), UNIV PENN,SCH MED,INST ENVIRONM MED,1 JOHN MORGAN BLDG,36TH & HAMILTON WALK,PHILADELPHIA,PA 19104, USA.				NHLBI NIH HHS [HL-02869] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002869] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEERS MF, 1992, AM J PHYSIOL, V263, pL151, DOI 10.1152/ajplung.1992.263.2.L151; BEERS MF, 1992, AM J PHYSIOL, V262, pL773, DOI 10.1152/ajplung.1992.262.6.L773; BEERS MF, 1992, AM J RESP CELL MOL, V7, P368, DOI 10.1165/ajrcmb/7.4.368; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDER A, 1983, BIOCHIM BIOPHYS ACTA, V753, P119, DOI 10.1016/0005-2760(83)90105-4; CURSTEDT T, 1987, EUR J BIOCHEM, V168, P255, DOI 10.1111/j.1432-1033.1987.tb13414.x; CURSTEDT T, 1990, P NATL ACAD SCI USA, V87, P2985, DOI 10.1073/pnas.87.8.2985; DOBBS LG, 1982, BIOCHIM BIOPHYS ACTA, V713, P118, DOI 10.1016/0005-2760(82)90174-6; DODIA C, 1991, FASEB J, V5, P1490; EMRIE PA, 1989, BIOCHIM BIOPHYS ACTA, V994, P215, DOI 10.1016/0167-4838(89)90296-3; FISHER AB, 1991, AM J PHYSIOL, V261, pL334, DOI 10.1152/ajplung.1991.261.4.L334; FISHER JH, 1991, AM J RESP CELL MOL, V5, P63, DOI 10.1165/ajrcmb/5.1.63; FISHER JH, 1989, BIOCHIM BIOPHYS ACTA, V995, P225, DOI 10.1016/0167-4838(89)90040-X; GLASSER SW, 1990, J BIOL CHEM, V265, P9; GLASSER SW, 1988, J BIOL CHEM, V257, P13135; GORDON RD, 1987, P NATL ACAD SCI USA, V84, P308, DOI 10.1073/pnas.84.1.308; HAWGOOD S, 1989, AM J PHYSIOL, V257, pL13, DOI 10.1152/ajplung.1989.257.2.L13; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; JOBE A, 1977, BIOCHIM BIOPHYS ACTA, V489, P440, DOI 10.1016/0005-2760(77)90165-5; JOHANNSEN J, 1990, METHODS PROTEIN SEQU, P197; KALINA M, 1992, AM J RESP CELL MOL, V6, P594, DOI 10.1165/ajrcmb/6.6.594; KATYAL SL, 1977, LAB INVEST, V36, P585; KELLER A, 1992, AM J RESP CELL MOL, V6, P601, DOI 10.1165/ajrcmb/6.6.601; KELLER A, 1991, BIOCHEM J, V277, P493, DOI 10.1042/bj2770493; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MATHIALAGAN N, 1990, BIOCHIM BIOPHYS ACTA, V1045, P121, DOI 10.1016/0005-2760(90)90140-S; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MILLER EJ, 1991, AM J PHYSIOL, V260, pL1, DOI 10.1152/ajplung.1991.260.2.L1; OOSTERLAKENDIJKSTERHUIS MA, 1991, BIOCHEM J, V274, P115, DOI 10.1042/bj2740115; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PHELPS DS, 1988, AM REV RESPIR DIS, V137, P939, DOI 10.1164/ajrccm/137.4.939; PHELPS DS, 1991, EXP LUNG RES, V17, P985, DOI 10.3109/01902149109064330; PHIZACKERLEY PJR, 1979, BIOCHEM J, V183, P731, DOI 10.1042/bj1830731; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHANNON JM, 1990, AM J RESP CELL MOL, V2, P183, DOI 10.1165/ajrcmb/2.2.183; SHINNICK TM, 1983, ANNU REV MICROBIOL, V37, P425, DOI 10.1146/annurev.mi.37.100183.002233; STULTS JT, 1991, AM J PHYSIOL, V261, pL118, DOI 10.1152/ajplung.1991.261.2.L118; VOORHOUT WF, 1993, MICROSC RES TECHNIQ, V26, P366, DOI 10.1002/jemt.1070260504; VORBROKER DK, 1992, BIOCHIM BIOPHYS ACTA, V1105, P161, DOI 10.1016/0005-2736(92)90175-L; WALI A, 1993, AM J PHYSIOL, V264, pL431, DOI 10.1152/ajplung.1993.264.5.L431; WEAVER TE, 1989, AM J PHYSIOL, V257, pL100, DOI 10.1152/ajplung.1989.257.2.L100; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WEAVER TE, 1992, AM J PHYSIOL, V263, pL95, DOI 10.1152/ajplung.1992.263.1.L95; WILLIAMS MC, 1988, AM REV RESPIR DIS, V137, P399, DOI 10.1164/ajrccm/137.2.399; WOHLFORDLENANE CL, 1992, AM J RESP CELL MOL, V6, P225, DOI 10.1165/ajrcmb/6.2.225	47	104	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20318	20328						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7519606				2022-12-25	WOS:A1994PB31700020
J	ZHOU, LB; LEE, DHS; PLESCIA, J; LAU, CY; ALTIERI, DC				ZHOU, LB; LEE, DHS; PLESCIA, J; LAU, CY; ALTIERI, DC			DIFFERENTIAL LIGAND-BINDING SPECIFICITIES OF RECOMBINANT CD11B/CD18 INTEGRIN I-DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT RECEPTOR; LEUKOCYTE ADHESION; MONOCLONAL-ANTIBODIES; GLYCOPROTEIN FAMILY; CELLULAR ADHESION; RECOGNITION SITE; MAC-1 CD11B/CD18; ESCHERICHIA-COLI; GAMMA-CHAIN; FIBRINOGEN	The alpha subunits of leukocyte CD11/CD18 integrins contain an similar to 200-amino acid ''inserted'' domain (I-domain) that may be important for multivalent adhesive recognitions. A recombinant form of the I-domain of CD11b/CD18 was generated and analyzed directly for interaction with complementary integrin ligands. CD11b I-domain bound the activation-dependent monoclonal antibody 7E3, and the functionally blocking anti-CD11b monoclonal antibodies OKM9, 60.1, and LM2/1, but not OKM1 or M1/70. Fibrinogen or soluble intercellular adhesion molecule-1 associated with CD11b I-domain in a concentration-dependent manner. Binding of I-125-fibrinogen to recombinant CD11b I-domain was saturable, governed by a K-d of similar to 0.22 +/- 0.06 mu M, and fully inhibited by molar excess of unlabeled fibrinogen, or by the P1 peptide (KY)GWTVFQKRLDGSV (IC50 similar to 2.5-5 mu M), duplicating the fibrinogen gamma chain sequence Gly(190)-Val(202). In contrast, I-125-factor X binding to CD11b I-domain was only partially inhibited (50-60%) by a molar excess of unlabeled factor X, and entirely unaffected by functionally blocking anti-CD11b monoclonal antibodies or by factor X-derived synthetic peptidyl antagonists. We conclude that the I-domain of CD11b participates in qualitative mechanisms of receptor activation and contains the binding site(s) for the CD11b/CD18 ligands fibrinogen and intercellular adhesion molecule-1, while it is only minimally implicated in the recognition of factor X.	Scripps Res Inst, RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; RW JOHNSON PHARMACEUT RES INST, DON MILLS M3C 1L9, ON, CANADA	Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043773] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43773] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, J IMMUNOL, V141, P2656; ALTIERI DC, 1991, SCIENCE, V254, P1200, DOI 10.1126/science.1957171; ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ANDERSON DC, 1986, J IMMUNOL, V137, P15; ARNAOUT MA, 1990, BLOOD, V75, P1037; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; BROWN EJ, 1988, J CLIN INVEST, V81, P365, DOI 10.1172/JCI113328; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; COLOMBATTI A, 1991, BLOOD, V77, P2305; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1990, J CELL BIOL, V107, P321; GUSTAFSON EJ, 1989, J CELL BIOL, V109, P377, DOI 10.1083/jcb.109.1.377; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; MARTIN S, 1993, ANTIMICROB AGENTS CH, V37, P1278, DOI 10.1128/AAC.37.6.1278; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MILLER LJ, 1986, J IMMUNOL, V137, P2891; PANG J, 1993, J IMMUNOL, V151, P6166; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHIFFENBAUM B, 1989, J IMMUNOL, V142, P3537; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TREZZINI C, 1988, BIOCHEM BIOPH RES CO, V156, P477, DOI 10.1016/S0006-291X(88)80866-0; WALLIS WJ, 1986, BLOOD, V67, P1007; WIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734	34	133	139	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17075	17079						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516332				2022-12-25	WOS:A1994NT84600017
J	FRIGUET, B; DJAVADIOHANIANCE, L; KING, J; GOLDBERG, ME				FRIGUET, B; DJAVADIOHANIANCE, L; KING, J; GOLDBERG, ME			IN-VITRO AND RIBOSOME-BOUND FOLDING INTERMEDIATES OF P22 TAILSPIKE PROTEIN DETECTED WITH MONOCLONAL-ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI TRYPTOPHAN SYNTHASE; RIBULOSE BISPHOSPHATE CARBOXYLASE; TAIL SPIKE ENDORHAMNOSIDASE; ESCHERICHIA-COLI; PHAGE-P22 TAILSPIKE; POLYPEPTIDE-CHAINS; RAMAN-SPECTROSCOPY; BETA-2 SUBUNIT; HEAT-SHOCK; WILD-TYPE	It remains unclear whether polypeptide chains renaturing in vitro from strong denaturants proceed through the same folding pathway as chains released from ribosomes within cells. Folding intermediates formed both in vivo and in vitro have been examined using three monoclonal antibodies shown previously to recognize different epitopes of the native P22 tailspike protein (Friguet, B., Djavadi-Ohaniance, L., Haase-Pettingell, C, A, King, J., and Goldberg, M. E. (1990) J. Biol. Chem. 265, 10347-10351). The tailspike protein was reconstituted from polypeptide chains unfolded by urea as described by Fuchs ct al. (Fuchs, A., Seiderer, C., and Seckler, R. (1991) Biochemistry 30, 6598-6604), and the appearance of immunoreactive forms during the refolding was monitored. The three antibodies discriminated intermediates at different stages in the folding pathway. On the basis of the reconstitution pathway determined from spectroscopic and hydrodynamic measurements by Fuchs ct al. (1991), monoclonal antibody (mAb) 236-3 recognized partially folded monomers, mAb 155-3 recognized folded protomers in a protrimer species, and mAb 33-2 recognized the native trimer. The kinetics of appearance of the immunoreactive forms during the in vitro refolding of the protein in crude extracts of phage-infected cells was similar to that observed with the pure tailspike. Thus, the antibodies provided probes for the chain folding and association pathway in vivo. The conformation of the ribosome-bound tailspike polypeptide chains of the infected cells was analyzed with the three antibodies. The antibodies recognizing native trimer and the protrimer did not bind chains associated with the ribosomes. Antibody 236-3, which recognized structured monomers in vitro, bound to the polypeptide chains still associated with ribosomes. This result suggests that steps that take place in solution during in vitro refolding may occur in a ribosome-bound state in vivo.	INST PASTEUR,UNITE BIOCHIM CELLULAIRE,CNRS,URA 1129,F-75724 PARIS 15,FRANCE; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Massachusetts Institute of Technology (MIT)				Friguet, Bertrand/0000-0001-8085-1961				BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BERGET PB, 1980, J VIROL, V34, P234, DOI 10.1128/JVI.34.1.234-243.1980; BLOND S, 1987, P NATL ACAD SCI USA, V84, P1147, DOI 10.1073/pnas.84.5.1147; BLONDELGUINDI S, 1990, BIOCHEMISTRY-US, V29, P2409, DOI 10.1021/bi00461a026; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CHEN BL, 1991, BIOCHEMISTRY-US, V30, P6260, DOI 10.1021/bi00239a026; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; DJAVADIOHANIANCE L, 1986, BIOCHEMISTRY-US, V25, P2502, DOI 10.1021/bi00357a033; DJAVADIOHANIANCE L, 1984, BIOCHEMISTRY-US, V23, P97, DOI 10.1021/bi00296a016; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; FEDOROV AN, 1992, J MOL BIOL, V228, P351, DOI 10.1016/0022-2836(92)90825-5; FRIGUET B, 1986, EUR J BIOCHEM, V160, P593, DOI 10.1111/j.1432-1033.1986.tb10079.x; FRIGUET B, 1990, J BIOL CHEM, V265, P10347; FRIGUET B, 1984, MOL IMMUNOL, V21, P673, DOI 10.1016/0161-5890(84)90053-1; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; GOLDBERG ME, 1985, TRENDS BIOCHEM SCI, V10, P388, DOI 10.1016/0968-0004(85)90066-0; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GOLDENBERG DP, 1982, J BIOL CHEM, V257, P7864; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HAMLIN J, 1972, P NATL ACAD SCI USA, V69, P412, DOI 10.1073/pnas.69.2.412; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; King J, 1986, Methods Enzymol, V131, P250; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; MURRYBRELIER A, 1988, BIOCHEMISTRY-US, V27, P7633, DOI 10.1021/bi00420a010; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PURVIS IJ, 1987, J MOL BIOL, V14, P1238; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SARGENT D, 1988, J MOL BIOL, V199, P491, DOI 10.1016/0022-2836(88)90620-1; SAUER RT, 1982, BIOCHEMISTRY-US, V21, P5811, DOI 10.1021/bi00266a014; SCHEIN CH, 1989, BIO-TECHNOL, V7, P1141; SCHONER RG, 1985, BIO-TECHNOL, V3, P151, DOI 10.1038/nbt0285-151; SCHWARZ JJ, 1989, J BIOL CHEM, V264, P20112; SECKLER R, 1989, J BIOL CHEM, V264, P11750; SMITH DH, 1981, J MOL BIOL, V145, P653, DOI 10.1016/0022-2836(81)90308-9; STURTEVANT JM, 1989, J BIOL CHEM, V264, P10693; THOMAS GJ, 1990, BIOCHEMISTRY-US, V29, P4181, DOI 10.1021/bi00469a022; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; YU MH, 1988, J BIOL CHEM, V263, P1424	48	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15945	15949						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	7515066				2022-12-25	WOS:A1994NP51300084
J	SMITH, WC; MILAM, AH; DUGGER, D; ARENDT, A; HARGRAVE, PA; PALCZEWSKI, K				SMITH, WC; MILAM, AH; DUGGER, D; ARENDT, A; HARGRAVE, PA; PALCZEWSKI, K			A SPLICE VARIANT OF ARRESTIN - MOLECULAR-CLONING AND LOCALIZATION IN BOVINE RETINA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COUPLED RECEPTOR KINASES; 48-KDA PROTEIN; S-ANTIGEN; PHOTOEXCITED RHODOPSIN; PHOTORECEPTORS; IDENTIFICATION; INACTIVATION; EXPRESSION; RODS; DNA	Inactivation of photolyzed rhodopsin requires phosphorylation of the receptor and binding of the 48-kDa regulatory protein arrestin. We recently isolated a novel form of arrestin, termed p(44), that is truncated at the COOH terminus (Palczewski, K., Buczylko, J., Ohguro, H., Annan, R. S., Carr, S. A., Crabb, J. W., Kaplan, M. W, Johnson, R. S., and Walsh, K. A. (1994) Protein Sci. 3, 319-329) and strongly inhibits G(t) activation by non-phosphorylated rhodopsin. p(44) is identical to arrestin except at the COOH terminus, where the 35 amino acids of arrestin are replaced by a single alanine residue. p(44) is identified as a splice variant of arrestin based on the identical cDNA sequence of p(44) with arrestin (except the 3' non-coding regions), the presence of an exon/intron junction at the Ser(369) codon, and identical Southern hybridization patterns generated by the 3' non-coding portion of arrestin and p(44). Immunocytochemistry reveals that p(44) is localized in the photoreceptor outer segment, whereas arrestin is present throughout the cell. This specificity of localization to the outer segment is persistent with a role of p(44) in the phototransduction cascade.	UNIV WASHINGTON,DEPT OPHTHALMOL,SEATTLE,WA 98195; UNIV FLORIDA,DEPT OPHTHALMOL,GAINESVILLE,FL 32610; UNIV FLORIDA,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610; UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Washington; University of Washington Seattle			Smith, W. Clay/AAQ-1589-2021		NATIONAL EYE INSTITUTE [R01EY001311, R01EY009339] Funding Source: NIH RePORTER; NEI NIH HHS [EY06225, EY01311, EY09339] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMUS G, 1988, Peptide Research, V1, P42; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BREITMAN ML, 1991, J BIOL CHEM, V266, P15505; BUCZYLKO J, 1993, METH NEUROSCI, V15, P226; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LEREA CL, 1989, NEURON, V3, P367, DOI 10.1016/0896-6273(89)90261-4; MANGINI NJ, 1988, INVEST OPHTH VIS SCI, V29, P1221; NIR I, 1992, J HISTOCHEM CYTOCHEM, V40, P343, DOI 10.1177/40.3.1372630; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P319; PALCZEWSKI K, 1992, NEURON, V8, P177; PARRUTI G, 1993, J BIOL CHEM, V268, P9753; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; WACKER WB, 1977, J IMMUNOL, V119, P1949; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174	24	91	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15407	15410						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	7515057				2022-12-25	WOS:A1994NP51300003
J	CHEN, J; PARSONS, S; BRAUTIGAN, DL				CHEN, J; PARSONS, S; BRAUTIGAN, DL			TYROSINE PHOSPHORYLATION OF PROTEIN PHOSPHATASE 2A IN RESPONSE TO GROWTH-STIMULATION AND V-SRC TRANSFORMATION OF FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; OKADAIC ACID; T-ANTIGENS; B-SUBUNIT; TYPE-2A; MODULATION; COMPLEXES; DISTINCT; HEPARIN; FORM	The catalytic subunit of protein phosphatase 2A (PP2A) is inactivated by in vitro phosphorylation of Tyr(307) by receptor and nonreceptor protein tyrosine kinases (Chen, J., Martin, B. L., and Brautigan, D. L. (1992) Science 257, 1261-1264). Here we show the phosphorylation of PP2A in cells under different growth conditions. In lysates of nontransformed murine 10T1/2 fibroblasts, there were two forms of PP2A at 36 kDa detected after two-dimensional gel electrophoresis and immunoblotting with anti-PP2A peptide antibody. These two forms exactly comigrated with unphosphorylated purified PP2A and the PP2A P-32-labeled by in vitro phosphorylation with p60(v-src) kinase. The phosphorylated form of PP2A recovered from red blood cells or produced by in vitro phosphorylation was eliminated by incubation with tyrosine-specific phosphatase (PTP1B). Transformation of 10T1/2 cells by expression of p60(v-src) resulted in most of the PP2A in the cells being converted to a phosphorylated form that was reactive with anti phosphotyrosine antibody. Serum starvation of cells reduced the amount of phosphorylated PP2A, whereas serum stimulation of quiescent cells caused an increase to the same relative amount of phosphorylated PP2A as in src-transformed cells. Addition of epidermal growth factor to quiescent NeoR cells (10T1/2 fibroblasts overexpressing epidermal growth factor receptors) temporarily increased the level of phosphorylation of PP2A, with a peak at 5-15 min and a return to basal level within 60 min. The results show that PP2A is phosphorylated in intact cells, and the extent of this modification is increased by growth factors or cell transformation, providing evidence for a physiological mechanism of PP2A regulation.	BROWN UNIV,DIV BIOL & MED,BIOCHEM SECT,PROVIDENCE,RI 02912; UNIV VIRGINIA,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908	Brown University; University of Virginia								BRAUTIGAN DL, 1991, P NATL ACAD SCI USA, V88, P6696, DOI 10.1073/pnas.88.15.6696; BRAUTIGAN DL, 1994, CELL CYCLE 93 REGULA; BRAUTIGAN DL, 1993, ADV PROT PHOSPHATASE, V7, P49; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHERNOFF J, 1983, J BIOL CHEM, V258, P7852; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CSORTOS C, 1990, BIOCHEM BIOPH RES CO, V169, P559, DOI 10.1016/0006-291X(90)90367-V; DAMUNI Z, 1993, P NATL ACAD SCI USA, V90, P2500; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; GUO H, 1993, J BIOL CHEM, V268, P11193; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HERMANN J, 1988, EUR J BIOCHEM, V173, P17, DOI 10.1111/j.1432-1033.1988.tb13961.x; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KIM YH, 1993, J BIOL CHEM, V268, P18513; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LUDLOW JW, 1992, ONCOGENE, V7, P1011; MARTIN BL, 1991, FEBS LETT, V285, P6, DOI 10.1016/0014-5793(91)80712-C; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PELECH S, 1985, EUR J BIOCHEM, V148, P245, DOI 10.1111/j.1432-1033.1985.tb08832.x; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; SELVA E, 1993, J BIOL CHEM, V268, P2250; SENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; UEMURA T, 1993, GENE DEV, V7, P429, DOI 10.1101/gad.7.3.429; USUI H, 1988, J BIOL CHEM, V263, P3752; WAELKENS E, 1987, J BIOL CHEM, V262, P1049; WALKER F, 1993, J BIOL CHEM, V268, P19552; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521	34	246	253	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7957	7962						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510677				2022-12-25	WOS:A1994NB40900022
J	DOMIN, J; HIGGINS, T; ROZENGURT, E				DOMIN, J; HIGGINS, T; ROZENGURT, E			PREFERENTIAL INHIBITION OF PLATELET-DERIVED GROWTH FACTOR-STIMULATED DNA-SYNTHESIS AND PROTEIN-TYROSINE PHOSPHORYLATION BY NORDIHYDROGUAIARETIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; SIMIAN SARCOMA-VIRUS; ARACHIDONIC-ACID; SIGNAL TRANSDUCTION; BIOLOGICAL-ACTIVITY; FACTOR RECEPTOR; KINASE-ACTIVITY; SH3 DOMAIN; BOMBESIN; VASOPRESSIN	Nordihydroguaiaretic acid (NDGA), a reportedly specific lipoxygenase inhibitor, was found to selectively inhibit platelet-derived growth factor (PDGF)-stimulated DNA synthesis in Swiss 3T3 cells. Maximal inhibition of PDGF-induced [H-3]thymidine incorporation (96%) was observed using 4 mu M NDGA (IC50 = 1.5 mu M). No effect of NDGA was observed upon DNA synthesis stimulated with either fetal bovine serum, bombesin, or epidermal growth factor (EGF) in the presence of insulin, or with the potent mitogen Pasteurella multocida toxin. The selective inhibition of PDGF-stimulated DNA synthesis by NDGA was also observed in diploid murine cells, rat, and human fibroblasts. Furthermore, 4 mu M NDGA also inhibited PDGF-stimulated anchorage-independent colony growth of rat-1 cells by 76%. Using Swiss 3T3 cells, we found that PDGF-stimulated arachidonic acid mobilization and prostaglandin E(2) production was abolished by NDGA in a dose-dependent manner. Inhibition of PDGF-stimulated arachidonic acid mobilization by NDGA could not, however, explain its potent inhibitory effect upon PDGF-stimulated DNA synthesis. Our results showed that NDGA also selectively inhibited PDGF receptor tyrosine phosphorylation in a dose-dependent manner in intact cells. Protein tyrosine phosphorylation stimulated by EGF or bombesin was not altered by NDGA treatment. Crucially, NDGA inhibited in vitro the tyrosine kinase activity of anti-phosphotyrosine and anti-PDGF receptor immunoprecipitates prepared from cultures stimulated with PDGF. This inhibition of receptor tyrosine phosphorylation in a cell-free system confirmed that NDGA acts directly at the level of the PDGF receptor tyrosine kinase domain. These results suggest that the potent and selective inhibitory effect of NDGA on PDGF-stimulated DNA synthesis results from its inhibitory action on tyrosine phosphorylation.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK								BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHANG J, 1984, INFLAMMATION, V8, P143, DOI 10.1007/BF00916090; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; DOMIN J, 1993, J BIOL CHEM, V268, P8927; DOMIN J, 1992, J BIOL CHEM, V267, P15217; DUAN DSR, 1991, J BIOL CHEM, V266, P413; ENGSTROM U, 1992, J BIOL CHEM, V267, P16581; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GIL J, 1991, J CELL BIOL, V113, P943, DOI 10.1083/jcb.113.4.943; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HOSANG M, 1985, J CELL BIOCHEM, V29, P265, DOI 10.1002/jcb.240290310; JOHNSSON A, 1985, NATURE, V317, P438, DOI 10.1038/317438a0; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORN SJ, 1990, MOL PHARMACOL, V38, P524; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOPEZRIVAS A, 1984, EMBO J, V3, P939, DOI 10.1002/j.1460-2075.1984.tb01911.x; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACDONALD ML, 1988, J BIOL CHEM, V263, P1575; MCCORMICK DL, 1987, CANCER LETT, V37, P139, DOI 10.1016/0304-3835(87)90156-X; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; MIYAZAWA K, 1985, JPN J PHARMACOL, V38, P119; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NOAR Z, 1988, MOL ENDOCRINOL, V2, P1043; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; RONDEAU E, 1990, BIOCHIM BIOPHYS ACTA, V1055, P165, DOI 10.1016/0167-4889(90)90117-V; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROZENGURT E, 1991, CANCER CELL-MON REV, V3, P397; ROZENGURT E, 1990, P NATL ACAD SCI USA, V87, P123, DOI 10.1073/pnas.87.1.123; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1975, P NATL ACAD SCI USA, V72, P4492, DOI 10.1073/pnas.72.11.4492; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANWAUWE J, 1983, PROSTAGLANDINS, V26, P725, DOI 10.1016/0090-6980(83)90057-6; VASSBOTN FS, 1992, J BIOL CHEM, V267, P15635; WESTERMARK B, 1991, CANCER RES, V51, P5087; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	56	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8260	8267						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510683				2022-12-25	WOS:A1994NB40900066
J	KING, SM; WITMAN, GB				KING, SM; WITMAN, GB			MULTIPLE SITES OF PHOSPHORYLATION WITHIN THE ALPHA-HEAVY-CHAIN OF CHLAMYDOMONAS OUTER ARM DYNEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-SITES; FLAGELLAR AXONEMES; MOLECULAR-WEIGHT; PARAMECIUM; PURIFICATION; REINHARDTII; PROTEINS; ATP; POLYPEPTIDE; TRANSPORT	We have examined the phosphorylation of the alpha dynein heavy chain (DHC) from the outer arm of the Chlamydomonas flagellum. Quantitative analysis indicates that this DHC is phosphorylated at a minimum of six sites. Using previously identified proteolytic and photocleavage sites (King, S. M., and Witman, G. B. (1988) J. Biol. Chem. 263, 9244-9255), we have mapped two regions that are phosphorylated in vivo. One is located in a 20-kDa section immediately N-terminal to the site of V1 photocleavage. Thus, this region is close to the ATP hydrolytic site and also to the predicted junction between the head and stem domains of the particle. The second encompasses the 90-kDa C-terminal region of the molecule, In this latter section, at least one site is found in an similar to 2-kDa region close to domains that are predicted to adopt a coiled-coil structure in those DHCs that have been sequenced. The alpha DHC also is specifically labeled by endogenous kinases in demembranated, washed axonemes, suggesting that at least one alpha DHC kinase is located close to, or is a component of, the outer arm in situ.	WORCESTER FDN EXPTL BIOL INC, CELL BIOL GRP, SHREWSBURY, MA 01545 USA	Worcester Foundation for Biomedical Research				Witman, George/0000-0002-9497-9218	NATIONAL CANCER INSTITUTE [P30CA012708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030626, R37GM030626] Funding Source: NIH RePORTER; NCI NIH HHS [CA12708] Funding Source: Medline; NIGMS NIH HHS [GM30626] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONINI NM, 1990, J CELL SCI, V95, P219; CHILCOTE TJ, 1990, J BIOL CHEM, V265, P17257; GIBBONS IR, 1991, NATURE, V352, P640, DOI 10.1038/352640a0; GOODENOUGH U, 1984, J MOL BIOL, V180, P1083, DOI 10.1016/0022-2836(84)90272-9; GOODENOUGH UW, 1982, J CELL BIOL, V95, P798, DOI 10.1083/jcb.95.3.798; HAMASAKI T, 1991, P NATL ACAD SCI USA, V88, P7918, DOI 10.1073/pnas.88.18.7918; JOHNSON KA, 1983, J CELL BIOL, V96, P669, DOI 10.1083/jcb.96.3.669; KAMIYA R, 1988, J CELL BIOL, V107, P2253, DOI 10.1083/jcb.107.6.2253; KINDLE KL, 1989, J CELL BIOL, V109, P2589, DOI 10.1083/jcb.109.6.2589; KING SM, 1986, METHOD ENZYMOL, V134, P291; KING SM, 1990, J BIOL CHEM, V265, P19807; KING SM, 1988, J BIOL CHEM, V263, P9244; KING SM, 1987, J BIOL CHEM, V262, P17596; KING SM, 1989, J BIOL CHEM, V264, P10210; King SM, 1989, CELL MOVEMENT DYNEIN, V1, P61; KOONCE MP, 1992, J CELL BIOL, V119, P1597, DOI 10.1083/jcb.119.6.1597; LARSEN J, 1991, J PROTOZOOL, V38, P55, DOI 10.1111/j.1550-7408.1991.tb04801.x; LEEEIFORD A, 1986, J BIOL CHEM, V261, P2337; Luck D.J.L., 1989, CELL MOVEMENT, V1, P49; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MIKAMI A, 1993, NEURON, V10, P787, DOI 10.1016/0896-6273(93)90195-W; MITCHELL DR, 1985, J CELL BIOL, V100, P1228, DOI 10.1083/jcb.100.4.1228; MITCHELL DR, 1994, IN PRESS J CELL SCI; MOCZ G, 1990, BIOCHEMISTRY-US, V29, P4839, DOI 10.1021/bi00472a013; OGAWA K, 1991, NATURE, V352, P643, DOI 10.1038/352643a0; PFISTER KK, 1982, CELL MOTIL CYTOSKEL, V2, P525, DOI 10.1002/cm.970020604; PFISTER KK, 1984, J BIOL CHEM, V259, P2072; PIPERNO G, 1991, J CELL BIOL, V112, P701, DOI 10.1083/jcb.112.4.701; PIPERNO G, 1981, CELL, V27, P331, DOI 10.1016/0092-8674(81)90416-5; PIPERNO G, 1979, J BIOL CHEM, V254, P3084; PORTER ME, 1983, J BIOL CHEM, V258, P6575; REMILLARD SP, 1982, J CELL BIOL, V93, P615, DOI 10.1083/jcb.93.3.615; SAKAKIBARA H, 1991, J CELL BIOL, V113, P615, DOI 10.1083/jcb.113.3.615; SAKAKIBARA H, 1993, J CELL BIOL, V122, P653, DOI 10.1083/jcb.122.3.653; SAKAKIBARA H, 1989, J CELL SCI, V92, P77; SCHROEDER CC, 1990, J CELL BIOL, V111, P2553, DOI 10.1083/jcb.111.6.2553; SEGAL RA, 1985, J CELL BIOL, V101, P1702, DOI 10.1083/jcb.101.5.1702; STEPHENS RE, 1992, J CELL SCI, V103, P999; WILKERSON CG, 1994, IN PRESS J CELL SCI; WITMAN GB, 1986, METHOD ENZYMOL, V134, P280; WITMAN GB, 1991, SERONO SYM, V75, P439; WITMAN GB, 1983, J SUBMICR CYTOL PATH, V15, P193; Witman George B., 1994, V13, P229	43	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5452	5457						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508939				2022-12-25	WOS:A1994MX57100111
J	GREENBERG, S; CHANG, P; SILVERSTEIN, SC				GREENBERG, S; CHANG, P; SILVERSTEIN, SC			TYROSINE PHOSPHORYLATION OF THE GAMMA-SUBUNIT OF FC(GAMMA)-RECEPTORS, P72(SYK), AND PAXILLIN DURING FC-RECEPTOR-MEDIATED PHAGOCYTOSIS IN MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; SIGNAL TRANSDUCTION; MOUSE MACROPHAGES; CROSS-LINKING; PROTEIN; ACTIVATION; KINASE; ANTIGEN; INTEGRINS; IGG	Fc receptor-mediated phagocytosis in mouse macrophages occurs by a tyrosine kinase-dependent pathway (Greenberg, S., Chang, P., and Silverstein, S. C. (1993) J. Exp. Med. 177, 529-534). To identify proteins that are phosphorylated on tyrosine residues during phagocytosis, we used anti-phosphotyrosine antibodies to perform immunoblotting and immunoprecipitation of lysates derived from Fc receptor-stimulated macrophages. Proteins of 26, 30, 35, 37, 40, 43, 47, 56, 60, 68, 83, 116, and 150 kDa displayed enhanced tyrosine phosphorylation during Fc receptor-mediated phagocytosis. Tyrosine phosphorylation of these proteins was not a consequence of actin polymerization since treatment with cytochalasin D did not alter the pattern of Fc receptor-stimulated protein tyrosine phosphorylation. The 68-kDa tyrosine phosphoprotein was identified as paxillin, a cytoskeletal-associated tyrosine kinase substrate previously identified in fibroblasts and shown to localize to focal adhesions (Turner, C. E., Glenney, J. R., and Burridge, K. (1990) J. Cell Biol. 111, 1059-1068). Paxillin colocalized with F-actin beneath nascent phagosomes. In addition to the above proteins detected by anti-phosphotyrosine immunoblotting, the gamma subunit of FcRI and III was shown to undergo tyrosine phosphorylation during Fc receptor-mediated phagocytosis. Of several candidate tyrosine kinases that may be activated during Fc receptor stimulation, p72syk, but not p125FAK, displayed enhanced tyrosine phosphorylation during Fc receptor aggregation. The coordinated tyrosine phosphorylation of the gamma subunit of macrophage Fc receptors, the tyrosine kinase syk, and the cytoskeletal-associated protein, paxillin, may be important steps in integrating signals between Fc receptors and the underlying cytoskeleton.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL & CELLULAR BIOPHYS,ROVER LAB CELLULAR PHYSIOL,NEW YORK,NY 10032	Columbia University	GREENBERG, S (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,DIV PULM,P&S 9-503,630 W 168TH ST,NEW YORK,NY 10032, USA.				NHLBI NIH HHS [HL-02641] Funding Source: Medline; NIAID NIH HHS [AI-20516] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020516, R37AI020516] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGARWAL A, 1993, J BIOL CHEM, V268, P15900; AMIGORENA S, 1992, NATURE, V358, P337, DOI 10.1038/358337a0; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BONNEROT C, 1992, EMBO J, V11, P2747, DOI 10.1002/j.1460-2075.1992.tb05340.x; BURRIDGE K, 1983, J CELL BIOL, V97, P359, DOI 10.1083/jcb.97.2.359; BURRIDGE K, 1992, CELL, V71, P649; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; EINSPAHR KJ, 1991, P NATL ACAD SCI USA, V88, P6279, DOI 10.1073/pnas.88.14.6279; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; FINLAY BB, 1991, J CELL SCI, V99, P283; FUORTES M, 1993, J CELL BIOL, V120, P777, DOI 10.1083/jcb.120.3.777; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; GREENBERG S, 1990, J EXP MED, V172, P1853, DOI 10.1084/jem.172.6.1853; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HO MK, 1982, J IMMUNOL, V128, P2281; HUANG CK, 1990, BIOCHEM J, V269, P431, DOI 10.1042/bj2690431; HUANG MM, 1992, J BIOL CHEM, V267, P5467; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RANKIN BM, 1993, J IMMUNOL, V150, P605; RETH M, 1989, NATURE, V338, P384; SALCEDO TW, 1993, J EXP MED, V177, P1475, DOI 10.1084/jem.177.5.1475; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SCHOLL PR, 1992, J IMMUNOL, V149, P1751; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TING AT, 1991, J IMMUNOL, V147, P3122; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; UNKELESS JC, 1977, J EXP MED, V145, P931, DOI 10.1084/jem.145.4.931; WEINSHANK RL, 1988, J EXP MED, V167, P1909, DOI 10.1084/jem.167.6.1909; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WIRTHMUELLER U, 1992, J EXP MED, V175, P1381, DOI 10.1084/jem.175.5.1381; YOUNG VB, 1992, J CELL BIOL, V116, P197, DOI 10.1083/jcb.116.1.197; YU KT, 1991, J BIOL CHEM, V266, P22564; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195	50	217	219	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3897	3902						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508923				2022-12-25	WOS:A1994MV63100112
J	CLIPSTONE, NA; FIORENTINO, DF; CRABTREE, GR				CLIPSTONE, NA; FIORENTINO, DF; CRABTREE, GR			MOLECULAR ANALYSIS OF THE INTERACTION OF CALCINEURIN WITH DRUG-IMMUNOPHILIN COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN PHOSPHATASE; CYCLOSPORINE-A; CATALYTIC SUBUNIT; NEUROSPORA-CRASSA; LYMPHOCYTES-T; CYCLOPHILIN; EXPRESSION; FK506; ACTIVATION; CLONING	The calcium/calmodulin-regulated phosphatase calcineurin (CN) is the site of action of the immunosuppressive drugs cyclosporin A (CsA) and FK506. CN has recently been established as a key signaling enzyme in the T cell signal transduction cascade and an important regulator of transcription factors such as MF-AT and GAP/Oct-1, which are involved in the expression of a number of important T cell early genes. CsA and FK506 act by forming complexes with their respective intracellular receptors cyclophilin and FKBP (immunophilins), which can then bind to CN, inhibiting its enzymatic activity and thereby preventing early gene expression. CN is comprised of two subunits: a 59-kDa catalytic subunit (CNA), which contains a calmodulin binding domain and autoinhibitory region, and a 19-kDa intrinsic calcium binding regulatory subunit (CNB). In this study, we have utilized a series of deletion mutants of the CNA subunit to investigate the subunit and molecular requirements that govern the interaction of CN with drug-immunophilin complexes. The calmodulin binding and autoinhibitory domains of the CNA subunit were found to be dispensable for the binding of CN to drug immunophilin complexes. In contrast, we found that the regulatory CNB subunit appears to play an obligatory role in this interaction and have defined an amino acid sequence of the CNA subunit which forms the binding site for CNB. Although necessary, the CNB subunit per se is not sufficient to mediate an interaction with drug-immunophilin complexes; amino acid residues of the the CNA subunit, specifically a region located within the putative catalytic domain, are rise required for the interaction of CN with both FKBP.FK506 and cyclophilin A.CsA.			CLIPSTONE, NA (corresponding author), STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA.			Fiorentino, David/0000-0001-7951-3674				ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; BICKEL M, 1987, P NATL ACAD SCI USA, V84, P3274, DOI 10.1073/pnas.84.10.3274; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BRAM RJ, 1993, MOL CELL BIOL, V13, P4670; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLIPSTONE NA, 1993, ANN NY ACAD SCI, V696, P20; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; DAVIES AA, 1987, LYMPHOCYTES PRACTICA, P229; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOOR F, 1992, NATURE, V360, P682; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GRANELLIPIPERNO A, 1986, J EXP MED, V163, P922, DOI 10.1084/jem.163.4.922; GUERINI D, 1992, J BIOL CHEM, V267, P22542; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HADDY A, 1992, FEBS LETT, V314, P37, DOI 10.1016/0014-5793(92)81456-V; HIGUCHI S, 1991, J BIOL CHEM, V266, P18104; HUSI H, 1994, J BIOL CHEM, V269, P14199; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KINCAID R, 1993, ADV SEC MESS PHOSPH, V27, P1; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LI W, 1993, J BIOL CHEM, V268, P14040; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; RYFFEL B, 1993, BIOCHEM BIOPH RES CO, V194, P1074, DOI 10.1006/bbrc.1993.1931; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THOMSON AW, 1989, IMMUNOL TODAY, V10, P6, DOI 10.1016/0167-5699(89)90057-1; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; UEKI K, 1992, BIOCHEM BIOPH RES CO, V187, P537, DOI 10.1016/S0006-291X(05)81527-X; YOKOYAMA N, 1990, J BIOL CHEM, V265, P8170	44	100	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26431	26437						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523407				2022-12-25	WOS:A1994PQ93000075
J	HENDERSON, SA; LEE, PH; AEBERHARD, EE; ADAMS, JW; IGNARRO, LJ; MURPHY, WJ; SHERMAN, MP				HENDERSON, SA; LEE, PH; AEBERHARD, EE; ADAMS, JW; IGNARRO, LJ; MURPHY, WJ; SHERMAN, MP			NITRIC-OXIDE REDUCES EARLY GROWTH RESPONSE-1 GENE-EXPRESSION IN RAT LUNG MACROPHAGES TREATED WITH INTERFERON-GAMMA AND LIPOPOLYSACCHARIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS; ALVEOLAR MACROPHAGES; MOUSE MACROPHAGES; MOLECULAR-BASIS; SYNTHASE GENE; DIFFERENTIATION; ACTIVATION; INDUCTION; EGR-1; PROTEIN	Since early growth response-1 (Egr-1) is required for macrophage differentiation and nitric oxide (NO) is immunosuppressive, we hypothesized that NO would reduce Egr-1 expression in rat lung macrophages. The inflammatory stimuli interferon-gamma and lipopolysaccharide induced an early, transient increase in Egr-1 mRNA (>5-fold at 2 h) and a sustained, high level of inducible NO synthase mRNA (>100-fold from 4 to 24 h). The NO metabolites nitrite and nitrate rose >10-fold in medium from stimulated versus unstimulated cells over 24 h. Concomitant with elevated nitrogen oxides, Egr-1 mRNA levels declined to 80% below unstimulated cells at 24 h. This decline was blocked by an inhibitor of NO production, N-G-monomethyl-L-arginine. Further, the NO donor S-nitroso-N-acetylpenicillamine inhibited Egr-1 expression in a dose dependent manner, producing complete inhibition at 0.5 mM. The effect of S-nitroso-N-acetylpenicillamine was not due to reduced macrophage viability. We conclude that Egr-1 induction precedes inducible NO synthase induction in stimulated rat macrophages and that subsequent NO production reduces macrophage expression of Egr-1. We propose that this mechanism is used to regulate macrophage differentiation in human immunodeficiency virus infection and other inflammatory states.	UNIV CALIF LOS ANGELES, DEPT PHARMACOL, LOS ANGELES, CA 90024 USA; UNIV KANSAS, DEPT MICROBIOL MOLEC GENET & IMMUNOL, KANSAS CITY, KS 66160 USA; UNIV KANSAS, DEPT PEDIAT, KANSAS CITY, KS 66160 USA; UNIV CALIF LOS ANGELES, DEPT PEDIAT, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of Kansas; University of California System; University of California Los Angeles	HENDERSON, SA (corresponding author), UNIV CALIF LOS ANGELES, DEPT PHYSIOL SCI, LIFE SCI BLDG, RM 2322, 405 HILGARD AVE, LOS ANGELES, CA 90024 USA.				NHLBI NIH HHS [HL50706, HL40922, HL35014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035014, R01HL040922, R29HL050706] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEL PM, 1992, FEMS MICROBIOL IMMUN, V105, P317; BARUCHEL S, 1992, J LEUKOCYTE BIOL, V52, P111, DOI 10.1002/jlb.52.1.111; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN DL, 1992, J IMMUNOL, V149, P3045; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; DENHAM S, 1992, CLIN EXP IMMUNOL, V87, P157; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FU ZF, 1993, J VIROL, V67, P6674; GILLIAM MB, 1993, ANAL BIOCHEM, V212, P359, DOI 10.1006/abio.1993.1341; GRAZIOSI C, 1993, AIDS, V7, pS53, DOI 10.1097/00002030-199311002-00012; GRIFFIN GE, 1991, RES VIROLOGY, V142, P233, DOI 10.1016/0923-2516(91)90062-8; HAYMAN M, 1993, NEUROSCIENCE, V53, P1, DOI 10.1016/0306-4522(93)90278-N; HELMKE RJ, 1989, IN VITRO CELL DEV B, V25, P44; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; IGNARRO LJ, 1987, CIRC RES, V61, P866, DOI 10.1161/01.RES.61.6.866; JAMIESON GA, 1989, J CELL PHYSIOL, V139, P262, DOI 10.1002/jcp.1041390207; KALTER DC, 1991, J IMMUNOL, V146, P298; KHARBANDA S, 1991, J CLIN INVEST, V88, P571, DOI 10.1172/JCI115341; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MACE K, 1993, RES VIROLOGY, V144, P27, DOI 10.1016/S0923-2516(06)80008-7; MAGRINAT G, 1992, BLOOD, V80, P1880; MERRYMAN PF, 1993, ARTHRITIS RHEUM, V36, P1414, DOI 10.1002/art.1780361014; MIESEL R, 1993, RHEUMATOL INT, V13, P95, DOI 10.1007/BF00290295; MILLS CD, 1991, J IMMUNOL, V146, P2719; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; PIETRAFORTE D, 1994, J LEUKOCYTE BIOL, V55, P175, DOI 10.1002/jlb.55.2.175; SAKAMOTO KM, 1992, ONCOGENE, V7, P2125; Sambrook J, 1989, MOL CLONING LABORATO; SHERMAN MP, 1993, BIOCHEM BIOPH RES CO, V191, P1301, DOI 10.1006/bbrc.1993.1359; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; VAGO L, 1989, Applied Pathology, V7, P298; VAIRO G, 1992, J CELL PHYSIOL, V151, P630, DOI 10.1002/jcp.1041510324; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	37	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25239	25242						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7523382				2022-12-25	WOS:A1994PQ49100002
J	BURKHARDT, AL; STEALEY, B; ROWLEY, RB; MAHAJAN, S; PRENDERGAST, M; FARGNOLI, J; BOLEN, JB				BURKHARDT, AL; STEALEY, B; ROWLEY, RB; MAHAJAN, S; PRENDERGAST, M; FARGNOLI, J; BOLEN, JB			TEMPORAL REGULATION OF NONTRANSMEMBRANE PROTEIN-TYROSINE KINASE ENZYME-ACTIVITY FOLLOWING T-CELL ANTIGEN RECEPTOR ENGAGEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ZETA-CHAIN; CROSS-LINKING; SRC FAMILY; ACTIVATION; P56LCK; ZAP-70; RESPONSIVENESS; ASSOCIATION; P59FYN	We evaluated in Jurkat T cells the time-dependent re sponses of Fyn, Lck, Syk, and Zap following antibody-mediated cross-linking of the T cell antigen receptor. Our results show that the protein kinase activities of Fyn and Lck were activated within seconds of receptor cross-linking. Fyn activity, as measured by autophosphorylation and tyrosine phosphorylation of an exogenous substrate, was maximal 5 s to 1 min following receptor cross-linking. Lck was also found to be activated within 5 s of antigen receptor cross-linking but differed from Fyn in that Lck activity was elevated for at least 30 min. Syk and Zap protein kinase activities were found to peak between 5 and 10 min following receptor crosslinking, returning to approximately basal activity levels by 60 min. The protein kinase activities of both Syk and Zap were found to parallel their reactivity in immunoblotting experiments with anti-phosphotyrosine antibodies. Both Syk and Zap were found to associate with the tyrosine-phosphorylated zeta subunit of the T cell antigen receptor. These observations imply that T cell antigen receptor signal transduction involves the activation of multiple members of at least two different families of non-transmembrane protein tyrosine kinases.			BURKHARDT, AL (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, SIGNAL TRANSDUCT LAB, POB 4000, PRINCETON, NJ 08543 USA.							ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ADAM D, 1993, J BIOL CHEM, V268, P19882; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BURKHARDT AL, 1994, MOL CELL BIOL, V14, P1095, DOI 10.1128/MCB.14.2.1095; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BURKHARDT AL, 1993, CURRENT PROTOCOLS IM, P1; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; EISEMAN E, 1992, NATURE, V355, P78; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LI ZH, 1992, BIOCHEM BIOPH RES CO, V187, P1536, DOI 10.1016/0006-291X(92)90477-3; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAROSI GA, 1992, INT IMMUNOL, V4, P1211, DOI 10.1093/intimm/4.11.1211; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N	40	106	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23642	23647						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7522230				2022-12-25	WOS:A1994PQ34500040
J	MULLHAUPT, B; FEREN, A; FODOR, E; JONES, A				MULLHAUPT, B; FEREN, A; FODOR, E; JONES, A			LIVER EXPRESSION OF EPIDERMAL GROWTH-FACTOR RNA - RAPID INCREASES IN IMMEDIATE-EARLY PHASE OF LIVER-REGENERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FACTOR PRECURSOR; FACTOR RECEPTOR; RAT-LIVER; NUCLEOTIDE-SEQUENCE; SIGNAL TRANSDUCTION; PARTIAL-HEPATECTOMY; MESSENGER-RNA; FACTOR-ALPHA; FACTOR CDNA; MOUSE	The liver exhibits a remarkable capacity to regenerate its mass following partial removal or after injury. Transmembrane receptors for epidermal growth factor (EGF) are highly expressed in liver cells, which quickly respond to this polypeptide mitogen by activating an intrinsically low rate of cell division. Although EGF appears to regulate liver growth, its significance has remained unclear, and only a small change in serum levels can be detected during hepatocellular proliferation. Using a reverse transcription-polymerase chain reaction assay, we report here the novel finding that EGF RNA transcripts are synthesized in a hepatic cell-specific pat tern, appearing in hepatocyte and lipocyte cell types. Our data reveal that within 15 min following a 70% liver removal, EGF RNA levels increase >10-fold and then diminish below basal levels prior to the first wave of regenerative cell division. Immunoanalysis of metabolically labeled hepatocytes shows that EGF accumulates as a large 60-kDa peptide. These results demonstrate that EGF transcription is a previously unrecognized component of hepatic gene expression, and rapid increases in EGF RNA levels in the immediate-early phase of liver regeneration point to EGF as an autocrine factor in the prereplicative hepatic growth program.	VET ADM MED CTR,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR ANAT & LIVER,SAN FRANCISCO,CA 94143	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco			Mullhaupt, Beat/O-3744-2016	Mullhaupt, Beat/0000-0002-9020-8192				AVIVI A, 1991, ONCOGENE, V6, P673; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BISSELL DM, 1973, J CELL BIOL, V59, P722; BREYER JA, 1990, J BIOL CHEM, V265, P16564; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EVARTS RP, 1992, MOL CARCINOGEN, V5, P25, DOI 10.1002/mc.2940050107; FAUSTO N, 1989, LAB INVEST, V60, P4; Fausto Nelson, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P117; FRIEDMAN SL, 1987, ANAL BIOCHEM, V161, P207, DOI 10.1016/0003-2697(87)90673-7; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; KINOSHITA T, 1991, BIOCHEM BIOPH RES CO, V177, P330, DOI 10.1016/0006-291X(91)91987-N; KOCH KS, 1990, IN VITRO CELL DEV B, V26, P1011; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LAKSHMANAN J, 1990, BIOCHEM BIOPH RES CO, V173, P902, DOI 10.1016/S0006-291X(05)80871-X; MARTI U, 1989, HEPATOLOGY, V9, P126, DOI 10.1002/hep.1840090122; MARTI U, 1991, HEPATOLOGY, V13, P15, DOI 10.1016/0270-9139(91)90210-M; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MROCZKOWSKI B, 1989, MOL CELL BIOL, V9, P2771, DOI 10.1128/MCB.9.7.2771; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PESONEN K, 1989, J CLIN ENDOCR METAB, V68, P486, DOI 10.1210/jcem-68-2-486; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; RAPER SE, 1987, GASTROENTEROLOGY, V92, P1243, DOI 10.1016/S0016-5085(87)91084-5; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SAGGI SJ, 1992, DNA CELL BIOL, V11, P481, DOI 10.1089/dna.1992.11.481; SCHAUDIES RP, 1993, AM J PHYSIOL, V264, pF523, DOI 10.1152/ajprenal.1993.264.3.F523; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; THOMPSON NL, 1986, CANCER RES, V46, P3111; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZARNEGAR R, 1991, BIOCHEM BIOPH RES CO, V177, P559, DOI 10.1016/0006-291X(91)92020-K	38	92	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19667	19670						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	7519599				2022-12-25	WOS:A1994PA12600003
J	ARREAZA, G; MELKONIAN, KA; LAFEVREBERNT, M; BROWN, DA				ARREAZA, G; MELKONIAN, KA; LAFEVREBERNT, M; BROWN, DA			TRITON X-100-RESISTANT MEMBRANE COMPLEXES FROM CULTURED KIDNEY EPITHELIAL-CELLS CONTAIN THE SRC FAMILY PROTEIN-TYROSINE KINASE P62(YES)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL-ANCHORED PROTEINS; MDCK CELLS; T-CELLS; EXPRESSION; ACTIVATION; SIGNAL; MOLECULES; RECEPTOR; SURFACE; PRODUCT	We have previously isolated detergent-resistant membrane complexes from lysates of cultured kidney epithelial cells. These structures are enriched in proteins anchored by glycosylphosphatidylinositol, which are localized to the apical plasma membrane of epithelial cells, and have a distinctive lipid composition. We now report that the membranes contain p62(yes), a non-receptor tyrosine kinase of the Src family. p62(yes) is the only major tyrosine-phosphorylated protein in the membrane complexes when they are isolated. Several proteins in the complexes can serve as substrates for phosphorylation by p62(yes) in vitro. The kinase is enriched at least 10-fold in the insoluble membranes compared to cellular membranes. p60(c-src) and p60(v-src), which are highly homologous to p62(yes), are not present in the complexes, even when the membranes are isolated from cells that overexpress the proteins. As p62(yes) is located near the apical plasma membrane of epithelial cells in several tissues in vivo, interaction of the kinase with other components of a detergent-resistant membrane microdomain may play an important role in transmembrane signal transduction.	SUNY STONY BROOK, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NIGMS NIH HHS [GM47897] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047897] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZUMA K, 1991, J BIOL CHEM, V266, P4831; BOHUSLAV J, 1993, EUR J IMMUNOL, V23, P825, DOI 10.1002/eji.1830230409; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CINEK T, 1992, J IMMUNOL, V149, P2262; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; HSI ED, 1989, J BIOL CHEM, V264, P10836; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; WARREN SL, 1987, MOL CELL BIOL, V7, P1326, DOI 10.1128/MCB.7.4.1326; WARREN SL, 1988, MOL CELL BIOL, V8, P632, DOI 10.1128/MCB.8.2.632; ZHAO YH, 1990, ONCOGENE, V5, P1629	25	79	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19123	19127						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7518450				2022-12-25	WOS:A1994NX32700064
J	RAJENDRA, S; LYNCH, JW; PIERCE, KD; FRENCH, CR; BARRY, PH; SCHOFIELD, PR				RAJENDRA, S; LYNCH, JW; PIERCE, KD; FRENCH, CR; BARRY, PH; SCHOFIELD, PR			STARTLE DISEASE MUTATIONS REDUCE THE AGONIST SENSITIVITY OF THE HUMAN INHIBITORY GLYCINE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GATED ION CHANNEL; FUNCTIONAL EXPRESSION; BINDING SUBUNIT; HYPEREKPLEXIA; SITE; GABA; DOMAINS; SHOWS; GENES; CELLS	The receptor for the inhibitory neurotransmitter glycine is a member of the ligand gated ion channel recep tor superfamily. Point mutations in the gene encoding the alpha 1 subunit of the glycine receptor channel complex (GlyR) have recently been identified in pedigrees with the autosomal dominant neurological disorder, startle disease (hyperekplexia). These mutations result in the substitution of leucine or glutamine for arginine 271. This charged residue is located near the ion channel region and is predicted to affect chloride permeation through the GlyR. We found little evidence for this role from the anion/cation selectivity and lack of pronounced rectification of currents flowing through recombinant human alpha 1 subunit GlyRs containing the startle disease mutations. We reveal, however, that the startle disease mutations profoundly disrupt GlyR func tion by causing 230-410-fold decreases in the sensitivity of receptor currents activated by the agonist glycine. Additionally, we report corresponding 56- and 120-fold reductions in the apparent binding affinity (K-i) of glycine to the mutant GlyRs, but no change in the binding affinity of the competitive antagonist, strychnine. Thus, startle disease reduces the efficacy of glycinergic inhibitory neurotransmission by producing GlyRs with diminished agonist responsiveness. Our results show that startle disease mutations define a novel receptor activation site.	ST VINCENTS HOSP,GARVAN INST MED RES,DARLINGHURST,NSW 2010,AUSTRALIA; UNIV NEW S WALES,SCH PHYSIOL & PHARMACOL,SYDNEY,NSW 2052,AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney			French, Chris/AHA-1801-2022; Pierce, Kerrie D/O-7300-2018; Lynch, Joseph/C-8636-2009; Schofield, Peter/C-9669-2011	Pierce, Kerrie D/0000-0003-0636-4836; Schofield, Peter/0000-0003-2967-9662; French, Christopher/0000-0002-1445-8704				AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; ANDERMANN F, 1988, BRAIN DEV, V10, P313; BAKER E, 1994, IN PRESS GENOMICS; BARRY PH, 1994, J NEUROSCI METH, V57, P107; BECKER CM, 1992, NEURON, V8, P283, DOI 10.1016/0896-6273(92)90295-O; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEVILLERSTHIERY A, 1994, J MEMBRANE BIOL, V136, P97; GOODMANGILMAN A, 1980, GOODMAN GILMANS PHAR, P587; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; KIRSTEIN L, 1958, ACTA PSYCH NEUROL, V33, P471, DOI 10.1111/j.1600-0447.1958.tb03533.x; KUHSE J, 1990, NEURON, V5, P867, DOI 10.1016/0896-6273(90)90346-H; KUHSE J, 1990, J BIOL CHEM, V265, P22317; LANGOSCH D, 1993, FEBS LETT, V336, P540, DOI 10.1016/0014-5793(93)80872-R; LANGOSCH D, 1991, BIOCHIM BIOPHYS ACTA, V1063, P36, DOI 10.1016/0005-2736(91)90350-H; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; RYAN SG, 1992, ANN NEUROL, V31, P663, DOI 10.1002/ana.410310615; RYAN SG, 1992, AM J HUM GENET, V51, P1334; RYAN SG, 1994, NAT GENET, V7, P131, DOI 10.1038/ng0694-131; SCHMIEDEN V, 1993, SCIENCE, V262, P256, DOI 10.1126/science.8211147; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SHIANG R, 1993, NAT GENET, V5, P351, DOI 10.1038/ng1293-351; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SONTHEIMER H, 1989, NEURON, V2, P1491, DOI 10.1016/0896-6273(89)90195-5; SUHREN O, 1966, J NEUROL SCI, V3, P577, DOI 10.1016/0022-510X(66)90047-5; VANDENBERG RJ, 1992, P NATL ACAD SCI USA, V89, P1765, DOI 10.1073/pnas.89.5.1765; VANDENBERG RJ, 1992, NEURON, V9, P491, DOI 10.1016/0896-6273(92)90186-H; VANDENBERG RJ, 1993, MOL PHARMACOL, V44, P198; WHITE WF, 1982, NATURE, V298, P655, DOI 10.1038/298655a0	34	105	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18739	18742						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7518444				2022-12-25	WOS:A1994NX32700010
J	CHAPPELL, DA; INOUE, I; FRY, GL; PLADET, MW; BOWEN, SL; IVERIUS, PH; LALOUEL, JM; STRICKLAND, DK				CHAPPELL, DA; INOUE, I; FRY, GL; PLADET, MW; BOWEN, SL; IVERIUS, PH; LALOUEL, JM; STRICKLAND, DK			CELLULAR CATABOLISM OF NORMAL VERY-LOW-DENSITY LIPOPROTEINS VIA THE LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN ALPHA(2)-MACROGLOBULIN RECEPTOR IS INDUCED BY THE C-TERMINAL DOMAIN OF LIPOPROTEIN-LIPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; HEPARAN-SULFATE; LDL-RECEPTOR; IN-VITRO; CHYLOMICRON REMNANTS; PROTEIN BINDS; METABOLISM; HYPERCHOLESTEROLEMIA; INTERNALIZATION; PROTEOGLYCANS	Lipoprotein lipase (LPL) binds to the low density lipoprotein receptor related protein (LRP)/alpha(2)-macroglobulin receptor and induces catabolism of normal human very low density lipoproteins (VLDL) via LRP in vitro. Recent studies showed that the C-terminal domain of LPL can bind LRP in solid phase assays and inhibit cellular catabolism of two LRP ligands, activated alpha(2)-macroglobulin and the 39-kDa receptor-associated protein (Williams, S. E., Inoue, I., Tran, H., Fry, G. L., Pladet, M. W., Iverius, P.-H., Lalouel, J.-M., Chappell, D. A., and Strickland, D. K. (1994) J. Biol. Chem. 269, 8653-8658). The current study investigated the potential for this region of LPL to promote cellular catabolism of VLDL via LRP. A fragment comprising the C-terminal domain of LPL (designated LPLC) was expressed in bacteria and found to promote cellular binding, uptake, and degradation of normal human VLDL in a dose dependent man ner. These effects were present whether LPLC was added simultaneously with I-125-VLDL or was prebound to cell surfaces prior to the assay. Mutations involving Lys(407), Trp(393), Trp(394), or deletion of the C terminal 14 residues reduced the effects of LPLC. Three LRP-binding proteins, the receptor-associated protein, lactoferrin, and a polyclonal antibody against LRP, competed for I-125-VLDL degradation induced by LPLC. Heparin or heparinase treatment of cells prevented LPLC-induced I-125-VLDL catabolism. Thus, cell-surface proteoglycans play an important role in this pathway. Interestingly, either LPLC or LPL when added in excess could block LPL-induced I-125-VLDL degradation presumably by interacting directly with LRP. However, unlabeled VLDL could not prevent catabolism of I-125-labeled LPLC or LPL. These data show that cellular fates for VLDL versus LPLC or LPL are divergent. This is probably due to independent catabolism of the latter via cell-surface proteoglycans. In summary, these in vitro studies indicate that a fragment of LPL corresponding to the C-terminal domain mimics the native enzyme with respect to induction of VLDL catabolism via LRP. Because LPLC lacks the catalytic site of native LPL, these studies establish that lipase activity is not required for LRP mediated lipoprotein catabolism.	AMER RED CROSS,BIOCHEM LAB,ROCKVILLE,MD 20855; VET AFFAIRS MED CTR,SALT LAKE CITY,UT 84148; UNIV UTAH,DEPT MED,SALT LAKE CITY,UT 84148; UNIV UTAH,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84148; UNIV UTAH,DEPT HUMAN GENET,SALT LAKE CITY,UT 84148	American Red Cross; US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	CHAPPELL, DA (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,E318 GH,IOWA CITY,IA 52242, USA.				NHLBI NIH HHS [HL30200, HL49264] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030200, P01HL049264] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; CHAPPELL DA, 1991, J BIOL CHEM, V266, P19296; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHAPPELL DA, 1993, J BIOL CHEM, V268, P25487; CHAPPELL DA, 1992, J BIOL CHEM, V267, P270; CHENG CF, 1981, J BIOL CHEM, V256, P2893; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; DICKSON RB, 1981, J BIOL CHEM, V256, P3454; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; GOTTO AM, 1986, METHOD ENZYMOL, V128, P3; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HOBBS HH, 1987, NEW ENGL J MED, V317, P734, DOI 10.1056/NEJM198709173171204; Iverius P H, 1986, Methods Enzymol, V129, P691; JACKLE S, 1992, J LIPID RES, V33, P419; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; LINDGREN FT, 1972, BLOOD LIPIDS LIPOPRO, P181; MAMO JCL, 1991, BIOCHIM BIOPHYS ACTA, V1081, P241, DOI 10.1016/0005-2760(91)90277-O; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SHIMADA M, 1993, J BIOL CHEM, V268, P17924; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; VOYTA JC, 1985, J BIOL CHEM, V260, P893; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; ZOU S, 1992, COMP BIOCHEM PHYS B, V103, P889, DOI 10.1016/0305-0491(92)90210-I	35	58	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					18001	18006						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	7517936				2022-12-25	WOS:A1994NV42200040
J	COMBETTES, L; HANNAERTMERAH, Z; COQUIL, JF; ROUSSEAU, C; CLARET, M; SWILLENS, S; CHAMPEIL, P				COMBETTES, L; HANNAERTMERAH, Z; COQUIL, JF; ROUSSEAU, C; CLARET, M; SWILLENS, S; CHAMPEIL, P			RAPID FILTRATION STUDIES OF THE EFFECT OF CYTOSOLIC CA2+ ON INOSITOL 1,4,5-TRISPHOSPHATE-INDUCED CA-45(2+) RELEASE FROM CEREBELLAR MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM VESICLES; LIMULUS VENTRAL PHOTORECEPTORS; CARDIAC SARCOLEMMAL VESICLES; FROG SKELETAL-MUSCLE; ONE-POOL MODEL; CALCIUM-RELEASE; ADENINE-NUCLEOTIDES; CA-2+ RELEASE; TRISPHOSPHATE RECEPTOR; SMOOTH-MUSCLE	Using microsomal membrane vesicles derived from sheep cerebellum, we measured the rate of inositol 1,4,5-trisphosphate (InsP(3))-dependent Ca-45(2+) afflux from Ca-45(2+)-loaded compartments during rapid perfusion with a medium containing InsP(3) and various concentrations of free Ca-40(2+) on the cytosolic side (pH 7.1, 5 mM Mg2+, in the absence of ATP at 20 degrees C). At 0.15 mu M InsP(3) and pCa 6.5, half-Ca-45(2+) release was attained within less than 200 ms. At low Ca2+ concentrations, the initial rate of Ca-45(2+) release depended smoothly on InsP(3) concentration, and InsP(3) activated release with moderate positive cooperativity. Preliminary experiments performed at various free Ca-40(2+) concentrations were consistent with a bell-shaped Ca-40(2+) dependence of Ca-45(2+) release. In the range of micromolar or higher free Ca-40(2+) concentrations, the apparent inhibition of Ca-45(2+) release was dependent on InsP(3) concentration, and Ca-45(2+) release for intermediate InsP(3) concentrations was transient; under selected conditions, a second perfusion period, identical to the first one but separated from it by a short recovery period, was found to allow renewed Ca-45(2+) efflux. At high Ca2+ concentration, fast reversible Ca2+-dependent desensitization of the channel, and not heterogeneity, was therefore responsible for the termination of InsP(3)-triggered Ca-45(2+) afflux at submaximal concentrations of InsP(3). At lower Ca2+ concentrations, a large fraction of the apparent activating effect of submicromolar Ca-40(2+) concentrations on Ca-45(2+) efflux that we had observed in the preliminary experiments proved to be the artifactual consequence of an inhibitory effect exerted by metal-free Ca2+ chelators on InsP(3)-dependent afflux at nanomolar Ca-40(2+) concentrations. 1,2-Bis(2-aminophenoxy)ethane-N,N,N'-N'-tetraacetic acid, EGTA, and fluo-3 were all effective inhibitors. When this inhibition was taken into account, a rise in free Ca-40(2+) concentration from 30 to 300 nM only weakly enhanced Ca-45(2+) fluxes in the presence of a low concentration of InsP(3+). As a result, submicromolar free Ca-40(2+) appears to be only a poor activator of InsP(3)-induced Ca2+ release under these experimental conditions.	CENS, CEA, CNRS, URA 1290, F-91191 GIF SUR YVETTE, FRANCE; CENS, CEA, DEPT BIOL CELLULAIRE & MOLEC, BIOPHYS PROT & MEMBRANES SECT, F-91191 GIF SUR YVETTE, FRANCE; ECOLE CENT PARIS, BIOL LAB, F-92295 CHATENAY MALABRY, FRANCE; FREE UNIV BRUSSELS, FAC MED, INST RECH INTERDISCIPLINAIRE, B-1070 BRUSSELS, BELGIUM	CEA; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Universite Libre de Bruxelles; Vrije Universiteit Brussel	COMBETTES, L (corresponding author), UNIV PARIS 11, INSERM, U274, UNITE RECH, F-91405 ORSAY, FRANCE.		Combettes, Laurent/L-1842-2013	Combettes, Laurent/0000-0002-1376-4574				ATRI A, 1993, BIOPHYS J, V65, P1727, DOI 10.1016/S0006-3495(93)81191-3; BEELER T, 1983, J MEMBRANE BIOL, V76, P165, DOI 10.1007/BF02000616; BERMAN MC, 1982, J BIOL CHEM, V257, P1953; BERMAN MC, 1990, BIOCHIM BIOPHYS ACTA, V1029, P235, DOI 10.1016/0005-2736(90)90159-L; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRCHMACHIN MA, 1986, BIOCHIM BIOPHYS ACTA, V855, P277, DOI 10.1016/0005-2736(86)90175-6; BROWN GR, 1992, BIOCHEM J, V282, P309, DOI 10.1042/bj2820309; BULL R, 1993, FEBS LETT, V331, P223, DOI 10.1016/0014-5793(93)80341-Q; CALLAMARAS N, 1994, CELL CALCIUM, V15, P66, DOI 10.1016/0143-4160(94)90105-8; CALVIELLO G, 1989, BIOCHEMISTRY-US, V28, P1301, DOI 10.1021/bi00429a053; CHAD JE, 1984, BIOPHYS J, V45, P993, DOI 10.1016/S0006-3495(84)84244-7; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; COMBETTES L, 1993, CELL CALCIUM, V14, P279, DOI 10.1016/0143-4160(93)90049-C; COMBETTES L, 1992, FEBS LETT, V301, P287, DOI 10.1016/0014-5793(92)80258-I; DEYOUNG GW, 1992, P NATL ACAD SCI USA, V89, P9895, DOI 10.1073/pnas.89.20.9895; DONOSO P, 1993, J BIOL CHEM, V268, P25432; DUPONT G, 1993, CELL CALCIUM, V14, P311, DOI 10.1016/0143-4160(93)90052-8; DUPONT Y, 1984, ANAL BIOCHEM, V142, P504, DOI 10.1016/0003-2697(84)90496-2; DUPONT Y, 1987, METHOD ENZYMOL, V148, P675; EBERHARD M, 1991, EUR J BIOCHEM, V202, P1333, DOI 10.1111/j.1432-1033.1991.tb16508.x; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GIRARD S, 1992, BIOPHYS J, V61, P509, DOI 10.1016/S0006-3495(92)81855-6; GUIMARAESMOTTA H, 1984, J BIOL CHEM, V259, P8699; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; HAIN J, 1994, BIOPHYS J, V66, pA225; HILLY M, 1993, J BIOL CHEM, V268, P16488; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; JOSEPH SK, 1989, MOL PHARMACOL, V36, P391; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; KATZ AM, 1980, BIOCHIM BIOPHYS ACTA, V596, P94, DOI 10.1016/0005-2736(80)90173-X; KHODAKHAH K, 1993, P NATL ACAD SCI USA, V90, P4976, DOI 10.1073/pnas.90.11.4976; KINDMAN LA, 1993, BIOCHEMISTRY-US, V32, P1270, DOI 10.1021/bi00056a011; LEVY S, 1993, J GEN PHYSIOL, V101, P67, DOI 10.1085/jgp.101.1.67; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MAGNUSSON A, 1993, FEBS LETT, V323, P229, DOI 10.1016/0014-5793(93)81345-Z; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; Martell A.E., 1974, CRITICAL STABILITY C, V1, P204; MATHEW J, 1991, NEUROTOXICOLOGY, V12, P245; MAYRLEITNER M, 1994, BIOPHYS J, V66, pA147; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; MINTA A, 1989, J BIOL CHEM, V264, P8171; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; MOUTIN MJ, 1988, J BIOL CHEM, V263, P4228; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; OGDEN D, 1994, BIOPHYS J, V66, pA49; OGDEN DC, 1990, J PHYSIOL-LONDON, V422, P585, DOI 10.1113/jphysiol.1990.sp018002; OGDEN DC, 1993, J EXP BIOL, V184, P105; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1993, J PHYSIOL-LONDON, V461, P133, DOI 10.1113/jphysiol.1993.sp019506; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PAYNE R, 1990, NEURON, V4, P547, DOI 10.1016/0896-6273(90)90112-S; PIERCE GN, 1987, MOL CELL BIOCHEM, V78, P89; PIETRI F, 1990, J BIOL CHEM, V265, P17478; RICHARDSON A, 1993, J BIOL CHEM, V268, P11528; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; SEGEL GB, 1981, J BIOL CHEM, V256, P6629; SMITH JA, 1993, FEBS LETT, V327, P137, DOI 10.1016/0014-5793(93)80157-P; SOMLYO AV, 1992, J BIOL CHEM, V267, P22316; SOMOGYI R, 1991, J BIOL CHEM, V266, P11068; SORENSON MM, 1977, BIOCHIM BIOPHYS ACTA, V465, P210, DOI 10.1016/0005-2736(77)90075-X; SPAT A, 1992, BIOCHEM J, V287, P335; STAUDERMAN KA, 1988, BIOCHEM J, V255, P677; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; Taylor Colin W., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P109; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; TAYLOR CW, 1992, TRENDS BIOCHEM SCI, V17, P403, DOI 10.1016/0968-0004(92)90009-X; TROSPER TL, 1984, CELL CALCIUM, V5, P211, DOI 10.1016/0143-4160(84)90037-X; TSHIPAMBA M, 1993, J CELL PHYSIOL, V155, P96, DOI 10.1002/jcp.1041550113; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; VOLPE P, 1990, AM J PHYSIOL, V258, pC1077, DOI 10.1152/ajpcell.1990.258.6.C1077; WAKUI M, 1990, FEBS LETT, V263, P206, DOI 10.1016/0014-5793(90)81374-W; WATRAS J, 1991, J NEUROSCI, V11, P3239; WILLIAMSON JR, 1985, INOSITOL PHOSPHOINOS, P423; WOLFF HU, 1983, EXPERIENTIA, V29, P241; WORLEY PF, 1987, NATURE, V325, P159, DOI 10.1038/325159a0; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; YAO Y, 1992, J PHYSIOL-LONDON, V458, P319, DOI 10.1113/jphysiol.1992.sp019420; YOO SH, 1994, BIOPHYS J, V66, pA384; ZHANG BX, 1993, J BIOL CHEM, V268, P10997; ZHAO H, 1990, J BIOL CHEM, V265, P21419	97	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17561	17571						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	7517399				2022-12-25	WOS:A1994NU12800037
J	SPANDAU, DF				SPANDAU, DF			DISTINCT CONFORMATIONS OF P53 ARE OBSERVED AT DIFFERENT STAGES OF KERATINOCYTE DIFFERENTIATION	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; SV40-TRANSFORMED CELLS; CELLULAR PROTEIN; GROWTH ARREST; E6 PROTEINS; ANTIGEN; MUTATIONS; BINDING	p53 is a multifunctional protein that has been shown to inhibit the growth of transformed cells, arrest the cell cycle of normal cells, regulate gene transcription and influence cellular differentiation, apoptosis and senescence. This study was undertaken to determine if the expression of p53 in keratinocytes varied during epidermal differentiation. Fresh frozen-sections of normal human epidermis were subjected to immunofluorescence using a panel of anti-p53 monoclonal antibodies. The monoclonal antibody 122 specifically stained the basal layer of the epidermis. No staining was observed in other cell layers of the epidermis using the 122 antibody. When the 240 antibody was used, p53 was only detected in granular layer cells. No other anti-p53 monoclonal antibody stained normal epidermis. Immunofluorescent analyses of cultured keratinocytes revealed staining patterns that correlated with the staining pattern seen in vivo. Immunoprecipitation assays of the cultured keratinocytes indicated that each monoclonal antibody, with the exception of DO-1, could only detect a fraction of the total p53 present in the cultures. This diversity of reactivity was presumed to be due to the masking and exposing of the various epitopes on p53 through the binding of other proteins. Finally, in cultured human keratinocytes, p53 was found to be a relatively stable protein with a half-life of 5 h.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis	SPANDAU, DF (corresponding author), INDIANA UNIV,SCH MED,DEPT DERMATOL,MED LIB BLDG,RM 349,975 W WALNUT ST,INDIANAPOLIS,IN 46202, USA.							AGOFF SN, 1993, SCIENCE, V259, P854; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FRITSCHE M, 1993, ONCOGENE, V8, P307; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HELANDER SD, 1993, J AM ACAD DERMATOL, V29, P741, DOI 10.1016/0190-9622(93)70240-T; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KASTAN MB, 1991, CANCER RES, V51, P4279; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LASSAM NJ, 1993, CANCER RES, V53, P2235; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MOLES JP, 1993, ONCOGENE, V8, P583; MONTENARH M, 1992, ONCOGENE, V7, P1673; RADY P, 1992, CANCER RES, V52, P3804; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SUZUKI K, 1992, BIOCHEM BIOPH RES CO, V183, P1175, DOI 10.1016/S0006-291X(05)80314-6; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	39	62	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1861	1868						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	7516060				2022-12-25	WOS:A1994NR68500008
J	TCHOU, J; BODEPUDI, V; SHIBUTANI, S; ANTOSHECHKIN, I; MILLER, J; GROLLMAN, AP; JOHNSON, F				TCHOU, J; BODEPUDI, V; SHIBUTANI, S; ANTOSHECHKIN, I; MILLER, J; GROLLMAN, AP; JOHNSON, F			SUBSTRATE-SPECIFICITY OF FPG PROTEIN - RECOGNITION AND CLEAVAGE OF OXIDATIVELY DAMAGED DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; ESCHERICHIA-COLI; IONIZING-RADIATION; ENDONUCLEASE-V; ABASIC SITES; AQUEOUS-SOLUTION; IMIDAZOLE RINGS; GLYCOSYLASE; REPAIR; 8-HYDROXYGUANINE	The 8-oxoguanine-DNA glycosylase of Escherichia coli, also known as formamidopyrimidine-DNA glycosylase (Fpg protein), has N-glycosylase and AP-lyase activities. This enzyme repairs oxidative DNA damage by efficiently removing formamidopyrimidine lesions and 8-oxoguanine residues from DNA. Defined oligodeoxynucleotides containing various 8-oxopurines were used to examine the substrate specificity of Fpg protein and to establish the role of functional groups in DNA on damage recognition and catalysis. Binding affinities of Fpg protein were established for duplex oligodeoxynucleotides containing 8-oxo-2'-deoxyguanine, 8-oxo-2'-deoxyadenine, 8-oxo-2'-deoxynebularine, 8-oxo-2'-deoxyinosine, abasic sites, and a ring-opened adduct of C8-aminofluorene guanine. The C8 keto group of 8-oxodG:dC presents in the major groove and is correlated with tight binding (K-d = 8.9 nM). Binding is much weaker when the C8 keto functional group is in the minor groove, as in 8-oxodG:dA (K-d = 340 nM). K-m and V-max were determined for the cleavage reaction. Specificity constants (K-cat/K-m) are consistently higher for oligodeoxynucleotide duplexes containing 8-oxopurines with C6 and C8 keto groups, as in 8-oxodG:dC and 8-oxodI:dC, where K-cat/K-m are 9.3 and 18 min(-1) nM x 10(-3), respectively. 8-oxodN:dC lacks the C6 keto group; the specificity constant is 0.024 min(-1) nM x 10(-3). Taken together, our data suggest that the C8 keto group of 8-oxodeoxyguanine and the carbonyl moiety of formamidopyrimidine enable Fpg protein to recognize and bind duplex DNA containing these modified bases. An enzyme-catalyzed reaction involving the C6 keto group of the substrate leads to removal of these lesions. A mechanism involving protonation at O-6 of 8-oxoguanine is proposed to account for the N-glycosylase activity of this enzyme.	SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of California System; University of California Los Angeles				Shibutani, Shinya/0000-0003-4190-9512	NATIONAL CANCER INSTITUTE [R01CA017395, R37CA017395] Funding Source: NIH RePORTER; NCI NIH HHS [CA17395] Funding Source: Medline; NIGMS NIH HHS [GM07518] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1989, MUTAT RES, V214, P41, DOI 10.1016/0027-5107(89)90196-6; BODEPUDI V, 1992, CHEM RES TOXICOL, V5, P608, DOI 10.1021/tx00029a004; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; BOITEUX S, 1984, NUCLEIC ACIDS RES, V12, P5429, DOI 10.1093/nar/12.13.5429; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; BOITEUX S, 1990, DNA REPAIR MECHANISM, P37; BOITEUX S, 1989, CARCINOGENESIS, V10, P1095; BREIMER LH, 1984, NUCLEIC ACIDS RES, V12, P6359, DOI 10.1093/nar/12.16.6359; CASTAING B, 1992, NUCLEIC ACIDS RES, V20, P389, DOI 10.1093/nar/20.3.389; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHETSANGA CJ, 1983, CARCINOGENESIS, V4, P997, DOI 10.1093/carcin/4.8.997; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; CHETSANGA CJ, 1981, BIOCHEMISTRY-US, V20, P5201, DOI 10.1021/bi00521a016; CHO BP, 1990, CHEM RES TOXICOL, V3, P445, DOI 10.1021/tx00017a010; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; GROLLMAN AP, 1992, 7TH P CONV BIOM STER, P165; GUSCHLBAUER W, 1991, NUCLEIC ACIDS RES, V19, P1753, DOI 10.1093/nar/19.8.1753; JETTER MC, 1993, BIOCHEMISTRY-US, V32, P3249, DOI 10.1021/bi00064a006; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P3262, DOI 10.1021/bi00227a014; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; KRIEK E, 1980, CARCINOGENESIS, V1, P459, DOI 10.1093/carcin/1.6.459; KRIEK E, 1969, Chemico-Biological Interactions, V1, P3, DOI 10.1016/0009-2797(69)90015-5; LAVAL J, 1990, MUTAT RES, V233, P73, DOI 10.1016/0027-5107(90)90152-T; LEATHERBARROW RJ, 1987, ENZFITTER VERSION 1; MANOHARAN M, 1988, J AM CHEM SOC, V110, P2690, DOI 10.1021/ja00216a074; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; ODA Y, 1991, NUCLEIC ACIDS RES, V19, P1407, DOI 10.1093/nar/19.7.1407; OLEYKOWSKI CA, 1993, J BIOL CHEM, V268, P7990; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PLUM GE, 1994, IN PRESS BIOCHEMISTR; SCHROCK RD, 1991, J BIOL CHEM, V266, P17631; SCHROCK RD, 1993, J BIOL CHEM, V268, P880; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIBUTANI S, 1990, J AM CHEM SOC, V112, P5667, DOI 10.1021/ja00170a056; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P4615, DOI 10.1021/bi00068a019; STEENKEN S, 1989, CHEM REV, V89, P503, DOI 10.1021/cr00093a003; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TCHOU J, 1993, J BIOL CHEM, V268, P26738; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011	51	302	305	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15318	15324						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7515054				2022-12-25	WOS:A1994NP73800069
J	AKIMOTO, K; MIZUNO, K; OSADA, S; HIRAI, S; TANUMA, S; SUZUKI, K; OHNO, S				AKIMOTO, K; MIZUNO, K; OSADA, S; HIRAI, S; TANUMA, S; SUZUKI, K; OHNO, S			A NEW MEMBER OF THE 3RD CLASS IN THE PROTEIN-KINASE-C FAMILY, PKC-LAMBDA, EXPRESSED DOMINANTLY IN AN UNDIFFERENTIATED MOUSE EMBRYONAL CARCINOMA CELL-LINE AND ALSO IN MANY TISSUES AND CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Protein kinase C (PHC)-related cDNA clones isolated from cDNA libraries of mouse P19 embryonal carcinoma cells and mouse brain encoded a 67-kDa protein, PKC lambda. PKC lambda shows the highest amino acid sequence identity with PKC zeta (72%), the third class of the PKC family. Northern blot analysis showed that the mRNA for PKC lambda is expressed in a wide variety of cells and tissues, including P19 and MH 3T3 cells, as well as brain, kidney, testis, and ovary. In undifferentiated P19 cells, the mRNA for PKC lambda is the most abundant among all the PKC family members. The differentiation of P19 cells results in an increase in PKC alpha and epsilon, and a decrease in PKC lambda. Antiserum raised against a peptide of PKC lambda identified a 74-kDa protein in P19 cell extracts as well as in extracts from COS cells transfected with the PKC lambda expression plasmid. Autophosphorylation of the PKC lambda that immunoprecipitated with the specific antiserum was observed, indicating that PKC lambda possesses protein kinase activity. A phorbol ester binding assay using intact COS cells expressing PKC lambda failed to detect binding activity specific to PKC lambda at phorbol dibutylate concentrations up to 300 nM, suggesting that PKC lambda does not possess phorbol ester binding activity. These results, in conjunction with the results obtained in parallel experiments with PKC zeta and other PKC members, suggest a biochemical similarity between PKC lambda and zeta and their clear difference from other PKC members.	YOKOHAMA CITY UNIV, SCH MED, DEPT MOLEC BIOL, KANAZAWA KU, YOKOHAMA 236, JAPAN; UNIV TOKYO, INST MOLEC & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN; SCI UNIV TOKYO, INST PHARMACOL SCI, DEPT BIOCHEM, SHINJUKU KU, TOKYO 162, JAPAN	Yokohama City University; University of Tokyo; Tokyo University of Science			Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269; Osada, Shin-Ichi/0000-0001-5387-085X				BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BENNER SA, 1991, ADV ENZYME REGUL, V31, P121, DOI 10.1016/0065-2571(91)90012-B; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; HATA A, 1993, J BIOL CHEM, V268, P9122; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; Maniatis T, 1989, MOL CLONING; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OHNO S, 1988, BIOCHEMISTRY-US, V27, P2083, DOI 10.1021/bi00406a040; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; OSADA S, 1990, J BIOL CHEM, V265, P22434; ROBERTSON EJ, 1987, TERATOCARCINOMAS EMB, P33; SCHEIBE RJ, 1991, J BIOL CHEM, V266, P21300; SNOEK GT, 1986, DEV BIOL, V115, P282, DOI 10.1016/0012-1606(86)90249-6; WAYS DK, 1992, J BIOL CHEM, V267, P4799	29	226	230	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12677	12683						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7513693				2022-12-25	WOS:A1994NH71600049
J	LIU, JW; SESSA, WC				LIU, JW; SESSA, WC			IDENTIFICATION OF COVALENTLY BOUND AMINO-TERMINAL MYRISTIC ACID IN ENDOTHELIAL NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOLECULAR-CLONING; PROTEINS; MYRISTOYLATION; EXPRESSION; ACYLATION; ENZYME; P60SRC; CELLS	Endothelial nitric oxide synthase (eNOS) is unique among the nitric oxide synthase family of proteins due to the presence of an N-myristoylation consensus se sequence elucidated from the cloning of its cDNA. Although eNOS was metabolically labeled with [H-3]myristic acid and mutation of glycine 2 in the N-myristoylation consensus sequence changed the particulate localization of the enzyme to a cytosolic form, the definitive characterization of eNOS as an N-myristoylprotein has not been demonstrated. Therefore, the purpose of the present study was to determine the nature of the fatty acid incorporated into eNOS. Wild-type or G2A mutant (mutation of glycine 2, the myristic acid acceptor site, to alanine) eNOS-transfected COS cells and bovine aortic endothelial cells (BAEC) were metabolically labeled with [H-3]myristic acid for 5 h. The radiolabel was primarily incorporated into membrane-associated eNOS from wild-type transfected COS cells and cultured BAEC but not into the mutant eNOS from G2A-transfected COS cells. Qualitatively similar amounts of immunoreactive protein were found in wild-type and G2A-transfected cells. In addition, linkage of the radiolabel to eNOS was insensitive to hydroxylamine treatment, and incorporation of the radiolabel into eNOS was abolished by cycloheximide. Chemical analysis of the fatty acid released by acid methanolysis of labeled eNOS verified the H-3-labeled fatty acid as protein-bound myristic acid. These results unequivocally demonstrate that eNOS incorporates myristic acid via an amide linkage with the aminoterminal glycine of the enzyme as a co-translational modification.	YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT PHARMACOL,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,MOLEC CARDIOBIOL PROGRAM,NEW HAVEN,CT 06536	Yale University; Yale University			Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938				AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; BUSS JE, 1988, MOL CELL BIOL, V8, P3960, DOI 10.1128/MCB.8.9.3960; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GORDON JI, 1991, J BIOL CHEM, V266, P8647; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MUSZBEK L, 1993, J BIOL CHEM, V268, P8251; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; OLSON EN, 1985, J BIOL CHEM, V260, P3784; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; POLLOCK JS, 1993, AM J PHYSIOL, V265, pC1379, DOI 10.1152/ajpcell.1993.265.5.C1379; RANDERATH K, 1963, LAYER CHROMATOGRAPHY, P133; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; SESSA WC, 1993, HYPERTENSION, V21, P934, DOI 10.1161/01.HYP.21.6.934; SESSA WC, 1993, CIRC RES, V72, P921, DOI 10.1161/01.RES.72.4.921; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SIMON SM, 1992, J BIOL CHEM, V267, P3922; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978; WOOD ER, 1993, BIOCHEM BIOPH RES CO, V191, P767, DOI 10.1006/bbrc.1993.1283; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	34	84	86	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11691	11694						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7512951				2022-12-25	WOS:A1994NG37700005
J	NILSSON, L; EMILSSON, V				NILSSON, L; EMILSSON, V			FACTOR FOR INVERSION STIMULATION-DEPENDENT GROWTH-RATE REGULATION OF INDIVIDUAL TRANSFER-RNA SPECIES IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA; FIS PROTEIN; RECOMBINATIONAL ENHANCER; CODON USAGE; UPSTREAM ACTIVATION; FEEDBACK-REGULATION; GENE EXPRESSIVITY; RESPECTIVE CODONS; STRINGENT CONTROL; PROMOTER	We have studied the involvement of the factor for inversion stimulation (FIS) in the growth rate-dependent expression of the arginine, leucine, and methionine acceptor tRNA species. The concentration of individual tRNA species relative to 16 S rRNA was determined by blot hybridization using RNA preparations from bacteria with the fis gene deleted and from isogenic wild type bacteria. The RNA preparations were obtained from bacteria growing under steady state conditions in different media. The levels of tRNA1Leu, tRNA2Arg, tRNA4Arg, and tRNA5Arg decreased in the fis bacteria, relative to the wild type. The difference in levels increased with increasing growth rate. Surprisingly, tRNA3Leu, tRNA(f)Met, and tRNA(e)Met showed the opposite response, with an increase of the tRNA/16 S ratio in the fis bacteria. The tRNA2Leu, tRNA4Leu, tRNA5Leu, and tRNA3Arg had unaffected tRNA/16 S ratios in fis cells. We conclude that FIS, directly or indirectly, is involved in growth rate regulation of some tRNA species and that it affects the composition of the cellular tRNA pool.			NILSSON, L (corresponding author), UPPSALA UNIV, CTR BIOMED, DEPT MOLEC BIOL, S-75124 UPPSALA, SWEDEN.			Emilsson, Valur/0000-0001-9982-0524				BALL CA, 1992, J BACTERIOL, V174, P8043, DOI 10.1128/JB.174.24.8043-8056.1992; BAUER BF, 1988, GENE, V63, P123, DOI 10.1016/0378-1119(88)90551-3; BAUMANN S, 1991, HOPPESEYLERS Z PHYSL, V372, P631; BOSCH L, 1990, BIOCHIM BIOPHYS ACTA, V1050, P293, DOI 10.1016/0167-4781(90)90184-4; BREMER H, 1948, ESCHERICHIA COLI SAL, V2, P1527; CHAVANCY G, 1981, BIOCHIMIE, V63, P187, DOI 10.1016/S0300-9084(81)80192-7; COLE JR, 1987, J MOL BIOL, V198, P383, DOI 10.1016/0022-2836(87)90288-9; CONDON C, 1992, EMBO J, V11, P4175, DOI 10.1002/j.1460-2075.1992.tb05511.x; DUESTER G, 1982, CELL, V30, P855, DOI 10.1016/0092-8674(82)90290-2; EHRENBERG M, 1984, Q REV BIOPHYS, V17, P45, DOI 10.1017/S0033583500005254; EMILSSON V, 1990, EMBO J, V9, P4359, DOI 10.1002/j.1460-2075.1990.tb07885.x; EMILSSON V, 1993, J MOL BIOL, V230, P483, DOI 10.1006/jmbi.1993.1165; FILUTOWICZ M, 1992, J BACTERIOL, V174, P398, DOI 10.1128/jb.174.2.398-407.1992; FINKEL SE, 1992, MOL MICROBIOL, V6, P3257, DOI 10.1111/j.1365-2958.1992.tb02193.x; FOURNIER MJ, 1985, MICROBIOL REV, V49, P379, DOI 10.1128/MMBR.49.4.379-397.1985; GAAL T, 1990, P NATL ACAD SCI USA, V87, P5533, DOI 10.1073/pnas.87.14.5533; GILLE H, 1991, NUCLEIC ACIDS RES, V19, P4167, DOI 10.1093/nar/19.15.4167; GOURSE RL, 1984, J BACTERIOL, V160, P1022, DOI 10.1128/JB.160.3.1022-1026.1984; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; GOUY M, 1982, NUCLEIC ACIDS RES, V10, P7055, DOI 10.1093/nar/10.22.7055; GRANTHAM R, 1981, NUCLEIC ACIDS RES, V9, pR43; GRANTHAM R, 1980, NUCLEIC ACIDS RES, V8, pR49, DOI 10.1093/nar/8.1.197-c; GRANTHAM R, 1980, NUCLEIC ACIDS RES, V10, P7055; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; GUYER MS, 1980, COLD SPRING HARB SYM, V45, P135, DOI 10.1101/SQB.1981.045.01.022; HENANDEZ VJ, 1990, J BIOL CHEM, V265, P11605; HSU LM, 1991, BIOCHEMISTRY-US, V30, P813, DOI 10.1021/bi00217a035; HSU LM, 1984, J MOL BIOL, V178, P509, DOI 10.1016/0022-2836(84)90236-5; HUBER HE, 1985, P NATL ACAD SCI USA, V82, P3776, DOI 10.1073/pnas.82.11.3776; HUBNER P, 1989, EMBO J, V8, P577, DOI 10.1002/j.1460-2075.1989.tb03412.x; IKEMURA T, 1982, COLD SPRING HARB SYM, V47, P1087, DOI 10.1101/SQB.1983.047.01.123; IKEMURA T, 1981, J MOL BIOL, V146, P1, DOI 10.1016/0022-2836(81)90363-6; IKEMURA T, 1981, J MOL BIOL, V151, P389, DOI 10.1016/0022-2836(81)90003-6; IKEMURA T, 1985, MOL BIOL EVOL, V2, P13; JENSEN KF, 1990, MICROBIOL REV, V54, P89, DOI 10.1128/MMBR.54.2.89-100.1990; JINKSROBERTSON S, 1983, CELL, V33, P865, DOI 10.1016/0092-8674(83)90029-6; JOHNSON RC, 1988, P NATL ACAD SCI USA, V85, P3484, DOI 10.1073/pnas.85.10.3484; JOHNSON RC, 1985, CELL, V41, P781, DOI 10.1016/S0092-8674(85)80059-3; KAHMANN R, 1985, CELL, V41, P771, DOI 10.1016/S0092-8674(85)80058-1; KOMINE Y, 1990, J MOL BIOL, V96, P69; KURLAND CG, 1993, BIOCHEM SOC T, V21, P841, DOI 10.1042/bst0210841; LAZARUS LR, 1993, EMBO J, V12, P2483, DOI 10.1002/j.1460-2075.1993.tb05903.x; LINDAHL L, 1982, ADV GENET, V21, P53, DOI 10.1016/S0065-2660(08)60297-7; Maniatis T., 1982, MOL CLONING; NAGASE T, 1988, GENE, V67, P49; NAKAJIMA N, 1981, CELL, V23, P239, DOI 10.1016/0092-8674(81)90288-9; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NILSSON L, 1990, EMBO J, V9, P727, DOI 10.1002/j.1460-2075.1990.tb08166.x; NILSSON L, 1992, J BACTERIOL, V174, P921, DOI 10.1128/jb.174.3.921-929.1992; NINNEMANN O, 1992, EMBO J, V11, P1075, DOI 10.1002/j.1460-2075.1992.tb05146.x; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; ROSS W, 1990, EMBO J, V9, P3733, DOI 10.1002/j.1460-2075.1990.tb07586.x; ROWLEY KB, 1993, J BACTERIOL, V175, P1309, DOI 10.1128/JB.175.5.1309-1315.1993; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; SARUBBI E, 1988, MOL GEN GENET, V213, P214, DOI 10.1007/BF00339584; SAXENA P, 1992, J BACTERIOL, V174, P1956, DOI 10.1128/jb.174.6.1956-1964.1992; SLANY RK, 1992, NUCLEIC ACIDS RES, V20, P4193, DOI 10.1093/nar/20.16.4193; TRAVERS AA, 1980, J BACTERIOL, V141, P973, DOI 10.1128/JB.141.2.973-976.1980; VERBEEK H, 1990, BIOCHIM BIOPHYS ACTA, V1050, P302, DOI 10.1016/0167-4781(90)90185-5	59	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9460	9465						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511587				2022-12-25	WOS:A1994NE05300013
J	ISHIZAKI, J; HANASAKI, K; HIGASHINO, K; KISHINO, J; KIKUCHI, N; OHARA, O; ARITA, H				ISHIZAKI, J; HANASAKI, K; HIGASHINO, K; KISHINO, J; KIKUCHI, N; OHARA, O; ARITA, H			MOLECULAR-CLONING OF PANCREATIC GROUP-I PHOSPHOLIPASE A(2) RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; MACROPHAGE MANNOSE RECEPTOR; BINDING-PROTEIN; RAT; DNA; RNA; POLYMERASE; EFFICIENT; SITES; LUNG	We have recently reported that mammalian pancreatic group I phospholipase A(2) (PLA(2)-I) has its specific receptor (PLA(2) receptor) on a variety of mammalian cells and that various biological responses are elicited by PLA(2)-I via this receptor. In this study, we cloned cDNAs encoding a protein corresponding to the bovine PLA(2) receptor purified from the corpora lutea on the basis of its partial amino acid sequences. The identity of a protein encoded by the cloned cDNA with the bovine PLA(2) receptor was verified by a transient expression experiment using COS-7 cells. Interestingly, the deduced primary structure of the PLA(2) receptor (1,463 amino acid residues) exhibits a close relatedness throughout the molecule to that of the macrophage mannose receptor, a unique member of Ca2+-dependent (C-type) animal lectin family, in spite of their functional diversity. Based on this sequence similarity between these two receptors, the domain organization of the PLA(2) receptor could be tentatively assigned as follows; 10 extracellular domains including 8 tandem repeats homologous to C-type carbohydrate-recognition domains (CRDs) and a single transmembrane region followed by a short cytoplasmic tail. The results of transient expression experiments for mutant PLA(2) receptors supported this assign ment and furthermore suggested the region responsible for PLA(2)-I binding corresponds to CRDs in the mannose receptor.	SHIONOGI & CO LTD,SHIONOGI RES LABS,FUKUSHIMA KU,OSAKA,JAPAN	Shionogi & Company Limited			Ohara, Osamu/G-5448-2015; Ohara, Osamu/A-9119-2012	Ohara, Osamu/0000-0002-3328-9571; 				BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; HANASAKI K, 1992, BIOCHIM BIOPHYS ACTA, V1127, P233, DOI 10.1016/0005-2760(92)90226-L; HARRIS N, 1992, BLOOD, V80, P2363; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; ISHIZAKI J, 1993, FEBS LETT, V324, P349, DOI 10.1016/0014-5793(93)80149-O; KANEMASA T, 1992, FEBS LETT, V303, P217, DOI 10.1016/0014-5793(92)80523-J; KANEMASA T, 1992, BIOCHIM BIOPHYS ACTA, V1125, P210, DOI 10.1016/0005-2760(92)90047-Y; KISHINO J, 1992, BIOCHEM BIOPH RES CO, V186, P1025, DOI 10.1016/0006-291X(92)90849-G; KORTESUO PT, 1993, INT J PANCREATOL, V13, P111; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LATHE R, 1984, DNA-J MOLEC CELL BIO, V3, P173, DOI 10.1089/dna.1984.3.173; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKATA T, 1989, BIOCHIM BIOPHYS ACTA, V1007, P124, DOI 10.1016/0167-4781(89)90141-3; Sambrook J, 1989, MOL CLONING LABORATO; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; STAHL PD, 1992, CURR OPIN IMMUNOL, V4, P49, DOI 10.1016/0952-7915(92)90123-V; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, BIOCHEM SOC T, V21, P468, DOI 10.1042/bst0210468; TOHKIN M, 1993, J BIOL CHEM, V268, P2865; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	34	180	187	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5897	5904						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509792				2022-12-25	WOS:A1994MY84000065
J	TAKAHASHI, N; BREITMAN, TR				TAKAHASHI, N; BREITMAN, TR			RETINOYLATION OF VIMENTIN IN THE HUMAN MYELOID-LEUKEMIA CELL-LINE HL-60	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTOR; INTERMEDIATE FILAMENT PROTEINS; MAMMARY EPITHELIAL-CELLS; AVIAN MYOGENIC CELLS; GRANULOCYTIC DIFFERENTIATION; EPIDERMAL-KERATINOCYTES; NUCLEAR-ENVELOPE; GENE-EXPRESSION; HL-60 CELLS	Retinoylation (retinoic acid acylation) is a posttranslational modification of proteins occurring in many eukaryotic cell lines. The widespread occurrence of retinoylation suggests that it may play a role in many effects of retinoic acid (RA) on cells. The regulatory subunits of cyclic AMP dependent protein kinase are retinoylated in the human myeloid leukemia cell line HL60 (Takahashi, N., Liapi, C., Anderson, W. B., and Breitman, T R. (1991) Arch. Biochem. Biophys. 290, 293-302), and cytokeratins are retinoylated in normal human keratinocytes (Takahashi, N., Jetten, A. M., and Breitman, T R. (1991) Biochem. Biophys. Res. Commun. 180, 393-400), We show, in this study, that the intermediate filament protein vimentin is retinoylated in HL60 cells during a 24-h exposure to 100 nM [H-3]RA. We found that a retinoylated protein of M(r) 55,000 coeluted on anion exchange chromatography and comigrated on either one- or two-dimensional polyacrylamide gel electrophoresis with a protein that also was stained on immunoblots by an anti-vimentin antibody. About 50% of the [H-3]RA was released from this M(r) 55,000 retinoylated protein after hydrolysis with either NH2OH (1 M, pH 10) or CH3OH, 0.1 m KOH. These results indicated that a large fraction of the RA was bound to vimentin by an ester bond. Both the M(r) 55,000 retinoylated protein and immunoreactive vimentin were associated with cell nuclei isolated by two procedures. They were detached during exposure to a nonionic detergent buffer, suggesting that they are bound to the nuclear envelope. These results indicate that retinoylation is a new modification of vimentin that may be an early event in RA-induced differentiation of HL60 cells.			TAKAHASHI, N (corresponding author), NCI, DIV CANC TREATMENT,DEV THERAPEUT PROGRAM, BIOL CHEM LAB,BLDG 37, RM 5D-02, BETHESDA, MD 20892 USA.							BELGRADER P, 1991, J CELL SCI, V98, P281; BERKOWIT.DM, 1969, J CELL BIOL, V42, P851, DOI 10.1083/jcb.42.3.851; BERNAL SD, 1982, CANCER RES, V42, P5106; BERTOLERO F, 1984, EXP CELL RES, V155, P64, DOI 10.1016/0014-4827(84)90768-7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BREITMAN TR, 1980, EXP CELL RES, V126, P494, DOI 10.1016/0014-4827(80)90296-7; BREITMAN TR, 1981, BLOOD, V57, P1000; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHAN D, 1989, P NATL ACAD SCI USA, V86, P2747, DOI 10.1073/pnas.86.8.2747; CHOMIENNE C, 1990, BLOOD, V76, P1710; CLARKE R, 1993, BREAST CANCER RES TR, V24, P227, DOI 10.1007/BF01833263; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; DAENEN S, 1986, BLOOD, V67, P559; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P1585, DOI 10.1093/nar/19.7.1585; DELLAGI K, 1983, EMBO J, V2, P1509, DOI 10.1002/j.1460-2075.1983.tb01615.x; DELLAGI K, 1984, LEUKEMIA RES, V8, P611, DOI 10.1016/0145-2126(84)90009-2; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DOMAGALA W, 1990, AM J PATHOL, V137, P1299; EVANS RM, 1988, FEBS LETT, V234, P73, DOI 10.1016/0014-5793(88)81306-1; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EVANS RM, 1984, J BIOL CHEM, V259, P5372; EVANS RM, 1982, CELL, V29, P43, DOI 10.1016/0092-8674(82)90088-5; FLYNN PJ, 1983, BLOOD, V62, P1211; FONTANA JA, 1986, CANCER-AM CANCER SOC, V57, P209, DOI 10.1002/1097-0142(19860115)57:2<209::AID-CNCR2820570204>3.0.CO;2-K; FRANKE WW, 1984, EXP CELL RES, V154, P567, DOI 10.1016/0014-4827(84)90181-2; GALLAGHER RE, 1985, LEUKEMIA RES, V9, P967, DOI 10.1016/0145-2126(85)90067-0; GARD DL, 1982, P NATL ACAD SCI-BIOL, V79, P6912, DOI 10.1073/pnas.79.22.6912; GARD DL, 1982, MOL CELL BIOL, V2, P1104, DOI 10.1128/MCB.2.9.1104; GEORGATOS SD, 1987, J CELL BIOL, V105, P117, DOI 10.1083/jcb.105.1.117; GEORGATOS SD, 1987, J CELL BIOL, V105, P105, DOI 10.1083/jcb.105.1.105; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V150, P1006, DOI 10.1016/0006-291X(88)90728-0; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUNT RC, 1990, J CELL PHYSIOL, V145, P187, DOI 10.1002/jcp.1041450202; IMAIZUMI M, 1987, CANCER RES, V47, P1434; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; ISAACS WB, 1989, J BIOL CHEM, V264, P17953; KEIDEL S, 1993, EUR J BIOCHEM, V212, P13, DOI 10.1111/j.1432-1033.1993.tb17627.x; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB NJC, 1989, J CELL BIOL, V108, P2409, DOI 10.1083/jcb.108.6.2409; LASZLO A, 1983, EXP CELL RES, V148, P221, DOI 10.1016/0014-4827(83)90201-X; LASZLO A, 1992, J CELL PHYSIOL, V151, P519, DOI 10.1002/jcp.1041510311; LEUNG MF, 1992, CANCER RES, V52, P949; LOCOCO F, 1991, BLOOD, V77, P1657; MORK C, 1990, DIFFERENTIATION, V43, P146; NELSON WJ, 1982, BIOCHEM BIOPH RES CO, V106, P1141, DOI 10.1016/0006-291X(82)91231-1; NGAI J, 1984, J CELL BIOL, V99, P306, DOI 10.1083/jcb.99.1.306; OCONNOR CM, 1981, CELL, V23, P135, DOI 10.1016/0092-8674(81)90278-6; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OSHIMA RG, 1981, J BIOL CHEM, V256, P8124; PAULINLEVASSEUR M, 1989, EUR J CELL BIOL, V50, P453; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PIEPER FR, 1992, EUR J BIOCHEM, V210, P509, DOI 10.1111/j.1432-1033.1992.tb17449.x; ROBERTSON KA, 1992, MOL CELL BIOL, V12, P3743, DOI 10.1128/MCB.12.9.3743; SARRIA AJ, 1992, J BIOL CHEM, V267, P19455; SARRIA AJ, 1990, J CELL BIOL, V111, P553, DOI 10.1083/jcb.111.2.553; SIEBERT PD, 1985, J BIOL CHEM, V260, P3868; SKALLI O, 1992, Trends in Cell Biology, V2, P308, DOI 10.1016/0962-8924(92)90121-3; SKALLI O, 1992, P NATL ACAD SCI USA, V89, P11959, DOI 10.1073/pnas.89.24.11959; SOMMERS CL, 1992, CANCER RES, V52, P5190; SOMMERS CL, 1989, CANCER RES, V49, P4258; TAIMI M, 1990, DIFFERENTIATION, V45, P55, DOI 10.1111/j.1432-0436.1990.tb00457.x; TAKAHASHI N, 1990, J BIOL CHEM, V265, P19158; TAKAHASHI N, 1991, ARCH BIOCHEM BIOPHYS, V285, P105, DOI 10.1016/0003-9861(91)90334-F; TAKAHASHI N, 1992, J STEROID BIOCHEM, V43, P489, DOI 10.1016/0960-0760(92)90235-B; TAKAHASHI N, 1991, BIOCHEM BIOPH RES CO, V180, P393, DOI 10.1016/S0006-291X(05)81306-3; TAKAHASHI N, 1989, IN VITRO CELL DEV B, V25, P1199; TAKAHASHI N, 1989, J BIOL CHEM, V264, P5159; TAKAHASHI N, 1991, ARCH BIOCHEM BIOPHYS, V290, P293, DOI 10.1016/0003-9861(91)90544-S; TAKAHASHI N, 1991, STATUS DIFFERENTIATI, V2, P255; TAKAHASHI N, 1984, VITAMIN A HLTH DISEA, P257; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TOKUI T, 1990, BIOCHEM BIOPH RES CO, V169, P896, DOI 10.1016/0006-291X(90)91977-Z; TSURU A, 1990, J CELL BIOL, V110, P1655, DOI 10.1083/jcb.110.5.1655; TUNG PS, 1993, J CELL PHYSIOL, V155, P139, DOI 10.1002/jcp.1041550118; VANMUIJEN GNP, 1987, LAB INVEST, V57, P359; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002	84	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5913	5917						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509793				2022-12-25	WOS:A1994MY84000067
J	GOPALAKRISHNAN, V; BENKOVIC, S				GOPALAKRISHNAN, V; BENKOVIC, S			EFFECT OF A THIOBENZIMIDAZOLONE DERIVATIVE ON DNA STRAND TRANSFER CATALYZED BY HIV-1 REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BINDING-SITE; INHIBITOR; AZT; SENSITIVITY; REPLICATION; POLYMERASE; ZIDOVUDINE; THERAPY; TARGET	Thiobenzimidazolone (TIBO) derivatives are known inhibitors of the DNA polymerase activity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). The effect of a TIBO derivative ((+)-S-4,5,6,7-tetrahydro-9-chloro-5-methyl-6-(3-methyl-2-butenyl)-imidazol[4,5,1-jk]1,4-benzodiazapine-2-thione) DNA strand transfer reaction catalyzed by HIV-1 RT (which is a function of both the DNA polymerase and RNase H activities) was investigated by delineating the effect of the drug on the constitutive DNA polymerase and RNase H activities. Single nucleotide incorporation on template-primer 1 was used to study the DNA polymerase activity of HIV-1 RT while template-primer 2 was used to study the effect of TIBO on the RNase H activity (polymerase independent). The drug was found to decrease the amplitude of the presteady-state burst when preequilibrated with the enzyme substrate complex besides decreasing the steady-state rate of single nucleotide incorporations. In the absence of preincubation, TIBO did not affect the burst amplitude but decreased the steady-state rate after the pre-transient phase. This suggested that binding of TIBO to RT was affected by the presence of template-primer and required dissociation of the enzyme from the template primer for effective binding. The polymerase-independent RNase H activity was activated in the presence of TIBO. The effect of TIBO on the overall process of DNA strand transfer is a balance between its inhibition of the polymerase activity and its activation of the RNase H activity.	PENN STATE UNIV, DEPT CHEM, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NIGMS NIH HHS [GM13306-23] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARROLL SS, 1993, J BIOL CHEM, V268, P276; COHEN KA, 1991, J BIOL CHEM, V266, P14670; DARBY G, 1992, BIOCHEM SOC T, V20, P505, DOI 10.1042/bst0200505; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DECLERCQ E, 1993, MED RES REV, V13, P229, DOI 10.1002/med.2610130303; DEVREESE K, 1992, VIROLOGY, V188, P900, DOI 10.1016/0042-6822(92)90550-9; DUEWEKE TJ, 1992, J BIOL CHEM, V267, P27; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; JOHNSON KA, 1993, 22ND SSTEENB S PROT, P20; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106	25	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4110	4115						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508439				2022-12-25	WOS:A1994MW98900035
J	CROOKSTON, KP; WEBB, DJ; WOLF, BB; GONIAS, SL				CROOKSTON, KP; WEBB, DJ; WOLF, BB; GONIAS, SL			CLASSIFICATION OF ALPHA(2)-MACROGLOBULIN-CYTOKINE INTERACTIONS BASED ON AFFINITY OF NONCOVALENT ASSOCIATION IN SOLUTION UNDER APPARENT EQUILIBRIUM CONDITIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; RECEPTOR-RELATED PROTEIN; ALPHA-MACROGLOBULIN; ALPHA-2-MACROGLOBULIN RECEPTOR; COVALENT BINDING; CYTOKINE BINDING; FAST FORMS; COMPLEXES; CLEARANCE; IDENTIFICATION	Alpha2-macroglobulin (alpha2M) binds numerous cytokines; however, since binding affinities have not been determined, it is difficult to compare various alpha2M-cytokine interaetions or predict whether alpha2M-cytokine complexes will form in the presence of other cytokine-binding macromolecules. In this investigation, we used a novel method to demonstrate that transforming growth factor-beta1 (TGF-beta1), TGF-beta2, nerve growth factor-beta (NGF-beta), platelet derived growth factor-BB (PDGF-BB), tumor necrosis factor-alpha (TNF-alpha), and basic fibroblast growth factor (bFGF) reversibly associate with alpha2M-methylamine to form noncovalent complexes. Apparent equilibrium was achieved in less than 15 min. Noncovalent alpha2M-cytokine complexes were converted into covalent complexes; however, this occurred slowly. Therefore, a rapid equilibrium assumption was applied and equilibrium dissociation constants were determined using a single binding site model. K(D) values for the binding of cytokines to alpha2M-methylamine varied by 2 orders of magnitude. The rank order of affinity was TGF-beta2 (13 +/- 2 nm) > TGF-beta1, NGF-beta > PDGF-BB greater-than-or-equal-to bFGF > TNF-alpha. Native alpha2M bound TGF-beta1, TGF-beta2, NGF-beta, PDGF-BB, and TNF-alpha. Interferon-gamma did not bind to native alpha2M or alpha2M-methylamine. Each cytokine bound native alpha2M with lower affinity than alpha2M-methylamine except for TGF-beta2 which bound both forms with equal affinity. In non-equilibrium systems, alpha2M-methylamine appeared to bind more TGF-beta2 due to the more rapid dissociation of TGF-beta2-native alpha2M complex. The classification of alpha2M-cytokine complexes according to binding affinity should predict which complexes are most likely to form in cell culture and under various conditions in vivo.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,BOX 214,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia					NATIONAL CANCER INSTITUTE [R01CA053462] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53462] Funding Source: Medline; NHLBI NIH HHS [HL-02272] Funding Source: Medline; NIGMS NIH HHS [GM 07267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELLA PM, 1979, BIOCHEM BIOPH RES CO, V87, P734, DOI 10.1016/0006-291X(79)92020-5; ASSOIAN RK, 1987, METHOD ENZYMOL, V146, P153; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BJORK I, 1982, BIOCHEM J, V207, P347; BONNER JC, 1992, J BIOL CHEM, V267, P12837; BONNER JC, 1990, J CELL PHYSIOL, V145, P1, DOI 10.1002/jcp.1041450102; BORTH W, 1989, J BIOL CHEM, V264, P5818; BORTH W, 1990, BLOOD, V75, P2388; BORTH W, 1990, J IMMUNOL, V145, P3747; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; CHU CT, 1991, BIOCHEMISTRY-US, V30, P1551, DOI 10.1021/bi00220a016; CROOKSTON KP, 1993, BIOCHEM J, V293, P443, DOI 10.1042/bj2930443; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DARLING TL, 1984, CELL CULTURE METHODS, V4, P79; DENNIS PA, 1989, J BIOL CHEM, V264, P7210; FEINMAN RD, 1983, ANN NY ACAD SCI, V421, P178, DOI 10.1111/j.1749-6632.1983.tb18108.x; GONIAS SL, 1989, J BIOL CHEM, V264, P9565; GONIAS SL, 1983, BIOCHEM J, V209, P99, DOI 10.1042/bj2090099; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; GONIAS SL, 1983, J BIOL CHEM, V258, P4682; GONIAS SL, 1992, EXP HEMATOL, V20, P302; HALL PK, 1978, BIOCHEM J, V173, P27, DOI 10.1042/bj1730027; HALL SW, 1992, BIOCHEM J, V281, P569, DOI 10.1042/bj2810569; HOWARD JB, 1981, P NATL ACAD SCI-BIOL, V78, P2235, DOI 10.1073/pnas.78.4.2235; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; JAMES K, 1992, IMMUNOL LETT, V32, P49, DOI 10.1016/0165-2478(92)90198-W; KOO PH, 1989, J NEUROSCI RES, V22, P247, DOI 10.1002/jnr.490220304; KRUMMEN LA, 1993, ENDOCRINOLOGY, V132, P431, DOI 10.1210/en.132.1.431; LAMARRE J, 1991, BIOCHIM BIOPHYS ACTA, V1091, P197, DOI 10.1016/0167-4889(91)90062-3; LAMARRE J, 1991, LAB INVEST, V65, P3; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; LIEBL DJ, 1993, BIOCHEM BIOPH RES CO, V193, P1255, DOI 10.1006/bbrc.1993.1760; MATSUDA T, 1989, J IMMUNOL, V142, P148; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; PHILIP A, 1991, J BIOL CHEM, V266, P22290; PIZZO SV, 1984, RECEPTORS, V1, P177; RAINES EW, 1984, P NATL ACAD SCI-BIOL, V81, P3424, DOI 10.1073/pnas.81.11.3424; RONNE H, 1979, BIOCHEM BIOPH RES CO, V87, P330, DOI 10.1016/0006-291X(79)91683-8; SALVESEN GS, 1981, BIOCHEM J, V195, P453, DOI 10.1042/bj1950453; SALVESEN GS, 1980, BIOCHEM J, V187, P695, DOI 10.1042/bj1870695; SOKER S, 1993, J BIOL CHEM, V268, P7685; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; STOUFFER GA, 1993, J BIOL CHEM, V268, P18340; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STRICKLAND DK, 1988, BIOCHEMISTRY-US, V27, P1458, DOI 10.1021/bi00405a010; SWENSON RP, 1979, J BIOL CHEM, V254, P4452; TEODORESCU M, 1991, MOL IMMUNOL, V28, P323, DOI 10.1016/0161-5890(91)90144-9; VAUGHAN JM, 1993, ENDOCRINOLOGY, V132, P2038, DOI 10.1210/en.132.5.2038; WEBB DJ, 1992, ARCH BIOCHEM BIOPHYS, V292, P487, DOI 10.1016/0003-9861(92)90020-W; WOLLENBERG GK, 1991, AM J PATHOL, V138, P265	55	113	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1533	1540						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507109				2022-12-25	WOS:A1994MR22000115
J	JACQUES, PS; WOHRL, BM; HOWARD, KJ; LEGRICE, SFJ				JACQUES, PS; WOHRL, BM; HOWARD, KJ; LEGRICE, SFJ			MODULATION OF HIV-1 REVERSE-TRANSCRIPTASE FUNCTION IN SELECTIVELY DELETED P66/P51 HETERODIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; METAL CHELATE ADSORBENT; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; DOMAIN-STRUCTURE; DNA-SYNTHESIS; TYPE-1; PRIMER; PURIFICATION; POLYMERASE	A contribution of the 51-kDa subunit of human immunodeficiency virus type-1 reverse transcriptase to activities of the parental heterodimer (p66/p51) was assessed in ''selectively deleted'' heterodimers whose p51 component contained C-terminal truncations of 13, 19, or 25 residues. Analyses included (i) efficiency of reconstitution into heterodimer, (ii) retention of polymerase and ribonuclease H (RNase H) function, and (iii) interaction with the HIV replication primer, tRNA(Lys,3). Our data suggest that these features of heterodimer reverse transcriptase can be modulated by the extent of the C-terminal p51 deletion. Severely impaired tRNA binding in a selectively deleted heterodimer whose 51-kDa subunit lacks 13 residues, despite retention of enzymatic functions, strengthens arguments for p51 involvement in tRNA binding.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DIV INFECT DIS,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031147] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 31147-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BAILLON JG, 1991, NEW BIOL, V3, P1015; BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751; BASU A, 1992, BIOCHEMISTRY-US, V31, P616, DOI 10.1021/bi00117a045; BENARTZI H, 1992, P NATL ACAD SCI USA, V89, P927, DOI 10.1073/pnas.89.3.927; BENARTZI H, 1992, NUCLEIC ACIDS RES, V20, P5115, DOI 10.1093/nar/20.19.5115; BOYER PL, 1992, J VIROL, V66, P1031, DOI 10.1128/JVI.66.2.1031-1039.1992; BUCK HM, 1990, SCIENCE, V248, P208, DOI 10.1126/science.2326635; CHENG N, 1991, BIOCHEM BIOPH RES CO, V174, P785, DOI 10.1016/0006-291X(91)91486-V; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; HOWARD KJ, 1991, J BIOL CHEM, V266, P23003; HUBER HE, 1990, J BIOL CHEM, V265, P10565; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOHLSTAEDT LA, 1992, P NATL ACAD SCI USA, V89, P9652, DOI 10.1073/pnas.89.20.9652; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEDERER H, 1992, EMBO J, V11, P1131, DOI 10.1002/j.1460-2075.1992.tb05153.x; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LEGRICE SFJ, 1991, J VIROL, V65, P7004, DOI 10.1128/JVI.65.12.7004-7007.1991; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LEGRICE SFJ, 1989, J BIOL CHEM, V264, P14902; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LOWE DM, 1988, BIOCHEMISTRY-US, V27, P8884, DOI 10.1021/bi00425a002; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; MULLER B, 1991, J BIOL CHEM, V266, P14709; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RICHTERCOOK NJ, 1992, J BIOL CHEM, V267, P12592; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SCHATZ O, 1990, ONCOGENESIS AIDS, P304; SOBOL RW, 1991, BIOCHEMISTRY-US, V30, P10623, DOI 10.1021/bi00108a004; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WEISS S, 1992, GENE, V111, P183, DOI 10.1016/0378-1119(92)90686-J; WOHRL BM, 1993, J BIOL CHEM, V268, P13617; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003	39	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1388	1393						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507107				2022-12-25	WOS:A1994MR22000096
J	DAUNCEY, MJ; BURTON, KA; WHITE, P; HARRISON, AP; GILMOUR, RS; DUCHAMP, C; CATTANEO, D				DAUNCEY, MJ; BURTON, KA; WHITE, P; HARRISON, AP; GILMOUR, RS; DUCHAMP, C; CATTANEO, D			NUTRITIONAL REGULATION OF GROWTH-HORMONE RECEPTOR GENE-EXPRESSION	FASEB JOURNAL			English	Note						ENERGY BALANCE; GROWTH; NUTRITION; THYROID HORMONES	FACTOR-I; ENVIRONMENTAL-TEMPERATURE; SKELETAL-MUSCLE; SOMATOTROPIC AXIS; MESSENGER-RNA; ENERGY-INTAKE; RAT-LIVER; IGF-I; BINDING; CELLS	The role of energy intake in regulating growth hormone receptor (GHR) gene expression has been assessed in young growing pigs living at thermal neutrality (26-degrees-C) for a 4-wk period. To determine the importance of altering metabolic demand while maintaining food intake constant, littermates were also studied in a cold environment (10-degrees-C). Results were tissue-specific: the level of GHR mRNA per unit total RNA in liver was greater on high than low (high = 2 x low) food intake (P < 0.001), whereas in muscle it was elevated on the low compared with the high intake diet (P < 0.02) and also at 10-degrees-C compared with 26-degrees-C (P < 0.04). When results for GHR mRNA were expressed per unit weight of tissue, only the effects of diet on liver and temperature on muscle remained significant. The changes in hepatic GHR mRNA may have been driven in part by nutritionally induced changes in thyroid status, because both plasma 3,5,3'-triiodothyronine concentration and liver 5'-deiodinase activity were greater on the high than the low intake diet (P < 0.001). Levels of liver GHR mRNA probably had a direct influence on growth of the animals, as they were positively correlated with plasma IGF-I and growth rate (P < 0.001), whereas muscle GHR mRNA may have had a metabolic role when energy supplies were limited.			DAUNCEY, MJ (corresponding author), AFRC,BABRAHAM INST,DEPT CELLULAR PHYSIOL,CAMBRIDGE CB2 4AT,ENGLAND.		Cattaneo, Donata/G-7509-2012; White, Peter/E-4301-2011	White, Peter/0000-0002-5218-5903				AYLING CM, 1992, GROWTH REGULAT, V2, P133; BORNFELDT KE, 1989, J ENDOCRINOL, V122, P651, DOI 10.1677/joe.0.1220651; BREIER BH, 1991, LIVEST PROD SCI, V27, P77, DOI 10.1016/0301-6226(91)90047-T; BREIER BH, 1988, J ENDOCRINOL, V116, P169, DOI 10.1677/joe.0.1160169; BUONOMO FC, 1991, J ANIM SCI, V69, P755; CABELLO G, 1989, REPROD NUTR DEV, V29, P387, DOI 10.1051/rnd:19890401; CATTINI PA, 1986, J BIOL CHEM, V261, P3367; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG CS, 1986, ENDOCRINOLOGY, V119, P780, DOI 10.1210/endo-119-2-780; CIOFFI JA, 1990, NUCLEIC ACIDS RES, V18, P6451, DOI 10.1093/nar/18.21.6451; CLARKE SD, 1992, FASEB J, V6, P3146, DOI 10.1096/fasebj.6.13.1397836; DARRAS VM, 1993, DOMEST ANIM ENDOCRIN, V10, P55, DOI 10.1016/0739-7240(93)90008-Y; DAUNCEY MJ, 1990, HORM METAB RES, V22, P524, DOI 10.1055/s-2007-1004963; DAUNCEY MJ, 1988, EUR J APPL PHYSIOL O, V58, P239, DOI 10.1007/BF00417256; DAUNCEY MJ, 1990, HORM METAB RES, V22, P261, DOI 10.1055/s-2007-1004898; DAUNCEY MJ, 1990, P NUTR SOC, V49, P203, DOI 10.1079/PNS19900024; DAUNCEY MJ, 1993, GROWTH REGULAT, V3, P198; HARRISON AP, 1993, IN PRESS AM J PHYSL; HOCHBERG Z, 1990, ENDOCRINOLOGY, V126, P325, DOI 10.1210/endo-126-1-325; Ingram D. L., 1986, Control and manipulation of animal growth. Proceedings of the 43rd Nottingham Easter School in Agricultural Science., P5; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; LAKEHAL F, 1989, BIOTECHNOLOGY GROWTH, P232; MA L, 1992, J THERM BIOL, V17, P89, DOI 10.1016/0306-4565(92)90004-Y; MOROVAT A, 1992, J ENDOCRINOL, V134, P67, DOI 10.1677/joe.0.1340067; NAIR PP, 1993, FASEB J, V7, P501, DOI 10.1096/fasebj.7.6.8472888; OWENS PC, 1991, J ENDOCRINOL, V128, P439, DOI 10.1677/joe.0.1280439; RETEGUISARDOU LA, 1977, MOL CELL BIOCHEM, V16, P87, DOI 10.1007/BF01732048; SAUNDERS JC, 1991, J MOL ENDOCRINOL, V7, P233, DOI 10.1677/jme.0.0070233; SLEBODZINSKI AB, 1982, J ENDOCRINOL, V95, P349, DOI 10.1677/joe.0.0950349; SLEBODZINSKI AB, 1985, COMP BIOCHEM PHYS A, V80, P559, DOI 10.1016/0300-9629(85)90412-8; STRAUS DS, 1990, MOL ENDOCRINOL, V4, P91, DOI 10.1210/mend-4-1-91	31	66	72	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1994	8	1					81	88		10.1096/fasebj.8.1.7507871	http://dx.doi.org/10.1096/fasebj.8.1.7507871			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	7507871				2022-12-25	WOS:A1994MV28200012
J	ROSENKILDE, MM; CAHIR, M; GETHER, U; HJORTH, SA; SCHWARTZ, TW				ROSENKILDE, MM; CAHIR, M; GETHER, U; HJORTH, SA; SCHWARTZ, TW			MUTATIONS ALONG TRANSMEMBRANE SEGMENT-II OF THE NK-1 RECEPTOR AFFECT SUBSTANCE-P COMPETITION WITH NONPEPTIDE ANTAGONISTS BUT NOT SUBSTANCE-P BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; NEUROKININ-1 RECEPTOR; NONPEPTIDE ANTAGONIST; SPECIES SELECTIVITY; MOLECULAR-BASIS; NK1 RECEPTOR; DOMAINS; SPECIFICITY; IDENTIFICATION; DELINEATION	Mutational analysis of the NK-1 receptor indicates that residues involved in non-peptide antagonist binding cluster around the outer portion of transmembrane segments (TM) V and VI. In contrast mutations affecting the binding of the natural peptide agonist, substance P, are scattered in the exterior part of the receptor. Recently it was reported that a number of mutations in TM-II also seriously impair substance P binding. Here we confirm that Ala substitutions for these residues located on a hydrophilic helical face of TM-II basically eliminate substance P binding to the NK-1 receptor, provided that a radiolabeled non-peptide antagonist is used as radioligand. Surprisingly, radiolabeled substance P bound well to all these mutant receptors and was displaced with only slightly reduced affinity by the unlabeled peptide and by the non-peptide antagonists. The wild-type homologous NK-2 receptor displayed properties similar to those observed in the mutated NK-1 receptors, i.e. concomitant high affinity binding of radiolabeled agonist peptide (in this case neurokinin A), yet low affinity, G-protein independent competition of unlabeled peptide with radiolabeled non-peptide antagonist. It is concluded that substitutions in TM-II of the NK-1 receptor do not affect the high affinity binding of substance P but instead block the ability of the peptides to compete for non-peptide antagonist binding. It is suggested that certain mutations can impair interchange between receptor conformations that each bind different ligands with high affinity.	UNIV COPENHAGEN,RIGSHOSP,DEPT CLIN BIOCHEM,MOLEC ENDOCRINOL LAB,DK-2100 COPENHAGEN,DENMARK	Rigshospitalet; University of Copenhagen				Hjorth, Siv Annegrethe/0000-0002-6470-650X; Schwartz, Thue W./0000-0002-0261-6904; Rosenkilde, Mette Marie/0000-0001-9600-3254; Gether, Ulrik/0000-0002-0020-3807				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BARKER EL, 1994, J BIOL CHEM, V269, P11687; BOYD ND, 1991, ANN NY ACAD SCI, V632, P79, DOI 10.1111/j.1749-6632.1991.tb33096.x; CASCIERI MA, 1994, J BIOL CHEM, V269, P6587; EMONDSALT X, 1992, LIFE SCI, V50, P101; FONG TM, 1994, J BIOL CHEM, V269, P2728; FONG TM, 1992, J BIOL CHEM, V267, P25668; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1993, NATURE, V362, P350; FUJII T, 1992, BRIT J PHARMACOL, V107, P785, DOI 10.1111/j.1476-5381.1992.tb14524.x; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, J BIOL CHEM, V268, P7893; GETHER U, 1993, P NATL ACAD SCI USA, V90, P6194, DOI 10.1073/pnas.90.13.6194; GETHER U, 1994, J BIOL CHEM, V269, P23959; GETHER U, 1994, MOL PHARMACOL, V45, P500; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; JENSEN CJ, 1994, MOL PHARMACOL, V45, P294; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KRYSTEK SR, 1994, J BIOL CHEM, V269, P12383; LEE JA, 1994, P NATL ACAD SCI USA, V91, P7164, DOI 10.1073/pnas.91.15.7164; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LOWE JA, 1992, J MED CHEM, V35, P2591, DOI 10.1021/jm00092a009; MIYAYASU K, 1993, MOL PHARMACOL, V44, P539; OLIVEIRA L, 1994, TRENDS PHARMACOL SCI, V15, P170, DOI 10.1016/0165-6147(94)90137-6; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; STRADER CD, 1991, J BIOL CHEM, V266, P5; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1989, J BIOL CHEM, V264, P13572; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649; ZOFFMANN S, 1993, FEBS LETT, V336, P506, DOI 10.1016/0014-5793(93)80865-R	38	108	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28160	28164						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525569				2022-12-25	WOS:A1994PV77200059
J	CONNOR, A; WIERSMA, E; SHULMAN, MJ				CONNOR, A; WIERSMA, E; SHULMAN, MJ			ON THE LINKAGE BETWEEN RNA PROCESSING AND RNA TRANSLATABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-MU-CHAIN; S MESSENGER-RNA; NONSENSE MUTATIONS; PREMESSENGER RNA; TRANSLATION; STABILITY; MEMBRANE; LOCUS; GENE; EXPRESSION	The immunoglobulin mu heavy chain gene of mouse hybridoma cells is expressed in two forms, mu s and mu m, differing in their use of 3' exons. As for many other mammalian genes, mutations in the mu gene which prematurely terminate translation often have the effect of reducing the amount of these mu RNAs. To test the generality of this relationship, we selected mutant hybridoma cell lines defective in IgM production and searched both for translation termination mutations which do not reduce the amount of mu RNA as well as for mutants which show the more commonly observed reduction in mu RNA. As observed previously, the amount of us RNA is normal in mutants terminating in the C mu 4 exon; by contrast the amount of um RNA is reduced in these mutants, indicating that the effect of the mutation is influenced by some feature near the 3' end of the RNA. Mutations terminating translation in other C region exons have a graded effect on RNA content, ranging from 10% the normal level for termination in the C mu 3 exon down to 1% for termination in the C mu 2 exon. By contrast, a mutant cell line terminating in the leader exon contained 25% the normal amount of mu RNA, suggesting that translation past some point might be required to fully engage the RNA degradation process.	UNIV TORONTO,DEPT IMMUNOL,TORONTO M5S 1A8,ON,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University of Toronto								BARKER GF, 1991, MOL CELL BIOL, V11, P2760, DOI 10.1128/MCB.11.5.2760; BASERGA SJ, 1992, P NATL ACAD SCI USA, V89, P2935, DOI 10.1073/pnas.89.7.2935; BAUMANN B, 1985, EMBO J, V4, P351, DOI 10.1002/j.1460-2075.1985.tb03636.x; BELGRADER P, 1993, P NATL ACAD SCI USA, V90, P482, DOI 10.1073/pnas.90.2.482; CATTANEO R, 1991, ANNU REV GENET, V25, P71, DOI 10.1146/annurev.ge.25.120191.000443; CHENG J, 1990, Molecular and Cellular Biology, V10, P5215; CHENG J, 1993, MOL CELL BIOL, V13, P1892, DOI 10.1128/MCB.13.3.1892; CONNOR A, 1993, SOMAT CELL MOLEC GEN, V19, P313, DOI 10.1007/BF01232744; DAAR IO, 1988, MOL CELL BIOL, V8, P802, DOI 10.1128/MCB.8.2.802; DANNER D, 1985, P NATL ACAD SCI USA, V82, P8658, DOI 10.1073/pnas.82.24.8658; DAVIS AC, 1989, J IMMUNOL, V43, P1352; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; ENSSLE J, 1993, P NATL ACAD SCI USA, V90, P10091, DOI 10.1073/pnas.90.21.10091; FISHER CW, 1993, AM J HUM GENET, V52, P414; GALLI G, 1987, GENE DEV, V1, P471, DOI 10.1101/gad.1.5.471; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; HAM KKY, 1985, IMMUNOL LETT, V10, P303, DOI 10.1016/0165-2478(85)90106-3; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; JACK HM, 1989, EUR J IMMUNOL, V19, P843, DOI 10.1002/eji.1830190510; KESSLER O, 1993, MOL CELL BIOL, V13, P6211, DOI 10.1128/MCB.13.10.6211; KOHLER G, 1982, EMBO J, V1, P555, DOI 10.1002/j.1460-2075.1982.tb01208.x; KOWALSKI J, 1989, MOL CELL BIOL, V9, P1946, DOI 10.1128/MCB.9.5.1946; KOZAK M, 1991, J BIOL CHEM, V266, P19867; MATHER EL, 1984, CELL, V36, P329, DOI 10.1016/0092-8674(84)90226-5; NAEGER LK, 1992, GENE DEV, V6, P1107, DOI 10.1101/gad.6.6.1107; NELSON KJ, 1983, MOL CELL BIOL, V3, P1317, DOI 10.1128/MCB.3.7.1317; PETERSON ML, 1986, P NATL ACAD SCI USA, V83, P8883, DOI 10.1073/pnas.83.23.8883; QIAN L, 1993, J IMMUNOL, V152, P6801; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; SIMPSON SB, 1994, MOL CELL BIOL, V14, P1835, DOI 10.1128/MCB.14.3.1835; TRIMBLE WS, 1986, SOMAT CELL MOLEC GEN, V12, P467, DOI 10.1007/BF01539918; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868	33	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25178	25184						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7523380				2022-12-25	WOS:A1994PQ49000097
J	HAYASHI, JI; OHTA, S; KAGAWA, Y; TAKAI, D; MIYABAYASHI, S; TADA, K; FUKUSHIMA, H; INUI, K; OKADA, S; GOTO, Y; NONAKA, I				HAYASHI, JI; OHTA, S; KAGAWA, Y; TAKAI, D; MIYABAYASHI, S; TADA, K; FUKUSHIMA, H; INUI, K; OKADA, S; GOTO, Y; NONAKA, I			FUNCTIONAL AND MORPHOLOGICAL ABNORMALITIES OF MITOCHONDRIA IN HUMAN-CELLS CONTAINING MITOCHONDRIAL-DNA WITH PATHOGENIC POINT MUTATIONS IN TRANSFER-RNA GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROKE-LIKE EPISODES; TRANSFER RNA(LEU(UUR)) GENE; TRANSFER RNALEU(UUR) GENE; TRANSFER-RNA GENES; LACTIC-ACIDOSIS; PROTEIN-SYNTHESIS; MYOCLONIC EPILEPSY; DIABETES-MELLITUS; MTDNA MUTATION; HELA-CELLS	mtDNA with a point mutation in the tRN(Ile) gene at nucleotide position 4269 found in a patient with fatal cardiomyopathy and mtDNA with a point mutation in the tRNA(Arg) gene at 10410 found in a patient with Alpers disease were transferred cytoplasmically to rho degrees HeLa cells (HeLa cells lacking mtDNA) to determine whether these novel mtDNA mutations in the tRNA genes are responsible for the defects in mitochondrial respiration function observed in these diseases. Cybrid clones (clones of rho degrees HeLa cells with mtDNA from the patients) were isolated, and respiratory function and morphology of the mitochondria of the cybrid clones containing wild-type mtDNA and mutant mtDNA predominantly were compared. The results showed that accumulation of mutant mtDNA at 4269 alone without defects in the nuclear genome was sufficient to produce a disease phenotype, while mutant mtDNA at 10410 was not related to pathogenesis and reflected one of the rare polymorphic sites of human mtDNA. Moreover, we found that mitochondria in living cells were significantly swollen only when they contained predominantly the pathogenic mutant mtDNA, suggesting that the functional abnormality of mitochondria induced by pathogenic mtDNA mutations in tRNA genes is always associated with their swollen structure.	JICHI MED SCH,DEPT BIOCHEM,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; TOHOKU UNIV,SCH MED,DEPT PEDIAT,SENDAI,MIYAGI 980,JAPAN; OSAKA UNIV,SCH MED,DEPT PEDIAT,SUITA,OSAKA 565,JAPAN; NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV ULTRASTRUCT RES,KODAIRA,TOKYO 187,JAPAN	Jichi Medical University; Tohoku University; Osaka University; National Center for Neurology & Psychiatry - Japan	HAYASHI, JI (corresponding author), UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN.							BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BINDOFF LA, 1993, J BIOL CHEM, V268, P19559; BIRKY CW, 1983, SCIENCE, V222, P468, DOI 10.1126/science.6353578; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602; GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1983, EXP CELL RES, V147, P51, DOI 10.1016/0014-4827(83)90270-7; HAYASHI JI, 1994, J BIOL CHEM, V269, P6878; HAYASHI JI, 1993, BIOCHEM BIOPH RES CO, V197, P1049, DOI 10.1006/bbrc.1993.2584; HAYASHI JI, 1991, PROG NEUROPATH, V7, P93; HAYASHI JI, 1992, SOMAT CELL MOLEC GEN, V18, P123, DOI 10.1007/BF01233159; HAYASHI JI, 1994, J CELL BIOL, V125, P43, DOI 10.1083/jcb.125.1.43; HAYASHI JI, 1984, CANCER RES, V44, P3957; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5; LAUBER J, 1991, NUCLEIC ACIDS RES, V19, P1393, DOI 10.1093/nar/19.7.1393; LERTRIT P, 1992, AM J HUM GENET, V51, P457; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; MIYABAYASHI S, 1989, J INHERIT METAB DIS, V12, P373, DOI 10.1007/BF01799245; MORAES CT, 1993, NAT GENET, V4, P284, DOI 10.1038/ng0793-284; MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913; MUNSCHER C, 1993, FEBS LETT, V317, P27, DOI 10.1016/0014-5793(93)81484-H; NONAKA I, 1989, J NEUROL SCI, V9, P193; REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3; SAKUTA R, 1993, AM J HUM GENET, V53, P964; SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SILVESTRI G, 1992, AM J HUM GENET, V51, P1213; TANAKA M, 1990, LANCET, V336, P1452, DOI 10.1016/0140-6736(90)93162-I; TANAKA M, 1991, BIOCHEM BIOPH RES CO, V174, P861, DOI 10.1016/0006-291X(91)91497-Z; TANIIKE M, 1992, BIOCHEM BIOPH RES CO, V186, P47, DOI 10.1016/S0006-291X(05)80773-9; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; VANDENOUWELAND JMW, 1992, NUCLEIC ACIDS RES, V20, P679, DOI 10.1093/nar/20.4.679; WALLACE DC, 1986, SOMAT CELL MOLEC GEN, V12, P41, DOI 10.1007/BF01560726; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; YOON KL, 1991, BIOCHEM BIOPH RES CO, V176, P1112, DOI 10.1016/0006-291X(91)90399-R; ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D; ZHANG CF, 1993, BIOCHEM BIOPH RES CO, V195, P1104, DOI 10.1006/bbrc.1993.2158	44	74	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19060	19066						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7518448				2022-12-25	WOS:A1994NX32700055
J	CHACKALAPARAMPIL, I; BAGRODIA, S; SHALLOWAY, D				CHACKALAPARAMPIL, I; BAGRODIA, S; SHALLOWAY, D			TYROSINE DEPHOSPHORYLATION OF PP60(C-SRC) IS STIMULATED BY A SERINE/THREONINE PHOSPHATASE INHIBITOR	ONCOGENE			English	Article							PROTEIN-KINASE-C; XENOPUS-LAEVIS OOCYTES; OKADAIC ACID; CELL-CYCLE; TUMOR PROMOTERS; AUTOPHOSPHORYLATION SITE; OVEREXPRESSED PP60C-SRC; NEGATIVE REGULATOR; SPONGE TOXIN; H1 KINASE	Incubation of NIH3T3-derived c-src overexpressor cells with okadaic acid, a specific serine/threonine phosphatase inhibitor, stimulates pp60(c-src) kinase activity about 2-3-fold. Activation is blocked if cells are simultaneously treated with orthovanadate, a tyrosine phosphatase inhibitor. Furthermore, okadaic acid treatment induces a small decrease in Tyr 527 phosphorylation of wild-type pp60(c-src) and a large decrease in Tyr 527 phosphorylation of kinase-defective pp60(c-src)(lys 295--> Arg). These results suggest that the activation is mediated by okadaic acid-induced changes in tyrosine phosphorylation of pp60(c-src) involving 'cross-over' from serine/threonine to tyrosine signal transduction pathways. Stimulation of pp60(c-src) activity and Tyr 527 dephosphorylation do not require changes in serine/threonine phosphorylation of pp60(c-src), suggesting that these changes result from modulation of an upstream Tyr 527 phosphatase or kinase which is itself regulated by altered serine/threonine phosphorylation. Since okadaic acid induces a pseudo-mitotic phenotype in rodent cells (K. Yamashita, H. Yasuda, J. Pines, K. Yasumoto, H. Nishitani, M. Ohtsubo, T. Hunter, T. Sugimura and T. Nishimoto, EMBO J., 9: 4331-4338, 1990), it is possible that these phenomena are induced by a biochemical mechanism similar to that which causes transient tyrosine dephosphorylation of pp60(c-src) during mitosis.	CORNELL UNIV, BIOCHEM MOLEC & CELL BIOL SECT, ITHACA, NY 14853 USA	Cornell University					NATIONAL CANCER INSTITUTE [R01CA008964, R01CA047333, R01CA032317] Funding Source: NIH RePORTER; NCI NIH HHS [CA08964, CA32317, CA47333] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BAGRODIA S, 1993, MOL CELL BIOL, V13, P1464, DOI 10.1128/MCB.13.3.1464; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRACONI S, 1992, BIOCHEM J, V286, P851, DOI 10.1042/bj2860851; BRAUTIGAN DL, 1991, P NATL ACAD SCI USA, V88, P6696, DOI 10.1073/pnas.88.15.6696; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHERNOFF J, 1983, J BIOL CHEM, V258, P7852; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COOPER JA, 1989, PEPTIDES PROTEIN PHO, P85; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; GAVIN AC, 1991, EXP CELL RES, V192, P75, DOI 10.1016/0014-4827(91)90159-R; GOPALAKRISHNA R, 1992, BIOCHEM BIOPH RES CO, V189, P950, DOI 10.1016/0006-291X(92)92296-A; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; GORIS J, 1988, BIOCHEM J, V256, P1029, DOI 10.1042/bj2561029; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; HAYSTEAD TAJ, 1990, EUR J BIOCHEM, V187, P199, DOI 10.1111/j.1432-1033.1990.tb15295.x; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HERMANN J, 1988, EUR J BIOCHEM, V173, P17, DOI 10.1111/j.1432-1033.1988.tb13961.x; HIROTA Y, 1988, MOL CELL BIOL, V8, P1826, DOI 10.1128/MCB.8.4.1826; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; HUNTER T, 1993, CURR OPIN GENET DEV, V3, P1, DOI 10.1016/S0959-437X(05)80333-8; HUNTER T, 1992, CIBA F SYMP, V170, P1; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KAECH S, 1993, ONCOGENE, V8, P575; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MEIER KE, 1991, J BIOL CHEM, V266, P1914; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MIYASAKA T, 1990, BIOCHEM BIOPH RES CO, V168, P1237, DOI 10.1016/0006-291X(90)91161-K; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; MUSTELIN T, 1990, ONCOGENE, V5, P809; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; OKADA M, 1989, J BIOL CHEM, V264, P20886; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARTANEN J, 1991, ONCOGENE, V6, P2013; PATSCHINSKY T, 1986, J VIROL, V59, P73, DOI 10.1128/JVI.59.1.73-81.1986; PICARD A, 1989, J CELL BIOL, V109, P3347, DOI 10.1083/jcb.109.6.3347; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PURCHIO AF, 1985, SCIENCE, V229, P1393, DOI 10.1126/science.2994221; RIME H, 1990, DEV BIOL, V141, P115, DOI 10.1016/0012-1606(90)90106-S; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SASSA T, 1989, BIOCHEM BIOPH RES CO, V159, P939, DOI 10.1016/0006-291X(89)92199-2; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STERNBERG DW, 1993, EMBO J, V12, P323, DOI 10.1002/j.1460-2075.1993.tb05660.x; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; TAKAI A, 1987, FEBS LETT, V217, P81, DOI 10.1016/0014-5793(87)81247-4; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; YACIUK P, 1989, MOL CELL BIOL, V9, P2453, DOI 10.1128/MCB.9.6.2453; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	73	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					1947	1955						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	7516061				2022-12-25	WOS:A1994NR68500019
J	FISCHER, TH; GATLING, MN; MCCORMICK, F; DUFFY, CM; WHITE, GC				FISCHER, TH; GATLING, MN; MCCORMICK, F; DUFFY, CM; WHITE, GC			INCORPORATION OF RAP-1B INTO THE PLATELET CYTOSKELETON IS DEPENDENT ON THROMBIN ACTIVATION AND EXTRACELLULAR CALCIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; GTP-BINDING PROTEINS; PUTATIVE EFFECTOR DOMAIN; INTACT HUMAN-PLATELETS; HUMAN-BLOOD-PLATELETS; SMG P21; MEMBRANE-PROTEINS; MOLECULAR-CLONING; KINASE SUBSTRATE; RAS-P21 GTPASE	Rap 1b is a 22-kDa low molecular mass GTP-binding protein which is both a member of the Ras superfamily and a substrate for cAMP-dependent protein kinase. Recently, evidence has been presented to show that Rap 1b is incorporated into the detergent-extracted cytoskeleton of platelets during thrombin-induced activation. The aims of this study were to compare the incorporation of Rap 1b into the detergent-extracted cytoskeleton after activation with different agonists, to examine the role of extracellular calcium on the incorporation of Rap 1b into the cytoskeleton, to investigate the relationship between the association of Rap 1b and other proteins with the cytoskeleton, and to determine the effect of phosphorylation of Rap 1b incorporation into the cytoskeleton. Platelets were activated with thrombin, A23187, phorbol myristate acetate, ADP, epinephrine, and collagen in the presence and absence of calcium. The time dependence of Rap 1b incorporation into the detergent-extracted cytoskeleton was then measured. When platelets were activated by thrombin in the presence of extracellular calcium, conditions which permit aggregation, incorporation of Rap 1b into the detergent-extracted cytoskeleton was biphasic. Approximately 20% of the total cellular Rap 1b incorporated into the cytoskeleton within seconds and was followed by a slower second phase of incorporation. In contrast, when platelets were activated by thrombin in the absence of calcium, conditions which inhibit aggregation, or by the other agents in the presence or absence of calcium, only the initial phase of Rap 1b incorporation into the cytoskeleton was measured. The incorporation of Rap 1b paralleled the incorporation of membrane glycoproteins (GP) IIb/IIIa and PECAM-1, but not the incorporation of pp60(c-src). The GTPase-activating protein for Ras (Ras-GAP) did not associate with the detergent-extracted cytoskeleton. Two-dimensional isoelectric focusing SDS-polyacrylamide gel electrophoresis of the total cellular and cytoskeletal Rap 1b showed that unphosphorylated as well as phosphorylated isoforms of Rap 1b were incorporated into the cytoskeleton in the same molar ratio as was present in the intact cell. Furthermore, the rates of incorporation of phosphorylated and unphosphorylated Rap 1b into the cytoskeleton were similar. These experiments show that Rap 1b can regulate events that take place within seconds after activation, such as the initial formation of the cytoskeleton, as well as longer term changes in the cytoskeleton that occur in response to thrombin-induced aggregation. Furthermore, phosphorylation could modulate the (unknown) functions of Rap 1b as a component of the cytoskeleton.	UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,DEPT PHARMACOL,CHAPEL HILL,NC 27599; ONYX PHARMACEUT,RICHMOND,CA 94806	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NHLBI NIH HHS [HL26309, K01-HL02521] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL026309, K04HL002521] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADUNYAH SE, 1987, BIOCHIM BIOPHYS ACTA, V930, P401, DOI 10.1016/0167-4889(87)90013-9; ADUNYAH SE, 1988, BIOCHIM BIOPHYS ACTA, V941, P63, DOI 10.1016/0005-2736(88)90214-3; CHURCH FC, 1986, ANAL BIOCHEM, V157, P77, DOI 10.1016/0003-2697(86)90198-3; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; COX AC, 1984, J CELL BIOL, V98, P8, DOI 10.1083/jcb.98.1.8; ENOUF J, 1987, BIOCHIM BIOPHYS ACTA, V928, P76, DOI 10.1016/0167-4889(87)90087-5; EVANS T, 1986, J BIOL CHEM, V261, P7052; FISCHER TH, 1987, BIOCHEM BIOPH RES CO, V149, P700, DOI 10.1016/0006-291X(87)90424-4; FISCHER TH, 1990, J BIOL CHEM, V265, P19405; FISCHER TH, 1991, FEBS LETT, V282, P173; FITZGERALD LA, 1985, ANAL BIOCHEM, V151, P169, DOI 10.1016/0003-2697(85)90067-3; FOX JEB, 1993, THROMB HAEMOSTASIS, V70, P884; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1987, J BIOL CHEM, V262, P12627; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HASLAM RJ, 1979, BIOCHEM J, V178, P397, DOI 10.1042/bj1780397; HASLAM RJ, 1980, PLATELETS CELLULAR R, P213; HATA Y, 1991, J BIOL CHEM, V266, P6571; HATA Y, 1990, J BIOL CHEM, V265, P7104; HETTASCH JM, 1987, BIOCHIM BIOPHYS ACTA, V931, P49, DOI 10.1016/0167-4889(87)90049-8; HOSHIJIMA M, 1988, BIOCHEM BIOPH RES CO, V157, P851, DOI 10.1016/S0006-291X(88)80953-7; JENNINGS LK, 1981, J BIOL CHEM, V256, P6927; KASERGLANZMANN R, 1979, BIOCHIM BIOPHYS ACTA, V558, P344, DOI 10.1016/0005-2736(79)90271-2; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KAWATA M, 1989, J BIOL CHEM, V264, P15688; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LEPEUCH CJ, 1983, BIOCHIM BIOPHYS ACTA, V731, P456, DOI 10.1016/0005-2736(83)90041-X; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; NAGATA K, 1989, BIOCHEM BIOPH RES CO, V160, P235, DOI 10.1016/0006-291X(89)91646-X; NEWMAN PJ, 1992, J CELL BIOL, V119, P239, DOI 10.1083/jcb.119.1.239; ODA A, 1992, J BIOL CHEM, V267, P20075; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARK S, 1992, J BIOL CHEM, V267, P11612; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; SIESS W, 1990, BIOCHEM BIOPH RES CO, V170, P944, DOI 10.1016/0006-291X(90)92182-Y; THIEL G, 1988, EUR J BIOCHEM, V174, P601, DOI 10.1111/j.1432-1033.1988.tb14141.x; TORTI M, 1991, BIOCHIM BIOPHYS ACTA, V1070, P20, DOI 10.1016/0005-2736(91)90141-T; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; WHEELER ME, 1984, J CLIN INVEST, V74, P1080, DOI 10.1172/JCI111475; WHITE GC, 1989, THROMB RES, V56, P575, DOI 10.1016/0049-3848(89)90265-X; WHITE TE, 1990, P NATL ACAD SCI USA, V87, P758, DOI 10.1073/pnas.87.2.758; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	47	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17257	17261						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516336				2022-12-25	WOS:A1994NT84600043
J	SOROKIN, A; MOHAMMADI, M; HUANG, JT; SCHLESSINGER, J				SOROKIN, A; MOHAMMADI, M; HUANG, JT; SCHLESSINGER, J			INTERNALIZATION OF FIBROBLAST GROWTH-FACTOR RECEPTOR IS INHIBITED BY A POINT MUTATION AT TYROSINE-766	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED INTERNALIZATION; KINASE-ACTIVITY; BINDING SPECIFICITY; ENDOTHELIAL-CELLS; FGF RECEPTORS; FACTOR FAMILY; EGF RECEPTOR; SH3 DOMAINS; DYNAMIN; ENDOCYTOSIS	Binding of fibroblast growth factor (FGF) to the fibroblast growth factor receptor leads to autophosphorylation of the receptor on several tyrosine residues. Wild-type FGF receptor 1 (flg) and a mutated receptor (Y766F), in which an autophosphorylation site (Tyr-766) was mutated to phenylalanine, were expressed in rat myoblasts and in hematopoietic Ba/F3 cells. It was found that the point mutation at Tyr-766 resulted in a decrease in FGF receptor internalization, as well as a reduction in both ligand-induced FGF receptor down-regulation and degradation. It has been shown previously that phosphorylation of Tyr-766 is essential for interaction with phospholipase C gamma and that the Y766F FGF receptor mutant is unable to stimulate phosphatidylinositol hydrolysis and Ca2+ release from internal stores. The results presented in this report indicate that Tyr-766 is also essential for cellular trafficking of FGF receptor.	NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA	New York University			Mohammadi, Moosa/ABA-6745-2020; kasaei, fahime/T-7197-2018	Mohammadi, Moosa/0000-0003-2434-9437; Sorokin, Andrey/0000-0002-5660-0190				AARONSON SA, 1991, ANN NY ACAD SCI, V638, P62, DOI 10.1111/j.1749-6632.1991.tb49018.x; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BIKFALVI A, 1989, EXP CELL RES, V181, P75, DOI 10.1016/0014-4827(89)90183-3; BRIOZZO P, 1991, EXP CELL RES, V194, P252, DOI 10.1016/0014-4827(91)90362-X; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; DELL KR, 1992, J BIOL CHEM, V267, P21225; DIONNE CA, 1991, ANN NY ACAD SCI, V638, P161, DOI 10.1111/j.1749-6632.1991.tb49026.x; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GANNOUNZAKI L, 1991, EXP CELL RES, V197, P272, DOI 10.1016/0014-4827(91)90433-U; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Gospodarowicz D, 1990, CLIN ORTHOP RELAT R, V257, P231; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUANG SS, 1986, J BIOL CHEM, V261, P9568; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KUROKAWA M, 1989, J BIOL CHEM, V264, P7686; Ledoux Dominique, 1992, Progress in Growth Factor Research, V4, P107, DOI 10.1016/0955-2235(92)90026-E; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Moenner M, 1989, GROWTH FACTORS, V1, P115, DOI 10.3109/08977198909029121; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; Moscatelli D, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037499; PEARSE BMF, 1989, METHOD CELL BIOL, V31, P229; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SORKIN A, 1993, ONCOGENE, V8, P3021; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALLEE RB, 1992, J MUSCLE RES CELL M, V13, P493, DOI 10.1007/BF01737991; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WALICKE PA, 1991, J NEUROSCI, V11, P2249; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILEY HS, 1991, J BIOL CHEM, V266, P11083; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; 1992, CATALOG PROTOCOLS	65	101	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17056	17061						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516330				2022-12-25	WOS:A1994NT84600014
J	ZIEGLERHEITBROCK, HWL; WEDEL, A; SCHRAUT, W; STROBEL, M; WENDELGASS, P; STERNSDORF, T; BAUERLE, PA; HAAS, JG; RIETHMULLER, G				ZIEGLERHEITBROCK, HWL; WEDEL, A; SCHRAUT, W; STROBEL, M; WENDELGASS, P; STERNSDORF, T; BAUERLE, PA; HAAS, JG; RIETHMULLER, G			TOLERANCE TO LIPOPOLYSACCHARIDE INVOLVES MOBILIZATION OF NUCLEAR FACTOR KAPPA-B WITH PREDOMINANCE OF P50 HOMODIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TUMOR-NECROSIS-FACTOR; TRANSCRIPTIONAL ACTIVATION; MOLECULAR MECHANISMS; FACTOR EXPRESSION; HUMAN MONOCYTES; DOWN-REGULATION; CELL-LINE; GENE; SUBUNIT; MACROPHAGES	Stimulation of the human monocytic cell line Mono Mac 6 with lipopolysaccharide (LPS) leads to rapid and transient expression of cytokines like tumor necrosis factor (TNF). When such cells are precultured for 2 days with a low dose of LPS (20 ng/ml) followed by stimulation with a high dose of LPS (1 mu g/ml), expression of the TNF gene is minimal, i.e. the cells are tolerant. In nuclear run-on analysis, such tolerant cells show only a low degree of transcription, indicating that tolerance operates at or upstream of the transcription level, The CD14 LPS receptor is, however, up-regulated (not down-regulated) in tolerant cells, and LPS can, in fact, still lead to activation of tolerant cells as evidenced by mobilization of the transcription factor nuclear factor kappa B (NF-kappa B). Resolution of the NF-kappa B complex in gel shift analysis shows that the binding protein, mobilized in naive Mono Mac 6 cells, consists mainly of p50-p65 heterodimers, while in tolerant cells, the p50 homodimer is predominant. This increase in p50 homodimers coincides with an increase in p105 mRNA, suggestive of a transcriptional up-regulation of p50. Reporter gene analysis reveals that the NF-kappa B complex mobilized in tolerant cells is functionally inactive in that NF-kappa B dependent luciferase constructs containing the human immunodeficiency virus long terminal repeat or the TNF 5'-region show only minimal transactivation after LPS stimulation. Similar to Mono Mac 6 cells, primary blood monocytes, when precultured with a low dose of LPS, also become tolerant and produce little TNF after LPS stimulation. The tolerant blood monocytes also up regulate CD14, and they mobilize NF-kappa B with a predominance of p50 homodimers. Taken together, these results demonstrate that tolerance to LPS is determined by post-receptor mechanisms that involve an altered composition of the NF-kappa B complex.	UNIV FREIBURG,INST BIOCHEM,D-79104 FREIBURG,GERMANY	University of Freiburg	ZIEGLERHEITBROCK, HWL (corresponding author), INST IMMUNOL,GOETHESTR 31,D-80336 MUNICH,GERMANY.							BACHELERIE F, 1991, NATURE, V350, P709, DOI 10.1038/350709a0; BEESON PB, 1947, J EXP MED, V86, P29, DOI 10.1084/jem.86.1.29; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COGSWELL PC, 1993, J IMMUNOL, V150, P2794; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FREUDENBERG MA, 1988, INFECT IMMUN, V56, P1352, DOI 10.1128/IAI.56.5.1352-1357.1988; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAAS JG, 1989, J LEUKOCYTE BIOL, V46, P11, DOI 10.1002/jlb.46.1.11; HAAS JG, 1990, P NATL ACAD SCI USA, V87, P9563, DOI 10.1073/pnas.87.24.9563; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; ISRAEL A, 1987, P NATL ACAD SCI USA, V84, P2653, DOI 10.1073/pnas.84.9.2653; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KAUFMAN PA, 1992, J CLIN INVEST, V90, P121, DOI 10.1172/JCI115824; LABETA MO, 1993, IMMUNOLOGY, V80, P415; MATHISON JC, 1990, J CLIN INVEST, V85, P1108, DOI 10.1172/JCI114542; MESSER G, 1991, J EXP MED, V173, P209, DOI 10.1084/jem.173.1.209; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OMALLEY WE, 1962, J NATL CANCER I, V29, P1169; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; UEBERLA K, 1993, J ACQ IMMUN DEF SYND, V6, P227; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; ZIEGLERHEITBROCK HWL, 1992, IMMUNOLOGY, V75, P264; ZIEGLERHEITBROCK HWL, 1994, J LEUKOCYTE BIOL, V55, P73, DOI 10.1002/jlb.55.1.73; ZIEGLERHEITBROCK HWL, 1993, IMMUNOL TODAY, V14, P121, DOI 10.1016/0167-5699(93)90212-4; ZIEGLERHEITBROCK HWL, 1992, J IMMUNOL, V148, P1753; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	35	264	271	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17001	17004						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7516328				2022-12-25	WOS:A1994NT84600005
J	XU, X; STAR, RA; TORTORICI, G; MUALLEM, S				XU, X; STAR, RA; TORTORICI, G; MUALLEM, S			DEPLETION OF INTRACELLULAR CA2+ STORES ACTIVATES NITRIC-OXIDE SYNTHASE TO GENERATE CGMP AND REGULATE CA2+ INFLUX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR CELL; CAPACITATIVE CALCIUM ENTRY; FREE CYTOSOLIC CALCIUM; ENDOPLASMIC-RETICULUM; AMYLASE RELEASE; RELAXING FACTOR; CA-2+ RELEASE; AR42J CELLS; POOL; STIMULATION	The mechanism of activation of the agonist-stimulated Ca2+ entry pathway in the plasma membrane is not known. To determine the role of nitric-oxide synthase (NOS) and cGMP in the regulation of this pathway, we used intact and streptolysin O (SLO)-permeable pancre atic acini and measured the relationship between Ca2+ release from internal stores, the NO metabolic pathway, generation of cGMP, and activation of Ca2+ entry. We found that agonist- or thapsigargin (Tg)-activated Ca2+ entry is inhibited by L-NA, a specific inhibitor of NOS, and by LY83583, an inhibitor of guanylyl cyclase. Inhibition of Ca2+ entry by inhibition of NOS was reversed by the NO releasing molecules NO, and sodium nitroprusside (SNP) and by Bt(2)cGMP. Inhibition of Ca2+ entry by inhibition of guanylyl cyclase was reversed by Bt(2)cGMF, but not by the NO releasing agents. The use of L-NA-treated cells and different concentrations of SNP revealed that cGMP has a dual effect on Ca2+ entry. Increasing cGMP up to 10-fold above control activated Ca2+ entry. Further increase in cGMP up to 80-fold above control inhibited Ca2+ entry in a concentration-dependent manner. Measurement of cellular cGMP in intact cells showed that carbachol, Tg, and NO, increased cGMP to similar levels. The effects of carbachol and Tg were inhibited by L-NA and LY83588, whereas the effect of NO, was inhibited only by LY83583. SLO-permeabilized cells were shown to be agonist competent in that the agonist induced Ca2+ release from the inositol 1,4,5-trisphosphate (IP3) pool and activated a NO-dependent generation of cGMP. These cells were used to study the regulation of NOS by Ca2+ and by Ca2+ content of the internal stores. When internal stores were maintained loaded with Ca2+, increasing medium [Ca2+] up to 2.5 mu M only modestly in creased NOS activity. In contrast, the depletion of Ca2+ from internal stores markedly increased NOS activity independent of medium [Ca2+]. Thus, NOS senses both cytosolic [Ca2+], and internal store Ca2+ load. We propose that activation of Ca2+ entry involves an agonist-mediated Ca2+ release from internal stores which activates a cellular pool of NOS to generate cGMP, which then modulates Ca2+ entry pathway in the plasma membrane. This mechanism can explain the capacitative nature of Ca2+ entry. The biphasic effect of cGMF provides the cells with a negative feedback mechanism which inhibits Ca2+ entry during periods of high cell [Ca2+](i). This could allow oscillatory behavior of Ca2+ entry.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	XU, X (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938, R01DK046591] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38938, DK45929, DK46591] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUZZONE R, 1985, BIOCHEM J, V226, P621, DOI 10.1042/bj2260621; FASALATO C, 1993, J BIOL CHEM, V268, P20737; FASOLATO C, 1993, P NATL ACAD SCI USA, V90, P3068, DOI 10.1073/pnas.90.7.3068; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURCHGOTT R F, 1988, P401; HALLAM TJ, 1989, BIOCHEM J, V259, P125, DOI 10.1042/bj2590125; HIRAMATSU Y, 1992, J MEMBRANE BIOL, V129, P277; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; LUMME P, 1965, ACTA CHEM SCAND, V19, P2175, DOI 10.3891/acta.chem.scand.19-2175; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUALLEM S, 1988, AM J PHYSIOL, V255, pG229, DOI 10.1152/ajpgi.1988.255.2.G229; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; MUALLEM S, 1987, BIOCHEM BIOPH RES CO, V149, P213, DOI 10.1016/0006-291X(87)91626-3; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; Muallem Shmuel, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P351; MULSCH A, 1991, FEBS LETT, V294, P252, DOI 10.1016/0014-5793(91)81441-A; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; OSULLIVAN AJ, 1992, BIOCHEM J, V285, P597, DOI 10.1042/bj2850597; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PANDOL SJ, 1985, J BIOL CHEM, V260, P81; PANDOL SJ, 1990, CELL CALCIUM, V11, P477, DOI 10.1016/0143-4160(90)90080-E; PANDOL SJ, 1990, J BIOL CHEM, V265, P12846; PANDOL SJ, 1989, CELL CALCIUM, V10, P255, DOI 10.1016/0143-4160(89)90008-0; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; POWIS G, 1990, J BIOL CHEM, V265, P10266; Putney James W. Jr, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P143; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SAGE SO, 1987, J BIOL CHEM, V262, P16364; SALUJA AK, 1992, J BIOL CHEM, V267, P11202; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAUFFER PL, 1993, J BIOL CHEM, V268, P19769; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; TSUNODA Y, 1990, AM J PHYSIOL, V259, pG792, DOI 10.1152/ajpgi.1990.259.5.G792; VANIN AF, 1991, FEBS LETT, V289, P1, DOI 10.1016/0014-5793(91)80894-9; ZHANG BX, 1993, J BIOL CHEM, V268, P10997; ZHANG BX, 1992, J BIOL CHEM, V267, P15419; ZHAO H, 1990, J BIOL CHEM, V265, P20856	48	190	193	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12645	12653						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7513692				2022-12-25	WOS:A1994NH71600045
J	KAMATA, T; PUZON, W; TAKADA, Y				KAMATA, T; PUZON, W; TAKADA, Y			IDENTIFICATION OF PUTATIVE LIGAND-BINDING SITES WITHIN I-DOMAIN OF INTEGRIN ALPHA-2-BETA-1 (VLA-2, CD49B/CD29)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION GLYCOPROTEIN; COMPLEMENT RECEPTOR TYPE-3; AMINO-ACID SEQUENCE; VONWILLEBRAND-FACTOR; COLLAGEN RECEPTOR; ALPHA-SUBUNIT; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; LAMININ RECEPTOR; VI COLLAGEN	Integrin alpha2beta1 is a cell surface adhesion receptor for collagen and echovirus 1. Here we localized the epitopes for anti-alpha2 monoclonal antibodies using interspecies (human/bovine) alpha2 chimeras with different lengths of human alpha2 sequence on the amino-terminal side and site-directed mutagenesis. The antibodies that block the collagen and/or echovirus 1 binding to human alpha2beta1 (6F1, RMAC11, 12F1, and AA10) recognizes a small region (residues 173-259) within the I domain. Asp-160 and Arg-242 are critical for binding of the two other function-inhibiting antibodies, P1H5 and 5E8, respectively. Notably, mutations of Asp-151 and Asp-254 block the binding of alpha2beta1 to collagen. These data suggest that the I domain (residues 140-359) is critically involved in the ligand/receptor interactions, and collagen and echovirus 1 binding sites are adjacent or overlapping within the I domain. The sequence of the residues 173-259 of alpha2 overlap with the peptide sequences (M11 and M20) that derive from von Willebrand factor A1 and A3 domains (homologous to the alpha2 I domain) and block von Willebrand factor/collagen interaction, suggesting that the epitope region of alpha2 (residues 173-259) may really be involved in ligand recognition.	Scripps Res Inst, DEPT VASC BIOL, CVB-2, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA	Scripps Research Institute				takada, yoshikazu/0000-0001-5481-9589	NIGMS NIH HHS [GM47157] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047157] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGRAVES WS, 1987, P NATL ACAD SCI USA, V84, P464, DOI 10.1073/pnas.84.2.464; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; BENTLEY DR, 1986, BIOCHEM J, V239, P339, DOI 10.1042/bj2390339; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BERGELSON JM, 1993, J CLIN INVEST, V92, P232, DOI 10.1172/JCI116555; BONALDO P, 1989, J BIOL CHEM, V264, P5575; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHEN FA, 1991, J EXP MED, V173, P1111, DOI 10.1084/jem.173.5.1111; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; COLLER BS, 1989, BLOOD, V74, P182; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; GOLDMAN R, 1992, EUR J IMMUNOL, V22, P1109, DOI 10.1002/eji.1830220502; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOLE JE, 1984, J BIOL CHEM, V259, P3407; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; OCONNELL PJ, 1991, IMMUNOL CELL BIOL, V69, P103, DOI 10.1038/icb.1991.16; PISCHEL KD, 1987, J IMMUNOL, V138, P226; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; ROTH GJ, 1986, BIOCHEMISTRY-US, V25, P8357, DOI 10.1021/bi00374a004; SANTORO SA, 1988, BIOCHEM BIOPH RES CO, V153, P217, DOI 10.1016/S0006-291X(88)81211-7; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1988, J CELL BIOCHEM, V37, P385, DOI 10.1002/jcb.240370406; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; YAMADA KM, 1990, CANCER RES, V50, P4485; YAMADA KM, 1991, J BIOL CHEM, V266, P12809	45	159	165	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9659	9663						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511592				2022-12-25	WOS:A1994NE05300042
J	ALTENBERG, GA; VANOYE, CG; HAN, ES; DEITMER, JW; REUSS, L				ALTENBERG, GA; VANOYE, CG; HAN, ES; DEITMER, JW; REUSS, L			RELATIONSHIPS BETWEEN RHODAMINE-123 TRANSPORT, CELL-VOLUME, AND ION-CHANNEL FUNCTION OF P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; CHLORIDE CHANNELS; MEMBRANE; ATPASE; LINES	The P-glycoprotein (Pgp), a plasma membrane protein overexpressed in multidrug-resistant tumor cells, is thought to be both an ATPase that actively exports cytotoxic drugs and a Cl- channel activated by cell swelling. The partial reversal of multidrug resistance by Cl- transport blockers suggests a possible role for Cl- in Pgp mediated drug transport. We used multidrug-resistant Chinese hamster fibroblasts and human breast cancer cells expressing Pgp to study the roles of Cl- (and also Na+ and HCO3-/CO2) on Pgp-mediated efflux of the fluorescent dye rhodamine 123 (R123). In Pgp-expressing Chinese hamster fibroblasts, exposed to isosmotic solutions, the unidirectional efflux of R123 was not measurably changed by a similar to 60-min removal of Cl- (or by exposure to Na+-free, or nominally HCO3-/CO2-free medium); short term (2-3 min) ion substitutions were also ineffective. In human breast cancer cells transfected with human mdr1 cDNA, hyposmotic solutions activated a Cl- current but had no effect on the Pgp-mediated unidirectional efflux of R123. Additionally, in human breast cancer cells, the intracellular presence of R123 did not prevent activation of the Cl- current by hyposmotic solution. The lack of detectable effect of removal of Cl-, Na+, or HCO3- on Pgp-mediated R123 transport rules out direct coupling between substrate transport and transport of either of these ions by Pgp. The persistence of Pgp-mediated R123 efflux in osmotically swollen cells indicates that activation of the Pgp-associated Cl- current does not hinder the Pgp pump function. The lack of effect of R123 on swelling-activated Cl- current denotes that Pgp-mediated transport of organic substrates and Pgp-associated Cl- currents can occur at the same time in a single cell. These results underscore the dissociation between Pgp-mediated active drug transport and electrodiffusive Cl- transport.	UNIV TEXAS,MED BRANCH,DEPT PHYSIOL & BIOPHYS,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston				Altenberg, Guillermo/0000-0002-8932-740X	NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007205] Funding Source: NIH RePORTER; NCRR NIH HHS [RR07205] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALTENBERG G, 1990, METHOD ENZYMOL, V192, P650; ALTENBERG GA, 1993, P NATL ACAD SCI USA, V90, P9735, DOI 10.1073/pnas.90.20.9735; ALTENBERG GA, 1994, IN PRESS CANCER RES; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; BECK WT, 1992, MOL CELLULAR BIOL MU, P215; COPELLO J, 1993, J GEN PHYSIOL, V102, P177, DOI 10.1085/jgp.102.2.177; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; FAIRCHILD CR, 1990, MOL PHARMACOL, V37, P801; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Higgins CF, 1993, CURR OPIN CELL BIOL, V5, P684, DOI 10.1016/0955-0674(93)90140-L; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HOWELL N, 1984, CANCER RES, V44, P4023; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; NAKAGAWA M, 1992, CANCER RES, V52, P6175; PON DJ, 1993, EUR J PHARM-MOLEC PH, V245, P119, DOI 10.1016/0922-4106(93)90119-T; RONINSON IB, 1984, NATURE, V309, P626, DOI 10.1038/309626a0; RONINSON IB, 1992, MOL CELLULAR BIOL MU, P91; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Shalinsky D. R., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P315; SOGNIER MA, 1992, BIOCHEM PHARMACOL, V44, P1859, DOI 10.1016/0006-2952(92)90082-T; TOTH K, 1992, AM J PATHOL, V140, P1009; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0	24	67	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7145	7149						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7510282				2022-12-25	WOS:A1994NA03200019
J	MARKEN, JS; BAJORATH, J; EDWARDS, CP; FARR, AG; SCHIEVEN, GL; HELLSTROM, I; HELLSTROM, KE; ARUFFO, A				MARKEN, JS; BAJORATH, J; EDWARDS, CP; FARR, AG; SCHIEVEN, GL; HELLSTROM, I; HELLSTROM, KE; ARUFFO, A			MEMBRANE TOPOLOGY OF THE L6 ANTIGEN AND IDENTIFICATION OF THE PROTEIN EPITOPE RECOGNIZED BY THE L6 MONOCLONAL-ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-ASSOCIATED ANTIGEN; MOLECULAR-CLONING; ANTIPROLIFERATIVE ANTIBODY; CELL-SURFACE; CDNA; EXPRESSION; TAPA-1; SITE; FAMILY; TARGET	The murine monoclonal antibody (mAb) L6 recognizes an integral membrane glycoprotein that is highly expressed on lung, breast, colon, and ovarian carcinomas and is referred to as the L6 antigen. This antigen is an attractive target for therapeutic intervention due to its high level expression on malignant cells. We have previously reported the isolation of a cDNA encoding the human L6 antigen (H-L6). Here, we report the isolation of a cDNA clone encoding the murine L6 antigen (M-L6). This cDNA contains one long open reading frame, which encodes a 220-amino acid polypeptide that is 78% homologous to H-L6. This protein contains short NH2- and COOH-terminal hydrophilic domains and four hydrophobic regions, each long enough to span the plasma membrane. Each of these hydrophobic domains is separated by a hydrophilic domain, the longest of which contains one possible N-linked glycosylation site and is located between the third and fourth hydrophobic domains. We have previously demonstrated that the murine L6 mAb recognizes a protein epitope expressed on human tumor-derived cell lines. Now, using chimeric cDNA constructs encoding human-murine L6 antigen hybrids in conjunction with monoclonal antibody binding experiments, we show that the 42-residue hydrophilic domain of the L6 antigen, located between the third and fourth hydrophobic domains, is outside the cell and that residues in the NH2-terminal region of this domain are critical for the binding of the murine L6 mAb to H-L6.	UNIV WASHINGTON,DEPT BIOL STRUCT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	MARKEN, JS (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121, USA.		Bajorath, Jürgen/F-7493-2014					AMIOT M, 1990, J IMMUNOL, V145, P4322; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLASSON BJ, 1989, J EXP MED, V169, P1497, DOI 10.1084/jem.169.4.1497; DENARDO SJ, 1991, NUCL MED BIOL, V18, P621, DOI 10.1016/0883-2897(91)90032-G; DENARDO SJ, 1991, RADIOIMMUNOTHERAPY I, P227; FELL HP, 1992, J BIOL CHEM, V267, P15552; GAUGITSCH HW, 1991, EUR J IMMUNOL, V21, P377, DOI 10.1002/eji.1830210219; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GOODMAN GE, 1990, J CLIN ONCOL, V8, P1083, DOI 10.1200/JCO.1990.8.6.1083; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; HELLSTROM I, 1986, CANCER RES, V46, P3917; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOTTA H, 1988, CANCER RES, V48, P2955; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEVY S, 1991, J BIOL CHEM, V266, P14597; MARKEN JS, 1992, P NATL ACAD SCI USA, V89, P3503, DOI 10.1073/pnas.89.8.3503; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; VAICKUS L, 1985, J IMMUNOL, V135, P1987; VANNOESEL CJM, 1993, IMMUNOL TODAY, V14, P8, DOI 10.1016/0167-5699(93)90316-D; WRIGHT MD, 1990, J IMMUNOL, V144, P3195	28	28	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7397	7401						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7510285				2022-12-25	WOS:A1994NA03200058
J	OHMICHI, M; SAWADA, T; KANDA, Y; KOIKE, K; HIROTA, K; MIYAKE, A; SALTIEL, AR				OHMICHI, M; SAWADA, T; KANDA, Y; KOIKE, K; HIROTA, K; MIYAKE, A; SALTIEL, AR			THYROTROPIN-RELEASING-HORMONE STIMULATES MAP KINASE-ACTIVITY IN GH3 CELLS BY DIVERGENT PATHWAYS - EVIDENCE OF A ROLE FOR EARLY TYROSINE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; MAMMOTROPIC PITUITARY-CELLS; SWISS 3T3 CELLS; PROLACTIN SECRETION; SIGNAL TRANSDUCTION; TRK PROTOONCOGENE; PHOSPHOLIPASE-C; INTACT-CELLS; RAS	Regulation of the mitogen-activated protein (MAP) kinase by thyrotropin-releasing hormone (TRH) in GH3 rat pituitary tumor cells was investigated. Both TRH and epidermal growth factor (EGF) acutely activated this enzyme, via tyrosine and serine/threonine phosphorylation. Down-regulation of cellular protein kinase C (PKC) only partly inhibited the phosphorylation of MAP kinase by TRH, suggesting both PKC-dependent and -independent pathways. Both TRH and EGF similarly increased the phosphorylation of raf-1, by a PKC-independent mechanism. Both TRH and EGF stimulated the formation of a ras-GTP complex. This activation of ras by growth factors is thought to involve the tyrosine phosphorylation of Shc. EGF stimulated the tyrosine phosphorylation of three Shc proteins and their subsequent association with its receptor. TRH stimulated the tyrosine phosphorylation of the 52-kDa Shc protein, although neither phorbol esters nor the calcium ionophore A23187 had any effect, indicating that this effect of TRH was not dependent on PKC. Both TRH and EGF induced the association of tyrosine phosphorylated Shc proteins with a fusion protein containing SH2 and SH3 domains of Grb2, another important component in ras activation. These results provide evidence that MAP kinase is acutely activated by TRH through a PKC-dependent pathway as well as a second pathway possibly involving tyrosine phosphorylation.	WARNER LAMBERT PARKE DAVIS,PHARMACEUT RES,DIV SIGNAL TRANSDUCT,2800 PLYMOUTH RD,ANN ARBOR,MI 48105; UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; OSAKA UNIV,SCH MED,DEPT OBSTET & GYNECOL,SUITA,OSAKA 565,JAPAN	Pfizer; University of Michigan System; University of Michigan; Osaka University			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				AHN NG, 1990, J BIOL CHEM, V265, P11487; ALTSCHULER LR, 1993, NEUROENDOCRINOLOGY, V57, P23, DOI 10.1159/000126337; ANDERSON NG, 1991, J BIOL CHEM, V266, P10131; ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; CAMORATTO AM, 1985, ENDOCRINOLOGY, V116, P1506, DOI 10.1210/endo-116-4-1506; CANONICO PL, 1983, NEUROENDOCRINOLOGY, V37, P212, DOI 10.1159/000123545; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DANNIES PS, 1976, NATURE, V261, P707, DOI 10.1038/261707a0; DRUMMOND AH, 1984, MOL PHARMACOL, V25, P201; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; JAISWAL RK, 1993, J BIOL CHEM, V268, P7055; KOLESNICK RN, 1984, AM J PHYSIOL, V246, pE458, DOI 10.1152/ajpendo.1984.246.5.E458; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KOVACINA KS, 1990, J BIOL CHEM, V265, P1215; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUTZ MP, 1993, J BIOL CHEM, V268, P11119; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; MATSUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; OHMICHI M, 1992, BIOCHEMISTRY-US, V31, P4034, DOI 10.1021/bi00131a019; OHMICHI M, 1993, BIOCHEMISTRY-US, V32, P4650, DOI 10.1021/bi00068a024; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; OHMICHI M, 1990, NEUROENDOCRINOLOGY, V52, P75, DOI 10.1159/000125542; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REBECCHI MJ, 1983, BIOCHEM J, V216, P287, DOI 10.1042/bj2160287; REBECCHI MJ, 1983, J BIOL CHEM, V258, P227; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHONBRUNN A, 1980, J CELL BIOL, V85, P786, DOI 10.1083/jcb.85.3.786; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; TASHJIAN AH, 1971, BIOCHEM BIOPH RES CO, V43, P516, DOI 10.1016/0006-291X(71)90644-9; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TSAO H, 1990, J BIOL CHEM, V265, P15741; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAJIMA Y, 1984, J CELL PHYSIOL, V120, P249, DOI 10.1002/jcp.1041200220; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126	61	157	158	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3783	3788						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508919				2022-12-25	WOS:A1994MV63100095
J	WEI, XY; NEELY, A; LACERDA, AE; OLCESE, R; STEFANI, E; PEREZREYES, E; BIRNBAUMER, L				WEI, XY; NEELY, A; LACERDA, AE; OLCESE, R; STEFANI, E; PEREZREYES, E; BIRNBAUMER, L			MODIFICATION OF CA2+ CHANNEL ACTIVITY BY DELETIONS AT THE CARBOXYL-TERMINUS OF THE CARDIAC ALPHA(1) SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; SHAKER POTASSIUM CHANNEL; SKELETAL-MUSCLE; BETA-SUBUNIT; DIHYDROPYRIDINE RECEPTOR; FUNCTIONAL EXPRESSION; COMPLEMENTARY-DNA; VENTRICULAR MYOCYTES; GAMMA-SUBUNIT; ALPHA-1-SUBUNIT	Voltage-sensitive Ca2+ channels are multisubunit complexes that include, among others, a large alpha1 subunit, which by itself is sufficient to form a channel. Several alpha1 genes encoding L-, N-, and P-type Ca2+ channels have been cloned. These alpha1 genes share a high degree of sequence homology in the putative transmembrane regions, but vary substantially in the putative intracellular loops and the flanking amino and carboxyl termini. In the present study, we investigated the functional roles of the 665-amino acid long carboxyl terminus of a cardiac al by constructing deletion mutants. Expression in Xenopus oocytes of DELTAC1856, DELTAC1733, and DELTAC1700, which lack from 307 to 472 amino acids at the carboxyl terminus, led to inward Ba2+ currents that were 4- to 6-fold greater than observed with the 2171-amino acid long wild type alpha1. Ionic currents increased without a change in the amount of charge moved during voltage-dependent gating, suggesting that the increase in ionic currents was not due to an increase in the number of channels that were expressed. Single channel analysis revealed an unaltered unitary conductance. Thus, removal of up to 70% of the carboxyl terminus increased current density by facilitating the coupling between the voltage-dependent gating and channel opening, leading to an increased opening probability of the channel.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV NEUROSCI, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	WEI, XY (corresponding author), BAYLOR COLL MED, DEPT MOLEC PHYSIOL & BIOPHYS, HOUSTON, TX 77030 USA.		Neely, Alan/A-8715-2009	Neely, Alan/0000-0002-6007-2159	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046702, P01HL037044, R55HL046702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038970] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46702, HL-37044] Funding Source: Medline; NIAMS NIH HHS [AR38970] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALDRICH RW, 1983, NATURE, V306, P436, DOI 10.1038/306436a0; BEAM KG, 1992, NATURE, V360, P169, DOI 10.1038/360169a0; BOSSE E, 1990, FEBS LETT, V267, P153, DOI 10.1016/0014-5793(90)80312-7; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; HESCHELER J, 1988, J PHYSIOL-LONDON, V404, P259, DOI 10.1113/jphysiol.1988.sp017289; Hofmann F, 1990, Curr Top Cell Regul, V31, P223; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KLOCKNER U, 1992, PFLUG ARCH EUR J PHY, V420, P413, DOI 10.1007/BF00374479; LACERDA AE, 1989, J GEN PHYSIOL, V93, P1243, DOI 10.1085/jgp.93.6.1243; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; PATLAK J, 1982, J GEN PHYSIOL, V79, P333, DOI 10.1085/jgp.79.3.333; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; RAKOWSKI RF, 1993, J GEN PHYSIOL, V101, P117, DOI 10.1085/jgp.101.1.117; REGULLA S, 1991, EMBO J, V10, P45, DOI 10.1002/j.1460-2075.1991.tb07919.x; ROTMAN EI, 1992, J BIOL CHEM, V267, P16100; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; TAGLIALATELA M, 1992, BIOPHYS J, V61, P78, DOI 10.1016/S0006-3495(92)81817-9; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1991, NATURE, V352, P800, DOI 10.1038/352800a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WEI XY, 1989, MOL PHARMACOL, V35, P541; WEI XY, 1991, J BIOL CHEM, V266, P21943; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	45	175	178	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1635	1640						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507480				2022-12-25	WOS:A1994MR98800017
J	HWANG, S; LOPEZ, CA; HECK, DE; GARDNER, CR; LASKIN, DL; LASKIN, JD; DENHARDT, DT				HWANG, S; LOPEZ, CA; HECK, DE; GARDNER, CR; LASKIN, DL; LASKIN, JD; DENHARDT, DT			OSTEOPONTIN INHIBITS INDUCTION OF NITRIC-OXIDE SYNTHASE GENE-EXPRESSION BY INFLAMMATORY MEDIATORS IN MOUSE KIDNEY EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELAXING FACTOR; RAT; OSTEOCLASTS; MESSENGER	We report that osteopontin (OPN), a secreted, Arg-Gly-Asp-containing phosphoprotein expressed at high levels in the kidney, suppresses nitric oxide (NO) synthesis induced by the inflammatory mediators gamma-interferon and lipopolysaccharide in primary mouse kidney proximal tubule epithelial cells. Northern blot and immunofluorescence analyses of inducible nitric oxide synthase (iNOS) expression revealed that the inflammatory mediators increased iNOS mRNA and protein levels. Recombinant human OPN (purified from both mammalian cells and from Escherichia coli) inhibited this response by a process that was blocked by anti-OPN antiserum and by the peptide GRGDS, but not GRGES. The data suggest that inhibition of NO synthesis by OPN in these kidney cells is mediated by an integrin, possibly the alpha(v)beta3 integrin, which is known to be an OPN receptor. NO is believed to control blood flow through the glomerulus, regulating salt and water balance, and to be important as a defense against tumor cells and infecting microorganisms. The ability of OPN to inhibit the induction of iNOS suggests that OPN may be an important regulator of the NO signaling pathway and NO-mediated cytotoxic processes.	RUTGERS UNIV,DEPT BIOL SCI,NELSON BIOL LABS,PISCATAWAY,NJ 08855; RUTGERS UNIV,DEPT PHARMACOL & TOXICOL,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT ENVIRONM & COMMUNITY MED,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center				Laskin, Debra/0000-0003-1832-7311	NIA NIH HHS [AG07972] Funding Source: Medline; NIDCD NIH HHS [DC01295] Funding Source: Medline; NIEHS NIH HHS [ES04738] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007972] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001295] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BREZIS M, 1991, J CLIN INVEST, V88, P390, DOI 10.1172/JCI115316; BROWN LF, 1992, MOL BIOL CELL, V3, P1169, DOI 10.1091/mbc.3.10.1169; CATTELL V, 1990, KIDNEY INT, V38, P1056, DOI 10.1038/ki.1990.312; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; COOK HT, 1991, AM J PATHOL, V139, P1047; DENHARDT DT, 1993, IN PRESS FASEB J; DING A, 1990, J IMMUNOL, V145, P940; ELLIGET KA, 1991, IN VITRO CELL DEV B, V27, P739; FLORES ME, 1992, EXP CELL RES, V201, P526, DOI 10.1016/0014-4827(92)90305-R; GIACHELLI CM, IN PRESS KIDNEY INT; GOUREAU O, 1993, P NATL ACAD SCI USA, V90, P4276, DOI 10.1073/pnas.90.9.4276; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HECK DE, 1992, J BIOL CHEM, V267, P21277; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; ISHII K, 1991, J PHARMACOL EXP THER, V256, P38; KHOKHA R, 1987, ANTICANCER RES, V7, P653; LOPEZ CA, 1993, LAB INVEST, V69, P355; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARKEWITZ BA, 1993, J CLIN INVEST, V91, P2138, DOI 10.1172/JCI116439; MCCALL TB, 1992, BIOCHEM BIOPH RES CO, V186, P680, DOI 10.1016/0006-291X(92)90800-Z; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NICOLSON AG, 1993, BIOCHEM BIOPH RES CO, V193, P1269, DOI 10.1006/bbrc.1993.1762; NORIS M, 1993, KIDNEY INT, V44, P445, DOI 10.1038/ki.1993.264; PUNJABI CJ, 1992, J IMMUNOL, V149, P2179; ROSS FP, 1993, J BIOL CHEM, V268, P9901; Sambrook J, 1989, MOL CLONING LABORATO; SCHINI VB, 1993, FASEB J, V7, pA243; STOOS BA, 1992, J CLIN INVEST, V89, P761, DOI 10.1172/JCI115653; WILCOX CS, 1992, P NATL ACAD SCI USA, V89, P11993, DOI 10.1073/pnas.89.24.11993; XUAN JW, IN PRESS J CELL BIOC; ZIMOLO Z, 1993, AM J PHYSIOL, V69, P355	32	168	178	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					711	715						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506262				2022-12-25	WOS:A1994MR21900111
J	LATHAM, GJ; LLOYD, RS				LATHAM, GJ; LLOYD, RS			DEOXYNUCLEOTIDE POLYMERIZATION BY HIV-1 REVERSE-TRANSCRIPTASE IS TERMINATED BY SITE-SPECIFIC STYRENE OXIDE ADDUCTS AFTER TRANSLESION SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							STEADY-STATE KINETICS; DNA-POLYMERASE-I; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; ZIDOVUDINE AZT; MECHANISM; TEMPLATE; VIRUS; SEQUENCE; REPLICATION	In an effort to integrate an understanding of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) structure with its function, the action of HIV-1 RT was examined in vitro on DNA templates modified with a model bulky DNA adduct. Styrene oxide was site-specifically and stereospecifically coupled to the N-6 position of adenine to form six different adducted templates. Primer extension assays were conducted under conditions defining both single and multiple encounters between the polymerase and the damaged template-primer. The extent of polymerization observed for each adduct was found to depend on both the chirality of the damage and the lesion sequence context. When HIV-1 RT polymerization was limited by single encounters with damaged DNA, the SO lesions were readily bypassed as evidenced by minimal pausing at the adducted base. However, RT replication of all SO-modified templates was significantly terminated 3-5 nucleotides after translesion synthesis but before reaching the end of the template. These truncated products could be readily extended when additional encounters between enzyme and template primer were permitted. A model is presented to explain these results in the context of HIV-1 RT structure during DNA replication.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555; VANDERBILT UNIV,CTR MOLEC TOXICOL,NASHVILLE,TN 37235; VANDERBILT UNIV,DEPT BIOCHEM,NASHVILLE,TN 37235	University of Texas System; University of Texas Medical Branch Galveston; Vanderbilt University; Vanderbilt University				Lloyd, R. Stephen/0000-0001-7273-372X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267, R01ES005509, P01ES005355] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05509, ES00267, ES05355] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; ABBOTTS J, 1988, J BIOL CHEM, V263, P15094; ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BASU AK, 1993, BIOCHEMISTRY-US, V32, P4708, DOI 10.1021/bi00069a004; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BELGUISEVALLADI.P, 1994, J MOL BIOL, V268, P10312; CAI H, 1993, J BIOL CHEM, V268, P23567; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; HARRIS CM, 1991, J AM CHEM SOC, V113, P4328, DOI 10.1021/ja00011a044; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; HRUSZKEWYCZ A, 1992, CARCINOGENESIS, V13, P2347, DOI 10.1093/carcin/13.12.2347; HRUSZKEWYCZ AM, 1991, CARCINOGENESIS, V12, P2185, DOI 10.1093/carcin/12.11.2185; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LATHAM GJ, 1993, J BIOL CHEM, V268, P23427; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; ODAY CL, 1992, NUCLEIC ACIDS RES, V20, P5403, DOI 10.1093/nar/20.20.5403; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; REARDON JE, 1993, J BIOL CHEM, V268, P8743; REY MA, 1984, BIOCHEM BIOPH RES CO, V121, P126, DOI 10.1016/0006-291X(84)90696-X; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P7531, DOI 10.1021/bi00080a027; SINGER B, 1989, P NATL ACAD SCI USA, V86, P8271, DOI 10.1073/pnas.86.21.8271; WANG CI, 1992, BIOCHEMISTRY-US, V31, P3671, DOI 10.1021/bi00129a016	32	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28527	28530						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7525577				2022-12-25	WOS:A1994PU16800002
J	CHEN, L; MAO, SJT; MCLEAN, LR; POWERS, RW; LARSEN, WJ				CHEN, L; MAO, SJT; MCLEAN, LR; POWERS, RW; LARSEN, WJ			PROTEINS OF THE INTER-ALPHA-TRYPSIN INHIBITOR FAMILY STABILIZE THE CUMULUS EXTRACELLULAR-MATRIX THROUGH THEIR DIRECT BINDING WITH HYALURONIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-OOCYTE COMPLEX; MOUSE; SERUM; IDENTIFICATION; EXPANSION; DOMAINS; MASS; LINK; CD44	We have previously identified a glycoprotein of the inter-alpha-trypsin inhibitor family of proteins as a serum factor responsible for the stabilization of the expanding cumulus mass. In this study, the mechanism of interaction of this cumulus extracellular matrix stabilizing factor (cESF) with hyaluronic acid (HA) has been explored. It was found that the pH optimum for binding of cESF and HA is 7 and that binding is sensitive to ionic strength. The dissociation constant is about 1.9 x 10(-8) ar in 10 mM sodium phosphate buffer (pH 7.2). Circular dichroism studies show that cESF contains about 24% alpha-helical and 42% beta-sheet structure. Gross conformational changes in cESF, however, are not detected in the presence of HA. me also found that modification of lysine residues of cESF with citraconic anhydride greatly reduced its binding with HA and completely abolished its cumulus stabilizing activity, and deblocking lysine residues restored its capacity to bind with HA and its cumulus matrix stabilizing activity. This evidence supports the hypotheses that cESF stabilizes the expanding cumulus extracellular matrix by directly binding with HA and that cESF may serve as a structural protein to organize the formation of the cumulus extracellular matrix. Our evidence also supports the view that binding of cESF and HA is through a stereo-specific charge interaction. Putative binding sites of cESF that interact with HA are postulated.	UNIV CINCINNATI, COLL MED, DEPT ANAT & CELL BIOL, CINCINNATI, OH 45267 USA; MARION MERRELL DOW RES INST, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati; Dow Chemical Company					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029894] Funding Source: NIH RePORTER; NICHD NIH HHS [HD29894] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASHER R, 1992, EXP CELL RES, V203, P80, DOI 10.1016/0014-4827(92)90042-7; Atassi M Z, 1972, Methods Enzymol, V25, P546, DOI 10.1016/S0076-6879(72)25053-4; BARTA E, 1993, BIOCHEM J, V292, P947, DOI 10.1042/bj2920947; CAMAIONI A, 1993, J BIOL CHEM, V268, P20473; CASTILLO GM, 1993, FEBS LETT, V318, P292, DOI 10.1016/0014-5793(93)80531-X; CHEN L, 1993, MOL REPROD DEV, V34, P87, DOI 10.1002/mrd.1080340114; CHEN L, 1992, J BIOL CHEM, V267, P12380; CHEN L, 1990, MOL REPROD DEV, V26, P236, DOI 10.1002/mrd.1080260307; DEKEL N, 1979, BIOL REPROD, V21, P9, DOI 10.1095/biolreprod21.1.9; DOWNS SM, 1986, GAMETE RES, V15, P115, DOI 10.1002/mrd.1120150203; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; ENGHILD JJ, 1993, J BIOL CHEM, V268, P8711; EPPIG JJ, 1979, NATURE, V281, P483, DOI 10.1038/281483a0; FRANCK C, 1983, SCAND J CLIN LAB INV, V43, P151; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HUANG L, 1993, J BIOL CHEM, V268, P26725; HUTADILOK N, 1988, ANN RHEUM DIS, V47, P377, DOI 10.1136/ard.47.5.377; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; MAFORTHING KG, 1992, RECEPTOR LIGAND INTE; MAHIBROWN CA, 1983, GAMETE RES, V8, P1, DOI 10.1002/mrd.1120080102; MCKEEHAN WL, 1986, J BIOL CHEM, V261, P5378; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; PERIDES G, 1989, J BIOL CHEM, V264, P5981; PERIDES G, 1991, BIOCHIM BIOPHYS ACTA, V1075, P248, DOI 10.1016/0304-4165(91)90273-J; POTEMPA J, 1989, J BIOL CHEM, V264, P15109; PRATT CW, 1987, BIOCHEMISTRY-US, V26, P2855, DOI 10.1021/bi00384a029; REISINGER P, 1985, BIOL CHEM H-S, V366, P479, DOI 10.1515/bchm3.1985.366.1.479; SALUSTRI A, 1989, J BIOL CHEM, V264, P13840; Sandson J, 1965, Trans Assoc Am Physicians, V78, P304; TENGBLAD A, 1979, BIOCHIM BIOPHYS ACTA, V578, P281, DOI 10.1016/0005-2795(79)90158-2; UNDERHILL CB, 1980, J BIOL CHEM, V255, P4544; YANG BH, 1993, J BIOL CHEM, V268, P8617; YANG JT, 1986, METHOD ENZYMOL, V130, P208	33	146	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28282	28287						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7525572				2022-12-25	WOS:A1994PV77200076
J	NAIM, HY; JACOB, R; NAIM, H; SAMBROOK, JF; GETHING, MJH				NAIM, HY; JACOB, R; NAIM, H; SAMBROOK, JF; GETHING, MJH			THE PRO REGION OF HUMAN INTESTINAL LACTASE-PHLORHIZIN HYDROLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; N-LINKED GLYCOSYLATION; BRUSH-BORDER MEMBRANE; CELL-FREE SYNTHESIS; PHLORHIZIN HYDROLASE; INTRAMOLECULAR CHAPERONE; INTRACELLULAR-TRANSPORT; SUCRASE-ISOMALTASE; EPITHELIAL-CELLS; O-GLYCOSYLATION	Human small intestinal lactase-phlorizin hydrolase (LPH) is synthesized as a single-chain polypeptide precursor, prepro-LPH, that undergoes two sequential cleavage steps: the first in the endoplasmic reticulum to pro-LPH (215-kDa) and the second, following terminal glycosylation in the Golgi apparatus, to mature 180-kDa LPH (denoted LPH beta). The LPH beta molecule is subsequently targetted to the brush-border membrane. Characterization of the N-terminal profragment (denoted LPH alpha) of pro-LPH using an epitope-specific, anti-peptide polyclonal antibody reveals that LPH alpha (i) has an apparent molecular weight of similar to 100,000, (ii) is not associated with LPH beta after cleavage of pro-LPH has occurred, and (iii) is not transported to the cell surface or secreted into the extracellular medium. In biosynthetic labeling experiments, a clear precursor/product relationship could be demonstrated between pro-LPH and the LPH alpha and LPH beta polypeptides. Further, LPH alpha has a significantly shorter half-life than LPH beta. LPH alpha is neither N- nor O-glycosylated, despite the presence of 5 potential N-glycosylation sites. LPH alpha, which is rich in cysteine and hydrophobic amino acid residues, may fold rapidly into a tight and rigid globular domain in which carbohydrate attachment sites are no longer accessible to glycosyltransferases. When expressed independently in COS-1 cells, the LPH beta polypeptide forms a misfolded, transport-incompetent molecule. We propose a role for the LPH alpha domain within the pro-LPH molecule as an intramolecular chaperone during folding in the ER.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	NAIM, HY (corresponding author), UNIV DUSSELDORF, INST MICROBIOL, PROT SECRET GRP, UNIV STR 1, D-40225 DUSSELDORF, GERMANY.				NIGMS NIH HHS [GM 37547] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037547] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BROWNING TH, 1969, J CLIN INVEST, V48, P1423, DOI 10.1172/JCI106108; BULLEID NJ, 1992, BIOCHEM J, V286, P275, DOI 10.1042/bj2860275; BULLER HA, 1987, J BIOL CHEM, V262, P17206; DANIELSEN EM, 1984, BIOCHEM BIOPH RES CO, V122, P82; EHLERS MRW, 1989, BIOCHEMISTRY-US, V28, P5311, DOI 10.1021/bi00439a001; ENDO Y, 1976, J BIOCHEM-TOKYO, V80, P1; FRANSEN JAM, 1985, EUR J CELL BIOL, V38, P6; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HENNING SJ, 1981, AM J PHYSIOL, V241, pG199, DOI 10.1152/ajpgi.1981.241.3.G199; HENNING SJ, 1985, ANNU REV PHYSIOL, V47, P231; HOOPER NM, 1987, BIOCHEM J, V247, P85, DOI 10.1042/bj2470085; INOUYE M, 1991, ENZYME, V45, P314, DOI 10.1159/000468904; JASCUR T, 1991, BIOCHEMISTRY-US, V30, P1908, DOI 10.1021/bi00221a025; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; KRETCHMER N, 1971, GASTROENTEROLOGY, V61, P805; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAIURI L, 1991, GASTROENTEROLOGY, V100, P359, DOI 10.1016/0016-5085(91)90203-W; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MONTGOMERY RK, 1991, FASEB J, V5, P2824, DOI 10.1096/fasebj.5.13.1916106; NAIM HY, 1992, BIOCHEM J, V286, P451, DOI 10.1042/bj2860451; NAIM HY, 1988, J BIOL CHEM, V263, P19709; NAIM HY, 1988, J BIOL CHEM, V263, P7242; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1992, J BIOL CHEM, V267, P25494; NAIM HY, 1991, J BIOL CHEM, V266, P12313; NAIM HY, 1992, BIOCHEM J, V285, P13, DOI 10.1042/bj2850013; NAIM HY, 1993, DYN NUTR R, V3, P102; Patchett A A, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P1; QUAN R, 1990, J BIOL CHEM, V265, P15882; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; SHAKINESHLEMAN SH, 1992, J BIOL CHEM, V267, P10690; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; STERCHI EE, 1980, CLIN CHIM ACTA, V102, P49, DOI 10.1016/0009-8981(80)90432-5; STERCHI EE, 1990, J CLIN INVEST, V86, P1329, DOI 10.1172/JCI114842; THOMSEN DR, 1984, P NATL ACAD SCI-BIOL, V81, P659, DOI 10.1073/pnas.81.3.659; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; WACKER H, 1992, J BIOL CHEM, V267, P18744; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; YEH KY, 1991, GASTROENTEROLOGY, V101, P312, DOI 10.1016/0016-5085(91)90005-6; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0; [No title captured]	47	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26933	26943						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7523415				2022-12-25	WOS:A1994PQ93100055
J	JACQUES, PS; WOHRL, BM; OTTMANN, M; DARLIX, JL; LEGRICE, SFJ				JACQUES, PS; WOHRL, BM; OTTMANN, M; DARLIX, JL; LEGRICE, SFJ			MUTATING THE PRIMER GRIP OF P66 HIV-1 REVERSE-TRANSCRIPTASE IMPLICATES TRYPTOPHAN-229 IN TEMPLATE-PRIMER UTILIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ANGSTROM RESOLUTION; TRANSFER RNA(LYS-3); CRYSTAL-STRUCTURE; DNA; HETERODIMER; POLYMERASE; CELLS; MUTAGENESIS; RETROVIRUS	''BcgI cassette'' mutagenesis was used to prepare variants of p66 human immunodeficiency virus (HIV)-1 reverse transcriptase with amino acid substitutions between residues Glu(224) and Trp(229). Mutant polypeptides were reconstituted in vitro with wild type p51 to generate the ''selectively mutated'' heterodimer series p66(224A)/p51-p66(229A)/p51. Purified enzymes were characterized with respect to dimerization, DNA polymerase, RNase H, and tRNA(Lys-3) binding. The combined analyses indicate that while alteration of p66 residues Glu(224)-Leu(228) has minimal consequences, the DNA polymerase activities of mutant p66(229A)/p51 are impaired. DNase I footprinting illustrates that this mutant does not form a stable replication complex with a model template-primer. In vivo studies indicate that the equivalent mutation eliminates viral infectivity, suggesting a contribution of Trp(229) toward architecture of the p66 primer grip.	CASE WESTERN RESERVE UNIV,SCH MED,DIV INFECT DIS,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; ECOLE NORMALE SUPER LYON,INSERM,LABORETRO,F-69364 LYON,FRANCE	Case Western Reserve University; Case Western Reserve University; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)			LUC, DARLIX JEAN/AAE-9268-2020	ottmann, michele/0000-0002-6911-0705	NIAID NIH HHS [AI 31147] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031147] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751; BENARTZI H, 1992, NUCLEIC ACIDS RES, V20, P5115, DOI 10.1093/nar/20.19.5115; BOYER PL, 1992, J VIROL, V66, P1031, DOI 10.1128/JVI.66.2.1031-1039.1992; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HIZI A, 1992, J BIOL CHEM, V267, P18255; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; HOSTOMSKY Z, 1994, J VIROL, V68, P1970, DOI 10.1128/JVI.68.3.1970-1971.1994; HOTTIGER M, 1994, J BIOL CHEM, V269, P986; HOWARD KJ, 1991, J BIOL CHEM, V266, P23003; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACQUES PS, 1994, J BIOL CHEM, V269, P1388; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KONG H, 1994, J BIOL CHEM, V269, P683; LEDERER H, 1992, EMBO J, V11, P1131, DOI 10.1002/j.1460-2075.1992.tb05153.x; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; MSERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911; MULLER B, 1991, J BIOL CHEM, V266, P14709; MURPHEYCORB M, 1986, NATURE, V321, P435, DOI 10.1038/321435a0; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; OLMSTED RA, 1989, P NATL ACAD SCI USA, V86, P2448, DOI 10.1073/pnas.86.7.2448; PRASAD VR, 1993, REVERSE TRANSCRIPTAS, P135; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RESTLE T, 1992, FEBS LETT, V300, P97, DOI 10.1016/0014-5793(92)80172-D; RICHTERCOOK NJ, 1992, J BIOL CHEM, V267, P15952; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SCHMITZ A, 1979, NUCLEIC ACIDS RES, V6, P111, DOI 10.1093/nar/6.1.111; SMITH SD, 1984, CANCER RES, V44, P5657; SOBOL RW, 1991, BIOCHEMISTRY-US, V30, P10623, DOI 10.1021/bi00108a004; STEPHENS RM, 1986, SCIENCE, V231, P589, DOI 10.1126/science.3003905; TELESNITSKY A, 1993, P NATL ACAD SCI USA, V90, P1276, DOI 10.1073/pnas.90.4.1276; WOHRL BM, 1993, J BIOL CHEM, V268, P13617; WOHRL BM, 1994, J BIOL CHEM, V269, P8541; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	42	71	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26472	26478						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7523408				2022-12-25	WOS:A1994PQ93000081
J	SEWELL, TJ; LAM, E; MARTIN, MM; LESZYK, J; WEIDNER, J; CALAYCAY, J; GRIFFIN, P; WILLIAMS, H; HUNG, S; CRYAN, J; SIGAL, NH; WIEDERRECHT, GJ				SEWELL, TJ; LAM, E; MARTIN, MM; LESZYK, J; WEIDNER, J; CALAYCAY, J; GRIFFIN, P; WILLIAMS, H; HUNG, S; CRYAN, J; SIGAL, NH; WIEDERRECHT, GJ			INHIBITION OF CALCINEURIN BY A NOVEL FK-506-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS ISOMERASE; CYTOSOLIC-BINDING-PROTEIN; AMINO-ACID-SEQUENCE; PEPTIDYL-PROLYL ISOMERASE; LYMPHOCYTE-T ACTIVATION; CALCIUM-RELEASE CHANNEL; CYCLOSPORINE-A; IMMUNOSUPPRESSANT FK506; RYANODINE RECEPTOR; FK506-BINDING PROTEIN	FK-506, a potent immunosuppressive drug, acts during the commitment phase of T-lymphocyte activation to block a subset of calcium-associated events necessary for transcription of certain early lymphokine genes. The drug binds to an abundant, cytosolic 11.8-kDa protein termed the FK-506-binding protein (FKBP12). The FKBP12.FK-506 complex inhibits calcineurin, a calcium-dependent phosphatase that is a component of the signal transduction pathway leading to early lymphokine gene transcription. FKBP12 is one member of a growing gene family. Prior to this report, all other FKBP family members had been irrelevant to the mechanism of action of FK-506 because no other FKBP.FK-506 complexes were able to bind and inhibit calcineurin. Here, we report the purification and characterization of a novel FK-506-binding protein, FKBP12.6. Having 85% amino acid sequence identity to FKBP12, FKBP12.6 is, among the FKBPs, most closely related to FKBP12. When complexed with FK-506, FKBP12.6 binds to and inhibits calcineurin, making it only the second FKBP discovered thus far to do so. The ability to inhibit calcineurin establishes the potential relevance of FKBP12.6 to the immunosuppressive or toxic side effects of FK-506.	MERCK SHARP & DOHME LTD,RES LABS,DEPT IMMUNOL RES,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,RES LABS,DEPT ANALYT BIOCHEM,RAHWAY,NJ 07065; WORCESTER FDN EXPTL BIOL INC,SHREWSBURY,MA 01545	Merck & Company; Merck & Company; Worcester Foundation for Biomedical Research								APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COLLINS JH, 1991, BIOCHEM BIOPH RES CO, V178, P1288, DOI 10.1016/0006-291X(91)91033-9; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FLIRI H, 1993, ANN NY ACAD SCI, V696, P47; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GALAT A, 1993, FEBS LETT, V216, P689; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1988, TRANSPLANTATION, V46, pS29; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KIEFFER LJ, 1992, J BIOL CHEM, V267, P5503; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; KOPRAK S, 1994, FASEB J, V8, pA567; KUMANO K, 1991, TRANSPL P, V23, P512; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LYSON T, 1993, CIRC RES, V73, P596, DOI 10.1161/01.RES.73.3.596; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; MCPHERSON PS, 1993, J BIOL CHEM, V268, P19785; MOZIER NM, 1990, EUR J BIOCHEM, V194, P19, DOI 10.1111/j.1432-1033.1990.tb19421.x; OHARA K, 1990, TRANSPLANT P, V22, P83; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHIVELY JE, 1987, ANAL BIOCHEM, V163, P517, DOI 10.1016/0003-2697(87)90257-0; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIEKIERKA JJ, 1990, J BIOL CHEM, V265, P21011; SIEKIERKA JJ, 1989, J IMMUNOL, V143, P1580; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STEINER J, 1992, P NATL ACAD SCI USA, V358, P584; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TIMERMAN AP, 1994, BIOCHEM BIOPH RES CO, V198, P701, DOI 10.1006/bbrc.1994.1101; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TRANDINH CC, 1992, FASEB J, V6, P3410, DOI 10.1096/fasebj.6.15.1464374; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WIEDERRECHT G, 1992, J BIOL CHEM, V267, P21753; Williams J W, 1979, Methods Enzymol, V63, P437	57	75	79	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21094	21102						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	7520438				2022-12-25	WOS:A1994PC40300044
J	LU, B; ROTHNAGEL, JA; LONGLEY, MA; TSAI, SY; ROOP, DR				LU, B; ROTHNAGEL, JA; LONGLEY, MA; TSAI, SY; ROOP, DR			DIFFERENTIATION-SPECIFIC EXPRESSION OF HUMAN KERATIN-1 IS MEDIATED BY A COMPOSITE AP-1 STEROID-HORMONE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS TYPE-18; MOUSE EPIDERMAL-CELLS; CULTURED HUMAN KERATINOCYTES; RETINOID X-RECEPTOR; THYROID-HORMONE; GENE-EXPRESSION; C-FOS; TERMINAL DIFFERENTIATION; TRANSCRIPTION FACTOR; CALCIUM REGULATION	Human keratin 1 (HK1) expression is associated with the loss of mitotic activity in epidermal keratinocytes and restricted to an intermediate stage of terminal differentiation. Recently, the control elements that mediate this differentiation-specific expression were identified (Huff, C. A, Yuspa, S. H., and Rosenthal, D. (1993) J. Biol. Chem. 268, 377-384). We now report the characterization of one of these elements. Footprint analysis on a 249-base pair fragment containing the calcium responsive element (CaRE) revealed two adjacent protected regions. The 5' most footprint contains an AP-1 consensus sequence while the 3' footprint encodes two inverted repeats of the canonical hormone response recognition sequence. Deletion of the AP-1 protected region abolished the calcium response in a reporter construct. Calcium activation of the reporter construct containing the intact CaRE was unaffected by the addition of thyroid hormone or estrogen. However, vitamin D-3 was able to suppress calcium induction by the CaRE, and this suppression could be abrogated by the coaddition of retinoic acid. These studies show that AP-1 factors bind to the 5' element to mediate the calcium response while members of the steroid hormone receptor superfamily interact with the 3' element to modulate the calcium response.	BAYLOR UNIV,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR UNIV,DEPT DERMATOL,HOUSTON,TX 77030	Baylor University; Baylor University			Rothnagel, Joe/A-4874-2010	Rothnagel, Joe/0000-0002-6710-3165	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025479] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25479] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASSELINEAU D, 1990, DIFFERENTIATION, V45, P221, DOI 10.1111/j.1432-0436.1990.tb00476.x; BIKLE DD, 1986, BIOCHEMISTRY-US, V25, P1545, DOI 10.1021/bi00355a013; BLUMENBERG M, 1992, J INVEST DERMATOL, V98, pS42, DOI 10.1111/1523-1747.ep12462194; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; CRIPE T P, 1990, New Biologist, V2, P450; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FISHER C, 1991, DEVELOPMENT, V111, P253; FISHER C, 1987, J INVEST DERMATOL, V88, P661, DOI 10.1111/1523-1747.ep12470281; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1981, CELL, V25, P617, DOI 10.1016/0092-8674(81)90169-0; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARPER JR, 1988, J INVEST DERMATOL, V91, P150, DOI 10.1111/1523-1747.ep12464396; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Higuchi R., 1989, PCR TECHNOLOGY, P61; HOGGARD N, 1991, MOL ENDOCRINOL, V5, P1748, DOI 10.1210/mend-5-11-1748; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; HOSOMI J, 1983, ENDOCRINOLOGY, V113, P1950, DOI 10.1210/endo-113-6-1950; HUFF CA, 1993, J BIOL CHEM, V268, P377; HUITFELDT HS, 1991, CARCINOGENESIS, V12, P2063, DOI 10.1093/carcin/12.11.2063; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KIM YK, 1989, GENE, V77, P123, DOI 10.1016/0378-1119(89)90366-1; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENORMAND P, 1992, MOL CELL BIOL, V12, P2793, DOI 10.1128/MCB.12.6.2793; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MALMQVIST KG, 1984, NUCL INSTRUM METH B, V3, P611, DOI 10.1016/0168-583X(84)90447-6; MATSUMOTO K, 1990, BIOCHEM BIOPH RES CO, V166, P916, DOI 10.1016/0006-291X(90)90898-W; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; OFFORD EA, 1990, J VIROL, V64, P4792, DOI 10.1128/JVI.64.10.4792-4798.1990; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; PASTORCIC M, 1986, MOL CELL BIOL, V6, P2784, DOI 10.1128/MCB.6.8.2784; PRIBNOW D, 1992, MOL ENDOCRINOL, V6, P1003, DOI 10.1210/me.6.7.1003; REGNIER M, 1991, DIFFERENTIATION, V47, P173, DOI 10.1111/j.1432-0436.1991.tb00235.x; REGNIER M, 1986, J INVEST DERMATOL, V87, P472, DOI 10.1111/1523-1747.ep12455517; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROOP DR, 1983, P NATL ACAD SCI-BIOL, V80, P716, DOI 10.1073/pnas.80.3.716; ROOP DR, 1988, BIOL WOOL HAIR, P311; ROOP DR, 1989, PHARM RETINOIDS SKIN, P1; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROSENTHAL DS, 1991, CELL GROWTH DIFFER, V2, P107; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; ROTHNAGEL JA, 1987, J BIOL CHEM, V262, P15643; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHWEIZER J, 1984, CELL, V37, P159, DOI 10.1016/0092-8674(84)90311-8; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; STUMPF WE, 1984, CELL TISSUE RES, V238, P489; TAMAI Y, 1991, GENE, V104, P169, DOI 10.1016/0378-1119(91)90247-9; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VAHLQUIST A, 1987, UPSALA J MED SCI, V92, P253, DOI 10.3109/03009738709178695; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WOODCOCKMITCHELL J, 1982, J CELL BIOL, V95, P580, DOI 10.1083/jcb.95.2.580; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	69	90	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7443	7449						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7510286				2022-12-25	WOS:A1994NA03200066
J	LAUDANNA, C; CONSTANTIN, G; BARON, P; SCARPINI, E; SCARLATO, G; CABRINI, G; DECHECCHI, C; ROSSI, F; CASSATELLA, MA; BERTON, G				LAUDANNA, C; CONSTANTIN, G; BARON, P; SCARPINI, E; SCARLATO, G; CABRINI, G; DECHECCHI, C; ROSSI, F; CASSATELLA, MA; BERTON, G			SULFATIDES TRIGGER INCREASE OF CYTOSOLIC-FREE CALCIUM AND ENHANCED EXPRESSION OF TUMOR-NECROSIS-FACTOR-ALPHA AND INTERLEUKIN-8 MESSENGER-RNA IN HUMAN NEUTROPHILS - EVIDENCE FOR A ROLE OF L-SELECTIN AS A SIGNALING MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; FUNCTION-ASSOCIATED ANTIGEN-1; ENDOTHELIAL CELL RECOGNITION; LYMPHOCYTE HOMING RECEPTOR; CENTRAL-NERVOUS-SYSTEM; ADHESION MOLECULE-1; T-CELLS; RESPIRATORY BURST; GENE-EXPRESSION; ACTIVATION	Sulfatides have been established recently as ligands for L-selectin, and we investigated whether they trigger transmembrane signals through ligation of L-selectin. We found that sulfatides trigger the increase of cytosolic free calcium in neutrophils and that this effect was strictly dependent on sulfation of the galactose ring, as non-sulfated galactocerebrosides were not stimulatory. Chymotrypsin and phorbol 12-myristate 13-acetate treatment of neutrophils caused shedding of L-selectin, but not of class I major histocompatibility complex antigens or beta 2 integrins, and blunted the capability of neutrophils to respond to sulfatides with an increase of cytosolic free calcium. Four different anti-L-selectin antibodies (DREG-200, LAM1/3, LAM1/6, and LAM1/10), but not four control antibodies directed against different surface molecules of neutrophils, also triggered an increase of cytosolic free calcium. The anti-L-selectin antibodies were stimulatory both if used in a soluble form, after cross linking with anti-mouse F(ab')(2) fragments, and immobilized to protein A of Staphylococcus aureus through the Fc fragment. With immobilized antibodies, an increase of cytosolic free calcium was found also by plating neutrophils on antibodies bound to protein A-coated coverslips and monitoring the increase of cytosolic free calcium by fluorescence microscopy. Both sulfatides and anti-L-selectin antibody effects were not inhibited by pertussis toxin, thus indicating that a pertussis toxin-sensitive GTP-binding protein was not involved in signal transduction. Sulfatides also triggered an increase of tumor necrosis factor-alpha and interleukin-8 mRNAs in neutrophils. Also to act as stimuli of cytokine mRNA expression, sulfatides required sulfation of the galactose ring, as non-sulfated galactocerebrosides were not stimulatory, and depended on expression of L-selectin, as shedding of this molecules induced by chymotrypsin blunted their effects. These findings suggest that L-selectin can transduce signals activating selective cell function.	UNIV VERONA,INST GEN PATHOL,I-37134 VERONA,ITALY; UNIV MILAN,DINO FERRARI CTR,DEPT NEUROL,MILAN,ITALY; CYST FIBROSIS CTR,VERONA,ITALY	University of Verona; University of Milan			Cabrini, Giulio/K-4761-2016; Cassatella, M A/B-8037-2013; Scarpini, Elio/K-6547-2016	Cabrini, Giulio/0000-0003-2720-0742; Cassatella, M A/0000-0001-7824-1806; Constantin, Gabriela/0000-0001-8978-3539; Scarpini, Elio/0000-0002-6395-2119				BAZZONI F, 1991, J LEUKOCYTE BIOL, V50, P223, DOI 10.1002/jlb.50.3.223; BAZZONI F, 1991, J EXP MED, V173, P771, DOI 10.1084/jem.173.3.771; BERTON G, 1992, J CELL BIOL, V116, P1007, DOI 10.1083/jcb.116.4.1007; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CASSATELLA MA, 1992, J IMMUNOL, V148, P3216; CASSATELLA MA, 1989, J CLIN INVEST, V83, P1570, DOI 10.1172/JCI114054; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DAVIS LS, 1990, J IMMUNOL, V145, P785; DECHECCHI MC, 1993, J BIOL CHEM, V268, P11321; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALMANNN R, 1991, BIOCHEM BIOPH RES CO, V174, P236; HUANG K, 1991, J CLIN INVEST, V88, P1778, DOI 10.1172/JCI115498; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; IMAI Y, 1993, NATURE, V361, P555; JUNG TM, 1990, J IMMUNOL, V144, P3130; JUTILA MA, 1991, CELL IMMUNOL, V132, P201, DOI 10.1016/0008-8749(91)90019-8; KAKINUMA K, 1982, FEBS LETT, V145, P16, DOI 10.1016/0014-5793(82)81197-6; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; KUHLMAN P, 1991, J IMMUNOL, V146, P1773; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAUDANNA C, 1993, IMMUNOLOGY, V80, P273; LEDBETTER JA, 1985, J IMMUNOL, V135, P1819; LEMONNIER FA, 1982, J IMMUNOL METHODS, V54, P9, DOI 10.1016/0022-1759(82)90108-9; LEW DP, 1993, CURR OPIN HEMATOL, V1, P106; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LLOYD AR, 1992, IMMUNOL TODAY, V13, P169, DOI 10.1016/0167-5699(92)90121-M; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; MOY VT, 1992, J EXP MED, V175, P1, DOI 10.1084/jem.175.1.1; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; SPERTINI O, 1991, J IMMUNOL, V147, P942; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SUZUKI Y, 1993, BIOCHEM BIOPH RES CO, V190, P426, DOI 10.1006/bbrc.1993.1065; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WACHOLTZ MC, 1989, J EXP MED, V170, P431, DOI 10.1084/jem.170.2.431; WILLENBORG DO, 1988, J IMMUNOL, V140, P3401; WILLENBORG DO, 1989, FASEB J, V3, P1968, DOI 10.1096/fasebj.3.8.2721857; YUROCHKO AD, 1992, P NATL ACAD SCI USA, V89, P9034, DOI 10.1073/pnas.89.19.9034	46	182	185	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4021	4026						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508438				2022-12-25	WOS:A1994MW98900021
J	LEEDS, FS; BRASS, EP				LEEDS, FS; BRASS, EP			HEPATIC COBALAMIN DEFICIENCY INDUCED BY HYDROXYCOBALAMIN[C-LACTAM] TREATMENT IN RATS IS ASSOCIATED WITH DECREASED MITOCHONDRIAL MESSENGER-RNA CONTENTS AND ACCUMULATION OF POLYCISTRONIC MITOCHONDRIAL RNAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; MAMMALIAN MITOCHONDRIA; METHYLMALONIC ACIDURIA; LIVER-MITOCHONDRIA; SKELETAL-MUSCLE; THYROID-HORMONE; TRANSCRIPTION; VITAMIN-B12; METHYLATION; DNA	Treatment of rats with hydroxycobalamin[c-lactam] (HCCL), a cobalamin antagonist, results in both increased hepatic mitochondrial content and the development of defects in mitochondrial ubiquinol:cytochrome c oxidoreductase and cytochrome c oxidase. The present study was designed to evaluate changes in hepatic mitochondrial RNA contents in response to HCCL treatment in rats. After 2 weeks of HCCL treatment, hepatic contents of the mature mitochondrial mRNAs (expressed normalized to 28 S rRNA) encoding subunit II of cytochrome c oxidase (CO II), subunit 1 of NADH dehydrogenase (ND1), and cytochrome b were reduced to values 40-60% of those observed in RNA from control liver tissue. In addition, HCCL induced a pronounced accumulation of high molecular weight RNA species which hybridized to mitochondrial probes and represented polycistronic RNA sequences. The polycistronic RNAs were products of the heavy strand of the mitochondrial genome, and major species demonstrated hybridization patterns consistent with identifications corresponding to the 12-16 S rRNA, 12-16 S-ND1, 16 S ND1, and CO II-ATP synthase subunit 6 regions of the mitochondrial genome. Maximal expression of the polycistronic mitochondrial RNA was observed after 2 weeks of HCCL treatment. Thus, HCCL treatment interferes with mitochondrial RNA processing and decreases the content of mature mitochondrial mRNAs. Altered expression of the mitochondrial genome may be responsible for the decreased electron transport chain activity known to result from HCCL administration.	CASE WESTERN RESERVE UNIV, DEPT MED, DIV CLIN PHARMACOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT PHARMACOL, DIV CLIN PHARMACOL, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University				Leeds, Frederic/0000-0002-8712-0915	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R23DK036069, R01DK036069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36069] Funding Source: Medline; NIGMS NIH HHS [2 T32 GM07250] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; AW TY, 1989, ANNU REV NUTR, V9, P229, DOI 10.1146/annurev.nu.09.070189.001305; BONNETT R, 1957, J CHEM SOC, P1158, DOI 10.1039/jr9570001158; BRASS EP, 1990, BIOCHEM J, V266, P809; BRASS EP, 1992, BIOCHEM J, V288, P175, DOI 10.1042/bj2880175; CANATORE P, 1987, FEBS LETT, V213, P144; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; CHRISTMAN JK, 1993, CARCINOGENESIS, V14, P551, DOI 10.1093/carcin/14.4.551; CHUMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; COLEMAN WB, 1991, BIOCHIM BIOPHYS ACTA, V1058, P178, DOI 10.1016/S0005-2728(05)80235-X; DOI T, 1989, J NUTR SCI VITAMINOL, V35, P1, DOI 10.3177/jnsv.35.1; Dolphin D., 1971, METHOD ENZYMOL, V18, P34; DUBIN DT, 1978, J MOL BIOL, V121, P523, DOI 10.1016/0022-2836(78)90398-4; DUBIN DT, 1978, NUCLEIC ACIDS RES, V5, P4385, DOI 10.1093/nar/5.11.4385; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; GAINES G, 1987, J BIOL CHEM, V262, P1907; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; GROSSMAN LI, 1990, AM J HUM GENET, V46, P415; HARE JF, 1982, J BIOL CHEM, V257, P3575; HEDDI A, 1993, J BIOL CHEM, V268, P12156; HERRERA E, 1968, BIOCHIM BIOPHYS ACTA, V170, P244, DOI 10.1016/0304-4165(68)90004-4; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; KADOWAKI T, 1988, FEBS LETT, V233, P51, DOI 10.1016/0014-5793(88)81354-1; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KLIASHEVA RI, 1983, BIOL NAUKI, V10, P17; KRAHENBUHL S, 1990, J CLIN INVEST, V86, P2054, DOI 10.1172/JCI114942; KRAHENBUHL S, 1991, J BIOL CHEM, V266, P20998; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; METZ J, 1992, ANNU REV NUTR, V12, P59, DOI 10.1146/annurev.nu.12.070192.000423; MUTVEI A, 1989, EUR J BIOCHEM, V180, P235, DOI 10.1111/j.1432-1033.1989.tb14638.x; NAGLEY P, 1991, TRENDS GENET, V7, P1, DOI 10.1016/0168-9525(91)90002-8; NARAYAN P, 1992, ADV ENZYMOL RAMB, V65, P255; NELSON BD, 1987, CURR TOP BIOENERG, V15, P221; PRINCE DL, 1986, MOL BIOL REP, V11, P51, DOI 10.1007/BF00417596; STABLER SP, 1991, J CLIN INVEST, V87, P1422, DOI 10.1172/JCI115148; TANDLER B, 1991, ANAT RECORD, V231, P1, DOI 10.1002/ar.1092310102; ULLU E, 1991, P NATL ACAD SCI USA, V88, P10074, DOI 10.1073/pnas.88.22.10074; VANITALLIE CM, 1988, MOL ENDOCRINOL, V2, P332, DOI 10.1210/mend-2-4-332; VANITALLIE CM, 1990, ENDOCRINOLOGY, V127, P55, DOI 10.1210/endo-127-1-55; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; WILSON SD, 1986, ARCH BIOCHEM BIOPHYS, V244, P248, DOI 10.1016/0003-9861(86)90114-1	45	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3947	3951						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508436				2022-12-25	WOS:A1994MW98900010
J	PENG, YL; SHIRANO, Y; OHTA, H; HIBINO, T; TANAKA, K; SHIBATA, D				PENG, YL; SHIRANO, Y; OHTA, H; HIBINO, T; TANAKA, K; SHIBATA, D			A NOVEL LIPOXYGENASE FROM RICE - PRIMARY STRUCTURE AND SPECIFIC EXPRESSION UPON INCOMPATIBLE INFECTION WITH RICE BLAST FUNGUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SATIVUM SEED LIPOXYGENASE; ESCHERICHIA-COLI; JASMONIC ACID; ACTIVE ENZYME; CDNA CLONING; LEAVES; SEQUENCE; GENE; MECHANISM; 5-LIPOXYGENASE	A novel lipoxygenase cDNA (3,007 base pairs) was isolated from rice leaves (Oryza sativa cv. Aichiasahi) which had been infected with an incompatible race of the rice blast fungus, Magnaporthe grisea. A single copy of the gene is present in the rice genome and encodes a protein of 923 residues with a molecular weight of 102,714. This gene product shares the least amino acid sequence homology among plant lipoxygenases identified to date. A novel feature of this gene product is a putative transit peptide sequence at the amino terminus, suggesting the enzyme is localized in chloroplasts. An active lipoxygenase was expressed from the cDNA in Escherichia coli and characterized. The lipoxygenase introduces molecular oxygen exclusively into the C-13 position of linoleic and linolenic acids. The gene is expressed at high levels 15 h after inoculation with an incompatible race of M. grisea, at a low level after inoculation with a compatible race of the pathogen, and is not expressed in mock-infected leaves. Gene expression begins at the same time that the pathogen begins to penetrate into leaf tissue. This novel lipoxygenase gene expression is a part of the early response of the host to pathogenic attack.	MITSUI PLANT BIOTECHNOL RES INST,TCI-A10,SENGEN 2-1-6,TSUKUBA,IBARAKI 305,JAPAN; KYOTO PREFECTURAL UNIV,DEPT AGR BIOCHEM,KYOTO 606,JAPAN	Kyoto Prefectural University			Ohta, Hiroyuki/B-1840-2014	Ohta, Hiroyuki/0000-0002-1068-3242				Axelrod B., 1981, METH ENZYMOL, V441, P451, DOI [10.1016/0076-6879(81)71055-3, DOI 10.1016/0076-6879(81)71055-3]; BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; CROFT KPC, 1990, PHYSIOL MOL PLANT P, V36, P49, DOI 10.1016/0885-5765(90)90091-B; EALING PM, 1989, BIOCHEM J, V264, P929, DOI 10.1042/bj2640929; EALING PM, 1988, BIOCHEM J, V253, P915, DOI 10.1042/bj2530915; FARMER EE, 1992, PLANT CELL, V4, P129, DOI 10.1105/tpc.4.2.129; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JOFUKU KD, 1988, PLANT MOL BIOL PRACT, P37; KATO T, 1992, PLANT PHYSIOL, V98, P324, DOI 10.1104/pp.98.1.324; KATO T, 1983, NATURWISSENSCHAFTEN, V70, P200, DOI 10.1007/BF01047565; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KOCH E, 1992, PLANT PHYSIOL, V99, P571, DOI 10.1104/pp.99.2.571; KODA Y, 1991, PHYTOCHEMISTRY, V30, P1435, DOI 10.1016/0031-9422(91)84180-Z; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LI WX, 1991, AGR BIOL CHEM TOKYO, V55, P1041, DOI 10.1080/00021369.1991.10870743; LOSEL DM, 1978, NEW PHYTOL, V80, P167, DOI 10.1111/j.1469-8137.1978.tb02277.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marston F. A. O., 1987, DNA CLONING, P59; MELAN MA, 1993, PLANT PHYSIOL, V101, P441, DOI 10.1104/pp.101.2.441; MINOR W, 1993, BIOCHEMISTRY-US, V32, P6320, DOI 10.1021/bi00076a003; OHTA H, 1991, PLANT PHYSIOL, V97, P94, DOI 10.1104/pp.97.1.94; OHTA H, 1992, EUR J BIOCHEM, V206, P331, DOI 10.1111/j.1432-1033.1992.tb16931.x; OHTA H, 1990, PLANT CELL PHYSIOL, V31, P1117; PEEVER TL, 1989, PLANT PHYSIOL, V90, P867, DOI 10.1104/pp.90.3.867; PENG YL, 1988, CAN J BOT, V66, P730, DOI 10.1139/b88-107; PENG YL, 1989, THESIS KYOTO U JAPAN; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBATA D, 1991, PLANT MOL BIOL, V16, P353, DOI 10.1007/BF00020569; SHIBATA D, 1987, J BIOL CHEM, V262, P10080; SHIBATA D, 1988, J BIOL CHEM, V263, P6816; SHIMURA M, 1983, AGR BIOL CHEM TOKYO, V47, P1983, DOI 10.1080/00021369.1983.10865897; SHIRANO Y, 1990, FEBS LETT, V271, P128, DOI 10.1016/0014-5793(90)80388-Y; SIEDOW JN, 1991, ANNU REV PLANT PHYS, V42, P145, DOI 10.1146/annurev.pp.42.060191.001045; YAMAMOTO H, 1986, J PHYTOPATHOL, V116, P329, DOI 10.1111/j.1439-0434.1986.tb00928.x; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; YENOFSKY RL, 1988, MOL GEN GENET, V211, P215, DOI 10.1007/BF00330597; 1994, IN PRESS PLANT MOL B, V12	41	145	170	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3755	3761						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508918				2022-12-25	WOS:A1994MV63100091
J	PLATANIAS, LC; SWEET, ME				PLATANIAS, LC; SWEET, ME			INTERFERON-ALPHA INDUCES RAPID TYROSINE PHOSPHORYLATION OF THE VAV PROTOONCOGENE PRODUCT IN HEMATOPOIETIC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSCRIPTION FACTOR; PROTOONCOGENE PRODUCT; SH3 DOMAINS; GENE; DIFFERENTIATION; INDUCTION; RECEPTOR; PROTEINS; KINASE; ACID	The vav proto-oncogene product (p95vav) is specifically expressed in cells of the hematopoietic system, contains one Src homology 2 and two Src homology 3 domains, and is a substrate for receptor and non-receptor tyrosine kinases. Immunoblotting experiments using an anti-phosphotyrosine monoclonal antibody showed that interferon alpha (IFNalpha) induces rapid tyrosine phosphorylation of p95vav after binding to its cell surface receptor in the U-266 human myeloma cell line. The IFNalpha-induced tyrosine phosphorylation of p950vav was time- and dose-dependent, confirming the specificity of the process. IFNalpha-dependent tyrosine phosphorylation of p95vav was also observed in other hematopoietic cell lines of B-cell origin (Daudi), T-cell origin (MOLT-4), and promyelocytic origin (HL-60). Immunoprecipitation experiments performed with P-32-labeled U-266 cells and phosphoaminoacid analysis of the bands corresponding to p95vav showed that p95vav is phosphorylated on serine residues prior to IFNalpha stimulation of the cells. After IFNa stimulation significant amounts of phosphorylation of p95vav on tyrosine residues were detectable. Tyrosine phosphorylation of p95vav in U-266 and HL-60 cells was also induced by two other Type I IFNs, IFNbeta and EFNomega. Altogether these data suggest that the vav proto-oncogene product is a substrate for a Type I IFN-regulated tyrosine kinase(s) and may be involved in the signal transduction pathway of Type I IFNs in hematopoietic cells.	EDWARD HINES VET ADM MED CTR,MAYWOOD,IL	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital	PLATANIAS, LC (corresponding author), LOYOLA UNIV,DIV HEMATOL ONCOL,BLDG 54,RM 49,2160 S 1ST AVE,MAYWOOD,IL 60153, USA.							ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; COLAMONICI OR, 1992, BLOOD, V80, P744; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COLAMONICI OR, 1994, IN PRESS J BIOL CHEM, V269; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GALLAND F, 1992, ONCOGENE, V7, P585; GULBINS E, 1993, SCIENCE, V260, P82; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; HEMMI H, 1987, BLOOD, V69, P501; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARAN A, 1990, MOL CELL BIOL, V10, P4424, DOI 10.1128/MCB.10.8.4424; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUGUCHI T, 1992, BLOOD S1, V80, pA247; PETSKA S, 1987, ANNU REV BIOCHEM, V56, P727; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; TOMIDA M, 1982, BIOCHEM BIOPH RES CO, V104, P30, DOI 10.1016/0006-291X(82)91936-2; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L	24	92	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3143	3146						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508909				2022-12-25	WOS:A1994MV63100006
J	IRMINGER, JC; VOLLENWEIDER, FM; NEERMANARBEZ, M; HALBAN, PA				IRMINGER, JC; VOLLENWEIDER, FM; NEERMANARBEZ, M; HALBAN, PA			HUMAN PROINSULIN CONVERSION IN THE REGULATED AND THE CONSTITUTIVE PATHWAYS OF TRANSFECTED ATT20 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RELATED PEPTIDES; PANCREATIC BETA-CELL; SECRETORY PATHWAY; SEQUENCE REQUIREMENTS; PRECURSOR CLEAVAGE; PROCESSING PROTEINASES; SUBTILISIN FAMILY; PLASMA-MEMBRANE; GOLGI-COMPLEX; ATT-20 CELLS	AtT20 (mouse pituitary corticotroph) cells were stably transfected with human proinsulin cDNA. Clone H12 displayed low basal release of insulin-like immunoreactivity (< 1% cell content/30 min) with 17-fold stimulation by isobutylmethylxanthine/forskolin. Clone H23, by contrast, showed higher basal release (2.8% cell content/30 min) and only 6-fold stimulation. To follow the kinetics of conversion and release of only newly synthesized proinsulin, cells were pulse-chased, and labeled proinsulin-related products were analyzed by high pressure liquid chromatography. In the cells of both clones, [H-3]proinsulin was converted to insulin with des-31,32-split proinsulin as the only detectable intermediate. While basal release of labeled products from H12 cells was low (3%/60 min), it was rapid and elevated from H23 cells (12.5% by 30 min and 24.8% by 60 min of chase) with [H-3]des-31,32-split proinsulin the predominant molecular form. Stimulation of [H-3] insulin release increased with time, reaching 3.8-fold by 90 min of chase, whereas that of [H-3]des-31,32-split proinsulin was approximately 1.5-fold regardless of the chase time. Rapid secretion of newly synthesized products that is insensitive to secretagogues is the hallmark of the constitutive pathway. Thus in H23 cells an unusually large amount of proinsulin is diverted to the constitutive pathway, where it is partially converted to des-31,32-split proinsulin before release.			IRMINGER, JC (corresponding author), UNIV GENEVA,MED CTR,LABS RECH LOUIS JEANTET,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND.			Neerman-Arbez, Marguerite/0000-0002-9351-4195	NIDDK NIH HHS [DK-35292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arvan Peter, 1992, Trends in Cell Biology, V2, P327; BAILYES EM, 1992, BIOCHEM J, V286, P223, DOI 10.1042/bj2860223; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRENNAN SO, 1991, J BIOL CHEM, V266, P21504; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; COHEN RM, 1986, METABOLISM, V35, P1137, DOI 10.1016/0026-0495(86)90027-2; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; FERBER S, 1991, MOL ENDOCRINOL, V5, P319, DOI 10.1210/mend-5-3-319; GIVEN BD, 1985, J CLIN INVEST, V76, P1398, DOI 10.1172/JCI112116; GOLD G, 1984, DIABETES, V33, P556, DOI 10.2337/diabetes.33.6.556; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GROSS D, 1988, FEBS LETT, V241, P205, DOI 10.1016/0014-5793(88)81062-7; GROSS DJ, 1989, J BIOL CHEM, V264, P21486; GROSS DJ, 1989, P NATL ACAD SCI USA, V86, P4107, DOI 10.1073/pnas.86.11.4107; GUMBINER B, 1982, CELL, V28, P51, DOI 10.1016/0092-8674(82)90374-9; HAKES DJ, 1991, ENDOCRINOLOGY, V129, P3053, DOI 10.1210/endo-129-6-3053; HALBAN PA, 1991, DIABETOLOGIA, V34, P767, DOI 10.1007/BF00408349; HALBAN PA, 1980, J BIOL CHEM, V255, P6003; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Huttner WB, 1989, CURR OPIN CELL BIOL, V1, P648, DOI 10.1016/0955-0674(89)90029-X; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; KARRENBAUER A, 1990, CELL, V63, P259, DOI 10.1016/0092-8674(90)90159-C; KAWABATA S, 1992, J BIOL CHEM, V267, P10331; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDGERWOOD EC, 1992, BIOCHIM BIOPHYS ACTA, V1159, P9, DOI 10.1016/0167-4838(92)90068-O; LINDBERG I, 1991, MOL ENDOCRINOL, V5, P1361, DOI 10.1210/mend-5-10-1361; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MOORE HP, 1983, NATURE, V302, P434, DOI 10.1038/302434a0; MOORE HPH, 1985, J CELL BIOL, V101, P1773, DOI 10.1083/jcb.101.5.1773; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; NAGAMATSU S, 1992, ENDOCRINOLOGY, V130, P748, DOI 10.1210/en.130.2.748; ORCI L, 1985, DIABETOLOGIA, V28, P528, DOI 10.1007/BF00281987; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; POWELL SK, 1988, J CELL BIOL, V106, P1843, DOI 10.1083/jcb.106.6.1843; REHEMTULLA A, 1992, BLOOD, V79, P2349; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SIZONENKO S, 1993, DIABETES, V42, P933, DOI 10.2337/diabetes.42.6.933; SIZONENKO SV, 1991, BIOCHEM J, V278, P621, DOI 10.1042/bj2780621; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; TAYLOR NA, 1992, BIOCHEM J, V286, P619, DOI 10.1042/bj2860619; Tooze S A, 1992, Semin Cell Biol, V3, P357, DOI 10.1016/1043-4682(92)90021-M; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VOLLENWEIDER F, 1992, J BIOL CHEM, V267, P14629; WATANABE T, 1992, J BIOL CHEM, V267, P8270	61	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1756	1762						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507483				2022-12-25	WOS:A1994MR98800035
J	PRESTON, GM; JUNG, JS; GUGGINO, WB; AGRE, P				PRESTON, GM; JUNG, JS; GUGGINO, WB; AGRE, P			MEMBRANE TOPOLOGY OF AQUAPORIN CHIP - ANALYSIS OF FUNCTIONAL EPITOPE-SCANNING MUTANTS BY VECTORIAL PROTEOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR INTRINSIC PROTEIN; WATER CHANNELS; XENOPUS-OOCYTES; CDNA; IDENTIFICATION; RECONSTITUTION; PURIFICATION; EXPRESSION; TRANSPORT; DOMAIN	CHIP is the archetypal member of the aquaporins, a widely expressed family of membrane water channels. The NH2- and COOH-terminal halves of CHIP are sequence-related, and hydropathy analysis predicted six membrane-spanning domains with five connecting loops (A-E). Here, we determined the membrane topology of CHIP expressed in Xenopus oocytes using biologically active recombinant channels. CHIP is glycosylated at Asn-42, indicating loop A is exofacial. An epitope from the coronavirus E1 glycoprotein was inserted into CHIP and localized to the outer or inner leaflet of the membrane by alpha-chymotrypsin digestion of intact oocytes or inside-out membrane vesicles. The E1 epitope at Thr-120 was protease-sensitive in intact oocytes, indicating that loop C is exofacial. The E1 epitope at Lys-6, Arg-162, or Lys-267 was protease-sensitive in inside-out membrane vesicles, confirming the cytoplasmic location of the NH2 and COOH termini and loop D. Insertions into loops B and E did not produce active water channels, but their cleavage patterns were consistent with inner (loop B) and outer (loop E) leaflet locations. This study indicates that the functional CHIP molecule is a unique structure with two internal repeats oriented 180-degrees to each other within the membrane.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	PRESTON, GM (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, 725 N WOLFE ST, BALTIMORE, MD 21205 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033991, R37HL048268, R01HL048268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032753, R37DK032753] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33991, HL48268] Funding Source: Medline; NIDDK NIH HHS [DK32753] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AERTS T, 1990, J BIOL CHEM, V265, P8675; AGRE P, 1993, AM J PHYSIOL, V265, pF463; AGRE P, 1993, AM J PHYSIOL, V265, pF461, DOI 10.1152/ajprenal.1993.265.3.F461; BONDY C, 1993, P NATL ACAD SCI USA, V90, P4500, DOI 10.1073/pnas.90.10.4500; DAVIS JQ, 1984, J BIOL CHEM, V259, P1874; DEEN PMT, 1992, BIOCHEM BIOPH RES CO, V188, P1267, DOI 10.1016/0006-291X(92)91368-Z; DENKER BM, 1988, J BIOL CHEM, V263, P15634; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; HORWITZ J, 1987, BIOCHEMISTRY-US, V26, P8092, DOI 10.1021/bi00399a012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LU L, 1990, BIOPHYS J, V57, P1117, DOI 10.1016/S0006-3495(90)82632-1; MACEY RI, 1984, AM J PHYSIOL, V246, pC195, DOI 10.1152/ajpcell.1984.246.3.C195; MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; MOON C, 1993, J BIOL CHEM, V268, P15772; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; NISHIMURA H, 1993, J BIOL CHEM, V268, P8514; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; PLUTA AF, 1992, J CELL BIOL, V116, P1081, DOI 10.1083/jcb.116.5.1081; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; SMITH BL, 1991, J BIOL CHEM, V266, P6407; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VANHOEK AN, 1991, J BIOL CHEM, V266, P16633; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; WISTOW GJ, 1991, TRENDS BIOCHEM SCI, V16, P170, DOI 10.1016/0968-0004(91)90065-4; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG R, 1990, J BIOL CHEM, V265, P15375; ZHANG RB, 1993, BIOCHEMISTRY-US, V32, P2938, DOI 10.1021/bi00063a002; ZHANG RB, 1993, J CELL BIOL, V120, P359, DOI 10.1083/jcb.120.2.359	35	149	152	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1668	1673						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507481				2022-12-25	WOS:A1994MR98800022
J	GOELZ, S; KUMAR, R; POTVIN, B; SUNDARAM, S; BRICKELMAIER, M; STANLEY, P				GOELZ, S; KUMAR, R; POTVIN, B; SUNDARAM, S; BRICKELMAIER, M; STANLEY, P			DIFFERENTIAL EXPRESSION OF AN E-SELECTIN LIGAND [SLE(X)] BY 2 CHINESE-HAMSTER OVARY CELL-LINES TRANSFECTED WITH THE SAME ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE (ELFT)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; N-LINKED OLIGOSACCHARIDES; SIALYL-LEX DETERMINANT; MOLECULE E-SELECTIN; LEWIS-X; EMBRYONIC ANTIGEN; ENDOTHELIAL-CELLS; MYELOID CELLS; TYPE-2 CHAIN; P-SELECTIN	The mammalian cDNA encoding alpha(1,3)-fucosyltransferase (alpha(1,3)Fuc-T) termed ELAM-1 ligand fucosyltransferase (ELFT) or Fuc-TIV was previously cloned by three groups who reported different results from transfection studies Goelz et al. (Goelz, S. E., Hession, C., Goff, D., Griffiths, B., Tizard, R., Newman, B., Chi-Rosso, G., and Lobb, R. (1990) Cell 63, 1349-1356) found that Chinese hamster ovary (CHO) cells expressing the ELFT cDNA had alpha(1,3)Fuc-T activity and were able to bind to E-selectin. In contrast, Lowe et al. (Lowe, J. B., Kukowska-Latallo, J. F., Nair, R. P., Larsen, R. D., Marks, R. M., Macher, B. A., Kelly, R. J., and Ernst, L. K. (1991) J. Biol. Chem. 266, 17467-17477) and Kumar et al. (Kumar, R., Potvin, B., Muller, W. A., and Stanley, P. (1991) J. Biol. Chem. 266, 21777-21783) found no binding to E-selectin of CHO transfectants expressing the same alpha(1,3)Fuc-T gene; nor did the latter transfectants synthesize a known E-selectin ligand, sialylated Le(x) (SLe(x)), although they had substantial alpha(1,3)Fuc-T activity. We now show that these discrepant results were due to a difference between the parental CHO cell lines. Following transfection of ELFT cDNA into Pro-5 or dihydrofolate reductase (DHFR)- CHO cells, only the DHFR- transfectants expressed SLe(x) and bound to E-selectin. Indirect evidence from monoclonal antibody and lectin binding studies indicates that the range of carbohydrate structures synthesized by the Pro-5 and DHFR- CHO cell lines differs. Since DHFR-/ELFT transfectants expressed cell surface SLe(x) but transferred fucose poorly to sialylated substrates in vitro, ELFT may be able to fucosylate a complex carbohydrate missing from Pro-5 cells. Alternatively, either CHO line may have an activity (such as an alpha(2,3)-sialyltransferase), that modifies alpha(1,3)-fucosylated lactosamines.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461; BIOGEN INC,BOSTON,MA 02142	Yeshiva University; Albert Einstein College of Medicine; Biogen				Stanley, Pamela/0000-0001-5704-3747	PHS HHS [R37 30645, P01 13330, R01 30644] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARSOUM J, 1990, DNA CELL BIOL, V9, P293, DOI 10.1089/dna.1990.9.293; CHANDRASEKARAN EV, 1992, J BIOL CHEM, V267, P23806; DEVRIES T, 1992, HISTOCHEM J, V24, P761, DOI 10.1007/BF01046347; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; EASTON EW, 1993, BLOOD, V81, P2978; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FUKUSHI Y, 1984, J BIOL CHEM, V259, P4681; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; HANISCH FG, 1988, CARBOHYD RES, V178, P23, DOI 10.1016/0008-6215(88)80099-5; HANSSON GC, 1985, J BIOL CHEM, V260, P9388; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; JOHNSON PH, 1985, BIOCHEM SOC T, V13, P1119, DOI 10.1042/bst0131119; KANNAGI R, 1982, J BIOL CHEM, V257, P4865; KOJIMA N, 1992, BIOCHEM BIOPH RES CO, V182, P1288, DOI 10.1016/0006-291X(92)91872-N; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LARKIN M, 1992, J BIOL CHEM, V267, P13661; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEEUWENBERG JFM, 1991, EUR J IMMUNOL, V21, P3057, DOI 10.1002/eji.1830211225; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; Liener I.E., 1986, LECTINS; LOBB RR, 1991, J IMMUNOL, V147, P124; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; MACHER BA, 1988, J BIOL CHEM, V263, P10186; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; NGUYEN M, 1992, J BIOL CHEM, V267, P26157; PAREKH RB, 1992, J BIOCH TOKYO D, V16, P137; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POTVIN B, 1991, CELL REGUL, V2, P989, DOI 10.1091/mbc.2.12.989; POTVIN B, 1990, J BIOL CHEM, V265, P1615; RAY MK, 1991, J BIOL CHEM, V266, P22818; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; SINGHAL AK, 1990, CANCER RES, V50, P1375; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANLEY P, 1992, GLYCOBIOLOGY, V2, P99, DOI 10.1093/glycob/2.2.99; STANLEY P, 1975, SOMAT CELL GENET, V1, P3, DOI 10.1007/BF01538729; STANLEY P, 1983, SOMAT CELL GENET, V9, P593, DOI 10.1007/BF01574260; STANLEY P, 1988, J BIOL CHEM, V263, P11374; TETTEROO PAT, 1987, J BIOL CHEM, V262, P15984; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; Vestweber D, 1992, Semin Cell Biol, V3, P211; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003	56	58	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1033	1040						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507103				2022-12-25	WOS:A1994MR22000042
